PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ding, Z; Joy, M; Bhargava, R; Gunsaulus, M; Lakshman, N; Miron-Mendoza, M; Petroll, M; Condeelis, J; Wells, A; Roy, P				Ding, Z.; Joy, M.; Bhargava, R.; Gunsaulus, M.; Lakshman, N.; Miron-Mendoza, M.; Petroll, M.; Condeelis, J.; Wells, A.; Roy, P.			Profilin-1 downregulation has contrasting effects on early vs late steps of breast cancer metastasis	ONCOGENE			English	Article						profilin-1; breast cancer; metastasis	TUMOR-CELLS; CARCINOMA-CELLS; MIGRATION; PROLIFERATION; CYTOKINESIS; MOTILITY; PROTEIN; OVEREXPRESSION; LAMELLIPODIN; INHIBITION	Profilin1 (Pfn1), a ubiquitously expressed actin-binding protein, has an indispensable role in migration and proliferation of normal cells. Seemingly contrary to its essential cellular functions, Pfn1's expression is downregulated in breast cancer, the significance of which is unclear. In this study, expression profiling of Pfn1 in human breast cancer specimens correlates lower Pfn1 expression levels with propensity to metastasize. Xenograft experiments further establish a causal relationship between loss of Pfn1 expression and increased dissemination of breast cancer cells (BCCs) from the primary mammary tumor. BCCs exhibit a hyperinvasive phenotype (marked by matrix metalloproteinase-9 upregulation, faster invasion through collagen matrix) and acquire increased proficiency to transmigrate through endothelial barrier (an obligatory step for vascular dissemination) when Pfn1 expression is suppressed. In Pfn1-deficient cells, hyperinvasiveness involves a phosphatidylinositol 3-kinase-PI(3,4)P-2 signaling axis while augmented transendothelial migration occurs in a vascular endothelial growth factor-dependent manner. Contrasting these dissemination promoting activities, loss of Pfn1, however, dramatically inhibits metastatic outgrowth of disseminated BCCs, suggesting that Pfn1 has a key role in the metastatic colonization process. In summary, this study shows that Pfn1 has a dichotomous role in early vs late steps of breast cancer metastasis.	[Ding, Z.; Joy, M.; Gunsaulus, M.; Wells, A.; Roy, P.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15219 USA; [Bhargava, R.; Wells, A.; Roy, P.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15219 USA; [Bhargava, R.] Magee Womens Hosp, Pittsburgh, PA USA; [Lakshman, N.; Miron-Mendoza, M.; Petroll, M.] Univ Texas SW Med Ctr Dallas, Dept Ophthalmol, Dallas, TX 75390 USA; [Condeelis, J.] Albert Einstein Coll Med, Dept Cell Biol & Anat, New York, NY USA; [Wells, A.; Roy, P.] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA; [Roy, P.] Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA 15219 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Southwestern Medical Center Dallas; Yeshiva University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Roy, P (corresponding author), Univ Pittsburgh, Dept Bioengn, 306 Ctr Bioengn,300 Technol Dr, Pittsburgh, PA 15219 USA.	par19@pitt.edu		Wells, Alan/0000-0002-1637-8150; Roy, Partha/0000-0002-4946-8531; Petroll, W. Matthew/0000-0003-0795-4539	National Cancer Institute of the National Institute of Health [2R01CA108607-07]; Magee Women's Research Institute; NATIONAL CANCER INSTITUTE [R01CA108607] Funding Source: NIH RePORTER	National Cancer Institute of the National Institute of Health; Magee Women's Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Cancer Institute of the National Institute of Health (2R01CA108607-07) and the Magee Women's Research Institute to PR.	Artym Vira V., 2009, V522, P211, DOI 10.1007/978-1-59745-413-1_15; Bae YH, 2010, P NATL ACAD SCI USA, V107, P21547, DOI 10.1073/pnas.1002309107; Bae YH, 2009, J CELL PHYSIOL, V219, P354, DOI 10.1002/jcp.21677; Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849; Bottcher RT, 2009, EMBO J, V28, P1157, DOI 10.1038/emboj.2009.58; Chao Y, 2012, CANCER MICROENVIRON, V5, P19, DOI 10.1007/s12307-011-0085-4; Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179; Ding ZJ, 2006, J CELL SCI, V119, P4127, DOI 10.1242/jcs.03178; Ding ZJ, 2009, EXP CELL RES, V315, P2963, DOI 10.1016/j.yexcr.2009.07.004; Fedele CG, 2010, P NATL ACAD SCI USA, V107, P22231, DOI 10.1073/pnas.1015245107; Gau D, 2011, CELL MOL BIOENG, V4, P1, DOI 10.1007/s12195-010-0133-z; Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Gorges TM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-178; Gronborg M, 2006, MOL CELL PROTEOMICS, V5, P157, DOI 10.1074/mcp.M500178-MCP200; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; Ho MY, 2012, MOL CANCER RES, V10, P1109, DOI 10.1158/1541-7786.MCR-12-0160; Janke J, 2000, J EXP MED, V191, P1675, DOI 10.1084/jem.191.10.1675; Jockusch BM, 2007, REV PHYSIOL BIOCH P, V159, P131, DOI 10.1007/112_2007_704; Karlsson R, 2007, MOL BIOL INTELL UNIT, P29, DOI 10.1007/978-0-387-46407-7_3; Khadka DK, 2009, DEV BIOL, V332, P396, DOI 10.1016/j.ydbio.2009.06.008; Kim A, 2010, INVEST OPHTH VIS SCI, V51, P864, DOI 10.1167/iovs.09-4200; Krause M, 2004, DEV CELL, V7, P571, DOI 10.1016/j.devcel.2004.07.024; Kullmann JA, 2012, EMBO REP, V13, P75, DOI 10.1038/embor.2011.211; Lederer M, 2005, J CELL SCI, V118, P331, DOI 10.1242/jcs.01618; Poincloux R, 2011, P NATL ACAD SCI USA, V108, P1943, DOI 10.1073/pnas.1010396108; Roy P, 2004, CELL MOTIL CYTOSKEL, V57, P84, DOI 10.1002/cm.10160; Sato A, 2006, DEVELOPMENT, V133, P4219, DOI 10.1242/dev.02590; Severson AF, 2002, CURR BIOL, V12, P2066, DOI 10.1016/S0960-9822(02)01355-6; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Smith K, 2010, CELL HOST MICROBE, V7, P13, DOI 10.1016/j.chom.2009.12.004; VERHEYEN EM, 1994, DEVELOPMENT, V120, P717; Witke W, 2004, TRENDS CELL BIOL, V14, P461, DOI 10.1016/j.tcb.2004.07.003; Wu N, 2006, PROTEOMICS, V6, P6095, DOI 10.1002/pmic.200500321; Zoidakis J, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.009449; Zou L, 2007, BRIT J CANCER, V97, P1361, DOI 10.1038/sj.bjc.6604038; Zou L, 2009, CELL MOTIL CYTOSKEL, V66, P1048, DOI 10.1002/cm.20407	38	41	41	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2065	2074		10.1038/onc.2013.166	http://dx.doi.org/10.1038/onc.2013.166			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23686314	Green Accepted			2022-12-17	WOS:000334599100006
J	Czyzyk-Krzeska, MF; Zhang, X				Czyzyk-Krzeska, M. F.; Zhang, X.			MiR-155 at the heart of oncogenic pathways	ONCOGENE			English	Editorial Material							HUMAN BREAST-TUMORS; MOLECULAR PORTRAITS; CANCER CELLS; MICRORNA-155; EXPRESSION; HYPOXIA; GROWTH	MicroRNAs are increasingly being recognized as oncogenes and tumor suppressors in cancer. MicroRNA-155 (miR-155) is an established oncomiR in breast cancer and regulates several pro-oncogenic pathways. In light of this, Chiang's group has discovered a novel pathway regulated by miR-155. MiR-155 directly targets the VHL tumor suppressor and, by doing so, promotes the activity of HIF transcription factors and angiogenesis. This pathway appears to be particularly relevant in triple-negative breast cancer.	[Czyzyk-Krzeska, M. F.; Zhang, X.] Univ Cincinnati, Vontz Ctr Mol Studies, Coll Med, Dept Canc Biol, Cincinnati, OH 45267 USA; [Czyzyk-Krzeska, M. F.] Dept Vet Affairs, VA Res Serv, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Czyzyk-Krzeska, MF (corresponding author), Univ Cincinnati, Vontz Ctr Mol Studies, Coll Med, Dept Canc Biol, 3125 Eden Ave, Cincinnati, OH 45267 USA.	Maria.Czyzykkrzeska@uc.edu			NCI NIH HHS [NCI CA122346, R01 CA122346] Funding Source: Medline; BLRD VA [I01 BX001110] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA122346] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); BLRD VA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Babar IA, 2011, CANCER BIOL THER, V12, P908, DOI 10.4161/cbt.12.10.17681; Bruning U, 2011, MOL CELL BIOL, V31, P4087, DOI 10.1128/MCB.01276-10; Chang SH, 2011, NAT MED, V17, P1275, DOI 10.1038/nm.2459; Chen J, 2012, J SURG ONCOL, V106, P260, DOI 10.1002/jso.22153; Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kong W, 2014, ONCOGENE, V33, P679, DOI 10.1038/onc.2012.636; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093	12	41	43	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					677	678		10.1038/onc.2013.26	http://dx.doi.org/10.1038/onc.2013.26			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23416982	Green Accepted			2022-12-17	WOS:000331129200002
J	Lonning, PE; Knappskog, S				Lonning, P. E.; Knappskog, S.			Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers	ONCOGENE			English	Review						chemoresistance; TP53; DNA repair; mutations; germline; chemotherapy	NEGATIVE BREAST-CANCER; NUCLEOTIDE EXCISION-REPAIR; TOPOISOMERASE-II-ALPHA; PATIENTS RECEIVING COMBINATION; PLATINUM-BASED CHEMOTHERAPY; TUMOR-SUPPRESSOR STATUS; DNA-DAMAGE RESPONSE; CELL-CYCLE ARREST; P53 TARGET GENES; OVARIAN-CANCER	Although new agents are implemented to cancer therapy, we lack fundamental understandings of the mechanisms of chemoresistance, the main obstacle to cure in cancer. Here we review clinical evidence linking molecular defects to drug resistance across different tumour forms and discuss contemporary experimental evidence exploring these mechanisms. Although evidence, in general, is sparse and fragmentary, merging knowledge links drug resistance, and also sensitivity, to defects in functional pathways having a key role in cell growth arrest or death and DNA repair. As these pathways may act in concert, there is a need to explore multiple mechanisms in parallel. Taking advantage of massive parallel sequencing and other novel high-throughput technologies and base research on biological hypotheses, we now have the possibility to characterize functional defects related to these key pathways and to design a new generation of studies identifying the mechanisms controlling resistance to different treatment regimens in different tumour forms.	[Lonning, P. E.; Knappskog, S.] Univ Bergen, Inst Med, Sect Oncol, Bergen, Norway; [Lonning, P. E.; Knappskog, S.] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Hordaland, Norway	University of Bergen; University of Bergen; Haukeland University Hospital	Lonning, PE (corresponding author), Haukeland Hosp, Dept Oncol, Jonas Lies Vei 65, N-5021 Bergen, Hordaland, Norway.	per.lonning@helse-bergen.no		Knappskog, Stian/0000-0002-4153-1655; Lonning, Per Eystein/0000-0002-8890-6303				Akakura S, 2010, CELL CYCLE, V9, P4656, DOI 10.4161/cc.9.23.13974; Al-Bahlani S, 2011, ONCOGENE, V30, P4219, DOI 10.1038/onc.2011.134; Aleskandarany MA, 2011, BREAST CANCER RES TR, V127, P407, DOI 10.1007/s10549-010-1012-y; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Allocati N, 2012, EXP CELL RES, V318, P1285, DOI 10.1016/j.yexcr.2012.01.023; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Alsop K, 2012, J CLIN ONCOL, V30, P2654, DOI 10.1200/JCO.2011.39.8545; Arun B, 2011, J CLIN ONCOL, V29, P3739, DOI 10.1200/JCO.2011.35.2682; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Atwal GS, 2009, P NATL ACAD SCI USA, V106, P10236, DOI 10.1073/pnas.0901298106; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Bachelot T, 2012, J CLIN ONCOL, V30, P2718, DOI 10.1200/JCO.2011.39.0708; Balana C, 2003, CLIN CANCER RES, V9, P1461; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Baselga J, 2011, ONCOLOGIST, V16, P12, DOI 10.1634/theoncologist.2011-S1-12; Baumbusch LO, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-47; Bayraktar S, 2011, BREAST CANCER RES TR, V130, P145, DOI 10.1007/s10549-011-1711-z; Beeram M, 2007, ANN ONCOL, V18, P1323, DOI 10.1093/annonc/mdm170; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Berge EO, 2011, CLIN EXP METASTAS, V28, P319, DOI 10.1007/s10585-011-9375-y; Berge EO, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-173; Bhana S, 2008, MUTAGENESIS, V23, P131, DOI 10.1093/mutage/gen001; Blackwell KL, 2012, J CLIN ONCOL, V30, P2585, DOI 10.1200/JCO.2011.35.6725; Bleeker FE, 2008, ONCOGENE, V27, P5648, DOI 10.1038/onc.2008.170; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bonnefoi H, 2011, LANCET ONCOL, V12, P527, DOI 10.1016/S1470-2045(11)70094-8; Bosco EE, 2007, J CLIN INVEST, V117, P218, DOI 10.1172/JCI28803; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bourdon JC, 2011, BREAST CANCER RES, V13, P1; Bowen C, 1998, CANCER RES, V58, P3275; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Brunner HG, 2002, AM J MED GENET, V112, P284, DOI 10.1002/ajmg.10778; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bukowski RM, 2012, EXPERT OPIN DRUG SAF, V11, P861, DOI 10.1517/14740338.2012.713344; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Byrski T, 2010, J CLIN ONCOL, V28, P375, DOI 10.1200/JCO.2008.20.7019; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Castillo P, 2011, DNA REPAIR, V10, P518, DOI 10.1016/j.dnarep.2011.02.007; Chabalier C, 2006, CELL CYCLE, V5, P1001, DOI 10.4161/cc.5.9.2726; Chang CJ, 2004, J BIOL CHEM, V279, P29841, DOI 10.1074/jbc.M401488200; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Chen JG, 2005, P NATL ACAD SCI USA, V102, P4813, DOI 10.1073/pnas.0407069102; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2003, J CLIN IMMUNOL, V23, P355, DOI 10.1023/A:1025365432325; Chrisanthar R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019249; Chrisanthar R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003062; Concin N, 2005, CLIN CANCER RES, V11, P8372, DOI 10.1158/1078-0432.CCR-05-0899; Cybulski C, 2004, AM J HUM GENET, V75, P1131, DOI 10.1086/426403; DABHOLKAR M, 1992, J NATL CANCER I, V84, P1512, DOI 10.1093/jnci/84.19.1512; Dal Bo M, 2010, BRIT J HAEMATOL, V150, P237, DOI 10.1111/j.1365-2141.2010.08185.x; Danks MK, 1998, CELL DEATH DIFFER, V5, P678, DOI 10.1038/sj.cdd.4400408; Dann RB, 2012, GYNECOL ONCOL, V125, P677, DOI 10.1016/j.ygyno.2012.03.006; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Dedes KJ, 2011, CELL CYCLE, V10, P1192, DOI 10.4161/cc.10.8.15273; DeGraffenried LA, 2004, CLIN CANCER RES, V10, P8059, DOI 10.1158/1078-0432.CCR-04-0035; Deissler H, 2004, ONCOL REP, V11, P1281; Depowski PL, 2001, MODERN PATHOL, V14, P672, DOI 10.1038/modpathol.3880371; Derenzini M, 2009, J PATHOL, V219, P373, DOI 10.1002/path.2612; Diaz-Padilla I, 2012, CANCER TREAT REV, V38, P767, DOI 10.1016/j.ctrv.2012.02.001; DICCIANNI MB, 1994, BLOOD, V84, P3105; Ding H, 2011, BREAST CANCER RES TR, V125, P473, DOI 10.1007/s10549-010-0977-x; Diouf B, 2011, NAT MED, V17, P1298, DOI 10.1038/nm.2430; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Domagala P, 2011, BREAST CANCER RES TR, V127, P861, DOI 10.1007/s10549-011-1441-2; Dommering CJ, 2012, FAM CANCER, V11, P225, DOI 10.1007/s10689-011-9505-3; Dowsett M, 2008, J CLIN ONCOL, V26, P1059, DOI 10.1200/JCO.2007.12.9437; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Dworkin AM, 2009, FAM CANCER, V8, P339, DOI 10.1007/s10689-009-9240-1; Easton D, 2004, AM J HUM GENET, V74, P1175, DOI 10.1086/421251; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Eisenhauer EA, 1997, ANN ONCOL, V8, P963, DOI 10.1023/A:1008240421028; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans DG, 2008, J MED GENET, V45, P62, DOI 10.1136/jmg.2007.054494; Evans DG, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-155; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feng LJ, 2006, CELL CYCLE, V5, P2812, DOI 10.4161/cc.5.23.3526; Fernandez-Cuesta L, 2012, BREAST CANCER RES, V14, P3; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Forslund A, 2008, MOL CANCER RES, V6, P205, DOI 10.1158/1541-7786.MCR-07-0239; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Fu YP, 2003, CANCER RES, V63, P2440; Gajjar M, 2012, CANCER CELL, V21, P25, DOI 10.1016/j.ccr.2011.11.016; Garcia AI, 2011, EMBO MOL MED, V3, P279, DOI 10.1002/emmm.201100136; Garcia JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062; Garcia MJ, 2008, CLIN TRANSL ONCOL, V10, P78, DOI 10.1007/s12094-008-0160-6; Geisler S, 2003, CLIN CANCER RES, V9, P5582; Geisler S, 2001, CANCER RES, V61, P2505; Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Gronwald J, 2009, J CLIN ONCOL S155, V27, P7; Grunwald V, 2002, CANCER RES, V62, P6141; Gurley KE, 2007, MOL CANCER RES, V5, P1312, DOI 10.1158/1541-7786.MCR-07-0223; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hastak K, 2010, CANCER RES, V70, P7970, DOI 10.1158/0008-5472.CAN-09-4521; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hennessy BTJ, 2010, J CLIN ONCOL, V28, P3570, DOI 10.1200/JCO.2009.27.2997; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Honecker F, 2009, J CLIN ONCOL, V27, P2129, DOI 10.1200/JCO.2008.18.8623; Hsu DSS, 2010, CLIN CANCER RES, V16, P4561, DOI 10.1158/1078-0432.CCR-10-0593; Hugh J, 2009, J CLIN ONCOL, V27, P1168, DOI 10.1200/JCO.2008.18.1024; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Ianari A, 2009, CANCER CELL, V15, P184, DOI 10.1016/j.ccr.2009.01.026; Ibrahim YH, 2012, CANCER DISCOV, V2, P1036, DOI 10.1158/2159-8290.CD-11-0348; Ichikawa A, 1997, NEW ENGL J MED, V337, P529, DOI 10.1056/NEJM199708213370804; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Jackson JG, 2012, CANCER CELL, V21, P793, DOI 10.1016/j.ccr.2012.04.027; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jemaa M, 2012, CELL CYCLE, V11, P2149, DOI 10.4161/cc.20621; Johnston S, 2009, J CLIN ONCOL, V27, P5538, DOI 10.1200/JCO.2009.23.3734; Juvekar A, 2012, CANCER DISCOV, V2, P1048, DOI 10.1158/2159-8290.CD-11-0336; Kaina B, 2007, DNA REPAIR, V6, P1079, DOI 10.1016/j.dnarep.2007.03.008; Kandioler D, 2008, J THORAC CARDIOV SUR, V135, P1036, DOI 10.1016/j.jtcvs.2007.10.072; Kandioler-Eckersberger D, 1999, J THORAC CARDIOV SUR, V117, P744, DOI 10.1016/S0022-5223(99)70295-3; Kandioler-Eckersberger D, 2000, CLIN CANCER RES, V6, P50; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970; Kaufman B, 2009, J CLIN ONCOL, V27, P5529, DOI 10.1200/JCO.2008.20.6847; Kerzendorfer C, 2009, DNA REPAIR, V8, P1139, DOI 10.1016/j.dnarep.2009.04.018; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Knappskog S, 2007, INT J CANCER, V121, P908, DOI 10.1002/ijc.22777; Knappskog S, 2012, EUR J CANCER, V48, P1988, DOI 10.1016/j.ejca.2011.10.024; Knappskog S, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3147; Knappskog S, 2011, CANCER CELL, V19, P273, DOI 10.1016/j.ccr.2010.12.019; Knoop AS, 2005, J CLIN ONCOL, V23, P7483, DOI 10.1200/JCO.2005.11.007; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Kriege M, 2012, CANCER-AM CANCER SOC, V118, P899, DOI 10.1002/cncr.26351; Kriege M, 2009, J CLIN ONCOL, V27, P3764, DOI 10.1200/JCO.2008.19.9067; Lachlan KL, 2007, J MED GENET, V44, DOI 10.1136/jmg.2007.049981; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lavarino C, 2000, J CLIN ONCOL, V18, P3936, DOI 10.1200/JCO.2000.18.23.3936; Ledermann J, 2012, NEW ENGL J MED, V366, P1382, DOI 10.1056/NEJMoa1105535; Lehmann S, 2012, J CLIN ONCOL, V30, P3633, DOI 10.1200/JCO.2011.40.7783; Lehmann-Che J, 2010, ONCOLOGIST, V15, P246, DOI 10.1634/theoncologist.2009-0243; Leong CO, 2007, J CLIN INVEST, V117, P1370, DOI 10.1172/JCI30866; Leontieva OV, 2010, CELL CYCLE, V9, P4323, DOI 10.4161/cc.9.21.13584; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lin WC, 2001, GENE DEV, V15, P1833; Liu XS, 2009, MOL CANCER RES, V7, P1686, DOI 10.1158/1541-7786.MCR-09-0299; Lonning PE, 2007, ANN ONCOL, V18, P1293, DOI 10.1093/annonc/mdm013; Lonning PE, 2004, TRENDS MOL MED, V10, P113, DOI 10.1016/j.molmed.2004.01.005; Lonning PE, 2003, LANCET ONCOL, V4, P177; Lonning PE, 2010, MOL ONCOL, V4, P284, DOI 10.1016/j.molonc.2010.04.005; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Loveday C, 2011, NAT GENET, V43, P879, DOI 10.1038/ng.893; Lynch HT, 2009, CLIN GENET, V76, P1, DOI 10.1111/j.1399-0004.2009.01230.x; Ma YL, 2011, BREAST CANCER RES TR, V125, P201, DOI 10.1007/s10549-010-0920-1; Marine JC, 2004, CELL CYCLE, V3, P900; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Martin SA, 2008, CURR OPIN GENET DEV, V18, P80, DOI 10.1016/j.gde.2008.01.016; Martin SA, 2009, EMBO MOL MED, V1, P323, DOI 10.1002/emmm.200900040; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004; Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569; Merel P, 2002, ONCOGENE, V21, P5654, DOI 10.1038/sj.onc.1205742; Metzger R, 1998, J CLIN ONCOL, V16, P309, DOI 10.1200/JCO.1998.16.1.309; Micol R, 2011, J ALLERGY CLIN IMMUN, V128, P382, DOI 10.1016/j.jaci.2011.03.052; Morachis JM, 2010, GENE DEV, V24, P135, DOI 10.1101/gad.1856710; MORRELL D, 1986, J NATL CANCER I, V77, P89; Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751; Moskwa P, 2011, MOL CELL, V41, P210, DOI 10.1016/j.molcel.2010.12.005; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Muthusamy V, 2006, GENE CHROMOSOME CANC, V45, P447, DOI 10.1002/gcc.20310; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Norgauer J, 2003, EUR J DERMATOL, V13, P4; Norquist B, 2011, J CLIN ONCOL, V29, P3008, DOI 10.1200/JCO.2010.34.2980; O'Malley FP, 2009, JNCI-J NATL CANCER I, V101, P644, DOI 10.1093/jnci/djp067; O'Shaughnessy J, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.1007; O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Orloff MS, 2013, AM J HUM GENET, V92, P76, DOI 10.1016/j.ajhg.2012.10.021; Oshima K, 2011, CANCER LETT, V307, P149, DOI 10.1016/j.canlet.2011.03.027; Paik SM, 1998, JNCI-J NATL CANCER I, V90, P1361, DOI 10.1093/jnci/90.18.1361; Park DJ, 2001, CANCER RES, V61, P8654; Park JS, 2011, GYNECOL ONCOL, V120, P275, DOI 10.1016/j.ygyno.2010.10.034; Patel AG, 2012, CLIN CANCER RES, V18, P1655, DOI 10.1158/1078-0432.CCR-11-2890; Paz MF, 2004, CLIN CANCER RES, V10, P4933, DOI 10.1158/1078-0432.CCR-04-0392; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Petit T, 2001, CLIN CANCER RES, V7, P1577; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Powers JT, 2004, MOL CANCER RES, V2, P203; Press MF, 2005, BREAST CANCER RES TR, V94, pS54; PREUDHOMME C, 1995, J CLIN ONCOL, V13, P812, DOI 10.1200/JCO.1995.13.4.812; Pritchard KI, 2006, NEW ENGL J MED, V354, P2103, DOI 10.1056/NEJMoa054504; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Rafnar T, 2011, NAT GENET, V43, P1104, DOI 10.1038/ng.955; Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959; Rakha EA, 2009, CLIN CANCER RES, V15, P2302, DOI 10.1158/1078-0432.CCR-08-2132; Ray RM, 2011, APOPTOSIS, V16, P35, DOI 10.1007/s10495-010-0538-0; Ray-Coquard I, 2012, LANCET ONCOL, V13, P1133, DOI 10.1016/S1470-2045(12)70474-6; Reardon JT, 1999, CANCER RES, V59, P3968; Rehman FL, 2010, NAT REV CLIN ONCOL, V7, P718, DOI 10.1038/nrclinonc.2010.172; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Righetti SC, 1996, CANCER RES, V56, P689; Riviere JB, 2012, NAT GENET, V44, P934, DOI 10.1038/ng.2331; Romeo F, 2011, INT J BIOCHEM CELL B, V43, P1754, DOI 10.1016/j.biocel.2011.08.011; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; ROSE C, 1985, LANCET, V1, P16; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Russnes HG, 2011, J CLIN INVEST, V121, P3810, DOI 10.1172/JCI57088; Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Santonocito C, 2012, CLIN CHIM ACTA, V413, P1519, DOI 10.1016/j.cca.2012.06.013; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitz KJ, 2004, MODERN PATHOL, V17, P15, DOI 10.1038/modpathol.3800002; Schrohl AS, 2006, CLIN CANCER RES, V12, P7054, DOI 10.1158/1078-0432.CCR-06-0950; Sharma A, 2007, CANCER RES, V67, P6192, DOI 10.1158/0008-5472.CAN-06-4424; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Sirohi B, 2008, ANN ONCOL, V19, P1847, DOI 10.1093/annonc/mdn395; Sirvent N, 2007, AM J SURG PATHOL, V31, P1476, DOI 10.1097/PAS.0b013e3180581fff; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smeenk L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017574; Smiraldo PG, 2005, CANCER RES, V65, P2089, DOI 10.1158/0008-5472.CAN-04-2079; Somyajit K, 2012, J BIOL CHEM, V287, P3366, DOI 10.1074/jbc.M111.311241; Song H, 2007, CELL CYCLE, V6, P1570, DOI 10.4161/cc.6.13.4456; Song SS, 2012, CELL RES, V22, P1285, DOI 10.1038/cr.2012.107; Sorensen NM, 2007, CLIN CANCER RES, V13, P4117, DOI 10.1158/1078-0432.CCR-07-0186; Staalesen V, 2004, ONCOGENE, V23, P8535, DOI 10.1038/sj.onc.1207928; Staalesen V, 2004, CLIN CANCER RES, V10, P3438, DOI 10.1158/1078-0432.CCR-03-0796; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stiewe T, 2007, NAT REV CANCER, V7, P165, DOI 10.1038/nrc2072; Swisher EM, 2008, CANCER RES, V68, P2581, DOI 10.1158/0008-5472.CAN-08-0088; Tan DSP, 2008, J CLIN ONCOL, V26, P5530, DOI 10.1200/JCO.2008.16.1703; Tanner M, 2006, J CLIN ONCOL, V24, P2428, DOI 10.1200/JCO.2005.02.9264; Tavtigian SV, 2009, AM J HUM GENET, V85, P427, DOI 10.1016/j.ajhg.2009.08.018; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Trotman LC, 2003, CANCER CELL, V3, P97, DOI 10.1016/S1535-6108(03)00022-9; Tsai CM, 2000, JPN J CANCER RES, V91, P213, DOI 10.1111/j.1349-7006.2000.tb00934.x; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Valeri A, 2011, CLIN TRANSL ONCOL, V13, P215, DOI 10.1007/s12094-011-0645-6; van der Kolk DM, 2010, BREAST CANCER RES TR, V124, P643, DOI 10.1007/s10549-010-0805-3; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Vencken PMLH, 2011, ANN ONCOL, V22, P1346, DOI 10.1093/annonc/mdq628; Viktorsson K, 2005, BIOCHEM BIOPH RES CO, V331, P868, DOI 10.1016/j.bbrc.2005.03.192; Villarroel MC, 2011, MOL CANCER THER, V10, P3, DOI 10.1158/1535-7163.MCT-10-0893; von Minckwitz G, 2011, J CLIN ONCOL, V29, P2150, DOI 10.1200/JCO.2010.31.9079; Walsh T, 2011, P NATL ACAD SCI USA, V108, P18032, DOI 10.1073/pnas.1115052108; Wang QE, 2011, MOL CANCER, V10; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Williams SA, 2011, HUM MOL GENET, V20, P4395, DOI 10.1093/hmg/ddr366; Witkiewicz AK, 2012, CLIN CANCER RES, V18, P5110, DOI 10.1158/1078-0432.CCR-12-0903; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xue YW, 2012, CELL CYCLE, V11, P4181, DOI 10.4161/cc.22413; Yang D, 2011, JAMA-J AM MED ASSOC, V306, P1557, DOI 10.1001/jama.2011.1456; Yang J, 2010, ONCOGENE, V29, P463, DOI 10.1038/onc.2009.327; Yoon H, 2002, P NATL ACAD SCI USA, V99, P15632, DOI 10.1073/pnas.242597299; Young SR, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-86; Yunokawa M, 2012, CANCER SCI, V103, P1665, DOI 10.1111/j.1349-7006.2012.02359.x; Zagorski WA, 2007, CANCER RES, V67, P8264, DOI 10.1158/0008-5472.CAN-06-4753; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zenz T, 2010, J CLIN ONCOL, V28, P4473, DOI 10.1200/JCO.2009.27.8762; Zenz T, 2009, BLOOD, V113, P3801, DOI 10.1182/blood-2008-08-172254; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang XP, 2011, P NATL ACAD SCI USA, V108, P8990, DOI 10.1073/pnas.1100600108; Zhang XB, 2012, EUR J CANCER, V48, P1581, DOI 10.1016/j.ejca.2012.02.053; Zhou W, 2004, CLIN CANCER RES, V10, P4939, DOI 10.1158/1078-0432.CCR-04-0247; Zurer I, 2004, CARCINOGENESIS, V25, P11, DOI 10.1093/carcin/bgg186; Zysman MA, 2002, AM J PATHOL, V160, P795, DOI 10.1016/S0002-9440(10)64902-4	283	41	41	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2013	32	46					5315	5330		10.1038/onc.2013.48	http://dx.doi.org/10.1038/onc.2013.48			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IU	23474753	hybrid			2022-12-17	WOS:000326922400001
J	Li, S; Wang, M; Ao, X; Chang, AK; Yang, C; Zhao, F; Bi, H; Liu, Y; Xiao, L; Wu, H				Li, S.; Wang, M.; Ao, X.; Chang, A. K.; Yang, C.; Zhao, F.; Bi, H.; Liu, Y.; Xiao, L.; Wu, H.			CLOCK is a substrate of SUMO and sumoylation of CLOCK upregulates the transcriptional activity of estrogen receptor-alpha	ONCOGENE			English	Article						CLOCK; ERa; estrogen; sumoylation	CIRCADIAN CLOCK; DIFFERENTIAL REGULATION; BREAST; NUCLEAR; ACTIVATION; MECHANISMS; EXPRESSION; GENES; BETA; PHOSPHORYLATION	Disruption of the circadian rhythm is now believed to associate with a number of hormone-related cancers, such as breast cancer, in which aberrant estrogen receptor-a (ERa) signaling is a major contributor. However, the molecular mechanisms underlying the function of core clock proteins in cancer are still largely undefined. In this study, we showed that circadian locomotor output cycles kaput (CLOCK), a key circadian protein, can interact with ERa. Furthermore, this interaction was enhanced by estrogen. We also showed that CLOCK can be sumoylated and sumoylation of CLOCK, which is also stimulated by estrogen, had two consequences: (1) it increased the transcriptional activity of CLOCK; and (2) it increased the CLOCK-modulated transcriptional activity of ERa, as shown by increased transcription of cyclin D1. Sumoylation of CLOCK occurred at two lysine residues, K67 and K851. The enhancement of ERa transcriptional activity exerted by wild-type but not mutant (2K/2R) CLOCK in response to estrogen indicated that sumoylation of CLOCK may have an important role in estrogen-dependent signaling. 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assay conducted with breast cancer cell lines (MCF-7 and T47D) demonstrated that sumoylation of CLOCK stimulated cell growth and increased the proportion of S phase cells in the cell cycle. The results of this study uncovered new insight into the connection between a major circadian protein and a major estrogen-dependent transcription factor, providing the basis for further research into the involvement of circadian proteins in breast cancer.	[Li, S.; Wang, M.; Ao, X.; Chang, A. K.; Yang, C.; Zhao, F.; Bi, H.; Liu, Y.; Xiao, L.; Wu, H.] Dalian Univ Technol, Sch Life Sci & Biotechnol, Dalian 116024, Peoples R China	Dalian University of Technology	Wu, H (corresponding author), Dalian Univ Technol, Sch Life Sci & Biotechnol, 2 Ling Gong Rd, Dalian 116024, Peoples R China.	wuhj@dlut.edu.cn	Liu, Ying/ABF-6380-2021	Liu, Ying/0000-0003-1699-9309	National Natural Science Foundation of China [31271500, 31171353]; Ministry of Science and Technology of China [2011CB504201]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	We are grateful to Dr Miche le Teboul (Universitede Nice-Sophia Antipolis) and Dr Urs Albrecht (University of Fribourg) for their present of mouse CLOCK and GAL4- DBDCLOCK constructs. This work was supported by grants (31171353, 31271500 to HW) from National Natural Science Foundation of China and grants (973 program: 2011CB504201 to HW) from the Ministry of Science and Technology of China.	Al-Dhaheri M, 2011, CANCER RES, V71, P2118, DOI 10.1158/0008-5472.CAN-10-2426; Antoch MP, 2008, CELL CYCLE, V7, P1197, DOI 10.4161/cc.7.9.5886; Bailey D, 2002, J GEN VIROL, V83, P2951, DOI 10.1099/0022-1317-83-12-2951; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Cai W, 2008, MOL CELL BIOL, V28, P784, DOI 10.1128/MCB.00233-07; Cardone L, 2005, SCIENCE, V309, P1390, DOI 10.1126/science.1110689; Cascone I, 2005, J CELL BIOL, V170, P993, DOI 10.1083/jcb.200507082; Chauchereau A, 2003, J BIOL CHEM, V278, P12335, DOI 10.1074/jbc.M207148200; Doi M, 2006, CELL, V125, P497, DOI 10.1016/j.cell.2006.03.033; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Dutertre M, 2003, MOL ENDOCRINOL, V17, P1296, DOI 10.1210/me.2001-0316; Gery S, 2007, ONCOGENE, V26, P7916, DOI 10.1038/sj.onc.1210585; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Gong L, 2006, J BIOL CHEM, V281, P15869, DOI 10.1074/jbc.M511658200; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Hoffman AE, 2010, CANCER RES, V70, P1459, DOI 10.1158/0008-5472.CAN-09-3798; Hong YD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023046; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Kuo SJ, 2009, VIRCHOWS ARCH, V454, P467, DOI 10.1007/s00428-009-0761-7; Lee CC, 2006, CANCER CAUSE CONTROL, V17, P525, DOI 10.1007/s10552-005-9003-8; Li SJ, 2012, BIOL CELL, V104, P287, DOI 10.1111/boc.201100116; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Pearce ST, 2004, CRIT REV ONCOL HEMAT, V50, P3, DOI 10.1016/j.critrevonc.2003.09.003; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; SHEIKH MS, 1994, INVAS METAST, V14, P329; Shim HS, 2007, EMBO REP, V8, P366, DOI 10.1038/sj.embor.7400920; Spengler ML, 2009, CELL CYCLE, V8, P4138, DOI 10.4161/cc.8.24.10273; Stade K, 2002, J BIOL CHEM, V277, P49554, DOI 10.1074/jbc.M207991200; Sternlicht MD, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1368; Tanimura N, 2011, TOXICOLOGY, V290, P203, DOI 10.1016/j.tox.2011.09.007; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Viswanathan AN, 2009, CANCER LETT, V281, P1, DOI 10.1016/j.canlet.2008.11.002; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Winter SL, 2007, NEOPLASIA, V9, P797, DOI 10.1593/neo.07595; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Wu HJ, 2006, J BIOL CHEM, V281, P21848, DOI 10.1074/jbc.M603772200; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yang CW, 2006, CANCER RES, V66, P11649, DOI 10.1158/0008-5472.CAN-06-1645; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576	48	41	49	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4883	4891		10.1038/onc.2012.518	http://dx.doi.org/10.1038/onc.2012.518			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23160374				2022-12-17	WOS:000325717800004
J	Chow, JPH; Poon, RYC				Chow, J. P. H.; Poon, R. Y. C.			The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery	ONCOGENE			English	Article						cell cycle; checkpoint; ionizing radiation	CELL-CYCLE; SOMATIC WEE1; PHOSPHORYLATION; CDC2; INACTIVATION; CHK1; ACTIVATION; ABROGATION; COMPLEXES; CLEAVAGE	Inhibition of cyclin-dependent kinase 1 (CDK1) by phosphorylation is a key regulatory mechanism for both the unperturbed cell cycle and the DNA damage checkpoint. Although both WEE1 and MYT1 can phosphorylate CDK1, little is known about the contribution of MYT1. We found that in contrast to WEE1, MYT1 was not important for the normal cell cycle or checkpoint activation. Time-lapse microscopy indicated that MYT1 did, however, have a rate-determining role during checkpoint recovery. Depletion of MYT1 induced precocious mitotic entry when the checkpoint was abrogated with inhibitors of either CHK1 or WEE1, indicating that MYT1 contributes to checkpoint recovery independently of WEE1. The acceleration of checkpoint recovery in MYT1-depleted cells was due to a lowering of threshold for CDK1 activation. The kinase activity of MYT1 was high during checkpoint activation and reduced during checkpoint recovery. Importantly, although depletion of MYT1 alone did not affect long-term cell growth, it potentiated with DNA damage to inhibit cell growth in clonogenic survival and tumor xenograft models. These results reveal the functions of MYT1 in checkpoint recovery and highlight the potential of MYT1 as a target for anti-cancer therapies.	[Poon, R. Y. C.] Hong Kong Univ Sci & Technol, Div Life Sci, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Ctr Canc Res, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Div Life Sci, Kowloon, Hong Kong, Peoples R China.	rycpoon@ust.hk		Poon, Randy/0000-0001-5571-6231	 [AOE-MG/M-08/06];  [HKU7/CRG/09]	; 	We thank Helen Piwnica-Worms and Katsumi Yamashita for generous gifts of reagents. This work was supported in part by grants AOE-MG/M-08/06 and HKU7/CRG/09 to RYCP.	Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Chan YW, 2009, ONCOGENE, V28, P170, DOI 10.1038/onc.2008.369; Chan YW, 2008, J BIOL CHEM, V283, P15716, DOI 10.1074/jbc.M800629200; Chan YW, 2008, CELL CYCLE, V7, P1449, DOI 10.4161/cc.7.10.5880; Chen Y, 2008, FRONT BIOSCI-LANDMRK, V13, P5016; Chen Y, 2012, MOL CANCER RES, V10, P626, DOI 10.1158/1541-7786.MCR-11-0491; Chow JPH, 2011, MOL CELL BIOL, V31, P1478, DOI 10.1128/MCB.00891-10; Chow JPH, 2003, J BIOL CHEM, V278, P40815, DOI 10.1074/jbc.M306683200; Fung TK, 2005, SEMIN CELL DEV BIOL, V16, P335, DOI 10.1016/j.semcdb.2005.02.014; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Karisson-Rosenthal C, 2006, TRENDS CELL BIOL, V16, P285, DOI 10.1016/j.tcb.2006.04.002; Katayama K, 2005, MOL CELL BIOL, V25, P5725, DOI 10.1128/MCB.25.13.5725-5737.2005; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Ma HT, 2009, MOL CELL BIOL, V29, P6500, DOI 10.1128/MCB.00669-09; Mizuarai S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-34; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nakajima H, 2008, J CELL BIOL, V181, P89, DOI 10.1083/jcb.200708176; Nakajo N, 2000, GENE DEV, V14, P328; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741; On KF, 2011, MOL CANCER THER, V10, P784, DOI 10.1158/1535-7163.MCT-10-0809; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Ruiz EJ, 2008, MOL CELL, V32, P210, DOI 10.1016/j.molcel.2008.08.029; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Stumpff J, 2004, CURR BIOL, V14, P2143, DOI 10.1016/j.cub.2004.11.050; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; van Vugt MATM, 2005, ONCOGENE, V24, P2844, DOI 10.1038/sj.onc.1208617; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Wang YL, 2004, CANCER BIOL THER, V3, P305, DOI 10.4161/cbt.3.3.697; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Wells NJ, 1999, J CELL SCI, V112, P3361; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158; Yam CH, 2001, P NATL ACAD SCI USA, V98, P497, DOI 10.1073/pnas.240461397	36	41	41	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4778	4788		10.1038/onc.2012.504	http://dx.doi.org/10.1038/onc.2012.504			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23146904				2022-12-17	WOS:000325274700006
J	Hartman, Z; Zhao, H; Agazie, YM				Hartman, Z.; Zhao, H.; Agazie, Y. M.			HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling	ONCOGENE			English	Article						HER2; EGFR; autophosphorylation; signaling; tumorigenesis	EPIDERMAL-GROWTH-FACTOR; CLATHRIN-COATED PITS; ERBB-RELATED GENE; FACTOR RECEPTOR; DOWN-REGULATION; CRYSTAL-STRUCTURE; BREAST-CANCER; MOLECULAR-MECHANISM; KINASE DOMAIN; ACTIVATION	One of the causes of breast cancer is overexpression of the human epidermal growth factor receptor 2 (HER2). Enhanced receptor autophosphorylation and resistance to activation-induced downregulation have been suggested as mechanisms for HER2-induced sustained signaling and cell transformation. However, the molecular mechanisms underlying these possibilities remain incompletely understood. In the current report, we present evidence that show that HER2 overexpression does not lead to receptor hyper-autophosphorylation, but alters patterns in a manner that favors receptor stability and sustained signaling. Specifically, HER2 overexpression blocks epidermal growth factor receptor (EGFR) tyrosine phosphorylation on Y1045 and Y1068, the known docking sites of c-Cbl and Grb2, respectively, whereas promoting phosphorylation on Y1173, the known docking site of the Gab adaptor proteins and phospholipase C gamma. Under these conditions, HER2 itself is phosphorylated on Y1221/1222, with no known role, and on Y1248 that corresponds to Y1173 of EGFR. Interestingly, suppressed EGFR autophosphorylation on the Grb2 and c-Cbl-binding sites correlated with receptor stability and sustained signaling, suggesting that HER2 accomplishes these tasks by altering autophosphorylation patterns. In conformity with these findings, mutation of the Grb2-binding site on EGFR (Y1068F-EGFR) conferred resistance to ligand-induced degradation, which in turn induced sustained signaling, and increased cell proliferation and transformation. These findings suggest that the Grb2-binding site on EGFR is redundant for signaling, but critical for receptor regulation. On the other hand, mutation of the putative Grb2-binding site in HER2 (Y1139) did not affect stability, signaling or transformation, suggesting that Y1139 in HER2 may not serve as a Grb2-binding site. In agreement with the role of EGFR in HER2 signaling, inhibition of EGFR expression reduced HER2-induced anchorage-independent growth and tumorigenesis. These results imply that complementing HER2-targeted therapies with anti-EGFR drugs may be beneficial in HER2-positive breast cancer.	[Hartman, Z.; Zhao, H.; Agazie, Y. M.] W Virginia Univ, Sch Med, Dept Biochem, Morgantown, WV 26506 USA; [Agazie, Y. M.] W Virginia Univ, Sch Med, Marry Babb Randolph Canc Ctr, Morgantown, WV 26506 USA	West Virginia University; West Virginia University	Agazie, YM (corresponding author), W Virginia Univ, Sch Med, Dept Biochem, 1 Med Ctr Dr, Morgantown, WV 26506 USA.	yagazie@hsc.wvu.edu			National Cancer Institute (NCI), a component of the National Institute of Health (NIH) [CA124940]; NATIONAL CANCER INSTITUTE [R01CA124940] Funding Source: NIH RePORTER	National Cancer Institute (NCI), a component of the National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a grant number CA124940 from the National Cancer Institute (NCI), a component of the National Institute of Health (NIH) to YMA.	Aertgeerts K, 2011, J BIOL CHEM, V286, P18756, DOI 10.1074/jbc.M110.206193; Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Agazie YM, 2003, ONCOGENE, V22, P6909, DOI 10.1038/sj.onc.1206798; Badache A, 2006, J MAMMARY GLAND BIOL, V11, P13, DOI 10.1007/s10911-006-9009-1; Baldys A, 2009, BIOCHEMISTRY-US, V48, P1462, DOI 10.1021/bi801771g; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; Carlsson J, 2004, BRIT J CANCER, V90, P2344, DOI 10.1038/sj.bjc.6601881; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DIONNE CA, 1991, ANN NY ACAD SCI, V638, P161, DOI 10.1111/j.1749-6632.1991.tb49026.x; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Ekman S, 1999, ONCOGENE, V18, P2481, DOI 10.1038/sj.onc.1202606; Fan YX, 2008, J BIOL CHEM, V283, P1588, DOI 10.1074/jbc.M708116200; FENG GS, 1994, ONCOGENE, V9, P1545; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Fragale A, 2004, HUM MUTAT, V23, P267, DOI 10.1002/humu.20005; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; HELIN K, 1991, J BIOL CHEM, V266, P8363; Hendriks BS, 2003, BIOPHYS J, V85, P2732, DOI 10.1016/S0006-3495(03)74696-7; Huang GC, 1999, J CELL BIOCHEM, V74, P23; Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Meng SS, 2005, BIOCHEM J, V391, P143, DOI 10.1042/BJ20050229; Monsey J, 2010, J BIOL CHEM, V285, P7035, DOI 10.1074/jbc.M109.096032; Morandell S, 2008, PROTEOMICS, V8, P4383, DOI 10.1002/pmic.200800204; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Ono M, 2006, CLIN CANCER RES, V12, P7242, DOI 10.1158/1078-0432.CCR-06-0646; Pamonsinlapatham P, 2009, BIOCHIMIE, V91, P320, DOI 10.1016/j.biochi.2008.10.010; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Rana P, BREAST CANC AUCKL, V6, P67; Ravichandran KS, 1995, ANN NY ACAD SCI, V766, P202, DOI 10.1111/j.1749-6632.1995.tb26663.x; Russo C, 2002, ANN NY ACAD SCI, V973, P323, DOI 10.1111/j.1749-6632.2002.tb04660.x; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHLESSINGER J, 1992, COLD SPRING HARB SYM, V57, P67, DOI 10.1101/SQB.1992.057.01.009; Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012; SORKIN A, 1993, ONCOGENE, V8, P3021; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Sperka T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027511; Sun J, 2007, EXP CELL RES, V313, P3935, DOI 10.1016/j.yexcr.2007.08.021; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yamanashi Y, J BIOCH, V151, P353; Yuan YL, 2008, J LARYNGOL OTOL, V122, P952, DOI 10.1017/S0022215107000606; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhou XD, 2012, CELL SIGNAL, V24, P140, DOI 10.1016/j.cellsig.2011.08.015; Zhou XD, 2009, J BIOL CHEM, V284, P12226, DOI 10.1074/jbc.M900020200	55	41	42	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2013	32	35					4169	4180		10.1038/onc.2012.418	http://dx.doi.org/10.1038/onc.2012.418			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23027125	Green Accepted			2022-12-17	WOS:000323748500012
J	Benayoun, BA; Anttonen, M; L'Hote, D; Bailly-Bechet, M; Andersson, N; Heikinheimo, M; Veitia, RA				Benayoun, B. A.; Anttonen, M.; L'Hote, D.; Bailly-Bechet, M.; Andersson, N.; Heikinheimo, M.; Veitia, R. A.			Adult ovarian granulosa cell tumor transcriptomics: prevalence of FOXL2 target genes misregulation gives insights into the pathogenic mechanism of the p.Cys134Trp somatic mutation	ONCOGENE			English	Article						FOXL2; ovarian granulosa cell tumor; ovary; transcriptome	EXPRESSION; VISUALIZATION; HALLMARKS; STRESS	Ovarian granulosa cell tumors (OGCT) are the most frequent kind of sex cord-stromal tumors, and represent similar to 2-5% of all ovarian malignancies. OGCTs exist as two entities, juvenile and adult types, with specific clinical and pathological characteristics. The molecular pathogenesis of these tumors has just begun to be unraveled. Indeed, recent studies have indicated that mutation and/or misregulation of the key ovarian transcription factor FOXL2 has a role in OGCT formation, although the mechanisms remain unclear. To better understand the molecular characteristics of OGCT, we studied the transcriptomic profiles of ten human adult-type OGCT samples, as well as ethnically matched granulosa cell (GC) controls. We find that the OGCT samples analyzed herein exhibit several hallmarks of cancer, including increased expression of genes linked to cell proliferation, but decreased expression of those conferring sensitivity to cell death. Moreover, genes differentially expressed in OGCTs are significantly enriched for known FOXL2 target genes, consistently with the prevalence of FOXL2 somatic mutation in these tumors. Expression of these targets is altered in a way expected to promote malignant transformation, for instance, through induction of genes associated with faster cell cycling and downregulation of genes associated with cell death. Over time, such defects may be responsible at least partly for the malignant transformation of healthy GCs into OGCT. These insights into the molecular pathogenesis of OGCTs may open the way to new efforts in the development of more targeted therapeutic strategies for OGCT patients.	[Benayoun, B. A.; L'Hote, D.; Veitia, R. A.] Inst Jacques Monod, F-75251 Paris, France; [Benayoun, B. A.; L'Hote, D.; Veitia, R. A.] Univ Paris 07, Paris 13, France; [Anttonen, M.] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00290 Helsinki, Finland; [Anttonen, M.; Andersson, N.; Heikinheimo, M.] Univ Helsinki, Childrens Hosp, Helsinki, Finland; [Anttonen, M.; Andersson, N.; Heikinheimo, M.] Univ Helsinki, Cent Hosp, Helsinki, Finland; [Bailly-Bechet, M.] Univ Lyon, UMR 5558, CNRS, Laborat Biometrie & Biol Evolut, Villeurbanne, France	UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); VetAgro Sup	Veitia, RA (corresponding author), Univ Paris 07, Batiment Buffon,15 Rue Helene Brion, Paris 13, France.	veitia.reiner@ijm.univ-paris-diderot.fr	Bailly-Bechet, Marc/B-6292-2012; Andersson, Noora/AAW-2030-2020; Benayoun, Bérénice A./K-7048-2012; LHOTE, David/AAD-5390-2020; L'Hote, David/L-2653-2017	Andersson, Noora/0000-0003-4708-7273; Benayoun, Bérénice A./0000-0002-7401-4777; L'Hote, David/0000-0001-5658-5018	AMN/Universite Paris Diderot-Paris 7; The Helsinki University Central Hospital Research Funds; Academy of Finland; Sigrid Juselius Foundation; Helsinki University Central Hospital; Universite Paris Diderot-Paris 7; CNRS; Universite Lyon 1; Institut Universitaire de France; Fondation pour la Recherche Medicale; Ligue Nationale Contre le Cancer (Comite de Paris); Groupement d'Entreprises Francaises dans la Lutte contre le Cancer; Universite Paris VII; Fondation pour la Recherche Medicale (FRM)	AMN/Universite Paris Diderot-Paris 7; The Helsinki University Central Hospital Research Funds; Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Helsinki University Central Hospital; Universite Paris Diderot-Paris 7; CNRS(Centre National de la Recherche Scientifique (CNRS)); Universite Lyon 1; Institut Universitaire de France; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Ligue Nationale Contre le Cancer (Comite de Paris); Groupement d'Entreprises Francaises dans la Lutte contre le Cancer; Universite Paris VII; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale)	We thank Dr Ralf Butzow and Dr Unkila-Kallio for help and collection of the human OGCT samples. We thank Dr Denis Mestivier for his advice on clustering analysis of the OGCT microarray samples. BAB was funded by AMN/Universite Paris Diderot-Paris 7 fellowships. MA was funded by a grant from The Helsinki University Central Hospital Research Funds. NA and MH were funded by Academy of Finland, Sigrid Juselius Foundation and Helsinki University Central Hospital. DL was funded by Universite Paris Diderot-Paris 7. MBB was funded by CNRS and Universite Lyon 1. RAV was funded by Institut Universitaire de France, Fondation pour la Recherche Medicale, Ligue Nationale Contre le Cancer (Comite de Paris), Groupement d'Entreprises Francaises dans la Lutte contre le Cancer, CNRS and Universite Paris VII. This work was supported by grants from Fondation pour la Recherche Medicale (FRM), from The Helsinki University Central Hospital Research Funds and from Academy of Finland, Sigrid Juselius Foundation and Helsinki University Central Hospital.	Batista F, 2007, P NATL ACAD SCI USA, V104, P3330, DOI 10.1073/pnas.0611326104; Benayoun BA, 2011, HUM MOL GENET, V20, P1673, DOI 10.1093/hmg/ddr042; Benayoun BA, 2010, BBA-REV CANCER, V1805, P1, DOI 10.1016/j.bbcan.2009.09.002; Benayoun BA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008789; Benayoun BA, 2009, HUM MOL GENET, V18, P632, DOI 10.1093/hmg/ddn389; Blount AL, 2009, J BIOL CHEM, V284, P7631, DOI 10.1074/jbc.M806676200; Chen C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017238; Cocquet J, 2002, J MED GENET, V39, P916, DOI 10.1136/jmg.39.12.916; Crisponi L, 2001, NAT GENET, V27, P159, DOI 10.1038/84781; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; East N, 2005, J OBSTET GYNAECOL CA, V27, P363, DOI 10.1016/S1701-2163(16)30464-9; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Fleming NI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014389; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jamieson S, 2010, MODERN PATHOL, V23, P1477, DOI 10.1038/modpathol.2010.145; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kalfa N, 2007, FERTIL STERIL, V87, P896, DOI 10.1016/j.fertnstert.2006.11.016; Kalfa N, 2009, GENOME MED, V1, DOI 10.1186/gm81; Kim HP, 1999, J BIOL CHEM, V274, P37455, DOI 10.1074/jbc.274.52.37455; Kim JH, 2011, ONCOGENE, V30, P1653, DOI 10.1038/onc.2010.541; Kim MS, 2010, J PATHOL, V221, P147, DOI 10.1002/path.2688; Kyronlahti A, 2010, ENDOCR-RELAT CANCER, V17, P709, DOI 10.1677/ERC-10-0041; Lee K, 2005, BIOCHEM BIOPH RES CO, V336, P876, DOI 10.1016/j.bbrc.2005.08.184; Moumne L, 2008, HUM MOL GENET, V17, P1010, DOI 10.1093/hmg/ddm373; Nagaraja AK, 2010, ENDOCRINOLOGY, V151, P4994, DOI 10.1210/en.2010-0428; Pangas SA, 2008, MOL CELL BIOL, V28, P248, DOI 10.1128/MCB.01404-07; Pectasides D, 2008, CANCER TREAT REV, V34, P1, DOI 10.1016/j.ctrv.2007.08.007; Rishi AK, 1999, NUCLEIC ACIDS RES, V27, P3111, DOI 10.1093/nar/27.15.3111; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Sambrook J, 2001, MOL CLONING LAB MANU; Schrader KA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007988; Schumer ST, 2003, J CLIN ONCOL, V21, P1180, DOI 10.1200/JCO.2003.10.019; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uhlenhaut NH, 2009, CELL, V139, P1130, DOI 10.1016/j.cell.2009.11.021; Zhang H, 2000, MOL HUM REPROD, V6, P146, DOI 10.1093/molehr/6.2.146	40	41	42	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2739	2746		10.1038/onc.2012.298	http://dx.doi.org/10.1038/onc.2012.298			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22797072				2022-12-17	WOS:000319808000005
J	Couts, KL; Anderson, EM; Gross, MM; Sullivan, K; Ahn, NG				Couts, K. L.; Anderson, E. M.; Gross, M. M.; Sullivan, K.; Ahn, N. G.			Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions	ONCOGENE			English	Article						B-Raf; melanoma; microRNAs; microarray; U0126	BRAF MUTATIONS; EXPRESSION; CLUSTER; CANCER; GENES; LINES; PROLIFERATION; SUPPRESSION; PROGRESSION; SIGNATURES	Over two-thirds of melanomas have activating mutations in B-Raf, leading to constitutive activation of the B-Raf/MKK/ERK signaling pathway. The most prevalent mutation, B-RafV600E, promotes cancer cell behavior through mechanisms that are still incompletely defined. Here, we used a sensitive microarray profiling platform to compare microRNA (miRNA) expression levels between primary melanocytes and B-RafV600E-positive melanoma cell lines, and between melanoma cells treated in the presence and absence of an MKK1/2 inhibitor. We identified a network of >20 miRNAs deregulated by B-Raf/MKK/ERK in melanoma cells, the majority of which modulate the expression of key cancer regulatory genes and functions. Importantly, miRNAs within the network converge on protein regulation and cancer phenotypes, suggesting that these miRNAs might function combinatorially. We show that miRNAs augment effects on protein repression and cell invasion when co-expressed, and gene-specific latency and interference effects between miRNAs were also observed. Thus, B-Raf/MKK/ERK controls key aspects of cancer cell behavior and gene expression by modulating a network of miRNAs with cross-regulatory functions. The findings highlight the potential for complex interactions between coordinately regulated miRNAs within a network. Oncogene (2013) 32, 1959-1970; doi:10.1038/onc.2012.209; published online 2 July 2012	[Couts, K. L.; Ahn, N. G.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; [Anderson, E. M.; Gross, M. M.; Sullivan, K.] Dharmacon Inc, Lafayette, CO USA; [Ahn, N. G.] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Ahn, NG (corresponding author), Univ Colorado, Dept Chem & Biochem, HHMI, Campus Box 215, Boulder, CO 80309 USA.	natalie.ahn@colorado.edu			NIH [R01-CA118972, T32-GM008759]; NATIONAL CANCER INSTITUTE [R01CA118972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008759] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are indebted to Meenhard Herlyn for melanoma cell lines used throughout these studies, and to Judith Leopold-Sebolt for a generous gift of CI-1040. We thank SwitchGear Genomics for providing 3'UTR constructs. Finally, we thank Thermo Fisher Scientific investigators Amanda Birmingham, Annaleen Vermeulen and Barbara Robertson for many helpful discussions. This study was financially supported by NIH R01-CA118972 (NGA) and NIH T32-GM008759 (KLC).	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Argast GM, 2009, ONCOGENE, V28, P2697, DOI 10.1038/onc.2009.133; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Braun J, 2010, ONCOGENE, V29, P4237, DOI 10.1038/onc.2010.169; Caramuta S, 2010, J INVEST DERMATOL, V130, P2062, DOI 10.1038/jid.2010.63; Chan E, 2011, CELL CYCLE, V10, P1845, DOI 10.4161/cc.10.11.15777; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen JM, 2010, AM J PATHOL, V176, P2520, DOI 10.2353/ajpath.2010.091061; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Edlundh-Rose E, 2006, MELANOMA RES, V16, P471, DOI 10.1097/01.cmr.0000232300.22032.86; Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232; Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56; Hingorani SR, 2003, CANCER RES, V63, P5198; Hsu MY, 1999, HUMAN CELL CULTURE, V1, P259; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Igoucheva O, 2009, BIOCHEM BIOPH RES CO, V379, P790, DOI 10.1016/j.bbrc.2008.12.152; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Koo HM, 2002, P NATL ACAD SCI USA, V99, P3052, DOI 10.1073/pnas.052707699; Landais S, 2007, CANCER RES, V67, P5699, DOI 10.1158/0008-5472.CAN-06-4478; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Mills CN, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-104; Mueller DW, 2009, J INVEST DERMATOL, V129, P1740, DOI 10.1038/jid.2008.452; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; Papadopoulos GL, 2009, NUCLEIC ACIDS RES, V37, pD155, DOI 10.1093/nar/gkn809; Paroo Z, 2009, CELL, V139, P112, DOI 10.1016/j.cell.2009.06.044; Philippidou D, 2010, CANCER RES, V70, P4163, DOI 10.1158/0008-5472.CAN-09-4512; Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007; Saetrom P, 2007, NUCLEIC ACIDS RES, V35, P2333, DOI 10.1093/nar/gkm133; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schulte JH, 2008, INT J CANCER, V122, P699, DOI 10.1002/ijc.23153; Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084; Xiong JH, 2010, FEBS J, V277, P1684, DOI 10.1111/j.1742-4658.2010.07594.x; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054	41	41	42	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1959	1970		10.1038/onc.2012.209	http://dx.doi.org/10.1038/onc.2012.209			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22751131	Green Published, hybrid			2022-12-17	WOS:000317599900010
J	Shchors, K; Nozawa, H; Xu, J; Rostker, F; Swigart-Brown, L; Evan, G; Hanahan, D				Shchors, K.; Nozawa, H.; Xu, J.; Rostker, F.; Swigart-Brown, L.; Evan, G.; Hanahan, D.			Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis	ONCOGENE			English	Article						tumor; metalloproteinase; invasion; cathepsin; Myc; interleukin-1 beta	MATRIX-METALLOPROTEINASE INHIBITORS; LYSOSOMAL CYSTEINE PROTEASES; CAPILLARY ENDOTHELIAL-CELLS; MARROW-DERIVED CELLS; CATHEPSIN-B; ANGIOGENIC SWITCH; PHASE-III; MULTISTAGE TUMORIGENESIS; MALIGNANT PROGRESSION; EXTRACELLULAR-MATRIX	Despite their apparent success in pre-clinical trials, metalloproteinase (MMP) inhibitors proved to be inefficacious in clinical settings. In an effort to understand the underlying causes of this unanticipated outcome, we modeled the consequences of long-term MMP inhibition by removing one of the major players in tumorigenesis, MMP9, in two complimentary mouse models of pancreatic neuroendocrine carcinogenesis: Myc;BclXI and RIP1-Tag2. By employing gel zymography and a fluoregenic solution assay, we first established that MMP9 is expressed and activated in Myc;BclXI tumors in an interleukin-1 beta-dependent manner. The genetic deletion of MMP9 in Myc;BclXI mice impairs tumor angiogenesis and growth analogous to its absence in the RIP1-Tag2 model. Notably, tumors that developed in the context of MMP9-deficient backgrounds in both models were markedly more invasive than their typical wild-type counterparts, and expressed elevated levels of pro-invasive cysteine cathepsin B. The increased invasion of MMP9-deficient tumors was associated with a switch in the spectrum of inflammatory cells at the tumor margins, involving homing of previously undetected, cathepsin-B expressing CD11b;Gr1-positive cells to the invasive fronts. Thus, plasticity in the tumor inflammatory compartment is partially responsible for changes in the expression pattern of tumor-associated proteases, and may contribute to the compensatory effects observed on MMP inhibition, hence accounting for the heightened tumor progression described in late stage clinical trials. Oncogene (2013) 32, 502-513; doi:10.1038/onc.2012.60; published online 5 March 2012	[Shchors, K.; Hanahan, D.] Swiss Fed Inst Technol Lausanne EPFL, Sch Life Sci, Swiss Inst Expt Canc Res, CH-1015 Lausanne, Switzerland; [Shchors, K.; Xu, J.; Rostker, F.; Swigart-Brown, L.; Evan, G.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Nozawa, H.; Hanahan, D.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Shchors, K (corresponding author), Swiss Fed Inst Technol Lausanne EPFL, Sch Life Sci, Swiss Inst Expt Canc Res, SV2818,Stn 19, CH-1015 Lausanne, Switzerland.	ksenya.shchors@epfl.ch			NCI; EPLF [F32-CA106039]; Cancer Research UK [12077] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [F32CA106039] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EPLF; Cancer Research UK(Cancer Research UK); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the NCI and by core support from EPLF to DH. KS is a recipient of F32-CA106039. We are extremely grateful to Dr Zena Werb (UCSF) providing the MMP9-deficient animal model. Special thanks to Drs Johanna Joyce and Vasilena Gocheva (MSKCC) for providing cathepsin activity probe, antibodies and experimental protocols. We are grateful to Dr Elizabeth Allen and Dr Masahiro Inoue for providing Sutent-treated RT2 samples and RT2;RipCre;VEGFA FL/FL samples, respectively. We are grateful to Drs Lisa Coussens, Luisa Iruela-Arrispe (UCLA), Enrico Giraudo (U of Torino) for helpful discussions and advice. We are grateful to Mr Jeffrey A Kasten (EPFL) for critical reading of the paper. Authors also would like to acknowledge the Bioimaging and Optics platform (PT-BIOP) and the Histology Core Facility at EPFL for their services.	Ahn GO, 2008, CANCER CELL, V13, P193, DOI 10.1016/j.ccr.2007.11.032; Apte RN, 2006, EUR J CANCER, V42, P751, DOI 10.1016/j.ejca.2006.01.010; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Batist G, 2002, ANN ONCOL, V13, P1259, DOI 10.1093/annonc/mdf195; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bissett D, 2005, J CLIN ONCOL, V23, P842, DOI 10.1200/JCO.2005.03.170; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CAMPBELL EJ, 1991, J IMMUNOL, V146, P1286; Chesler L, 2007, CANCER RES, V67, P9435, DOI 10.1158/0008-5472.CAN-07-1316; Chintala SK, 1999, INT J DEV NEUROSCI, V17, P495, DOI 10.1016/S0736-5748(99)00010-6; Chun MGH, 2010, P NATL ACAD SCI USA, V107, P17268, DOI 10.1073/pnas.1012705107; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Creemers LB, 1998, MATRIX BIOL, V16, P575, DOI 10.1016/S0945-053X(98)90068-3; Czyzewska J, 2008, FOLIA HISTOCHEM CYTO, V46, P57, DOI 10.2478/v10042-008-0007-6; DALETFUMERON V, 1993, FEBS LETT, V332, P251, DOI 10.1016/0014-5793(93)80643-9; Deryugina EI, 2010, BBA-MOL CELL RES, V1803, P103, DOI 10.1016/j.bbamcr.2009.09.017; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Elaraj DM, 2006, CLIN CANCER RES, V12, P1088, DOI 10.1158/1078-0432.CCR-05-1603; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Geraghty P, 2007, J IMMUNOL, V178, P5871, DOI 10.4049/jimmunol.178.9.5871; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gocheva V, 2007, CELL CYCLE, V6, P60, DOI 10.4161/cc.6.1.3669; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Grimm J, 2005, P NATL ACAD SCI USA, V102, P14404, DOI 10.1073/pnas.0503920102; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HERRON GS, 1986, J BIOL CHEM, V261, P2810; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Jodele S, 2005, CANCER RES, V65, P3200, DOI 10.1158/0008-5472.CAN-04-3770; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kamat AA, 2006, CLIN CANCER RES, V12, P1707, DOI 10.1158/1078-0432.CCR-05-2338; Kirschke H, 1997, J CANCER RES CLIN, V123, P402, DOI 10.1007/s004320050078; Kruger A, 2001, CANCER RES, V61, P1272; LAH TT, 1989, CLIN EXP METASTAS, V7, P461, DOI 10.1007/BF01753666; Lawlor ER, 2006, CANCER RES, V66, P4591, DOI 10.1158/0008-5472.CAN-05-3826; Lee HT, 2004, J BIOL CHEM, V279, P32325, DOI 10.1074/jbc.M405208200; Levicar N, 2003, ACTA NEUROCHIR, V145, P825, DOI 10.1007/s00701-003-0097-z; Levin VA, 2006, J NEURO-ONCOL, V78, P295, DOI 10.1007/s11060-005-9098-5; Littlepage LE, 2010, CANCER RES, V70, P2224, DOI 10.1158/0008-5472.CAN-09-3515; Lockwood CJ, 2006, AM J PATHOL, V168, P445, DOI 10.2353/ajpath.2006.050082; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; McCawley LJ, 2008, AM J PATHOL, V173, P1528, DOI 10.2353/ajpath.2008.080132; MELCHIORI A, 1992, CANCER RES, V52, P2353; Moore MJ, 2003, J CLIN ONCOL, V21, P3296, DOI 10.1200/JCO.2003.02.098; Mountain DJH, 2007, AM J PHYSIOL-CELL PH, V292, pC867, DOI 10.1152/ajpcell.00161.2006; Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pahler J, 2008, NEOPLASIA, V10, P329, DOI 10.1593/neo.07871; Pavlaki M, 2003, CANCER METAST REV, V22, P177, DOI 10.1023/A:1023047431869; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061; Raymond L, 2006, J CELL PHYSIOL, V207, P683, DOI 10.1002/jcp.20608; Sekhon HS, 2008, LUNG CANCER, V60, P347, DOI 10.1016/j.lungcan.2007.10.028; Shchors K, 2006, GENE DEV, V20, P2527, DOI 10.1101/gad.1455706; Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323; Sillanpaa S, 2007, GYNECOL ONCOL, V104, P296, DOI 10.1016/j.ygyno.2006.09.004; Sounni NE, 2010, DIS MODEL MECH, V3, P317, DOI 10.1242/dmm.003863; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; Tazawa H, 2003, AM J PATHOL, V163, P2221, DOI 10.1016/S0002-9440(10)63580-8; Turk V, 2002, ADV ENZYME REGUL, V42, P285, DOI 10.1016/S0065-2571(01)00034-6; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; van Kempen LCL, 2006, EUR J CANCER, V42, P728, DOI 10.1016/j.ejca.2006.01.004; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	71	41	42	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2013	32	4					502	513		10.1038/onc.2012.60	http://dx.doi.org/10.1038/onc.2012.60			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22391572	Green Published			2022-12-17	WOS:000315551300011
J	Brazzatti, JA; Klingler-Hoffmann, M; Haylock-Jacobs, S; Harata-Lee, Y; Niu, M; Higgins, MD; Kochetkova, M; Hoffmann, P; McColl, SR				Brazzatti, J. A.; Klingler-Hoffmann, M.; Haylock-Jacobs, S.; Harata-Lee, Y.; Niu, M.; Higgins, M. D.; Kochetkova, M.; Hoffmann, P.; McColl, S. R.			Differential roles for the p101 and p84 regulatory subunits of PI3K gamma in tumor growth and metastasis	ONCOGENE			English	Article						phosphoinositide 3-kinase gamma; p101; p84/p87(PIKAP); breast cancer; apoptosis	G-BETA-GAMMA; I PHOSPHOINOSITIDE 3-KINASE; BREAST-CANCER METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; ONCOGENIC TRANSFORMATION; GENETIC ALTERATIONS; EPITHELIAL-CELLS; PI 3-KINASE; CLASS IPI3K	Phosphoinositide 3-kinase gamma (PI3K gamma) consists of a catalytic subunit p110 gamma, which forms mutually exclusive dimers with one of the regulatory subunits called p101 and p84/p87(PIKAP). Recently, PI3K gamma emerged as being a potential oncogene because overexpression of the catalytic subunit p110 gamma or the regulatory subunit p101 leads to oncogenic cellular transformation and malignancy. However, the contribution of the individual subunits to tumor growth and metastasis and the mechanisms involved are not understood. We therefore individually knocked down the PI3K gamma subunits (p84, p101 and p110 gamma) in MDA-MB-231 cells, which reduced in vitro migration of the cell lines. Knockdown of p110 gamma or p101 inhibited apoptosis, Akt phosphorylation and lung colonization in SCID mice. Similarly, the knockdown of p110 gamma and p101 in murine epithelial carcinoma 4T1.2 cells inhibited primary tumor growth and spontaneous metastasis, as well as lung colonization. In contrast, knockdown of p84 in MDA-MB-231 cells enhanced Akt phosphorylation and lung colonization. These findings are the first to implicate differential functions of the two PI3K gamma regulatory subunits in the process of oncogenesis, and indicate that loss of p101 is sufficient to reduce in vivo tumor growth and metastasis to the same extent as that of p110 gamma. Oncogene (2012) 31, 2350-2361; doi:10.1038/onc.2011.414; published online 26 September 2011	[Brazzatti, J. A.; Klingler-Hoffmann, M.; Haylock-Jacobs, S.; Harata-Lee, Y.; Niu, M.; Higgins, M. D.; Kochetkova, M.; Hoffmann, P.; McColl, S. R.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia	University of Adelaide	McColl, SR (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia.	shaun.mccoll@adelaide.edu.au	Hoffmann, Peter/U-5996-2017; Kochetkova, Marina/ABE-9538-2021; Klingler-Hoffmann, Manuela/D-1934-2018	Hoffmann, Peter/0000-0001-8493-2208; Brazzatti, Julie/0000-0002-4015-9679; Klingler-Hoffmann, Manuela/0000-0003-2165-7813; Kochetkova, Marina/0000-0002-0599-7378	National Health and Medical Research Council of Australia	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	We thank Mark Bunting for assistance with animal experiments, John Brazzatti for assistance with statistical analysis and Francisco Olmo for assistance with apoptosis experiments. The work was supported by grants from the National Health and Medical Research Council of Australia.	Akekawatchai C, 2005, J BIOL CHEM, V280, P39701, DOI 10.1074/jbc.M509829200; Al-Aoukaty A, 1999, J IMMUNOL, V162, P3249; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; Barber DF, 2005, NAT MED, V11, P933, DOI 10.1038/nm1291; Benistant C, 2000, ONCOGENE, V19, P5083, DOI 10.1038/sj.onc.1203871; Bohnacker T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000259; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Bretland AJ, 2001, CELL PROLIFERAT, V34, P199, DOI 10.1046/j.1365-2184.2001.00198.x; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Ching TT, 1999, J BIOL CHEM, V274, P8611, DOI 10.1074/jbc.274.13.8611; Costa C, 2007, P NATL ACAD SCI USA, V104, P14354, DOI 10.1073/pnas.0703175104; David M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009741; Deane JA, 2004, ANNU REV IMMUNOL, V22, P563, DOI 10.1146/annurev.immunol.22.012703.104721; Denley A, 2008, ONCOGENE, V27, P2561, DOI 10.1038/sj.onc.1210918; Denley A, 2009, MOL CANCER RES, V7, P1132, DOI 10.1158/1541-7786.MCR-09-0068; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Eckhardt BL, 2005, MOL CANCER RES, V3, P1; Edling CE, 2010, CLIN CANCER RES, V16, P4928, DOI 10.1158/1078-0432.CCR-10-1210; El Haibi CP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-85; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Goldberg GS, 2001, CANCER RES, V61, P1334; Hawkins PT, 2006, BIOCHEM SOC T, V34, P647, DOI 10.1042/BST0340647; Holland JD, 2006, CANCER RES, V66, P4117, DOI 10.1158/0008-5472.CAN-05-1631; Johnson C, 2007, ONCOGENE, V26, P7049, DOI 10.1038/sj.onc.1210504; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Kim JH, 2011, J CELL PHYSIOL, V226, P2881, DOI 10.1002/jcp.22631; Knobbe CB, 2003, BRAIN PATHOL, V13, P507; Kochetkova M, 2009, CELL DEATH DIFFER, V16, P664, DOI 10.1038/cdd.2008.190; Krugmann S, 1999, J BIOL CHEM, V274, P17152, DOI 10.1074/jbc.274.24.17152; Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Metjian A, 1999, J BIOL CHEM, V274, P27943, DOI 10.1074/jbc.274.39.27943; Mizoguchi M, 2004, BRAIN PATHOL, V14, P372, DOI 10.1111/j.1750-3639.2004.tb00080.x; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Orme MH, 2006, NAT CELL BIOL, V8, P1298, DOI 10.1038/ncb1493; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; PONS S, 1995, MOL CELL BIOL, V15, P4453; Procko E, 2005, BIOESSAYS, V27, P153, DOI 10.1002/bies.20157; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Rodrigues DH, 2010, J NEUROIMMUNOL, V222, P90, DOI 10.1016/j.jneuroim.2010.02.016; Savagner P, 2010, ANN ONCOL, V21, P89, DOI 10.1093/annonc/mdq292; Shi M, 2007, CANCER LETT, V258, P268, DOI 10.1016/j.canlet.2007.09.003; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Sotsios Y, 1999, J IMMUNOL, V163, P5954; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Suire S, 2005, CURR BIOL, V15, P566, DOI 10.1016/j.cub.2005.02.020; Suire S, 2006, NAT CELL BIOL, V8, P1303, DOI 10.1038/ncb1494; Tang MKS, 2010, NEOPLASIA, V12, P128, DOI 10.1593/neo.91438; Tao K, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-228; Valentijn AJ, 2004, BIOCHEM SOC T, V32, P421, DOI 10.1042/BST0320421; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(00)00088-5; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Wang LH, 2004, MT SINAI J MED, V71, P361; Williams SA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-250; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Yamada M, 2004, BIOCHEM J, V378, P649, DOI 10.1042/BJ20031398; YU G, 1995, J BIOL CHEM, V270, P4792, DOI 10.1074/jbc.270.9.4792; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244; Zhao M, 2008, BREAST CANCER RES TR, V110, P211, DOI 10.1007/s10549-007-9712-7; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8	69	41	42	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	18					2350	2361		10.1038/onc.2011.414	http://dx.doi.org/10.1038/onc.2011.414			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21996737				2022-12-17	WOS:000303610800009
J	Chen, PH; Chang, H; Chang, JT; Lin, P				Chen, P-H; Chang, H.; Chang, J. T.; Lin, P.			Aryl hydrocarbon receptor in association with RelA modulates IL-6 expression in non-smoking lung cancer	ONCOGENE			English	Article						AhR; NF kappa B; IL-6; non-smokers; lung adeno carcinoma	NF-KAPPA-B; NEVER-SMOKERS; CONSTITUTIVE ACTIVATION; PROSTATE-CANCER; AH RECEPTOR; IN-VIVO; CELLS; OVEREXPRESSION; INTERLEUKIN-6; RISK	Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that is activated by cigarette smoke. Previously, we demonstrated that AhR is overexpressed in lung adenocarcinomas (ADs). In this study we observed that AhR expression is significantly correlated with nuclear RelA (a nuclear factor-kappa B (NF kappa B) subunit) and cytosolic interleukin-6 (IL-6) in 200 non-small cell lung cancer patients, especially among never smokers. Overexpression of AhR increased IL-6 expression in H1355 cells and immortalized human bronchial epithelial cells BEAS-2B. As NF kappa B inhibitor and knockdown RelA expression greatly reduced constitutive AhR-induced IL-6 expression, we hypothesized that AhR expression, in the absence of exogenous ligand, is able to modulate NF kappa B activity and subsequently upregulate IL-6 expression, thus promoting the development of lung AD. Specifically, AhR overexpression significantly increased NF kappa B activity, whereas interference with AhR expression significantly reduced NF kappa B activity and IL-6 expression in H1355 cells. We demonstrated that AhR associates with RelA in the cytosol and nucleus of human lung cells. Furthermore, AhR overexpression enhanced nuclear localization of AhR and RelA, and increased the association of AhR-RelA with the NF kappa B response element of the IL-6 promoter. However, p50 was not involved. Our results indicate that AhR, without exposure to a ligand, associates with RelA, which then positively modulates NF kappa B activity and then upregulates IL-6 expression in human lung cells. Thus we have identified a new mechanism for lung tumorigenesis in non-smokers. Oncogene (2012) 31, 2555-2565; doi:10.1038/onc.2011.438; published online 26 September 2011	[Chen, P-H; Chang, J. T.; Lin, P.] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Chen, P-H; Chang, J. T.; Lin, P.] Chung Shan Med Univ, Inst Med & Mol Toxicol, Taichung, Taiwan; [Chen, P-H; Lin, P.] Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, Zhunan 350, Miaoli County, Taiwan; [Chang, H.] China Med Univ Hosp, Dept Pathol, Taichung, Taiwan; [Chang, H.] China Med Univ, Sch Med, Taichung, Taiwan; [Chang, J. T.] Chung Shan Med Univ Hosp, Dept Med Oncol & Chest Med, Taichung, Taiwan	Chung Shan Medical University; Chung Shan Medical University; National Health Research Institutes - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Chung Shan Medical University; Chung Shan Medical University Hospital	Chang, JT (corresponding author), Chung Shan Med Univ, Inst Med, 110,Sect 1,Jianguo N Rd, Taichung, Taiwan.	jinghuat@csmu.edu.tw; pplin@nhri.org.tw	Lin, PinPin/A-2006-2019; Chang, Jinghua/AAV-5620-2021; Lin, Pinpin/B-2668-2010	Lin, PinPin/0000-0001-5459-907X; Lin, Pinpin/0000-0001-5459-907X	National Health Research Institutes [99A1-EOPP02-014]; National Science Council of Taiwan [NSC 97-2320-B-040-016, NSC 97-2314-B-400-010]	National Health Research Institutes(National Health Research Institutes, Japan); National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by grants from the National Health Research Institutes (99A1-EOPP02-014) and the National Science Council (NSC 97-2320-B-040-016 and NSC 97-2314-B-400-010) of Taiwan.	Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Ando M, 2003, INT J CANCER, V105, P249, DOI 10.1002/ijc.11043; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Barouki R, 2007, FEBS LETT, V581, P3608, DOI 10.1016/j.febslet.2007.03.046; Bryant A, 2007, CHEST, V132, P185, DOI 10.1378/chest.07-0442; Camacho IA, 2005, J IMMUNOL, V175, P90, DOI 10.4049/jimmunol.175.1.90; Carolan BJ, 2008, J IMMUNOL, V181, P5760, DOI 10.4049/jimmunol.181.8.5760; Chang JHT, 2007, CLIN CANCER RES, V13, P38, DOI 10.1158/1078-0432.CCR-06-1166; Chang LW, 2007, CARCINOGENESIS, V28, P1606, DOI 10.1093/carcin/bgm013; Chen CL, 2004, JAMA-J AM MED ASSOC, V292, P2984, DOI 10.1001/jama.292.24.2984; Chen JY, 2005, CARCINOGENESIS, V26, P1035, DOI 10.1093/carcin/bgi052; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen YC, 2004, CANCER-AM CANCER SOC, V101, P1428, DOI 10.1002/cncr.20538; Dalwadi H, 2005, CLIN CANCER RES, V11, P7674, DOI 10.1158/1078-0432.CCR-05-1205; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Devesa SS, 2005, INT J CANCER, V117, P294, DOI 10.1002/ijc.21183; Dhar A, 2002, MOL CELL BIOCHEM, V234, P185, DOI 10.1023/A:1015948505117; Dietrich C, 2010, CARCINOGENESIS, V31, P1319, DOI 10.1093/carcin/bgq028; Dijsselbloem N, 2004, BIOCHEM PHARMACOL, V68, P1171, DOI 10.1016/j.bcp.2004.05.036; DiNatale BC, 2010, J BIOL CHEM, V285, P24388, DOI 10.1074/jbc.M110.118570; Fukuda I, 2007, BIOCHEM BIOPH RES CO, V359, P822, DOI 10.1016/j.bbrc.2007.05.199; Gao Shu-geng, 2007, Zhonghua Yi Xue Za Zhi, V87, P1701; Hayashibara T, 2003, BIOCHEM BIOPH RES CO, V300, P128, DOI 10.1016/S0006-291X(02)02793-6; Ishida M, 2010, CARCINOGENESIS, V31, P287, DOI 10.1093/carcin/bgp222; Izawa H, 2008, BIOSCI BIOTECH BIOCH, V72, P1235, DOI 10.1271/bbb.70705; Jensen Brenda A, 2003, Environ Health, V2, P16, DOI 10.1186/1476-069X-2-16; Kasai A, 2006, CANCER RES, V66, P7143, DOI 10.1158/0008-5472.CAN-05-4541; Ke S, 2001, J BIOL CHEM, V276, P39638, DOI 10.1074/jbc.M106286200; Kim DW, 2000, ONCOGENE, V19, P5498, DOI 10.1038/sj.onc.1203945; Liaw YP, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-22; Lin PH, 2007, TOXICOL LETT, V172, P146, DOI 10.1016/j.toxlet.2007.06.003; Lin PP, 2003, TOXICOL PATHOL, V31, P22, DOI 10.1080/01926230309746; Lu F, 2008, CANCER PREV RES, V1, P135, DOI 10.1158/1940-6207.CAPR-08-0037; Matsumoto Y, 2007, ENVIRON SCI TECHNOL, V41, P3775, DOI 10.1021/es062793g; Mukai M, 2007, TOXICOL SCI, V95, P172, DOI 10.1093/toxsci/kfl126; Oesch-Bartlomowicz B, 2005, P NATL ACAD SCI USA, V102, P9218, DOI 10.1073/pnas.0503488102; Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683; Peng TL, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-27; Pollenz RS, 2002, CHEM-BIOL INTERACT, V141, P41, DOI 10.1016/S0009-2797(02)00065-0; Puga A, 2000, BIOCHEM PHARMACOL, V59, P997, DOI 10.1016/S0006-2952(99)00406-2; Scagliotti GV, 2009, CURR OPIN ONCOL, V21, P99, DOI 10.1097/CCO.0b013e328321049e; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Shimba S, 2002, J BIOCHEM, V132, P795, DOI 10.1093/oxfordjournals.jbchem.a003289; Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6; Su JM, 2009, ANTICANCER RES, V29, P509; Subramanian J, 2007, J THORAC ONCOL, V2, P827, DOI 10.1097/JTO.0b013e318145af79; Tan XL, 2009, CLIN CANCER RES, V15, P7562, DOI 10.1158/1078-0432.CCR-09-1694; Thun MJ, 2008, PLOS MED, V5, P1357, DOI 10.1371/journal.pmed.0050185; Tian YA, 2009, BIOCHEM PHARMACOL, V77, P670, DOI 10.1016/j.bcp.2008.10.023; Trikha M, 2003, CLIN CANCER RES, V9, P4653; Tse LA, 2009, AM J EPIDEMIOL, V169, P533, DOI 10.1093/aje/kwn385; Vanden Berghe W, 2006, CANCER RES, V66, P4852, DOI 10.1158/0008-5472.CAN-05-2957; Wang CK, 2009, INT J CANCER, V125, P807, DOI 10.1002/ijc.24348; Wang XR, 2009, CANCER CAUSE CONTROL, V20, P757, DOI 10.1007/s10552-008-9289-4; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Yu ITS, 2006, CANCER RES, V66, P4961, DOI 10.1158/0008-5472.CAN-05-2932; Zerbini LF, 2003, CANCER RES, V63, P2206	57	41	44	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	20					2555	2565		10.1038/onc.2011.438	http://dx.doi.org/10.1038/onc.2011.438			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	21996739				2022-12-17	WOS:000304191800006
J	Cherkasova, E; Malinzak, E; Rao, S; Takahashi, Y; Senchenko, VN; Kudryavtseva, AV; Nickerson, ML; Merino, M; Hong, JA; Schrump, DS; Srinivasan, R; Linehan, WM; Tian, X; Lerman, MI; Childs, RW				Cherkasova, E.; Malinzak, E.; Rao, S.; Takahashi, Y.; Senchenko, V. N.; Kudryavtseva, A. V.; Nickerson, M. L.; Merino, M.; Hong, J. A.; Schrump, D. S.; Srinivasan, R.; Linehan, W. M.; Tian, X.; Lerman, M. I.; Childs, R. W.			Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer	ONCOGENE			English	Article						renal cell carcinoma; endogenous retrovirus; VHL; HIF; DNA methylation	RENAL-CELL CARCINOMA; HYPOXIA-INDUCIBLE FACTORS; HERV-K18 SUPERANTIGEN; BREAST-CANCER; MESSENGER-RNA; B-CELLS; GENE; METHYLATION; TRANSPLANTATION; PROTEIN	A human endogenous retrovirus type E (HERV-E) was recently found to be selectively expressed in most renal cell carcinomas (RCCs). Importantly, antigens derived from this provirus are immunogenic, stimulating cytotoxic T cells that kill RCC cells in vitro and in vivo. Here, we show HERV-E expression is restricted to the clear cell subtype of RCC (ccRCC) characterized by an inactivation of the von Hippel-Lindau (VHL) tumor-suppressor gene with subsequent stabilization of hypoxia-inducible transcription factors (HIFs)-1 alpha and -2 alpha. HERV-E expression in ccRCC linearly correlated with HIF-2 alpha levels and could be silenced in tumor cells by either transfection of normal VHL or small interfering RNA inhibition of HIF-2 alpha. Using chromatin immunoprecipitation, we demonstrated that HIF-2 alpha can serve as transcriptional factor for HERV-E by binding with HIF response element (HRE) localized in the proviral 5' long terminal repeat (LTR). Remarkably, the LTR was found to be hypomethylated only in HERV-E-expressing ccRCC while other tumors and normal tissues possessed a hypermethylated LTR preventing proviral expression. Taken altogether, these findings provide the first evidence that inactivation of a tumor suppressor gene can result in aberrant proviral expression in a human tumor and give insights needed for translational research aimed at boosting human immunity against antigenic components of this HERV-E. Oncogene (2011) 30, 4697-4706; doi:10.1038/onc.2011.179; published online 23 May 2011	[Cherkasova, E.; Malinzak, E.; Rao, S.; Takahashi, Y.; Lerman, M. I.; Childs, R. W.] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA; [Senchenko, V. N.; Kudryavtseva, A. V.] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow, Russia; [Nickerson, M. L.] NCI, Canc & Inflammat Program, NIH, Frederick, MD 21701 USA; [Merino, M.] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; [Hong, J. A.; Schrump, D. S.] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA; [Srinivasan, R.; Linehan, W. M.] NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA; [Tian, X.] NHLBI, Off Biostat Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Childs, RW (corresponding author), NHLBI, Hematol Branch, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.	childsr@mail.nih.gov	Takahashi, Yoshiyuki/I-1929-2012; Senchenko, Vera N/C-8992-2014; Kudryavtseva, Anna V/C-9032-2014	Senchenko, Vera N/0000-0002-3119-515X; Kudryavtseva, Anna V/0000-0002-3722-8207; Cherkasova, Elena/0000-0002-7269-6516	NIH, National Heart, Lung, and Blood Institute, Hematology Branch; ACKC (Action to Cure Kidney Cancer); Dean R O'Neill Memorial Fellowship; NATIONAL CANCER INSTITUTE [ZIABC011028, ZIABC011405, ZIABC011038, ZIDBC011092, ZIDBC011089, ZIABC011043, ZIABC010696] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002345] Funding Source: NIH RePORTER	NIH, National Heart, Lung, and Blood Institute, Hematology Branch; ACKC (Action to Cure Kidney Cancer); Dean R O'Neill Memorial Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the intramural research program of NIH, National Heart, Lung, and Blood Institute, Hematology Branch. We wish to acknowledge ACKC (Action to Cure Kidney Cancer) for their support of the ACKC fellow who conducted this research and the Dean R O'Neill Memorial Fellowship for generous contributions supporting this research. We also thank Bill and Giuliana Rancic for their contributions supporting kidney cancer research. We thank Robert Worrell for his assistance in providing tissue samples.	Bregni M, 2002, BLOOD, V99, P4234, DOI 10.1182/blood.V99.11.4234; Childs R, 2000, NEW ENGL J MED, V343, P750, DOI 10.1056/NEJM200009143431101; Cohen CJ, 2009, GENE, V448, P105, DOI 10.1016/j.gene.2009.06.020; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524; Ghosh AK, 2009, BLOOD, V113, P5568, DOI 10.1182/blood-2008-10-185686; Gimenez J, 2010, NUCLEIC ACIDS RES, V38, P2229, DOI 10.1093/nar/gkp1214; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Hahn S, 2008, AIDS RES HUM RETROV, V24, P717, DOI 10.1089/aid.2007.0286; Hsiao FC, 2006, J IMMUNOL, V177, P2056, DOI 10.4049/jimmunol.177.4.2056; Hsiao FC, 2009, VIROLOGY, V385, P261, DOI 10.1016/j.virol.2008.11.025; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Kaelin WG, 2009, CANCER-AM CANCER SOC, V115, P2262, DOI 10.1002/cncr.24232; Kim CM, 2006, J UROLOGY, V175, P1908, DOI 10.1016/S0022-5347(05)00890-6; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Lavie L, 2005, J VIROL, V79, P876, DOI 10.1128/JVI.79.2.876-883.2005; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Menendez L, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-12; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Rao S, 2008, P 99 ANN M AM ASS CA; Rini BI, 2002, J CLIN ONCOL, V20, P2017, DOI 10.1200/JCO.2002.08.068; Romanish MT, 2010, SEMIN CANCER BIOL, V20, P246, DOI 10.1016/j.semcancer.2010.05.005; Ruprecht K, 2008, CELL MOL LIFE SCI, V65, P3366, DOI 10.1007/s00018-008-8496-1; Sandlund J, 2009, ACTA ONCOL, V48, P909, DOI 10.1080/02841860902824891; Szpakowski S, 2009, GENE, V448, P151, DOI 10.1016/j.gene.2009.08.006; Takahashi Y, 2008, J CLIN INVEST, V118, P1099, DOI 10.1172/JCI34409; Turner KJ, 2002, CANCER RES, V62, P2957; Wang-Johanning F, 2008, CANCER RES, V68, P5869, DOI 10.1158/0008-5472.CAN-07-6838; Wenger RH, 1998, EUR J BIOCHEM, V253, P771, DOI 10.1046/j.1432-1327.1998.2530771.x; Wright TM, 2010, J BIOL CHEM, V285, P12916, DOI 10.1074/jbc.M109.073924	30	41	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	47					4697	4706		10.1038/onc.2011.179	http://dx.doi.org/10.1038/onc.2011.179			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	861QG	21602888	Green Accepted			2022-12-17	WOS:000298033700002
J	Astro, V; Asperti, C; Cangi, G; Doglioni, C; de Curtis, I				Astro, V.; Asperti, C.; Cangi, G.; Doglioni, C.; de Curtis, I.			Liprin-alpha 1 regulates breast cancer cell invasion by affecting cell motility, invadopodia and extracellular matrix degradation	ONCOGENE			English	Article						cell migration; invadopodia; invasion; lamellipodia; liprins	PROTEIN-TYROSINE-PHOSPHATASE; SUPPRESSOR GENE; IDENTIFICATION; CORTACTIN; ADHESION; LIPRINS	Migration of cells and degradation of the extracellular matrix (ECM) are required for efficient tumor cell invasion, but the underlying molecular mechanisms are only partially known. The PPFIA1 gene for liprin-alpha 1 is frequently amplified in human breast cancers. We recently demonstrated that liprin-alpha 1 is an important regulator of cell edge dynamics during motility. We show, herein, that the liprin-alpha 1 protein is highly expressed in human breast tumors. Functional analysis shows that liprin-alpha 1 is specifically required for the migration and invasion of highly invasive human breast cancer MDA-MB-231 cells. We used time-lapse analysis to demonstrate defects in the motility of liprin-alpha 1-depleted cells that include a striking instability of the lamellipodia. Liprin-alpha 1 levels altered by either RNA interference or overexpression affected also cell spreading and the number of invadopodia per cell, but not the density of invadopodia per unit of surface area. On the other hand, silencing of liprin-alpha 1 inhibited the degradation of the ECM, whereas its overexpression enhanced degradation, resulting in significant negative or positive effects, respectively, on the area of degradation per invadopodium. Transfection of fluorescent-labeled cortactin revealed that depletion of liprin-alpha 1 also affected the assembly and disassembly of invadopodia, with decrease of their lifetime. Our results strongly support a novel important role of liprin-alpha 1 in the regulation of human tumor cell invasion. Oncogene (2011) 30, 1841-1849; doi:10.1038/onc.2010.562; published online 13 December 2010	[Astro, V.; Asperti, C.; de Curtis, I.] Ist Sci San Raffaele, Div Neurosci, Cell Adhes Unit, I-20132 Milan, Italy; [Astro, V.; Asperti, C.; Cangi, G.; Doglioni, C.; de Curtis, I.] San Raffaele Univ, Milan, Italy; [Cangi, G.; Doglioni, C.] Ist Sci San Raffaele, Pathol Unit, I-20132 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	de Curtis, I (corresponding author), Ist Sci San Raffaele, Div Neurosci, Cell Adhes Unit, Via Olgettina 58, I-20132 Milan, Italy.	decurtis.ivan@hsr.it	Cangi, M.Giulia/CAF-1459-2022; Asperti, Claudia/ABG-5481-2020	Cangi, M.Giulia/0000-0002-9472-0935; DOGLIONI, Claudio/0000-0002-4969-5216; DE CURTIS, Ivanmatteo/0000-0002-7651-1515; Astro, Veronica/0000-0001-7852-7046	AIRC (Italian Association for Cancer Research) [5060]; Italian Telethon Foundation [GGP09078]	AIRC (Italian Association for Cancer Research)(Fondazione AIRC per la ricerca sul cancro); Italian Telethon Foundation(Fondazione Telethon)	Support to I de Curtis by the AIRC (Italian Association for Cancer Research, grant no. 5060) and by the Italian Telethon Foundation (grant no. GGP09078) is gratefully acknowledged. The plasmid for DsRed-Cortactin was generously provided by Mark A McNiven (Mayo Clinic, Rochester, MN, USA). We thank Cesare Covino of the Alembic facility at our Institute for his support in the morphological analysis, Rosanna Latino and Maurizio Ferrari for the cytogenetic analysis, and Jacopo Meldolesi for critical reading of the manuscript.	Al-Kuraya K, 2004, CANCER RES, V64, P8534, DOI 10.1158/0008-5472.CAN-04-1945; Albiges-Rizo C, 2009, J CELL SCI, V122, P3037, DOI 10.1242/jcs.052704; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Asperti C, 2010, EXP CELL RES, V316, P915, DOI 10.1016/j.yexcr.2010.01.017; Asperti C, 2009, J CELL SCI, V122, P3225, DOI 10.1242/jcs.054155; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; de Curtis I, 2011, EXP CELL RES, V317, P1, DOI 10.1016/j.yexcr.2010.09.014; Frank SR, 2006, EMBO J, V25, P1848, DOI 10.1038/sj.emboj.7601092; Jarvinen AK, 2006, ONCOGENE, V25, P6997, DOI 10.1038/sj.onc.1209690; Katoh M, 2005, INT J ONCOL, V27, P281; Kim S, 2004, P NATL ACAD SCI USA, V101, P16251, DOI 10.1073/pnas.0407158101; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Nachat R, 2009, J CELL SCI, V122, P4035, DOI 10.1242/jcs.047266; Pankov R, 2005, J CELL BIOL, V170, P793, DOI 10.1083/jcb.200503152; Qiao Feng, 2005, Sci STKE, V2005, pre7, DOI 10.1126/stke.2862005re7; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Shaw Leslie M., 2004, V294, P97; Shen JC, 2007, CANCER RES, V67, P2552, DOI 10.1158/0008-5472.CAN-06-3870; Spangler SA, 2007, BIOCHEM SOC T, V35, P1278, DOI 10.1042/BST0351278; Tan KD, 2008, GENE CHROMOSOME CANC, V47, P353, DOI 10.1002/gcc.20539; Totaro A, 2007, MOL BIOL CELL, V18, P5124, DOI 10.1091/mbc.E07-06-0550; Weaver AM, 2008, CURR BIOL, V18, pR362, DOI 10.1016/j.cub.2008.02.028	23	41	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	15					1841	1849		10.1038/onc.2010.562	http://dx.doi.org/10.1038/onc.2010.562			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21151172				2022-12-17	WOS:000289512200011
J	Xu, K; Rajagopal, S; Klebba, I; Dong, S; Ji, Y; Liu, J; Kuperwasser, C; Garlick, JA; Naber, SP; Buchsbaum, RJ				Xu, K.; Rajagopal, S.; Klebba, I.; Dong, S.; Ji, Y.; Liu, J.; Kuperwasser, C.; Garlick, J. A.; Naber, S. P.; Buchsbaum, R. J.			The role of fibroblast Tiam1 in tumor cell invasion and metastasis	ONCOGENE			English	Article						Tiam1; Rac; tumor-associated fibroblasts; invasion; metastasis	RAC ACTIVATOR TIAM1; NUCLEOTIDE-EXCHANGE FACTORS; RHO-GTPASES; GENETIC ALTERATIONS; ACTIN CYTOSKELETON; CANCER METASTASIS; EPITHELIAL-CELLS; PROGRESSION; SKIN; PROTEINS	The co-evolution of tumors and their microenvironment involves bidirectional communication between tumor cells and tumor-associated stroma. Various cell types are present in tumor-associated stroma, of which fibroblasts are the most abundant. The Rac exchange factor Tiam1 is implicated in multiple signaling pathways in epithelial tumor cells and lack of Tiam1 in tumor cells retards tumor growth in Tiam1 knockout mouse models. Conversely, tumors arising in Tiam1 knockout mice have increased invasiveness. We have investigated the role of Tiam1 in tumor-associated fibroblasts as a modulator of tumor cell invasion and metastasis, using retroviral delivery of short hairpin RNA to suppress Tiam1 levels in three different experimental models. In spheroid co-culture of mammary epithelial cells and fibroblasts, Tiam1 silencing in fibroblasts led to increased epithelial cell outgrowth into matrix. In tissue-engineered human skin, Tiam1 silencing in dermal fibroblasts led to increased invasiveness of epidermal keratinocytes with pre-malignant features. In a model of human breast cancer in mice, co-implantation of mammary fibroblasts inhibited tumor invasion and metastasis, which was reversed by Tiam1 silencing in co-injected fibroblasts. These results suggest that stromal Tiam1 may have a role in modulating the effects of the tumor microenvironment on malignant cell invasion and metastasis. This suggests a set of pathways for further investigation, with implications for future therapeutic targets. Oncogene (2010) 29, 6533-6542; doi:10.1038/onc.2010.385; published online 30 August 2010	[Xu, K.; Rajagopal, S.; Dong, S.; Ji, Y.; Liu, J.; Buchsbaum, R. J.] Tufts Univ, Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; [Dong, S.; Kuperwasser, C.; Garlick, J. A.; Buchsbaum, R. J.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA; [Naber, S. P.] Tufts Univ, Tufts Med Ctr, Dept Pathol, Boston, MA 02111 USA; [Buchsbaum, R. J.] Tufts Univ, Tufts Med Ctr, Dept Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts University; Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University	Buchsbaum, RJ (corresponding author), Tufts Univ, Tufts Med Ctr, Mol Oncol Res Inst, 800 Washington St,Box 245, Boston, MA 02111 USA.	rbuchsbaum@tuftsmedicalcenter.org			NIH [CA 095559, CA12555]; Vermont Community Foundation; Breast Cancer Research Foundation; Diane Connolly-Zaniboni Research Scholarship in Breast Cancer; Tufts Medical Center GRASP Digestive Disease Center [P30-DK34928]; Design and Data Resource Center of the Tufts Clinical; Translational Science Institute (National Center for Research Resources) [UL1 RR025752]; NATIONAL CANCER INSTITUTE [R01CA095559, R01CA125554] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vermont Community Foundation; Breast Cancer Research Foundation; Diane Connolly-Zaniboni Research Scholarship in Breast Cancer; Tufts Medical Center GRASP Digestive Disease Center; Design and Data Resource Center of the Tufts Clinical; Translational Science Institute (National Center for Research Resources)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the NIH (RB: CA 095559 and CK: CA12555), the Landmann Family Fund of the Vermont Community Foundation (RB), the Breast Cancer Research Foundation (CK), the Diane Connolly-Zaniboni Research Scholarship in Breast Cancer (RB), the Tufts Medical Center GRASP Digestive Disease Center (RB, P30-DK34928) and the Design and Data Resource Center of the Tufts Clinical and Translational Science Institute (National Center for Research Resources: UL1 RR025752).	Andriani F, 2004, INT J CANCER, V108, P348, DOI 10.1002/ijc.11525; Baines AT, 2006, METHOD ENZYMOL, V407, P556, DOI 10.1016/S0076-6879(05)07045-X; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOUKAMP P, 1990, CANCER RES, V50, P2840; Buchsbaum RJ, 2007, J CELL SCI, V120, P1149, DOI 10.1242/jcs.03428; Connolly BA, 2005, MOL CELL BIOL, V25, P4602, DOI 10.1128/MCB.25.11.4602-4614.2005; Cruz-Monserrate Z, 2008, NEOPLASIA, V10, P408, DOI 10.1593/neo.07868; Cunha G R, 1989, Cancer Treat Res, V46, P159; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Fusenig NE, 1998, MOL CARCINOGEN, V23, P144, DOI 10.1002/(SICI)1098-2744(199811)23:3<144::AID-MC3>3.0.CO;2-U; Garlick JA, 2007, ADV BIOCHEM ENG BIOT, V103, P207; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hou M, 2004, ACTA BIOCH BIOPH SIN, V36, P537, DOI 10.1093/abbs/36.8.537; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; Kim JB, 2005, SEMIN CANCER BIOL, V15, P365, DOI 10.1016/j.semcancer.2005.05.002; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Kuperwasser C, 2005, CANCER RES, V65, P6130, DOI 10.1158/0008-5472.CAN-04-1408; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Li HC, 2007, J CELL BIOCHEM, V101, P805, DOI 10.1002/jcb.21159; Liu L, 2006, NEOPLASIA, V8, P917, DOI 10.1593/neo.06364; Liu L, 2005, WORLD J GASTROENTERO, V11, P705, DOI 10.3748/wjg.v11.i5.705; Malliri A, 2006, J BIOL CHEM, V281, P543, DOI 10.1074/jbc.M507582200; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Margulis A, 2005, CANCER RES, V65, P1783, DOI 10.1158/0008-5472.CAN-04-3399; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6; Minard ME, 2005, ONCOGENE, V24, P2568, DOI 10.1038/sj.onc.1208503; Moinfar F, 2000, CANCER RES, V60, P2562; Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825; Rajagopal S, 2010, J BIOL CHEM, V285, P18060, DOI 10.1074/jbc.M109.051490; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Rygiel TP, 2008, J CELL SCI, V121, P1183, DOI 10.1242/jcs.017194; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Segal N, 2008, MATRIX BIOL, V27, P163, DOI 10.1016/j.matbio.2007.09.002; Strumane K, 2008, LEUKEMIA RES, V32, P113, DOI 10.1016/j.leukres.2007.03.034; Supriatno, 2003, ONCOL REP, V10, P527; Tse JC, 2007, J CELL BIOCHEM, V101, P816, DOI 10.1002/jcb.21215; Willhauck MJ, 2007, CARCINOGENESIS, V28, P595, DOI 10.1093/carcin/bgl188; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006	46	41	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	50					6533	6542		10.1038/onc.2010.385	http://dx.doi.org/10.1038/onc.2010.385			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20802514	Green Accepted			2022-12-17	WOS:000285380200003
J	Iadevaia, V; Caldarola, S; Biondini, L; Gismondi, A; Karlsson, S; Dianzani, I; Loreni, F				Iadevaia, V.; Caldarola, S.; Biondini, L.; Gismondi, A.; Karlsson, S.; Dianzani, I.; Loreni, F.			PIM1 kinase is destabilized by ribosomal stress causing inhibition of cell cycle progression	ONCOGENE			English	Article						ribosome synthesis; cell cycle arrest; erythroleukemia cells; PIM1; RPS19; p27(Kip1)	DIAMOND-BLACKFAN ANEMIA; ACTIVATION; P53; PROTEINS; PROLIFERATION; BIOGENESIS; DISRUPTION; REGULATORS; P27(KIP1); STABILITY	PIM1 is a constitutively active serine/threonine kinase regulated by cytokines, growth factors and hormones. It has been implicated in the control of cell cycle progression and apoptosis and its overexpression has been associated with various kinds of lymphoid and hematopoietic malignancies. The activity of PIM1 is dependent on the phosphorylation of several targets involved in transcription, cell cycle and apoptosis. We have recently observed that PIM1 interacts with ribosomal protein (RP) S19 and cosediments with ribosomes. Defects in ribosome synthesis (ribosomal stress) have been shown to activate a p53-dependent growth arrest response. To investigate if PIM1 could have a role in the response to ribosomal stress, we induced ribosome synthesis alterations in TF-1 and K562 erythroid cell lines. We found that RP deficiency, induced by RNA interference or treatment with inhibitor of nucleolar functions, causes a drastic destabilization of PIM1. The lower level of PIM1 induces an increase in the cell cycle inhibitor p27(Kip1) and blocks cell proliferation even in the absence of p53. Notably, restoring PIM1 level by transfection causes a recovery of cell growth. Our data indicate that PIM1 may act as a sensor for ribosomal stress independently of or in concert with the known p53-dependent mechanisms. Oncogene (2010) 29, 5490-5499; doi:10.1038/onc.2010.279; published online 19 July 2010	[Iadevaia, V.; Caldarola, S.; Biondini, L.; Gismondi, A.; Loreni, F.] Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; [Karlsson, S.] Univ Lund Hosp, Lund Stem Cell Ctr, Dept Mol Med & Gene Therapy, S-22185 Lund, Sweden; [Dianzani, I.] Univ Piemonte Orientale, Dept Med Sci, Novara, Italy	University of Rome Tor Vergata; Lund University; Skane University Hospital; University of Eastern Piedmont Amedeo Avogadro	Loreni, F (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	loreni@uniroma2.it	Iadevaia, Valentina/J-8613-2017; Gismondi, Angelo/N-4264-2015; Iadevaia, Valentina/H-2950-2019	Iadevaia, Valentina/0000-0002-8393-8541; Gismondi, Angelo/0000-0002-9257-9667; Iadevaia, Valentina/0000-0002-8393-8541	Telethon, Italy [GGP07242]; Diamond Blackfan Anemia Foundation Inc.; Italian Ministry for University and Research (MIUR)	Telethon, Italy(Fondazione Telethon); Diamond Blackfan Anemia Foundation Inc.; Italian Ministry for University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR))	We thank Marcello Giorgi for expert technical assistance. The financial support of Telethon, Italy (Grant No. GGP07242) is gratefully acknowledged. This work was also supported by grants from Diamond Blackfan Anemia Foundation Inc. and the Italian Ministry for University and Research (MIUR) FIRB and PRIN.	Anderson SJ, 2007, IMMUNITY, V26, P759, DOI 10.1016/j.immuni.2007.04.012; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Badhai J, 2009, FEBS LETT, V583, P2049, DOI 10.1016/j.febslet.2009.05.023; Caldarola S, 2009, FEBS J, V276, P3199, DOI 10.1111/j.1742-4658.2009.07036.x; Chiocchetti A, 2005, HAEMATOLOGICA, V90, P1453; Danilova N, 2008, BLOOD, V112, P5228, DOI 10.1182/blood-2008-01-132290; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Hammerman PS, 2005, BLOOD, V105, P4477, DOI 10.1182/blood-2004-09-3706; Idol RA, 2007, BLOOD CELL MOL DIS, V39, P35, DOI 10.1016/j.bcmd.2007.02.001; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; Larrea MD, 2009, CELL CYCLE, V8, P3455, DOI 10.4161/cc.8.21.9789; Liu JM, 2006, BLOOD, V107, P4583, DOI 10.1182/blood-2005-12-4831; Losman JA, 2003, J BIOL CHEM, V278, P4800, DOI 10.1074/jbc.M208246200; Mayer C, 2005, CELL CYCLE, V4, P1036, DOI 10.4161/cc.4.8.1925; McGowan KA, 2008, NAT GENET, V40, P963, DOI 10.1038/ng.188; Miyake K, 2005, MOL THER, V11, P627, DOI 10.1016/j.ymthe.2004.12.001; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; Orru S, 2007, MOL CELL PROTEOMICS, V6, P382, DOI 10.1074/mcp.M600156-MCP200; Panic L, 2007, CELL CYCLE, V6, P20, DOI 10.4161/cc.6.1.3666; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; Shah N, 2008, EUR J CANCER, V44, P2144, DOI 10.1016/j.ejca.2008.06.044; Shay KP, 2005, MOL CANCER RES, V3, P170; Soeiro I, 2006, MOL CELL BIOL, V26, P6170, DOI 10.1128/MCB.02182-05; Steinman RA, 2002, ONCOGENE, V21, P3403, DOI 10.1038/sj.onc.1205325; Sulic S, 2005, GENE DEV, V19, P3070, DOI 10.1101/gad.359305; Urashima M, 1998, BLOOD, V92, P959, DOI 10.1182/blood.V92.3.959.414k21_959_967; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Wang Z, 2001, J Vet Sci, V2, P167; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	34	41	41	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	40					5490	5499		10.1038/onc.2010.279	http://dx.doi.org/10.1038/onc.2010.279			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20639905				2022-12-17	WOS:000282945800006
J	Sakamoto, K; Triplett, AA; Schuler, LA; Wagner, KU				Sakamoto, K.; Triplett, A. A.; Schuler, L. A.; Wagner, K-U			Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer	ONCOGENE			English	Article						prolactin; Janus kinase 2; Stat5; gene targeting; transgenic; breast cancer	GROWTH-FACTOR-ALPHA; BREAST-CANCER; EPITHELIAL-CELLS; SIGNAL TRANSDUCER; ER-ALPHA; EXPRESSION; ACTIVATION; RECEPTOR; STAT5A; GENE	The prolactin receptor (PRLR), its associated Janus kinase 2 (Jak2) and the signal transducer and activator of transcription 5 (Stat5) are essential for normal mammary gland development. Owing to the upregulation of the PRLR and the local synthesis of its ligand in neoplastic cells, it has been proposed that PRL can act as a local growth factor in human breast cancers. This notion is supported by experimental evidence in transgenic mice, which showed that the mammary-specific expression of PRL contributes to carcinogenesis in vivo. To assess the importance of Jak2/Stat5 signaling during mammary cancer initiation and progression, we generated a PRL-induced mammary cancer model that allows the functional ablation of the Jak2 gene in the mammary epithelium before and after neoplastic transformation. Collectively, the results of this study show that the functional ablation of Jak2 protects against the onset of PRL-induced mammary tumorigenesis, suggesting that targeting this kinase is a relevant strategy for mammary cancer prevention. Surprisingly, Jak2 deficiency did not affect the growth and survival of PRL-induced mammary cancer cells in culture and in vivo. Consequently, Jak2 cannot be a sole therapeutic target to treat the established disease. PRL-induced mammary cancers exhibited an upregulation of ErbB2 and other ErbB receptor tyrosine kinases that may supersede the functionality of PRLR signaling through Jak2. Oncogene (2010) 29, 5359-5369; doi: 10.1038/onc.2010.274; published online 19 July 2010	[Sakamoto, K.; Triplett, A. A.; Wagner, K-U] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Schuler, L. A.] Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA; [Wagner, K-U] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Wisconsin System; University of Wisconsin Madison; University of Nebraska System; University of Nebraska Medical Center	Wagner, KU (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, DRCII Room 5033, Omaha, NE 68198 USA.	kuwagner@unmc.edu	Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226	National Cancer Institute [CA117930, CA78312]; Nebraska Cancer and Smoking Disease Research Program [NE DHHS LB506 2009-45]; Susan G Komen Breast Cancer Foundation [PDF0600835]; NATIONAL CANCER INSTITUTE [R01CA117930, R01CA078312] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Nebraska Cancer and Smoking Disease Research Program; Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Public Health Service Grant CA117930 (to K-UW) as well as Grant CA78312 (to LAS) from the National Cancer Institute. Additional financial support provided to K-UW by the Nebraska Cancer and Smoking Disease Research Program (NE DHHS LB506 2009-45) was imperative to finance the maintenance of the Jak2 conditional knockout model. KS received a postdoctoral fellowship from the Susan G Komen Breast Cancer Foundation (PDF0600835).	AOUIJAMALI MA, 2003, CANCER RES, V63, P3764; Arendt LM, 2008, AM J PATHOL, V172, P194, DOI 10.2353/ajpath.2008.070597; Arendt LM, 2006, AM J PATHOL, V168, P1365, DOI 10.2353/ajpath.2006.050861; Boulanger CA, 2005, ONCOGENE, V24, P552, DOI 10.1038/sj.onc.1208185; Brockman JL, 2005, MOL CELL ENDOCRINOL, V239, P45, DOI 10.1016/j.mce.2005.04.006; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Cardiff RD, 1998, J MAMMARY GLAND BIOL, V3, P3, DOI 10.1023/A:1018714016205; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dominguez-Caceres MA, 2004, ONCOGENE, V23, P7378, DOI 10.1038/sj.onc.1208002; GINSBURG E, 1995, CANCER RES, V55, P2591; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; Iavnilovitch E, 2004, INT J CANCER, V112, P607, DOI 10.1002/ijc.20484; Iavnilovitch E, 2002, MOL CANCER RES, V1, P32; Kim A, 2005, BREAST CANCER RES, V7, pR708, DOI 10.1186/bcr1281; Krempler A, 2004, GENESIS, V40, P52, DOI 10.1002/gene.20063; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Garcia-Martinez JM, 2010, CELL SIGNAL, V22, P415, DOI 10.1016/j.cellsig.2009.10.013; Matulka LA, 2005, DRUG DISCOV TODAY, V2, P1, DOI DOI 10.1016/J.DDMOD.2005.05.008; Matulka LA, 2007, DEV BIOL, V303, P29, DOI 10.1016/j.ydbio.2006.12.017; MEDINA D, 2000, METHODS MAMMARY GLAN, P137; Miermont AM, 2010, CARCINOGENESIS, V31, P1124, DOI 10.1093/carcin/bgq048; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Oakes SR, 2007, ONCOGENE, V26, P543, DOI 10.1038/sj.onc.1209838; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; Pardanani A, 2008, LEUKEMIA, V22, P23, DOI 10.1038/sj.leu.2404948; Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Sakamoto K, 2007, MOL ENDOCRINOL, V21, P1877, DOI 10.1210/me.2006-0316; Sakamoto K, 2009, CANCER RES, V69, P6642, DOI 10.1158/0008-5472.CAN-09-0746; Shillingford JM, 2002, MOL ENDOCRINOL, V16, P563, DOI 10.1210/me.16.3.563; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tang JZ, 2010, ENDOCRINOLOGY, V151, P43, DOI 10.1210/en.2009-0651; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TORNELL J, 1991, INT J CANCER, V49, P114, DOI 10.1002/ijc.2910490121; Tran TH, 2010, CANCER RES, V70, P1711, DOI 10.1158/0008-5472.CAN-09-2314; Triplett AA, 2008, NEOPLASIA, V10, P1325, DOI 10.1593/neo.08524; Tworoger SS, 2006, CANCER LETT, V243, P160, DOI 10.1016/j.canlet.2006.01.032; Wagner KU, 2008, J MAMMARY GLAND BIOL, V13, P93, DOI 10.1007/s10911-008-9062-z; Wagner Kay-Uwe, 1997, Genes and Function, V1, P233; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Wagner KU, 2004, MOL CELL BIOL, V24, P5510, DOI 10.1128/MCB.24.12.5510-5520.2004; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; WELLINGS SR, 1975, J NATL CANCER I, V55, P231; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820	52	41	42	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5359	5369		10.1038/onc.2010.274	http://dx.doi.org/10.1038/onc.2010.274			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20639901	Green Accepted			2022-12-17	WOS:000282944500003
J	Kurita, S; Mott, JL; Almada, LL; Bronk, SF; Werneburg, NW; Sun, SY; Roberts, LR; Fernandez-Zapico, ME; Gores, GJ				Kurita, S.; Mott, J. L.; Almada, L. L.; Bronk, S. F.; Werneburg, N. W.; Sun, S-Y; Roberts, L. R.; Fernandez-Zapico, M. E.; Gores, G. J.			GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis	ONCOGENE			English	Article						apoptosis; cholangiocarcinoma; GLI transcription factors; TRAIL	BASAL-CELL CARCINOMA; CHOLANGIOCARCINOMA CELLS; SIGNALING PATHWAY; DEATH RECEPTOR-4; SONIC HEDGEHOG; CYTOCHROME-C; EXPRESSION; RESISTANCE; CANCER; REQUIREMENT	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis through its cognate receptors death receptor 4 (DR4) and death receptor 5 (DR5), preferentially in malignant cells. However, many malignant cells remain resistant to TRAIL cytotoxicity by poorly characterized mechanisms. Here, using cholangiocarcinoma cells, as a model for TRAIL resistance, we identified a role for the oncogenic Hedgehog (Hh)-GLI pathway in the regulation of TRAIL cytotoxicity. Blockade of Hh using pharmacological and genetic tools sensitizes the cells to TRAIL cytotoxicity. Restoration of apoptosis sensitivity coincided with upregulation of DR4 expression, while expression of other death effector proteins remained unaltered. Knockdown of DR4 mimics Hh-mediated resistance to TRAIL cytotoxicity. Hh regulates the expression of DR4 by modulating the activity of its promoter. Luciferase, chromatin immunoprecipitation and expression assays show that the transcription factor GLI3 binds to the DR4 promoter and Hh requires an intact GLI3-repression activity to silence DR4 expression. Finally, small interfering RNA (siRNA)-targeted knockdown of GLI3, but not GLI1 or GLI2, restores DR4 expression and TRAIL sensitivity, indicating that the Hh effect is exclusively mediated by this transcription factor. In conclusion, these data provide evidence of a regulatory mechanism, which modulates TRAIL signaling in cancer cells and suggest new therapeutic approaches for TRAIL-resistant neoplasms. Oncogene (2010) 29, 4848-4858; doi:10.1038/onc.2010.235; published online 21 June 2010	[Kurita, S.; Mott, J. L.; Almada, L. L.; Bronk, S. F.; Werneburg, N. W.; Roberts, L. R.; Fernandez-Zapico, M. E.; Gores, G. J.] Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; [Almada, L. L.; Fernandez-Zapico, M. E.] Mayo Clin, Schulze Ctr Novel Therapeut, Div Oncol Res, Rochester, MN 55905 USA; [Sun, S-Y] Emory Univ, Sch Med, Dept Hematol, Winship Canc Inst, Atlanta, GA USA; [Sun, S-Y] Emory Univ, Sch Med, Dept Med Oncol, Winship Canc Inst, Atlanta, GA USA	Mayo Clinic; Mayo Clinic; Emory University; Emory University	Gores, GJ (corresponding author), Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu		Mott, Justin/0000-0002-2927-6962; Roberts, Lewis/0000-0001-7885-8574	NIH [DK59427, CA136526, CA100882, P30 DK 84567]; Mayo Foundation; Mayo Clinic [P50 CA102701]; NATIONAL CANCER INSTITUTE [P50CA102701, R01CA100882, R56CA100882, R01CA136526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK084567, R01DK059427, K01DK079875, R56DK059427] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation; Mayo Clinic; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Erin Nystuen-Bungum for her excellent secretarial assistance. This work was supported by NIH R01 Grants DK59427 (GJG), CA136526, (MEF-Z), CA100882 (LRR), the Clinical and Optical Microscopy Cores for P30 DK 84567, Mayo Clinic Pancreatic SPORE P50 CA102701 (MEF-Z), and the Mayo Foundation.	Akazawa Y, 2009, GASTROENTEROLOGY, V136, P2365, DOI 10.1053/j.gastro.2009.02.071; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen MH, 2009, GENE DEV, V23, P1910, DOI 10.1101/gad.1794109; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Eggert A, 2001, CANCER RES, V61, P1314; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Guan BX, 2002, ONCOGENE, V21, P3121, DOI 10.1038/sj.onc.1205430; Guan BX, 2001, J CELL PHYSIOL, V188, P98, DOI 10.1002/jcp.1101; Higuchi H, 2001, J BIOL CHEM, V276, P38610, DOI 10.1074/jbc.M105300200; Ishimura N, 2006, AM J PHYSIOL-GASTR L, V290, pG129, DOI 10.1152/ajpgi.00242.2005; Isomoto H, 2007, GASTROENTEROLOGY, V132, P384, DOI 10.1053/j.gastro.2006.10.037; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kobayashi S, 2005, GASTROENTEROLOGY, V128, P2054, DOI 10.1053/j.gastro.2005.03.010; Kump E, 2008, ONCOGENE, V27, P3856, DOI 10.1038/onc.2008.5; Lees C, 2005, GASTROENTEROLOGY, V129, P1696, DOI 10.1053/j.gastro.2005.05.010; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mendoza FJ, 2008, APOPTOSIS, V13, P756, DOI 10.1007/s10495-008-0210-0; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Parkin CA, 2008, AM J PHYSIOL-GASTR L, V294, pG363, DOI 10.1152/ajpgi.00457.2007; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wehbe H, 2006, J PHARMACOL EXP THER, V319, P1153, DOI 10.1124/jpet.106.109835; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	33	41	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	34					4848	4858		10.1038/onc.2010.235	http://dx.doi.org/10.1038/onc.2010.235			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20562908	Green Accepted			2022-12-17	WOS:000281326400010
J	Zhu, XG; Zhao, L; Willingham, MC; Cheng, SY				Zhu, X-G; Zhao, L.; Willingham, M. C.; Cheng, S-Y			Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma	ONCOGENE			English	Article						thyroid cancer; mouse model; mutations of thyroid hormone receptors	DOMINANT-NEGATIVE ACTIVITY; SECRETING PITUITARY-TUMOR; TRANSFORMING GENE PTTG; CLEAR-CELL CARCINOMA; LINKED KINASE ILK; BETA-RECEPTOR; TRANSCRIPTIONAL ACTIVITY; NUCLEAR RECEPTORS; TRANSGENIC MICE; V-ERBA	Aberrant expression and mutations of thyroid hormone receptor genes (TRs) are closely associated with several types of human cancers. To test the hypothesis that TRs could function as tumor suppressors, we took advantage of mice with deletion of all functional TRs (TR alpha 1(-/-)TR beta(-/-) mice). As these mice aged, they spontaneously developed follicular thyroid carcinoma with pathological progression from hyperplasia to capsular invasion, vascular invasion, anaplasia and metastasis to the lung, similar to human thyroid cancer. Detailed molecular analysis revealed that known tumor promoters such as pituitary tumor-transforming gene were activated and tumor suppressors such as peroxisome proliferator-activated receptor gamma and p53 were suppressed during carcinogenesis. In addition, consistent with the human cancer, AKT-mTOR-p70(S6K) signaling and vascular growth factor and its receptor were activated to facilitate tumor progression. This report presents in vivo evidence that functional loss of both TR alpha 1 and TR beta genes promotes tumor development and metastasis. Thus, TRs could function as tumor suppressors in a mouse model of metastatic follicular thyroid cancer. Oncogene (2010) 29, 1909-1919; doi:10.1038/onc.2009.476; published online 11 January 2010	[Zhu, X-G; Zhao, L.; Cheng, S-Y] NCI, Mol Biol Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Willingham, M. C.] Wake Forest Univ, Dept Pathol, Winston Salem, NC 27109 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University	Cheng, SY (corresponding author), NCI, Mol Biol Lab, Ctr Canc Res, 37 Convent Dr,Room 5128, Bethesda, MD 20892 USA.	chengs@mail.nih.gov			Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health; NATIONAL CANCER INSTITUTE [ZIABC011191, ZIABC008752] Funding Source: NIH RePORTER	Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health. We thank Drs H Ying and Y Kato for the analyses of survival curves and thyroid growth in the early phase of the present work.	Ando S, 2001, MOL ENDOCRINOL, V15, P1529, DOI 10.1210/me.15.9.1529; Ando S, 2001, J CLIN ENDOCR METAB, V86, P5572, DOI 10.1210/jc.86.11.5572; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; Davis PJ, 2008, FRONT NEUROENDOCRIN, V29, P211, DOI 10.1016/j.yfrne.2007.09.003; Fagin JA, 2002, MOL ENDOCRINOL, V16, P903, DOI 10.1210/me.16.5.903; Forrest D, 1996, NAT GENET, V13, P354, DOI 10.1038/ng0796-354; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; Forrest D, 2000, THYROID, V10, P41, DOI 10.1089/thy.2000.10.41; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Furuya F, 2009, STEROIDS, V74, P628, DOI 10.1016/j.steroids.2008.10.009; Garcia-Silva S, 2004, MOL CELL BIOL, V24, P7514, DOI 10.1128/MCB.24.17.7514-7523.2004; Gothe S, 1999, GENE DEV, V13, P1329, DOI 10.1101/gad.13.10.1329; Guigon CJ, 2008, MOL CELL BIOL, V28, P4598, DOI 10.1128/MCB.02192-07; Heaney AP, 2001, J CLIN ENDOCR METAB, V86, P5025, DOI 10.1210/jc.86.10.5025; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Kamiya Y, 2002, CARCINOGENESIS, V23, P25, DOI 10.1093/carcin/23.1.25; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kato Y, 2006, ONCOGENE, V25, P2736, DOI 10.1038/sj.onc.1209299; Kato Y, 2004, ENDOCRINOLOGY, V145, P4430, DOI 10.1210/en.2004-0612; Kim CS, 2007, CARCINOGENESIS, V28, P932, DOI 10.1093/carcin/bgl231; Kim DS, 2006, J CLIN ENDOCR METAB, V91, P4603, DOI 10.1210/jc.2006-1291; Kim DS, 2003, CLIN OTOLARYNGOL, V28, P386, DOI 10.1046/j.1365-2273.2003.00732.x; Lawal O, 2001, EUR J SURG ONCOL, V27, P157, DOI 10.1053/ejso.2000.1085; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; Li Z, 2002, CANCER RES, V62, P1939; Lin KH, 1999, MOL CARCINOGEN, V26, P53, DOI 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z; MAEDA K, 1995, J CLIN ONCOL, V13, P477, DOI 10.1200/JCO.1995.13.2.477; Martinez-Iglesias O, 2009, CANCER RES, V69, P501, DOI 10.1158/0008-5472.CAN-08-2198; McCabe CJ, 2002, J CLIN ENDOCR METAB, V87, P4238, DOI 10.1210/jc.2002-020309; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; Miyakawa M, 2003, ENDOCR J, V50, P77, DOI 10.1507/endocrj.50.77; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Puzianowska-Kuznicka M, 2002, J CLIN ENDOCR METAB, V87, P1120, DOI 10.1210/jc.87.3.1120; Puzianowska-Kuznicka M, 2000, CANCER LETT, V155, P145, DOI 10.1016/S0304-3835(00)00416-X; Puzianowska-Kuznicka M, 2006, ACTA BIOCHIM POL, V53, P641, DOI 10.18388/abp.2006_3292; Ringel MD, 2001, CANCER RES, V61, P6105; Safer JD, 2001, THYROID, V11, P281, DOI 10.1089/105072501750159750; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Shen WT, 2005, THYROID, V15, P594, DOI 10.1089/thy.2005.15.594; Suzuki H, 2003, MOL ENDOCRINOL, V17, P895, DOI 10.1210/me.2002-0326; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Takano T, 2003, J CLIN ENDOCR METAB, V88, P3447, DOI 10.1210/jc.2003-030012; Teresi RE, 2008, PPAR RES, V2008, DOI 10.1155/2008/932632; Thormeyer D, 1999, INT J MOL MED, V4, P351; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Turpeenniemi-Hujanen T, 2005, BIOCHIMIE, V87, P287, DOI 10.1016/j.biochi.2005.01.014; Ward J M, 1986, Adv Exp Med Biol, V206, P529; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; Weiss R E, 2000, Rev Endocr Metab Disord, V1, P97, DOI 10.1023/A:1010072605757; Wikstrom L, 1998, EMBO J, V17, P455, DOI 10.1093/emboj/17.2.455; YEN PM, 1994, J BIOL CHEM, V269, P903; Ying H, 2003, CANCER RES, V63, P5274; Ying H, 2003, CARCINOGENESIS, V24, P1467, DOI 10.1093/carcin/bgg111; Ying H, 2006, J CLIN INVEST, V116, P2972, DOI 10.1172/JCI28598; Zeiger MA, 1997, ENDOCRINOLOGY, V138, P3133, DOI 10.1210/en.138.8.3133; Zhang XY, 2002, MOL ENDOCRINOL, V16, P2077, DOI 10.1210/me.2002-0080; Zimonjic DB, 2005, CANCER GENET CYTOGEN, V161, P104, DOI 10.1016/j.cancergencyto.2005.02.007	63	41	42	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	13					1909	1919		10.1038/onc.2009.476	http://dx.doi.org/10.1038/onc.2009.476			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20062085	Green Accepted			2022-12-17	WOS:000276199600004
J	Yao, Z; Duan, S; Hou, D; Wang, W; Wang, G; Liu, Y; Wen, L; Wu, M				Yao, Z.; Duan, S.; Hou, D.; Wang, W.; Wang, G.; Liu, Y.; Wen, L.; Wu, M.			B23 acts as a nucleolar stress sensor and promotes cell survival through its dynamic interaction with hnRNPU and hnRNPA1	ONCOGENE			English	Article						B23/NPM; hnRNPs; nucleolar stress; cell survival; apoptosis	MESSENGER-RNA; PROTEIN; NUCLEOPHOSMIN; A1; ACTINOMYCIN; P53	The nucleolus is one of the functional nuclear compartments in which the ribosome biogenesis takes place. Proteomic analysis revealed a large number of nucleolar proteins that are involved in diverse cellular processes, including biogenesis of ribonucleoprotein particles, stress responses, cell proliferation and cell cycle progression. Here, we report that in response to transcription repression-induced nucleolar segregation, B23, a nucleolar protein required for rRNA processing, is localized to the cytoplasm and forms a complex with the mRNA-binding proteins hnRNPU and hnRNPA1 in a sequential manner. In addition, RNA Polymerase I, but not RNA Polymerase II inhibition, was found to account for the translocation-dependent assembly of B23/hnRNPU/hnRNPA1. We also showed that interactions among these proteins are regulated by hnRNPU-bound mRNAs such as the 30-untranslated region (UTR) of Bcl-xL mRNA. Ectopically expressed 30-UTR of Bcl-xL mRNA, which disrupted the interactions among B23, hnRNPU and hnRNPA1, led to enhanced cell apoptosis induced by either actinomycin D treatment or mitotic arrest. Overall, these data highlight a novel function of B23 as a stress sensor in the assembly of B23/hnRNPU/hnRNPA1 complex to promote cell survival. Oncogene (2010) 29, 1821-1834; doi:10.1038/onc.2009.473; published online 18 January 2010	[Yao, Z.; Duan, S.; Hou, D.; Wang, W.; Wang, G.; Wen, L.; Wu, M.] Univ Sci & Technol China, Sch Life Sci, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; [Liu, Y.] Univ Sci & Technol China, Sch Life Sci, Ctr Tech Serv Life Sci, Hefei 230027, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Wu, M (corresponding author), Univ Sci & Technol China, Sch Life Sci, Hefei Natl Lab Phys Sci Microscale, 96 Huangshan Rd, Hefei 230027, Anhui, Peoples R China.	wumian@ustc.edu.cn	Yao, Zhan/AAK-6756-2020; Wu, Mian/H-2494-2018; Yao, Zhan/K-1839-2013	Wen, Longping/0000-0003-0384-4578; YAO, ZHAN/0000-0001-5391-5691; Wu, Mian/0000-0002-2714-0500; WANG, Wenyu/0000-0001-8947-4867	National Natural Science Foundation of China [30530200, 30871290, 30728003]; Ministry of Science and Technology of China [2006CB933300, 2006CB910300]; Chinese Academy of Sciences [KSCX1-YW-R-57]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Chinese Academy of Sciences(Chinese Academy of Sciences)	We are grateful to Dr Yinon Ben-Neriah (The Hebrew University-Hadassah Medical School, Israel) for kindly providing the pFLAG-CMV-2-hnRNPU plasmid. This research was supported by grants from the National Natural Science Foundation of China (30530200, 30871290 and 30728003), the Ministry of Science and Technology of China (2006CB933300 and 2006CB910300) and the Chinese Academy of Sciences (KSCX1-YW-R-57).	Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Duan SS, 2007, EMBO J, V26, P3062, DOI 10.1038/sj.emboj.7601749; FREI E, 1974, CANCER CHEMOTH REP 1, V58, P49; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Iervolino A, 2002, MOL CELL BIOL, V22, P2255, DOI 10.1128/MCB.22.7.2255-2266.2002; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Johnson RF, 2006, J VIROL, V80, P5135, DOI 10.1128/JVI.01857-05; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kukalev A, 2005, NAT STRUCT MOL BIOL, V12, P238, DOI 10.1038/nsmb904; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Okuwaki M, 2008, J BIOCHEM, V143, P441, DOI 10.1093/jb/mvm222; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Wu MH, 2002, INT J CANCER, V97, P297, DOI 10.1002/ijc.1606; Yugami M, 2007, FEBS LETT, V581, P1, DOI 10.1016/j.febslet.2006.11.062; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8	22	41	43	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1821	1834		10.1038/onc.2009.473	http://dx.doi.org/10.1038/onc.2009.473			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20101230				2022-12-17	WOS:000276022800011
J	Najdi, R; Syed, A; Arce, L; Theisen, H; Ting, JHT; Atcha, F; Nguyen, AV; Martinez, M; Holcombe, RF; Edwards, RA; Marsh, JL; Waterman, ML				Najdi, R.; Syed, A.; Arce, L.; Theisen, H.; Ting, J-H T.; Atcha, F.; Nguyen, A. V.; Martinez, M.; Holcombe, R. F.; Edwards, R. A.; Marsh, J. L.; Waterman, M. L.			A Wnt kinase network alters nuclear localization of TCF-1 in colon cancer	ONCOGENE			English	Article						CaMKII; colon cancer; export; TCF-1; Wnt	COLORECTAL-CANCER; BETA-CATENIN; TRANSCRIPTION FACTORS; CELLS; PATHWAY; DISEASE; EXPORT; PHOSPHORYLATION; PROTEINS; ISOFORMS	Constitutive activation of the Wnt/beta-catenin pathway has been implicated as the primary cause of colon cancer. However, the major transducers of Wnt signaling in the intestine, T-cell factor 1 (TCF-1) and TCF-4, have opposing functions. Knockout of TCF-4 suppresses growth and maintenance of crypt stem cells, whereas knockout of TCF-1 leads to adenomas. These phenotypes suggest that TCF-4 is Wnt-promoting, whereas TCF-1 acts like a tumor suppressor. Our study of TCF expression in human colon crypts reveals a mechanistic basis for this paradox. In normal colon cells, a dominant-negative isoform of TCF-1 (dnTCF-1) is expressed that is equally distributed between nuclear and cytoplasmic compartments. In colon cancer cells, TCF-1 is predominantly cytoplasmic. Localization is because of active nuclear export and is directed by an autocrine-acting Wnt ligand that requires Ca2+/calmodulin-dependent kinase II (CaMKII) activity for secretion and a downstream step in the export pathway. TCF-4 remains nuclear; its unopposed activity is accompanied by downregulation of dnTCF-1 and increased expression of full-length isoforms. Thus, the dnTCF-1 and TCF-4 balance is corrupted in cancer by two mechanisms, a Wnt/CaMKII kinase signal for nuclear export and decreased dnTCF-1 expression. We propose that dnTCF-1 provides homeostatic regulation of Wnt signaling and growth in normal colon, and the alterations in nuclear export and promoter usage contribute to aberrant Wnt activity in colon cancer. Oncogene (2009) 28, 4133-4146; doi: 10.1038/onc.2009.271; published online 14 September 2009	[Syed, A.; Theisen, H.; Marsh, J. L.] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; [Najdi, R.; Arce, L.; Ting, J-H T.; Atcha, F.; Waterman, M. L.] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; [Syed, A.; Theisen, H.; Marsh, J. L.] Univ Calif Irvine, Ctr Dev Biol, Irvine, CA 92697 USA; [Nguyen, A. V.; Martinez, M.; Holcombe, R. F.] Univ Calif Irvine, Div Hematol Oncol, Dept Med, Irvine, CA 92697 USA; [Edwards, R. A.; Marsh, J. L.] Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Marsh, JL (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA.	jlmarsh@uci.edu; mlwaterm@uci.edu			NIH [RO1 HD36081, RO1 HD36049, T32 CA113265, CA096878, CA108697, R21 DK071591, CA-82450]; Cancer Center Support Grant at the University of California, Irvine [CA-62203]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036049, R01HD036081] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K24CA082450, R01CA096878, T32CA113265, P30CA062203, R01CA108697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK071591] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Support Grant at the University of California, Irvine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We specially thank Didi Mwengela, Amanda Chamberlain, Candice Solomon and David Hernandez for help in cloning and sequencing TCF-1 cDNA. We also thank Eric J Stanbridge for critical reading of the manuscript, Michelle Digman for help with confocal imaging, Tohru Ishitani, Bang Hoang and Randall T Moon for reagents and advice. This work was supported by NIH grants RO1 HD36081 and RO1 HD36049 to JLM, NIH T32 CA113265, CA096878 and CA108697 to MLW, R21 DK071591 to RAE and NIH grant CA-82450 to RFH. This work was made possible, in part, through access to the confocal facility of the Optical Biology Shared Resource of the Cancer Center Support Grant (CA-62203) at the University of California, Irvine.	Arce L, 2006, ONCOGENE, V25, P7492, DOI 10.1038/sj.onc.1210056; Atcha FA, 2007, MOL CELL BIOL, V27, P8352, DOI 10.1128/MCB.02132-06; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096; Chang MV, 2008, CURR BIOL, V18, P1877, DOI 10.1016/j.cub.2008.10.047; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Griffith LC, 2008, CELL, V133, P397, DOI 10.1016/j.cell.2008.04.018; Hatzis P, 2008, MOL CELL BIOL, V28, P2732, DOI 10.1128/MCB.02175-07; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/ng0501-53; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Kohn AD, 2005, CELL CALCIUM, V38, P439, DOI 10.1016/j.ceca.2005.06.022; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Lo MC, 2004, CELL, V117, P95, DOI 10.1016/S0092-8674(04)00203-X; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Sievers S, 2006, BIOMARKERS, V11, P270, DOI 10.1080/13547500600633954; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Tang W, 2008, P NATL ACAD SCI USA, V105, P9697, DOI 10.1073/pnas.0804709105; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; Yamada M, 2006, J BIOL CHEM, V281, P20749, DOI 10.1074/jbc.M602089200	30	41	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2009	28	47					4133	4146		10.1038/onc.2009.271	http://dx.doi.org/10.1038/onc.2009.271			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DQ	19749792	Green Accepted, Bronze, Green Submitted			2022-12-17	WOS:000272876100001
J	Agnihotri, S; Wolf, A; Picard, D; Hawkins, C; Guha, A				Agnihotri, S.; Wolf, A.; Picard, D.; Hawkins, C.; Guha, A.			GATA4 is a regulator of astrocyte cell proliferation and apoptosis in the human and murine central nervous system	ONCOGENE			English	Article						GATA4; astrocyte; proliferation; apoptosis; INK4B; CNS	TRANSCRIPTION FACTOR; GENE-EXPRESSION; CYCLE ARREST; IN-VITRO; MOUSE; P15(INK4B); PATHWAY; FAMILY; CANCER; HYPERMETHYLATION	The GATA transcription factors consist of six family members, which bind to the consensus DNA-binding element, W-GATA-R, and are poorly characterized in the central nervous system (CNS). Using retroviral gene trapping on transgenic mouse glioma models, we identified GATA6 to be a novel tumor suppressor gene in glioblastoma multiforme. We now show GATA4, a family member of GATA6, to be expressed in the neurons and glia of normal murine and human embryonic and adult CNS. Silencing GATA4 in normal astrocytes did not alter their growth properties. In contrast, knockdown of Gata4 in p53 null non-transformed murine astrocytes induced transformation, with increased proliferation and resistance to chemotherapy or radiation-induced apoptosis. Furthermore, GATA4 expression was lost in a panel of human malignant astrocytoma cell lines. GATA4 overexpression in normal human and murine astrocytes resulted in a cell cycle block in G1 phase, with increased apoptosis. Mechanistically, GATA4 was a transcriptional inducer of the cyclin-dependent kinase inhibitor, p15INK4B, leading to the attenuation of cyclin D1. GATA4 expression was also induced by transforming growth factor-beta, leading to the inhibition of astrocyte proliferation. Collectively, we show that GATA4 is expressed in the embryonic and adult CNS and acts as a negative regulator of astrocyte proliferation and growth. Oncogene (2009) 28, 3033-3046; doi:10.1038/onc.2009.159; published online 22 June 2009	[Guha, A.] Univ Toronto, Toronto Western Hosp, Div Neurosurg, Toronto, ON M5T 2S8, Canada; [Agnihotri, S.; Wolf, A.; Picard, D.; Guha, A.] Univ Toronto, Hosp Sick Children, Res Inst, Arthur & Sonia Labatts Brain Tumor Res Ctr, Toronto, ON M5T 2S8, Canada; [Hawkins, C.] Univ Toronto, Hosp Sick Children, Div Pathol, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Guha, A (corresponding author), Univ Toronto, Toronto Western Hosp, Div Neurosurg, Room 4W-446,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	abhijit.guha@uhn.on.ca	Hawkins, Cynthia/M-2571-2019	AGNIHOTRI, SAMEER/0000-0001-6584-3795	Hospital for Sick Children and an Ontario Institute of Cancer Research; National Cancer Institute of Canada; Brain Tumor Society; National Brain Tumor Foundation	Hospital for Sick Children and an Ontario Institute of Cancer Research; National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Brain Tumor Society; National Brain Tumor Foundation	SA was supported by a RESTRACOMP studentship award from the Hospital for Sick Children and an Ontario Institute of Cancer Research award. Thanks to Dr Deepak Kamnasaran for technical advice and Jing Ma for technical assistance on IHC. AG was funded for this study by the National Cancer Institute of Canada, Brain Tumor Society and National Brain Tumor Foundation.	Afouda BA, 2005, DEVELOPMENT, V132, P763, DOI 10.1242/dev.01647; Anttonen M, 2006, J MOL ENDOCRINOL, V36, P557, DOI 10.1677/jme.1.01962; Belaguli NS, 2007, AM J PHYSIOL-GASTR L, V292, pG1520, DOI 10.1152/ajpgi.00236.2006; Bogler O, 1999, CELL GROWTH DIFFER, V10, P73; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Capo-Chichi CD, 2003, CANCER RES, V63, P4967; Caslini C, 2006, ONCOGENE, V25, P5446, DOI 10.1038/sj.onc.1209533; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; Guo MZ, 2006, INT J CANCER, V119, P2078, DOI 10.1002/ijc.22092; Guo MZ, 2004, CLIN CANCER RES, V10, P7917, DOI 10.1158/1078-0432.CCR-04-1140; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Kamnasaran D, 2005, DEV BRAIN RES, V160, P90, DOI 10.1016/j.devbrainres.2005.07.012; Kamnasaran D, 2007, P NATL ACAD SCI USA, V104, P8053, DOI 10.1073/pnas.0611669104; Kobayashi S, 2006, FASEB J, V20, P800, DOI 10.1096/fj.05-5426fje; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lawson MA, 1998, MOL CELL ENDOCRINOL, V140, P157, DOI 10.1016/S0303-7207(98)00044-6; Lawson MA, 1998, MOL ENDOCRINOL, V12, P364, DOI 10.1210/me.12.3.364; Lowry JA, 2000, J MOL EVOL, V50, P103, DOI 10.1007/s002399910012; Luo Y, 2000, J IMMUNOL, V165, P4015, DOI 10.4049/jimmunol.165.7.4015; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Perlman H, 1998, J BIOL CHEM, V273, P13713, DOI 10.1074/jbc.273.22.13713; QUELLE DE, 1995, ONCOGENE, V11, P635; Ray A, 2004, CLIN CANCER RES, V10, P7613, DOI 10.1158/1078-0432.CCR-04-0499; Reamon-Buettner SM, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-38; Reilly KM, 2000, NAT GENET, V26, P109, DOI 10.1038/79075; Rempe DA, 2007, J BIOL CHEM, V282, P16187, DOI 10.1074/jbc.M702203200; Rich JN, 1999, J BIOL CHEM, V274, P35053, DOI 10.1074/jbc.274.49.35053; Setogawa T, 2006, BIOCHEM BIOPH RES CO, V343, P1186, DOI 10.1016/j.bbrc.2006.03.077; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sonoda Y, 2001, CANCER RES, V61, P4956; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057	34	41	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2009	28	34					3033	3046		10.1038/onc.2009.159	http://dx.doi.org/10.1038/onc.2009.159			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487ZU	19543315				2022-12-17	WOS:000269319000003
J	Dasgupta, S; Wasson, LM; Rauniyar, N; Prokai, L; Borejdo, J; Vishwanatha, JK				Dasgupta, S.; Wasson, L. M.; Rauniyar, N.; Prokai, L.; Borejdo, J.; Vishwanatha, J. K.			Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells	ONCOGENE			English	Article						C17orf37; 17q12; prostate cancer; migration; invasion; NF-kappa B	PLASMINOGEN-ACTIVATOR; PROTEIN PRENYLATION; BREAST-CANCER; NUDE-MICE; ANGIOGENESIS; METASTASIS; PATHWAY; AMPLIFICATION; PROGRESSION; EXPRESSION	C17orf37/MGC14832, a novel gene located on human chromosome 17q12 in the ERBB2 amplicon, is abundantly expressed in breast cancer. C17orf37 expression has been reported to positively correlate with grade and stage of cancer progression; however the functional significance of C17orf37 overexpression in cancer biology is not known. Here, we show that C17orf37 is highly expressed in prostate cancer cell lines and tumors, compared to minimal expression in normal prostate cells and tissues. Cellular localization studies by confocal and total internal reflection fluorescence microscopy revealed predominant expression of C17orf37 in the cytosol with intense staining in the membrane of prostate cancer cells. RNA-interference-mediated downregulation of C17orf37 resulted in decreased migration and invasion of DU-145 prostate cancer cells, and suppressed the DNA-binding activity of nuclear factor-kappa B (NF-kappa B) transcription factor resulting in reduced expression of downstream target genes matrix metalloproteinase 9, urokinase plasminogen activator and vascular endothelial growth factor. Phosphorylation of PKB/Akt was also reduced upon C17orf37 downregulation, suggesting C17orf37 acts as a signaling molecule that increases invasive potential of prostate cancer cells by NF-kappa B-mediated downstream target genes. Our data strongly suggest C17orf37 overexpression in prostate cancer functionally enhances migration and invasion of tumor cells, and is an important target for cancer therapy. Oncogene (2009) 28, 2860-2872; doi:10.1038/onc.2009.145; published online 8 June 2009	[Vishwanatha, J. K.] Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Grad Sch Biomed Sci, Ft Worth, TX 76107 USA; [Dasgupta, S.; Vishwanatha, J. K.] Univ N Texas, Hlth Sci Ctr, Dept Biomed Sci, Ft Worth, TX 76107 USA; [Dasgupta, S.; Vishwanatha, J. K.] Univ N Texas, Hlth Sci Ctr, Inst Canc Res, Ft Worth, TX 76107 USA; [Wasson, L. M.] Harris Methodist Ft Worth Hosp, Dept Pathol, Ft Worth, TX USA	University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center	Vishwanatha, JK (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Grad Sch Biomed Sci, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	jvishwan@hsc.unt.edu	Dasgupta, Subhamoy/I-6022-2015; Rauniyar, Navin/A-3318-2016	Dasgupta, Subhamoy/0000-0001-7167-908X; Prokai, Laszlo/0000-0002-4559-3458; Vishwanatha, Jamboor/0000-0002-0266-6020	NIH [CA109593, MD 001633]; DOD PCRP Training Award [PC081282]; NCI Cancer Center Support [P30 CA36727]; Nebraska Department of Health Institutional [LB595]; NATIONAL CANCER INSTITUTE [R21CA109593, P30CA036727] Funding Source: NIH RePORTER; NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P20MD001633] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD PCRP Training Award; NCI Cancer Center Support(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Nebraska Department of Health Institutional; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	We thank Dr Linda Cunnighum (UNTHSC) for assistance with immunohistochemistry and Dr Kapil Mehta (MD Anderson Cancer Center, TX) for help with migration assays. The present work is supported by grant nos. CA109593 and MD 001633 (JKV) from NIH and DOD PCRP Training Award PC081282 (SD). UNMC/Eppley Cancer Center Tumor Bank was supported by an NCI Cancer Center Support Grant P30 CA36727 and Nebraska Department of Health Institutional LB595 Grant for Cancer and Smoking Disease Research.	Arya M, 2006, SURG ONCOL, V15, P117, DOI 10.1016/j.suronc.2006.10.002; Axelrod D, 2001, J BIOMED OPT, V6, P6, DOI 10.1117/1.1335689; Banerjee Abhijit G, 2003, Mol Cancer, V2, P34, DOI 10.1186/1476-4598-2-34; Berger R, 2006, CANCER RES, V66, P5723, DOI 10.1158/0008-5472.CAN-05-3928; Burghardt TP, 2006, BIOCHEMISTRY-US, V45, P4058, DOI 10.1021/bi052097d; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Connolly JM, 1998, J UROLOGY, V160, P932, DOI 10.1016/S0022-5347(01)62835-0; Das S, 2007, PROSTATE, V67, P1550, DOI 10.1002/pros.20640; Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90; Evans EE, 2006, MOL CANCER THER, V5, P2919, DOI 10.1158/1535-7163.MCT-06-0389; Fu HW, 1999, RECENT PROG HORM RES, V54, P315; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Helenius MA, 2006, BJU INT, V97, P404, DOI 10.1111/j.1464-410X.2005.05912.x; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Jo MJ, 2005, J BIOL CHEM, V280, P17449, DOI 10.1074/jbc.M413141200; Kauraniemi P, 2006, ENDOCR-RELAT CANCER, V13, P39, DOI 10.1677/erc.1.01147; Kelly P, 2006, J BIOL CHEM, V281, P26483, DOI 10.1074/jbc.M604376200; Li Y, 2007, CANCER TREAT REV, V33, P521, DOI 10.1016/j.ctrv.2007.06.003; Lokeshwar BL, 1999, ANN NY ACAD SCI, V878, P271, DOI 10.1111/j.1749-6632.1999.tb07690.x; Maurer-Stroh S, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-6-r55; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; Pienta Kenneth J, 2005, Clin Prostate Cancer, V4, P24, DOI 10.3816/CGC.2005.n.008; Price JT, 1997, CRIT REV BIOCHEM MOL, V32, P175, DOI 10.3109/10409239709082573; Rothermund CA, 2002, PROSTATE CANCER P D, V5, P236, DOI 10.1038/sj.pcan.4500582; Sheng SJ, 2001, CANCER METAST REV, V20, P287, DOI 10.1023/A:1015539612576; Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Sun J, 2008, NAT GENET, V40, P1153, DOI 10.1038/ng.214; THALMANN GN, 1994, CANCER RES, V54, P2577; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Virtanen SS, 2002, CANCER RES, V62, P2708; WILSON MJ, 1993, CELL MOL BIOL RES, V39, P751; Wilson SR, 2004, PROSTATE, V60, P168, DOI 10.1002/pros.20047; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319	37	41	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2860	2872		10.1038/onc.2009.145	http://dx.doi.org/10.1038/onc.2009.145			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19503095	Green Accepted			2022-12-17	WOS:000268917100002
J	Chaturvedi, D; Gao, X; Cohen, MS; Taunton, J; Patel, TB				Chaturvedi, D.; Gao, X.; Cohen, M. S.; Taunton, J.; Patel, T. B.			Rapamycin induces transactivation of the EGFR and increases cell survival	ONCOGENE			English	Article						mTOR; rapamycin; transactivation; EGFR; c-Src; apoptosis	GROWTH-FACTOR RECEPTOR; RIBOSOMAL S6 KINASE; MAMMALIAN TARGET; CANCER-CELLS; CARDIAC-HYPERTROPHY; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; MTOR; PATHWAY; AKT	The mammalian target of rapamycin (mTOR) signa ling network regulates cell growth, proliferation and cell survival. Deregulated activation of this pathway is a common event in diverse human diseases such as cancers, cardiac hypertrophy, vascular restenosis and nephrotic hypertrophy. Although mTOR inhibitor, rapamycin, has been widely used to inhibit the aberrant signaling due to mTOR activation that plays a major role in hyperproliferative diseases, in some cases rapamycin does not attenuate the cell proliferation and survival. Thus, we studied the mechanism(s) by which cells may confer resistance to rapamycin. Our data show that in a variety of cell types the mTOR inhibitor rapamycin activates extracellularly regulated kinases (Erk1/2) signa ling. Rapamycin-mediated activation of the Erk1/2 signaling requires (a) the epidermal growth factor receptor (EGFR), (b) its tyrosine kinase activity and (c) intact autophosphorylation sites on the receptor. Rapamycin treatment increases tyrosine phosphorylation of EGFR without the addition of growth factor and this transactivation of receptor involves activation of c-Src. We also show that rapamycin treatment triggers activation of cell survival signaling pathway by activating the prosurvival kinases Erk1/2 and p90RSK. These studies provide a novel paradigm by which cells escape the apoptotic actions of rapamycin and its derivatives that inhibit the mTOR pathway.	[Chaturvedi, D.; Gao, X.; Patel, T. B.] Loyola Univ, Med Ctr, Stritch Sch Med, Dept Pharmacol & Expt Therapeut, Maywood, IL 60153 USA; [Cohen, M. S.; Taunton, J.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	Loyola University Chicago; University of California System; University of California San Francisco	Chaturvedi, D (corresponding author), Loyola Univ, Med Ctr, Stritch Sch Med, Dept Pharmacol & Expt Therapeut, 2160 S 1st Ave,Bldg 101,Rm 2716, Maywood, IL 60153 USA.	dchaturvedi@lumc.edu			American Heart Association-SDG [AHA-ID-0830411Z]; NIH [GM071434, GM 079226, GM73181]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079226, R01GM073181, R01GM071434] Funding Source: NIH RePORTER	American Heart Association-SDG(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are indebted to Dr PJ Bertics for providing us with the B82L cells, the EGFR cDNA and EGFR antibodies and to Ms Kuldeep Patel for the immunocytochemical analyses. This study was supported by American Heart Association-SDG AHA-ID-0830411Z ( to DC) and NIH Grants GM071434 ( to JT), GM 079226 and GM73181 ( to TBP).	Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Azzariti A, 2008, BIOCHEM PHARMACOL, V75, P1035, DOI 10.1016/j.bcp.2007.11.018; Banko JL, 2006, J NEUROSCI, V26, P2167, DOI 10.1523/JNEUROSCI.5196-05.2006; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Boluyt MO, 2004, CARDIOVASC DRUG THER, V18, P257, DOI 10.1023/B:CARD.0000041245.61136.56; Chaturvedi D, 2006, MOL CELL BIOL, V26, P4586, DOI 10.1128/MCB.01422-05; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367; Costa LJ, 2007, UROLOGY, V69, P596, DOI 10.1016/j.urology.2007.01.053; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dormond O, 2007, J BIOL CHEM, V282, P23679, DOI 10.1074/jbc.M700563200; Dummler BA, 2005, J BIOL CHEM, V280, P13304, DOI 10.1074/jbc.M408194200; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fumarola C, 2005, CELL DEATH DIFFER, V12, P1344, DOI 10.1038/sj.cdd.4401660; Galanis E, 2005, J CLIN ONCOL, V23, P5294, DOI 10.1200/JCO.2005.23.622; Goudar RK, 2005, MOL CANCER THER, V4, P101; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Hardie DG, 2006, J PHYSIOL-LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Jin W, 2007, CANCER RES, V67, P3192, DOI 10.1158/0008-5472.CAN-06-3526; Kiley SC, 2007, AM J PHYSIOL-RENAL, V293, pF895, DOI 10.1152/ajprenal.00227.2007; Kris MG, 2007, J CLIN ONCOL, V25, p18s; Kudo N, 1996, BBA-LIPID LIPID MET, V1301, P67, DOI 10.1016/0005-2760(96)00013-6; Li J, 1999, J BIOL CHEM, V274, P11209, DOI 10.1074/jbc.274.16.11209; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; McMullen JR, 2004, CIRCULATION, V109, P3050, DOI 10.1161/01.CIR.0000130641.08705.45; Metro G, 2006, REV RECENT CLIN TRIA, V1, P1, DOI 10.2174/157488706775246157; Milton DT, 2007, CANCER-AM CANCER SOC, V110, P599, DOI 10.1002/cncr.22816; Myers AP, 2004, MOL CELL BIOL, V24, P4255, DOI 10.1128/MCB.24.10.4255-4266.2004; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Parry TJ, 2005, EUR J PHARMACOL, V524, P19, DOI 10.1016/j.ejphar.2005.09.042; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Roux PP, 2003, MOL CELL BIOL, V23, P4796, DOI 10.1128/MCB.23.14.4796-4804.2003; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sharma S, 2006, CARDIOLOGY, V105, P128, DOI 10.1159/000090550; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; VanderWeele DJ, 2004, MOL CANCER THER, V3, P1605; Vega F, 2006, CANCER RES, V66, P6589, DOI 10.1158/0008-5472.CAN-05-3018; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	61	41	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	2009	28	9					1187	1196		10.1038/onc.2008.490	http://dx.doi.org/10.1038/onc.2008.490			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151764	Green Accepted, Green Submitted			2022-12-17	WOS:000263906200003
J	Ahmed, KM; Fan, M; Nantajit, D; Cao, N; Li, JJ				Ahmed, K. M.; Fan, M.; Nantajit, D.; Cao, N.; Li, J. J.			Cyclin D1 in low-dose radiation-induced adaptive resistance	ONCOGENE			English	Article						radiation resistance; cyclin D1; 14-3-3; Bax; human keratinocytes; adaptive response	FACTOR-KAPPA-B; IONIZING-RADIATION; GENOMIC INSTABILITY; APOPTOTIC RESPONSE; HUMAN-LYMPHOCYTES; GENE-EXPRESSION; CANCER CELLS; X-RAYS; PROTEIN; BAX	Cyclin D1 is involved in cell-cycle arrest in DNA-damage response. This study tested the hypothesis that cyclin D1 regulates mitochondrial apoptosis. Cycl in D1 was induced by low-dose ionizing radiation (LDIR; 10-cGy X-ray) in human keratinocytes with an adaptive radioresistance that can be inhibited by short interfering RNA (siRNA)mediated cyclin D1 inhibition. Cyclin D1 was found to form complex with chaperon 14-3-3 zeta in unstressed cells and mutation of 14-3-3 zeta Ser-58 to Asp (S58D) significantly impaired 14-3-3 zeta binding to cyclin D1. The formation of cyclin D1/14-3-3 zeta complex was differently regulated by exposure to low (10-cGy X-ray) versus high (5-Gy gamma-ray) doses of radiation. Unlike exposure to 5-Gy that predominantly enhanced cyclin D1 nuclear accumulation, LDIR induced the dissociation of the cyclin D1/14-3-3 zeta complex without nuclear translocation, indicating that cytosolic accumulation of cyclin D1 was required for LDIR-induced adaptive response. Further studies revealed a direct interaction of cyclin D1 with proapoptotic Bax and an improved mitochondrial membrane potential (Delta psi(m)) in LDIR-treated cells. Consistently, blocking cyclin D1/Bax formation by cyclin D1 siRNA reversed Delta psi(m) and inhibited the LDIR-associated antiapoptotic response. These results demonstrate the evidence that cytosolic cyclin D1 is able to regulate apoptosis by interaction with Bax in LDIR-induced adaptive resistance.	[Ahmed, K. M.; Fan, M.; Nantajit, D.; Cao, N.; Li, J. J.] Purdue Univ, Sch Hlth Sci, Div Mol Radiobiol, W Lafayette, IN 47907 USA; [Ahmed, K. M.; Fan, M.; Nantajit, D.; Cao, N.; Li, J. J.] Purdue Univ, Sch Hlth Sci, Grad Program Radiat & Canc Biol, W Lafayette, IN 47907 USA; [Li, J. J.] Purdue Canc Ctr, W Lafayette, IN USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Li, JJ (corresponding author), Purdue Univ, Sch Hlth Sci, Div Mol Radiobiol, 550 Stadium Mall Dr, W Lafayette, IN 47907 USA.	jjli@purdue.edu	Cao, Ning/F-9480-2013; Cao, Ning/I-3094-2013; Nantajit, Danupon/CAF-7353-2022	Cao, Ning/0000-0002-3929-8604	NIH NCI [RO1 101990]; Department of Energy [DE-FG02-03ER63634]	NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Energy(United States Department of Energy (DOE))	We thank Dr N Colburn (National Cancer Institute, NIH) for providing human keratinocytes HK18 cells, Dr S Liu (Purdue University School of Health Sciences) for invaluable help with animal experiments. This work was supported by NIH NCI grant RO1 101990 and the Department of Energy grant DE-FG02-03ER63634 to JJL.	Ahmed KM, 2006, MOL CANCER RES, V4, P945, DOI 10.1158/1541-7786.MCR-06-0291; Biliran H, 2005, CLIN CANCER RES, V11, P6075, DOI 10.1158/1078-0432.CCR-04-2419; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen XF, 2002, CANCER RES, V62, P1213; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Daosukho C, 2002, ONCOGENE, V21, P3603, DOI 10.1038/sj.onc.1205448; Fan M, 2007, CANCER RES, V67, P3220, DOI 10.1158/0008-5472.CAN-06-2728; Feinendegen LE, 1996, MUTAT RES-FUND MOL M, V358, P199, DOI 10.1016/S0027-5107(96)00121-2; Guo GZ, 2003, MOL CELL BIOL, V23, P2362, DOI 10.1128/MCB.23.7.2362-2378.2003; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; KELSEY KT, 1991, MUTAT RES, V263, P197, DOI 10.1016/0165-7992(91)90001-K; Klokov D, 2004, MUTAT RES-FUND MOL M, V568, P97, DOI 10.1016/j.mrfmmm.2004.06.049; Limoli CL, 2001, FREE RADICAL BIO MED, V31, P10, DOI 10.1016/S0891-5849(01)00542-1; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Oyama T, 1998, CANCER RES, V58, P2876; Pandey BN, 2006, ANTIOXID REDOX SIGN, V8, P1253, DOI 10.1089/ars.2006.8.1253; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Powell DW, 2003, MOL CELL BIOL, V23, P5376, DOI 10.1128/MCB.23.15.5376-5387.2003; Qi WQ, 2003, RADIAT RES, V160, P217, DOI 10.1667/RR3038; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Sakamaki T, 2006, MOL CELL BIOL, V26, P5449, DOI 10.1128/MCB.02074-05; SHADLEY JD, 1987, RADIAT RES, V111, P511, DOI 10.2307/3576936; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sumrejkanchanakij P, 2003, ONCOGENE, V22, P8723, DOI 10.1038/sj.onc.1206870; Ulsh BA, 2004, J ENVIRON RADIOACTIV, V74, P73, DOI 10.1016/j.jenvrad.2004.01.005; Wang T, 2005, J BIOL CHEM, V280, P12593, DOI 10.1074/jbc.M410982200; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	32	41	45	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2008	27	53					6738	6748		10.1038/onc.2008.265	http://dx.doi.org/10.1038/onc.2008.265			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO	18695676	Green Accepted			2022-12-17	WOS:000260866200004
J	Gehen, SC; Staversky, RJ; Bambara, RA; Keng, PC; O'Reilly, MA				Gehen, S. C.; Staversky, R. J.; Bambara, R. A.; Keng, P. C.; O'Reilly, M. A.			hSMG-1 and ATM sequentially and independently regulate the G(1) checkpoint during oxidative stress	ONCOGENE			English	Article						cell cycle; DNA damage; p53; reactive oxygen species	DAMAGE-INDUCED PHOSPHORYLATION; RNA SURVEILLANCE PROTEIN; DOUBLE-STRAND BREAKS; DNA-DAMAGE; IONIZING-RADIATION; DEPENDENT PHOSPHORYLATION; HUMAN SMG-1; KINASE; P53; UBIQUITINATION	Genotoxic stress activates the phosphatidylinositol 3-kinase-like kinases ( PIKKs) that phosphorylate proteins involved in cell cycle arrest, DNA repair and apoptosis. Previous work showed that the PIKK ataxia telangiectasia mutated ( ATM) but not ATM and Rad3 related phosphorylates p53 ( Ser15) during hyperoxia, a model of prolonged oxidative stress and DNA damage. Here, we show hSMG-1 is responsible for the rapid and early phosphorylation of p53 ( Ser15) and that ATM helps maintain phosphorylation after 24 h. Despite reduced p53 phosphorylation and abundance in cells depleted of hSMG-1 or ATM, levels of the p53 target p21 were still elevated and the G(1) checkpoint remained intact. Conditional overexpression of p21 in p53-deficient cells revealed that hyperoxia also stimulates wortmannin-sensitive degradation of p21. siRNA depletion of hSMG-1 or ATM restored p21 stability and the G(1) checkpoint during hyperoxia. These findings establish hSMG-1 as a proximal regulator of DNA damage signaling and reveal that the G1 checkpoint is tightly regulated during prolonged oxidative stress by both PIKK-dependent synthesis and proteolysis of p21.	[Staversky, R. J.; O'Reilly, M. A.] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA; [Gehen, S. C.] Univ Rochester, Dept Environm Med, Rochester, NY 14642 USA; [Bambara, R. A.] Univ Rochester, Dept Biochem & Biophys, Rochester, NY 14642 USA; [Keng, P. C.] Univ Rochester, Dept Radiat Oncol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	O'Reilly, MA (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pediat, 601 Elmwood Ave,Box 850, Rochester, NY 14642 USA.	michael_oreilly@urmc.rochester.edu			NHLBI NIH HHS [HL-67392, R01 HL067392, R01 HL067392-06] Funding Source: Medline; NIEHS NIH HHS [T32 ES007026-21, P30 ES001247, ES-07026, P30 ES001247-349022, T32 ES007026, ES-01247, R01 ES007026] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007026, T32ES007026, P30ES001247] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abraham RT, 2005, SCIENCE, V308, P510, DOI 10.1126/science.1112069; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brumbaugh KM, 2004, MOL CELL, V14, P585, DOI 10.1016/j.molcel.2004.05.005; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; Das KC, 2004, AM J PHYSIOL-LUNG C, V286, pL87, DOI 10.1152/ajplung.00203.2002; Denning G, 2001, J BIOL CHEM, V276, P22709, DOI 10.1074/jbc.C100144200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Engel FB, 2003, MOL CELL BIOL, V23, P555, DOI 10.1128/MCB.23.2.555-565.2003; Gehen SC, 2007, AM J PHYSIOL-LUNG C, V292, pL716, DOI 10.1152/ajplung.00135.2006; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Helt CE, 2004, AM J PHYSIOL-LUNG C, V286, pL506, DOI 10.1152/ajplung.00243.2003; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; O'Reilly MA, 2001, AM J RESP CELL MOL, V24, P703, DOI 10.1165/ajrcmb.24.6.4355; OConnor PM, 1997, CANCER SURV, V29, P151; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Vitiello PF, 2006, AM J PATHOL, V168, P1838, DOI 10.2353/ajpath.2006.051162; Yamashita A, 2001, GENE DEV, V15, P2215, DOI 10.1101/gad.913001; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134	36	41	41	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4065	4074		10.1038/onc.2008.48	http://dx.doi.org/10.1038/onc.2008.48			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18332866	Green Accepted			2022-12-17	WOS:000257325100006
J	Leal, JFM; Fominaya, J; Cascon, A; Guijarro, MV; Blanco-Aparicio, C; Lleonart, M; Castro, ME; Cajal, SRY; Robledo, M; Beach, DH; Carnero, A				Leal, J. F. M.; Fominaya, J.; Cascon, A.; Guijarro, M. V.; Blanco-Aparicio, C.; Lleonart, M.; Castro, M. E.; Ramon y Cajal, S.; Robledo, M.; Beach, D. H.; Carnero, A.			Cellular senescence bypass screen identifies new putative tumor suppressor genes	ONCOGENE			English	Article						senescence; genetic screening; tumor suppressor; p53; BRF1; Csn2	COP9 SIGNALOSOME; CANCER-THERAPY; HUMAN-CELLS; P53; ACCUMULATION; DEGRADATION; P16(INK4A); DISRUPTION; HALLMARKS; ABSENCE	Senescence is a mechanism that limits cellular lifespan and constitutes a barrier against cellular immortalization. To identify new senescence regulatory genes that might play a role in tumorigenesis, we have designed and performed a large-scale antisense-based genetic screen in primary mouse embryo. broblasts (MEFs). Out of this screen, we have identified five different genes through which loss of function partially bypasses senescence. These genes belong to very different biochemical families: csn2 (component of the Cop9 signalosome), aldose reductase (a metabolic enzyme) and brf1 (subunit of the RNA polymerase II complex), S-adenosyl homocysteine hydrolase and Bub1. Inactivation, at least partial, of these genes confers resistance to both p53- and p16INK4a-induced proliferation arrest. Furthermore, such inactivation inhibits p53 but not E2F1 transcriptional activity and impairs DNA-damage-induced transcription of p21. Since the aim of the screen was to identify new regulators of tumorigenesis, we have tested their inactivation in human tumors. We have found, either by northern blot or quantitative reverse transcriptase-PCR analysis, that the expression of three genes, Csn2, Aldose reductase and Brf1, is lost at different ratios in tumors of different origins. These genes are located at common positions of loss of heterogeneity (15q21.2, 7q35 and 14q32.33); therefore, we have measured genomic losses of these specific genes in different tumors. We have found that Csn2 and Brf1 also show genomic losses of one allele in different tumors. Our data suggest that the three genes identified in the genome-wide loss-of-function genetic screen are putative tumor suppressors located at 15q21.2; 7q35 and 14q32.33.	[Leal, J. F. M.; Fominaya, J.; Guijarro, M. V.; Blanco-Aparicio, C.; Castro, M. E.; Carnero, A.] CNIO, Expt Therapeut Programme, Madrid 28029, Spain; [Cascon, A.; Robledo, M.] CNIO, Mol Pathol Programme, Madrid 28029, Spain; [Lleonart, M.; Ramon y Cajal, S.] Hosp Valle De Hebron, Dept Patol, Barcelona, Spain; [Beach, D. H.] Ctr Cutaneous Biol, Inst Cell & Mol Sci, London, England	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitari Vall d'Hebron; University of London; Queen Mary University London	Carnero, A (corresponding author), CNIO, Expt Therapeut Programme, C Melchor Fernandez Almagro 3, Madrid 28029, Spain.	acarnero@cnio.es	IBIS, CANCER/P-3323-2015; Leal, Juan F Martinez/N-6328-2013; LLeonart, Matilde E./Q-2662-2019; Ramon y Cajal, Santiago/H-4955-2016; Blanco-Aparicio, Carmen/I-3162-2015; Espinosas, Maribel/H-8083-2012; Robledo, Mercedes/O-2230-2013; Cascon, Alberto/G-3160-2014	Leal, Juan F Martinez/0000-0002-7538-0875; LLeonart, Matilde E./0000-0002-6196-7405; Ramon y Cajal, Santiago/0000-0002-3867-1390; Blanco-Aparicio, Carmen/0000-0002-3249-6595; Robledo, Mercedes/0000-0001-6256-5902; Cascon, Alberto/0000-0003-2119-891X; Carnero, Amancio/0000-0003-4357-3979	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bech-Otschir D, 2002, J CELL SCI, V115, P467; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Campisi J, 2005, SCIENCE, V309, P886, DOI 10.1126/science.1116801; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Carnero A, 2004, ONCOGENE, V23, P6006, DOI 10.1038/sj.onc.1207839; Carnero A, 2000, NUCLEIC ACIDS RES, V28, P2234, DOI 10.1093/nar/28.11.2234; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Eichhorn K, 2001, J BIOL CHEM, V276, P21158, DOI 10.1074/jbc.M102295200; Greider Carol W., 2004, Cell, VS116, pS83, DOI 10.1016/S0092-8674(04)00053-4; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; Lefrancois-Martinez AM, 2004, J CLIN ENDOCR METAB, V89, P3010, DOI 10.1210/jc.2003-031830; Lleonart ME, 2006, ONCOL REP, V16, P603; Lykke-Andersen K, 2003, MOL CELL BIOL, V23, P6790, DOI 10.1128/MCB.23.19.6790-6797.2003; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Suzuki K, 2001, RADIAT RES, V155, P248, DOI 10.1667/0033-7587(2001)155[0248:RISLGA]2.0.CO;2; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yang XM, 2002, CURR BIOL, V12, P667, DOI 10.1016/S0960-9822(02)00791-1; Yoneda-Kato N, 2005, EMBO J, V24, P1739, DOI 10.1038/sj.emboj.7600656	31	41	44	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					1961	1970		10.1038/sj.onc.1210846	http://dx.doi.org/10.1038/sj.onc.1210846			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17968325				2022-12-17	WOS:000254359100001
J	Sauermann, M; Sahin, O; Sultmann, H; Hahne, F; Blaszkiewicz, S; Majety, M; Zatloukal, K; Fuzesi, L; Poustka, A; Wiemann, S; Arlt, D				Sauermann, M.; Sahin, Oe; Sueltmann, H.; Hahne, F.; Blaszkiewicz, S.; Majety, M.; Zatloukal, K.; Fuezesi, L.; Poustka, A.; Wiemann, S.; Arlt, D.			Reduced expression of vacuole membrane protein 1 affects the invasion capacity of tumor cells	ONCOGENE			English	Article						metastasis; invasion; detachment; initial cell-cell contact; cell junctions	GENE-EXPRESSION; E-CADHERIN; PROTEINS; CLASSIFICATION; CARCINOMA; PATTERNS; CANCER; FLOW	Vacuole membrane protein 1 (Vmp1) is described as a cancer-relevant cell cycle modulator, but the function of this protein and its mode of action in tumor progression are still unknown. In this study, we show that the VMP1 mRNA level is significantly reduced in kidney cancer metastases as compared to primary tumors. Further, VMP1 expression is also decreased in the invasive breast cancer cell lines HCC1954 and MDA-MB-231 as compared to the non-invasive cell lines MCF-12A, T-47D and MCF-7. We show for the first time that Vmp1 is a plasma membrane protein and an essential component of initial cell-cell contacts and tight junction formation. It interacts with the tight junction protein Zonula Occludens-1 and colocalizes in spots between neighboring HEK293 cells. Downregulation of VMP1 by RNAi results in loss of cell adherence, and increases the invasion capacity of the non-invasive kidney cancer cell line Caki-2. In conclusion, our findings establish Vmp1 to be a novel cell-cell adhesion protein and that its expression level determines the invasion and metastatic potential of cancer cells.	[Sauermann, M.; Sahin, Oe; Sueltmann, H.; Hahne, F.; Blaszkiewicz, S.; Majety, M.; Poustka, A.; Wiemann, S.; Arlt, D.] German Canc Res Ctr, Div Mol Genome Anal, DKFZ, D-69120 Heidelberg, Germany; [Zatloukal, K.] Med Univ Graz, Inst Pathol, Graz, Austria; [Fuezesi, L.] Univ Gottingen, Hosp Gottingen, Inst Pathol, Dept Gastroenteropathol, Gottingen, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Medical University of Graz; University of Gottingen	Arlt, D (corresponding author), German Canc Res Ctr, Div Mol Genome Anal, DKFZ, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	d.arlt@dkfz.de	Wiemann, Stefan/E-4424-2013; Sültmann, Holger/E-4534-2013; Sahin, Özgür/F-4403-2014	Wiemann, Stefan/0000-0003-4683-3174; Sültmann, Holger/0000-0002-5257-8600; Sahin, Özgür/0000-0002-8033-7089				Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Arlt D, 2005, CANCER RES, V65, P7733, DOI 10.1158/0008-5472.CAN-05-0642; Benoliel AM, 2003, ANTICANCER RES, V23, P4891; Boer JM, 2001, GENOME RES, V11, P1861, DOI 10.1101/gr.184501; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Dusetti NJ, 2002, BIOCHEM BIOPH RES CO, V290, P641, DOI 10.1006/bbrc.2001.6244; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Martin TA, 2001, HISTOL HISTOPATHOL, V16, P1183, DOI 10.14670/HH-16.1183; Mehrle A, 2006, NUCLEIC ACIDS RES, V34, pD415, DOI 10.1093/nar/gkj139; Sahin O, 2007, P NATL ACAD SCI USA, V104, P6579, DOI 10.1073/pnas.0606827104; Sauermann M, 2007, J BIOMOL SCREEN, V12, P510, DOI 10.1177/1087057107301271; Starkuviene V, 2004, GENOME RES, V14, P1948, DOI 10.1101/gr.2658304; Sultmann H, 2005, CLIN CANCER RES, V11, P646; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wiemann S, 2001, GENOME RES, V11, P422, DOI 10.1101/gr.GR1547R	16	41	54	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1320	1326		10.1038/sj.onc.1210743	http://dx.doi.org/10.1038/sj.onc.1210743			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17724469				2022-12-17	WOS:000253407000016
J	Yoshida, K; Ozaki, T; Furuya, K; Nakanishi, M; Kikuchi, H; Yamamoto, H; Ono, S; Koda, T; Omura, K; Nakagawara, A				Yoshida, K.; Ozaki, T.; Furuya, K.; Nakanishi, M.; Kikuchi, H.; Yamamoto, H.; Ono, S.; Koda, T.; Omura, K.; Nakagawara, A.			ATM-dependent nuclear accumulation of IKK-alpha plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin	ONCOGENE			English	Article						apoptosis; ATM; cisplatin; IKK; p73; ubiquitination	B-KINASE-ALPHA; MICE LACKING; LIVER DEGENERATION; KAPPA; PHOSPHORYLATION; ACTIVATION; SUBUNIT; SKIN	I kappa B kinase ( IKK) complex plays an important role in the regulation of signaling pathway that activates nuclear factor-kappa-B (NF-kappa B). Recently, we reported that cisplatin ( CDDP) treatment causes a remarkable nuclear accumulation of IKK-alpha in association with stabilization and activation of p73. However, underlying mechanisms of CDDP-induced nuclear accumulation of IKK-alpha are elusive. Here, we found that ataxia-telangiectasia mutated ( ATM) is one of upstream mediators of IKK-alpha during CDDP-induced apoptosis. In response to CDDP, ATM was phosphorylated at Ser-1981, which was accompanied with nuclear accumulation of IKK-alpha in HepG2 cells, whereas CDDP treatment had undetectable effects on IKK-alpha in ATM-deficient cells. Indirect immuno fluorescence experiments demonstrated that phosphorylated form of ATM colocalizes with nuclear IKK-alpha in response to CDDP. In vitro kinase assay indicated that ATM phosphorylates IKK-alpha at Ser-473. Moreover, IKK-alpha-deficient MEFs displayed CDDP-resistant phenotype as compared with wild-type MEFs. Taken together, our present results suggest that ATM-mediated phosphorylation of nuclear IKK-alpha, which stabilizes p73, is one of the main apoptotic pathways in response to CDDP.	[Yoshida, K.; Ozaki, T.; Furuya, K.; Nakanishi, M.; Kikuchi, H.; Yamamoto, H.; Nakagawara, A.] Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; [Yoshida, K.; Omura, K.] Tokyo Med & Dent Univ, Dept Oral & Maxillofacial Surg, Tokyo, Japan; [Ono, S.; Koda, T.] Hisamitsu Pharmaceut Co Inc, Res Ctr Funct Genom, Chiba, Japan	Chiba Cancer Center; Tokyo Medical & Dental University (TMDU); Hisamitsu Pharmaceutical Co Ltd	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp						Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Furuya K, 2007, J BIOL CHEM, V282, P18365, DOI 10.1074/jbc.M610522200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huynh QK, 2000, J BIOL CHEM, V275, P25883, DOI 10.1074/jbc.M000296200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Saito H, 2002, GYNECOL OBSTET INVES, V53, P46, DOI 10.1159/000049424; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Verma UN, 2004, J BIOL CHEM, V279, P3509, DOI 10.1074/jbc.M309300200; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576	21	41	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1183	1188		10.1038/sj.onc.1210722	http://dx.doi.org/10.1038/sj.onc.1210722			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700524				2022-12-17	WOS:000253136700019
J	Chang, TW; Chen, CC; Chen, KY; Su, JH; Chang, JH; Chang, MC				Chang, T-W; Chen, C-C; Chen, K-Y; Su, J-H; Chang, J-H; Chang, M-C			Ribosomal phosphoprotein P0 interacts with GCIP and overexpression of P0 is associated with cellular proliferation in breast and liver carcinoma cells	ONCOGENE			English	Article						ribosomal P0; GCIP; DIP1/HHM; cyclin D1; breast cancer; hepatocellular carcinoma	GTPASE-ASSOCIATED DOMAIN; LOOP-HELIX PROTEIN; HUMAN HOMOLOG; EXPRESSION; P2; MAID; RNA; P1; HEPATOCARCINOGENESIS; COMPONENTS	The ribosomal acidic P0 protein, an essential component of the eukaryotic ribosomal stalk, was found to interact with the helix-loop-helix protein human Grap2 and cyclin D interacting protein (GCIP)/D-type cyclin-interacting protein 1/human homolog of MAID protein. Using in vivo and in vitro binding assays, we show that P0 can interact with the N and C termini of GCIP via its N-terminal 39-114 amino-acid residues. Although the P0-GCIP complex was detected mainly in cytoplasmic fraction, polysome pro. le analysis indicated that the P0-GCIP complex did not coelute with either polysomes or 60S ribosomes, suggesting that GCIP associates with the free form of P0 in the cytoplasm. Transfection of GCIP into MCF-7 cells resulted in decreased levels of pRb phosphorylation. Cotransfection of P0 with GCIP, however, resulted in GCIP-mediated reduction of pRb phosphorylation level which was repressed by P0. Furthermore, overexpression of P0 in breast cancer and hepatocellular cancer cell lines promoted cell growth and colony formation compared to control transfectants. Overexpression of P0 also increased cyclin D1 expression and phosphorylation of pRb at Ser780. Interestingly, P0 mRNA was overexpressed in 12 of 20 pairs of breast cancer/ normal breast specimens (60%). Together, these data indicate that P0 overexpression may cause tumorigenesis in breast and liver tissues at least in part by inhibiting GCIP-mediated tumor suppression.	[Chang, T-W; Chang, M-C] Natl Cheng Kung Univ, Coll Med, Basic Med Sci, Dept Biochem & Mol Biol, Tainan 704, Taiwan; [Chang, T-W] Natl Cheng Kung Univ, Coll Med, Dept Surg, Tainan 704, Taiwan; [Chen, C-C; Chen, K-Y; Chang, J-H; Chang, M-C] Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Inst Biotechnol, Tainan 704, Taiwan; [Su, J-H] Chia Na Univ Pharm & Sci, Coll Med, Dept Biotechnol, Tainan, Taiwan; [Chang, J-H] Natl Cheng Kung Univ, Coll Med, Dept Parasitol, Tainan 704, Taiwan; [Chang, M-C] Natl Cheng Kung Univ, Coll Med, Basic Med Sci, Dept Biochem & Mol Biol, Tainan 704, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University	Chang, MC (corresponding author), Natl Cheng Kung Univ, Coll Med, Basic Med Sci, Dept Biochem & Mol Biol, 138 Sheng Li Rd, Tainan 704, Taiwan.	mcchang@mail.ncku.edu.tw		Chen, Kuanyu/0000-0001-9350-2699				BARNARD GF, 1992, CANCER RES, V52, P3067; Chang MS, 2000, BIOCHEM BIOPH RES CO, V279, P732, DOI 10.1006/bbrc.2000.3992; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; GRABOWSKI DT, 1992, CARCINOGENESIS, V13, P259, DOI 10.1093/carcin/13.2.259; Hosokawa Y, 1996, J LAB CLIN MED, V127, P246, DOI 10.1016/S0022-2143(96)90092-X; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kondoh N, 1999, CANCER RES, V59, P4990; Ma W, 2006, ONCOGENE, V25, P4207, DOI 10.1038/sj.onc.1209450; Ma WB, 2007, J CELL BIOCHEM, V100, P1376, DOI 10.1002/jcb.21140; Remacha M, 1995, BIOCHEM CELL BIOL, V73, P959, DOI 10.1139/o95-103; Shimizu T, 2002, NUCLEIC ACIDS RES, V30, P2620, DOI 10.1093/nar/gkf379; Sonnenberg-Riethmacher E, 2007, HEPATOLOGY, V45, P404, DOI 10.1002/hep.21461; Takami T, 2005, GASTROENTEROLOGY, V128, P1369, DOI 10.1053/j.gastro.2005.03.014; Tchorzewski M, 2003, INT J BIOCHEM CELL B, V35, P203, DOI 10.1016/S1357-2725(02)00133-4; Terai S, 2000, HEPATOLOGY, V32, P357, DOI 10.1053/jhep.2000.9092; Uchiumi T, 1997, J BIOL CHEM, V272, P3302, DOI 10.1074/jbc.272.6.3302; WOOL IG, 1991, BIOCHIMIE, V73, P861, DOI 10.1016/0300-9084(91)90127-M; Wu SB, 2005, CRYOBIOLOGY, V50, P71, DOI 10.1016/j.cryobiol.2004.11.001; Xia CZ, 2000, J BIOL CHEM, V275, P20942, DOI 10.1074/jbc.M002598200; Yao Y, 2000, EXP CELL RES, V257, P22, DOI 10.1006/excr.2000.4884	20	41	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					332	338		10.1038/sj.onc.1210651	http://dx.doi.org/10.1038/sj.onc.1210651			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621266				2022-12-17	WOS:000252256000009
J	Yang, HY; Wen, YY; Lin, YI; Pham, L; Su, CH; Yang, H; Chen, J; Lee, MH				Yang, H-Y; Wen, Y-Y; Lin, Y-I; Pham, L.; Su, C-H; Yang, H.; Chen, J.; Lee, M-H			Roles for negative cell regulator 14-3-3 sigma in control of MDM2 activities	ONCOGENE			English	Article						MDM2; 14-3-3; NEDDylation; p53; RB	NUCLEAR EXPORT; DNA-DAMAGE; P53; PROTEIN; CANCER; DOMAIN; AMPLIFICATION; PROGRESSION; INHIBITOR	The 14-3-3 sigma, upregulated by p53 in response to DNA damage, can have a positive-feedback impact driving p53 activities and is a human cancer epithelial marker downregulated in various tumors. However, the precise roles of 14-3-3 sigma during tumorigenesis are not well characterized. Here, we show that 14-3-3 sigma is a critical regulator of murine double minute oncogene (MDM2). 14-3-3 sigma interacts with MDM2 at the RING domain. The C-terminal region of 14-3-3 sigma binds to MDM2 very efficiently. Importantly, 14-3-3 sigma overexpression leads to destabilization of MDM2 through enhancing MDM2 self-ubiquitination and accelerating turnover rate. Conversely, loss of 14-3-3 sigma results in a significant increase in MDM2 protein. Moreover, live-cell images indicated that 14-3-3 sigma can affect the location of MDM2 from the nucleus to the cytoplasm, and that MDM2-mediated cytoplasmic localization of p53 can be reversed by the presence of 14-3-3 sigma. Significantly, we further showed that 14-3-3 sigma causes MDM2 downregulation, thereby stabilizing p53 and inhibiting tumor growth in animal tumors. Also, 14-3-3 sigma blocks MDM2-mediated retinoblastoma degradation and p53 NEDDylation. Our results provide evidence that 14-3-3 sigma is a pivotal MDM2 regulator involved in blocking a variety of activities of MDM2.	Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Gen & Dev, Houston, TX USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX USA; Zhongshan Univ, Dept Pathophysiol, Guangzhou, Peoples R China; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System; Sun Yat Sen University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mhlee@mdanderson.org		Phan, Liem/0000-0003-1194-216X; Lee, Mong-Hong/0000-0001-8675-8215	NATIONAL CANCER INSTITUTE [R01CA089266, P30CA016672, R56CA089266] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, R01 CA089266, R56 CA089266, R01CA089266] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee MH, 2006, SEMIN CANCER BIOL, V16, P225, DOI 10.1016/j.semcancer.2006.03.009; Miwa S, 2006, BIOCHEM BIOPH RES CO, V340, P54, DOI 10.1016/j.bbrc.2005.11.148; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Wang LK, 2005, HANDB ENVIRON ENG, V2, P1; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yang HL, 2006, CANCER RES, V66, P3096, DOI 10.1158/0008-5472.CAN-05-3620; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhang RW, 2000, CURR PHARM DESIGN, V6, P393, DOI 10.2174/1381612003400911; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	23	41	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7355	7362		10.1038/sj.onc.1210540	http://dx.doi.org/10.1038/sj.onc.1210540			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17546054				2022-12-17	WOS:000250955700007
J	Rahmanto, YS; Dunn, LL; Richardson, DR				Rahmanto, Y. Suryo; Dunn, L. L.; Richardson, D. R.			The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark - from iron metabolism to tumorigenesis	ONCOGENE			English	Review						melanotransferrin; tumorigenesis; iron metabolism; melanoma	PHOSPHATE-ACTIVATED GLUTAMINASE; BOUND TRANSFERRIN HOMOLOG; ENDOTHELIAL GROWTH-FACTOR; GPI-ANCHORED PROTEINS; CELL-SURFACE; PLASMINOGEN ACTIVATION; CHONDROGENIC DIFFERENTIATION; REACTIVE MICROGLIA; APOLIPOPROTEIN D; LINKED PROTEINS	Melanotransferrin (MTf) or melanoma tumor antigen p97 is a transferrin (Tf) homolog that is found predominantly bound to the cell membrane via a glycosyl phosphatidylinositol anchor. The molecule is a member of the Tf superfamily and binds iron through a single high-affinity iron(III)-binding site. Since its discovery on the plasma membrane of melanoma cells, the function of MTf has remained intriguing, particularly in relation to its role in cancer cell iron transport. In fact, considering the crucial role of iron in many metabolic pathways, e. g., DNA synthesis, it was important to understand the function of MTf in the transport of this vital nutrient. MTf has also been implicated in diverse physiological processes, such as plasminogen activation, angiogenesis and cell migration. However, recent studies using a knockout mouse and post-transcriptional gene silencing have demonstrated that MTf is not involved in iron metabolism, but plays a vital role in melanoma cell proliferation and tumorigenesis. In this review, we discuss the possible biological functions of MTf, particularly in relation to cancer.	Univ Sydney, Dept Pathol, Iron Metab & Chelation Program, Sydney, NSW 2006, Australia	University of Sydney	Richardson, DR (corresponding author), Univ Sydney, Sydney, NSW 2006, Australia.	d.richardson@pathology.usyd.edu.au	Suryo Rahmanto, Yohan/K-8043-2018	Suryo Rahmanto, Yohan/0000-0003-1453-7872; Richardson, Des/0000-0002-5506-3274; Richardson, Des/0000-0003-0960-6415				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ALEDO JC, 1994, FEBS LETT, V341, P39, DOI 10.1016/0014-5793(94)80236-X; ALEMANY R, 1993, J CELL SCI, V104, P1155; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; BAKER EN, 1992, J INORG BIOCHEM, V47, P147, DOI 10.1016/0162-0134(92)84061-Q; BAKER EN, 1992, FEBS LETT, V298, P215, DOI 10.1016/0014-5793(92)80060-T; BEARD JL, 1993, NUTR REV, V51, P157, DOI 10.1111/j.1753-4887.1993.tb03096.x; Birck A, 1999, MELANOMA RES, V9, P375, DOI 10.1097/00008390-199908000-00006; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BROWN D, 1992, J AM SOC NEPHROL, V3, P895; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN JP, 1982, NATURE, V296, P171, DOI 10.1038/296171a0; BROWN JP, 1981, P NATL ACAD SCI-BIOL, V78, P539, DOI 10.1073/pnas.78.1.539; BROWN JP, 1981, J IMMUNOL, V127, P539; Choong PFM, 2003, CLIN ORTHOP RELAT R, pS46, DOI 10.1097/01.blo.0000093845.72468.bd; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DANIELSEN EM, 1995, J CELL BIOL, V131, P939, DOI 10.1083/jcb.131.4.939; Demeule M, 2003, BLOOD, V102, P1723, DOI 10.1182/blood-2003-01-0166; Demeule M, 2002, J NEUROCHEM, V83, P924, DOI 10.1046/j.1471-4159.2002.01201.x; DENIJN M, 1993, MELANOMA RES, V3, P5, DOI 10.1097/00008390-199304000-00002; Desrosiers RR, 2003, BIOCHEM J, V374, P463, DOI 10.1042/BJ20030240; DUCHANGE N, 1992, NUCLEIC ACIDS RES, V20, P2853, DOI 10.1093/nar/20.11.2853; Dunn LL, 2006, CARCINOGENESIS, V27, P2157, DOI 10.1093/carcin/bgl045; ESTIN CD, 1989, J NATL CANCER I, V81, P445, DOI 10.1093/jnci/81.6.445; Food MR, 2002, EUR J BIOCHEM, V269, P4435, DOI 10.1046/j.1432-1033.2002.03140.x; FOOD MR, 1994, J BIOL CHEM, V269, P3034; Furumura M, 2001, J BIOL CHEM, V276, P28147, DOI 10.1074/jbc.M101626200; GARRATT RC, 1992, FEBS LETT, V305, P55, DOI 10.1016/0014-5793(92)80654-Y; Graeven U, 2001, CANCER RES, V61, P7282; Graham TA, 2001, NAT STRUCT BIOL, V8, P1048, DOI 10.1038/nsb718; Jefferies WA, 1996, BRAIN RES, V712, P122, DOI 10.1016/0006-8993(95)01407-1; Kalinowski DS, 2005, PHARMACOL REV, V57, P547, DOI 10.1124/pr.57.4.2; KAMEYAMA K, 1986, J INVEST DERMATOL, V87, P313, DOI 10.1111/1523-1747.ep12524381; KATO Y, 2001, WO2001011368; Kawabata H, 2004, BRIT J HAEMATOL, V127, P464, DOI 10.1111/j.1365-2141.2004.05224.x; Kawamoto T, 1998, EUR J BIOCHEM, V256, P503, DOI 10.1046/j.1432-1327.1998.2560503.x; Kennard ML, 1996, NAT MED, V2, P1230, DOI 10.1038/nm1196-1230; KENNARD ML, 1995, EMBO J, V14, P4178, DOI 10.1002/j.1460-2075.1995.tb00091.x; Kim DK, 2001, NEUROPSYCHOPHARMACOL, V25, P84, DOI 10.1016/S0893-133X(00)00230-X; Kvamme E, 2000, NEUROCHEM RES, V25, P1407, DOI 10.1023/A:1007668801570; Kwok JC, 2002, CRIT REV ONCOL HEMAT, V42, P65, DOI 10.1016/S1040-8428(01)00213-X; Lambert LA, 2005, COMP BIOCHEM PHYS B, V142, P129, DOI 10.1016/j.cbpb.2005.07.007; Lambert LA, 2005, COMP BIOCHEM PHYS B, V140, P11, DOI 10.1016/j.cbpc.2004.09.012; LEBEAU MM, 1986, HUM GENET, V72, P294, DOI 10.1007/BF00290951; Liao SK, 1996, ANTICANCER RES, V16, P171; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; Loertscher R, 2002, TRANSPL IMMUNOL, V9, P93, DOI 10.1016/S0966-3274(02)00013-8; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LOW MG, 1991, BIOCHEM J, V279, P483, DOI 10.1042/bj2790483; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; McNagny KM, 1996, BLOOD, V87, P1343, DOI 10.1182/blood.V87.4.1343.bloodjournal8741343; MEDINA MA, 1992, MOL CELL BIOCHEM, V113, P1; METZ CN, 1991, CELL BIOL INT REP, V15, P875, DOI 10.1016/0309-1651(91)90039-L; Michaud-Levesque J, 2005, EXP CELL RES, V308, P479, DOI 10.1016/j.yexcr.2005.05.004; Michaud-Levesque J, 2007, CARCINOGENESIS, V28, P280, DOI 10.1093/carcin/bgl123; MIYATA T, 1994, NEW ENGL J MED, V330, P249, DOI 10.1056/NEJM199401273300404; MONTGOMERY AMP, 1993, CANCER RES, V53, P693; MORGAN EH, 1981, MOL ASPECTS MED, V4, P1, DOI 10.1016/0098-2997(81)90003-0; Moroo I, 2003, MICROCIRCULATION, V10, P457, DOI 10.1038/sj.mn.7800213; Nakamasu K, 1999, BBA-GENE STRUCT EXPR, V1447, P258, DOI 10.1016/S0167-4781(99)00173-6; Nakamasu K, 2001, EUR J BIOCHEM, V268, P1468, DOI 10.1046/j.1432-1327.2001.02017.x; Nappi AJ, 2000, CELL MOL BIOL, V46, P637; NATALI PG, 1987, CANCER, V59, P55, DOI 10.1002/1097-0142(19870101)59:1<55::AID-CNCR2820590115>3.0.CO;2-R; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; NECKERS LM, 1983, P NATL ACAD SCI-BIOL, V80, P3494, DOI 10.1073/pnas.80.11.3494; Neitzel LT, 1999, ANN SURG ONCOL, V6, P70, DOI 10.1007/s10434-999-0070-z; Pan WH, 2004, J CELL SCI, V117, P5071, DOI 10.1242/jcs.01381; PLOWMAN GD, 1983, NATURE, V303, P70, DOI 10.1038/303070a0; Ribatti D, 1992, EXS, V61, P415; RICHARDSON D, 1991, BIOCHIM BIOPHYS ACTA, V1093, P20, DOI 10.1016/0167-4889(91)90133-I; RICHARDSON D, 1992, J BIOL CHEM, V267, P13972; Richardson DR, 2004, BBA-MOL BASIS DIS, V1690, P124, DOI 10.1016/j.bbadis.2004.06.002; RICHARDSON DR, 1994, J CELL PHYSIOL, V161, P160, DOI 10.1002/jcp.1041610119; RICHARDSON DR, 1992, J BIOL CHEM, V267, P21384; RICHARDSON DR, 1990, BIOCHIM BIOPHYS ACTA, V1053, P1, DOI 10.1016/0167-4889(90)90018-9; RICHARDSON DR, 1991, BIOCHIM BIOPHYS ACTA, V1091, P294, DOI 10.1016/0167-4889(91)90192-Z; Richardson DR, 2000, EUR J BIOCHEM, V267, P1290, DOI 10.1046/j.1432-1327.2000.01079.x; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; ROSE TM, 1986, P NATL ACAD SCI USA, V83, P1261, DOI 10.1073/pnas.83.5.1261; Rothenberger S, 1996, BRAIN RES, V712, P117, DOI 10.1016/0006-8993(96)88505-2; RozeHeusse A, 1996, BIOCHEM J, V318, P883, DOI 10.1042/bj3180883; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sala R, 2002, EUR J CELL BIOL, V81, P599, DOI 10.1078/0171-9335-00280; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCIOT R, 1989, LIVER, V9, P110; Sekyere E, 2000, FEBS LETT, V483, P11, DOI 10.1016/S0014-5793(00)02079-2; Sekyere E, 2003, FEBS LETT, V547, P233, DOI 10.1016/S0014-5793(03)00658-6; Sekyere E, 2002, FEBS LETT, V512, P350, DOI 10.1016/S0014-5793(02)02248-2; Sekyere EO, 2006, BLOOD, V107, P2599, DOI 10.1182/blood-2005-10-4174; Sekyere EO, 2005, BBA-GEN SUBJECTS, V1722, P131, DOI 10.1016/j.bbagen.2004.12.002; SELIGMAN PA, 1986, AM J HUM GENET, V38, P540; Sharom FJ, 2002, BIOCHEM CELL BIOL, V80, P535, DOI 10.1139/O02-146; STAHL A, 1994, CANCER RES, V54, P3066; Suardita K, 2002, J BIOL CHEM, V277, P48579, DOI 10.1074/jbc.M209243200; SUGIMOTO K, 1994, J STEROID BIOCHEM, V51, P167, DOI 10.1016/0960-0760(94)90090-6; Terrisse L, 1998, J NEUROCHEM, V71, P1643; Ware RE, 1998, BLOOD, V92, P2541, DOI 10.1182/blood.V92.7.2541.2541_2541_2550; WOODBURY RG, 1980, P NATL ACAD SCI-BIOL, V77, P2183, DOI 10.1073/pnas.77.4.2183; Yamada T, 1999, BRAIN RES, V845, P1, DOI 10.1016/S0006-8993(99)01767-9; YANG FM, 1984, P NATL ACAD SCI-BIOL, V81, P2752, DOI 10.1073/pnas.81.9.2752; Zhao M, 1999, MOL CELL BIOL, V19, P21	105	41	43	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6113	6124		10.1038/sj.onc.1210442	http://dx.doi.org/10.1038/sj.onc.1210442			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17452986				2022-12-17	WOS:000249401300001
J	Kusters, B; Kats, G; Roodink, I; Verrijp, K; Wesseling, P; Ruiter, DJ; de Waal, RMW; Leenders, WPJ				Kuesters, B.; Kats, G.; Roodink, I.; Verrijp, K.; Wesseling, P.; Ruiter, D. J.; de Waal, R. M. W.; Leenders, W. P. J.			Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis	ONCOGENE			English	Article						VEGF-A; metastasis; melanoma; tumor; emboli; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; INFLAMMATORY BREAST-CARCINOMA; VESSEL CO-OPTION; BRAIN METASTASIS; HUMAN-MELANOMA; TUMOR-CELLS; SPROUTING ANGIOGENESIS; CANCER METASTASIS; PROGNOSTIC-FACTOR; BONE-MARROW	How and why tumors metastasize is still a matter of debate. The assumption is that mutations render tumor cells with a metastatic phenotype, enabling entrance in and transport through lymph or blood vessels. Distant outgrowth is thought to occur only in a suitable microenvironment (the seed and soil hypothesis). However, the anatomical location of most metastases in cancer patients suggests entrapment of tumor cells in the first microcapillary bed that is encountered. We here investigated how vascular endothelial growth factor-A (VEGF-A) attributes to the metastatic process. We describe here that VEGF-A enhances spontaneous metastasis by inducing intravasation of heterogeneous tumor cell clusters, surrounded by vessel wall elements, via an invasion-independent mechanism. These tumor clusters generate metastatic tissue embolisms in pulmonary arteries. Treatment of tumor-bearing mice with the antiangiogenic compound ZD6474 prevented the development of this metastatic phenotype. This work shows that tumors with high constitutive VEGF-A expression metastasize via the formation of tumor emboli and provides an alternative rationale for anti-VEGF-A therapy, namely to inhibit metastasis formation.	Radboud Univ Nijmegen Med Ctr, Dept Pathol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Leenders, WPJ (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Pathol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	w.leenders@pathol.umcn.nl	Kusters, B./L-4465-2015; Waal, R.M.W./L-4739-2015; Leenders, William/O-2541-2019; Ruiter, D.J./L-4617-2015; verrijp, kiek/F-4783-2018; Leenders, William P/O-9843-2014; Wesseling, P./H-8114-2014	Leenders, William/0000-0003-0066-220X; Leenders, William P/0000-0003-0066-220X; Wesseling, P./0000-0001-5453-5201				Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Alpaugh ML, 2002, ONCOGENE, V21, P3631, DOI 10.1038/sj.onc.1205389; Auguste P, 2005, CRIT REV ONCOL HEMAT, V54, P53, DOI 10.1016/j.critrevonc.2004.11.006; Ellis LM, 1996, EUR J CANCER, V32A, P2451, DOI 10.1016/S0959-8049(96)00389-9; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Fidler IJ, 1999, CANCER METAST REV, V18, P387, DOI 10.1023/A:1006329410433; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FIDLER IJ, 1973, EUR J CANCER, V9, P223, DOI 10.1016/S0014-2964(73)80022-2; Fidler IJ, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P203; FIDLER IJ, 1986, CANCER RES, V46, P5167; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Gannon G, 2002, CANCER RES, V62, P603; GLAVES D, 1983, BRIT J CANCER, V48, P665, DOI 10.1038/bjc.1983.248; Hasan J, 2002, BRIT J CANCER, V86, P1566, DOI 10.1038/sj.bjc.6600315; Kanayama H, 1999, CLIN EXP METASTAS, V17, P831, DOI 10.1023/A:1006792007063; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Killion JJ, 1998, CANCER METAST REV, V17, P279, DOI 10.1023/A:1006140513233; KIM ES, 2002, P NATL ACAD SCI USA, V12, P12; Kusters B, 2003, CANCER RES, V63, P5408; Kusters B, 2002, CANCER RES, V62, P341; Kusters B, 2001, INT J CANCER, V92, P176; Leenders WPJ, 2004, CLIN CANCER RES, V10, P6222, DOI 10.1158/1078-0432.CCR-04-0823; Leenders WPJ, 2002, ENDOTHELIUM-J ENDOTH, V9, P83, DOI 10.1080/10623320212006; LIOTTA LA, 1976, CANCER RES, V36, P889; MOFFETT BF, 1992, CANCER RES, V52, P1737; Neves S, 2001, CLIN NEUROPATHOL, V20, P38; Passalidou E, 2002, BRIT J CANCER, V86, P244, DOI 10.1038/sj.bjc.6600015; Pezzella F, 2000, LANCET, V355, P1787; Pezzella F, 1997, AM J PATHOL, V151, P1417; Ruiter DJ, 2001, LANCET ONCOL, V2, P109, DOI 10.1016/S1470-2045(00)00229-1; Span PN, 2000, INT J BIOL MARKER, V15, P184, DOI 10.1177/172460080001500210; Sugino T, 2002, AM J PATHOL, V160, P1973, DOI 10.1016/S0002-9440(10)61147-9; SUGINO T, 1993, INT J CANCER, V55, P141, DOI 10.1002/ijc.2910550125; Sugino T, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-9; Tomlinson JS, 2001, CANCER RES, V61, P5231; Vermeulen PB, 2001, J PATHOL, V195, P336, DOI 10.1002/path.966; Vlems FA, 2003, EUR J SURG ONCOL, V29, P289, DOI 10.1053/ejso.2002.1394; Wedge SR, 2002, CANCER RES, V62, P4645; Weidner N, 2002, AM J PATHOL, V160, P1937, DOI 10.1016/S0002-9440(10)61141-8; Weidner N, 1998, J PATHOL, V184, P119, DOI 10.1002/(SICI)1096-9896(199802)184:2<119::AID-PATH17>3.0.CO;2-D; Weidner Noel, 1996, P167; Westphal JR, 2000, INT J CANCER, V86, P768, DOI 10.1002/(SICI)1097-0215(20000615)86:6<768::AID-IJC3>3.3.CO;2-5; Yano S, 2000, CANCER RES, V60, P4959	43	41	46	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5808	5815		10.1038/sj.onc.1210360	http://dx.doi.org/10.1038/sj.onc.1210360			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353901				2022-12-17	WOS:000248885100012
J	Wu, YH; Chang, JHT; Cheng, YW; Wu, TC; Chen, CY; Lee, H				Wu, Y-H; Chang, J-H Tsai; Cheng, Y-W; Wu, T-C; Chen, C-Y; Lee, H.			Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers	ONCOGENE			English	Article						xeroderma pigmentosum group C (XPC); promoter methylation; p53 mutation; non-small cell; lung cancer	NUCLEOTIDE EXCISION-REPAIR; DNA-REPAIR; HEPATOCELLULAR-CARCINOMA; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; MUTANT MICE; TOBACCO-SMOKE; DAMAGED DNA; CPG ISLANDS; GROUP-A; XPC	Reduced DNA repair capability is associated with developing lung cancer, especially in nonsmokers. XPC participates in the initial recognition of DNA damage during the DNA nucleotide excision repair process. We hypothesize that inactivation of XPC by promoter hypermethylation may play an important role in the reduction of DNA repair capability to cause p53 mutation during lung carcinogenesis. In this report we demonstrate that hypermethylation of 17 CpG islands between - 175 and - 1 of the XPC promoter correlates very well with XPC expression levels in eight lung cancer cell lines. When cells with hypermethylated XPC promoters were treated with the demethylating agent 5-aza-20-deoxycytidine, XPC expression was de-repressed. Interestingly, XPC hypermethylation was found in 4 of 5 (80%) lung cancer cell lines harbored p53 mutation, but not observed in two lung cancer cells which had a wild- type p53 gene. Among the analysis of the hypermethylation status of 158 lung tumors, XPC hypermethylation is more common in nonsmokers (39 of 94, 41%) than in smokers (14 of 64, 22%; P = 0.010). Additionally, XPC hypermethylation is more often with G -> T or G -> C mutations in the p53 gene. To verify whether XPC inactivation is involved in the occurrence of p53 mutation, XPC gene of A549 cells was knockdown by a small interference RNA and then XPC-inactivated cells were treated with benzo[a] pynrene for different passages. Surprisingly, G-T mutation in p53 gene at codon 215 was indeed detected in XPC-inactivated A549 cells of passages 15 and confirmed by loss of transcription activity of mdm2. These results show that hypermethylation of the XPC promoter may play a crucial role in XPC inactivation, which may partly contribute to the occurrence of p53 mutations during lung tumorigenesis, especially nonsmokers.	Chung Shan Med Univ, Inst Med & Mol Toxicol, Lung Canc Res Ctr, Taichung, Taiwan; Chung Shan Med Univ, Inst Med, Taichung, Taiwan; Chung Shan Med Univ, Dept Internal Med, Taichung, Taiwan; Chung Shan Med Univ, Lung Canc Res Ctr, Taichung, Taiwan; China Med Univ, Dept Thorac Surg, Taichung, Taiwan	Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University; China Medical University Taiwan	Lee, H (corresponding author), Chung Shan Med Univ, Inst Med & Mol Toxicol, Lung Canc Res Ctr, 110,Sec 1,Chien Kuo N Rd, Taichung, Taiwan.	hl@csmu.edu.tw	Lee, Huei/B-2664-2010					Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; ALAIN S, 2001, CANCER RES, V61, P2480; Azzam EI, 2002, J INVEST DERMATOL, V119, P1350, DOI 10.1046/j.1523-1747.2002.19628.x; Bosken CH, 2002, JNCI-J NATL CANCER I, V94, P1091; Chang JT, 2004, ANAL BIOCHEM, V334, P199, DOI 10.1016/j.ab.2004.07.018; Chang MY, 2005, CANCER LETT, V222, P195, DOI 10.1016/j.canlet.2004.11.020; Cheo DL, 1999, CANCER RES, V59, P771; Emmert S, 2000, P NATL ACAD SCI USA, V97, P2151, DOI 10.1073/pnas.040559697; Esteller M, 2000, CANCER RES, V60, P2368; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Gao WM, 2003, LUNG CANCER-J IASLC, V40, P141, DOI 10.1016/S0169-5002(03)00035-7; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hollander MC, 2005, P NATL ACAD SCI USA, V102, P13200, DOI 10.1073/pnas.0503133102; Hu ZB, 2005, INT J CANCER, V115, P478, DOI 10.1002/ijc.20911; Inga A, 2002, ONCOGENE, V21, P5704, DOI 10.1038/sj.onc.1205779; Janicijevic A, 2003, DNA REPAIR, V2, P325, DOI 10.1016/S1568-7864(02)00222-7; Kang MS, 1996, INT J CANCER, V67, P898, DOI 10.1002/(SICI)1097-0215(19960917)67:6<898::AID-IJC22>3.0.CO;2-X; Kim DH, 2001, CANCER RES, V61, P3419; Ko JL, 2002, DNA REPAIR, V1, P755, DOI 10.1016/S1568-7864(02)00094-0; Ko JL, 2000, INT J CANCER, V89, P265, DOI 10.1002/1097-0215(20000520)89:3<265::AID-IJC9>3.0.CO;2-N; Le Calvez F, 2005, CANCER RES, V65, P5076, DOI 10.1158/0008-5472.CAN-05-0551; Marin MS, 2004, CANCER EPIDEM BIOMAR, V13, P1788; Marsit CJ, 2006, CARCINOGENESIS, V27, P112, DOI 10.1093/carcin/bgi172; Matsukura S, 2003, BRIT J CANCER, V88, P521, DOI 10.1038/sj.bjc.6600743; Mellon I, 2002, DNA REPAIR, V1, P531, DOI 10.1016/S1568-7864(02)00053-8; Nahari D, 2004, DNA REPAIR, V3, P379, DOI 10.1016/j.dnarep.2003.03.001; Neumann AS, 2005, MOL CARCINOGEN, V42, P65, DOI 10.1002/mc.20069; Nutt CL, 1999, CARCINOGENESIS, V20, P2361, DOI 10.1093/carcin/20.12.2361; Park JY, 2002, CANCER EPIDEM BIOMAR, V11, P993; Pavanello S, 2005, CARCINOGENESIS, V26, P169, DOI 10.1093/carcin/bgh303; Piao CQ, 1999, CARCINOGENESIS, V20, P1529, DOI 10.1093/carcin/20.8.1529; Pulling LC, 2004, CANCER RES, V64, P3844, DOI 10.1158/0008-5472.CAN-03-2119; Reis AM, 2000, CANCER RES, V60, P1571; Riedl T, 2003, EMBO J, V22, P5293, DOI 10.1093/emboj/cdg489; RYK C, 2006, CANC LETT, V8, P142; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338; Shen HB, 2003, INT J CANCER, V107, P84, DOI 10.1002/ijc.11346; Soria JC, 2002, CANCER RES, V62, P351; Srivenugopal KS, 2001, CLIN CANCER RES, V7, P1398; Suk R, 2005, CLIN CANCER RES, V11, P1534, DOI 10.1158/1078-0432.CCR-04-1953; Tapias A, 2004, J BIOL CHEM, V279, P19074, DOI 10.1074/jbc.M312611200; Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787; Toyooka S, 2003, HUM MUTAT, V21, P229, DOI 10.1002/humu.10177; Vodicka P, 2004, ENVIRON MOL MUTAGEN, V44, P283, DOI 10.1002/em.20055; Wei QY, 2000, J NATL CANCER I, V92, P1764; Wolf P, 2001, CANCER RES, V61, P8113; Wu MF, 2005, INT J CANCER, V113, P440, DOI 10.1002/ijc.20597; Zhang YJ, 2003, INT J CANCER, V103, P440, DOI 10.1002/ijc.10852	49	41	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4761	4773		10.1038/sj.onc.1210284	http://dx.doi.org/10.1038/sj.onc.1210284			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17325666				2022-12-17	WOS:000248170400002
J	Wang, L; Kurosaki, T; Corey, SJ				Wang, L.; Kurosaki, T.; Corey, S. J.			Engagement of the B-cell antigen receptor activates STAT through Lyn in a Jak-independent pathway	ONCOGENE			English	Article						Lyn; STAT; Jak; B-cell antigen receptor	STIMULATING FACTOR-RECEPTOR; TYROSINE KINASE; BCR-ABL; NUCLEAR EXPRESSION; PROTEIN; SRC; PHOSPHORYLATION; REGIONS; SITE; SYK	Engagement of the B-cell antigen receptor (BCR) initiated by the Src kinase Lyn triggers rapid signaling cascades, leading to proliferation, differentiation or growth arrest of B cells. The Janus kinase (JAK)-STAT (signal transducer and activator of transcription) pathway, activated through cytokine receptors, mediates similar responses. Hypothesizing that Src and JAK pathways engage in crosstalk in B-cell signaling, we studied wild-type and Lyn-null B-cell lines, which express BCR. We found that activated BCR results in tyrosine phosphorylation of JAK-STAT, which required Lyn. To confirm that STAT activation is not due to JAK, we cloned the chicken homologs of JAK1 and JAK2 and made their antisense constructs. In cells expressing antisense JAK1 and JAK2, tyrosine phosphorylation of STAT was not inhibited following BCR stimulation. Using activation loop-specific phosphotyrosine antibodies, we did not detect phospho-JAK1 and phospho-JAK2 after BCR stimulation. The JAK inhibitor AG490 did not inhibit the tyrosine phosphorylation of Lyn or STAT after BCR simulation. An in vitro phosphorylation assay showed that Lyn directly phosphorylates STAT3. In an electrophoretic mobility shift assay, BCR stimulation led to enhanced DNA binding of the STAT3 in DT40, but not in the Lyn-null cells. We conclude that BCR engagement activates the STAT pathway via Lyn, independent of JAK.	Univ Texas, MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA; RIKEN, Lymphocyte Differentiat Res Ctr Allergy & Immunol, Yokohama, Kanagawa, Japan	University of Texas System; UTMD Anderson Cancer Center; RIKEN	Corey, SJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Pediat, 1515 Holcombe Blvd,Unit 853, Houston, TX 77030 USA.	sjcorey@mdanderson.org	Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X				Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chin H, 1998, BLOOD, V91, P3734; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Coppo P, 2003, ONCOGENE, V22, P4102, DOI 10.1038/sj.onc.1206607; Corey SJ, 1998, J BIOL CHEM, V273, P3230, DOI 10.1074/jbc.273.6.3230; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; DeFranco AL, 1995, ANN NY ACAD SCI, V766, P195, DOI 10.1111/j.1749-6632.1995.tb26662.x; Dorsey JF, 2002, LEUKEMIA, V16, P1589, DOI 10.1038/sj.leu.2402678; Fan H, 2001, EUR J IMMUNOL, V31, P665, DOI 10.1002/1521-4141(200102)31:2<665::AID-IMMU665>3.0.CO;2-1; FINBLOOM DS, 1995, CELL SIGNAL, V7, P739, DOI 10.1016/0898-6568(95)02004-7; Hibbs ML, 2002, J EXP MED, V196, P1593, DOI 10.1084/jem.20020515; Ihle J N, 1995, Semin Immunol, V7, P247, DOI 10.1006/smim.1995.0029; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Ishikawa H, 2002, BLOOD, V99, P2172, DOI 10.1182/blood.V99.6.2172; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Karras JG, 1996, J IMMUNOL, V157, P2299; Karras JG, 1996, J IMMUNOL, V157, P39; Keshvara LM, 1998, J IMMUNOL, V161, P5276; Koay DC, 2002, CELL SIGNAL, V14, P239, DOI 10.1016/S0898-6568(01)00237-6; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lund TC, 1999, CELL SIGNAL, V11, P789, DOI 10.1016/S0898-6568(99)00045-5; Mirnics ZK, 2004, J IMMUNOL, V172, P4133, DOI 10.4049/jimmunol.172.7.4133; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; Okutani Y, 2001, ONCOGENE, V20, P6643, DOI 10.1038/sj.onc.1204807; Pereira S, 2003, J IMMUNOL, V171, P1319, DOI 10.4049/jimmunol.171.3.1319; Saharinen P, 2003, MOL BIOL CELL, V14, P1448, DOI 10.1091/mbc.E02-06-0342; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; Sarmay G, 1997, IMMUNOL LETT, V57, P159, DOI 10.1016/S0165-2478(97)00055-2; Scheeren FA, 2005, NAT IMMUNOL, V6, P303, DOI 10.1038/ni1172; Sternberg DW, 2004, J CLIN ONCOL, V22, P361, DOI 10.1200/JCO.2004.10.124; Su L, 1999, J BIOL CHEM, V274, P31770, DOI 10.1074/jbc.274.45.31770; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TWEARDY DJ, 1995, BLOOD, V86, P4409, DOI 10.1182/blood.V86.12.4409.bloodjournal86124409; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; Winding P, 2001, J IMMUNOL METHODS, V249, P1, DOI 10.1016/S0022-1759(00)00333-1; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu CL, 1997, J IMMUNOL, V159, P5206; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	43	41	44	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2851	2859		10.1038/sj.onc.1210092	http://dx.doi.org/10.1038/sj.onc.1210092			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17146444				2022-12-17	WOS:000246210800005
J	Pfeiffer, P; Qvortrup, C; Eriksen, JG				Pfeiffer, P.; Qvortrup, C.; Eriksen, J. G.			Current role of antibody therapy in patients with metastatic colorectal cancer	ONCOGENE			English	Review						metastatic colorectal cancer; antibodies; bevacizumab; cetuximab; panitumumab	GROWTH-FACTOR RECEPTOR; MULTICENTER PHASE-II; BEVACIZUMAB PLUS FLUOROURACIL; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; MONOCLONAL-ANTIBODY; BOLUS FLUOROURACIL; MOLECULAR DETERMINANTS; 3RD-LINE CHEMOTHERAPY; CONTINUOUS-INFUSION	In less than 10 years, the number and importance of nonsurgical treatment modalities in patients with colorectal cancer (CRC) have increased dramatically, both in the adjuvant and the advanced settings. However, despite the improvement of cytotoxic therapy in CRC, many patients still develop progressive disease and unfortunately in patients with disease resistant to 5-fluorouracil/folinic acid, irinotecan and oxaliplatin, no effective cytotoxic therapy is known. The rapidly expanding knowledge in tumor biology has encouraged optimism for the possibility to find and target tumor-specific mechanisms and thereby increase both efficacy and tolerance. A great number of 'targeted drugs' are being tested in clinical trials and some of these new drugs, like bevacizumab, cetuximab and panitumumab, are available for routine use in health care. These new targeted drugs will expand the therapeutic arsenal in CRC to a great extent, but they will also add to the complexity of treatment of CRC. In this review, we summarize the current status of antibody therapy in patients with CRC.	Odense Univ Hosp, Dept Oncol, DK-5000 Odense C, Denmark	University of Southern Denmark; Odense University Hospital	Pfeiffer, P (corresponding author), Odense Univ Hosp, Dept Oncol, Sdr Blvd 29, DK-5000 Odense C, Denmark.	per.pfeiffer@ouh.regionsyddanmark.dk	Qvortrup, Camilla/AAD-3366-2019	Qvortrup, Camilla/0000-0001-9338-9841; Pfeiffer, Per/0000-0002-2925-0586				Abubakr Y, 2006, J CLIN ONCOL, V24, p160S; Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16; Adams GP, 2001, CANCER RES, V61, P4750; Agero ALC, 2006, J AM ACAD DERMATOL, V55, P657, DOI 10.1016/j.jaad.2005.10.010; ANDRE T, 2007, P ASCO GI; Arnold D, 2006, ANN ONCOL, V17, pX122, DOI 10.1093/annonc/mdl249; Azuma M, 2006, CLIN COLORECTAL CANC, V6, P214, DOI 10.3816/CCC.2006.n.038; Barber TD, 2004, NEW ENGL J MED, V351, P2883, DOI 10.1056/NEJM200412303512724; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; BERRY SR, 2006, P ASCO GI; Borner M, 2006, J CLIN ONCOL, V24, p158S; Bouche O, 2005, ANN ONCOL, V16, P1711, DOI 10.1093/annonc/mdi300; Busam KJ, 2001, BRIT J DERMATOL, V144, P1169, DOI 10.1046/j.1365-2133.2001.04226.x; Carmichael J, 2002, J CLIN ONCOL, V20, P3617, DOI 10.1200/JCO.2002.10.129; Carson EJ, 2005, J CLIN ONCOL, V23, p284S; Cassidy J, 2006, ANN ONCOL, V17; Chen HX, 2006, J CLIN ONCOL, V24, P3354, DOI 10.1200/JCO.2005.05.1573; Chong G, 2006, ANN ONCOL, V17, P437, DOI 10.1093/annonc/mdj090; Chung KY, 2005, J CLIN ONCOL, V23, P1803, DOI 10.1200/JCO.2005.08.037; Ciardiello F, 2003, EUR J CANCER, V39, P1348, DOI 10.1016/S0959-8049(03)00235-1; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; Cunningham MP, 2006, CANCER RES, V66, P7708, DOI 10.1158/0008-5472.CAN-06-1000; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; deGramont A, 1997, J CLIN ONCOL, V15, P808, DOI 10.1200/JCO.1997.15.2.808; Dittrich C, 2006, ANN ONCOL, V17, P24; Douillard JY, 2002, J CLIN ONCOL, V20, P3605, DOI 10.1200/JCO.2002.04.123; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Ellis LM, 2005, J CLIN ONCOL, V23, P4853, DOI 10.1200/JCO.2005.23.754; Fakih MG, 2006, CLIN COLORECTAL CANC, V6, P152, DOI 10.3816/CCC.2006.n.033; Falcone A, 2006, J CLIN ONCOL, V24, p149S; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Folprecht G, 2005, ANN ONCOL, V16, P1311, DOI 10.1093/annonc/mdi246; Folprecht G, 2006, ANN ONCOL, V17, P450, DOI 10.1093/annonc/mdj084; Fuchs C, 2006, J CLIN ONCOL, V24, p147S; Fyfe GA, 2004, J CLIN ONCOL, V22, p274S; Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136; Giantonio BJ, 2006, ANN ONCOL, V17, P1399, DOI 10.1093/annonc/mdl161; Giantonio BJ, 2005, J CLIN ONCOL, V23, p1S; GIANTONIO BJ, 2006, J CLIN ONCOL, V24; Gibson TB, 2006, CLIN COLORECTAL CANC, V6, P29, DOI 10.3816/CCC.2006.n.01; GLIMELIUS B, 2005, EUR J CANC S, V3; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Grabau DA, 1998, APPL IMMUNOHISTOCHEM, V6, P209, DOI 10.1097/00022744-199812000-00006; Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037; Grothey A, 2005, J CLIN ONCOL, V23, P9441, DOI 10.1200/JCO.2005.04.4792; Grothey A, 2002, P AM SOC CLIN ONCOL, V21; GROTHEY A, 2003, EUR J CANC, V90; Gruenberger T, 2006, J CLIN ONCOL, V24, P2592, DOI 10.1200/JCO.2005.05.2910; HAMBLETON J, 2005, J CLIN ONCOL, V23; HAMBLETON J, 2004, J CLIN ONCOL, V22; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARARI PM, 2003, P AM SOC CLIN ONCOL, V22; Hebbar M, 2006, ANTI-CANCER DRUG, V17, P855, DOI 10.1097/01.cad.0000217425.44584.9f; Hecht J, 2006, J CLIN ONCOL, V24, p157S; HECHT J, 2006, P ASCO GI; HEDRICK E, 2004, J CLIN ONCOL, V22; HEINEMANN V, 2006, J CLIN ONCOL, V24; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Hillner BE, 2005, CANCER-AM CANCER SOC, V104, P1871, DOI 10.1002/cncr.21411; Ho C, 2006, J CLIN ONCOL, V24, P3214, DOI 10.1200/JCO.2006.06.5128; HOLDEN SN, 2005, J CLIN ONCOL, V23; Howdieshell TR, 2001, J SURG RES, V96, P173, DOI 10.1006/jsre.2001.6089; Huang SM, 2004, CANCER RES, V64, P5355, DOI 10.1158/0008-5472.CAN-04-0562; HUMBLET Y, 2005, J CLIN ONCOL, V23; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Ince WL, 2005, JNCI-J NATL CANCER I, V97, P981, DOI 10.1093/jnci/dji174; JENNIS A, 2005, J CLIN ONCOL, V23; Jubb AM, 2006, J CLIN ONCOL, V24, P217, DOI 10.1200/JCO.2005.01.5388; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112; Kemeny N, 2004, J CLIN ONCOL, V22, P4753, DOI 10.1200/JCO.2004.03.119; Kohne CH, 2003, J CLIN ONCOL, V21, P3721, DOI 10.1200/JCO.2003.11.122; KOZLOFF M, 2006, J CLIN ONCOL, V24; KRETZSCHMAR A, 2006, ASCO GI; KUBICKA S, 2006, ASCO GI; LABIANCA R, 2006, J CLIN ONCOL, V24; Lenz HJ, 2006, J CLIN ONCOL, V24, P4914, DOI 10.1200/JCO.2006.06.7595; Leung RC, 2007, J CLIN ONCOL, V25; Lim DH, 2005, CANCER CHEMOTH PHARM, V56, P10, DOI 10.1007/s00280-004-0963-2; Luo FR, 2005, CLIN CANCER RES, V11, P5558, DOI 10.1158/1078-0432.CCR-05-0368; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Lyseng-Williamson KA, 2006, AM J CANC, V5, P43; Maindrault-Goebel F, 2007, J CLIN ONCOL, V25; Malik I, 2005, J CLIN ONCOL, V23, p251S; Matar P, 2004, CLIN CANCER RES, V10, P6487, DOI 10.1158/1078-0432.CCR-04-0870; Meropol NJ, 2005, J CLIN ONCOL, V23, P1791, DOI 10.1200/JCO.2005.10.951; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; MINERS AH, 2005, BMJ-BRIT MED J, V330, P365; MORELLI MP, 2006, J CLIN ONCOL, V24; Moroni M, 2005, LANCET ONCOL, V6, P279, DOI 10.1016/S1470-2045(05)70102-9; NOVOTNY WF, 2004, J CLIN ONCOL, V22; Nygren P, 2005, ACTA ONCOL, V44, P203, DOI 10.1080/02841860510029798; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Paramore LC, 2006, CLIN COLORECTAL CANC, V6, P52, DOI 10.3816/CCC.2006.n.021; PEETERS M, 2006, PHASE 3 MULTICENTER; Perez-Soler R, 2006, J CLIN ONCOL, V24, p129S; Personeni N, 2005, SEMIN ONCOL, V32, pS59, DOI 10.1053/j.seminoncol.2005.04.029; Pfeiffer P, 2006, ANN ONCOL, V17, P252, DOI 10.1093/annonc/mdj060; PFEIFFER P, 2007, P ASCO GI; PFEIFFER P, 2007, IN PRESS ACTA ONCOL; PITOT HC, 2005, J CLIN ONCOL, V23; Punt CJA, 2002, LANCET, V360, P671, DOI 10.1016/S0140-6736(02)09836-7; Ragnhammar P, 2001, ACTA ONCOL, V40, P282, DOI 10.1080/02841860151116367; Repertinger SK, 2004, J INVEST DERMATOL, V123, P982, DOI 10.1111/j.0022-202X.2004.23478.x; Robert C, 2005, LANCET ONCOL, V6, P491, DOI 10.1016/S1470-2045(05)70243-6; Rosati G, 2003, ANTICANCER RES, V23, P2981; Rothenberg ML, 2003, J CLIN ONCOL, V21, P2059, DOI 10.1200/JCO.2003.11.126; Rougier P, 1998, LANCET, V352, P1407, DOI 10.1016/S0140-6736(98)03085-2; ROUGIER P, 2004, J CLIN ONCOL, V23; Saif MW, 2006, CLIN COLORECTAL CANC, V6, P118, DOI 10.3816/CCC.2006.n.028; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Saltz L., 2001, P AM SOC CLIN ONCOL, V20, p3a; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; SALTZ LB, 2005, J CLIN ONCOL, V23; SALTZ LB, 2006, J CLIN ONCOL, V24; Saunders M, 2006, BRIT J CANCER, V95, P131, DOI 10.1038/sj.bjc.6603233; Scappaticci FA, 2005, J SURG ONCOL, V91, P173, DOI 10.1002/jso.20301; Scartozzi M, 2004, J CLIN ONCOL, V22, P4772, DOI 10.1200/JCO.2004.00.117; Schrag D, 2005, J NATL CANCER I, V97, P1221, DOI 10.1093/jnci/dji242; Schrag D, 2004, NEW ENGL J MED, V351, P317, DOI 10.1056/NEJMp048143; Shia J, 2005, MODERN PATHOL, V18, P1350, DOI 10.1038/modpathol.3800417; Skillings JR, 2005, J CLIN ONCOL, V23, p196S; Sorbye H, 2004, J CLIN ONCOL, V22, P31, DOI 10.1200/JCO.2004.05.188; Souglakos J, 2006, BRIT J CANCER, V94, P798, DOI 10.1038/sj.bjc.6603011; Starling Naureen, 2005, Curr Oncol Rep, V7, P173, DOI 10.1007/s11912-005-0070-5; Stern M, 2005, CRIT REV ONCOL HEMAT, V54, P11, DOI 10.1016/j.critrevonc.2004.10.011; Sugrue M, 2006, J CLIN ONCOL, V24, p154S; TABERNERO J, 2006, J CLIN ONCOL, V24; Tabernero JM, 2004, J CLIN ONCOL, V22, p248S; Tonra JR, 2006, CLIN CANCER RES, V12, P2197, DOI 10.1158/1078-0432.CCR-05-1682; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Tsuchihashi Z, 2005, NEW ENGL J MED, V353, P208, DOI 10.1056/NEJM200507143530218; Vallbohmer D, 2005, J CLIN ONCOL, V23, P3536, DOI 10.1200/jco.2005.23.16_suppl.3536; Van Cutsem E, 2004, BRIT J CANCER, V90, P1190, DOI 10.1038/sj.bjc.6601676; Van Cutsem E, 2006, EUR J CANCER, V42, P2212, DOI 10.1016/j.ejca.2006.04.012; van Doorn R, 2002, BRIT J DERMATOL, V147, P598, DOI 10.1046/j.1365-2133.2002.04864.x; VANCUTSEM E, 2007, P ASCO GI; VANCUTSEM E, 2007, P ASCO GI 2007; Venook A, 2006, J CLIN ONCOL, V24, p148S; Veronese ML, 2004, EUR J CANCER, V40, P1292, DOI 10.1016/j.ejca.2004.02.014; Vincenzi B, 2006, BRIT J CANCER, V94, P792, DOI 10.1038/sj.bjc.6603018; Vincenzi B, 2006, Ann Oncol, V17, P527, DOI 10.1093/annonc/mdj014; Vincenzi B, 2006, ANN ONCOL, V17, P835, DOI 10.1093/annonc/mdl031; Wilke H, 2006, J CLIN ONCOL, V24, p158S; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Yamamoto Deanna Sanchez, 2004, Clin J Oncol Nurs, V8, P654	148	41	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3661	3678		10.1038/sj.onc.1210377	http://dx.doi.org/10.1038/sj.onc.1210377			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530020				2022-12-17	WOS:000246816100009
J	Gerber, AN; Wilson, CW; Li, YJ; Chuang, PT				Gerber, A. N.; Wilson, C. W.; Li, Y-J; Chuang, P-T			The hedgehog regulated oncogenes Gli1 and Gli2 block myoblast differentiation by inhibiting MyoD-mediated transcriptional activation	ONCOGENE			English	Review						Gli; MyoD; hedgehog; cancer; rhabdomyosarcoma; development	LOOP-HELIX PROTEINS; SONIC HEDGEHOG; SKELETAL-MUSCLE; SIGNALING PATHWAY; TERMINAL DIFFERENTIATION; BRANCHING MORPHOGENESIS; REPRESSOR FUNCTIONS; FAMILY-MEMBERS; UP-REGULATION; DNA-BINDING	The mechanism by which activation of the Hedgehog (Hh) pathway modulates differentiation and promotes oncogenesis in specific tissues is poorly understood. We therefore, analysed rhabdomyosarcomas from mice that were haploinsufficient for the Hh-binding protein, Hip1, or for the Hh receptor, Patched 1 (Ptch1). Transfection of the Hh-regulated transcription factor Gli1, which is expressed in a subset of mouse and human rhabdomyosarcomas, suppressed differentiation of myogenic rhabdomyosarcoma lines generated from Hip1(+/+) and Ptch1(+/+) mice. The closely related factor, Gli2, had similar effects. Gli1 and Gli2 inhibited myogenesis by repressing the capacity of MyoD to activate transcription. Deletion analysis of Gli1 indicated that multiple domains of Gli1 are required for efficient inhibition of MyoD. Gli1 reduced the ability of MyoD to heterodimerize with E12 and bind DNA, providing one mechanism whereby the Gli proteins modulate the activity of MyoD. This novel activity of Gli proteins provides new insights into how Hh signaling modulates terminal differentiation through inhibition of tissue-specific factors such as MyoD. This mechanism may contribute to the broad role of Hh signaling and the Gli proteins in differentiation decisions and cancer formation.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Chuang, PT (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA.	pao-tien.chuang@ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL077159, R01HL067822, U01HL066600, T35HL007715] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL077159-01A1, HL067822, K08 HL077159, K08HL07715, U01 HL066600, R01 HL067822, HL66600, T35 HL007715] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Amthor H, 1999, DEVELOPMENT, V126, P1041; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Aza-Blanc P, 2000, DEVELOPMENT, V127, P4293; Azmi S, 2003, J BIOL CHEM, V278, P20098, DOI 10.1074/jbc.M210427200; Bai CYB, 2001, DEVELOPMENT, V128, P5161; BALL DW, 1993, P NATL ACAD SCI USA, V90, P5648, DOI 10.1073/pnas.90.12.5648; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; BENGAL E, 1994, P NATL ACAD SCI USA, V91, P6221, DOI 10.1073/pnas.91.13.6221; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Blandford MC, 2006, PEDIATR BLOOD CANCER, V46, P329, DOI 10.1002/pbc.20466; Borycki AG, 1999, DEVELOPMENT, V126, P4053; Bren-Mattison Y, 2002, DEV BIOL, V242, P130, DOI 10.1006/dbio.2001.0528; Briscoe J, 2005, DEV CELL, V8, P143, DOI 10.1016/j.devcel.2005.01.008; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Buckingham M, 2003, J ANAT, V202, P59, DOI 10.1046/j.1469-7580.2003.00139.x; Chen MH, 2004, GENE DEV, V18, P641, DOI 10.1101/gad.1185804; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Chuang PT, 2003, GENE DEV, V17, P342, DOI 10.1101/gad.1026303; Chuang PT, 2003, TRENDS CELL BIOL, V13, P86, DOI 10.1016/S0962-8924(02)00031-4; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dai Z, 2004, CURR TOP MED CHEM, V4, P1347; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Dodou E, 2003, MECH DEVELOP, V120, P1021, DOI 10.1016/S0925-4773(03)00178-3; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; Duprez D, 1998, DEVELOPMENT, V125, P495; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Guo CS, 2003, J BIOL CHEM, V278, P22615, DOI 10.1074/jbc.M301943200; Gustafsson MK, 2002, GENE DEV, V16, P114, DOI 10.1101/gad.940702; Hahn H, 1999, J MOL MED-JMM, V77, P459, DOI 10.1007/s001099900018; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Iezzi S, 2002, P NATL ACAD SCI USA, V99, P7757, DOI 10.1073/pnas.112218599; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jeong JH, 2005, DEVELOPMENT, V132, P143, DOI 10.1242/dev.01566; Kappler R, 2004, ONCOGENE, V23, P8785, DOI 10.1038/sj.onc.1208133; Kappler R, 2003, J PATHOL, V200, P348, DOI 10.1002/path.1361; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Koleva M, 2005, CELL MOL LIFE SCI, V62, P1863, DOI 10.1007/s00018-005-5072-9; Kruger M, 2001, DEVELOPMENT, V128, P743; Kuang S, 2006, J CELL BIOL, V172, P103, DOI 10.1083/jcb.200508001; Li Xiaopeng, 2004, BMC Dev Biol, V4, P9, DOI 10.1186/1471-213X-4-9; Liu AM, 2005, DEVELOPMENT, V132, P3103, DOI 10.1242/dev.01894; Liu D, 2004, EMBO J, V23, P1557, DOI 10.1038/sj.emboj.7600179; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Lu QR, 2000, NEURON, V25, P317, DOI 10.1016/S0896-6273(00)80897-1; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Mal A, 2003, P NATL ACAD SCI USA, V100, P1735, DOI 10.1073/pnas.0437843100; Marigo V, 1996, DEVELOPMENT, V122, P1225; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; May SR, 2005, DEV BIOL, V287, P378, DOI 10.1016/j.ydbio.2005.08.050; McDermott A, 2005, DEVELOPMENT, V132, P345, DOI 10.1242/dev.01537; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; Nagy A., 2003, MANIPULATING MOUSE E; Narumi O, 2000, J BIOL CHEM, V275, P3510, DOI 10.1074/jbc.275.5.3510; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; Nieuwenhuis E, 2005, CLIN GENET, V67, P193, DOI 10.1111/j.1399-0004.2004.00360.x; Olguin HC, 2004, DEV BIOL, V275, P375, DOI 10.1016/j.ydbio.2004.08.015; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Relaix F, 2006, J CELL BIOL, V172, P91, DOI 10.1083/jcb.200508044; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Sambrook J., 2001, MOL CLONING LAB MANU, DOI DOI 10.1086/394015; Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008-5472.CAN-05-4505; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Sirri V, 2003, ONCOGENE, V22, P5658, DOI 10.1038/sj.onc.1206690; Sun JX, 2001, J BIOL CHEM, V276, P18591, DOI 10.1074/jbc.M101163200; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Teboul L, 2003, GENE DEV, V17, P2870, DOI 10.1101/gad.1117603; Tiffin N, 2003, BRIT J CANCER, V89, P327, DOI 10.1038/sj.bjc.6601040; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Verzi MP, 2002, DEV BIOL, V249, P174, DOI 10.1006/dbio.2002.0753; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Watson Joseph, 2004, Ear Nose Throat J, V83, P716; Weiner HL, 2002, CANCER RES, V62, P6385; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; Wolff C, 2003, CURR BIOL, V13, P1169, DOI 10.1016/S0960-9822(03)00461-5; Yoon JW, 1998, J BIOL CHEM, V273, P3496, DOI 10.1074/jbc.273.6.3496	101	41	47	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1122	1136		10.1038/sj.onc.1209891	http://dx.doi.org/10.1038/sj.onc.1209891			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16964293	Green Accepted			2022-12-17	WOS:000244406400003
J	Nakai-Murakami, C; Shimura, M; Kinomoto, M; Takizawa, Y; Tokunaga, K; Taguchi, T; Hoshino, S; Miyagawa, K; Sata, T; Kurumizaka, H; Yuo, A; Ishizaka, Y				Nakai-Murakami, C.; Shimura, M.; Kinomoto, M.; Takizawa, Y.; Tokunaga, K.; Taguchi, T.; Hoshino, S.; Miyagawa, K.; Sata, T.; Kurumizaka, H.; Yuo, A.; Ishizaka, Y.			HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination	ONCOGENE			English	Article						HIV-1; Vpr; DNA double-strand breaks; homologous recombination; non-AIDS defining malignancies	VIRUS TYPE-1 VPR; AIDS-DEFINING CANCERS; DOUBLE-STRAND BREAKS; VIRAL-PROTEIN-R; DNA-DAMAGE; MICRONUCLEI FORMATION; ACCESSORY GENE; CYCLE ARREST; EARLY STEPS; P53	An ATM-dependent cellular signal, a DNA-damage response, has been shown to be involved during infection of human immunodeficiency virus type-1 (HIV-1), and a high incidence of malignant tumor development has been observed in HIV-1-positive patients. Vpr, an accessory gene product of HIV-1, delays the progression of the cell cycle at the G2/M phase, and ATR-Chk1-Wee-1, another DNA-damage signal, is a proposed cellular pathway responsible for the Vpr-induced cell cycle arrest. In this study, we present evidence that Vpr also activates ATM, and induces expression of gamma-H2AX and phosphorylation of Chk2. Strikingly, Vpr was found to stimulate the focus formation of Rad51 and BRCA1, which are involved in repair of DNA double-strand breaks (DSBs) by homologous recombination (1411), and biochemical analysis revealed that Vpr dissociates the interaction of p53 and Rad51 in the chromatin fraction, as observed under irradiation-induced DSBs. Vpr was consistently found to increase the rate of HR in the locus of I-Scel, a rare cutting-enzyme site that had been introduced into the genome. An increase of the HR rate enhanced by Vpr was attenuated by an ATM inhibitor, KU55933, suggesting that Vpr-induced DSBs activate ATM-dependent cellular signal that enhances the intracellular recombination potential. In context with a recent report that KU55933 attenuated the integration of HIV-1 into host genomes, we discuss the possible role of Vpr-induced DSBs in viral integration and also in HIV-1 associated malignancy.	Int Med Ctr Japan, Dept Intractable Dis, Shinjuku Ku, Tokyo 1628655, Japan; Int Med Ctr Japan, Dept Hematol, Shinjuku Ku, Tokyo 1628655, Japan; Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Tokyo, Japan; Waseda Univ, Sch Sci & Engn, Shinjuku Ku, Tokyo 169, Japan; Univ Tokyo, Grad Sch Med, Sect Radiat Biol, Bunkyo Ku, Tokyo, Japan	National Center for Global Health & Medicine - Japan; National Center for Global Health & Medicine - Japan; National Institute of Infectious Diseases (NIID); Waseda University; University of Tokyo	Ishizaka, Y (corresponding author), Int Med Ctr Japan, Dept Intractable Dis, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	zakay@ri.imcj.go.jp	Takizawa, Yoshimasa/G-2956-2015; Tokunaga, Kenzo/Q-9914-2018	Takizawa, Yoshimasa/0000-0002-6265-4830; Tokunaga, Kenzo/0000-0002-2625-5322; Kurumizaka, Hitoshi/0000-0001-7412-3722				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Anglana M, 1999, NUCLEIC ACIDS RES, V27, P4276, DOI 10.1093/nar/27.21.4276; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Biggar RJ, 1996, INT J CANCER, V68, P754; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3; Burgi A, 2005, CANCER-AM CANCER SOC, V104, P1505, DOI 10.1002/cncr.21334; Chadburn A, 1997, SEMIN DIAGN PATHOL, V14, P15; Cromie GA, 2001, MOL CELL, V8, P1163, DOI 10.1016/S1097-2765(01)00419-1; Daniel R, 2005, J VIROL, V79, P2058, DOI 10.1128/JVI.79.4.2058-2065.2005; Daniel R, 2004, J VIROL, V78, P8573, DOI 10.1128/JVI.78.16.8573-8581.2004; Daniel R, 2003, P NATL ACAD SCI USA, V100, P4778, DOI 10.1073/pnas.0730887100; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Elder RT, 2002, FRONT BIOSCI-LANDMRK, V7, pD349, DOI 10.2741/elder; ElenitobaJohnson KSJ, 1997, SEMIN DIAGN PATHOL, V14, P35; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Groschel B, 2005, J VIROL, V79, P5695, DOI 10.1128/JVI.79.9.5695-5704.2005; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; Henklein P, 2000, J BIOL CHEM, V275, P32016, DOI 10.1074/jbc.M004044200; Herida M, 2003, J CLIN ONCOL, V21, P3447, DOI 10.1200/JCO.2003.01.096; HOSHINO S, 2006, UNPUB; Huang MB, 2000, J NEUROVIROL, V6, P202, DOI 10.3109/13550280009015823; HUANG X, 2006, CYTOMETER A, V67, P222; ISHIZAKA Y, 1995, P NATL ACAD SCI USA, V92, P3224, DOI 10.1073/pnas.92.8.3224; Jeanson L, 2002, VIROLOGY, V300, P100, DOI 10.1006/viro.2002.1515; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Kagawa W, 2001, J BIOL CHEM, V276, P35201, DOI 10.1074/jbc.M104938200; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874; Knowles DM, 2003, HEMATOL ONCOL CLIN N, V17, P785, DOI 10.1016/S0889-8588(03)00050-9; Kurumizaka H, 1999, J MOL BIOL, V291, P537, DOI 10.1006/jmbi.1999.2950; Lai MY, 2005, J VIROL, V79, P15443, DOI 10.1128/JVI.79.24.15443-15451.2005; Lau A, 2005, NAT CELL BIOL, V7, P493, DOI 10.1038/ncb1250; Lau A, 2004, EMBO J, V23, P3421, DOI 10.1038/sj.emboj.7600348; LAURENCE J, 1991, P NATL ACAD SCI USA, V88, P7635, DOI 10.1073/pnas.88.17.7635; LEVYDN, 1994, P NATL ACAD SCI USA, V91, P10873; Li L, 2001, EMBO J, V20, P3272, DOI 10.1093/emboj/20.12.3272; Lim Soon Thye, 2005, Curr HIV/AIDS Rep, V2, P146, DOI 10.1007/s11904-005-0008-4; Linke SP, 2003, CANCER RES, V63, P2596; Mahalingam S, 1998, P NATL ACAD SCI USA, V95, P3419, DOI 10.1073/pnas.95.7.3419; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; MAYER V, 1995, EUR J CANCER PREV, V4, P211, DOI 10.1097/00008469-199506000-00001; Nunnari G, 2005, VIROLOGY, V335, P177, DOI 10.1016/j.virol.2005.02.015; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Roshal M, 2003, J BIOL CHEM, V278, P25879, DOI 10.1074/jbc.M303948200; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shimura M, 2005, AIDS, V19, P1434, DOI 10.1097/01.aids.0000180788.92627.e7; Shimura M, 1999, CANCER RES, V59, P2259; Shimura M, 1999, FASEB J, V13, P621, DOI 10.1096/fasebj.13.6.621; Slebos RJC, 2001, BIOCHEM BIOPH RES CO, V281, P212, DOI 10.1006/bbrc.2001.4335; Straus D J, 2001, Curr Oncol Rep, V3, P260, DOI 10.1007/s11912-001-0059-7; Tachiwana H, 2006, CANCER RES, V66, P627, DOI 10.1158/0008-5472.CAN-05-3144; Taguchi T, 2004, BIOCHEM BIOPH RES CO, V320, P18, DOI 10.1016/j.bbrc.2004.05.126; Tokunaga K, 2001, J VIROL, V75, P6776, DOI 10.1128/JVI.75.15.6776-6785.2001; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; WALDMAN AS, 1987, P NATL ACAD SCI USA, V84, P5340, DOI 10.1073/pnas.84.15.5340; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430; Yoon D, 2004, J MOL BIOL, V336, P639, DOI 10.1016/j.jmb.2003.12.050; Yuan HD, 2004, J VIROL, V78, P8183, DOI 10.1128/JVI.78.15.8183-8190.2004; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zimmerman ES, 2004, MOL CELL BIOL, V24, P9286, DOI 10.1128/MCB.24.21.9286-9294.2004	67	41	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					477	486		10.1038/sj.onc.1209831	http://dx.doi.org/10.1038/sj.onc.1209831			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16983346				2022-12-17	WOS:000243731600001
J	Shiraishi, K; Yamasaki, K; Nanba, D; Inoue, H; Hanakawa, Y; Shirakata, Y; Hashimoto, K; Higashiyama, S				Shiraishi, K.; Yamasaki, K.; Nanba, D.; Inoue, H.; Hanakawa, Y.; Shirakata, Y.; Hashimoto, K.; Higashiyama, S.			Pre-B-cell leukemia transcription factor 1 is a major target of promyelocytic leukemia zinc-finger-mediated melanoma cell growth suppression	ONCOGENE			English	Article						Pbx1; PLZF; Hox; melanoma	PLZF-RAR-ALPHA; DNA-BINDING; TRANSLOCATION PROTEIN; GENE; PROLIFERATION; EXPRESSION; HOXB7; ANGIOGENESIS; REPRESSION; CARCINOMA	Promyelocytic leukemia zinc-finger ( PLZF) is a transcriptional repressor and tumor suppressor. PLZF is expressed in melanocytes but not in melanoma cells, and recovery of PLZF expression markedly suppresses melanoma cell growth. Several target genes regulated by PLZF have been identified, but the precise function of PLZF remains uncertain. Here, we searched for candidate target genes of PLZF by DNA microarray analysis. Pre-B-cell leukemia transcription factor 1 (Pbx1) was one of the prominently suppressed genes. Pbx1 was highly expressed in melanoma cells, and its expression was reduced by transduction with the PLZF gene. Moreover, the growth suppression mediated by PLZF was reversed by enforced expression of Pbx1. Knockdown of Pbx1 by specific small interfering RNAs suppressed melanoma cell growth. We also found that Pbx1 binds HoxB7. Reverse transcription-polymerase chain reaction analysis demonstrated that repression of Pbx1 by PLZF reduces the expression of HoxB7 target genes, including tumor-associated neoangiogenesis factors such as basic fibroblast growth factor, angiopoietin-2 and matrix metalloprotease 9. These findings suggest that deregulation of Pbx1 expression owing to loss of PLZF expression contributes to the progression and/or pathogenesis of melanoma.	Ehime Univ, Grad Sch Med, Dept Biochem & Mol Genet, Toon, Ehime 7910295, Japan; Ehime Univ, Grad Sch Med, Dept Dermatol, Toon, Ehime 7910295, Japan; Japan Sci & Technol Corp JST, PRESTO, Kawaguchi, Saitama, Japan	Ehime University; Ehime University; Japan Science & Technology Agency (JST)	Higashiyama, S (corresponding author), Ehime Univ, Grad Sch Med, Dept Biochem & Mol Genet, Toon, Ehime 7910295, Japan.	shigeki@m.ehime-u.ac.jp	Yamasaki, Kenshi/C-8905-2018	Yamasaki, Kenshi/0000-0002-5495-4956				Ahmad SA, 2001, CANCER RES, V61, P1255; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Care A, 1998, ONCOGENE, V16, P3285, DOI 10.1038/sj.onc.1201875; Care A, 1996, MOL CELL BIOL, V16, P4842; Care A, 2001, CANCER RES, V61, P6532; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Etoh T, 2001, CANCER RES, V61, P2145; Felicetti F, 2004, ONCOGENE, V23, P4567, DOI 10.1038/sj.onc.1207597; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Johnson C, 2004, CIRC RES, V94, P262, DOI 10.1161/01.RES.0000111527.42357.62; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Shanmugam K, 1997, J BIOL CHEM, V272, P19081, DOI 10.1074/jbc.272.30.19081; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Tanaka M, 2004, J BIOL CHEM, V279, P41950, DOI 10.1074/jbc.M400086200; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375	27	41	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					339	348		10.1038/sj.onc.1209800	http://dx.doi.org/10.1038/sj.onc.1209800			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16862184				2022-12-17	WOS:000243544000003
J	Freilinger, A; Rosner, M; Krupitza, G; Nishino, M; Lubec, G; Korsmeyer, SJ; Hengstschlager, M				Freilinger, A.; Rosner, M.; Krupitza, G.; Nishino, M.; Lubec, G.; Korsmeyer, S. J.; Hengstschlaeger, M.			Tuberin activates the proapoptotic molecule BAD	ONCOGENE			English	Article						TSC2; tuberin; BAD; apoptosis	TUMOR-SUPPRESSOR GENE; CELL-SURVIVAL; SCLEROSIS COMPLEX; PRODUCT; TSC2; PHOSPHORYLATION; GROWTH; DEATH; AKT; TARGET	TSC1, encoding hamartin, and TSC2, encoding tuberin, are tumor suppressor genes responsible for the autosomal dominantly inherited disease tuberous sclerosis (TSC). TSC affects similar to 1 in 6000 individuals and is characterized by the development of tumors, named hamartomas, in different organs. Hamartin and tuberin form a complex, of which tuberin is assumed to be the functional component. The TSC proteins have been implicated in the control of cell cycle and cell size. In addition to enhanced growth, reduced death rates can lead to tumor development. Therefore, defects in the apoptosis-inducing pathways contribute to neoplastic cell expansion. Here, we show that tuberin triggers apoptosis, accompanied by downregulation of p70S6K activity and of phosphorylation of BAD on residue Ser136, and by upregulation of the interaction of BAD/BCL-2 and BAD/BCL-X-L. AKT phosphorylation negatively regulates tuberin's potential to trigger apoptosis. Experiments with BAD-/- cells demonstrate BAD to be a mediator of tuberin's effects on the regulation of apoptosis. Tuberin interferes with insulin-like growth factor-1-induced BAD Ser136 phosphorylation and cell survival. Our work proposes a model in which tuberin-mediated inhibition of p70S6K activates BAD to heterodimerize with BCL-2 and BCL-XL to promote apoptosis. A mutation of TSC2 - as it occurs in TSC patients - attenuates this proapoptotic potential, underscoring the relevance of our findings for human pathophysiology.	Med Univ Vienna, Gen Hosp, A-1090 Vienna, Austria; Med Univ Vienna, Inst Clin Pathol, Vienna, Austria; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dana Farber Canc Inst,Dept Pathol, Boston, MA USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dana Farber Canc Inst,Dept Med, Boston, MA USA; Med Univ Vienna, Dept Pediat, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Medical University of Vienna	Hengstschlager, M (corresponding author), Med Univ Vienna, Gen Hosp, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	markus.hengstschlaeger@meduniwien.ac.at		Krupitza, Georg/0000-0003-2949-7906; Lubec, Gert/0000-0002-6333-9461				Arrebola F, 2005, APOPTOSIS, V10, P1317, DOI 10.1007/s10495-005-2718-x; Astrinidis A, 2005, ONCOGENE, V24, P7475, DOI 10.1038/sj.onc.1209090; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Chong-Kopera H, 2006, J BIOL CHEM, V281, P8313, DOI 10.1074/jbc.C500451200; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Grusch M, 2002, CELL DEATH DIFFER, V9, P169, DOI 10.1038/sj.cdd.4400937; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Kolb TM, 2005, TOXICOL SCI, V88, P331, DOI 10.1093/toxsci/kfi310; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; NELLIST M, 1993, CELL, V75, P1305; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Rosner M, 2004, J BIOL CHEM, V279, P48707, DOI 10.1074/jbc.M405528200; Rosner M, 2003, ONCOGENE, V22, P4786, DOI 10.1038/sj.onc.1206776; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wohlfart S, 2004, AM J PATHOL, V164, P1081, DOI 10.1016/S0002-9440(10)63195-1; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	42	41	41	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2006	25	49					6467	6479		10.1038/sj.onc.1209660	http://dx.doi.org/10.1038/sj.onc.1209660			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702951				2022-12-17	WOS:000241395100003
J	Falvella, FS; Manenti, G; Spinola, M; Pignatiello, C; Conti, B; Pastorino, U; Dragani, TA				Falvella, F. S.; Manenti, G.; Spinola, M.; Pignatiello, C.; Conti, B.; Pastorino, U.; Dragani, T. A.			Identification of RASSF8 as a candidate lung tumor suppressor gene	ONCOGENE			English	Article						lung cancer; KRAS; RAS genes; cancer progression	ANCHORAGE-INDEPENDENT GROWTH; K-RAS; METASTASIS; CANCER; ONCOGENE; MUTATIONS; PROTEIN; PATHWAY	The RASSF8 gene, which maps close to the KRAS2 gene, contains a RAS-associated domain and encodes a protein that is evolutionarily conserved from fish to humans. Analysis of the RASSF8 transcript revealed a complex expression pattern of 5'-UTR mRNA isoforms in normal lung and in lung adenocarcinomas (ADCAs), with no apparent differences. However, RASSF8 gene transcript levels were similar to seven-fold-lower in lung ADCAs as compared to normal lung tissue. Expression of RASSF8 protein by transfected lung cancer cells led to inhibition of anchorage-independent growth in soft agar in A549 cells and reduction of clonogenic activity in NCI-H520 cells. These results raise the possibility protein encoded by RASSF8 is a novel tumor suppressor for lung cancer.	Ist Nazl Tumori, Dept Expt Oncol & Labs, I-20133 Milan, Italy; Ist Nazl Tumori, Unit Thorac Surg, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol & Labs, Via Venezian 1, I-20133 Milan, Italy.	tommaso.dragani@istitutotumori.mi.it	Manenti, Giacomo/J-3339-2017; Dragani, Tommaso A./K-4493-2016; Pastorino, Ugo/C-2712-2017	Manenti, Giacomo/0000-0002-4887-4482; Dragani, Tommaso A./0000-0001-5915-4598; Pastorino, Ugo/0000-0001-9974-7902				Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Clezardin P, 1998, CELL MOL LIFE SCI, V54, P541, DOI 10.1007/s000180050182; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; De Gregorio L, 1998, INT J CANCER, V79, P269, DOI 10.1002/(SICI)1097-0215(19980619)79:3<269::AID-IJC10>3.3.CO;2-J; Debeer P, 2002, J MED GENET, V39, P98, DOI 10.1136/jmg.39.2.98; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Huncharek M, 1999, CARCINOGENESIS, V20, P1507, DOI 10.1093/carcin/20.8.1507; Jiang YX, 2001, ONCOGENE, V20, P2254, DOI 10.1038/sj.onc.1204293; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kiel C, 2005, J MOL BIOL, V348, P759, DOI 10.1016/j.jmb.2005.02.046; Malaney S, 2001, J MAMMARY GLAND BIOL, V6, P101, DOI 10.1023/A:1009572700317; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Mascaux C, 2005, BRIT J CANCER, V92, P131, DOI 10.1038/sj.bjc.6602258; Nakanishi K, 2002, CANCER RES, V62, P2971; Nikiforov MA, 1996, ONCOGENE, V13, P1709; Wall JD, 2003, NAT REV GENET, V4, P587, DOI 10.1038/nrg1123; Wohlgemuth S, 2005, J MOL BIOL, V348, P741, DOI 10.1016/j.jmb.2005.02.048	19	41	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3934	3938		10.1038/sj.onc.1209422	http://dx.doi.org/10.1038/sj.onc.1209422			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16462760				2022-12-17	WOS:000238668800006
J	Quimby, BB; Yong-Gonzalez, V; Anan, T; Strunnikov, AV; Dasso, M				Quimby, B. B.; Yong-Gonzalez, V.; Anan, T.; Strunnikov, A. V.; Dasso, M.			The promyelocytic leukemia protein stimulates SUMO conjugation in yeast	ONCOGENE			English	Article						promyelocytic leukemia protein (PML); SUMO-1; budding yeast; SUMO ligase; PML : RAR alpha	NUCLEAR-BODY; RAR-ALPHA; PML; ENZYME; PATHOGENESIS; HOMOLOG; LIGASE; GENE; RING	The promyelocytic leukemia gene was first identified through its fusion to the gene encoding the retinoic acid receptor alpha (RAR alpha) in acute promyelocytic leukemia (APL) patients. The promyelocytic leukemia gene product (PML) becomes conjugated in vivo to the small ubiquitin-like protein SUMO-1, altering its behavior and capacity to recruit other proteins to PML nuclear bodies (PML-NBs). In the NB4 cell line, which was derived from an APL patient and expresses PML: RARa, we observed a retinoic acid-dependent change in the modi. cation of specific proteins by SUMO-1. To dissect the interaction of PML with the SUMO-1 modi. cation pathway, we used the budding yeast Saccharomyces cerevisiae as a model system through expression of PML and human SUMO-1 (hSUMO-1). We found that PML stimulated hSUMO-1 modi. cation in yeast, in a manner that was dependent upon PML's RING-finger domain. PML: RARa also stimulated hSUMO-1 conjugation in yeast. Interestingly, however, PML and PML: RARa differentially complemented yeast Smt3p conjugation pathway mutants. These findings point toward a potential function of PML and PML: RARa as SUMO E3 enzymes or E3 regulators, and suggest that fusion of RARa to PML may affect this activity.	NICHD, Lab Gene Regulat & Dev, Sect Cell Cycle Regulat, NIH, Bethesda, MD 20892 USA; NICHD, Unit Chromosome Struct & Funct, Lab Gene Regulat & Dev, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dasso, M (corresponding author), NICHD, Lab Gene Regulat & Dev, Sect Cell Cycle Regulat, NIH, Bldg 18T,Room 106,18 Lib Dr, Bethesda, MD 20892 USA.	mdasso@helix.nih.gov		Strunnikov, Alexander/0000-0002-9058-2256; Dasso, Mary/0000-0002-5410-1371	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001902, Z01HD001903] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 HD001902-13] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Azuma Y, 2001, FASEB J, V15, P1825, DOI 10.1096/fj.00-0818fje; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Chen XL, 2005, MOL CELL BIOL, V25, P4311, DOI 10.1128/MCB.25.10.4311-4320.2005; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Duprez E, 1999, J CELL SCI, V112, P381; GODDARD AD, 1992, LEUKEMIA, V6, pS117; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Quimby BB, 2000, MOL BIOL CELL, V11, P2617, DOI 10.1091/mbc.11.8.2617; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Strudwick S, 2002, LEUKEMIA, V16, P1906, DOI 10.1038/sj.leu.2402724; Strunnikov AV, 2001, GENETICS, V158, P95; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Zhao XL, 2005, P NATL ACAD SCI USA, V102, P4777, DOI 10.1073/pnas.0500537102; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	31	41	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					2999	3005		10.1038/sj.onc.1209335	http://dx.doi.org/10.1038/sj.onc.1209335			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16501610				2022-12-17	WOS:000237950800004
J	Katuri, V; Tang, Y; Li, C; Jogunoori, W; Deng, CX; Rashid, A; Sidawy, AN; Evans, S; Reddy, EP; Mishra, B; Mishra, L				Katuri, V; Tang, Y; Li, C; Jogunoori, W; Deng, CX; Rashid, A; Sidawy, AN; Evans, S; Reddy, EP; Mishra, B; Mishra, L			Critical interactions between TGF-beta signaling/ELF, and E-cadherin/beta-catenin mediated tumor suppression	ONCOGENE			English	Article						ELF; Smad4; spectrin; gastrointestinal cancer; E-cadherin	CELL-CELL ADHESION; GASTRIC-CANCER; MESENCHYMAL TRANSITION; LIVER DEVELOPMENT; IN-VITRO; SPECTRIN; CARCINOMA; MEMBRANE; PROTEIN; MICE	Inactivation of the transforming growth factor-beta (TGF-beta) pathway occurs often in malignancies of the gastrointestinal (GI) system. However, only a fraction of sporadic GI tumors exhibit inactivating mutations in early stages of cancer formation, suggesting that other mechanisms play a critical role in the inactivation of this pathway. Here, we show a wide range of GI tumors, including those of the stomach, liver and colon in elf(+/-) and elf(+/-)/Smad4(+/-) mutant mice. We found that embryonic liver fodrin ( ELF), a beta-Spectrin originally identified in endodermal stem/progenitor cells committed to foregut lineage, possesses potent antioncogenic activity and is frequently inactivated in GI cancers. Specifically, E-cadherin accumulation at cell-cell contacts and E-cadherin-beta-catenin-dependent epithelial cell-cell adhesion is disrupted in elf(+/-)/Smad4(+)/(-) mutant gastric epithelial cells, and could be rescued by ectopic expression of full-length elf, but not Smad3 or Smad4. Subcellular fractionation revealed that E-cadherin is expressed mainly at the cell membrane after TGF-beta stimulation. In contrast, elf(+/-)/Smad4(+/-) mutant tissues showed abnormal distribution of E-cadherin that could be rescued by overexpression of ELF but not Smad3 or Smad4. Our results identify a group of common lethal malignancies in which inactivation of TGF-beta signaling, which is essential for tumor suppression, is disrupted by inactivation of the ELF adaptor protein.	Georgetown Univ, Lab Canc Genet Digest Dis & Dev Mol Biol, Dept Surg, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Dept Surg, Washington, DC USA; Dept Vet Affairs, Washington, DC USA; Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Mishra, B (corresponding author), Georgetown Univ, Lab Canc Genet Digest Dis & Dev Mol Biol, Dept Surg, Vincent T Lombardi Canc Res Ctr, Med Dent Bldg NW 210-212,3900 Reservoir Rd,NW, Washington, DC 20007 USA.	bm72@georgetown.edu; lopamishra@yahoo.com	Reddy, E. Premkumar/F-6233-2011; deng, chuxia/N-6713-2016	Mishra, Lopa/0000-0002-6850-0808	NCI NIH HHS [R01 CA106614A, R01 CA106614] Funding Source: Medline; NIDDK NIH HHS [R01 DK58637, R01 DK56111, R01 DK056111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056111, Z01DK056012] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Brooks-Wilson AR, 2004, J MED GENET, V41, P508, DOI 10.1136/jmg.2004.018275; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Fath KR, 1997, J CELL BIOL, V139, P1169, DOI 10.1083/jcb.139.5.1169; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hadzija MP, 2004, MUTAT RES-FUND MOL M, V548, P61, DOI 10.1016/j.mrfmmm.2003.12.018; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li WM, 2003, DEVELOPMENT, V130, P6143, DOI 10.1242/dev.00820; Mishra L, 1999, ONCOGENE, V18, P353, DOI 10.1038/sj.onc.1202313; Mishra L, 1998, INT J DEV BIOL, V42, P221; Miyaki M, 1999, CANCER RES, V59, P4506; Muller N, 2002, ONCOGENE, V21, P6049, DOI 10.1038/sj.onc.1205766; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Piepenhagen PA, 1998, MOL BIOL CELL, V9, P3161, DOI 10.1091/mbc.9.11.3161; Pinder JC, 2000, NATURE, V406, P253, DOI 10.1038/35018679; ROBERTS AB, 1990, TRANSFORMING GROWTH; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Scartozzi M, 2004, CANCER TREAT REV, V30, P451, DOI 10.1016/j.ctrv.2004.01.001; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Sormunen RT, 1999, J PATHOL, V187, P416; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tang Y, 2005, CANCER RES, V65, P4228, DOI 10.1158/0008-5472.CAN-04-4585; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	35	41	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1871	1886		10.1038/sj.onc.1209211	http://dx.doi.org/10.1038/sj.onc.1209211			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16288220	Green Accepted			2022-12-17	WOS:000236224800004
J	Cruz-Munoz, W; Kim, I; Khokha, R				Cruz-Munoz, W; Kim, I; Khokha, R			TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis	ONCOGENE			English	Article						TIMP-3; host stroma; B16F10; teratoma; angiogenesis	TISSUE INHIBITOR; MATRIX METALLOPROTEINASES; CELL-DEATH; GENE; EXPRESSION; SUPPRESSION; CANCER; COMBINATION; MEMBRANE; PROMOTER	Tumor cells, stromal cell compartment and the extracellular matrix (ECM) together generate a multifaceted tumor microenvironment. Matrix metalloproteinases and their tissue inhibitors (TIMPs) provide a means for tumor-stromal interaction during tumorigenesis. Among TIMPs, TIMP-3 is uniquely localized to the ECM and is frequently silenced in human cancers. Here, we asked whether the absence of TIMP-3 in the tumor cell or the host affects the process of tumorigenesis. Timp-3(-/-) ES-cell clones were generated and used to develop teratomas in nude mice. Timp-3(-/-) teratomas showed similar tumor take, growth, and angiogenesis compared to timp-3(-/-) teratomas. To study the effect of TIMP-3 ablation in the host stroma, we measured the growth kinetics of subcutaneous B16F10 melanomas in timp-3(-/-) and wildtype littermates. Tumors grew significantly faster in timp3(-/-) than in wild-type mice and their CD31 content was significantly higher indicating increased angiogenesis. Augmented angiogenesis in timp-3(-/-) mice was directly tested using Matrigel plug and Gelfoam assays. In response to FGF-2, timp-3(-/-) endothelial cells invaded more efficiently, leading to enhanced formation of functional blood vessels. Thus, TIMP-3 deficiency in the host, but not in the tumor per se, leads to enhanced tumor growth and angiogenesis. TIMP-3 located within the tumor microenvironment inhibits tumorigenesis.	Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Khokha, R (corresponding author), Dept Lab Med & Pathobiol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rkhokha@uhnres.utoronto.ca						AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; Andreu T, 1998, J BIOL CHEM, V273, P13848, DOI 10.1074/jbc.273.22.13848; Bachman KE, 1999, CANCER RES, V59, P798; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; BOOKS PC, 1996, CELL, V85, P683; Boulay A, 2001, CANCER RES, V61, P2189; Chan VT, 1998, J INVEST DERMATOL, V111, P1153, DOI 10.1046/j.1523-1747.1998.00416.x; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; DeClerck YA, 2000, EUR J CANCER, V36, P1258, DOI 10.1016/S0959-8049(00)00094-0; Dulaimi E, 2004, CLIN CANCER RES, V10, P3972, DOI 10.1158/1078-0432.CCR-04-0175; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI200113171; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Itoh T, 1998, CANCER RES, V58, P1048; Kassiri Z, 2005, CIRC RES, V97, P380, DOI 10.1161/01.RES.0000178789.16929.cf; Kato T, 2001, FEBS LETT, V508, P187, DOI 10.1016/S0014-5793(01)02897-6; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Kruger A, 1997, BLOOD, V90, P1993, DOI 10.1182/blood.V90.5.1993; Leco KJ, 2001, J CLIN INVEST, V108, P817, DOI 10.1172/JCI12067; Leighl NB, 2005, J CLIN ONCOL, V23, P2831, DOI 10.1200/JCO.2005.04.044; Loging WT, 1999, ONCOGENE, V18, P7608, DOI 10.1038/sj.onc.1203135; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Martin DC, 1996, ONCOGENE, V13, P569; Masson V, 2004, FASEB J, V18, P234, DOI 10.1096/fj.04-2140fje; McCarty MF, 2002, INT J ONCOL, V21, P5; Michael M, 1999, J CLIN ONCOL, V17, P1802, DOI 10.1200/JCO.1999.17.6.1802; Mori M, 2000, INT J CANCER, V88, P575, DOI 10.1002/1097-0215(20001115)88:4<575::AID-IJC9>3.0.CO;2-C; Murphy G, 2003, BIOCHEM SOC SYMP, V70, P65, DOI 10.1042/bss0700065; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PASSANITI A, 1992, LAB INVEST, V67, P519; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Remacle A, 2000, INT J CANCER, V89, P118, DOI 10.1002/(SICI)1097-0215(20000320)89:2<118::AID-IJC3>3.0.CO;2-8; Sang Q X, 1998, Cell Res, V8, P171; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sogawa K, 2003, CANCER, V98, P1822, DOI 10.1002/cncr.11725; Soloway PD, 1996, ONCOGENE, V13, P2307; Spurbeck WW, 2003, CANCER GENE THER, V10, P161, DOI 10.1038/sj.cgt.7700577; Spurbeck WW, 2002, BLOOD, V100, P3361, DOI 10.1182/blood.V100.9.3361; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; Sun Y, 1996, ANTICANCER RES, V16, P1; Thurston G, 1996, AM J PHYSIOL-HEART C, V271, pH2547, DOI 10.1152/ajpheart.1996.271.6.H2547; Wild A, 2003, J CLIN ENDOCR METAB, V88, P1367, DOI 10.1210/jc.2002-021027; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200	44	41	45	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					650	655		10.1038/sj.onc.1209104	http://dx.doi.org/10.1038/sj.onc.1209104			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16186800				2022-12-17	WOS:000234897400016
J	Oliveira, C; Velho, R; Domingo, E; Preto, A; Hofstra, RMW; Hamelin, R; Yamamoto, H; Seruca, R; Schwartz, S				Oliveira, C; Velho, R; Domingo, E; Preto, A; Hofstra, RMW; Hamelin, R; Yamamoto, H; Seruca, R; Schwartz, S			Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer	ONCOGENE			English	Article						RASSF1A promoter methylation; KRAS; BRAF; colorectal cancer; gastric cancer; MSI	MISMATCH REPAIR DEFICIENCY; EPIGENETIC INACTIVATION; PROMOTER METHYLATION; KRAS MUTATIONS; RAS MUTATIONS; BRAF MUTATION; HMLH1; TUMORIGENESIS; CARCINOMAS; PATTERNS	Methylation-associated inactivation of RASSF1A has frequently been observed in several human malignancies including sporadic colorectal and gastric cancer. However, nothing is known about the RASSF1A methylation status in the setting of MMR-deficient gastrointestinal tumours. In this study, we analysed systematically alterations in KRAS, BRAF and RASSF1A, in order to de. ne the frequency and the pattern of these genetic/epigenetic alterations in three distinct subsets of MSI gastrointestinal tumours. Further, an association study was performed between RASSF1A methylation and the clinicopathological parameters in order to determine the pro. le of tumours harbouring this epigenetic event. A total of 56 MSI sporadic gastrointestinal tumours (31 colorectal and 25 gastric) and 20 MSI HNPCC analysed for KRAS/BRAF were analysed for RASSF1A promoter hypermethylation by MSP and DNA sequencing. No significant differences were found between the frequency of RASSF1A methylation in sporadic MSI colorectal and gastric carcinomas and HNPCC carcinomas (P = 0.31). Methylation of RASSF1A was present in 16 of 31 (52%) sporadic MSI colorectal and 11 of 25 (44%) MSI gastric carcinomas, and in six of 20 (30%) HNPCC carcinomas. Nearly 36% of MSI sporadic colorectal carcinomas (CRCs) had RASSF1A methylation and activating mutations at KRAS and/or BRAF. In contrast, only 10 and 8% of HNPCC and sporadic gastric carcinomas, respectively, had concomitant KRAS mutations and RASSF1A methylation. The MSI sporadic gastric and CRCs with RASSF1A methylation were preferentially poorly differentiated (P = 0.03, 0.05, respectively). We show that the pro. le of alterations RASSF1A, KRAS/BRAF is different among the three groups of MSI gastrointestinal tumours. Further, we demonstrate that MSI sporadic CRCs accumulated significantly more epigenetic/genetic alterations in RASSF1A, KRAS/BRAF than MSI sporadic gastric or HNPCC carcinomas (P = 0.016). These results are likely to have therapeutic implications in the near future, due to the possibilities of using specific kinase inhibitors alone or in association with demethylating agents in MSI tumour types harbouring KRAS or BRAF mutations and RASSF1A methylation.	Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, P-4200465 Oporto, Portugal; Hosp Univ Vall Hebron, Ctr Invest Bioquim & Biol Mol, Barcelona 08035, Spain; Univ Groningen, Dept Med Genet, NL-9713 AW Groningen, Netherlands; Ctr Etud Polymorphisme Humain, INSERM, U434, F-75010 Paris, France; Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan; Univ Porto, Fac Med, P-4100 Oporto, Portugal	Universidade do Porto; Hospital Universitari Vall d'Hebron; University of Groningen; Institut National de la Sante et de la Recherche Medicale (Inserm); Sapporo Medical University; Universidade do Porto	Seruca, R (corresponding author), Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, Rua Roberto Frias S-N, P-4200465 Oporto, Portugal.	rseruca@ipatimup.pt	seruca, raquel/F-8187-2011; Schwartz, Simo/H-7776-2012; Oliveira, Carla/F-8188-2011; Velho, Sérgia/B-8501-2013; Preto, Ana/H-8112-2012; Domingo, Enric/A-9099-2018	Oliveira, Carla/0000-0001-8340-2264; Velho, Sérgia/0000-0002-7104-8234; Preto, Ana/0000-0002-7302-0630; Domingo, Enric/0000-0003-4390-8767; Seruca, Raquel/0000-0002-8851-4166; Schwartz, Simo/0000-0001-8297-7971; Hofstra, Robert/0000-0001-7498-3829				Brennetot C, 2003, GASTROENTEROLOGY, V125, P1282, DOI 10.1016/j.gastro.2003.02.002; BYUN D, 2002, CANCER RES, V61, P7034; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3; Domingo E, 2004, J MED GENET, V41, P664, DOI 10.1136/jmg.2004.020651; Domingo E, 2004, GENE CHROMOSOME CANC, V39, P138, DOI 10.1002/gcc.10310; Ibanez de Caceres I, 2004, CANCER RES, V64, P6476; Koinuma K, 2004, INT J CANCER, V108, P237, DOI 10.1002/ijc.11523; Lerman MI, 2000, CANCER RES, V60, P6116; McGivern A, 2004, Fam Cancer, V3, P101; Oliveira C, 2003, ONCOGENE, V22, P9192, DOI 10.1038/sj.onc.1207061; Oliveira C, 2004, HUM MOL GENET, V13, P2303, DOI 10.1093/hmg/ddh238; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Reifenberger J, 2004, INT J CANCER, V109, P377, DOI 10.1002/ijc.11722; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Umar A, 2004, NAT REV CANCER, V4, P153, DOI 10.1038/nrc1278; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; Xing MZ, 2004, CANCER RES, V64, P1664, DOI 10.1158/0008-5472.CAN-03-3242; Yuen ST, 2002, CANCER RES, V62, P6451	24	41	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7630	7634		10.1038/sj.onc.1208906	http://dx.doi.org/10.1038/sj.onc.1208906			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16007118				2022-12-17	WOS:000233333800013
J	Kronenwett, R; Butterweck, U; Steidl, U; Kliszewski, S; Neumann, F; Bork, S; Blanco, ED; Roes, N; Graf, T; Brors, B; Eils, R; Maercker, C; Kobbe, G; Gattermann, N; Haas, R				Kronenwett, R; Butterweck, U; Steidl, U; Kliszewski, S; Neumann, F; Bork, S; Blanco, ED; Roes, N; Graf, T; Brors, B; Eils, R; Maercker, C; Kobbe, G; Gattermann, N; Haas, R			Distinct molecular phenotype of malignant CD34+hematopoietic stem and progenitor cells in chronic myelogenous leukemia	ONCOGENE			English	Article						CML; CD34+cells; gene expression; G protein-coupled receptors	CHRONIC MYELOID-LEUKEMIA; CD34(+) HEMATOPOIETIC STEM; TYROSINE KINASE-ACTIVITY; BCR-ABL; GENE-EXPRESSION; PHILADELPHIA-CHROMOSOME; BONE-MARROW; CXCR4 ANTAGONIST; IN-VITRO; TRANSFORMATION	Chronic myelogenous leukemia (CML) is a malignant disorder of the hematopoietic stem cell characterized by the BCR-ABL oncogene. We examined gene expression profiles of highly enriched CD34+ hematopoietic stem and progenitor cells from patients with CML in chronic phase using cDNA arrays covering 1.185 genes. Comparing CML CD34+ cells with normal CD34+ cells, we found 158 genes which were significantly differentially expressed. Gene expression patterns reflected BCR-ABL-induced functional alterations such as increased cell-cycle and proteasome activity. Detoxification enzymes and DNA repair proteins were downregulated in CML CD34+ cells, which might contribute to genetic instability. Decreased expression of junction plakoglobulin and CXC chemokine receptor 4 (CXCR-4) might facilitate the release of immature precursors from bone marrow in CML. GATA-2 was upregulated in CML CD34+ cells, suggesting an increased self-renewal in comparison with normal CD34+ cells. Moreover, we found upregulation of the proto-oncogene SKI and of receptors for neuromediators such as opioid mu 1 receptor, GABA B receptor, adenosine A1 receptor, orexin 1 and 2 receptors and corticotropine-releasing hormone receptor. Treatment of CML progenitor cells with the selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine ( DPCPX) resulted in a dose-dependent significant inhibition of clonogenic growth by 40% at a concentration of 10(-5) M, which could be reversed by the equimolar addition of the receptor agonist 2-chloro-N6-cyclopentyladenosine (P < 0.05). The incubation of normal progenitor cells with DPCPX resulted in an inhibition of clonogenic growth to a significantly lesser extent in comparison with CML cells (P < 0.05), suggesting that the adenosine A1 receptor is of functional relevance in CML hematopoietic progenitor cells.	Univ Dusseldorf, Dept Hematol, D-40225 Dusseldorf, Germany; Howard Hughes Med Inst, Div Hematol Oncol, Boston, MA 02115 USA; German Canc Res Ctr, D-69120 Heidelberg, Germany; German Resource Ctr Genome Res, D-69120 Heidelberg, Germany	Heinrich Heine University Dusseldorf; Howard Hughes Medical Institute; Helmholtz Association; German Cancer Research Center (DKFZ)	Kronenwett, R (corresponding author), Univ Dusseldorf, Dept Hematol, Moorenstr 5, D-40225 Dusseldorf, Germany.	kronenwett@med.uni-duesseldorf.de	Brors, Benedikt/E-5620-2013; Eils, Roland/B-6121-2009; Kobbe, Guido/ABG-9472-2021	Brors, Benedikt/0000-0001-5940-3101; Eils, Roland/0000-0002-0034-4036; 				BEDI A, 1994, BLOOD, V83, P2038; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Devine SM, 2004, J CLIN ONCOL, V22, P1095, DOI 10.1200/JCO.2004.07.131; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Gora-Tybor J, 1998, BRIT J HAEMATOL, V103, P716, DOI 10.1046/j.1365-2141.1998.01039.x; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; Graf L, 2001, BIOL BLOOD MARROW TR, V7, P486, DOI 10.1053/bbmt.2001.v7.pm11669215; Haase D, 2002, LEUKEMIA RES, V26, P249, DOI 10.1016/S0145-2126(01)00124-2; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Izumi T, 1996, INT J HEMATOL, V64, P73; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Kronenwett R, 1998, BLOOD, V91, P852, DOI 10.1182/blood.V91.3.852.852_852_862; Kronenwett R, 2002, CANCER GENE THER, V9, P587, DOI 10.1038/sj.cgt.7700474; Liebermann DA, 1998, ONCOGENE, V17, P3319, DOI 10.1038/sj.onc.1202574; Liles WC, 2003, BLOOD, V102, P2728, DOI 10.1182/blood-2003-02-0663; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; McLean LA, 2004, CLIN CANCER RES, V10, P155, DOI 10.1158/1078-0432.CCR-0784-3; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; NAMCIU S, 1995, DEV DYNAM, V204, P291, DOI 10.1002/aja.1002040307; Neumann F, 2003, EUR J HAEMATOL, V70, P1, DOI 10.1034/j.1600-0609.2003.02811.x; Ng YY, 2004, J LEUKOCYTE BIOL, V75, P314, DOI 10.1189/jlb.0603287; Nowicki MO, 2003, ONCOGENE, V22, P3952, DOI 10.1038/sj.onc.1206620; Ohmine K, 2001, ONCOGENE, V20, P8249, DOI 10.1038/sj.onc.1205029; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Pospisil M, 2001, EXP HEMATOL, V29, P557, DOI 10.1016/S0301-472X(01)00622-1; Soligo D, 2001, BRIT J HAEMATOL, V113, P126, DOI 10.1046/j.1365-2141.2001.02683.x; Steidl U, 2003, VITAM HORM, V66, P1, DOI 10.1016/S0083-6729(03)01001-X; Steidl U, 2002, BLOOD, V99, P2037, DOI 10.1182/blood.V99.6.2037; Steidl U, 2004, BLOOD, V104, P81, DOI 10.1182/blood-2004-01-0373; Szaniszlo P, 2004, CYTOM PART A, V59A, P191, DOI 10.1002/cyto.a.20055; Tian MT, 1997, J EXP MED, V185, P1517, DOI 10.1084/jem.185.8.1517; Traycoff CM, 1998, BRIT J HAEMATOL, V102, P759, DOI 10.1046/j.1365-2141.1998.00839.x; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; Wain HM, 2002, GENOMICS, V79, P464, DOI 10.1006/geno.2002.6748; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wlodarska I, 1996, LEUKEMIA LYMPHOMA, V23, P287, DOI 10.3109/10428199609054831; Yu CR, 2003, BLOOD, V102, P3765, DOI 10.1182/blood-2003-03-0737; Zhu J, 2002, ONCOGENE, V21, P3295, DOI 10.1038/sj.onc.1205318	45	41	43	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 11	2005	24	34					5313	5324		10.1038/sj.onc.1208596	http://dx.doi.org/10.1038/sj.onc.1208596			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15806158				2022-12-17	WOS:000231158500005
J	Jaworski, M; Buchmann, A; Bauer, P; Riess, O; Schwarz, M				Jaworski, M; Buchmann, A; Bauer, P; Riess, O; Schwarz, M			B-Raf and Ha-ras mutations in chemically induced mouse liver tumors	ONCOGENE			English	Article						mouse hepatocarcinogenesis; B-Raf; Ha-ras; mutation analysis; pyrosequencing	SIGNALING PATHWAY; BRAF GENE; APOPTOSIS; HEPATOCARCINOGENESIS; CANCER; KINASE; MICE; MITOCHONDRIA; DOWNSTREAM; ACTIVATION	The mitogen-activated protein kinase signalling pathway is a central regulator of tumor growth, which is constitutively activated in chemically induced mouse liver tumors. In about 30-50% of cases this effect can be related to activation of the Ha-ras gene by point mutations, whereas in the remaining cases mutations may occur in other members within this pathway, such as Raf kinases. Recently, B-raf has been shown to be frequently mutated in human melanomas and certain other cancers, with a V599E amino-acid change representing the most predominant mutation type. We now screened 82 N-nitrosodiethylamine-induced liver tumors from C3H/He mice for mutations within the hotspot positions in the Ha-ras and B-raf genes. About 50% (39/82) of tumors showed Ha-ras codon 61 mutations and 16 tumors (similar to20%) harbored mutations at codon 624 of the B-raf gene, which corresponds to codon 599 in human B-raf. None of the tumors was mutated in both Ha-ras and B-raf. The high prevalence of Ha-ras and B-raf mutations in mouse liver tumors is in striking contrast to human hepatocellular cancers which very infrequently harbor mutations in the two genes. These fundamental differences between the biology of liver tumors in mice and man may be of toxicological relevance.	Univ Tubingen, Abt Toxikol, Inst Pharmakol & Toxikol, D-72074 Tubingen, Germany; Univ Tubingen, Inst Humangenet, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen	Schwarz, M (corresponding author), Univ Tubingen, Abt Toxikol, Inst Pharmakol & Toxikol, Wilhelmstr 56, D-72074 Tubingen, Germany.	michael.schwarz@uni-tuebingen.de						BAUERHOFMANN R, 1992, MOL CARCINOGEN, V6, P60, DOI 10.1002/mc.2940060110; Berg Lars M, 2002, Expert Rev Mol Diagn, V2, P361, DOI 10.1586/14737159.2.4.361; BUCHMANN A, 1991, P NATL ACAD SCI USA, V88, P911, DOI 10.1073/pnas.88.3.911; Chang FM, 2003, INT J ONCOL, V22, P469; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DRAGANI TA, 1991, ONCOGENE, V6, P333; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Frey S, 2000, CARCINOGENESIS, V21, P161, DOI 10.1093/carcin/21.2.161; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Kalkuhl A, 1998, HEPATOLOGY, V27, P1081, DOI 10.1002/hep.510270425; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; MARONPOT RR, 1995, TOXICOLOGY, V101, P125, DOI 10.1016/0300-483X(95)03112-S; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; O'Neill E, 2004, BRIT J CANCER, V90, P283, DOI 10.1038/sj.bjc.6601488; Schwarz M, 1995, MUTAT RES-FUND MOL M, V333, P69, DOI 10.1016/0027-5107(95)00133-6; Tannapfel A, 2003, GUT, V52, P706, DOI 10.1136/gut.52.5.706; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Xiao WZ, 2001, HUM MUTAT, V17, P439, DOI 10.1002/humu.1130.abs; Yuen ST, 2002, CANCER RES, V62, P6451	26	41	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1290	1295		10.1038/sj.onc.1208265	http://dx.doi.org/10.1038/sj.onc.1208265			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592514				2022-12-17	WOS:000226898700017
J	Westmark, CJ; Bartleson, VB; Malter, JS				Westmark, CJ; Bartleson, VB; Malter, JS			RhoB mRNA is stabilized by HuR after UV light	ONCOGENE			English	Article						RhoB; HuR; ARE; mRNA stability; UVL	ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; P38 SIGNALING CASCADE; AU-RICH ELEMENTS; BINDING-PROTEIN; GTPASE RHOB; DOWN-REGULATION; CYCLOOXYGENASE-2 EXPRESSION; TRANSCRIPTIONAL ACTIVATION; ULTRAVIOLET-IRRADIATION	RhoB is a small GTP-binding protein that is involved in apoptotic signal transduction. We have cloned the mouse RhoB mRNA including a 1377 nucleotide 3'-untranslated region (UTR) that contains six AU-rich elements (AREs) as well as several uridine-rich stretches. There is 94% homology overall between the mouse and rat RhoB genes and 92% homology between the mouse and a putative human clone. Ultraviolet light (UVL) induces RhoB production through regulated changes in gene transcription and mRNA stabilization although the latter mechanism is unknown. We observed that UVL increased the half-life of RhoB mRNA from 63 min to 3.3 h in NIH/3T3 cells and from 87 min to 2.7 h in normal human keratinocyte cells. In vitro mobility shift assays demonstrated that HuR bound the 3'-UTR of RhoB at three distinct locations (nucleotides 1342-1696, 1765-1920 and 1897-1977) suggesting a regulatory role for this RNA-binding protein. HuR immunoprecipitations were positive for RhoB mRNA indicating an in vivo association, and Western blot analysis and immunofluorescence demonstrated that HuR rapidly partitions from the nucleus to the cytoplasm after UVL. Therefore, we propose a model in which UVL induces stress-activated signal transduction leading to nuclear/cytoplasmic shuttling of HuR and subsequent stabilization of RhoB mRNA.	Univ Wisconsin, Waisman Ctr Dev Disabil, Dept Pathol & Lab Med, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Malter, JS (corresponding author), Univ Wisconsin, Waisman Ctr Dev Disabil, Dept Pathol & Lab Med, Waisman Ctr Rm T509,1500 Highland Ave, Madison, WI 53705 USA.	jsmalter@facstaff.wisc.edu	Westmark, Cara J/L-4647-2019; Westmark, Cara/AAX-4408-2020		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061666] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH61666] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adnane J, 2002, CLIN CANCER RES, V8, P2225; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Carninci P, 1999, METHOD ENZYMOL, V303, P19; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Delarue FL, 2001, ONCOGENE, V20, P6531, DOI 10.1038/sj.onc.1204801; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI12973; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fritz G, 2000, BIOCHEM BIOPH RES CO, V268, P784, DOI 10.1006/bbrc.2000.2211; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Fritz G, 1999, ANTICANCER RES, V19, P1681; Fritz G, 2001, NUCLEIC ACIDS RES, V29, P792, DOI 10.1093/nar/29.3.792; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; Hernandez-Perera O, 2000, CIRC RES, V87, P616, DOI 10.1161/01.RES.87.7.616; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Jiang K, 2004, ONCOGENE, V23, P1136, DOI 10.1038/sj.onc.1207236; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Kasashima K, 2002, NUCLEIC ACIDS RES, V30, P4519, DOI 10.1093/nar/gkf567; Kirigiti P, 2001, MOL PHARMACOL, V60, P1308, DOI 10.1124/mol.60.6.1308; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Malcolm T, 2003, ONCOGENE, V22, P6142, DOI 10.1038/sj.onc.1206638; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Miyakawa Y, 2001, BIOCHEM BIOPH RES CO, V284, P71, DOI 10.1006/bbrc.2001.4950; Montero L, 1999, CANCER RES, V59, P5286; Nakamura T, 1996, BIOCHEM BIOPH RES CO, V226, P688, DOI 10.1006/bbrc.1996.1415; Park-Lee S, 2003, J BIOL CHEM, V278, P39801, DOI 10.1074/jbc.M307105200; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Pillaire MJ, 2000, BIOCHEM BIOPH RES CO, V278, P724, DOI 10.1006/bbrc.2000.3877; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; Trapp T, 2003, MOL CELL NEUROSCI, V23, P302, DOI 10.1016/S1044-7431(03)00013-7; Trapp T, 2001, MOL CELL NEUROSCI, V17, P883, DOI 10.1006/mcne.2001.0971; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Westmark CJ, 2001, MOL BRAIN RES, V90, P193, DOI 10.1016/S0169-328X(01)00112-7; Westmark CJ, 2001, J BIOL CHEM, V276, P1119, DOI 10.1074/jbc.M009435200; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yang CL, 2001, J BIOL CHEM, V276, P47277, DOI 10.1074/jbc.M105396200; 1998, GENOME RES, V8, P1097	63	41	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					502	511		10.1038/sj.onc.1208224	http://dx.doi.org/10.1038/sj.onc.1208224			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15543229				2022-12-17	WOS:000226279700020
J	Klopfer, A; Hasenjager, A; Belka, C; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Klopfer, A; Hasenjager, A; Belka, C; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway	ONCOGENE			English	Article						2CdA; FAraA; apoptosis; FADD; CD95/Fas; caspase-8; Bcl-2	DRUG-RESISTANCE; LEUKEMIA-CELLS; WILD-TYPE; BCL-2; CASPASE; LIGAND; DNA; SENSITIVITY; DOXORUBICIN; RADIATION	The adenine deoxynucleosides cladribine (2CdA) and fludarabine (FAraA) are DNA-damaging agents that interfere with DNA repair and induce apoptosis in nonproliferating lymphoid cells. Although both drugs are clinically used for the treatment of indolent lymphoproliferative diseases, the pathways of apoptosis induction remain largely unknown. In the present work, we demonstrate that both drugs induce apoptosis independently of death receptor signaling but activate the mitochondrial cell death pathway. To dissect the signaling pathways, we employed Jurkat cells either deficient for FADD or caspase-8 or overexpressing Bcl-2. In Bcl-2 overexpressing cells, apoptosis and cytochrome c release were blocked whereas processing of caspase-9, -3 and -8 was partially inhibited. In contrast, neither the deficiency of FADD or caspase-8 nor the interference with death receptor signaling by neutralizing anti-CD95/Fas antibodies affected cell death. Inhibitor experiments revealed that caspase-8 is processed by caspase-3- like caspases. Moreover, cytochrome c release and processing of caspase-9 and - 3 occurred to an equal extent in wild-type FADD -/- and caspase-8 -/- Jurkat cells. Likewise, apoptosis induction by cladribine or fludarabine was not hampered upon inhibition of caspase-8 in MOLT-3 and MOLT-4 cells or overexpression of a dominant-negative FADD mutant in BJAB cells. Thus, we conclude that apoptosis induced by nucleoside analogues is independent from death receptor signaling as well as from a proposed direct effect on APAF-1, but rather follows the mitochondrial signaling pathway of cytochrome c release and subsequent processing of caspase-9 and -3.	Humboldt Univ, Univ Med Ctr Charite, Dpet Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Med Sch, Dept Radiat Oncol, Tubingen, Germany; Univ Med Sch, Inst Mol Med, Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Daniel, PT (corresponding author), Humboldt Univ, Univ Med Ctr Charite, Dpet Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Bosanquet AG, 1996, BLOOD, V87, P1962; Bosanquet AG, 1999, BRIT J HAEMATOL, V106, P71, DOI 10.1046/j.1365-2141.1999.01516.x; BROMIDGE TJ, 1995, CYTOMETRY, V20, P257, DOI 10.1002/cyto.990200309; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; DHEIN J, 1992, J IMMUNOL, V149, P3166; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Genini D, 2000, BLOOD, V96, P3537; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Huang P, 1995, CLIN CANCER RES, V1, P1005; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leoni LM, 1998, P NATL ACAD SCI USA, V95, P9567, DOI 10.1073/pnas.95.16.9567; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Marzo I, 2001, BIOCHEM J, V359, P537, DOI 10.1042/0264-6021:3590537; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nomura Y, 2000, LEUKEMIA, V14, P299, DOI 10.1038/sj.leu.2401649; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378	29	41	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9408	9418		10.1038/sj.onc.1207975	http://dx.doi.org/10.1038/sj.onc.1207975			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15516989				2022-12-17	WOS:000225764100012
J	Bowie, ML; Dietze, EC; Delrow, J; Bean, GR; Troch, MM; Marjoram, RJ; Seewaldt, VL				Bowie, ML; Dietze, EC; Delrow, J; Bean, GR; Troch, MM; Marjoram, RJ; Seewaldt, VL			Interferon-regulatory factor-1 is critical for tamoxifen-mediated apoptosis in human mammary epithelial cells	ONCOGENE			English	Article						IRF-1; tamoxifen; CBP; breast cancer	CREB-BINDING PROTEIN; GAMMA INHIBITS GROWTH; RETINOIC-ACID; BREAST-CANCER; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; STIMULATED GENES; CARCINOMA-CELLS; UP-REGULATION; BETA	Unlike estrogen receptor-positive (ER(+)) breast cancers, normal human mammary epithelial cells (HMECs) typically express low nuclear levels of ER ( ER poor). We previously demonstrated that 1.0 muM tamoxifen (Tam) promotes apoptosis in acutely damaged ER-poor HMECs through a rapid, 'nonclassic' signaling pathway. Interferon-regulatory factor-1 (IRF-1), a target of signal transducer and activator of transcription-1 transcriptional regulation, has been shown to promote apoptosis following DNA damage. Here we show that 1.0 muM Tam promotes apoptosis in acutely damaged ER-poor HMECs through IRF-1 induction and caspase-1/3 activation. Treatment of acutely damaged HMEC-E6 cells with 1.0 muM Tam resulted in recruitment of CBP to the gamma-IFN-activated sequence element of the IRF-1 promoter, induction of IRF-1, and sequential activation of caspase-1 and -3. The effects of Tam were blocked by expression of siRNA directed against IRF-1 and caspase-1 inhibitors. These data indicate that Tam induces apoptosis in HMEC-E6 cells through a novel IRF-1-mediated signaling pathway that results in activated caspase-1 and -3.	Duke Univ, Med Ctr, Div Med Oncol, Durham, NC 27710 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98120 USA; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Fred Hutchinson Cancer Center; Duke University	Seewaldt, VL (corresponding author), Duke Univ, Med Ctr, Div Med Oncol, Box 2628, Durham, NC 27710 USA.	seewa001@mc.duke.edu			NATIONAL CANCER INSTITUTE [R01CA088799, P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA88799, 2P30CA14236-26, R01CA984441] Funding Source: Medline; NIDDK NIH HHS [2P30DK 35816-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiba-Masago S, 2001, CELL SIGNAL, V13, P617, DOI 10.1016/S0898-6568(01)00183-8; Anderson E, 1998, J MAMMARY GLAND BIOL, V3, P23, DOI 10.1023/A:1018718117113; Andrews HN, 2002, J BIOL CHEM, V277, P26225, DOI 10.1074/jbc.M201316200; Aubele MM, 2000, DIAGN MOL PATHOL, V9, P14, DOI 10.1097/00019606-200003000-00003; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bjornstrom L, 2002, MOL ENDOCRINOL, V16, P2202, DOI 10.1210/me.2002-0072; Chatterjee-Kishore M, 1998, J BIOL CHEM, V273, P16177, DOI 10.1074/jbc.273.26.16177; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Coradini D, 1997, TUMOR BIOL, V18, P22, DOI 10.1159/000218012; Creagh EM, 2003, IMMUNOL REV, V193, P10, DOI 10.1034/j.1600-065X.2003.00048.x; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Detjen KM, 2002, INT J ONCOL, V21, P1133; Detjen KM, 2001, GUT, V49, P251, DOI 10.1136/gut.49.2.251; Dietze EC, 2004, ONCOGENE, V23, P3851, DOI 10.1038/sj.onc.1207480; Dietze EC, 2001, J BIOL CHEM, V276, P5384, DOI 10.1074/jbc.M007915200; Doherty GM, 2001, ANN SURG, V233, P623, DOI 10.1097/00000658-200105000-00005; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GIBSON DFC, 1993, BREAST CANCER RES TR, V25, P141, DOI 10.1007/BF00662139; Giles RH, 1997, LEUKEMIA, V11, P2087, DOI 10.1038/sj.leu.2400882; Giles RH, 1997, GENOMICS, V42, P96, DOI 10.1006/geno.1997.4699; Gjermandsen IM, 2000, CYTOKINE, V12, P233, DOI 10.1006/cyto.1999.0549; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Henderson YC, 1997, BRIT J HAEMATOL, V96, P566, DOI 10.1046/j.1365-2141.1997.d01-2057.x; Hiroi M, 2003, J BIOL CHEM, V278, P651, DOI 10.1074/jbc.M204544200; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Hoshiya Y, 2003, J BIOL CHEM, V278, P51703, DOI 10.1074/jbc.M307626200; Iacopino F, 1997, INT J CANCER, V71, P1103, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1103::AID-IJC29>3.0.CO;2-C; Jiang B, 2004, TOXICON, V43, P53, DOI 10.1016/j.toxicon.2003.10.017; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; Karlsen AE, 2000, J CLIN ENDOCR METAB, V85, P830, DOI 10.1210/jc.85.2.830; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Kim EJ, 2002, J CELL BIOCHEM, V85, P369, DOI 10.1002/jcb.10142; Kim PKM, 2004, ONCOGENE, V23, P1125, DOI 10.1038/sj.onc.1207023; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Kovacs KA, 2003, J BIOL CHEM, V278, P36959, DOI 10.1074/jbc.M303147200; Kroger A, 2002, J INTERF CYTOK RES, V22, P5, DOI 10.1089/107999002753452610; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Kumar-Sinha C, 2002, J BIOL CHEM, V277, P575, DOI 10.1074/jbc.M107795200; Lindner DJ, 1997, J INTERF CYTOK RES, V17, P681, DOI 10.1089/jir.1997.17.681; Lindner DJ, 1997, MOL CELL BIOCHEM, V167, P169, DOI 10.1023/A:1006854110122; Lininger RA, 1998, HUM PATHOL, V29, P1113, DOI 10.1016/S0046-8177(98)90422-1; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; Pasinelli P, 2000, P NATL ACAD SCI USA, V97, P13901, DOI 10.1073/pnas.240305897; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; PINE R, 1994, EMBO J, V16, P406; RASMUSSEN UB, 1993, CANCER RES, V53, P4096; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Romeo G, 2002, J INTERF CYTOK RES, V22, P39, DOI 10.1089/107999002753452647; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Seewaldt VL, 1999, CELL GROWTH DIFFER, V10, P49; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; Seewaldt VL, 2001, CANCER RES, V61, P616; Seewaldt VL, 1999, EXP CELL RES, V249, P70, DOI 10.1006/excr.1999.4462; Seewaldt VL, 1997, EXP CELL RES, V236, P16, DOI 10.1006/excr.1997.3694; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAMPFER M, 1985, J TISSUE CULT METHOD, V9, P109; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tsuda H, 1998, JPN J CLIN ONCOL, V28, P5, DOI 10.1093/jjco/28.1.5; Tzoanopoulos D, 2002, BRIT J HAEMATOL, V119, P46, DOI 10.1046/j.1365-2141.2002.03829.x; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Widschwendter M, 1996, ANTICANCER RES, V16, P369; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yim JH, 1997, J IMMUNOL, V158, P1284; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang SP, 2003, J BIOL CHEM, V278, P52810, DOI 10.1074/jbc.M308244200	83	41	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8743	8755		10.1038/sj.onc.1208120	http://dx.doi.org/10.1038/sj.onc.1208120			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467738				2022-12-17	WOS:000225165100004
J	Poulin, G; Nandakumar, R; Ahringer, J				Poulin, G; Nandakumar, R; Ahringer, J			Genome-wide RNAi screens in Caenorhabditis elegans: impact on cancer research	ONCOGENE			English	Article						RNAi; C. elegans; Ras; apoptosis; cancer; synthetic interaction	PROGRAMMED CELL-DEATH; KSR-1 GENE ENCODES; C-ELEGANS; FATE DETERMINATION; VULVAL DEVELOPMENT; BINDING-PROTEIN; NURD-COMPLEX; INTERFERENCE; ANTAGONIZE; NEMATODE	Genes linked to human cancers often function in evolutionary conserved pathways, and research in C. elegans has been instrumental in dissecting some of the pathways affected, such as apoptosis and Ras signalling. The advent of RNA interference (RNAi) technology has allowed high-throughput loss-of-function analyses of C. elegans gene functions. Here we review some of the most recent genome-wide RNAi screens that have been conducted and discuss their impact on cancer research and possibilities for future screens. We also show that genes causally implicated in human cancers are significantly more likely to have a C. elegans homologue than average, validating the use of C. elegans as a cancer gene discovery platform. We foresee that genome-wide RNAi screens in C. elegans will continue to be productive in identifying new cancer gene candidates and will provide further insights into cancer gene functions.	Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QR, England	University of Cambridge	Ahringer, J (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	j.ahringer@gurdon.cam.ac.uk		Poulin, Gino/0000-0003-1016-348X	Wellcome Trust [054523] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Berry LW, 1997, DEVELOPMENT, V124, P925; Boulton SJ, 2004, CURR BIOL, V14, P33, DOI 10.1016/j.cub.2003.11.029; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; de Jager M, 2002, GENE DEV, V16, P2173, DOI 10.1101/gad.1025402; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fay DS, 2000, GENESIS, V26, P279, DOI 10.1002/(SICI)1526-968X(200004)26:4<279::AID-GENE100>3.0.CO;2-C; Feng Q, 2003, CURR TOP MICROBIOL, V274, P269; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; Harris TW, 2004, NUCLEIC ACIDS RES, V32, pD411, DOI 10.1093/nar/gkh066; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Kostic I, 2003, DEV BIOL, V263, P242, DOI 10.1016/S0012-1606(03)00452-4; LETTRE G, 2004, IN PRESS CELL DEATH; Liu QA, 1999, ANN NY ACAD SCI, V887, P92, DOI 10.1111/j.1749-6632.1999.tb07925.x; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Moghal N, 2003, EXP CELL RES, V284, P150, DOI 10.1016/S0014-4827(02)00097-6; Nollen EAA, 2004, P NATL ACAD SCI USA, V101, P6403, DOI 10.1073/pnas.0307697101; Parrish JZ, 2003, MOL CELL, V11, P987, DOI 10.1016/S1097-2765(03)00095-9; Pothof J, 2003, GENE DEV, V17, P443, DOI 10.1101/gad.1060703; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Sherwood DR, 2003, DEV CELL, V5, P21, DOI 10.1016/S1534-5807(03)00168-0; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Solari F, 2000, CURR BIOL, V10, P223, DOI 10.1016/S0960-9822(00)00343-2; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Sternberg PW, 2001, CELL, V105, P173, DOI 10.1016/S0092-8674(01)00308-7; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Tan PBO, 1999, TRENDS GENET, V15, P145, DOI 10.1016/S0168-9525(99)01694-7; Tijsterman M, 2002, GENETICS, V161, P651; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; VANHAAFTEN, COMMUNICATION; von Zelewsky T, 2000, DEVELOPMENT, V127, P5277; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941	43	41	46	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8340	8345		10.1038/sj.onc.1208010	http://dx.doi.org/10.1038/sj.onc.1208010			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517014				2022-12-17	WOS:000224815900003
J	Feng, H; Xiang, H; Mao, YW; Wang, J; Liu, JP; Huang, XQ; Liu, Y; Liu, SJ; Luo, C; Zhang, XJ; Liu, Y; Li, DWC				Feng, H; Xiang, H; Mao, YW; Wang, J; Liu, JP; Huang, XQ; Liu, Y; Liu, SJ; Luo, C; Zhang, XJ; Liu, Y; Li, DWC			Human Bcl-2 activates ERK signaling pathway to regulate activating protein-1, lens epithelium-derived growth factor and downstream genes	ONCOGENE			English	Article						Bcl-2; ERK1/2; c-jun; c-fos; AP-1; LEDGF; lens	NF-KAPPA-B; PROGRAMMED CELL-DEATH; STRESS-RELATED GENES; C-JUN; DEPENDENT PATHWAY; OXIDATIVE STRESS; DOWN-REGULATION; MESSENGER-RNA; MAP KINASE; EXPRESSION	The proto-oncogene, bcl-2, has various functions besides its role in protecting cells from apoptosis. One of the functions is to regulate expression of other genes. Previous studies have demonstrated that Bcl-2 regulates activities of several important transcription factors including NF-kappaB and p53, and also their downstream genes. In our recent studies, we reported that Bcl-2 substantially downregulates expression of the endogenous alphaB-crystallin gene through modulating the transcriptional activity of lens epithelium-derived growth factor ( LEDGF). In the present communication, we report that human Bcl-2 can positively regulate expression of the proto-oncogenes c-jun and c-fos. Moreover, it enhances the DNA binding activity and transactivity of the activating protein-1 (AP-1). Furthermore, we present evidence to show that Bcl-2 can also activate both ERK1 and ERK2 MAP kinases. Inhibition of the activities of these kinases or the upstream activating kinases by pharmacological inhibitors or dominant-negative mutants abolishes the Bcl-2-mediated regulation of AP-1, LEDGF and their downstream genes. Together, our results demonstrate that through activation of the ERK kinase signaling pathway, Bcl-2 regulates the transcriptional activities of multiple transcription factors, and hence modulates the expression of their downstream genes. Thus, our results provide a mechanism to explain how Bcl-2 may regulate expression of other genes.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Hunan Normal Univ, Coll Life Sci, Changsha, Hunan, Peoples R China; Univ Med & Dent New Jersey, Dept Mol Biol, Stratford, NJ USA	University of Minnesota System; Hunan Normal University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Li, DWC (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	dwli1688@hotmail.com	Li, David/AAN-9205-2021	xiang, hua/0000-0003-0369-1225; Mao, Yingwei/0000-0001-7339-1565	PHS HHS [NEI 11372] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY011372] Funding Source: NIH RePORTER	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Chen DB, 2003, MOL CELL ENDOCRINOL, V200, P141, DOI 10.1016/S0303-7207(02)00379-9; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1987, ONCOGENE, V2, P79; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Fatma N, 2001, J BIOL CHEM, V276, P48899, DOI 10.1074/jbc.M100733200; Feng LX, 1999, J CELL BIOCHEM, V74, P576, DOI 10.1002/(SICI)1097-4644(19990915)74:4<576::AID-JCB7>3.0.CO;2-N; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GRUDA MC, 1994, ONCOGENE, V9, P2537; Hilton M, 1997, CURR BIOL, V7, P798, DOI 10.1016/S0960-9822(06)00339-3; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kubo E, 2002, J MOL BIOL, V320, P1053, DOI 10.1016/S0022-2836(02)00551-X; Kukushkin AN, 2002, ONCOGENE, V21, P719, DOI 10.1038/sj.onc.1205118; Kumar NV, 2001, J BIOL CHEM, V276, P32362, DOI 10.1074/jbc.M103677200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Li DWC, 1998, EUR J BIOCHEM, V257, P351, DOI 10.1046/j.1432-1327.1998.2570351.x; Li DWC, 2003, INVEST OPHTH VIS SCI, V44, P5277, DOI 10.1167/iovs.03-0348; Li DWC, 1997, MOL CELL BIOCHEM, V173, P59, DOI 10.1023/A:1006828402225; Li DWC, 2001, INVEST OPHTH VIS SCI, V42, P2603; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; LI WC, 1994, EXP EYE RES, V59, P179, DOI 10.1006/exer.1994.1096; LI WC, 1995, J CELL BIOL, V130, P169, DOI 10.1083/jcb.130.1.169; LU PJ, 1995, J CELL BIOL, V129, P1363, DOI 10.1083/jcb.129.5.1363; MACGREGOR PF, 1990, ONCOGENE, V5, P451; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; McDermott JB, 1997, INVEST OPHTH VIS SCI, V38, P951; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; NIESON DA, 1983, P NATL ACAD SCI USA, V80, P5198; OReilly LA, 1997, INT IMMUNOL, V9, P1291, DOI 10.1093/intimm/9.9.1291; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Schwarz CS, 2002, NEUROREPORT, V13, P2439, DOI 10.1097/00001756-200212200-00013; Shinohara T, 2002, PROG RETIN EYE RES, V21, P341, DOI 10.1016/S1350-9462(02)00007-1; Singh DP, 2001, BIOCHEM BIOPH RES CO, V283, P943, DOI 10.1006/bbrc.2001.4887; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Xiang H, 2000, BIOCHEM BIOPH RES CO, V278, P503, DOI 10.1006/bbrc.2000.3834; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200; Zhan QM, 1999, ONCOGENE, V18, P297, DOI 10.1038/sj.onc.1202310	64	41	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7310	7321		10.1038/sj.onc.1208041	http://dx.doi.org/10.1038/sj.onc.1208041			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15326476				2022-12-17	WOS:000224021400002
J	Saleh, AZM; Fang, AT; Arch, AE; Neupane, D; El Fiky, A; Krolewski, JJ				Saleh, AZM; Fang, AT; Arch, AE; Neupane, D; El Fiky, A; Krolewski, JJ			Regulated proteolysis of the IFNaR2 subunit of the interferon-alpha receptor	ONCOGENE			English	Article						interferon; intramembrane protease; presenilin; protein kinase C	PROTEIN-KINASE-C; GAMMA-SECRETASE ACTIVITY; CONVERTING-ENZYME; SIGNAL-TRANSDUCTION; I INTERFERON; INTRAMEMBRANE PROTEOLYSIS; INTRACELLULAR DOMAIN; CYTOPLASMIC DOMAIN; ALZHEIMERS-DISEASE; TYROSINE KINASE	The type I interferons (IFNs) bind surface receptors, induce JAK kinases and activate STAT transcription factors to stimulate the transcription of genes downstream of IFN-stimulated response elements (ISREs). In this study, we demonstrate that IFNaR2, a subunit of the type I IFN receptor, is proteolytically cleaved in a regulated manner. Immunoblotting shows that multi-step cleavage occurs in response to phorbol ester (PMA) and IFN-alpha, generating both a transmembrane 'stub' and the intracellular domain (ICD), similar to Notch proteolysis. Isolated membrane fractions process IFNaR2 to release the ICD. A chimeric receptor construct is utilized to show that cleavage requires the presenilins and occurs in response to epidermal growth factor and protein kinase C-delta overexpression, as well as PMA and type I IFNs. Fluorescence microscopy demonstrates that a green fluorescent protein ICD fusion localizes predominantly to the nucleus. A fusion between the ICD and the Gal4 DNA-binding domain represses transcription, in a histone deacetylase-dependent manner, of a Gal4 upstream activating sequence-regulated reporter, while overexpression of the ICD alone represses transcription of a reporter linked to an ISRE. Proteolytic cleavage events may facilitate receptor turnover or, more likely, function as a mechanism for signaling similar to that employed by Notch and the Alzheimer's precursor protein.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Chao Family Comprehens Canc Ctr, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Krolewski, JJ (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA.	jkrolews@uci.edu			NATIONAL CANCER INSTITUTE [R01CA056862] Funding Source: NIH RePORTER; NCI NIH HHS [CA56862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baumann G, 2002, J ENDOCRINOL, V174, P361, DOI 10.1677/joe.0.1740361; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Chill JH, 2003, STRUCTURE, V11, P791, DOI 10.1016/S0969-2126(03)00120-5; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; Cruts M, 1998, HUM MUTAT, V11, P183, DOI 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.3.CO;2-M; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hinkle CL, 2004, J BIOL CHEM, V279, P24179, DOI 10.1074/jbc.M312141200; Improta T, 1997, CYTOKINE, V9, P383, DOI 10.1006/cyto.1996.0180; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; Karlstrom H, 2002, J BIOL CHEM, V277, P6763, DOI 10.1074/jbc.C100649200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Kubota S, 2001, DNA CELL BIOL, V20, P563, DOI 10.1089/104454901317094972; Kumar KGS, 2003, EMBO J, V22, P5480; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Nadeau OW, 1999, J BIOL CHEM, V274, P4045, DOI 10.1074/jbc.274.7.4045; Nguyen VP, 2002, J BIOL CHEM, V277, P9713, DOI 10.1074/jbc.m111161200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Saleh AZM, 2002, BIOCHEMISTRY-US, V41, P11261, DOI 10.1021/bi025913f; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Struhl G, 2001, P NATL ACAD SCI USA, V98, P229, DOI 10.1073/pnas.011530298; Takasugi N, 2002, J BIOL CHEM, V277, P50198, DOI 10.1074/jbc.M205352200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200; Wilhelmsen K, 2004, MOL CELL BIOL, V24, P454, DOI 10.1128/MCB.24.1.454-464.2004; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yan H, 1996, MOL CELL BIOL, V16, P2074; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	54	41	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7076	7086		10.1038/sj.onc.1207955	http://dx.doi.org/10.1038/sj.onc.1207955			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15286706				2022-12-17	WOS:000223885100008
J	Kim, H; Nam, SW; Rhee, H; Li, LS; Kang, HJ; Koh, KH; Kim, NK; Song, J; Liu, ETB; Kim, H				Kim, H; Nam, SW; Rhee, H; Li, LS; Kang, HJ; Koh, KH; Kim, NK; Song, J; Liu, ETB; Kim, H			Different gene expression profiles between microsatellite instability-high and microsatellite stable colorectal carcinomas	ONCOGENE			English	Article						colorectal carcinomas; microsatellite instability; oligonucleotide microarray; gene expression profile; molecular classification	COLON-CANCER; OLIGONUCLEOTIDE ARRAYS; TARGET GENES; BETA-CATENIN; SEQUENCES; MUTATIONS; PATHWAY; CARCINOGENESIS; IDENTIFICATION; MICROARRAYS	Recent molecular genetic studies have revealed that two major types of genomic instabilities, chromosomal instability (CIN) and microsatellite instability (MSI), exist in colorectal carcinomas. In order to clarify the molecular signature related to the CIN and MSI in colorectal carcinomas, we performed transcriptomic expression analysis on eight microsatellite instability-high (MSI-H) colorectal carcinomas and compared the results obtained with that of nine microsatellite stable (MSS) colorectal carcinomas using oligonucleotide microarrays containing 17 334 known genes and 1331 unknown genes or expression sequence tags ( ESTs). Unsupervised two-way hierarchical clustering with 5724 genes successfully classified tumors from normal mucosa, and displayed a distinctive MSI-H carcinomas subgroup. Based on intensive filtering, 57 known genes and eight ESTs were found to be highly relevant to the differentiation of MSI-H and MSS colorectal carcinomas. These genes successfully distinguish the new test set of six MSI-H and five MSS colorectal carcinomas. Many up- and downregulated genes in MSI-H colorectal carcinomas were related to the previously reported phenotypic characteristics; increased mucin production and intense peritumoral immune response in MSI-H carcinomas. Some of these differences were confirmed by semiquantitative reverse transcription-PCR and immunohistochemical analysis. Our findings indicate that there are many different genetic and transcriptomic characteristics between MSI-H and MSS colorectal carcinomas, and some of these differently expressed genes can be used as diagnostic or prognostic markers.	Yonsei Univ, Coll Med, Dept Pathol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Projects Med Sci 21, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Dept Surg, Seoul 120752, South Korea; Genome Inst Singapore, Singapore 138672, Singapore; Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137710, South Korea; Sungkyunkwan Univ, Coll Life Sci & Nat Resources, Dept Genet Engn, Suwon 440746, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Catholic University of Korea; Sungkyunkwan University (SKKU)	Kim, H (corresponding author), Yonsei Univ, Coll Med, Dept Pathol, CPO Box 8044, Seoul 120752, South Korea.	hkyonsei@yumc.yonsei.ac.kr	Liu, Edison/C-4141-2008	Kim, Nam-Kyu/0000-0003-0639-5632; Kim, Hyunki/0000-0003-2292-5584				Alexander J, 2001, AM J PATHOL, V158, P527, DOI 10.1016/S0002-9440(10)63994-6; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Bertucci F, 2004, ONCOGENE, V23, P1377, DOI 10.1038/sj.onc.1207262; Biemer-Huttmann AE, 2000, CLIN CANCER RES, V6, P1909; Birkenkamp-Demtroder K, 2002, CANCER RES, V62, P4352; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dunican DS, 2002, ONCOGENE, V21, P3253, DOI 10.1038/sj.onc.1205431; Duval A, 2002, CANCER RES, V62, P2447; Guidoboni M, 2001, AM J PATHOL, V159, P297, DOI 10.1016/S0002-9440(10)61695-1; Hiraga Y, 1998, ONCOLOGY-BASEL, V55, P307, DOI 10.1159/000011868; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KIM HG, 1994, AM J PATHOL, V145, P148; Kim NG, 2002, ONCOGENE, V21, P5081, DOI 10.1038/sj.onc.1205703; Kim NG, 2001, CANCER RES, V61, P36; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitahara O, 2001, CANCER RES, V61, P3544; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mori Y, 2003, CANCER RES, V63, P4577; Notterman DA, 2001, CANCER RES, V61, P3124; Stenger S, 1999, IMMUNOL TODAY, V20, P390, DOI 10.1016/S0167-5699(99)01449-8; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Ward R, 2001, GUT, V48, P821, DOI 10.1136/gut.48.6.821	26	41	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6218	6225		10.1038/sj.onc.1207853	http://dx.doi.org/10.1038/sj.onc.1207853			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208663				2022-12-17	WOS:000223399000006
J	Maillart, E; Brengel-Pesce, K; Capela, D; Roget, A; Livache, T; Canva, M; Levy, Y; Soussi, T				Maillart, E; Brengel-Pesce, K; Capela, D; Roget, A; Livache, T; Canva, M; Levy, Y; Soussi, T			Versatile analysis of multiple macromolecular interactions by SPR imaging: application to p53 and DNA interaction	ONCOGENE			English	Article						p53 tumor suppressor gene; DNA binding; SPR imaging; EMSA; polypyrrole	TRANSCRIPTION FACTOR; MUTANT P53; LABEL-FREE; BINDING; PROTEIN; CANCER; GENES; APOPTOSIS; MUTATIONS; SEQUENCE	The greatest challenge in the postgenomic era is the description of proteome interactions, such as protein-protein or protein-DNA interactions. Surface plasmon resonance (SPR) is an optical technique in which binding of an analyte to the surface changes the refractive index at the surface/solution interface. Molecular interactions are analysed in real time without a labeling step. Currently, the limit to SPR imaging is the small number of reactions that can be simultaneously analysed. Using a novel grafting technology and a new imaging system, we increased the throughput of SPR imaging. The interaction between p53 and DNA was chosen as a paradigm for validation of this assay. Using a tagged DNA methodology, we simultaneously targeted multiple DNA sequences on a single chip. The interaction between p53 and these DNA sequences was monitored by SPR imaging. Qualitative and quantitative analysis provides results similar to those obtained with conventional technologies.	UPMC IC, Hop Tenon, Lab Genotoxicol Tumeurs, EA 3493, F-75019 Paris, France; Univ Paris 11, Lab Charles Fabry, Inst Opt, CNRS,UMR 8501, F-91403 Orsay, France; Dept Rech Fondamentale Mat Condensee, CREAB, UMR 5819, CEA,CNRS,UJF, F-38054 Grenoble, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Soussi, T (corresponding author), UPMC IC, Hop Tenon, Lab Genotoxicol Tumeurs, EA 3493, 4 Rue Chine, F-75019 Paris, France.	thierry.soussi@tnn.ap-hop-paris.fr	Canva, Michael TG/D-4014-2009	Canva, Michael TG/0000-0001-5286-2380; soussi, thierry/0000-0001-8184-3293				BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Deppert W, 2000, J CELL BIOCHEM, P115; Dong SM, 2001, J NATL CANCER I, V93, P858, DOI 10.1093/jnci/93.11.858; Drewes G, 2003, CURR OPIN CELL BIOL, V15, P199, DOI 10.1016/S0955-0674(03)00005-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Favis R, 2000, NAT BIOTECHNOL, V18, P561, DOI 10.1038/75452; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; Gerry NP, 1999, J MOL BIOL, V292, P251, DOI 10.1006/jmbi.1999.3063; Guedon P, 2000, ANAL CHEM, V72, P6003, DOI 10.1021/ac000122+; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kim E, 2003, BIOCHEM CELL BIOL, V81, P141, DOI 10.1139/o03-046; Livache T, 2003, J PHARMACEUT BIOMED, V32, P687, DOI 10.1016/S0731-7085(03)00176-6; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Muller BF, 1996, ONCOGENE, V12, P1941; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Rich RL, 2000, CURR OPIN BIOTECH, V11, P54, DOI 10.1016/S0958-1669(99)00054-3; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Soussi T, 2003, HUM MUTAT, V21, P192, DOI 10.1002/humu.10189; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; TOKINO T, 1994, HUM MOL GENET, V3, P1357; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walhout AJM, 2001, NAT REV MOL CELL BIO, V2, P55, DOI 10.1038/35048107	32	41	42	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5543	5550		10.1038/sj.onc.1207639	http://dx.doi.org/10.1038/sj.onc.1207639			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15184889				2022-12-17	WOS:000222588400014
J	Shollar, D; Del Valle, L; Khalili, K; Otte, J; Gordon, J				Shollar, D; Del Valle, L; Khalili, K; Otte, J; Gordon, J			JCV T-antigen interacts with the neurofibromatosis type 2 gene product in a transgenic mouse model of malignant peripheral nerve sheath tumors	ONCOGENE			English	Article						mpnst; polyomavirus; NF2; p53; animal model; JC virus; T-antigen	HUMAN NEUROTROPIC POLYOMAVIRUS; BRAIN-TUMORS; VIRUS; EXPRESSION; PROTEIN; INVOLVEMENT; SUPPRESSOR; MERLIN	The human polyomavirus, JC virus, has recently been associated with several human CNS tumors, including medulloblastomas and a broad range of glial-origin tumors. This ubiquitous virus is the causative agent of the rare demyelinating disease, progressive multifocal leukoencephalopathy in immunocompromised individuals. Expression of the viral protein, T-antigen, which possesses the ability to transform cells of neural origin, has been detected in human CNS tumors. In an effort to further understand the transforming potential of JCV T-antigen, transgenic mice expressing JCV T-antigen under the control of the Mad-4 promoter were generated. As described previously, approximately 50% of the animals developed pituitary tumors by 1 year of age. However, a small subset of the animals developed solid masses arising from the soft tissues surrounding the salivary gland, the sciatic nerve, and along the extremities that histologically resemble malignant peripheral nerve sheath tumors, rare neoplasms that occur in individuals with neurofibromatosis type 1 (NF1). JCV T-antigen was detected in tumor tissue by immunohistochemistry and immunoprecipitation/Western blotting, but not in normal tissues and was colocalized with NF2, the putative tumor suppressor protein associated with neurofibromatosis type 2, in the nucleus of some cells. In addition, T-antigen was co-precipitated with NF2, but not with NF1 protein, although NF1 was detectable in tumor tissue. Furthermore, precipitated immunocomplexes contained T-antigen, NF2, and p53, suggesting that these three proteins may form a ternary complex. The importance of these findings on mechanisms of T-antigen-mediated tumorigenesis and the pathogenesis of neurofibromatosis are discussed.	Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Gordon, J (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, 1900 N 12th St,015-96,Room 203, Philadelphia, PA 19122 USA.	jennifer.gordon@temple.edu	Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206				Baser ME, 2002, NEUROLOGY, V59, P290, DOI 10.1212/WNL.59.2.290; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; Del Valle L, 2001, CANCER RES, V61, P4287; DELVALLE L, 2001, HUMAN POLYOMAVIRUSES, P409; Enam S, 2002, CANCER RES, V62, P7093; Frank D, 2003, CANCER GENET CYTOGEN, V144, P18, DOI 10.1016/S0165-4608(02)00870-1; Franks RR, 1996, ONCOGENE, V12, P2573; Gan DD, 2001, ONCOGENE, V20, P4864, DOI 10.1038/sj.onc.1204670; Gordon J, 2000, ONCOGENE, V19, P4840, DOI 10.1038/sj.onc.1203849; Kim H, 2004, J BIOL CHEM, V279, P7812, DOI 10.1074/jbc.M305526200; Kim H.S., 2001, HUMAN POLYOMAVIRUSES, P73; Kressel M, 2002, HUM MOL GENET, V11, P2269, DOI 10.1093/hmg/11.19.2269; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; LOUIS DN, 2000, PATHOLOGY GENETICS T, P219; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; McClatchey AI, 2001, BBA-REV CANCER, V1471, pM73, DOI 10.1016/S0304-419X(00)00026-3; OHSUMI S, 1986, ACTA PATHOL JAPON, V36, P815; RESSETAR HG, 1990, LAB INVEST, V62, P287; REY JA, 1993, CANCER GENET CYTOGEN, V66, P28, DOI 10.1016/0165-4608(93)90144-B; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; Schmucker B, 1999, HUM MOL GENET, V8, P1561, DOI 10.1093/hmg/8.8.1561; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Testa JR, 1998, CANCER RES, V58, P4505; THEILE M, 1990, ARCH VIROL, V113, P221, DOI 10.1007/BF01316675; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; VONDEIMLING A, 2000, PATHOLOGY GENETICS T, P216; Woodruff J.M., 2000, PATHOLOGY GENETICS T, P172; ZURHEIN GM, 1983, POLYOMAVIRUSES HUMAN, P205	38	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5459	5467		10.1038/sj.onc.1207728	http://dx.doi.org/10.1038/sj.onc.1207728			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15133494				2022-12-17	WOS:000222588400005
J	Sun, LX; Vitolo, MI; Qiao, M; Anglin, IE; Passaniti, A				Sun, LX; Vitolo, MI; Qiao, M; Anglin, IE; Passaniti, A			Regulation of TGF beta(1)-mediated growth inhibition and apoptosis by RUNX2 isoforms in endothelial cells	ONCOGENE			English	Article						transcription factors; endothelial cells; proliferation; apoptosis	TRANSCRIPTION FACTOR PEBP2/CBF; ANGIOGENESIS IN-VITRO; FACTOR-BETA; EXTRACELLULAR-MATRIX; TGF-BETA; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; TUMOR ANGIOGENESIS; DEPENDENT KINASE; BONE-DEVELOPMENT	Runx transcription factors regulate viral growth, hematopoiesis, bone formation, angiogenesis, and gastric epithelial development through specific DNA-binding motifs on target gene promoters. Vascular endothelial cells (ECs) express RUNX genes that are activated by angiogenic factors. The RUNX2 gene also activates the vascular endothelial growth factor promoter. Alternatively spliced forms of RUNX genes have been described, but their functions in angiogenesis have not been elucidated. In this study, expression of a novel alternatively spliced variant of RUNX2 (RUNX2Delta8), lacking the region encoded by exon 8, was detected in aortic tissue undergoing angiogenesis in vitro and in ECs. Expression of RUNX2 and RUNX2Delta8 increased in vascular sprouts concomitant with expression of cellular proteases and cytokines known to mediate angiogenesis. RUNX2 DNA-binding activity was expressed in proliferating but not quiescent ECs. Ectopic expression of RUNX2 in ECs increased cell sprouting, cell proliferation, DNA synthesis, and phosphorylation of phosphorylated retinoblastoma relative to control transfectants while RUNX2, but not RUNX2Delta8 transfectants, acquired resistance to growth inhibition by transforming growth factor (TGFbeta(1)). Furthermore, RUNX2Delta8-transfected cells were more sensitive to TGFbeta(1)-induced apoptosis than RUNX2 transfectants. Consistent with these data, the RUNX2 gene was a strong repressor of the promoter of the cyclin-dependent kinase inhibitor, p21(CIP1), while RUNX2Delta8 was a competitive inhibitor of RUNX2 and exhibited weak repression activity. These results support the hypothesis that ECs regulate growth and apoptosis, in part, by alternative splicing events in the RUNX2 transcription factor to affect the TGFbeta(1) signaling pathway. The exon 8 domain of RUNX2 may contribute to the strong repression activity of RUNX2 for some target gene promoters.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Passaniti, A (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, 655 W Baltimore St, Baltimore, MD 21201 USA.	apass001@umaryland.edu		Vitolo, Michele/0000-0001-8055-9645	NCI NIH HHS [CA95350-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA095350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; ASAHARA T, 1995, CIRCULATION, V92, P365, DOI 10.1161/01.CIR.92.9.365; Baltzinger M, 1999, DEV DYNAM, V216, P420, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<420::AID-DVDY10>3.0.CO;2-C; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090; Bravo J, 2001, NAT STRUCT BIOL, V8, P371, DOI 10.1038/86264; Burchardt M, 1999, BIOL REPROD, V60, P398, DOI 10.1095/biolreprod60.2.398; Carmeliet P, 2000, J PATHOL, V190, P387; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferrara N, 2000, RECENT PROG HORM RES, V55, P15; FLAUMENHAFT R, 1992, J CELL BIOL, V118, P901, DOI 10.1083/jcb.118.4.901; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; Gothie E, 2000, J BIOL CHEM, V275, P6922, DOI 10.1074/jbc.275.10.6922; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hata-Sugi N, 2002, BIOL PHARM BULL, V25, P446, DOI 10.1248/bpb.25.446; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Huang YQ, 2000, BLOOD, V95, P1993, DOI 10.1182/blood.V95.6.1993; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Kalluri R, 2000, CURR OPIN NEPHROL HY, V9, P413, DOI 10.1097/00041552-200007000-00013; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kriventseva EV, 2003, TRENDS GENET, V19, P124, DOI 10.1016/S0168-9525(03)00023-4; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lehr JE, 1998, J NATL CANCER I, V90, P118, DOI 10.1093/jnci/90.2.118; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li WW, 2000, ACAD RADIOL, V7, P800, DOI 10.1016/S1076-6332(00)80629-7; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; NEWTON LK, 1990, EXP CELL RES, V190, P127, DOI 10.1016/0014-4827(90)90153-2; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; NICOSIA RF, 1990, LAB INVEST, V63, P115; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; NICOSIA RF, 1994, AM J PATHOL, V145, P1023; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Perry C, 2002, ONCOGENE, V21, P8428, DOI 10.1038/sj.onc.1205945; Pollman MJ, 1999, J CELL PHYSIOL, V178, P359, DOI 10.1002/(SICI)1097-4652(199903)178:3<359::AID-JCP10>3.3.CO;2-F; Rabbani SA, 1998, IN VIVO, V12, P135; Riccioni T, 1998, GENE THER, V5, P747, DOI 10.1038/sj.gt.3300681; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sato Y, 2000, PHARMACOL THERAPEUT, V87, P51, DOI 10.1016/S0163-7258(00)00067-X; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Smith JS, 2002, TRENDS CELL BIOL, V12, P404, DOI 10.1016/S0962-8924(02)02342-5; Sorek R, 2001, NAT BIOTECHNOL, V19, P196, DOI 10.1038/85613; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Sun LX, 2001, CANCER RES, V61, P4994; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; TAKECHI H, 1994, MOL CELL BIOL, V14, P567, DOI 10.1128/MCB.14.1.567; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wang WG, 1999, J CELL BIOCHEM, V73, P321; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Yang CL, 1996, CELL GROWTH DIFFER, V7, P161; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2; Zhang YW, 1997, ONCOGENE, V15, P367, DOI 10.1038/sj.onc.1201352	77	41	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4722	4734		10.1038/sj.onc.1207589	http://dx.doi.org/10.1038/sj.onc.1207589			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15107836				2022-12-17	WOS:000221799200007
J	Guda, K; Upender, MB; Belinsky, G; Flynn, C; Nakanishi, M; Marino, JN; Ried, T; Rosenberg, DW				Guda, K; Upender, MB; Belinsky, G; Flynn, C; Nakanishi, M; Marino, JN; Ried, T; Rosenberg, DW			Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability	ONCOGENE			English	Article						azoxymethane; mice; colon tumorigenesis; chromosomal instability; spectral karyotyping; microsatellite instability	COLORECTAL-CANCER; GENOMIC INSTABILITY; BETA-CATENIN; ALTERED EXPRESSION; HIGH-FREQUENCY; AZOXYMETHANE; MUTATIONS; PATHWAYS; DNA; TUMORIGENESIS	The azoxymethane (AOM)-induced mouse colon tumor model recapitulates many of the histopathological features associated with the multistage progression of human sporadic colorectal cancers (CRCs). To better de. ne the genetic events associated with tumorigenesis in this murine model, we analysed tumors from A/J mice for chromosomal (CIN) and microsatellite (MSI) instabilities, two fundamental pathways of genomic instability that play a critical role in the pathogenesis of human CRCs. Male A/J mice, 6-week old, were injected with either AOM (n=5) (10 mg/kg b.w., i.p.) or vehicle (n=5) (0.9% NaCl solution) once a week for 6 weeks. At 32 weeks after the last dose, comparative genomic hybridization (CGH) was performed on 16 tumors harvested from five animals. Although 25% of the tumors displayed either a gain of chromosome 2 or loss of Y, the majority (75%) showed no genomic imbalances. Further analysis of chromosomal aberrations, using CGH and spectral karyotyping (SKY) was performed in our recently established A/J colon tumor-derived cell line, AJ02-NM0. Results showed a pseudotetraploid karyotype with loss of only the Y chromosome in these cultured cells, thereby providing additional evidence for the minimal role of CIN in the primary AOM-induced tumors. Interestingly, the majority (81%) of A/J tumors displayed low-level microsatellite instability (MSI-L) when analysed using mono- and dinucleotide repeat markers, and showed a significant expansion to high-level instability (MSI-H) in the AJ02-NM0 cells. This finding in cultured cells additionally provides evidence that a mild mutator pathway may contribute to the development of behaviorally benign carcinomas in situ in A/J mice. To better understand the tumorigenic process in the A/J colons, we screened for mutational alterations in key regions of the K-ras and Apc genes. Results showed a very low frequency (6%) of K-ras activating mutations, together with the absence of Apc truncation mutations in primary tumors and AJ02-NM0 cells. However, these tumors displayed intense nuclear accumulation of beta-catenin protein, indicating activation of the Wnt signaling pathway. Based on our molecular and cytogenetic findings, we propose that carcinogen-induced tumors may develop via mechanisms independent of the 'classical' CIN or MSI pathways.	NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Univ Connecticut, Ctr Hlth, Ctr Mol Med, Farmington, CT 06030 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Connecticut	Ried, T (corresponding author), NCI, Genet Branch, Ctr Canc Res, NIH, 50 South Dr,Room 1306, Bethesda, MD 20892 USA.	riedt@mail.nih.gov	guda, kishore/E-3389-2010		DIVISION OF CLINICAL SCIENCES - NCI [Z01SC010299] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA081428] Funding Source: NIH RePORTER; NCI NIH HHS [CA81428] Funding Source: Medline	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009; Calvert PM, 2002, ANN INTERN MED, V137, P603, DOI 10.7326/0003-4819-137-7-200210010-00012; Chan TL, 2001, ONCOGENE, V20, P4871, DOI 10.1038/sj.onc.1204653; Corpet DE, 2003, CANCER EPIDEM BIOMAR, V12, P391; De Filippo C, 1998, BRIT J CANCER, V77, P2148, DOI 10.1038/bjc.1998.359; Doug M, 2003, CARCINOGENESIS, V24, P307, DOI 10.1093/carcin/24.2.307; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; Goel A, 2003, CANCER RES, V63, P1608; Guda K, 2001, MOL CARCINOGEN, V31, P204, DOI 10.1002/mc.1055; Haag JD, 1999, MOL CARCINOGEN, V24, P47, DOI 10.1002/(SICI)1098-2744(199901)24:1<47::AID-MC7>3.0.CO;2-B; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hoglund M, 2002, CANCER RES, V62, P5939; Iino H, 1999, J CLIN PATHOL, V52, P5, DOI 10.1136/jcp.52.1.5; Jass JR, 2002, EUR J CANCER, V38, P858, DOI 10.1016/S0959-8049(02)00041-2; Jass JR, 1999, J CLIN PATHOL, V52, P455, DOI 10.1136/jcp.52.6.455; Jass JR, 2003, J PATHOL, V199, P267, DOI 10.1002/path.1266; Kambara T, 2001, CANCER RES, V61, P7743; Kislitsin D, 2002, DIGEST DIS SCI, V47, P1073, DOI 10.1023/A:1015090124153; Kohonen-Corish MRJ, 2002, CANCER RES, V62, P2092; Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lindblom A, 2001, CURR OPIN ONCOL, V13, P63, DOI 10.1097/00001622-200101000-00013; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; LOTHE RA, 1993, CANCER RES, V53, P5849; Luceri C, 2000, CARCINOGENESIS, V21, P1753, DOI 10.1093/carcin/21.9.1753; Nambiar PR, 2003, INT J ONCOL, V22, P145; Nambiar PR, 2002, CANCER RES, V62, P3667; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8; Sheng HM, 1998, CARCINOGENESIS, V19, P543, DOI 10.1093/carcin/19.4.543; Sohn KJ, 2003, CARCINOGENESIS, V24, P217, DOI 10.1093/carcin/24.2.217; Takahashi M, 2000, CARCINOGENESIS, V21, P1117, DOI 10.1093/carcin/21.6.1117; Takahashi M, 2000, CARCINOGENESIS, V21, P1319, DOI 10.1093/carcin/21.7.1319; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tomlinson I, 2002, J PATHOL, V197, P6, DOI 10.1002/path.1071; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Walchle C, 1999, TOXICOL APPL PHARM, V157, P9, DOI 10.1006/taap.1999.8662; Wang QS, 1998, CARCINOGENESIS, V19, P2001, DOI 10.1093/carcin/19.11.2001; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Whitehall VLJ, 2001, CANCER RES, V61, P827; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Young J, 2001, AM J PATHOL, V159, P2107, DOI 10.1016/S0002-9440(10)63062-3	48	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3813	3821		10.1038/sj.onc.1207489	http://dx.doi.org/10.1038/sj.onc.1207489			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021908				2022-12-17	WOS:000221242500008
J	Maschler, S; Grunert, S; Danielopol, A; Beug, H; Wirl, G				Maschler, S; Grunert, S; Danielopol, A; Beug, H; Wirl, G			Enhanced tenascin-C expression and matrix deposition during Ras/TGF-beta-induced progression of mammary tumor cells	ONCOGENE			English	Article						tenascin-C; Ha-Ras; TGF beta; mammary tumorigenesis; epithelial/mesenchymal transition	GROWTH-FACTOR-BETA; SIGNAL-REGULATED KINASE; EXTRACELLULAR-MATRIX; BREAST-CANCER; EPITHELIAL-CELLS; SURFACE TRANSGLUTAMINASE; DIFFERENTIAL EXPRESSION; DOWN-REGULATION; PROTEIN CAUSES; H-RAS	Overexpression of tenascin-C (TN-C) in breast carcinomas has been associated with a migratory or even invasive tumor cell phenotype. The mechanisms regulating expression and matrix deposition of TN-C in normal and cancerous breast tissues are, however, little understood. Here, we demonstrate that mouse mammary epithelial cells (EpH4) trans formed by oncogenic Ha-Ras (EpRas) overexpress TN-C, which accumulates in the cytoplasm. When EpRas cells undergo epithelial-mesenchymal transition (EMT) in response to TGFbeta1, they secrete TN-C into the culture medium. In EpRas cells undergoing TGFbeta1-induced EMT in three-dimensional (3D)-collagen gel cultures, TN-C was deposited into an extracellular matrix (ECM) already containing fibronectin and perlecan. Under less physiological 2D plastic cultures, EpRas cells undergoing EMT failed to deposit TN-C into an ( apparently incomplete) ECM. Ras-downstream signaling was dissected by pharmacological inhibitors and effector-specific Ras mutants (V12S35, V12C40), specifically inhibiting or activating ERK/MAPK or PI3K signaling, respectively. We showed that TN-C overexpression required a hyperactive ERK/MAPK-signaling pathway, while elevated PI3K signaling did not enhance TN-C expression. Similarly, tumors induced by cells exhibiting hyperactive ERK/MAPK signaling showed expression of TN-C in the tumor cells themselves, while only endothelial cells expressed TN-C in tumors caused by the V12C40 mutant ( incapable of EMT in vivo). Taken together, our data indicate that hyperactive ERK/MAPK signaling causes enhanced expression of TN-C, while its secretion is induced by TGFb1 and both signals cooperate in TN-C matrix deposition. Importantly, both signals also cooperate to induce EMT in vitro and tumor progression/ metastasis in vivo.	Inst Mol Pathol, A-1030 Vienna, Austria; Austrian Acad Sci, Inst Mol Biol, A-5020 Salzburg, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Austrian Academy of Sciences	Beug, H (corresponding author), Inst Mol Pathol, Dr Bohrgasse 7, A-1030 Vienna, Austria.	beug@nt.imp.univie.ac.at	Gruenert, Stefan/B-7598-2016; Gruenert, Stefan/T-7755-2019	Gruenert, Stefan/0000-0003-0241-9297; Gruenert, Stefan/0000-0003-0241-9297				Adams M, 2002, CANCER RES, V62, P3289; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 2002, J CLIN INVEST, V109, P1533, DOI 10.1172/JCI200215970; Akimov SS, 2001, J CELL SCI, V114, P2989; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; BOS JL, 1989, CANCER RES, V49, P4682; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; CANFIELD AE, 1995, J CELL SCI, V108, P797; CARNEMOLLA B, 1992, EUR J BIOCHEM, V205, P561, DOI 10.1111/j.1432-1033.1992.tb16813.x; CHAMMAS R, 1994, J CELL SCI, V107, P1031; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; CHIQUETEHRISMANN R, 1991, CELL REGUL, V2, P927, DOI 10.1091/mbc.2.11.927; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; CHIQUETEHRISMANN R, 1989, CANCER RES, V49, P4322; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHUNG CY, 1995, J BIOL CHEM, V270, P29012, DOI 10.1074/jbc.270.48.29012; Chung CY, 1997, J CELL SCI, V110, P1413; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dandachi N, 2001, J PATHOL, V193, P181, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH752>3.0.CO;2-V; Defilippi P, 1997, ONCOGENE, V14, P1933, DOI 10.1038/sj.onc.1201027; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Deryugina EI, 1996, J CELL SCI, V109, P643; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Huang WT, 2001, CANCER RES, V61, P8586; Jahkola T, 1998, BRIT J CANCER, V78, P1507, DOI 10.1038/bjc.1998.714; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Jansen B, 1999, P NATL ACAD SCI USA, V96, P14019, DOI 10.1073/pnas.96.24.14019; Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.0.CO;2-G; Jones PL, 2000, MATRIX BIOL, V19, P581, DOI 10.1016/S0945-053X(00)00106-2; Jones PL, 2001, LANCET, V357, P1992, DOI 10.1016/S0140-6736(00)05133-3; LIGHTNER VA, 1994, EXP CELL RES, V210, P177, DOI 10.1006/excr.1994.1027; Martin D, 2003, J CELL BIOL, V160, P171, DOI 10.1083/jcb.200206109; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; Midwood KS, 2002, MOL BIOL CELL, V13, P3601, DOI 10.1091/mbc.E02-05-0292; Miyakis S, 1998, BIOCHEM BIOPH RES CO, V251, P609, DOI 10.1006/bbrc.1998.9527; Moon A, 2000, INT J CANCER, V85, P176, DOI 10.1002/(SICI)1097-0215(20000115)85:2<176::AID-IJC5>3.0.CO;2-E; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Nagata M, 2003, INT J CANCER, V106, P683, DOI 10.1002/ijc.11283; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RETTIG WJ, 1994, J CELL SCI, V107, P487; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; SAGINATI M, 1992, EUR J BIOCHEM, V205, P545, DOI 10.1111/j.1432-1033.1992.tb16811.x; SAKAI T, 1995, INT J CANCER, V63, P720, DOI 10.1002/ijc.2910630519; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Swindle CS, 2001, J CELL BIOL, V154, P459, DOI 10.1083/jcb.200103103; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Tokes AM, 1999, PATHOL RES PRACT, V195, P821; Tsunoda T, 2003, AM J PATHOL, V162, P1857, DOI 10.1016/S0002-9440(10)64320-9; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Weeks BH, 2001, CANCER RES, V61, P7435; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355; WIRL G, 1995, J CELL SCI, V108, P2445; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Yoshida T, 1997, J PATHOL, V182, P421; Zagzag D, 2002, CANCER RES, V62, P2660	77	41	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3622	3633		10.1038/sj.onc.1207403	http://dx.doi.org/10.1038/sj.onc.1207403			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116096				2022-12-17	WOS:000221101700014
J	Park, J; Song, SH; Kim, TY; Choi, MC; Jong, HS; Kim, TY; Lee, JW; Kim, NK; Kim, WH; Bang, YJ				Park, J; Song, SH; Kim, TY; Choi, MC; Jong, HS; Kim, TY; Lee, JW; Kim, NK; Kim, WH; Bang, YJ			Aberrant methylation of integrin alpha 4 gene in human gastric cancer cells	ONCOGENE			English	Article						integrin alpha 4; methylation; gastric cancer	TUMOR-SUPPRESSOR GENE; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; PROMOTER HYPERMETHYLATION; METALLOPROTEINASE-3 GENE; ALPHA-4 INTEGRINS; TISSUE INHIBITOR; 5'-CPG ISLAND; EXPRESSION; INACTIVATION	Integrins are adhesion receptors that mediate both cell extracellular matrix and cell-cell interactions. It has also been reported that the loss of integrin alpha4 expression might be associated with metastasis in several cancers. However, the molecular mechanism for loss of their expression in cancers has not been explored. In the present study, we found that the integrin alpha4 expression is lost in human gastric cancer cell lines and that this is recovered by treatment with DNA methyltransferase inhibitor, implying transcriptional silencing by DNA methylation. Methylation-specific PCR (MSP) and bisulfite genomic DNA sequencing demonstrated the CpG methylation-dependent silencing of integrin alpha4 expression in eight of nine (88.8%) gastric cancer cell lines and in 84.7% of 46 primary tumors. We also investigated whether the restoration of integrin alpha4 in integrin alpha4-inactivated cells affects their ability to invade extracellular matrix, using matrigel assays. Interestingly, integrin alpha4-stable transfectants had markedly less invasive ability than the parental cells. Taken together, these results suggest that the transcriptional repression of the integrin alpha4 gene is caused by aberrant DNA methylation, and that this may play an important role in human gastric carcinogenesis.	Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Natl Res Lab Canc Epigenet, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Bang, YJ (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 28 Yongon Dong, Seoul 110744, South Korea.	bangyj@plaza.snu.ac.kr	Bang, Yung Jue/J-2759-2012; Lee, Jung Weon/F-9149-2012; Kim, Tae-You/J-2750-2012; Lee, Jung Weon/AAC-1146-2020	Bang, Yung Jue/0000-0001-6000-4597; Lee, Jung Weon/0000-0003-2722-8200; KIM, TAI YOUNG/0000-0001-8086-2476				Akama TO, 1997, CANCER RES, V57, P3294; Bachman KE, 1999, CANCER RES, V59, P798; Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; Ebert MPA, 2003, J CLIN ONCOL, V21, P1708, DOI 10.1200/JCO.2003.10.017; Felding-Habermann B, 2003, CLIN EXP METASTAS, V20, P203, DOI 10.1023/A:1022983000355; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GAROFALO A, 1995, CANCER RES, V55, P414; Gosslar U, 1996, P NATL ACAD SCI USA, V93, P4821, DOI 10.1073/pnas.93.10.4821; HAMANN A, 1994, J IMMUNOL, V152, P3282; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Holzmann B, 1998, CURR TOP MICROBIOL, V231, P125; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jong HS, 1999, CANCER, V86, P559, DOI 10.1002/(SICI)1097-0142(19990815)86:4<559::AID-CNCR3>3.0.CO;2-4; Kang GH, 2003, LAB INVEST, V83, P519, DOI 10.1097/01.LAB.0000064704.53132.65; Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146; Kang SH, 2000, INT J CANCER, V86, P632, DOI 10.1002/(SICI)1097-0215(20000601)86:5<632::AID-IJC5>3.0.CO;2-5; Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; Kuroki T, 2003, CANCER RES, V63, P3352; Leung WK, 2001, CANCER-AM CANCER SOC, V91, P2294; Li H, 2003, P NATL ACAD SCI USA, V100, P8412, DOI 10.1073/pnas.1430846100; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; Lu QJ, 2002, BLOOD, V99, P4503, DOI 10.1182/blood.V99.12.4503; Michetti M, 2000, GASTROENTEROLOGY, V119, P109, DOI 10.1053/gast.2000.8548; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RINCON J, 1992, INT J CANCER, V51, P452, DOI 10.1002/ijc.2910510319; Sato S, 1998, ONCOGENE, V17, P105, DOI 10.1038/sj.onc.1201913; Song SH, 2000, INT J CANCER, V87, P236, DOI 10.1002/1097-0215(20000715)87:2<236::AID-IJC14>3.0.CO;2-M; Song SH, 2001, CANCER RES, V61, P4628; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; Stirzaker C, 1997, CANCER RES, V57, P2229; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; Toyooka S, 2002, CANCER RES, V62, P3382; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zhu ZY, 2001, CANCER RES, V61, P1707	43	41	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3474	3480		10.1038/sj.onc.1207470	http://dx.doi.org/10.1038/sj.onc.1207470			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	14990990				2022-12-17	WOS:000220975000022
J	de Marval, PLM; Macias, E; Conti, CJ; Rodriguez-Puebla, ML				de Marval, PLM; Macias, E; Conti, CJ; Rodriguez-Puebla, ML			Enhanced malignant tumorigenesis in Cdk4 transgenic mice	ONCOGENE			English	Article						CDK4; carcinogenesis; skin; cell-cycle; cyclin; papillomas	SKIN TUMOR-DEVELOPMENT; CYCLIN-DEPENDENT KINASES; SENCAR MOUSE SKIN; CELL-CYCLE; GERMLINE MUTATIONS; PREMALIGNANT PROGRESSION; HOMOZYGOUS DELETION; IN-VIVO; EXPRESSION; OVEREXPRESSION	In a previous study, we reported that overexpression of cyclin-dependent kinase-4 (CDK4) in mouse epidermis results in epidermal hyperplasia, hypertrophy and severe dermal fibrosis. In this study, we have investigated the susceptibility to skin tumor formation by forced expression of CDK4. Skin tumors from transgenic mice showed a dramatic increase in the rate of malignant progression to squamous cell carcinomas (SCC) in an initiation-promotion protocol. Histopathological analysis of papillomas from transgenic mice showed an elevated number of premalignant lesions characterized by dysplasia and marked atypia. Interestingly, transgenic mice also developed tumors in initiated but not promoted skin, demonstrating that CDK4 replaced the action of tumor promoters. These results suggest that expression of cyclin D1 upon ras activation synergizes with CDK4 overexpression. However, cyclin D1 transgenic mice and double transgenic mice for cyclin D1 and CDK4 did not show increased malignant progression in comparison to CDK4 transgenic mice. Biochemical analysis of tumors showed that CDK4 sequesters the CDK2 inhibitors p27(Kip1) and p21(Cip1), suggesting that indirect activation of CDK2 plays an important role in tumor development. These results indicate that, contrary to the general assumption, the catalytic subunit, CDK4, has higher oncogenic activity than cyclin D1, revealing a potential use of CDK4 as therapeutic target.	N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27606 USA; Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX 78957 USA	University of North Carolina; North Carolina State University; University of Texas System; UTMD Anderson Cancer Center	Rodriguez-Puebla, ML (corresponding author), N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, 4700 Hillsborough St, Raleigh, NC 27606 USA.	marcelo_rodriguez-puebla@ncsu.edu			NATIONAL CANCER INSTITUTE [P01CA057596, R01CA042157, P30CA016672, R01CA090864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90864, P30 CA016672, R01 CA042157, CA 57596, CA 16672, R01 CA090864, CA 42157, R01 CA090864-02] Funding Source: Medline; NIEHS NIH HHS [P30 ES007784, ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALDAZ M, 1989, EXPT CLIN ASPECTS; An HX, 1999, AM J PATHOL, V154, P113, DOI 10.1016/S0002-9440(10)65257-1; BERENBLUM I, 1954, ADV CANCER RES, V2, P129, DOI 10.1016/S0065-230X(08)60493-5; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BOUTWELL RK, 1964, PROG EXP TUMOR RES, V4, P207; CONTI C, 1992, CANC B, V54, P62; de Marval PLM, 2001, AM J PATHOL, V159, P369, DOI 10.1016/S0002-9440(10)61703-8; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; Kanoe H, 1998, ANTICANCER RES, V18, P2317; Lam PYP, 2000, BRIT J NEUROSURG, V14, P28; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; Malumbres M, 2000, BIOL CHEM, V381, P827, DOI 10.1515/BC.2000.105; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Morris M, 2002, ONCOGENE, V21, P4277, DOI 10.1038/sj.onc.1205492; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; NEVINS JR, 1991, COLD SH Q B, V56, P157; NEVINS JR, 1992, SCIENCE, V258, P424; Nikitakis NG, 2002, EXP MOL PATHOL, V73, P198, DOI 10.1006/exmp.2002.2465; OHTA M, 1994, CANCER RES, V54, P5269; Parry D, 1999, MOL CELL BIOL, V19, P1775; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; Ramirez RD, 2003, ONCOGENE, V22, P433, DOI 10.1038/sj.onc.1206046; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rodriguez-Puebla ML, 1999, CELL GROWTH DIFFER, V10, P467; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V24, P1, DOI 10.1002/(SICI)1098-2744(199901)24:1<1::AID-MC1>3.0.CO;2-E; Rodriguez-Puebla ML, 1998, ONCOGENE, V17, P2251, DOI 10.1038/sj.onc.1202131; Rodriguez-Puebla ML, 2002, AM J PATHOL, V161, P405, DOI 10.1016/S0002-9440(10)64196-X; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V26, P150, DOI 10.1002/(SICI)1098-2744(199911)26:3<150::AID-MC3>3.0.CO;2-P; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLAGA T J, 1989, P1; SONODA Y, 1995, ONCOGENE, V11, P2145; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; TOLFGARD R, 1985, CARCINOGENESIS, V6, P655; Tos APD, 2000, J PATHOL, V190, P531; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Weinberg RA, 1996, CYTOKINES MOL THER, V2, P105; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; YUSPA SH, 1990, ENVIRON HEALTH PERSP, V88, P193; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	61	41	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1863	1873		10.1038/sj.onc.1207309	http://dx.doi.org/10.1038/sj.onc.1207309			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14647432	Green Accepted			2022-12-17	WOS:000220129500008
J	Jones, GG; Reaper, PM; Pettitt, AR; Sherrington, PD				Jones, GG; Reaper, PM; Pettitt, AR; Sherrington, PD			The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes	ONCOGENE			English	Article						ATR; p53; lymphocytes; chronic lymphocytic leukaemia; cell cycle	NUCLEOTIDE EXCISION-REPAIR; CELL-CYCLE CHECKPOINT; DNA-DAMAGE RESPONSE; ATAXIA-TELANGIECTASIA; STRAND BREAKS; CHROMOSOMAL FRAGMENTATION; TARGETED DISRUPTION; P53 DYSFUNCTION; ATR PROTEIN; PHOSPHORYLATION	Chronic lymphocytic leukaemia (CLL) results from the accumulation of apoptosis-resistant clonal B cells that are arrested in G0/G1, and is heterogeneous with respect to clinical outcome. An aggressive form of the disease is identified by an impaired p53 response to ionizing radiation (IR). This is associated with inactivating mutations of either p53 or ATM, a regulator of p53 activated by IR-induced DNA damage. Since other forms of DNA damage activate p53 via ATR, a kinase closely related to ATM, abnormalities of the ATR-p53 pathway also have the potential to result in p53 dysfunction. We therefore tested cases of CLL for abnormal p53 responses to ultraviolet irradiation (UVC), a known activator of ATR, to screen for additional forms of p53 dysfunction. CLL cells and normal peripheral blood mononuclear cell (PBMC) preparations (predominantly noncycling lymphocytes) were treated with UVC and assessed for p53 responses. In all of the CLL cases and PBMC preparations tested, we were unable to detect p53 accumulation, phosphorylation or transcriptional consequences in response to UVC-induced DNA damage. The most likely explanation for the absence of UVC-induced p53 activation in CLL and normal lymphocytes was that, in contrast to other cell types, the UVC-induced ATR pathway was inactive. This notion was confirmed by showing that ATR protein was absent or undetectable in all of the cases of CLL and normal PBMCs screened. This was an unexpected finding because ATR was thought to be essential for the viability of somatic cells and for normal human and murine embryonic development. An obvious difference between the cell lines used as positive controls for ATR antibodies and the CLL cells/PBMCs was that the former were actively cycling while the latter were quiescent. We therefore hypothesized that the ATR-p53 pathway is selectively downregulated in noncycling lymphocytes. To test this, we induced cycling in the T-cell fraction of PBMC preparations and demonstrated that ATR protein expression was restored. Furthermore, p53 was upregulated and phosphorylated in response to UVC in these cells. Our data support the conclusion that the ATR-p53 pathway is suppressed in noncycling lymphocytes via ATR downregulation. We tentatively suggest that this repressed DNA damage response may have evolved to protect quiescent lymphocytes from the potential for p53-dependent apoptosis in the face of some forms of endurable genotoxic stress. If this is the case, DNA repair and genome stability might be compromised in quiescent lymphocytes with potentially negative consequences.	Royal Liverpool Univ Hosp, Dept Haematol, Liverpool L7 8XP, Merseyside, England; Univ Cambridge, Wellcome Trust Canc Res UK Inst Canc & Dev Biol, Cambridge CB2 1TN, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of Cambridge	Sherrington, PD (corresponding author), Royal Liverpool Univ Hosp, Dept Haematol, Prescot St, Liverpool L7 8XP, Merseyside, England.	pds@liv.ac.uk						Abou-Zahr F, 1999, AM J MED GENET, V83, P388, DOI 10.1002/(SICI)1096-8628(19990423)83:5<388::AID-AJMG9>3.0.CO;2-1; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Blagosklonny MV, 2002, INT J CANCER, V98, P161, DOI 10.1002/ijc.10158; Bogdanov KV, 1997, BRIT J HAEMATOL, V98, P869, DOI 10.1046/j.1365-2141.1997.2913109.x; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Brown JM, 1999, CANCER RES, V59, P1391; BUTLER MG, 1987, AM J MED GENET, V27, P645, DOI 10.1002/ajmg.1320270318; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chanan-Khan Asher, 2003, Haematologica, V88, pECR14; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Friedburg E.C., 1995, DNA REPAIR MUTAGENES; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lawrence CW, 2001, BIOCHEM SOC T, V29, P187, DOI 10.1042/0300-5127:0290187; Lin K, 2002, BLOOD, V100, P1404, DOI 10.1182/blood-2001-11-0066; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; Lyons AB, 2000, J IMMUNOL METHODS, V243, P147, DOI 10.1016/S0022-1759(00)00231-3; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; Mitchell JR, 2003, CURR OPIN CELL BIOL, V15, P232, DOI 10.1016/S0955-0674(03)00018-8; MunchPetersen B, 1997, MUTAT RES-DNA REPAIR, V383, P143, DOI 10.1016/S0921-8777(96)00054-7; NAKONA K, 2000, ONCOGENE, V19, P4283; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Peller S, 2003, HUM MUTAT, V21, P277, DOI 10.1002/humu.10190; Pettitt AR, 2003, BRIT J HAEMATOL, V121, P692, DOI 10.1046/j.1365-2141.2003.04336.x; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; Phillips DH, 1999, MUTAT RES-GEN TOX EN, V443, P139, DOI 10.1016/S1383-5742(99)00016-2; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; SHERRINGTON PD, 1994, ONCOGENE, V9, P2377; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Starostik P, 1998, CANCER RES, V58, P4552; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tuck A, 2000, MUTAT RES-DNA REPAIR, V459, P73, DOI 10.1016/S0921-8777(99)00060-9; Tuck A, 1999, LEUKEMIA LYMPHOMA, V36, P169, DOI 10.3109/10428199909145961; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang P, 1997, GENE CHROMOSOME CANC, V20, P282, DOI 10.1002/(SICI)1098-2264(199711)20:3<282::AID-GCC9>3.0.CO;2-Z; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	66	41	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1911	1921		10.1038/sj.onc.1207318	http://dx.doi.org/10.1038/sj.onc.1207318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14755251				2022-12-17	WOS:000220129500013
J	Coombes, MM; Briggs, KL; Bone, JR; Clayman, GL; El-Naggar, AK; Dent, SYR				Coombes, MM; Briggs, KL; Bone, JR; Clayman, GL; El-Naggar, AK; Dent, SYR			Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation	ONCOGENE			English	Article						squamous cell carcinoma; head and neck; chromatin; acetylation	DEACETYLASE INHIBITORS; LYSINE-9 METHYLATION; X-CHROMOSOME; CANCER-CELLS; GENE; H3; CHROMATIN; HETEROCHROMATIN; REPRESSOR; BINDING	Head and neck squamous cell carcinoma (HNSCC) is the fifth most frequent cancer in the US. Several genetic and epigenetic alterations are associated with HNSCC tumorigenesis, including inactivation of CDKN2A, which encodes the p16 tumor suppressor, in cell lines and primary tumors by DNA methylation. Reactivation of tumor suppressor genes by DNA-demethylating agents and histone deacetylase (HDAC) inhibitors shows therapeutic promise for other cancers. Therefore, we investigated the ability of these agents to reactivate p16 in Tu159 HNSCC cells. Treatment of cells with 5-aza-2' deoxycytidine (5-aza-dC) increases CDKN2A expression and slightly increases histone H3 acetylation at this gene. No reactivation of CDKN2A is observed upon treatment with the HDAC inhibitor trichostatin A (TSA), but synergistic reactivation of CDKN2A is observed upon sequential treatment of Tu159 cells with both 5-aza-dC and TSA. Silencing of CDKN2A in Tu159 cells is correlated with increased methylation of histone H3 at lysine 9 and decreased methylation at lysine 4 relative to the upstream p15 gene promoter. Interestingly, global levels of H3-K9 methylation are decreased upon treatment with 5-aza-dC. Together these data indicate that DNA methylation is a dominant epigenetic mark for silencing of CDKN2A in Tu159 tumor cells. Moreover, changes in DNA methylation can reset the histone code by impacting multiple H3 modifications.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Dent, SYR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	syr@mdacc.tmc.edu	Dent, Sharon YR/F-1746-2011	Dent, Sharon YR/0000-0002-4824-3269				Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; Baylin SB, 1998, ADV CANCER RES, V72, P141; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Bird A, 2001, SCIENCE, V294, P2113, DOI 10.1126/science.1066726; Burgess-Beusse B, 2002, P NATL ACAD SCI USA, V99, P16433, DOI 10.1073/pnas.162342499; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Carapeti M, 1999, CANCER GENET CYTOGEN, V113, P70, DOI 10.1016/S0165-4608(99)00007-2; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Czermin B, 2001, EMBO REP, V2, P915, DOI 10.1093/embo-reports/kve210; Deplus R, 2002, NUCLEIC ACIDS RES, V30, P3831, DOI 10.1093/nar/gkf509; Edmondson DG, 2002, J BIOL CHEM, V277, P29496, DOI 10.1074/jbc.M200651200; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; Enders GH, 1996, ONCOGENE, V12, P1239; Eng C, 2000, NAT GENET, V24, P101, DOI 10.1038/72730; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Goldman Michael A., 2002, Trends in Genetics, V18, P390, DOI 10.1016/S0168-9525(02)02735-X; Gonzalez MV, 1997, J CLIN PATHOL, V50, P509, DOI 10.1136/jcp.50.6.509; Hasegawa M, 2002, ONCOGENE, V21, P4231, DOI 10.1038/sj.onc.1205528; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jarrard DF, 1997, GENE CHROMOSOME CANC, V19, P90, DOI 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.0.CO;2-V; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 2001, TRENDS CELL BIOL, V11, P266, DOI 10.1016/S0962-8924(01)02001-3; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lachner M, 2002, CURR BIOL, V12, pR434, DOI 10.1016/S0960-9822(02)00919-3; Lai S, 1999, LAB INVEST, V79, P255; Lee MH, 2001, CELL MOL LIFE SCI, V58, P1907, DOI 10.1007/PL00000826; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mermoud JE, 2002, CURR BIOL, V12, P247, DOI 10.1016/S0960-9822(02)00660-7; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nguyen CT, 2002, CANCER RES, V62, P6456; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428; Reed AL, 1996, CANCER RES, V56, P3630; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Rice JC, 2001, NATURE, V414, P258, DOI 10.1038/35104721; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Schutte M, 1997, CANCER RES, V57, P3126; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; Wolffe A. P., 1999, CHROMATIN STRUCTURE; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	79	41	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8902	8911		10.1038/sj.onc.1207050	http://dx.doi.org/10.1038/sj.onc.1207050			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654786				2022-12-17	WOS:000186982200011
J	Cheng, SH; Hsia, CY; Leone, G; Liou, HC				Cheng, SH; Hsia, CY; Leone, G; Liou, HC			Cyclin E and Bcl-x(L) cooperatively induce cell cycle progression in c-Rel(-/-) B cells	ONCOGENE			English	Article						B cell; lymphoma; leukemia; Rel; cyclin E; Bcl-x(L)	NF-KAPPA-B; C-REL; RETINOBLASTOMA PROTEIN; ANTIGEN RECEPTOR; S-PHASE; TRANSCRIPTIONAL REGULATION; TRANSACTIVATION DOMAIN; REGULATED EXPRESSION; MECHANISMS CONTROL; INDUCED APOPTOSIS	Aberrant overexpression of the c-rel protooncogene is associated with lymphoid malignancy, while c-rel deletion produces severe lymphoproliferative defects and immunodeficiency. To investigate the mechanism of c-rel-induced proliferation and cell cycle progression in B lymphocytes, we have compared signaling events elicited through the BCR in c-rel(-/-) and wild-type B cells. BCR stimulation of c-rel(-/-) B cells fails to induce proper cyclin expression, resulting in G(1) phase arrest, but it is unclear whether these defects are in fact secondary events of decreased B-cell survival, since c-rel deletion also affects the expression of antiapoptotic genes such as bcl-x(L). Here, we use the bcl-x(L) transgene to correct the viability of c-rel-deficient B cells, and show that the inhibition of apoptosis does not necessarily confer hyperproliferation of B cells activated through the BCR. c-rel(-/-) B cells still fail to enter the S phase despite improved survival by bcl-x(L) overexpression, suggesting that c-Rel-associated cell cycle progression is dependent on more than just enhanced cell viability. Overexpression of cyclin E protein, however, can cooperate with Bcl-x(L) to restore cell cycle progression to c-rel(-/-) B cells via induction of the cyclin-CDK/Rb-E2F pathway. Furthermore, we show that c-Rel can directly regulate transcription of the e2f3a promoter/enhancer, which is then likely to lead to transcriptional activation of the cyclin E promoter by E2F3a. Hence, these studies provide clear evidence that control of lymphocyte proliferation via c-Rel is linked to a cyclin-dependent process, and suggest that c-Rel not only activates antiapoptotic signaling but also the induction of cell cycle progression.	Cornell Univ, Weill Med Coll, Dept Med, Div Immunol, New York, NY 10021 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	Cornell University; University System of Ohio; Ohio State University	Liou, HC (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Immunol, 515 E 71st St,Room S-210, New York, NY 10021 USA.		Giuseppe Leone, Full Professor/I-9166-2019	Giuseppe Leone, Full Professor/0000-0002-7812-5300	NCI NIH HHS [CA 68155, CA 90405] Funding Source: Medline; PHS HHS [1 T32 A1 07621] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068155, R01CA090405, R55CA068155] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Andjelic S, 2000, J IMMUNOL, V165, P3860, DOI 10.4049/jimmunol.165.7.3860; Aronica MA, 1999, J IMMUNOL, V163, P5116; BARTH TF, 2003, BLOOD, V2, P2; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; Bernal A, 2001, BLOOD, V98, P3050, DOI 10.1182/blood.V98.10.3050; Botz J, 1996, MOL CELL BIOL, V16, P3401; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Carman JA, 1996, J IMMUNOL, V156, P4562; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen EY, 1998, BIOCHEM BIOPH RES CO, V249, P728, DOI 10.1006/bbrc.1998.9224; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Donovan CE, 1999, J IMMUNOL, V163, P6827; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Edelstein LC, 2003, MOL CELL BIOL, V23, P2749, DOI 10.1128/MCB.23.8.2749-2761.2003; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Finn PW, 2001, J IMMUNOL, V167, P5994, DOI 10.4049/jimmunol.167.10.5994; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Furukawa Y, 1999, ONCOGENE, V18, P2003, DOI 10.1038/sj.onc.1202500; Geng Y, 1996, ONCOGENE, V12, P1173; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 1996, ONCOGENE, V13, P1367; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Hilliard BA, 2002, J CLIN INVEST, V110, P843, DOI 10.1172/JCI200215254; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; Houldsworth J, 1996, BLOOD, V87, P25; Hsia CY, 2002, INT IMMUNOL, V14, P905, DOI 10.1093/intimm/dxf055; Humbert PO, 2000, GENE DEV, V14, P690; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Lavia P, 1999, BIOESSAYS, V21, P221; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Liou HC, 2002, J BIOCHEM MOL BIOL, V35, P537; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liu JJ, 2002, J IMMUNOL, V169, P581, DOI 10.4049/jimmunol.169.1.581; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Mason N, 2002, J IMMUNOL, V168, P2590, DOI 10.4049/jimmunol.168.6.2590; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Monroe JG, 2000, CURR TOP MICROBIOL, V245, P1; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nakamura Y, 2002, MOL CELL BIOL, V22, P5563, DOI 10.1128/MCB.22.15.5563-5574.2002; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Owyang AM, 2001, J IMMUNOL, V167, P4948, DOI 10.4049/jimmunol.167.9.4948; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Tumang JR, 2002, CELL IMMUNOL, V217, P47, DOI 10.1016/S0008-8749(02)00513-0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yang H, 2002, TRANSPLANTATION, V74, P291, DOI 10.1097/00007890-200208150-00002; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	79	41	43	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8472	8486		10.1038/sj.onc.1206917	http://dx.doi.org/10.1038/sj.onc.1206917			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627988				2022-12-17	WOS:000186650300011
J	Mishra, S; Reichert, A; Cunnick, J; Senadheera, D; Hemmeryckx, B; Heisterkamp, N; Groffen, J				Mishra, S; Reichert, A; Cunnick, J; Senadheera, D; Hemmeryckx, B; Heisterkamp, N; Groffen, J			Protein kinase CKII alpha interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells	ONCOGENE			English	Article						Bcr; Bcr/Abl P190; CKII alpha; acute lymphoblastic leukemia; TBB	ABL ONCOPROTEIN; TRANSGENIC MICE; OLIGOMERIZATION DOMAIN; CATALYTIC SUBUNIT; TYROSINE KINASES; CASEIN KINASE-2; II-ALPHA; CK2; TRANSFORMATION; LEUKEMIA	The Bcr protein was originally identified because of its fusion to Abl as a consequence of the Philadelphia chromosome translocation found in chronic myelogenous and acute lymphoblastic leukemias. The Bcr moiety is essential for the transforming activity of the Bcr/Abl oncogene. In search of physiologically relevant Bcr and Bcr/Abl-interacting proteins, we performed an interaction screen in yeast using the entire Bcr protein as bait. We here report that the alpha catalytic subunit of protein kinase CKII strongly and specifically forms a complex with Bcr in yeast in mouse lysates. The region in Bcr responsible for CKIIalpha binding was localized to residues 242-413. CKIIalpha was previously shown to be involved in leukemogenesis and tumorigenesis using different experimental approaches including mouse models. Inhibition of Bcr/Abl P190 in lymphoma cells from Bcr/Abl transgenic mice using imatinib reduced CKIIalpha activity. A highly selective inhibitor of CKIIalpha, 4,5,6,7-tetrabromo-2-benzotriazole, inhibited the growth of murine lymphoid cells with induced P210 Bcr/Abl expression and of P190 lymphoma cells. Our results demonstrate that CKIIalpha plays an important role in the proliferation of Bcr/Abl expressing cells, and suggests that inhibitors of CKIIalpha may have therapeutic potential in the treatment of Bcr/Abl-positive leukemia patients.	Childrens Hosp Los Angeles, Res Inst, Div Hematol Oncol, Sect Mol Carcinogenesis, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California	Groffen, J (corresponding author), Childrens Hosp Los Angeles, Res Inst, Div Hematol Oncol, Sect Mol Carcinogenesis, Ms 54,4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Cunnick, Jess/F-1715-2018; Hemmeryckx, Bianca/AAR-2360-2021; Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NATIONAL CANCER INSTITUTE [R01CA090321, R01CA050248] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50248, CA 90321] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Battistutta R, 2001, PROTEIN SCI, V10, P2200, DOI 10.1110/ps.19601; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; De Langhe S, 2002, INT J MOL MED, V9, P451; Deininger MWN, 2003, J CLIN ONCOL, V21, P1637, DOI 10.1200/JCO.2003.11.143; Donella-Deana A, 2003, BIOCHEM J, V372, P841, DOI 10.1042/BJ20021905; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; FIORETOS T, 1995, CELL MOL BIOL RES, V41, P97; Ghaffari S, 1999, LEUKEMIA, V13, P1200, DOI 10.1038/sj.leu.2401467; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Haataja L, 1998, INT J MOL MED, V1, P665; Hawk N, 2002, CANCER RES, V62, P386; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 2001, CHRONIC MYELOID LEUK, P3; Heriche JK, 1998, ONCOGENE, V17, P13, DOI 10.1038/sj.onc.1201900; Kaartinen V, 2001, DEVELOPMENT, V128, P4217; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Laurent E, 2001, CANCER RES, V61, P2343; Lebrin F, 2001, ONCOGENE, V20, P2010, DOI 10.1038/sj.onc.1204307; Ling XY, 2003, CANCER RES, V63, P298; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Ma GZ, 1997, ONCOGENE, V14, P2367, DOI 10.1038/sj.onc.1201053; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Pinna LA, 2003, ACCOUNTS CHEM RES, V36, P378, DOI 10.1021/ar020164f; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Rifkin IR, 1998, J IMMUNOL, V161, P5164; Rudert F, 1996, GENE, V169, P281, DOI 10.1016/0378-1119(95)00820-9; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Sarno S, 2002, PHARMACOL THERAPEUT, V93, P159, DOI 10.1016/S0163-7258(02)00185-7; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Senadheera D, 2001, INT J MOL MED, V8, P127; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Takeda N, 1999, P NATL ACAD SCI USA, V96, P203, DOI 10.1073/pnas.96.1.203; VONCKEN JW, 1992, BLOOD, V79, P1029; VONCKEN JW, 1992, CANCER RES, V52, P4534; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang Y, 2001, CANCER RES, V61, P138; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729; Xu X, 1999, MOL CELL BIOCHEM, V191, P65, DOI 10.1023/A:1006866412652; Zhao X, 2002, NAT STRUCT BIOL, V9, P117	46	41	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8255	8262		10.1038/sj.onc.1207156	http://dx.doi.org/10.1038/sj.onc.1207156			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614449				2022-12-17	WOS:000186541500004
J	Niwa, O				Niwa, O			Induced genomic instability in irradiated germ cells and in the offspring; reconciling discrepancies among the human and animal studies	ONCOGENE			English	Article						radiation; genomic instability; minisatellite; transgenerational	MINISATELLITE MUTATION-RATE; EYED UNSTABLE MUTATION; F-1 MICE BORN; IONIZING-RADIATION; DOSE-RESPONSE; HUMAN SPERM; TEST SYSTEM; X-RAYS; MOUSE; INDUCTION	Many studies confirmed that radiation induces genomic instability in whole-body systems. However, the results of the studies are not always consistent with each other. Attempts are made in the present review to resolve the discrepancies. Many of the studies in human and experimental animals utilize the length change mutation of minisatellite sequences as a marker of genomic instability. Minisatellite sequences frequently change their length, and the data obtained by conventional Southern blotting give rather qualitative information, which is sometimes difficult to scrutinize quantitatively. This is the problem inevitably associated with the study of minisatellite mutations and the source of some conflicts among studies in humans and mice. Radiation induction of genomic instability has also been assessed in whole-body experimental systems, using other markers such as the mouse pink-eyed unstable allele and the specific pigmentation loci of medaka fish (Oryzias latipes). Even though there are some contradictions, all these studies have demonstrated that genomic instability is induced in the germ cells of irradiated parents, especially of males, and in offspring born to them. Among these, transmission of genomic instability to the second generation of irradiated parents is limited to the mouse minisatellite system, and awaits further clarification in other experimental systems.	Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Niwa, O (corresponding author), Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Yoshida Konoe, Kyoto 6068501, Japan.	tsimura@house.rbc.kyoto-u.ac.jp						Adler ID, 1996, MUTAT RES-FUND MOL M, V352, P169, DOI 10.1016/0027-5107(95)00223-5; AUERBACH C, 1976, MUTAT RES, P270; Barber R, 2002, P NATL ACAD SCI USA, V99, P6877, DOI 10.1073/pnas.102015399; Barber R, 2000, MUTAT RES-FUND MOL M, V457, P79, DOI 10.1016/S0027-5107(00)00130-5; Bishop AJR, 2000, MUTAT RES-FUND MOL M, V457, P31, DOI 10.1016/S0027-5107(00)00118-4; Boudsocq F, 2002, DNA REPAIR, V1, P343, DOI 10.1016/S1568-7864(02)00019-8; Bridges BA, 2001, RADIAT RES, V156, P631, DOI 10.1667/0033-7587(2001)156[0631:RAGMAR]2.0.CO;2; BRILLIANT MH, 1994, MAMM GENOME, V5, pS104; Buard J, 2000, GENOMICS, V65, P95, DOI 10.1006/geno.2000.6161; Buard J, 1998, EMBO J, V17, P3495, DOI 10.1093/emboj/17.12.3495; Cho C, 2003, BIOL REPROD, V69, P211, DOI 10.1095/biolreprod.102.015115; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; CROMPTON NEA, 1990, RADIAT RES, V124, P300, DOI 10.2307/3577843; Dubrova YE, 2000, MUTAT RES-FUND MOL M, V453, P17, DOI 10.1016/S0027-5107(00)00068-3; Dubrova YE, 1998, INT J RADIAT BIOL, V74, P689, DOI 10.1080/095530098140952; Dubrova YE, 1998, P NATL ACAD SCI USA, V95, P6251, DOI 10.1073/pnas.95.11.6251; Dubrova YE, 1997, MUTAT RES-FUND MOL M, V381, P267; Dubrova YE, 1996, NATURE, V380, P683, DOI 10.1038/380683a0; Dubrova YE, 2002, AM J HUM GENET, V71, P801, DOI 10.1086/342729; Dubrova YE, 2002, SCIENCE, V295, P1037, DOI 10.1126/science.1068102; DUBROVA YE, 1993, NAT GENET, V5, P92, DOI 10.1038/ng0993-92; FAN YJ, 1995, INT J RADIAT BIOL, V68, P177, DOI 10.1080/09553009514551081; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P59; GIBBS M, 1993, GENOMICS, V17, P121, DOI 10.1006/geno.1993.1292; GONDO Y, 1993, P NATL ACAD SCI USA, V90, P297, DOI 10.1073/pnas.90.1.297; Goodhead DT, 1999, J RADIAT RES, V40, P1, DOI 10.1269/jrr.40.S1; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; HILL CK, 1984, INT J RADIAT BIOL, V46, P11, DOI 10.1080/09553008414551011; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; Jeffreys AJ, 1997, CLIN SCI, V93, P383, DOI 10.1042/cs0930383; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JEFFREYS AJ, 1997, HUM MOL GENET, P136; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; Kitajima TS, 2003, SCIENCE, V300, P1152, DOI 10.1126/science.1083634; Kiuru A, 2003, RADIAT RES, V159, P651, DOI 10.1667/0033-7587(2003)159[0651:HMMATO]2.0.CO;2; KODAIRA M, 1995, AM J HUM GENET, V57, P1275; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Livshits LA, 2001, RADIAT RES, V155, P74, DOI 10.1667/0033-7587(2001)155[0074:COCCWD]2.0.CO;2; Mannazzu I, 2002, APPL ENVIRON MICROB, V68, P5437, DOI 10.1128/AEM.68.11.5437-5444.2002; Martini E, 2002, MOL CELL, V9, P700, DOI 10.1016/S1097-2765(02)00512-9; May CA, 2000, MUTAT RES-FUND MOL M, V453, P67, DOI 10.1016/S0027-5107(00)00085-3; MITANI K, 1990, J BIOL CHEM, V265, P15203; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; *NAT AC SCI, 1990, 5 BEIRR NAT AC SCI N; NEEL JV, 1990, AM J HUM GENET, V46, P1053; Nikjoo H, 1999, J RADIAT RES, V40, P85, DOI 10.1269/jrr.40.S85; Niwa O, 1996, J RADIAT RES, V37, P217, DOI 10.1269/jrr.37.217; Niwa O, 2001, P NATL ACAD SCI USA, V98, P1705, DOI 10.1073/pnas.031439298; Radman M, 2001, NATURE, V413, P115, DOI 10.1038/35093178; Rassoulzadegan M, 2002, EMBO J, V21, P440, DOI 10.1093/emboj/21.3.440; Richard GF, 2000, EMBO REP, V1, P122, DOI 10.1093/embo-reports/kvd031; RUSSELL LB, 1991, MUTAT RES, V262, P101, DOI 10.1016/0165-7992(91)90114-J; RUSSELL LB, 1990, BANBURY REPORT, V34, P271; RUSSELL WL, 1982, P NATL ACAD SCI-BIOL, V79, P542, DOI 10.1073/pnas.79.2.542; Russell WL, 1998, GENETICS, V148, P1567; SADAMOTO S, 1994, INT J RADIAT BIOL, V65, P549, DOI 10.1080/09553009414550641; Sankaranarayanan K, 2000, MUTAT RES-FUND MOL M, V453, P107, DOI 10.1016/S0027-5107(00)00108-1; Satoh C, 1996, NATURE, V383, P226, DOI 10.1038/383226a0; Schiestl RH, 1997, P NATL ACAD SCI USA, V94, P4576, DOI 10.1073/pnas.94.9.4576; SCHIESTL RH, 1994, SCIENCE, V266, P1573, DOI 10.1126/science.7985029; Schwacha A, 1997, CELL, V90, P1123, DOI 10.1016/S0092-8674(00)80378-5; SHIMA A, 1991, P NATL ACAD SCI USA, V88, P2545, DOI 10.1073/pnas.88.6.2545; Shimada A, 1998, MUTAT RES-FUND MOL M, V399, P149, DOI 10.1016/S0027-5107(97)00253-4; Shimada A, 2001, MUTAT RES-GEN TOX EN, V495, P33, DOI 10.1016/S1383-5718(01)00193-0; Shimura T, 2002, MOL CELL BIOL, V22, P2220, DOI 10.1128/MCB.22.7.2220-2228.2002; Shiraishi K, 2002, RADIAT RES, V157, P661, DOI 10.1667/0033-7587(2002)157[0661:PIOSRO]2.0.CO;2; *UN SCI COMM, 2000, UN SCI COMM EFF AT R; *UN SCI COMM, 1993, UN SCI COMM EFF AT R; WYMAN AR, 1980, P NATL ACAD SCI-BIOL, V77, P6754, DOI 10.1073/pnas.77.11.6754; Yauk CL, 2002, MUTAT RES-FUND MOL M, V500, P147, DOI 10.1016/S0027-5107(02)00005-2; Yokomori K, 2003, CURR TOP MICROBIOL, V274, P79; Zheng NJ, 2000, ENVIRON MOL MUTAGEN, V36, P134, DOI 10.1002/1098-2280(2000)36:2<134::AID-EM8>3.0.CO;2-D	73	41	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2003	22	45					7078	7086		10.1038/sj.onc.1207037	http://dx.doi.org/10.1038/sj.onc.1207037			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557813				2022-12-17	WOS:000185903900013
J	Desai, AA; Innocenti, F; Ratain, MJ				Desai, AA; Innocenti, F; Ratain, MJ			Pharmacogenomics: road to anticancer therapeutics nirvana?	ONCOGENE			English	Review						pharmacogenomics; cancer chemotherapy; EGFR; irinotecan; thymidylate synthase	EPIDERMAL-GROWTH-FACTOR; THYMIDYLATE-SYNTHASE GENE; HUMAN UDP-GLUCURONOSYLTRANSFERASES; ACTIVE METABOLITE; REPEATED SEQUENCES; IRINOTECAN CPT-11; COLORECTAL-CANCER; REGULATORY REGION; UGT1A1 PROMOTER; ENHANCER REGION	Interindividual differences in the toxicity and response to anticancer therapies are currently observed for essentially all available treatment regimens. Such 'unpredictable' drug responses are particularly dangerous in the context of anticancer agents that have narrow therapeutic indices. Pharmacogenomics attempts to elucidate the inherited basis of interindividual differences in drug response, with the eventual goal of minimizing such variability through the use of 'individualized' treatments. There are several emerging examples of genetic polymorphisms of drug-metabolizing enzymes, DNA repair genes and drug targets that have been shown to influence the toxicity and efficacy of anticancer treatment. This review discusses the role of genetic variants of UGT1A1, TS and EGFR to exemplify the potential impact of phramacogenomics on the field of anticancer therapeutics.	Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Comm Clin Pharmacol & Pharmacogenom, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Ratain, MJ (corresponding author), Univ Chicago, Canc Res Ctr, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.	mratain@medicine.bsd.uchicago.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061393] Funding Source: NIH RePORTER; NIGMS NIH HHS [U01GM61393] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acuna Gonzalo, 2002, Pharmacogenomics Journal, V2, P327, DOI 10.1038/sj.tpj.6500123; ADAMSON ED, 1981, MOL CELL BIOCHEM, V34, P129, DOI 10.1007/BF02359619; Akaba K, 1998, BIOCHEM MOL BIOL INT, V46, P21; Akimoto T, 1999, CLIN CANCER RES, V5, P2884; Ando Y, 2000, CANCER RES, V60, P6921; ARAKI E, 1993, JPN J CANCER RES, V84, P697, DOI 10.1111/j.1349-7006.1993.tb02031.x; Aschele C, 1999, J CLIN ONCOL, V17, P1760, DOI 10.1200/JCO.1999.17.6.1760; Beutler E, 1998, P NATL ACAD SCI USA, V95, P8170, DOI 10.1073/pnas.95.14.8170; BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; BRUNO R, 2003, P ASCO, V22; BURCHELL B, 1995, LIFE SCI, V57, P1819, DOI 10.1016/0024-3205(95)02073-R; Burchell B, 1999, J GASTROEN HEPATOL, V14, P960, DOI 10.1046/j.1440-1746.1999.01984.x; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chen Z, 2000, ANTICANCER RES, V20, P899; Chi D. D., 1992, Human Molecular Genetics, V1, P135, DOI 10.1093/hmg/1.2.135; CHRYSOGELOS SA, 1993, NUCLEIC ACIDS RES, V21, P5736, DOI 10.1093/nar/21.24.5736; Chu E, 1999, CANC DRUG DISC DEV, P397; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; CLARK GM, 2003, P ASCO, V22; Cohen EEW, 2003, J CLIN ONCOL, V21, P1980, DOI 10.1200/JCO.2003.10.051; Dolnick BJ, 2000, CANCER J, V6, P215; EVANS DAP, 1968, ANN NY ACAD SCI, V151, P723, DOI 10.1111/j.1749-6632.1968.tb11933.x; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; Fuchs CS, 2003, J CLIN ONCOL, V21, P807, DOI 10.1200/JCO.2003.08.058; Fukuoka M, 2002, P AN M AM SOC CLIN, V21, p298a; Gebhardt F, 1999, J BIOL CHEM, V274, P13176, DOI 10.1074/jbc.274.19.13176; GRAU JJ, 2003, P ASCO, V22; GUPTA E, 1994, CANCER RES, V54, P3723; HALEY JD, 1991, J BIOL CHEM, V266, P1746; Hidalgo M, 2001, J CLIN ONCOL, V19, P3267, DOI 10.1200/JCO.2001.19.13.3267; HORIE N, 1995, CELL STRUCT FUNCT, V20, P191, DOI 10.1247/csf.20.191; Huang CS, 2000, PHARMACOGENETICS, V10, P539, DOI 10.1097/00008571-200008000-00007; Humerickhouse R, 2000, CANCER RES, V60, P1189; Innocenti F, 2002, PHARMACOGENETICS, V12, P725, DOI 10.1097/00008571-200212000-00006; Innocenti F, 2002, EUR J CANCER, V38, P639, DOI 10.1016/S0959-8049(01)00434-8; INNOCENTI F, 2003, P ASCO, V22; Innocenti F, 2002, PHARMACOGENOMICS SEA; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; Iyer L, 1999, CLIN PHARMACOL THER, V65, P576, DOI 10.1016/S0009-9236(99)70078-0; Iyer L, 1998, CANCER CHEMOTH PHARM, V42, pS31, DOI 10.1007/s002800051077; Iyer L., 2002, Pharmacogenomics Journal, V2, P43, DOI 10.1038/sj.tpj.6500072; Iyer L, 1998, J CLIN INVEST, V101, P847, DOI 10.1172/JCI915; JOHNSTON PG, 1994, J CLIN ONCOL, V12, P2640, DOI 10.1200/JCO.1994.12.12.2640; JOHNSTON PG, 1992, CANCER RES, V52, P4306; JOHNSTON PG, 1995, CANCER RES, V55, P1407; KALOW W, 1956, LANCET, V271, P576; KANEDA S, 1987, NUCLEIC ACIDS RES, V15, P1259, DOI 10.1093/nar/15.3.1259; KAWABE S, 2003, P AM SOC CLIN ONCOLO, V22; Kawakami K., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P436; Kohn EC, 1997, J CLIN ONCOL, V15, P1985, DOI 10.1200/JCO.1997.15.5.1985; Korn EL, 2001, J CLIN ONCOL, V19, P265, DOI 10.1200/JCO.2001.19.1.265; Kornmann M, 1997, CANCER LETT, V118, P29, DOI 10.1016/S0304-3835(97)00220-6; KRIS MG, 2002, P ASCO, V21; Leichman CG, 1997, J CLIN ONCOL, V15, P3223, DOI 10.1200/JCO.1997.15.10.3223; Lenz HJ, 1996, J CLIN ONCOL, V14, P176, DOI 10.1200/JCO.1996.14.1.176; Liu WQ, 2003, CLIN CANCER RES, V9, P1009; Luo HR, 2002, BIOCHEM GENET, V40, P41, DOI 10.1023/A:1014589105977; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; Mandola MV, 2003, CANCER RES, V63, P2898; Marsh S, 2000, Hum Mutat, V16, P528; Marsh S, 2001, INT J ONCOL, V19, P383; MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722; MERLINO GT, 1985, J CLIN INVEST, V75, P1077, DOI 10.1172/JCI111770; Monaghan G, 1997, PHARMACOGENETICS, V7, P153, DOI 10.1097/00008571-199704000-00010; Monaghan G, 1996, LANCET, V347, P578, DOI 10.1016/S0140-6736(96)91273-8; Nagasubramanian R, 2003, ANNU REV MED, V54, P437, DOI 10.1146/annurev.med.54.101601.152352; Noda W, 2002, NEW ENGL J MED, V346, P85, DOI 10.1056/NEJMoa003034; PESTALOZZI BC, 1995, BRIT J CANCER, V71, P1151, DOI 10.1038/bjc.1995.225; Peus D, 1997, J INVEST DERMATOL, V109, P751, DOI 10.1111/1523-1747.ep12340759; Porebska I, 2000, TUMOR BIOL, V21, P105, DOI 10.1159/000030116; Pullarkat S. T., 2001, Pharmacogenomics Journal, V1, P65; Ratain MJ, 2001, NAT MED, V7, P283, DOI 10.1038/85414; Reardon David A, 2003, Oncology (Williston Park), V17, P9; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SALTZ L, 2002, P ASCO, V21; Saltz LB, 2003, P ASCO, V22, p817a; Sampietro M, 1999, HAEMATOLOGICA, V84, P150; Santos A, 2000, CLIN CANCER RES, V6, P2012; Sato H, 1996, LANCET, V347, P557, DOI 10.1016/S0140-6736(96)91266-0; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SOONG R, 2003, P ASCO, V22; Stadler WM, 2000, INVEST NEW DRUG, V18, P7, DOI 10.1023/A:1006371512390; Sugatani J, 2002, BIOCHEM BIOPH RES CO, V292, P492, DOI 10.1006/bbrc.2002.6683; Sung T, 2000, BRAIN PATHOL, V10, P249, DOI 10.1111/j.1750-3639.2000.tb00258.x; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Vanhoefer U, 2001, J CLIN ONCOL, V19, P1501, DOI 10.1200/JCO.2001.19.5.1501; Villafranca E, 2001, J CLIN ONCOL, V19, P1779, DOI 10.1200/JCO.2001.19.6.1779	90	41	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6621	6628		10.1038/sj.onc.1206958	http://dx.doi.org/10.1038/sj.onc.1206958			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528287				2022-12-17	WOS:000185700700019
J	Quintanilla, M; Ramirez, JR; Perez-Gomez, E; Romero, D; Velasco, B; Letarte, M; Lopez-Novoa, JM; Bernabeu, C				Quintanilla, M; Ramirez, JR; Perez-Gomez, E; Romero, D; Velasco, B; Letarte, M; Lopez-Novoa, JM; Bernabeu, C			Expression of the TGF-beta coreceptor endoglin in epidermal keratinocytes and its dual role in multistage mouse skin carcinogenesis	ONCOGENE			English	Article						endoglin; TGF-beta; keratinocyte; tumor progression	GROWTH-FACTOR-BETA; HEREDITARY HEMORRHAGIC TELANGIECTASIA; VASCULAR ENDOTHELIAL-CELLS; BINDING-PROTEIN ENDOGLIN; TRANSFORMING GROWTH-FACTOR-BETA-1; CHEMICAL CARCINOGENESIS; MONOCLONAL-ANTIBODIES; CELLULAR-RESPONSES; SPINDLE CARCINOMAS; TUMOR PROGRESSION	Endoglin is an integral membrane glycoprotein primarily expressed in the vascular endothelium, but also found on macrophages and stromal cells. It binds several members of the transforming growth factor (TGF)-beta family of growth factors and modulates TGF-beta(1)-dependent cellular responses. However, it lacks cytoplasmic signaling motifs and is considered as an auxiliary receptor for TGF-beta. We show here that endoglin is expressed in mouse and human epidermis and in skin appendages, such as hair follicles and sweat glands, as determined by immunohistochemistry. In normal interfollicular epidermis, endoglin was restricted to basal keratinocytes and absent in differentiating cells of suprabasal layers. Follicular expression of endoglin was high in hair bulb keratinocytes, but decreased in parts distal from the bulb. To address the role of endoglin in skin carcinogenesis in vivo, Endoglin heterozygous mice were subjected to long-term chemical carcinogenesis treatment. Reduction in endoglin had a dual effect during multistage carcinogenesis, by inhibiting the early appearance of benign papillomas, but increasing malignant progression to highly undifferentiated carcinomas. Our results are strikingly similar to those previously reported for transgenic mice overexpressing TGF-beta(1) in the epidermis. These data suggest that endoglin might attenuate TGF-beta(1) signaling in normal epidermis and interfere with progression of skin carcinogenesis.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Hosp Gomez Ulla, Dept Anat Patol, Madrid 28047, Spain; CSIC, Ctr Invest Biol, Madrid 28040, Spain; Hosp Sick Children, Blood & Canc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 1X8, Canada; Univ Salamanca, Fac Med, Dept Fisiol & Farmacol, Salamanca 37007, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Salamanca	Quintanilla, M (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	mquintanilla@iib.uam.es	Lopez-Novoa, Jose M/A-3672-2008; Bernabeu, Carmelo/P-4662-2019; Pérez-Gómez, Eduardo/GYA-5856-2022; Bernabeu, Carmelo/L-3226-2014; Quintanilla, Miguel/K-9293-2017; Perez-gomez, Eduardo/F-5906-2015	Bernabeu, Carmelo/0000-0002-1563-6162; Pérez-Gómez, Eduardo/0000-0003-0160-5565; Bernabeu, Carmelo/0000-0002-1563-6162; Perez-gomez, Eduardo/0000-0003-0160-5565; Lopez-Novoa, Jose M./0000-0002-6211-7269; Quintanilla, Miguel/0000-0002-2124-7657				AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Altomonte M, 1996, BRIT J CANCER, V74, P1586, DOI 10.1038/bjc.1996.593; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Bodey B, 1998, ANTICANCER RES, V18, P2701; Bolontrade MF, 1998, CARCINOGENESIS, V19, P2107, DOI 10.1093/carcin/19.12.2107; Bourdeau A, 2001, AM J PATHOL, V158, P2011, DOI 10.1016/S0002-9440(10)64673-1; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; BUCHMANN A, 1991, CANCER RES, V51, P4097; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DIAZGUERRA M, 1992, CANCER RES, V52, P680; Diez-Marques L, 2002, BBA-MOL BASIS DIS, V1587, P36, DOI 10.1016/S0925-4439(02)00051-0; Fonsatti E, 2001, J CELL PHYSIOL, V188, P1, DOI 10.1002/jcp.1095; FOWLIS DJ, 1992, CELL GROWTH DIFFER, V3, P81; Frontelo P, 1998, EXP CELL RES, V244, P420, DOI 10.1006/excr.1998.4219; GE AZ, 1994, GENE, V138, P201, DOI 10.1016/0378-1119(94)90808-7; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARUTA Y, 1986, P NATL ACAD SCI USA, V83, P7898, DOI 10.1073/pnas.83.20.7898; JINDAL SK, 1995, BIOL REPROD, V52, P1027, DOI 10.1095/biolreprod52.5.1027; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; Kumar S, 1999, CANCER RES, V59, P856; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Letamendia A, 1998, INT J CANCER, V76, P541, DOI 10.1002/(SICI)1097-0215(19980518)76:4<541::AID-IJC16>3.0.CO;2-A; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Li CG, 2001, MICROSC RES TECHNIQ, V52, P437, DOI 10.1002/1097-0029(20010215)52:4<437::AID-JEMT1029>3.0.CO;2-G; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; MARCHUK DA, 2001, METABOLIC MOL BASES, V4, P5419; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; PATAMALAI B, 1994, MOL CARCINOGEN, V9, P220, DOI 10.1002/mc.2940090406; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; Qu R, 1998, CELL TISSUE RES, V292, P333, DOI 10.1007/s004410051064; QUACKENBUSH EJ, 1985, J IMMUNOL, V134, P1276; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REINERS JJ, 1984, CARCINOGENESIS, V5, P301, DOI 10.1093/carcin/5.3.301; Rich JN, 2001, MICROSC RES TECHNIQ, V52, P363, DOI 10.1002/1097-0029(20010215)52:4<363::AID-JEMT1021>3.3.CO;2-6; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; Robledo MM, 1996, BRIT J HAEMATOL, V93, P507, DOI 10.1046/j.1365-2141.1996.d01-1698.x; Rodriguez-Pena A, 2002, HYPERTENSION, V40, P713, DOI 10.1161/01.HYP.0000037429.73954.27; Shovlin CL, 1999, THORAX, V54, P714, DOI 10.1136/thx.54.8.714; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; Takahashi N, 2001, CANCER RES, V61, P7846; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Velasco B, 2001, GENE THER, V8, P897, DOI 10.1038/sj.gt.3301468; Vincent EB, 1998, DEV DYNAM, V213, P237, DOI 10.1002/(SICI)1097-0177(199811)213:3<237::AID-AJA1>3.0.CO;2-M; YUSPA SH, 1986, CARCINOGENESIS, V7, P949, DOI 10.1093/carcin/7.6.949; YUSPA SH, 1994, CANCER RES, V54, P1178; Zhang HW, 1996, J IMMUNOL, V156, P565	70	41	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5976	5985		10.1038/sj.onc.1206841	http://dx.doi.org/10.1038/sj.onc.1206841			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955076	Green Submitted			2022-12-17	WOS:000185137800006
J	Gurrola-Diaz, C; Lacroix, J; Dihlmann, S; Becker, CM; Doeberitz, MV				Gurrola-Diaz, C; Lacroix, J; Dihlmann, S; Becker, CM; Doeberitz, MV			Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor alpha 1 subunit in small-cell lung cancer cells	ONCOGENE			English	Article						glycine receptor alpha-1 subunit; GLRA1; NRSF; NRSE; neuroendocrine differentiation; small-cell lung cancer; SCLC; NSCLC	GENE-EXPRESSION; MAMMALIAN-CELLS; DNA-BINDING; REPRESSOR; PROTEIN; IDENTIFICATION; VARIANT; REST4; RAT	Small-cell lung cancer (SCLC) cells express various markers of neuronal differentiation associated with deficient activity of the neuron-restricted silencer factor (NRSF). Here, we characterize mechanisms by which NRSF target genes are upregulated in SCLC and their functional consequences for cell survival. Since the glycine receptor (GlyR) alpha1 subunit gene, GLRA1, contains a sequence motif for NRSF binding (NRSE) within its 5' UTR, it served as a cellular surrogate marker for NRSF activity. Expression of GLRA1 in nontransformed cells is largely restricted to cells in the spinal cord, retina and brain stem. In experiments described here, we detected GLRA1 transcripts in three out of four SCLC-derived cell lines and in three of five biopsy samples obtained from SCLCs. In contrast, no GLRA1 transcripts were found in 10 nonmalignant nor 15 non-small-cell lung cancer biopsies. Consistent with this observation, NRSF-mediated suppression of an expression construct harbouring the NRSE of the GLRA1 (GLRA1 NRSE) gene was impaired in three of four 'classic' SCLC cell lines, whereas exogenous overexpression of NRSF in NRSF-deficient SCLC cell lines reconstituted silencing of the reporter plasmid. The level of NRSF transcripts as well as the level of specifically bound NRSF to the NRSE correlated with the level of GLRA1 transcripts in SCLC cell lines. Splice variants encoding truncated NRSF proteins and expressed in some SCLC did not antagonize the repression of NRSE-containing genes. Most interestingly, reconstitution of NRSF expression induced apoptosis in SCLC cells, suggesting that inhibition of NRSF activity is a crucial step in the carcinogenesis of a subgroup of SCLC.	Heidelberg Univ, Inst Mol Pathol, D-69120 Heidelberg, Germany; Univ Erlangen Nurnberg, Emil Fischer Ctr, Inst Biochem, D-91054 Erlangen, Germany	Ruprecht Karls University Heidelberg; University of Erlangen Nuremberg	Doeberitz, MV (corresponding author), Heidelberg Univ, Inst Mol Pathol, Neuenheimer Feld 220, D-69120 Heidelberg, Germany.	knebel@med.uni-heidelberg.de		Dihlmann, Susanne/0000-0002-3737-7755; Gurrola-Diaz, Carmen Magdalena/0000-0002-9851-8961				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Betz H, 1999, ANN NY ACAD SCI, V868, P667, DOI 10.1111/j.1749-6632.1999.tb11343.x; Breitinger HG, 2002, CHEMBIOCHEM, V3, P1043, DOI 10.1002/1439-7633(20021104)3:11<1042::AID-CBIC1042>3.0.CO;2-7; CARNEY DN, 1985, CANCER RES, V45, P2913; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Coulson JM, 1999, CANCER RES, V59, P5123; Coulson JM, 2000, CANCER RES, V60, P1840; ENZ R, 1995, VISUAL NEUROSCI, V12, P501, DOI 10.1017/S0952523800008403; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Lawinger P, 2000, NAT MED, V6, P826, DOI 10.1038/77565; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Magin A, 2002, NEUROCHEM INT, V40, P195, DOI 10.1016/S0197-0186(01)00091-2; Monani U, 1996, GENOME RES, V6, P1200, DOI 10.1101/gr.6.12.1200; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Palm K, 1999, MOL BRAIN RES, V72, P30, DOI 10.1016/S0169-328X(99)00196-5; Palm K, 1998, J NEUROSCI, V18, P1280; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; PARKIN DM, 1994, ANTICANCER RES, V14, P277; Quinn JP, 2002, REGUL PEPTIDES, V108, P135, DOI 10.1016/S0167-0115(02)00103-9; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Scholl T, 1996, J IMMUNOL, V156, P1448; Shimojo M, 1999, MOL CELL BIOL, V19, P6788; Shimojo M, 2001, J BIOL CHEM, V276, P13121, DOI 10.1074/jbc.M011193200	25	41	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5636	5645		10.1038/sj.onc.1206790	http://dx.doi.org/10.1038/sj.onc.1206790			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944912				2022-12-17	WOS:000184865900013
J	Higuchi, E; Chandraratna, RAS; Hong, WK; Lotan, R				Higuchi, E; Chandraratna, RAS; Hong, WK; Lotan, R			Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype	ONCOGENE			English	Article						ALL-trans retinoic acid; tazarotene-induced gene 3; head and neck cancer; lung cancer	RECEPTOR-SELECTIVE RETINOIDS; INDUCIBLE GENE; RAS MUTATIONS; CANCER CELLS; EXPRESSION; DIFFERENTIATION; CLONING; GROWTH; ALPHA; BETA	Retinoids can regulate the proliferation and differentiation of various tumor cells. It is thought that nuclear retinoid receptors mediate these effects by regulating gene transcription. The identity of specific retinoid target genes is only beginning to be unraveled. One candidate for mediating retinoid-induced growth suppression is the novel class II tumor suppressor gene tazarotene-induced gene 3 (TIG3). We examined the constitutive and all-trans retinoic acid (ATRA)-inducible expression of TIG3 mRNA in five head and neck squamous cell carcinoma (HNSCC) and five nonsmall cell lung carcinoma (NSCLC) cell tines to determine whether it is associated with their responsiveness to ATRA. The expression patterns of retinoic acid receptor beta (RARbeta), another putative retinoid-inducible tumor suppressor gene, were also examined. The constitutive TIG3 expression was high in one HNSCC cell line and two NSCLC cell tines, and moderate to very low in the other cells. Some RARbeta-expressing cells had either low or undetectable TIG3 levels and vice versa. ATRA (1 mum; 48 h) increased TIG3 mRNA in 4/5 HNSCCs and 3/5 NSCLCs and RARbeta mRNA in some of the same cell lines, but also in cells that did not show TIG3 induction. TIG3 mRNA was induced by ATRA between 6 and 12 h in most of the responsive cells. ATRA concentrations required for TIG3 induction ranged from 1 to 500 nM depending on the cell line. The pan-RAR antagonists AGN193109 and the RARalpha antagonist Ro 41-5253 blocked TIG3 induction by ATRA. ATRA suppressed anchorage-independent colony formation in most cells that had a high or moderate constitutive or induced TIG3 expression level. In contrast, RARbeta mRNA expression pattern was not correlated with sensitivity to ATRA. These results suggest that TIG3 is regulated by ATRA via retinoid receptors in certain aerodigestive tract cancer cells, and its induction by ATRA is associated with the suppression of anchorage-independent growth.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Allergan Pharmaceut Inc, Irvine, CA 92623 USA	University of Texas System; UTMD Anderson Cancer Center; AbbVie; Allergan	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 432,1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA16672, P01 CA52051, U19 CA68437] Funding Source: Medline; NIDCR NIH HHS [P50 DE11906] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA068437, P30CA016672, P01CA052051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011906] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; AOUDJIT F, 1995, CELL GROWTH DIFFER, V6, P515; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Casanova B, 2001, LEUKEMIA, V15, P1521, DOI 10.1038/sj.leu.2402243; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Cheng YJ, 1998, J BIOL CHEM, V273, P35008, DOI 10.1074/jbc.273.52.35008; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Deucher A, 2000, INT J ONCOL, V17, P1195; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Dressler D, 2002, INT J ONCOL, V20, P897; Duvic M, 2000, CLIN CANCER RES, V6, P3249; Gudas Lorraine J., 1994, P443; HAJNAL A, 1994, ONCOGENE, V9, P479; Hong Waun Ki, 1994, P597; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Huang SL, 2002, ANTICANCER RES, V22, P799; Huang SL, 2000, MOL CELL ENDOCRINOL, V159, P15, DOI 10.1016/S0303-7207(99)00207-5; Husmann K, 1998, ONCOGENE, V17, P1305, DOI 10.1038/sj.onc.1202060; JOHNSON AT, 1995, J MED CHEM, V38, P4764, DOI 10.1021/jm00024a003; LaVistaPicard N, 1996, MOL CELL BIOL, V16, P4137; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEHMAN TA, 1991, CANCER RES, V51, P4090; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Mangelsdorf David J., 1994, P319; Mao M, 1996, P NATL ACAD SCI USA, V93, P5910, DOI 10.1073/pnas.93.12.5910; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Moon Richard C., 1994, P573; MORONI MC, 1993, MECH DEVELOP, V44, P139, DOI 10.1016/0925-4773(93)90063-4; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; Oridate N, 1996, ONCOGENE, V12, P2019; Oridate N, 1996, IN VITRO CELL DEV-AN, V32, P192; REISS M, 1992, ONCOL RES, V4, P349; Sun SY, 2000, CLIN CANCER RES, V6, P1563; Sun SY, 1997, CANCER RES, V57, P4931; Wakeman JA, 1998, ONCOGENE, V17, P179, DOI 10.1038/sj.onc.1201942; Wan HS, 2001, CANCER RES, V61, P556; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	40	41	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4627	4635		10.1038/sj.onc.1206235	http://dx.doi.org/10.1038/sj.onc.1206235			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879006				2022-12-17	WOS:000184157000002
J	Zhuang, SG; Ouedraogo, GD; Kochevar, IE				Zhuang, SG; Ouedraogo, GD; Kochevar, IE			Downregulation of epidermal growth factor receptor signaling by singlet oxygen through activation of caspase-3 and protein phosphatases	ONCOGENE			English	Article						apoptosis; epidermal growth factor receptor; caspase; keratinocyte; protein phosphatase; singlet oxygen	RABBIT SKELETAL-MUSCLE; REVERSIBLE INACTIVATION; ULTRAVIOLET-LIGHT; OXIDATIVE STRESS; EGF RECEPTOR; APOPTOSIS; CLEAVAGE; INHIBITION; INDUCTION; ACID	Downregulation of survival signaling pathways contributes to the cytotoxicity of reactive oxygen species (ROS) and may underlie certain therapies for hyperproliferative diseases. We have investigated the role of singlet oxygen, an ROS formed by photosensitization, in the regulation of survival signaling via the epidermal growth factor receptor (EGFR). Exposure of human keratinocytes to singlet oxygen resulted in rapid loss of EGFR, which was not blocked by either inhibition of receptor internalization or by interrupting the major proteolytic pathways (proteasome, lysosome or calpain). However, pretreatment with a caspase-3 inhibitor, DEVD-FMK, inhibited EGFR degradation. Caspase-3 cleavage was detected as early as 5 min after singlet oxygen treatment, and recombinant active caspase-3 completely cleaved EGFR in a keratinocyte membrane fraction. The singlet oxygen-induced loss of EGFR was accompanied by dephosphorylation of EGFR as well as of Akt and extracellular signal-regulated kinase 1/2 (ERK)1/2. Singlet oxygen-induced protein dephosphorylation was not dependent on activation of caspase-3. In contrast, inhibition of protein phosphatases (PPs) with okadaic acid completely blocked dephosphorylation of EGFR, ERK1/2 and Akt as well as degradation of EGFR. These results indicate that the oxidative stress produced by singlet oxygen rapidly disrupts EGFR-mediated signaling by decreasing both the protein level and its phosphorylation. These responses depended on intertwined activation of caspase-3 and PPs.	Harvard Univ, Sch Med, Wellman Labs Photomed, Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Kochevar, IE (corresponding author), Harvard Univ, Sch Med, Wellman Labs Photomed, Massachusetts Gen Hosp, WEL-224,55 Fruit St, Boston, MA 02114 USA.	kochevar@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030755] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30755] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad N, 2001, ONCOGENE, V20, P2314, DOI 10.1038/sj.onc.1204313; An B, 1996, FEBS LETT, V399, P158, DOI 10.1016/S0014-5793(96)01311-7; Authier F, 1999, J BIOL CHEM, V274, P33723, DOI 10.1074/jbc.274.47.33723; Bae SS, 2001, FEBS LETT, V491, P16, DOI 10.1016/S0014-5793(01)02167-6; BAKER A, 1992, PHOTOCHEM PHOTOBIOL, V55, P523, DOI 10.1111/j.1751-1097.1992.tb04273.x; BARSAGI D, 1988, J CELL BIOL, V106, P1649, DOI 10.1083/jcb.106.5.1649; Boulougouris P, 2001, ANTICANCER RES, V21, P2769; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CAYLA X, 1994, J BIOL CHEM, V269, P15668; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Fladmark KE, 1999, CELL DEATH DIFFER, V6, P1099, DOI 10.1038/sj.cdd.4400590; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GREGORIOU M, 1994, EUR J BIOCHEM, V223, P455, DOI 10.1111/j.1432-1033.1994.tb19013.x; Grether-Beck S, 2000, EMBO J, V19, P5793, DOI 10.1093/emboj/19.21.5793; Hunter I, 2001, J BONE MINER RES, V16, P466, DOI 10.1359/jbmr.2001.16.3.466; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kamata H, 2000, EUR J BIOCHEM, V267, P1933, DOI 10.1046/j.1432-1327.2000.01194.x; KATOH S, 1994, BIOL PHARM BULL, V17, P1003; Kessel D, 2001, PHOTOCHEM PHOTOBIOL, V74, P318, DOI 10.1562/0031-8655(2001)074<0318:ETBITT>2.0.CO;2; Kidd VJ, 2000, SEMIN CELL DEV BIOL, V11, P191, DOI 10.1006/scdb.2000.0165; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; KRUEGER JG, 1990, J INVEST DERMATOL, V94, pS135, DOI 10.1111/1523-1747.ep12876121; LASKIN JD, 1986, P NATL ACAD SCI USA, V83, P8211, DOI 10.1073/pnas.83.21.8211; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; Lin CP, 2000, EXP CELL RES, V259, P351, DOI 10.1006/excr.2000.4979; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; Maziere C, 2001, BIOCHEM BIOPH RES CO, V281, P289, DOI 10.1006/bbrc.2001.4348; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Morita A, 1997, J EXP MED, V186, P1763, DOI 10.1084/jem.186.10.1763; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; Posmantur R, 1997, J NEUROCHEM, V68, P2328; Ravid T, 2002, J BIOL CHEM, V277, P31214, DOI 10.1074/jbc.M204677200; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Scheving LA, 1998, AM J PHYSIOL-CELL PH, V274, pC1363, DOI 10.1152/ajpcell.1998.274.5.C1363; Schutze S, 1999, J BIOL CHEM, V274, P10203, DOI 10.1074/jbc.274.15.10203; Separovic D, 1998, PHOTOCHEM PHOTOBIOL, V68, P101, DOI 10.1111/j.1751-1097.1998.tb03259.x; SILBERMAN SR, 1984, J BIOL CHEM, V259, P2913; SONG QZ, 1993, BIOCHEM BIOPH RES CO, V190, P47, DOI 10.1006/bbrc.1993.1009; Spizz G, 1997, J BIOL CHEM, V272, P23833, DOI 10.1074/jbc.272.38.23833; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; van der Vliet A, 1998, J BIOL CHEM, V273, P31860, DOI 10.1074/jbc.273.48.31860; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1046/j.1365-2613.2000.00169.x; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Yarden Y, 2001, EUR J CANCER, V37, pS3; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200; Zhuang SG, 1999, EXP CELL RES, V250, P203, DOI 10.1006/excr.1999.4501	60	41	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4413	4424		10.1038/sj.onc.1206604	http://dx.doi.org/10.1038/sj.onc.1206604			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853978				2022-12-17	WOS:000183978900011
J	Penengo, L; Rubin, C; Yarden, Y; Gaudino, G				Penengo, L; Rubin, C; Yarden, Y; Gaudino, G			c-Cbl is a critical modulator of the Ron tyrosine kinase receptor	ONCOGENE			English	Article						c-Cbl; Grb2; Ron; ubiquitylation	MACROPHAGE-STIMULATING PROTEIN; GROWTH-FACTOR RECEPTOR; DOWN-REGULATION; BINDING DOMAIN; RING FINGER; ACTIVATION; PHOSPHORYLATION; MET; PROTOONCOGENE; REGULATOR	Ron, the receptor tyrosine kinase (RTK) for the macrophage stimulating protein (MSP), activates multiple signaling pathways by recruiting several positive regulators to a multifunctional docking site. Here we show that stimulation by MSP also recruits a negative regulator, the c-Cbl ubiquitin ligase, to the multifunctional docking site as well as to a juxtamembrane tyrosine autophosphorylation site. c-Cbl recruitment to these two sites results in polyubiquitylation of Ron molecules, which are subsequently sorted for endocytosis and degradation. Both the phosphotyrosine binding domain of c-Cbl and its RING domain are essential for downregulation of Ron. Although Ron and c-Cbl are found also in physical complexes that include Grb2, these associations are insufficient for productive ubiquitylation of Ron. Our results shed light on the mechanism of receptor desensitization mediated by c-Cbl and its binding partner Grb2.	Univ Piemonte Orientale, Dept Med Sci, I-28100 Novara, Italy; Weizmann Inst Sci, Dept Biol Sci, IL-76100 Rehovot, Israel	University of Eastern Piedmont Amedeo Avogadro; Weizmann Institute of Science	Gaudino, G (corresponding author), Univ Piemonte Orientale, Dept Med Sci, I-28100 Novara, Italy.		YARDEN, YOSEF/K-1467-2012	PENENGO, Lorenza/0000-0001-7888-4473				Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Chen YQ, 1998, J IMMUNOL, V161, P4950; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Correll Pamela H., 1997, Genes and Function, V1, P69; Danilkovitch A, 1999, EXP CELL RES, V248, P575, DOI 10.1006/excr.1999.4429; Danilkovitch-Miagkova A, 2001, APOPTOSIS, V6, P183, DOI 10.1023/A:1011384609811; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fournier TM, 2000, MOL BIOL CELL, V11, P3397, DOI 10.1091/mbc.11.10.3397; Garcia-Guzman M, 2000, ONCOGENE, V19, P4058, DOI 10.1038/sj.onc.1203750; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Morrison AC, 2002, J IMMUNOL, V168, P853, DOI 10.4049/jimmunol.168.2.853; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	36	41	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3669	3679		10.1038/sj.onc.1206585	http://dx.doi.org/10.1038/sj.onc.1206585			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802274				2022-12-17	WOS:000183551000001
J	del Rincon, SV; Rousseau, C; Samanta, R; Miller, WH				del Rincon, SV; Rousseau, C; Samanta, R; Miller, WH			Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI 3-kinase/AKT pathway	ONCOGENE			English	Article						retinoic acid; IRS-1; IGF; AKT; breast cancer	BREAST-CANCER CELLS; INSULIN-RECEPTOR SUBSTRATE-1; FACTOR-I RECEPTOR; FACTOR-BINDING PROTEIN-3; IGF-I; PHOSPHATIDYLINOSITOL 3-KINASE; THERAPEUTIC IMPLICATIONS; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; CYCLIN D1	In the MCF-7 breast cancer cell line, insulin-like growth factors (IGFs) are known to elicit antiproliferative actions via the insulin receptor substrate-1 (IRS-1)/PI 3-kinase/AKT pathway. All-trans retinoic acid (RA) is a potent inhibitor of MCF-7 cell proliferation, but the mechanism by which growth regulation is achieved remains unclear. We investigated the effects of RA on the regulation of the IGF-IR and its key signaling elements: IRS-1, IRS-2, and SHC. Treatment of MCF-7 cells with RA caused a significant reduction in IRS-1 protein and tyrosine phosphorylation levels at a concentration and time consistent with RA-mediated growth inhibition. IRS-1 regulation is selective, as RA did not influence IRS-2 or SHC levels. Downstream signaling events were also selectively reduced, as RA abrogated IGF-I-stimulated AKT activation but did not alter erk1/2 activation. To confirm the importance of IRS-1 regulation by RA, we examined the response to RA in MCF-7 cells overexpressing IGF-IR and IRS-1. RA resistance was observed in MCF-7 cells overexpressing IRS-I but not IGF-IR. This suggests that RA-mediated growth inhibition requires the selective downregulation of IRS-1 and AKT. Therapeutic agents targeting the IRS-1/PI 3-kinase/AKT pathway may enhance the cytostatic effects of RA in breast cancer, since overexpression of IRS-1 and AKT have been reported in primary breast tumors.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Miller, WH (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.							Agadir A, 1999, J BIOL CHEM, V274, P29779, DOI 10.1074/jbc.274.42.29779; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Allen LF, 2002, SEMIN ONCOL, V29, P11, DOI 10.1053/sonc.2002.34049; Ando S, 1998, BIOCHEM BIOPH RES CO, V253, P315, DOI 10.1006/bbrc.1998.9330; ANZANO MA, 1994, CANCER RES, V54, P4614; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Blakesley VA, 1996, ENDOCRINOLOGY, V137, P410, DOI 10.1210/en.137.2.410; Chang Q, 2002, CANCER RES, V62, P6035; CULLEN KJ, 1990, CANCER RES, V50, P48; DE LUCA LM, 1991, FASEB J, V5, P2924; DeVente JE, 1996, J BIOL CHEM, V271, P32276, DOI 10.1074/jbc.271.50.32276; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; Dragnev K H, 2000, Oncologist, V5, P361, DOI 10.1634/theoncologist.5-5-361; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; FONTANA JA, 1991, ENDOCRINOLOGY, V128, P1115, DOI 10.1210/endo-128-2-1115; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; Guruswamy S, 2001, JNCI-J NATL CANCER I, V93, P516, DOI 10.1093/jnci/93.7.516; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; Ishibashi K, 2001, J CLIN INVEST, V107, P1193, DOI 10.1172/JCI11753; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; JONES PF, 1991, NATURE, V376, P599; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Li Qun, 2002, Current Topics in Medicinal Chemistry, V2, P939, DOI 10.2174/1568026023393318; LI XS, 1994, EXP CELL RES, V211, P68, DOI 10.1006/excr.1994.1060; Li YW, 2002, CLIN CANCER RES, V8, P2369; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Moon RC, 1997, BREAST CANCER RES TR, V46, P181, DOI 10.1023/A:1005995925246; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Nolan MK, 1997, INT J CANCER, V72, P828, DOI 10.1002/(SICI)1097-0215(19970904)72:5<828::AID-IJC20>3.0.CO;2-3; O'Connor R, 2000, BIOCHEM SOC T, V28, P47, DOI 10.1042/bst0280047; Pollak M, 2000, EUR J CANCER, V36, P1224, DOI 10.1016/S0959-8049(00)00102-7; Rocha RL, 1997, CLIN CANCER RES, V3, P103; Rosenauer A, 1998, CANCER RES, V58, P5110; Rozen F, 1999, INT J ONCOL, V15, P589; RUBIN M, 1994, CANCER RES, V54, P6549; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Salerno M, 1999, INT J CANCER, V81, P299; Shang YF, 1999, J BIOL CHEM, V274, P18005, DOI 10.1074/jbc.274.25.18005; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; SPORN MB, 1994, RETINOIDS BIOL CHEM, P573; Straker SM, 2001, REV ENGL STUD, V52, P1; Sueoka N, 1999, CANCER RES, V59, P3838; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Tanaka T, 2001, BIOCHEM PHARMACOL, V61, P1347, DOI 10.1016/S0006-2952(01)00600-1; Taouis M, 1998, MOL CELL ENDOCRINOL, V137, P177, DOI 10.1016/S0303-7207(97)00245-1; Tari AM, 2002, ONCOGENE, V21, P5224, DOI 10.1038/sj.onc.1205660; Torrisi R, 2001, DRUGS, V61, P909, DOI 10.2165/00003495-200161070-00002; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; Wang Q, 2000, CANCER RES, V60, P2040; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1997, DIABETOLOGIA, V40, P2; Xie SP, 1997, J ENDOCRINOL, V154, P495, DOI 10.1677/joe.0.1540495; Xie SP, 1999, EUR J CANCER, V35, P1717, DOI 10.1016/S0959-8049(99)00200-2; Yakes FM, 2002, CANCER RES, V62, P4132; Yoshida H, 1996, CANCER RES, V56, P2945; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhang H, 2000, J BIOL CHEM, V275, P22558, DOI 10.1074/jbc.M000412200; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	74	41	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3353	3360		10.1038/sj.onc.1206485	http://dx.doi.org/10.1038/sj.onc.1206485			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776186	Green Submitted			2022-12-17	WOS:000183128500001
J	Wang, QF; Cleaves, R; Kummalue, T; Nerlov, C; Friedman, AD				Wang, QF; Cleaves, R; Kummalue, T; Nerlov, C; Friedman, AD			Cell cycle inhibition mediated by the outer surface of the C/EBP alpha basic region is required but not sufficient for granulopoiesis	ONCOGENE			English	Article						C/EBP alpha; E2F; granulopoiesis; cell cycle; differentiation	ENHANCER-BINDING-PROTEIN; SERUM-ALBUMIN GENE; C-MYB; GRANULOCYTE DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; MYELOID-LEUKEMIA; NUCLEAR-PROTEIN; GROWTH ARREST; PROLIFERATION; EXPRESSION	CCAAT/enhancer binding protein alpha (C/EBPalpha) transactivates target genes dependent upon DNA binding via its basic region-leucine zipper domain and slows G1 progression by interaction with E2F, cdk2, or cdk4. E2F interacts with the non-DNA-binding surface of the C/EBPalpha basic region and C/EBPa residues 1-70 are required for repressing E2F targets, while cdk2 and cdk4 bind residues 177-191. C/EBPalpha-ER induces the 32D c13 myeloblast cell line to differentiate to granulocytes. C/EBPalpha-ER variants incapable of binding DNA slowed G1, but did not induce early or late granulopoiesis, indicating that cell cycle inhibition as mediated by C/EBPalpha is not sufficient for differentiation. C/EBPalpha-ER variants lacking residues 1170 or residues 11-70 and 178-200 both slowed the G1 to S transition. C/EBPalpha(GZ)-ER, containing the GCN4 rather than the C/EBPalpha leucine zipper, also slowed G1. In contrast, C/EBPalpha(BRM2)-ER, carrying mutations in the outer surface of the basic region required for interaction with E2F, did not slow G1. C/EBPalpha:(BRM2)-ER induced early markers of granulopoiesis much less efficiently than C/EBPalpha-ER and did not direct terminal maturation. Inhibition of G1 progression using mimosine increased induction of late markers by G-CSF. Thus, both DNA binding and cell cycle arrest, mediated by opposite surfaces of the C/EBPalpha basic region, are required for granulopoiesis.	Johns Hopkins Univ, Div Pediat Oncol, Baltimore, MD 21231 USA; European Mol Biol Lab, I-00016 Monterotondo, Italy	Johns Hopkins University; European Molecular Biology Laboratory (EMBL)	Friedman, AD (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Canc Res Bldg,Room 253,1650 Orleans St, Baltimore, MD 21231 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062274] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL62274, HL62274] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P105; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Friedman AD, 2002, J CELL BIOCHEM, V86, P624, DOI 10.1002/jcb.10271; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; Muller C, 1999, P NATL ACAD SCI USA, V96, P7276, DOI 10.1073/pnas.96.13.7276; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; SCOTT LM, 1992, BLOOD, V80, P1725; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Wang G, 2000, EXP CELL RES, V254, P64, DOI 10.1006/excr.1999.4743; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	43	41	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2548	2557		10.1038/sj.onc.1206360	http://dx.doi.org/10.1038/sj.onc.1206360			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730669				2022-12-17	WOS:000182569000002
J	Stoica, GE; Franke, TF; Wellstein, A; Morgan, E; Czubayko, F; List, HJ; Reiter, R; Martin, MB; Stoica, A				Stoica, GE; Franke, TF; Wellstein, A; Morgan, E; Czubayko, F; List, HJ; Reiter, R; Martin, MB; Stoica, A			RETRACTED: Heregulin-beta 1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway (Retracted Article. See vol 24, pg 1964, 2005)	ONCOGENE			English	Review; Retracted Publication						estrogen receptor; HRG-beta 1; ErbB2; Akt	BREAST-CANCER CELLS; EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE-B; SIGNAL-TRANSDUCTION PATHWAYS; MESSENGER-RIBONUCLEIC-ACID; STEROID-HORMONE RECEPTORS; MAMMARY-TUMOR CELLS; ATHYMIC NUDE-MICE; PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-SITES	This study examines whether the serine/threonine protein kinase, Akt, is involved in the crosstalk between the ErbB2 and estrogen receptor-alpha (ER-alpha) pathways. Treatment of MCF-7 cells with 10(-9) M heregulin-beta1 (HRG-beta) resulted in a rapid phosphorylation of Akt and a 15-fold increase in Akt activity. Akt phosphorylation was blocked by inhibitors of phosphatidylinositol 3-kinase (PI 3-K), by antiestrogens, the protein tyrosine kinase inhibitor, genistein, and by AG825, a selective ErbB2 inhibitor; but not by AG30, a selective EGFR inhibitor. Akt phosphorylation by HRG-beta1 was abrogated by an arginine to cysteine mutation (R25C) in the pleckstrin homology (PH) domain of Akt, and HRG-beta1 did not induce Akt phosphorylation in the ER-negative variant of MCF-7, MCF-7/ADR. Transient transfection of ER-alpha into these cells restored Akt phosphorylation by HRG-beta1, suggesting the requirement of ER-alpha. HRG-beta1 did not activate Akt in MCF-7 cells stably transfected with an anti-ErbB2-targeted ribozyme, further confirming a role for ErbB2. Stable transfection of the cells with a dominant negative Akt or with the R25C-Akt mutant, as well as PI 3-K inhibitors, blocked the effect of HRG-beta1 on ER-alpha expression and activity and on the growth of MCF-7 cells. Stable transfection of MCF-7 cells with a constitutively active Akt mimicked the effect of HRG-beta1. Experiments employing selective ErbB inhibitors demonstrate that the effect of HRG-beta1 on ER-alpha expression and activity is also mediated by ErbB2 and not by EGFR, demonstrating that ErbB2 is the primary mediator of the effects of HRG-beta1 on ER-a regulation. Taken together, our data suggest that HRG-beta1, bound to the ErbB2 ErbB3 heterodimer, in the presence of membrane ER-alpha, interacts with and activates PI 3-K/Akt. Akt leads to nuclear ER-alpha phosphorylation, thereby altering its expression and transcriptional activity.	Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA; Georgetown Univ, Sch Nursing & Hlth Studies, Washington, DC 20007 USA; Univ Marburg, Sch Med, Dept Pharmacol & Toxicol, D-35033 Marburg, Germany	Georgetown University; Columbia University; Georgetown University; Philipps University Marburg	Stoica, A (corresponding author), E411 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	stoicaa@georgetown.edu		Wellstein, Anton/0000-0002-0570-4950	NCI NIH HHS [P50-CA-58185, P30-CA-51008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185, P30CA051008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Angus WGR, 2000, MOL CELL ENDOCRINOL, V170, P1, DOI 10.1016/S0303-7207(00)00337-3; ANTONIOTTI S, 1992, EUR J CANCER, V28A, P318, DOI 10.1016/S0959-8049(05)80045-0; Bates NP, 1997, ONCOGENE, V15, P473, DOI 10.1038/sj.onc.1201368; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BERNS EMJJ, 1992, J STEROID BIOCHEM, V43, P13, DOI 10.1016/0960-0760(92)90182-I; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BERTHOIS Y, 1986, J STEROID BIOCHEM, V25, P963, DOI 10.1016/0022-4731(86)90330-4; Brockhoff G, 2001, CYTOMETRY, V44, P338, DOI 10.1002/1097-0320(20010801)44:4<338::AID-CYTO1125>3.0.CO;2-V; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chen XM, 2000, BIOCHEM BIOPH RES CO, V277, P757, DOI 10.1006/bbrc.2000.3731; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Chung YL, 2002, INT J CANCER, V97, P306, DOI 10.1002/ijc.1614; Daly RJ, 1999, GROWTH FACTORS, V16, P255, DOI 10.3109/08977199909069144; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DEPOTTER CR, 1990, INT J CANCER, V45, P55, DOI 10.1002/ijc.2910450112; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; ElTanani MKK, 1997, J STEROID BIOCHEM, V60, P269, DOI 10.1016/S0960-0760(96)00226-9; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; GULLICK W J, 1990, Progress in Growth Factor Research, V2, P1, DOI 10.1016/0955-2235(90)90006-6; GULLICK WJ, 1991, HUM EXP TOXICOL, V10, P398, DOI 10.1177/096032719101000604; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; HODA K, 2000, J NEUROSCI RES, V60, P321; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; Juhl H, 1997, J BIOL CHEM, V272, P29482, DOI 10.1074/jbc.272.47.29482; Kato  S, 2001, Breast Cancer, V8, P3, DOI 10.1007/BF02967472; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; KIM HH, 1994, J BIOL CHEM, V269, P24747; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kurokawa H, 2000, CANCER RES, V60, P5887; Lichtner RB, 1999, J STEROID BIOCHEM, V71, P181, DOI 10.1016/S0960-0760(99)00136-3; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; LUPU R, 1992, BIOCHEMISTRY-US, V31, P7330, DOI 10.1021/bi00147a018; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729; Martin MB, 2000, ENDOCRINOLOGY, V141, P4503, DOI 10.1210/en.141.12.4503; MATSUDA S, 1993, P NATL ACAD SCI USA, V90, P10803, DOI 10.1073/pnas.90.22.10803; MCLESKEY SW, 1993, CANCER RES, V53, P2168; Menard S, 2000, J NATL CANCER I, V92, P943; Mermelstein PG, 1996, J NEUROSCI, V16, P595; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; MIMNAUGH EG, 1991, BIOCHEM PHARMACOL, V42, P391, DOI 10.1016/0006-2952(91)90727-M; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; NICHOLSON RI, 1993, EUR J CANCER, V29A, P1018, DOI 10.1016/S0959-8049(05)80215-1; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIERCE JH, 1991, ONCOGENE, V6, P1189; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Puricelli L, 2002, INT J CANCER, V100, P642, DOI 10.1002/ijc.10533; QUENEL N, 1995, BREAST CANCER RES TR, V35, P283, DOI 10.1007/BF00665980; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295; READ LD, 1990, CANCER RES, V50, P3947; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; RUSSELL KS, 1992, CANCER RES, V52, P6624; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157; Saceda M, 1996, ENDOCRINOLOGY, V137, P4322, DOI 10.1210/en.137.10.4322; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Stevis PE, 1999, ENDOCRINOLOGY, V140, P5455, DOI 10.1210/en.140.11.5455; Stoica A, 2000, J CELL BIOCHEM, V76, P605, DOI 10.1002/(SICI)1097-4644(20000315)76:4<605::AID-JCB9>3.0.CO;2-T; Stoica A, 2000, J ENDOCRINOL, V165, P371, DOI 10.1677/joe.0.1650371; Stoica A, 1997, ENDOCRINOLOGY, V138, P1498, DOI 10.1210/en.138.4.1498; STOICA GE, 2003, UNPUB ONCOGENE; STOICA GE, 2003, IN PRESS MOL ENDOCRI; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; Tan M, 1999, CANCER RES, V59, P1620; Tang CK, 1996, CANCER RES, V56, P3350; TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471; TAVERNA D, 1994, INT J CANCER, V56, P522, DOI 10.1002/ijc.2910560411; Tsutsui S, 2002, J SURG ONCOL, V79, P216, DOI 10.1002/jso.10079; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Wosikowski K, 1997, CLIN CANCER RES, V3, P2405; WRIGHT C, 1992, BRIT J CANCER, V65, P271, DOI 10.1038/bjc.1992.54; Yamamoto T, 1986, Princess Takamatsu Symp, V17, P203; Yoo JY, 1998, BREAST CANCER RES TR, V51, P71, DOI 10.1023/A:1006035603635; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	118	41	41	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2073	2087		10.1038/sj.onc.1206311	http://dx.doi.org/10.1038/sj.onc.1206311			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687010				2022-12-17	WOS:000182066900002
J	Pourtier-Manzanedo, A; Vercamer, C; Van Belle, E; Mattot, V; Mouquet, F; Vandenbunder, B				Pourtier-Manzanedo, A; Vercamer, C; Van Belle, E; Mattot, V; Mouquet, F; Vandenbunder, B			Expression of an Ets-1 dominant-negative mutant perturbs normal and tumor angiogenesis in a mouse ear model	ONCOGENE			English	Article						in vivo model; growth factors; tumor; angiogenesis; inhibition; Ets-1	TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; PLASMINOGEN-ACTIVATOR; MAST-CELLS; GROWTH; GENE; PROMOTER; FAMILY; INHIBITOR; TNP-470	We and others have shown that members of the Ets family of transcription factors are involved in morphogenic properties of endothelial cells in vitro. To investigate the role of these factors in the transcriptional regulation of angiogenesis in vivo, we set up a nontramnatic model that allows daily macroscopic examination of both growth factor- and tumor-induced angiogenesis in mouse ears. In the same animal, we were thus able to record variations in the patterns of neovessels induced and cell populations recruited by the angiogenic factors FGF-2 and VEGF. In this model, inhibition of FGF-2-induced angiogenesis by the pharmacological compound TNP-470 was readily observed, demonstrating that the mouse ear model is also useful in the evaluation of antiangiogenic strategies. Our functional analysis of Ets transcription factors activity utilized a competitor protein, Ets1-DB, a dominant negative Ets1 mutant lacking the transactivation domain. Retrovirus-mediated expression of Ets1-DB inhibited FGF-2-induced angiogenesis, while the expression of Ets1-DB in cancerous and stromal cells disturbed tumor-induced angiogenesis. These results illustrate the value of the ear model and highlight the role of Ets family members in the transcriptional regulation of tumor angiogenesis.	Univ Lille 2, CNRS, Inst Biol Lille,FRE 2353, Inst Pasteur, F-59021 Lille, France; Univ Lille 2, CNRS, Inst Biol Lille,UMR 8526, Inst Pasteur, F-59021 Lille, France; Univ Lille 2, Hop Cardiol, Serv Cardiol & Hemodynam B, F-59037 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille	Vandenbunder, B (corresponding author), Univ Lille 2, CNRS, Inst Biol Lille,IPL, FRE 2527, 1 Rue Calmette,BP 447, F-59021 Lille, France.	bernard.vandenbunder@ibl.fr	POURTIER, ALBIN/G-7401-2012; Mouquet, Frederic/P-6899-2019	POURTIER, ALBIN/0000-0002-1576-3946; VAN BELLE, ERIC/0000-0001-6509-443X				Anderson MK, 1999, DEVELOPMENT, V126, P3131; Artuc M, 1999, EXP DERMATOL, V8, P1, DOI 10.1111/j.1600-0625.1999.tb00342.x; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; Behrens P, 2001, INT J MOL MED, V8, P149; Bolon I, 1996, LAB INVEST, V75, P1; BOLON I, 1995, AM J PATHOL, V147, P1298; Bond SJ, 2000, J SURG RES, V92, P18, DOI 10.1006/jsre.2000.5854; COURDENT AD, 1996, INT J DEV BIOL, V40, P1097; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Dellian M, 1996, AM J PATHOL, V149, P59; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; Edel MJ, 1998, ANTICANCER RES, V18, P4505; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Ito M, 1998, BIOCHEM BIOPH RES CO, V246, P123, DOI 10.1006/bbrc.1998.8585; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; Konerding MA, 1998, AM J PATHOL, V152, P1607; Kria L, 1998, CURR EYE RES, V17, P986, DOI 10.1076/ceyr.17.10.986.5245; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Lichtenberg J, 1997, PHARMACOL TOXICOL, V81, P280; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Macias D, 1998, ANAT EMBRYOL, V198, P307, DOI 10.1007/s004290050186; Mager AM, 1998, INT J DEV BIOL, V42, P561; Maier JAM, 1997, ANTI-CANCER DRUG, V8, P238, DOI 10.1097/00001813-199703000-00004; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; MCLACHLIN JR, 1993, VIROLOGY, V195, P1, DOI 10.1006/viro.1993.1340; Nakano T, 2000, J CELL PHYSIOL, V184, P255, DOI 10.1002/1097-4652(200008)184:2<255::AID-JCP14>3.0.CO;2-J; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Rinsch C, 2001, GENE THER, V8, P523, DOI 10.1038/sj.gt.3301436; Sapi E, 1998, CANCER RES, V58, P1027; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Tanaka K, 1998, J CELL PHYSIOL, V176, P235, DOI 10.1002/(SICI)1097-4652(199808)176:2<235::AID-JCP2>3.0.CO;2-P; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4	43	41	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1795	1806		10.1038/sj.onc.1206215	http://dx.doi.org/10.1038/sj.onc.1206215			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660815				2022-12-17	WOS:000181678200006
J	Seker, H; Rubbi, C; Linke, SP; Bowman, ED; Garfield, S; Hansen, L; Borden, KLB; Milner, J; Harris, CC				Seker, H; Rubbi, C; Linke, SP; Bowman, ED; Garfield, S; Hansen, L; Borden, KLB; Milner, J; Harris, CC			UV-C-induced DNA damage leads to p53-dependent nuclear trafficking of PML	ONCOGENE			English	Article						P53; PML; DNA repair; BLM	NUCLEOTIDE EXCISION-REPAIR; ACUTE PROMYELOCYTIC LEUKEMIA; BLOOM-SYNDROME; PREMATURE SENESCENCE; TUMOR SUPPRESSION; SYNDROME PROTEIN; MESSENGER-RNA; ONCOGENIC RAS; CELL-CYCLE; P53	The promyelocytic leukemia protein (PML) is a nuclear phosphoprotein that localizes to distinct domains in the nucleus, described as PML nuclear bodies (PML-NBs). Recent findings indicate that PML regulates the p53 response to oncogenic signals. Here, we define a p53-dependent role for PML in response to DNA damage. We exposed cells to ultraviolet light (UV-C) and imaged the nuclear distribution of PML, p53, and the BLM helicase by confocal microscopy. After DNA damage, PML partially relocated out of the PML-NBs, and colocalized with BLM and p53 at sites of DNA repair. In addition, using the isogenic HCT116 cell tines (p53+/+ and -/-), we show that the redistribution of PML was dependent on functional p53. Western analysis revealed that the level of PML protein remained unaltered after UV-C treatment. These results are consistent with the hypothesis that PML, in conjunction with p53 and BLM, contributes to the cellular response to UV-C-induced DNA damage and its repair.	NCI, Human Carcinogenesis Lab, CCR, NIH, Bethesda, MD 20892 USA; Univ York, Dept Biol, YCR Lab P53, York YO1 5DD, N Yorkshire, England; NCI, Expt Carcinogenesis Lab, CCR, NIH, Bethesda, MD 20892 USA; Creighton Univ, Sch Med, Dept Biomed Sci, Omaha, NE 68178 USA; Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of York - UK; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Creighton University; Icahn School of Medicine at Mount Sinai	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, CCR, NIH, 37 Convent Dr,Bldg 37,Room 2C05, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov		Linke, Steven/0000-0001-8584-4947	NATIONAL CANCER INSTITUTE [Z01BC005795, ZIABC005795] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamson AL, 2001, J VIROL, V75, P2388, DOI 10.1128/JVI.75.5.2388-2399.2001; Ahn JH, 2000, VIROLOGY, V274, P39, DOI 10.1006/viro.2000.0448; Auerbach Arleen D., 1997, Current Opinion in Pediatrics, V9, P600, DOI 10.1097/00008480-199712000-00010; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan JYH, 1997, BIOCHEM BIOPH RES CO, V240, P640, DOI 10.1006/bbrc.1997.7692; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; CONCHELLO JA, 1994, APPL OPTICS, V33, P3740, DOI 10.1364/AO.33.003740; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Ellis NA, 2001, HUM GENET, V108, P167, DOI 10.1007/s004390000447; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hu P, 2001, HUM MOL GENET, V10, P1287, DOI 10.1093/hmg/10.12.1287; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Robles AI, 1999, ONCOGENE, V18, P4681, DOI 10.1038/sj.onc.1202862; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Rubbi CP, 2001, CARCINOGENESIS, V22, P1789, DOI 10.1093/carcin/22.11.1789; Ruggero D, 2000, BIOESSAYS, V22, P827, DOI 10.1002/1521-1878(200009)22:9<827::AID-BIES8>3.3.CO;2-T; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sanz MM, 2000, CYTOGENET CELL GENET, V91, P217, DOI 10.1159/000056848; Stadler M, 1995, ONCOGENE, V11, P2565; STUURMAN N, 1992, J CELL SCI, V101, P773; Tchang F, 1999, EXP CELL RES, V251, P46, DOI 10.1006/excr.1999.4570; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Yankiwski V, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-11; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	53	41	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2003	22	11					1620	1628		10.1038/sj.onc.1206140	http://dx.doi.org/10.1038/sj.onc.1206140			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642865				2022-12-17	WOS:000181580500004
J	Lee, SH; Kim, JW; Lee, HW; Cho, YS; Oh, SH; Kim, YJ; Jung, CH; Zhang, W; Lee, JH				Lee, SH; Kim, JW; Lee, HW; Cho, YS; Oh, SH; Kim, YJ; Jung, CH; Zhang, W; Lee, JH			Interferon regulatory factor-1 (IRF-1) is a mediator for interferon-gamma induced attenuation of telomerase activity and human telomerase reverse transcriptase (hTERT) expression	ONCOGENE			English	Article						telomerase; hTERT; interferon-gamma (INF-gamma); IRF-1	HUMAN-PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR GENE; CELL-CYCLE ARREST; MESSENGER-RNA; DAUDI CELLS; APOPTOSIS; CANCER; DEGRADATION; PROTEIN; P53	Constitutive activation of the telomerase is a key step in the development of human cancers. Interferon-gamma (IFN-gamma) signaling induces growth arrest in many tumors through multiple regulatory mechanisms. In this study, we show that IFN-gamma signaling represses telomerase activity and human telomerase reverse transcriptase (hTERT) transcription, and suggest that this signaling is mediated by IRF-1. Ectopic expression of IRF-1 attenuated hTERT promoter activity. Murine embryonic fibroblasts (MEFs) genetically deficient in IRF-1 (IRF-1(-/-)) showed an elevated level (> 15 times) of hTERT promoter activity as compared to the hTERT promoter activity of wild-type MEFs. The telomerase activity and hTERT expression in IRF-1(-/-) MEFs were downregulated by IRF-1 transfection. Interestingly, less extent of telomerase repression was observed in HPV E6 and E7 negative, p53 mutant HT-3 cells than in HPV 18 E6 and E7 positive HeLa cells (intact p53). These findings provide evidence that IRF-1 is a potential mediator of IFN-gamma-induced attenuation of telomerase activity and hTERT expression.	Sungkyunkwan Univ, Coll Med,Mol Therapy Res Ctr, Samsung Med Ctr Annex 8F, Kangnam Gu, Seoul 130710, South Korea; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Sungkyunkwan Univ, Coll Med, Dept Mol Biol, Jangan Gu, Suwon 440746, South Korea; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Sungkyunkwan University (SKKU); University of Pennsylvania; Sungkyunkwan University (SKKU); University of Texas System; UTMD Anderson Cancer Center	Lee, JH (corresponding author), Sungkyunkwan Univ, Coll Med,Mol Therapy Res Ctr, Samsung Med Ctr Annex 8F, Kangnam Gu, 50 ILwon Dong, Seoul 135710, South Korea.	jeholee@samsung.co.kr		Kim, Jung-whan/0000-0002-7829-1480				Akiyama M, 1999, CANCER LETT, V142, P23, DOI 10.1016/S0304-3835(99)00109-3; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; Baege AC, 2002, AM J PATHOL, V160, P1251, DOI 10.1016/S0002-9440(10)62552-7; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Boyer SN, 1996, CANCER RES, V56, P4620; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chapman RS, 2000, ONCOGENE, V19, P6386, DOI 10.1038/sj.onc.1204016; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Crowe DL, 2001, BBA-GENE STRUCT EXPR, V1518, P1, DOI 10.1016/S0167-4781(00)00296-7; De Maeyer E, 1998, Int Rev Immunol, V17, P53, DOI 10.3109/08830189809084487; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DRON M, 1986, MOL CELL BIOL, V6, P1374, DOI 10.1128/MCB.6.5.1374; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Holt SE, 1999, J CELL PHYSIOL, V180, P10, DOI 10.1002/(SICI)1097-4652(199907)180:1<10::AID-JCP2>3.0.CO;2-D; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; Kim J, 1999, CANCER GENE THER, V6, P172, DOI 10.1038/sj.cgt.7700006; Kim KY, 2000, J GEN VIROL, V81, P695, DOI 10.1099/0022-1317-81-3-695; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; MACIEJEWSKI JP, 1995, J CLIN INVEST, V96, P1085, DOI 10.1172/JCI118094; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nozawa H, 1998, INT J CANCER, V77, P522, DOI 10.1002/(SICI)1097-0215(19980812)77:4<522::AID-IJC8>3.0.CO;2-W; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Ogasawara S, 1996, GASTROENTEROLOGY, V110, P52, DOI 10.1053/gast.1996.v110.pm8536888; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHIFFMAN MH, 1992, JNCI-J NATL CANCER I, V84, P394, DOI 10.1093/jnci/84.6.394; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; SHAY JW, 1995, MOL MED TODAY, V1, P378, DOI 10.1016/S1357-4310(95)93872-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shiratsuchi M, 1999, LEUKEMIA LYMPHOMA, V34, P349, DOI 10.3109/10428199909050960; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Wright WE, 1996, DEV GENET, V18, P173; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2000, BLOOD, V96, P4313, DOI 10.1182/blood.V96.13.4313.h8004313_4313_4318; YASUI W, 1988, JPN J CANCER RES, V89, P1099; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	56	41	47	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					381	391		10.1038/sj.onc.1206133	http://dx.doi.org/10.1038/sj.onc.1206133			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545159				2022-12-17	WOS:000180379100007
J	Maria, DA; Manenti, G; Galbiati, F; Ribeiro, OG; Cabrera, WHK; Barrera, RG; Pettinicchio, A; De Franco, M; Starobinas, N; Siqueira, M; Dragani, TA; Ibanez, OM				Maria, DA; Manenti, G; Galbiati, F; Ribeiro, OG; Cabrera, WHK; Barrera, RG; Pettinicchio, A; De Franco, M; Starobinas, N; Siqueira, M; Dragani, TA; Ibanez, OM			Pulmonary adenoma susceptibility 1 (Pas1) locus affects inflammatory response	ONCOGENE			English	Article						Pas1; cancer modifier loci; linkage disequilibrium; genetic polymorphisms	PREVIOUS LUNG-DISEASE; LINKAGE DISEQUILIBRIUM; RESISTANCE LOCUS; OUTBRED MICE; CANCER; MOUSE; RISK; GENE; RESPONSIVENESS; CHROMOSOME-6	Two outbred mouse lines, phenotypically selected for differential subcutaneous (s.c.) acute inflammatory response (AIR), were analysed for urethane-induced lung inflammatory response and susceptibility to lung tumorigenesis. AIR(min) Mice, which show a low response to s.c. acute inflammation, developed a persistent subacute lung inflammatory response and a 40-fold higher lung tumor multiplicity than did AIR(max) mice, which are selected for high response to s.c. acute inflammation and showed a transient lung inflammatory response. A highly significant linkage disequilibrium pattern was observed in AIR(max) and AIR(min) mice at marker alleles located within a 452-kb pulmonary adenoma susceptibility 1 (Pas1) locus region, thus defining the location of gene candidacy for inflammatory response and for the biological effects of Pas1 in this region. AIRmin and AIRmax mice segregated by descent the Pas1(s) and Pas1(r) alleles, respectively, providing evidence for the involvement of the Pas1 locus in the inflammatory response. The 452-kb region contains Kras2 and four additional genes, including the lymphoid-restricted membrane protein (Lrmp) gene, whose Pro --> Leu nonconservative variation was linked with inflammatory response and Pas1 allelotype. These results provide a model to explore the mechanism underlying inherited predisposition to lung cancer in the context of a link to inflammation.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Inst Butantan, Lab Imunogenet, Sao Paulo, Brazil	Fondazione IRCCS Istituto Nazionale Tumori Milan; Instituto Butantan	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.		Starobinas, Nancy/B-9178-2015; Ibañez, Olga CM/B-9627-2015; Dragani, Tommaso A./K-4493-2016; Gianni-Barrera, Roberto/ACU-4280-2022; Manenti, Giacomo/J-3339-2017; DE FRANCO, MARCELO/S-5870-2019; Ribeiro, Orlando Garcia/B-5241-2016; Cabrera, Wafa HK/F-7189-2016	Starobinas, Nancy/0000-0001-5716-3394; Ibañez, Olga CM/0000-0002-2672-4758; Dragani, Tommaso A./0000-0001-5915-4598; Gianni-Barrera, Roberto/0000-0001-6303-4513; Manenti, Giacomo/0000-0002-4887-4482; DE FRANCO, MARCELO/0000-0002-0417-8215; 				Askling J, 1999, AM J RESP CRIT CARE, V160, P1668, DOI 10.1164/ajrccm.160.5.9904045; Bauer AK, 2001, EXP LUNG RES, V27, P197, DOI 10.1080/019021401300053948; Biozzi G, 1998, CARCINOGENESIS, V19, P337, DOI 10.1093/carcin/19.2.337; Brownson RC, 2000, CANCER CAUSE CONTROL, V11, P853, DOI 10.1023/A:1008999202040; De Sanctis GT, 1999, AM J PHYSIOL-LUNG C, V277, pL1118, DOI 10.1152/ajplung.1999.277.6.L1118; DELACHAPELLE A, 1993, J MED GENET, V30, P857, DOI 10.1136/jmg.30.10.857; Eden A, 1999, FEBS LETT, V457, P255, DOI 10.1016/S0014-5793(99)01054-6; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; JORDE LB, 1995, AM J HUM GENET, V56, P11; Lang SM, 1999, GUT, V44, P822, DOI 10.1136/gut.44.6.822; Malkinson AM, 2002, CARCINOGENESIS, V23, P411, DOI 10.1093/carcin/23.3.411; Manenti G, 1996, NAT GENET, V12, P455, DOI 10.1038/ng0496-455; Manenti G, 1999, GENOME RES, V9, P639; Mayne ST, 1999, AM J EPIDEMIOL, V149, P13; Moody TW, 2001, ANTICANCER RES, V21, P1749; Obata M, 1996, ONCOGENE, V13, P1599; Pataer A, 1997, CANCER RES, V57, P2904; Peissel B, 2000, MAMM GENOME, V11, P979, DOI 10.1007/s003350010184; Prows DR, 1999, AM J PHYSIOL-LUNG C, V277, pL372, DOI 10.1152/ajplung.1999.277.2.L372; Snyder HL, 1997, J EXP MED, V186, P1087, DOI 10.1084/jem.186.7.1087; *STAT SAS I, 1988, SAS US GUID STAT; Talbot CJ, 1999, NAT GENET, V21, P305, DOI 10.1038/6825; Tsunematsu S, 1997, J GASTROEN HEPATOL, V12, P319, DOI 10.1111/j.1440-1746.1997.tb00428.x; YANAGISAWA A, 1993, CANCER RES, V53, P953	25	41	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					426	432		10.1038/sj.onc.1206157	http://dx.doi.org/10.1038/sj.onc.1206157			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545163				2022-12-17	WOS:000180379100011
J	Yin, D; Xie, D; Hofmann, WK; Miller, CW; Black, KL; Koeffler, HP				Yin, D; Xie, D; Hofmann, WK; Miller, CW; Black, KL; Koeffler, HP			Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors	ONCOGENE			English	Article						Methylation; p14(ARF); p15(INK4B); p16(INK4A); RB; brain tumors; p53 mutation	HOMOZYGOUS DELETION; SUPPRESSOR GENE; CPG ISLAND; P16 GENE; SOMATIC MUTATIONS; FAMILIAL MELANOMA; P16(INK4A) GENES; DNA METHYLATION; STABILIZES P53; HUMAN CANCERS	Methylation status of the p(15INK4B), p16(INK4A), p14(ARF) and retinoblastoma (RB) genes was studied using methylation specific polymerase chain reaction (MSP) in 85 human brain tumors of various subtypes and four normal brain samples. These genes play an important role in the control of the cell cycle. Twenty-four out of 85 cases (28%) had at least one of these genes methylated. The frequency of p14ARF methylation was 15 out of 85 (18%) cases, and the expression of p14(ARF) in methylated gliomas was significantly lower than in unmethylated gliomas. The incidence of methylation of p15(INK4B), p16(INK4A) and RB gene was 4%, 7%, and 4%, respective . Samples with p14(ARF) methylation did not have p16(INK4A) methylation even though both genes physically overlap. None of the target genes was methylated in the normal brain samples. In addition, the p53 gene was mutated in 19 out of 85 (22%) samples as determined by single strand conformation polymorphism (SSCP) analysis and DNA sequencing. Thirty out of 85 (35%) brain tumors had either a p53 mutation or methylation of p14(ARF). Also, the p14(ARF) expression in p53 wild-type gliomas was lower than levels in p53 mutated gliomas. This finding is consistent with wild-type p53 being able to autoregulate its levels by down-regulating expression of p14(ARF). In summary, inactivation of the apoptosis pathway that included the p14(ARF) and p53 genes by hypermethylation and mutation, respectively, occurred frequently in human brain tumors. Down-regulation of p14(ARF) in gliomas was associated with hypermethylation of its promoter and the presence of a wild-type p53 in these samples.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Yin, D (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol & Oncol, 8700 Beverly Blvd,Suite BM-1,Room 109, Los Angeles, CA 90048 USA.			Black, Keith/0000-0002-0546-4934; Xie, Dong/0000-0002-1150-8657				BARTSCH D, 1995, GENE CHROMOSOME CANC, V14, P189, DOI 10.1002/gcc.2870140306; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Costello JF, 1996, CANCER RES, V56, P2405; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Duro D, 1996, CANCER RES, V56, P848; Esteller M, 2000, CANCER RES, V60, P129; GREGER V, 1994, HUM GENET, V94, P491; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; IGAKI H, 1994, BIOCHEM BIOPH RES CO, V203, P1090, DOI 10.1006/bbrc.1994.2294; IMAI Y, 1994, MODERN PATHOL, V7, P766; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LIU L, 1995, ONCOGENE, V11, P405; LIU QY, 1995, ONCOGENE, V10, P619; LOUIS DN, 1994, J NEUROPATH EXP NEUR, V53, P11, DOI 10.1097/00005072-199401000-00002; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nakamura M, 2001, CANCER RES, V61, P6335; Nakamura M, 2001, BRAIN PATHOL, V11, P159; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; QUELLE DE, 1995, CELL, V83, P993; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; SAKAI T, 1991, AM J HUM GENET, V48, P880; Schmidt EE, 1997, BRIT J CANCER, V75, P2, DOI 10.1038/bjc.1997.2; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Simon M, 1999, ACTA NEUROPATHOL, V98, P444, DOI 10.1007/s004010051107; Simpson DJ, 2000, CANCER RES, V60, P1211; Stirzaker C, 1997, CANCER RES, V57, P2229; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Watanabe T, 2001, ACTA NEUROPATHOL, V101, P185; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	49	41	43	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8372	8378		10.1038/sj.onc.1206031	http://dx.doi.org/10.1038/sj.onc.1206031			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447702				2022-12-17	WOS:000179323900017
J	Bindels, EMJ; Lallemand, F; Balkenende, A; Verwoerd, D; Michalides, R				Bindels, EMJ; Lallemand, F; Balkenende, A; Verwoerd, D; Michalides, R			Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells	ONCOGENE			English	Article						antiestrogens; Gl/S cyclins; breast cancer; cell cycle; estrogen receptor	RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; TRANSCRIPTIONAL ACTIVATION; ECTOPIC EXPRESSION; TRANSGENIC MICE; GENE-EXPRESSION; CDK INHIBITORS; D1; PHOSPHORYLATION; PROGRESSION	Estrogen receptor-mediated transcription is enhanced by overexpression of G1/S cyclins D1, E or A in the presence as well in the absence of estradiol. Excess of G1/S cyclins also prevents the inhibition of transactivation of estrogen receptor (ER) by the pure antiestrogen ICI 182780. Cyclin D1 mediates this transactivation independent of complex formation to its CDK4/6 partner. This raises the possibility that overexpression of G1/S cyclins renders growth of ER-positive breast cancer hormone-independent and resistant to treatment with antiestrogens. Transient transfection of ER-positive breast cancer cell lines T47D and MCF7 with G1/S cyclins could overcome the growth arrest induced by ICI 182780 treatment. The ability of various cyclin D1 mutants to overcome the ICI 182780 mediated growth arrest corresponded with their ability to stimulate cyclin A- and E2F- promoter based reporter activities in the presence of ICI 182780. Transfection of a mutant cyclin D1 (cyclin D1-KE) that was unable to bind CDK4 and was reported to transactivate ER in the presence of ICI 182780, could not stimulate proliferation in ICI 182780 treated cells. On the other hand, cyclin D1-LALA, which is unable to stimulate ERE transactivation, could overcome the ICI 182780 cell cycle arrest. Furthermore, transient transfection of T47D cells using cyclin D1 together with a catalytic inactive mutant of CDK4 (CDK4-DN) indicated that the observed effect is due to binding to CDK inhibitors. However, a moderate, sixfold overexpression of cyclin D1 in stably transfected MCF7 cells did not overcome the ICI 182780 mediated growth arrest. These results indicate that CDK-independent transactivation of the estrogen receptor by cyclin D1 is by itself, not sufficient to result in estradiol-independent growth of breast cancer cells, whereas a vast overexpression of G1/S cyclins is able to do so, most likely by capturing of CDK inhibitors.	Netherlands Canc Inst, Div Tumor Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Michalides, R (corresponding author), Netherlands Canc Inst, Div Tumor Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.michalides@nki.nl						Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Anderson JJ, 1996, J PATHOL, V180, P65, DOI 10.1002/(SICI)1096-9896(199609)180:1<65::AID-PATH607>3.0.CO;2-C; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Favoni RE, 1998, TRENDS PHARMACOL SCI, V19, P406, DOI 10.1016/S0165-6147(98)01252-8; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; KEYOMARSI K, 1994, CANCER RES, V54, P380; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb J, 2000, MOL CELL BIOL, V20, P8667, DOI 10.1128/MCB.20.23.8667-8675.2000; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; Latham KM, 1996, MOL CELL BIOL, V16, P4445; LIPPMAN M, 1976, CANCER RES, V36, P4595; Michalides R, 2002, BRIT J CANCER, V86, P402, DOI 10.1038/sj.bjc.6600072; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NIELSEN NH, 1999, BREAST CANC RES TREA, V74, P874; Pacilio C, 1998, CANCER RES, V58, P871; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P307, DOI 10.1016/0277-5379(83)90127-X; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Varma H, 2000, ONCOGENE, V19, P4746, DOI 10.1038/sj.onc.1203827; WAKELING AE, 1991, CANCER RES, V51, P3867; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	45	41	45	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8158	8165		10.1038/sj.onc.1206012	http://dx.doi.org/10.1038/sj.onc.1206012			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444551				2022-12-17	WOS:000179231400009
J	Huang, YH; Wu, JYJ; Zhang, YJ; Wu, MX				Huang, YH; Wu, JYJ; Zhang, YJ; Wu, MX			Synergistic and opposing regulation of the stress-responsive gene IEX-1 by p53, c-Myc, and multiple NF-kappa B/rel complexes	ONCOGENE			English	Article						NF-kappa B; p53; c-Myc; IEX-1 and transcription	IMMEDIATE-EARLY GENE; INDUCED CELL-DEATH; MICE LACKING; TARGET GENE; B RELA; APOPTOSIS; EXPRESSION; PROTEIN; BINDING; GROWTH	NF-kappaB/rel proteins, tumor suppressor p53, and oncogene c-Myc are critical transcription factors involved in coordinating cellular decision-making events in response to external stimuli. Consensus sequences for binding these three transcription factors are found in the promoter region of IEX-1 (Immediate Early response gene X-1) gene that can either suppress or induce apoptosis in a cell- and stimulus-dependent manner. Utilizing an electrophoretic mobility shift assay (EMSA) and a promoter/reporter assay, we show that the NF-kappaB/rel consensus sequence in the IEX-1 promoter is specifically bound and activated by multiple NF-kappaB/rel complexes in descending order p65-c-rel-->p65-50-->p50-50. Interestingly, NF-kappaB/rel-mediated activation of IEX-1 expression was synergized by p53, but strongly inhibited by c-Myc in a dose-dependent fashion. Moreover, the ability of c-Myc to inhibit IEX-1 expression requires the presence of functional p53, which may partially contribute to the varying effects of p53 on IEX-1 expression in different cells. In support of coordinated regulation of IEX-1 expression by these three transcription factors in vivo, binding of endogenous p53, c-Myc and NF-kappaB/rel proteins, including p50, p65 and c-rel, to the IEX-1 promoter was demonstrated in living cells by chromatin immunoprecipitation using specific antibodies. The study reveals a novel integrative regulation of specific gene expression by NF-kappaB/rel, p53 and c-Myc transcription factors.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Shionogi BioRes, Lexington, MA 02420 USA	Baylor College of Medicine; Shionogi & Company Limited	Wu, MX (corresponding author), Boston Med Ctr, Dept Mol & Cell Biol, 715 Albany St Evans 4, Boston, MA 02118 USA.				NIAID NIH HHS [AI45003] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045003] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; CHARLES CH, 1993, ONCOGENE, V8, P797; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Domachowske JB, 2000, J INFECT DIS, V181, P824, DOI 10.1086/315319; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Feldmann KA, 2001, HISTOCHEM CELL BIOL, V115, P489; GRILLI M, 1993, INT REV CYTOL, V143, P1; Grobe O, 2001, FEBS LETT, V494, P196, DOI 10.1016/S0014-5793(01)02344-4; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Ikeda A, 2000, BIOCHEM BIOPH RES CO, V272, P375, DOI 10.1006/bbrc.2000.2786; Im HJ, 2002, J BIOL CHEM, V277, P14612, DOI 10.1074/jbc.M109414200; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; Kawai H, 1999, CANCER RES, V59, P6038; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P868, DOI 10.1006/bbrc.1998.9556; Kondratyev AD, 1996, CANCER RES, V56, P1498; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kumar R, 1998, BIOCHEM BIOPH RES CO, V253, P336, DOI 10.1006/bbrc.1998.9692; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; Pietzsch A, 1998, BIOCHEM BIOPH RES CO, V245, P651, DOI 10.1006/bbrc.1998.8500; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Ravi R, 1998, CANCER RES, V58, P4531; Sala A, 1996, CANCER RES, V56, P1991; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Schafer H, 1999, PANCREAS, V18, P378, DOI 10.1097/00006676-199905000-00008; Schafer H, 1998, ONCOGENE, V16, P2479, DOI 10.1038/sj.onc.1201788; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VAN AD, 1996, SCIENCE, V274, P787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P878, DOI 10.1073/pnas.022326699	50	41	46	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6819	6828		10.1038/sj.onc.1205854	http://dx.doi.org/10.1038/sj.onc.1205854			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360408				2022-12-17	WOS:000178315800012
J	Wu, Y; Pan, SJ; Lu, WP; Lin, SH; Kuang, J				Wu, Y; Pan, SJ; Lu, WP; Lin, SH; Kuang, J			Hp95 promotes anoikis and inhibits tumorigenicity of HeLa cells	ONCOGENE			English	Article						Hp95; anoikis; tumorigenicity; cell morphology	SIGNAL-TRANSDUCTION; PROTEIN; GENE; APOPTOSIS; ADHESION; CLONING; ALG-2; IDENTIFICATION; ASTROCYTES; INTEGRINS	p95 is a putative signal transduction protein of similar to 95 kDa that contains multiple tyrosine residues that are conserved from yeast to human, a Src phosphorylation consensus sequence and a proline-rich C-terminus that binds SH3-domains. Previous studies have established that mammalian p95 is physically associated with proteins that regulate apoptotic induction and cell transformation; however, it is unclear whether p95 is a positive or negative regulator in these processes. Moreover, a p95 partner protein has been localized at both focal adhesions and actin-cytoskeletons in rat astrocytes. However, there is no evidence that mammalian p95 has roles in regulating cell adhesion or morphology. In this study, we examined the effects of p95 on the anchorage-independent growth and tumorigenicity of malignant HeLa cells, and on the growth and morphology of non-transformed NIH3T3 cells. In HeLa cells, p95 overexpression promoted detachment-induced apoptosis (anoikis), inhibited detachment of viable cells from substratum and reduced tumorigenicity. In NIH3T3 cells, p95 overexpression promoted flat cell morphology and slowed cell proliferation, whereas p95 downregulation had opposite effects. These findings indicate that the mammalian p95 is a positive regulator in apoptotic signaling and a negative regulator in cell transformation. They also suggest that p95 has roles in regulating cell adhesion and morphology.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kuang, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Box 019,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; ARAI T, 1976, GANN, V67, P493; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Bogler O, 2000, NEURO-ONCOLOGY, V2, P6, DOI 10.1093/neuonc/2.1.6; Braga V, 2000, NAT CELL BIOL, V2, pE182, DOI 10.1038/35036433; BUNGE R, 1979, J SUPRAMOL STR CELL, V11, P175, DOI 10.1002/jss.400110207; Che SL, 1999, J BIOL CHEM, V274, P5522, DOI 10.1074/jbc.274.9.5522; Che SL, 1997, BBA-GENE STRUCT EXPR, V1354, P231, DOI 10.1016/S0167-4781(97)00112-7; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; Krebs J, 2000, BBA-MOL CELL RES, V1498, P153, DOI 10.1016/S0167-4889(00)00091-4; Kuang J, 2001, CLIN CANCER RES, V7, P3629; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; NegreteUrtasun S, 1997, J BACTERIOL, V179, P1832, DOI 10.1128/jb.179.5.1832-1835.1997; Nickas ME, 1996, MOL CELL BIOL, V16, P2585; ROCKWELL SC, 1972, J NATL CANCER I, V49, P735; Ruoslahti E, 1996, EXP CELL RES, V227, P1, DOI 10.1006/excr.1996.0243; Spiryda LB, 1998, J CELL SCI, V111, P3253; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wu Y, 2001, DIFFERENTIATION, V67, P139, DOI 10.1046/j.1432-0436.2001.670406.x	22	41	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6801	6808		10.1038/sj.onc.1205849	http://dx.doi.org/10.1038/sj.onc.1205849			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360406				2022-12-17	WOS:000178315800010
J	Janz, C; Wiesmuller, L				Janz, C; Wiesmuller, L			Wild-type p53 inhibits replication-associated homologous recombination	ONCOGENE			English	Article						aphidicolin; DNA synthesis; gene conversion; SV40 chromosomes; tumor suppressor	SIMIAN-VIRUS 40; DNA-REPLICATION; MAMMALIAN-CELLS; IN-VITRO; MIMOSINE; PROTEIN; REPAIR; PHOSPHORYLATION; DISSOCIATION; CHECKPOINT	In mammalian cells homologous recombination is stimulated, when the replication fork stalls at DNA breaks or unrepaired lesions. The tumor suppressor p53 downregulates homologous recombination independently of its transcriptional transactivation function and has been linked to enzymes of DNA recombination and replication. To study recombination with respect to replication, we utilized a SV40 virus based assay, to follow the synchronous events after primate cell infection. gamma-ray treatment at different times after viral entry unveiled an increase of interchromosomal exchange frequencies, when the damage was introduced during DNA synthesis. Elevated recombination frequencies were fully suppressed by p53. With respect to the downregulation of spontaneous recombination, we noticed a requirement for active p53 molecules, when replication started. After a transient treatment with replication inhibitors, we observed inhibition of the drug induced recombination by p53, particularly for the elongation inhibitor aphidicolin. Consequently, we propose that p53 is a surveillance factor of homologous recombination at replication forks, when they stall as a consequence of endogenous or of exogenously introduced damage.	Univ Frauenklin & Poliklin, D-89075 Ulm, Germany; Heinrich Pette Inst, Hamburg, Germany	Ulm University; Heinrich Pette Institute	Wiesmuller, L (corresponding author), Univ Frauenklin & Poliklin, Prittwitzstr 43, D-89075 Ulm, Germany.							AKYUZ N, 2002, IN PRESS MOL CELL BI; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; Brush GS, 1995, METHOD ENZYMOL, V262, P522; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; DAI YM, 1994, VIROLOGY, V205, P210, DOI 10.1006/viro.1994.1636; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Fernandez JL, 2001, EXP CELL RES, V270, P102, DOI 10.1006/excr.2001.5328; Gersten KM, 1997, NAT GENET, V17, P378, DOI 10.1038/ng1297-378; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; Janz C, 2002, ONCOGENE, V21, P2130, DOI 10.1038/sj.onc.1205292; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kalejta RF, 1997, EXP CELL RES, V231, P173, DOI 10.1006/excr.1996.3444; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; KAWASAKI I, 1994, MOL CELL BIOL, V14, P4173, DOI 10.1128/MCB.14.6.4173; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; Larner JM, 1999, NUCLEIC ACIDS RES, V27, P803, DOI 10.1093/nar/27.3.803; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; SARASIN AR, 1978, P NATL ACAD SCI USA, V75, P346, DOI 10.1073/pnas.75.1.346; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Tooze J, 1980, DNA TUMOR VIRUSES; VONDERWETH A, 1993, J VIROL, V67, P886, DOI 10.1128/JVI.67.2.886-893.1993; Wiesmuller L, 1996, J VIROL, V70, P737; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	43	41	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5929	5933		10.1038/sj.onc.1205757	http://dx.doi.org/10.1038/sj.onc.1205757			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185593				2022-12-17	WOS:000177520900013
J	Beck, MT; Peirce, SK; Chen, WY				Beck, MT; Peirce, SK; Chen, WY			Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R	ONCOGENE			English	Article						prolactin; prolactin antagonist; Bcl-2; breast cancer; apoptosis	MAMMARY-GLAND INVOLUTION; MESSENGER-RNA; CDNA MICROARRAY; APOPTOSIS; RECEPTOR; HORMONE; FAMILY; PROTEIN; BAX; IDENTIFICATION	To gain insight into the molecular basis of human prolactin (hPRL) antagonist induced apoptosis, we compared the differential gene expression profile of four human breast cancer cell lines following treatment with hPRL and its antagonist (hPRL-G129R). Among the genes identified, the bcl-2 gene was of particular interest. We found that bcl-2 mRNA was up regulated in three of the four cell lines that were treated with hPRL. To further confirm these results, real time RT-PCR and ELISA analyses were used to detect bcl-2 mRNA and Bcl-2 protein, respectively, in 11 different breast cancer cell lines after hPRL or hPRL-G129R treatment. Our data suggests that Bcl-2 is up-regulated in response to hPRL stimulation and is competitively inhibited by hPRL-G129R in the majority of the cell lines tested. Thus, we propose that the anti-apoptotic role of hPRL in breast cancer is mediated, at least in part, through regulation of Bcl-2.	Greenville Hosp Syst, Oncol Res Inst, Greenville, SC 29605 USA; Clemson Univ, Dept Microbiol & Mol Med, Clemson, SC 29630 USA	Greenville Health System; Clemson University	Chen, WY (corresponding author), Greenville Hosp Syst, Oncol Res Inst, 900 W Faris Rd, Greenville, SC 29605 USA.	wchen@ghs.org			NATIONAL CANCER INSTITUTE [R21CA087093] Funding Source: NIH RePORTER; NCI NIH HHS [1R21CA87093] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Beck MT, 2001, BIOTECHNIQUES, V31, P782, DOI 10.2144/01314st04; Binder C, 1996, ANN ONCOL, V7, P129; BLACKWELL RE, 1999, HORMONAL CONTROL NOR, P3; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen NY, 2002, INT J ONCOL, V20, P813; Chen WY, 1999, CLIN CANCER RES, V5, P3583; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; DeRisi J, 1996, NAT GENET, V14, P457; GINSBURG E, 1995, CANCER RES, V55, P2591; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Goffin V, 1997, J MAMMARY GLAND BIOL, V2, P7, DOI 10.1023/A:1026313211704; Green L, 1999, IEEE CIRCUITS DEVICE, V15, P7, DOI 10.1109/101.808850; Greenberg RK, 2000, J ENDOVASC THER, V7, P1, DOI 10.1583/1545-1550(2000)007<0001:AEMOHC>2.3.CO;2; Guiliano D, 1999, BIOTECHNIQUES, V27, P146, DOI 10.2144/99271rr03; HAKVOORT TBM, 1994, NUCLEIC ACIDS RES, V22, P878, DOI 10.1093/nar/22.5.878; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Krumenacker JS, 1998, ENDOCRINE, V9, P163, DOI 10.1385/ENDO:9:2:163; Kuang WW, 1998, NUCLEIC ACIDS RES, V26, P1116, DOI 10.1093/nar/26.4.1116; Kumar R, 2000, ENDOCR-RELAT CANCER, V7, P257, DOI 10.1677/erc.0.0070257; Leff MA, 1996, ENDOCRINOLOGY, V137, P5456, DOI 10.1210/en.137.12.5456; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815; Llovera M, 2000, ONCOGENE, V19, P4695, DOI 10.1038/sj.onc.1203846; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; NAGASAWA H, 1985, EXP CLIN ENDOCRINOL, V86, P357, DOI 10.1055/s-0029-1210509; Oh JJ, 1999, NUCLEIC ACIDS RES, V27, P4008, DOI 10.1093/nar/27.20.4008; Ormandy CJ, 1997, J CLIN ENDOCR METAB, V82, P3692, DOI 10.1210/jc.82.11.3692; Peirce SK, 2001, J ENDOCRINOL, V171, pR1, DOI 10.1677/joe.0.171R001; Ramamoorthy P, 2001, INT J ONCOL, V18, P25; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Schorr K, 1999, CANCER RES, V59, P2541; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; ShawBruha CM, 1997, BREAST CANCER RES TR, V44, P243, DOI 10.1023/A:1005879103367; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Vonderhaar BK, 1998, PHARMACOL THERAPEUT, V79, P169, DOI 10.1016/S0163-7258(98)00017-5; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410; Yamauchi T, 2000, J BIOL CHEM, V275, P33937, DOI 10.1074/jbc.M000743200; Yang GP, 1999, NUCLEIC ACIDS RES, V27, P1517, DOI 10.1093/nar/27.6.1517; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhan JH, 1997, BIOTECHNIQUES, V22, P500, DOI 10.2144/97223st05	45	41	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5047	5055		10.1038/sj.onc.1205637	http://dx.doi.org/10.1038/sj.onc.1205637			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140755				2022-12-17	WOS:000176975900003
J	Herrant, M; Luciano, F; Loubat, A; Auberger, P				Herrant, M; Luciano, F; Loubat, A; Auberger, P			The protective effect of phorbol esters on Fas-mediated apoptosis in T cells. Transcriptional and postranscriptional regulation	ONCOGENE			English	Article						apoptosis; phorbol esters; cDNA arrays; death and survival genes	PROTEIN-KINASE-C; EXPRESSION INDUCES APOPTOSIS; MYC EXPRESSION; ENDOTHELIAL-CELLS; DOWN-MODULATION; GROWTH ARREST; KNOCKOUT MICE; DEATH; ACTIVATION; PATHWAY	Phorbol esters are tumor promoters that bind and activate both conventional and new Protein kinase C (PKC) isoforms. In various circumstances, PKC-dependent signaling pathways can promote cell survival and protect against cell death. This was first analysed in Jurkat T cells where Phorbol Myristate Acetate (PMA) was found to inhibit Fas-mediated apoptosis as judged by DiOC6(3) staining, caspase activation and DNA fragmentation, indicating that PMA exerts its protective effect upstream or at the mitochondrial level in these cells. PMA activated most of the main kinase pathways in T cells such as PKCs, p42/44MAPK, p38MAPK and p90Rsk but not JNK and Akt. A pharmacological approach allowed us to identify that nPKCs are both necessary and likely sufficient to promote T cell survival. Besides this post-transcriptional regulation, nPKCs may also regulate apoptosis at the transcriptional level. cDNA arrays were used to identify a set of genes whose expression was modulated in death versus survival conditions. Following PMA treatment, expression of Mcl-l and Bcl-x increased while that of cMyc was significantly reduced. Moreover, survivin expression decreased upon CH11 or PMA treatment. cMyc, survivin and Bcl-x modulation seems to be regulated at the transcriptional level while decrease in Mcl-1 protein in CH11-treated cells resulted especially from a caspase-dependent proteolysis. Taken together, our data demonstrate that PMA-mediated inhibition of apoptosis is a complex process that is integrated at both the transcriptional and post-transcriptional level and point out to the potential role of Mcl-1, Bcl-x, c-Myc and survivin in this process.	Fac Med, IFR 50, INSERM, U526,Equipe Labellisee Ligue Natl Contre Canc, F-06107 Nice 2, France; Fac Med, IFR 50, INSERM, U364, F-06107 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Auberger, P (corresponding author), Fac Med, IFR 50, INSERM, U526,Equipe Labellisee Ligue Natl Contre Canc, Ave Valombrose, F-06107 Nice 2, France.		KHATIB, Abdel-Majid/A-9948-2015; luciano, frederic/P-6264-2016; AUBERGER, Patrick/G-1491-2013	KHATIB, Abdel-Majid/0000-0001-6957-0384; luciano, frederic/0000-0001-9253-4998; AUBERGER, Patrick/0000-0002-2481-8275				ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; Bannerman DD, 2001, J BIOL CHEM, V276, P14924, DOI 10.1074/jbc.M100819200; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chan FKM, 2000, IMMUNITY, V13, P419, DOI 10.1016/S1074-7613(00)00041-8; Chen CY, 1999, J BIOL CHEM, V274, P15320, DOI 10.1074/jbc.274.22.15320; Dang CV, 1999, MOL CELL BIOL, V19, P1; Datta R, 2000, J BIOL CHEM, V275, P41000, DOI 10.1074/jbc.M009322200; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; Genestier L, 1999, J EXP MED, V189, P231, DOI 10.1084/jem.189.2.231; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kasibhatla S, 2000, CURR BIOL, V10, P1205, DOI 10.1016/S0960-9822(00)00727-2; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu HT, 2001, J EXP MED, V194, P113, DOI 10.1084/jem.194.2.113; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luciano F, 2001, ONCOGENE, V20, P4935, DOI 10.1038/sj.onc.1204661; Mari B, 1997, FASEB J, V11, P869, DOI 10.1096/fasebj.11.11.9285485; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Mochly-Rosen D, 1998, FASEB J, V12, P35; Muchmore SW, 2000, MOL CELL, V6, P173, DOI 10.1016/S1097-2765(00)00018-6; Nagata S, 1998, J HUM GENET, V43, P2, DOI 10.1007/s100380050029; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nikiforov MA, 2000, ONCOGENE, V19, P4828, DOI 10.1038/sj.onc.1203880; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Oberg F, 2001, LEUKEMIA, V15, P217, DOI 10.1038/sj.leu.2402025; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Ricci JE, 1999, ONCOGENE, V18, P3963, DOI 10.1038/sj.onc.1202782; Ricci JE, 2001, FASEB J, V15, P1777, DOI 10.1096/fj.00-0665fje; Ricci JE, 2001, EUR CYTOKINE NETW, V12, P126; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Santamaria P, 2001, CURR OPIN IMMUNOL, V13, P663, DOI 10.1016/S0952-7915(01)00276-X; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sonenshein GE, 1997, J IMMUNOL, V158, P1994; Sordet O, 2001, BLOOD, V97, P3931, DOI 10.1182/blood.V97.12.3931; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tiberio L, 2001, CELL DEATH DIFFER, V8, P967, DOI 10.1038/sj.cdd.4400909; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Villalba M, 2001, J IMMUNOL, V166, P5955, DOI 10.4049/jimmunol.166.10.5955; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Wu M, 1996, MOL CELL BIOL, V16, P5015; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	62	41	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4957	4968		10.1038/sj.onc.1205689	http://dx.doi.org/10.1038/sj.onc.1205689			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118374				2022-12-17	WOS:000176874800010
J	Bernardi, R; Grisendi, S; Pandolfi, PP				Bernardi, R; Grisendi, S; Pandolfi, PP			Modelling haematopoietic malignancies in the mouse and therapeutical implications	ONCOGENE			English	Article						animal models; leukaemias and lymphomas; transgenic mice; knock-in; tetracycline-inducible system; Cre-loxP system	ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; ACID RECEPTOR-ALPHA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANS-RETINOIC ACID; TYROSINE KINASE INHIBITOR; ARSENIC TRIOXIDE AS2O3; ZINC-FINGER GENE; C-MYC ONCOGENE; PML/RAR-ALPHA	Modelling human disease in the mouse has become an essential activity in biomedical research in order to unravel molecular mechanisms underlying pathological conditions as well as to determine in vivo the consequences of aberrant gene function. The mouse is by far the most accessible mammalian system physiologically similar to humans. Furthermore, the development of novel techniques for manipulating the murine genome, which allow the in vivo modification of virtually any genomic region in a time and/or tissue specific manner, renders the mouse an ideal model system to study human pathological conditions. Modelling human diseases in mice has reached an even greater relevance in the field of haematological malignancies, due to the already advanced characterization of the molecular basis of many haematological disorders. In this review, we describe the most important technological developments that made it possible to reproduce in the mouse the genetic lesions that characterize human haematological malignancies, thus often generating faithful mouse models of the human condition. We provide specific examples of the advantages and limitations of the various genetic approaches utilized to model leukaemia and lymphoma in the mouse. Finally, we discuss the power of mouse modelling in developing and testing novel therapeutic modalities in pre-clinical studies.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst,Mol Biol Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst,Dept Pathol, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst,Mol Biol Program, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org	bernardi, rosa/B-1650-2013	bernardi, rosa/0000-0002-3607-6336				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Benedetti L, 1996, BLOOD, V87, P1939; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Buchdunger E, 1996, CANCER RES, V56, P100; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; Buchholz F, 2000, EMBO REP, V1, P133, DOI 10.1093/embo-reports/kvd027; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; Chen GQ, 1997, BLOOD, V89, P3345; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Condorelli GL, 1996, CANCER RES, V56, P5113; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; CROCE CM, 1984, CURR TOP MICROBIOL, V113, P133; Curtis DJ, 1997, ONCOGENE, V15, P2975, DOI 10.1038/sj.onc.1201467; David G, 1997, ONCOGENE, V14, P1547, DOI 10.1038/sj.onc.1200989; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Ding W, 1998, BLOOD, V92, P1172, DOI 10.1182/blood.V92.4.1172.416k02_1172_1183; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Farley FW, 2000, GENESIS, V28, P106, DOI 10.1002/1526-968X(200011/12)28:3/4<106::AID-GENE30>3.0.CO;2-T; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fenaux P, 1997, NEW ENGL J MED, V337, P1076, DOI 10.1056/NEJM199710093371509; Glass CK, 2000, GENE DEV, V14, P121; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRIFFITHS SD, 1992, ONCOGENE, V7, P1391; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Heisterkamp Nora, 1991, Transgenic Research, V1, P45, DOI 10.1007/BF02512996; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Imaizumi M, 1998, BLOOD, V92, P374, DOI 10.1182/blood.V92.2.374.414a40_374_382; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; LARSON RC, 1994, ONCOGENE, V9, P3675; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARIN MC, 1995, EXP CELL RES, V217, P240, DOI 10.1006/excr.1995.1083; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Nason-Burchenal K, 1998, BLOOD, V92, P1758, DOI 10.1182/blood.V92.5.1758.417k28_1758_1767; O'Neil J, 2001, ONCOGENE, V20, P3897, DOI 10.1038/sj.onc.1204519; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pandolfi PP, 1996, HAEMATOLOGICA, V81, P472; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Pollock JL, 1999, P NATL ACAD SCI USA, V96, P15103, DOI 10.1073/pnas.96.26.15103; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Reichert A, 2001, BLOOD, V97, P1399, DOI 10.1182/blood.V97.5.1399; Rhoades KL, 2000, BLOOD, V96, P2108; RUBNITZ JE, 1994, BLOOD, V84, P1747; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; STRASSER A, 1993, ONCOGENE, V8, P1; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, BLOOD, V82, P1949, DOI 10.1182/blood.V82.7.1949.bloodjournal8271949; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; WILDIN RS, 1995, J IMMUNOL, V155, P1286; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	96	41	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3445	3458		10.1038/sj.onc.1205313	http://dx.doi.org/10.1038/sj.onc.1205313			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032781				2022-12-17	WOS:000175633300016
J	Bernardin, F; Friedman, AD				Bernardin, F; Friedman, AD			AML1 stimulates G1 to S progression via its transactivation domain	ONCOGENE			English	Article						AML1; RUNX1; CBF; cell cycle; leukemia	ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; T-CELL-RECEPTOR; DNA-BINDING; TRANSCRIPTION FACTOR; FETAL LIVER; MURINE MYELOPEROXIDASE; PROTEIN; CBF; EXPRESSION	Inhibition of AML1-mediated transactivation potently slows G1 to S cell cycle progression. In Ba/F3 cells, activation of exogenous AML1 (RUNX1)-ER with 4-hydroxytamoxifen prevents inhibition of G1 progression mediated by CBFbeta-SMMHC, a CBF oncoprotein. We expressed three AML1-ER variants with CBFbeta-SMMHC in Ba/F3 cells. In these lines, CBFP-SMMHC expression is regulated by the zinc-responsive metallothionein promoter. Deletion of 72 AML1 C-terminal residues, which includes a transrepression domain, did not alter the activity of AML1-ER, whereas further deletion of 98 residues, removing the most potent AML1 transactivation domain (TAD), prevented rescue of cell cycle inhibition. Notably, the two variants which did not stimulate G1 exacerbated CBFbeta-SMMHC-mediated cell cycle arrest, suggesting that they dominantly inhibit AML1 activities. In addition, the two variants which stimulated G I also induced apoptosis in 5-15% of the cells, an effect consistent with excessive G1 stimulation. These observations indicate that AML1 activates transcription of one or more genes critical for the G1 to S transition via its C-terminal transactivation domain. Inactivation of AML in acute leukemia is expected to slow proliferation unless additional genetic alterations co-exist which accelerate G1.	Johns Hopkins Oncol Ctr, Div Pediat Oncol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Friedman, AD (corresponding author), Johns Hopkins Univ, Canc Res Bldg,Room 253,1650 Orleans St, Baltimore, MD 21231 USA.	adfrdman@jhmi.edu						Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAE SC, 1993, ONCOGENE, V8, P809; BritosBray M, 1996, LEUKEMIA, V10, P984; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kummalue T, 2001, BLOOD, V98, p834A; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; Mao SF, 1999, MOL CELL BIOL, V19, P3635; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 2000, MOL CELL BIOL, V20, P319, DOI 10.1128/MCB.20.1.319-328.2000; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; QUIN XQ, 1994, P NATL ACAD SCI USA, V91, P11544; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; YANG Y, 2002, IN PRESS CANC RES; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	44	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3247	3252		10.1038/sj.onc.1205447	http://dx.doi.org/10.1038/sj.onc.1205447			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082641				2022-12-17	WOS:000175373600017
J	Busuttil, V; Bottero, V; Frelin, C; Imbert, V; Ricci, JE; Auberger, P; Peyron, JF				Busuttil, V; Bottero, V; Frelin, C; Imbert, V; Ricci, JE; Auberger, P; Peyron, JF			Blocking NF-kappa B activation in Jurkat leukemic T cells converts the survival agent and tumor promoter PMA into an apoptotic effector	ONCOGENE			English	Article						NF-kappa B; tumor promoter PMA; Jurkat; leukemic cells; survival; apoptosis	PROTEIN-KINASE-C; SEVERE LIVER DEGENERATION; GAMMA-DEFICIENT MICE; MEDIATED APOPTOSIS; INCONTINENTIA PIGMENTI; EMBRYONIC LETHALITY; ALPHA PROTEOLYSIS; PHORBOL ESTER; IKK; PHOSPHORYLATION	The transcription factor NF-kappaB promotes cell survival. Using a variant of Jurkat leukemic T cells expressing IkappaB-alphaDeltaN, a super-repressor of NF-kappaB activation we first show that the tumor promoter PMA could prevent Fas-induced apoptosis via activation of NF-kappaB. Moreover, we demonstrate that in the absence of NF-kappaB activation, PNIA became a strong inducer of apoptosis through stimulation of the upstream caspases 8 and 9 as well as of the effector caspase 3. A RNase-protection analysis showed that PNIA stimulated the expression of several known anti-apoptotic genes (TRAF1, TRAF4, c-IAP-1, c-IAP-2, Bfl-1, Bcl-xl). In the absence of NF-kappaB activation, these survival influences were strongly lowered revealing the apoptotic effect of PMA. These results suggest that NF-kappaB activation could be an important step in the tumor promoting effect of PMA.	La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; Fac Med Pasteur, INSERM, U526, IFR 50 Genet & Signalisat Mol, F-06107 Nice 02, France	La Jolla Institute for Immunology; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Peyron, JF (corresponding author), La Jolla Inst Allergy & Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Peyron, Jean-Francois/M-5682-2016; AUBERGER, Patrick/G-1491-2013; RICCI, Jean Ehrland/AAS-4379-2020; Ricci, Jean Ehrland/I-7117-2016; Imbert, Véronique/I-6093-2016; Jean-Francois, Peyron/AAA-9496-2022	Peyron, Jean-Francois/0000-0001-6113-916X; AUBERGER, Patrick/0000-0002-2481-8275; RICCI, Jean Ehrland/0000-0003-1585-8117; Ricci, Jean Ehrland/0000-0003-1585-8117; Imbert, Véronique/0000-0003-2103-6718; Jean-Francois, Peyron/0000-0001-6113-916X				Altman A, 2000, IMMUNOL TODAY, V21, P567, DOI 10.1016/S0167-5699(00)01749-7; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Drew L, 1998, INT IMMUNOL, V10, P877, DOI 10.1093/intimm/10.7.877; Dudley E, 1999, EUR J IMMUNOL, V29, P878, DOI 10.1002/(SICI)1521-4141(199903)29:03<878::AID-IMMU878>3.0.CO;2-9; FORBES IJ, 1992, EXP CELL RES, V198, P367, DOI 10.1016/0014-4827(92)90393-M; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; ILLERA VA, 1993, J IMMUNOL, V151, P2965; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Pagliari LJ, 2000, MOL CELL BIOL, V20, P8855, DOI 10.1128/MCB.20.23.8855-8865.2000; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RODRIGUEZTARDUCHY G, 1989, BIOCHEM BIOPH RES CO, V164, P1069, DOI 10.1016/0006-291X(89)91778-6; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Sarker M, 2001, CELL DEATH DIFFER, V8, P172, DOI 10.1038/sj.cdd.4400791; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VAN AD, 1996, SCIENCE, V274, P787; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X	49	41	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3213	3224		10.1038/sj.onc.1205433	http://dx.doi.org/10.1038/sj.onc.1205433			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082637				2022-12-17	WOS:000175373600013
J	Yu, DN; Thomas-Tikhonenko, A				Yu, DN; Thomas-Tikhonenko, A			A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis	ONCOGENE			English	Article						Myc; p53; B-lymphoma; immunoglobulins; gene rearrangement	EPSTEIN-BARR-VIRUS; C-MYC; BURKITT-LYMPHOMA; TRANSGENIC MICE; APOPTOSIS; GENE; REARRANGEMENTS; TRANSLOCATION; EXPRESSION; PROTEIN	The c-Myc oncoprotein is strongly implicated in B-cell neoplasms such as human Burkitt lymphomas and mouse plasmocytomas. Transgenic mice in which the myc gene is juxtaposed to an immunoglobulin enhancer (Emu-myc) also develop B-cell lymphomas, but relatively late in life. In addition, these neoplasms are invariably clonal, suggesting the involvement of additional mutations. Such mutations frequently affect the p53 tumour suppressor gene or its positive regulator Arf, hinting that inactivation of the p53 pathway might be the second hit required for the progression towards malignancy. However, even tumours arising in Emu-myc/Arf-null animals are thought to be clonal. This observation raised doubts whether overexpression of Myc in p53-null B-cell precursors is sufficient for tumorigenesis. To address this question, we have established a new, non-transgenic mouse model of B-lymphoma. This model is based on isolation of primary bone marrow (BM) cells, admixing them with packaging cells producing a Myc-encoding retrovirus (LMycSN), and subcutaneous injection into a host with which BM cells are syngeneic. Predictably, wild type BM cells infected in vivo by LMycSN were not tumorigenic. However, LMycSN-infected p53-null BM cells readily gave rise to B-cell lymphomas composed predominantly of late pro-B/small pre-B-cells. In these tumours, heavy chain gene rearrangements were analysed using two independent PCR-based assays. All neoplasms with DJ-rearrangements were found to be polyclonal. This result suggests that inactivation of p53 and overexpression of Myc is all that is necessary for the development of full-fledged B-lymphomas. Our model would also be instrumental in assessing the transforming potential of Myc mutants and in studying cooperation between Myc and other oncogenes.	Univ Penn, Dept Pathobiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Thomas-Tikhonenko, A (corresponding author), Univ Penn, Dept Pathobiol, 3800 Spruce St, Philadelphia, PA 19104 USA.	andreit@mail.vet.upenn.edu	Thomas-Tikhonenko, Andrei/E-5329-2011	Thomas-Tikhonenko, Andrei/0000-0002-2739-2206	NATIONAL CANCER INSTITUTE [R55CA071881, R29CA071881] Funding Source: NIH RePORTER; NCI NIH HHS [CA 71881] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; Bower M, 2001, BRIT J HAEMATOL, V112, P863, DOI 10.1046/j.1365-2141.2001.02654.x; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; Cory S, 1999, CANCER RES, V59, p1685S; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HSU B, 1995, ONCOGENE, V11, P175; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; KLEIN G, 1993, GENE, V135, P189, DOI 10.1016/0378-1119(93)90065-B; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; NEWCOMB EW, 1995, LEUKEMIA LYMPHOMA, V17, P211, DOI 10.3109/10428199509056825; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PELICCI PG, 1986, J EXP MED, V164, P2049, DOI 10.1084/jem.164.6.2049; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TENBOEKEL E, 1995, INT IMMUNOL, V7, P1013; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; Yu DN, 2001, CANCER LETT, V173, P145, DOI 10.1016/S0304-3835(01)00612-7; Zimber-Strobl U, 1999, CURR TOP MICROBIOL, V246, P315; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	49	41	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1922	1927		10.1038/sj.onc.1205244	http://dx.doi.org/10.1038/sj.onc.1205244			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896625				2022-12-17	WOS:000174284500015
J	Lottin, S; Vercoutter-Edouart, AS; Adriaenssens, E; Czeszak, X; Lemoine, J; Roudbaraki, M; Coll, J; Hondermarck, H; Dugimont, T; Curgy, JJ				Lottin, S; Vercoutter-Edouart, AS; Adriaenssens, E; Czeszak, X; Lemoine, J; Roudbaraki, M; Coll, J; Hondermarck, H; Dugimont, T; Curgy, JJ			Thioredoxin post-transcriptional regulation by H19 provides a new function to mRNA-like non-coding RNA	ONCOGENE			English	Article						H19 gene; non-coding RNA; riboregulator; proteomic; thioredoxin; oncogene	REDOX REGULATION; POSSIBLE ASSOCIATION; GENE-EXPRESSION; IMPRINTED H19; TRANSCRIPT; CARCINOMA; ANTISENSE; RECEPTOR; PRODUCT; OVEREXPRESSION	Classically, the functional product of coding genes is a protein whose synthesis is directed by an mRNA-template. However, in the last few years several genes yielding an mRNA-like non-coding RNA as a functional product have been identified. In most cases these transcripts are synthesized by the RNA polymerase II, capped, spliced and polyadenylated, like classical mRNA. These latter have non-conserved open reading frames and seem to be untranslated. Consequently, it has been proposed and admitted that these genes act at the RNA level, and are so-called 'riboregulators'. H19 belongs to this class of gene and its role remains a matter of debate: for some authors it is an oncogene, for others a tumour suppressor. Here, we demonstrate, using a proteomic approach, that an H19 overexpression in human cancerous mammary epithelial cells stably transfected with genomic DNA containing the entire H19 gene is responsible for positively regulating at the post-transcriptional level the thioredoxin, a key protein of the cellular redox metabolism. Interestingly, this protein accumulates in many cancerous tissues, such as breast carcinomas in which we have also demonstrated an overexpression of the H19 gene.	USTL, UPRES EA 1033, Dev Biol Lab, F-59655 Villeneuve Dascq, France; Lab Immunopathol Cellulaire Malad Infect, UMR 8527, F-59021 Lille, France; USTL, CNRS, UMR 8576, Chim Biol Lab, F-59655 Villeneuve Dascq, France; USTL, INSERM 9938, Lab Physiol & Physiopathol Prostate Humaine, F-59655 Villeneuve Dascq, France	Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Curgy, JJ (corresponding author), USTL, UPRES EA 1033, Dev Biol Lab, SN3, F-59655 Villeneuve Dascq, France.	curgy@univ-lille1.fr	lemoine, jerome/C-4272-2014	lemoine, jerome/0000-0002-5497-6880; Vercoutter-Edouart, Anne-Sophie/0000-0002-3243-7122; Morad, Roudbaraki/0000-0001-5751-3323				Adriaenssens E, 1998, AM J PATHOL, V153, P1597, DOI 10.1016/S0002-9440(10)65748-3; Adriaenssens E, 1999, ONCOGENE, V18, P4460, DOI 10.1038/sj.onc.1202819; Ariel I, 1997, J CLIN PATHOL-MOL PA, V50, P34, DOI 10.1136/mp.50.1.34; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DOUCRASY S, 1993, INT J ONCOL, V2, P753; Dugimont T, 1995, BIOL CELL, V85, P117, DOI 10.1016/0248-4900(96)85272-5; ELKIN M, 1995, FEBS LETT, V374, P57, DOI 10.1016/0014-5793(95)01074-O; Erdmann VA, 2000, NUCLEIC ACIDS RES, V28, P197, DOI 10.1093/nar/28.1.197; Erdmann VA, 2001, NUCLEIC ACIDS RES, V29, P189, DOI 10.1093/nar/29.1.189; Ferret PJ, 2000, BIOCHEM J, V346, P759, DOI 10.1042/0264-6021:3460759; FUJII S, 1991, CANCER, V68, P1583, DOI 10.1002/1097-0142(19911001)68:7<1583::AID-CNCR2820680720>3.0.CO;2-N; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; Grogan TM, 2000, HUM PATHOL, V31, P475, DOI 10.1053/hp.2000.6546; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.biochem.54.1.237; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; Joubel A, 1996, CELL MOL BIOL, V42, P1159; Juan V, 2000, NUCLEIC ACIDS RES, V28, P1221, DOI 10.1093/nar/28.5.1221; Kawahara N, 1996, CANCER RES, V56, P5330; Kelley RL, 2000, CELL, V103, P9, DOI 10.1016/S0092-8674(00)00099-4; KONDO M, 1995, ONCOGENE, V10, P1193; Lease RA, 1998, P NATL ACAD SCI USA, V95, P12456, DOI 10.1073/pnas.95.21.12456; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; Milligan L, 2000, ONCOGENE, V19, P5810, DOI 10.1038/sj.onc.1203965; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Ueno M, 2000, IMMUNOL LETT, V75, P15, DOI 10.1016/S0165-2478(00)00284-4; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; Vercoutter-Edouart AS, 2001, EXP CELL RES, V262, P59, DOI 10.1006/excr.2000.5066; Wevrick R, 1997, HUM MOL GENET, V6, P325, DOI 10.1093/hmg/6.2.325; Wilkin F, 2000, EUR J BIOCHEM, V267, P4020, DOI 10.1046/j.1432-1327.2000.01438.x; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	49	41	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1625	1631		10.1038/sj.onc.1205233	http://dx.doi.org/10.1038/sj.onc.1205233			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896592				2022-12-17	WOS:000173956800019
J	Miyakoda, M; Suzuki, K; Kodama, S; Watanabe, M				Miyakoda, M; Suzuki, K; Kodama, S; Watanabe, M			Activation of ATM and phosphorylation of p53 by heat shock	ONCOGENE			English	Article						ATM; p53; heat shock; serine 15; phosphorylation	TUMOR-SUPPRESSOR PROTEIN; DAMAGE-INDUCED PHOSPHORYLATION; CELL-CYCLE CHECKPOINT; DOUBLE-STRAND BREAKS; N-TERMINAL SITES; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; DEPENDENT PHOSPHORYLATION; IONIZING-RADIATION; POTENTIAL MEDIATOR	p53 protein is phosphorylated in response to various stresses. Here we examined phosphorylation of p53 protein in normal human diploid cells after heat shock at 43degreesC for 2 h. We found that heat shock stimulates phosphorylation of p53 at Ser15 but not at Ser20, while X-irradiation at 4 Gy and 10 J/m(2) of UV induces phosphorylation of p53 at Ser15 and less significantly at Ser20. Increased phosphorylation of Ser15 was also observed in heat shocked GM638, the SV40-transformed human fibroblast cell line. Although X-ray irradiation induced phosphorylation of Ser6, 9, 20, and 37 in GM638 cells, heat shock did not affect the phosphorylation level of these serines. We observed little or no phosphorylation of p53 at Ser15 in two primary ataxia telangiectasia fibroblast cells, that are defective in ATM. Using an in vitro kinase assay, we confirmed that immunoprecipitated ATM from both heat-shocked and X-irradiated normal human diploid cells can phosphorylate p53 at Ser15 to a similar extent. These results indicate that heat shock induces phosphorylation of p53, especially at Ser15, and its phosphorylation is mediated by ATM kinase.	Nagasaki Univ, Sch Pharmaceut Sci, Lab Radiat & Life Sci, Nagasaki 8528521, Japan	Nagasaki University	Watanabe, M (corresponding author), Nagasaki Univ, Sch Pharmaceut Sci, Lab Radiat & Life Sci, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.	nabe@net.nagasaki-u.ac.jp						Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1993, ONCOGENE, V8, P1519; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Ikeda M, 1999, BIOL REPROD, V61, P393, DOI 10.1095/biolreprod61.2.393; JORRITSMA JBM, 1984, RADIAT RES, V98, P198, DOI 10.2307/3576063; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lavin MF, 2000, NAT CELL BIOL, V2, pE215, DOI 10.1038/35046628; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MILNE DM, 1992, ONCOGENE, V7, P1361; Miyakoda M, 1999, BIOCHEM BIOPH RES CO, V266, P377, DOI 10.1006/bbrc.1999.1829; MIYASHITA T, 1995, CELL, V80, P293; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; WATANABE M, 1992, INT J RADIAT BIOL, V62, P711, DOI 10.1080/09553009214552661; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	54	41	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1090	1096		10.1038/sj/onc/1205196	http://dx.doi.org/10.1038/sj/onc/1205196			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850826				2022-12-17	WOS:000173580100012
J	Rong, R; He, Q; Liu, Y; Sheikh, MS; Huang, Y				Rong, R; He, Q; Liu, Y; Sheikh, MS; Huang, Y			TC21 mediates transformation and cell survival via activation of phosphatidylinositol 3-kinase/Akt and NF-kappa B signaling pathway	ONCOGENE			English	Article						TC21; PI3-K; Akt; transformation; cell survival; NF-kappa B	PHOSPHOINOSITIDE 3-KINASE; KINASE CASCADE; RAS; PROTEIN; AKT; EXPRESSION; INDUCTION; TARGET; FAMILY; DEATH	The signaling pathways of TC21-mediated transformation and cell survival are not well-established. In this study, we have investigated the role of PI3-K/Akt signaling pathway in oncogenic-TC21-mediated transformation and cell survival. We found that oncogenic-TC21 stimulated the PI3-K activity. This was associated with the activation of Akt, a key, component of PI3-K signaling pathway. We also found that TC21 interacted and formed complex with PI3-K. Mutations in the GTP-binding region of TC21, which enhanced GTP-binding potential of this protein, also stimulated its association with PI3-K, suggesting that PI3-K may preferentially interact with the GTP-bound form. Suppression of PI3-K and Akt by specific inhibitors LY294002 and Wortmannin reversed TC21-induced transformation. Likewise, inhibition of PI3-K activity by the PI3-K phosphotase PTEN reduced TC21-mediated focus formation in NIH3T3 cells. Investigation of TC21's effect on cell survival revealed that mutant-TC21 expressing cells were more resistant to etoposide- and cisplatin-induced cell death, and this was associated with the activation of anti-apoptotic protein NF-kappaB, a downstream target of Akt. Treatment of PI3-K inhibitor LY294002 significantly suppressed TC21-mediated NF-kappaB activation. In conclusion, we have identified PI3-K as an effector of TC21 and demonstrated that the PI3-K/Akt signaling pathway plays important roles in TC21-mediated transformation and cell survival.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Huang, Y (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	huangy@mail.upstate.edu	Liu, Yusen/E-3527-2011	Liu, Yusen/0000-0002-0994-0109				Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; AUGER KR, 1992, J BIOL CHEM, V267, P5408; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Clark GJ, 1996, ONCOGENE, V12, P169; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Graham WJ, 1996, HEALTH POLICY PLANN, V11, P16, DOI 10.1093/heapol/11.1.16; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUANG Y, 1995, ONCOGENE, V11, P1255; Huang Y, 2000, J BIOL CHEM, V275, P18234, DOI 10.1074/jbc.M909431199; HUTTER D, 2000, BIOCH J 1, V15, P352; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marais R, 1996, CANCER SURV, V27, P101; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Ozes ON, 1999, NATURE, V401, P82; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; WIRTH T, 1988, EMBO J, V7, P3109, DOI 10.1002/j.1460-2075.1988.tb03177.x; Woodgett JR, 1996, CANCER SURV, V27, P127; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	59	41	43	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1062	1070		10.1038/sj.onc.1205154	http://dx.doi.org/10.1038/sj.onc.1205154			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850823				2022-12-17	WOS:000173580100009
J	Zhong, MH; Lu, ZM; Foster, DA				Zhong, MH; Lu, ZM; Foster, DA			Downregulating PKC delta provides a PI3K/Akt-independent survival signal that overcomes apoptotic signals generated by c-Src overexpression	ONCOGENE			English	Article						apoptosis; c-Src; PKC delta; tumor promoter; TPA	PROTEIN-KINASE-C; V-SRC; EMBRYO FIBROBLASTS; CELL-SURVIVAL; ACTIVATION; RAS; CANCER; DEGRADATION; SUPPRESSION; CODON-531	3Y1 rat fibroblasts overexpressing the tyrosine kinase c-Src (3Y1(c-Src) cells) become transformed by downregulation of protein kinase C delta (PKC delta). However, when 3Y1(c-Src) cells were subjected to serum withdrawal, they underwent apoptosis via a cytochrome c/caspase 9 pathway. In contrast, neither parental nor v-Src-transformed 3Y1 cells underwent apoptosis when subjected to serum withdrawal. If PKC delta was downregulated, the apoptotic phenotypes induced by serum withdrawal in the 3Y1(c-Src) cells were suppressed. The apparent survival signal generated by PKC delta downregulation was independent of the phosphatidylinositol-3-kinase (PI3K)/Akt survival pathway. Collectively, these data indicate that (1) c-Src overexpression renders cells sensitive to apoptotic stress, and (2) that downregulation of PKC delta provides a novel PI3K/Akt-independent survival signal capable of suppressing apoptotic signals.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.				NCI NIH HHS [CA 46677] Funding Source: Medline; NCRR NIH HHS [RR 03037] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CRESSMAN CM, 1995, FEBS LETT, V367, P223, DOI 10.1016/0014-5793(95)00543-I; Daigo Y, 1999, CANCER RES, V59, P4222; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DOTTO GP, 1985, NATURE, V318, P472; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Wang NM, 2000, CANCER LETT, V150, P201, DOI 10.1016/S0304-3835(99)00398-5; Webb BL, 2000, MOL CELL BIOL, V20, P9271, DOI 10.1128/MCB.20.24.9271-9280.2000; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	39	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1071	1078		10.1038/sj/onc/1205165	http://dx.doi.org/10.1038/sj/onc/1205165			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850824				2022-12-17	WOS:000173580100010
J	Gurova, KV; Roklin, OW; Krivokrysenko, VI; Chumakov, PM; Cohen, MB; Feinstein, E; Gudkov, AV				Gurova, KV; Roklin, OW; Krivokrysenko, VI; Chumakov, PM; Cohen, MB; Feinstein, E; Gudkov, AV			Expression of prostate specific antigen (PSA) is negatively regulated by p53	ONCOGENE			English	Article						prostate specific antigen; p53; transcription; prostate cancer	WILD-TYPE P53; ADENOCARCINOMA CELL-LINE; RADICAL PROSTATECTOMY; HORMONAL-REGULATION; GENE-EXPRESSION; MESSENGER-RNA; CANCER; CARCINOMA; LNCAP; REPRESSION	Although prostate-specific antigen (PSA) is considered a uniquely important tumor marker and is broadly used for early detection of prostate cancer, the molecular mechanisms underlying its elevated expression in tumors have been unknown. By using cDNA microarray gene expression profiling, we found a fourfold increase in the PSA mRNA level in prostatic carcinoma cell line LNCaP, in which the p53 pathway was suppressed by a dominant negative p53 mutant. Consistently, p53 suppression caused a 4-8-fold increase in secretion of PSA protein in culture medium, suggesting that PSA gene expression is under negative control of p53. While wild type p53 strongly repressed, dominant negative p53 mutants stimulated PSA promoter-driven transcription and secretion of PSA in transient transfection experiments. The inhibitory effect of wild type p53 was undetectable in the presence of trychostatin A, suggesting the involvement of histone deacetylation in negative regulation of PSA promoter activity. Thus, PSA is likely to be a tissue specific indicator of transformation-associated p53 suppression in prostate cells. This finding provides a plausible explanation for a frequent increase of PSA levels in advanced prostate cancer.	Cleveland Clin Fdn, Dept Mol Biol NC20, Lerner Res Inst, Cleveland, OH 44195 USA; Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; Quark Biotech Inc, Pleasonton, CA 94566 USA	Cleveland Clinic Foundation; University of Iowa	Gudkov, AV (corresponding author), Cleveland Clin Fdn, Dept Mol Biol NC20, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Chumakov, Peter M/E-7731-2014	Chumakov, Peter/0000-0002-8078-2908; Gudkov, Andrei/0000-0003-2548-0154	NATIONAL CANCER INSTITUTE [R01CA076673, R01CA075179] Funding Source: NIH RePORTER; NCI NIH HHS [CA76673, CA75179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; COFFEY DS, 1993, CANCER, V71, P880, DOI 10.1002/1097-0142(19930201)71:3+<880::AID-CNCR2820711403>3.0.CO;2-6; CordonCardo C, 1997, SEMIN SURG ONCOL, V13, P319, DOI 10.1002/(SICI)1098-2388(199709/10)13:5<319::AID-SSU5>3.0.CO;2-G; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Kim J, 1999, UROL CLIN N AM, V26, P281, DOI 10.1016/S0094-0143(05)70068-9; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Osman I, 1999, CLIN CANCER RES, V5, P2082; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Ozen M, 2000, ANTICANCER RES, V20, P1905; Quinn DI, 2000, CANCER RES, V60, P1585; Rokhlin OW, 2000, ONCOGENE, V19, P1959, DOI 10.1038/sj.onc.1203453; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Stackhouse GB, 1999, J UROLOGY, V162, P2040, DOI 10.1016/S0022-5347(05)68095-0; Steele RJC, 1998, BRIT J SURG, V85, P1460; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Szende B, 1999, UROL INT, V63, P115, DOI 10.1159/000030429; Trapman J, 1997, SEMIN CANCER BIOL, V8, P29, DOI 10.1006/scbi.1997.0050; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Yeung F, 2000, J BIOL CHEM, V275, P40846, DOI 10.1074/jbc.M002755200; YOUNG CYF, 1991, CANCER RES, V51, P3748; Zhang JY, 1997, NUCLEIC ACIDS RES, V25, P3143, DOI 10.1093/nar/25.15.3143; Zhang SB, 1997, BIOCHEM BIOPH RES CO, V231, P784, DOI 10.1006/bbrc.1997.6197	25	41	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2002	21	1					153	157		10.1038/sj.onc.1205001	http://dx.doi.org/10.1038/sj.onc.1205001			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791186				2022-12-17	WOS:000172887800016
J	Le, XF; Marcelli, M; McWatters, A; Nan, BC; Mills, GB; O'Brian, CA; Bast, RC				Le, XF; Marcelli, M; McWatters, A; Nan, BC; Mills, GB; O'Brian, CA; Bast, RC			Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity	ONCOGENE			English	Article						heregulin; protein kinase C; apoptosis; Bcl-2; caspase-7; HER2	BREAST-CANCER CELLS; NEU DIFFERENTIATION FACTOR; TUMOR-CELLS; GROWTH-FACTOR; SIGNALING NETWORK; PROSTATE-CANCER; LINE LNCAP; IN-VIVO; RECEPTOR; LIGAND	Heregulins are a group of growth factors that play diverse and critical roles in the signaling network of the human epidermal growth factor receptor (HER or EGFR) superfamily. Our earlier studies have shown that recombinant heregulin beta1 (HRG) induces apoptosis in SKBr3 breast cancer cells that overexpress HER2. Here we report molecular mechanisms of HRG-induced apoptosis. HRG treatment of SKBr3 cells for 72 h decreased the level of Bcl-2 protein. HRG treatment led to degradation of poly (ADP-ribose) polymerase (PARP) and activated both caspase-9 and caspase-7. No significant activation of caspase-3, -6, or -8 was detected. Expression of exogenous caspase-7 by adenovirus-caspase-7 (Ad-casp-7) in SKBr3 cells resulted in apoptosis, which mimicked the effect of HRG treatment. Expression of exogenous caspase-7 had no impact on Bcl-2 expression, but promoted PARP degradation. Two highly selective inhibitors of protein kinase C (PKC), GF109203X (GF) and Ro318425 (Ro), significantly enhanced HRG-induced apoptosis as determined by flow cytometric analysis and DNA fragmentation assay. Accordingly, the PKC inhibitor GF further decreased the level of Bcl-2 protein and further degraded PARP in HRG-treated cells. Assay of PKC activity indicated that HRG activated PKC in SKBr3 cells, predominantly affecting the PKC alpha isoform. To confirm which PKC isoform(s) mediated potentiation of HRG-induced apoptosis, the profile of PKC isoforms was measured in SKBr3 cells. Five PKC isoforms, PKC alpha, PKCi, PKC zeta, PKC lambda, and PKC delta as well as their receptors (RACK1) were expressed in this cell line. Treatment with PKC inhibitors GF and Ro decreased protein levels of both PKC alpha and PKC delta at 24 h. PKC alpha levels were still depressed at 72 h. GF and Ro had little effect on the expression of other PKC isoforms. An inhibitor of classical PKC isoforms (Go6976) enhanced HRG-induced apoptosis, whereas the PKC delta selective inhibitor rottlerin did not. As PKCa was the only classical isoform expressed in SKBr3 cells, the effect of Go6976 on HRG-induced apoptosis largely related to inhibition of PKCa. Constitutive expression of wild-type PKC alpha attenuated the apoptosis produced by HRG and GF. Consequently, HRG-induced apoptosis in SKBr3 cells appeared to involve down-regulation of Bcl-2 protein, activation of caspase-9 and caspase-7, and degradation of PARP. Inhibition of PKC function enhanced HRG-induced apoptosis, leading to synergistic down-regulation of Bcl-2 expression. Impairment of the PKC alpha isoform alone was sufficient to potentiate HRG-induced apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine	Bast, RC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 355, Houston, TX 77030 USA.		marcelli, marco/AGR-6853-2022; Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NATIONAL CANCER INSTITUTE [R01CA039930] Funding Source: NIH RePORTER; NCI NIH HHS [CA39930] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adlkofer K, 2000, GLIA, V29, P104, DOI 10.1002/(SICI)1098-1136(20000115)29:2<104::AID-GLIA2>3.0.CO;2-2; Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Alexandre S, 2000, EXP CELL RES, V255, P30, DOI 10.1006/excr.1999.4759; Alexandre S, 2000, BIOCHIMIE, V82, P1115, DOI 10.1016/S0300-9084(00)01194-9; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; Bagheri-Yarmand R, 2000, J BIOL CHEM, V275, P39451, DOI 10.1074/jbc.M006150200; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Daly JM, 1997, CANCER RES, V57, P3804; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deacon EM, 1997, J CLIN PATHOL-MOL PA, V50, P124, DOI 10.1136/mp.50.3.124; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Emoto Y, 1996, BLOOD, V87, P1990; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Gottlieb RA, 2000, FEBS LETT, V482, P6, DOI 10.1016/S0014-5793(00)02010-X; Grimm S, 1998, J EXP MED, V188, P1535, DOI 10.1084/jem.188.8.1535; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Guerra-Vladusic FK, 1999, INT J ONCOL, V15, P883; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Harris LN, 1998, CLIN CANCER RES, V4, P1005; Hijazi MM, 2000, INT J ONCOL, V17, P629; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Krane IM, 1996, ONCOGENE, V12, P1781; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Le XF, 2000, CLIN CANCER RES, V6, P260; Le XF, 2000, CANCER RES, V60, P3522; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Lewis GD, 1996, CANCER RES, V56, P1457; Machleidt T, 1998, FEBS LETT, V436, P51, DOI 10.1016/S0014-5793(98)01095-3; Marcelli M, 1999, CANCER RES, V59, P382; Marcelli M, 1998, CANCER RES, V58, P76; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Panvichian R, 1998, CANCER RES, V58, P4667; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rokhlin OW, 1998, CANCER RES, V58, P5870; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Tan M, 1999, CANCER RES, V59, P1620; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Ward NE, 2000, BIOCHEMISTRY-US, V39, P10319, DOI 10.1021/bi000781g; Weinstein EJ, 2000, CANCER RES, V60, P3856; Weinstein EJ, 1998, ONCOGENE, V17, P2107, DOI 10.1038/sj.onc.1202428; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Xu FJ, 1997, CLIN CANCER RES, V3, P1629; Xu FJ, 1999, CLIN CANCER RES, V5, P3653; Yen L, 2000, ONCOGENE, V19, P3460, DOI 10.1038/sj.onc.1203685; Zhang LM, 1997, PARASITE, V4, P94; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200	62	41	44	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2001	20	57					8258	8269		10.1038/sj.onc.1205039	http://dx.doi.org/10.1038/sj.onc.1205039			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781840				2022-12-17	WOS:000172507800009
J	Umansky, M; Yasui, W; Hallak, A; Brill, S; Shapira, I; Halpern, Z; Hibshoosh, H; Rattan, J; Meltzer, S; Tahara, E; Arber, N				Umansky, M; Yasui, W; Hallak, A; Brill, S; Shapira, I; Halpern, Z; Hibshoosh, H; Rattan, J; Meltzer, S; Tahara, E; Arber, N			Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus	ONCOGENE			English	Article						cell cycle; Barrett's esophagus; cyclins; cyclin-dependent kinase inhibitors; proton pump inhibitors	PHOTODYNAMIC THERAPY; INCREASED EXPRESSION; GASTRIC CARDIA; CDK INHIBITORS; ADENOCARCINOMA; CANCER; GENE; PROGRESSION; D1; OVEREXPRESSION	Neoplastic progression in Barrett's esophagus is a multistep process in which the metaplastic columnar epithelium sequentially evolves through a metaplasia-dysplasia-carcinoma sequence. The expression and DNA copy number of key cell cycle regulatory genes in paired normal and Barrett's esophagus samples was evaluated. Protein levels were evaluated in 60 formalin-fixed, paraffin-embedded human tissues by immunohistochemistry. DNA copy number from 20 fresh tissue pairs was analysed by Southern blot analysis. All normal mucosal samples expressed the p27(kip1) protein, but did not display appreciable nuclear staining for p16(kip4), p22(cip1) or cyclins DI and E. Barrett's metaplastic specimens displayed increased expression levels of p16(kip4) (74%), p21(cip1) (89%) and cyclins DI (43%) and E (37%). p27 protein was absent in three cases. There was a significant correlation between the expression of p16(kip4) and cyclin E, and p21(cip1) and p27(kip4) with cyclin D1. DNA analysis did not reveal any amplification or deletion of these genes. Acid suppression, however, was associated with significantly lower expression levels of key cell cycle proteins. Increased expression of key cell cycle regulatory genes appears to occur early in the neoplastic progression associated with Barrett's esophagus. Treatment with proton pump inhibitors appears to alter this increased expression.	Tel Aviv Med Ctr & Sch Med, GI Oncol Unit, Dept Gastroenterol, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, IL-69978 Tel Aviv, Israel; Columbia Univ, Dept Pathol, New York, NY USA; Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD USA; Hiroshima Med Ctr, Dept Pathol, Hiroshima, Japan	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Columbia University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Arber, N (corresponding author), Tel Aviv Med Ctr & Sch Med, GI Oncol Unit, Dept Gastroenterol, IL-64239 Tel Aviv, Israel.			Arber, Nadir/0000-0001-5283-6991	NATIONAL CANCER INSTITUTE [R01CA077057, R01CA078843, U01CA085069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER; NCI NIH HHS [CA78843, CA85069, CA77057] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arber N, 1996, CANCER EPIDEM BIOMAR, V5, P457; Arber N, 1996, ONCOGENE, V12, P1903; Arber N, 1999, HUM PATHOL, V30, P1087, DOI 10.1016/S0046-8177(99)90227-7; BARRETT NR, 1957, SURGERY, V41, P881; BILIR N, 1994, GASTROENTEROLOGY, V106, pA372; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BLOT WJ, 1993, JAMA-J AM MED ASSOC, V270, P1320, DOI 10.1001/jama.270.11.1320; Brien TP, 2000, HUM PATHOL, V31, P35, DOI 10.1016/S0046-8177(00)80195-1; BRIER SS, 1980, BIOMETRIKA, V67, P591; CHOW WH, 1995, JAMA-J AM MED ASSOC, V274, P474, DOI 10.1001/jama.274.6.474; CLARK GWB, 1995, ANN CHIR GYNAECOL FE, V84, P139; FINKEL RG, 1994, GASTROENTEROLOGY, V106, pA431; Fitzgerald RC, 1996, J CLIN INVEST, V98, P2120, DOI 10.1172/JCI119018; Fitzgerald RC, 1998, DIGEST DIS, V16, P63, DOI 10.1159/000016850; FLEJOU JF, 1994, GASTROENTEROLOGY, V106, pA386; Gimenez A, 1999, ARCH PATHOL LAB MED, V123, P1260; GORE S, 1993, ALIMENT PHARM THERAP, V7, P623; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1992, CANCER RES, V52, P2980; KIM R, 1992, GASTROENTEROLOGY, V106, pA402; LIGHTDALE CJ, 1995, GASTROINTEST ENDOSC, V42, P96, DOI 10.1016/S0016-5107(95)70256-3; McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996; Overholt BF, 1996, AM J GASTROENTEROL, V91, P1719; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PERA M, 1993, GASTROENTEROLOGY, V104, P510, DOI 10.1016/0016-5085(93)90420-H; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; QUATOLASCAR O, 1999, GASTROENTEROLOGY, V117, P327; REDD JL, 1994, GASTROENTEROLOGY, V106, pA431; REID BJ, 1993, GASTROENTEROLOGY, V105, P119, DOI 10.1016/0016-5085(93)90017-7; REID BJ, 1991, GASTROENTEROL CLIN N, V20, P817; SAGAR PM, 1995, BRIT J SURG, V82, P806, DOI 10.1002/bjs.1800820628; Sampliner RE, 1996, GASTROINTEST ENDOSC, V44, P532, DOI 10.1016/S0016-5107(96)70004-4; SAMPLINER RE, 1994, AM J GASTROENTEROL, V89, P1844; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKINNER DB, 1983, ANN SURG, V198, P554, DOI 10.1097/00000658-198310000-00016; Spechler SJ, 1996, GASTROENTEROLOGY, V110, P614, DOI 10.1053/gast.1996.v110.agast960614; Younes M, 1999, HUM PATHOL, V30, P1309, DOI 10.1016/S0046-8177(99)90061-8	39	41	43	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					7987	7991		10.1038/sj.onc.1204947	http://dx.doi.org/10.1038/sj.onc.1204947			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753681				2022-12-17	WOS:000172288700007
J	Riley, D; Carragher, N; Frame, MC; Wyke, JA				Riley, D; Carragher, N; Frame, MC; Wyke, JA			The mechanism of cell cycle regulation by v-Src	ONCOGENE			English	Article						v-Src; ERK; P13-K; p27; cell cycle	PROTEIN-KINASE KINASE; D-DEPENDENT KINASES; CDK INHIBITORS; EXPRESSION; P21; PHOSPHORYLATION; ONCOPROTEIN; BINDING; GENE; MITOGENESIS	The tyrosine kinase oncoprotein v-Src can overcome the requirements for serum growth factors and anchorage which restrain normal cell growth. Here we investigated the biochemical mechanisms whereby v-Src induces quiescent cells to enter S phase in the absence of serum mitogens. Activating a temperature sensitive v-Src in quiescent cells sequentially induced cyclins D1, E and A and also down regulated p27. We addressed whether p27 down regulation was required to activate cyclin D1/ CDK4/6 or cyclin E/CDK2 by engineering cells with inducible p27. Both S phase entry and activation of cyclin/CDKs were inhibited by over expression of p27. Using cells engineered with inducible p16 we showed that Cyclin D/CDK4/6 activity was required for v-Src to increase expression of cyclin A but not cyclin E. To determine which downstream kinases mediated these effects of v-Src we added pharmacological inhibitors of phosphatidylinositol 3-kinase (PI3-K), LY294002 or mitogen activated protein kinase kinase (MEK), U0126. PI3-K was required for v-Src to activate MEK and MEK was required for v-Src to increase expression of cyclins DI and E. However, the MEK inhibitor prevented p27 protein down regulation whereas the PI3K inhibitor did not. This was because reduced PI3-K activity lead to proteolytic degradation of p27.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Wyke, JA (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.			Carragher, Neil/0000-0001-5541-9747				Adachi M, 1997, BLOOD, V90, P126; Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Botz J, 1996, MOL CELL BIOL, V16, P3401; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Farrell A, 2000, MOL CELL BIOL, V20, P749, DOI 10.1128/MCB.20.3.749-754.2000; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fotedar R, 1996, ONCOGENE, V12, P2155; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAEFNER B, 1995, J BIOL CHEM, V270, P7937, DOI 10.1074/jbc.270.14.7937; HALL M, 1995, ONCOGENE, V11, P1581; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; Kaldis P, 2000, EUR J BIOCHEM, V267, P4213, DOI 10.1046/j.1432-1327.2000.01455.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Lee KM, 1999, CURR BIOL, V9, P441, DOI 10.1016/S0960-9822(99)80194-8; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morisaki H, 1999, EXP CELL RES, V253, P503, DOI 10.1006/excr.1999.4698; Nishiwaki E, 2000, MOL CELL BIOL, V20, P7726, DOI 10.1128/MCB.20.20.7726-7734.2000; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WHITE MK, 1988, MOL CELL BIOL, V8, P138, DOI 10.1128/MCB.8.1.138; WYKE AW, 1993, CELL GROWTH DIFFER, V4, P671; WYKE AW, 1995, CELL GROWTH DIFFER, V6, P1225	47	41	45	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					5941	5950		10.1038/sj.onc.1204826	http://dx.doi.org/10.1038/sj.onc.1204826			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593401				2022-12-17	WOS:000171056300001
J	Jiang, YX; Cui, L; Yie, TA; Rom, WN; Cheng, H; Tchou-Wong, KM				Jiang, YX; Cui, L; Yie, TA; Rom, WN; Cheng, H; Tchou-Wong, KM			Inhibition of anchorage-independent growth and lung metastasis of A549 lung carcinoma cells by I kappa B beta	ONCOGENE			English	Article						I kappa B beta; anchorage-independent; growth in low serum; apoptosis; metastasis	TRANSCRIPTION FACTOR; CANCER CELLS; TUMOR-GROWTH; ACTIVATION; ALPHA; TUMORIGENICITY; EXPRESSION; APOPTOSIS; RAS; TRANSFORMATION	To evaluate the role of the NF-kappaB signaling pathway in oncogenic transformation, we expressed I kappaB beta, a specific inhibitor of NF-kappaB, in two human lung adenocarcinoma cell lines, A549 and H441, Expression of I kappaB beta significantly reduced NF-kappaB activation induced by cotransfection with p65/RelA or TNF-alpha and abrogated the basal NF-kappaB activity in A549 cells. Transfection of I kappaB beta into A549, H441 and K-uas-transformed NIH3T3 cells suppressed anchorage-independent growth as measured by colony formation in soft agar, Anchorage-independent growth of vector-transfected A549 cells in reduced serum could be enhanced by both EGF and IGF-I. In contrast, only EGF but not IGF-I could induce anchorage-independent growth of I kappaB beta -expressing A549 cells, suggesting that the IGF-I signaling pathway regulating growth and survival may be blocked by I kappaB beta. Interestingly, expression of I kappaB beta suppressed growth of A549 cells in low serum in vitro without affecting in vivo growth subcutaneously in nude mice, However, metastatic growth of I kappaB beta -expressing A549 cells in the lungs of nude mice was significantly inhibited, These results provide evidence that NF kappaB plays an important role in anchorage-independent growth and metastatic growth of lung carcinoma cells.	NYU, Sch Med, Dept Med, Div Pulm & Crit Care Med, New York, NY 10016 USA; NYU, Sch Med, Dept Pediat, New York, NY 10016 USA; NYU, Sch Med, Dept Environm Med, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University; New York University; New York University; New York University	Tchou-Wong, KM (corresponding author), NYU, Sch Med, Dept Med, Div Pulm & Crit Care Med, 550 1st Ave,MSB 147, New York, NY 10016 USA.			Rom, William/0000-0002-8793-7028	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059832, R01HL062055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009161] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62055, R01 HL59832] Funding Source: Medline; NIEHS NIH HHS [R01 ES09161] Funding Source: Medline; PHS HHS [M0100096 GCRC] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Batra RK, 1999, AM J RESP CELL MOL, V21, P238, DOI 10.1165/ajrcmb.21.2.3470; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Bost F, 1999, MOL CELL BIOL, V19, P1938; DODSON MG, 1981, CANCER RES, V41, P1441; Duffey DC, 1999, CANCER RES, V59, P3468; Feig BW, 1999, SURGERY, V126, P399, DOI 10.1016/S0039-6060(99)70184-4; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Foo SY, 1999, TRENDS GENET, V15, P229; HASTINGS RJ, 1981, INT J CANCER, V27, P15, DOI 10.1002/ijc.2910270104; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Huang S, 2000, CLIN CANCER RES, V6, P2573; Jiang YX, 1999, ONCOGENE, V18, P6071, DOI 10.1038/sj.onc.1202984; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Jones DR, 2000, ANN THORAC SURG, V70, P930, DOI 10.1016/S0003-4975(00)01635-0; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; OVADIA H, 1975, EUR J CANCER, V11, P413, DOI 10.1016/0014-2964(75)90072-9; Piette J, 1997, BIOL CHEM, V378, P1237; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Sharma HW, 1996, ANTICANCER RES, V16, P589; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEGFRIED JM, 1987, CANCER RES, V47, P2903; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	35	41	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2254	2263		10.1038/sj.onc.1204293	http://dx.doi.org/10.1038/sj.onc.1204293			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402320				2022-12-17	WOS:000168404500007
J	Aigner, A; Juhl, H; Malerczyk, C; Tkybusch, A; Benz, CC; Czubayko, F				Aigner, A; Juhl, H; Malerczyk, C; Tkybusch, A; Benz, CC; Czubayko, F			Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation	ONCOGENE			English	Article						HER2; c-erbB2 (neu); HER2-ECD; gastric cancer; breast cancer; ribozyme	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; BREAST-CANCER; OVARIAN-CANCER; GENE ENCODES; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; CARCINOMA-CELLS; FACTOR RECEPTOR; MESSENGER-RNA	Overexpression of the HER2 (neu/c-erbB-2) oncogene frequently coincides with an aggressive clinical course of certain human adenocarcinomas. Expression and secretion of aberrant HER2 splice variants has been reported in various cell lines and tissues and can interfere with the oncogenic HER2 activity. Here we demonstrate, using two different approaches, that expression of a truncated 100 kDa HER2 variant which encodes the extracellular domain of HER2 (HER-ECD) inhibits growth factor-mediated tumour cell proliferation. A HER2-ECD cDNA encoding the truncated variant was overexpressed in MCF7 breast cancer cells, HER2-ECD overexpression decreased spontaneous proliferation of MCF7 cells as well as heregulin-mediated soft agar colony formation, Concomitantly, heregulin-induced phosphorylation of HER4 as well as downstream activation of p44/p42 MAP-kinases was decreased. To confirm these data, ribozymes were targeted to the 3'-untranslated region of the 2.3 kb HER2-ECD mRNA which is spontaneously expressed in MKN7 gastric cancer cells. HER2-ECD-targeted ribozymes downregulated HER2-ECD expression and enhanced EGF-mediated soft agar colony formation of MKN7 cells. In parallel, EGF-induced activation of p44/p42 MAP-kinases and activation of c-Fos expression were increased in ribozyme-transfected MKN7 cells. Finally, in RT-PCR we found a trend towards a progressive loss of 2.3 kb HER2-ECD mRNA expression in more advanced gastric tumours, These data show that the HER2-ECD variant inhibits growth factor-mediated tumour cell proliferation suggesting an important role during the progression of human cancer.	Univ Marburg, Dept Pharmacol & Toxicol, D-35033 Marburg, Germany; Georgetown Univ, Lombardi Canc Ctr, Washington, DC 20007 USA; Univ Hosp Kiel, Dept Surg, D-24105 Kiel, Germany; Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA	Philipps University Marburg; Georgetown University; University of Kiel; Schleswig Holstein University Hospital; University of California System; University of California San Francisco	Czubayko, F (corresponding author), Univ Marburg, Dept Pharmacol & Toxicol, Karl von Frisch Str 1, D-35033 Marburg, Germany.		Aigner, Achim/R-4429-2017	Aigner, Achim/0000-0002-2778-6256	NATIONAL CANCER INSTITUTE [P30CA051008] Funding Source: NIH RePORTER; NCI NIH HHS [2P30-CA-51008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aigner A, 2000, GROWTH FACTORS, V18, P51, DOI 10.3109/08977190009003233; Allgayer H, 2000, J CLIN ONCOL, V18, P2201, DOI 10.1200/JCO.2000.18.11.2201; Colomer R, 2000, CLIN CANCER RES, V6, P2356; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; Gebhardt F, 1998, BIOCHEM BIOPH RES CO, V247, P319, DOI 10.1006/bbrc.1998.8779; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Hsieh SS, 2000, INT J CANCER, V86, P644, DOI 10.1002/(SICI)1097-0215(20000601)86:5<644::AID-IJC7>3.0.CO;2-T; Juhl H, 1997, J BIOL CHEM, V272, P29482, DOI 10.1074/jbc.272.47.29482; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Lee H, 1998, ONCOGENE, V16, P3243, DOI 10.1038/sj.onc.1201866; Lewis GD, 1996, CANCER RES, V56, P1457; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Reiter JL, 1996, NUCLEIC ACIDS RES, V24, P4050, DOI 10.1093/nar/24.20.4050; RUBIN LA, 1985, J IMMUNOL, V135, P3172; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	30	41	49	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2101	2111		10.1038/sj.onc.1204305	http://dx.doi.org/10.1038/sj.onc.1204305			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360194				2022-12-17	WOS:000168116700005
J	Decesse, JT; Medjkane, S; Datto, MB; Cremisi, CE				Decesse, JT; Medjkane, S; Datto, MB; Cremisi, CE			RB regulates transcription of the p21/WAF1/CIP1 gene	ONCOGENE			English	Article						RB; p21(WAF1/CIP); Spl; epithelial cells; differentiation	CDK-INHIBITOR P21(WAF1/CIP1); SV40 T-ANTIGEN; CELL-CYCLE; RETINOBLASTOMA PROTEIN; SP1-MEDIATED TRANSCRIPTION; FUNCTIONAL-ANALYSIS; EPITHELIAL-CELLS; PRODUCT RB; EXPRESSION; DIFFERENTIATION	We have previously shown that RB plays an important role in the maintenance of the epithelial phenotype, p21 is also involved in several terminal differentiation systems including keratinocytes. We report here that p21 is an RB target gene in epithelial cells, but not in fibroblasts where RB is unable to transactivate p21 transcriptional expression. In epithelial cells, when RB family factors were inactivated by SV40 T antigen (LT), p21 expression was strongly repressed, whereas its expression was not affected when the cells were transformed by a mutated LT leaving RB active but inactivating p53. Moreover, retransformation by RB of LT transformed epithelial cells totally restored p21 expression. By cotransfection experiments and using deletions and point mutations of the p21 promoter, we show that the minimal region required for the RB-mediated transcriptional activation maps to a GC-rich region located between -83 and -74. This region is shown to interact specifically with the transcription factor Sp1 and Sp3. Thus for the first time, we show a positive transcriptional relationship between RB and p21 in epithelial cells. Since p21 keeps RB in a hypophosphorylated state important for its transcriptional activity during differentiation, our results imply an auto-loop of regulation between RB and p21 that may be essential for the maintenance of the differentiation state. We propose that this transcriptional relationship might be necessary of their roles in cell cycle arrest and in several differentiation pathways.	Inst Andre Lwoff, Lab Oncogenese Differenciat & Transduct Signal, CNRS, UPR 9079, F-94801 Villejuif, France; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	Centre National de la Recherche Scientifique (CNRS); Duke University	Cremisi, CE (corresponding author), Inst Andre Lwoff, Lab Oncogenese Differenciat & Transduct Signal, CNRS, UPR 9079, 7 Rue Guy Moquet, F-94801 Villejuif, France.			Medjkane, Souhila/0000-0001-7973-7707				Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FUCHS E, 1993, J CELL SCI, P197; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; JIANG HP, 1994, ONCOGENE, V9, P3397; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Martel C, 1997, CELL GROWTH DIFFER, V8, P165; Martel C, 1996, CELL DEATH DIFFER, V3, P285; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	43	41	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2001	20	8					962	971		10.1038/sj.onc.1204169	http://dx.doi.org/10.1038/sj.onc.1204169			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314031				2022-12-17	WOS:000167097000007
J	Sandhu, C; Donovan, J; Bhattacharya, N; Stampfer, M; Worland, P; Slingerland, J				Sandhu, C; Donovan, J; Bhattacharya, N; Stampfer, M; Worland, P; Slingerland, J			Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells	ONCOGENE			English	Article						senescence; cell cycle; Cdc25A; p15(INK4B); cyclin E-cdk2; HMEC	GROWTH-FACTOR-BETA; CELLULAR SENESCENCE; HUMAN FIBROBLASTS; REPLICATIVE SENESCENCE; CDK INHIBITORS; DNA-SYNTHESIS; G(1)/S TRANSITION; DEPENDENT KINASES; PROTEIN-KINASE; GENE STATUS	Replicative senescence may be an important tumor suppressive mechanism for human cells. We investigated the mechanism of cell cycle arrest at senescence in human mammary epithelial cells (HMECs) that have undergone a period of 'self-selection', and as a consequence exhibit diminished p16(INK4A) levels. As HMECs approached senescence, the proportion of cells with a 2N DNA content increased and that in S phase decreased progressively. Cyclin D1-cdk4, cyclin E-cdk2 and cyclin A-cdk2 activities were not abruptly inhibited, but rather diminished steadily with increasing population age. In contrast to observations in fibroblast, p21(Cip1) was not increased at senescence in HMECs. There was no increase in p27(Kip1) levels nor in KIP association with targets cdks. While p15(INK4B) and its binding to both cdk4 and cdk6 increased with increasing passage, some cyclin D1-bound cdk4 and cdk6 persisted in senescent cells, whose inhibition could not be attributed to p15(INK4B). The inhibition of cyclin E-cdk2 in senescent HMECs was accompanied by increased inhibitory phosphorylation of cdk2, in association with a progressive loss of Cdc25A. Recombinant Cdc25A strongly reactivated cyclin E-cdk2 from senescent HMECs suggesting that reduction of Cdc25A contributes to cyclin E-cdk2 inhibition and G1 arrest at senescence. Although ectopic expression of Cdc25A failed to extend the lifespan of HMECs, the exogenous Cdc25A appeared to lack activity in these cells, since it neither shortened the G1-to-S phase interval nor activated cyclin E-cdk2. In contrast, in the breast cancer-derived MCF-7 line, Cdc25A overexpression increased both cyclin E-cdk2 activity and the S phase fraction. Thus, mechanisms leading to HMEC immortalization may involve not only the re-induction of Cdc25A expression, but also activation of this phosphatase.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Res, Toronto, ON M4N 3M5, Canada; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Mitotix Inc, Cambridge, MA 02139 USA	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Slingerland, J (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Res, S-238,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.				NCI NIH HHS [CA-24844] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA024844, R37CA024844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRENNER AJ, 1995, CANCER RES, V55, P2892; BRENNER AJ, 1998, IN PRESS ONCOGENE; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; CRISTOFALO VJ, 1973, EXP CELL RES, V76, P419, DOI 10.1016/0014-4827(73)90394-7; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; Enders GH, 1996, ONCOGENE, V12, P1239; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Foster SA, 1996, ONCOGENE, V12, P1773; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Garbe J, 1999, ONCOGENE, V18, P2169, DOI 10.1038/sj.onc.1202523; Gasparotto D, 1997, CANCER RES, V57, P2366; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HERMAN JG, 1995, CANCER RES, V55, P4525; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAMB A, 1994, SCIENCE, V264, P440; Kim IY, 1996, ENDOCRINOLOGY, V137, P991, DOI 10.1210/en.137.3.991; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nijjar T, 1999, CANCER RES, V59, P5112; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKINSON K, 1990, CARCINOGENESIS, V11, P195, DOI 10.1093/carcin/11.2.195; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Reznikoff CA, 1996, CANCER RES, V56, P2886; Roberts L, 1998, FORSCH KOMPLEMENTMED, V5, P82, DOI 10.1159/000057115; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; Sandhu C, 2000, CANCER RES, V60, P2616; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; STAMPFER MR, 1992, TRANSFORMATION HUMAN, P117; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2392; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wong DJ, 1997, CANCER RES, V57, P2619; YAMASHITA M, 1992, DEV BIOL, V1, P8; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	71	41	46	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5314	5323		10.1038/sj.onc.1203908	http://dx.doi.org/10.1038/sj.onc.1203908			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103932	Green Published			2022-12-17	WOS:000165302300002
J	Benoit, V; Hellin, AC; Huygen, S; Gielen, J; Bours, V; Merville, MP				Benoit, V; Hellin, AC; Huygen, S; Gielen, J; Bours, V; Merville, MP			Additive effect between NF-kappa B subunits and p53 protein for transcriptional activation of human p53 promoter	ONCOGENE			English	Article						p53; autoregulation; NF-kappa B; transcription factors	TUMOR-SUPPRESSOR P53; WILD-TYPE P53; NUCLEAR-FACTOR; BINDING PROTEIN; DNA-BINDING; GENE-EXPRESSION; OWN TRANSCRIPTION; IN-VITRO; CANCER; CELL	The tumor suppressor p53 plays a pivotal role in the cellular response to DNA damage as it controls DNA repair, cell cycle arrest and apoptosis, We studied the autoregulation of human p53 gene transcription in colon cancer cell lines. Wild-type p53 has been show positively or negatively and probably in a cell-type-specific manner. Indeed, a p53 binding site has been described in the human and murine p53 promoters, but a direct binding of wild-type p53 protein to this site has never been reported. In this study, we demonstrated a transactivation of human p53 pn to autoregulate its own transcription either promoter by wild-type p53 in human colon cancer cells. We identified in the human p53 promoter a novel potential p53-responsive element that binds wildtype p53. Moreover, wild-type p53 protein transactivated a reporter plasmid containing a luciferase gene driven by a minimal promoter harboring this p53 binding site. Finally, as the p53 promoter contains an NF-kappa B binding site, we demonstrated an additive effect when NF-kappa B subunits and p53 protein combined to transactivate the human p53 promoter.	Univ Liege, Lab Med Chem & Med Oncol, B-4000 Liege, Belgium	University of Liege	Merville, MP (corresponding author), Univ Liege, Lab Med Chem & Med Oncol, Pathol B23, B-4000 Liege, Belgium.			BENOIT, Valerie/0000-0002-1098-9452				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Baichwal V. R., 1997, CURR BIOL, V7, P94; Balint E, 1996, CANCER RES, V56, P1648; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HAINAUT P, 1993, CANCER RES, V53, P4469; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; HUDSON JM, 1995, DNA CELL BIOL, V14, P759, DOI 10.1089/dna.1995.14.759; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ravi R, 1998, CANCER RES, V58, P4531; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; SUN XG, 1995, MOL CELL BIOL, V15, P4489; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; VAN AD, 1996, SCIENCE, V274, P787; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768	49	41	44	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2000	19	41					4787	4794		10.1038/sj.onc.1203831	http://dx.doi.org/10.1038/sj.onc.1203831			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032029				2022-12-17	WOS:000089528800013
J	Rusyn, EV; Reynolds, ER; Shao, HP; Grana, TM; Chan, TO; Andres, DA; Cox, AD				Rusyn, EV; Reynolds, ER; Shao, HP; Grana, TM; Chan, TO; Andres, DA; Cox, AD			Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways	ONCOGENE			English	Article						Rit; Ras; signaling; transformation; lipid modification; farnesyltransferase	GDP DISSOCIATION STIMULATOR; C-FOS PROMOTER; R-RAS; CELLULAR-TRANSFORMATION; FARNESYLTRANSFERASE INHIBITORS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; INDEPENDENT PATHWAYS; SIGNALING PATHWAYS; BIOLOGICAL ASSAYS	The biological functions of Rit (Ras-like protein in tissues) and Rin (Ras-like protein in neurons), members of a novel branch of Ras-related GTP-binding proteins that are similar to 50% identical to Ras, have not been characterized. Therefore, we assessed their activity in growth control, transformation and signaling. NM cells stably expressing a constitutively activated mutant of Rit [Rit(79L)] (analogous to the oncogenic mutant H-Ras(61L)) demonstrated strong growth transformation, proliferating rapidly in low serum and forming colonies in soft agar and tumors in nude mice. Although Rit(79L) alone did not promote morphologically transformed foci, it cooperated with both Raf and RhoA to form Rac/Rho-like foci, Rin [Rin(78L)] cooperated only with Raf, Rit(79L) but not Rin(78L) stimulated transcription from luciferase reporter constructs regulated by SRF, NF-kappa B, Elk-l and Jun. However, neither activated ERK, JNK or p38, or PI3-K/Akt kinases in immune complex kinase assays. Interestingly, although Rit lacks any known recognition signal for C-terminal lipidation, Rit-transformed cell growth and survival in low serum is dependent on a farnesylated protein, as treatment with farnesyltransferase inhibitors caused apoptosis, Rin cooperated with Raf in focus assays but did not otherwise function in these assays, perhaps due to a lack of appropriate effector pathways in NIH3T3 fibroblasts for this neural-specific Ras family member. In summary, although Rit shares most core effector domain residues with Ras, our results suggest that Rit uses novel effector pathways to regulate proliferation and transformation.	Univ N Carolina, Lineberger Canc Ctr, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Kentucky; Jefferson University	Cox, AD (corresponding author), Univ N Carolina, Lineberger Canc Ctr, Dept Radiat Oncol, CB 7512, Chapel Hill, NC 27599 USA.			Chan, Tung/0000-0001-6574-9555; Cox, Adrienne D./0000-0002-4901-2454	NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY011231] Funding Source: NIH RePORTER; NCI NIH HHS [CA67771, CA70692] Funding Source: Medline; NEI NIH HHS [EY11231] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COX AD, 1994, METHOD ENZYMOL, V238, P277; COX AD, 1995, METHOD ENZYMOL, V255, P195; COX AD, 1994, ONCOGENE, V9, P3281; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Downward J, 1997, CURR BIOL, V7, pR258, DOI 10.1016/S0960-9822(06)00116-3; Du W, 1999, CANCER RES, V59, P4208; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIRODALISI JJ, 2000, IN PRESS METHODS ENZ, V332; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Graham SM, 1996, MOL CELL BIOL, V16, P6132; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Lebowitz PF, 1997, CANCER RES, V57, P708; Lee CHJ, 1996, J NEUROSCI, V16, P6784; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Murai H, 1997, J BIOL CHEM, V272, P10483; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Oliff A, 1999, BBA-REV CANCER, V1423, pC19, DOI 10.1016/S0304-419X(99)00007-4; Osada M, 1999, MOL CELL BIOL, V19, P6333; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; SAEZ R, 1994, ONCOGENE, V9, P2977; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Shao HP, 2000, J BIOL CHEM, V275, P26914; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; YEN A, 1994, EUR J CELL BIOL, V65, P103; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	60	41	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4685	4694		10.1038/sj.onc.1203836	http://dx.doi.org/10.1038/sj.onc.1203836			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032018				2022-12-17	WOS:000089528800002
J	Merienne, K; Jacquot, S; Zeniou, M; Pannetier, S; Sassone-Corsi, P; Hanauer, A				Merienne, K; Jacquot, S; Zeniou, M; Pannetier, S; Sassone-Corsi, P; Hanauer, A			Activation of RSK by UV-light: phosphorylation dynamics and involvement of the MAPK pathway	ONCOGENE			English	Article						RSK; phosphorylation; UV radiation	RIBOSOMAL S6 KINASE; COFFIN-LOWRY-SYNDROME; SIGNAL-TRANSDUCTION PATHWAYS; KAPPA-B-ALPHA; PROTEIN-KINASE; MENTAL-RETARDATION; DOCKING SITE; CREB KINASE; HEAT-SHOCK; HISTONE H3	Ribosomal S6 kinases (RSKs) are serine/threonine kinases activated by mitogenic signals through the Mitogen-Activated Protein Kinases/Extracellular Signal-Regulated Kinases (MAPK/ERK), RSKs contain two heterologous complete protein kinase domains. Phosphorylation by ERK of the C-terminal kinase domain allows activation of the N-terminal kinase domain, which mediates substrate phosphorylation, In human, there are three isoforms of RSK (RSK1, RSK2, RSK3), whose functional specificity remains undefined. Importantly, we have shown that mutations in the RSK2 gene lead to the Coffin-Lowry syndrome (CLS), In this study, we characterize two monoclonal antibodies raised against phosphorylated forms of the N- and C-terminal domain of RSK2 (P-S227 and P-T577, respectively). Using these two antibodies, we show that stress signals, such as UV light, induce phosphorylation and activation of the three RSKs to an extent which is comparable to Epidermal Growth Factor (EGF)-mediated activation. The use of specific kinase inhibitors indicates that UV-induced phosphorylation and activation of RSK2 is mediated by the MAPK/ERK pathway, but that the Stress-Activated Protein Kinase 2 (SAPK2)/p38 pathway is also involved. These results modify the view of RSKs as kinases restricted to the mitogenic response and reveal a previously unappreciated role of MAPKs in stress induced signaling.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hanauer, A (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Strasbourg, France.			Merienne, Karine/0000-0003-2549-2315				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Jacquot S, 1998, AM J HUM GENET, V63, P1631, DOI 10.1086/302153; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Merienne K, 1999, NAT GENET, V22, P13, DOI 10.1038/8719; Merienne K, 1998, J MED GENET, V35, P890, DOI 10.1136/jmg.35.11.890; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; New L, 1999, J BIOL CHEM, V274, P1026, DOI 10.1074/jbc.274.2.1026; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; Swanson KD, 1999, J BIOL CHEM, V274, P3385, DOI 10.1074/jbc.274.6.3385; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; XIA Z, 1995, SCIENCE, V269, P403; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YOUNG ID, 1988, J MED GENET, V25, P344, DOI 10.1136/jmg.25.5.344; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353; ZHAO Y, 1996, J BIOL CHEM, V271, P29778	57	41	42	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4221	4229		10.1038/sj.onc.1203712	http://dx.doi.org/10.1038/sj.onc.1203712			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980595				2022-12-17	WOS:000089032900004
J	Kimmelman, AC; Osada, M; Chan, AML				Kimmelman, AC; Osada, M; Chan, AML			R-Ras3, a brain-specific Ras-related protein, activates Akt and promotes cell survival in PC12 cells	ONCOGENE			English	Article						R-Ras3; M-Ras; PI3-K; Akt; survival	NERVE GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; NEURONAL SURVIVAL; NEURITE OUTGROWTH; ONCOGENIC RAS; R-RAS; TRANSFORMATION; KINASE; TARGET	The GTP-binding protein, R-Ras3/M-Ras, is a novel member of the Ras subfamily of GTPases which shows highest sequence similarity to the TC21 gene. R-Ras3 is highly expressed in both human and mouse brain and ectopic expression of a constitutively active mutant of R-Ras3 induces cellular transformation in NIH3T3 cells. To gain further insight into the normal cellular function of R-Ras3, we examined the ability of R-Ras3 in activating several known intracellular signaling cascades. We observed that R-Ras3 is a relatively weak activator of the mitogen-activated protein kinase/extracellular-signal-regulated kinases (MAPK/ERKs) when compared to the EI-Ras oncogene. On the contrary, both R-Ras3 and H-Ras activated the Jun N-terminal kinase (JNK) to a similar extent, Under similar experimental conditions, R-Ras3 significantly stimulated one of the phosphatidylinositol 3-kinase (PI3-K) downstream substrates, Akt/PKB/RAC (Akt), which has been extensively implicated in mediating cell survival signaling. The activation of Akt by R-Ras3 was most likely to be PI3-K-dependent since this biochemical event was blocked by the pharmacological inhibitors, Wortmannin and LY294002, as well as by a dominant negative mutant of PI3-K. More importantly, R-Ras3 affinity-precipitated PI3-K from cell extracts in a GTP-dependent manner, and associated lipid kinase activity,vas readily detectable in R-Ras3 immune complexes. The biological significance of R-Ras3 in inducing Akt kinase activity is evidenced by the ability of an activated R-Ras3 to confer cell survival in the rat pheochromocytoma cell line, PC12, As expected, this biological activity of R-Ras3 was also abrogated by the addition of LY294002. Thus, R-Ras3 represents a novel G-protein which may play a role in cell survival of neural-derived cells.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Chan, AML (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA.		Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464	NATIONAL CANCER INSTITUTE [R01CA066654, R29CA078509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059771] Funding Source: NIH RePORTER; NCI NIH HHS [CA78509, CA66654] Funding Source: Medline; NIMH NIH HHS [MH59771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; BOS JL, 1989, CANCER RES, V49, P4682; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHAN AML, 1994, P NATL ACAD SCI USA, V82, P2394; COLLINS F, 1991, J NEUROSCI, V11, P2582; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COX AD, 1994, ONCOGENE, V9, P3281; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Deshmukh M, 1997, MOL PHARMACOL, V51, P897, DOI 10.1124/mol.51.6.897; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HUANG Y, 1995, ONCOGENE, V11, P1255; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; LACAL JC, 1986, MOL CELL BIOL, V6, P1002, DOI 10.1128/MCB.6.4.1002; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; Matsumoto K, 1997, ONCOGENE, V15, P2409, DOI 10.1038/sj.onc.1201416; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SAEZ R, 1994, ONCOGENE, V9, P2977; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785	48	41	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2014	2022		10.1038/sj.onc.1203530	http://dx.doi.org/10.1038/sj.onc.1203530			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803462				2022-12-17	WOS:000086613200005
J	Atlas, E; Stramwasser, M; Whiskin, K; Mueller, CR				Atlas, E; Stramwasser, M; Whiskin, K; Mueller, CR			GA-binding protein alpha/beta is a critical regulator of the BRCA1 promoter	ONCOGENE			English	Article						BRCA1; expression; GABP alpha/beta; breast cancer	SPORADIC BREAST-CANCER; MESSENGER-RNA; GENE; EXPRESSION; METHYLATION; MUTATIONS; CELLS; SITE; REGION; DIFFERENTIATION	Decreased expression of BRCA1 may play a role in the etiology of sporadic breast cancer. Deletion and point mutant analysis of proximal promoter elements in the BRCA1 1a promoter revealed a 22 bp region which was critical for the expression of the promoter in MCF-7 cells, but had a much reduced effect in T47D cells, The main transcription factor interacting with this site was identified as GABP alpha/beta, and a discrete DNA binding complex was only observed in nuclear extracts from MCF-7 cells, Cotransfection experiments with GABP alpha and beta 1 expression vectors produced transactivation of this element in both lines, These results suggest that GABP alpha/beta is a critical activator of BRCA1 expression, and that its activity may differ in human breast cell lines.	Queens Univ, Dept Biochem, Can Res Labs, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Mueller, CR (corresponding author), Queens Univ, Dept Biochem, Can Res Labs, Kingston, ON K7L 3N6, Canada.							Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Boccia LM, 1996, MOL CELL BIOL, V16, P1929; Brown MA, 1996, ONCOGENE, V12, P2507; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; Dobrovic A, 1997, CANCER RES, V57, P3347; Favy DA, 1999, BIOCHEM BIOPH RES CO, V258, P284, DOI 10.1006/bbrc.1999.0602; Fromm L, 1998, GENE DEV, V12, P3074, DOI 10.1101/gad.12.19.3074; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hoare S, 1999, ENDOCRINOLOGY, V140, P2268, DOI 10.1210/en.140.5.2268; Jarvis EM, 1998, CANCER GENET CYTOGEN, V101, P109, DOI 10.1016/S0165-4608(97)00267-7; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Ozcelik H, 1998, INT J CANCER, V77, P1; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Rio PG, 1999, INT J CANCER, V80, P823, DOI 10.1002/(SICI)1097-0215(19990315)80:6<823::AID-IJC5>3.0.CO;2-3; Sawa C, 1996, NUCLEIC ACIDS RES, V24, P4954, DOI 10.1093/nar/24.24.4954; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yokomori N, 1998, MOL ENDOCRINOL, V12, P1241, DOI 10.1210/me.12.8.1241	42	41	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2000	19	15					1933	1940		10.1038/sj.onc.1203516	http://dx.doi.org/10.1038/sj.onc.1203516			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773883				2022-12-17	WOS:000086424300009
J	Kogel, D; Bierbaum, H; Preuss, U; Scheidtmann, KH				Kogel, D; Bierbaum, H; Preuss, U; Scheidtmann, KH			C-terminal truncation of Dlk/ZIP kinase leads to abrogation of nuclear transport and high apoptotic activity	ONCOGENE			English	Article						Dlk/ZIP kinase; nuclear transport; PML bodies; actin filaments; apoptosis	PROTEIN-KINASE; CELL-DEATH; SERINE/THREONINE KINASE; SIGNAL-TRANSDUCTION; NASCENT RNA; PATHWAYS; PML; IDENTIFICATION; BODIES	Dlk (also termed ZIP kinase) is a novel serine/threonine kinase with a unique C-terminal domain that is rich in arginine and contains three putative NLS motifs and a functional lecuine zipper. Dlk is indeed localized in the nucleus where it shows a speckled distribution, To elucidate the biological functions of Dlk, we wanted to identify the signals relevant for nuclear transport and further the nuclear structures which Dlk binds to. Expression of various deletion and point mutations of Dlk as GFP fusion proteins revealed that the leucine zipper is required for association with speckles and the most C-terminal NLS is necessary and sufficient for nuclear transport. Interestingly, a C-terminal deletion mutant defective for nuclear transport exhibited a pronounced colocalization with actin filaments and, even more strikingly, was a very potent inducer of apoptosis, This apoptotic activity was abrogated, however, when this mutant was retargeted to the nucleus via a heterologous NLS from large T, indicating that Dlk only exerts an apoptotic activity in the cytoplasm, To identify the speckle like structures to which Dlk binds we performed immunofluorescence analyses with antibodies directed against representative marker proteins of replication, transcription, or splicing centers. None of these marker proteins revealed a colocalization with Dlk. Instead, we found a partial colocalization with PML bodies which seem to play a key role in regulation of apoptosis, Taken together, these data strongly suggest a functional role for Dlk in control of cell survival which is dependent on its subcellular localization.	Univ Bonn, Inst Genet, D-53117 Bonn, Germany	University of Bonn	Scheidtmann, KH (corresponding author), Univ Bonn, Inst Genet, Roemerstr 164, D-53117 Bonn, Germany.			Kogel, Donat/0000-0003-1209-0210				Bloch DB, 1999, MOL CELL BIOL, V19, P4423; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fabrizio P, 1997, EMBO J, V16, P4092, DOI 10.1093/emboj/16.13.4092; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HOZAK P, 1994, J CELL SCI, V107, P2191; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Page G, 1999, ONCOGENE, V18, P7265, DOI 10.1038/sj.onc.1203170; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rangnekar VM, 1998, APOPTOSIS, V3, P61, DOI 10.1023/A:1009666705875; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RITTNER K, 1991, Methods in Molecular and Cellular Biology, V2, P176; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STUURMAN N, 1992, J CELL SCI, V101, P773; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	36	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7212	7218		10.1038/sj.onc.1203169	http://dx.doi.org/10.1038/sj.onc.1203169			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602474				2022-12-17	WOS:000084119400004
J	Bruzzoni-Giovanelli, H; Faille, A; Linares-Cruz, G; Nemani, M; Le Deist, F; Germani, A; Chassoux, D; Millot, G; Roperch, JP; Amson, R; Telerman, A; Calvo, F				Bruzzoni-Giovanelli, H; Faille, A; Linares-Cruz, G; Nemani, M; Le Deist, F; Germani, A; Chassoux, D; Millot, G; Roperch, JP; Amson, R; Telerman, A; Calvo, F			SIAH-1 inhibits cell growth by altering the mitotic process	ONCOGENE			English	Article						SIAH-1; mitosis; multinucleated cell; cytokinesis; apoptosis; p21	DROSOPHILA EYE DEVELOPMENT; TUMOR SUPPRESSION; DNA-REPLICATION; HUMAN HOMOLOG; SINA GENE; APOPTOSIS; ABSENTIA; P21(WAF1/CIP1); CYTOKINESIS; ACTIVATION	SIAH-1, the human homologue of the drosophila seven in absentia gene, is a p53-p21(Waf-1) inducible gene. We report that stable transfection with SIAH-1 of the epithelial breast cancer cell line MCF-7 blocks its growth process. The transfectants show a redistribution of SIAH-1 protein within the nucleus, more specifically to the nuclear matrix, associated to dramatic changes in cell morphology and defective mitosis. Multinucleated giant cells (2-12 nuclei in more than 50% cells) were a most striking observation associated with tubulin spindle disorganization and defective cytokinesis, There were also present at high frequency abortive mitotic figures, DNA bridges and persistance of intercellular bridges and midbodies, along with an increased expression of p21(Waf-1) These results indicate that the mechanism of growth arrest induced by SIAH-1 in MCF-7 cells involves disorganization of the mitotic program, mainly during nuclei separation and cytokinesis.	Hop St Louis, Inst Genet Mol, Lab Pharmacol Expt, F-75010 Paris, France; Hop St Louis, Inst Genet Mol, Clin INSERM EP 9932, F-75010 Paris, France; CEPH, Fdn Jean Dausset, Paris, France; Hop Necker Enfants Malad, INSERM Unite 429, Paris, France; Hop Cochin, INSERM Unite 363, F-75674 Paris, France; Inst Curie, INRA, Unite 806, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Foundation Jean Dausset-CEPH; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; INRAE; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Calvo, F (corresponding author), Hop St Louis, Inst Genet Mol, Lab Pharmacol Expt, 27 Rue Juliette Dodu, F-75010 Paris, France.			calvo, fabien/0000-0002-0298-7633; VARIN-BLANK, Nadine/0000-0003-2769-018X				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Berezney R, 1996, J CELL BIOCHEM, V62, P223, DOI 10.1002/(SICI)1097-4644(199608)62:2<223::AID-JCB10>3.3.CO;2-M; BRUZZONIGIOVANE.H, 1998, ADV MOL TOXICOLOGY, P25; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CARTHEW RW, 1994, P NATL ACAD SCI USA, V91, P11689, DOI 10.1073/pnas.91.24.11689; DELLA NG, 1993, DEVELOPMENT, V117, P1333; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; Goodson HV, 1997, CURR OPIN CELL BIOL, V9, P18, DOI 10.1016/S0955-0674(97)80147-0; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lai ZC, 1996, P NATL ACAD SCI USA, V93, P5025, DOI 10.1073/pnas.93.10.5025; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Linares-Cruz G, 1998, P NATL ACAD SCI USA, V95, P1131, DOI 10.1073/pnas.95.3.1131; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Mandelkow E, 1999, CURR OPIN CELL BIOL, V11, P34, DOI 10.1016/S0955-0674(99)80005-2; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Nagata Y, 1997, J CELL BIOL, V139, P449, DOI 10.1083/jcb.139.2.449; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Neufeld TP, 1998, GENETICS, V148, P277; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Vitrat N, 1998, BLOOD, V91, P3711	38	41	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	1999	18	50					7101	7109		10.1038/sj.onc.1203187	http://dx.doi.org/10.1038/sj.onc.1203187			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597311				2022-12-17	WOS:000083901900017
J	Tamura, T; Mancini, A; Joos, H; Koch, A; Hakim, C; Dumanski, J; Weidner, KM; Niemann, H				Tamura, T; Mancini, A; Joos, H; Koch, A; Hakim, C; Dumanski, J; Weidner, KM; Niemann, H			FMIP, a novel Fms-interacting protein, affects granulocyte/macrophage differentiation	ONCOGENE			English	Article						novel c-Fms-interacting protein; M-CSF-receptor; granulocyte/macrophage differentiation; lineage control	COLONY-STIMULATING FACTOR; M-CSF RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASE; ONCOGENE PRODUCT; PROGENITOR CELLS; BINDING-SITE; SH2 DOMAINS; GM-CSF; ACTIVATION	Hematopoietic cell growth, differentiation, and commitment to a restricted lineage are guided by a set of cytokines acting exclusively on cells expressing the corresponding cytokine receptor. The macrophage colony stimulating factor (M-CSF, also termed CSF-1) and its cognate receptor, the tyrosine kinase c-Fms, are essential for monocyte and macrophage development. The underlying molecular mechanism, however, is poorly understood. Here we identified a novel Fms-interacting protein (FMIP, MW 78 kDa) which binds transiently via its N-terminal 144 residues to the cytoplasmic domain of activated Fms-molecules. Binding of FMIP was paralleled by rapid tyrosine phosphorylation within the binding domain which drastically reduced its ability to associate with Fms. Binding was specific as evidenced by co-immunoprecipitation and association with recombinant GST-Fms fusion proteins. No binding was observed with the tyrosine phosphorylated cytoplasmic domains of c-Kit, TrkA, c-Met, and the insulin receptor. The role of FMIP in hematopoietic differentiation was studied in the bipotential myeloid progenitor cell line, FDC-P1Mac11. Overexpression of FMIP prevented M-CSF induced macrophage differentiation. Instead, cells differentiated into granulocytes. Our data suggest that the level of FMIP expression could form a threshold that decides about differentiation either into macrophages or into granulocytes.	Hannover Med Sch, Inst Biochem, D-30623 Hannover, Germany; Karolinska Inst, Dept Mol Med, S-17176 Stockholm, Sweden; Roche Pharma Res Werk Penzberg, D-82372 Penzberg, Germany	Hannover Medical School; Karolinska Institutet	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE 4310,Carl-Neuberg-Str 1, D-30623 Hannover, Germany.			Dumanski, Jan Piotr/0000-0002-1489-1452				Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; CROSS MA, 1997, CIBA F SYMP, P3; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; Helftenbein G, 1996, ONCOGENE, V12, P931; Joos H, 1996, J BIOL CHEM, V271, P24476, DOI 10.1074/jbc.271.40.24476; JUST U, 1993, GROWTH FACTORS, V9, P291, DOI 10.3109/08977199308991589; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Novak U, 1996, ONCOGENE, V13, P2607; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pierce A, 1998, J CELL BIOL, V140, P1511, DOI 10.1083/jcb.140.6.1511; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; TAMURA T, 1986, MOL CELL BIOL, V6, P4745, DOI 10.1128/MCB.6.12.4745; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WHETTON AD, 1994, J CELL BIOL, V125, P651, DOI 10.1083/jcb.125.3.651; XIE YG, 1993, HUM MOL GENET, V2, P1361; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	27	41	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6488	6495		10.1038/sj.onc.1203062	http://dx.doi.org/10.1038/sj.onc.1203062			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597251				2022-12-17	WOS:000083709200011
J	Allay, E; Veigl, M; Gerson, SL				Allay, E; Veigl, M; Gerson, SL			Mice over-expressing human O(6)alkylguanine-DNA alkyltransferase selectively reduce O(6)methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea	ONCOGENE			English	Article						Big Blue lacI mice; mutation frequency; hMGMT mice; N-methyl-N-nitrosourea induced lymphoma	INDUCED THYMIC LYMPHOMAS; TRANSGENIC MICE; DNA ALKYLTRANSFERASE; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; HUMAN-FIBROBLASTS; EXCISION-REPAIR; CELLS; PROTECTS; GENE; N-METHYL-N'-NITRO-N-NITROSOGUANIDINE	While it is well known that MNU induces thymic lymphomas in the mouse, it remains unclear which premutagenic lesions are responsible for lymphomagenic transformation. One lesion thought to play a critical role is O(6)methylguanine [O(6)mG] which initiates G:C to A:T transition mutations in K-ras and other oncogenes, O(6)alkylguanine-DNA alkyltransferase (AGT), encoded by the methylguanine methyltransferase gene [MGMT], removes the methyl group thereby preventing the mutation from occurring, When overexpressed in the thymus, MGMT protects mice from MNU-induced thymic lymphomas, To determine whether MGMT overexpression reduced G:C to A:T mutation frequency after MNU, Big Blue(TM) IacI and MGMT+/Big Blue(TM) mice were treated with MNU and analysed for mutations in the lacI and K-ras genes. The incidence of MNU-induced lymphomas was 84% in Big Blue(TM) lacI mice compared to 14% in MGMT+Big Blue(TM) lad mice. Sixty-two per cent of the lymphomas had a GGT to GAT activating mutation in codon 12 of K-I ns consistent with O(6)mG adduct-mediated paint mutagenesis, LacI mutation frequency in thymus of MNU treated Big Blue(TM) mice was 45-fold above background whereas it was ii-fold above background in MNU treated MGMT+/Big Blue(TM) mice, Most IacI mutations were G:C to A:T transitions, implicating O(6)mG even in the MGMT+ mice. No mutations were attributable to chromosomal aberrations or rearrangements, Thus, O(6)mG adducts account for the carcinogenic effect of MNU and MGMT overexpression is selectively able to reduce O(6)methylguanine adducts below a carcinogenic threshold. Other adducts are mutagenic but appear to contribute much less to malignant transformation or oncogene activation.	Case Western Reserve Univ, Div Hematol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Gerson, SL (corresponding author), Case Western Reserve Univ, Div Hematol Oncol, Cleveland, OH 44106 USA.				NCI NIH HHS [P30CA43703, R01CA63193] Funding Source: Medline; NIEHS NIH HHS [R01ES06288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA063193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ali RB, 1998, MOL CELL BIOL, V18, P1660, DOI 10.1128/MCB.18.3.1660; Becker K, 1996, CANCER RES, V56, P3244; CHA RS, 1994, P NATL ACAD SCI USA, V91, P3749, DOI 10.1073/pnas.91.9.3749; COROMINAS M, 1991, CANCER RES, V51, P5129; de Boer JG, 1998, MUTAGENESIS, V13, P109; Dobo KL, 1998, CARCINOGENESIS, V19, P755, DOI 10.1093/carcin/19.5.755; DOMORADZKI J, 1985, CARCINOGENESIS, V6, P1823, DOI 10.1093/carcin/6.12.1823; DOSANJH MK, 1991, BIOCHEMISTRY-US, V30, P7027, DOI 10.1021/bi00242a031; DOSANJH MK, 1993, CARCINOGENESIS, V14, P1915, DOI 10.1093/carcin/14.9.1915; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; GALLOWAY SM, 1995, MUTAT RES LETT, V346, P231, DOI 10.1016/0165-7992(95)90040-3; GERSON SL, 1985, J CLIN INVEST, V76, P2106, DOI 10.1172/JCI112215; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; LIU LL, 1994, CANCER RES, V54, P4648; LUKASH LL, 1991, MUTAT RES, V250, P397, DOI 10.1016/0027-5107(91)90196-U; MORIWAKI S, 1991, CANCER RES, V51, P6219; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; Nivard MJM, 1996, MUTAT RES-FUND MOL M, V352, P97, DOI 10.1016/0027-5107(96)00011-5; SASSANFAR M, 1991, J BIOL CHEM, V266, P2767; Sitaram A, 1997, MOL CELL BIOL, V17, P564, DOI 10.1128/MCB.17.2.564; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; TREY JE, 1989, CANCER RES, V49, P1899; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; ZAIDI NH, 1995, CARCINOGENESIS, V16, P1047, DOI 10.1093/carcin/16.5.1047; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	25	41	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3783	3787		10.1038/sj.onc.1202697	http://dx.doi.org/10.1038/sj.onc.1202697			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391687				2022-12-17	WOS:000081140200013
J	Garbe, J; Wong, M; Wigington, D; Yaswen, P; Stampfer, MR				Garbe, J; Wong, M; Wigington, D; Yaswen, P; Stampfer, MR			Viral oncogenes accelerate conversion to immortality of cultured conditionally immortal human mammary epithelial cells	ONCOGENE			English	Article						immortalization; telomerase; p53; TGF beta; human papillomavirus; SV40T	HUMAN PAPILLOMAVIRUS TYPE-16; LARGE T-ANTIGEN; TELOMERASE ACTIVITY; HUMAN FIBROBLASTS; BREAST-CANCER; P16 INACTIVATION; TUMOR-ANTIGEN; P53 GENE; E6; PROTEIN	Our recent studies on the process of immortalization of cultured human mammary epithelial cells (HMEC) have uncovered a previously undescribed, apparently epigenetic step, termed conversion. When first isolated, clonally derived HMEC lines of indefinite lifespan showed little or no telomerase activity or ability to maintain growth in the presence of TGF beta. Cell populations whose mean terminal restriction fragment length had declined to <3 kb also exhibited slow heterogeneous growth, and contained many non-proliferative cells. With continued passage, these conditionally immortal cell populations very gradually converted to a fully immortal phenotype of good growth+/-TGF beta, expression of high levels of telomerase activity, and stabilization of telomere length. We now show that exposure of the early passage conditionally immortal 184A1 HMEC line to the viral oncogenes human papillomavirus type 16 (HPV16)-E6, -E7, or SV40T, results in either immediate (E6) or rapid (E7; SV40T) conversion of these telomerase negative, TGF beta sensitive conditionally immortal cells to the fully immortal phenotype. Unlike conditional immortal 184A1, the HPV16-E7 and SV40T exposed cells were able to maintain growth in TGF beta prior to expression of high levels of telomerase activity. A mutated HPV16-E6 oncogene, unable to inactivate p53, was still capable of rapidly converting conditional immortal 184A1. Our studies provide further evidence that the transforming potential of these viral oncogenes may involve activities beyond their inactivation of p53 and pRB functions. These additional activities may greatly accelerate a step in HMEC immortal transformation, conversion, that would be rate-limiting in the absence of viral oncogene exposure.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Stampfer, MR (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Bldg 934, Berkeley, CA 94720 USA.				NATIONAL CANCER INSTITUTE [R37CA024844, R01CA024844] Funding Source: NIH RePORTER; NCI NIH HHS [CA-24844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bacchetti S, 1996, CANCER SURV, V28, P197; BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; Band V, 1998, INT J ONCOL, V12, P499; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; BRENNER AJ, 1995, CANCER RES, V55, P2892; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; CHOO CK, 1993, EXP CELL RES, V208, P161, DOI 10.1006/excr.1993.1234; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; Ethier SP, 1996, J MAMMARY GLAND BIOL, V1, P111, DOI 10.1007/BF02096306; FINER MH, 1994, BLOOD, V83, P43; Gollahon LS, 1996, ONCOGENE, V12, P715; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HARRIS CC, 1987, CANCER RES, V47, P1; HARTMANN A, 1995, ONCOGENE, V10, P681; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RENAN MJ, 1993, MOL CARCINOGEN, V7, P139; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; STAMPFER M, 1994, CANC SURVEYS, V18, P7; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; STAMPFER MR, 1982, IN VITRO CELL DEV B, V18, P531; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STAMPFER MR, 1988, BREAST CANCER CELLUL, P1; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VIALLET J, 1994, EXP CELL RES, V212, P36, DOI 10.1006/excr.1994.1115; WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; Woodworth CD, 1996, CELL GROWTH DIFFER, V7, P811; ZerfassThome K, 1996, ONCOGENE, V13, P2323	53	41	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2169	2180		10.1038/sj.onc.1202523	http://dx.doi.org/10.1038/sj.onc.1202523			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327063				2022-12-17	WOS:000079525100001
J	Zeng, WR; Watson, P; Lin, J; Jothy, S; Lidereau, R; Park, M; Nepveu, A				Zeng, WR; Watson, P; Lin, J; Jothy, S; Lidereau, R; Park, M; Nepveu, A			Refined mapping of the region of loss of heterozygosity on the long arm of chromosome 7 in human breast cancer defines the location of a second tumor suppressor gene at 7q22 in the region of the CUTL1 gene	ONCOGENE			English	Article						breast cancer; tumor suppressor gene; chromosome 7q22; CUTL1; human Cut homeobox gene; loss of heterozygosity	CCAAT DISPLACEMENT PROTEIN; HOMEODOMAIN PROTEIN; UTERINE LEIOMYOMATA; DROSOPHILA CUT; SUSCEPTIBILITY; EXPRESSION; PROMOTER; DELETION; 7Q31; LOCALIZATION	In breast cancer, loss of heterozygosity (LOH) has been described on the long arm of chromosome 7, at band q31, suggesting the presence of a tumor suppressor gene in this region, In this study, we have identified a second region of LOH on 7q, at band 7q22. Deletion of genetic material at 7q22 was found in all tumor types and grades and was associated with increased tumor size. The region of LOH at 7q22 in every case included one or more of three polymorphic markers that are located within the CUTL1 gene. LOH of 7q22 has also been documented in the case of human uterine leiomyomas (Zeng et al., 1997; Ishmad et al., 1997), Interestingly, in both leiomyomas and mammary tumors induced in transgenic mice expressing the Polyomavirus (PyV) large T (LT) antigen, immunocomplexes of CUTL1 and PyV LT antigen were detected (Webster et al., 1998), Altogether, genetic data in human breast cancer and biochemical analyses in breast tumors from transgenic mice suggest that CUTL1 is a candidate tumor suppressor gene.	McGill Univ, Mol Oncol Grp, Dept Med, Montreal, PQ, Canada; McGill Univ, Mol Oncol Grp, Dept Oncol, Montreal, PQ, Canada; Univ Manitoba, Fac Med, Dept Pathol & Physiol, Winnipeg, MB R3T 2N2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Ctr Rene Huguenin, Lab Oncogenet, F-92211 St Cloud, France	McGill University; McGill University; University of Manitoba; University of Toronto; Rene Huguenin Hospital	Nepveu, A (corresponding author), McGill Univ, Mol Oncol Grp, Dept Med, Montreal, PQ, Canada.		/AAB-8315-2020	Watson, Peter/0000-0002-1642-0638				ANDRES V, 1992, DEVELOPMENT, V116, P321; Berker-Karauzum S, 1998, CANCER GENET CYTOGEN, V100, P114, DOI 10.1016/S0165-4608(96)00422-0; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Bieche I, 1997, CLIN CANCER RES, V3, P1009; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; CALLAHAN R, 1993, CLIN CHIM ACTA, V217, P63, DOI 10.1016/0009-8981(93)90238-Y; CHAMPEME MH, 1995, GENE CHROMOSOME CANC, V12, P304, DOI 10.1002/gcc.2870120411; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; DAVE BJ, 1995, CANCER EPIDEM BIOMAR, V4, P743; DENG G, 1994, CANCER RES, V54, P499; Devilee P, 1997, GENE CHROMOSOME CANC, V18, P193; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; Fischer K, 1998, RECENT RESULTS CANC, V144, P46; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HARADA R, 1994, J BIOL CHEM, V269, P2062; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; Ishwad CS, 1997, GENE CHROMOSOME CANC, V19, P156, DOI 10.1002/(SICI)1098-2264(199707)19:3<156::AID-GCC4>3.0.CO;2-X; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; Kerangueven F, 1997, CANCER RES, V57, P5469; Kristjansson AK, 1997, ANTICANCER RES, V17, P93; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; Lin JC, 1996, ONCOGENE, V13, P2001; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; LUNDGREN R, 1991, SCAND J UROL NEPHROL, P1; Mailly F, 1996, MOL CELL BIOL, V16, P5346; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; Mertens F, 1997, CANCER RES, V57, P2765; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; OZISIK YY, 1993, CANCER GENET CYTOGEN, V71, P1, DOI 10.1016/0165-4608(93)90195-R; Quaggin SE, 1996, J BIOL CHEM, V271, P22624, DOI 10.1074/jbc.271.37.22624; SARGENT MS, 1994, CANCER GENET CYTOGEN, V77, P65, DOI 10.1016/0165-4608(94)90151-1; SATO T, 1990, CANCER RES, V50, P7184; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SolinasToldo S, 1996, CANCER RES, V56, P3803; STORTO PD, 1990, GENE CHROMOSOME CANC, V2, P300, DOI 10.1002/gcc.2870020408; Tougas L, 1996, CLIN INVEST MED, V19, P222; VALARCHE I, 1993, DEVELOPMENT, V119, P881; Watson PH, 1996, CAN MED ASSOC J, V155, P281; WATSON PH, 1993, J NATL CANCER I, V85, P902, DOI 10.1093/jnci/85.11.902; Webster MA, 1998, ONCOGENE, V16, P1963, DOI 10.1038/sj.onc.1201707; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xing YP, 1997, CANCER GENET CYTOGEN, V98, P69; YOON SO, 1994, J BIOL CHEM, V269, P18453; Zeng WR, 1997, ONCOGENE, V14, P2355, DOI 10.1038/sj.onc.1201076; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155	48	41	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	1999	18	11					2015	2021		10.1038/sj.onc.1202519	http://dx.doi.org/10.1038/sj.onc.1202519			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208423				2022-12-17	WOS:000079191300011
J	Frank, RC; Sun, X; Berguido, FJ; Jakubowiak, A; Nimer, SD				Frank, RC; Sun, X; Berguido, FJ; Jakubowiak, A; Nimer, SD			The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1	ONCOGENE			English	Article						AML1/ETO; transformation; AP-1	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; FETAL LIVER HEMATOPOIESIS; DNA-BINDING; TRANSCRIPTION FACTOR; C-JUN; CHIMERIC ONCOPROTEIN; RETINOIC ACID; GENE	The 8;21 translocation is the most common cytogenetic abnormality in human acute myelogenous leukemia, joining the AML1 gene on chromosome 21, to the ETO gene on chromosome 8, forming the AML1/ETO fusion gene, The AML1/ETO fusion protein has been shown to function mainly as a transcriptional repressor of AML1 target genes and to block AML1 function in vitro and in vivo. However, AML1/ETO can also activate the BCL-2 promoter and cause enhanced hematopoietic progenitor self-renewal in vitro, suggesting gain-of-functions unique to the fusion protein. We used NIH3T3 cells to determine the transforming capacity of AML1/ETO, and to further characterize its mechanism of action. Expression of AML1/ETO in NIH3T3 cells caused cell-type specific cell death, and cellular transformation, characterized by phenotypic changes, anchorage-independent growth, and tumor formation in nude mice, In contrast, neither expression of AML1A, AML1B or ETO altered the normal growth pattern of the cells, To investigate the mechanism of transformation by AML1/ETO, we analysed the levels of activated, phosphorylated c-Jun (ser63) and other constituents of the AP-1 complex, in the presence of various AML1/ETO related proteins. Expression of AML1/ETO increased the level of c-Jun-P (ser63), and activated AP-1 dependent transcription, which was inhibited by expression of a dominant-negative c-Jun protein. Mutational analysis revealed that the runt homology domain (RHD) and a C-terminal transcriptional repression domain in AML1/ETO are required for transformation, activation of c-Jun and increased AP-1 activity, These results establish the transforming potential of the t(8;21) fusion protein and link this gain-of-function property to modulation of AP-1 activity.	Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, 1275 York Ave,H-701,Box 575, New York, NY 10021 USA.				NCI NIH HHS [CA09207, K08 CA70388] Funding Source: Medline; NIDDK NIH HHS [DK 43025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA070388, T32CA009207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKEW DS, 1991, ONCOGENE, V6, P1915; ASOU H, 1991, BLOOD, V77, P2031; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BROWN PH, 1993, ONCOGENE, V8, P877; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; Darley RL, 1997, J EXP MED, V185, P1337, DOI 10.1084/jem.185.7.1337; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; DOWNING JR, 1993, BLOOD, V81, P2860; ERICKSON P, 1992, BLOOD, V80, P1825; Erickson PF, 1996, BLOOD, V88, P1813; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEINSTEIN PG, 1995, GENETICS, V140, P573; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; Frank R, 1995, ONCOGENE, V11, P2667; Golling G, 1996, MOL CELL BIOL, V16, P932; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; KURIE JM, 1993, DIFFERENTIATION, V54, P115; Kurokawa M, 1996, ONCOGENE, V12, P883; KUROKAWA M, 1995, ONCOGENE, V11, P833; LENNY N, 1995, ONCOGENE, V11, P1761; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; MANDANAS RA, 1993, BLOOD, V82, P1838; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Sawyers CL, 1997, LANCET, V349, P196, DOI 10.1016/S0140-6736(96)07535-6; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Smith KS, 1997, ONCOGENE, V14, P2917, DOI 10.1038/sj.onc.1201249; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Uchida H, 1997, J IMMUNOL, V158, P2251; Wang J., 1997, Blood, V90, p245A; Wang JX, 1997, CANCER RES, V57, P2951; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247	64	41	44	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1701	1710		10.1038/sj.onc.1202459	http://dx.doi.org/10.1038/sj.onc.1202459			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208431				2022-12-17	WOS:000079025000005
J	Wan, MH; Sun, T; Vyas, R; Zheng, JP; Granada, E; Dubeau, L				Wan, MH; Sun, T; Vyas, R; Zheng, JP; Granada, E; Dubeau, L			Suppression of tumorigenicity in human ovarian cancer cell lines is controlled by a 2 cM fragment in chromosomal region 6q24-q25	ONCOGENE			English	Article						tumor suppressor; chromosome 6; ovarian cancer; chromosome transfer	ACUTE LYMPHOBLASTIC-LEUKEMIA; COMMONLY DELETED REGION; KARYOTYPIC ANALYSIS; FREQUENT LOSS; HUMAN GENOME; LONG ARM; 6Q; HETEROZYGOSITY; CARCINOMAS; TUMORS	Multiple distinct regions of chromosome 6 are frequently affected by losses of heterozygosity in primary human ovarian carcinomas. We introduced a normal human chromosome 6 into HEY and SKOV-3 ovarian carcinoma cell lines using microcell-mediated chromosome transfer techniques to further investigate the role of this chromosome in ovarian tumorigenesis, The exogenous chromosome was stably propagated in the recipient cells based on fluorescence in situ hybridization (FISH) analyses with a chromosome 6 painting probe. The tumorigenicity of HEY and SKOV-3 cells was completely suppressed after transfer of chromosome 6, but not after transfer of a chromosome 11q13-qter fragment used as control. Using 46 polymorphic microsatellite markers, the region bounded by D6S1649 and D6S1564 was found to be commonly deleted in HEY: chromosome 6 tumorigenic revertant clones. The boundaries of the commonly deleted region could be further narrowed down to a 2 cM (based on the Whitehead genetic map) or 0.36 megabase (based on gdb mapping data) region between D6S1637 and D6S1564 after transferring the exogenous chromosome from revertants into mouse L cells and performing allelic deletion mapping studies against this mouse background. We conclude that this region contains a tumor suppressor gene important for the control of ovarian tumor development.	Univ So Calif, Sch Med, Dept Pathol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Urol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Dubeau, L (corresponding author), Univ So Calif, Sch Med, Dept Pathol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA.				NATIONAL CANCER INSTITUTE [R01CA051167] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA51167] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; BUICK RN, 1985, CANCER RES, V45, P3668; CLIBY W, 1993, CANCER RES, V53, P2393; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooney KA, 1996, CANCER RES, V56, P4150; Deger RB, 1997, CANCER GENET CYTOGEN, V96, P166, DOI 10.1016/S0165-4608(96)00327-5; DEVILEE P, 1991, ONCOGENE, V6, P1705; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EHLEN T, 1990, ONCOGENE, V5, P219; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; Gerard B, 1997, LEUKEMIA, V11, P228, DOI 10.1038/sj.leu.2400566; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; LEE JH, 1990, CANCER RES, V50, P2724; LUGO TG, 1987, MOL CELL BIOL, V7, P2814, DOI 10.1128/MCB.7.8.2814; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MERLO A, 1994, CANCER RES, V54, P2322; NEGRINI M, 1994, CANCER RES, V54, P1331; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; ORPHANOS V, 1994, GENOMICS, V20, P301, DOI 10.1006/geno.1994.1172; SAHA V, 1995, GENE CHROMOSOME CANC, V14, P220, DOI 10.1002/gcc.2870140311; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; Sandhu AK, 1996, ONCOGENE, V12, P247; SHEER D, 1987, CANCER GENET CYTOGEN, V26, P339, DOI 10.1016/0165-4608(87)90068-9; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; Tibiletti MG, 1996, CANCER RES, V56, P4493; Tibiletti MG, 1997, BRIT J CANCER, V75, P1831, DOI 10.1038/bjc.1997.312; Tibiletti MG, 1998, ONCOGENE, V16, P1639, DOI 10.1038/sj.onc.1201654; TRENT JM, 1981, CANCER GENET CYTOGEN, V3, P279, DOI 10.1016/0165-4608(81)90037-6; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; VOLTZ A, 1994, GENOMICS, V21, P464; WAKE N, 1980, CANCER RES, V40, P4512; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; Wan M, 1996, BRIT J CANCER, V73, P1398, DOI 10.1038/bjc.1996.265; WAN MH, 1994, INT J ONCOL, V5, P1043; WELCH DR, 1994, ONCOGENE, V9, P255; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X	39	41	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1545	1551		10.1038/sj.onc.1202476	http://dx.doi.org/10.1038/sj.onc.1202476			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102624				2022-12-17	WOS:000078770700004
J	Jinno, S; Hung, SC; Okayama, H				Jinno, S; Hung, SC; Okayama, H			Cell cycle start from quiescence controlled by tyrosine phosphorylation of Cdk4	ONCOGENE			English	Article						Cdk4; G(0)-G(1) transition; quiescence; tyrosine phosphorylation; UV	DEPENDENT KINASES; PROTEIN-KINASE; G1 ARREST; TGF-BETA; ACTIVATION; INHIBITION; CDC25A; GROWTH; SITES; PHASE	In mammals Cdk4 (or Cdk6 in some cell types) is required for starting the cell cycle. Recently we showed that Cdk4 is regulated by tyrosine phosphorylation and dephosphorylation, and that this regulation is required for a DNA damage-induced G(1) arrest. We report here that a generic anti-phosphotyrosine antibody can detect tyrosine-phosphorylated Cdk4 and that as revealed by immunoblot detection and kinase assay, this regulation is employed for DIVA damage-responsive checkpoint control during cell cycle start from quiescence. In rat fibroblasts traversing G(1) or arrested in G(1) by deprivation of anchorage, Cdk4 does not undergo tyrosine phosphorylation, Tyrosine phosphorylation occurs only during cell's arrest in quiescence and dephosphorylation during their cell cycle start. Ultraviolet irradiation blocks dephosphorylation and concomitant activation of Cdk4, thereby preventing the start of cell cycling, Thus, unlike tyrosine phosphorylation of Cdc2, which controls phase transition in the regular cell cycle, tyrosine phosphorylation of Cdk4 is employed for controlling cell cycle start from quiescence in a rat fibroblast.	Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Grad Sch Med, Dept Orthoped Surg, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo; University of Tokyo	Okayama, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 113, Japan.							BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V5, P2981; HAN A, 1978, RADIAT RES, V74, P88, DOI 10.2307/3574759; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Iavarone A, 1997, NATURE, V387, P417; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Jung E G, 1986, Curr Probl Dermatol, V15, P117; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUME K, 1992, NEW BIOL, V4, P504; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MILLER JB, 1992, CELL, V63, P407; NAGATA A, 1991, NEW BIOL, V3, P959; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Okada S., 1970, RAD BIOCH, VI; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SEFTON BM, 1995, CURRENT PROTOCOL PRO; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; THOMPSON LH, 1970, RADIAT RES, V41, P183, DOI 10.2307/3572905; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	31	41	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					565	571		10.1038/sj.onc.1202347	http://dx.doi.org/10.1038/sj.onc.1202347			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989806				2022-12-17	WOS:000078394400001
J	Zwicker, J; Brusselbach, S; Jooss, KU; Sewing, A; Behn, M; Lucibello, FC; Muller, R				Zwicker, J; Brusselbach, S; Jooss, KU; Sewing, A; Behn, M; Lucibello, FC; Muller, R			Functional domains in cyclin D1: pRb-kinase activity is not essential for transformation	ONCOGENE			English	Article						cyclin D1; transformation; retinoblastoma protein (Rb); Ras, cooperation with cyclin D1; CDK4	RETINOBLASTOMA PROTEIN; TRANSGENIC MICE; EXPRESSION; ONCOGENE; YEAST; GENE; DNA; PHOSPHORYLATION; PHASE; CDK4	Although cyclin D1 plays a major role during cell cycle progression and is involved in human tumourigenesis, its domain structure is still poorly understood. In the present study, we have generated a series of cyclin D1 N- and C1-terminal deletion constructs. These mutants were used to define the domains required for transformation of rat embryonal fibroblasts (REF) in cooperation with activated Ha-ras and and to establish correlations with defined biochemical properties of cyclin D1, Protein binding and REF assays showed that the region of the cyclin box required for the interaction with CDK4 as well as C-terminal sequences determining protein stability were crucial for transformation. Surprisingly, however, the N-terminal deletion of 20 amino acids which impaired pRb kinase activity did not affect the transforming ability of cyclin D1, Likewise, no effect on transformation was observed with mutants defective in p21(CIP) interaction. These observations argue against a crucial role of pRb inactivation or p21(CIP) squelching in cyclin D1-mediated transformation.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOUBIN F, 1995, ONCOGENE, V10, P2281; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Han EKH, 1998, PROSTATE, V35, P95, DOI 10.1002/(SICI)1097-0045(19980501)35:2<95::AID-PROS2>3.0.CO;2-F; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; JOOSS KU, 1994, EMBO J, V13, P1467, DOI 10.1002/j.1460-2075.1994.tb06401.x; KATO J, 1993, GENE DEV, V7, P331; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Maeda K, 1998, ONCOLOGY-BASEL, V55, P145, DOI 10.1159/000011849; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG CL, 1993, ONCOGENE, V8, P519; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; SEWING A, 1994, ONCOGENE, V9, P2733; SEWING A, 1993, J CELL SCI, V104, P545; SIKORSKI RS, 1989, GENETICS, V122, P19; TAM SW, 1994, ONCOGENE, V9, P2663; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	40	41	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					19	25		10.1038/sj.onc.1202286	http://dx.doi.org/10.1038/sj.onc.1202286			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926916				2022-12-17	WOS:000078166000003
J	Heriche, JK; Chambaz, EM				Heriche, JK; Chambaz, EM			Protein kinase CK2 alpha is a target for the Abl and Bcr-Abl tyrosine kinases	ONCOGENE			English	Article						CK2; Abl; Bcr-Abl; signal transduction	GLYCOGEN-SYNTHASE KINASE-3; CASEIN KINASE; GROWTH-FACTOR; BETA-SUBUNIT; PHOSPHORYLATION; CELLS; ACTIVATION	Protein kinase CK2 is a ubiquitous serine-threonine kinase in which a catalytic alpha subunit often associates with a beta subunit, CK2 alpha is required for cell survival in yeast and has been proposed to be involved in cell growth control; however, its regulation in cells remains unclear. Here we present evidence that CK2 alpha may be an associated substrate for the normal and oncogenic forms of the Abl tyrosine kinase. By probing CK2 alpha with antiphosphotyrosine antibodies, we found that CK2 alpha can be phosphorylated on tyrosine in quiescent cells. In vitro phosphorylation of CK2 alpha-containing immunoprecipitates showed that CK2 alpha is substrate of an associated tyrosine kinase activity. Immunoprecipitation experiments revealed that CK2 alpha is associated with normal c-Abl in mouse NIH3T3 fibroblasts and with the Bcr-Abl fusion protein in K562 human myeloid leukemia cells. Coexpression of Bcr-Abl and CK2 alpha in NIH3T3 cells also leads to the formation of a Bcr-Abl/CK2 alpha complex and to the inhibition of CK2 alpha activity, Bcr-Abl-induced inhibition of CK2 alpha could be reverted by incubating CK2 alpha with a tyrosine phosphatase. These observations clearly support the idea that a signal transduction pathway contributes to CK2 regulation and point to CK2 alpha as a possible mediator of Bcr-Abl effects.	INSERM, U244, F-38054 Grenoble, France; CEA Grenoble, Dept Biol Mol & Struct, Lab Biochim Regulat Cellulaires Endocrines, F-38054 Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CEA	Heriche, JK (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.			Heriche, Jean-Karim/0000-0001-6867-9425				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; GLOVER CVC, 1983, J BIOL CHEM, V258, P3258; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; PICTON C, 1982, FEBS LETT, V150, P191, DOI 10.1016/0014-5793(82)81332-X; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; SCHMIDTSPANIOL I, 1993, CELL MOL BIOL RES, V39, P761; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	21	41	41	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					13	18		10.1038/sj.onc.1201900	http://dx.doi.org/10.1038/sj.onc.1201900			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671309				2022-12-17	WOS:000074677800002
J	de Vries, A; Berg, RJW; Wijnhoven, S; Westerman, A; Wester, PW; van Kreijl, CF; Capel, PJA; de Gruijl, FR; van Kranen, HJ; van Steeg, H				de Vries, A; Berg, RJW; Wijnhoven, S; Westerman, A; Wester, PW; van Kreijl, CF; Capel, PJA; de Gruijl, FR; van Kranen, HJ; van Steeg, H			XPA-deficiency in hairless mice causes a shift in skin tumor types and mutational target genes after exposure to low doses of UVB	ONCOGENE			English	Article						XPA; UVB; p53; ras; papilloma; squamous cell carcinoma	XERODERMA-PIGMENTOSUM PATIENTS; SQUAMOUS-CELL CARCINOMAS; P53 GENE; ULTRAVIOLET-RADIATION; MOLECULAR ANALYSIS; EXCISION-REPAIR; RAS MUTATIONS; MOUSE SKIN; GROUP-A; CANCER	Xeroderma pigmentosum (XP) patients with a defect in the nucleotide excision repair gene XPA, develop tumors with a high frequency on sun-exposed areas of the skin. Here we describe that hairless XPA-deficient mice also develop skin tumors with a short latency time and a 100% prevalence after daily exposure to low doses of U.V.B. Surprisingly and in contrast to U.V.B.-exposed repair proficient hairless mice who mainly develop squamous cell carcinomas, the XPA-deficient mice developed papillomas with a high frequency (31%) at a U.V. dose of 32 J/m(2) daily, At the highest daily dose of 80 J/m(2) mainly squamous cell carcinomas (56%) and only 10% of papillomas were found in XPA-deficient hairless mice, p53 gene mutations were examined in exons 5, 7 and 8 and were detected in only 3 out of 37 of these skin tumors, whereas in tumors of control U.V.B.-irradiated wild type littermates this frequency was higher (45%) and more in line with our previous data. Strikingly, a high incidence of activating ras gene mutations were observed in U.V.B.-induced papillomas (in 11 out of 14 tumors analysed). In only two out of 14 squamous cell carcinomas we found similar ras gene mutations. The observed shift from squamous cell carcinomas in wild type hairless mice to papillomas in XPA-deficient hairless mice, and a corresponding shift in mutated cancer genes in these tumors, provide new clues on the pathogenesis of chemically-versus U.V.B.-induced skin carcinogenesis.	Natl Inst Publ Hlth & Environm, Dept Carcinogenesis Mutagenesis & Genet, Hlth Effects Res Lab, NL-3720 BA Bilthoven, Netherlands; Natl Inst Publ Hlth & Environm, Lab Pathol & Immunobiol, NL-3720 BA Bilthoven, Netherlands; Univ Utrecht, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Dept Dermatol, NL-3584 CX Utrecht, Netherlands	Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University	van Steeg, H (corresponding author), Natl Inst Publ Hlth & Environm, Dept Carcinogenesis Mutagenesis & Genet, Hlth Effects Res Lab, POB 1, NL-3720 BA Bilthoven, Netherlands.							Berg RJW, 1997, CANCER RES, V57, P581; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; Brown K, 1995, TOXICOL LETT, V82-3, P123, DOI 10.1016/0378-4274(95)03549-4; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; CAMPBELL C, 1993, BRIT J DERMATOL, V128, P111, DOI 10.1111/j.1365-2133.1993.tb15137.x; Cleaver JE, 1995, METABOLIC MOL BASES, VIII, P4393; DAYAGROSJEAN L, 1995, J PHOTOCH PHOTOBIO B, V28, P115, DOI 10.1016/1011-1344(95)07130-T; DEGRUIJL FR, 1993, CANCER RES, V53, P53; DEGRUIJL FR, 1995, BIOESSAYS, V17, P651, DOI 10.1002/bies.950170711; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; DORADO G, 1991, J MOL BIOL, V217, P217, DOI 10.1016/0022-2836(91)90533-C; DUMAZ N, 1994, MUTAT RES, V307, P375, DOI 10.1016/0027-5107(94)90311-5; Dumaz N, 1997, CARCINOGENESIS, V18, P897, DOI 10.1093/carcin/18.5.897; *IARC, 1992, MON EV CARC RISK HUM, V55; KANJILAL S, 1993, CANCER RES, V53, P2961; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; KRESS S, 1992, CANCER RES, V52, P6400; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; LUNGMANN M, 1996, ONCOGENE, V13, P823; MATSUMURA Y, 1995, J INVEST DERMATOL, V105, P399, DOI 10.1111/1523-1747.ep12321051; Matsumura Y, 1996, INT J CANCER, V65, P778; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; MiyauchiHashimoto H, 1996, J INVEST DERMATOL, V107, P343, DOI 10.1111/1523-1747.ep12363295; Mukhtar H, 1996, PHOTOCHEM PHOTOBIOL, V63, P355, DOI 10.1111/j.1751-1097.1996.tb03040.x; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P218, DOI 10.1111/j.1751-1097.1995.tb05262.x; REES J, 1994, J INVEST DERMATOL, V103, P747, DOI 10.1111/1523-1747.ep12412256; RUVEN HJT, 1994, ONCOGENE, V9, P3427; SATO M, 1993, CANCER RES, V53, P2944; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; vanKranen HJ, 1997, CANCER RES, V57, P1238; VANKRANEN HJ, 1995, CARCINOGENESIS, V16, P1141; YAGI T, 1991, CANCER RES, V51, P3177; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	36	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	1998	16	17					2205	2212		10.1038/sj.onc.1201744	http://dx.doi.org/10.1038/sj.onc.1201744			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619829				2022-12-17	WOS:000073298000005
J	Yokote, K; Hellman, U; Ekman, S; Saito, Y; Ronnstrand, L; Saito, Y; Heldin, CH; Mori, S				Yokote, K; Hellman, U; Ekman, S; Saito, Y; Ronnstrand, L; Saito, Y; Heldin, CH; Mori, S			Identification of Tyr-762 in the platelet-derived growth factor alpha-receptor as the binding site for Crk proteins	ONCOGENE			English	Article						PDGF alpha-receptor; Crk autophosphorylation site; C3G	CHRONIC MYELOGENOUS LEUKEMIA; SMOOTH-MUSCLE CELLS; PDGF BETA-RECEPTOR; PHOSPHORYLATION-DEPENDENT MANNER; SOLID-PHASE SYNTHESIS; COMPLEXES IN-VIVO; SIGNALING PATHWAYS; SH3 DOMAIN; TYROSINE PHOSPHORYLATION; C-CRK	Tyr-762 is an autophosphorylation site in the human platelet-derived growth factor (PDGF) alpha-receptor. In order to investigate whether phosphorylated Tyr-762 serves as a docking site for downstream signal transduction molecules, affinity purification using an immobilized synthetic peptide containing phosphorylated Tyr-762 and its surrounding amino acid residues was performed. Proteins in HeLa cell lysate of molecular sizes 27, 38 and 40 kDa bound to the phosphorylated, but not to the unphosphorylated peptide, Analyses of partial amino acid sequences of the purified proteins indicated that they were identical to CrkI, CrkII and CrkL respectively. The wild-type PDGF alpha-receptor, when expressed in porcine aortic endothelial cells, formed complexes with CrkII and CrkL upon ligand stimulation, which was specifically inhibited by a synthetic peptide containing phosphorylated Tyr-762, Replacement of Tyr-762 with a phenylalanine residue in the PDGF alpha-receptor abrogated ligand-induced binding of Crk proteins, Tyrosine phosphorylation of CrkII and CrkL increased by 1.8- and 1.3-fold, respectively, upon ligand stimulation of the wild-type alpha-receptor, In contrast, the Y762F mutant PDGF alpha-receptor failed to induce tyrosine phosphorylation of Crk proteins, CrkII and CrkL constitutively formed complex with the guanine nucleotide exchange factor C3G, in unstimulated as well as PDGF-stimulated cells, Moreover, the activated wild-type PDGF alpha-receptor but not the Y762F mutant receptor was found in a C3G immunoprecipitate, suggesting that a ternary complex between the activated PDGF alpha-receptor, Crk and C3G was formed. DNA synthesis stimulated by PDGF-BB as well as PDGF-induced MAP kinase activation was similar in cells expressing wild-type and mutant receptors. Interestingly, the activated PDGF beta-receptor was found not to bind Crk proteins. Instead, Tyr-771 of the beta-receptor, which is localized at an analogous position to Tyr-762 in the alpha-receptor, binds RasGAP, RasGAP is not bound to the alpha-receptor. Thus, this region in the kinase inserts of the two receptors may be important for the divergency in signaling from the two PDGF receptors.	Chiba Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Chiba 260, Japan; Ludwig Inst Canc Res, Uppsala Branch, S-75124 Uppsala, Sweden	Chiba University; Ludwig Institute for Cancer Research	Yokote, K (corresponding author), Chiba Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 1-8-1 Inohana, Chiba 260, Japan.		Ekman, Simon/AAB-9387-2021; Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				ANDREWS DM, 1991, INT J PEPT PROT RES, V38, P469; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BAZENET CE, 1994, ONCOGENE, V9, P517; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; BEITZ JG, 1991, P NATL ACAD SCI USA, V88, P2021, DOI 10.1073/pnas.88.5.2021; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLOCK LH, 1989, P NATL ACAD SCI USA, V86, P2388, DOI 10.1073/pnas.86.7.2388; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DILIBERTO PA, 1992, J BIOL CHEM, V267, P11888; DO MS, 1992, ONCOGENE, V7, P1567; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; HELDIN CH, 1994, GUIDEBOOK CYTOKINES; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HENRIKSEN R, 1993, CANCER RES, V53, P4550; HOSANG M, 1989, J CELL PHYSIOL, V140, P558, DOI 10.1002/jcp.1041400322; INUI H, 1994, J BIOL CHEM, V269, P30546; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KOYAMA N, 1992, J BIOL CHEM, V267, P22806; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALHANY KE, 1992, J CELL PHYSIOL, V150, P386, DOI 10.1002/jcp.1041500223; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; Smit L, 1996, ONCOGENE, V13, P381; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; SMITS A, 1991, P NATL ACAD SCI USA, V88, P8159, DOI 10.1073/pnas.88.18.8159; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Yokote K, 1996, J BIOL CHEM, V271, P5101; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	70	41	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	1998	16	10					1229	1239		10.1038/sj.onc.1201641	http://dx.doi.org/10.1038/sj.onc.1201641			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546424				2022-12-17	WOS:000072422000001
J	Edelson, MI; Lau, CC; Colitti, CV; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC				Edelson, MI; Lau, CC; Colitti, CV; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC			A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors	ONCOGENE			English	Article						ovary; cancer; borderline; loss of heterozygosity; chromosome Xq	ANDROGEN-RECEPTOR GENE; HUMAN PROSTATE-CANCER; TERM FOLLOW-UP; X-CHROMOSOME; LINKAGE MAP; MALIGNANCY; MUTATION; CARCINOMAS; HETEROZYGOSITY; PROGRESSION	We have used polymerase chain reaction (PCR) amplification of tandem repeats to study the pattern of allelic loss on chromosome X11.2-q12 in borderline and invasive epithelial ovarian tumors, Using eight microsatellite markers spanning Xq11.2-q12, 41 borderline and 65 invasive ovarian tumors, together with their corresponding normal tissues, were analysed, The highest percentage of loss of heterozygosity (LOH) was observed at the DXS1194 locus in borderline tumors (four of 16 informative cases, 25%) and at the androgen receptor (AR) locus in invasive epithelial ovarian tumors (18 of 47 informative cases, 38%), X chromosome activation studies performed in cases with LOH at the AR locus showed that the allelic loss at the AR locus is not confined to the inactive allele, A one centimorgan region including the AR locus and flanked by the primers DXS1161 and PGK1P1 was identified as the smallest common loss region in both borderline and invasive epithelial ovarian tumors.	Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol, Lab Gynecol Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Texas Childrens Hosp, Div Hematol Oncol, Houston, TX 77030 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Baylor College of Medicine	Mok, SC (corresponding author), Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol, Lab Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA.				NCI NIH HHS [R01CA63381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RC, 1992, AM J HUM GENET, V51, P1229; BARAKAT RR, 1994, OBSTET GYN CLIN N AM, V21, P93; BELL DA, 1994, CANCER, V73, P1859, DOI 10.1002/1097-0142(19940401)73:7<1859::AID-CNCR2820730714>3.0.CO;2-L; BOSTWICK DG, 1986, CANCER, V58, P2052, DOI 10.1002/1097-0142(19861101)58:9<2052::AID-CNCR2820580916>3.0.CO;2-5; CASEY AC, 1993, GYNECOL ONCOL, V50, P316, DOI 10.1006/gyno.1993.1218; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; DODSON MK, 1993, CANCER RES, V53, P4456; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; KIM TM, 1994, CANCER RES, V54, P605; LEAKE JF, 1992, CURR OPIN OBSTET GYN, V4, P81; LEAKE JF, 1992, GYNECOL ONCOL, V47, P150, DOI 10.1016/0090-8258(92)90099-5; LOBACCARO JM, 1993, HUM MOL GENET, V2, P1799, DOI 10.1093/hmg/2.11.1799; MOK SCH, 1993, CANCER RES, V53, P1489; NELSON DL, 1995, CYTOGENET CELL GENET, V71, P308; NEWMARK JR, 1992, P NATL ACAD SCI USA, V89, P6319, DOI 10.1073/pnas.89.14.6319; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SCHOENBERG MP, 1994, P ANN M AM ASS CANC, V35, pA1653; SCULLY RE, 1982, B CANCER, V69, P228; Tangir J, 1996, CANCER RES, V56, P2501; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tilley WD, 1996, CLIN CANCER RES, V2, P277; TSAO SW, 1993, GYNECOL ONCOL, V48, P5, DOI 10.1006/gyno.1993.1002; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WEEKS DE, 1995, GENOMICS, V26, P39, DOI 10.1016/0888-7543(95)80080-6; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549	28	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					197	202		10.1038/sj.onc.1201479	http://dx.doi.org/10.1038/sj.onc.1201479			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464537				2022-12-17	WOS:000071427100006
J	Maguer-Satta, V; Burl, S; Liu, L; Damen, J; Chahine, H; Krystal, G; Eaves, A; Eaves, C				Maguer-Satta, V; Burl, S; Liu, L; Damen, J; Chahine, H; Krystal, G; Eaves, A; Eaves, C			BCR-ABL accelerates C2-ceramide-induced apoptosis	ONCOGENE			English	Article						CML; BCR-ABL; ceramide; apoptosis; tyrosine phosphorylation	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; HUMAN HEMATOPOIETIC-CELLS; ACTIVATED PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE-ACTIVITY; RAS SIGNALING PATHWAY; LONG-TERM CULTURE; HUMAN BONE-MARROW	In patients with chronic myeloid leukemia (CML), the neoplastic (BCR-ABL(+)) progenitor cells are characterized by an increased proliferative activity, Whether these cells are also resistant to apoptosis and if so, under what conditions remains controversial, We now show that highly purified populations of very primitive neoplastic progenitor cells obtained directly from CML patients survive and proliferate in vitro for several weeks in the absence of any added growth factors (except insulin), In contrast, purified primary normal progenitors maintained under the same conditions die rapidly, Nevertheless, both primary CML cells and BCR-ABL(+) BAF3 cells show the same dose-dependent sensitivity to TNF-alpha or ceramide-induced apoptosis as their respective normal counterparts, In fact, time course studies demonstrated an even faster onset of apoptosis in ceramide-treated BCR-ABL(+) BAF3 cells as compared to normal controls, BCR-ABL(+) cells treated with ceramide also showed a rapid and sequential increase in the tyrosine phosphorylation of p210(BCR-ABL), p46-56(SHC) and p120(Cbl), These findings suggest growth factor deprivation and treatment with TNF-alpha or ceramide trigger different initial events both of which can lead to apoptosis in factor-dependent hematopoietic cells, However, in the first case, activation of apoptosis is blocked by the basal activity of p210(BCR-ABL), whereas in the second, the presence of p210(BCR-ABL) appears to accelerate the onset of apoptosis by a mechanism that may involve an activation of its kinase function.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Expt Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; Univ Victor Segalen, Lab Greffe de Moelle, CNRS, UMR 5540, Bordeaux, France; Univ British Columbia, Dept Med, Vancouver, BC, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada	British Columbia Cancer Agency; University of British Columbia; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; University of British Columbia; University of British Columbia	Eaves, C (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.		Maguer-Satta, Veronique/U-8857-2019	Maguer-Satta, Veronique/0000-0002-1556-068X; Krystal, Gerald/0000-0002-1961-6281				AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Albrecht T, 1996, BRIT J HAEMATOL, V95, P501, DOI 10.1046/j.1365-2141.1996.d01-1934.x; AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CARLESSO N, 1994, ONCOGENE, V9, P149; CASHMAN JD, 1992, LEUKEMIA, V6, P886; Chacko GW, 1996, J IMMUNOL, V157, P2234; CHEN M, 1995, CANCER RES, V55, P991; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; EAVES AC, 1986, P NATL ACAD SCI USA, V83, P5306, DOI 10.1073/pnas.83.14.5306; Eaves C J, 1987, Baillieres Clin Haematol, V1, P931, DOI 10.1016/S0950-3536(87)80033-1; EAVES CJ, 1993, P NATL ACAD SCI USA, V90, P12015, DOI 10.1073/pnas.90.24.12015; FIALKOW PJ, 1981, BLOOD, V58, P158, DOI 10.1182/blood.V58.1.158.158; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Hariharan I K, 1988, Oncogene Res, V3, P387; HAWLEY RG, 1994, GENE THER, V1, P136; Hogge DE, 1996, BLOOD, V88, P3765, DOI 10.1182/blood.V88.10.3765.bloodjournal88103765; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIM MY, 1991, J BIOL CHEM, V266, P484; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Kitanaka A, 1996, BLOOD, V88, P590, DOI 10.1182/blood.V88.2.590.bloodjournal882590; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LANSDORP PM, 1992, J EXP MED, V175, P1501, DOI 10.1084/jem.175.6.1501; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MaguerSatta V, 1996, BLOOD, V88, P1796; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nishii K, 1996, ONCOGENE, V13, P2225; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Petzer AL, 1996, J EXP MED, V183, P2551, DOI 10.1084/jem.183.6.2551; Petzer AL, 1996, BLOOD, V88, P2162, DOI 10.1182/blood.V88.6.2162.bloodjournal8862162; Petzer AL, 1997, BLOOD, V90, P64; PONCHIO L, 1995, BLOOD, V86, P3314, DOI 10.1182/blood.V86.9.3314.bloodjournal8693314; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SANTUCCI MA, 1993, INT J RADIAT ONCOL, V26, P831, DOI 10.1016/0360-3016(93)90498-K; Sattler M, 1996, ONCOGENE, V12, P839; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Selleri C, 1997, BLOOD, V89, P957, DOI 10.1182/blood.V89.3.957; SIRARD C, 1994, BLOOD, V83, P1575; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; STRIFE A, 1988, CANCER RES, V48, P1035; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SUTHERLAND HJ, 1991, BLOOD, V78, P666, DOI 10.1182/blood.V78.3.666.bloodjournal783666; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TOKER A, 1994, J BIOL CHEM, V269, P32358; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; UDOMSAKDI C, 1992, P NATL ACAD SCI USA, V89, P6192, DOI 10.1073/pnas.89.13.6192; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WIEDEMANN LM, 1988, BLOOD, V71, P349; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	85	41	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	1998	16	2					237	248		10.1038/sj.onc.1201533	http://dx.doi.org/10.1038/sj.onc.1201533			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464542				2022-12-17	WOS:000071427100011
J	Queimado, L; Reis, A; Fonseca, I; Martins, C; Lovett, M; Soares, J; Parreira, L				Queimado, L; Reis, A; Fonseca, I; Martins, C; Lovett, M; Soares, J; Parreira, L			A refined localization of two deleted regions in chromosome 6q associated with salivary gland carcinomas	ONCOGENE			English	Article						salivary gland carcinomas; chromosome 6q; loss of heterozygosity (LOH); deletions; histological subtypes	MANGANESE SUPEROXIDE-DISMUTASE; TUMOR-SUPPRESSOR GENE; LONG ARM; BREAST-CARCINOMA; OVARIAN CANCERS; MELANOMA-CELLS; HUMAN GENOME; HETEROZYGOSITY; TUMORIGENICITY; IDENTIFICATION	Deletions within chromosome 6 (6q25 to 6qter) are the most consistent structural change observed in salivary gland carcinomas, To better define the location of these deletions we investigated loss of heterozygosity (LOH) for 23 polymorphic markers within 19 salivary gland carcinomas covering several histological subtypes, LOH was observed in 47% of tumors, confirming previous reports that such losses are frequent and occur in almost all histological subtypes of tumors, The highest frequency of LOH was found at, or distal to, D6S437, Seven tumors had allelic losses for D6S297 and/or D6S37, A second peak of loss was also observed at D6S262 and D6S32, In some tumors we observed LOH in one or the other of these two regions, In other tumors we observed loss of both regions with retention of intervening loci, These data suggest that two small deletions commonly occur, one between D6S262 and D6S32 (estimated to cover less than 1.5 Mb) and another between D6S297 and D6S446 (estimated to cover similar to 2 Mb), These results extend previous studies by sublocalizing the regions of LOH and suggest that inactivation of one or more tumor suppressor genes located in these regions may be an important step in salivary gland carcinogenesis.	Univ Texas, SW Med Ctr, McDermott Ctr, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Otorhinolaryngol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA; Fac Med Lisboa, Inst Histol & Embriol, Lisbon, Portugal; Inst Portugues Oncol Francisco Gentil, Dept Patol Morfol, Lisbon, Portugal; Inst Portugues Oncol Francisco Gentil, Ctr Invest Patobiol Mol, Lisbon, Portugal; Fac Med Lisboa, Inst Histol & Embriol, Lisbon, Portugal	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Universidade de Lisboa; Portuguese Institute of Oncology; Portuguese Institute of Oncology; Universidade de Lisboa	Queimado, L (corresponding author), Univ Texas, SW Med Ctr, McDermott Ctr, NB10106, Dallas, TX 75235 USA.		Queimado, Lurdes/AAY-2545-2021; Fonseca, Isabel/A-7396-2008; Soares, Jorge/C-7429-2015; Queimado, Lurdes/L-7465-2013; Parreira, Leonor/S-2304-2019	Queimado, Lurdes/0000-0002-1106-4873; Fonseca, Isabel/0000-0002-1359-6494; Soares, Jorge/0000-0002-1359-6494; Queimado, Lurdes/0000-0002-1106-4873; Martins, Carmo/0000-0002-7901-7600; Parreira, Leonor/0000-0002-1970-9285				Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Bockmuhl U, 1996, CANCER RES, V56, P5325; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooke IE, 1996, MAMM GENOME, V7, P157, DOI 10.1007/s003359900040; Cooney KA, 1996, CANCER RES, V56, P4150; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1991, CANCER RES, V51, P1020; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; GARCIA M, 1992, P NATL ACAD SCI USA, V89, P11538, DOI 10.1073/pnas.89.23.11538; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; Hankins GR, 1996, ONCOGENE, V12, P2003; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JIN Y, 1994, BRIT J CANCER, V70, P42, DOI 10.1038/bjc.1994.247; Johns MM, 1996, CANCER RES, V56, P1151; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MORITA R, 1991, CANCER RES, V51, P5817; MULLENBACH R, 1989, TRENDS GENET, V5, P391; NORDKVIST A, 1994, GENE CHROMOSOME CANC, V10, P115, DOI 10.1002/gcc.2870100206; Noviello C, 1996, CLIN CANCER RES, V2, P1601; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; SAFFORD SE, 1994, CANCER RES, V54, P4261; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; Sandhu AK, 1996, ONCOGENE, V12, P247; SANDROS J, 1990, CANCER GENET CYTOGEN, V44, P153, DOI 10.1016/0165-4608(90)90042-9; SEIFERT G, 1990, PATHOL RES PRACT, V186, P555, DOI 10.1016/S0344-0338(11)80220-7; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; Simonic I, 1996, HUM GENET, V97, P524; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; TAGUCHI T, 1993, CANCER RES, V53, P4349; Tahara H, 1996, CANCER RES, V56, P599; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WELCH DR, 1994, ONCOGENE, V9, P255	40	41	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					83	88		10.1038/sj.onc.1201480	http://dx.doi.org/10.1038/sj.onc.1201480			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467946				2022-12-17	WOS:000071236800010
J	Hande, MP; Balajee, AS; Natarajan, AT				Hande, MP; Balajee, AS; Natarajan, AT			Induction of telomerase activity by UV-irradiation in Chinese hamster cells	ONCOGENE			English	Article						telomeres; telomerase; UV radiation; hamster cells	HUMAN-CHROMOSOMES; CANCER; ACQUISITION; ASSOCIATION; ACTIVATION; SEQUENCES; (TTAGGG)N; TISSUES; REPEATS; ENZYME	Telomerase is a ribonucleoprotein whose activity has been detected in germline cells and in neoplastic and immortal cells. Telomerase compensates the telomere loss arising by the end replication problem by synthesizing telomeric repeats at the 3' end of the eukaryotic chromosomes, Telomerase is reactivated during cancer progression in human and mice. In order to determine whether the telomerase activity can be upregulated in vitro in response to DNA damaging agents, we examined the telomerase activity in five Chinese hamster cell lines following exposure to 5 J/m(2) or 40 J/m(2) UV-C radiation, All the cell lines tested showed an increase in telomerase activity in the PCR-based telomeric repeat amplification protocol (TRAP) in a dose dependent manner, This increase in telomerase activity correlated well with the number of cells being in the S and G(2)/M phase after UV exposure, However, in unirradiated control cells, similar levels of telomerase activity were observed in different phases of the cell cycle, Furthermore, telomeric signals were clustered in one or more parts of the disintegrating nuclear particles of the apoptotic cell as detected by fluorescence in situ hybridization (FISH), This is the first study to demonstrate the induction of telomerase activity following exposure to DNA-damaging agents like UV radiation in Chinese hamster cells in vitro.	LEIDEN STATE UNIV,DEPT RADIAT GENET & CHEM MUTAGENESIS,MGC,NL-2333 AL LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Hande, M. Prakash/B-1645-2008	Hande, M. Prakash/0000-0002-4511-6256				ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; Bacchetti S, 1996, SEMIN CELL DEV BIOL, V7, P31, DOI 10.1006/scdb.1996.0006; Balajee AS, 1996, MUTAT RES-FUND MOL M, V372, P163, DOI 10.1016/S0027-5107(96)00136-4; BARNETT MA, 1993, NUCLEIC ACIDS RES, V21, P27, DOI 10.1093/nar/21.1.27; BERTONI L, 1994, GENOMICS, V24, P53, DOI 10.1006/geno.1994.1581; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; CHADENEAU C, 1995, ONCOGENE, V11, P893; CHADENEAU C, 1995, CANCER RES, V55, P2533; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; Duchaud E, 1996, CANCER RES, V56, P1400; FLINT J, 1994, AM J HUM GENET, V55, P505; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1996, MOL CELL BIOL, V16, P2932; IJDO JW, 1991, NUCLEIC ACIDS RES, V19, P4780, DOI 10.1093/nar/19.17.4780; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1995, NAT GENET, V9, P104, DOI 10.1038/ng0295-104; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MURNANE JP, 1993, MOL CELL BIOL, V13, P977, DOI 10.1128/MCB.13.2.977; OH HJ, 1997, UNPUB BR J CANC; Pandita TK, 1996, ONCOGENE, V13, P1423; SABATIER L, 1995, RADIAT ENVIRON BIOPH, V34, P229, DOI 10.1007/BF01209747; Slijepcevic P, 1996, CHROMOSOMA, V104, P596, DOI 10.1007/s004120050152; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; Ueda M, 1997, CANCER RES, V57, P370; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wright WE, 1996, DEV GENET, V18, P173; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	34	41	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1747	1752		10.1038/sj.onc.1201327	http://dx.doi.org/10.1038/sj.onc.1201327			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349510				2022-12-17	WOS:A1997XY63100016
J	McWhirter, JR; Wang, JYJ				McWhirter, JR; Wang, JYJ			Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein	ONCOGENE			English	Article						actin filaments; ALL CML; Dbl-homology; tyrosine kinase	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BONE-MARROW STROMA; TYROSINE KINASE; C-ABL; PHILADELPHIA-CHROMOSOME; HEMATOPOIETIC PROGENITORS; COILED-COIL; BINDING; PROTEIN	In Philadelphia chromosome (Phl)-positive human leukemia, the c-Abl tyrosine kinase is activated by fusion to sequences encoded by the breakpoint cluster region (bcr) gene, Two major types of Bcr-Abl fusion proteins have been found in human leukemia, Fusion of the N-terminal 426 amino acids of Bcr generates p190(Bcr-Abl) which is mostly found in acute lymphocytic leukemia (ALL), whereas fusion of the N-terminal 902 or 927 amino acids of Bcr generates p210(Bcr-Abl) mostly found with chronic myelogenous leukemia (CML). Previous studies have demonstrated that both the Bcr and the Abl functional domains contribute to the oncogenic activity of Bcr-Abl proteins, Present in both p190 and p210 is the N-terminal coiled-coil of Bcr (aa 1-63), which is shown here to be functionally replaceable with the leucine zipper of the yeast transcription factor GCN4, The ZIP-Bcr-Abl protein transforms Rat-1/myc cells, is autophosphorylated on tyrosine and localized predominantly to actin filaments, Thus, formation of homo-oligomers through either Bcr or GCN4 coiled-coil can activate the tyrosine kinase and F-actin binding functions of Abl, We also found that a Bcr-Abl fusion containing only Bcr amino acids (1-191) can efficiently transform Rat-1/myc cells. Fusion of additional Bcr sequences (aa 192-923) did not affect the transformation of Rat-1/myc cells but progressively reduced the disruptive effect on the actin cytoskeleton, In particular, the Dbl homology domain present in p210(Bcr-Abl) but not in p190(Bcr-Abl) contributes to the stabilization of actin fibers, The modulatory effect of Bcr sequences on actin structure may underlie the apparent pathogenic variations between the different Bcr-Abl fusion proteins.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOL GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [CA43054, R37 CA043054, R01 CA043054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATIA R, 1995, J CLIN INVEST, V96, P931, DOI 10.1172/JCI118141; BHATIA R, 1994, J CLIN INVEST, V94, P384, DOI 10.1172/JCI117333; CAMPBELL ML, 1990, ONCOGENE, V5, P773; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DOWDING C, 1991, BLOOD, V78, P499; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Golub TR, 1996, MOL CELL BIOL, V16, P4107; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KOJI T, 1995, J BIOL CHEM, V279, P27880; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARU Y, 1995, MOL CELL BIOL, V15, P835; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Melo JV, 1996, LEUKEMIA, V10, P751; Miao YJ, 1996, J BIOL CHEM, V271, P22823, DOI 10.1074/jbc.271.37.22823; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; vanRhee F, 1996, BLOOD, V87, P5213, DOI 10.1182/blood.V87.12.5213.bloodjournal87125213; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; VERFAILLIE CM, 1992, BLOOD, V79, P2821; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; WilsonRawls J, 1996, CANCER RES, V56, P3426	48	41	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	1997	15	14					1625	1634		10.1038/sj.onc.1201342	http://dx.doi.org/10.1038/sj.onc.1201342			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349495				2022-12-17	WOS:A1997XY63100001
J	Dong, JA; Naito, M; Tsuruo, T				Dong, JA; Naito, M; Tsuruo, T			c-Myc plays a role in cellular susceptibility to death receptor-mediated and chemotherapy-induced apoptosis in human monocytic leukemia U937 cells	ONCOGENE			English	Article						c-myc; TNF-alpha; Fas; antitumor agents; CPP32; apoptosis	AGENT-INDUCED APOPTOSIS; ANTICANCER DRUGS; INDUCTION; BCL-2; RESISTANCE; EXPRESSION; GENE; FAS; CYTOTOXICITY; HOMOLOG	Human monocytic leukemia U937 cells readily undergo apoptosis when they are treated with TNF-alpha, anti-Fas antibody and anticancer drugs such as etoposide and Ara-C, To study the mechanism of apoptosis, we developed a novel apoptosis-resistant variant, UC, from U937 cells, The UC cells showed resistance to apoptosis induced by TNF-alpha, anti-Fas antibody, etoposide and Ara-C, Somatic cell hybridization between U937 and UC showed that apoptosis-resistance to TNF-alpha in UC was genetically recessive and resistance to etoposide was dominant, suggesting that UC has at least two different mutations functionally involved in apoptosis, Mechanistic analysis revealed that UC cells expressed reduced amounts of c-Myc, Transfection of the c-myc gene into UC cells restored the sensitivity of the cells to undergo apoptosis induced by TNF-alpha and anti-Fas, which attributes apoptosis-resistance in this circumstance to the reduced expression of c-Myc, On the other hand, c-myc transfection into UC cells could not restore their sensitivity to etoposide- and Ara-C-induced apoptosis, arguing against the role of c-myc in chemotherapy-induced apoptosis, However, treating the parental U937 cells with antisense oligonucleotides designed to reduce c-Myc expression rendered the cells resistant to etoposide-induced as well as to TNF-alpha-induced apoptosis, These results indicate that the reduced expression of c-Myc in UC is strongly associated with the resistance to etoposide-induced apoptosis, Our finding that c-myc transfection into UC could not restore the sensitivity to etoposide-induced apoptosis, suggests UC could have a second mutation that confers resistance to etoposide-induced apoptosis in a genetically dominant manner, Taken together, our present results indicate that c-Myc plays a role in cellular susceptibility to death receptor-mediated and chemotherapy-induced apoptosis.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; Japanese Foundation for Cancer Research								AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; Baker SJ, 1996, ONCOGENE, V12, P1; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chen ZH, 1996, CANCER RES, V56, P5224; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; FUJITA M, 1995, ONCOGENE, V11, P15; FUJITA N, 1993, CANCER RES, V53, P5022; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KATAOKA S, 1994, EXP CELL RES, V215, P199, DOI 10.1006/excr.1994.1332; Kerr J. F., 1991, APOPTOSIS MOL BASIS, V3, P5; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; Mikami K, 1996, CANCER RES, V56, P2823; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; NIIMI S, 1991, BRIT J CANCER, V63, P237, DOI 10.1038/bjc.1991.56; Noguchi K, 1996, ONCOGENE, V13, P39; NOGUCHI K, 1995, CELL GROWTH DIFFER, V6, P1271; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; WOOD AC, 1995, BRIT J CANCER, V71, P937, DOI 10.1038/bjc.1995.181; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONEHARA S, 1989, J EXP MED, V169, P1749	33	41	45	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					639	647		10.1038/sj.onc.1201237	http://dx.doi.org/10.1038/sj.onc.1201237			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264404				2022-12-17	WOS:A1997XP68300003
J	Ciana, P; Neri, A; Cappellini, C; Cavallo, F; Pomati, M; Chang, CC; Maiolo, AT; Lombardi, L				Ciana, P; Neri, A; Cappellini, C; Cavallo, F; Pomati, M; Chang, CC; Maiolo, AT; Lombardi, L			Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts	ONCOGENE			English	Article						NF-kappa B; NFKB-2; transcription factor; transformation	NF-KAPPA-B; V-REL; TYROSINE KINASE; GENE-PRODUCT; P65 SUBUNIT; NUCLEAR; ONCOGENE; CLONING; CELLS; BCL-3	The NFKB-2 (Lyt-10) gene codes for an NF-kappa B-related transcription factor containing rel-polyG-ankyrin domains. Rearrangements of the NFKB-2 locus leading to the production of 3' truncated NFKB-2 proteins are recurrently found in lymphoid neoplasms, particularly cutaneous lymphomas, Such mutant NFKB-2 proteins have lost the ability to repress transcription that is typical of NFKB-2 subunit p52, and function as constitutive transcriptional activators. To verify whether the expression of abnormal NFKB-2 proteins can lead to malignant transformations in mammalian cells, we transfected human lymphoblastoid cell lines and murine fibroblasts (Balb/3T3) with expression vectors carrying the cDNAs coding far normal NFKB-2p52, Lyt-10C alpha or LB40 proteins, which are representative of the abnormal types found in lymphoma cases. The expression of both normal and mutant NFKB-2 proteins has a lethal effect on lymphoblastoid cells and a cytotoxic effect was also observed in murine fibroblasts. The fibroblast cell lines expressing Lyt-10C alpha or LB40, but not those expressing normal MFKB-2p52, were capable of forming colonies in soft agar. The analysis of individual clones revealed that cloning efficiency correlated with the expression levels of the abnormal proteins, Injection of the Lyt-10C alpha-transfected Balb cells in SCID mice led to tumor formation in all of the animals, whereas no tumors were observed in the mice injected with control or NFKB-2p52-transfected cells, thus indicating that abnormal NFKB-2 protein expression is tumorigenic in vivo. Our results show that mutant NFKB-2 proteins can lead to the transformed phenotype, and support the hypothesis that alterations in NFKB-2 genes may play a role in lymphomagenesis.	UNIV MILAN,OSPED MAGGIORE IRCCS,IST SCI MED,SERV EMATOL,LAB EMATOL SPERIMENTALE & GENET MOL,MILAN,ITALY; UNIV TURIN,DIPARTIMENTO SCI CLIN BIOL,TURIN,ITALY; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY	University of Milan; University of Turin; Columbia University			Ciana, Paolo/F-9224-2012; Neri, Antonino/I-9690-2014; Cavallo, Federica/C-5666-2011	Neri, Antonino/0000-0001-9047-5912; CIANA, PAOLO/0000-0001-5771-5638; Cavallo, Federica/0000-0003-4571-1060; Critelli, Salvatore/0000-0001-7325-0228				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; CHANG CC, 1994, ONCOGENE, V9, P923; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GRILLI M, 1992, INT REV CYTOL, V143, P1; GRIMM S, 1994, ONCOGENE, V9, P2391; GU W, 1993, P NATL ACAD SCI USA, V90, P2913; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; LU D, 1991, ONCOGENE, V6, P1235; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; TARPLEY WG, 1984, MOL CELL BIOL, V4, P2653, DOI 10.1128/MCB.4.12.2653; ZHANG JD, 1994, ONCOGENE, V9, P1931; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	33	41	42	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1805	1810		10.1038/sj.onc.1201015	http://dx.doi.org/10.1038/sj.onc.1201015			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150386	Green Published			2022-12-17	WOS:A1997WW16600006
J	Broome, MA; Hunter, T				Broome, MA; Hunter, T			The PDGF receptor phosphorylates Tyr 138 in the c-Src SH3 domain in vivo reducing peptide ligand binding	ONCOGENE			English	Article						PDGF receptors; c-Src; SH3 domain; tyrosine phosphorylation	PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; PROLINE-RICH PEPTIDES; MUTANT MICE; BACULOVIRUS EXPRESSION; CRYSTAL-STRUCTURE; SARCOMA VIRUS; BETA-RECEPTOR; CELL-CYCLE; 3T3 CELLS	Treatment of quiescent NIH3T3 cells with PDGF BE results in the transient activation and hyperphosphorylation of the protein-tyrosine kinase, c-Src. These effects correlate with novel serine and tyrosine phosphorylations in the N-terminal non-catalytic region of the molecule, which contains an SH3 and SH2 domain. In this study, a site of PDGF-induced tyrosine phosphorylation was mapped to Tyr 138 in the SH3 domain; Tyr 138 is exposed on the SH3 peptide binding surface. This same site is phosphorylated in vitro by the PDGF receptor when purified baculovirus-expressed c-Src is complexed with the activated receptor. Phosphorylation of Tyr 138 required association of c-Src with the PDGF receptor via its SH2 domain. When a c-Src Phe 138 mutant was stably expressed in Src(-) mouse fibroblasts, it was activated to the same extent as wild type c-Src following PDGF stimulation, indicating that phosphorylation of this site is not required for PDGF-mediated activation. However, Tyr 138 phosphorylation was found to diminish SH3 domain peptide ligand binding ability in vitro.	SALK INST BIOL STUDIES, MOL BIOL & VIROL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	Salk Institute; University of California System; University of California San Diego					NCI NIH HHS [CA14195, CA39780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1980, NATURE, V285, P167, DOI 10.1038/285167a0; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GARTNER T, 1992, EUR J BIOCHEM, V208, P91, DOI 10.1111/j.1432-1033.1992.tb17162.x; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Ishino M, 1995, ONCOGENE, V11, P2331; KARN J, 1989, ONCOGENE, V4, P773; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LIU XQ, 1993, ONCOGENE, V8, P1119; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSTELIN T, 1994, SRC FAMILY TYROSINE; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OKADA M, 1993, J BIOL CHEM, V268, P18070; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PENG ZY, 1995, ONCOGENE, V11, P1955; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Possee RD., 1992, BACULOVIRUS EXPRESSI; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RAMER SE, 1991, P NATL ACAD SCI USA, V88, P6254, DOI 10.1073/pnas.88.14.6254; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Stover DR, 1996, J BIOL CHEM, V271, P12481, DOI 10.1074/jbc.271.21.12481; Summers MD, 1987, MANUAL METHODS BACUL; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WALKER F, 1993, J BIOL CHEM, V268, P19552; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YU KT, 1985, J BIOL CHEM, V260, P5838; ZHANG S, 1991, Cellular Physiology and Biochemistry, V1, P24, DOI 10.1159/000154590	83	41	41	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	1997	14	1					17	34		10.1038/sj.onc.1200798	http://dx.doi.org/10.1038/sj.onc.1200798			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010229				2022-12-17	WOS:A1997WB76000002
J	Kaul, SC; Mitsui, Y; Komatsu, Y; Reddel, RR; Wadhwa, R				Kaul, SC; Mitsui, Y; Komatsu, Y; Reddel, RR; Wadhwa, R			A highly expressed 81 kDa protein in immortalized mouse fibroblasts: Its proliferative function and identity with ezrin	ONCOGENE			English	Article						ezrin; mouse fibroblasts; proliferation; contact inhibition	MEMBRANE-CYTOSKELETAL LINKER; ACTIN-BASED CYTOSKELETONS; ERM FAMILY MEMBERS; CELLULAR MORTALITY; APICAL MICROVILLI; PARIETAL-CELLS; IDENTIFICATION; PHOSPHORYLATION; ASSOCIATION; CLEAVAGE	An 81 kDa protein was found to be highly expressed in spontaneously immortalized CD1-ICR mouse fibroblasts, RS-4, as compared to normal fibroblasts. RS-4 cells have a reduced serum requirement and exhibit multilayered growth in vitro but are not tumorigenic, The protein was purified from RS-4 cell extracts and used to obtain a polyclonal antibody that specifically immunoprecipitated an 81 kDa protein from cell lysates. Immunocloning of its cDNA and sequence analysis revealed its identity with ezrin, an F-actin binding protein that is a component of the cortical cytoskeleton, Microinjection of the purified IgG fraction of the anti-p81 antiserum into the cytoplasm of RS-4 cells blocked their entry into S phase suggesting that the protein has a proliferative function, Immunostaining of normal mouse tissues showed that the expression of p81/ezrin was highest in proliferating cell populations. Unlike RS-4, NIH3T3 cells exhibit contact inhibition and express levels of p81/ezrin similar to those of normal fibroblasts, When NIH3T3 cells were transfected with p81/ezrin cDNA they lost contact inhibition and thus resembled RS-4 cells, The study demonstrates a proliferative function of p81/ezrin and suggests its involvement in pathways that negatively regulate contact inhibition.	CHILDRENS MED RES INST,SYDNEY,NSW 2145,AUSTRALIA; CHUGAI RES INST MOL MED,NIIHARI,IBARAKI 30041,JAPAN	Children's Medical Research Institute - Australia; University of Sydney	Kaul, SC (corresponding author), AGCY IND SCI & TECHNOL,NATL INST BIOSCI & HUMAN TECHNOL,1-1 HIGASHI,TSUKUBA,IBARAKI 305,JAPAN.		Reddel, Roger R/A-6635-2014; Kaul, Sunil C/L-8671-2018; Wadhwa, Renu/L-8898-2018	Reddel, Roger R/0000-0002-6302-6107; Kaul, Sunil C/0000-0002-0046-3916; Wadhwa, Renu/0000-0001-8248-5192				ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; AMIEVA MR, 1994, EXP CELL RES, V210, P140, DOI 10.1006/excr.1994.1021; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; EDWARDS KA, 1994, P NATL ACAD SCI USA, V91, P4589, DOI 10.1073/pnas.91.10.4589; FAZIOLI F, 1993, ONCOGENE, V8, P1335; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HENRY M, 1995, 1995 M CYT CELL FUNC, P69; Herman IM, 1993, CURR OPIN CELL BIOL, V5, P48, DOI 10.1016/S0955-0674(05)80007-9; KAUL SC, 1994, BBA-GEN SUBJECTS, V1201, P389, DOI 10.1016/0304-4165(94)90067-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Sambrook J, 1989, MOL CLONING LAB MANU; SHUSTER CB, 1995, J CELL BIOL, V128, P837, DOI 10.1083/jcb.128.5.837; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; WADHWA R, 1991, MUTAT RES, V256, P243, DOI 10.1016/0921-8734(91)90015-4; WADHWA R, 1993, J BIOL CHEM, V268, P6615; WADHWA R, 1993, EXP CELL RES, V207, P442, DOI 10.1006/excr.1993.1213; WADHWA R, 1994, CELL STRUCT FUNCT, V19, P1, DOI 10.1247/csf.19.1; WADHWA R, 1991, BIOCHEM BIOPH RES CO, V178, P269, DOI 10.1016/0006-291X(91)91809-Q; YAO XB, 1993, AM J PHYSIOL, V265, pC36, DOI 10.1152/ajpcell.1993.265.1.C36; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437	29	41	45	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1231	1237						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808697				2022-12-17	WOS:A1996VJ20200014
J	Milia, E; DiSomma, MM; Baldoni, F; Chiari, R; Lanfrancone, L; Pelicci, PG; Telford, JL; Baldari, CT				Milia, E; DiSomma, MM; Baldoni, F; Chiari, R; Lanfrancone, L; Pelicci, PG; Telford, JL; Baldari, CT			The aminoterminal phosphotyrosine binding domain of Shc associates with ZAP-70 and mediates TCR dependent gene activation	ONCOGENE			English	Article						Shr; ZAP-70; PTB domain; TCR; T-cell	CELL ANTIGEN RECEPTOR; SEVERE COMBINED IMMUNODEFICIENCY; PROTEIN-TYROSINE KINASE; GRB2 ADAPTER PROTEIN; JURKAT T-CELLS; SIGNAL-TRANSDUCTION; ZETA-CHAIN; LYMPHOCYTE-ACTIVATION; NUCLEOTIDE EXCHANGE; PHOSPHORYLATION	T-cell antigen receptor stimulation results in recruitment to the zeta chain and phosphorylation both of the syk family protein tyrosine kinase ZAP-70 and of the She adaptor protein, which transduces activating signals to Pas, Both ZAP-70 and Pas are required for T-cell activation. We have investigated the functional link between these two molecules in TCR signaling, She was found to associate with ZAP-70 in response to TCR triggering. This association was dependent on the presence of the aminoterminal phosphotyrosine binding (PTB) domain of She. The analysis of She binding to a potential PTB domain binding site on ZAP-70 confirmed the interaction of the She PTB domain with ZAP-70 and identified the ZAP-70 phosphotyrosine residue involved in this interaction, To test the role of the She PTB domain in transducing TCR derived signals we measured the effects of the isolated She PTB domain on the activation of the T-cell specific transcription factor NF-AT, The isolated She PTB domain was designed to compete non productively with endogenous She for binding to upstream tyrosine phosphorylated proteins and thus interfere with coupling to regulators of Pas activation, A significant inhibition of NP-AT activation by TCR triggering was observed, showing a functional involvement of She in TCR signaling through its PTB domain and suggesting an important role for She association with ZAP-70.	UNIV SIENA,DEPT EVOLUTIONARY BIOL,I-53100 SIENA,ITALY; IRIS,I-53100 SIENA,ITALY; MONTELUCE POLICLIN,MED CLIN 1,I-06100 PERUGIA,ITALY; IST EUROPEO ONCOL,MILAN,ITALY	University of Siena; Novartis; IRCCS European Institute of Oncology (IEO)			Lanfrancone, Luisa/AAC-8671-2019; Telford, John Laird/ABG-8144-2020; Pelicci, Pier Giuseppe/AAL-6572-2020	Lanfrancone, Luisa/0000-0002-4523-3815; chiari, rita/0000-0002-7649-273X	Telethon [E.0207] Funding Source: Medline	Telethon(Fondazione Telethon)		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BALDARI CT, 1995, EUR J IMMUNOL, V25, P1843, DOI 10.1002/eji.1830250708; BALDARI CT, 1992, FEBS LETT, V304, P261, DOI 10.1016/0014-5793(92)80633-R; BALDARI CT, 1995, ONCOGENE, V10, P1141; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BORST J, 1990, HUM IMMUNOL, V2, P175; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; DEMARTIN R, 1993, GENE, V124, P137, DOI 10.1016/0378-1119(93)90776-Y; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LAMINET A, 1996, IN PRESS J BIOL CHEM; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; OSMAN N, 1995, EUR J IMMUNOL, V25, P2863, DOI 10.1002/eji.1830251023; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	53	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					767	775						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761298				2022-12-17	WOS:A1996VD43300012
J	Gleeson, CM; Sloan, JM; McGuigan, JA; Ritchie, AJ; Weber, JL; Russell, SEH				Gleeson, CM; Sloan, JM; McGuigan, JA; Ritchie, AJ; Weber, JL; Russell, SEH			Widespread microsatellite instability occurs infrequently in adenocarcinoma of the gastric cardia	ONCOGENE			English	Article						adenocarcinoma; gastric cardia; microsatellite instability; replication errors; DNA mismatch repair	NONPOLYPOSIS COLORECTAL-CANCER; LYNCH SYNDROME-II; GENETIC INSTABILITY; CARCINOMA; MUTATIONS; HOMOLOG; HISTORY; FAMILY; TUMORS; COLON	Hereditary non-polyposis colorectal cancer (HNPCC) is associated with an increased predisposition to colorectal cancer and extra-colonic cancers of the gastro-intestinal, urological and female reproductive tracts, These tumours are characterised by an underlying defect in DNA mismatch repair and exhibit numerous replication errors throughout the genome (RER(+) phenotype), HNPCC-associated gastric tumours, and a subset of sporadic, distally-located gastric tumours exhibit this RER(+) phenotype, It is recognised that proximal gastric tumours exhibit distinct epidemiological features, In this study we investigated the occurrence of microsatellite instability in a series of 38 primary gastric adenocarcinomas, arising in the proximal stomach, A total of 138 microsatellite markers, comprising mainly dinucleotide and tetranucleotide repeat units and covering all autosomal arms, excluding acrocentric arms, were analysed, One tumour demonstrated somatic microsatellite alterations at 62% (26 of 42) of loci tested, A further 32 tumours demonstrated levels of microsatellite instability ranging from 0.8% (1 of 128)-11.4% (15 of 132) of loci tested, Five tumours demonstrated no microsatellite alterations at any of the loci tested, These findings suggest that a high percentage of proximal gastric carcinomas exhibit a low level of microsatellite alterations at dinucleotide and tetranucleotide repeat loci, However, ubiquitous somatic alterations at these loci, characteristic of HNPCC-associated tumours, occur in a relatively small proportion of tumours.	QUEENS UNIV BELFAST,BELFAST CITY HOSP,DEPT MED GENET,BELFAST BT9 7AB,ANTRIM,NORTH IRELAND; ROYAL VICTORIA HOSP,DEPT PATHOL,BELFAST BT12 6BJ,ANTRIM,NORTH IRELAND; ROYAL VICTORIA HOSP,REG THORAC UNIT,BELFAST BT12 6BJ,ANTRIM,NORTH IRELAND; MARSHFIELD MED RES FDN,MARSHFIELD,WI 54449	Belfast City Hospital; Queens University Belfast					PHS HHS [NG00835] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CRISTOFARO G, 1987, CANCER, V60, P51, DOI 10.1002/1097-0142(19870701)60:1<51::AID-CNCR2820600110>3.0.CO;2-V; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FONG KM, 1995, CANCER RES, V55, P28; GAO XA, 1994, ONCOGENE, V9, P2999; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KNUDSON AG, 1985, CANCER RES, V45, P1437; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAUREN P, 1965, ACTA PATHOL MIC SC, V5, P145; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; LYNCH HT, 1988, AM J GASTROENTEROL, V83, P741; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2098; MIRONOV NM, 1994, CANCER RES, V54, P41; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OGASAWARA S, 1995, CANCER RES, V55, P891; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; POWELL J, 1990, BRIT J CANCER, V62, P440, DOI 10.1038/bjc.1990.314; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SERUCA R, 1995, INT J CANCER, V64, P32, DOI 10.1002/ijc.2910640108; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SIDONI A, 1989, TUMORI, V75, P605, DOI 10.1177/030089168907500619; STRICKLER JG, 1994, CANCER RES, V54, P4750; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YEE CJ, 1994, CANCER RES, V54, P1641	45	41	41	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1653	1662						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622885				2022-12-17	WOS:A1996UG45800007
J	Charlesworth, A; Broad, S; Rozengurt, E				Charlesworth, A; Broad, S; Rozengurt, E			The bombesin/GRP receptor transfected into Rat-1 fibroblasts couples to phospholipase C activation, tyrosine phosphorylation of p125(FAK) and paxillin and cell proliferation	ONCOGENE			English	Article						neuropeptides; growth factors; Ca2+ mobilisation; protein kinase C	SWISS 3T3 CELLS; PROTEIN-KINASE-C; GASTRIN-RELEASING PEPTIDE; LUNG-CARCINOMA CELLS; MOLECULAR-CLONING; MAJOR SUBSTRATE; GROWTH-FACTOR; DNA-SYNTHESIS; STIMULATION; VASOPRESSIN	Bombesin elicits multiple signalling pathways in various cell types, It is not clear, however, whether these responses are mediated by a single receptor subtype or by different subtypes that couple preferentially to specific pathways. To resolve this we transfected the mouse bombesin/GRP receptor into Rat-1 fibroblasts and investigated the pathways activated by bombesin, Expression of the transfected receptors was verified by binding of [I-125]GRP and two clones were selected, BOR5 and BOR15. Bombesin stimulation of BOR5 and BOR15 cells caused intracellular Ca2+ mobilisation and increased the phosphorylation of 80K/MARCKS, a prominent protein kinase C substrate, The transfected receptor conferred a proliferative response to bombesin demonstrated by incorporation of [H-3]thymidine after 18 h and an increase in total cell numbers after 1-2 days. In BOR5 and BOR15 cells, bombesin rapidly stimulated the tyrosine phosphorylation of multiple proteins M(r) 110000-130000 and 70000-80000 including p125(FAK) and paxillin, at low concentrations (half maximum 0.3 nM). The specific bombesin/GRP receptor antagonist, D-F-5-Phe(6), D-Ala(11)-Bombesin(6-13)OMe, inhibited an the above responses. These results show that phospholipase C activation, cell growth and tyrosine phosphorylation emanate from a single class of bombesin receptor.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BOLD RJ, 1994, J CELL PHYSIOL, V161, P519, DOI 10.1002/jcp.1041610315; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CARNEY DN, 1987, CANCER RES, V47, P821; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; COY DH, 1992, PEPTIDES, V13, P775, DOI 10.1016/0196-9781(92)90186-7; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; FATHI Z, 1993, J BIOL CHEM, V268, P5979; GORBULEV V, 1992, EUR J BIOCHEM, V208, P405, DOI 10.1111/j.1432-1033.1992.tb17201.x; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1995, CANCER SURV, V24, P81; ROZENGURT E, 1995, OXFORD TXB ONCOLOGY, P12; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL M, 1993, J BIOL CHEM, V268, P9548; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SETHI T, 1992, CANCER RES, V52, pS2737; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1994, J CELL SCI, V107, P1583; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZACHARY I, 1987, EMBO J, V6, P2233, DOI 10.1002/j.1460-2075.1987.tb02495.x; ZACHARY I, 1987, J BIOL CHEM, V262, P3947	45	41	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1337	1345						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649836				2022-12-17	WOS:A1996UC06700019
J	Zariwala, M; Liu, E; Xiong, Y				Zariwala, M; Liu, E; Xiong, Y			Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15(INK4b) and p18(INK4c) in tumor-derived cell lines and primary tumors	ONCOGENE			English	Article						p18(Ink4c); INK CDK inhibitors; mutation		The growth suppressing activity of the retinoblastoma susceptibility gene product, pRb, is down regulated by cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) whose kinase activity is negatively regulated by CDK inhibitors of the pld family. We have examined the genomic status of two recently isolated p16-related CDK inhibitors, p15 and p18, in 15 normal and 73 tumor-derived cell lines established from 23 different tissues, as well as 26 invasive primary breast cancers and 20 acute myelogenous leukemias. p15 was found to be homozygously deleted in 22% of the tumor derived cell Lines, but no point mutations were found in either the cultured cells or the two types of primary tumors. With the exception of one breast cancer cell line, no deletions or mutations were found in the p18 gene in either cultured cell lines or primary tumors. These results indicate that mutation of the p18 gene occurs rarely in human tumors. Thus, while they share a very similar biochemical mechanism of inhibiting the kinase activity of CDK4 and CDK6, members of the p16 gene family play different roles in controlling cell proliferation and suppressing tumor growth.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill			Liu, Edison/C-4141-2008		NCI NIH HHS [CA 65572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIECHE I, 1994, CANCER RES, V54, P4274; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUAN KL, IN PRESS MOL BIOL CE; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V52, P205; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; HE J, 1994, CANCER RES, V54, P5804; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNAPEK DF, 1995, CANCER RES, V55, P1607; KODURU PRK, IN PRESS BLOOD; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OTSUKI T, 1995, CANCER RES, V55, P1436; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; WASHIMI O, 1995, CANCER RES, V55, P514; XU L, 1994, CANCER RES, V54, P5262; YOSHIDA S, 1995, CANCER RES, V55, P2756; ZHANG SY, 1994, CANCER RES, V54, P5050	32	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					451	455						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570224				2022-12-17	WOS:A1996TR53800026
J	WICK, ST; DUBAY, MM; IMANIL, I; BRIZUELA, L				WICK, ST; DUBAY, MM; IMANIL, I; BRIZUELA, L			BIOCHEMICAL AND MUTAGENIC ANALYSIS OF THE MELANOMA TUMOR-SUPPRESSOR GENE-PRODUCT P16	ONCOGENE			English	Article						P16; MTS1; CDK4; ANKYRIN REPEATS	D-TYPE CYCLINS; CELL-CYCLE; IDENTIFICATION; PROTEIN; G(1)	P16 was originally discovered by its ability to interact with CDK4 and to specifically inhibit the catalytic activity of the CDK4/D1 kinase. Increased attention has focused on the p16 gene because of its location on chromosome 9p21, a region involved in chromosomal rearrangements in a large number of tumor types. The p16 gene is also mutated in a large number of tumor cell lines and primary tumor cells. Furthermore, linkage analysis studies suggest that the p16 gene is involved in familial melanoma susceptibility. Due to the oncogenic potential of mutations in this tumor suppressor, it is important to identify and characterize those mutations which alter p16 activity. We have performed a systematic analysis of melanoma associated p16 mutants and of mutants generated in charge to Ala mutagenesis. Using microtiter plate assays to measure both p16-cdk4 binding and cdk4/D1 kinase activity, we show here that the melanoma associated mutants are defective, as are some of the Ala mutants. These results support the idea that p16 mutation, via its deregulation of the cdk4/D1 pathway, is of biological significance in the development of melanoma. Furthermore, we have defined a region within the p16 molecule in which changes are likely to result in a defective protein.			WICK, ST (corresponding author), MITOTIX INC,1 KENDALL SQ,BLD 600,CAMBRIDGE,MA 02139, USA.			Wick, Scott/0000-0002-6906-4980				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DIUNPHY WG, 1989, CELL, V54, P423; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GIANI C, 1994, CANCER RES, V54, P6338; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V24, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KARP JE, 1995, NAT MED, V1, P309, DOI 10.1038/nm0495-309; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LAMB A, 1994, SCIENCE, V264, P346; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OHTSUBO M, 1995, IN PRESS MOL CELL BI; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SEGEL IH, 1975, ENZYME KINETICS, P129; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	42	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2013	2019						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478520				2022-12-17	WOS:A1995TF29700011
J	PANAGOPOULOS, I; MANDAHL, N; MITELMAN, F; AMAN, P				PANAGOPOULOS, I; MANDAHL, N; MITELMAN, F; AMAN, P			2 DISTINCT FUS BREAKPOINT CLUSTERS IN MYXOID LIPOSARCOMA AND ACUTE MYELOID-LEUKEMIA WITH THE TRANSLOCATIONS T(12-16) AND T(16-21)	ONCOGENE			English	Article						MYXOID LIPOSARCOMA; ACUTE MYELOID LEUKEMIA; T(12-16); T(16-21); BREAKPOINT MAPPING; FUS GENE	GENE; CHOP; LOCALIZATION; ERG	The PUS gene, which maps to 16p11, is fused to the CHOP gene in the t(12;16) (q13;p11) that characterizes myxoid liposarcomas (MLS) and to the ERG gene in acute myeloid leukemia (AML) with t(16;21) (p11;q22). In the present study we have mapped the breakpoints within FUS in 13 MLS with t(12;16) and in one AML with t(16;21). This region of PUS is about 3.9 kb and contains four exons. The breakpoints clustered to two zones (1 and 2). A strong association was found between the two known types of PUS/CHOP transcripts and the genomic localization of the breakpoints. In all cases expressing only type I or both type I and II PUS/CHOP transcript the genomic breakpoints mapped to zone 1. In all cases expressing only the type II transcript the breakpoints occurred in zone 2. The breakpoint in the AML case was in zone 1, suggesting that in-frame fusion transcripts are selected by similar mechanisms in both MLS and AML.			PANAGOPOULOS, I (corresponding author), UNIV LUND HOSP,DEPT CLIN GENET,S-22185 LUND,SWEDEN.			Aman, Pierre/0000-0002-1482-8875; Panagopoulos, Ioannis/0000-0003-2159-5341				AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; ENEROTH M, 1990, CANCER GENET CYTOGEN, V48, P101, DOI 10.1016/0165-4608(90)90222-V; ICHIKAWA H, 1994, CANCER RES, V54, P2865; LADANYI M, 1994, CANCER RES, V54, P2837; MANDAHL N, 1994, INT J ONCOL, V4, P307; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; PONCE MR, 1992, NUCLEIC ACIDS RES, V29, P623; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; Sambrook J., 1989, MOL CLONING LAB MANU; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	18	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1133	1137						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566973				2022-12-17	WOS:A1995RX18000016
J	ZAKUT, R; GIVOL, D				ZAKUT, R; GIVOL, D			THE TUMOR SUPPRESSION FUNCTION OF P21(WAF) IS CONTAINED IN ITS N-TERMINAL HALF (HALF-WAF)	ONCOGENE			English	Note						WAF-1; P53; TUMOR SUPPRESSOR; N-TERMINAL HALF; GENE THERAPY	CYCLIN-DEPENDENT KINASES; P53; GENE	The Waf-1 encoded protein, p21, mediates p53 suppression of tumor cell growth. Overexpression of p21 in the H1299 tumor cell line suppresses colony formation similar to that resulted;from p53 overexpression. In an effort to localize the tumor suppression function within the structure of p21 we utilized vectors constructed with systematic truncations of p21 and tested their efficiency in suppressing tumor cell growth. We demonstrate that the N-terminal half of the p21 molecule (residues 1-80 and 1-89) shows better tumor cell growth suppression than the entire p21 molecule whereas the C-terminal half of p21 does not show this effect, These results may have implications for gene therapy of cancer.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								BODNER SM, 1992, ONCOGENE, V7, P743; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY SW, 1994, CANCER RES, V154, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HALEVY O, 1995, SCIENCE, V267, P1024; HARPER JW, 1993, CELL, V75, P805; JIANG HP, 1994, ONCOGENE, V9, P3397; MICHIELI P, 1994, CANCER RES, V54, P3391; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PARKER SB, 1995, SCIENCE, V267, P1018; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; SCOTT WL, 1994, SCIENCE, V266, P807; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TOYOSHIMA H, 1994, CELL, V79, P67; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V36, P701	21	41	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					393	395						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624153				2022-12-17	WOS:A1995RK95700020
J	WOLF, DA; HERMEKING, H; ALBERT, T; HERZINGER, T; KIND, P; EICK, D				WOLF, DA; HERMEKING, H; ALBERT, T; HERZINGER, T; KIND, P; EICK, D			A COMPLEX BETWEEN E2F AND THE PRB-RELATED PROTEIN P130 IS SPECIFICALLY TARGETED BY THE SIMIAN-VIRUS-40 LARGE T-ANTIGEN DURING CELL-TRANSFORMATION	ONCOGENE			English	Article						TRANSFORMATION; E2F; P130; SV40 LARGE T ANTIGEN; CELL CYCLE	RETINOBLASTOMA SUSCEPTIBILITY GENE; TRANSCRIPTION FACTOR E2F; CYCLIN-A; VIRAL ONCOPROTEINS; BINDING PROTEIN; PRODUCT; RB; INHIBITION; EXPRESSION; KINASE	The p130 protein is a recently cloned member of the retinoblastoma protein family. We show here that transformation of NIH3T3-L1 fibroblasts (L1 cells) by the simian virus 40 large T antigen (LTAg) depends on the disruption of DNA binding complexes between transcription factor E2F and p130. LTAg binds to the pocket region of p130 in vivo and disrupts the E2F-p130 complexes. E2F-p130 complexes are present only in quiescent L1 cells and disappear at the G1/S phase boundary concomitantly to induction of DNA synthesis and expression of the E2F-regulated cdc2 gene. p130 is a substrate of cyclin-dependent kinase 2 (Cdk2) in vitro and associates with a Cdk in vivo which is activated upon serum stimulation in late G1. Overexpression of p130 inhibits cdc2 promoter activity and entry of quiescent L1 cells into S phase. The results demonstrate that p130 is a negative regulator of cell cycle progression which is specifically targeted by LTAg during cell transformation.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY; UNIV MUNICH,DERMATOL KLIN & POLIKLIN,MOLEK PATHOL ABT,D-80337 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich			Wolf, Dieter/AAE-5890-2021	Wolf, Dieter/0000-0002-3761-1070; Albert, Thomas Karl/0000-0002-2488-0706				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEW J, 1992, J BIOL CHEM, V267, P25922; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MAYOL X, 1993, ONCOGENE, V8, P2561; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NEVINS JR, 1992, SCIENCE, V258, P424; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNEIDER JW, 1994, SCIENCE, V246, P1467; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOLF DA, 1991, BRIT J CANCER, V64, P47, DOI 10.1038/bjc.1991.237; WOLF DA, 1993, MOL ENDOCRINOL, V7, P924, DOI 10.1210/me.7.7.924; YEUNG RS, 1993, ONCOGENE, V8, P3465; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	59	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2067	2078						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784051				2022-12-17	WOS:A1995RB70300001
J	PAPIN, C; EYCHENE, A; BRUNET, A; PAGES, G; POUYSSEGUR, J; CALOTHY, G; BARNIER, JV				PAPIN, C; EYCHENE, A; BRUNET, A; PAGES, G; POUYSSEGUR, J; CALOTHY, G; BARNIER, JV			B-RAF PROTEIN ISOFORMS INTERACT WITH AND PHOSPHORYLATE MEK-1 ON SERINE RESIDUE-218 AND RESIDUE-222	ONCOGENE			English	Note						B-RAF; C-RMIL; MEK-1; MAP KINASE CASCADE; SERINE THREONINE KINASES	KINASE; PROTOONCOGENE; COMPLEX; CELLS	The B-raf/c-Rmil proto-oncogene belongs to the raf/mil family of serine/threonine protein kinases, Tt encodes multiple protein isoforms resulting from alternative splicing of two exons located upstream of the kinase domain, Recent studies suggested that B-Raf could be the intermediate molecule between Ras and Mek-1 (MAP Kinase Kinase) in signalling pathways specific of neural cells. However, there has been no evidence for a direct interaction between B-Raf and Mek-1, We report here that different B-Raf isoforms can be co-immunoprecipitated with anti-Mek-1 antisera in COS-1 cells and that the kinase activity of B-Raf is not required for its interaction with Mek-1. We also show that all B-Raf isoforms tested phosphorylate Mek-1 in a time-dependent manner, whereas kinase defective mutants fail to do so. Finally, we demonstrate that the constitutively activated S218D, S222D and S218D/S222D mutants of Mek-1 interact similarly with B-Raf. However, only the S218D and S222D mutants, and not the S218D/S222D double mutant, can be phosphorylated by B-Raf isoforms. Therefore, serine residues 218 and 222, previously shown to regulate Mek-1 activity, appear to be the major phosphorylation sites by B-Raf in vitro.	CTR UNIV ORSAY,INST CURIE,LAB 110,CNRS,UNITE MIXTE RECH 146,F-91405 ORSAY,FRANCE; UNIV NICE,CTR BIOCHIM,CNRS,F-06108 NICE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Eychene, Alain/M-8838-2017; Pages, Gilles/N-7135-2017	EYCHENE, Alain/0000-0002-6818-7225				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BRUNET A, 1994, ONCOGENE, V9, P3379; CALOGERAKI I, 1993, BIOCHEM BIOPH RES CO, V193, P1324, DOI 10.1006/bbrc.1993.1770; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; EYCHENE A, 1995, ONCOGENE, V10, P1159; EYCHENE A, 1992, ONCOGENE, V7, P1315; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	21	41	41	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1647	1651						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731720				2022-12-17	WOS:A1995QU68100022
J	WYLLIE, FS; HAUGHTON, MF; BLAYDES, JP; SCHLUMBERGER, M; WYNFORDTHOMAS, D				WYLLIE, FS; HAUGHTON, MF; BLAYDES, JP; SCHLUMBERGER, M; WYNFORDTHOMAS, D			EVASION OF P53-MEDIATED GROWTH-CONTROL OCCURS BY 3 ALTERNATIVE MECHANISMS IN TRANSFORMED THYROID EPITHELIAL-CELLS	ONCOGENE			English	Article						P53; CELL CYCLE; CHECK-POINT; TUMOR PROGRESSION; THYRO	WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; LARGE-T-ANTIGEN; MONOCLONAL-ANTIBODIES; ATAXIA-TELANGIECTASIA; SIMIAN VIRUS-40; MDM-2 ONCOGENE; DNA DAMAGE; MUTANT P53; CARCINOMA	Using the thyroid as a model of multistep epithelial tumorigenesis, we have used representative cell lines to correlate the degree of malignant transformation with the functional status of p53 and the integrity of cell-cycle check-points. Three distinct phenotypes were observed: Type I lines, derived from poorly-differentiate human thyroid cancers, expressed high levels of mutant p53 protein; Type II, also poorly-differentiate but derived from rat, showed over-expression of wild-type (wt) p53 with marked cell-cell heterogeneity: Type III, from well-differentiated human cancers, contained uniformly low levels of wt p53, All cell lines containing wt p53 retained a near-normal induction of p53 by DNA damage. However, the ability to undergo growth arrest differed strikingly, Whereas Type I and II lines had lost both G2/M and G1/S check points, Type III cells retained both. In Type III cells, as in diploid human fibroblasts, mutant p53 expression specifically abrogated G1/S check-point function with no other change in phenotype, These data demonstrate 3 mechanisms for evasion of p53 growth control: (i) direct mutation (ii) indirect inactivation, or (iii) 'avoidance' of activation, most probably due to failure to reach a critical threshold of DNA damage.	UNIV WALES COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOUR BIOL RES GRP,CARDIFF CF4 4XN,S GLAM,WALES; INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE	Cardiff University; UNICANCER; Gustave Roussy			Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARNES DM, 1993, J PATHOL S, V169, P231; BLAYDES JP, IN PRESS ONCOGENE; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BOND JA, 1994, ONCOGENE, V9, P1885; BRASH DE, 1987, MOL CELL BIOL, V7, P2031, DOI 10.1128/MCB.7.5.2031; BURNS JS, 1992, MOL CARCINOGEN, V6, P129, DOI 10.1002/mc.2940060208; CHALLETON C, 1992, J ENDOCRINOL INVE S2, V15, P32; COOK PR, 1976, NATURE, V263, P679, DOI 10.1038/263679a0; CRAMER P, 1981, NATURE, V291, P671, DOI 10.1038/291671a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GORETZKI PE, 1989, ANN ENDOCRINOL, V50, P145; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTWELL LH, 1992, CELL, V71, P541; HSU TC, 1989, INT J CANCER, V43, P403, DOI 10.1002/ijc.2910430310; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOPEZLARRAZA D, 1990, MUTAT RES, V232, P57, DOI 10.1016/0027-5107(90)90110-P; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; SAKAMOTO A, 1983, CANCER, V52, P1849, DOI 10.1002/1097-0142(19831115)52:10<1849::AID-CNCR2820521015>3.0.CO;2-X; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WILLIAMS DW, 1989, THYROID TUMOURS MOL, P57; WILLIAMS NW, 1989, EXP CELL RES, V184, P316, DOI 10.1016/0014-4827(89)90331-5; WRIGHT PA, 1991, ONCOGENE, V6, P1693; WRIGHT PA, 1993, J PATH S, V169, P230; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1991, MOL CELL ENDOCRINOL, V76, P13, DOI 10.1016/0303-7207(91)90255-Q; WYLLIE FS, 1992, P ONCOGENES GROWTH C; WYNFORDTHOMAS D, 1990, MOL CELL BIOL, V10, P5365, DOI 10.1128/MCB.10.10.5365; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	54	41	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					49	59						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7529918				2022-12-17	WOS:A1995QA98000007
J	MCCRACKEN, S; LEUNG, S; BOSSELUT, R; GHYSDAEL, J; MIYAMOTO, NG				MCCRACKEN, S; LEUNG, S; BOSSELUT, R; GHYSDAEL, J; MIYAMOTO, NG			MYB AND ETS RELATED TRANSCRIPTION FACTORS ARE REQUIRED FOR ACTIVITY OF THE HUMAN LCK TYPE-I PROMOTER	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; T-CELL DEVELOPMENT; LONG TERMINAL REPEAT; DIFFERENTIAL EXPRESSION; THYMOCYTE DEVELOPMENT; GENE; PROTEIN; ACTIVATION; PRODUCT; P56LCK	The lck gene, which encodes a lymphoid-specific Src family tyrosine kinase, is transcribed from two promoters that are differentially utilized during T cell development. We have shown previously that the human lck type I promoter, which is preferentially expressed in immature thymocytes, requires a binding site (-97 to -90) for the Ets family of transcription factors for its activity in Jurkat T leukemia cells. Three putative Myb binding sites (-86 to -82, -77 to -72 and -59 to -54) were analysed for their ability to activate the lck type I promoter. In vitro assays demonstrated specific binding of purified, bacterially expressed c-Myb DNA binding domain to the Myb (-59 to -54) site. Transient transfection assays using the site-directed mutants of the lck type I promoter in Jurkat cells revealed that mutation of the Myb (-59 to -54) site abolished transcriptional activity. In transiently transfected HeLa cells, the lck type I promoter was activated by cotransfection with a vector that expresses c-Myb. This c-Myb dependent activation required the presence of intact Myb and Ets binding sites, indicating that the expressed c-Myb functions with endogenous Ets related transcription factors to activate the lck type I promoter. This effect was further enhanced by co-transfection with vectors that express either Ets1 or Ets2. These results demonstrate that Myb and Ets related transcription factors synergistically activate the human lck type I promoter.	INST CURIE,BIOL SECT,CNRS,U1443,F-91405 ORSAY,FRANCE; PRINCESS MARGARET HOSP,ONTARIO CANC INST,DIV CELLULAR & MOLEC BIOL,TORONTO M4X 1K9,ON,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ON,CANADA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto			GHYSDAEL, Jacques/F-3377-2013					ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; ALLEN JM, 1992, MOL CELL BIOL, V12, P2758, DOI 10.1128/MCB.12.6.2758; ASCIONE R, 1992, INT J ONCOL, V1, P631; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOSSELUT R, 1992, VIROLOGY, V186, P764, DOI 10.1016/0042-6822(92)90044-P; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; CASSEL DL, 1983, CANCER RES, V43, P4582; CLEVERS HC, 1993, IMMUNOL TODAY, V14, P591, DOI 10.1016/0167-5699(93)90198-T; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; LEUNG S, 1993, ONCOGENE, V8, P989; LEUNG S, 1991, J CELL PHYSIOL, V148, P344, DOI 10.1002/jcp.1041480304; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.iy.11.040193.001333; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699	37	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3609	3615						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970721				2022-12-17	WOS:A1994PT39200024
J	YAGI, T; SHIGETANI, Y; FURUTA, Y; NADA, S; OKADO, N; IKAWA, Y; AIZAWA, S				YAGI, T; SHIGETANI, Y; FURUTA, Y; NADA, S; OKADO, N; IKAWA, Y; AIZAWA, S			FYN EXPRESSION DURING EARLY NEUROGENESIS IN MOUSE EMBRYOS	ONCOGENE			English	Article							SEGMENT-SPECIFIC EXPRESSION; ADHERENS-TYPE JUNCTIONS; PERIPHERAL T-CELLS; NEURAL-TUBE; MICE LACKING; MUTANT MICE; GENE; HINDBRAIN; PHOSPHORYLATION; KINASES	Fyn is a member of the Src family of tyrosine kinases which are thought to play important roles in cell to cell interactions during morphogenesis. The developmental profile of Fyn expression was examined using mutant mice in which lacZ gene was introduced into this locus. The expression was characteristic in the neural system, Though at low levels, it was detected in the headfold at embryonic day (E) 7.5 and in the luminal surface of neuroectoderm along the entire neural groove at E8.5. The expression appeared regional in rhombomeres at E8.5 and E9.5. Consistent expression was also found at a low level in the notochord. The expression was high in later stages of the neural tube which consists of three layers; it was in the marginal layer but not in the germinal layer. High expression was also found in developing dorsal root filaments of neural crest origin; Non-expression in dividing neuroepithelial cells and expression in developing neural fibers appeared ubiquitous features of Fyn expression throughout the entire brain.	INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOLEC ONCOL LAB, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, INST BASIC MED SCI, DEPT ANAT, TSUKUBA, IBARAKI 305, JAPAN; OSAKA UNIV, INST PROT RES, DIV PROT METAB, SUITA, OSAKA 565, JAPAN	RIKEN; University of Tsukuba; Osaka University								ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BALLYCUIF L, 1993, DEVELOPMENT, V117, P543; BARE DJ, 1993, ONCOGENE, V8, P1429; BRUGGE JS, 1987, MOL CELL BIOL, V7, P2180, DOI 10.1128/MCB.7.6.2180; COOPER JA, 1984, J BIOL CHEM, V259, P7835; EASTER SS, 1993, J NEUROSCI, V13, P285; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FIGDOR MC, 1993, NATURE, V363, P630, DOI 10.1038/363630a0; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HIRSCH MR, 1991, FEBS LETT, V287, P197, DOI 10.1016/0014-5793(91)80050-D; HORAK ID, 1990, ONCOGENE, V5, P597; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; KARFUNKEL P, 1972, J EXP ZOOL, V181, P289, DOI 10.1002/jez.1401810302; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LOWELL C, 1993, MOUSE MOL GENETICS, P70; MAHER PA, 1991, J CELL BIOL, V112, P955, DOI 10.1083/jcb.112.5.955; MANESS PF, 1986, DEV BIOL, V117, P83, DOI 10.1016/0012-1606(86)90350-7; MOASE CE, 1991, DEVELOPMENT, V113, P1049; MOLINA TJ, 1993, J IMMUNOL, V151, P699; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NOMURA S, 1989, DEVELOPMENT, V105, P575; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; VOLBERG T, 1991, CELL REGUL, V2, P105, DOI 10.1091/mbc.2.2.105; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; Windle WF, 1936, J COMP NEUROL, V63, P431, DOI 10.1002/cne.900630304; Windle WF, 1936, J COMP NEUROL, V63, P173, DOI 10.1002/cne.900630202; YAGI T, 1993, ONCOGENE, V8, P3343; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; YAMANASHI Y, 1986, P NATL ACAD SCI USA, V83, P5459	45	41	41	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2433	2440						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058305				2022-12-17	WOS:A1994PC05400001
J	SANG, BC; CHEN, JY; MINNA, J; BARBOSA, MS				SANG, BC; CHEN, JY; MINNA, J; BARBOSA, MS			DISTINCT REGIONS OF P53 HAVE A DIFFERENTIAL ROLE IN TRANSCRIPTIONAL ACTIVATION AND REPRESSION FUNCTIONS	ONCOGENE			English	Article							WILD-TYPE P53; CELL LUNG-CANCER; DNA-BINDING; T-ANTIGEN; GENE-EXPRESSION; PROTEINS BIND; MUTANT P53; SEQUENCE; MUTATIONS; INVITRO	The wild type p53 tumor suppressor protein transactivates genes carrying p53 responsive elements and represses several TATA containing promoters. We report in vivo gene regulation assays where deletion of the N-terminal 75 residues (Delta N75) results in loss of transactivation of p53CON and repression of an HPV 6 reporter. In contrast, removal of the C-terminal 75 (Delta C75) amino acids resulted in a truncated protein capable of trans-activating p53CON but not able to repress the HPV 6 reporter. In vitro protein association assays revealed that the Delta N75 protein, but not the Delta C75 truncated protein, could oligomerize with the wild type p53 protein. Co-transfection assays with wild type p53 showed that the Delta N75 mutant protein has a dominant negative effect on trans-activation function. However, it does not affect the ability of wild type p53 to repress transcription from the HPV 6 reporter. The Delta C75 protein had no effect on the ability of the wild type p53 to activate p53CON or repress the HPV 6 reporter. These results suggest that distinct regions of p53 have a differential role in transcriptional activation and repression functions.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,SIMMONS CANC CTR,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Chen, Joanne Jeou-Yuan/S-7022-2018		NCI NIH HHS [CA55703, CA58220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055703, P20CA058220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWER M, 1986, CANCER RES, V46, P798; CHEN JY, 1993, ONCOGENE, V8, P2159; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MITSUDOMI T, 1992, ONCOGENE, V7, P171; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SOUSSI T, 1990, ONCOGENE, V5, P945; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1992, ONCOGENE, V7, P1153; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	49	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					853	859						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108128				2022-12-17	WOS:A1994MW55100021
J	HAINAUT, P; HALL, A; MILNER, J				HAINAUT, P; HALL, A; MILNER, J			ANALYSIS OF P53 QUATERNARY STRUCTURE IN RELATION TO SEQUENCE-SPECIFIC DNA-BINDING	ONCOGENE			English	Article							TUMOR SUPPRESSOR PROTEIN; WILD-TYPE; MUTANT P53; CELL-CYCLE; GENE-EXPRESSION; CONFORMATION; FORMS; TRANSFORMATION; TRANSCRIPTION; PROLIFERATION	Quaternary interactions of p53 influence its tertiary structure which, in turn, is critical for sequence-specific DNA binding and tumour suppressor function. Given its regulatory potential we have sought to define the quaternary structure of p53 involved in sequence-specific DNA binding. Double stranded DNA [5'-GGACATGCCCG GGCATGTCC-3'; Funk et al. (1992) Mol. Cell. Biol., 12, 2866-2871] was used to test p53 binding capacity in vitro. The p53 protein was translated in vitro and size fractionated prior to the DNA binding reaction. Two independent DNA binding assays were employed. The first detected electromobility shift of P-32-labelled DNA and was carried out in the presence of PAb421, which stabilises and supershifts p53-DNA complexes. The second detected S-35-labelled p53 bound to biotinylated target DNA in the absence of PAb421. Sequence-specific DNA binding was found to be a property of full length, oligomeric p53. Greatest binding activity involved tetramers and/or higher molecular weight forms of p53, minimal binding was observed for dimers. This size profile was unaffected by PAb421 and it therefore seems unlikely that PAb421 dissociates high molecular weight forms of p53 into dimers. We conclude that high molecular weight forms of p53 are the most effective structures for sequence-specific DNA binding in vitro; these structures may represent tetramers and/or heterogeneous complexes of p53 with other proteins.	UNIV YORK,DEPT BIOL,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK			Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P1266; GANNON JV, 1990, EMBO J, V9, P1591; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HALAZONETIS TD, 1993, EMBO J, V12, P1221; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEDCALF EA, 1992, ONCOGENE, V7, P71; MEDCALF EA, 1993, IN PRESS ONCOGENE; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RIVAS CI, 1992, BLOOD, V79, P1982; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TRUANT R, 1993, J BIOL CHEM, V268, P2284; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHANG W, 1992, ONCOGENE, V7, P1039	48	41	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					299	303						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302593				2022-12-17	WOS:A1994MW24700036
J	PEREZ, JL; SHEN, XY; FINKERNAGEL, S; SCIORRA, L; JENKINS, NA; GILBERT, DJ; COPELAND, NG; WONG, TW				PEREZ, JL; SHEN, XY; FINKERNAGEL, S; SCIORRA, L; JENKINS, NA; GILBERT, DJ; COPELAND, NG; WONG, TW			IDENTIFICATION AND CHROMOSOMAL MAPPING OF A RECEPTOR TYROSINE KINASE WITH A PUTATIVE PHOSPHOLIPID-BINDING SEQUENCE IN ITS ECTODOMAIN	ONCOGENE			English	Article							FACTOR-VIII; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; GENETIC-LINKAGE; DNA-SEQUENCES; FACTOR-V; C-KIT; FAMILY; MOUSE; ACID	We have cloned a novel receptor tyrosine kinase that has an unusual ectodomain. The extracellular sequence consists of 416 amino acids and has none of the structural motifs that have been found in other receptor tyrosine kinases. The 150 amino acids in the amino terminus of the receptor is homologous to a putative phospholipid-binding sequence that is found also in other cell adhesion molecules such as the neuronal A5 antigen and coagulation factors V and VIII. The kinase domain has a short cytoplasmic tail and contains a short insert between subdomains I and II. The structure of this receptor kinase suggests that it belongs to a new family of receptors involved in cell-cell interactions. The cell adhesion kinase (Cak) is expressed at low levels in most adult tissues and expression is highest in the brain and lung. Using fluorescence in situ hybridization and interspecific backcross mapping, the Cak gene was localized to human chromosome 6 and mouse chromosome 17.	ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,PISCATAWAY,NJ 08854; ROBERT WOOD JOHNSON MED SCH,DEPT PEDIAT,PISCATAWAY,NJ 08854; NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; GOODWIN RH, UNPUB; Green EL, 1981, GENETICS PROBABILITY, P77; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JABS EW, 1987, AM J HUM GENET, V41, P374; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JENNINGS CGB, 1993, P NATL ACAD SCI USA, V90, P2895, DOI 10.1073/pnas.90.7.2895; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANE WH, 1988, BLOOD, V71, P539; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MUNOZDORADO J, 1991, CELL, V67, P995, DOI 10.1016/0092-8674(91)90372-6; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PAWSON T, 1990, TRENDS GENET, V6, P110; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; RESCIGNO J, 1991, ONCOGENE, V6, P1909; ROSNET O, 1991, ONCOGENE, V6, P1641; RYDER LP, 1981, ANNU REV GENET, V15, P169, DOI 10.1146/annurev.ge.15.120181.001125; SHIER P, 1989, J BIOL CHEM, V264, P14605; SIRACUSA LD, 1991, GENETICS, V127, P169; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; ZHU H, 1993, APP CYTOGENET, V19, P33; ZIEGLER SF, 1993, ONCOGENE, V8, P663	43	41	45	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					211	219						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302582				2022-12-17	WOS:A1994MW24700026
J	TAKAHASHI, K; SUZUKI, K				TAKAHASHI, K; SUZUKI, K			DNA SYNTHESIS-ASSOCIATED NUCLEAR EXCLUSION OF P53 IN NORMAL HUMAN BREAST EPITHELIAL-CELLS IN CULTURE	ONCOGENE			English	Article							TRANSFORMATION-RELATED PROTEIN; MONOCLONAL-ANTIBODIES; 3T3 CELLS; WILD-TYPE; GROWTH; PHOSPHORYLATION; LYMPHOCYTES; ANTIGEN; CYCLE; MOUSE	Immunohistochemical staining using three monoclonal antibodies to p53 revealed that most normal human breast epithelial cells (HBEC) in the exponential growth phase, have p53 located in the nucleus but that some cells have the protein in the cytoplasm. Cytoplasmic staining of p53 with the monoclonal antibody PAb240 was inhibited by the specific oligopeptide, NTFRHSVVVP, that corresponds to the amino acids between 210 and 219 in p53 and which includes the epitope domain for PAb240. It was not inhibited by the control oligopeptide SPFVTVHNVR. Growth arrest of HBEC achieved by EGF depletion resulted in predominant nuclear location of p53 and stimulation of arrested cells with EGF induced transient nuclear exclusion of the protein when the induced DNA synthesis level was maximal. These observations suggest that p53 in normal HBEC becomes inactivated by nuclear exclusion during cellular DNA synthesis.			TAKAHASHI, K (corresponding author), KANAGAWA CANC CTR,RES INST,DEPT BIOCHEM,ASAHI KU,54-2 NAKAO CHO,YOKOHAMA,KANAGAWA 241,JAPAN.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KERN SE, 1991, ONCOGENE, V6, P131; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOSNER J, 1992, ONCOGENE, V7, P661; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; STEINMEYER K, 1988, ONCOGENE, V3, P501; SUZUKI K, 1992, BIOCHEM BIOPH RES CO, V183, P1175, DOI 10.1016/S0006-291X(05)80314-6; TAKAHASHI K, 1989, INT J CANCER, V43, P870, DOI 10.1002/ijc.2910430522; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ZHANG W, 1992, ONCOGENE, V7, P1645	31	41	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					183	188						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302577				2022-12-17	WOS:A1994MW24700022
J	CRESSMAN, DE; TAUB, R				CRESSMAN, DE; TAUB, R			I-KAPPA-B-ALPHA CAN LOCALIZE IN THE NUCLEUS BUT SHOWS NO DIRECT TRANSACTIVATION POTENTIAL	ONCOGENE			English	Note							DNA-BINDING ACTIVITY; REL-ASSOCIATED PP40; TRANSCRIPTION FACTOR; REGENERATING LIVER; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; 65-KD SUBUNIT; ACTIVATION; INHIBITOR; PRECURSOR	Although IkappaB is a cytoplasmic inhibitor of NF-kappaB and c-Rel that prevents nuclear translocation of NF-kappaB, some forms of IkappaB have been found in the nucleus. Given that some other proteins with ankyrin-type repeats are transcription factors, we wondered if a nuclear form Of IkappaBalpha could itself be a transcriptional activator. We found that Gal4-IkappaBalpha fusion proteins strongly transactivate a Gal4 site-containing promoter in 3T3 fibroblasts. The IkappaBalpha domain responsible for this transactivation is not the acidic domain of IkappaBalpha, but the ankyrin repeat domain which is responsible for protein-protein interactions. To enhance our ability to detect cellular IkappaBalpha by immunofluorescence, we overexpressed the protein in transfected cells, and found that overexpressed IkappaBalpha is largely cytoplasmic in serum-deprived cells, but nuclear in serum-stimulated cells. However, in cell fractionation studies under all treatment conditions, IkappaBalpha appears mainly in cytoplasmic fractions, suggesting that it can rapidly move out of the nucleus through nuclear pores during extract preparation. Using double antibody immunoprecipitations, we found that IkappaBalpha in proliferating cells is strongly associated with RelA(p65). When IkappaBalpha is fused to the Gal4 DNA-binding domain, nuclear Gal4-IkappaBalpha is associated with RelA(p65). Thus, the activation domain of the associated RetA(p65) molecule could account for the ability of Gal4-IkappaBalpha to transactivate the Gal4 promoter. Unlike Bcl-3, an IkappaB which has been recently shown to directly transactivate through kappaB sites when associated with NFKB2 (p52), IkappaBalpha shows no ability to directly transactivate target promoters via its association with RelA(p65).	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania								Alberts B., 2017, MOL BIOL CELL; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; FAUSTO N, 1989, LAB INVEST, V60, P4; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1015; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEMARCO K, 1991, SCIENCE, V253, P789; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; MORIN PJ, 1993, IN PRESS NUCLEIC ACI; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P649; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEWARI M, 1992, NUCLEIC ACIDS RES, V20, P607, DOI 10.1093/nar/20.3.607; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	41	41	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2567	2573						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361766				2022-12-17	WOS:A1993LT36800030
J	SARKAR, S; GILMORE, TD				SARKAR, S; GILMORE, TD			TRANSFORMATION BY THE VREL ONCOPROTEIN REQUIRES SEQUENCES CARBOXY-TERMINAL TO THE REL HOMOLOGY DOMAIN	ONCOGENE			English	Article							NF-KAPPA-B; CHICKEN-EMBRYO FIBROBLASTS; VIRUS-STRAIN-T; V-REL; C-REL; RETICULOENDOTHELIOSIS VIRUS; SPLEEN-CELLS; TRANSCRIPTIONAL ACTIVATOR; ONCOGENIC TRANSFORMATION; CELLULAR PROTEINS	The vRel oncoprotein of the avian Rev-T retrovirus is a member of the Rel/NF-kappaB family of transcription factors. The highly conserved amino-terminal Rel Homology (RH) domain in these proteins is required for DNA binding, protein-protein interactions and nuclear localization, and many mutations within this domain abolish transformation by vRel. We demonstrate here that overexpression of the vRel RH domain alone is insufficient to induce transformation of chicken spleen cells, indicating that sequences from the nonconserved carboxy terminus are necessary for the vRel transforming function. Thererfore, we constructed and assayed several vRel mutants with deletions of carboxy-terminal sequences. These mutant vRel proteins did not transform spleen cells with equal efficiency, even though they were functionally similar by several other criteria. Our results demonstrate that there are two regions (aa 389 to 432 and aa 437 to 503) within the carboxy-terminal half of vRel that are important for transformation: mutant vRel proteins containing the RH domain and one or both of these carboxy-terminal regions can transform at roughly wild-type levels. Analysis of Gal4 fusion proteins containing carboxy-terminal sequences from the vRel mutants indicated that there is a correlation between the ability of these mutant proteins to transform avian spleen cells and their ability to activate transcription. These observations suggest that vRel induces malignant transformation by directly altering gene expression.	BOSTON UNIV,DEPT BIOL,5 CUMMINGTON ST,BOSTON,MA 02215	Boston University					NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GARSON K, 1990, ONCOGENE, V5, P1431; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; MORRISON LE, 1989, ONCOGENE, V4, P677; MORRISON LE, 1992, ONCOGENE, V7, P1137; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	44	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2245	2252						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336947				2022-12-17	WOS:A1993LP17100026
J	ALILECHE, A; PLAISANCE, S; HAN, DS; RUBINSTEIN, E; MINGARI, C; BELLOMO, R; JASMIN, C; AZZARONE, B				ALILECHE, A; PLAISANCE, S; HAN, DS; RUBINSTEIN, E; MINGARI, C; BELLOMO, R; JASMIN, C; AZZARONE, B			HUMAN-MELANOMA CELL-LINE M14 SECRETES A FUNCTIONAL INTERLEUKIN-2	ONCOGENE			English	Article							T-CELL; LYMPHOCYTES-T; MONOCLONAL-ANTIBODIES; ACTIVE INTERLEUKIN-2; HUMAN-PLACENTA; EXPRESSION; RECEPTOR; GENE; PROLIFERATION; PROMOTER	Interleukin 2 (IL2) is an important regulator of the immune system. In this report, we have analysed five human melanoma cell lines expressing the IL2R for their ability to secrete IL2. In the M14 melanoma cell line, we observed the appearance of the 0.9 kb transcript specific for the IL2 gene, 72 h after subculture, and the secretion of a biologically active IL2 which specifically sustains the proliferation of the IL2 dependent murine lymphoid cell tine CTLL2. In M14 cells, IL2 gene activation is transient as in lymphoid cells but is not inhibited by the immunosuppressive drugs cyclosporine-A and FK506 which are effective on PHA-blasts. In M14 cells, recombinant IL2 (36 pM) induces the down modulation of ICAM-1 expression at the surface of M14 cells. Overnight incubation of these cells with polyclonal anti-IL2 antibodies leads to an increased expression of ICAM-1 and a decreased membrane detection of the IL2Ralpha, suggesting the existence of an autocrine/paracrine loop involved in the surface expression of these antigens. A decreased expression of the ICAM-1 protein could help some melanoma cells to escape from cytolytic recognition and therefore favour their metastasis.	HOP PAUL BROUSSE,INSERM,UNITE 268,14 AV PAUL VAILLANT COUTURIER,F-94800 VILLEJUIF,FRANCE; IST,GENOA,ITALY	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Rubinstein, Eric/B-4650-2019; Azzarone, Bruno/AAH-9251-2019; Plaisance, Stephane/B-3488-2009; Plaisance, Stephane/ABI-6307-2020	Rubinstein, Eric/0000-0001-7623-9665; Azzarone, Bruno/0000-0002-5962-3849; Plaisance, Stephane/0000-0002-1651-241X; Plaisance, Stephane/0000-0002-1651-241X				ARYA SK, 1984, BIOCHEMISTRY-US, V23, P6686; BENVENISTE EN, 1988, J NEUROIMMUNOL, V17, P301, DOI 10.1016/0165-5728(88)90121-X; BOEHM KD, 1989, P NATL ACAD SCI USA, V86, P656, DOI 10.1073/pnas.86.2.656; CARLONI G, 1989, ONCOGENE, V4, P873; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CILLO C, 1984, INT J CANCER, V34, P11, DOI 10.1002/ijc.2910340104; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DOMZIG W, 1983, J IMMUNOL, V130, P1970; DRENO B, 1986, J INVEST DERMATOL, V86, P359, DOI 10.1111/1523-1747.ep12285581; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; EFRAT S, 1984, P NATL ACAD SCI-BIOL, V81, P2601, DOI 10.1073/pnas.81.9.2601; EFRAT S, 1982, NATURE, V297, P236, DOI 10.1038/297236a0; EITAN S, 1992, P NATL ACAD SCI USA, V89, P5442, DOI 10.1073/pnas.89.12.5442; FARRAR JJ, 1982, IMMUNOL REV, V63, P129, DOI 10.1111/j.1600-065X.1982.tb00414.x; FARRAR WL, 1981, J IMMUNOL, V126, P1120; FLOMENBERG N, 1983, J IMMUNOL, V130, P2635; FRAZIERSCOTT K, 1988, J CLIN INVEST, V82, P1877; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; GRIMM EA, 1983, J EXP MED, V157, P884, DOI 10.1084/jem.157.3.884; HENNEY CS, 1982, TRANSPLANT P, V14, P565; HERLYN M, 1990, CLIN EXP METASTAS, V8, P9; Hicks C, 1991, Growth Factors, V5, P201, DOI 10.3109/08977199109000284; JANKOVIC DL, 1990, J IMMUNOL, V145, P4136; JOHNSON JP, 1981, EUR J IMMUNOL, V11, P825, DOI 10.1002/eji.1830111015; JONJIC N, 1992, EUR J IMMUNOL, V22, P2255, DOI 10.1002/eji.1830220912; LANTZ O, 1991, J IMMUNOL METHODS, V137, P121, DOI 10.1016/0022-1759(91)90401-Z; LEIBSON HJ, 1981, J EXP MED, V154, P1681, DOI 10.1084/jem.154.5.1681; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; NABEL GJ, 1988, P NATL ACAD SCI USA, V85, P2934, DOI 10.1073/pnas.85.9.2934; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PLAISANCE S, 1992, INT IMMUNOL, V4, P739, DOI 10.1093/intimm/4.7.739; PLAISANCE S, 1993, NATO ASI SERIES H, V67, P103; SANETO RP, 1986, P NATL ACAD SCI USA, V83, P9221, DOI 10.1073/pnas.83.23.9221; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; SMITH KA, 1988, ADV IMMUNOL, V42, P165, DOI 10.1016/S0065-2776(08)60844-5; SOUBIRAN P, 1987, J REPROD IMMUNOL, V12, P225, DOI 10.1016/0165-0378(87)90026-X; SWAIN SL, 1981, P NATL ACAD SCI-BIOL, V78, P2517, DOI 10.1073/pnas.78.4.2517; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WALKER E, 1988, J IMMUNOL, V140, P859; WEIDMANN E, 1992, CANCER RES, V52, P5963; WILLIAMS TM, 1988, J IMMUNOL, V141, P662; YAMADA G, 1992, PROGR IMMUNOLOGY, V6, P469	45	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1791	1796						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8099724				2022-12-17	WOS:A1993LG68200010
J	BONHAM, K; FUJITA, DJ				BONHAM, K; FUJITA, DJ			ORGANIZATION AND ANALYSIS OF THE PROMOTER REGION AND 5' NONCODING EXONS OF THE HUMAN C-SRC PROTOONCOGENE	ONCOGENE			English	Article							EXPRESS HIGH-LEVELS; GENE-PRODUCT; MAMMALIAN-CELLS; KINASE-ACTIVITY; NEURONAL CELLS; PLASMID DNA; V-SRC; PP60C-SRC; SEQUENCE; FORM	In order to help clarify the cellular mechanisms that regulate expression of the human c-src proto-oncogene, we have isolated a series of overlapping genomic clones that contain the c-src promoter region, as well as three previously uncharacterized exons. These exons encode the 350-bp 5' untranslated region of the c-src mRNA and span 35 kb of genomic DNA, extending the human c-src locus to approximately 60 kb. Subcloning and sequence analysis of the 5' flanking region of the gene revealed a high GC content and several consensus Sp1 and AP2 binding sites. However, TATA or CAAT boxes were not present, a characteristic shared by other GC-rich promoters. Promoter-CAT constructs demonstrated that the promoter was functional in transfection assays and that its activity was dependent on correct orientation. CAT-promoter deletion constructs were used to define the 5' boundary for maximal promoter activity and to reveal the presence of both positive and negative regulatory elements. S1 analyses of human c-src mRNA from cell lines indicated that multiple transcription start sites were utilized.	UNIV CALGARY,MED CTR,CELL REGULAT GRP,CALGARY T2N 4N1,AB,CANADA; UNIV CALGARY,DEPT MED BIOCHEM,MRC,SIGNAL TRANSDUCT GRP,CALGARY T2N 4N1,AB,CANADA	University of Calgary; University of Calgary								ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOLEN JB, 1985, P NATL ACAD SCI USA, V82, P7275, DOI 10.1073/pnas.82.21.7275; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DORAI T, 1991, MOL CELL BIOL, V11, P4165, DOI 10.1128/MCB.11.8.4165; DORAI T, 1990, MOL CELL BIOL, V10, P4068, DOI 10.1128/MCB.10.8.4068; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; EVANS T, 1988, J MOL BIOL, V199, P61, DOI 10.1016/0022-2836(88)90379-8; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FULTS DW, 1985, MOL CELL BIOL, V5, P327; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GHOSN CR, 1992, ONCOGENE, V7, P2345; GIBBS CP, 1985, J VIROL, V53, P19, DOI 10.1128/JVI.53.1.19-24.1985; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTKIND JS, 1991, MOL CELL BIOL, V11, P1500, DOI 10.1128/MCB.11.3.1500; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HOFFMANFALK H, 1983, CELL, V32, P589, DOI 10.1016/0092-8674(83)90478-6; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JORCYK CL, 1990, ONCOGENE, V6, P323; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15505; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KREIG P, 1983, ANAL BIOCHEM, V134, P288; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LICHTENBERG U, 1992, ONCOGENE, V7, P849; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAVROTHALASSITIS GJ, 1990, ONCOGENE, V5, P1337; OCONNOR TJ, 1992, CELL GROWTH DIFFER, V3, P435; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; PATEL M, 1990, ONCOGENE, V5, P201; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; ROSEN N, 1986, J BIOL CHEM, V261, P13745; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SUDOL M, 1988, ONCOGENE RES, V2, P345; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1990, ONCOGENE RES, V5, P305; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TANAKA A, 1986, MOL CELL BIOL, V6, P3900, DOI 10.1128/MCB.6.11.3900; ZAFARULLAH M, 1988, MOL CELL BIOL, V8, P4469, DOI 10.1128/MCB.8.10.4469; ZIEGLER SF, 1991, ONCOGENE, V6, P283	53	41	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1973	1981						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510939				2022-12-17	WOS:A1993LG68200030
J	HADMAN, M; LOO, M; BOS, TJ				HADMAN, M; LOO, M; BOS, TJ			INVIVO VIRAL AND CELLULAR JUN COMPLEXES EXHIBIT DIFFERENTIAL INTERACTION WITH A NUMBER OF INVITRO GENERATED AP-1-LIKE AND CREB-LIKE TARGET SEQUENCES	ONCOGENE			English	Article							C-JUN; LEUCINE ZIPPER; FOS PROTEIN; EMBRYO FIBROBLASTS; V-JUN; DNA; AP-1; TRANSCRIPTION; DOMAIN; ONCOGENE	A direct comparison of the relative DNA-binding capabilities of in vivo Jun-containing complexes derived from overexpression of the highly transforming viral Jun (VJ-1 CEF), the weakly transforming chicken cellular Jun (CJ-3 CEF) or background endogenous Jun (RCAS CEF) was assessed by gel mobility-shift assays using a synthetic oligonucleotide containing the consensus sequence TGACTCA (consensus AP-1). Chicken embryo fibroblasts (CEFs) expressing background c-Jun levels (RCAS CEF) contain almost undetectable levels of c-Jun but retain significant DNA-binding activity with two distinct complexes capable of binding specifically to the consensus AP-1 site. CEFs overexpressing either v-Jun or c-Jun contain these same two complexes and, while showing marked increases in Jun protein levels, do not exhibit any increase in DNA binding or transcriptional activation activity, suggesting that much of the overexpressed protein is inactive. Gel-shift assays performed in the presence of a Jun-specific antibody revealed a reduction in binding by both complexes, suggesting that each contains Jun or a Jun cross-reactive protein. Antibodies specific for Jun B, c-Fos, Fos B and CREB failed to interact with either complex. However, antibody specific for Fra-2 caused a slight supershift, suggesting that one or both complexes may contain Fra-2. Gel-shift competition assays with 16 'AP-1- and CREB-like' target sequences revealed that, within each cell type, the two protein complexes varied in their ability to recognize the mutant target sequences. These results clearly indicate differences in potential target recognition by each specific in vivo complex, and suggest that each may preferentially bind its own subset of target DNAs. In addition, a comparison of binding by individual complexes derived from CEFs overexpressing v-Jun and c-Jun also revealed differences in target recognition. Thus, in vivo complexes formed by overexpression of v-Jun and c-Jun vary in their ability to recognize and bind to a number of 'AP-1- and CREB-like' target sequences. This has important implications with regard to the mechanisms involved in cell transformation by v-Jun.	EASTERN VIRGINIA MED SCH, DEPT MICROBIOL & IMMUNOL, POB 1980, NORFOLK, VA 23501 USA	Eastern Virginia Medical School					NCI NIH HHS [NCI R29 CA 51982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1990, ONCOGENE, V5, P929; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GROSSI M, 1991, ONCOGENE, V6, P1767; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; RANSONE LJ, 1990, MOL CELL BIOL, V10, P4565, DOI 10.1128/MCB.10.9.4565; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RYSECK RP, 1991, ONCOGENE, V6, P533; RYSECK RP, 1990, ONCOGENE, V5, P1091; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHARMA A, 1989, P NATL ACAD SCI USA, V86, P491, DOI 10.1073/pnas.86.2.491; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SU HY, 1991, ONCOGENE, V6, P1759; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; VOGT PK, 1990, CANCER BIOL, V1, P27	37	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1895	1903						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510933				2022-12-17	WOS:A1993LG68200022
J	MA, A; MOROY, T; COLLUM, R; WEINTRAUB, H; ALT, FW; BLACKWELL, TK				MA, A; MOROY, T; COLLUM, R; WEINTRAUB, H; ALT, FW; BLACKWELL, TK			DNA-BINDING BY N-MYC AND L-MYC PROTEINS	ONCOGENE			English	Note							LOOP-HELIX PROTEIN; LEUCINE-ZIPPER REGION; C-MYC; TRANSCRIPTION FACTOR; ACTIVATES TRANSCRIPTION; TRANSGENIC MICE; ENHANCER; MYOD; OLIGOMERIZATION; EXPRESSION	N- and L-Myc, like c-Myc, contain adjacent basic region (BR), helix-loop-helix (HLH) and leucine zipper (LZ) motifs, which characterize a family of DNA-binding proteins. We have used a polymerase chain reaction (PCR)-based binding site selection technique to demonstrate that the most highly preferred binding site for both N- and L-Myc fusion proteins contains a CACGTG motif, the core binding sequence previously identified for c-Myc. Further analysis identified other N-Myc binding sequences, including asymmetric sequences such as CATGTG. N-Myc, like c-Myc, preferentially forms heterodimeric DNA-binding complexes with Max protein. Mutational analyses of N-Myc basic region (BR), helix-loop-helix (HLH) and leucine zipper (LZ) regions revealed that all three regions are necessary for DNA binding by N-Myc-Max complexes, and that dimerization requires both HLH and LZ motifs, while BR sequences are needed only for DNA binding. Our findings support the notion that the LZ motif is a critical element in dimer formation by bHLH-LZ proteins.	CHILDRENS HOSP MED CTR,HOWARD HUGHES MED INST,BOSTON,MA 02115; FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center			Moroy, Tarik/D-9923-2011		NCI NIH HHS [CA23767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALOZENETIS T, 1992, SCIENCE, V255, P464; HALOZENETIS T, 1991, P NATL ACAD SCI USA, V88, P6162; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKAJIMA H, 1989, ONCOGENE, V4, P999; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	39	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1093	1098						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455937				2022-12-17	WOS:A1993KT22000036
J	CHAMPIONARNAUD, P; GESNEL, MC; FOULKES, N; RONSIN, C; SASSONECORSI, P; BREATHNACH, R				CHAMPIONARNAUD, P; GESNEL, MC; FOULKES, N; RONSIN, C; SASSONECORSI, P; BREATHNACH, R			ACTIVATION OF TRANSCRIPTION VIA AP-1 OR CREB REGULATORY SITES IS BLOCKED BY PROTEIN TYROSINE PHOSPHATASES	ONCOGENE			English	Article							HUMAN ESTROGEN-RECEPTOR; EPIDERMAL GROWTH-FACTOR; ROUS-SARCOMA VIRUS; HUMAN-PLACENTA; CYCLIC-AMP; RAT FIBROBLASTS; MESSENGER-RNA; C-JUN; GENE; KINASE	Transcriptional activation endowed by AP-1 or CREB binding sites can be significantly reduced in transient transfection tests by expression from the corresponding cloned cDNAs of protein tyrosine phosphatases. Both the protein tyrosine phosphatase 1B and the T-cell protein tyrosine phosphatase, as well as a novel form of this latter protein generated by an alternative splicing event show this activity. The effect is specific, as none of the protein tyrosine phosphatases alters transcriptional activation by either the estrogen receptor, GAL4, or a GAL4-VP16 fusion protein. Furthermore, the activities of the SV40 early gene promoter and a Moloney murine leukemia virus long terminal repeat promoter are not reduced by these phosphatases. We conclude that a yet to be identified protein phosphorylated on tyrosine is necessary for a full transcriptional response via AP-1 or CREB binding sites.	UNIV NANTES,FAC SCI & TECH,F-44035 NANTES,FRANCE; CHR NANTES,INSERM,U211,F-44035 NANTES,FRANCE; FAC MED STRASBOURG,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,F-67085 STRASBOURG,FRANCE	Nantes Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	BREATHNACH, R (corresponding author), UNIV NANTES,FAC SCI & TECH,F-44035 NANTES,FRANCE.		Breathnach, Richard/K-7599-2015					ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P9035; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; Sambrook J., 1989, MOL CLONING LAB MANU; SASSONECORSI P, 1990, ONCOGENE, V5, P423; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	50	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1203	1209						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650442				2022-12-17	WOS:A1991GV26000016
J	JAHNER, D; HUNTER, T				JAHNER, D; HUNTER, T			THE STIMULATION OF QUIESCENT RAT FIBROBLASTS BY V-SRC AND V-FPS ONCOGENIC PROTEIN-TYROSINE KINASES LEADS TO THE INDUCTION OF A SUBSET OF IMMEDIATE EARLY GENES	ONCOGENE			English	Article								The stimulation of quiescent murine fibroblasts by growth factors and by phorbol esters results in a rapid and transient transcriptional activation of a large group of so-called immediate early genes. Several such genes were found to be induced in chicken embryo fibroblasts following activation of a temperature sensitive (ts) Rous sarcoma virus v-src mutant following temperature shift (Simmons et al., 1989). In contrast, the classical immediate early genes c-myc, c-fos and c-jun were essentially uninducible upon activation of a ts v-src mutant in rat-1 fibroblasts (Welham et al., 1990). We have cloned 9 cDNAs of genes that are rapidly and transiently inducible in rat fibroblasts by ts v-src mutants, and by a ts Fujinami sarcoma virus v-fps mutant. Six of these cDNAs are derived from the known immediate early genes NGFI-A, KC, c-fos, tissue factor, PC4 and ornithine decarboxylase; the other three cDNAs have not been described before. These 9 genes showed individual profiles of inducibility by fetal calf serum, epidermal growth factor (EGF) and by phorbol esters. Their response to the retroviral oncogenic protein-tyrosine kinases correlated best with the one to EGF, suggesting a common pathway of signal transduction. c-fos did not respond strongly to this pathway but was well induced by fetal calf serum. NGFI-A, however, was induced to a similar extent by all activators tested. Furthermore, we demonstrated that the induction of several of these genes by the retroviral oncogenic protein-tyrosine kinases is rapid, direct and occurs at the transcriptional level.	SALK INST, MOLEC BIOL & VIROL LAB, POB 85800, SAN DIEGO, CA 92186 USA	Salk Institute	HUNTER, T (corresponding author), SALK INST, MOLEC BIOL & VIROL LAB, POB 85800, SAN DIEGO, CA 92186 USA.				NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER; NCI NIH HHS [CA-14195, CA-39780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BELL JG, 1975, J GEN VIROL, V27, P127, DOI 10.1099/0022-1317-27-2-127; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; Bogenberger J, 1988, Oncogene Res, V3, P301; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHEN YC, 1977, CELL, V11, P513, DOI 10.1016/0092-8674(77)90069-1; CHIARUGI V, 1987, ONCOGENE, V2, P37; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1987, ONCOGENE, V2, P79; DURKIN JP, 1984, J CELL PHYSIOL, V120, P135, DOI 10.1002/jcp.1041200205; DURKIN JP, 1991, IN PRESS CELL SIGNAL; DUTTA A, 1990, GENE DEV, V4, P243, DOI 10.1101/gad.4.2.243; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FELLOUS M, 1982, P NATL ACAD SCI-BIOL, V79, P3082, DOI 10.1073/pnas.79.10.3082; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GILMAN MZ, 1988, COLD SPRING HARB SYM, V53, P761, DOI 10.1101/SQB.1988.053.01.086; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; JAHNER D, 1991, IN PRESS MOL CELL BI; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; KAHANA C, 1985, P NATL ACAD SCI USA, V82, P1673, DOI 10.1073/pnas.82.6.1673; KAMPS MP, 1988, ONCOGENE RES, V3, P105; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRUEGER JG, 1980, VIROLOGY, V101, P25, DOI 10.1016/0042-6822(80)90480-8; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTINS TJ, 1989, J CELL BIOL, V108, P683, DOI 10.1083/jcb.108.2.683; MARTINSGREEN M, 1990, J CELL BIOL, V110, P581, DOI 10.1083/jcb.110.3.581; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MOSS P, 1984, J VIROL, V52, P557, DOI 10.1128/JVI.52.2.557-565.1984; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; PRYWES R, 1988, COLD SPRING HARB SYM, V53, P739, DOI 10.1101/SQB.1988.053.01.084; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAN W, 1986, P NATL ACAD SCI USA, V83, P8216, DOI 10.1073/pnas.83.21.8216; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; ROLLINS BJ, 1987, SCIENCE, V238, P1269, DOI 10.1126/science.3685976; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; STOECKLE M Y, 1990, New Biologist, V2, P313; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TIRONE F, 1989, P NATL ACAD SCI USA, V86, P2088, DOI 10.1073/pnas.86.6.2088; VARNUM BC, 1989, ONCOGENE, V4, P1263; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x; WEINMASTER GA, 1988, J VIROL, V62, P3849, DOI 10.1128/JVI.62.10.3849-3854.1988; WELHAM MJ, 1990, ONCOGENE, V5, P161; WHITE MK, 1988, MOL CELL BIOL, V8, P138, DOI 10.1128/MCB.8.1.138; WILLINGHAM MC, 1979, CELL, V18, P125, DOI 10.1016/0092-8674(79)90361-1	85	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1259	1268						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861868				2022-12-17	WOS:A1991GV26000023
J	CHENEVIXTRENCH, G; MARTIN, NG; ELLEM, KAO				CHENEVIXTRENCH, G; MARTIN, NG; ELLEM, KAO			GENE-EXPRESSION IN MELANOMA CELL-LINES AND CULTURED MELANOCYTES - CORRELATION BETWEEN LEVELS OF C-SRC-1, C-MYC AND P53	ONCOGENE			English	Article									UNIV QUEENSLAND,DEPT PATHOL,BRISBANE,QLD 4000,AUSTRALIA	University of Queensland	CHENEVIXTRENCH, G (corresponding author), QUEENSLAND INST MED RES,JOINT ONCOL PROGRAM,BRAMSTON TERRACE,HERSTON,QLD 4006,AUSTRALIA.			Chenevix-Trench, Georgia/0000-0002-1878-2587				ADELAIDE J, 1988, ONCOGENE, V2, P413; ALBINO AP, 1988, ADV PIGMENT CELL RES, V256, P361; ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DALLAFAVERA R, 1981, NATURE, V292, P31; de Vries J E, 1974, Int J Cancer, V14, P427, DOI 10.1002/ijc.2910140402; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; DRACOPOLI NC, 1985, P NATL ACAD SCI USA, V82, P1470, DOI 10.1073/pnas.82.5.1470; EDLUND T, 1983, P NATL ACAD SCI-BIOL, V80, P349, DOI 10.1073/pnas.80.2.349; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; ELLEM KAO, 1988, CARCINOGENESIS, V9, P797, DOI 10.1093/carcin/9.5.797; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GERHARD DS, 1987, NATURE, V325, P73, DOI 10.1038/325073a0; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GOSS P, 1977, CANCER RES, V37, P152; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; HALABAN R, 1988, ONCOGENE RES, V3, P177; Halaban R, 1988, PIGM CELL RES, V1, P18; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HAYWARD NK, 1988, HUM GENET, V78, P115, DOI 10.1007/BF00278178; IMANISHI K, 1989, BRIT J CANCER, V59, P761, DOI 10.1038/bjc.1989.159; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KODA T, 1987, JPN J CANCER RES, V78, P325; KUROKAWA T, 1987, FEBS LETT, V213, P189, DOI 10.1016/0014-5793(87)81489-8; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LINNENBACH AJ, 1988, P NATL ACAD SCI USA, V85, P74, DOI 10.1073/pnas.85.1.74; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maniatis T., 1982, MOL CLONING; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOORE GE, 1980, CANCER-AM CANCER SOC, V45, P2311, DOI 10.1002/1097-0142(19800501)45:9<2311::AID-CNCR2820450914>3.0.CO;2-W; MURRAY JC, 1986, NUCLEIC ACIDS RES, V14, P7136, DOI 10.1093/nar/14.17.7136; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; OGISO Y, 1988, J INVEST DERMATOL, V90, P841, DOI 10.1111/1523-1747.ep12462078; PADUA RA, 1984, NATURE, V311, P671, DOI 10.1038/311671a0; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; POPE JH, 1979, PATHOLOGY, V11, P191, DOI 10.3109/00313027909061945; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; RIJKEN DC, 1981, J BIOL CHEM, V256, P7035; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RONAI ZA, 1988, ONCOGENE, V2, P201; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SEMBA K, 1985, SCIENCE, V227, P1038, DOI 10.1126/science.2983418; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; VANHAERINGEN A, 1989, GENOMICS, V5, P61, DOI 10.1016/0888-7543(89)90086-4; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; 1988, SPSS PC ADV STATISTI	64	41	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1187	1193						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	1697409				2022-12-17	WOS:A1990DX36100011
J	VARNUM, BC; LIM, RW; HERSCHMAN, HR				VARNUM, BC; LIM, RW; HERSCHMAN, HR			CHARACTERIZATION OF TIS7, A GENE INDUCED IN SWISS 3T3 CELLS BY THE TUMOR PROMOTER TETRADECANOYL PHORBOL ACETATE	ONCOGENE			English	Note									UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOL CHEM,WARREN HALL,900 VET AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,BIOMED & ENVIRONM SCI LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM 24797, 2T32 GM07104] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007104, R01GM024797] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; ARENANDER AT, 1989, IN PRESS J NEUROSCI; BURD PR, 1987, J IMMUNOL, V139, P3126; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Curran T, 1988, ONCOGENE HDB, P307; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KUJUBU DA, 1987, ONCOGENE, V1, P257; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; LIM RW, 1989, MOL CELL BIOL, V9, P1790, DOI 10.1128/MCB.9.4.1790; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; RYSECK RP, 1989, EXP CELL RES, V180, P266, DOI 10.1016/0014-4827(89)90230-9; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SKUP D, 1982, NUCLEIC ACIDS RES, V10, P3069, DOI 10.1093/nar/10.10.3069; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TIPPETTS MT, 1988, MOL CELL BIOL, V8, P4570, DOI 10.1128/MCB.8.10.4570; TIRONE F, 1989, P NATL ACAD SCI USA, V86, P2088, DOI 10.1073/pnas.86.6.2088; VARNUM BC, 1989, ONCOGENE, V4, P119; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445	21	41	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1263	1265						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2797820				2022-12-17	WOS:A1989AU50800015
J	MOLDERS, H; JENUWEIN, T; ADAMKIEWICZ, J; MULLER, R				MOLDERS, H; JENUWEIN, T; ADAMKIEWICZ, J; MULLER, R			ISOLATION AND STRUCTURAL-ANALYSIS OF A BIOLOGICALLY-ACTIVE CHICKEN C-FOS-CDNA - IDENTIFICATION OF EVOLUTIONARILY CONSERVED DOMAINS IN FOS-PROTEIN	ONCOGENE			English	Article									EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,D-6900 HEIDELBERG,FED REP GER	European Molecular Biology Laboratory (EMBL)			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHUVPILO SA, 1984, FEBS LETT, V179, P34; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1984, CELL, V36, P259; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; FINKEL MP, 1975, FRONTIERS RADIATION, V10, P28; FRANZA BR, 1987, ONCOGENE, V1, P213; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; HAYMERLE H, 1986, NUCLEIC ACIDS RES, V14, P8615, DOI 10.1093/nar/14.21.8615; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; JENUWEIN T, IN PRESS GENES SIGNA; LEVY JA, 1973, J NATL CANCER I, V51, P525; MANIATIS T, 1982, MOL CLONING LABORATO; Maxam A M, 1980, Methods Enzymol, V65, P499; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER AD, 1984, CELL, V36, P51; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; MULLER R, IN PRESS CELLULAR ON; MULLER R, 1987, IN PRESS ONCOGENE RE; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1634; RENZ M, 1987, NUCLEIC ACIDS RES, V15, P277, DOI 10.1093/nar/15.1.277; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SEYTOYAMA C, 1986, BIOCH BIOPHYS RES CO, V136, P1042; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; WARD JM, 1976, CANCER RES, V36, P3985	41	41	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	4					377	385						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	3330781				2022-12-17	WOS:A1987K748300006
J	REYNOLDS, VL; LEBOVITZ, RM; WARREN, S; HAWLEY, TS; GODWIN, AK; LIEBERMAN, MW				REYNOLDS, VL; LEBOVITZ, RM; WARREN, S; HAWLEY, TS; GODWIN, AK; LIEBERMAN, MW			REGULATION OF A METALLOTHIONEIN-RAST24 FUSION GENE BY ZINC RESULTS IN GRADED ALTERATIONS IN CELL MORPHOLOGY AND GROWTH	ONCOGENE			English	Article									FOX CHASE CANC CTR,DEPT PATHOL,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [CA39392, T32-CA09035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009035, R37CA039392, R01CA039392] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1986, CARCINOGENESIS, V7, P1037, DOI 10.1093/carcin/7.7.1037; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CICHUTEK K, 1986, P NATL ACAD SCI USA, V83, P2340, DOI 10.1073/pnas.83.8.2340; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; Farber E, 1980, Adv Cancer Res, V31, P125, DOI 10.1016/S0065-230X(08)60658-2; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FERAMISCO JR, 1985, NATURE, V314, P639, DOI 10.1038/314639a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUERRERO I, 1985, P NATL ACAD SCI USA, V82, P7810, DOI 10.1073/pnas.82.23.7810; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; LACAL JC, 1986, CELL, V44, P609, DOI 10.1016/0092-8674(86)90270-9; LIEBERMAN MW, 1983, CELL, V35, P207, DOI 10.1016/0092-8674(83)90223-4; MACARTHUR CA, 1986, CARCINOGENESIS, V7, P1487, DOI 10.1093/carcin/7.9.1487; MACARTHUR CA, 1985, CARCINOGENESIS, V6, P887, DOI 10.1093/carcin/6.6.887; MANIATIS T, 1982, MOL CLONING LABORATO; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TRIMBLE WS, 1986, NATURE, V321, P782, DOI 10.1038/321782a0; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WINTER E, 1986, MOL CELL BIOL, V6, P2562, DOI 10.1128/MCB.6.7.2562; ZIEVE G, 1976, CELL, V8, P19, DOI 10.1016/0092-8674(76)90181-1	32	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	3					323	330						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J9705	3330778				2022-12-17	WOS:A1987J970500015
J	Zhang, YL; Kong, Y; Ma, Y; Ni, SL; Wikerholmen, T; Xi, KY; Zhao, FH; Zhao, ZM; Wang, JP; Huang, B; Chen, AJ; Yao, Z; Han, MZ; Feng, ZC; Hu, YT; Thorsen, F; Wang, J; Li, XG				Zhang, Yulin; Kong, Yang; Ma, Yuan; Ni, Shilei; Wikerholmen, Tobias; Xi, Kaiyan; Zhao, Feihu; Zhao, Zhimin; Wang, Junpeng; Huang, Bin; Chen, Anjing; Yao, Zhong; Han, Mingzhi; Feng, Zichao; Hu, Yaotian; Thorsen, Frits; Wang, Jian; Li, Xingang			Loss of COPZ1 induces NCOA4 mediated autophagy and ferroptosis in glioblastoma cell lines	ONCOGENE			English	Article							IRON; CANCER; METABOLISM; DEATH; TEMOZOLOMIDE; DEGRADATION; COATOMER; FERRITIN; BIOLOGY; SCREEN	Dysregulated iron metabolism is a hallmark of many cancers, including glioblastoma (GBM). However, its role in tumor progression remains unclear. Herein, we identified coatomer protein complex subunit zeta 1 (COPZ1) as a therapeutic target candidate which significantly dysregulated iron metabolism in GBM cells. Overexpression of COPZ1 was associated with increasing tumor grade and poor prognosis in glioma patients based on analysis of expression data from the publicly available database The Cancer Genome Atlas (P < 0.001). Protein levels of COPZ1 were significantly increased in GBM compared to non-neoplastic brain tissue samples in immunohistochemistry and western blot analysis. SiRNA knockdown of COPZ1 suppressed proliferation of U87MG, U251 and P3#GBM in vitro. Stable expression of a COPZ1 shRNA construct in U87MG inhibited tumor growth in vivo by similar to 60% relative to controls at day 21 after implantation (P < 0.001). Kaplan-Meier analysis of the survival data demonstrated that the overall survival of tumor bearing animals increased from 20.8 days (control) to 27.8 days (knockdown, P < 0.05). COPZ1 knockdown also led to the increase in nuclear receptor coactivator 4 (NCOA4), resulting in the degradation of ferritin, and a subsequent increase in the intracellular levels of ferrous iron and ultimately ferroptosis. These data demonstrate that COPZ1 is a critical mediator in iron metabolism. The COPZ1/NCOA4/FTH1 axis is therefore a novel therapeutic target for the treatment of human GBM.	[Zhang, Yulin; Kong, Yang; Ma, Yuan; Ni, Shilei; Xi, Kaiyan; Zhao, Feihu; Zhao, Zhimin; Wang, Junpeng; Huang, Bin; Chen, Anjing; Yao, Zhong; Feng, Zichao; Hu, Yaotian; Thorsen, Frits; Wang, Jian; Li, Xingang] Shandong Univ, Dept Neurosurg, Qilu Hosp, Cheeloo Coll Med, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Zhang, Yulin; Kong, Yang; Ma, Yuan; Ni, Shilei; Xi, Kaiyan; Zhao, Feihu; Zhao, Zhimin; Wang, Junpeng; Huang, Bin; Chen, Anjing; Yao, Zhong; Feng, Zichao; Hu, Yaotian; Thorsen, Frits; Wang, Jian; Li, Xingang] Shandong Univ, Dept Neurosurg, Inst Brain & Brain Inspired Sci, Cheeloo Coll Med, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Zhang, Yulin; Kong, Yang; Ma, Yuan; Ni, Shilei; Xi, Kaiyan; Zhao, Feihu; Zhao, Zhimin; Wang, Junpeng; Huang, Bin; Chen, Anjing; Yao, Zhong; Feng, Zichao; Hu, Yaotian; Wang, Jian; Li, Xingang] Shandong Key Lab Brain Funct Remodeling, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Zhang, Yulin; Kong, Yang; Wikerholmen, Tobias; Han, Mingzhi; Thorsen, Frits; Wang, Jian] Univ Bergen, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway; [Thorsen, Frits] Univ Bergen, Dept Biomed, Mol Imaging Ctr, Jonas Lies Vei 91, N-5009 Bergen, Norway	Shandong University; Shandong University; University of Bergen; University of Bergen	Thorsen, F; Wang, J; Li, XG (corresponding author), Shandong Univ, Dept Neurosurg, Qilu Hosp, Cheeloo Coll Med, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Thorsen, F; Wang, J; Li, XG (corresponding author), Shandong Univ, Dept Neurosurg, Inst Brain & Brain Inspired Sci, Cheeloo Coll Med, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Wang, J; Li, XG (corresponding author), Shandong Key Lab Brain Funct Remodeling, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Thorsen, F; Wang, J (corresponding author), Univ Bergen, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway.; Thorsen, F (corresponding author), Univ Bergen, Dept Biomed, Mol Imaging Ctr, Jonas Lies Vei 91, N-5009 Bergen, Norway.	Frits.Thorsen@uib.no; Jian.Wang@uib.no; lixg@sdu.edu.cn	Chen, Anjing/GYE-2355-2022; Huang, Bin/AAT-4514-2021	Zhang, Yulin/0000-0002-0031-1808; Wikerholmen, Tobias/0000-0002-2925-6144	National Natural Science Foundation of China [81972351, 81874082, 82073219, 81702474]; Department of Science & Technology of Shandong Province [2017CXGC1502, 2018GSF118094, 2018CXGC1503]; Special Foundation for Taishan Scholars [tshw201502056, ts20110814, tsqn201909173]; China Postdoctoral Science Foundation [2018M642666]; Jinan Science and Technology Bureau of Shandong Province [2019GXRC006, 201821049]; Shandong Research Institute of Industrial Technology	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Department of Science & Technology of Shandong Province; Special Foundation for Taishan Scholars; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Jinan Science and Technology Bureau of Shandong Province; Shandong Research Institute of Industrial Technology	This work was supported by the National Natural Science Foundation of China (81972351, 81874082, 82073219, and 81702474), the Department of Science & Technology of Shandong Province (2017CXGC1502, 2018GSF118094 and 2018CXGC1503), the Special Foundation for Taishan Scholars (tshw201502056, ts20110814 and tsqn201909173), the China Postdoctoral Science Foundation (2018M642666), the Jinan Science and Technology Bureau of Shandong Province (2019GXRC006 and 201821049) and the Shandong Research Institute of Industrial Technology.	Anania MC, 2017, CANCER LETT, V410, P201, DOI 10.1016/j.canlet.2017.09.024; Angeli JPF, 2019, NAT REV CANCER, V19, P405, DOI 10.1038/s41568-019-0149-1; Beck R, 2009, FEBS LETT, V583, P2701, DOI 10.1016/j.febslet.2009.07.032; Chen JJ, 2018, TRENDS CELL BIOL, V28, P77, DOI 10.1016/j.tcb.2017.11.007; Collinet C, 2010, NATURE, V464, P243, DOI 10.1038/nature08779; Cooper MS, 2019, BRAIN, V142, DOI 10.1093/brain/awz183; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218; Dowdle WE, 2014, NAT CELL BIOL, V16, P1069, DOI 10.1038/ncb3053; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; Gao MH, 2019, MOL CELL, V73, P354, DOI 10.1016/j.molcel.2018.10.042; Gao MH, 2016, CELL RES, V26, P1021, DOI 10.1038/cr.2016.95; Han MZ, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201910924; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hassannia B, 2019, CANCER CELL, V35, P830, DOI 10.1016/j.ccell.2019.04.002; Hou W, 2016, AUTOPHAGY, V12, P1425, DOI 10.1080/15548627.2016.1187366; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Legendre C, 2015, TRENDS ENDOCRIN MET, V26, P322, DOI 10.1016/j.tem.2015.03.008; Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143; Madsen E, 2007, ANNU REV NEUROSCI, V30, P317, DOI 10.1146/annurev.neuro.30.051606.094232; Mancias JD, 2015, ELIFE, V4, DOI 10.7554/eLife.10308; Mancias JD, 2014, NATURE, V509, P105, DOI 10.1038/nature13148; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mleczko-Sanecka K, 2017, HAEMATOLOGICA, V102, P1173, DOI 10.3324/haematol.2016.162917; Mleczko-Sanecka K, 2014, BLOOD, V123, P1574, DOI 10.1182/blood-2013-07-515957; Murphy MP, 2018, NAT CELL BIOL, V20, P1104, DOI 10.1038/s41556-018-0209-x; Pignatello JJ, 2006, CRIT REV ENV SCI TEC, V36, P1, DOI 10.1080/10643380500326564; Razi M, 2009, J CELL BIOL, V185, P305, DOI 10.1083/jcb.200810098; Ryu MS, 2017, J CLIN INVEST, V127, P1786, DOI 10.1172/JCI90519; Salvador GA, 2010, BIOFACTORS, V36, P103, DOI 10.1002/biof.80; Schoenfeld JD, 2017, CANCER CELL, V31, P487, DOI 10.1016/j.ccell.2017.02.018; Shin D, 2020, REDOX BIOL, V30, DOI 10.1016/j.redox.2019.101418; Shtutman M, 2011, P NATL ACAD SCI USA, V108, P12449, DOI 10.1073/pnas.1103842108; Simon T, 2020, ONCOGENE, V39, P4477, DOI 10.1038/s41388-020-1308-2; Sosa V, 2013, AGEING RES REV, V12, P376, DOI 10.1016/j.arr.2012.10.004; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sukseree S, 2020, AUTOPHAGY, V16, P1851, DOI 10.1080/15548627.2019.1709764; Sun X, 2015, ONCOGENE, V34, P5617, DOI 10.1038/onc.2015.32; Teng J, 2018, NEURO-ONCOLOGY, V20, P642, DOI 10.1093/neuonc/nox198; Theil EC, 2004, ANNU REV NUTR, V24, P327, DOI 10.1146/annurev.nutr.24.012003.132212; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; van Swelm RPL, 2020, NAT REV NEPHROL, V16, P77, DOI 10.1038/s41581-019-0197-5; Wang YF, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010095; Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158; Zhang YL, 2020, ACS APPL MATER INTER, V12, P43408, DOI 10.1021/acsami.0c12042; Zhang ZL, 2018, AUTOPHAGY, V14, P2083, DOI 10.1080/15548627.2018.1503146	47	40	41	7	32	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1425	1439		10.1038/s41388-020-01622-3	http://dx.doi.org/10.1038/s41388-020-01622-3		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33420375	Green Published, hybrid			2022-12-17	WOS:000607346000013
J	Sorolla, A; Wang, E; Golden, E; Duffy, C; Henriques, ST; Redfern, AD; Blancafort, P				Sorolla, Anabel; Wang, Edina; Golden, Emily; Duffy, Ciara; Henriques, Sonia T.; Redfern, Andrew D.; Blancafort, Pilar			Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics	ONCOGENE			English	Review							CELL-PENETRATING PEPTIDES; VIVO HALF-LIFE; TRANSCRIPTION-FACTOR; IN-VIVO; BREAST-CANCER; HOX GENES; LUNG-CANCER; MYC; INHIBITION; PROTEINS	In molecular cancer therapeutics only 10% of known cancer gene products are targetable with current pharmacological agents. Major oncogenic drivers, such as MYC and KRAS proteins are frequently highly overexpressed or mutated in multiple human malignancies. However, despite their key role in oncogenesis, these proteins are hard to target with traditional small molecule drugs due to their large, featureless protein interfaces and lack of deep pockets. In addition, they are inaccessible to large biologicals, which are unable to cross cell membranes. Designer interference peptides (iPeps) represent emerging pharmacological agents created to block selective interactions between protein partners that are difficult to target with conventional small molecule chemicals or with large biologicals. iPeps have demonstrated successful inhibition of multiple oncogenic drivers with some now entering clinical settings. However, the clinical translation of iPeps has been hampered by certain intrinsic limitations including intracellular localization, targeting tissue specificity and pharmacological potency. Herein, we outline recent advances for the selective inhibition of major cancer oncoproteins via iPep approaches and discuss the development of multimodal peptides to overcome limitations of the first generations of iPeps. Since many protein-protein interfaces are cell-type specific, this approach opens the door to novel programmable, precision medicine tools in cancer research and treatment for selective manipulation and reprogramming of the cancer cell oncoproteome.	[Sorolla, Anabel; Wang, Edina; Golden, Emily; Duffy, Ciara; Blancafort, Pilar] Univ Western Australia, QEII Med Ctr, Harry Perkins Inst Med Res, Nedlands, WA 6009, Australia; [Sorolla, Anabel; Wang, Edina; Golden, Emily; Duffy, Ciara; Blancafort, Pilar] Univ Western Australia, Ctr Med Res, Nedlands, WA 6009, Australia; [Henriques, Sonia T.] Queensland Univ Technol, Translat Res Inst, Inst Hlth & Biomed Innovat, Sch Biomed Sci,Fac Hlth, Brisbane, Qld 4102, Australia; [Redfern, Andrew D.] Univ Western Australia, Sch Med, Crawley, WA 6009, Australia	Harry Perkins Institute of Medical Research; University of Western Australia; University of Western Australia; Queensland University of Technology (QUT); University of Western Australia	Sorolla, A; Blancafort, P (corresponding author), Univ Western Australia, QEII Med Ctr, Harry Perkins Inst Med Res, Nedlands, WA 6009, Australia.; Sorolla, A; Blancafort, P (corresponding author), Univ Western Australia, Ctr Med Res, Nedlands, WA 6009, Australia.	anabel.sorollabardaji@perkins.uwa.edu.au; pilar.blancafort@uwa.edu.au	Redfern, Andrew/ABA-4597-2020; Troeira Henriques, Sonia/J-3500-2016	Troeira Henriques, Sonia/0000-0001-9564-9651; Redfern, Andrew/0000-0001-6728-8713; Blancafort, Pilar/0000-0002-3881-7396; Golden, Emily/0000-0001-6386-201X; Wang, Edina/0000-0002-9652-3513; Sorolla, Anabel/0000-0001-8238-8763	Australian Research Council (ARC) [FT130101767]; Cancer Council of Western Australia (CCWA) Research Fellowship; National Health and Medical Research Council (NHMRC) [APP1069308, APP1147528, APP1165208]; NBCF [PF-15-001]; Raine Medical Research Foundation; Australian Government Research Training Program (RTP) Scholarship; Cancer Council of Western Australia PhD Top-Up Scholarship; ARC [FT150100398]; NHMRC [APP1084965]; Australian Government; CCWA [APP1083745, APP1147435]	Australian Research Council (ARC)(Australian Research Council); Cancer Council of Western Australia (CCWA) Research Fellowship; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NBCF; Raine Medical Research Foundation; Australian Government Research Training Program (RTP) Scholarship(Australian GovernmentDepartment of Industry, Innovation and Science); Cancer Council of Western Australia PhD Top-Up Scholarship; ARC(Australian Research Council); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Australian Government(Australian GovernmentCGIAR); CCWA(Cancer Council Western Australia)	This work was supported by the following grants awarded to PB: the Australian Research Council (ARC) Future Fellowship FT130101767, the Cancer Council of Western Australia (CCWA) Research Fellowship and CCWA project grants APP1083745 and APP1147435, and National Health and Medical Research Council (NHMRC) grants APP1069308, APP1147528, and APP1165208. AS acknowledges the postdoctoral fellowship from the NBCF, PF-15-001 and the research funds from the Raine Medical Research Foundation. CD acknowledges the Australian Government Research Training Program (RTP) Scholarship and the Cancer Council of Western Australia PhD Top-Up Scholarship. STH acknowledges ARC Future Fellowship FT150100398 and NHMRC project grant APP1084965. The Translational Research Institute is supported by a grant from the Australian Government. The authors would like to acknowledge Dr. Kade Roberts for critical reading and review of the paper.	Alharbi RA, 2013, LEUKEMIA, V27, P1000, DOI 10.1038/leu.2012.356; Alvarez-Fischer D, 2011, NAT NEUROSCI, V14, P1260, DOI 10.1038/nn.2916; Annibali D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5632; Avramis VI, 2002, BLOOD, V99, P1986, DOI 10.1182/blood.V99.6.1986; Bale SS, 2010, ACS NANO, V4, P1493, DOI 10.1021/nn901586e; Beaulieu ME, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aar5012; Beltran AS, 2014, ONCOGENE, V33, P4767, DOI 10.1038/onc.2013.422; Benayed R, 2005, AM J HUM GENET, V77, P851, DOI 10.1086/497705; Bernal F, 2010, CANCER CELL, V18, P411, DOI 10.1016/j.ccr.2010.10.024; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bhatlekar S, 2018, J CELL PHYSIOL, V233, P727, DOI 10.1002/jcp.25981; Bidwell GL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055104; Bidwell GL, 2005, MOL CANCER THER, V4, P1076, DOI 10.1158/1535-7163.MCT-04-0253; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blundell TL, 2000, BIOL CHEM, V381, P955, DOI 10.1515/BC.2000.117; BOS JL, 1989, CANCER RES, V49, P4682; Brown RV, 2011, J BIOL CHEM, V286, P41018, DOI 10.1074/jbc.M111.274720; Bruno BJ, 2013, THER DELIV, V4, P1443, DOI [10.4155/tde.13.104, 10.4155/TDE.13.104]; Buckton LK, 2018, ORG LETT, V20, P506, DOI 10.1021/acs.orglett.7b03363; Caruso C, 2019, CANCER DISCOV, V9, P988, DOI 10.1158/2159-8290.CD-NB2019-073; Carvajal LA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao3003; Chang YS, 2013, P NATL ACAD SCI USA, V110, pE3445, DOI 10.1073/pnas.1303002110; Clark RJ, 2005, P NATL ACAD SCI USA, V102, P13767, DOI 10.1073/pnas.0504613102; Craik DJ, 2013, CHEM BIOL DRUG DES, V81, P136, DOI 10.1111/cbdd.12055; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; dos Santos MTMA, 2011, NEURAL DEV, V6, DOI 10.1186/1749-8104-6-23; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Farkhani SM, 2014, PEPTIDES, V57, P78, DOI 10.1016/j.peptides.2014.04.015; Fosgerau K, 2015, DRUG DISCOV TODAY, V20, P122, DOI 10.1016/j.drudis.2014.10.003; Fukazawa T, 2010, ANTICANCER RES, V30, P4193; Gandhi Neha S, 2018, Oncotarget, V9, P22383, DOI 10.18632/oncotarget.25025; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; Giorello L, 1998, CANCER RES, V58, P3654; GREEN M, 1989, CELL, V58, P215, DOI 10.1016/0092-8674(89)90417-0; Gu Z, 2011, CHEM SOC REV, V40, P3638, DOI 10.1039/c0cs00227e; Han G, 2012, ONCOL RES, V20, P149, DOI 10.3727/096504012X13522227232237; Hao XY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138911; Harbour JW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1341, DOI 10.1001/archopht.120.10.1341; Hoffmann K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30790-2; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006; Kater AP, 2019, J CLIN ONCOL, V37, P269, DOI 10.1200/JCO.18.01580; Khan I, 2019, ONCOGENE, V38, P2984, DOI 10.1038/s41388-018-0636-y; Kretzmann JA, 2019, CHEM SCI, V10, P7718, DOI 10.1039/c9sc01432b; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Leshchiner ES, 2015, P NATL ACAD SCI USA, V112, P1761, DOI 10.1073/pnas.1413185112; Li L, 2016, J CONTROL RELEASE, V232, P62, DOI 10.1016/j.jconrel.2016.04.021; Li ZG, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.187; Liu M, 2010, P NATL ACAD SCI USA, V107, P14321, DOI 10.1073/pnas.1008930107; Liu Y, 2011, ANGEW CHEM INT EDIT, V50, P3058, DOI 10.1002/anie.201005740; Luo M, 2017, NAT NANOTECHNOL, V12, P648, DOI [10.1038/nnano.2017.52, 10.1038/NNANO.2017.52]; Marier JF, 2008, J CLIN PHARMACOL, V48, P1289, DOI 10.1177/0091270008320605; Mas-Moruno C, 2010, ANTI-CANCER AGENT ME, V10, P753, DOI 10.2174/187152010794728639; Mathur D, 2016, SCI REP, V6; Morgan R, 2007, CANCER RES, V67, P5806, DOI 10.1158/0008-5472.CAN-06-4231; Morgan R, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-5215; Morgan R, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2106-7; Morgan R, 2014, BMC UROL, V14, DOI 10.1186/1471-2490-14-17; Morgan R, 2012, BREAST CANCER RES TR, V136, P389, DOI 10.1007/s10549-012-2259-2; Morgan R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-89; Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116; Mundargi RC, 2008, J CONTROL RELEASE, V125, P193, DOI 10.1016/j.jconrel.2007.09.013; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; Oliva R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27231-5; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pandha H, 2012, BJU INT, V110, pE287, DOI 10.1111/j.1464-410X.2012.11208.x; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Patel S, 2014, ACS NANO, V8, P8959, DOI 10.1021/nn501589f; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Penchala SC, 2015, NAT CHEM BIOL, V11, P793, DOI [10.1038/NCHEMBIO.1907, 10.1038/nchembio.1907]; Plowright L, 2009, BRIT J CANCER, V100, P470, DOI 10.1038/sj.bjc.6604857; Schellenberger V, 2009, NAT BIOTECHNOL, V27, P1186, DOI 10.1038/nbt.1588; Shears L, 2008, J UROLOGY, V180, P2196, DOI 10.1016/j.juro.2008.07.018; SHEINESS D, 1978, J VIROL, V28, P600, DOI 10.1128/JVI.28.2.600-610.1978; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411; Sorolla A, 2016, NANOSCALE, V8, P9343, DOI 10.1039/c5nr08331a; Sorolla A, 2019, NANOMED-NANOTECHNOL, V20, DOI 10.1016/j.nano.2019.04.006; Sorolla A, 2012, MOL ONCOL, V6, P530, DOI 10.1016/j.molonc.2012.06.006; Soucek L, 2004, CELL DEATH DIFFER, V11, P1038, DOI 10.1038/sj.cdd.4401443; Soucek L, 2002, CANCER RES, V62, P3507; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Spencer-Smith R, 2017, NAT CHEM BIOL, V13, P62, DOI [10.1038/NCHEMBIO.2231, 10.1038/nchembio.2231]; Tang R, 2013, ACS NANO, V7, P6667, DOI 10.1021/nn402753y; Trinh TB, 2016, ACS COMB SCI, V18, P75, DOI 10.1021/acscombsci.5b00164; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Verdine GL, 2007, CLIN CANCER RES, V13, P7264, DOI 10.1158/1078-0432.CCR-07-2184; Vogler M, 2009, BLOOD, V113, P4403, DOI 10.1182/blood-2008-08-173310; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wang E, 2019, ONCOGENE, V38, P140, DOI 10.1038/s41388-018-0421-y; Wang S, 2013, CLIN CANCER RES, V19, P128, DOI 10.1158/1078-0432.CCR-12-2654; Warren CFA, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1407-6; Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526; Wu XH, 2013, MEDCHEMCOMM, V4, P378, DOI 10.1039/c2md20329d	100	40	40	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1167	1184		10.1038/s41388-019-1056-3	http://dx.doi.org/10.1038/s41388-019-1056-3			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31636382	Green Published, hybrid			2022-12-17	WOS:000526714600001
J	Yang, W; Li, YY; Gao, RL; Xiu, ZH; Sun, T				Yang, Wei; Li, Yanyan; Gao, Ruoling; Xiu, Zenghe; Sun, Ting			MHC class I dysfunction of glioma stem cells escapes from CTL-mediated immune response via activation of Wnt/beta-catenin signaling pathway	ONCOGENE			English	Article							DENDRITIC CELLS; T-CELLS; CANCER; RECOGNITION; EXPRESSION; SENSITIVITY; INHIBITORS; MEMORY; P53	Glioma stem cells (GSCs) decrease T cells cognition and evade systemic immunosurveillance via downregulations or defects of major histocompatibility complex class I (MHC-I) molecule and antigen-processing machinery (APM) components. Improvement of tumor surface antigens of GSCs may be effective strategy to trigger an adaptive immune response and activate cytotoxic T cells (CTLs) to eliminate glioma. In this study, our data indicated that downregulations of MHC-I and APM components expressions were associated with Wnt pathway activation in GSCs. Histone deacetylases (HDAC) inhibition improved MHC-I and APM components expressions, which could be partly reverted by Wnt pathway activation. Blocking CTLs-mediated killing decreased the anti-tumor effect of tumor lysate vaccine. The enhancement of T cells immune response resulting from HDAC inhibition was dependent on CTLs cognition on tumor antigens presented by upregulated MHC-I molecule in GSCs. These data suggest that suppression of stemness pathway may be effective for GSCs-based immunotherapy against immune-escaped tumors.	[Yang, Wei; Gao, Ruoling; Xiu, Zenghe] Soochow Univ, Sch Radiat Med & Protect, State Key Lab Radiat Med & Protect, Suzhou 215123, Jiangsu, Peoples R China; [Yang, Wei; Gao, Ruoling; Xiu, Zenghe] Soochow Univ, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, Suzhou 215123, Jiangsu, Peoples R China; [Li, Yanyan; Sun, Ting] Soochow Univ, Neurosurg & Brain & Nerve Res Lab, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China	Yang, W (corresponding author), Soochow Univ, Sch Radiat Med & Protect, State Key Lab Radiat Med & Protect, Suzhou 215123, Jiangsu, Peoples R China.; Yang, W (corresponding author), Soochow Univ, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, Suzhou 215123, Jiangsu, Peoples R China.; Sun, T (corresponding author), Soochow Univ, Neurosurg & Brain & Nerve Res Lab, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China.	detachedy@aliyun.com; sunting1979st@aliyun.com			National Natural Science Foundation of China [81874080, 31870844, 31570851]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by the National Natural Science Foundation of China (81874080, 31870844, 31570851) and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Alimonti J, 2000, NAT BIOTECHNOL, V18, P515, DOI 10.1038/75373; Brown SD, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1556080; Cai L, 2019, CLIN CANCER RES, V25, P2644, DOI 10.1158/1078-0432.CCR-18-1401; Carugo A, 2019, CANCER CELL, V35, P204, DOI 10.1016/j.ccell.2019.01.006; Chang CC, 2015, J BIOL CHEM, V290, P26562, DOI 10.1074/jbc.M115.676130; Di Tomaso T, 2010, CLIN CANCER RES, V16, P800, DOI 10.1158/1078-0432.CCR-09-2730; Durgeau A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00014; Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360; Finocchiaro G, 2016, CANCER IMMUNOL IMMUN, V65, P101, DOI 10.1007/s00262-015-1754-9; GABATHULER R, 1994, J EXP MED, V180, P1415, DOI 10.1084/jem.180.4.1415; JEFFERIES WA, 1993, J IMMUNOL, V151, P2974; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lou YM, 2005, CANCER RES, V65, P7926, DOI 10.1158/0008-5472.CAN-04-3977; Lou YM, 2007, VACCINE, V25, P2331, DOI 10.1016/j.vaccine.2006.11.064; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Morgan MA, 2018, CANCER RES, V78, P6713, DOI 10.1158/0008-5472.CAN-18-2439; Morrison BJ, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4389-3; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Sadahiro H, 2014, BRAIN TUMOR PATHOL, V31, P77, DOI 10.1007/s10014-013-0149-x; Setiadi AF, 2007, MOL CELL BIOL, V27, P7886, DOI 10.1128/MCB.01547-07; Setiadi AF, 2008, CANCER RES, V68, P9601, DOI 10.1158/0008-5472.CAN-07-5270; Sun T, 2017, ONCOTARGET, V8, P74451, DOI 10.18632/oncotarget.20165; Szatmari T, 2006, CANCER SCI, V97, P546, DOI 10.1111/j.1349-7006.2006.00208.x; Topper MJ, 2017, CELL, V171, P1284, DOI 10.1016/j.cell.2017.10.022; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; Vik-Mo EO, 2013, CANCER IMMUNOL IMMUN, V62, P1499, DOI 10.1007/s00262-013-1453-3; Wang B, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3359; Woan KV, 2012, IMMUNOL CELL BIOL, V90, P55, DOI 10.1038/icb.2011.96; Wong TS, 2018, ONCOL LETT, V16, P2887, DOI 10.3892/ol.2018.9041; Wu A, 2010, NEURO-ONCOLOGY, V12, P1113, DOI 10.1093/neuonc/noq082; Yang W, 2018, CANCER LETT, V415, P164, DOI 10.1016/j.canlet.2017.12.005; Yang W, 2016, ONCOTARGET, V7, P41505, DOI 10.18632/oncotarget.9214; Yang W, 2014, EXP CELL RES, V326, P22, DOI 10.1016/j.yexcr.2014.05.022; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	34	40	43	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1098	1111		10.1038/s41388-019-1045-6	http://dx.doi.org/10.1038/s41388-019-1045-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31591480				2022-12-17	WOS:000511209700011
J	Dent, P; Booth, L; Roberts, JL; Liu, JC; Poklepovic, A; Lalani, AS; Tuveson, D; Martinez, J; Hancock, JF				Dent, Paul; Booth, Laurence; Roberts, Jane L.; Liu, Junchen; Poklepovic, Andrew; Lalani, Alshad S.; Tuveson, David; Martinez, Jennifer; Hancock, John F.			Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells	ONCOGENE			English	Article							PROTEIN-KINASE; PATHWAY; LIVER; RISK	Prior studies demonstrated that the irreversible ERBB1/2/4 inhibitor neratinib caused plasma membrane-associated mutant K-RAS to localize in intracellular vesicles, concomitant with its degradation. Herein, we discovered that neratinib interacted with the chemically distinct irreversible ERBB1/2/4 inhibitor afatinib to reduce expression of ERBB1, ERBB2, K-RAS and N-RAS; this was associated with greater-than-additive cell killing of pancreatic tumor cells. Knock down of Beclin1, ATG16L1, Rubicon or cathepsin B significantly lowered the ability of neratinib to reduce ERBB1 and K-RAS expression, and to cause tumor cell death. Knock down of ATM-AMPK suppressed vesicle formation and knock down of cathepsin B-AIF significantly reduced neratinib lethality. PKG phosphorylates K-RAS and HMG CoA reductase inhibitors reduce K-RAS farnesylation both of which remove K-RAS from the plasma membrane, abolishing its activity. Neratinib interacted with the PKG activator sildenafil and the HMG CoA reductase inhibitor atorvastatin to further reduce K-RAS expression, and to further enhance cell killing Neratinib is also a Ste20 kinase family inhibitor and in carcinoma cells, and hematopoietic cancer cells lacking ERBB1/2/4, it reduced K-RAS expression and the phosphorylation of MST1/3/4/Ezrin by similar to 30%. Neratinib increased LATS1 phosphorylation as well as that of YAP and TAZ also by similar to 30%, caused the majority of YAP to translocate into the cytosol and reduced YAP/TAZ protein levels. Neratinib lethality was enhanced by knock down of YAP. Neratinib, in a Rubicon-dependent fashion, reduced PAK1 phosphorylation and that of its substrate Merlin. Our data demonstrate that neratinib coordinately suppresses both mutant K-RAS and YAP function to kill pancreatic tumor cells.	[Dent, Paul; Booth, Laurence; Roberts, Jane L.] Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA; [Dent, Paul; Booth, Laurence; Roberts, Jane L.] Virginia Commonwealth Univ, Dept Mol Biol, Med Coll Virginia Campus, Richmond, VA 23298 USA; [Liu, Junchen; Hancock, John F.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Poklepovic, Andrew] Virginia Commonwealth Univ, Dept Med, Med Coll Virginia Campus, Richmond, VA 23298 USA; [Lalani, Alshad S.] Puma Biotechnol Inc, 1880 Wilshire Blvd, Los Angeles, CA 90024 USA; [Tuveson, David] Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA; [Martinez, Jennifer] NIEHS, Inflammat & Autoimmun Grp, POB 12233, Res Triangle Pk, NC 27709 USA	Virginia Commonwealth University; Virginia Commonwealth University; University of Texas System; University of Texas Health Science Center Houston; Virginia Commonwealth University; Cold Spring Harbor Laboratory; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Dent, P (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.; Dent, P (corresponding author), Virginia Commonwealth Univ, Dept Mol Biol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	paul.dent@vcuhealth.org	Martinez, Jennifer/C-3740-2019	Martinez, Jennifer/0000-0002-3060-2518; Hancock, John/0000-0003-0542-4710; Liu, Junchen/0000-0003-2765-9780	Massey Cancer Center; Universal Inc.; Chair in Signal Transduction Research; NATIONAL CANCER INSTITUTE [R01CA192613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES103286] Funding Source: NIH RePORTER	Massey Cancer Center; Universal Inc.; Chair in Signal Transduction Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Support for the present study was funded from philanthropic funding from Massey Cancer Center and the Universal Inc. Chair in Signal Transduction Research.	Abdel-Rahman O, 2019, CLIN TRANSL ONCOL, V21, P810, DOI 10.1007/s12094-018-1992-3; Archibugi L, 2019, DIGEST LIVER DIS, V51, P28, DOI 10.1016/j.dld.2018.09.007; Avruch J, 2012, SEMIN CELL DEV BIOL, V23, P770, DOI 10.1016/j.semcdb.2012.07.002; Bae SJ, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171469; Bitra A, 2017, SCI REP-UK, V7, DOI 10.1038/srep45020; Booth L, 2019, CANCER BIOL THER, V20, P700, DOI 10.1080/15384047.2018.1551747; Booth L, 2019, J CELL PHYSIOL, V234, P4874, DOI 10.1002/jcp.27276; Booth Laurence, 2018, Oncotarget, V9, P6062, DOI 10.18632/oncotarget.23681; Booth L, 2017, ONCOTARGET, V8, P90262, DOI 10.18632/oncotarget.21660; Booth L, 2017, ONCOTARGET, V8, P16367, DOI 10.18632/oncotarget.14829; Booth L, 2016, ONCOTARGET, V7, P19620, DOI 10.18632/oncotarget.7746; Burada F, 2016, PATHOL ONCOL RES, V22, P317, DOI 10.1007/s12253-015-0006-9; Chandra A, 2012, NAT CELL BIOL, V14, P148, DOI 10.1038/ncb2394; Chen M, 2018, J BIOL CHEM, V293, P14455, DOI 10.1074/jbc.RA118.003279; Chen S, 2018, AGING DIS, V9, P537, DOI 10.14336/AD.2017.0702; Cho KJ, 2016, MOL CELL BIOL, V36, P3086, DOI 10.1128/MCB.00365-16; Crawford JJ, 2018, EXPERT OPIN THER PAT, V28, P867, DOI 10.1080/13543776.2018.1549226; Davis MI, 2011, NAT BIOTECHNOL, V29, P1046, DOI 10.1038/nbt.1990; E JY, 2018, CURR MED CHEM, V25, P2595, DOI 10.2174/0929867324666170412145232; Hamada T, 2018, CLIN GASTROENTEROL H, V16, P1300, DOI 10.1016/j.cgh.2018.02.022; Hergovich A, 2016, GENES-BASEL, V7, DOI 10.3390/genes7050021; Hergovich A, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-32; Hsu CL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03340-7; Hsu PC, 2018, J CELL MOL MED, V22, P3073, DOI 10.1111/jcmm.13582; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kong DL, 2015, J DRUG TARGET, V23, P125, DOI 10.3109/1061186X.2014.983522; Kruspig B, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao2565; Lassen KG, 2014, P NATL ACAD SCI USA, V111, P7741, DOI 10.1073/pnas.1407001111; Lavoie S, 2019, ELIFE, V8, DOI 10.7554/eLife.39982; Li SX, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.38; Liu YT, 2019, ONCOL REP, V41, P1455, DOI 10.3892/or.2019.6956; Martinez J, 2018, CURR OPIN IMMUNOL, V55, P54, DOI 10.1016/j.coi.2018.09.011; Meng ZP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9357; Mohamed AD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33852-7; Moll HP, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao2301; Muniz-Feliciano L, 2017, AUTOPHAGY, V13, P2072, DOI 10.1080/15548627.2017.1380124; Nussinov R, 2016, SEMIN CELL DEV BIOL, V58, P79, DOI 10.1016/j.semcdb.2016.04.001; Park JY, 2018, MICROELECTRON ENG, V200, P1, DOI 10.1016/j.mee.2018.08.004; Patel SH, 2017, GASTROENTEROLOGY, V152, P533, DOI 10.1053/j.gastro.2016.10.047; Rawat SJ, 2015, TRENDS BIOCHEM SCI, V40, P149, DOI 10.1016/j.tibs.2015.01.001; Sadabad MS, 2015, GUT, V64, P1546, DOI 10.1136/gutjnl-2014-307289; Singh H, 2018, CLIN CANCER RES, V24, P3486, DOI 10.1158/1078-0432.CCR-17-3628; Stegert MR, 2005, MOL CELL BIOL, V25, P11019, DOI 10.1128/MCB.25.24.11019-11029.2005; Thompson BJ, 2015, J CELL BIOL, V210, P871, DOI 10.1083/jcb.201507005; Wang MH, 2012, INFLAMM BOWEL DIS, V18, P2277, DOI 10.1002/ibd.22931; Wang OH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152300; Waters AM, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aao3332; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049; Zhang Y, 2019, PANCREAS, V48, P142, DOI 10.1097/MPA.0000000000001226; Zheng YG, 2015, DEV CELL, V34, P642, DOI 10.1016/j.devcel.2015.08.014	50	40	43	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2019	38	30					5890	5904		10.1038/s41388-019-0849-8	http://dx.doi.org/10.1038/s41388-019-0849-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3FY	31253872	Green Accepted			2022-12-17	WOS:000482739300004
J	Chen, C; Bai, LP; Cao, FQ; Wang, SN; He, HW; Song, MC; Chen, HL; Liu, Y; Guo, J; Si, Q; Pan, YD; Zhu, RZ; Chuang, TH; Xiang, R; Luo, YP				Chen, Chong; Bai, Lipeng; Cao, Fengqi; Wang, Shengnan; He, Huiwen; Song, Mingcheng; Chen, Huilin; Liu, Yan; Guo, Jian; Si, Qin; Pan, Yundi; Zhu, Ruizhe; Chuang, Tsung-Hsien; Xiang, Rong; Luo, Yunping			Targeting LIN28B reprograms tumor glucose metabolism and acidic microenvironment to suppress cancer stemness and metastasis	ONCOGENE			English	Article							EXTRACELLULAR PH; MELANOMA-CELLS; MYC; HETEROGENEITY; MITOCHONDRIAL; EXPRESSION; GROWTH; REPRESSION	The altered metabolism and acidic microenvironment plays an important role in promoting tumor malignant characteristics. A small population of cancer stem cells (CSCs) were considered as a therapy target to reserve tumor relapse, resistance, and metastasis. However, the molecular mechanism that regulates CSCs metabolism remains poorly understood. In this study, we demonstrate a fundamental role of stemness gene LIN28B in maintaining CSCs glycolysis metabolism. Using LIN28B-expressing cancer cell lines, we found that the rate of extracellular acidification, glucose uptake, and lactate secretion are all suppressed by LIN28B knockdown in vitro and in vivo. Importantly, metabolic analyses reveal that CSCs have enhanced aerobic glycolysis metabolic characteristics and the glycolytic product lactate further promotes cancer associated stemness properties. LIN28B silencing suppresses MYC expression that further increases miR-34a-5p level. Furthermore, the glycolysis metabolism of human breast cancer cell line MDA-MB-231 is suppressed by either MYC siRNA or miR-34a-5p mimic Clinically, high MYC and low miR-34a-5p level are correlated with high LIN28B expression and poor prognosis in human breast cancer patients. Notably, blocking LIN28B/MYC/miR-34a-5p signaling pathway by LIN28B-specific inhibitor causes dramatic inhibition of tumor growth and metastasis in immunodeficient orthotopic mouse models of human breast cancer cell MDA-MB-231. Taken together, our findings offer a preclinical investigation of targeting LIN28B to suppress CSCs glycolysis metabolism and tumor progression that may improve the therapeutic benefit for cancer patients.	[Chen, Chong; Bai, Lipeng; Cao, Fengqi; Wang, Shengnan; He, Huiwen; Song, Mingcheng; Chen, Huilin; Liu, Yan; Guo, Jian; Si, Qin; Pan, Yundi; Zhu, Ruizhe; Luo, Yunping] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Immunol, Beijing 100005, Peoples R China; [Chen, Chong; Bai, Lipeng; Cao, Fengqi; Wang, Shengnan; He, Huiwen; Song, Mingcheng; Chen, Huilin; Liu, Yan; Guo, Jian; Si, Qin; Pan, Yundi; Zhu, Ruizhe; Luo, Yunping] Peking Union Med Coll, Sch Basic Med, Beijing 100005, Peoples R China; [Chen, Chong; Bai, Lipeng; Cao, Fengqi; Wang, Shengnan; He, Huiwen; Song, Mingcheng; Chen, Huilin; Liu, Yan; Guo, Jian; Si, Qin; Pan, Yundi; Zhu, Ruizhe; Luo, Yunping] Chinese Acad Med Sci, Inst Basic Med Sci, Collaborat Innovat Ctr Biotherapy, Beijing 100005, Peoples R China; [Bai, Lipeng] Jiangxi Canc Hosp, Dept Clin Lab, Nanchang 330029, Jiangxi, Peoples R China; [Chuang, Tsung-Hsien] Natl Hlth Res Inst, Immunol Res Ctr, Miaoli, Taiwan; [Xiang, Rong] Nankai Univ, Dept Immunol, Tianjin 300071, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; National Health Research Institutes - Taiwan; Nankai University	Luo, YP (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Dept Immunol, Beijing 100005, Peoples R China.; Luo, YP (corresponding author), Peking Union Med Coll, Sch Basic Med, Beijing 100005, Peoples R China.; Luo, YP (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Collaborat Innovat Ctr Biotherapy, Beijing 100005, Peoples R China.	ypluo@ibms.pumc.edu.cn	Chuang, Tsung-Hsien/F-9679-2010; Zhu, Ruizhe/HGF-1928-2022		973 Program of China [2013CB967202]; Fundamental Research Funds for the Central Universities [33320140173]; National Natural Science Foundation of China [91029734, 81071711, 81502562]	973 Program of China(National Basic Research Program of China); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This project was supported by grants from the 973 Program of China (2013CB967202, Yunping Luo); the National Natural Science Foundation of China (91029734 and 81071711, Yunping Luo), the National Natural Science Foundation of China (81502562, Chong Chen); and the Fundamental Research Funds for the Central Universities (33320140173, Chong Chen). We thank Zhigang Wang (Department of Bioengineering, Chinese Academy of Medical Sciences) for the bioinformatics analysis in this study and Cameron R. Mckay (Department of Immunology, Nankai University) for critically reading and polishing this manuscript.	ALBRIGHT JD, 1981, J MED CHEM, V24, P592, DOI 10.1021/jm00137a020; American Type Culture Collection, 2007, ATCC TECHN B, V8; Bu PC, 2013, CELL STEM CELL, V12, P602, DOI 10.1016/j.stem.2013.03.002; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen C, 2015, CANCER RES, V75, P1725, DOI 10.1158/0008-5472.CAN-14-2111; Ciavardelli D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.285; Corbet C, 2016, CELL METAB, V24, P311, DOI 10.1016/j.cmet.2016.07.003; Davidson SM, 2016, CELL METAB, V23, P517, DOI 10.1016/j.cmet.2016.01.007; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Faubert B, 2017, CELL, V171, P358, DOI 10.1016/j.cell.2017.09.019; Feng C, 2012, CELL CYCLE, V11, P2486, DOI 10.4161/cc.20893; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hensley CT, 2016, CELL, V164, P681, DOI 10.1016/j.cell.2015.12.034; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088893; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Ito K, 2012, NAT MED, V18, P1350, DOI 10.1038/nm.2882; Janiszewska M, 2012, GENE DEV, V26, P1926, DOI 10.1101/gad.188292.112; King CE, 2011, CANCER RES, V71, P4260, DOI 10.1158/0008-5472.CAN-10-4637; Kleppe M, 2014, NAT MED, V20, P342, DOI 10.1038/nm.3522; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee KM, 2017, CELL METAB, V26, P633, DOI 10.1016/j.cmet.2017.09.009; Levi BP, 2009, BLOOD, V113, P1670, DOI 10.1182/blood-2008-05-156752; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Ma XY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6212; Mayr F, 2013, INT J MOL SCI, V14, P16532, DOI 10.3390/ijms140816532; Moellering RE, 2008, CLIN EXP METASTAS, V25, P411, DOI 10.1007/s10585-008-9145-7; Nguyen LH, 2014, CANCER CELL, V26, P248, DOI 10.1016/j.ccr.2014.06.018; Park EY, 2014, CANCER RES, V74, P7573, DOI 10.1158/0008-5472.CAN-14-1140; Piskounova E, 2011, CELL, V147, P1066, DOI 10.1016/j.cell.2011.10.039; Qiu CH, 2010, NUCLEIC ACIDS RES, V38, P1240, DOI 10.1093/nar/gkp1071; Rofstad EK, 2006, CANCER RES, V66, P6699, DOI 10.1158/0008-5472.CAN-06-0983; Roos M, 2016, ACS CHEM BIOL, V11, P2773, DOI 10.1021/acschembio.6b00232; Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015; Shyh-Chang N, 2013, CELL STEM CELL, V12, P395, DOI 10.1016/j.stem.2013.03.005; Silva AS, 2009, CANCER RES, V69, P2677, DOI 10.1158/0008-5472.CAN-08-2394; Spinelli JB, 2017, SCIENCE, V358, P941, DOI 10.1126/science.aam9305; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Valton J, 2014, METHODS, V69, P151, DOI 10.1016/j.ymeth.2014.06.013; Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wu LW, 2015, ELIFE, V4, DOI 10.7554/eLife.09431; Xiao ZG, 2014, CANCER RES, V74, P6236, DOI 10.1158/0008-5472.CAN-14-0855; Ye XQ, 2011, INT J CANCER, V129, P820, DOI 10.1002/ijc.25944; Zhang J, 2016, CELL STEM CELL, V19, P66, DOI 10.1016/j.stem.2016.05.009; Zhang SY, 2014, CANCER RES, V74, P5311, DOI 10.1158/0008-5472.CAN-14-0529; Zhu H, 2010, NAT GENET, V42, P626, DOI 10.1038/ng.593	53	40	42	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4527	4539		10.1038/s41388-019-0735-4	http://dx.doi.org/10.1038/s41388-019-0735-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30742065				2022-12-17	WOS:000470240300007
J	Shimizu, M; Tanaka, N				Shimizu, Masahiro; Tanaka, Nobuyuki			IL-8-induced O-GlcNAc modification via GLUT3 and GFAT regulates cancer stem cell-like properties in colon and lung cancer cells	ONCOGENE			English	Article							GLUCOSE-METABOLISM; HIGH EXPRESSION; TUMORIGENESIS; INTERLEUKIN-8; GLCNACYLATION; TRANSCRIPTION; MECHANISMS; PATHWAY; SOX2; PHOSPHORYLATION	Interleukin-8 (IL-8) is a pro-inflammatory chemokine that is associated with induction of chemotaxis and degranulation of neutrophils. IL-8 is overexpressed in many tumors, including colon and lung cancer, and recent studies demonstrated essential roles for IL-8 in tumor progression within the tumor microenvironment. However, the molecular mechanism underlying the functions of IL-8 in tumor progression is unclear. In this study, we found that IL-8 is overexpressed in colon and lung cancer cells with cancer stem cell (CSC)-like characteristics and is required for CSC properties, including tumor-initiating abilities. These findings suggest that IL-8 plays an essential role in the development of CSCs. We also showed that IL-8 stimulation of colon and lung cancer cells-induced glucose uptake and expressions of glucose transporter 3 (GLUT3) and glucosamine fructose-6-phosphate aminotransferase (GFAT), a regulator of glucose flux to the hexosamine biosynthetic pathway, resulting in enhancement of protein O-GlcNAcylation. We demonstrated that these events are required for the generation and maintenance CSC-like characteristics of colon and lung cancer cells. Moreover, an O-GlcNAcylation inhibitor, OSMI1, reduced CSC number and tumor development in vivo. Together, these results reveal that IL-8-induced O-GlcNAcylation is required for generation and maintenance of CSCs of colon and lung cancer cells and suggests this regulatory pathway as a candidate therapeutic target of CSCs.	[Shimizu, Masahiro; Tanaka, Nobuyuki] Nippon Med Sch, Inst Adv Med Sci, Dept Mol Oncol, Kawasaki, Kanagawa, Japan	Nippon Medical School	Tanaka, N (corresponding author), Nippon Med Sch, Inst Adv Med Sci, Dept Mol Oncol, Kawasaki, Kanagawa, Japan.	nobuta@nms.ac.jp		Tanaka, Nobuyuki/0000-0002-6373-2220	Ministry of Education, Science, Sports, and Culture of Japan (MEXT/JSPS KAKEN) [17H04554]	Ministry of Education, Science, Sports, and Culture of Japan (MEXT/JSPS KAKEN)	We thank Y. Abe. Y. Nakajima, A. Tanimura, and I. Uehara for discussion, and Y. Asano, M. Kawagoe and T. Takatera for technical support. This work was supported by Grants-in-Aid for scientific research from the Ministry of Education, Science, Sports, and Culture of Japan (MEXT/JSPS KAKEN Grant Number 17H04554). We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Alfaro C, 2017, CANCER TREAT REV, V60, P24, DOI 10.1016/j.ctrv.2017.08.004; Allison DF, 2012, P NATL ACAD SCI USA, V109, P16888, DOI 10.1073/pnas.1208468109; Arwert EN, 2012, NAT REV CANCER, V12, P170, DOI 10.1038/nrc3217; Bareiss PM, 2013, CANCER RES, V73, P5544, DOI 10.1158/0008-5472.CAN-12-4177; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Caldwell SA, 2010, ONCOGENE, V29, P2831, DOI 10.1038/onc.2010.41; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chu CS, 2014, P NATL ACAD SCI USA, V111, P1355, DOI 10.1073/pnas.1323226111; Corbet C, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00958; David JM, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030022; Dong TY, 2016, TUMOR BIOL, V37, P8159, DOI 10.1007/s13277-015-4729-8; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Gloster TM, 2011, NAT CHEM BIOL, V7, P174, DOI [10.1038/nchembio.520, 10.1038/NCHEMBIO.520]; Guo HB, 2017, J BIOL CHEM, V292, P4123, DOI 10.1074/jbc.M116.763201; Ha H, 2017, THERANOSTICS, V7, P1543, DOI 10.7150/thno.15625; Hardiville S, 2014, CELL METAB, V20, P208, DOI 10.1016/j.cmet.2014.07.014; Hwang WL, 2011, GASTROENTEROLOGY, V141, P279, DOI 10.1053/j.gastro.2011.04.008; Jang H, 2012, CELL STEM CELL, V11, P62, DOI 10.1016/j.stem.2012.03.001; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; King JB, 2009, J BIOL CHEM, V284, P9059, DOI 10.1074/jbc.M809608200; Kuang R, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.88815; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li LL, 2017, ONCOTARGET, V8, P19205, DOI 10.18632/oncotarget.15164; Liu BQ, 2011, EXP MOL MED, V43, P487, DOI 10.3858/emm.2011.43.9.055; Liu Q, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0597-1; Liu Q, 2016, CYTOKINE GROWTH F R, V31, P61, DOI 10.1016/j.cytogfr.2016.08.002; Ma ZY, 2013, J BIOL CHEM, V288, P15121, DOI 10.1074/jbc.M113.470047; Mi WY, 2011, BBA-MOL BASIS DIS, V1812, P514, DOI 10.1016/j.bbadis.2011.01.009; Mo L, 2016, INT J CLIN EXP PATHO, V9, P9555; Nakajima W, 2016, ONCOTARGET, V7, P36353, DOI 10.18632/oncotarget.9217; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Oikari S, 2016, GLYCOBIOLOGY, V26, P710, DOI 10.1093/glycob/cww019; Ortiz-Meoz RF, 2015, ACS CHEM BIOL, V10, P1392, DOI 10.1021/acschembio.5b00004; Rodrigues-Ferreira C, 2012, J BIOENERG BIOMEMBR, V44, P39, DOI 10.1007/s10863-012-9413-8; Schafer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455; Shahzad Aamir, 2010, Int Arch Med, V3, P11, DOI 10.1186/1755-7682-3-11; Shi L, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-70; Singh JP, 2015, CANCER LETT, V356, P244, DOI 10.1016/j.canlet.2014.04.014; Singh S, 2011, MICROVASC RES, V82, P318, DOI 10.1016/j.mvr.2011.06.011; Slawson C, 2011, NAT REV CANCER, V11, P678, DOI 10.1038/nrc3114; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105; Visciano C, 2015, ONCOGENE, V34, P5175, DOI 10.1038/onc.2014.441; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wang JC, 2015, ONCOTARGET, V6, P42825, DOI 10.18632/oncotarget.5739; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Xiang R, 2011, BRIT J CANCER, V104, P1410, DOI 10.1038/bjc.2011.94; Yang XY, 2017, NAT REV MOL CELL BIO, V18, P452, DOI 10.1038/nrm.2017.22; Yuzwa SA, 2008, NAT CHEM BIOL, V4, P483, DOI 10.1038/nchembio.96; Zhang YB, 2015, ONCOL LETT, V9, P2809, DOI 10.3892/ol.2015.3075; Zheng JH, 2017, ONCOTARGET, V8, P98635, DOI 10.18632/oncotarget.21709; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137	54	40	43	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1520	1533		10.1038/s41388-018-0533-4	http://dx.doi.org/10.1038/s41388-018-0533-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30305725				2022-12-17	WOS:000459945800011
J	Bai, MZ; Yang, LL; Liao, H; Liang, XY; Xie, BY; Xiong, J; Tao, X; Chen, X; Cheng, YL; Chen, XJ; Feng, YJ; Zhang, ZB; Zheng, WX				Bai, Mingzhu; Yang, Linlin; Liao, Hong; Liang, Xiaoyan; Xie, Bingying; Xiong, Ji; Tao, Xiang; Chen, Xiong; Cheng, Yali; Chen, Xiaojun; Feng, Youji; Zhang, Zhenbo; Zheng, Wenxin			Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism	ONCOGENE			English	Article							PREDICT LONGER SURVIVAL; GLUTAMINE-METABOLISM; PROGESTIN RESISTANCE; OXIDATIVE STRESS; GASTRIC-CANCER; UP-REGULATION; GENE; P53; IDH1; PROMOTES	Chemoresistance is the major obstacle to cure endometrial cancer, whereas metformin has demonstrated sensitization to chemotherapy in endometrial cancer. A novel finding states that isocitrate dehydrogenase 1 (IDH1) involves in cancer chemoresistance. Recent studies have revealed that epigenetic modifications facilitate chemoresistance. However, whether IDH1 play a role in metformin-induced endometrial cancer chemosensitivity through epigenetic modification is incompletely understood. Immunohistochemistry and Elisa assays were used to evaluate the expression pattern of IDH1 in endometrial tissue and serum, respectively. Western blot was performed to determine changes in expression of key molecules in the IDH1-alpha-KG-TET1-Nrf2 signaling pathway after various treatments. Dot blot assays were used to assess global hydroxymethylation levels after metformin administration or plasmid transfection. Antioxidant response element (ARE) activity in the IDH1 promoter region was monitored by luciferase assay. Cancer cell sensitivity to chemotherapy was detected by SRB assay. We found that activation of the IDH1 signaling pathway in endometrial cancer tissue resulting from aberrant expression of IDH1 and its downstream mediators conferred chemoresistance. We found that this effect was abated by metformin treatment. Dot blot and HMeDIP assays revealed that metformin blocked IDH1-alpha-KG-TET1-mediated enhancement of Nrf2 hydroxymethylation levels, eliminating chemoresistance. Moreover, we observed that chemoresistance was enhanced via a regulatory loop in which Nrf2 activated IDH1-alpha-KG-TET1-Nrf2 signaling via binding to the ARE sites in the IDH1 promoter region. Our findings highlight a critical role of IDH1-alpha-KG-TET1-Nrf2 signaling in chemoresistance and suggest that rational combination therapy with metformin and chemotherapeutics has the potential to suppress chemoresistance. These authors contributed equally: Mingzhu Bai, Linlin Yang, Hong Liao.	[Bai, Mingzhu; Yang, Linlin; Xie, Bingying; Feng, Youji; Zhang, Zhenbo] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Obstet & Gynecol, Reprod Med Ctr, Shanghai 200080, Peoples R China; [Yang, Linlin; Liang, Xiaoyan; Chen, Xiong; Zhang, Zhenbo] Shanghai First Peoples Hosp, Baoshan Branch, Dept Obstet & Gynecol, Shanghai 201900, Peoples R China; [Liao, Hong] Tongji Univ, Sch Med, Shanghai Matern & Infant Hosp 1, Dept Cerv Dis, Shanghai 200040, Peoples R China; [Xiong, Ji] Fudan Univ, Huashan Hosp, Dept Pathol, Shanghai 200040, Peoples R China; [Tao, Xiang] Fudan Univ, Obstet & Gynecol Hosp, Dept Pathol, Shanghai 200011, Peoples R China; [Cheng, Yali; Chen, Xiaojun] Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol, Shanghai 200011, Peoples R China; [Zheng, Wenxin] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Zheng, Wenxin] Univ Texas Southwestern Med Ctr Dallas, Dept Obstet & Gynecol, Dallas, TX 75390 USA	Shanghai Jiao Tong University; Tongji University; Fudan University; Fudan University; Fudan University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Zhang, ZB (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Obstet & Gynecol, Reprod Med Ctr, Shanghai 200080, Peoples R China.; Zhang, ZB (corresponding author), Shanghai First Peoples Hosp, Baoshan Branch, Dept Obstet & Gynecol, Shanghai 201900, Peoples R China.; Zheng, WX (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.; Zheng, WX (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Obstet & Gynecol, Dallas, TX 75390 USA.	zhangzhenbozzb@aliyun.com; Wenxin.Zheng@UTSouthwestern.edu		Bai, Mingzhu/0000-0001-6210-4890; , Linlin/0000-0002-4260-1934	National Natural Science Foundation of China [81672562, 81370074]; Shanghai Municipal Public Health Bureau [XYQ2013119]; "Chenxing Project" from Shanghai Jiao Tong University; Mark and Jane Gibson distinguished professorship endowment fund	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Public Health Bureau; "Chenxing Project" from Shanghai Jiao Tong University; Mark and Jane Gibson distinguished professorship endowment fund	We thank Prof. Zhao Shimin (Fudan University, Shanghai, China) for providing the plasmids pcDNA3.0-TET1-flag and pRSF-Duet1-IDH1. We also thank Prof. Shi Yujiang (Harvard University, Cambridge, MA) for providing pPB-TET1 plasmid. This work was supported by grants from the National Natural Science Foundation of China (grant numbers 81672562, 81370074), the Shanghai Municipal Public Health Bureau (grant number XYQ2013119) and the "Chenxing Project" from Shanghai Jiao Tong University to ZZ. The work was also partially supported by the Mark and Jane Gibson distinguished professorship endowment fund to WZ. We thank Dr. Yinhua Yu (The University of Texas, M.D. Anderson Cancer Center) for helpful discussions.	Antony S, 2017, MOL CARCINOGEN, V56, P2643, DOI 10.1002/mc.22708; Bajpai R, 2016, ONCOGENE, V35, P3955, DOI 10.1038/onc.2015.464; Cairncross JG, 2014, J CLIN ONCOL, V32, P783, DOI 10.1200/JCO.2013.49.3726; Calvert AE, 2017, CELL REP, V19, P1858, DOI 10.1016/j.celrep.2017.05.014; Chaudhry P, 2009, ENDOCR-RELAT CANCER, V16, P363, DOI 10.1677/ERC-08-0266; Chen HF, 2016, BIOMEDICINE-TAIWAN, V6, P1, DOI 10.7603/s40681-016-0001-9; Chen J, 2016, ONCOGENE, V35, P2506, DOI 10.1038/onc.2015.316; Chen N, 2011, INT J CLIN EXP PATHO, V4, P85; Chin RM, 2014, NATURE, V510, P397, DOI 10.1038/nature13264; Cho JM, 2008, CANCER LETT, V260, P96, DOI 10.1016/j.canlet.2007.10.022; Cuyas E, 2017, CELL CYCLE, V16, P1022, DOI 10.1080/15384101.2017.1310353; Dong LL, 2012, J OBSTET GYNAECOL RE, V38, P1077, DOI 10.1111/j.1447-0756.2011.01839.x; El-Ashmawy NE, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317692235; Fadare O, 2013, MODERN PATHOL, V26, P1101, DOI 10.1038/modpathol.2013.35; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Gasparre G, 2011, CANCER RES, V71, P6220, DOI 10.1158/0008-5472.CAN-11-1042; Goodwin PJ, 2009, J CLIN ONCOL, V27, P3271, DOI 10.1200/JCO.2009.22.1630; Hanna RK, 2012, GYNECOL ONCOL, V125, P458, DOI 10.1016/j.ygyno.2012.01.009; Hernandez AV, 2015, EUR J CANCER, V51, P2747, DOI 10.1016/j.ejca.2015.08.031; Houillier C, 2010, NEUROLOGY, V75, P1560, DOI 10.1212/WNL.0b013e3181f96282; Hu X, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-43; Ikeda H, 2004, BIOCHEM J, V380, P515, DOI 10.1042/BJ20031948; Jia L, 2008, CLIN CANCER RES, V14, P2263, DOI 10.1158/1078-0432.CCR-07-4837; Jiang T, 2010, CANCER RES, V70, P5486, DOI 10.1158/0008-5472.CAN-10-0713; Kang KA, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.149; Kastl L, 2010, INT J ONCOL, V36, P1235, DOI 10.3892/ijo_00000607; Keenan MM, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005599; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Khor TO, 2008, PLANTA MED, V74, P1540, DOI 10.1055/s-0028-1088303; Kim YR, 2010, J PATHOL, V220, P446, DOI 10.1002/path.2653; Kwon OH, 2013, CANCER SCI, V104, P391, DOI 10.1111/cas.12076; Li B, 2016, ONCOTARGET, V7, P59458, DOI 10.18632/oncotarget.10694; Liu Y, 2017, ONCOTARGET, V8, P75206, DOI 10.18632/oncotarget.20663; Lu YX, 2017, CANCER RES, V77, P1709, DOI 10.1158/0008-5472.CAN-16-2773; Lv QY, 2017, J CANCER, V8, P894, DOI 10.7150/jca.17064; Ma QL, 2015, INT J CANCER, V137, P1058, DOI 10.1002/ijc.29395; MacLeod AK, 2009, CARCINOGENESIS, V30, P1571, DOI 10.1093/carcin/bgp176; Matassa DS, 2016, CELL DEATH DIFFER, V23, P1542, DOI 10.1038/cdd.2016.39; Meireles CG, 2017, GYNECOL ONCOL, V147, P167, DOI 10.1016/j.ygyno.2017.07.120; Do MT, 2014, FREE RADICAL BIO MED, V74, P21, DOI [10.1016/j.freeradbiomed.2014.06.010, 10.1016/j.freeradbiomed2014.06.010]; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Molenaar RJ, 2015, CANCER RES, V75, P4790, DOI 10.1158/0008-5472.CAN-14-3603; Montgomery RM, 2015, ARQ NEURO-PSIQUIAT, V73, P561, DOI 10.1590/0004-282X20150059; Nanduri J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119762; Ning CC, 2016, CANCER RES, V76, P1354, DOI 10.1158/0008-5472.CAN-15-1260; Ogura R, 2015, NEUROPATHOLOGY, V35, P324, DOI 10.1111/neup.12196; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Qi ST, 2012, CANCER SCI, V103, P269, DOI 10.1111/j.1349-7006.2011.02134.x; Rena G, 2017, DIABETOLOGIA, V60, P1577, DOI 10.1007/s00125-017-4342-z; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Saygin C, 2017, J EXP MED, V214, P2715, DOI 10.1084/jem.20170438; Shim GS, 2009, FREE RADICAL BIO MED, V47, P1619, DOI 10.1016/j.freeradbiomed.2009.09.006; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Sorosky JI, 2012, OBSTET GYNECOL, V120, P383, DOI 10.1097/AOG.0b013e3182605bf1; Stacy DR, 2006, HEAD NECK-J SCI SPEC, V28, P813, DOI 10.1002/hed.20430; Sun N, 2013, CLIN CANCER RES, V19, P5136, DOI 10.1158/1078-0432.CCR-13-0046; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tan BK, 2011, J CLIN ENDOCR METAB, V96, P808, DOI 10.1210/jc.2010-1803; Tanaka K, 2015, J CLIN INVEST, V125, P1591, DOI 10.1172/JCI78239; Tao X, 2013, ENDOCR-RELAT CANCER, V20, P415, DOI 10.1530/ERC-12-0005; Tsai YP, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0513-0; Valtorta S, 2017, ONCOTARGET, V8, P113090, DOI 10.18632/oncotarget.23028; Vatrinet R, 2017, CANCER METAB, V5, DOI 10.1186/s40170-017-0165-0; Wang JB, 2014, ASIAN PAC J CANCER P, V15, P427, DOI 10.7314/APJCP.2014.15.1.427; Wang LW, 2008, WORLD J GASTROENTERO, V14, P7192, DOI 10.3748/wjg.14.7192; Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095; Wang YY, 2016, ONCOTARGET, V7, P10363, DOI 10.18632/oncotarget.7004; Wei KR, 2013, CHINA CANC, V22, P605; Wei Kuang-rong, 2012, Zhonghua Fu Chan Ke Za Zhi, V47, P445; Xiang L, 2012, GYNECOL ONCOL, V127, P595, DOI 10.1016/j.ygyno.2012.08.028; Xu T, 2015, DIABETES CARE, V38, P1858, DOI 10.2337/dc15-0658; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang SH, 2016, ONCOTARGET, V7, P78787, DOI 10.18632/oncotarget.12859; Yates MS, 2007, MOL CANCER THER, V6, P154, DOI 10.1158/1535-7163.MCT-06-0516; Yu GZ, 2015, ONCOTARGET, V6, P12748, DOI 10.18632/oncotarget.3327; Zarei M, 2017, CANCER RES, V77, P4460, DOI 10.1158/0008-5472.CAN-17-0015; Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974; Zhang HH, 2016, CANCER CHEMOTH PHARM, V78, P13, DOI 10.1007/s00280-016-3037-3; Zhang P, 2010, MOL CANCER THER, V9, P336, DOI 10.1158/1535-7163.MCT-09-0589; Zhang YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081264; Zhang ZB, 2012, CANCER LETT, V319, P89, DOI 10.1016/j.canlet.2011.12.033; Zhang ZB, 2011, INT J GYNECOL CANCER, V21, P213, DOI 10.1097/IGC.0b013e318207dac7; Zhuo ZH, 2016, ARCH GYNECOL OBSTET, V294, P1055, DOI 10.1007/s00404-016-4148-0	85	40	42	2	33	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2018	37	42					5666	5681		10.1038/s41388-018-0360-7	http://dx.doi.org/10.1038/s41388-018-0360-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX3JJ	29921847				2022-12-17	WOS:000447619100006
J	Heukers, R; Fan, TS; de Wit, RH; van Senten, JR; De Groof, TWM; Bebelman, MP; Lagerweij, T; Vieira, J; de Munnik, SM; Smits-de Vries, L; van Offenbeek, J; Rahbar, A; van Hoorick, D; Soderberg-Naucler, C; Wurdinger, T; Leurs, R; Siderius, M; Vischer, HF; Smit, MJ				Heukers, Raimond; Fan, Tian Shu; de Wit, Raymond H.; van Senten, Jeffrey R.; De Groof, Timo W. M.; Bebelman, Maarten P.; Lagerweij, Tonny; Vieira, Joao; de Munnik, Sabrina M.; Smits-de Vries, Laura; van Offenbeek, Jody; Rahbar, Afsar; van Hoorick, Diane; Soderberg-Naucler, Cecilia; Wurdinger, Thomas; Leurs, Rob; Siderius, Marco; Vischer, Henry F.; Smit, Martine J.			The constitutive activity of the virally encoded chemokine receptor US28 accelerates glioblastoma growth	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTOR; HUMAN CYTOMEGALOVIRUS US28; IN-VIVO; NERVOUS-SYSTEM; NECK-CANCER; NANOBODIES; CELLS; PROMOTES; INFECTION; THERAPY	Glioblastoma (GBM) is the most aggressive and an incurable type of brain cancer. Human cytomegalovirus (HCMV) DNA and encoded proteins, including the chemokine receptor US28, have been detected in GBM tumors. US28 displays constitutive activity and is able to bind several human chemokines, leading to the activation of various proliferative and inflammatory signaling pathways. Here we show that HCMV, through the expression of US28, significantly enhanced the growth of 3D spheroids of U251- and neurospheres of primary glioblastoma cells. Moreover, US28 expression accelerated the growth of glioblastoma cells in an orthotopic intracranial GBM-model in mice. We developed highly potent and selective US28-targeting nanobodies, which bind to the extracellular domain of US28 and detect US28 in GBM tissue. The nanobodies inhibited chemokine binding and reduced the constitutive US28-mediated signaling with nanomolar potencies and significantly impaired HCMV/US28-mediated tumor growth in vitro and in vivo. This study emphasizes the oncomodulatory role of HCMV-encoded US28 and provides a potential therapeutic approach for HCMV-positive tumors using the nanobody technology.	[Heukers, Raimond; Fan, Tian Shu; de Wit, Raymond H.; van Senten, Jeffrey R.; De Groof, Timo W. M.; Bebelman, Maarten P.; de Munnik, Sabrina M.; Smits-de Vries, Laura; van Offenbeek, Jody; Leurs, Rob; Siderius, Marco; Vischer, Henry F.; Smit, Martine J.] Vrije Univ, Fac Sci, Div Med Chem, AIMMS, De Boelelaan 1108, NL-1081 HZ Amsterdam, Netherlands; [Lagerweij, Tonny; Wurdinger, Thomas] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Neurooncol Res Grp, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands; [Vieira, Joao; van Hoorick, Diane] Ablynx NV, Technol Pk 21, B-9052 Zwijnaarde, Belgium; [Rahbar, Afsar; Soderberg-Naucler, Cecilia] Karolinska Inst, Dept Med Solna, Ctr Mol Med, Expt Cardiovasc Res Unit, S-17177 Stockholm, Sweden; [Rahbar, Afsar; Soderberg-Naucler, Cecilia] Karolinska Inst, Ctr Mol Med, Dept Med & Neurol, S-17177 Stockholm, Sweden	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Karolinska Institutet; Karolinska Institutet	Smit, MJ (corresponding author), Vrije Univ, Fac Sci, Div Med Chem, AIMMS, De Boelelaan 1108, NL-1081 HZ Amsterdam, Netherlands.	mj.smit@vu.nl	Lagerweij, Tonny/AAY-7128-2020; Wurdinger, Thomas/AAA-5645-2022; Leurs, Rob/ABB-4299-2021; van Senten, Jeffrey/AAH-4348-2021; Leurs, Rob/AAC-8508-2022; Heukers, Raimond/H-9403-2013	Leurs, Rob/0000-0003-1354-2848; Rahbar, Afsar/0000-0003-1158-2512; De Groof, Timo/0000-0001-6918-2955; van Senten, Jeffrey Roy/0000-0002-1096-6891; Heukers, Raimond/0000-0003-4498-7751; Smit, Martine/0000-0003-2713-0238; Bebelman, Maarten/0000-0003-4007-5093	Netherlands Organization for Scientific Research (NWO: Vici grant) [016.140.657]; Dutch Technology Foundation (STW) [11462]	Netherlands Organization for Scientific Research (NWO: Vici grant)(Netherlands Organization for Scientific Research (NWO)); Dutch Technology Foundation (STW)(Technologiestichting STW)	This work was supported by the Netherlands Organization for Scientific Research (NWO: Vici grant 016.140.657) and the Dutch Technology Foundation (STW, 11462).	Baryawno N, 2011, J CLIN INVEST, V121, P4043, DOI 10.1172/JCI57147; Bhattacharjee B, 2012, J VIROL, V86, P6815, DOI 10.1128/JVI.00015-12; Bongers G, 2010, J CLIN INVEST, V120, P3969, DOI 10.1172/JCI42563; Bradley ME, 2015, MOL PHARMACOL, V87, P251, DOI 10.1124/mol.114.094821; Burg JS, 2015, SCIENCE, V347, P1113, DOI 10.1126/science.aaa5026; Burger M, 1999, J IMMUNOL, V163, P2017; Bush NAO, 2017, NEUROSURG REV, V40, P1, DOI 10.1007/s10143-016-0709-8; Caretti V, 2014, ACTA NEUROPATHOL, V127, P897, DOI 10.1007/s00401-014-1272-4; Casarosa P, 2003, J BIOL CHEM, V278, P5172, DOI 10.1074/jbc.M210033200; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Cobbs C, 2014, NEURO-ONCOLOGY, V16, P1435, DOI 10.1093/neuonc/nou295; Cobbs CS, 2002, CANCER RES, V62, P3347; De Tavernier E, 2016, J BIOL CHEM, V291, P15243, DOI 10.1074/jbc.M115.684241; de Wit RH, 2017, J PHARMACOL EXP THER, V363, P35, DOI 10.1124/jpet.117.242735; de Wit RH, 2016, ONCOTARGET, V7, P67966, DOI 10.18632/oncotarget.11817; Dziurzynski K, 2012, NEURO-ONCOLOGY, V14, P246, DOI 10.1093/neuonc/nor227; GAO JL, 1994, J BIOL CHEM, V269, P28539; Hadaczek P, 2013, CLIN CANCER RES, V19, P6473, DOI 10.1158/1078-0432.CCR-13-1121; Harkins L, 2002, LANCET, V360, P1557, DOI 10.1016/S0140-6736(02)11524-8; Humby MS, 2016, J VIROL, V90, P2959, DOI 10.1128/JVI.02507-15; Jahnichen S, 2010, P NATL ACAD SCI USA, V107, P20565, DOI 10.1073/pnas.1012865107; Jansen MHA, 2016, MOL CANCER THER, V15, P2166, DOI 10.1158/1535-7163.MCT-15-0558; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; Krishna BA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14321; Lamszus K, 2003, CLIN CANCER RES, V9, P1399; Langemeijer EV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048935; Li YM, 2010, TOXINS, V2, P2645, DOI 10.3390/toxins2112645; Lollinga WT, 2017, TRANSPLANTATION, V101, P531, DOI 10.1097/TP.0000000000001289; Manglik A, 2017, ANNU REV PHARMACOL, V57, P19, DOI 10.1146/annurev-pharmtox-010716-104710; Mason GM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003635; Maussang D, 2006, P NATL ACAD SCI USA, V103, P13068, DOI 10.1073/pnas.0604433103; Maussang D, 2013, J BIOL CHEM, V288, P29562, DOI 10.1074/jbc.M113.498436; Maussang D, 2009, CANCER RES, V69, P2861, DOI 10.1158/0008-5472.CAN-08-2487; Mitchell DA, 2015, NATURE, V519, P366, DOI 10.1038/nature14320; Mujic-Delic A, 2014, TRENDS PHARMACOL SCI, V35, P247, DOI 10.1016/j.tips.2014.03.003; Noriega VM, 2014, VIRUSES-BASEL, V6, P1202, DOI 10.3390/v6031202; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI [10.1093/neuonc/nov189, 10.1093/neuonc/noaa200, 10.1093/neuonc/noab200]; Peng CW, 2016, MOL CLIN ONCOL, V4, P154, DOI 10.3892/mco.2015.692; Rahbar Afsar, 2012, Herpesviridae, V3, P3, DOI 10.1186/2042-4280-3-3; Sinclair JH, 2013, VIRUSES-BASEL, V5, P2803, DOI 10.3390/v5112803; Slinger E, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001180; SoderbergNaucler C, 1997, CELL, V91, P119, DOI 10.1016/S0092-8674(01)80014-3; Soderberg-Naucler C, 2013, NEW ENGL J MED, V369, P985, DOI 10.1056/NEJMc1302145; Soroceanu L, 2011, CANCER RES, V71, P6643, DOI 10.1158/0008-5472.CAN-11-0744; Stanton RJ, 2010, J CLIN INVEST, V120, P3191, DOI 10.1172/JCI42955; STEENSGAARD J, 1977, IMMUNOLOGY, V32, P445; Stragliotto G, 2013, INT J CANCER, V133, P1204, DOI 10.1002/ijc.28111; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Taha MS, 2016, BRIT J NEUROSURG, V30, P307, DOI 10.3109/02688697.2015.1119241; Tijink BM, 2008, MOL CANCER THER, V7, P2288, DOI 10.1158/1535-7163.MCT-07-2384; van Driel PBAA, 2016, J CONTROL RELEASE, V229, P93, DOI 10.1016/j.jconrel.2016.03.014; Vischer HF, 2014, NAT REV DRUG DISCOV, V13, P123, DOI 10.1038/nrd4189; Wurdinger T, 2008, NAT METHODS, V5, P171, DOI 10.1038/NMETH.1177	55	40	41	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4110	4121		10.1038/s41388-018-0255-7	http://dx.doi.org/10.1038/s41388-018-0255-7			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29706656	Green Published, hybrid			2022-12-17	WOS:000439847000005
J	Wang, S; Zou, Z; Luo, X; Mi, Y; Chang, H; Xing, D				Wang, S.; Zou, Z.; Luo, X.; Mi, Y.; Chang, H.; Xing, D.			LRH1 enhances cell resistance to chemotherapy by transcriptionally activating MDC1 expression and attenuating DNA damage in human breast cancer	ONCOGENE			English	Article							LIVER RECEPTOR HOMOLOG-1; DEPENDENT DIMERIZATION; MOLECULAR-BASIS; HISTONE H2AX; TUMOR CELLS; CDKN1A GENE; PHOSPHORYLATION; RECOGNITION; ASSOCIATION; SENSITIVITY	Liver receptor homolog-1 (LRH1) has been shown to promote tumor proliferation and development. However, the functions of LRH1 in mediating cancer cells chemoresistance are still not clear. Here, we found LRH1 levels were significantly elevated in primary breast cancer tissues in patients who developed early recurrence. Similarly, adriamycin (ADR)-resistant breast cancer cell lines also exerted high LRH1 expression. Indeed, overexpression of LRH1 attenuated cytotoxicity of chemotherapeutic drugs ADR and cisplatin (DDP) in breast cancer cells in vitro and in nude mice tumor model. Comet and BrdU assays showed overexpression of LRH1 blocked breast cancer cells DNA damage by chemotherapeutic drug, whereas depletion of LRH1 enhanced DNA damage. Remarkably, knockdown of LRH1 decreased the levels and foci of DNA damage marker gamma H2AX induced by ADR and DDP. Furthermore, plasmid end joining assay indicated that knockdown of LRH1 significantly decreased non-homologous end joining (NHEJ)-mediated double-strand break (DSB) repair efficiencies. Afterwards, we provided evidences that LRH1 promoted MDC1 transcription by directly activating MDC1 promoter and therefore increased gamma H2AX levels. Importantly, a LRH1-binding site mapped between -1812 and -1804 bp of the proximal MDC1 promoter was identified. Moreover, LRH1 and MDC1 mRNA levels were positively correlated in recurrent breast cancer samples. These results implied LRH1 enhanced breast cancer cell chemoresistance by upregulating MDC1 and attenuating DNA damage. Additionally, we elucidated the coactivator NCOA3 acted synergistically with LRH1 to promote MDC1 expression and chemoresistance. Altogether, LRH1-MDC1 signaling might be considered as a novel molecular target for designing novel therapeutic regimen in chemotherapy resistance breast cancer.	[Wang, S.; Zou, Z.; Chang, H.; Xing, D.] South China Normal Univ, Coll Biophoton, MOE Key Lab Laser Life Sci, Guangzhou, Guangdong, Peoples R China; [Wang, S.; Zou, Z.; Chang, H.; Xing, D.] South China Normal Univ, Coll Biophoton, Inst Laser Life Sci, Guangzhou, Guangdong, Peoples R China; [Luo, X.] Zhengzhou Univ, Affiliated Luoyang Cent Hosp, Dept Oncol, Luoyang, Peoples R China; [Mi, Y.] Xiamen Univ, Affiliated Hosp 1, Dept Thorac Surg, Xiamen, Peoples R China	South China Normal University; South China Normal University; Zhengzhou University; Xiamen University	Zou, Z; Xing, D (corresponding author), South China Normal Univ, Coll Biophoton, MOE Key Lab Laser Life Sci, Guangzhou, Guangdong, Peoples R China.; Zou, Z; Xing, D (corresponding author), South China Normal Univ, Coll Biophoton, Inst Laser Life Sci, Guangzhou, Guangdong, Peoples R China.	zouzhengzhi@scnu.edu.cn; xingda@scnu.edu.cn			National Natural Science Foundation of China [81772803, 81630046, 81402187]; Natural Science Foundation of Guangdong Province [2014A030310505]; Foundation for Distinguished Young Talents in Higher Education of Guangdong [C1085229]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Foundation for Distinguished Young Talents in Higher Education of Guangdong	We are grateful to Dr. Simak Ali (Imperial College London, London) for providing pCI-HA3-LRH1 plasmid, to Dr. Michal Goldberg (Hebrew University of Jerusalem, Jerusalem) for providing HA-MDC1 plasmid, to Dr. Vera Gorbunova for providing the pEGFP-Pem1-Ad2 plasmid, to Prof. B-A Li (Xiamen University) for providing the MDA-MB-231/ADR and T47D/ADR cells. This study was supported by grants from the National Natural Science Foundation of China (No. 81772803, 81630046, 81402187); Ph.D. Start-Up Fund of Natural Science Foundation of Guangdong Province (No. 2014A030310505 to ZZ); Foundation for Distinguished Young Talents in Higher Education of Guangdong (No. C1085229 to ZZ).	Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Annicotte JS, 2005, ONCOGENE, V24, P8167, DOI 10.1038/sj.onc.1208950; Ao X, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.367; Ashwell S, 2008, CLIN CANCER RES, V14, P4032, DOI 10.1158/1078-0432.CCR-07-5138; Audet-Walsh E, 2016, CELL REP, V14, P920, DOI 10.1016/j.celrep.2015.12.086; Baldock RA, 2015, CELL REP, V13, P2081, DOI 10.1016/j.celrep.2015.10.074; Benod C, 2011, P NATL ACAD SCI USA, V108, P16927, DOI 10.1073/pnas.1112047108; Bianco S, 2015, ONCOGENE, V34, P4509, DOI 10.1038/onc.2014.382; Bianco S, 2014, CANCER RES, V74, P2015, DOI 10.1158/0008-5472.CAN-13-2351; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342; Burgess RC, 2014, CELL REP, V9, P1703, DOI 10.1016/j.celrep.2014.10.060; Burwinkel B, 2005, CLIN CANCER RES, V11, P2169, DOI 10.1158/1078-0432.CCR-04-1621; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Chand AL, 2010, ENDOCR-RELAT CANCER, V17, P965, DOI 10.1677/ERC-10-0179; Coster G, 2007, J BIOL CHEM, V282, P32053, DOI 10.1074/jbc.M705890200; Coster G, 2010, NUCLEUS-PHILA, V1, P166, DOI 10.4161/nucl.1.2.11176; Cree IA, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-2999-1; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Fayard E, 2004, TRENDS CELL BIOL, V14, P250, DOI 10.1016/j.tcb.2004.03.008; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Gong C, 2015, J BIOL CHEM, V290, P14811, DOI 10.1074/jbc.M115.652628; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Gruosso T, 2016, EMBO MOL MED, V8, P527, DOI 10.15252/emmm.201505891; Gu PL, 2005, MOL CELL BIOL, V25, P3492, DOI 10.1128/MCB.25.9.3492-3505.2005; Heng JCD, 2010, CELL STEM CELL, V6, P167, DOI 10.1016/j.stem.2009.12.009; Holmstrom SR, 2011, GENE DEV, V25, P1674, DOI 10.1101/gad.16860911; Jungmichel S, 2012, NUCLEIC ACIDS RES, V40, P3913, DOI 10.1093/nar/gkr1300; Klammer H, 2010, CANCER RES, V70, P8498, DOI 10.1158/0008-5472.CAN-10-1181; Kramer HB, 2016, NUCLEIC ACIDS RES, V44, P582, DOI 10.1093/nar/gkv948; Lai CF, 2013, NUCLEIC ACIDS RES, V41, P10228, DOI 10.1093/nar/gkt827; Lazarus KA, 2012, J STEROID BIOCHEM, V130, P138, DOI 10.1016/j.jsbmb.2011.12.017; Liu JP, 2012, NUCLEIC ACIDS RES, V40, P3898, DOI 10.1093/nar/gkr1296; Liu XL, 2015, TUMOR BIOL, V36, P4261, DOI 10.1007/s13277-015-3063-5; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Luo XY, 2016, ONCOTARGET, V7, P26480, DOI 10.18632/oncotarget.8419; Petersen GM, 2010, NAT GENET, V42, P224, DOI 10.1038/ng.522; Schoonjans K, 2005, P NATL ACAD SCI USA, V102, P2058, DOI 10.1073/pnas.0409756102; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Sidler D, 2011, ONCOGENE, V30, P2411, DOI 10.1038/onc.2010.629; Sirianni R, 2002, J ENDOCRINOL, V174, pR13, DOI 10.1677/joe.0.174R013; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Thiruchelvam PTR, 2011, BREAST CANCER RES TR, V127, P385, DOI 10.1007/s10549-010-0994-9; Zhang Z, 2016, J EARTHQ ENG, V25, P1, DOI DOI 10.1089/ARS.2016.6634; Zhang ZZ, 2016, FASEB J, V30, P466, DOI 10.1096/fj.15-274258; Zhu J., 2016, ADV ENERGY MATER, V7, P1; Zou ZZ, 2016, BIOCHEM BIOPH RES CO, V478, P227, DOI 10.1016/j.bbrc.2016.07.063; Zou ZZ, 2012, AUTOPHAGY, V8, P1798, DOI 10.4161/auto.22110	51	40	41	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3243	3259		10.1038/s41388-018-0193-4	http://dx.doi.org/10.1038/s41388-018-0193-4			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29545602				2022-12-17	WOS:000435526600005
J	Chen, SH; Gong, X; Zhang, Y; Van Horn, RD; Yin, T; Huber, L; Burke, TF; Manro, J; Iversen, PW; Wu, W; Bhagwat, SV; Beckmann, RP; Tiu, RV; Buchanan, SG; Peng, SB				Chen, S-H; Gong, X.; Zhang, Y.; Van Horn, R. D.; Yin, T.; Huber, L.; Burke, T. F.; Manro, J.; Iversen, P. W.; Wu, W.; Bhagwat, S. V.; Beckmann, R. P.; Tiu, R. V.; Buchanan, S. G.; Peng, S-B			RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1	ONCOGENE			English	Article							CELL-CYCLE; ANTITUMOR ACTIVITIES; METASTATIC MELANOMA; ONCOGENIC MUTATIONS; MAPK PATHWAY; B-RAF; VEMURAFENIB; RESISTANCE; REACTIVATION; BRAF(V600E)	KRAS, NRAS and BRAF mutations are among the most important oncogenic drivers in many major cancer types, such as melanoma, lung, colorectal and pancreatic cancer. There is currently no effective therapy for the treatment of RAS mutant cancers. LY3009120, a pan-RAF and RAF dimer inhibitor advanced to clinical study has been shown to inhibit both RAS and BRAF mutant cell proliferation in vitro and xenograft tumor growth in vivo. Abemaciclib, a CDK4/6-selective inhibitor, is currently in phase III studies for ER-positive breast cancer and KRAS mutant lung cancer. In this study, we found that combinatory treatment with LY3009120 and abemaciclib synergistically inhibited proliferation of tumor cells in vitro and led to tumor growth regression in xenograft models with a KRAS, NRAS or BRAF mutation at the doses of two drugs that were well tolerated in combination. Further in vitro screen in 328 tumor cell lines revealed that tumor cells with KRAS, NRAS or BRAF mutation, or cyclin D activation are more sensitive, whereas tumor cells with PTEN, PIK3CA, PIK3R1 or retinoblastoma (Rb) mutation are more resistant to this combination treatment. Molecular analysis revealed that abemaciclib alone inhibited Rb phosphorylation partially and caused an increase of cyclin D1. The combinatory treatment cooperatively demonstrated more complete inhibition of Rb phosphorylation, and LY3009120 suppressed the cyclin D1 upregulation mediated by abemaciclib. These results were further verified by CDK4/6 siRNA knockdown. Importantly, the more complete phospho-Rb inhibition and cyclin D1 suppression by LY3009120 and abemaciclib combination led to more significant cell cycle G(0)/G(1) arrest of tumor cells. These preclinical findings suggest that combined inhibition of RAF and D-cyclin-dependent kinases might provide an effective approach to treat patients with tumors harboring mutations in RAS or RAF genes.	[Chen, S-H; Gong, X.; Zhang, Y.; Van Horn, R. D.; Yin, T.; Huber, L.; Burke, T. F.; Wu, W.; Bhagwat, S. V.; Beckmann, R. P.; Buchanan, S. G.; Peng, S-B] Eli Lilly & Co, Oncol Res, Indianapolis, IN 46285 USA; [Manro, J.; Iversen, P. W.] Eli Lilly & Co, Stat, Indianapolis, IN 46285 USA; [Tiu, R. V.] Eli Lilly & Co, Early Phase Oncol & Oncol Business Unit, Indianapolis, IN 46285 USA	Eli Lilly; Eli Lilly; Eli Lilly	Peng, SB (corresponding author), Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA.	peng_sheng-bin@lilly.com			Eli Lilly and Company	Eli Lilly and Company(Eli Lilly)	All authors are employees of Eli Lilly and Company at the time that the work was done. All research described herein was funded by Eli Lilly and Company.	Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen SH, 2016, CANCER DISCOV, V6, P300, DOI 10.1158/2159-8290.CD-15-0896; Chudnovsky Y, 2005, NAT GENET, V37, P745, DOI 10.1038/ng1586; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Dong JL, 2003, CANCER RES, V63, P3883; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gelbert LM, 2014, INVEST NEW DRUG, V32, P825, DOI 10.1007/s10637-014-0120-7; Goel VK, 2009, ONCOGENE, V28, P2289, DOI 10.1038/onc.2009.95; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Henry JR, 2015, J MED CHEM, V58, P4165, DOI 10.1021/acs.jmedchem.5b00067; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Johnpulle RAN, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912-015-0485-6; King AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067583; Klein EA, 2008, J CELL SCI, V121, P3853, DOI 10.1242/jcs.039131; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Lito P, 2012, CANCER CELL, V22, P668, DOI 10.1016/j.ccr.2012.10.009; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Monahan KB, 2010, ONCOGENE, V29, P5809, DOI 10.1038/onc.2010.314; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Patnaik A, 2016, CANCER DISCOV, V6, P740, DOI 10.1158/2159-8290.CD-16-0095; Peng SB, 2015, CANCER CELL, V28, P384, DOI 10.1016/j.ccell.2015.08.002; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rader J, 2013, CLIN CANCER RES, V19, P6173, DOI 10.1158/1078-0432.CCR-13-1675; Sanchez-Laorden B, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004815; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Yadav V, 2015, PHARMACOL THERAPEUT, V149, P139, DOI 10.1016/j.pharmthera.2014.12.003; Yadav V, 2014, MOL CANCER THER, V13, P2253, DOI 10.1158/1535-7163.MCT-14-0257; Yadav V, 2012, J BIOL CHEM, V287, P28087, DOI 10.1074/jbc.M112.377218; Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646	48	40	43	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					821	832		10.1038/onc.2017.384	http://dx.doi.org/10.1038/onc.2017.384			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059158				2022-12-17	WOS:000424628100013
J	West, AC; Tang, K; Tye, H; Yu, L; Deng, N; Najdovska, M; Lin, SJ; Balic, JJ; Okochi-Takada, E; McGuirk, P; Keogh, B; McCormack, W; Bhathal, PS; Reilly, M; Oshima, M; Ushijima, T; Tan, P; Jenkins, BJ				West, A. C.; Tang, K.; Tye, H.; Yu, L.; Deng, N.; Najdovska, M.; Lin, S. J.; Balic, J. J.; Okochi-Takada, E.; McGuirk, P.; Keogh, B.; McCormack, W.; Bhathal, P. S.; Reilly, M.; Oshima, M.; Ushijima, T.; Tan, P.; Jenkins, B. J.			Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancer	ONCOGENE			English	Article							TOLL-LIKE RECEPTORS; HELICOBACTER-PYLORI; INNATE IMMUNITY; TUMORIGENESIS; EXPRESSION; PROGRESSION; CARCINOMA; PROTEIN; TLR2; TOLL-LIKE-RECEPTOR-2	Toll-like receptors (TLRs) are key regulators of innate immune responses, and their dysregulation is observed in numerous inflammation-associated malignancies, including gastric cancer (GC). However, the identity of specific TLRs and their molecular targets which promote the pathogenesis of human GC is ill-defined. Here, we sought to determine the clinical utility of TLR2 in human GC. TLR2 mRNA and protein expression levels were elevated in >50% of GC patient tumors across multiple ethnicities. TLR2 was also widely expressed among human GC cell lines, and DNA microarray-based expression profiling demonstrated that the TLR2-induced growth responsiveness of human GC cells corresponded with the up-regulation of six anti-apoptotic (BCL2A1, BCL2, BIRC3, CFLAR, IER3, TNFAIP3) and down-regulation of two tumor suppressor (PDCD4, TP53INP1) genes. The TLR2-mediated regulation of these anti-apoptotic and tumor suppressor genes was also supported by their increased and reduced expression, respectively, in two independent genetic GC mouse models (gp130(F/F) and Gan) characterized by high tumor TLR2 expression. Notably, enrichment of this TLR2-regulated gene signature also positively correlated with augmented TLR2 expression in human GC tumors, and served as an indicator of poor patient survival. Furthermore, treatment of gp130(F/F) and cell line-derived xenograft (MKN1) GC mouse models with a humanized anti-TLR2 antibody suppressed gastric tumor growth, which was coincident with alterations to the TLR2-driven gene signature. Collectively, our study demonstrates that in the majority of GC patients, elevated TLR2 expression is associated with a growth-potentiating gene signature which predicts poor patient outcomes, thus supporting TLR2 as a promising therapeutic target in GC.	[West, A. C.; Tang, K.; Tye, H.; Yu, L.; Najdovska, M.; Balic, J. J.; Jenkins, B. J.] Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, 27-31 Wright St, Clayton, Vic 3168, Australia; [West, A. C.; Tang, K.; Yu, L.; Balic, J. J.; Bhathal, P. S.; Jenkins, B. J.] Monash Univ, Fac Med Nursing & Hlth Sci, Dept Mol Translat Sci, Clayton, Vic, Australia; [Deng, N.; Lin, S. J.; Tan, P.] Genome Inst Singapore, Singapore, Singapore; [Okochi-Takada, E.; Ushijima, T.] Natl Canc Ctr, Div Epigen, Tokyo, Japan; [McGuirk, P.; Keogh, B.; McCormack, W.; Reilly, M.] Opsona Therapeut Ltd, Dublin, Ireland; [Oshima, M.] Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa, Japan; [Tan, P.] Duke NUS Med Sch, Canc & Stem Cell Biol, Singapore, Singapore; [Tan, P.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore	Hudson Institute of Medical Research; Monash University; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National Cancer Center - Japan; Kanazawa University; National University of Singapore; National University of Singapore	Jenkins, BJ (corresponding author), Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, 27-31 Wright St, Clayton, Vic 3168, Australia.	Brendan.Jenkins@hudson.org.au	Oshima, Masanobu/F-9958-2014; Ushijima, Toshikazu/AAP-5742-2021	Oshima, Masanobu/0000-0002-3304-0004; Ushijima, Toshikazu/0000-0003-3405-7817; Deng, Niantao/0000-0001-9717-2236; Jenkins, Brendan/0000-0002-7552-4656; Balic, Jesse/0000-0002-9681-6834	National Health and Medical Research Council (NHMRC) of Australia; Cancer Council Victoria; Victorian Government of Australia; NHMRC; Monash Graduate Scholarship; Monash International Postgraduate Research Scholarship	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Victorian Government of Australia; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Monash Graduate Scholarship(Monash University); Monash International Postgraduate Research Scholarship(Monash University)	This work was supported by research grants awarded by the National Health and Medical Research Council (NHMRC) of Australia and Cancer Council Victoria, as well as the Operational Infrastructure Support Program by the Victorian Government of Australia. AW is supported by an NHMRC Early Career Fellowship, KT is supported by Monash Graduate and Monash International Postgraduate Research Scholarships and BJJ is supported by an NHMRC Senior Medical Research Fellowship.	[Anonymous], 2012, TUMORI, V98, P663; Asprodites N, 2008, FASEB J, V22, P3628, DOI 10.1096/fj.08-108274; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Castano-Rodriguez N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060327; Chen SY, 2015, LEUKEMIA RES, V39, P976, DOI 10.1016/j.leukres.2015.06.004; Choi HJ, 2010, BIOCHEM BIOPH RES CO, V400, P396, DOI 10.1016/j.bbrc.2010.08.084; Conti L, 2013, FASEB J, V27, P4731, DOI 10.1096/fj.13-230201; Correa Pelayo, 2011, US Gastroenterol Hepatol Rev, V7, P59; Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; de Oliveira JG, 2012, WORLD J GASTROENTERO, V18, P1235, DOI 10.3748/wjg.v18.i11.1235; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; Fox JG, 2007, J CLIN INVEST, V117, P60, DOI 10.1172/JCI30111; Itadani H, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-615; Jiang PH, 2006, WORLD J GASTROENTERO, V12, P691, DOI 10.3748/wjg.v12.i5.691; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kennedy CL, 2014, ONCOGENE, V33, P2540, DOI 10.1038/onc.2013.205; Kennedy CL, 2011, J PATHOL, V225, P255, DOI 10.1002/path.2933; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Li ZS, 2011, CANCER LETT, V313, P192, DOI 10.1016/j.canlet.2011.09.007; Lordick F, 2014, CANCER TREAT REV, V40, P692, DOI 10.1016/j.ctrv.2014.03.002; Ma G, 2013, TUMOR BIOL, V34, P3879, DOI 10.1007/s13277-013-0975-9; Maeda Y, 2016, CANCER PREV RES, V9, P253, DOI 10.1158/1940-6207.CAPR-15-0315; Mandell L, 2004, INFECT IMMUN, V72, P6446, DOI 10.1128/IAI.72.11.6446-6454.2004; Meng GX, 2004, J CLIN INVEST, V113, P1473, DOI 10.1172/JCI200420762; Niccolai E, 2015, WORLD J GASTROENTERO, V21, P5778, DOI 10.3748/wjg.v21.i19.5778; Nihon-Yanagi Y, 2012, CANCER IMMUNOL IMMUN, V61, P71, DOI 10.1007/s00262-011-1085-4; Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676; Oshima H, 2006, GASTROENTEROLOGY, V131, P1086, DOI 10.1053/j.gastro.2006.07.014; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Pimentel-Nunes P, 2013, HELICOBACTER, V18, P22, DOI 10.1111/hel.12008; Pimentel-Nunes P, 2011, PATHOL ONCOL RES, V17, P677, DOI 10.1007/s12253-011-9368-9; Piva R, 2006, J CLIN INVEST, V116, P3171, DOI 10.1172/JCI29401; Reilly M, 2013, CLIN PHARMACOL THER, V94, P593, DOI 10.1038/clpt.2013.150; Savva A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00387; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Seya T, 2015, CANCER SCI, V106, P1659, DOI 10.1111/cas.12824; Shi WN, 2014, TUMOR BIOL, V35, P9627, DOI 10.1007/s13277-014-2268-3; Tahara T, 2007, CANCER SCI, V98, P1790, DOI 10.1111/j.1349-7006.2007.00590.x; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; Uno K, 2007, AM J PHYSIOL-GASTR L, V293, pG1004, DOI 10.1152/ajpgi.00096.2007; Wei Q, 2012, IUBMB LIFE, V64, P697, DOI 10.1002/iub.1051; Wu MX, 2003, APOPTOSIS, V8, P11, DOI 10.1023/A:1021688600370; Wu YH, 2013, GUT, V62, P1100, DOI 10.1136/gutjnl-2011-301373; Yang HZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006520; Yang H, 2014, ANN CLIN LAB SCI, V44, P158; Zeng HM, 2011, CANCER EPIDEM BIOMAR, V20, P2594, DOI 10.1158/1055-9965.EPI-11-0702; Zhen Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.376; Zhou XD, 2004, CLIN SCI, V106, P397, DOI 10.1042/CS20030238	50	40	45	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5134	5144		10.1038/onc.2017.121	http://dx.doi.org/10.1038/onc.2017.121			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481875				2022-12-17	WOS:000409371100005
J	Dovmark, TH; Saccomano, M; Hulikova, A; Alves, F; Swietach, P				Dovmark, T. H.; Saccomano, M.; Hulikova, A.; Alves, F.; Swietach, P.			Connexin-43 channels are a pathway for discharging lactate from glycolytic pancreatic ductal adenocarcinoma cells	ONCOGENE			English	Article							GAP-JUNCTION; TUMOR-CELLS; CANCER; HYPOXIA; ACID; PH; EXPRESSION; GROWTH; MCT4; COMMUNICATION	Glycolytic cancer cells produce large quantities of lactate that must be removed to sustain metabolism in the absence of oxidative phosphorylation. The only venting mechanism described to do this at an adequate rate is H--(+) coupled lactate efflux on monocarboxylate transporters (MCTs). Outward MCT activity is, however, thermodynamically inhibited by extracellular acidity, a hallmark of solid tumours. This inhibition would feedback unfavourably on metabolism and growth, raising the possibility that other venting mechanisms become important in under-perfused tumours. We investigated connexin-assembled gap junctions as an alternative route for discharging lactate from pancreatic ductal adenocarcinoma (PDAC) cells. Diffusive coupling (calcein transmission) in vitro was strong between Colo357 cells, weaker yet hypoxia-inducible between BxPC3 cells, and very low between MiaPaCa2 cells. Coupling correlated with levels of connexin-43 (Cx43), a protein previously linked to late-stage disease. Evoked lactate dynamics, imaged in Colo357 spheroids using cytoplasmic pH as a read-out, indicated that lactate anions permeate gap junctions faster than highly-buffered H+ ions. At steady-state, junctional transmission of lactate (a chemical base) from the spheroid core had an alkalinizing effect on the rim, producing therein a milieu conducive for growth. Metabolite assays demonstrated that Cx43 knockdown increased cytoplasmic lactate retention in Colo357 spheroids (diameter similar to 150 mu m). MiaPaCa2 cells, which are Cx43 negative in monolayer culture, showed markedly increased Cx43 immunoreactivity at areas of invasion in orthotopic xenograft mouse models. These tissue areas were associated with chronic extracellular acidosis (as indicated by the marker LAMP2 near/at the plasmalemma), which can explain the advantage of junctional transmission over MCT in vivo. We propose that Cx43 channels are important conduits for dissipating lactate anions from glycolytic PDAC cells. Furthermore, lactate entry into the better-perfused recipient cells has a favourable alkalinizing effect and supplies substrate for oxidative phosphorylation. Cx43 is thus a novel target for influencing metabolite handling in junctionally-coupled tumours.	[Dovmark, T. H.; Hulikova, A.; Swietach, P.] Univ Oxford, Dept Physiol Anat & Genet, Pk Rd, Oxford OX1 3PT, England; [Saccomano, M.; Alves, F.] Max Planck Inst Expt Med, Gottingen, Germany; [Alves, F.] Univ Med Ctr Goettingen, Inst Diagnost & Intervent Radiol, Gottingen, Germany; [Alves, F.] Univ Med Ctr Goettingen, Dept Haematol & Med Oncol, Gottingen, Germany	University of Oxford; Max Planck Society; University of Gottingen; University of Gottingen	Swietach, P (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Pk Rd, Oxford OX1 3PT, England.	pawel.swietach@dpag.ox.ac.uk	Swietach, Pawel/AAK-4169-2020	Swietach, Pawel/0000-0002-9945-9473	European Commission through the IONTRAC Marie Curie Initial Training Network (FP7-PEOPLE-ITN Grant) [289648]; Worldwide Cancer Research [2012/0027]; Royal Society; Worldwide Cancer Research [12-0027] Funding Source: researchfish	European Commission through the IONTRAC Marie Curie Initial Training Network (FP7-PEOPLE-ITN Grant); Worldwide Cancer Research; Royal Society(Royal Society of London); Worldwide Cancer Research	We thank Barbel Heidrich, Sabine Wolfgramm and Bettina Jeep for excellent technical assistance. We thank Vicky Ball for performing measurements on the ABX Pentra 400 system. This study is supported by the European Commission through the IONTRAC Marie Curie Initial Training Network (FP7-PEOPLE-2011-ITN Grant 289648), Royal Society and Worldwide Cancer Research (2012/0027).	Damaghi M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9752; Deer EL, 2010, PANCREAS, V39, P425, DOI 10.1097/MPA.0b013e3181c15963; ELSABBAN ME, 1991, J CELL BIOL, V115, P1375, DOI 10.1083/jcb.115.5.1375; Elzarrad MK, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-20; Faller BA, 2009, BIOL-TARGETS THER, V3, P419; Gadaleta E, 2011, NUCLEIC ACIDS RES, V39, P7900, DOI 10.1093/nar/gkr533; Gatenby RA, 2006, CANCER RES, V66, P5216, DOI 10.1158/0008-5472.CAN-05-4193; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gillies RJ, 2002, J MAGN RESON IMAGING, V16, P430, DOI 10.1002/jmri.10181; Grillo-Hill BK, 2015, ELIFE, V4, DOI 10.7554/eLife.03270; Guillaumond F, 2013, P NATL ACAD SCI USA, V110, P3919, DOI 10.1073/pnas.1219555110; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Hulikova A, 2016, P NATL ACAD SCI USA, V113, pE5344, DOI 10.1073/pnas.1610954113; Hulikova A, 2014, J BIOL CHEM, V289, P25418, DOI 10.1074/jbc.M114.547844; Hulikova A, 2011, J BIOL CHEM, V286, P13815, DOI 10.1074/jbc.M111.219899; Ito A, 2000, J CLIN INVEST, V105, P1189, DOI 10.1172/JCI8257; Kennedy KM, 2010, FUTURE ONCOL, V6, P127, DOI 10.2217/FON.09.145; Koong AC, 2000, INT J RADIAT ONCOL, V48, P919, DOI 10.1016/S0360-3016(00)00803-8; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108; Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22-11-04302.2002; LOEWENSTEIN WR, 1966, NATURE, V209, P1248, DOI 10.1038/2091248a0; Maupin KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013002; McLachlan E, 2006, CANCER RES, V66, P9886, DOI 10.1158/0008-5472.CAN-05-4302; Mesnil M, 2002, BIOL CELL, V94, P493, DOI 10.1016/S0248-4900(02)00025-4; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Moll W, 2008, J APPL PHYSIOL, V105, P365, DOI 10.1152/japplphysiol.zdg-8016-pcpcomm.2008; MORGAN RT, 1980, INT J CANCER, V25, P591, DOI 10.1002/ijc.2910250507; Naus CC, 2010, NAT REV CANCER, V10, P435, DOI 10.1038/nrc2841; Ojugo ASE, 1999, NMR BIOMED, V12, P495, DOI 10.1002/(SICI)1099-1492(199912)12:8<495::AID-NBM594>3.0.CO;2-K; Oliveira-Cunha Melissa, 2011, Cancers (Basel), V3, P1513, DOI 10.3390/cancers3021513; Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579; Putney LK, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-46; Richards M, 2016, CARDIOVASC RES, V110, P395, DOI 10.1093/cvr/cvw080; Saccomano M, 2016, INT J CANCER, V139, P2277, DOI 10.1002/ijc.30277; San Martin A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057712; Schilling F, 2013, NMR BIOMED, V26, P557, DOI 10.1002/nbm.2892; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Swietach P, 2007, CIRC RES, V100, P1045, DOI 10.1161/01.RES.0000264071.11619.47; Swietach P, 2009, J BIOL CHEM, V284, P20299, DOI 10.1074/jbc.M109.006478; TANNOCK IF, 1989, CANCER RES, V49, P4373; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; VAUPEL P, 1990, ADV EXP MED BIOL, V277, P895; Whitaker-Menezes D, 2011, CELL CYCLE, V10, P1772, DOI 10.4161/cc.10.11.15659; Zhang A, 2015, ONCOTARGET, V6, P11640, DOI 10.18632/oncotarget.3449	45	40	42	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4538	4550		10.1038/onc.2017.71	http://dx.doi.org/10.1038/onc.2017.71			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368405	Green Accepted, Green Published, Green Submitted, hybrid			2022-12-17	WOS:000407246200002
J	Ruan, D; He, J; Li, CF; Lee, HJ; Liu, J; Lin, HK; Chan, CH				Ruan, D.; He, J.; Li, C-F; Lee, H-J; Liu, J.; Lin, H-K; Chan, C-H			Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist	ONCOGENE			English	Article							TRANSCRIPTION FACTOR TWIST; MESENCHYMAL TRANSITION; DOCETAXEL RESISTANCE; IMPROVES SURVIVAL; EXPRESSION; P27; UBIQUITINATION; INHIBITOR; CARCINOMA; TUMORIGENESIS	Castration-resistant prostate cancer (CRPC) remains a major clinical challenge because of the lack of effective targeted therapy for its treatment. The mechanism underlying how CRPC gains resistance toward hormone depletion and other forms of chemotherapy is poorly understood. Research on understanding the factors that drive these processes is desperately needed to generate new therapies to cure the disease. Here, we discovered a fundamental role of S-phase protein kinase 2 (Skp2) in the formation and progression of CRPC. In transgenic adenocarcinoma mouse prostate model, Skp2 depletion leads to a profound repression of prostate tumor growth and distal metastasis and substantially prolonged overall survival. We revealed that Skp2 regulates CRPC through Twist-mediated oncogenic functions including epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) acquisitions. Mechanistically, Skp2 interacted with Twist and promoted the non-degradative ubiquitination of Twist. Consequently, Skp2 stabilized Twist protein expression by preventing proteasomal degradation of Twist by beta-TrCP. We found that Twist overexpression augments CSC self-renewal and population and that Skp2 inhibition reverts Twist's effects on CSC regulation. Furthermore, genetically depleting or pharmacologically inactivating Skp2 synergistically re-sensitized CRPC cells toward chemotherapies such as paclitaxel or doxorubicin. Together, this study uncovering Skp2-mediated Twist stabilization and oncogenic functions in CRPC offers new knowledge on how CRPC progresses and acquires chemoresistance during tumor progression. It provides proof of principle that Skp2 targeting is a promising approach to combat metastatic CRPC by targeting Twist and CSCs.	[Ruan, D.; He, J.; Lee, H-J; Lin, H-K; Chan, C-H] SUNY Stony Brook, Dept Pharmacol Sci, 101 Nicolls Rd,BST8-121, Stony Brook, NY 11794 USA; [Ruan, D.; Lee, H-J; Chan, C-H] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY USA; [Li, C-F] Chi Mei Foundat Med Ctr, Dept Pathol, Tainan, Taiwan; [Li, C-F] Natl Inst Canc Res, Natl Hlth Res Inst, Tainan, Taiwan; [Li, C-F] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Liu, J.] SUNY Stony Brook, Dept Pathol, Stony Brook, NY USA; [Lin, H-K; Chan, C-H] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Lin, H-K] Wake Forest Univ, Dept Canc Biol, Sch Med, Winston Salem, NC USA; [Lin, H-K] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; National Health Research Institutes - Taiwan; Southern Taiwan University of Science & Technology; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Texas System; UTMD Anderson Cancer Center; Wake Forest University; China Medical University Taiwan	Lin, HK; Chan, CH (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, 101 Nicolls Rd,BST8-121, Stony Brook, NY 11794 USA.	hulin@wakehealth.edu; chia-hsin.chan@stonybrook.edu	Chan, Chia-Hsin/AAT-7782-2020	Chan, Chia-Hsin/0000-0001-8506-7500; Li, Chien-Feng/0000-0002-9527-7576	Stony Brook School of Medicine and Cancer Center Fund; NYS grant [DOH01-C31845GG-3450000]; Feldstein Medical Foundation Award; NIH [5 K22 CA181412, R01 CA182424, R01CA193813]; MOHW [MOHW103-TDU-M-221-123017]; NHRI [CA-106-PP-36]; NATIONAL CANCER INSTITUTE [R01CA193813, R01CA182424, K22CA181412] Funding Source: NIH RePORTER	Stony Brook School of Medicine and Cancer Center Fund; NYS grant; Feldstein Medical Foundation Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MOHW(Ministry of Health & Welfare (MOHW), Republic of Korea); NHRI(National Health Research Institutes - Taiwan); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We sincerely appreciate Dr Keiichi I Nakayama for providing Skp2<SUP>+/-</SUP> mice. This work was supported by the Stony Brook School of Medicine and Cancer Center Fund, the Feldstein Medical Foundation Award, a NYS grant (DOH01-C31845GG-3450000) and a NIH grant (5 K22 CA181412) to C-HC, and a MOHW grant (MOHW103-TDU-M-221-123017) and a NHRI grant (CA-106-PP-36) to C-FL, as well as NIH grants (R01 CA182424 and R01CA193813) to H-KL.	Ardiani A, 2013, CLIN CANCER RES, V19, P6205, DOI 10.1158/1078-0432.CCR-13-1026; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chan CH, 2014, CELL CYCLE, V13, P679, DOI 10.4161/cc.27853; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065; Chan CH, 2011, J MOL MED, V89, P857, DOI 10.1007/s00109-011-0766-y; Chan CH, 2010, THESCIENTIFICWORLDJO, V10, P1001, DOI 10.1100/tsw.2010.89; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904; Chen ZJJ, 2012, IMMUNOL REV, V246, P95, DOI 10.1111/j.1600-065X.2012.01108.x; Chiaverotti T, 2008, AM J PATHOL, V172, P236, DOI 10.2353/ajpath.2008.070602; Cookson MS, 2013, J UROLOGY, V190, P429, DOI 10.1016/j.juro.2013.05.005; Dave N, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.168625; Dayyani F, 2011, JNCI-J NATL CANCER I, V103, P1665, DOI 10.1093/jnci/djr362; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Gingrich JR, 1997, CANCER RES, V57, P4687; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Haider M, 2016, CLIN EXP METASTAS, V33, P239, DOI 10.1007/s10585-015-9773-7; Inuzuka H, 2012, CELL, V150, P179, DOI 10.1016/j.cell.2012.05.038; Johnson Sara, 2013, Bio Protoc, V3; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kitagawa M, 2008, MOL CELL, V29, P217, DOI 10.1016/j.molcel.2007.11.036; Kwilas AR, 2015, ONCOTARGET, V6, P28194, DOI 10.18632/oncotarget.4442; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Lee HJ, 2016, MOL CELL, V63, P1021, DOI 10.1016/j.molcel.2016.08.009; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lu W, 2017, ONCOGENE, V36, P1364, DOI 10.1038/onc.2016.300; Marchiani S, 2010, INT J ANDROL, V33, P784, DOI 10.1111/j.1365-2605.2009.01030.x; Marin-Aguilera M, 2014, MOL CANCER THER, V13, P1270, DOI 10.1158/1535-7163.MCT-13-0775; Nguyen PL, 2011, UROL ONCOL-SEMIN ORI, V29, P302, DOI 10.1016/j.urolonc.2009.03.022; Oh M, 2016, ANGEW CHEM INT EDIT, V55, P602, DOI 10.1002/anie.201508716; Plymate SR, 2015, CANCER CELL, V27, P158, DOI 10.1016/j.ccell.2015.01.008; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Puhr M, 2012, AM J PATHOL, V181, P2188, DOI 10.1016/j.ajpath.2012.08.011; Rescigno P, 2012, CURR DRUG TARGETS, V13, P1676, DOI 10.2174/138945012803529956; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Shim EH, 2003, CANCER RES, V63, P1583; Shiota M, 2010, ONCOGENE, V29, P237, DOI 10.1038/onc.2009.322; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Wang HB, 2008, J CELL SCI, V121, P2578, DOI 10.1242/jcs.030742; Wang W, 2008, AM J SURG PATHOL, V32, P65, DOI 10.1097/PAS.0b013e318058a96b; Wang ZW, 2012, BBA-REV CANCER, V1825, P11, DOI 10.1016/j.bbcan.2011.09.002; Wei SO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047298; Wu L, 2012, CHEM BIOL, V19, P1515, DOI 10.1016/j.chembiol.2012.09.015; Yang G, 2002, CLIN CANCER RES, V8, P3419; Yang YG, 2016, ONCOL REP, V36, P559, DOI 10.3892/or.2016.4809; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Yun EJ, 2016, CLIN CANCER RES, V22, P670, DOI 10.1158/1078-0432.CCR-15-0190; Zhang D, 2016, NAT COMMUN, V7, P1; Zhao H, 2016, ONCOGENE, P1; Zhao HL, 2013, CANCER CELL, V24, P645, DOI 10.1016/j.ccr.2013.09.021; Zhong JT, 2013, DISCOV MED, V15, P7	56	40	45	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4299	4310		10.1038/onc.2017.64	http://dx.doi.org/10.1038/onc.2017.64			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28346424	Green Accepted			2022-12-17	WOS:000406360600007
J	Crosas-Molist, E; Bertran, E; Rodriguez-Hernandez, I; Herraiz, C; Cantelli, G; Fabra, A; Sanz-Moreno, V; Fabregat, I				Crosas-Molist, E.; Bertran, E.; Rodriguez-Hernandez, I.; Herraiz, C.; Cantelli, G.; Fabra, A.; Sanz-Moreno, V.; Fabregat, I.			The NADPH oxidase NOX4 represses epithelial to amoeboid transition and efficient tumour dissemination	ONCOGENE			English	Article							TGF-BETA; HEPATOCELLULAR-CARCINOMA; MESENCHYMAL TRANSITION; CELL INVASION; MIGRATION; ACTIVATION; EXPRESSION; METASTASIS; PLASTICITY; ADHESION	Epithelial to mesenchymal transition is a common event during tumour dissemination. However, direct epithelial to amoeboid transition has not been characterized to date. Here we provide evidence that cells from hepatocellular carcinoma (HCC), a highly metastatic cancer, undergo epithelial to amoeboid transition in physiological environments, such as organoids or three-dimensional complex matrices. Furthermore, the NADPH oxidase NOX4 inhibits this transition and therefore suppresses efficient amoeboid bleb-based invasion. Moreover, NOX4 expression is associated with E-cadherin levels and inversely correlated with invasive features. NOX4 is necessary to maintain parenchymal structures, increase cell-cell and cell-to-matrix adhesion, and impair actomyosin contractility and amoeboid invasion. Importantly, NOX4 gene deletions are frequent in HCC patients, correlating with higher tumour grade. Contrary to that observed in mesenchymal cell types, here NOX4 suppresses Rho and Cdc42 GTPase expression and downstream actomyosin contractility. In HCC patients, NOX4 expression inversely correlates with RhoC and Cdc42 levels. Moreover, low expression of NOX4 combined with high expression of either RhoC or Cdc42 is associated with worse prognosis. Therefore, loss of NOX4 increases actomyosin levels and favours an epithelial to amoeboid transition contributing to tumour aggressiveness.	[Crosas-Molist, E.; Bertran, E.; Fabra, A.; Fabregat, I.] Bellvitge Biomed Res Inst IDIBELL, Mol Oncol, Gran Via Hosp 199, Barcelona 08908, Spain; [Crosas-Molist, E.; Rodriguez-Hernandez, I.; Herraiz, C.; Cantelli, G.; Sanz-Moreno, V.] Kings Coll London, Tumour Plast Lab, Randall Div Cell & Mol Biophys, New Hunts House,Guys Campus, London SE1 1UL, England; [Fabregat, I.] Univ Barcelona, Dept Ciencies Fisiol 2, Barcelona, Spain; [Herraiz, C.] Univ Murcia, Sch Med, Dept Biochem & Mol Biol, Murcia, Spain; [Herraiz, C.] IMIB Arrixaca, Murcia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of London; King's College London; University of Barcelona; University of Murcia; Hospital Clinico Universitario Virgen de la Arrixaca	Fabregat, I (corresponding author), Bellvitge Biomed Res Inst IDIBELL, Mol Oncol, Gran Via Hosp 199, Barcelona 08908, Spain.; Sanz-Moreno, V (corresponding author), Kings Coll London, Tumour Plast Lab, Randall Div Cell & Mol Biophys, New Hunts House,Guys Campus, London SE1 1UL, England.	victoria.sanz_moreno@kcl.ac.uk; ifabregat@idibell.cat	Serrano, Cecilia Herraiz/H-2550-2015; Bertran, Esther/GZK-5458-2022; Fabregat, Isabel/H-7038-2015	Serrano, Cecilia Herraiz/0000-0001-6912-0738; Fabregat, Isabel/0000-0003-0136-8440; Sanz-Moreno, Victoria/0000-0002-5096-9456; Bertran Rodriguez, Esther/0000-0001-9356-7409; Cantelli, Gaia/0000-0003-2650-6280; Rodriguez-Hernandez, Irene/0000-0002-6487-452X	MINECO (FEDER funds), Spain [BFU2012-35538, SAF 2015-64149-R, PIE13/00022, ISCIII-RTICC RD12-0036-0029]; MINECO (European Regional Development Fund), Spain [BFU2012-35538, SAF 2015-64149-R, PIE13/00022, ISCIII-RTICC RD12-0036-0029]; AGAUR, Generalitat de Catalunya [2014SGR0334]; CRUK [c33043/A12065]; Royal Society [RG110591]; Fundacion Alfonso Martin Escudero; FEBS fellowship; MRC [C97993H]; European Cooperation in Science and Technology (COST Action) [BM1203/EU-ROS]; Cancer Research UK [24478, 12065] Funding Source: researchfish	MINECO (FEDER funds), Spain; MINECO (European Regional Development Fund), Spain; AGAUR, Generalitat de Catalunya(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)Generalitat de Catalunya); CRUK(Cancer Research UK); Royal Society(Royal Society of London); Fundacion Alfonso Martin Escudero; FEBS fellowship; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Cooperation in Science and Technology (COST Action)(European Cooperation in Science and Technology (COST)); Cancer Research UK(Cancer Research UK)	We acknowledge Pahini Pandya for critical reading of the manuscript. Grants to IF from MINECO (co-funded by FEDER funds and the European Regional Development Fund: a way to build Europe), Spain (Grant numbers: BFU2012-35538, SAF 2015-64149-R, PIE13/00022 and ISCIII-RTICC RD12-0036-0029) and the AGAUR, Generalitat de Catalunya (2014SGR0334). Grants to VS-M and EC-M from CRUK (c33043/A12065) and to VS-M from Royal Society (RG110591). EC-M. was founded by the FPU program (MECD, Spain), IR-H was supported by Fundacion Alfonso Martin Escudero, CH by a FEBS fellowship and GC from MRC (C97993H). IF group is also supported by the European Cooperation in Science and Technology (COST Action BM1203/EU-ROS).	Ahn J, 2012, J CELL SCI, V125, P1814, DOI 10.1242/jcs.101444; Nieto MA, 2012, SEMIN CANCER BIOL, V22, P361, DOI 10.1016/j.semcancer.2012.05.003; Aoyama T, 2012, HEPATOLOGY, V56, P2316, DOI 10.1002/hep.25938; Bergert M, 2015, NAT CELL BIOL, V17, P524, DOI 10.1038/ncb3134; Bertran E, 2013, HEPATOLOGY, V58, P2032, DOI 10.1002/hep.26597; Blaser H, 2006, DEV CELL, V11, P613, DOI 10.1016/j.devcel.2006.09.023; Boudreau HE, 2014, BRIT J CANCER, V110, P2569, DOI 10.1038/bjc.2014.165; Brandes RP, 2014, FREE RADICAL BIO MED, V76, P208, DOI 10.1016/j.freeradbiomed.2014.07.046; Brown DI, 2009, FREE RADICAL BIO MED, V47, P1239, DOI 10.1016/j.freeradbiomed.2009.07.023; Bruix J, 2016, GASTROENTEROLOGY, V150, P835, DOI 10.1053/j.gastro.2015.12.041; Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627; Calvo F, 2011, NAT CELL BIOL, V13, P819, DOI 10.1038/ncb2271; Cantelli G, 2015, CURR BIOL, V25, P2899, DOI 10.1016/j.cub.2015.09.054; Carmona-Cuenca I, 2008, J HEPATOL, V49, P965, DOI 10.1016/j.jhep.2008.07.021; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Crosas-Molist E, 2015, REDOX BIOL, V6, P106, DOI 10.1016/j.redox.2015.07.005; Crosas-Molist E, 2014, FREE RADICAL BIO MED, V69, P338, DOI 10.1016/j.freeradbiomed.2014.01.040; de Rezende FF, 2012, FREE RADICAL BIO MED, V53, P521, DOI 10.1016/j.freeradbiomed.2012.05.032; Del Duca D, 2004, J NEURO-ONCOL, V67, P295, DOI 10.1023/B:NEON.0000024220.07063.70; Fernandez I, 2015, ARTERIOSCL THROM VAS, V35, P1198, DOI 10.1161/ATVBAHA.114.305185; Fernando J, 2015, INT J CANCER, V136, pE161, DOI 10.1002/ijc.29097; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Gadea G, 2008, CURR BIOL, V18, P1456, DOI 10.1016/j.cub.2008.08.053; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Gregg JL, 2014, CANCER RES, V74, P3501, DOI 10.1158/0008-5472.CAN-13-2979; Ha SY, 2016, GUT LIVER, V10, P826, DOI 10.5009/gnl15543; Herraiz C, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv289; Ito M, 2004, MOL CELL BIOCHEM, V259, P197, DOI 10.1023/B:MCBI.0000021373.14288.00; Jacobelli J, 2010, NAT IMMUNOL, V11, P953, DOI 10.1038/ni.1936; Kim HJ, 2015, ONCOTARGET, V6, P16287, DOI 10.18632/oncotarget.3843; Lai KKY, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002147; Lambeth JD, 2007, FREE RADICAL BIO MED, V43, P319, DOI 10.1016/j.freeradbiomed.2007.03.028; Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740; Li J, 2015, ONCOTARGET, V6, P1031, DOI 10.18632/oncotarget.2671; Liu YJ, 2015, CELL, V160, P659, DOI 10.1016/j.cell.2015.01.007; Llovet JM, 2014, CLIN CANCER RES, V20, P2072, DOI 10.1158/1078-0432.CCR-13-0547; Lorentzen A, 2011, J CELL SCI, V124, P1256, DOI 10.1242/jcs.074849; Martyn KD, 2006, CELL SIGNAL, V18, P69, DOI 10.1016/j.cellsig.2005.03.023; Montenegro MF, 2015, FREE RADICAL BIO MED, V85, P288, DOI 10.1016/j.freeradbiomed.2015.05.011; Murray TVA, 2015, FREE RADICAL BIO MED, V89, P918, DOI 10.1016/j.freeradbiomed.2015.09.015; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Reichl P, 2012, CURR PHARM DESIGN, V18, P4135, DOI 10.2174/138161212802430477; Ruiz-Ontanon P, 2013, STEM CELLS, V31, P1075, DOI 10.1002/stem.1349; Ruprecht V, 2015, CELL, V160, P673, DOI 10.1016/j.cell.2015.01.008; Sadok Amine, 2014, Small GTPases, V5, pe29710, DOI 10.4161/sgtp.29710; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Sanz-Moreno V, 2012, CURR BIOL, V22, pR449, DOI 10.1016/j.cub.2012.04.024; Sanz-Moreno V, 2011, CANCER CELL, V20, P229, DOI 10.1016/j.ccr.2011.06.018; Senturk S, 2010, HEPATOLOGY, V52, P966, DOI 10.1002/hep.23769; Serrander L, 2007, BIOCHEM J, V406, P105, DOI 10.1042/BJ20061903; Smith BN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020017; Stanley A, 2014, ANTIOXID REDOX SIGN, V20, P2026, DOI 10.1089/ars.2013.5713; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tozluoglu M, 2013, NAT CELL BIOL, V15, P751, DOI 10.1038/ncb2775; Valdivia A, 2015, CURR PHARM DESIGN, V21, P6009, DOI 10.2174/1381612821666151029112624; Yu JH, 2012, HEPATOLOGY, V56, P2375, DOI 10.1002/hep.25900; Zavattari P, 2015, HEPATOLOGY, V62, P851, DOI 10.1002/hep.27790	61	40	42	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					3002	3014		10.1038/onc.2016.454	http://dx.doi.org/10.1038/onc.2016.454			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	27941881	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000402000400008
J	Stirzaker, C; Song, JZ; Ng, W; Du, Q; Armstrong, NJ; Locke, WJ; Statham, AL; French, H; Pidsley, R; Valdes-Mora, F; Zotenko, E; Clark, SJ				Stirzaker, C.; Song, J. Z.; Ng, W.; Du, Q.; Armstrong, N. J.; Locke, W. J.; Statham, A. L.; French, H.; Pidsley, R.; Valdes-Mora, F.; Zotenko, E.; Clark, S. J.			Methyl-CpG-binding protein MBD2 plays a key role in maintenance and spread of DNA methylation at CpG islands and shores in cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENES; DOMAIN PROTEIN-2; X-CHROMOSOME; CHROMATIN; PROMOTER; HYPERMETHYLATION; REPRESSION; COMPLEX; ASSOCIATION; EXPRESSION	Cancer is characterised by DNA hypermethylation and gene silencing of CpG island-associated promoters, including tumoursuppressor genes. The methyl-CpG-binding domain (MBD) family of proteins bind to methylated DNA and can aid in the mediation of gene silencing through interaction with histone deacetylases and histone methyltransferases. However, the mechanisms responsible for eliciting CpG island hypermethylation in cancer, and the potential role that MBD proteins play in modulation of the methylome remain unclear. Our previous work demonstrated that MBD2 preferentially binds to the hypermethylated GSTP1 promoter CpG island in prostate cancer cells. Here, we use functional genetic approaches to investigate if MBD2 plays an active role in reshaping the DNA methylation landscape at this locus and genome-wide. First, we show that loss of MBD2 results in inhibition of both maintenance and spread of de novo methylation of a transfected construct containing the GSTP1 promoter CpG island in prostate cancer cells and Mbd2(-/-) mouse fibroblasts. De novo methylation was rescued by transient expression of Mbd2 in Mbd2(-/-) cells. Second, we show that MBD2 depletion triggers significant hypomethylation genome-wide in prostate cancer cells with concomitant loss of MBD2 binding at promoter and enhancer regulatory regions. Finally, CpG islands and shores that become hypomethylated after MBD2 depletion in LNCaP cancer cells show significant hypermethylation in clinical prostate cancer samples, highlighting a potential active role of MBD2 in promoting cancer-specific hypermethylation. Importantly, co-immunoprecipiation of MBD2 shows that MBD2 associates with DNA methyltransferase enzymes 1 and 3A. Together our results demonstrate that MBD2 has a critical role in `rewriting' the cancer methylome at specific regulatory regions.	[Stirzaker, C.; Song, J. Z.; Ng, W.; Du, Q.; Locke, W. J.; Statham, A. L.; French, H.; Pidsley, R.; Valdes-Mora, F.; Zotenko, E.; Clark, S. J.] Garvan Inst Med Res, Genom & Epigenet Div, Epigenet Res Lab, Sydney, NSW, Australia; [Stirzaker, C.; Clark, S. J.] Univ NSW, St Vincents Clin Sch, Sydney, NSW, Australia; [Armstrong, N. J.] Murdoch Univ, SEIT, Math & Stat, Murdoch, WA, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney; Murdoch University	Clark, SJ (corresponding author), Garvan Inst Med Res, Genom & Epigenet Div, 384 Victoria St, Sydney, NSW 2010, Australia.	s.clark@garvan.org.au	Armstrong, Nicola J./AAF-3045-2021; Mora, Fatima Valdes/AAB-9728-2021; Clark, Susan J/B-2272-2008; Locke, Warwick/G-3152-2017; French, Hugh/L-7817-2014	Armstrong, Nicola J./0000-0002-4477-293X; Mora, Fatima Valdes/0000-0001-7490-0114; Clark, Susan J/0000-0001-5925-5030; Locke, Warwick/0000-0002-9281-0363; Du, Qian/0000-0003-3393-681X; Pidsley, Ruth/0000-0002-1386-1374; Stirzaker, Clare/0000-0001-5601-3140; French, Hugh/0000-0001-7464-6929	National Health and Medical Research Council project grants [1029584, 1088144]; NHMRC Fellowship [1063559]	National Health and Medical Research Council project grants; NHMRC Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	We thank Brigid O'Gorman for preparation of figures and reviewing the manuscript. Mouse fibroblast Mbd2 - / - and wild-type cells were gratefully received as a gift from Adrian Bird. The results published here are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. We thank the Ramaciotti Centre, University of New South Wales (Sydney, Australia) for conducting the Affymetrix array experiments and the Australian Genome Research Facility for the HM450K arrays. This work is supported by National Health and Medical Research Council project grants (1029584 and 1088144) and NHMRC Fellowship to SJC (1063559) The contents of the published material are solely the responsibility of the administering institution and individual authors and do not reflect the views of the NHMRC.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Auriol E, 2005, NUCLEIC ACIDS RES, V33, P4243, DOI 10.1093/nar/gki729; Ballestar E, 2005, BIOCHEM CELL BIOL, V83, P374, DOI 10.1139/o05-035; Barr H, 2007, MOL CELL BIOL, V27, P3750, DOI 10.1128/MCB.02204-06; Baubec T, 2014, CURR OPIN GENET DEV, V25, P85, DOI 10.1016/j.gde.2013.11.015; Baubec T, 2013, CELL, V153, P480, DOI 10.1016/j.cell.2013.03.011; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Berger J, 2005, BIOCHEM SOC T, V33, P1537, DOI 10.1042/BST0331537; Bert SA, 2013, CANCER CELL, V23, P9, DOI 10.1016/j.ccr.2012.11.006; BESTOR TH, 1988, GENE, V74, P9, DOI 10.1016/0378-1119(88)90238-7; Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; Cai Y, 2014, ONCOGENE, V33, P2157, DOI 10.1038/onc.2013.178; Chatagnon A, 2011, EPIGENETICS-US, V6, P1295, DOI 10.4161/epi.6.11.17875; Chatagnon A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009665; Chatagnon A, 2009, CARCINOGENESIS, V30, P28, DOI 10.1093/carcin/bgn240; Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023; Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471; Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587; Du Q, 2015, EPIGENOMICS-UK, V7, P1051, DOI 10.2217/epi.15.39; Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; Gunther K, 2013, NUCLEIC ACIDS RES, V41, P3010, DOI 10.1093/nar/gkt035; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Kalyuga M, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001461; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Lopez-Serra L, 2008, ONCOGENE, V27, P3556, DOI 10.1038/sj.onc.1211022; Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Menafra R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099603; Mian OY, 2011, MOL CANCER RES, V9, P1152, DOI 10.1158/1541-7786.MCR-11-0252; Millar DS, 1999, ONCOGENE, V18, P1313, DOI 10.1038/sj.onc.1202415; Mohammed H, 2016, NAT PROTOC, V11, P316, DOI 10.1038/nprot.2016.020; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Pulukuri SM, 2006, ONCOGENE, V25, P4559, DOI 10.1038/sj.onc.1209462; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153; Stefanska B, 2011, CANCER RES, V71, P5891, DOI 10.1158/0008-5472.CAN-10-3823; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; Stirzaker C, 2014, TRENDS GENET, V30, P75, DOI 10.1016/j.tig.2013.11.004; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wang LQ, 2013, MOL CELL BIOL, V33, P4106, DOI 10.1128/MCB.00144-13; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	55	40	44	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1328	1338		10.1038/onc.2016.297	http://dx.doi.org/10.1038/onc.2016.297			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27593931				2022-12-17	WOS:000395862500002
J	Milewski, D; Pradhan, A; Wang, X; Cai, Y; Le, T; Turpin, B; Kalinichenko, VV; Kalin, TV				Milewski, D.; Pradhan, A.; Wang, X.; Cai, Y.; Le, T.; Turpin, B.; Kalinichenko, V. V.; Kalin, T. V.			FoxF1 and FoxF2 transcription factors synergistically promote rhabdomyosarcoma carcinogenesis by repressing transcription of p21(Cip1) CDK inhibitor	ONCOGENE			English	Article							FORKHEAD BOX F1; TO-MESENCHYMAL TRANSITION; MICE HETEROZYGOUS NULL; CHILDHOOD RHABDOMYOSARCOMA; ALVEOLAR RHABDOMYOSARCOMA; DIFFERENTIAL EXPRESSION; LUNG-CANCER; GENE; FUSION; CELLS	The role of Forkhead Box F1 (FoxF1) transcription factor in carcinogenesis is not well characterized. Depending on tissue and histological type of cancer, FoxF1 has been shown to be either an oncogene or a tumor suppressor. Alveolar rhabdomyosarcoma ( RMS) is the most aggressive pediatric soft-tissue sarcoma. Although FoxF1 is highly expressed in alveolar RMS, the functional role of FoxF1 in RMS is unknown. The present study demonstrates that expression of FoxF1 and its closely related transcription factor FoxF2 are essential for RMS tumor growth. Depletion of FoxF1 or FoxF2 in RMS cells decreased tumor growth in orthotopic mouse models of RMS. The decreased tumorigenesis was associated with reduced tumor cell proliferation. Cell cycle regulatory proteins Cdk2, Cdk4/6, Cyclin D1 and Cyclin E2 were decreased in FoxF1-and FoxF2-deficient RMS tumors. Depletion of either FoxF1 or FoxF2 delayed G1-S cell cycle progression, decreased levels of phosphorylated retinoblastoma protein (Rb) and increased protein levels of the CDK inhibitors, p21(Cip1) and p27(Kip1). Depletion of both FoxF1 and FoxF2 in tumor cells completely abrogated RMS tumor growth in mice. Overexpression of either FoxF1 or FoxF2 in tumor cells was sufficient to increase tumor growth in orthotopic RMS mouse model. FoxF1 and FoxF2 directly bound to and repressed transcriptional activity of p21Cip1 promoter through - 556/ - 545 bp region, but did not affect p27Kip1 transcription. Knockdown of p21Cip1 restored cell cycle progression in the FoxF1-or FoxF2-deficient tumor cells. Altogether, FoxF1 and FoxF2 promoted RMS tumorigenesis by inducing tumor cell proliferation via transcriptional repression of p21Cip1 gene promoter. Because of the robust oncogenic activity in RMS tumors, FoxF1 and FoxF2 may represent promising targets for anti-tumor therapy.	[Milewski, D.; Pradhan, A.; Wang, X.; Cai, Y.; Le, T.; Kalinichenko, V. V.; Kalin, T. V.] Cincinnati Childrens Hosp Res Fdn, Perinatal Inst, Div Pulm Biol, Cincinnati, OH USA; [Wang, X.] Cincinnati Childrens Hosp Res Fdn, Div Human Genet, Cincinnati, OH USA; [Turpin, B.] Univ Cincinnati, Dept Pediat, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Kalin, TV (corresponding author), Cincinnati Childrens Hosp Res Fdn, Div Pulm Biol, 3333 Burnet Ave,MLC 7009, Cincinnati, OH 45229 USA.	Tatiana.kalin@cchmc.org	Milewski, David/GPF-5870-2022	Milewski, David/0000-0002-9778-8548	American Cancer Society [125011-RSG-13-325-01-CSM]; NIH [R01 CA142724, R01 HL84151]; NATIONAL CANCER INSTITUTE [R01CA142724] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084151, R01HL132849, R01HL123490] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the Research Grant from the American Cancer Society 125011-RSG-13-325-01-CSM (to TVK), NIH grants R01 CA142724 (to TVK) and R01 HL84151 (to VVK).	Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744; Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Aitola M, 2000, DEV DYNAM, V218, P136, DOI 10.1002/(SICI)1097-0177(200005)218:1<136::AID-DVDY12>3.0.CO;2-U; Armeanu-Ebinger S, 2011, INT J ONCOL, V38, P993, DOI 10.3892/ijo.2011.921; Balli D, 2012, ONCOGENE, V31, P3875, DOI 10.1038/onc.2011.549; Balli D, 2013, EMBO J, V32, P231, DOI 10.1038/emboj.2012.336; Balli D, 2011, CANCER RES, V71, P40, DOI 10.1158/0008-5472.CAN-10-2004; Bolte C, 2015, J BIOL CHEM, V290, P7563, DOI 10.1074/jbc.M114.609487; Breneman JC, 2003, J CLIN ONCOL, V21, P78, DOI 10.1200/JCO.2003.06.129; Cheng XH, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004656; Davicioni E, 2009, AM J PATHOL, V174, P550, DOI 10.2353/ajpath.2009.080631; DAVIS RJ, 1994, CANCER RES, V54, P2869; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gialmanidis IP, 2013, LUNG, V191, P511, DOI 10.1007/s00408-013-9490-4; Hayes-Jordan A, 2009, CURR OPIN PEDIATR, V21, P373, DOI 10.1097/MOP.0b013e32832b4171; Hellqvist M, 1996, J BIOL CHEM, V271, P4482; HOSOI H, 1992, INT J CANCER, V50, P977, DOI 10.1002/ijc.2910500626; Kalin TV, 2008, AM J RESP CELL MOL, V39, P390, DOI 10.1165/rcmb.2008-0044OC; Kalin TV, 2011, CELL CYCLE, V10, P396, DOI 10.4161/cc.10.3.14709; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Kalinichenko VV, 2003, GENE EXPR PATTERNS, V3, P153, DOI 10.1016/S1567-133X(03)00010-3; Kalinichenko VV, 2003, HEPATOLOGY, V37, P107, DOI 10.1053/jhep.2003.50005; Kalinichenko VV, 2002, J BIOL CHEM, V277, P12369, DOI 10.1074/jbc.M112162200; Kalinichenko VV, 2001, DEV BIOL, V235, P489, DOI 10.1006/dbio.2001.0322; Kong PZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061591; Kundu ST, 2016, ONCOGENE, V35, P173, DOI 10.1038/onc.2015.71; Lae M, 2007, J PATHOL, V212, P143, DOI 10.1002/path.2170; Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744; Lo PK, 2012, CELL SIGNAL, V24, P316, DOI 10.1016/j.cellsig.2011.09.017; Lo PK, 2010, CANCER RES, V70, P6047, DOI 10.1158/0008-5472.CAN-10-1576; Mahlapuu M, 2001, DEVELOPMENT, V128, P155; McDowell HP, 2003, ARCH DIS CHILD, V88, P354, DOI 10.1136/adc.88.4.354; Mclin VA, 2010, INT J DEV BIOL, V54, P919, DOI 10.1387/ijdb.092916vm; Mclin VA, 2009, GASTROENTEROLOGY, V136, P2074, DOI 10.1053/j.gastro.2009.03.001; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Nik AM, 2013, GASTROENTEROLOGY, V144, P1001, DOI 10.1053/j.gastro.2013.01.045; Nilsson J, 2010, CANCER RES, V70, P2020, DOI 10.1158/0008-5472.CAN-09-1677; Ormestad M, 2004, DEV DYNAM, V229, P328, DOI 10.1002/dvdy.10426; Pappo I, 2004, ANN SURG ONCOL, V11, P52, DOI 10.1007/BF02524346; Peterson RS, 1997, MECH DEVELOP, V69, P53, DOI 10.1016/S0925-4773(97)00153-6; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Qualman Stephen J, 2002, Curr Oncol Rep, V4, P123, DOI 10.1007/s11912-002-0073-4; Ren XM, 2014, CIRC RES, V115, P709, DOI 10.1161/CIRCRESAHA.115.304382; Singh TR, 2010, MOL CELL, V37, P879, DOI 10.1016/j.molcel.2010.01.036; Tamura M, 2014, ONCOGENE, V33, P4837, DOI 10.1038/onc.2013.427; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Wang IC, 2008, ONCOGENE, V27, P4137, DOI 10.1038/onc.2008.60; Wang IC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006609; Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474; Wei HJ, 2014, ONCOTARGET, V5, P9514, DOI 10.18632/oncotarget.2413; Weigel BJ, 2003, CLIN CANCER RES, V9, P3105; Wendling DS, 2008, INT J MOL MED, V22, P787, DOI 10.3892/ijmm_00000086; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	54	40	42	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					850	862		10.1038/onc.2016.254	http://dx.doi.org/10.1038/onc.2016.254			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27425595	Green Accepted			2022-12-17	WOS:000394168200012
J	Hollstein, M; Alexandrov, LB; Wild, CP; Ardin, M; Zavadil, J				Hollstein, M.; Alexandrov, L. B.; Wild, C. P.; Ardin, M.; Zavadil, J.			Base changes in tumour DNA have the power to reveal the causes and evolution of cancer	ONCOGENE			English	Review							MUTATIONAL SIGNATURES; HEPATOCELLULAR-CARCINOMA; P53 MUTATIONS; LUNG-CANCER; SOMATIC MUTATIONS; ARISTOLOCHIC ACID; GENOMIC LANDSCAPE; CELL CARCINOMA; RISK-FACTORS; GENE	Next-generation sequencing (NGS) technology has demonstrated that the cancer genomes are peppered with mutations. Although most somatic tumour mutations are unlikely to have any role in the cancer process per se, the spectra of DNA sequence changes in tumour mutation catalogues have the potential to identify the mutagens, and to reveal the mutagenic processes responsible for human cancer. Very recently, a novel approach for data mining of the vast compilations of tumour NGS data succeeded in separating and precisely defining at least 30 distinct patterns of sequence change hidden in mutation databases. At least half of these mutational signatures can be readily assigned to known human carcinogenic exposures or endogenous mechanisms of mutagenesis. A quantum leap in our knowledge of mutagenesis in human cancers has resulted, stimulating a flurry of research activity. We trace here the major findings leading first to the hypothesis that carcinogenic insults leave characteristic imprints on the DNA sequence of tumours, and culminating in empirical evidence from NGS data that well-defined carcinogen mutational signatures are indeed present in tumour genomic DNA from a variety of cancer types. The notion that tumour DNAs can divulge environmental sources of mutation is now a well-accepted fact. This approach to cancer aetiology has also incriminated various endogenous, enzyme-driven processes that increase the somatic mutation load in sporadic cancers. The tasks now confronting the field of molecular epidemiology are to assign mutagenic processes to orphan and newly discovered tumour mutation patterns, and to determine whether avoidable cancer risk factors influence signatures produced by endogenous enzymatic mechanisms. Innovative research with experimental models and exploitation of the geographical heterogeneity in cancer incidence can address these challenges.	[Hollstein, M.; Ardin, M.; Zavadil, J.] World Hlth Org, Int Agcy Res Canc, Mol Mech & Biomarkers, 150 Cours Albert Thomas, F-69008 Lyon, France; [Hollstein, M.] Univ Leeds, Fac Med & Hlth, Leeds LS2 9JT, W Yorkshire, England; [Alexandrov, L. B.] Los Alamos Natl Lab, Theoret Biol & Biophys T 6, POB 1663, Los Alamos, NM 87545 USA; [Alexandrov, L. B.] Los Alamos Natl Lab, Ctr Nonlinear Studies, Los Alamos, NM USA; [Wild, C. P.] World Hlth Org, Int Agcy Res Canc, Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC); University of Leeds; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; World Health Organization; International Agency for Research on Cancer (IARC)	Hollstein, M; Zavadil, J (corresponding author), World Hlth Org, Int Agcy Res Canc, Mol Mech & Biomarkers, 150 Cours Albert Thomas, F-69008 Lyon, France.; Alexandrov, LB (corresponding author), Los Alamos Natl Lab, Theoret Biol & Biophys T 6, POB 1663, Los Alamos, NM 87545 USA.	M.Hollstein@leeds.ac.uk; lba@lanl.gov; zavadilj@iarc.fr	Alexandrov, Ludmil/AAS-1454-2021; Zavadil, Jiri/ABG-1780-2020; Wild, Christopher/ABC-6260-2020	Alexandrov, Ludmil/0000-0003-3596-4515; Zavadil, Jiri/0000-0003-0640-5562; Wild, Christopher/0000-0003-0249-8669	INCa-INSERM Plan Cancer grant; J. Robert Oppenheimer Fellowship at Los Alamos National Laboratory	INCa-INSERM Plan Cancer grant; J. Robert Oppenheimer Fellowship at Los Alamos National Laboratory	We acknowledge these funding sources: INCa-INSERM 2015 Plan Cancer grant to JZ; LBA is supported through the J. Robert Oppenheimer Fellowship at Los Alamos National Laboratory.	Alexandrov LB, 2015, NAT GENET, V47, P1402, DOI 10.1038/ng.3441; Alexandrov LB, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9683; Alexandrov LB, 2014, CURR OPIN GENET DEV, V24, P52, DOI 10.1016/j.gde.2013.11.014; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008; Andor N, 2016, NAT MED, V22, P105, DOI 10.1038/nm.3984; ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brash DE, 2015, PHOTOCHEM PHOTOBIOL, V91, P15, DOI 10.1111/php.12377; Brennan P, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005522; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Castells X, 2015, CANCER EPIDEM BIOMAR, V24, P1873, DOI 10.1158/1055-9965.EPI-15-0553; Chan K, 2015, NAT GENET, V47, P1067, DOI 10.1038/ng.3378; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Dulak AM, 2013, NAT GENET, V45, P478, DOI 10.1038/ng.2591; Fedeles BI, 2015, P NATL ACAD SCI USA, V112, pE4571, DOI 10.1073/pnas.1507709112; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fischer A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r39; Flibotte S, 2010, GENETICS, V185, P431, DOI 10.1534/genetics.110.116616; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gohler S, 2016, J CANCER RES CLIN, V142, P273, DOI 10.1007/s00432-015-2038-7; Govindan R, 2012, CELL, V150, P1121, DOI 10.1016/j.cell.2012.08.024; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Grollman AP, 2007, P NATL ACAD SCI USA, V104, P12129, DOI 10.1073/pnas.0701248104; Grollman AP, 2013, ENVIRON MOL MUTAGEN, V54, P1, DOI 10.1002/em.21756; Gu XW, 2012, CURR OPIN HEMATOL, V19, P292, DOI 10.1097/MOH.0b013e328353da3a; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Hedegaard J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098187; Helleday T, 2014, NAT REV GENET, V15, P585, DOI 10.1038/nrg3729; Henderson S, 2014, CELL REP, V7, P1833, DOI 10.1016/j.celrep.2014.05.012; Hoang ML, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006200; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 2013, MUTAT RES-REV MUTAT, V753, P41, DOI 10.1016/j.mrrev.2013.02.003; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Jelakovic B, 2015, INT J CANCER, V136, P2967, DOI 10.1002/ijc.29338; Johnson BE, 2014, SCIENCE, V343, P189, DOI 10.1126/science.1239947; Kazanov MD, 2015, CELL REP, V13, P1103, DOI 10.1016/j.celrep.2015.09.077; Krishnan VG, 2014, CANCER RES, V74, P6071, DOI 10.1158/0008-5472.CAN-13-3195; Lee DD, 1999, NATURE, V401, P788, DOI 10.1038/44565; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Liu Zhipei, 2007, Genet Eng (N Y), V28, P45, DOI 10.1007/978-0-387-34504-8_3; Liu ZP, 2004, P NATL ACAD SCI USA, V101, P2963, DOI 10.1073/pnas.0308607101; Marnett LJ, 2001, TRENDS GENET, V17, P214, DOI 10.1016/S0168-9525(01)02239-9; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; Maslov AY, 2015, MUTAT RES-FUND MOL M, V776, P136, DOI 10.1016/j.mrfmmm.2015.03.014; MCCANN J, 1975, P NATL ACAD SCI USA, V72, P5135, DOI 10.1073/pnas.72.12.5135; Meier B, 2014, GENOME RES, V24, P1624, DOI 10.1101/gr.175547.114; MILLER JH, 1982, CELL, V31, P5, DOI 10.1016/0092-8674(82)90398-1; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Nassar D, 2015, NAT MED, V21, P946, DOI 10.1038/nm.3878; Nik-Zainal S, 2015, MUTAGENESIS, V30, P763, DOI 10.1093/mutage/gev073; Nik-Zainal S, 2014, NAT GENET, V46, P487, DOI 10.1038/ng.2955; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Olivier M, 2014, SCI REP-UK, V4, DOI 10.1038/srep04482; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Pettersen HS, 2015, DNA REPAIR, V25, P60, DOI 10.1016/j.dnarep.2014.11.006; Pfeifer GP, 2015, CURR OPIN ONCOL, V27, P71, DOI 10.1097/CCO.0000000000000152; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Pickering CR, 2014, CLIN CANCER RES, V20, P3842, DOI 10.1158/1078-0432.CCR-14-0565; Poon SL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0161-3; Poon SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006086; Rebhandl Stefan, 2015, Oncoscience, V2, P320; Roberts SA, 2014, BIOESSAYS, V36, P382, DOI 10.1002/bies.201300140; Ross-Innes CS, 2015, NAT GENET, V47, P1038, DOI 10.1038/ng.3357; Scelo G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6135; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Segovia R, 2015, TRENDS GENET, V31, P465, DOI 10.1016/j.tig.2015.04.001; Severson PL, 2014, MUTAT RES-GEN TOX EN, V775, P48, DOI 10.1016/j.mrgentox.2014.10.011; Shiraishi Y, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005657; Shlien A, 2015, NAT GENET, V47, P257, DOI 10.1038/ng.3202; Smith HC, 2012, SEMIN CELL DEV BIOL, V23, P258, DOI 10.1016/j.semcdb.2011.10.004; Stewart BW, 2014, WORLD CANC REPORT 20; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Tam AS, 2016, G3-GENES GENOM GENET, V6, P133, DOI 10.1534/g3.115.021915; Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Warren CJ, 2015, J VIROL, V89, P688, DOI 10.1128/JVI.02383-14; Weaver JMJ, 2014, NAT GENET, V46, P837, DOI 10.1038/ng.3013; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898; WOGAN GN, 1992, CANCER RES, V52, pS2114; Wu S, 2016, NATURE, V529, P43, DOI 10.1038/nature16166; Zhang L, 2015, AM J HUM GENET, V96, P597, DOI 10.1016/j.ajhg.2015.02.017; Zhang YN, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/190629; Zou SS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6696; zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046	99	40	43	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					158	167		10.1038/onc.2016.192	http://dx.doi.org/10.1038/onc.2016.192			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270430	hybrid, Green Published, Green Submitted			2022-12-17	WOS:000393938100002
J	Turpin, J; Ling, C; Crosby, EJ; Hartman, ZC; Simond, AM; Chodosh, LA; Rennhack, JP; Andrechek, ER; Ozcelik, J; Hallett, M; Mills, GB; Cardiff, RD; Gray, JW; Griffith, OL; Muller, WJ				Turpin, J.; Ling, C.; Crosby, E. J.; Hartman, Z. C.; Simond, A. M.; Chodosh, L. A.; Rennhack, J. P.; Andrechek, E. R.; Ozcelik, J.; Hallett, M.; Mills, G. B.; Cardiff, R. D.; Gray, J. W.; Griffith, O. L.; Muller, W. J.			The ErbB2 Delta Ex16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TRANSGENIC MICE; MAMMARY-TUMORS; ACTIVATING MUTATIONS; ELEVATED EXPRESSION; ENRICHMENT ANALYSIS; NEU PROTOONCOGENE; PROGRESSION; INDUCTION; HER2	Amplification and overexpression of erbB2/neu proto-oncogene is observed in 20-30% human breast cancer and is inversely correlated with the survival of the patient. Despite this, somatic activating mutations within erbB2 in human breast cancers are rare. However, we have previously reported that a splice isoform of erbB2, containing an in-frame deletion of exon 16 (herein referred to as ErbB2 Delta Ex16), results in oncogenic activation of erbB2 because of constitutive dimerization of the ErbB2 receptor. Here, we demonstrate that the ErbB2 Delta Ex16 is a major oncogenic driver in breast cancer that constitutively signals from the cell surface. We further show that inducible expression of the ErbB2 Delta Ex16 variant in mammary gland of transgenic mice results in the rapid development of metastatic multifocal mammary tumors. Genetic and biochemical characterization of the ErbB2 Delta Ex16-derived mammary tumors exhibit several unique features that distinguish this model from the conventional ErbB2 ones expressing the erbB2 proto-oncogene in mammary epithelium. Unlike the wild-type ErbB2-derived tumors that express luminal keratins, ErbB2 Delta Ex16-derived tumors exhibit high degree of intratumoral heterogeneity co-expressing both basal and luminal keratins. Consistent with these distinct pathological features, the ErbB2 Delta Ex16 tumors exhibit distinct signaling and gene expression profiles that correlate with activation of number of key transcription factors implicated in breast cancer metastasis and cancer stem cell renewal.	[Turpin, J.; Ling, C.; Simond, A. M.; Ozcelik, J.; Hallett, M.; Muller, W. J.] Goodman Canc Ctr, Room 516,1160 Pine Ave West, Montreal, PQ H3A 1A3, Canada; [Turpin, J.; Muller, W. J.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Crosby, E. J.; Hartman, Z. C.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Chodosh, L. A.] Univ Penn, Perelman Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; [Rennhack, J. P.; Andrechek, E. R.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; [Mills, G. B.] MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX USA; [Cardiff, R. D.] Univ Calif Davis, Dept Pathol, Ctr Comparat Med, Davis, CA 95616 USA; [Gray, J. W.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA; [Griffith, O. L.] Washington Univ, Sch Med, McDonnell Genome Inst, St Louis, MO USA; [Muller, W. J.] McGill Univ, Dept Med, Montreal, PQ, Canada	McGill University; Duke University; University of Pennsylvania; Pennsylvania Medicine; Michigan State University; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Davis; Oregon Health & Science University; Washington University (WUSTL); McGill University	Muller, WJ (corresponding author), Goodman Canc Ctr, Room 516,1160 Pine Ave West, Montreal, PQ H3A 1A3, Canada.	william.muller@mcgill.ca	Gray, Joe/AAX-9549-2020	Andrechek, Eran/0000-0002-8680-3423; Hallett, Michael/0000-0001-6738-6786; Rennhack, Jonathan/0000-0001-6306-195X	Terry Fox Foundation [020002]; Canadian Institutes of Health Research [MOP 93525, MOP 89751]; National Institutes of Health [PO1 (2PO1CA099031-06A1)]; CRC Chair in Molecular Oncology; Department of Defense Breast Cancer Predoctoral Traineeship [W81XWH 10-1-0114]; Susan G Komen Breast Cancer Foundation [CCR14299200]; NIH-NCI [T32-CA009111]; NIH [R01CA160514]; US-NCI [U01 CA141582]; NATIONAL CANCER INSTITUTE [P30CA016672, U01CA141582, P01CA099031, T32CA009111, R01CA160514, F99CA212221] Funding Source: NIH RePORTER	Terry Fox Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CRC Chair in Molecular Oncology; Department of Defense Breast Cancer Predoctoral Traineeship; Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Jonathan Rayment, Dr Dongmei Zuo, and Ms Virginie Sanguin-Gendreau for their important involvement in this project. This study was supported by grants awarded to WJM from the Terry Fox Foundation (#020002), the Canadian Institutes of Health Research (MOP 93525 and MOP 89751) and the National Institutes of Health PO1 (2PO1CA099031-06A1). WJM is supported by CRC Chair in Molecular Oncology. JT was supported by the Department of Defense Breast Cancer Predoctoral Traineeship award #W81XWH 10-1-0114. ZCH was supported by Susan G Komen Breast Cancer Foundation (CCR14299200) and NIH-NCI (T32-CA009111). ERA is supported by NIH grant R01CA160514. RDC is supported by a US-NCI grant U01 CA141582. MMTV/ErbB2 transgenic mice were a generous donation from Genentech.	Alajati A, 2013, CANCER RES, V73, P5320, DOI 10.1158/0008-5472.CAN-12-3186; Andrechek ER, 2002, MOL CELL BIOL, V22, P4714, DOI 10.1128/MCB.22.13.4714-4722.2002; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Castagnoli L, 2014, CANCER RES, V74, P6248, DOI 10.1158/0008-5472.CAN-14-0983; Castiglioni F, 2006, ENDOCR-RELAT CANCER, V13, P221, DOI 10.1677/erc.1.01047; Chan R, 1999, ANN NY ACAD SCI, V889, P45, DOI 10.1111/j.1749-6632.1999.tb08722.x; Chang JT, 2009, MOL CELL, V34, P104, DOI 10.1016/j.molcel.2009.02.030; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen YL, 2015, J CLIN INVEST, V125, P1147, DOI 10.1172/JCI74725; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Diessner J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.115; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135; Finkle D, 2004, CLIN CANCER RES, V10, P2499, DOI 10.1158/1078-0432.CCR-03-0448; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Gautrey H, 2015, RNA BIOL, V12, P1139, DOI 10.1080/15476286.2015.1076610; Griffith M, 2010, NAT METHODS, V7, P843, DOI [10.1038/NMETH.1503, 10.1038/nmeth.1503]; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; Jones LM, 2016, CANCER RES, V76, P1416, DOI 10.1158/0008-5472.CAN-15-2770; Korsching E, 2005, J PATHOL, V206, P451, DOI 10.1002/path.1797; Kwong KY, 1998, MOL CARCINOGEN, V23, P62, DOI 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Marcotte R, 2009, MOL CELL BIOL, V29, P5858, DOI 10.1128/MCB.01731-08; McCormack VA, 2016, CANCER EPIDEMIOL, V40, P141, DOI 10.1016/j.canep.2015.11.015; Mitra D, 2009, MOL CANCER THER, V8, P2152, DOI 10.1158/1535-7163.MCT-09-0295; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Mouw JK, 2014, NAT MED, V20, P360, DOI 10.1038/nm.3497; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Perry MC, 2014, MOL CELL BIOL, V34, P4232, DOI 10.1128/MCB.00895-14; Ranger JJ, 2009, CANCER RES, V69, P6823, DOI 10.1158/0008-5472.CAN-09-1684; Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Ursini-Siegel J, 2007, MOL CELL BIOL, V27, P6361, DOI 10.1128/MCB.00686-07; Yu M, 2009, GENE DEV, V23, P1737, DOI 10.1101/gad.1809309	46	40	42	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6053	6064		10.1038/onc.2016.129	http://dx.doi.org/10.1038/onc.2016.129			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27157621	Green Submitted, Green Accepted			2022-12-17	WOS:000388509800002
J	Schmid, F; Wang, Q; Huska, MR; Andrade-Navarro, MA; Lemm, M; Fichtner, I; Dahlmann, M; Kobelt, D; Walther, W; Smith, J; Schlag, PM; Stein, U				Schmid, F.; Wang, Q.; Huska, M. R.; Andrade-Navarro, M. A.; Lemm, M.; Fichtner, I.; Dahlmann, M.; Kobelt, D.; Walther, W.; Smith, J.; Schlag, P. M.; Stein, U.			SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient survival	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX PROTEIN; EXPRESSION ANALYSIS; MET; SPONDIN-2; MARKER; HGF	MACC1 (metastasis associated in colon cancer 1) is a prognostic biomarker for tumor progression, metastasis and survival of a variety of solid cancers including colorectal cancer (CRC). Here we aimed to identify the MACC1-induced transcriptome and key players mediating the MACC1-induced effects in CRC. We performed microarray analyses using CRC cells ectopically overexpressing MACC1. We identified more than 1300 genes at least twofold differentially expressed, including the gene SPON2 (Spondin 2) as 90-fold upregulated transcriptional target of MACC1. MACC1-dependent SPON2 expression regulation was validated on mRNA and protein levels in MACC1 high (endogenously or ectopically) and low (endogenously or by knockdown) expressing cells. Chromatin immunoprecipitation analysis demonstrated the binding of MACC1 to the gene promoter of SPON2. In cell culture, ectopic SPON2 overexpression induced cell viability, migration, invasion and colony formation in endogenously MACC1 and SPON2 low expressing cells, whereas SPON2 knockdown reduced proliferative, migratory and invasive abilities in CRC cells with high endogenous MACC1 and SPON2 expression. In intrasplenically transplanted NOD/SCID mice, metastasis induction was analyzed with control or SPON2-overexpressing CRC cells. Tumors with SPON2 overexpression induced liver metastasis (vs control animals without any metastases, P = 0.0036). In CRC patients, SPON2 expression was determined in primary tumors (stages I-III), and survival time was analyzed by Kaplan-Meier method. CRC patients with high SPON2 expressing primary tumors demonstrated 8 months shorter metastasis-free survival (MFS) compared with patients with low SPON2 levels (P = 0.053). Combining high levels of SPON2 and MACC1 improved the identification of high-risk patients with a 20-month shorter MFS vs patients with low biomarker expression. In summary, SPON2 is a transcriptional target of the metastasis gene MACC1. SPON2 induces cell motility in vitro and CRC metastasis in mice. In patients, SPON2 serves as prognostic indicator for CRC metastasis and survival, and might represent a promising target for therapeutic approaches.	[Schmid, F.; Wang, Q.; Dahlmann, M.; Kobelt, D.; Walther, W.; Smith, J.; Stein, U.] Charite, Expt & Clin Res Ctr, Robert Rossle Str 10, D-13125 Berlin, Germany; [Schmid, F.; Wang, Q.; Huska, M. R.; Andrade-Navarro, M. A.; Lemm, M.; Fichtner, I.; Dahlmann, M.; Kobelt, D.; Walther, W.; Smith, J.; Stein, U.] Helmholtz Assoc, Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany; [Schlag, P. M.] Charite Comprehens Canc Ctr, Berlin, Germany; [Stein, U.] German Canc Consortium DKTK, Heidelberg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Cancer Research Center (DKFZ)	Stein, U (corresponding author), Charite, Expt & Clin Res Ctr, Robert Rossle Str 10, D-13125 Berlin, Germany.; Stein, U (corresponding author), Helmholtz Assoc, Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.	ustein@mdc-berlin.de		Huska, Matthew/0000-0002-0912-745X; Stein, Ulrike/0000-0001-7006-282X; Dahlmann, Mathias/0000-0002-0036-5283; Walther, Wolfgang/0000-0003-2360-1370	German Cancer Consortium (DKTK)	German Cancer Consortium (DKTK)	We are thankful to Wolfgang Kemmner and his laboratory for the help with the microarray experiments. We thank Maria Stecklum and Nadine Basler for support with the in vivo bioluminescence imaging, and Jutta Aumann for assistance on expression analyses. We thank Manisha Juneja and Katharina Ilm for help with the combinatorial biomarker analysis in the CRC patients. We are grateful to Markus Niederstrasser for statistical advice. This work was supported by the German Cancer Consortium (DKTK).	Anderson GL, 2010, JNCI-J NATL CANCER I, V102, P26, DOI 10.1093/jnci/djp438; Arlt F, 2009, INT J BIOCHEM CELL B, V41, P2356, DOI 10.1016/j.biocel.2009.08.001; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Burock S, 2015, WORLD J GASTROENTERO, V21, P333, DOI 10.3748/wjg.v21.i1.333; Carvalho B, 2012, CELL ONCOL, V35, P53, DOI 10.1007/s13402-011-0065-1; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Edwards S, 2005, BRIT J CANCER, V92, P376, DOI 10.1038/sj.bjc.6602261; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Galimi F, 2011, CLIN CANCER RES, V17, P3146, DOI 10.1158/1078-0432.CCR-10-3377; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Hagemann C, 2013, NEURO-ONCOLOGY, V15, P1696, DOI 10.1093/neuonc/not136; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Ilm K, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0316-2; Jia W, 2005, BLOOD, V106, P3854, DOI 10.1182/blood-2005-04-1658; Juneja M, 2013, MOL ONCOL, V7, P929, DOI 10.1016/j.molonc.2013.05.003; Koelzer VH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1150-z; Li H, 2006, EMBO J, V25, P4097, DOI 10.1038/sj.emboj.7601289; Lucarelli G, 2013, J UROLOGY, V190, P2271, DOI 10.1016/j.juro.2013.05.004; Manda R, 1999, GENOMICS, V61, P5, DOI 10.1006/geno.1999.5939; Neufeld G, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006718; Nitsche U, 2012, ANN SURG, V256, P763, DOI 10.1097/SLA.0b013e318272de87; Parry R, 2005, CANCER RES, V65, P8397, DOI 10.1158/0008-5472.CAN-05-1203; Pichorner A, 2012, CLIN EXP METASTAS, V29, P573, DOI 10.1007/s10585-012-9472-6; Qian XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037225; Rajkumar T, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-45; Ridley AJ, 2001, J CELL SCI, V114, P2713; Romanuik TL, 2009, AM J PATHOL, V175, P2264, DOI 10.2353/ajpath.2009.080868; Sakurai A, 2012, CELL RES, V22, P23, DOI 10.1038/cr.2011.198; Schmid F, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-49; Simon I, 2007, GYNECOL ONCOL, V106, P112, DOI 10.1016/j.ygyno.2007.03.007; Stein Ulrike, 2007, V176, P61; Stein U, 2013, EXPERT OPIN THER TAR, V17, P1039, DOI 10.1517/14728222.2013.815727; Stein U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049249; Stein U, 2011, NEOPLASIA, V13, P131, DOI 10.1593/neo.101172; Stein U, 2010, J MOL MED, V88, P11, DOI 10.1007/s00109-009-0537-1; Stein U, 2009, CELL CYCLE, V8, P2467, DOI 10.4161/cc.8.15.9018; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Wagstaff L, 2011, FRONT BIOSCI-LANDMRK, V16, P1861, DOI 10.2741/3827; Wang Nina, 2012, Nan Fang Yi Ke Da Xue Xue Bao, V32, P312; Zhang Q, 2015, ONCOTARGET, V6, P15095, DOI 10.18632/oncotarget.3822	42	40	43	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					5942	5952		10.1038/onc.2015.451	http://dx.doi.org/10.1038/onc.2015.451			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	26686083				2022-12-17	WOS:000388509400002
J	Du, L; Chen, X; Cao, Y; Lu, L; Zhang, F; Bornstein, S; Li, Y; Owens, P; Malkoski, S; Said, S; Jin, F; Kulesz-Martin, M; Gross, N; Wang, XJ; Lu, SL				Du, L.; Chen, X.; Cao, Y.; Lu, L.; Zhang, F.; Bornstein, S.; Li, Y.; Owens, P.; Malkoski, S.; Said, S.; Jin, F.; Kulesz-Martin, M.; Gross, N.; Wang, X-J; Lu, S-L			Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGF beta signaling	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; SQUAMOUS-CELL-CARCINOMA; AKT ACTIVATION; CHEMICAL CARCINOGENESIS; 3-KINASE PATHWAY; PI3K PATHWAY; MOUSE MODELS; CANCER; MUTATION; GROWTH	Head and neck squamous cell carcinoma (HNSCC) patients have a poor prognosis, with invasion and metastasis as major causes of mortality. The phosphatidylinositol 3-kinase (PI3K) pathway regulates a wide range of cellular processes crucial for tumorigenesis, and PIK3CA amplification and mutation are among the most common genetic alterations in human HNSCC. Compared with the well-documented roles of the PI3K pathway in cell growth and survival, the roles of the PI3K pathway in tumor invasion and metastasis have not been well delineated. We generated a PIK3CA genetically engineered mouse model (PIK3CA-GEMM) in which wild-type PIK3CA is overexpressed in head and neck epithelium. Although PIK3CA overexpression alone was not sufficient to initiate HNSCC formation, it significantly increased tumor susceptibility in an oral carcinogenesis mouse model. PIK3CA overexpression in mouse oral epithelium increased tumor invasiveness and metastasis by increasing epithelial-mesenchymal transition and by enriching a cancer stem cell phenotype in tumor epithelial cells. In addition to these epithelial alterations, we also observed marked inflammation in tumor stroma. AKT is a central signaling mediator of the PI3K pathway. However, molecular analysis suggested that progression of PIK3CA-driven HNSCC is facilitated by 3-phosphoinositide-dependent protein kinase (PDK1) and enhanced transforming growth factor beta (TGF beta) signaling rather than by AKT. Examination of human HNSCC clinical samples revealed that both PIK3CA and PDK1 protein levels correlated with tumor progression, highlighting the significance of this pathway. In summary, our results offer significant insight into how PIK3CA overexpression drives HNSCC invasion and metastasis, providing a rationale for targeting PI3K/PDK1 and TGF beta signaling in advanced HNSCC patients with PIK3CA amplification.	[Du, L.; Chen, X.; Cao, Y.; Lu, L.; Zhang, F.; Lu, S-L] Univ Colorado, Dept Otolaryngol, Anschutz Med Campus, 12700 E 19th Ave,Mail Stop 8606, Aurora, CO 80045 USA; [Du, L.] China Med Univ, Univ Hosp 4, Dept Otolaryngol, Shenyang, Peoples R China; [Cao, Y.; Jin, F.] China Med Univ, Univ Hosp 1, Dept Surg Oncol, Shenyang, Liaoning, Peoples R China; [Bornstein, S.; Li, Y.; Owens, P.; Gross, N.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA; [Malkoski, S.] Univ Colorado, Dept Med, Anschutz Med Campus, Aurora, CO USA; [Said, S.; Wang, X-J; Lu, S-L] Univ Colorado, Dept Pathol, Anschutz Med Campus, Aurora, CO USA; [Kulesz-Martin, M.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA; [Lu, S-L] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; China Medical University; China Medical University; Oregon Health & Science University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Oregon Health & Science University; University of Colorado System; University of Colorado Anschutz Medical Campus	Lu, SL (corresponding author), Univ Colorado, Dept Otolaryngol, Anschutz Med Campus, 12700 E 19th Ave,Mail Stop 8606, Aurora, CO 80045 USA.	shi-long.lu@ucdenver.edu			National Institutes of Health [R01DE021788, R01DE015953]; University of Colorado Academic Enrichment Fund; American Cancer Society; University of Colorado Cancer Center; Cancer League of Colorado; NATIONAL CANCER INSTITUTE [K08CA131483, T32CA106195, R01CA192405, P30CA046934, R21CA194662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR057212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE021788] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Colorado Academic Enrichment Fund; American Cancer Society(American Cancer Society); University of Colorado Cancer Center; Cancer League of Colorado; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work is supported by National Institutes of Health grant R01DE021788 (to S-L Lu), R01DE015953 (to X-J Wang). University of Colorado Academic Enrichment Fund (to S-L Lu), American Cancer Society (to S-L Lu), University of Colorado Cancer Center (to S-L Lu), and Cancer League of Colorado (to S-L Lu). S-L Lu is an investigator of THANC foundation. We thank the Transgenic Core of Oregon Health and Science University for generating founders of the mouse model, and the University of Colorado Skin Disease Research Center Morphology Phenotyping Core (P30 AR057212) for assisting with histological work.	Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Bhola NE, 2012, MOL CANCER THER, V11, P1236, DOI 10.1158/1535-7163.MCT-11-0936; Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854; Curry NL, 2013, CANCER DISCOV, V3, P908, DOI 10.1158/2159-8290.CD-12-0507; Du L, 2012, J ONCOL, V2012, DOI 10.1155/2012/450179; Du Y, 2014, PHARMACOL THERAPEUT, V142, P88, DOI 10.1016/j.pharmthera.2013.11.007; Durban VM, 2013, J CLIN INVEST, V123, P5104, DOI 10.1172/JCI69619; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Eser S, 2013, CANCER CELL, V23, P406, DOI 10.1016/j.ccr.2013.01.023; Estilo CL, 2003, CLIN CANCER RES, V9, P2300; Fan QW, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000014; Feng QT, 2010, MOL CELL BIOL, V30, P3711, DOI 10.1128/MCB.00420-10; Fenic I, 2007, ONCOL REP, V18, P253; Finlay DK, 2009, J EXP MED, V206, P2441, DOI 10.1084/jem.20090219; Garcia-Carracedo D, 2013, CLIN CANCER RES, V19, P6830, DOI 10.1158/1078-0432.CCR-13-0624; Han G, 2005, J CLIN INVEST, V115, P1714, DOI 10.1172/JCI24399; Hare LM, 2014, BIOCHEM J, V458, P251, DOI 10.1042/BJ20131412; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Iglesias-Bartolome R, 2013, CANCER DISCOV, V3, P722, DOI 10.1158/2159-8290.CD-13-0239; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kinross KM, 2012, J CLIN INVEST, V122, P553, DOI 10.1172/JCI59309; Klarenbeek S, 2013, MOL ONCOL, V7, P146, DOI 10.1016/j.molonc.2013.02.003; Kozaki KI, 2006, CANCER SCI, V97, P1351, DOI 10.1111/j.1349-7006.2006.00343.x; Lauring J, 2010, ONCOGENE, V29, P2337, DOI 10.1038/onc.2009.516; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306; Lu SL, 2004, CANCER RES, V64, P4405, DOI 10.1158/0008-5472.CAN-04-1032; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820; Moral M, 2009, CANCER RES, V69, P1099, DOI 10.1158/0008-5472.CAN-08-3240; Morri LGT, 2011, P NATL ACAD SCI USA, V108, P19024, DOI 10.1073/pnas.1111963108; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Pickering CR, 2013, CANCER DISCOV, V3, P770, DOI 10.1158/2159-8290.CD-12-0537; Raimondi C, 2012, J CELL SCI, V125, P3153, DOI 10.1242/jcs.100511; Scortegagna M, 2014, ONCOGENE, V33, P4330, DOI 10.1038/onc.2013.383; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Signore M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.188; Tan J, 2013, CANCER DISCOV, V3, P1156, DOI 10.1158/2159-8290.CD-12-0595; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Vitale-Cross L, 2009, CANCER PREV RES, V2, P419, DOI 10.1158/1940-6207.CAPR-09-0058; Vogt PK, 2009, CURR OPIN GENET DEV, V19, P12, DOI 10.1016/j.gde.2008.11.011; Wallin JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036402; Weber SM, 2011, INT J ONCOL, V39, P1193, DOI 10.3892/ijo.2011.1149; Woenckhaus J, 2002, J PATHOL, V198, P335, DOI 10.1002/path.1207; Wong KK, 2009, CANCER PREV RES, V2, P10, DOI 10.1158/1940-6207.CAPR-08-0234; Xue GD, 2012, CANCER DISCOV, V2, P248, DOI 10.1158/2159-8290.CD-11-0270; Yi JY, 2005, J BIOL CHEM, V280, P10870, DOI 10.1074/jbc.M413223200; Zhang L, 2013, TRENDS BIOCHEM SCI, V38, P612, DOI 10.1016/j.tibs.2013.10.001	54	40	41	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4641	4652		10.1038/onc.2016.1	http://dx.doi.org/10.1038/onc.2016.1			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26876212	Green Accepted			2022-12-17	WOS:000382336300010
J	Semprucci, E; Tocci, P; Cianfrocca, R; Sestito, R; Caprara, V; Veglione, M; Di Castro, V; Spadaro, F; Ferrandina, G; Bagnato, A; Rosano, L				Semprucci, E.; Tocci, P.; Cianfrocca, R.; Sestito, R.; Caprara, V.; Veglione, M.; Di Castro, V.; Spadaro, F.; Ferrandina, G.; Bagnato, A.; Rosano, L.			Endothelin A receptor drives invadopodia function and cell motility through the beta-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; CANCER CELLS; EPITHELIAL CARCINOMA; ACTIN REORGANIZATION; PDZ-RHOGEF; N-WASP; MIGRATION; ACTIVATION; RHOC; INVASION	The endothelin-1 (ET-1)/ET A receptor (ETAR) signalling pathway is a well-established driver of epithelial ovarian cancer (EOC) progression. One key process promoted by ET-1 is tumor cell invasion, which requires the scaffolding functions of beta-arrestin-1 (beta-arr1) downstream of the receptor; however, the potential role of ET-1 in inducing invadopodia, which are crucial for cellular invasion and tumor metastasis, is completely unknown. We describe here that ET-1/ETAR, through beta-arr1, activates RhoA and RhoC GTPase and downstream ROCK (Rho-associated coiled coil-forming kinase) kinase activity, promoting actin-based dynamic remodelling and enhanced cell invasion. This is accomplished by the direct interaction of beta-arr1 with PDZ-RhoGEF (postsynaptic density protein 95/disc-large/zonula occludens-RhoGEF). Interestingly, ETAR-mediated invasive properties are related to the regulation of invadopodia, as evaluated by colocalization of actin with cortactin, as well as with TKS5 and MT1-MMP (membrane type 1-matrix metalloproteinase) with areas of matrix degradation, and activation of cofilin pathway, which is crucial for regulating invadopodia activity. Depletion of PDZ-RhoGEF, or beta-arr1, or RhoC, as well as the treatment with the dual ET-1 receptor antagonist macitentan, significantly impairs invadopodia function, MMP activity and invasion, demonstrating that beta-arr1/PDZ-RhoGEF interaction mediates ETAR-driven ROCK-LIMK-cofilin pathway through the control of RhoC activity. In vivo, macitentan is able to inhibit metastatic dissemination and cofilin phosphorylation. Collectively, our data unveil a noncanonical activation of the RhoC/ROCK pathway through the beta-arr1/PDZ-RhoGEF complex as a regulator of ETAR-induced motility and metastasis, establishing ET-1 axis as a novel regulator of invadopodia protrusions through the RhoC/ROCK/LIMK/cofilin pathway during the initial steps of EOC invasion.	[Semprucci, E.; Tocci, P.; Cianfrocca, R.; Sestito, R.; Caprara, V.; Veglione, M.; Di Castro, V.; Bagnato, A.; Rosano, L.] Regina Elena Natl Canc Inst Rome, Via Elio Chianesi 53, I-00144 Rome, Italy; [Spadaro, F.] Ist Super Sanita, Dept Haematol Oncol & Mol Med, Sect Expt Immunotherapy, Rome, Italy; [Ferrandina, G.] Univ Cattolica Sacro Cuore, Gynecol Oncol Unit, Rome, Italy	Istituto Superiore di Sanita (ISS); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Bagnato, A; Rosano, L (corresponding author), Regina Elena Natl Canc Inst Rome, Via Elio Chianesi 53, I-00144 Rome, Italy.	bagnato@ifo.it; rosano@ifo.it	Rosanò, Laura/B-2863-2018; Spadaro, Francesca/M-7512-2017; ROSANO', Laura/AAK-1424-2020; Ferrandina, Gabriella/AAA-9083-2019; Sestito, Rosanna/K-2361-2018; Di Castro, Valeriana/H-8873-2017; Tocci, Piera/AAX-9815-2021; Bagnato, Anna/G-9747-2016; Tocci, Piera/ABH-7630-2020; Rosanò, Laura/AAB-7821-2019	Rosanò, Laura/0000-0002-9962-6411; Spadaro, Francesca/0000-0002-6610-350X; ROSANO', Laura/0000-0002-9962-6411; Sestito, Rosanna/0000-0001-5460-2777; Di Castro, Valeriana/0000-0002-1899-3683; Tocci, Piera/0000-0003-3771-013X; Bagnato, Anna/0000-0002-7269-9522; Rosanò, Laura/0000-0002-3981-8593; FERRANDINA, Maria Gabriella/0000-0003-4672-4197	Associazione Italiana Ricerca sul Cancro (AIRC) [AIRC 14199, AIRC 12852]; Fondazione Italiana Ricerca sul Cancro (FIRC) fellowship	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Italiana Ricerca sul Cancro (FIRC) fellowship(Fondazione AIRC per la ricerca sul cancro)	We gratefully acknowledge Aldo Lupo for excellent technical assistance, Maria Vincenza Sarcone for secretarial assistance. This work was supported by Associazione Italiana Ricerca sul Cancro (AIRC) to AB (AIRC 14199) and LR (AIRC 12852). PT is recipient of Fondazione Italiana Ricerca sul Cancro (FIRC) fellowship.	Aittaleb M, 2009, CELL SIGNAL, V21, P1569, DOI 10.1016/j.cellsig.2009.06.003; Anthony DF, 2011, MOL CELL BIOL, V31, P1066, DOI 10.1128/MCB.00883-10; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; Bravo-Cordero JJ, 2013, NAT REV MOL CELL BIO, V14, P405, DOI 10.1038/nrm3609; Bravo-Cordero JJ, 2011, CURR BIOL, V21, P635, DOI 10.1016/j.cub.2011.03.039; Chen S, 2013, INT J MOL SCI, V14, P24187, DOI 10.3390/ijms141224187; Chikumi H, 2004, ONCOGENE, V23, P233, DOI 10.1038/sj.onc.1207012; Cleghorn WM, 2015, MOL BIOL CELL, V26, P622, DOI 10.1091/mbc.E14-02-0740; Coffman L, 2013, CANCER BIOL THER, V14, P184, DOI 10.4161/cbt.22959; Cook DR, 2014, ONCOGENE, V33, P4021, DOI 10.1038/onc.2013.362; DeFea KA, 2013, PROG MOL BIOL TRANSL, V118, P205, DOI 10.1016/B978-0-12-394440-5.00008-5; Dunn HA, 2015, MOL PHARMACOL, V88, P624, DOI 10.1124/mol.115.098509; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Gligorijevic B, 2012, J CELL SCI, V125, P724, DOI 10.1242/jcs.092726; Gou WF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-477; Hall A, 2009, CANCER METAST REV, V28, P5, DOI 10.1007/s10555-008-9166-3; Horiuchi A, 2003, LAB INVEST, V83, P861, DOI 10.1097/01.LAB.0000073128.16098.31; Jaiswal M, 2011, J BIOL CHEM, V286, P18202, DOI 10.1074/jbc.M111.226431; Kim SJ, 2015, CLIN CANCER RES, V21, P4630, DOI 10.1158/1078-0432.CCR-14-3195; Kim SJ, 2012, TRANSL ONCOL, V5, P39, DOI 10.1593/tlo.11286; Kim SJ, 2011, NEOPLASIA, V13, P167, DOI 10.1593/neo.10806; Korkina O, 2013, J BIOL CHEM, V288, P5364, DOI 10.1074/jbc.M112.414060; Ma XJ, 2014, J BIOL CHEM, V289, P13638, DOI 10.1074/jbc.M113.511360; Ma XJ, 2012, J BIOL CHEM, V287, P18925, DOI 10.1074/jbc.M112.352260; Martin-Villar E, 2015, ONCOGENE, V34, P4531, DOI 10.1038/onc.2014.388; Mikelis CM, 2013, J BIOL CHEM, V288, P12232, DOI 10.1074/jbc.M112.428599; Min JA, 2011, MOL PHARMACOL, V80, P760, DOI 10.1124/mol.111.072470; Mittal N, 2013, CELL REP, V5, P1010, DOI 10.1016/j.celrep.2013.10.015; Moshfegh Y, 2014, NAT CELL BIOL, V16, P571, DOI 10.1038/ncb2972; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106; Ogata S, 2009, INT J GYNECOL CANCER, V19, P1473, DOI 10.1111/IGC.0b013e3181c03909; Patel M, 2014, MOL PHARMACOL, V86, P252, DOI 10.1124/mol.114.093914; Pichot CS, 2010, CANCER RES, V70, P8347, DOI 10.1158/0008-5472.CAN-09-4149; Ridley AJ, 2013, J MICROSC-OXFORD, V251, P242, DOI 10.1111/jmi.12025; Roh-Johnson M, 2014, ONCOGENE, V33, P4203, DOI 10.1038/onc.2013.377; Rosano L, 2005, CANCER RES, V65, P11649, DOI 10.1158/0008-5472.CAN-05-2123; Rosano L, 2013, ONCOGENE, V32, P5066, DOI 10.1038/onc.2012.527; Rosano L, 2001, CANCER RES, V61, P8340; Rosano L, 2014, CANCER RES, V74, P7453, DOI 10.1158/0008-5472.CAN-13-3133; Rosano L, 2013, NAT REV CANCER, V13, P637, DOI 10.1038/nrc3546; Rosano L, 2011, CLIN CANCER RES, V17, P2350, DOI 10.1158/1078-0432.CCR-10-2325; Rosano L, 2009, P NATL ACAD SCI USA, V106, P2806, DOI 10.1073/pnas.0807158106; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Saykali BA, 2014, CELL COMMUN ADHES, V21, P207, DOI 10.3109/15419061.2014.923845; Shankar H, 2010, J BIOL CHEM, V285, P8316, DOI 10.1074/jbc.M109.062521; Shukla AK, 2011, TRENDS BIOCHEM SCI, V36, P457, DOI 10.1016/j.tibs.2011.06.003; Siehler S, 2009, BRIT J PHARMACOL, V158, P41, DOI 10.1111/j.1476-5381.2009.00121.x; Spiering D, 2011, CELL ADHES MIGR, V5, P170, DOI 10.4161/cam.5.2.14403; Spinella F, 2013, J MOL MED, V91, P395, DOI 10.1007/s00109-012-0956-2; Struckhoff AP, 2013, J CELL SCI, V126, P4514, DOI 10.1242/jcs.132381; Ward JD, 2015, CANCER LETT, V356, P382, DOI 10.1016/j.canlet.2014.09.030; Xiao K, 2007, P NATL ACAD SCI USA, V104, P12011, DOI 10.1073/pnas.0704849104; Zhao Y, 2013, GYNECOL ONCOL, V130, P570, DOI 10.1016/j.ygyno.2013.06.004; Zhao Y, 2010, GYNECOL ONCOL, V116, P563, DOI 10.1016/j.ygyno.2009.11.015; Zheng R, 2006, ONCOGENE, V25, P5942, DOI 10.1038/sj.onc.1209586; Zoudilova M, 2010, J BIOL CHEM, V285, P14318, DOI 10.1074/jbc.M109.055806	57	40	40	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3432	3442		10.1038/onc.2015.403	http://dx.doi.org/10.1038/onc.2015.403			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26522724				2022-12-17	WOS:000379270100008
J	Silginer, M; Burghardt, I; Gramatzki, D; Bunse, L; Leske, H; Rushing, EJ; Hao, N; Platten, M; Weller, M; Roth, P				Silginer, M.; Burghardt, I.; Gramatzki, D.; Bunse, L.; Leske, H.; Rushing, E. J.; Hao, N.; Platten, M.; Weller, M.; Roth, P.			The aryl hydrocarbon receptor links integrin signaling to the TGF-beta pathway	ONCOGENE			English	Article							TRANSFORMING GROWTH FACTOR-BETA(1); CELL-CELL CONTACT; DIOXIN RECEPTOR; MEDIATED INDUCTION; EPITHELIAL-CELLS; DOWN-REGULATION; LIGAND-BINDING; GLIOMA-CELLS; IN-VITRO; EXPRESSION	Glioblastoma is the most common and aggressive form of intrinsic brain tumor. Transforming growth factor (TGF)-beta represents a central mediator of the malignant phenotype of these tumors by promoting invasiveness and angiogenesis, maintaining tumor cell stemness and inducing profound immunosuppression. Integrins, which are highly expressed in glioma cells, interact with the TGF-beta pathway. Furthermore, a link has been described between activity of the transcription factor aryl hydrocarbon receptor (AhR) and TGF-beta expression. Here we demonstrate that integrin inhibition, using alpha v, beta 3 or beta 5 neutralizing antibodies, RNA interference-mediated integrin gene silencing or pharmacological inhibition by the cyclic RGD peptide EMD 121974 (cilengitide) or the non-peptidic molecule GLPG0187, inhibits AhR activity. These effects are independent of cell detachment or cell density. While AhR mRNA expression was not affected by integrin inhibition, AhR total and nuclear protein levels were reduced, suggesting that integrin inhibition-mediated regulation of AhR may occur at a post-transcriptional level. AhR-null astrocytes, AhR-null hepatocytes or glioblastoma cells with a transiently silenced AhR gene showed reduced sensitivity to integrin inhibition-mediated alterations in TGF-beta signaling, indicating that AhR mediates integrin control of the TGF-beta pathway. Accordingly, there was a significant correlation of av integrin levels with nuclear AhR and pSmad2 levels as determined by immunohistochemistry in human glioblastoma in vivo. In summary, this study identifies a signaling network comprising integrins, AhR and TGF-beta and validates integrin inhibition as a promising strategy not only to inhibit angiogenesis, but also to block AhR-and TGF-beta-controlled features of malignancy in human glioblastoma.	[Silginer, M.; Burghardt, I.; Gramatzki, D.; Weller, M.; Roth, P.] Univ Zurich, Univ Zurich Hosp, Dept Neurol, Lab Mol Neurooncol, Zurich, Switzerland; [Bunse, L.; Platten, M.] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Dept Neurol, Heidelberg, Germany; [Bunse, L.; Platten, M.] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany; [Leske, H.; Rushing, E. J.] Univ Zurich, Univ Zurich Hosp, Inst Neuropathol, Zurich, Switzerland; [Hao, N.] Univ Adelaide, Sch Biol Sci, Adelaide, SA, Australia	University of Zurich; University Zurich Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Zurich; University Zurich Hospital; University of Adelaide	Roth, P (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklinikstr 26, CH-8091 Zurich, Switzerland.	patrick.roth@usz.ch	Platten, Michael/F-2902-2013; Bunse, Lukas/L-2975-2016; Roth, Patrick/R-6671-2018; Hao, Nan/H-2129-2016	Platten, Michael/0000-0002-4746-887X; Bunse, Lukas/0000-0002-4490-7574; Roth, Patrick/0000-0003-3897-214X; Hao, Nan/0000-0001-5836-3507; Silginer, Manuela/0000-0003-2538-1244; Weller, Michael/0000-0002-1748-174X	Novartis Foundation for medical-biological research; Kurt und Senta Herrmann Foundation; Heidelberg University Innovation Fund FRONTIER	Novartis Foundation for medical-biological research; Kurt und Senta Herrmann Foundation; Heidelberg University Innovation Fund FRONTIER	This study was supported by grants from the Novartis Foundation for medical-biological research and the Kurt und Senta Herrmann Foundation to PR and the Heidelberg University Innovation Fund FRONTIER to MP.	Abe Y, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-27; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Carraro G, 2005, MOL CELL PROBE, V19, P181, DOI 10.1016/j.mcp.2004.11.004; Cho YC, 2004, TOXICOL APPL PHARM, V199, P220, DOI 10.1016/j.taap.2003.12.025; Codo P, 2014, ONCOTARGET, V5, P7651, DOI 10.18632/oncotarget.2287; Corchero J, 2004, INT J EXP PATHOL, V85, P295, DOI 10.1111/j.0959-9673.2004.00397.x; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; Denison MS, 2002, CURR PROTOC TOXICOL; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dietrich C, 2010, CARCINOGENESIS, V31, P1319, DOI 10.1093/carcin/bgq028; Dohr O, 1997, MOL PHARMACOL, V51, P703, DOI 10.1124/mol.51.5.703; Feng SL, 2013, BBA-REV CANCER, V1836, P197, DOI 10.1016/j.bbcan.2013.05.001; GAIDO KW, 1992, J BIOL CHEM, V267, P24591; Goodman SL, 2012, BIOL OPEN, V1, P329, DOI 10.1242/bio.2012364; Gramatzki D, 2009, ONCOGENE, V28, P2593, DOI 10.1038/onc.2009.104; Hao N, 2012, MOL PHARMACOL, V82, P1082, DOI 10.1124/mol.112.078873; Ikuta T, 2004, J BIOL CHEM, V279, P19209, DOI 10.1074/jbc.M310492200; Joseph JV, 2013, BIOCHEM PHARMACOL, V85, P478, DOI 10.1016/j.bcp.2012.11.005; Juan SH, 2006, EUR J PHARMACOL, V530, P1, DOI 10.1016/j.ejphar.2005.11.023; KINSEL LB, 1989, CANCER RES, V49, P1052; Kraus JA, 2012, MODERN PATHOL, V25, P869, DOI 10.1038/modpathol.2011.219; Kress S, 1998, EUR J BIOCHEM, V258, P803, DOI 10.1046/j.1432-1327.1998.2580803.x; Kung T, 2009, BIOCHEM PHARMACOL, V77, P536, DOI 10.1016/j.bcp.2008.09.031; MASON GGF, 1994, J BIOL CHEM, V269, P4438; Maurer GD, 2009, NEURO-ONCOLOGY, V11, P747, DOI 10.1215/15228517-2009-012; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Monteiro P, 2007, BIOCHEM BIOPH RES CO, V358, P442, DOI 10.1016/j.bbrc.2007.04.111; Mulero-Navarro S, 2005, J BIOL CHEM, V280, P28731, DOI 10.1074/jbc.M504538200; Murray IA, 2005, ARCH BIOCHEM BIOPHYS, V442, P59, DOI 10.1016/j.abb.2005.07.014; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; Nguyen LP, 2008, CHEM RES TOXICOL, V21, P102, DOI 10.1021/tx7001965; Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491; Prell RA, 1997, J IMMUNOL, V158, P2695; Riecke K, 2003, ARCH TOXICOL, V77, P358, DOI 10.1007/s00204-003-0445-z; Rodon J, 2015, INVEST NEW DRUG, V33, P357, DOI 10.1007/s10637-014-0192-4; Roth P, 2013, BRAIN, V136, P564, DOI 10.1093/brain/aws351; SADEK CM, 1994, J BIOL CHEM, V269, P16067; SADEK CM, 1994, J BIOL CHEM, V269, P31505; Safe S, 2013, TOXICOL SCI, V135, P1, DOI 10.1093/toxsci/kft128; Santiago-Josefat B, 2004, J CELL SCI, V117, P849, DOI 10.1242/jcs.00932; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Silginer M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.543; Stockinger B, 2014, ANNU REV IMMUNOL, V32, P403, DOI 10.1146/annurev-immunol-032713-120245; TOWNSEND D, 1981, J EXP ZOOL, V216, P113, DOI 10.1002/jez.1402160112; VOGEL C, 1995, ARCH TOXICOL, V69, P259, DOI 10.1007/s002040050168; Wirsching HG, 2014, BRAIN, V137, P433, DOI 10.1093/brain/awt333; Wolff S, 2001, MOL PHARMACOL, V59, P716, DOI 10.1124/mol.59.4.716	47	40	42	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3260	3271		10.1038/onc.2015.387	http://dx.doi.org/10.1038/onc.2015.387			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26500056	Green Accepted			2022-12-17	WOS:000378306400005
J	Kitatani, K; Usui, T; Sriraman, SK; Toyoshima, M; Ishibashi, M; Shigeta, S; Nagase, S; Sakamoto, M; Ogiso, H; Okazaki, T; Hannun, YA; Torchilin, VP; Yaegashi, N				Kitatani, K.; Usui, T.; Sriraman, S. K.; Toyoshima, M.; Ishibashi, M.; Shigeta, S.; Nagase, S.; Sakamoto, M.; Ogiso, H.; Okazaki, T.; Hannun, Y. A.; Torchilin, V. P.; Yaegashi, N.			Ceramide limits phosphatidylinositol-3-kinase C2 beta-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; SHORT-CHAIN CERAMIDE; ACTIVATED PROTEIN-KINASE; LIPOSOMAL DELIVERY; INDUCED APOPTOSIS; ARACHIDONIC-ACID; EPITHELIAL-CELLS; FACTOR RECEPTOR; OKADAIC ACID; C2 DOMAIN	Targeting cell motility, which is required for dissemination and metastasis, has therapeutic potential for ovarian cancer metastasis, and regulatory mechanisms of cell motility need to be uncovered for developing novel therapeutics. Invasive ovarian cancer cells spontaneously formed protrusions, such as lamellipodia, which are required for generating locomotive force in cell motility. Short interfering RNA screening identified class II phosphatidylinositol 3-kinase C2 beta (PI3KC2 beta) as the predominant isoform of PI3K involved in lamellipodia formation of ovarian cancer cells. The bioactive sphingolipid ceramide has emerged as an antitumorigenic lipid, and treatment with short-chain C-6-ceramide decreased the number of ovarian cancer cells with PI3KC2 beta-driven lamellipodia. Pharmacological analysis demonstrated that long-chain ceramide regenerated from C-6-ceramide through the salvage/recycling pathway, at least in part, mediated the action of C-6-ceramide. Mechanistically, ceramide was revealed to interact with the PIK-catalytic domain of PI3KC2 beta and affect its compartmentalization, thereby suppressing PI3KC2 beta activation and its driven cell motility. Ceramide treatment also suppressed cell motility promoted by epithelial growth factor, which is a prometastatic factor. To examine the role of ceramide in ovarian cancer metastasis, ceramide liposomes were employed and confirmed to suppress cell motility in vitro. Ceramide liposomes had an inhibitory effect on peritoneal metastasis in a murine xenograft model of human ovarian cancer. Metastasis of PI3KC2 beta knocked-down cells was insensitive to treatment with ceramide liposomes, suggesting specific involvement of ceramide interaction with PI3KC2 beta in metastasis suppression. Our study identified ceramide as a bioactive lipid that limits PI3KC2 beta-governed cell motility, and ceramide is proposed to serve as a metastasis-suppressor lipid in ovarian cancer. These findings could be translated into developing ceramide-based therapy for metastatic diseases.	[Kitatani, K.; Usui, T.; Yaegashi, N.] Tohoku Univ, Grad Sch Med, Tohoku Med Megabank Org, Sendai, Miyagi 980, Japan; [Kitatani, K.; Toyoshima, M.; Ishibashi, M.; Shigeta, S.; Sakamoto, M.; Yaegashi, N.] Tohoku Univ, Grad Sch Med, Dept Obstet & Gynecol, Sendai, Miyagi 980, Japan; [Sriraman, S. K.; Torchilin, V. P.] Northeastern Univ, Ctr Pharmaceut Biotechnol & Nanomed, Dept Pharmaceut Sci, Boston, MA 02115 USA; [Nagase, S.] Yamagata Univ, Dept Obstet & Gynecol, Yamagata 990, Japan; [Ogiso, H.; Okazaki, T.] Kanazawa Med Univ, Dept Life Sci, Med Res Inst, Uchinada, Ishikawa 92002, Japan; [Okazaki, T.] Kanazawa Med Univ, Dept Med, Div Hematol Immunol, Uchinada, Ishikawa 92002, Japan; [Hannun, Y. A.] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA; [Hannun, Y. A.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA	Tohoku University; Tohoku University; Northeastern University; Yamagata University; Kanazawa Medical University; Kanazawa Medical University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kitatani, K (corresponding author), Tohoku Univ, Grad Sch Med, Dept Obstet & Gynecol, Tohoku Med Megabank Org,Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9800873, Japan.	kitatani@med.tohoku.ac.jp	Kitatani, Kazuyuki/H-7100-2019	Kitatani, Kazuyuki/0000-0002-8516-6135; Nagase, Satoru/0000-0001-5212-1128; xing zhi, shi zhi/0000-0003-3289-5681; Ogiso, Hideo/0000-0002-8241-3006	JSPS KAKENHI [40539235, 24390375, 23791801]; Health Labour Sciences Research Grant [201221019A]; National Institutes of Health [U54 CA151881, CA087584]; NATIONAL CANCER INSTITUTE [U54CA151881, R01CA172517, P01CA097132, R01CA087584] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [26462509, 26670710] Funding Source: KAKEN	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Health Labour Sciences Research Grant(Ministry of Health, Labour and Welfare, Japan); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported in part by JSPS KAKENHI Grants (40539235 to KK, 24390375 to NY and 23791801 to MT), a Health Labour Sciences Research Grant (201221019A to NY), and National Institutes of Health grants (U54 CA151881 to VPT and CA087584 to YAH). We also thank the laboratory members of the Departments of Microbiology and Immunology, and Obstetrics and Gynecology (Tohoku University, Sendai) for critical discussion.	Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; Aschrafi A, 2003, BBA-MOL CELL BIOL L, V1634, P30, DOI 10.1016/j.bbalip.2003.08.004; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Banerjee S, 2013, CLIN CANCER RES, V19, P961, DOI 10.1158/1078-0432.CCR-12-2243; Bartlett JMS, 1996, BRIT J CANCER, V73, P301, DOI 10.1038/bjc.1996.53; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boddapati SV, 2008, NANO LETT, V8, P2559, DOI 10.1021/nl801908y; Boller D, 2012, ANTICANCER RES, V32, P3015; Calzolari A, 2007, BLOOD CELL MOL DIS, V39, P82, DOI 10.1016/j.bcmd.2007.02.003; Chalfant CE, 2004, J LIPID RES, V45, P496, DOI 10.1194/jlr.M300347-JLR200; Clarke CJ, 2007, J BIOL CHEM, V282, P1384, DOI 10.1074/jbc.M609216200; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; Edmond V, 2015, ONCOGENE, V34, P996, DOI 10.1038/onc.2014.55; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Garzotto M, 1998, CANCER RES, V58, P2260; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Huwiler A, 2001, FASEB J, V15, P7; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; Ip CKM, 2011, ONCOGENE, V30, P2420, DOI 10.1038/onc.2010.615; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Karahatay S, 2007, CANCER LETT, V256, P101, DOI 10.1016/j.canlet.2007.06.003; Kitatani K, 2008, CELL SIGNAL, V20, P1010, DOI 10.1016/j.cellsig.2007.12.006; Kitatani K, 2007, J BIOL CHEM, V282, P20647, DOI 10.1074/jbc.M609162200; Kitatani K, 2006, J BIOL CHEM, V281, P36793, DOI 10.1074/jbc.M608137200; Kitatani K, 2009, J BIOL CHEM, V284, P12979, DOI 10.1074/jbc.M809500200; Koshkaryev A, 2012, CANCER BIOL THER, V13, P50, DOI 10.4161/cbt.13.1.18871; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Maffucci T, 2005, J CELL BIOL, V169, P789, DOI 10.1083/jcb.200408005; Meyer AS, 2012, J CELL BIOL, V197, P721, DOI 10.1083/jcb.201201003; Morad SAF, 2013, NAT REV CANCER, V13, P51, DOI 10.1038/nrc3398; Mukhopadhyay A, 2009, FASEB J, V23, P751, DOI 10.1096/fj.08-120550; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Niikura H, 1997, INT J GYNECOL PATHOL, V16, P60, DOI 10.1097/00004347-199701000-00010; Nitta M, 2001, GYNECOL ONCOL, V81, P10, DOI 10.1006/gyno.2000.6084; Nurnberg A, 2011, NAT REV CANCER, V11, P177, DOI 10.1038/nrc3003; Ogiso H, 2014, METABOLITES, V4, P98, DOI 10.3390/metabo4010098; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Park JW, 2014, BBA-MOL CELL BIOL L, V1841, P671, DOI 10.1016/j.bbalip.2013.08.019; Pua TL, 2009, FUTURE ONCOL, V5, P1659, DOI [10.2217/fon.09.120, 10.2217/FON.09.120]; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Stover T, 2003, J PHARMACOL EXP THER, V307, P468, DOI 10.1124/jpet.103.054056; Stover TC, 2005, CLIN CANCER RES, V11, P3465, DOI 10.1158/1078-0432.CCR-04-1770; Stratford S, 2004, J BIOL CHEM, V279, P36608, DOI 10.1074/jbc.M406499200; Sun Y, 2008, J LEUKOCYTE BIOL, V83, P1512, DOI 10.1189/jlb.0108076; Takeda S, 2006, J BIOCHEM, V139, P255, DOI 10.1093/jb/mvj026; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632; Tran MA, 2008, CLIN CANCER RES, V14, P3571, DOI 10.1158/1078-0432.CCR-07-4881; van Vlerken LE, 2007, CANCER RES, V67, P4843, DOI 10.1158/0008-5472.CAN-06-1648; WANG E, 1991, J BIOL CHEM, V266, P14486; Wells A, 2013, TRENDS PHARMACOL SCI, V34, P283, DOI 10.1016/j.tips.2013.03.001; Wijesinghe DS, 2005, J LIPID RES, V46, P2706, DOI 10.1194/jlr.M500313-JLR200; Xue GD, 2013, JNCI-J NATL CANCER I, V105, P393, DOI 10.1093/jnci/djs648; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yin XL, 2009, CELL PHYSIOL BIOCHEM, V24, P219, DOI 10.1159/000233248; Yoshizaki H, 2007, MOL BIOL CELL, V18, P119, DOI 10.1091/mbc.E06-05-0467; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zhou HY, 2007, ENDOCRINOLOGY, V148, P5195, DOI 10.1210/en.2007-0361	70	40	40	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2801	2812		10.1038/onc.2015.330	http://dx.doi.org/10.1038/onc.2015.330			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26364609	Green Accepted			2022-12-17	WOS:000377472700013
J	Deguchi, A; Tomita, T; Ohto, U; Takemura, K; Kitao, A; Akashi-Takamura, S; Miyake, K; Maru, Y				Deguchi, A.; Tomita, T.; Ohto, U.; Takemura, K.; Kitao, A.; Akashi-Takamura, S.; Miyake, K.; Maru, Y.			Eritoran inhibits S100A8-mediated TLR4/MD-2 activation and tumor growth by changing the immune microenvironment	ONCOGENE			English	Article							CALCIUM-BINDING PROTEINS; TOLL-LIKE RECEPTORS; NF-KAPPA-B; S100 PROTEINS; SIGNAL-TRANSDUCTION; SUPPRESSOR-CELLS; STRUCTURAL BASIS; MYELOID CELLS; TLR4; EXPRESSION	S100A8/A9 is a major component of the acute phase of inflammation, and appears to regulate cell proliferation, redox regulation and chemotaxis. We previously reported that S100A8/S100A9 are upregulated in the premetastatic lung. However, the detailed mechanisms by which S100A8 contributes to tumor progression have not been elucidated. In this study, we investigated the TLR4/MD-2 dependency by S100A8 on tumor progression. We found that S100A8 (2-89) peptide stimulated cell migration in a manner dependent on TLR4, MD-2 and MyD88. The S100A8 (2-89) peptide also activated p38 and NF-kappa B in TLR4-dependent manner. The peptide induced the upregulation of both IL-6 and Ccl2 in peritoneal macrophages obtained from wild-type mice, but not TLR4-deficient mice. We then investigated the responsible region of S100A8 for TLR4/MD-2 binding by a binding assay, and found that C-terminal region of S100A8 binds to TLR4/MD-2 complex. To further evaluate the TLR4 dependency on tumor microenvironment, Lewis lung carcinoma-bearing mice were treated with Eritoran, an antagonist of TLR4/MD-2 complex. We found that both tumor volume and pulmonary recruitment of myeloid-derived suppressor cells were reduced with the treatment of Eritoran for five consecutive days. Eritoran reduced the development of tumor vasculature, and increased tumor-infiltration of CD8(+) T-cells. Taken together, S100A8 appears to play a crucial role in the activation of the TLR4/MD-2 pathway and the promotion of a tumor growth-enhancing immune microenvironment.	[Deguchi, A.; Tomita, T.; Maru, Y.] Tokyo Womens Med Univ, Dept Pharmacol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan; [Ohto, U.] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo, Japan; [Takemura, K.; Kitao, A.] Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo, Japan; [Akashi-Takamura, S.] Aichi Med Univ, Dept Microbiol & Immunol, Nagakute, Aichi 48011, Japan; [Miyake, K.] Univ Tokyo, Inst Med Sci, Div Infect Genet, Tokyo, Japan	Tokyo Women's Medical University; University of Tokyo; University of Tokyo; Aichi Medical University; University of Tokyo	Deguchi, A; Maru, Y (corresponding author), Tokyo Womens Med Univ, Dept Pharmacol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	deguchi@research.twmu.ac.jp; ymaru@research.twmu.ac.jp	Kitao, Akio/B-8371-2008	Kitao, Akio/0000-0002-5221-0806; Takemura, Kazuhiro/0000-0001-5946-4502; Tomita, Takeshi/0000-0001-6815-2244	Ministry of Education, Culture, Sports, Science and Technology of Japan [21117008, 24501321, 26440063]; Grants-in-Aid for Scientific Research [15H04357] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Drs Hiroyuki Aburatani and Akira Watanabe (Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo) for providing an expression system for mammalian cell-derived S100A8, and Dr Mihich (Roswell Park Cancer Institute, NY, USA) for providing E0771 cells. We thank Dr Tatsuya Shimizu (Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University) for cell sorting technology. We also thank Dr Sachie Hiratsuka for valuable discussion and Messr. Tsutomu Omori and Taishi Mishima for technical assistance. This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to YM, 21117008) (to AD, 24501321) (to TT, 26440063).	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Andreani V, 2007, CANCER RES, V67, P10519, DOI 10.1158/0008-5472.CAN-07-0079; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Bjork P, 2009, PLOS BIOL, V7, P800, DOI 10.1371/journal.pbio.1000097; Chen KQ, 2007, INT IMMUNOPHARMACOL, V7, P1271, DOI 10.1016/j.intimp.2007.05.016; Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389; Deguchi A, 2013, J IMMUNOL, V191, P1856, DOI 10.4049/jimmunol.1201996; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Doyle SL, 2006, BIOCHEM PHARMACOL, V72, P1102, DOI 10.1016/j.bcp.2006.07.010; Eckert RL, 2004, J INVEST DERMATOL, V123, P23, DOI 10.1111/j.0022-202X.2004.22719.x; Ehrchen JM, 2009, J LEUKOCYTE BIOL, V86, P557, DOI 10.1189/jlb.1008647; Ewens A, 2005, ANTICANCER RES, V25, P3905; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Ghavami S, 2008, J LEUKOCYTE BIOL, V83, P1484, DOI 10.1189/jlb.0607397; Grimbaldeston MA, 2003, J INVEST DERMATOL, V121, P1168, DOI 10.1046/j.1523-1747.2003.12561.x; Healy AM, 2006, CIRCULATION, V113, P2278, DOI 10.1161/CIRCULATIONAHA.105.607333; HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197, DOI 10.1002/jlb.53.2.197; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hiratsuka S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2856; Hsu K, 2005, J IMMUNOL, V174, P2318, DOI 10.4049/jimmunol.174.4.2318; Hsu RYC, 2011, CANCER RES, V71, P1989, DOI 10.1158/0008-5472.CAN-10-2833; Huang YH, 2012, P NATL ACAD SCI USA, V109, P17561, DOI 10.1073/pnas.1215397109; Hunter MJ, 1998, J BIOL CHEM, V273, P12427, DOI 10.1074/jbc.273.20.12427; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kawasaki K, 2001, J ENDOTOXIN RES, V7, P232, DOI 10.1177/09680519010070030701; Kerkhoff C, 2005, FASEB J, V19, P467, DOI 10.1096/fj.04-2377fje; Kim HM, 2007, CELL, V130, P906, DOI 10.1016/j.cell.2007.08.002; Kitamura T, 2010, P NATL ACAD SCI USA, V107, P13063, DOI 10.1073/pnas.1002372107; Kumar A, 2003, INT ARCH ALLERGY IMM, V132, P40, DOI 10.1159/000073263; Kumar RK, 2001, J LEUKOCYTE BIOL, V70, P59; Mantovani A, 2015, J EXP MED, V212, P435, DOI 10.1084/jem.20150295; McCormick MM, 2005, J BIOL CHEM, V280, P41521, DOI 10.1074/jbc.M509442200; Merline R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001868; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Ohto U, 2012, P NATL ACAD SCI USA, V109, P7421, DOI 10.1073/pnas.1201193109; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Omori S, 2013, PROTEINS, V81, P1005, DOI 10.1002/prot.24252; Pal D, 2012, NAT MED, V18, P1279, DOI 10.1038/nm.2851; Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830; Passey RJ, 1999, J IMMUNOL, V163, P2209; Pierce BG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024657; Propper C, 1999, J BIOL CHEM, V274, P183, DOI 10.1074/jbc.274.1.183; Qin H, 2014, NAT MED, V20, P676, DOI 10.1038/nm.3560; Rahimi F, 2005, FEBS J, V272, P2811, DOI 10.1111/j.1742-4658.2005.04703.x; Rajput S, 2013, MOL CANCER THER, V12, P1676, DOI 10.1158/1535-7163.MCT-12-1019; Rammes A, 1997, J BIOL CHEM, V272, P9496; Riva M, 2012, IMMUNOLOGY, V137, P172, DOI 10.1111/j.1365-2567.2012.03619.x; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Schaefer L, 2005, J CLIN INVEST, V115, P2223, DOI 10.1172/JCI23755; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; Shi C, 2011, IMMUNITY, V34, P590, DOI 10.1016/j.immuni.2011.02.016; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Szajnik M, 2009, ONCOGENE, V28, P4353, DOI 10.1038/onc.2009.289; Szczepanski MJ, 2009, CANCER RES, V69, P3105, DOI 10.1158/0008-5472.CAN-08-3838; Tomita T, 2011, ONCOGENE, V30, P3429, DOI 10.1038/onc.2011.53; Turovskaya O, 2008, CARCINOGENESIS, V29, P2035, DOI 10.1093/carcin/bgn188; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Vogl T, 2004, BLOOD, V104, P4260, DOI 10.1182/blood-2004-02-0446; Vogl T, 2006, BBA-MOL CELL RES, V1763, P1298, DOI 10.1016/j.bbamcr.2006.08.028; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Volk-Draper L, 2014, CANCER RES, V74, P5421, DOI 10.1158/0008-5472.CAN-14-0067; Xu K, 2001, J IMMUNOL, V166, P6358, DOI 10.4049/jimmunol.166.10.6358; Yang HA, 2010, P NATL ACAD SCI USA, V107, P11942, DOI 10.1073/pnas.1003893107; Yen T, 1997, BLOOD, V90, P4812, DOI 10.1182/blood.V90.12.4812.4812_4812_4821; Zreiqat H, 2007, J MOL HISTOL, V38, P381, DOI 10.1007/s10735-007-9117-2	73	40	43	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1445	1456		10.1038/onc.2015.211	http://dx.doi.org/10.1038/onc.2015.211			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26165843				2022-12-17	WOS:000372196400010
J	Pytel, D; Majsterek, I; Diehl, JA				Pytel, D.; Majsterek, I.; Diehl, J. A.			Tumor progression and the different faces of the PERK kinase	ONCOGENE			English	Review							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; ELEMENT-MEDIATED EXPRESSION; INDUCED GENE-EXPRESSION; CUL3-BASED E3 LIGASE; INDUCED ER STRESS; TRANSCRIPTION FACTOR; PHOSPHATIDIC-ACID; TRANSLATIONAL CONTROL; DEPENDENT REGULATION	The serine/threonine endoplasmic reticulum (ER) kinase, protein kinase R (PKR)-like ER kinase (PERK), is a pro-adaptive protein kinase whose activity is regulated indirectly by protein misfolding within the ER. As the oxidative folding environment in the ER is sensitive to a variety of cellular stresses, many of which occur during neoplastic transformation and in the tumor microenvironment, there has been considerable interest in defining whether PERK positively contributes to tumor progression and whether it represents a significant therapeutic target. Herein, we review the current knowledge of PERK-dependent signaling pathways, the contribution of downstream substrates including recently characterized new PERK substrates transcription factors Forkhead box O protein and diacyglycerol a lipid signaling second messenger, and efforts to develop small molecule PERK inhibitors.	[Pytel, D.; Diehl, J. A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Hollings Canc Ctr, HO-712F, Charleston, SC 29425 USA; [Majsterek, I.] Med Univ Lodz, Dept Clin Chem & Biochem, Hallera 1, Lodz, Poland	Medical University of South Carolina; Medical University Lodz	Pytel, D; Diehl, JA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Hollings Canc Ctr, HO-712F, Charleston, SC 29425 USA.	pytel@musc.edu; diehl@musc.edu		Majsterek, Ireneusz/0000-0001-6231-3334	National Institutes of Health [CA104838]; Polish National Science Centre (NCN) 'HARMONIA 5' grant [2013/10/M/N21/00280]; NATIONAL CANCER INSTITUTE [T32CA009140, P01CA104838] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Polish National Science Centre (NCN) 'HARMONIA 5' grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health grant CA104838 (JAD); Polish National Science Centre (NCN) 'HARMONIA 5' grant no. 2013/10/M/N21/00280.	Ackerman D, 2014, TRENDS CELL BIOL, V24, P472, DOI 10.1016/j.tcb.2014.06.001; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Atkins C, 2013, CANCER RES, V73, P1993, DOI 10.1158/0008-5472.CAN-12-3109; Axten JM, 2013, ACS MED CHEM LETT, V4, P964, DOI 10.1021/ml400228e; Axten JM, 2012, J MED CHEM, V55, P7193, DOI 10.1021/jm300713s; B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563; Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Bhattacharya S, 2013, ONCOGENE, V32, P4214, DOI 10.1038/onc.2012.439; Bhattacharya S, 2011, BLOOD, V118, P4179, DOI 10.1182/blood-2010-12-325373; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Bobrovnikova-Marjon E, 2010, ONCOGENE, V29, P3881, DOI 10.1038/onc.2010.153; Bobrovnikova-Marjon E, 2008, P NATL ACAD SCI USA, V105, P16314, DOI 10.1073/pnas.0808517105; Bobrovnikova-Marjon E, 2012, MOL CELL BIOL, V32, P2268, DOI 10.1128/MCB.00063-12; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brewer JW, 1997, EMBO J, V16, P7207, DOI 10.1093/emboj/16.23.7207; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Byrd AE, 2012, J CELL BIOL, V196, P689, DOI 10.1083/jcb.201201077; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Carbajo-Pescador S, 2014, CURR MED CHEM, V21, P1231, DOI 10.2174/0929867321666131228205703; Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chang RCC, 2002, NEUROREPORT, V13, P2429, DOI 10.1097/00001756-200212200-00011; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chikka MR, 2013, J BIOL CHEM, V288, P4405, DOI 10.1074/jbc.M112.432344; Chitnis N, 2013, TRENDS BIOCHEM SCI, V38, P447, DOI 10.1016/j.tibs.2013.06.012; Chitnis NS, 2012, MOL CELL, V48, P353, DOI 10.1016/j.molcel.2012.08.025; Coelho DS, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00076; Cox JS, 1997, MOL BIOL CELL, V8, P1805, DOI 10.1091/mbc.8.9.1805; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Cross BCS, 2012, P NATL ACAD SCI USA, V109, pE869, DOI 10.1073/pnas.1115623109; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Cullinan SB, 2006, INT J BIOCHEM CELL B, V38, P317, DOI 10.1016/j.biocel.2005.09.018; Del Vecchio CA, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001945; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; DeVries-Seimon T, 2005, J CELL BIOL, V171, P61, DOI 10.1083/jcb.200502078; DeZwaan-McCabe D, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003937; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Dimcheff DE, 2003, J VIROL, V77, P12617, DOI 10.1128/JVI.77.23.12617-12629.2003; Espenshade PJ, 2007, ANNU REV GENET, V41, P401, DOI 10.1146/annurev.genet.41.110306.130315; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Finnie JW, 2000, VET PATHOL, V37, P677, DOI 10.1354/vp.37-6-677; Frohlich DA, 2008, ONCOGENE, V27, P4353, DOI 10.1038/onc.2008.79; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Gao Y, 2012, MOL CELL BIOL, V32, P5129, DOI 10.1128/MCB.01009-12; de la Cadena SC, 2014, APOPTOSIS, V19, P414, DOI 10.1007/s10495-013-0930-7; Garg AD, 2012, TRENDS MOL MED, V18, P589, DOI 10.1016/j.molmed.2012.06.010; Ghosh R, 2014, CELL, V158, P534, DOI 10.1016/j.cell.2014.07.002; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; Gupta S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.74; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hamanaka RB, 2009, ONCOGENE, V28, P910, DOI 10.1038/onc.2008.428; Hamanaka RB, 2005, MOL BIOL CELL, V16, P5493, DOI 10.1091/mbc.E05-03-0268; Hami LS, 2004, CYTOTHERAPY, V6, P554, DOI 10.1080/14653240410005348; Han J, 2013, NAT CELL BIOL, V15, P481, DOI 10.1038/ncb2738; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hoozemans JJM, 2007, BIOCHEM BIOPH RES CO, V354, P707, DOI 10.1016/j.bbrc.2007.01.043; Hoozemans JJM, 2005, ACTA NEUROPATHOL, V110, P165, DOI 10.1007/s00401-005-1038-0; Hu P, 2004, J BIOL CHEM, V279, P49420, DOI 10.1074/jbc.M407700200; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Isler JA, 2005, J VIROL, V79, P6890, DOI 10.1128/JVI.79.11.6890-6899.2005; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; Kanamori M, 2015, NEURO-ONCOLOGY, V17, P555, DOI 10.1093/neuonc/nou282; Karaskov E, 2006, ENDOCRINOLOGY, V147, P3398, DOI 10.1210/en.2005-1494; Keniry M, 2013, GENE DEV, V27, P916, DOI 10.1101/gad.214049.113; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Kim YI, 2014, MOL CELL BIOL, V34, P4368, DOI 10.1128/MCB.00599-14; Kincaid MM, 2007, ANTIOXID REDOX SIGN, V9, P2373, DOI 10.1089/ars.2007.1817; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Kusio-Kobialka M, 2012, CELL CYCLE, V11, P4069, DOI 10.4161/cc.22387; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lees JR, 2007, J CLIN INVEST, V117, P297, DOI 10.1172/JCI31254; Leung L, 2003, J BIOL CHEM, V278, P48021, DOI 10.1074/jbc.M308439200; Li W, 2008, BBA-MOL CELL RES, V1783, P1847, DOI 10.1016/j.bbamcr.2008.05.024; Lim HK, 2003, J BIOL CHEM, V278, P45117, DOI 10.1074/jbc.M303789200; Lin WS, 2007, J CLIN INVEST, V117, P448, DOI 10.1172/JCI29571; Ma K, 2002, J BIOL CHEM, V277, P18728, DOI 10.1074/jbc.M200903200; Mahadevan NR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051845; Mahadevan NR, 2011, P NATL ACAD SCI USA, V108, P6561, DOI 10.1073/pnas.1008942108; Malhi H, 2008, SEMIN LIVER DIS, V28, P360, DOI 10.1055/s-0028-1091980; Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006; Meares GP, 2014, MOL CELL BIOL, V34, P3911, DOI 10.1128/MCB.00980-14; MILLER PF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P151, DOI 10.1016/0167-4781(90)90157-W; Mohammad MK, 2012, TOXICOL APPL PHARM, V265, P73, DOI 10.1016/j.taap.2012.09.021; Mor A, 2007, NAT CELL BIOL, V9, P713, DOI 10.1038/ncb1592; Moreno JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006767; Moreno JA, 2012, NATURE, V485, P507, DOI 10.1038/nature11058; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nagata T, 2007, NEUROL RES, V29, P767, DOI 10.1179/016164107X229803; Natalini PM, 2014, EXP EYE RES, V125, P142, DOI 10.1016/j.exer.2014.06.007; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531; Oda T, 2008, NEUROSCI RES, V60, P29, DOI 10.1016/j.neures.2007.09.005; Okada T, 2003, J BIOL CHEM, V278, P31024, DOI 10.1074/jbc.M300923200; Papandreou I, 2011, BLOOD, V117, P1311, DOI 10.1182/blood-2010-08-303099; Petzer JP, 2003, CHEM RES TOXICOL, V16, P1463, DOI 10.1021/tx034154e; Pineau L, 2009, TRAFFIC, V10, P673, DOI 10.1111/j.1600-0854.2009.00903.x; Poli A, 2014, ONCOTARGET, V5, P11526, DOI 10.18632/oncotarget.2578; Pytel D, 2014, J BIOMOL SCREEN, V19, P1024, DOI 10.1177/1087057114525853; Qian ZK, 2012, J VIROL, V86, P6712, DOI 10.1128/JVI.00200-12; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rosalia RA, 2013, CANCER IMMUNOL IMMUN, V62, P1161, DOI 10.1007/s00262-013-1411-0; Ryu EJ, 2002, J NEUROSCI, V22, P10690; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Saito S, 2009, CANCER RES, V69, P4225, DOI 10.1158/0008-5472.CAN-08-2689; Schroder M, 2008, CELL MOL LIFE SCI, V65, P862, DOI 10.1007/s00018-007-7383-5; Schroder M, 2006, MOL BIOTECHNOL, V34, P279, DOI 10.1385/MB:34:2:279; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Shiozaki K, 2015, FASEB J, V29, P2099, DOI 10.1096/fj.14-262543; Spitzer J A, 1989, Prog Clin Biol Res, V308, P575; Suzuki HI, 2011, MOL CELL, V44, P424, DOI 10.1016/j.molcel.2011.09.012; Szendroedi J, 2014, P NATL ACAD SCI USA, V111, P9597, DOI 10.1073/pnas.1409229111; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Ulianichl L, 2014, FRONT MED, V1, DOI 10.3389/fmed.2014.00055; Upton JP, 2012, SCIENCE, V338, P818, DOI 10.1126/science.1226191; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Volkmann K, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.199737; Volmer R, 2015, CURR OPIN CELL BIOL, V33, P67, DOI 10.1016/j.ceb.2014.12.002; Volmer R, 2013, P NATL ACAD SCI USA, V110, P4628, DOI 10.1073/pnas.1217611110; Wang LJ, 2014, NEUROBIOL DIS, V71, P317, DOI 10.1016/j.nbd.2014.08.010; Wang LJ, 2011, HUM MOL GENET, V20, P1008, DOI 10.1093/hmg/ddq546; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131; WATOWICH SS, 1991, J VIROL, V65, P3590, DOI 10.1128/JVI.65.7.3590-3597.1991; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wilhelmus MMM, 2011, BRAIN PATHOL, V21, P130, DOI 10.1111/j.1750-3639.2010.00429.x; Xie LK, 2012, BLOOD, V119, P3503, DOI 10.1182/blood-2011-09-381905; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; Yan Y, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-445; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhang KZ, 2006, CELL, V124, P587, DOI 10.1016/j.cell.2005.11.040; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zhang W, 2006, CELL METAB, V4, P491, DOI 10.1016/j.cmet.2006.11.002; Zhang W, 2013, GENE DEV, V27, P441, DOI 10.1101/gad.201731.112; Zhao C, 2007, NAT CELL BIOL, V9, P706, DOI 10.1038/ncb1594; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	165	40	40	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1207	1215		10.1038/onc.2015.178	http://dx.doi.org/10.1038/onc.2015.178			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26028033	Green Accepted			2022-12-17	WOS:000371763100001
J	Lin, C; Liu, SY; Lee, EHY				Lin, Ch; Liu, S. Y.; Lee, E. H. Y.			SUMO modification of Akt regulates global SUMOylation and substrate SUMOylation specificity through Akt phosphorylation of Ubc9 and SUMO1	ONCOGENE			English	Article							CELL-PROLIFERATION; E3; TUMORIGENESIS; CONJUGATION; EXPRESSION; STABILITY; PATHWAY	SUMOylation is an important post-translational modification, and Akt SUMOylation was found to regulate cell proliferation, tumorigenesis and cell cycle, but the molecular mechanism of Akt SUMOylation is less well known. Here, we show both endogenous and ectopic Akt SUMOylation and Lys276 is the major SUMO acceptor on Akt. Further, Akt SUMOylation is Akt phosphorylation dependent and Akt SUMOylation increases Akt kinase activity without affecting the phosphorylation level of Akt. Moreover, endogenous Akt SUMOylation is enhanced by insulin treatment and this is Akt activity dependent. Heat-shock stimulus also increases Akt SUMOylation and it is also Akt activity dependent. Endogenous Akt SUMOylation is also found in the rat brain and it is enhanced by insulin-like growth factor-1 stimulation. In addition, Akt directly phosphorylates Ubc9 at Thr35 and phosphorylates SUMO1 at Thr76. Ubc9 phosphorylation at Thr35 promotes Ubc9 thioester bond formation and SUMO1 phosphorylation at Thr76 stabilizes the SUMO1 protein. Through these distinct mechanisms, Akt SUMOylation regulates global SUMOylation, including Akt and Ubc9 SUMOylation, and substrate SUMOylation specificity, including STAT1 and CREB SUMOylation, in different manners. Akt SUMOylation also enhances phosphatase and tensin homolog (PTEN) SUMOylation through Akt phosphorylation of Ubc9 and SUMO1, which serves as an endogenous mechanism to stop the positive feedback loop resulted from Akt activation. Further, Akt SUMOylation increases cyclin D1 expression and cell proliferation, and these effects are also mediated through Ubc9 phosphorylation at Thr35 and SUMO1 phosphorylation at Thr76. Here, we have identified a novel mechanism for SUMOylation regulation. Because of the important role Akt plays in tumorigenesis, this mechanism may also be involved in Akt-regulated tumorigenesis.	[Lin, Ch; Liu, S. Y.; Lee, E. H. Y.] Acad Sinica, Inst Biomed Sci, Div Neurosci, Taipei 115, Taiwan	Academia Sinica - Taiwan	Lee, EHY (corresponding author), Acad Sinica, Inst Biomed Sci, 128,Sec 2,Acad Rd, Taipei 115, Taiwan.	eminy@gate.sinica.edu.tw	Lee, Eminy H.Y./S-7014-2018	Lee, Eminy/0000-0001-6342-0940; Ma, Yun Li/0000-0002-6321-8889	Ministry of Science and Technology in Taiwan [MOST 102-2321-B-001-004]	Ministry of Science and Technology in Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by a Grant from the Ministry of Science and Technology in Taiwan (MOST 102-2321-B-001-004). Thank is given to the Proteomics Core Facility of the Institute of Biomedical Sciences, Academia Sinica, Taiwan.	Chen YC, 2014, J NEUROSCI, V34, P9574, DOI 10.1523/JNEUROSCI.4302-13.2014; Chiou HYC, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-53; de la Cruz-Herrera CF, 2014, ONCOGENE, P1; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Fatrai S, 2006, DIABETES, V55, P318, DOI 10.2337/diabetes.55.02.06.db05-0757; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Hay RT, 2013, BIOCHEM SOC T, V41, P463, DOI 10.1042/BST20130015; Huang J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1919; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Klug H, 2013, MOL CELL, V50, P625, DOI 10.1016/j.molcel.2013.03.027; Knipscheer P, 2008, MOL CELL, V31, P371, DOI 10.1016/j.molcel.2008.05.022; Li R, 2013, CANCER RES, V73, P5742, DOI 10.1158/0008-5472.CAN-13-0538; Liao Y, 2010, AM J TRANSL RES, V2, P19; Lin CH, 2001, NEURON, V31, P841, DOI 10.1016/S0896-6273(01)00433-0; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Risso G, 2013, CELL CYCLE, V12, P3165, DOI 10.4161/cc.26183; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Su YF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034250; Tai DJC, 2011, EMBO J, V30, P205, DOI 10.1038/emboj.2010.290; Tai DJC, 2009, J BIOL CHEM, V284, P4073, DOI 10.1074/jbc.M805055200; Yang WL, 2010, CELL CYCLE, V9, P486, DOI 10.4161/cc.9.3.10508; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065	26	40	46	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					595	607		10.1038/onc.2015.115	http://dx.doi.org/10.1038/onc.2015.115			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25867063				2022-12-17	WOS:000369548800007
J	Gao, J; He, Q; Subudhi, S; Aparicio, A; Zurita-Saavedra, A; Lee, DH; Jimenez, C; Suarez-Almazor, M; Sharma, P				Gao, J.; He, Q.; Subudhi, S.; Aparicio, A.; Zurita-Saavedra, A.; Lee, D. H.; Jimenez, C.; Suarez-Almazor, M.; Sharma, P.			Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience	ONCOGENE			English	Review							LYMPHOCYTE-ASSOCIATED ANTIGEN-4; DOSE-ESCALATION TRIAL; REGULATORY T-CELLS; STAGE-IV MELANOMA; METASTATIC MELANOMA; CTLA-4 BLOCKADE; AUTOIMMUNE HYPOPHYSITIS; MONOCLONAL-ANTIBODY; ANTI-CTLA-4; THERAPY	Targeting a T-cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols.	[Gao, J.; He, Q.; Subudhi, S.; Aparicio, A.; Zurita-Saavedra, A.; Lee, D. H.; Sharma, P.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Jimenez, C.] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia, Houston, TX 77030 USA; [Suarez-Almazor, M.] Univ Texas MD Anderson Canc Ctr, Dept Gen Internal Med, Houston, TX 77030 USA; [Sharma, P.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Sharma, P (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol & Immunol, 1155 Pressler St,Unit 1374, Houston, TX 77030 USA.	PadSharma@mdanderson.org		Subudhi, Sumit/0000-0001-5208-7732	American Society of Clinical Oncology Young Investigator Award; NIH K12 grant; NIH R01 grant [1-R01 CA1633793-01]; Cancer Prevention Institute of Texas [RP120108]; Prostate Cancer Foundation Challenge Grant in Immunology; American Association for Cancer Research/Cancer Research Institute/Stand-Up-To-Cancer Dream Team grant; NATIONAL CANCER INSTITUTE [R01CA163793] Funding Source: NIH RePORTER	American Society of Clinical Oncology Young Investigator Award; NIH K12 grant; NIH R01 grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Institute of Texas; Prostate Cancer Foundation Challenge Grant in Immunology; American Association for Cancer Research/Cancer Research Institute/Stand-Up-To-Cancer Dream Team grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	JG's work is supported by an American Society of Clinical Oncology Young Investigator Award and an NIH K12 grant. PS's work is supported by an NIH R01 grant (1-R01 CA1633793-01), a research grant form Cancer Prevention Institute of Texas (RP120108), a Prostate Cancer Foundation Challenge Grant in Immunology and an American Association for Cancer Research/Cancer Research Institute/Stand-Up-To-Cancer Dream Team grant. PS also serves as a consultant for Bristol Myers-Squibb, Glaxo-Smith Kline and MedImmune/Astrazeneca. PS is also a founder and consultant for Jounce Therapeutics. The remaining authors declare no conflict of interest.	Alegre ML, 1998, J IMMUNOL, V161, P3347; Beck KE, 2006, J CLIN ONCOL, V24, P2283, DOI 10.1200/JCO.2005.04.5716; Berman David, 2010, Cancer Immun, V10, P11; Bhatia S, 2009, J IMMUNOTHER, V32, P203, DOI 10.1097/CJI.0b013e318193a206; Blansfield JA, 2005, J IMMUNOTHER, V28, P593, DOI 10.1097/01.cji.0000178913.41256.06; Delyon J, 2011, NEW ENGL J MED, V365, P1747, DOI 10.1056/NEJMc1110923; Dillard T, 2010, PITUITARY, V13, P29, DOI 10.1007/s11102-009-0193-z; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Fadel F, 2009, NEW ENGL J MED, V361, P211, DOI 10.1056/NEJMc0904283; Fasso M, 2008, P NATL ACAD SCI USA, V105, P3509, DOI 10.1073/pnas.0712269105; Fecher LA, 2013, ONCOLOGIST, V18, P733, DOI 10.1634/theoncologist.2012-0483; Garber K, 2012, NAT BIOTECHNOL, V30, P475, DOI 10.1038/nbt0612-475; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; Jaber SH, 2006, ARCH DERMATOL, V142, P166, DOI 10.1001/archderm.142.2.166; Klein O, 2009, CLIN CANCER RES, V15, P2507, DOI 10.1158/1078-0432.CCR-08-2424; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470-2045(14)70189-5; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Madan RA, 2012, LANCET ONCOL, V13, P501, DOI 10.1016/S1470-2045(12)70006-2; Min L, 2011, EUR J ENDOCRINOL, V164, P303, DOI 10.1530/EJE-10-0833; O'Day SJ, 2010, ANN ONCOL, V21, P1712, DOI 10.1093/annonc/mdq013; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Postow MA, 2012, NEW ENGL J MED, V366, P925, DOI 10.1056/NEJMoa1112824; Quezada SA, 2006, J CLIN INVEST, V116, P1935, DOI 10.1172/JCI27745; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Robinson MR, 2004, J IMMUNOTHER, V27, P478, DOI 10.1097/00002371-200411000-00008; Sanderson K, 2005, J CLIN ONCOL, V23, P741, DOI 10.1200/JCO.2005.01.128; Schadendorf D, 2013, EUR J CANCER, V49, p24LBA; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; Sun Jingjing, 2008, Cancer Immun, V8, P9; Tarhini A, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/857519; van den Eertwegh AJM, 2012, LANCET ONCOL, V13, P509, DOI 10.1016/S1470-2045(12)70007-4; von Euw E, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-35; Voskens CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053745; Weber JS, 2012, J CLIN ONCOL, V30, P2691, DOI 10.1200/JCO.2012.41.6750; Wilgenhof S, 2011, ANN ONCOL, V22, P991, DOI 10.1093/annonc/mdr028; Wolchok JD, 2013, ANN NY ACAD SCI, V1291, P1, DOI 10.1111/nyas.12180; Wolchok JD, 2010, LANCET ONCOL, V11, P155, DOI 10.1016/S1470-2045(09)70334-1; Ying HY, 2010, J IMMUNOL, V185, P1375, DOI 10.4049/jimmunol.0903369; Yuan JD, 2008, P NATL ACAD SCI USA, V105, P20410, DOI 10.1073/pnas.0810114105	41	40	43	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5411	5417		10.1038/onc.2015.5	http://dx.doi.org/10.1038/onc.2015.5			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25659583	Green Accepted			2022-12-17	WOS:000363479700001
J	Goyama, S; Huang, G; Kurokawa, M; Mulloy, JC				Goyama, S.; Huang, G.; Kurokawa, M.; Mulloy, J. C.			Posttranslational modifications of RUNX1 as potential anticancer targets	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; FAMILIAL PLATELET DISORDER; HEMATOPOIETIC STEM-CELLS; E3 UBIQUITIN LIGASE; POINT MUTATIONS; MYELODYSPLASTIC SYNDROME; TUMOR-SUPPRESSOR; AML1/RUNX1 GENE; DOWN-REGULATION	The transcription factor RUNX1 is a master regulator of hematopoiesis. Disruption of RUNX1 activity has been implicated in the development of hematopoietic neoplasms. Recent studies also highlight the importance of RUNX1 in solid tumors both as a tumor promoter and a suppressor. Given its central role in cancer development, RUNX1 is an excellent candidate for targeted therapy. A potential strategy to target RUNX1 is through modulation of its posttranslational modifications (PTMs). Numerous studies have shown that RUNX1 activity is regulated by PTMs, including phosphorylation, acetylation, methylation and ubiquitination. These PTMs regulate RUNX1 activity either positively or negatively by altering RUNX1-mediated transcription, promoting protein degradation and affecting protein interactions. In this review, we first summarize the available data on the context-and dosagedependent roles of RUNX1 in various types of neoplasms. We then provide a comprehensive overview of RUNX1 PTMs from biochemical and biologic perspectives. Finally, we discuss how aberrant PTMs of RUNX1 might contribute to tumorigenesis and also strategies to develop anticancer therapies targeting RUNX1 PTMs.	[Goyama, S.; Huang, G.; Mulloy, J. C.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Kurokawa, M.] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo, Japan	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Tokyo	Mulloy, JC (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA.	susumu.goyama@cchmc.org; james.mulloy@cchmc.org			Grants-in-Aid for Scientific Research [15H01481] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Aho TL, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-21; Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Ben-Ami O, 2013, CELL REP, V4, P1131, DOI 10.1016/j.celrep.2013.08.020; Biggs JR, 2006, MOL CELL BIOL, V26, P7420, DOI 10.1128/MCB.00597-06; Biggs JR, 2005, MOL CANCER RES, V3, P391, DOI 10.1158/1541-7786.MCR-04-0184; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Bresciani E, 2014, BLOOD, V124, P70, DOI 10.1182/blood-2013-10-531988; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; Cunningham L, 2012, P NATL ACAD SCI USA, V109, P14592, DOI 10.1073/pnas.1200037109; Della Gatta G, 2012, NAT MED, V18, P436, DOI 10.1038/nm.2610; Dulak AM, 2012, CANCER RES, V72, P4383, DOI 10.1158/0008-5472.CAN-11-3893; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Fijneman RJA, 2012, CANCER SCI, V103, P593, DOI 10.1111/j.1349-7006.2011.02189.x; Gaidzik VI, 2011, J CLIN ONCOL, V29, P1364, DOI 10.1200/JCO.2010.30.7926; Giambra V, 2012, NAT MED, V18, P1693, DOI 10.1038/nm.2960; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gorczynski MJ, 2007, CHEM BIOL, V14, P1186, DOI 10.1016/j.chembiol.2007.09.006; Goyama S, 2004, BLOOD, V104, P3558, DOI 10.1182/blood-2004-04-1535; Goyama S, 2013, J CLIN INVEST, V123, P3876, DOI 10.1172/JCI68557; Goyama S, 2011, INT J HEMATOL, V94, P126, DOI 10.1007/s12185-011-0858-z; Greif PA, 2012, HAEMATOL-HEMATOL J, V97, P1909, DOI 10.3324/haematol.2012.064667; Grossmann V, 2013, GENE CHROMOSOME CANC, V52, P410, DOI 10.1002/gcc.22039; Grossmann V, 2011, HAEMATOL-HEMATOL J, V96, P1874, DOI 10.3324/haematol.2011.043919; Gu JA, 2010, CANCER PREV RES, V3, P1176, DOI 10.1158/1940-6207.CAPR-09-0265; Guo H, 2011, J BIOL CHEM, V286, P208, DOI 10.1074/jbc.M110.149013; Haferlach T, 2014, LEUKEMIA, V28, P241, DOI 10.1038/leu.2013.336; Harada H, 2004, BLOOD, V103, P2316, DOI 10.1182/blood-2003-09-3074; Herglotz J, 2013, ONCOGENE, V32, P2565, DOI 10.1038/onc.2012.274; Hoi CSL, 2010, MOL CELL BIOL, V30, P2518, DOI 10.1128/MCB.01308-09; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Huang G, 2011, BLOOD, V118, P6544, DOI 10.1182/blood-2010-11-317909; Huang H, 2012, GENE DEV, V26, P1587, DOI 10.1101/gad.192054.112; Huang SP, 2011, BJU INT, V107, P486, DOI 10.1111/j.1464-410X.2010.09512.x; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Itzykson R, 2013, J CLIN ONCOL, V31, P2428, DOI 10.1200/JCO.2012.47.3314; Jacob B, 2010, BLOOD, V115, P1610, DOI 10.1182/blood-2009-07-232249; Kadota M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009201; Kamikubo Y, 2010, CANCER CELL, V17, P455, DOI 10.1016/j.ccr.2010.03.022; Kawazu M, 2005, J IMMUNOL, V174, P3526, DOI 10.4049/jimmunol.174.6.3526; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Komeno Y, 2014, BLOOD, V123, P3760, DOI 10.1182/blood-2013-08-521252; Kurokawa M, 2006, INT J HEMATOL, V84, P136, DOI 10.1532/IJH97.06070; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670; Link KA, 2010, J CELL PHYSIOL, V222, P50, DOI 10.1002/jcp.21950; Lo-Coco F, 2013, NEW ENGL J MED, V369, P111, DOI 10.1056/NEJMoa1300874; Ma SK, 2001, LEUKEMIA, V15, P1442, DOI 10.1038/sj.leu.2402202; Mendler JH, 2012, J CLIN ONCOL, V30, P3109, DOI 10.1200/JCO.2011.40.6652; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Migas A, 2011, PEDIATR BLOOD CANCER, V57, P583, DOI 10.1002/pbc.22980; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; Motoda L, 2007, STEM CELLS, V25, P2976, DOI 10.1634/stemcells.2007-0061; Neel BG, 2012, GENE DEV, V26, P1520, DOI 10.1101/gad.198051.112; Niebuhr B, 2013, BLOOD, V122, P413, DOI 10.1182/blood-2013-01-480244; Nishimoto N, 2011, BLOOD, V118, P2541, DOI 10.1182/blood-2010-10-315440; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Owen CJ, 2008, BLOOD, V112, P4639, DOI 10.1182/blood-2008-05-156745; Peter A, 2009, EUR J HAEMATOL, V83, P420, DOI 10.1111/j.1600-0609.2009.01315.x; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Reed-Inderbitzin E, 2006, ONCOGENE, V25, P5777, DOI 10.1038/sj.onc.1209591; Rocquain J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-401; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Scheitz CJF, 2013, J CELL BIOCHEM, V114, P985, DOI 10.1002/jcb.24453; Scheitz CJF, 2012, EMBO J, V31, P4124, DOI 10.1038/emboj.2012.270; Schwaab J, 2013, BLOOD, V122, P2460, DOI 10.1182/blood-2013-04-496448; Shang Y, 2009, BIOCHEM BIOPH RES CO, V386, P242, DOI 10.1016/j.bbrc.2009.06.043; Shia WJ, 2012, BLOOD, V119, P4953, DOI 10.1182/blood-2011-04-347476; Slattery ML, 2011, CARCINOGENESIS, V32, P318, DOI 10.1093/carcin/bgq245; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Tachibana M, 2008, BIOCHEM BIOPH RES CO, V368, P536, DOI 10.1016/j.bbrc.2008.01.124; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Tang JL, 2009, BLOOD, V114, P5352, DOI 10.1182/blood-2009-05-223784; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Vu LP, 2013, CELL REP, V5, P1625, DOI 10.1016/j.celrep.2013.11.025; Wang CQ, 2014, CELL REP, V8, P767, DOI 10.1016/j.celrep.2014.06.046; Wang L, 2011, SCIENCE, V333, P765, DOI 10.1126/science.1201662; Wang L, 2009, BLOOD CELL MOL DIS, V43, P30, DOI 10.1016/j.bcmd.2009.03.005; Wang LX, 2011, P NATL ACAD SCI USA, V108, pE803, DOI 10.1073/pnas.1103423108; Wee HJ, 2008, BLOOD, V112, P3777, DOI 10.1182/blood-2008-01-134122; Wilkinson AC, 2013, CELL REP, V3, P116, DOI 10.1016/j.celrep.2012.12.016; Wotton S, 2002, CANCER RES, V62, P7181; Yamaguchi Y, 2004, J BIOL CHEM, V279, P15630, DOI 10.1074/jbc.M400355200; Yan CH, 2013, BBA-REV CANCER, V1835, P76, DOI 10.1016/j.bbcan.2012.11.002; Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443; Yoshimi M, 2012, EUR J IMMUNOL, V42, P1044, DOI 10.1002/eji.201040746; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Zhang LS, 2008, BLOOD, V111, P1193, DOI 10.1182/blood-2007-08-109702; Zhang YH, 2004, J BIOL CHEM, V279, P53116, DOI 10.1074/jbc.M405502200; Zhao XH, 2014, BLOOD, V123, P1729, DOI 10.1182/blood-2013-03-489575; Zhao X, 2008, GENE DEV, V22, P640, DOI 10.1101/gad.1632608	102	40	41	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3483	3492		10.1038/onc.2014.305	http://dx.doi.org/10.1038/onc.2014.305			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25263451				2022-12-17	WOS:000357434900001
J	Kastrati, I; Canestrari, E; Frasor, J				Kastrati, I.; Canestrari, E.; Frasor, J.			PHLDA1 expression is controlled by an estrogen receptor-NF kappa B-miR-181 regulatory loop and is essential for formation of ER plus mammospheres	ONCOGENE			English	Article							CANCER STEM-CELLS; NF-KAPPA-B; RESISTANT BREAST-CANCER; IN-VITRO PROPAGATION; PROINFLAMMATORY CYTOKINES; RECEPTOR; METASTASIS; SURVIVAL; ACTIVATION; INHIBITOR	Crosstalk between estrogen receptor (ER) and the inflammatory nuclear factor kappa B (NF kappa B) pathway in ER+ breast cancers may contribute to a more aggressive phenotype. Pleckstrin Homology-Like Domain, Family A, member 1 (PHLDA1), a target gene of ER-NF kappa B crosstalk, has been implicated in cell survival and stem cell properties. 17 beta-estradiol (E2), acting through ER alpha, and pro-inflammatory cytokines, acting through NF kappa B, increase the nascent transcript and PHLDA1 messenger RNA stability, indicating both transcriptional and post-transcriptional control of PHLDA1 expression. We show that PHLDA1 is a direct target of miR-181 and that mature miR-181a and b, as well as their host gene, are synergistically downregulated by E2 and tumor necrosis factor a, also in an ER-and NF kappa B-dependent manner. Thus, ER and NF kappa B work together to upregulate PHLDA1 directly through enhanced transcription and indirectly through repression of miR-181a and b. Previous studies have suggested that PHLDA1 may be a stem cell marker in the human intestine that contributes to tumorigenesis. Our findings that PHLDA1 is upregulated in mammospheres (MS) of ER+ breast cancer cells and that PHLDA1 knockdown impairs both MS formation and the expansion of aldehyde dehydrogenase (ALDH)-positive population, suggest that PHLDA1 may play a similar role in breast cancer cells. Upregulation of PHLDA1 in MS is largely dependent on the NF kappa B pathway, with downregulated miR-181 expression a contributing factor. Over-expression of miR-181 phenocopied PHLDA1 knockdown and significantly impaired MS formation, which was reversed, in part, by protection of the PHLDA1 3' untranslated region (UTR) or overexpression of PHLDA1 lacking the 3' UTR. Furthermore, we find that elevated PHLDA1 expression is associated with a higher risk of distant metastasis in ER+ breast cancer patients. Altogether, these data suggest that high PHLDA1 expression is controlled through an ER-NF kappa B-miR-181 regulatory axis and may contribute to a poor clinical outcome in patients with ER+ breast tumors by enhancing stem-like properties in these tumors.	[Kastrati, I.; Canestrari, E.; Frasor, J.] Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Frasor, J (corresponding author), Univ Illinois, Dept Physiol & Biophys, 835 S Wolcott,E202 MSB,MC901, Chicago, IL 60612 USA.	jfrasor@uic.edu	Kastrati, Irida/L-4641-2019	Kastrati, Irida/0000-0002-8086-1411	National Institute of Health [R01 CA130932-05]; University of Illinois at Chicago through the Chancellor's Discovery Fund; Susan G Komen for the Cure [PDF12229484]; NATIONAL CANCER INSTITUTE [R01CA130932] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Illinois at Chicago through the Chancellor's Discovery Fund; Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Shuangping Zhao, Bryant Marure and Tuan-Ahn Tran for technical assistance. We are grateful for the financial support provided by the National Institute of Health (R01 CA130932-05 to JF), the University of Illinois at Chicago through the Chancellor's Discovery Fund (JF), and by a postdoctoral fellowship grant from Susan G Komen for the Cure to IK (PDF12229484).	Baumgarten SC, 2012, MOL ENDOCRINOL, V26, P360, DOI 10.1210/me.2011-1302; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bisso A, 2013, CELL CYCLE, V12, P1679, DOI 10.4161/cc.24757; Bridge G, 2012, BLOOD, V120, P5063, DOI 10.1182/blood-2012-04-423004; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Charafe-Jauffret E, 2008, PATHOBIOLOGY, V75, P75, DOI 10.1159/000123845; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Choi WY, 2007, SCIENCE, V318, P271, DOI 10.1126/science.1147535; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Cormier Catherine Y., 2011, Journal of Structural and Functional Genomics, V12, P55, DOI 10.1007/s10969-011-9100-8; Cormier CY, 2010, NUCLEIC ACIDS RES, V38, pD743, DOI 10.1093/nar/gkp999; Croker AK, 2008, J CELL MOL MED, V12, P374, DOI 10.1111/j.1582-4934.2007.00211.x; deGraffenried LA, 2004, ANN ONCOL, V15, P885, DOI 10.1093/annonc/mdh232; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Fillmore CM, 2010, P NATL ACAD SCI USA, V107, P21737, DOI 10.1073/pnas.1007863107; Frasor J, 2009, CANCER RES, V69, P8918, DOI 10.1158/0008-5472.CAN-09-2608; Frasor J, 2008, ENDOCRINOLOGY, V149, P6272, DOI 10.1210/en.2008-0352; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Johnson EO, 2011, J CELL SCI, V124, P2711, DOI 10.1242/jcs.084970; Jones RL, 2011, J CLIN PATHOL, V64, P130, DOI 10.1136/jcp.2010.082966; Kim K, 2013, HORM CANCER-US, V4, P78, DOI 10.1007/s12672-012-0129-3; Knauss JL, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00163; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lobry C, 2014, BLOOD, V123, P2451, DOI 10.1182/blood-2013-08-355818; Maillot G, 2009, CANCER RES, V69, P8332, DOI 10.1158/0008-5472.CAN-09-2206; Makino K, 2013, J INVEST DERMATOL, V133, P110, DOI 10.1038/jid.2012.252; Meier-Noorden M, 2004, GENE, V338, P197, DOI 10.1016/j.gene.2004.05.006; Murohashi M, 2010, BRIT J CANCER, V102, P206, DOI 10.1038/sj.bjc.6605468; Neel JC, 2013, CELL SIGNAL, V25, P1556, DOI 10.1016/j.cellsig.2013.03.013; O'Brien CS, 2009, J MAMMARY GLAND BIOL, V14, P45, DOI 10.1007/s10911-009-9115-y; Ouyang YB, 2012, MITOCHONDRION, V12, P213, DOI 10.1016/j.mito.2011.09.001; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Pradhan M, 2012, MOL CELL BIOL, V32, P569, DOI 10.1128/MCB.05869-11; Pradhan M, 2010, J BIOL CHEM, V285, P31100, DOI 10.1074/jbc.M110.155309; Riggins RB, 2005, MOL CANCER THER, V4, P33; Sakthianandeswaren A, 2011, CANCER RES, V71, P3709, DOI 10.1158/0008-5472.CAN-10-2342; Seiler CY, 2014, NUCLEIC ACIDS RES, V42, pD1253, DOI 10.1093/nar/gkt1060; Stanculescu Adina, 2010, Hormones & Cancer, V1, P127, DOI 10.1007/s12672-010-0018-6; Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946; Thorner AR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013073; Toyoshima Y, 2004, J BIOL CHEM, V279, P25898, DOI 10.1074/jbc.M400661200; Van Laere S, 2010, CANCER-AM CANCER SOC, V116, P2794, DOI 10.1002/cncr.25180; Velasco-Velazquez MA, 2011, AM J PATHOL, V179, P2, DOI 10.1016/j.ajpath.2011.03.005; Yang XP, 2011, NAT METHODS, V8, P659, DOI [10.1038/NMETH.1638, 10.1038/nmeth.1638]; Zhou YM, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-59; Zhou YM, 2005, INT J BIOCHEM CELL B, V37, P1130, DOI 10.1016/j.biocel.2004.09.006	50	40	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2309	2316		10.1038/onc.2014.180	http://dx.doi.org/10.1038/onc.2014.180			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24954507	Green Accepted			2022-12-17	WOS:000353824800004
J	Carrillo, AM; Bouska, A; Arrate, MP; Eischen, CM				Carrillo, A. M.; Bouska, A.; Arrate, M. P.; Eischen, C. M.			Mdmx promotes genomic instability independent of p53 and Mdm2	ONCOGENE			English	Article							STRAND BREAK REPAIR; DNA-DAMAGE; TUMOR-FORMATION; ATM ACTIVATION; HISTONE H2AX; S-PHASE; EXPRESSION; COMPLEX; DEGRADATION; PROTEIN	The oncogene Mdmx is overexpressed in many man malignancies, and together with Mdm2, negatively regulates the p53 tumor suppressor. However, a p53-independent function of Mdmx that impacts genome stability has been described, but this function is not well understood. In the present study, we determined that of the 13 different cancer types evaluated, 6-90% of those that had elevated levels of Mdmx had concurrent inactivation (mutated or deleted) of p53. We show elevated levels of Mdmx-inhibited double-strand DNA break repair and induced chromosome and chromatid breaks independent of p53, leading to genome instability. Mdmx impaired early DNA damage-response signaling, such as phosphorylation of the serine/threonine-glutamine motif, mediated by the ATM kinase. Moreover, we identified Mdmx associated with Nbs1 of the Mre11-Rad50-Nbs1 (MRN) DNA repair complex, and this association increased upon DNA damage and was detected at chromatin. Elevated Mdmx levels also increased cellular transformation in a p53-independent manner. Unexpectedly, all Mdmx-mediated phenotypes also occurred in cells lacking Mdm2 and were independent of the Mdm2-binding domain (RING) of Mdmx. Therefore, Mdmx-mediated inhibition of the DNA damage response resulted in delayed DNA repair and increased genome instability and transformation independent of p53 and Mdm2. Our results reveal a novel p53- and Mdm2-independent oncogenic function of Mdmx that provides new insight into the many cancers that overexpress Mdmx.	[Carrillo, A. M.; Arrate, M. P.; Eischen, C. M.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Bouska, A.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA	Vanderbilt University; University of Nebraska System; University of Nebraska Medical Center	Eischen, CM (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, MCN C3321 1161 21st Ave South, Nashville, TN 37232 USA.	christine.eischen@vanderbilt.edu		Bouska, Alyssa/0000-0003-1324-6678; Carrillo, Alexia/0000-0002-2827-6952	NCI [F31CA150546, T32CA009582, R01CA117935, R01CA160432]; NCI Cancer Center [P30CA068485]; NATIONAL CANCER INSTITUTE [R01CA160432, F31CA150546, R01CA117935, P30CA068485, T32CA009582] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Brandon Metge for technical expertise; Dr Jean-Christophe Marine for providing the Mdmx vector; Dr Stephen Jones for providing the Mdmx<SUP>-/-</SUP>p53<SUP>-/-</SUP>MEFs; members of the Eischen lab for thoughtful discussions and critical review of this manuscript. This work was supported by NCI grants F31CA150546 (AMC), T32CA009582 (AMC), R01CA117935 (CME) and R01CA160432 (CME), and NCI Cancer Center Support Grant P30CA068485 utilizing the Flow Cytometry Shared Resource.	Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Bekker-Jensen S, 2010, DNA REPAIR, V9, P1219, DOI 10.1016/j.dnarep.2010.09.010; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Braden WA, 2006, MOL CELL BIOL, V26, P7667, DOI 10.1128/MCB.00045-06; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; De Clercq S, 2010, MOL CELL BIOL, V30, P5394, DOI 10.1128/MCB.00330-10; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; Giglio S, 2005, CANCER RES, V65, P9687, DOI 10.1158/0008-5472.CAN-05-0450; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kamijo T, 1999, CANCER RES, V59, P2464; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lam S, 2010, ONCOGENE, V29, P2415, DOI 10.1038/onc.2009.522; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Leventaki V, 2012, BRIT J HAEMATOL, V158, P763, DOI 10.1111/j.1365-2141.2012.09243.x; Li X, 2012, ONCOGENE, V31, P3721, DOI 10.1038/onc.2011.534; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362; Matijasevic Z, 2008, CELL CYCLE, V7, P2967, DOI 10.4161/cc.7.19.6797; Matijasevic Z, 2008, MOL CELL BIOL, V28, P1265, DOI 10.1128/MCB.01108-07; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Melo Alexia N, 2012, Genes Cancer, V3, P283, DOI 10.1177/1947601912454139; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108; Pei DS, 2012, ONCOTARGET, V3, P228; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Ramos YFM, 2001, CANCER RES, V61, P1839; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Stracker TH, 2011, NAT REV MOL CELL BIO, V12, P90, DOI 10.1038/nrm3047; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wang P, 2008, ONCOGENE, V27, P1590, DOI 10.1038/sj.onc.1210788; White JS, 2008, CELL CYCLE, V7, P1277, DOI 10.4161/cc.7.9.5961; White JS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000758; Xiong SB, 2010, CANCER RES, V70, P7148, DOI 10.1158/0008-5472.CAN-10-1457; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	55	40	40	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					846	856		10.1038/onc.2014.27	http://dx.doi.org/10.1038/onc.2014.27			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24608433	Green Accepted			2022-12-17	WOS:000349472000005
J	Montenegro, MF; Sanchez-del-Campo, L; Fernandez-Perez, MP; Saez-Ayala, M; Cabezas-Herrera, J; Rodriguez-Lopez, JN				Montenegro, M. F.; Sanchez-del-Campo, L.; Fernandez-Perez, M. P.; Saez-Ayala, M.; Cabezas-Herrera, J.; Rodriguez-Lopez, J. N.			Targeting the epigenetic machinery of cancer cells	ONCOGENE			English	Review						methionine; anti-folates; methylation; epigenetics; cancer therapy	SERUM FOLATE LEVELS; DNA METHYLATION; DIHYDROFOLATE-REDUCTASE; FOLIC-ACID; FUNCTIONAL-CHARACTERIZATION; CARBOXYL METHYLTRANSFERASE; MICROPHTHALMIA LOCUS; S-ADENOSYLMETHIONINE; ANTIFOLATE ACTIVITY; LYSINE METHYLATION	Cancer is characterized by uncontrolled cell growth and the acquisition of metastatic properties. In most cases, the activation of oncogenes and/or deactivation of tumour suppressor genes lead to uncontrolled cell cycle progression and inactivation of apoptotic mechanisms. Although the underlying mechanisms of carcinogenesis remain unknown, increasing evidence links aberrant regulation of methylation to tumourigenesis. In addition to the methylation of DNA and histones, methylation of nonhistone proteins, such as transcription factors, is also implicated in the biology and development of cancer. Because the metabolic cycling of methionine is a key pathway for many of these methylating reactions, strategies to target the epigenetic machinery of cancer cells could result in novel and efficient anticancer therapies. The application of these new epigenetic therapies could be of utility in the promotion of E2F1-dependent apoptosis in cancer cells, in avoiding metastatic pathways and/or in sensitizing tumour cells to radiotherapy.	[Montenegro, M. F.; Fernandez-Perez, M. P.; Saez-Ayala, M.; Rodriguez-Lopez, J. N.] Univ Murcia, Dept Biochem & Mol Biol A, E-30100 Murcia, Spain; [Sanchez-del-Campo, L.] Univ Oxford, Nuffield Dept Clin Med, Ludwig Inst Canc Res, Oxford, England; [Cabezas-Herrera, J.] Univ Hosp Virgen de la Arrixaca IMIB, Translat Canc Res Grp, Murcia, Spain	University of Murcia; Ludwig Institute for Cancer Research; University of Oxford	Rodriguez-Lopez, JN (corresponding author), Univ Murcia, Dept Biochem & Mol Biol A, Campus Espinardo, E-30100 Murcia, Spain.	neptuno@um.es	Montenegro, Maria Fernanda/AAF-2695-2021; Saez Ayala, Magali/T-9810-2017; Neptuno, Jose/F-5012-2016; del Campo, Luis Sanchez/R-1308-2018; CABEZAS-HERRERA, JUAN/J-9434-2015; Cabezas-Herrera, Juan/F-3850-2016	Saez Ayala, Magali/0000-0002-8726-0053; CABEZAS-HERRERA, JUAN/0000-0001-9053-5380; Montenegro, Maria Fernanda/0000-0002-0064-0484; Rodriguez-Lopez, Jose Neptuno/0000-0001-6863-1173; Cabezas-Herrera, Juan/0000-0002-6833-4977; FERNANDEZ PEREZ, MARIA PIEDAD/0000-0003-4916-1959; Sanchez del Campo, Luis/0000-0002-9537-7761	Ministerio de Ciencia e Innovacion (MICINN) [SAF2009-12043-C02-01]; Fundacion Seneca (FS) [15230/PI/10]; Fundacion de la Asociacion Espanola contra el Cancer (FAECC)	Ministerio de Ciencia e Innovacion (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Fundacion Seneca (FS)(Fundacion Seneca); Fundacion de la Asociacion Espanola contra el Cancer (FAECC)	This work was supported by grants from the Ministerio de Ciencia e Innovacion (MICINN) (SAF2009-12043-C02-01) and Fundacion Seneca (FS) (15230/PI/10). MFM is contracted by the Fundacion de la Asociacion Espanola contra el Cancer (FAECC).	Alemdaroglu NC, 2007, PLANTA MED, V73, P27, DOI 10.1055/s-2006-951745; Anderson ME, 1998, CHEM-BIOL INTERACT, V112, P1; Arnheiter H, 2010, PIGM CELL MELANOMA R, V23, P729, DOI 10.1111/j.1755-148X.2010.00759.x; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Cellarier E, 2003, CANCER TREAT REV, V29, P489, DOI 10.1016/S0305-7372(03)00118-X; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Chen KG, 2006, P NATL ACAD SCI USA, V103, P9903, DOI 10.1073/pnas.0600213103; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Copeland RA, 2009, NAT REV DRUG DISCOV, V8, P724, DOI 10.1038/nrd2974; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; FIDLER IJ, 1978, CANCER RES, V38, P2651; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Guo C, 2011, J BIOL CHEM, V286, P6253, DOI 10.1074/jbc.M110.178210; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hannewald P, 2008, ANAL BIOANAL CHEM, V392, P1335, DOI 10.1007/s00216-008-2409-x; He YL, 2012, ACTA BIOCH BIOPH SIN, V44, P70, DOI 10.1093/abbs/gmr109; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; HOFFMAN DR, 1980, J BIOL CHEM, V255, P822; Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Huang ZM, 2012, P NATL ACAD SCI USA, V109, P553, DOI 10.1073/pnas.1118366109; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Ibanez C, 2012, ELECTROPHORESIS, V33, P2328, DOI 10.1002/elps.201200143; Issa JPJ, 2007, CLIN CANCER RES, V13, P1634, DOI 10.1158/1078-0432.CCR-06-2076; Jenal M, 2009, MOL CANCER RES, V7, P916, DOI 10.1158/1541-7786.MCR-08-0359; Jiang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036780; Jin Bilian, 2011, Genes Cancer, V2, P607, DOI 10.1177/1947601910393957; Johnson C, 2013, CANC LETT; Jorgensen S, 2007, J CELL BIOL, V179, P1337, DOI 10.1083/jcb.200706150; Kao TT, 2008, DRUG METAB DISPOS, V36, P508, DOI 10.1124/dmd.107.019299; Kawamoto K, 2007, CLIN CANCER RES, V13, P2541, DOI 10.1158/1078-0432.CCR-06-2225; Kishi T, 2000, CANCER-AM CANCER SOC, V89, P925, DOI 10.1002/1097-0142(20000815)89:4<925::AID-CNCR28>3.0.CO;2-W; Kobi D, 2010, PIGM CELL MELANOMA R, V23, P404, DOI 10.1111/j.1755-148X.2010.00697.x; Kontaki H, 2010, CELL CYCLE, V9, P3836, DOI 10.4161/cc.9.19.13384; Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; KUFE DW, 1980, J INVEST DERMATOL, V75, P357, DOI 10.1111/1523-1747.ep12531146; Kurash JK, 2008, MOL CELL, V29, P392, DOI 10.1016/j.molcel.2007.12.025; Lee J, 1996, P NATL ACAD SCI USA, V93, P6043, DOI 10.1073/pnas.93.12.6043; Lee JA, 2007, J BIOL CHEM, V282, P30974, DOI 10.1074/jbc.M704861200; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Limm K, 2013, EUR J CANCER, V49, P1305, DOI 10.1016/j.ejca.2012.11.026; Lin WC, 2001, GENE DEV, V15, P1833; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Matsuzaki M, 2008, J OBSTET GYNAECOL RE, V34, P971, DOI 10.1111/j.1447-0756.2008.00821.x; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Montenegro MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052231; Mund C, 2010, BIOESSAYS, V32, P949, DOI 10.1002/bies.201000061; Navarro-Martinez MD, 2006, J ANTIMICROB CHEMOTH, V57, P1083, DOI 10.1093/jac/dkl124; Navarro-Martinez MD, 2005, ANTIMICROB AGENTS CH, V49, P2914, DOI 10.1128/AAC.49.7.2914-2920.2005; Navarro-Peran E, 2005, BIOCHEMISTRY-US, V44, P7512, DOI 10.1021/bi050160t; Navarro-Peran E, 2005, CANCER RES, V65, P2059, DOI 10.1158/0008-5472.CAN-04-3469; Navarro-Peran E, 2007, INT J BIOCHEM CELL B, V39, P2215, DOI 10.1016/j.biocel.2007.06.005; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Pardee AB, 2004, CELL CYCLE, V3, P1091; Pei HD, 2011, NATURE, V470, P124, DOI 10.1038/nature09658; Philips Mark R, 2004, Sci STKE, V2004, ppe13, DOI 10.1126/stke.2252004pe13; Fernandez-Perez MP, 2013, NEOPLASIA, V15, P826, DOI 10.1593/neo.13320; Probst AV, 2009, NAT REV MOL CELL BIO, V10, P192, DOI 10.1038/nrm2640; Prokhortchouk E, 2002, ONCOGENE, V21, P5394, DOI 10.1038/sj.onc.1205631; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Saez-Ayala M, 2013, CANCER CELL, V24, P105, DOI 10.1016/j.ccr.2013.05.009; Saez-Ayala M, 2012, EXP CELL RES, V318, P1146, DOI 10.1016/j.yexcr.2012.03.022; Saez-Ayala M, 2011, CHEMMEDCHEM, V6, P440, DOI 10.1002/cmdc.201000482; Sanchez-del-Campo L, 2008, INT J CANCER, V123, P2446, DOI 10.1002/ijc.23813; Sanchez-Del-Campo L, 2008, J MED CHEM, V51, P2018, DOI 10.1021/jm701346h; Sanchez-del-Campo L, 2010, J CELL BIOCHEM, V110, P1399, DOI 10.1002/jcb.22656; Sanchez-del-Campo L, 2009, PIGM CELL MELANOMA R, V22, P588, DOI 10.1111/j.1755-148X.2009.00586.x; Sanchez-del-Campo L, 2009, MOL PHARMACEUT, V6, P883, DOI 10.1021/mp800259k; Schulze JM, 2009, MOL CELL, V35, P626, DOI 10.1016/j.molcel.2009.07.017; Shi XB, 2007, MOL CELL, V27, P636, DOI 10.1016/j.molcel.2007.07.012; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shiraishi M, 2010, BIOSCI TRENDS, V4, P225; Spano D, 2013, CLIN EXP METASTAS, V30, P47, DOI 10.1007/s10585-012-9506-0; Spina M, 2008, PROTEINS, V72, P240, DOI 10.1002/prot.21914; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Surova O, 2013, ONCOGENE, V32, P3789, DOI 10.1038/onc.2012.556; Szyf M, 2009, ANNU REV PHARMACOL, V49, P243, DOI 10.1146/annurev-pharmtox-061008-103102; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Ulrey CL, 2005, HUM MOL GENET, V14, pR139, DOI 10.1093/hmg/ddi100; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x; Versteeg R, 1997, AM J HUM GENET, V60, P751; VOLKER C, 1995, METHOD ENZYMOL, V255, P65; Wakeman TP, 2012, EMBO J, V31, P2169, DOI 10.1038/emboj.2012.50; Wang A, 2005, CANCER RES, V65, P7809, DOI 10.1158/0008-5472.CAN-05-0888; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606; Winter-Vann AM, 2003, P NATL ACAD SCI USA, V100, P6529, DOI 10.1073/pnas.1135239100; Xie Q, 2011, J RECEPT SIG TRANSD, V31, P139, DOI 10.3109/10799893.2011.552914; Xie T, 2009, CANCER RES, V69, P992, DOI 10.1158/0008-5472.CAN-08-0506; Yan PS, 2003, CANCER RES, V63, P6178; Yun J, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00163	116	40	41	2	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					135	143		10.1038/onc.2013.605	http://dx.doi.org/10.1038/onc.2013.605			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24469033				2022-12-17	WOS:000347790500001
J	Mukherjee, M; Ge, G; Zhang, N; Edwards, DG; Sumazin, P; Sharan, S; Rao, PH; Medina, D; Pati, D				Mukherjee, M.; Ge, G.; Zhang, N.; Edwards, D. G.; Sumazin, P.; Sharan, S. K.; Rao, P. H.; Medina, D.; Pati, D.			MMTV-Espl1 transgenic mice develop aneuploid, estrogen receptor alpha (ER alpha)-positive mammary adenocarcinomas	ONCOGENE			English	Article						Separase; Espl1; aneuploidy; p53; cohesin; mammary tumor animal model	HUMAN BREAST-CANCER; CHROMOSOMAL INSTABILITY; MOLECULAR CHARACTERIZATION; CLONAL EVOLUTION; GENE-EXPRESSION; TUMORS; TUMORIGENESIS; SEPARASE; CELLS; PROTEIN	Separase, a protease encoded by the ESPL1 gene, cleaves the chromosomal cohesin during mitosis. Separase protein and transcripts are overexpressed in a wide range of human cancers. To investigate the physiological consequence of Separase overexpression in animals, we have generated a transgenic MMTV-Espl1 mouse model that overexpresses Separase protein in the mammary glands. MMTV-Espl1 mice in a C57BL/6 genetic background develop aggressive, highly aneuploid and estrogen receptor alpha-positive (ER alpha-) mammary adenocarcinomas with an 80% penetrance. The mammary tumors caused by overexpression of Separase, alone or combined with p53 heterozygosity, in mammary epithelium mimic several aspects of the most aggressive forms of human breast cancer, including high levels of genetic instability, cell cycle defects, poor differentiation, distant metastasis and metaplasia. Histopathologically, MMTV-Espl1 tumors are highly heterogeneous showing features of both luminal as well as basal subtypes of breast cancers, with aggressive disease phenotype. In addition to aneuploidy, Separase overexpression results in chromosomal instability (CIN) including premature chromatid separation (PCS), lagging chromosomes, anaphase bridges, micronuclei, centrosome amplification, multinucleated cells, gradual accumulation of DNA damage and progressive loss of tumor suppressors p53 and cadherin gene loci. These results suggest that Separase-overexpressing mammary cells are not only susceptible to chromosomal missegregation-induced aneuploidy but also other genetic instabilities including DNA damage and loss of key tumor suppressor gene loci, which in combination can initiate tumorigenesis and disease progression.	[Mukherjee, M.; Ge, G.; Zhang, N.; Sumazin, P.; Rao, P. H.; Pati, D.] Texas Childrens Canc Ctr, Dep Pediat Hematol Oncol, Houston, TX USA; [Edwards, D. G.; Medina, D.; Pati, D.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Sharan, S. K.] NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21701 USA	Texas Children's Cancer Center; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pati, D (corresponding author), Baylor Coll Med, Dept Pediat, 6621 Fannin St,MC3-3320 1102 Bates St, Houston, TX 77030 USA.	pati@bcm.edu	Sumazin, Pavel/AAE-6607-2020	Sumazin, Pavel/0000-0002-1215-4977	National Cancer Institute [1RO1 CA109330, 1RO1 CA109478]; NATIONAL CANCER INSTITUTE [R01CA109478, R01CA109330, ZIABC010387] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the grants from the National Cancer Institute (1RO1 CA109330 and 1RO1 CA109478) to D. Pati.	Arnold A, 2005, J CLIN ONCOL, V23, P4215, DOI 10.1200/JCO.2005.05.064; Berman J, 2010, NATURE, V468, P183, DOI 10.1038/468183a; Blackburn AC, 2004, CANCER RES, V64, P5140, DOI 10.1158/0008-5472.CAN-03-3435; Cardiff RD, 2010, J MAMMARY GLAND BIOL, V15, P225, DOI 10.1007/s10911-010-9184-y; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Duesberg P, 1998, P NATL ACAD SCI USA, V95, P13692, DOI 10.1073/pnas.95.23.13692; Fantozzi A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1530; Ganmore I, 2009, HUM MOL GENET, V18, pR84, DOI 10.1093/hmg/ddp084; Gao CF, 2007, P NATL ACAD SCI USA, V104, P8995, DOI 10.1073/pnas.0700631104; Han S, 1999, BREAST CANCER RES TR, V55, P161; Heilig CE, 2010, J CELL MOL MED, V14, P895, DOI 10.1111/j.1582-4934.2009.00905.x; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Holland AJ, 2012, EMBO REP, V13, P501, DOI 10.1038/embor.2012.55; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; Lacroix M, 2004, MOL CELL ENDOCRINOL, V219, P1, DOI 10.1016/j.mce.2004.02.021; Lacroix M, 2004, ENDOCR-RELAT CANCER, V11, P497, DOI 10.1677/erc.1.00758; Lu XD, 2011, MOL CANCER RES, V9, P430, DOI 10.1158/1541-7786.MCR-10-0277; McClelland SE, 2009, CELL CYCLE, V8, P3262, DOI 10.4161/cc.8.20.9690; McGranahan N, 2012, EMBO REP, V13, P528, DOI 10.1038/embor.2012.61; MEDINA D, 2000, METHODS MAMMARY GLAN, P137; Meyer R, 2009, CLIN CANCER RES, V15, P2703, DOI 10.1158/1078-0432.CCR-08-2454; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Mukherjee M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022167; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nasmyth K, 2009, ANNU REV GENET, V43, P525, DOI 10.1146/annurev-genet-102108-134233; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; Panigrahi AK, 2009, CRIT REV ONCOL HEMAT, V72, P181, DOI 10.1016/j.critrevonc.2008.12.002; Pariente N, 2012, EMBO REP, V13, P472, DOI 10.1038/embor.2012.66; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Pati D, 2004, CANCER RES, V64, P5608, DOI 10.1158/0008-5472.CAN-03-0629; Pavelka N, 2010, NATURE, V468, P321, DOI 10.1038/nature09529; Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Radaelli E, 2009, FUTURE ONCOL, V5, P1113, DOI [10.2217/fon.09.93, 10.2217/FON.09.93]; Sheltzer JM, 2011, TRENDS GENET, V27, P446, DOI 10.1016/j.tig.2011.07.003; Shepard JL, 2007, GENE DEV, V21, P55, DOI 10.1101/gad.1470407; Solomon DA, 2011, SCIENCE, V333, P1039, DOI 10.1126/science.1203619; SONNENBERG A, 1987, EMBO J, V6, P121, DOI 10.1002/j.1460-2075.1987.tb04728.x; Stefansson OA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2334; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Zhang NG, 2008, P NATL ACAD SCI USA, V105, P13033, DOI 10.1073/pnas.0801610105	50	40	40	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2014	33	48					5511	5522		10.1038/onc.2013.493	http://dx.doi.org/10.1038/onc.2013.493			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZO	24276237	Green Accepted			2022-12-17	WOS:000346087900004
J	Sung, M; Giannakakou, P				Sung, M.; Giannakakou, P.			BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling	ONCOGENE			English	Article						BRCA1; microtubule; dynamics; taxane; drug resistance	MESSENGER-RNA EXPRESSION; POSITIVE BREAST-CANCER; GAMMA-TUBULIN-BINDING; ADJUVANT CHEMOTHERAPY; NUCLEAR ACCUMULATION; TUMOR-SUPPRESSOR; SUPPORTIVE CARE; DOCETAXEL PLUS; PROTEIN; PACLITAXEL	The taxanes are effective microtubule-stabilizing chemotherapy drugs used in the treatment of various solid tumors. However, the emergence of drug resistance hampers their clinical efficacy. The molecular basis of clinical taxane resistance remains poorly understood. Breast cancer 1, early onset gene, BRCA1, is a tumor-suppressor gene, whose expression has been correlated with taxane sensitivity in many solid tumors including non-small cell lung cancer. However, the molecular mechanism underlying the relationship between BRCA1 (B1) expression and taxane activity remains unclear. To this end, we created a stable B1 knockdown A549 cell line (B1-KD) to investigate B1's role in microtubule biology and response to taxane treatment. We show that B1-KD rendered A549 cells resistant to paclitaxel (PTX), phenocopying clinical studies showing that low B1 expression correlated with taxane resistance. As previously reported, we show that loss of B1 enhanced centrosomal g-tubulin localization and microtubule nucleation. Interestingly, we found that the B1-KD cells exhibited increased microtubule dynamics as compared with parental A549 cells, as assessed by live-cell confocal microscopy using enhanced green fluorescent protein-tagged a-tubulin or EB1 protein. In addition, we showed that loss of B1 impairs the ability of PTX to induce microtubule polymerization using immunofluorescence microscopy and a cell-based tubulin polymerization assay. Furthermore, B1-KD cells exhibited significantly lower intracellular binding of a fluorescently labeled PTX to microtubules. Recent studies have shown that PTX-stabilized microtubules serves as a scaffold for pro-caspase-8 binding and induction of apoptosis downstream of induced-proximity activation of caspase-8. Here we show that loss of B1 reduces the association of pro-caspase-8 with microtubules and subsequently leads to impaired PTX-induced activation of apoptosis. Taken together, our data show that B1 regulates indirectly endogenous microtubule dynamics and stability while its loss leads to microtubules that are more dynamic and less susceptible to PTX-induced stabilization conferring taxane resistance.	[Sung, M.; Giannakakou, P.] Cornell Univ, Weill Med Coll, Dept Med, Div Hematol & Med Oncol, New York, NY 10065 USA	Cornell University	Giannakakou, P (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Hematol & Med Oncol, 1300 York Ave,C610C, New York, NY 10065 USA.	pag2015@med.cornell.edu			National Institutes of Health [T32 CA062948, RO1 CA137020, NCI U54 CA143876]; NATIONAL CANCER INSTITUTE [R01CA137020, U54CA143876, T32CA062948] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr Geri Kreitzer (Weill Cornell Medical College), Dr Mary Ann Jordan (University of California, Santa Barbara) and Dr Richard Baer (Columbia University) for their kind gifts. We would also like to thank Dr Siddhartha Sen for help with the flow cytometry experiments. Work by Matthew Sung was supported by the National Institutes of Health (T32 CA062948, RO1 CA137020, NCI U54 CA143876).	Bieling P, 2007, NATURE, V450, P1100, DOI 10.1038/nature06386; Bouissou A, 2009, J CELL BIOL, V187, P327, DOI 10.1083/jcb.200905060; Buzdar AU, 2002, CLIN CANCER RES, V8, P1073; Byrski T, 2008, BREAST CANCER RES TR, V108, P289, DOI 10.1007/s10549-007-9600-1; Carbonaro M, 2012, J BIOL CHEM, V287, P11859, DOI 10.1074/jbc.M112.345587; Carbonaro M, 2011, J CELL BIOL, V192, P83, DOI 10.1083/jcb.201004145; Chen L, 2012, P NATL ACAD SCI USA, V109, P11842, DOI 10.1073/pnas.1121180109; Choy H, 1999, ONCOLOGY-NY, V13, P23; Coene ED, 2011, J CELL BIOL, V192, P497, DOI 10.1083/jcb.201004136; Darshan MS, 2011, CANCER RES, V71, P6019, DOI 10.1158/0008-5472.CAN-11-1417; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Etienne-Manneville S, 2010, CURR OPIN CELL BIOL, V22, P104, DOI 10.1016/j.ceb.2009.11.008; Font A, 2011, ANN ONCOL, V22, P139, DOI 10.1093/annonc/mdq333; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; Goncalves A, 2001, P NATL ACAD SCI USA, V98, P11737, DOI 10.1073/pnas.191388598; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Hennessy BTJ, 2010, J CLIN ONCOL, V28, P3570, DOI 10.1200/JCO.2009.27.2997; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hsu LC, 2001, CANCER RES, V61, P7713; Jin SQ, 2009, J BIOL CHEM, V284, P22970, DOI 10.1074/jbc.M109.009134; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Kauh J, 2011, CANCER-AM CANCER SOC, V117, P4049, DOI 10.1002/cncr.26004; Komlodi-Pasztor E, 2011, NAT REV CLIN ONCOL, V8, P244, DOI [10.1038/nrclinonc.2010.228, 10.1038/nrclinonc.2010.228-c2]; Lynch HT, 2008, BREAST J, V14, P3, DOI 10.1111/j.1524-4741.2007.00515.x; Mamounas EP, 2005, J CLIN ONCOL, V23, P3686, DOI 10.1200/JCO.2005.10.517; Marcus AI, 2006, CANCER RES, V66, P8838, DOI 10.1158/0008-5472.CAN-06-0699; Marcus AI, 2005, CANCER RES, V65, P3883, DOI 10.1158/0008-5472.CAN-04-3757; Martin M, 2005, NEW ENGL J MED, V352, P2302, DOI 10.1056/NEJMoa043681; Martin M, 2010, NEW ENGL J MED, V363, P2200, DOI 10.1056/NEJMoa0910320; McAlpine JN, 2012, MODERN PATHOL, V25, P740, DOI 10.1038/modpathol.2011.211; Mielgo A, 2009, ONCOGENE, V28, P3551, DOI 10.1038/onc.2009.210; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Parvin JD, 2009, ENVIRON MOL MUTAGEN, V50, P649, DOI 10.1002/em.20475; PARYSEK LM, 1984, J CELL BIOL, V99, P1309, DOI 10.1083/jcb.99.4.1309; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Quinn JE, 2007, CLIN CANCER RES, V13, P7413, DOI 10.1158/1078-0432.CCR-07-1083; Ranson M, 2000, JNCI-J NATL CANCER I, V92, P1074, DOI 10.1093/jnci/92.13.1074; Reguart N, 2008, CLIN LUNG CANCER, V9, P331, DOI 10.3816/CLC.2008.n.048; Rhiem K, 2010, ANTICANCER RES, V30, P3445; Roche H, 2006, J CLIN ONCOL, V24, P5664, DOI 10.1200/JCO.2006.07.3916; Rosell R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005133; Roszkowski K, 2000, LUNG CANCER-J IASLC, V27, P145, DOI 10.1016/S0169-5002(00)00094-5; Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B; Saiki Y, 2011, INT J OTOLARYNGOL, V2011; Sankaran S, 2005, MOL CELL BIOL, V25, P8656, DOI 10.1128/MCB.25.19.8656-8668.2005; Sankaran S, 2007, CANCER BIOL THER, V6, P1853, DOI 10.4161/cbt.6.12.5164; Schoffski P, 2011, EUR J CANCER, V47, P1006, DOI 10.1016/j.ejca.2011.01.016; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Tassone P, 2003, BRIT J CANCER, V88, P1285, DOI 10.1038/sj.bjc.6600859; Thoma CR, 2010, J CELL BIOL, V190, P991, DOI 10.1083/jcb.201006059; Vaughan KT, 2005, J CELL BIOL, V171, P197, DOI 10.1083/jcb.200509150; Wei J, 2011, J NATL CANCER I, V103, P1552, DOI 10.1093/jnci/djr326; Wen YD, 2004, KENYON REV, V26, P1; WILSON L, 1995, CHEM BIOL, V2, P569, DOI 10.1016/1074-5521(95)90119-1; Xu GQ, 2010, NAT BIOTECHNOL, V28, P868, DOI 10.1038/nbt.1654; Zhang JR, 2005, MOL CANCER RES, V3, P531, DOI 10.1158/1541-7786.MCR-05-0192; Zhou J, 2009, J BIOL CHEM, V284, P9648, DOI 10.1074/jbc.M808708200; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	63	40	40	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1418	1428		10.1038/onc.2013.85	http://dx.doi.org/10.1038/onc.2013.85			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23524581	Green Accepted			2022-12-17	WOS:000332943500009
J	Wetterskog, D; Shiu, KK; Chong, I; Meijer, T; Mackay, A; Lambros, M; Cunningham, D; Reis-Filho, JS; Lord, CJ; Ashworth, A				Wetterskog, D.; Shiu, K-K; Chong, I.; Meijer, T.; Mackay, A.; Lambros, M.; Cunningham, D.; Reis-Filho, J. S.; Lord, C. J.; Ashworth, A.			Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers	ONCOGENE			English	Article						HER2; ERBB2-positive breast cancer; lapatinib resistance; RNAi screen; NIBP; TRAPPC9	GROWTH-FACTOR RECEPTOR; NF-KAPPA-B; NEU DIFFERENTIATION FACTOR; IN-SITU HYBRIDIZATION; HUMAN-BREAST-CANCER; TRASTUZUMAB RESISTANCE; GENE-EXPRESSION; ACTIVATION; INHIBITOR; ANTIBODY	The gene encoding the receptor tyrosine kinase ERBB2, also known as HER2, is amplified and/or overexpressed in up to 15% of breast cancers. These tumours are characterised by an aggressive phenotype and poor clinical outcome. Although therapies targeted at ERBB2 have proven effective, many patients fail to respond to treatment or become resistant and the reasons for this are still largely unknown. Using a high-throughput functional screen we assessed whether genes found to be recurrently amplified and overexpressed in ERBB2+ve breast cancers mediate resistance to the ERBB2-targeted agent lapatinib. Lapatinib-resistant ERBB2-amplified breast cancer cell lines were screened, in the presence or absence of lapatinib, with an RNA interference library targeting 369 genes recurrently amplified and overexpressed in both ERBB2-amplified breast cancer tumours and cell lines. Small interfering RNAs targeting a number of genes caused sensitivity to lapatinib in this context. The mechanisms of resistance conferred by the identified genes were further investigated and in the case of NIBP (TRAPPC9), lapatinib resistance was found to be mediated through NF-kappa B signalling. Our results indicate that specific amplified and/or overexpressed genes found in ERBB2-amplified breast cancer may mediate response to ERBB2-targeting agents.	[Wetterskog, D.; Shiu, K-K; Chong, I.; Meijer, T.; Mackay, A.; Lambros, M.; Reis-Filho, J. S.; Lord, C. J.; Ashworth, A.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Chong, I.; Cunningham, D.] Royal Marsden Hosp, GI Unit, Sutton, Surrey, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Reis-Filho, JS (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, ICR, 237 Fulham Rd, London SW3 6JB, England.	reisfilj@mskcc.org; Chris.Lord@icr.ac.uk; Alan.Ashworth@icr.ac.uk	Lord, Christopher/AAX-7130-2021; Lord, Christopher J/B-3295-2012	Lord, Christopher J/0000-0002-3226-0515; Cunningham, David/0000-0001-5158-1069; Chong, Irene Y/0000-0003-1692-4411	Breakthrough Breast Cancer; AACR SU2C; NHS	Breakthrough Breast Cancer; AACR SU2C; NHS	We thank Breakthrough Breast Cancer and AACR SU2C for funding this work. We acknowledge NHS funding to the NIHR RMH Biomedical research Centre. We thank Dr David Watkins from the Royal Marsden hospital for the kind donation of the CR-OE33 cell line.	Alvarez RH, 2010, J CLIN ONCOL, V28, P3366, DOI 10.1200/JCO.2009.25.4011; Baehner FL, 2010, J CLIN ONCOL, V28, P4300, DOI 10.1200/JCO.2009.24.8211; Bang YJ, 2010, LANCET, V376, P1302; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Brough R, 2011, CANCER DISCOV, V1, P260, DOI 10.1158/2159-8290.CD-11-0107; Campbell KJ, 2004, CELL CYCLE, V3, P869; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Christianson TA, 1998, CANCER RES, V58, P5123; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Codony-Servat J, 1999, CANCER RES, V59, P1196; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Dokmanovic M, 2009, MOL CANCER THER, V8, P1557, DOI 10.1158/1535-7163.MCT-09-0140; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Harris LN, 2007, CLIN CANCER RES, V13, P1198, DOI 10.1158/1078-0432.CCR-06-1304; Hu WH, 2005, J BIOL CHEM, V280, P29233, DOI 10.1074/jbc.M501670200; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Lal P, 2004, AM J CLIN PATHOL, V121, P631, DOI 10.1309/VE7862V2646BR6EX; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Marchio C, 2008, J PATHOL, V216, P399, DOI 10.1002/path.2423; Merkhofer EC, 2010, ONCOGENE, V29, P1238, DOI 10.1038/onc.2009.410; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Owens Marilyn A, 2004, Clin Breast Cancer, V5, P63, DOI 10.3816/CBC.2004.n.011; Park S, 2010, CANCER CELL, V18, P160, DOI 10.1016/j.ccr.2010.06.014; Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Sacher M, 2001, MOL CELL, V7, P433, DOI 10.1016/S1097-2765(01)00190-3; Saini KS, 2011, BREAST, V20, pS20, DOI 10.1016/S0960-9776(11)70289-2; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; Scaltriti M, 2010, CLIN CANCER RES, V16, P2688, DOI 10.1158/1078-0432.CCR-09-3407; Shiu KK, 2014, ONCOGENE, V33, P619, DOI 10.1038/onc.2012.625; Shiu KK, 2010, FUTURE ONCOL, V6, P967, DOI 10.2217/FON.10.56; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Sperinde J, 2010, CLIN CANCER RES, V16, P4226, DOI 10.1158/1078-0432.CCR-10-0410; Staaf J, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2568; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Tanner M, 2005, ANN ONCOL, V16, P273, DOI 10.1093/annonc/mdi064; Tse CH, 2011, J CLIN ONCOL, V29, P4168, DOI 10.1200/JCO.2011.36.0107; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Xia WL, 2010, MOL CANCER THER, V9, P292, DOI 10.1158/1535-7163.MCT-09-1041; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yakes FM, 2002, CANCER RES, V62, P4132	55	40	42	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					966	976		10.1038/onc.2013.41	http://dx.doi.org/10.1038/onc.2013.41			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23474757				2022-12-17	WOS:000331933200004
J	Todd, JR; Scurr, LL; Becker, TM; Kefford, RF; Rizos, H				Todd, J. R.; Scurr, L. L.; Becker, T. M.; Kefford, R. F.; Rizos, H.			The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma	ONCOGENE			English	Article						c-Kit; stem cell factor; melanoma; melanocytes; MAPK; PI3K	GASTROINTESTINAL STROMAL TUMORS; TYROSINE KINASE; METASTATIC MELANOMA; PROTEIN EXPRESSION; IMATINIB MESYLATE; HUMAN MELANOCYTES; MUCOSAL MELANOMA; MAJOR RESPONSE; RESISTANCE; MUTATIONS	Stimulation of the c-Kit receptor tyrosine kinase has a critical role in the development and migration of melanocytes, and oncogenic c-Kit mutants contribute to the progression of some melanomas. c-Kit signalling activates the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways and their relative contribution to the activities of oncogenic and ligand-dependent c-Kit remains uncertain. We show that PI3K is a major regulator of MAPK activation in response to c-Kit activity and the dominant effector of c-Kit-driven melanocyte proliferation and melanoma survival. Nevertheless, inhibition of the PI3K pathway in c-Kit mutant melanoma cells did not replicate the apoptotic efficacy of the c-Kit inhibitor, imatinib mesylate. Instead, the simultaneous suppression of the PI3K and MAPK pathways promoted a strong synergistic apoptotic effect. These data indicate that MAPK functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma. Thus, the concurrent inhibition of PI3K and MAPK signalling is required to suppress oncogenic c-Kit activity and may provide an effective therapeutic strategy in c-Kit mutant melanomas.	[Todd, J. R.; Scurr, L. L.; Becker, T. M.; Kefford, R. F.; Rizos, H.] Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead Hosp, Westmead, NSW 2145, Australia; [Kefford, R. F.] Melanoma Inst Australia, Sydney, NSW, Australia	University of Sydney; Westmead Institute for Medical Research; Melanoma Institute Australia	Rizos, H (corresponding author), Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead Hosp, Darcy Rd, Westmead, NSW 2145, Australia.	helen.rizos@sydney.edu.au		Becker, Therese/0000-0002-5636-9902; Kefford, Richard/0000-0001-9251-9229; Rizos, Helen/0000-0002-2094-9198	National Health and Medical Research Council of Australia (NHMRC) [633004]; Health Department of NSW through Sydney West Area Health Service; Australian Cancer Research Foundation; Cancer Institute New South Wales; NHMRC; Australian Postgraduate Award; Westmead Medical Research Foundation; Melanoma Foundation of the University of Sydney	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Health Department of NSW through Sydney West Area Health Service; Australian Cancer Research Foundation; Cancer Institute New South Wales; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Award(Australian Government); Westmead Medical Research Foundation; Melanoma Foundation of the University of Sydney(University of Sydney)	We are grateful to Antoni Ribas, Peter Hersey and Meenhard Herlyn for providing c-Kit mutant melanoma cells lines. This work is supported by Programme Grant 633004 and project grants of the National Health and Medical Research Council of Australia (NHMRC) and an infrastructure grant to Westmead Millennium Institute by the Health Department of NSW through Sydney West Area Health Service. Westmead Institute for Cancer Research is the recipient of capital grant funding from the Australian Cancer Research Foundation. HR is a recipient of a Cancer Institute New South Wales, Research Fellowship and a NHMRC Senior Research Fellowship. JT is supported by an Australian Postgraduate Award and a Westmead Medical Research Foundation Top-up Award. The support of the Melanoma Foundation of the University of Sydney and colleagues from Melanoma Institute Australia and the Department of Anatomical Pathology at the Royal Prince Alfred Hospital are also gratefully acknowledged.	Aksamitiene E, 2012, BIOCHEM SOC T, V40, P139, DOI 10.1042/BST20110609; Alexeev V, 2006, J INVEST DERMATOL, V126, P1102, DOI 10.1038/sj.jid.5700125; Antonescu CR, 2007, INT J CANCER, V121, P257, DOI 10.1002/ijc.22681; Atefi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028973; Bauer S, 2007, ONCOGENE, V26, P7560, DOI 10.1038/sj.onc.1210558; Beadling C, 2008, CLIN CANCER RES, V14, P6821, DOI 10.1158/1078-0432.CCR-08-0575; Carvajal RD, 2011, JAMA-J AM MED ASSOC, V305, P2327, DOI 10.1001/jama.2011.746; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Garrido MC, 2010, J INVEST DERMATOL, V130, P20, DOI 10.1038/jid.2009.334; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Gounder MM, 2011, CANCER CHEMOTH PHARM, V67, P25, DOI 10.1007/s00280-010-1526-3; Guo J, 2011, J CLIN ONCOL, V29, P2904, DOI 10.1200/JCO.2010.33.9275; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; Handolias D, 2010, PIGM CELL MELANOMA R, V23, P210, DOI 10.1111/j.1755-148X.2010.00671.x; Heinrich MC, 2002, J CLIN ONCOL, V20, P1692, DOI 10.1200/JCO.2002.20.6.1692; Hodi FS, 2008, J CLIN ONCOL, V26, P2046, DOI 10.1200/JCO.2007.14.0707; Jeon S, 2009, PIGM CELL MELANOMA R, V22, P77, DOI 10.1111/j.1755-148X.2008.00519.x; Jiang XF, 2008, CLIN CANCER RES, V14, P7726, DOI 10.1158/1078-0432.CCR-08-1144; Kim Kwang Young, 2011, Algae, V26, P1, DOI 10.4490/algae.2011.26.1.001; Kontogianni-Katsarou K, 2008, WORLD J GASTROENTERO, V14, P1891, DOI 10.3748/wjg.14.1891; Larribere L, 2005, GENE DEV, V19, P1980, DOI 10.1101/gad.335905; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; Lefevre G, 2004, J BIOL CHEM, V279, P31769, DOI 10.1074/jbc.M403907200; Liang RX, 2011, PIGM CELL MELANOMA R, V24, P714, DOI 10.1111/j.1755-148X.2011.00870.x; Lutzky J, 2008, PIGM CELL MELANOMA R, V21, P492, DOI 10.1111/j.1755-148X.2008.00475.x; Martin J, 2005, J CLIN ONCOL, V23, P6190, DOI 10.1200/JCO.2005.19.554; Monsel G, 2010, ONCOGENE, V29, P227, DOI 10.1038/onc.2009.320; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Omholt K, 2011, CLIN CANCER RES, V17, P3933, DOI 10.1158/1078-0432.CCR-10-2917; Rivera RS, 2008, VIRCHOWS ARCH, V452, P27, DOI 10.1007/s00428-007-0524-2; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V337, P1, DOI 10.1016/j.bbrc.2005.08.055; Shi HB, 2011, CANCER RES, V71, P5067, DOI 10.1158/0008-5472.CAN-11-0140; Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381; Si L, 2012, J CLIN ONCOL, V30, pE37, DOI 10.1200/JCO.2011.37.9644; Smalley KSM, 2008, CANCER RES, V68, P5743, DOI 10.1158/0008-5472.CAN-08-0235; Takayama Y, 2008, CANCER LETT, V264, P241, DOI 10.1016/j.canlet.2008.01.035; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wardelmann E, 2002, MODERN PATHOL, V15, P125, DOI 10.1038/modpathol.3880504; Woodman SE, 2009, MOL CANCER THER, V8, P2079, DOI 10.1158/1535-7163.MCT-09-0459; Yoshida H, 2001, J INVEST DERM SYMP P, V6, P1, DOI 10.1046/j.0022-202x.2001.00006.x	41	40	41	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					236	245		10.1038/onc.2012.562	http://dx.doi.org/10.1038/onc.2012.562			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23246970	Bronze			2022-12-17	WOS:000329440700011
J	Ho, L; Ali, SA; Al-Jazrawe, M; Kandel, R; Wunder, JS; Alman, BA				Ho, L.; Ali, S. A.; Al-Jazrawe, M.; Kandel, R.; Wunder, J. S.; Alman, B. A.			Primary cilia attenuate hedgehog signalling in neoplastic chondrocytes	ONCOGENE			English	Article						chondrosarcoma; primary cilia; hedgehog pathway; enchondroma; cartilage	RENAL-CELL CARCINOMA; INTRAFLAGELLAR TRANSPORT; GROWTH-PLATE; CARTILAGE HISTOPATHOLOGY; REPRESSOR FUNCTIONS; EXPRESSION; ACTIVATOR; DEFECTS; PATHWAY; CANCER	Primary cilia can act as either a negative or positive regulator of the hedgehog (Hh) signaling pathway. Many cartilage tumors are characterized by abnormal activation of the Hh pathway. Here, we report that the presence of primary cilia occurs at a low frequency (12.4%) in neoplastic chondrocytes from malignant human chondrosarcomas, compared with chondrocytes from normal articular cartilage (67.7%). To determine the function of primary cilia in cartilaginous neoplasia, we studied benign cartilage tumors that are formed in mice by chondrocyte-specific overexpression of Gli2, a downstream transcriptional activator of the Hh pathway. Col2A1-Gli2 mice were crossed with Ift88+/- mice, which display a partial loss of ciliogenesis. Surprisingly, cartilage tumors developed in Ift88+/- mice that were phenotypically similar to those that arise in Col2A1-Gli2 mice. Further activation of the Hh pathway was observed in Col2A1-Gli2; Ift88+/- mice compared with either Col2A1-Gli2 or Ift88+/- mice, which was associated with an increased incidence of cartilage tumors. Chondrosarcomas were established in explant cultures, and treated with choral hydrate, which disrupts the functional primary cilia. Thus, treatment resulted in hyperactivity of the Hh signaling pathway, as well as cellular changes that could promote tumor growth. Primary cilia functions to inhibit Hh signaling in neoplastic chondrocytes. The activation of Hh signaling is sufficient to induce benign cartilage tumors without another oncogenic initiating event. Moreover, as primary cilia suppress Hh pathway activation in chondrosarcoma, cellular mechanisms inhibiting proper cilia function may be important in maintaining the neoplastic phenotype.	[Ho, L.; Ali, S. A.; Al-Jazrawe, M.; Alman, B. A.] Hosp Sick Children, Program Dev & Stem Cell Biol, Toronto, ON M5G 1X8, Canada; [Ho, L.; Al-Jazrawe, M.; Kandel, R.; Alman, B. A.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Ali, S. A.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Kandel, R.; Wunder, J. S.] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Wunder, J. S.; Alman, B. A.] Univ Toronto, Dept Surg, Div Orthopaed Surg, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Alman, BA (corresponding author), Hosp Sick Children, Program Dev & Stem Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	benjamin.alman@sickkids.ca	Kandel, Rita/E-2149-2017; Kandel, Rita/AAU-9908-2021	Kandel, Rita/0000-0003-4047-3913; Kandel, Rita/0000-0003-4047-3913; Ali, Shabana/0000-0002-4339-9467	Canadian Institutes of Health Research [MOP- 37913]; University of Toronto Fellowship; Hospital for Sick Children (RESTRACOMP); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK074038] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); University of Toronto Fellowship(University of Toronto); Hospital for Sick Children (RESTRACOMP); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Wewould like to acknowledge the Canadian Institutes of Health Research for supporting this research project through operating grant no, MOP- 37913. Funding by the University of Toronto Fellowship and Hospital for Sick Children (RESTRACOMP) is also gratefully acknowledged.	Chang CF, 2012, OSTEOARTHR CARTILAGE, V20, P152, DOI 10.1016/j.joca.2011.11.009; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; de Andrea CE, 2010, LAB INVEST, V90, P1091, DOI 10.1038/labinvest.2010.81; Dormoy V, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-123; Goetz SC, 2010, NAT REV GENET, V11, P331, DOI 10.1038/nrg2774; Hallor KH, 2009, CLIN CANCER RES, V15, P2685, DOI 10.1158/1078-0432.CCR-08-2330; Han YG, 2009, NAT MED, V15, P1062, DOI 10.1038/nm.2020; Haycraft CJ, 2005, PLOS GENET, V1, P480, DOI 10.1371/journal.pgen.0010053; Haycraft CJ, 2007, DEVELOPMENT, V134, P307, DOI 10.1242/dev.02732; Ho L, 2009, CANCER CELL, V16, P126, DOI 10.1016/j.ccr.2009.05.013; Hopyan S, 2002, NAT GENET, V30, P306, DOI 10.1038/ng844; Hsu SHC, 2011, DEVELOPMENT, V138, P3791, DOI 10.1242/dev.069492; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Kim J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027410; LEE GM, 1987, J CELL SCI, V88, P603; Lin AC, 2009, NAT MED, V15, P1421, DOI 10.1038/nm.2055; Liu AM, 2005, DEVELOPMENT, V132, P3103, DOI 10.1242/dev.01894; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; May SR, 2005, DEV BIOL, V287, P378, DOI 10.1016/j.ydbio.2005.08.050; McGlashan SR, 2008, DEV DYNAM, V237, P2013, DOI 10.1002/dvdy.21501; McGlashan SR, 2007, MATRIX BIOL, V26, P234, DOI 10.1016/j.matbio.2006.12.003; Moser JJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-448; Pansuriya TC, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-2; Pauli C, 2012, OSTEOARTHR CARTILAGE, V20, P476, DOI 10.1016/j.joca.2011.12.018; Poon R, 2001, ONCOGENE, V20, P451, DOI 10.1038/sj.onc.1204107; Praetorius HA, 2003, J MEMBRANE BIOL, V191, P69, DOI 10.1007/s00232-002-1042-4; Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014; Schraml P, 2009, MODERN PATHOL, V22, P31, DOI 10.1038/modpathol.2008.132; Seeley ES, 2009, CANCER RES, V69, P422, DOI 10.1158/0008-5472.CAN-08-1290; Serra R, 2008, ANAT REC, V291, P1049, DOI 10.1002/ar.20634; Song B, 2007, DEV BIOL, V305, P202, DOI 10.1016/j.ydbio.2007.02.003; Tiet TD, 2006, AM J PATHOL, V168, P321, DOI 10.2353/ajpath.2006.050001; Tobin JL, 2009, GENET MED, V11, P386, DOI 10.1097/GIM.0b013e3181a02882; Wong SY, 2009, NAT MED, V15, P1055, DOI 10.1038/nm.2011; Yan TQ, 2008, CLIN ORTHOP RELAT R, V466, P2184, DOI 10.1007/s11999-008-0332-2; Yuan K, 2010, J HISTOCHEM CYTOCHEM, V58, P857, DOI 10.1369/jhc.2010.955856	36	40	44	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2013	32	47					5388	5396		10.1038/onc.2012.588	http://dx.doi.org/10.1038/onc.2012.588			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	254PM	23246966	Green Published, hybrid			2022-12-17	WOS:000327177600002
J	Berger, T; Ueda, T; Arpaia, E; Chio, IIC; Shirdel, EA; Jurisica, I; Hamada, K; You-Ten, A; Haight, J; Wakeham, A; Cheung, CC; Mak, TW				Berger, T.; Ueda, T.; Arpaia, E.; Chio, I. I. C.; Shirdel, E. A.; Jurisica, I.; Hamada, K.; You-Ten, A.; Haight, J.; Wakeham, A.; Cheung, C. C.; Mak, T. W.			Flotillin-2 deficiency leads to reduced lung metastases in a mouse breast cancer model	ONCOGENE			English	Article						breast cancer; metastasis; MMTV-PyMT; flotillin-1; reggie1/2	SIGNAL-TRANSDUCTION; UP-REGULATION; LIPID RAFTS; CELL-LINES; MICROARRAY; EXPRESSION; PROTEINS; DISEASE; GENOME; CYTOSKELETON	Flotillin microdomains, specialized lipid raft domains in cell membranes, serve as physical platforms for many different molecules important in crucial intracellular signaling pathways. Flotillin-2 (Flot2), together with flotillin-1, is a marker for lipid raft microdomains distinct from caveolar lipid rafts, and has been implicated in the progression of cancer and metastasis formation. Based largely on studies in xenograft models, flotillin-2 has been implicated in the progression of multiple types of human tumors, including breast cancer. In our studies, we identified flotillin-2 as highly amplified in a high-throughput comparative genomic hybridization screen of human breast cancer cell lines and breast tumor samples. Short hairpin RNA-mediated reduction of flotillin-2 protein levels significantly reduced the tumorigenicity and metastatic capability of a human breast cancer cell line in vivo. We generated mice deficient for flotillin-2 and also found a reduction of flotillin-1 protein levels and complete absence of flotillin-specific membrane microdomains in these mice. To examine the role of Flot2 in mammary tumorigenesis and lung metastasis, we used an in vivo molecular genetics approach, crossing a well-characterized transgenic mouse model of breast cancer, the MMTV-PyMT (mouse mammary tumor virus-polyoma middle T antigen) mouse, with gene-targeted Flot2(-/-) mice. Flotillin-2 deficiency lead to a striking reduction in the number of lung metastasis observed, but had no influence on primary tumor formation in this model. Our results indicate, using a novel in vivo animal model approach, that Flot2 is an important regulator of mammary tumor-derived lung metastasis.	[Berger, T.; Ueda, T.; Arpaia, E.; Chio, I. I. C.; Shirdel, E. A.; You-Ten, A.; Haight, J.; Wakeham, A.; Mak, T. W.] Univ Hlth Network, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2M9, Canada; [Ueda, T.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dis Model, Hiroshima, Japan; [Shirdel, E. A.; Jurisica, I.] Univ Hlth Network, Techna Inst, Toronto, ON, Canada; [Shirdel, E. A.; Jurisica, I.] IBM Life Sci Discovery Ctr, Toronto, ON, Canada; [Jurisica, I.; Mak, T. W.] Univ Toronto, Dept Med Phys, Toronto, ON, Canada; [Jurisica, I.; Mak, T. W.] Univ Toronto, Dept Immunol, Toronto, ON, Canada; [Jurisica, I.] Univ Toronto, Dept Comp Sci, Toronto, ON, Canada; [Hamada, K.] Kumamoto Univ, Ctr AIDS Res, Okada Projects, Kumamoto, Japan; [Cheung, C. C.] Univ Hlth Network, Dept Pathol, Toronto, ON, Canada; [Mak, T. W.] Univ Hlth Network, Ontario Canc Inst, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Hiroshima University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; Kumamoto University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Mak, TW (corresponding author), Univ Hlth Network, Campbell Family Inst Breast Canc Res, 620 Univ Ave,Suite 706, Toronto, ON M5G 2M9, Canada.	tmak@uhnresearch.ca	Berger, Thorsten/J-7632-2012	Ueda, Takeshi/0000-0001-9823-6764	Ontario Research Fund [GL2-01-030]; Canada Research Chair Program; Canadian Institutes of Health Research [179815]	Ontario Research Fund; Canada Research Chair Program(Canada Research Chairs); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We thank Lily Zhou for expert technical assistance, and Dr Mary Saunders for insightful scientific editing. This work was supported by grant no. 179815 from the Canadian Institutes of Health Research to TWM. This research was funded in part by the Ontario Ministry of Health and Long Term Care. The views expressed do not necessarily reflect those of the OMOHLTC. ES is in part supported by Ontario Research Fund (GL2-01-030) to IJ, and IJ was in part supported by Canada Research Chair Program.	Arpaia E, 2012, ONCOGENE, V31, P884, DOI 10.1038/onc.2011.288; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Boyle P, 2008, WORLD CANC REPORT 20; Buccione R, 2009, CANCER METAST REV, V28, P137, DOI 10.1007/s10555-008-9176-1; de Laurentiis Angela, 2007, Open Biochem J, V1, P12, DOI 10.2174/1874091X00701010012; de Leeuw RJ, 2004, HUM MOL GENET, V13, P1827, DOI 10.1093/hmg/ddh195; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hazarika P, 2004, CANCER RES, V64, P7361, DOI 10.1158/0008-5472.CAN-04-0823; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; LEMOYEC L, 1992, BRIT J CANCER, V66, P623, DOI 10.1038/bjc.1992.327; Lin CY, 2011, CLIN CANCER RES, V17, P3089, DOI 10.1158/1078-0432.CCR-10-3068; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Ludwig A, 2010, J CELL BIOL, V191, P771, DOI 10.1083/jcb.201005140; Maglione JE, 2001, CANCER RES, V61, P8298; Neumann-Giesen C, 2007, J CELL SCI, V120, P395, DOI 10.1242/jcs.03336; Nohara K, 1998, BREAST CANCER RES TR, V48, P149, DOI 10.1023/A:1005986606010; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Qiu TH, 2004, CANCER RES, V64, P5973, DOI 10.1158/0008-5472.CAN-04-0242; Rickman DS, 2008, ONCOGENE, V27, P6607, DOI 10.1038/onc.2008.251; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5; Schulte T, 1997, DEVELOPMENT, V124, P577; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stuermer CAO, 2004, FASEB J, V18, P1731, DOI 10.1096/fj.04-2150fje; Watson SK, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-6; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P551, DOI 10.1083/jcb.1.6.551; Yamaguchi H, 2009, CANCER RES, V69, P8594, DOI 10.1158/0008-5472.CAN-09-2305	28	40	44	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4989	4994		10.1038/onc.2012.499	http://dx.doi.org/10.1038/onc.2012.499			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23146906				2022-12-17	WOS:000325717800015
J	Martino, JJ; Wall, BA; Mastrantoni, E; Wilimczyk, BJ; La Cava, SN; Degenhardt, K; White, E; Chen, S				Martino, J. J.; Wall, B. A.; Mastrantoni, E.; Wilimczyk, B. J.; La Cava, S. N.; Degenhardt, K.; White, E.; Chen, S.			Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells	ONCOGENE			English	Article						Grm1; glutamatergic signaling; oncogene; cell transformation; kidney epithelial cells; carcinoma	PROTEIN-COUPLED RECEPTORS; SIGNALING PATHWAYS; MALIGNANT-MELANOMA; HUMAN MELANOCYTES; TRANSGENIC MICE; CANCER; GROWTH; GLUTAMATE-RECEPTOR-1; EXPRESSION; TARGETS	Non-neuronal expression of components of the glutamatergic system has been increasingly observed, and our laboratory previously had demonstrated the etiological role of ectopically expressed metabotropic glutamate receptor 1 (Grm1/mGluR1) in mouse models of melanoma. We hypothesize that inappropriate glutamatergic signaling in other cell types can dysregulate growth leading to transformation and tumorigenesis. As most cancers are carcinomas, we selected an immortalized primary baby mouse kidney (iBMK) cell model to assess whether Grm1 can transform epithelial cells. These iBMK cells, engineered to be immortal yet nontumorigenic and retaining normal epithelial characteristics, were used as recipients for exogenous Grm1 cDNA. Several stable Grm1-expressing clones were isolated and the Grm1-receptors were shown to be functional, as evidenced by the accumulation of second messengers in response to Grm1 agonist. Additionally activated by agonist were mitogen-activated protein kinase (MAPK) and AKT/protein kinase B signaling cascades, the major intracellular pathways shown by many investigators to be critical in melanomagenesis and other neoplasms. These Grm1-iBMK cells exhibited enhanced cell proliferation in in vitro methylthiazolyldiphenyl-tetrazolium bromide (MTT) assays and significant tumorigenicity in in vivo allografts. Persistent Grm1 expression was required for the maintenance of the in vivo tumorigenic phenotype as demonstrated by an inducible Grm1-silencing RNA. These are the first results that indicate that Grm1 can be an oncogene in epithelial cells. In addition, relevance to human disease in the corresponding tumor type of renal cell carcinoma (RCC) may be suggested by observed expression of GRM1/mGluR1 in a number of RCC tumor biopsy samples and cell lines, and the effects of GRM1 modulation on tumorigenicity therein. Moreover, RCC cell lines exhibited elevated levels of extracellular glutamate, and some lines responded to drugs, which modulate the glutamatergic system. These findings imply a possible role for glutamate signaling apparatus in RCC cell growth, and that the glutamatergic system may be a therapeutic target in RCC.	[Martino, J. J.; Wall, B. A.; Mastrantoni, E.; Wilimczyk, B. J.; La Cava, S. N.; Chen, S.] Rutgers State Univ, Ernest Mario Sch Pharm, Susan Lehman Cullman Lab Canc Res, Dept Biol Chem, Piscataway, NJ 08854 USA; [Mastrantoni, E.] Univ Rome Sapienze, Dept Physiol & Pharmacol, Rome, Italy; [Degenhardt, K.] Touro Coll Osteopath Med, Dept Basic Biomed Sci, New York, NY USA; [White, E.; Chen, S.] Canc Inst New Jersey, New Brunswick, NJ USA; [White, E.] Rutgers State Univ, Dept Mol & Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick	Chen, S (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Susan Lehman Cullman Lab Canc Res, Dept Biol Chem, 164 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	suziec@rci.rutgers.edu	White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	Department of Physiology and Pharmacology, University of Rome "Sapienza", Rome, Itally;  [R01CA108720];  [09-1143-CCR-EO]; NATIONAL CANCER INSTITUTE [R01CA108720, P30CA072720, R01CA130893, R01CA074077] Funding Source: NIH RePORTER	Department of Physiology and Pharmacology, University of Rome "Sapienza", Rome, Itally; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants R01CA108720 and 09-1143-CCR-EO (SC) and PhD fellowship from the Department of Physiology and Pharmacology, University of Rome "Sapienza", Rome, Itally (EM). We would like to acknowledge the generosity of Dr WM Linehan (Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA) for RCC lines, Dr Daiya Takai (The University of Tokyo Hospital, Tokyo, Japan) for TetR plasmid components, Dr Tony Kong (Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA) for Aperio digital slide scanning/quantification system access and Dr Hao Wu (The Cancer Institute of New Jersey, New Brunswick, NJ, USA) for keen pathological insights.	American Cancer Society, 2012, CANC FACTS FIG; ANGLARD P, 1992, CANCER RES, V52, P348; Bracarda S, 2009, EUR UROL SUPPL, V8, P787, DOI 10.1016/j.eursup.2009.07.007; Carroll FY, 2001, MOL PHARMACOL, V59, P965, DOI 10.1124/mol.59.5.965; Choi KY, 2011, P NATL ACAD SCI USA, V108, P15219, DOI 10.1073/pnas.1107304108; Cicenas J, 2008, INT J BIOL MARKER, V23, P1, DOI 10.1177/172460080802300101; Cohen-Solal KA, 2002, PIGM CELL RES, V15, P282, DOI 10.1034/j.1600-0749.2002.02024.x; D'Onofrio M, 2003, J NEUROCHEM, V84, P1288, DOI 10.1046/j.1471-4159.2003.01633.x; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Degenhardt K, 2006, CLIN CANCER RES, V12, P5298, DOI 10.1158/1078-0432.CCR-06-0439; Ferraguti F, 2008, PHARMACOL REV, V60, P536, DOI 10.1124/pr.108.000166; Frati C, 2000, J CELL PHYSIOL, V183, P364, DOI 10.1002/(SICI)1097-4652(200006)183:3<364::AID-JCP9>3.3.CO;2-O; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Genever PG, 1999, J INVEST DERMATOL, V112, P337, DOI 10.1046/j.1523-1747.1999.00509.x; Gill SS, 1999, BRAIN RES BULL, V48, P143, DOI 10.1016/S0361-9230(98)00154-3; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004; Hoogduijn MJ, 2006, PIGM CELL RES, V19, P58, DOI 10.1111/j.1600-0749.2005.00284.x; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Iacovelli L, 2006, J NEUROSCI, V26, P8388, DOI 10.1523/JNEUROSCI.2285-06.2006; Jong YJI, 2007, J NEUROCHEM, V101, P458, DOI 10.1111/j.1471-4159.2006.04382.x; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Kohler BA, 2011, JNCI-J NATL CANCER I, V103, P714, DOI 10.1093/jnci/djr077; Lappano R, 2011, NAT REV DRUG DISCOV, V10, P47, DOI 10.1038/nrd3320; Le MN, 2010, J INVEST DERMATOL, V130, P2240, DOI 10.1038/jid.2010.126; Lee HJ, 2011, CLIN CANCER RES, V17, P7080, DOI 10.1158/1078-0432.CCR-11-0098; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Machado-Vieira R, 2009, CURR PHARM DESIGN, V15, P1595, DOI 10.2174/138161209788168010; Marin YE, 2006, CELL SIGNAL, V18, P1279, DOI 10.1016/j.cellsig.2005.10.012; Marin YE, 2004, J MOL MED, V82, P735, DOI 10.1007/s00109-004-0566-8; Mathew A, 2002, EUR J CANCER PREV, V11, P171, DOI 10.1097/00008469-200204000-00010; Matsukura S, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng077; Melchiorri D, 2007, NEUROPHARMACOLOGY, V53, P473, DOI 10.1016/j.neuropharm.2007.05.031; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; Miller RG, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001447.pub2; Milligan G, 2000, SCIENCE, V288, P65, DOI 10.1126/science.288.5463.65; Morimoto R, 2006, EMBO J, V25, P4175, DOI 10.1038/sj.emboj.7601317; Namkoong J, 2007, CANCER RES, V67, P2298, DOI 10.1158/0008-5472.CAN-06-3665; Nicoletti F, 2007, TRENDS PHARMACOL SCI, V28, P206, DOI 10.1016/j.tips.2007.03.008; Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148; Prezeau L, 1996, MOL PHARMACOL, V49, P422; Prickett TD, 2011, NAT GENET, V43, P1119, DOI 10.1038/ng.950; Recasens M, 2007, CURR DRUG TARGETS, V8, P651, DOI 10.2174/138945007780618544; Schmid-Wendtner MH, 2001, BRIT J DERMATOL, V145, P981, DOI 10.1046/j.1365-2133.2001.04507.x; Seidlitz EP, 2009, CLIN EXP METASTAS, V26, P781, DOI 10.1007/s10585-009-9277-4; Sharma MK, 2010, BIOCHEM BIOPH RES CO, V391, P91, DOI 10.1016/j.bbrc.2009.10.168; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Shin SS, 2008, NEUROPHARMACOLOGY, V55, P396, DOI 10.1016/j.neuropharm.2008.04.021; Shin SS, 2010, PIGM CELL MELANOMA R, V23, P103, DOI 10.1111/j.1755-148X.2009.00648.x; Speyer CL, 2012, BREAST CANCER RES TR, V132, P565, DOI 10.1007/s10549-011-1624-x; Steelman LS, 2011, AGING-US, V3, P192, DOI 10.18632/aging.100296; Stepulak A, 2005, P NATL ACAD SCI USA, V102, P15605, DOI 10.1073/pnas.0507679102; Storto M, 2000, HEPATOLOGY, V31, P649, DOI 10.1002/hep.510310315; Storto M, 2006, MOL PHARMACOL, V69, P1234, DOI 10.1124/mol.105.018390; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Teh Jessica, 2012, Wiley Interdiscip Rev Membr Transp Signal, V1, P211; Thandi S, 2002, J NEUROCHEM, V83, P1139, DOI 10.1046/j.1471-4159.2002.01217.x; Tihan T, 1996, CANCER-AM CANCER SOC, V77, P2325, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2325::AID-CNCR22>3.0.CO;2-Y; Tong QC, 2002, AM J PHYSIOL-ENDOC M, V282, pE1324, DOI 10.1152/ajpendo.00460.2001; Tripathi VB, 2008, CNS NEUROL DISORD-DR, V7, P11; Wangari-Talbot J, MOL CANCER RES, DOI [10.1158/1541-7786.MCR-12-0158, DOI 10.1158/1541-7786.MCR-12-0158)]; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; Wieronska JM, 2009, NEUROCHEM INT, V55, P85, DOI 10.1016/j.neuint.2009.02.019; Wu TY, 2012, MOL CARCINOGEN, V51, P761, DOI 10.1002/mc.20841; Yip D, 2009, CLIN CANCER RES, V15, P3896, DOI 10.1158/1078-0432.CCR-08-3303; Young VR, 2000, J NUTR, V130, p892S, DOI 10.1093/jn/130.4.892S; Zhu H, 1999, MOL BRAIN RES, V73, P93, DOI 10.1016/S0169-328X(99)00239-9; Zhu H, 1998, J INVEST DERMATOL, V110, P247, DOI 10.1046/j.1523-1747.1998.00133.x	70	40	41	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2013	32	37					4366	4376		10.1038/onc.2012.471	http://dx.doi.org/10.1038/onc.2012.471			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23085756	Green Accepted			2022-12-17	WOS:000324404200005
J	Koyama-Nasu, R; Nasu-Nishimura, Y; Todo, T; Ino, Y; Saito, N; Aburatani, H; Funato, K; Echizen, K; Sugano, H; Haruta, R; Matsui, M; Takahashi, R; Manabe, E; Oda, T; Akiyama, T				Koyama-Nasu, R.; Nasu-Nishimura, Y.; Todo, T.; Ino, Y.; Saito, N.; Aburatani, H.; Funato, K.; Echizen, K.; Sugano, H.; Haruta, R.; Matsui, M.; Takahashi, R.; Manabe, E.; Oda, T.; Akiyama, T.			The critical role of cyclin D2 in cell cycle progression and tumorigenicity of glioblastoma stem cells	ONCOGENE			English	Article						cancer stem cells; cell cycle; cyclin D2; glioblastoma	CANCER; PROLIFERATION; PATHWAYS; GLIOMAS; ORIGIN; TUMORS; BRAIN; LINES	Cancer stem cells are believed to be responsible for tumor initiation and development. Much current research on human brain tumors is focused on the stem-like properties of glioblastoma stem cells (GSCs). However, little is known about the molecular mechanisms of cell cycle regulation that discriminate between GSCs and differentiated glioblastoma cells. Here we show that cyclin D2 is the cyclin that is predominantly expressed in GSCs and suppression of its expression by RNA interference causes G1 arrest in vitro and growth retardation of GSCs xenografted into immunocompromised mice in vivo. We also demonstrate that the expression of cyclin D2 is suppressed upon serum-induced differentiation similar to what was observed for the cancer stem cell marker CD133. Taken together, our results demonstrate that cyclin D2 has a critical role in cell cycle progression and the tumorigenicity of GSCs.	[Koyama-Nasu, R.; Nasu-Nishimura, Y.; Funato, K.; Echizen, K.; Sugano, H.; Haruta, R.; Matsui, M.; Takahashi, R.; Manabe, E.; Oda, T.; Akiyama, T.] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1100032, Japan; [Todo, T.; Ino, Y.; Saito, N.] Tokyo Univ Hosp, Dept Neurosurg, Bunkyo Ku, Tokyo 113, Japan; [Aburatani, H.] Univ Tokyo, Genome Sci Div, Res Ctr Adv Sci & Technol, Meguro Ku, Tokyo 1100032, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1100032, Japan.	akiyama@iam.u-tokyo.ac.jp		Funato, Kosuke/0000-0003-2437-1116; Todo, Tomoki/0000-0003-0523-8010	Research Program of Innovative Cell Biology by Innovative Technology (Integrated Systems Analysis of Cellular Oncogenic Signaling Networks); Integrative Research on Cancer Microenvironment Network; Takeda Science Foundation; MEXT, Japan; Grants-in-Aid for Scientific Research [25670138] Funding Source: KAKEN	Research Program of Innovative Cell Biology by Innovative Technology (Integrated Systems Analysis of Cellular Oncogenic Signaling Networks); Integrative Research on Cancer Microenvironment Network; Takeda Science Foundation(Takeda Science Foundation (TSF)); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Research Program of Innovative Cell Biology by Innovative Technology (Integrated Systems Analysis of Cellular Oncogenic Signaling Networks), Grants-in-Aid for Scientific Research on Innovative Areas (Integrative Research on Cancer Microenvironment Network), Takeda Science Foundation and in part by Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan.	Alison MR, 2011, J PATHOL, V223, P147, DOI 10.1002/path.2793; [Anonymous], 2008, NATURE, V455, P1061; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Kowalczyk A, 2004, J CELL BIOL, V167, P209, DOI 10.1083/jcb.200404181; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lottaz C, 2010, CANCER RES, V70, P2030, DOI 10.1158/0008-5472.CAN-09-1707; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Mizrak D, 2008, J PATHOL, V214, P3, DOI 10.1002/path.2283; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Singh SK, 2003, CANCER RES, V63, P5821; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Walzlein JH, 2008, STEM CELLS, V26, P2945, DOI 10.1634/stemcells.2008-0307; Zhang X, 2005, J CLIN NEUROSCI, V12, P166, DOI 10.1016/j.jocn.2004.03.036	17	40	41	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2013	32	33					3840	3845		10.1038/onc.2012.399	http://dx.doi.org/10.1038/onc.2012.399			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	22964630				2022-12-17	WOS:000323210200006
J	da Silva-Diz, V; Sole-Sanchez, S; Valdes-Gutierrez, A; Urpi, M; Riba-Artes, D; Penin, RM; Pascual, G; Gonzalez-Suarez, E; Casanovas, O; Vinals, F; Paramio, JM; Batlle, E; Munoz, P				da Silva-Diz, V.; Sole-Sanchez, S.; Valdes-Gutierrez, A.; Urpi, M.; Riba-Artes, D.; Penin, R. M.; Pascual, G.; Gonzalez-Suarez, E.; Casanovas, O.; Vinals, F.; Paramio, J. M.; Batlle, E.; Munoz, P.			Progeny of Lgr5-expressing hair follicle stem cell contributes to papillomavirus-induced tumor development in epidermis	ONCOGENE			English	Article						cell lineage tracing; hair follicle stem cells; carcinogenesis mouse models; papillomavirus; squamous cell carcinoma	SQUAMOUS-CELL; BETA-CATENIN; TRANSGENIC MICE; SKIN TUMORS; CARCINOMA; CANCER; DIFFERENTIATION; CARCINOGENESIS; MORPHOGENESIS; EXPRESSION	Epidermal keratinocytes and hair follicle (HF) stem cells (SCs) expressing oncogenes are competent at developing squamous cell carcinomas (SCCs) in epidermis and HFs, respectively. To determine whether bulge and hair germ (HG) SCs from HF contribute to SCC generation at distant epidermis, the most frequent epidermal region where these lesions arise in human skin, we used a skin cancer mouse model expressing E6 and E7 oncoproteins from Human papillomavirus (HPV) 16 in SCs and basal keratinocytes. This previously described mouse model recapitulates the human skin papillomavirus-induced SCC pathology. We show that E6 and E7 expression promote the expansion of keratin 15 (K15)-expressing cells. These K15(+) aberrant cells exhibit some HGSC markers and diminished expression of Tcf3 and Sox9 hair SC specification genes, which are accumulated in HFs and mislocalized to interfollicular epidermis. Leucine-rich G-protein-coupled receptor 5 (Lgr5)-expressing SCs, localized in the bulge and HG, are the origin of the expanded K15(+) cell population. A large subset of the Lgr5(+) SC progeny, expressing K15 and P-cadherin, is aberrantly mobilized to the upper region of HFs and the epidermis, and accumulates at E6/E7-induced pre-neoplastic lesions and epidermal tumors. These findings indicate that aberrant accumulation of altered SCs in HFs and their subsequent migration to the epidermis contribute to HPV-induced tumor development.	[da Silva-Diz, V.; Sole-Sanchez, S.; Valdes-Gutierrez, A.; Urpi, M.; Riba-Artes, D.; Gonzalez-Suarez, E.; Munoz, P.] Bellvitge Biomed Res Inst IDIBELL, PEBC, Barcelona 08907, Spain; [Penin, R. M.] Hosp Univ Bellvitge IDIBELL, Pathol Serv, Barcelona, Spain; [Pascual, G.] CRG, Dept Cell Differentiat & Canc, Barcelona, Spain; [Casanovas, O.; Vinals, F.] Catalan Inst Oncol ICO IDIBELL, Translat Res Lab, Barcelona, Spain; [Vinals, F.] Univ Barcelona IDIBELL, Dept Ciencies Fisiol 2, Unitat Bioquim & Biol Mol, Barcelona, Spain; [Paramio, J. M.] Ctr Invstigac Energet Medioambientales & Tecnol, Mol Oncol Unit, Madrid, Spain; [Batlle, E.] IRB, Oncol Program, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona	Munoz, P (corresponding author), Bellvitge Biomed Res Inst IDIBELL, PEBC, Aging & Canc Grp, Av Gran Via LHospitalet 199-203, Barcelona 08907, Spain.	p.munoz@idibell.cat	Vinals, Francesc/P-6278-2019; Paramio, Jesus M/M-8482-2014; Viñals, Francesc/F-5928-2016; Angulo, Gloria Pascual/AAA-7668-2019; Batlle, Eduard/K-8080-2014; Gonzalez-Suarez, Eva/L-6298-2014; Casanovas, Oriol/L-5210-2014	Paramio, Jesus M/0000-0001-7520-3177; Viñals, Francesc/0000-0002-9918-6751; Angulo, Gloria Pascual/0000-0003-3810-6647; Batlle, Eduard/0000-0003-2422-0326; Gonzalez-Suarez, Eva/0000-0003-0858-8171; Casanovas, Oriol/0000-0002-4298-3995; Valdes, Antonio/0000-0002-9119-3092	Spanish Ministry of Science and Innovation [SAF2008-01173]; Spanish Ministry of Education; IDIBELL fellowship; Catalan Department of Health (Generalitat de Catalunya)	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Spanish Ministry of Education(Spanish Government); IDIBELL fellowship; Catalan Department of Health (Generalitat de Catalunya)	We thank D Hanahan and JM Arbeit (NCI MMHCC Repository) for the K14-HPV16 mice, A Villanueva for helpful advice, S Gonzalo for critical reading of the manuscript, R Alvarez, J Comas and E Castano (Universitat de Barcelona-SCT) for their technical support in flow cytometry and the IDIBELL animal facility service for mouse care. VdSD is funded by a Spanish Ministry of Science and Innovation fellowship, SSS is funded by a Spanish Ministry of Education fellowship and DRA and AVG received an IDIBELL fellowship. The research of PM's group is supported by the Spanish Ministry of Science and Innovation (SAF2008-01173) and by the Catalan Department of Health (Generalitat de Catalunya).	Alam M, 2001, NEW ENGL J MED, V344, P975, DOI 10.1056/NEJM200103293441306; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; Arwert EN, 2010, P NATL ACAD SCI USA, V107, P19903, DOI 10.1073/pnas.1007404107; Blanco R, 2007, GENE DEV, V21, P206, DOI 10.1101/gad.406207; Blanpain C, 2009, NAT REV MOL CELL BIO, V10, P207, DOI 10.1038/nrm2636; Boccardo E, 2010, CARCINOGENESIS, V31, P1905, DOI 10.1093/carcin/bgq176; Boxman ILA, 1999, J CLIN MICROBIOL, V37, P2270, DOI 10.1128/JCM.37.7.2270-2273.1999; Bulut G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027243; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Coussens LM, 1996, AM J PATHOL, V149, P1899; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; Ghittoni R, 2010, VIRUS GENES, V40, P1, DOI 10.1007/s11262-009-0412-8; Gormley RH, 2011, J AM ACAD DERMATOL, V64, P981, DOI 10.1016/j.jaad.2009.10.044; Greco V, 2009, CELL STEM CELL, V4, P155, DOI 10.1016/j.stem.2008.12.009; Hama N, 2006, J DERMATOL, V33, P331, DOI 10.1111/j.1346-8138.2006.00078.x; Hsu YC, 2011, CELL, V144, P92, DOI 10.1016/j.cell.2010.11.049; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239; Jensen KB, 2009, CELL STEM CELL, V4, P427, DOI 10.1016/j.stem.2009.04.014; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Karagas MR, 2006, J NATL CANCER I, V98, P389, DOI 10.1093/jnci/djj092; Kasper M, 2011, P NATL ACAD SCI USA, V108, P4099, DOI 10.1073/pnas.1014489108; Lapouge G, 2011, P NATL ACAD SCI USA, V108, P7431, DOI 10.1073/pnas.1012720108; Liu Y, 2009, CELL STEM CELL, V4, P37, DOI 10.1016/j.stem.2008.11.006; Lorz C, 2010, STEM CELL REV REP, V6, P162, DOI 10.1007/s12015-010-9139-0; Lowry WE, 2005, GENE DEV, V19, P1596, DOI 10.1101/gad.1324905; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Martinez-Cruz AB, 2008, CANCER RES, V68, P683, DOI 10.1158/0008-5472.CAN-07-3049; McLaughlin-Drubin ME, 2009, VIRUS RES, V143, P195, DOI 10.1016/j.virusres.2009.06.008; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Muller-Rover S, 1999, EXP DERMATOL, V8, P237; Munoz P, 2005, NAT GENET, V37, P1063, DOI 10.1038/ng1633; Nguyen H, 2006, CELL, V127, P171, DOI 10.1016/j.cell.2006.07.036; Nowak JA, 2008, CELL STEM CELL, V3, P33, DOI 10.1016/j.stem.2008.05.009; Petersson M, 2011, EMBO J, V30, P3004, DOI 10.1038/emboj.2011.199; Rhee H, 2006, SCIENCE, V312, P1946, DOI 10.1126/science.1128004; Rodriguez-Sastre MA, 2005, GYNECOL ONCOL, V97, P330, DOI 10.1016/j.ygyno.2004.12.062; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Schaper ID, 2005, CANCER RES, V65, P1394, DOI 10.1158/0008-5472.CAN-04-3263; Schober M, 2011, P NATL ACAD SCI USA, V108, P10544, DOI 10.1073/pnas.1107807108; Shinohara A, 2001, GYNECOL ONCOL, V82, P450, DOI 10.1006/gyno.2001.6298; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523-1747.2003.12088.x; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; Vidal VPI, 2005, CURR BIOL, V15, P1340, DOI 10.1016/j.cub.2005.06.064; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Watt FM, 2009, EMBO MOL MED, V1, P260, DOI 10.1002/emmm.200900033; White AC, 2011, P NATL ACAD SCI USA, V108, P7425, DOI 10.1073/pnas.1012670108; Wong SY, 2011, P NATL ACAD SCI USA, V108, P4093, DOI 10.1073/pnas.1013098108; Youssef KK, 2010, NAT CELL BIOL, V12, P299, DOI 10.1038/ncb2031; zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046	57	40	40	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2013	32	32					3732	3743		10.1038/onc.2012.375	http://dx.doi.org/10.1038/onc.2012.375			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22945646				2022-12-17	WOS:000322904400008
J	Whale, AD; Dart, A; Holt, M; Jones, GE; Wells, CM				Whale, A. D.; Dart, A.; Holt, M.; Jones, G. E.; Wells, C. M.			PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity	ONCOGENE			English	Article						prostate; cancer; motility	CHRONIC MYELOID-LEUKEMIA; SIGNALING PATHWAY; LIM KINASE; CANCER; MIGRATION; INVASION; LOOP; RESISTANCE; IMATINIB; COFILIN	Hepatocyte growth factor (HGF) and its receptor (c-Met) are associated with cancer cell motility and invasiveness. p21-activated kinase 4 (PAK4), a potential therapeutic target, is recruited to and activated by c-Met. In response, PAK4 phosphorylates LIM kinase 1 (LIMK1) in an HGF-dependent manner in metastatic prostate carcinoma cells. PAK4 overexpression is known to induce increased cell migration speed but the requirement for kinase activity has not been established. We have used a panel of PAK4 truncations and mutations in a combination of overexpression and RNAi rescue experiments to determine the requirement for PAK4 kinase activity during carcinoma cell motility downstream of HGF. We find that neither the kinase domain alone nor a PAK4 mutant unable to bind Cdc42 is able to fully rescue cell motility in a PAK4-deficient background. Nevertheless, we find that PAK4 kinase activity and associated LIMK1 activity are essential for carcinoma cell motility, highlighting PAK4 as a potential anti-metastatic therapeutic target. We also show here that overexpression of PAK4 harbouring a somatic mutation, E329K, increased the HGF-driven motility of metastatic prostate carcinoma cells. E329 lies within the glycine-rich loop region of the kinase. Our data suggest that E329K mutation leads to a modest increase in kinase activity, conferring resistance to competitive ATP inhibitors in addition to promoting cell migration. The existence of such a mutation may have implications for the development of PAK4-specific competitive ATP inhibitors should PAK4 be further explored for clinical inhibition. Oncogene (2013) 32, 2114-2120; doi:10.1038/onc.2012.233; published online 11 June 2012	[Whale, A. D.; Holt, M.; Jones, G. E.] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; [Whale, A. D.; Dart, A.; Wells, C. M.] Kings Coll London, Div Canc Studies, London SE1 1UL, England	University of London; King's College London; University of London; King's College London	Wells, CM (corresponding author), Kings Coll London, Div Canc Studies, New Hunts House,Guys Campus, London SE1 1UL, England.	claire.wells@kcl.ac.uk	Jones, Gareth E/H-2282-2012	Jones, Gareth E/0000-0001-5879-3048; Dart, Anna/0000-0002-2412-3502; Holt, Mark/0000-0001-7775-8539	Cancer Research UK; Breast Cancer Campaign	Cancer Research UK(Cancer Research UK); Breast Cancer Campaign	ADW and work in the laboratories of GEJ and CMW is supported by a grant from the Cancer Research UK. AD is supported by a grant from Breast Cancer Campaign. We would like to thank Matthias Krause for gateway destination and pGIPZ-control shRNA vectors. We also thank Mary Holdom for helpful discussion and advice with protein structure analysis and Mike Olsen for practical advice with using LIMKi.	Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Ahmed T, 2008, CELL SIGNAL, V20, P1320, DOI 10.1016/j.cellsig.2008.02.021; Baldassa S, 2010, J CELL PHYSIOL, V224, P722, DOI 10.1002/jcp.22172; Barouch-Bentov R, 2009, MOL CELL, V33, P43, DOI 10.1016/j.molcel.2008.12.024; Callow MG, 2005, J CELL SCI, V118, P1861, DOI 10.1242/jcs.02313; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Cecchi F, 2010, EUR J CANCER, V46, P1260, DOI 10.1016/j.ejca.2010.02.028; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Eswaran J, 2007, STRUCTURE, V15, P201, DOI 10.1016/j.str.2007.01.001; Eswaran J, 2009, CANCER METAST REV, V28, P209, DOI 10.1007/s10555-008-9181-4; Finkelstein E, 2004, J CELL SCI, V117, P1533, DOI 10.1242/jcs.00986; Ghosh M, 2004, SCIENCE, V304, P743, DOI 10.1126/science.1094561; Girdler F, 2008, CHEM BIOL, V15, P552, DOI 10.1016/j.chembiol.2008.04.013; Grant BD, 1998, BIOCHEMISTRY-US, V37, P7708, DOI 10.1021/bi972987w; Griswold IJ, 2006, MOL CELL BIOL, V26, P6082, DOI 10.1128/MCB.02202-05; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Knudsen BS, 2008, CURR OPIN GENET DEV, V18, P87, DOI 10.1016/j.gde.2008.02.001; Lai AZ, 2009, TRENDS CELL BIOL, V19, P542, DOI 10.1016/j.tcb.2009.07.002; Lai FP, 2008, EMBO J, V27, P982, DOI 10.1038/emboj.2008.34; Li ZL, 2010, MOL BIOL CELL, V21, P3317, DOI 10.1091/mbc.E10-03-0245; Li ZL, 2010, J BIOL CHEM, V285, P23699, DOI 10.1074/jbc.M110.123497; Liu YY, 2008, MOL CANCER RES, V6, P1215, DOI 10.1158/1541-7786.MCR-08-0087; Murray BW, 2010, P NATL ACAD SCI USA, V107, P9446, DOI 10.1073/pnas.0911863107; Paliouras GN, 2009, MOL CELL BIOL, V29, P3018, DOI 10.1128/MCB.01286-08; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Pavlovsky C, 2009, AM J HEMATOL, V84, P287, DOI 10.1002/ajh.21380; Scott RW, 2010, J CELL BIOL, V191, P169, DOI 10.1083/jcb.201002041; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Siu MKY, 2010, P NATL ACAD SCI USA, V107, P18622, DOI 10.1073/pnas.0907481107; Skaggs BJ, 2006, P NATL ACAD SCI USA, V103, P19466, DOI 10.1073/pnas.0609239103; Soosairajah J, 2005, EMBO J, V24, P473, DOI 10.1038/sj.emboj.7600543; Wells CM, 2010, J CELL SCI, V123, P1663, DOI 10.1242/jcs.055707; Whale A, 2011, FRONT BIOSCI-LANDMRK, V16, P849, DOI 10.2741/3724; Yamamoto M, 2004, BIOCHEM BIOPH RES CO, V319, P1272, DOI 10.1016/j.bbrc.2004.05.113; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100; Zhao Zhuo-Shen, 2010, F1000 Biol Rep, V2, P70, DOI 10.3410/B2-70; Zicha D, 1997, Methods Mol Biol, V75, P449	37	40	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2114	2120		10.1038/onc.2012.233	http://dx.doi.org/10.1038/onc.2012.233			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22689056	Green Accepted			2022-12-17	WOS:000317919900013
J	Yasaei, H; Gilham, E; Pickles, JC; Roberts, TP; O'Donovan, M; Newbold, RF				Yasaei, H.; Gilham, E.; Pickles, J. C.; Roberts, T. P.; O'Donovan, M.; Newbold, R. F.			Carcinogen-specific mutational and epigenetic alterations in INK4A, INK4B and p53 tumour-suppressor genes drive induced senescence bypass in normal diploid mammalian cells	ONCOGENE			English	Article						oncogene/stress-induced senescence; chemical carcinogen; ionizing radiation; Syrian hamster dermal cells; cell transformation assay	CELLULAR SENESCENCE; HUMAN CANCER; CHEEK-POUCH; P16(INK4A)/CDKN2A ALTERATIONS; DIOL EPOXIDE; LUNG-TUMORS; HAMSTER P16; RAS; IMMORTALIZATION; METHYLATION	Immortalization (senescence bypass) is a critical rate-limiting step in the malignant transformation of mammalian somatic cells. Human cells must breach at least two distinct senescence barriers to permit unfettered clonal evolution during cancer development: (1) stress- or oncogene-induced premature senescence (SIPS/OIS), mediated via the p16-Rb and/or ARF-p53-p21 tumour-suppressive pathways, and (2) replicative senescence triggered by telomere shortening. In contrast, because their telomerase is constitutively active, cells from small rodents possess only the SIPS/OIS barrier, and are therefore useful for studying SIPS/OIS bypass in isolation. Dermal fibroblasts from the Syrian hamster (SHD cells) are exceptionally resistant to spontaneous SIPS bypass, but it can be readily induced following exposure to a wide range of chemical and physical carcinogens. Here we show that a spectrum of carcinogen-specific mutational and epigenetic alterations involving the INK4A (p16), p53 and INK4B (p15) genes are associated with induced SIPS bypass. With ionizing radiation, immortalization is invariably accompanied by efficient biallelic deletion of the complete INK4/CDKN2 locus. In comparison, SHD cells immortalized by the powerful polycyclic hydrocarbon carcinogen benzo(a)pyrene display transversion point mutations in the DNA-binding domain of p53 coupled with INK4 alterations such as loss of expression of p15. Epimutational silencing of p16 is the primary event associated with immortalization by nickel, a human non-genotoxic carcinogen. As SIPS/OIS bypass is a prerequisite for the immortalization of normal diploid human epithelial cells, our results with the SHD model will provide a basis for delineating combinations of key molecular changes underpinning this important event in human carcinogenesis. Oncogene (2013) 32, 171-179; doi:10.1038/onc.2012.45; published online 12 March 2012	[Yasaei, H.; Gilham, E.; Pickles, J. C.; Roberts, T. P.; Newbold, R. F.] Brunel Univ, Sch Hlth Sci & Social Care, Inst Canc Genet & Pharmacogen, Div Biosci, Uxbridge UB8 3PH, Middx, England; [O'Donovan, M.] AstraZeneca R&D, Safety Assessment Grp, Macclesfield, Cheshire, England	Brunel University; AstraZeneca	Newbold, RF (corresponding author), Brunel Univ, Sch Hlth Sci & Social Care, Inst Canc Genet & Pharmacogen, Div Biosci, Kingston Lane, Uxbridge UB8 3PH, Middx, England.	robert.newbold@brunel.ac.uk	Yasaei, Hemad/A-6351-2014; Roberts, Terry/A-8211-2014	Pickles, Jessica/0000-0001-7888-1723	(UK) National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) [G0800697/1]; UK BBSRC-CASE Studentship; Unilever Plc.; AstraZeneca; National Centre for the Replacement [NC/K500045/1, G0800697/1] Funding Source: researchfish	(UK) National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs); UK BBSRC-CASE Studentship; Unilever Plc.; AstraZeneca(AstraZeneca); National Centre for the Replacement	This work was fully funded by triennial Project Grant to RFN and MUD (ID G0800697/1) from the (UK) National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). JCP is funded by a UK BBSRC-CASE Studentship award with Unilever Plc. EG was funded by a grant from AstraZeneca. We acknowledge Mrs Alison Marriott and Dr Rana Hasan for their expert technical assistance. We dedicate this article to colleagues Professor Philip D Lawley (1927-2011) who pioneered research into the reaction of alkylating carcinogens with DNA; and to Steven Pash (1955-2011) who assisted expertly with the generation of hamster cell cultures.	Arita A, 2009, METALLOMICS, V1, P222, DOI 10.1039/b903049b; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Camacho CV, 2010, CARCINOGENESIS, V31, P1889, DOI 10.1093/carcin/bgq153; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chang KW, 2000, CARCINOGENESIS, V21, P1441, DOI 10.1093/carcin/21.7.1441; Chang KW, 1996, CARCINOGENESIS, V17, P595, DOI 10.1093/carcin/17.3.595; CHANG KW, 1994, CANCER RES, V54, P3878; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Creton S, 2012, MUTAGENESIS, V27, P93, DOI 10.1093/mutage/ger053; Csepregi A, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-317; Florl AR, 2003, GENE CHROMOSOME CANC, V37, P141, DOI 10.1002/gcc.10192; Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270; GimenezConti IB, 1996, MOL CARCINOGEN, V16, P197, DOI 10.1002/(SICI)1098-2744(199608)16:4<197::AID-MC3>3.0.CO;2-D; Goh AM, 2011, J PATHOL, V223, P116, DOI 10.1002/path.2784; Grafstrom E, 2005, CLIN CANCER RES, V11, P2991, DOI 10.1158/1078-0432.CCR-04-1731; Haga K, 2007, CANCER SCI, V98, P147, DOI 10.1111/j.1349-7006.2006.00373.x; Hanaoka M, 2005, BIOCHEM BIOPH RES CO, V333, P1249, DOI 10.1016/j.bbrc.2005.06.034; He J, 2008, NAT STRUCT MOL BIOL, V15, P1169, DOI 10.1038/nsmb.1499; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; LACONI S, 1995, CANCER RES, V55, P2560; Lam TK, 2009, ANN EPIDEMIOL, V19, P546, DOI 10.1016/j.annepidem.2009.03.003; LEGROS Y, 1992, GENE, V112, P247, DOI 10.1016/0378-1119(92)90384-2; Li JN, 2004, CARCINOGENESIS, V25, P263, DOI 10.1093/carcin/bgh007; Li JN, 2003, BIOCHEM BIOPH RES CO, V304, P241, DOI 10.1016/S0006-291X(03)00577-1; Li J, 2008, MOL CARCINOGEN, V47, P733, DOI 10.1002/mc.20424; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Liu ZP, 2005, CANCER RES, V65, P2583, DOI 10.1158/0008-5472.CAN-04-3675; Muscarella P, 2001, GENE, V278, P235, DOI 10.1016/S0378-1119(01)00728-4; NEWBOLD RF, 1977, MUTAT RES, V43, P101, DOI 10.1016/0027-5107(77)90136-1; NEWBOLD RF, 1976, NATURE, V261, P52, DOI 10.1038/261052a0; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NEWBOLD RF, 1980, NATURE, V283, P596, DOI 10.1038/283596a0; Newbold RF, 2005, INTRO CELLULAR MOL B, P170; Odell A, 2010, AGING-US, V2, P160, DOI 10.18632/aging.100129; OREFFO VIC, 1993, CARCINOGENESIS, V14, P451, DOI 10.1093/carcin/14.3.451; Peters G, 2008, NAT STRUCT MOL BIOL, V15, P1133, DOI 10.1038/nsmb1108-1133; POPESCU NC, 1995, CYTOGENET CELL GENET, V68, P71, DOI 10.1159/000133893; Raschke S, 2005, GENE CHROMOSOME CANC, V42, P58, DOI 10.1002/gcc.20119; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo I, 1998, ONCOGENE, V17, P3417, DOI 10.1038/sj.onc.1202261; Seluanov A, 2008, AGING CELL, V7, P813, DOI 10.1111/j.1474-9726.2008.00431.x; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sikora E, 2011, AGEING RES REV, V10, P146, DOI 10.1016/j.arr.2010.10.002; TROTT DA, 1995, CARCINOGENESIS, V16, P193, DOI 10.1093/carcin/16.2.193; Whibley C, 2010, J BIOL CHEM, V285, P11326, DOI 10.1074/jbc.M109.064444; Windhofer F, 2008, MUTAT RES-FUND MOL M, V638, P56, DOI 10.1016/j.mrfmmm.2007.08.016; Yaswen P, 2002, INT J BIOCHEM CELL B, V34, P1382, DOI 10.1016/S1357-2725(02)00047-X	50	40	42	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					171	179		10.1038/onc.2012.45	http://dx.doi.org/10.1038/onc.2012.45			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22410783	Bronze			2022-12-17	WOS:000314075500005
J	Mitra, A; Menezes, ME; Pannell, LK; Mulekar, MS; Honkanen, RE; Shevde, LA; Samant, RS				Mitra, A.; Menezes, M. E.; Pannell, L. K.; Mulekar, M. S.; Honkanen, R. E.; Shevde, L. A.; Samant, R. S.			DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3 beta to downregulate beta-catenin transcription target, osteopontin	ONCOGENE			English	Article						DNAJB6; cancer; SPP1; OPN; GSK3 beta; PP2A	PROTEIN PHOSPHATASE 2A; MRJ CO-CHAPERONE; METASTATIC MELANOMA; TUMOR-SUPPRESSOR; BREAST-CANCER; J-DOMAIN; T-CELLS; EXPRESSION; PROGRESSION; WNT	Elevated levels of the oncoprotein, osteopontin (OPN), are associated with poor outcome of several types of cancers including melanoma. We have previously reported an important involvement of DNAJB6, a member of heat-shock protein 40 (HSP40) family, in negatively impacting tumor growth. The current study was prompted by our observations reported here which revealed a reciprocal relationship between DNAJB6 and OPN in melanoma specimens. The 'J domain' is the most conserved domain of HSP40 family of proteins. Hence, we assessed the functional role of the J domain in activities of DNAJB6. We report that the J domain of DNAJB6 is involved in mediating OPN suppression. Deletion of the J domain renders DNAJB6 incapable of impeding malignancy and suppressing OPN. Our mechanistic investigations reveal that DNAJB6 binds HSPA8 (heat-shock cognate protein, HSC70) and causes dephosphorylation of glycogen synthase kinase 3 beta (GSK3 beta) at Ser 9 by recruiting protein phosphatase, PP2A. This dephosphorylation activates GSK3 beta, leading to degradation of beta-catenin and subsequent loss of TCF/LEF (T cell factor1/lymphoid enhancer factor1) activity. Deletion of the J domain abrogates assembly of this multiprotein complex and renders GSK3 beta inactive, thus, stabilizing beta-catenin, a transcription coactivator for OPN expression. Our in-vitro and in-vivo functional analyses show that silencing OPN expression in the background of deletion of the J domain renders the resultant tumor cells less malignant despite the presence of stabilized beta-catenin. Thus, we have uncovered a new mechanism for regulation of GSK3 beta activity leading to inhibition of Wnt/beta-catenin signaling. Oncogene (2012) 31, 4472-4483; doi: 10.1038/onc.2011.623; published online 23 January 2012	[Mitra, A.; Menezes, M. E.; Pannell, L. K.; Shevde, L. A.; Samant, R. S.] Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, Mobile, AL 36604 USA; [Mulekar, M. S.] Univ S Alabama, Dept Math & Stat, Mobile, AL 36604 USA; [Honkanen, R. E.] Univ S Alabama, Dept Biochem & Mol Biol, Mobile, AL 36604 USA	University of South Alabama; University of South Alabama; University of South Alabama	Samant, RS (corresponding author), Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, 1660 Spring Hill Ave, Mobile, AL 36604 USA.	rsamant@usouthal.edu		Samant, Rajeev/0000-0001-5681-4976	USPHS [CA140472, CA138850]; Mayer Mitchell Award for Excellence in Cancer Research; NATIONAL CANCER INSTITUTE [R01CA138850, R01CA060750, R01CA140472] Funding Source: NIH RePORTER	USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); Mayer Mitchell Award for Excellence in Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by USPHS grants CA140472 (RSS) and CA138850 (LAS). RSS is the recipient of the Mayer Mitchell Award for Excellence in Cancer Research and acknowledges the support. We thank Dr Randall Moon (HHMI University of Washington) for providing the TOP-Flash reporter.	Alonso SR, 2007, CANCER RES, V67, P3450, DOI 10.1158/0008-5472.CAN-06-3481; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Buback F, 2009, EXP DERMATOL, V18, P750, DOI 10.1111/j.1600-0625.2009.00926.x; Chakraborty G, 2006, CURR MOL MED, V6, P819, DOI 10.2174/156652406779010803; Chiodoni C, 2010, CANCER METAST REV, V29, P295, DOI 10.1007/s10555-010-9221-8; Chuang JZ, 2002, J BIOL CHEM, V277, P19831, DOI 10.1074/jbc.M109613200; Clark DW, 2008, CURR CANCER DRUG TAR, V8, P421, DOI 10.2174/156800908785133196; Dai YS, 2005, MOL CELL BIOL, V25, P9936, DOI 10.1128/MCB.25.22.9936-9948.2005; Das S, 2009, J BIOL CHEM, V284, P22888, DOI 10.1074/jbc.M109.021949; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Denhardt D, 2005, J INVEST DERMATOL, V124, pXVI, DOI 10.1111/j.0022-202X.2005.23708.x; Dey S, 2009, MOL CELL BIOCHEM, V322, P137, DOI 10.1007/s11010-008-9950-y; Dhennin-Duthille I, 2011, J BIOL CHEM, V286, P5034, DOI 10.1074/jbc.M110.155903; Edwards KM, 2004, ONCOGENE, V23, P8419, DOI 10.1038/sj.onc.1207732; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; El-Tanani M, 2001, CANCER RES, V61, P5619; El-Tanani MK, 2006, CYTOKINE GROWTH F R, V17, P463, DOI 10.1016/j.cytogfr.2006.09.010; Fan CY, 2003, CELL STRESS CHAPERON, V8, P309, DOI 10.1379/1466-1268(2003)008<0309:MFROHF>2.0.CO;2; Fernandez JJ, 2002, CURR MED CHEM, V9, P229, DOI 10.2174/0929867023371247; Fillmore RA, 2009, INT J CANCER, V125, P556, DOI 10.1002/ijc.24276; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Greillier L, 2008, MOL DIAGN THER, V12, P375, DOI 10.2165/1250444-200812060-00004; Hennessy F, 2005, PROTEIN SCI, V14, P1697, DOI 10.1110/ps.051406805; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Howe LR, 2003, CANCER RES, V63, P1906; Hunter PJ, 1999, DEVELOPMENT, V126, P1247; Kampinga HH, 2010, NAT REV MOL CELL BIO, V11, P579, DOI 10.1038/nrm2941; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kurzik-Dumke U, 2008, INT J MOL MED, V21, P19; Kurzik-Dumke U, 2007, CELL SIGNAL, V19, P1973, DOI 10.1016/j.cellsig.2007.05.008; Kushiro K, 2011, CLIN EXP METASTAS, V28, P877, DOI 10.1007/s10585-011-9418-4; Larue L, 2006, FRONT BIOSCI-LANDMRK, V11, P733, DOI 10.2741/1831; Lin Kimberly, 2010, Genes Cancer, V1, P409; Lopez-Bergami P, 2008, PHOTOCHEM PHOTOBIOL, V84, P289, DOI 10.1111/j.1751-1097.2007.00254.x; Lucero OM, 2010, CURR ONCOL REP, V12, P314, DOI 10.1007/s11912-010-0114-3; Martin MJ, 2009, CANCER CELL, V15, P163, DOI 10.1016/j.ccr.2009.02.006; Menezes ME, 2012, INT J CANCER, V130, P1477, DOI 10.1002/ijc.26449; Metge BJ, 2010, ONCOLOGY-BASEL, V78, P75, DOI 10.1159/000292363; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Mitra A, 2010, J BIOL CHEM, V285, P24686, DOI 10.1074/jbc.M109.094847; Mitra A, 2009, CLIN EXP METASTAS, V26, P559, DOI 10.1007/s10585-009-9255-x; Mitra A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1874; Moore SR, 2008, CLIN CANCER RES, V14, P2927, DOI 10.1158/1078-0432.CCR-07-4068; O'Connell MP, 2009, PIGM CELL MELANOMA R, V22, P724, DOI 10.1111/j.1755-148X.2009.00627.x; Ohtsuka K, 2000, CELL STRESS CHAPERON, V5, P98, DOI 10.1379/1466-1268(2000)005<0098:MHDHCO>2.0.CO;2; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Pecina-Slaus N, 2007, J CUTAN PATHOL, V34, P239, DOI 10.1111/j.1600-0560.2006.00601.x; PolanowskaGrabowska R, 1997, BLOOD, V90, P1516, DOI 10.1182/blood.V90.4.1516.1516_1516_1526; Qiu XB, 2006, CELL MOL LIFE SCI, V63, P2560, DOI 10.1007/s00018-006-6192-6; Reinhold MI, 2006, J BIOL CHEM, V281, P1381, DOI 10.1074/jbc.M504875200; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Rodolfo M, 2004, CANCER LETT, V214, P133, DOI 10.1016/j.canlet.2004.06.049; Sablina AA, 2010, CANCER RES, V70, P10474, DOI 10.1158/0008-5472.CAN-10-2855; Sablina AA, 2007, CELL ADHES MIGR, V1, P140, DOI 10.4161/cam.1.3.4986; Saika S, 2007, LAB INVEST, V87, P130, DOI 10.1038/labinvest.3700508; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shevde LA, 2010, CURR MOL MED, V10, P71, DOI 10.2174/156652410791065381; Shevde LA, 2006, CLIN EXP METASTAS, V23, P123, DOI 10.1007/s10585-006-9013-2; Shih IM, 2009, FUTURE ONCOL, V5, P1641, DOI [10.2217/fon.09.126, 10.2217/FON.09.126]; Tsai MF, 2006, JNCI-J NATL CANCER I, V98, P825, DOI 10.1093/jnci/djj229; Tuck AB, 2007, J CELL BIOCHEM, V102, P859, DOI 10.1002/jcb.21520; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Vos MJ, 2008, BIOCHEMISTRY-US, V47, P7001, DOI 10.1021/bi800639z; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Wang HZ, 2011, CYTOKINE, V53, P130, DOI 10.1016/j.cyto.2010.10.009; Watson ED, 2007, DEVELOPMENT, V134, P1809, DOI 10.1242/dev.02843; Watson ED, 2009, DEV DYNAM, V238, P2564, DOI 10.1002/dvdy.22088; Weeraratna AT, 2005, CANCER METAST REV, V24, P237, DOI 10.1007/s10555-005-1574-z; Whalen KA, 2005, J VIROL, V79, P9982, DOI 10.1128/JVI.79.15.9982-9990.2005; Yeatman TJ, 2003, CLIN EXP METASTAS, V20, P85, DOI 10.1023/A:1022502805474; Zhang W, 2009, J BIOL CHEM, V284, P22649, DOI 10.1074/jbc.M109.013698; Zhang YF, 2008, BIOCHEM J, V413, P239, DOI 10.1042/BJ20071510; Zhou BHP, 2005, CELL CYCLE, V4, P772, DOI 10.4161/cc.4.6.1744; Zhou YW, 2005, J INVEST DERMATOL, V124, P1044, DOI 10.1111/j.0022-202X.2005.23680.x; Zuidervaart W, 2007, MELANOMA RES, V17, P380, DOI 10.1097/CMR.0b013e3282f1d302	75	40	40	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	41					4472	4483		10.1038/onc.2011.623	http://dx.doi.org/10.1038/onc.2011.623			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	018YR	22266849	Green Accepted			2022-12-17	WOS:000309704500005
J	Wanka, C; Brucker, DP; Bahr, O; Ronellenfitsch, M; Weller, M; Steinbach, JP; Rieger, J				Wanka, C.; Brucker, D. P.; Baehr, O.; Ronellenfitsch, M.; Weller, M.; Steinbach, J. P.; Rieger, J.			Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death	ONCOGENE			English	Article						p53; SCO2; hypoxia; glioma; respiration	ENERGY-METABOLISM; P53; GENE; ANTIANGIOGENESIS; EXPRESSION; STRATEGIES; EVOLUTION; PATHWAYS; ARREST; SCO2	P53 has an important role in the processing of starvation signals. P53-dependent molecular mediators of the Warburg effect reduce glucose consumption and promote mitochondrial function. We therefore hypothesized that the retention of wild-type p53 characteristic of primary glioblastomas limits metabolic demands induced by deregulated signal transduction in the presence of hypoxia and nutrient depletion. Here we report that short hairpin RNA-mediated gene suppression of wild-type p53 or ectopic expression of mutant temperature-sensitive dominant-negative p53(V135A) increased glucose consumption and lactate production, decreased oxygen consumption and enhanced hypoxia-induced cell death in p53 wild-type human glioblastoma cells. Similarly, genetic knockout of p53 in HCT116 colon carcinoma cells resulted in reduced respiration and hypersensitivity towards hypoxia-induced cell death. Further, wild-type p53 gene silencing reduced the expression of synthesis of cytochrome c oxidase 2 (SCO2), an effector necessary for respiratory chain function. An SCO2 transgene reverted the metabolic phenotype and restored resistance towards hypoxia in p53-depleted and p53 mutant glioma cells in a rotenone-sensitive manner, demonstrating that this effect was dependent on intact oxidative phosphorylation. Supplementation with methyl-pyruvate, a mitochondrial substrate, rescued p53 wild-type but not p53 mutant cells from hypoxic cell death, demonstrating a p53-mediated selective aptitude to metabolize mitochondrial substrates. Further, SCO2 gene silencing in p53 wild-type glioma cells sensitized these cells towards hypoxia. Finally, lentiviral gene suppression of SCO2 significantly enhanced tumor necrosis in a subcutaneous HCT116 xenograft tumor model, compatible with impaired energy metabolism in these cells. These findings demonstrate that glioma and colon cancer cells with p53 wild-type status can skew the Warburg effect and thereby reduce their vulnerability towards tumor hypoxia in an SCO2-dependent manner. Targeting SCO2 may therefore represent a valuable strategy to enhance sensitivity towards hypoxia and may complement strategies targeting glucose metabolism. Oncogene (2012) 31, 3764-3776; doi:10.1038/onc.2011.530; published online 28 November 2011	[Wanka, C.; Brucker, D. P.; Baehr, O.; Ronellenfitsch, M.; Steinbach, J. P.; Rieger, J.] Goethe Univ Frankfurt, Dr Senckenberg Inst Neurooncol, D-60528 Frankfurt, Germany; [Wanka, C.; Brucker, D. P.; Steinbach, J. P.] Univ Tubingen Hosp, Dept Neurol, Tubingen, Germany; [Weller, M.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland	Goethe University Frankfurt; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Zurich; University Zurich Hospital	Rieger, J (corresponding author), Goethe Univ Frankfurt, Dr Senckenberg Inst Neurooncol, Schleusenweg 2-16, D-60528 Frankfurt, Germany.	johannes.rieger@med.uni-frankfurt.de	Ronellenfitsch, Michael/AAW-8201-2020	Ronellenfitsch, Michael/0000-0002-1402-6290; Brucker, Daniel Peer/0000-0002-1808-5917; Rieger, Johannes/0000-0002-7918-1777; Weller, Michael/0000-0002-1748-174X	Deutsche Forschungsgemeinschaft [GRK 1302/1]; Hertie foundation; Dr Senckenberg foundation	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Hertie foundation; Dr Senckenberg foundation	We thank P Hwang for providing the SCO2 expression plasmid and B Vogelstein for the HCT116 p53<SUP>+/+</SUP> and p53<SUP>-/-</SUP> cell lines. This work was supported by The Deutsche Forschungsgemeinschaft (GRK 1302/1). The Dr Senckenberg Institute of Neurooncology is supported by the Hertie foundation and the Dr Senckenberg foundation. JPS is 'Hertie Professor for Neurooncology'.	Anderson ARA, 2006, CELL, V127, P905, DOI 10.1016/j.cell.2006.09.042; Barnes K, 2002, J CELL SCI, V115, P2433; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bhonde MR, 2006, ONCOGENE, V25, P165, DOI 10.1038/sj.onc.1209017; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447; Chan DA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002394; Choe G, 2003, CANCER RES, V63, P2742; Corcoran CA, 2006, CANCER BIOL THER, V5, P1610, DOI 10.4161/cbt.5.12.3617; CURI R, 1988, BIOCHEM J, V250, P383, DOI 10.1042/bj2500383; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dyer BW, 2000, ANAL BIOCHEM, V282, P158, DOI 10.1006/abio.2000.4605; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Ehrmann J, 1995, Cesk Patol, V31, P87; FULTS D, 1992, CANCER RES, V52, P674; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gottlieb E, 2009, NATURE, V461, P44, DOI 10.1038/461044a; GUPPY M, 1993, EUR J BIOCHEM, V212, P95, DOI 10.1111/j.1432-1033.1993.tb17637.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jansen M, 2004, BRAIN RES REV, V45, P143, DOI 10.1016/j.brainresrev.2004.03.001; Jiang BH, 2008, BBA-PROTEINS PROTEOM, V1784, P150, DOI 10.1016/j.bbapap.2007.09.008; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kim E, 2009, BIOCHEM PHARMACOL, V77, P11, DOI 10.1016/j.bcp.2008.08.030; Kondoh H, 2005, CANCER RES, V65, P177; KOPPER L, 1975, CANCER RES, V35, P2704; Leary SC, 2004, HUM MOL GENET, V13, P1839, DOI 10.1093/hmg/ddh197; Leary SC, 2009, HUM MOL GENET, V18, P2230, DOI 10.1093/hmg/ddp158; Liu T, 2007, CELL DEATH DIFFER, V14, P411, DOI 10.1038/sj.cdd.4402022; Ma WZ, 2007, J BIOENERG BIOMEMBR, V39, P243, DOI 10.1007/s10863-007-9083-0; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x; Naumann U, 1998, ONCOGENE, V17, P1567, DOI 10.1038/sj.onc.1202071; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Puduvalli VK, 2000, J NEURO-ONCOL, V50, P189, DOI 10.1023/A:1006469830739; Rieger J, 2010, J NEURO-ONCOL, V99, P49, DOI 10.1007/s11060-009-0098-8; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Steinbach JP, 2003, CELL DEATH DIFFER, V10, P823, DOI 10.1038/sj.cdd.4401252; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Sung HJ, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1003; Tohma Y, 1998, J NEUROPATH EXP NEUR, V57, P239, DOI 10.1097/00005072-199803000-00005; VAN MEIR EG, 1994, CANCER RES, V54, P649; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WARBURG O, 1956, SCIENCE, V124, P269; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Wischhusen J, 2004, CELL DEATH DIFFER, V11, P1150, DOI 10.1038/sj.cdd.4401477; Wischhusen J, 2003, ONCOGENE, V22, P8233, DOI 10.1038/sj.onc.1207198; Yoon CH, 2009, P NATL ACAD SCI USA, V106, P7852, DOI 10.1073/pnas.0812148106; Zhao Y, 2009, J ZHEJIANG UNIV-SC B, V10, P404, DOI 10.1631/jzus.B0820293	52	40	41	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	33					3764	3776		10.1038/onc.2011.530	http://dx.doi.org/10.1038/onc.2011.530			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22120717	Green Accepted			2022-12-17	WOS:000307924900003
J	Lin, TY; Cheng, YC; Yang, HC; Lin, WC; Wang, CC; Lai, PL; Shieh, SY				Lin, T-Y; Cheng, Y-C; Yang, H-C; Lin, W-C; Wang, C-C; Lai, P-L; Shieh, S-Y			Loss of the candidate tumor suppressor BTG3 triggers acute cellular senescence via the ERK-JMJD3-p16(INK4a) signaling axis	ONCOGENE			English	Article						BTG3; ERK; JMJD3/KDM6B; cellular senescence	DEMETHYLASE JMJD3 CONTRIBUTES; ONCOGENE-INDUCED SENESCENCE; DNA-DAMAGE RESPONSE; INK4A-ARF LOCUS; FAMILY; PROTEINS; BARRIER; STRESS; TARGET; RB	The B-cell translocation gene 3 (BTG3) is a member of the antiproliferative BTG gene family and a downstream target of p53. BTG3 also binds and inhibits E2F1. Although it connects functionally two major growth-regulatory pathways, the physiological role of BTG3 remains largely uncharacterized. Here, we present evidence that loss of BTG3 in normal cells induced cellular senescence, which was correlated with enhanced ERK-AP1 signaling and elevated expression of the histone H3K27me3 demethylase JMJD3/KDM6B, leading to acute induction of p16(INK4a). Importantly, we also found that BTG3 expression is specifically downregulated in prostate cancer, thus providing a physiological link with human cancers. Our data suggest that BTG3 may have a fail-safe role against tumorigenic progression. Oncogene (2012) 31, 3287-3297; doi:10.1038/onc.2011.491; published online 24 October 2011	[Lin, T-Y; Cheng, Y-C; Yang, H-C; Shieh, S-Y] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Cheng, Y-C] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Lin, W-C; Wang, C-C; Lai, P-L] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; National Taiwan University; National Taiwan University Hospital	Shieh, SY (corresponding author), Acad Sinica, Inst Biomed Sci, 128,Sec 2,Acad Rd, Taipei 115, Taiwan.	sy88@ibms.sinica.edu.tw	Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430	National Science Council of Taiwan; Academia Sinica	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Academia Sinica(Academia Sinica - Taiwan)	This work was supported by grants from the National Science Council of Taiwan and Academia Sinica to S-Y Shieh.	Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Mallette FA, 2007, CELL CYCLE, V6, P1831, DOI 10.4161/cc.6.15.4516; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Ou YH, 2005, MOL BIOL CELL, V16, P1684, DOI 10.1091/mbc.E04-08-0689; Ou YH, 2007, EMBO J, V26, P3968, DOI 10.1038/sj.emboj.7601825; Rahmani Z, 2006, J CELL SCI, V119, P646, DOI 10.1242/jcs.02778; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; Winkler GS, 2010, J CELL PHYSIOL, V222, P66, DOI 10.1002/jcp.21919; Yoneda M, 2009, CANCER SCI, V100, P225, DOI 10.1111/j.1349-7006.2008.01030.x; Young AP, 2008, NAT CELL BIOL, V10, P361, DOI 10.1038/ncb1699	26	40	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	27					3287	3297		10.1038/onc.2011.491	http://dx.doi.org/10.1038/onc.2011.491			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22020331				2022-12-17	WOS:000306113400008
J	Paroni, G; Fratelli, M; Gardini, G; Bassano, C; Flora, M; Zanetti, A; Guarnaccia, V; Ubezio, P; Centritto, F; Terao, M; Garattini, E				Paroni, G.; Fratelli, M.; Gardini, G.; Bassano, C.; Flora, M.; Zanetti, A.; Guarnaccia, V.; Ubezio, P.; Centritto, F.; Terao, M.; Garattini, E.			Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA	ONCOGENE			English	Article						targeted therapy; retinoic acid; differentiation; apoptosis; HER2/neu; lapatinib	PROMYELOCYTIC LEUKEMIA-CELLS; ACID RECEPTOR-ALPHA; GROWTH-FACTOR-BETA; TGF-BETA; GENE-EXPRESSION; TERMINAL DIFFERENTIATION; TUMOR SUPPRESSION; APOPTOSIS; TRASTUZUMAB; INDUCTION	All-trans retinoic acid (ATRA), the only clinically available cyto-differentiating agent, has potential for the therapy/chemoprevention of breast carcinoma. Given the heterogeneous nature of this tumor, a rational use of ATRA and derivatives (retinoids) in the clinic requires the identification of patients that would benefit from retinoid-based protocols. Here, we demonstrate that 23-32% of the human ERBB2(+) breast cancers show coamplification of retinoic acid receptor alpha (RARA), encoding the retinoic acid receptor, RAR alpha. This represents a novel subtype of breast cancer characterized by remarkable sensitivity to ATRA and RAR alpha agonists, regardless of positivity to the estrogen receptor, a known modulator of retinoid sensitivity. In estrogen-receptor-negative cellular models showing coamplification of ERBB2 and RARA, simultaneous targeting of the corresponding gene products with combinations of lapatinib and ATRA causes synergistic growth inhibition, cyto-differentiation and apoptosis. This provides proof-of-principle that coamplification of ERBB2 and RARA can be exploited for the stratified and targeted therapy of a novel subtype of breast cancer patients, with an approach characterized by tumor cell selectivity and low predicted toxicity. The available cellular models were exploited to define the molecular mechanisms underlying the antitumor activity of combinations between lapatinib and ATRA. Global gene expression and functional approaches provide evidence for three components of the antiproliferative/apoptotic responses triggered by lapatinib+ATRA. Induction of the retinoid-dependent RARRES3 protein by ATRA stabilizes the effect of lapatinib inhibiting ERBB2 phosphorylation. Upregulation and activation of the transcription factor FOXO3A integrates ATRA-dependent transcriptional and lapatinib-dependent posttranscriptional signals, controlling the levels of effector proteins like the antiapoptotic factor, BIRC5. Stimulation of the TGF beta pathway by ATRA mediates other components of the apoptotic process set in motion by simultaneous targeting of ERBB2 and RAR alpha. Oncogene (2012) 31, 3431-3443; doi:10.1038/onc.2011.506; published online 7 November 2011	[Paroni, G.; Fratelli, M.; Zanetti, A.; Guarnaccia, V.; Centritto, F.; Terao, M.; Garattini, E.] Ist Ric Farmacol Mario Negri, Mol Biol Lab, I-20156 Milan, Italy; [Gardini, G.; Bassano, C.; Flora, M.] IRCCS Osped Santa Maria Nuova, Anat Pathol Unit, Reggio Emilia, Italy; [Ubezio, P.] Ist Ric Farmacol Mario Negri, Dept Oncol, I-20156 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Garattini, E (corresponding author), Ist Ric Farmacol Mario Negri, Mol Biol Lab, Via La Masa 19, I-20156 Milan, Italy.	enrico.garattini@marionegri.it	adriana, zanetti/ABA-1189-2020; Paroni, Gabriela/J-4848-2018; terao, mineko/AAU-8089-2020; ubezio, paolo/AAA-6704-2020; Garattini, Enrico/AAI-1998-2019; Fratelli, Maddalena/AAA-6446-2020; Ubezio, Paolo/AAA-6455-2020; Terao, Mineko/AAA-6415-2020	adriana, zanetti/0000-0002-5825-9707; Paroni, Gabriela/0000-0003-0132-0869; Fratelli, Maddalena/0000-0002-1769-3427; Ubezio, Paolo/0000-0003-0412-9891; Terao, Mineko/0000-0002-9976-9869; Garattini, Enrico/0000-0001-8983-886X	Associazione Italiana per la Ricerca contro il Cancro (AIRC); Fondazione Italo Monzino; Negri-Weizmann Foundation; Ministero della Salute	Associazione Italiana per la Ricerca contro il Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Italo Monzino; Negri-Weizmann Foundation; Ministero della Salute(Ministry of Health, Italy)	The experimental work of our talented PhD student, Roberta Affatato, is acknowledged. We would like to thank Silvio Garattini and Rony Seger (Weizmann Institute, Rehovot, Israel) for the critical reading of the manuscript. Grants from the Associazione Italiana per la Ricerca contro il Cancro (AIRC), the Fondazione Italo Monzino and the Negri-Weizmann Foundation were fundamental for the completion of this work. The work was also partially supported with grants from the Ministero della Salute.	Abramson V, 2011, CLIN CANCER RES, V17, P952, DOI 10.1158/1078-0432.CCR-09-1947; Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; Aryee MJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-409; Balmer JE, 2005, J STEROID BIOCHEM, V96, P347, DOI 10.1016/j.jsbmb.2005.05.005; Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; Barral PM, 2009, PHARMACOL THERAPEUT, V124, P219, DOI 10.1016/j.pharmthera.2009.06.012; Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Buck MB, 2006, ANN NY ACAD SCI, V1089, P119, DOI 10.1196/annals.1386.024; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Colombo V, 2011, CANCER CHEMOTH PHARM, V67, P369, DOI 10.1007/s00280-010-1335-8; Danforth DN, 2004, J ENDOCRINOL, V183, P395, DOI 10.1677/joe.1.05497; Decensi A, 2000, J CELL BIOCHEM, P84; Dokmanovic M, 2002, CANCER BIOL THER, V1, P24, DOI 10.4161/cbt.1.1.35; Dusek RL, 2011, NAT REV CANCER, V11, P317, DOI 10.1038/nrc3051; Esteva FJ, 2010, NAT REV CLIN ONCOL, V7, P98, DOI 10.1038/nrclinonc.2009.216; Fitzgerald P, 1997, CANCER RES, V57, P2642; Garattini E, 2004, BLOOD, V103, P194, DOI 10.1182/blood-2003-05-1577; Garattini E, 2007, CURR PHARM DESIGN, V13, P1375, DOI 10.2174/138161207780618786; Gianni M, 1996, BLOOD, V87, P1520, DOI 10.1182/blood.V87.4.1520.bloodjournal8741520; GIANNI M, 1993, BIOCHEM BIOPH RES CO, V196, P252, DOI 10.1006/bbrc.1993.2242; Gianni M, 1996, BIOCHEM BIOPH RES CO, V224, P50, DOI 10.1006/bbrc.1996.0983; Gianni M, 2009, CANCER RES, V69, P1016, DOI 10.1158/0008-5472.CAN-08-2603; Guha M, 2009, CANCER RES, V69, P4954, DOI 10.1158/0008-5472.CAN-09-0584; Huang SL, 2000, MOL CELL ENDOCRINOL, V159, P15, DOI 10.1016/S0303-7207(99)00207-5; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Koay DC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2625; Lupi M, 2004, CANCER RES, V64, P2825, DOI 10.1158/0008-5472.CAN-03-3810; Mariani G, 2009, NAT CLIN PRACT ONCOL, V6, P93, DOI 10.1038/ncponc1298; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; Moreira C, 2010, EXPERT REV ANTICANC, V10, P1171, DOI [10.1586/era.10.113, 10.1586/ERA.10.113]; Mucida D, 2007, CELL ADHES MIGR, V1, P142, DOI 10.4161/cam.1.3.5062; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Ou CC, 2008, CARCINOGENESIS, V29, P299, DOI 10.1093/carcin/bgm263; Paik J, 2003, CANCER INVEST, V21, P304, DOI 10.1081/CNV-120016425; Paroni G, 2011, METHODS MOL BIOL, V740, P65, DOI 10.1007/978-1-61779-108-6_9; Puntoni Matteo, 2009, Eur J Cancer, V45 Suppl 1, P346, DOI 10.1016/S0959-8049(09)70049-8; ROMAN SD, 1993, CANCER RES, V53, P5940; Rubin I, 2001, ANN ONCOL, V12, P3, DOI 10.1023/A:1011195320446; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; Shyu RY, 2005, ANTICANCER RES, V25, P2453; Srinivas H, 2006, BIOCHEM J, V395, P653, DOI 10.1042/BJ20051794; Sturniolo MT, 2003, J BIOL CHEM, V278, P48066, DOI 10.1074/jbc.M307215200; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; Tan AR, 2009, BREAST CANCER RES TR, V115, P453, DOI 10.1007/s10549-008-0184-1; Terao M, 2011, J BIOL CHEM, V286, P4027, DOI 10.1074/jbc.M110.184994; Tsai FM, 2007, CELL SIGNAL, V19, P989, DOI 10.1016/j.cellsig.2006.11.005; Tsai FM, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-15; Wang Y, 2007, EXP CELL RES, V313, P357, DOI 10.1016/j.yexcr.2006.10.016; Xiao S, 2008, J IMMUNOL, V181, P2277, DOI 10.4049/jimmunol.181.4.2277; Yang J, 2008, ONCOGENE, V27, P5326, DOI 10.1038/onc.2008.165; Yang JY, 2009, CLIN CANCER RES, V15, P752, DOI 10.1158/1078-0432.CCR-08-0124; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Yang QF, 2002, BREAST CANCER RES TR, V76, P167, DOI 10.1023/A:1020576606004; Zujewski J, 2001, BREAST CANCER RES, V3, P66, DOI 10.1186/bcr273	56	40	46	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	29					3431	3443		10.1038/onc.2011.506	http://dx.doi.org/10.1038/onc.2011.506			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	976FN	22056878				2022-12-17	WOS:000306566400004
J	Zaynagetdinov, R; Stathopoulos, GT; Sherrill, TP; Cheng, DS; McLoed, AG; Ausborn, JA; Polosukhin, VV; Connelly, L; Zhou, W; Fingleton, B; Peebles, RS; Prince, LS; Yull, FE; Blackwell, TS				Zaynagetdinov, R.; Stathopoulos, G. T.; Sherrill, T. P.; Cheng, D-S; McLoed, A. G.; Ausborn, J. A.; Polosukhin, V. V.; Connelly, L.; Zhou, W.; Fingleton, B.; Peebles, R. S.; Prince, L. S.; Yull, F. E.; Blackwell, T. S.			Epithelial nuclear factor-kappa B signaling promotes lung carcinogenesis via recruitment of regulatory T lymphocytes	ONCOGENE			English	Article						mouse; lung; cancer; Treg; inflammation; NF-kappa B	OBSTRUCTIVE PULMONARY-DISEASE; ANTI-CD25 MONOCLONAL-ANTIBODY; FUNCTIONAL INACTIVATION; CHRONIC INFLAMMATION; SMOKING-CESSATION; CUTTING EDGE; CANCER; CELLS; COPD; DEPLETION	The mechanisms by which chronic inflammatory lung diseases, particularly chronic obstructive pulmonary disease, confer enhanced risk for lung cancer are not well-defined. To investigate whether nuclear factor (NF)-kappa B, a key mediator of immune and inflammatory responses, provides an interface between persistent lung inflammation and carcinogenesis, we utilized tetracycline-inducible transgenic mice expressing constitutively active I kappa B kinase beta in airway epithelium (IKTA (IKK beta trans-activated) mice). Intraperitoneal injection of ethyl carbamate (urethane), or 3-methylcholanthrene (MCA) and butylated hydroxytoluene (BHT) was used to induce lung tumorigenesis. Doxycycline-treated IKTA mice developed chronic airway inflammation and markedly increased numbers of lung tumors in response to urethane, even when transgene expression (and therefore epithelial NF-kappa B activation) was begun after exposure to carcinogen. Studies using a separate tumor initiator/promoter model (MCA+BHT) indicated that NF-kappa B functions as an independent tumor promoter. Enhanced tumor formation in IKTA mice was preceded by increased proliferation and reduced apoptosis of alveolar epithelium, resulting in increased formation of premalignant lesions. Investigation of inflammatory cells in lungs of IKTA mice revealed a substantial increase in macrophages and lymphocytes, including functional CD4+/CD25+/FoxP3+ regulatory T lymphocytes (Tregs). Importantly, Treg depletion using repetitive injections of anti-CD25 antibodies limited excessive tumor formation in IKTA mice. At 6 weeks following urethane injection, antibody-mediated Treg depletion in IKTA mice reduced the number of premalignant lesions in the lungs in association with an increase in CD8 lymphocytes. Thus, persistent NF-kappa B signaling in airway epithelium facilitates carcinogenesis by sculpting the immune/inflammatory environment in the lungs. Oncogene (2012) 31, 3164-3176; doi:10.1038/onc.2011.480; published online 17 October 2011	[Blackwell, T. S.] Vanderbilt Univ, Sch Med, Ctr Lung Res, Dept Med,Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; [McLoed, A. G.; Ausborn, J. A.; Connelly, L.; Fingleton, B.; Yull, F. E.; Blackwell, T. S.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; [Prince, L. S.; Blackwell, T. S.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA; [Peebles, R. S.; Blackwell, T. S.] Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA; [Prince, L. S.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University	Blackwell, TS (corresponding author), Vanderbilt Univ, Sch Med, Ctr Lung Res, Dept Med,Div Allergy Pulm & Crit Care Med, 1161 21st Ave S,T-1218 MCN, Nashville, TN 37232 USA.	timothy.blackwell@vanderbilt.edu	Connelly, Linda/GVS-4612-2022; Stathopoulos, Georgios/D-6576-2013; Stathopoulos, Georgios/AAE-6884-2020	Stathopoulos, Georgios/0000-0002-9215-6461; 	Department of Veterans Affairs; Vanderbilt Cancer Center; National Institutes of Health [5T32HL094296-03, CA113734]; NATIONAL CANCER INSTITUTE [T32CA009592, R01CA113734] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086324, T32HL094296, R01HL097195] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); Vanderbilt Cancer Center; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by Department of Veterans Affairs (TSB), Vanderbilt Cancer Center Support Grant 2010 (TSB), National Institutes of Health Grants (no.5T32HL094296-03, RZ and CA113734, FEY).	Alberg AJ, 2007, CHEST, V132, p29S, DOI 10.1378/chest.07-1347; Banerjee DK, 2006, BLOOD, V108, P2655, DOI 10.1182/blood-2006-03-011353; Barnes PJ, 2009, EUR RESPIR J, V33, P1165, DOI 10.1183/09031936.00128008; Barnes Peter J, 2008, Proc Am Thorac Soc, V5, P857, DOI 10.1513/pats.200807-069TH; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Bauer AK, 2005, J NATL CANCER I, V97, P1778, DOI 10.1093/jnci/dji403; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; Bonvallot V, 2001, AM J RESP CELL MOL, V25, P515, DOI 10.1165/ajrcmb.25.4.4515; Brody Jerome S, 2006, Proc Am Thorac Soc, V3, P535, DOI 10.1513/pats.200603-089MS; Cheng DS, 2007, J IMMUNOL, V178, P6504, DOI 10.4049/jimmunol.178.10.6504; Chung KF, 2008, EUR RESPIR J, V31, P1334, DOI 10.1183/09031936.00018908; Colombo MP, 2007, NAT REV CANCER, V7, P880, DOI 10.1038/nrc2250; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Degl'Innocenti E, 2008, CANCER RES, V68, P292, DOI 10.1158/0008-5472.CAN-07-2429; Gamble E, 2007, EUR RESPIR J, V30, P467, DOI 10.1183/09031936.00013006; Granville CA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005061; Hashimoto K, 2005, J IMMUNOL, V174, P525, DOI 10.4049/jimmunol.174.1.525; Houghton AM, 2008, NAT MED, V14, P1023, DOI 10.1038/nm1008-1023; Kohm AP, 2006, J IMMUNOL, V176, P3301, DOI 10.4049/jimmunol.176.6.3301; Lane N, 2010, CLIN SCI, V119, P75, DOI 10.1042/CS20100033; Lapperre TS, 2006, THORAX, V61, P115, DOI 10.1136/thx.2005.040519; Lee SH, 2007, NAT MED, V13, P567, DOI 10.1038/nm1583; Malkinson AM, 2000, CHEST, V117, p228S, DOI 10.1378/chest.117.5_suppl_1.228S; Malkinson AM, 1997, CANCER RES, V57, P2832; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Miller YE, 2005, AM J RESP CELL MOL, V33, P216, DOI 10.1165/rcmb.2005-0158OE; Moghaddam SJ, 2009, AM J RESP CELL MOL, V40, P443, DOI 10.1165/rcmb.2008-0198OC; Mougiakakos D, 2010, ADV CANCER RES, V107, P57, DOI 10.1016/S0065-230X(10)07003-X; Nummer D, 2007, J NATL CANCER I, V99, P1188, DOI 10.1093/jnci/djm064; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pasparakis M, 2009, NAT REV IMMUNOL, V9, P778, DOI 10.1038/nri2655; Perl AKT, 2002, TRANSGENIC RES, V11, P21, DOI 10.1023/A:1013986627504; Plumb J, 2009, EUR RESPIR J, V34, P89, DOI 10.1183/09031936.00100708; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Schneider T, 2011, J THORAC ONCOL, V6, P432, DOI 10.1097/JTO.0b013e31820b80ca; Schottenfeld D, 2006, CA-CANCER J CLIN, V56, P69, DOI 10.3322/canjclin.56.2.69; Setiady YY, 2010, EUR J IMMUNOL, V40, P780, DOI 10.1002/eji.200939613; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; SKILLRUD DM, 1986, ANN INTERN MED, V105, P503, DOI 10.7326/0003-4819-105-4-503; Smale ST, 2010, CELL, V140, P833, DOI 10.1016/j.cell.2010.01.037; Smyth LJC, 2007, CHEST, V132, P156, DOI 10.1378/chest.07-0083; Stathopoulos GT, 2007, P NATL ACAD SCI USA, V104, P18514, DOI 10.1073/pnas.0705316104; Stephens LA, 2006, J IMMUNOL, V177, P2036, DOI 10.4049/jimmunol.177.4.2036; Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008; Tang XM, 2006, CANCER, V107, P2637, DOI 10.1002/cncr.22315; Thiberville L, 2009, EUR RESPIR J, V33, P974, DOI 10.1183/09031936.00083708; TOCKMAN MS, 1987, ANN INTERN MED, V106, P512, DOI 10.7326/0003-4819-106-4-512; Wilke CM, 2010, INT J CANCER, V127, P748, DOI 10.1002/ijc.25464; Willemse BWM, 2005, EUR RESPIR J, V26, P835, DOI 10.1183/09031936.05.00108904; Young RP, 2009, EUR RESPIR J, V34, P380, DOI 10.1183/09031936.00144208; Yull FE, 2003, J HISTOCHEM CYTOCHEM, V51, P741, DOI 10.1177/002215540305100605; Zelenay S, 2006, J IMMUNOL, V177, P2036, DOI 10.4049/jimmunol.177.4.2036-a	54	40	42	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	26					3164	3176		10.1038/onc.2011.480	http://dx.doi.org/10.1038/onc.2011.480			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	967UX	22002309	Green Accepted			2022-12-17	WOS:000305934400005
J	Grepin, R; Guyot, M; Jacquin, M; Durivault, J; Chamorey, E; Sudaka, A; Serdjebi, C; Lacarelle, B; Scoazec, JY; Negrier, S; Simonnet, H; Pages, G				Grepin, R.; Guyot, M.; Jacquin, M.; Durivault, J.; Chamorey, E.; Sudaka, A.; Serdjebi, C.; Lacarelle, B.; Scoazec, J-Y; Negrier, S.; Simonnet, H.; Pages, G.			Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines	ONCOGENE			English	Article						angiogenesis; bevacizumab; CXCL cytokines; VEGF	PHASE-II TRIAL; TUMOR-GROWTH; IN-VITRO; CANCER; INTERLEUKIN-8; CHEMOKINES; RECEPTORS; ERLOTINIB; ANGIOGENESIS; COMBINATION	The anti-VEGF targeted antibody bevacizumab (BVZ) has been approved for treating renal cell carcinomas (RCCs). Although BVZ increases the progression-free survival of patients with metastatic RCC, the effect on overall survival is poor. To gain insight into the limited efficacy of BVZ on overall survival, we analyzed patient samples of RCC for angiogenic factors that may participate in escape from anti-VEGF therapy. Our study shows that the level of vascular endothelial growth factor (VEGF) in tumors was increased compared with normal tissue. The level of interleukin-8/CXCL8, a pro-angiogenic member of the CXCL family of cytokines, was also increased in tumors. These observations gave us a good reason to analyze the combined effects of BVZ and anti-CXCL8 antibodies on tumor growth. Surprisingly, we report that BVZ accelerates the growth of RCC in nude mice with in vivo selection of tumor cells with an increased growth capacity. Downregulation of receptor tyrosine phosphatase-kappa, a phosphatase implicated in EGF receptor regulation, may partly explain this phenomenon. Modification of the vascular network and development of lymphatic vessels through VEGF-C production and compensatory production of pro-angiogenic CXCL cytokines were also observed. The apparent normalization of the vascular network prompted us to associate BVZ with the chemotherapeutic agent paclitaxel. While efficient in vitro, paclitaxel did not reverse the anti-VEGF effects in vivo. Anti-CXCL8-targeting antibodies were promising as they decreased intra-tumor VEGF production; decreased the pro-angiogenic CXCL/anti-angiogenic CXCL ratio and did not induce lymphangiogenesis. These observations hold clinical implication as they highlight putative markers implicated in escape from BVZ treatment. They also recommend proceeding with caution in the use of anti-VEGF therapy alone for treatment of RCC. Oncogene (2012) 31, 1683-1694; doi:10.1038/onc.2011.360; published online 12 September 2011	[Pages, G.] Univ Nice Sophia Antipolis, CNRS, UMR 6543, IBDC,Ctr Antoine Lacassagne, F-06189 Nice, France; [Chamorey, E.; Sudaka, A.] Ctr Antoine Lacassagne, Dept Stat EC, F-06054 Nice, France; [Chamorey, E.; Sudaka, A.] Ctr Antoine Lacassagne, Dept Anatomopathol AS, F-06054 Nice, France; [Serdjebi, C.; Lacarelle, B.] Univ Marseille, UFR Pharm, Lab Pharmacocinet, Marseille, France; [Scoazec, J-Y] Fac Laennec, IFR62, INSERM, UMR S865, Lyon, France; [Negrier, S.] Ctr Leon Berard, F-69373 Lyon, France; [Simonnet, H.] Fac Med Grange Blanche, UMR 5201, Lille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; UNICANCER; Centre Antoine Lacassagne; UNICANCER; Centre Antoine Lacassagne; UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Pages, G (corresponding author), Univ Nice Sophia Antipolis, CNRS, UMR 6543, IBDC,Ctr Antoine Lacassagne, 33 Ave Valombrose, F-06189 Nice, France.	gpages@unice.fr	lacarelle, bruno/C-5585-2015; Chamorey, Emmanuel/AGO-9982-2022; Pages, Gilles/N-7135-2017	lacarelle, bruno/0000-0002-7122-5851; Durivault, Jerome/0000-0002-8228-2915	National Institute of Cancer (INCA); French Association for Cancer Research (ARC) [4932]; Roche France	National Institute of Cancer (INCA)(Institut National du Cancer (INCA) France); French Association for Cancer Research (ARC); Roche France(Roche Holding)	We thank Dr Marc Colombel (patients' informed consent), Dr Jean Claude Chambard (lentivirus expressing the luciferase gene), Dr Elodie Delaplanche (biopsy management), Dr Florence Mege-Lechevallier (anatomo-pathology determination), Ms Cendrine Dubaud (animal studies) and Dr M Christiane Brahimi-Horn (careful reading of the manuscript). Financial support: Contract VEGFIL from the National Institute of Cancer (INCA), the French Association for Cancer Research (ARC, contract no. 4932) and Roche France.	Bertini R, 2004, P NATL ACAD SCI USA, V101, P11791, DOI 10.1073/pnas.0402090101; Bieche I, 2007, ENDOCR-RELAT CANCER, V14, P1039, DOI 10.1677/erc.1.01301; Cao Y, 2008, CANCER RES, V68, P8667, DOI 10.1158/0008-5472.CAN-08-2614; Cascone T, 2011, J CLIN INVEST, V121, P1313, DOI 10.1172/JCI42405; Cervi D, 2008, BLOOD, V111, P1201, DOI 10.1182/blood-2007-04-084798; Cohen EEW, 2009, LANCET ONCOL, V10, P247, DOI 10.1016/S1470-2045(09)70002-6; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7; Escudier B, 2010, J CLIN ONCOL, V28, P2144, DOI 10.1200/JCO.2009.26.7849; Essafi-Benkhadir K, 2007, MOL BIOL CELL, V18, P4648, DOI 10.1091/mbc.E07-06-0570; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Hainsworth JD, 2007, CLIN GENITOURIN CANC, V5, P427, DOI 10.3816/CGC.2007.n.030; Hainsworth JD, 2007, J CLIN ONCOL, V25, P1747, DOI 10.1200/JCO.2006.09.3047; Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505; Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Kim JY, 2008, MOL CELL PROTEOMICS, V7, P431, DOI 10.1074/mcp.M700194-MCP200; Kopetz S, 2010, J CLIN ONCOL, V28, P453, DOI 10.1200/JCO.2009.24.8252; Kubota Y, 2009, J EXP MED, V206, P1089, DOI 10.1084/jem.20081605; Levashova ZB, 2007, J AM SOC NEPHROL, V18, P2359, DOI 10.1681/ASN.2006040380; Lubner SJ, 2010, J CLIN ONCOL, V28, P3491, DOI 10.1200/JCO.2010.28.4075; Merritt WM, 2008, J NATL CANCER I, V100, P359, DOI 10.1093/jnci/djn024; Mestas J, 2005, J IMMUNOL, V175, P5351, DOI 10.4049/jimmunol.175.8.5351; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Oliver G, 2010, DEVELOPMENT, V137, P363, DOI 10.1242/dev.035360; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pillai MM, 2006, BLOOD, V107, P3520, DOI 10.1182/blood-2005-10-4285; Quatrale AE, 2011, FRONT BIOSCI-LANDMRK, V16, P1962, DOI 10.2741/3833; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Vandercappellen J, 2008, CANCER LETT, V267, P226, DOI 10.1016/j.canlet.2008.04.050; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Xu L, 2009, CANCER RES, V69, P7905, DOI 10.1158/0008-5472.CAN-09-2099; Xu YR, 2005, J BIOL CHEM, V280, P42694, DOI 10.1074/jbc.M507722200; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491	37	40	46	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	13					1683	1694		10.1038/onc.2011.360	http://dx.doi.org/10.1038/onc.2011.360			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21909141				2022-12-17	WOS:000302231400007
J	Yang, D; Tao, J; Li, L; Kedei, N; Toth, ZE; Czap, A; Velasquez, JF; Mihova, D; Michalowski, AM; Yuspa, SH; Blumberg, PM				Yang, D.; Tao, J.; Li, L.; Kedei, N.; Toth, Z. E.; Czap, A.; Velasquez, J. F.; Mihova, D.; Michalowski, A. M.; Yuspa, S. H.; Blumberg, P. M.			RasGRP3, a Ras activator, contributes to signaling and the tumorigenic phenotype in human melanoma	ONCOGENE			English	Article						Ras activator; Akt; HGF; melanoma; cell transformation; guanine nucleotide exchange factor	POLYMERASE-CHAIN-REACTION; PHORBOL ESTERS; KINASE ACTIVATION; B-RAF; FUNCTIONAL-ANALYSIS; CELL PROLIFERATION; COLORECTAL TUMORS; REGULATED KINASE; BRAF MUTATIONS; PHOSPHORYLATION	RasGRP3, an activator for H-Ras, R-Ras and Ras-associated protein-1/2, has emerged as an important mediator of signaling downstream from receptor coupled phosphoinositide turnover in B and T cells. Here, we report that RasGRP3 showed a high level of expression in multiple human melanoma cell lines as well as in a subset of human melanoma tissue samples. Suppression of endogenous RasGRP3 expression in these melanoma cell lines reduced Ras-GTP formation as well as c-Met expression and Akt phosphorylation downstream from hepatocyte growth factor (HGF) or epidermal growth factor (EGF) stimulation. RasGRP3 suppression also inhibited cell proliferation and reduced both colony formation in soft agar and xenograft tumor growth in immunodeficient mice, demonstrating the importance of RasGRP3 for the transformed phenotype of the melanoma cells. Reciprocally, overexpression of RasGRP3 in human primary melanocytes altered cellular morphology, markedly enhanced cell proliferation and rendered the cells tumorigenic in a mouse xenograft model. Suppression of RasGRP3 expression in these cells inhibited downstream RasGRP3 responses and suppressed cell growth, confirming the functional role of RasGRP3 in the altered behavior of these cells. The identification of the role of RasGRP3 in melanoma highlights its importance, as a Ras activator, in the phosphoinositide signaling pathway in human melanoma and provides a new potential therapeutic target. Oncogene (2011) 30, 4590-4600; doi: 10.1038/onc.2011.166; published online 23 May 2011	[Yang, D.; Tao, J.; Li, L.; Kedei, N.; Czap, A.; Velasquez, J. F.; Mihova, D.; Michalowski, A. M.; Yuspa, S. H.; Blumberg, P. M.] NCI, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA; [Toth, Z. E.] Semmelweis Univ, Dept Anat Histol & Embryol, Neuromorphol & Neuroendocrine Res Lab, Budapest, Hungary; [Toth, Z. E.] Hungarian Acad Sci, Budapest, Hungary	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Semmelweis University; Hungarian Academy of Sciences	Blumberg, PM (corresponding author), NCI, Lab Canc Biol & Genet, Ctr Canc Res, Room 4048,Bldg 37,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.	blumberp@dc37a.nci.nih.gov	Li, Lili/Q-5750-2018; Tao, Qian/T-4743-2018; Chan, Anthony Tak Cheung/R-3940-2018	Li, Lili/0000-0002-0292-5889; Tao, Qian/0000-0001-5383-4808; Chan, Anthony Tak Cheung/0000-0002-6912-8091	NIH, Center for Cancer Research, National Cancer Institute [Z1A BC 005270]; ETT [495/09]; Bolyai fellowship; NATIONAL CANCER INSTITUTE [ZIABC004504, ZIABC005445, ZIABC005270, Z01BC005270] Funding Source: NIH RePORTER	NIH, Center for Cancer Research, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ETT; Bolyai fellowship(Hungarian Academy of Sciences); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported in part by the intramural program of the NIH, Center for Cancer Research, National Cancer Institute (project number Z1A BC 005270) and in part by grant ETT 495/09. ZE Toth is supported by the Bolyai fellowship. We thank Glenn Merlino for helpful comments.	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Aiba Y, 2004, P NATL ACAD SCI USA, V101, P16612, DOI 10.1073/pnas.0407468101; BALL NJ, 1994, J INVEST DERMATOL, V102, P285, DOI 10.1111/1523-1747.ep12371783; Bastian BC, 2003, AM J PATHOL, V163, P1765, DOI 10.1016/S0002-9440(10)63536-5; Bauer J, 2006, DERMATOL THER, V19, P40, DOI 10.1111/j.1529-8019.2005.00055.x; Brodie C, 2004, MOL PHARMACOL, V66, P76, DOI 10.1124/mol.66.1.76; Coughlin JJ, 2005, J IMMUNOL, V175, P7179, DOI 10.4049/jimmunol.175.11.7179; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Eckhart L, 2000, BIOCHEM BIOPH RES CO, V271, P726, DOI 10.1006/bbrc.2000.2716; Furge KA, 2001, P NATL ACAD SCI USA, V98, P10722, DOI 10.1073/pnas.191067898; Gao L, 2006, CANCER RES, V66, P7880, DOI 10.1158/0008-5472.CAN-06-0254; Gawecka JE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011269; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; Haluska Frank G, 2006, Curr Oncol Rep, V8, P400, DOI 10.1007/s11912-006-0065-x; Hingorani SR, 2003, CANCER RES, V63, P5198; Houben Roland, 2004, J Carcinog, V3, P6, DOI 10.1186/1477-3163-3-6; Huang HP, 2008, J AGR FOOD CHEM, V56, P9286, DOI 10.1021/jf8013102; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Ikenoue T, 2003, CANCER RES, V63, P8132; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; Lorenzo PS, 2001, CANCER RES, V61, P943; Oh-Hora M, 2003, J EXP MED, V198, P1841, DOI 10.1084/jem.20031547; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Oki-Idouchi CE, 2007, CANCER RES, V67, P276, DOI 10.1158/0008-5472.CAN-06-3080; Orian-Rousseau W, 2007, MOL BIOL CELL, V18, P76, DOI 10.1091/mbc.E06-08-0674; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Powell MB, 1999, CARCINOGENESIS, V20, P1747, DOI 10.1093/carcin/20.9.1747; Pu YM, 2005, J BIOL CHEM, V280, P27329, DOI 10.1074/jbc.M414132200; Roberts DM, 2004, MOL CELL BIOL, V24, P10515, DOI 10.1128/MCB.24.24.10515-10528.2004; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Satyamoorthy K, 2003, CANCER RES, V63, P756; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stark M, 2007, CANCER RES, V67, P2632, DOI 10.1158/0008-5472.CAN-06-4152; Stone JC, 2006, BIOCHEM SOC T, V34, P858, DOI 10.1042/BST0340858; Stope MB, 2004, MOL CELL BIOL, V24, P4664, DOI 10.1128/MCB.24.11.4664-4676.2004; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Sutlovic D, 2005, CROAT MED J, V46, P556; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Teixeira C, 2003, BLOOD, V102, P1414, DOI 10.1182/blood-2002-11-3621; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; van Elsas A, 1995, Recent Results Cancer Res, V139, P57; Wang DZ, 2000, ONCOGENE, V19, P4647, DOI 10.1038/sj.onc.1203820; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; Yang DZ, 2010, CANCER RES, V70, P7905, DOI 10.1158/0008-5472.CAN-09-4729; Zheng H, 2009, CANCER RES, V69, P449, DOI 10.1158/0008-5472.CAN-08-2399; Zheng Y, 2005, BLOOD, V105, P3648, DOI 10.1182/blood-2004-10-3916	54	40	43	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2011	30	45					4590	4600		10.1038/onc.2011.166	http://dx.doi.org/10.1038/onc.2011.166			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	846IO	22139084	Green Accepted			2022-12-17	WOS:000296890700006
J	Rajan, N; Elliott, R; Clewes, O; Mackay, A; Reis-Filho, JS; Burn, J; Langtry, J; Sieber-Blum, M; Lord, CJ; Ashworth, A				Rajan, N.; Elliott, R.; Clewes, O.; Mackay, A.; Reis-Filho, J. S.; Burn, J.; Langtry, J.; Sieber-Blum, M.; Lord, C. J.; Ashworth, A.			Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours	ONCOGENE			English	Article						cylindroma; tropomyosin receptor kinase; TRK; microarray; comparative genomic hybridization; CYLD	NF-KAPPA-B; BASAL-CELL CARCINOMAS; NERVE GROWTH-FACTOR; DEUBIQUITINATING ENZYME; NEUROTROPHIN RECEPTORS; DERMAL CYLINDROMA; BREAST CANCERS; EXPRESSION; GENE; MUTATIONS	Individuals with germline mutations in the tumour-suppressor gene CYLD are at high risk of developing disfiguring cutaneous appendageal tumours, the defining tumour being the highly organised cylindroma. Here, we analysed CYLD mutant tumour genomes by array comparative genomic hybridisation and gene expression microarray analysis. CYLD mutant tumours were characterised by an absence of copy-number aberrations apart from LOH chromosome 16q, the genomic location of the CYLD gene. Gene expression profiling of CYLD mutant tumours showed dysregulated tropomyosin kinase (TRK) signalling, with overexpression of TRKB and TRKC in tumours when compared with perilesional skin. Immunohistochemical analysis of a tumour microarray showed strong membranous TRKB and TRKC staining in cylindromas, as well as elevated levels of ERK phosphorylation and BCL2 expression. Membranous TRKC overexpression was also observed in 70% of sporadic BCCs. RNA interference-mediated silencing of TRKB and TRKC, as well as treatment with the small-molecule TRK inhibitor lestaurtinib, reduced colony formation and proliferation in 3D primary cell cultures established from CYLD mutant tumours. These results suggest that TRK inhibition could be used as a strategy to treat tumours with loss of functional CYLD. Oncogene (2011) 30, 4243-4260; doi: 10.1038/onc.2011.133; published online 9 May 2011	[Rajan, N.; Clewes, O.; Burn, J.; Sieber-Blum, M.] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; [Elliott, R.; Mackay, A.; Reis-Filho, J. S.; Lord, C. J.; Ashworth, A.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Langtry, J.] Royal Victoria Infirm, Dept Dermatol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Newcastle University - UK	Rajan, N (corresponding author), Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.	neil.rajan@ncl.ac.uk	Lord, Christopher/AAX-7130-2021; Rajan, Neil/AAL-7702-2021; Lord, Christopher J/B-3295-2012	Rajan, Neil/0000-0002-5850-5680; Lord, Christopher J/0000-0002-3226-0515; Burn, John/0000-0002-9823-2322	Newcastle Healthcare Charities Trust; North East Skin Research Fund; Breakthrough Breast Cancer; Cancer Research UK; Medical Research Council; MRC [G0701367] Funding Source: UKRI; Medical Research Council [G0701367] Funding Source: researchfish	Newcastle Healthcare Charities Trust; North East Skin Research Fund; Breakthrough Breast Cancer; Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was funded in part by grants from the Newcastle Healthcare Charities Trust, the North East Skin Research Fund, Breakthrough Breast Cancer, Cancer Research UK and the Medical Research Council. N Rajan is a MRC Clinical Training Fellow.	Adly MA, 2005, BRIT J DERMATOL, V153, P514, DOI 10.1111/j.1365-2133.2005.06763.x; Alvarez-Rodiguez R, 2007, J BIOL CHEM, V282, P37170, DOI 10.1074/jbc.M705414200; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; April C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008162; Arevalo JC, 2006, NEURON, V50, P549, DOI 10.1016/j.neuron.2006.03.044; Blasing H, 2005, ARCH DERMATOL RES, V296, P580, DOI 10.1007/s00403-005-0563-y; Bowen S, 2005, J INVEST DERMATOL, V124, P919, DOI 10.1111/j.0022-202X.2005.23688.x; BRUCKNERTUDERMAN L, 1991, J INVEST DERMATOL, V96, P729, DOI 10.1111/1523-1747.ep12470965; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; BUTTI MG, 1995, GENOMICS, V28, P15, DOI 10.1006/geno.1995.1100; Chen-Tsai CP, 2004, DERMATOL SURG, V30, P1009, DOI 10.1111/j.1524-4725.2004.30306.x; Coe BP, 2007, GENOMICS, V89, P647, DOI 10.1016/j.ygeno.2006.12.012; Demchenko YN, 2010, BLOOD, V115, P3541, DOI 10.1182/blood-2009-09-243535; Donovan J, 2009, DERMATOL SURG, V35, P1311, DOI 10.1111/j.1524-4725.2009.01236.x; Dunning MJ, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-85; Dutton R, 1999, CLIN EXP PHARMACOL P, V26, P746, DOI 10.1046/j.1440-1681.1999.03108.x; Gao JM, 2008, J BIOL CHEM, V283, P8802, DOI 10.1074/jbc.M708470200; Geetha T, 2005, MOL CELL, V20, P301, DOI 10.1016/j.molcel.2005.09.014; Geetha T, 2008, BIOCHEM BIOPH RES CO, V374, P33, DOI 10.1016/j.bbrc.2008.06.082; GERRETSEN AL, 1993, CANCER-AM CANCER SOC, V72, P1618, DOI 10.1002/1097-0142(19930901)72:5<1618::AID-CNCR2820720521>3.0.CO;2-5; Gunnarsson R, 2008, GENE CHROMOSOME CANC, V47, P697, DOI 10.1002/gcc.20575; Hellerbrand C, 2007, CARCINOGENESIS, V28, P21, DOI 10.1093/carcin/bgl081; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; *ILL INC, 2009, BEADST GEN EXPR MOD; Jenner MW, 2007, BLOOD, V110, P3291, DOI 10.1182/blood-2007-02-075069; Jin W, 2007, CANCER RES, V67, P9869, DOI 10.1158/0008-5472.CAN-07-0436; Kavanagh DO, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-1; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590; Komander D, 2008, MOL CELL, V29, P451, DOI 10.1016/j.molcel.2007.12.018; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kriegl L, 2009, BRIT J DERMATOL, V160, P1353, DOI 10.1111/j.1365-2133.2009.09144.x; Lagadec C, 2009, ONCOGENE, V28, P1960, DOI 10.1038/onc.2009.61; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Liu HH, 2006, P NATL ACAD SCI USA, V103, P11677, DOI 10.1073/pnas.0603089103; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Marchio C, 2008, J PATHOL, V216, P399, DOI 10.1002/path.2423; Marshall JL, 2005, INVEST NEW DRUG, V23, P31, DOI 10.1023/B:DRUG.0000047103.64335.b0; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; MATSUMOTO K, 1995, CANCER RES, V55, P1798; Meybehm M, 1997, AM J DERMATOPATH, V19, P154, DOI 10.1097/00000372-199704000-00009; Miller SC, 2010, BIOCHEM PHARMACOL, V79, P1272, DOI 10.1016/j.bcp.2009.12.021; Natrajan R, 2010, BREAST CANCER RES TR, V121, P575, DOI 10.1007/s10549-009-0501-3; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Oosterkamp HM, 2006, BRIT J DERMATOL, V155, P182, DOI 10.1111/j.1365-2133.2006.07224.x; Qiao W, 2006, ONCOGENE, V25, P207, DOI 10.1038/sj.onc.1209029; Rajan N, 2009, ARCH DERMATOL, V145, P1277, DOI 10.1001/archdermatol.2009.262; Reiley W, 2004, J BIOL CHEM, V279, P55161, DOI 10.1074/jbc.M411049200; Reiley WW, 2007, J EXP MED, V204, P1475, DOI 10.1084/jem.20062694; Reiley WW, 2006, NAT IMMUNOL, V7, P411, DOI 10.1038/ni1315; Ricci A, 2001, AM J RESP CELL MOL, V25, P439, DOI 10.1165/ajrcmb.25.4.4470; Saggar S, 2008, J MED GENET, V45, P298, DOI 10.1136/jmg.2007.056127; Saha RN, 2006, J NEUROIMMUNE PHARM, V1, P212, DOI 10.1007/s11481-006-9020-8; Saini HS, 2004, J NEUROCHEM, V89, P951, DOI 10.1111/j.1471-4159.2004.02365.x; Scala S, 1996, CANCER RES, V56, P3737; Shabbir M, 2010, EXPERT OPIN INV DRUG, V19, P427, DOI 10.1517/13543781003598862; Stegmeier F, 2007, P NATL ACAD SCI USA, V104, P8869, DOI 10.1073/pnas.0703268104; Stokes A, 2006, CELL SIGNAL, V18, P1584, DOI 10.1016/j.cellsig.2005.12.009; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117; Tan DSP, 2007, LAB INVEST, V87, P737, DOI 10.1038/labinvest.3700593; Tauriello DVF, 2010, MOL CELL, V37, P607, DOI 10.1016/j.molcel.2010.01.035; Teh MT, 2005, CANCER RES, V65, P8597, DOI 10.1158/0008-5472.CAN-05-0842; TELLECHEA O, 1995, AM J DERMATOPATH, V17, P260, DOI 10.1097/00000372-199506000-00008; Thress K, 2009, MOL CANCER THER, V8, P1818, DOI 10.1158/1535-7163.MCT-09-0036; TIMPL R, 1984, CIBA F SYMP, V108, P25; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Trompouki E, 2009, NEOPLASIA, V11, P469, DOI 10.1593/neo.81424; Tunggal L, 2002, AM J PATHOL, V160, P459, DOI 10.1016/S0002-9440(10)64865-1; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Weeraratna AT, 2000, PROSTATE, V45, P140, DOI 10.1002/1097-0045(20001001)45:2<140::AID-PROS8>3.0.CO;2-#; WORKMAN C, 2002, GENOME BIOL, V0003; Wu CB, 2007, TRAFFIC, V8, P1503, DOI 10.1111/j.1600-0854.2007.00636.x; Yang SH, 2008, NAT GENET, V40, P1130, DOI 10.1038/ng.192; Zhang J, 2006, J CLIN INVEST, V116, P3042, DOI 10.1172/JCI28746; Zhong S, 2007, ONCOGENE, V26, P2621, DOI 10.1038/sj.onc.1210041	78	40	40	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	41					4243	4260		10.1038/onc.2011.133	http://dx.doi.org/10.1038/onc.2011.133			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HO	21552290	Green Accepted			2022-12-17	WOS:000296356300003
J	Liu, G; Gramling, S; Munoz, D; Cheng, D; Azad, AK; Mirshams, M; Chen, Z; Xu, W; Roberts, H; Shepherd, FA; Tsao, MS; Reisman, D				Liu, G.; Gramling, S.; Munoz, D.; Cheng, D.; Azad, A. K.; Mirshams, M.; Chen, Z.; Xu, W.; Roberts, H.; Shepherd, F. A.; Tsao, M. S.; Reisman, D.			Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk	ONCOGENE			English	Article						genetic polymorphism; BRG1; SWI/SNF; chromatin remodeling; lung cancer	SMALL-CELL-LUNG; CHROMATIN REMODELING COMPLEXES; SWI/SNF COMPLEX; BREAST-CANCER; SUSCEPTIBILITY LOCUS; PROTEIN EXPRESSION; CYCLE ARREST; DNA-DAMAGE; GENE; BRG1	SWI/SNF (SWItch/sucrose non-fermentable) complexes are ATP-dependent chromatin remodeling enzymes critically involved in the regulation of multiple functions, including gene expression, differentiation, development, DNA repair, cell adhesion and cell cycle control. BRM, a key SWI/SNF complex subunit, is silenced in 15-20% of many solid tumors. As BRM-deficient mice develop 10-fold more tumors when exposed to carcinogens, BRM is a strong candidate for a cancer susceptibility gene. In this paper, we show that BRM is regulated by transcription, thus demonstrating that the promoter region is important for BRM expression. We sequenced the BRM promoter region, finding two novel promoter indel polymorphisms, BRM -741 and BRM -1321, that are in linkage disequilibrium (D'>= 0.83). The variant insertion alleles of both polymorphisms produce sequence variants that are highly homologous to myocyte enhancer factor-2 (MEF2) transcription factor-binding sites; MEF2 is known to recruit histone deacetylases that silence BRM expression. Each polymorphic BRM insertion variant is found in similar to 20% of Caucasians, and each correlates strongly with the loss of protein expression of BRM, both in cancer cell lines (P = 0.009) and in primary human lung tumor specimens (P = 0.015). With such strong functional evidence, we conducted a case-control study of 1199 smokers. We found an increased risk of lung cancer when both BRM homozygous promoter insertion variants were present: adjusted odds ratio of 2.19 (95% confidence interval, 1.40-3.43). Thus, we here demonstrate a strong functional association between these polymorphisms and loss of BRM expression. These polymorphisms thus have the potential to identify a sub-population of smokers at greater lung cancer risk, wherein this risk could be driven by an aberrant SWI/SNF chromatin-remodeling pathway. Oncogene (2011) 30, 3295-3304; doi:10.1038/onc.2011.81; published online 11 April 2011	[Gramling, S.; Munoz, D.; Reisman, D.] Univ Florida, Dept Med, Div Hematol Oncol, Gainesville, FL 32611 USA; [Liu, G.; Shepherd, F. A.] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Ontario Canc Inst,Div Med Oncol & Hematol,Dept Me, Toronto, ON, Canada; [Liu, G.; Cheng, D.; Azad, A. K.; Mirshams, M.; Chen, Z.; Tsao, M. S.] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Ontario Canc Inst,Dept Med Biophys, Toronto, ON, Canada; [Xu, W.] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Ontario Canc Inst,Biostat Dept, Toronto, ON, Canada; [Roberts, H.] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Dept Radiol, Toronto, ON, Canada; [Tsao, M. S.] Univ Toronto, Univ Hlth Network, Dept Pathol & Lab Med, Toronto, ON, Canada	State University System of Florida; University of Florida; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Reisman, D (corresponding author), Univ Florida, Dept Med, Div Hematol Oncol, Canc Genet Bldg Off 290,Off 294,2033 Mowry Rd, Gainesville, FL 32611 USA.	dnreisman@ufl.edu	Azad, Abul Kalam/G-3729-2010; Tsao, Ming-Sound/M-3503-2017; Liu, Geoffrey/N-4421-2016; Tsao, Ming Sound/AFQ-7332-2022	Azad, Abul Kalam/0000-0002-9236-9598; Tsao, Ming Sound/0000-0002-9160-5405; Liu, Geoffrey/0000-0002-2603-7296	Alan B Brown Chair in Molecular Genomics; CCO Chair in Experimental Therapeutics and Population Studies; Posluns Family Foundation; Ontario Ministry of Health and Long Term Care (OMHLTC); Lucy Wong Fund; NCI [7R03CA128038-02]; NATIONAL CANCER INSTITUTE [R03CA128038, T32CA009126] Funding Source: NIH RePORTER	Alan B Brown Chair in Molecular Genomics; CCO Chair in Experimental Therapeutics and Population Studies; Posluns Family Foundation; Ontario Ministry of Health and Long Term Care (OMHLTC)(Ministry of Health and Long-Term Care, Ontario); Lucy Wong Fund; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	GL is funded by the Alan B Brown Chair in Molecular Genomics, CCO Chair in Experimental Therapeutics and Population Studies, and Posluns Family Foundation; FAS holds the Scott Taylor Chair in Lung Cancer Research; MST holds the M Qasim Chair in Lung Cancer Translational Research; Supported by the Ontario Ministry of Health and Long Term Care (OMHLTC) and the Lucy Wong Fund. The results presented do not necessarily reflect the views of OMHLTC. Reisman lab funding is from NCI:7R03CA128038-02.	An HX, 1999, CANCER RES, V59, P3941; Bailey-Wilson JE, 2004, AM J HUM GENET, V75, P460, DOI 10.1086/423857; BARTLETT C, 2010, J CELL PHYSL; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bourachot B, 2003, EMBO J, V22, P6505, DOI 10.1093/emboj/cdg621; Chen PY, 2005, BIOL CHEM, V386, P1205, DOI 10.1515/BC.2005.139; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fickett JW, 1996, MOL CELL BIOL, V16, P437; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Gaillard H, 2003, J BIOL CHEM, V278, P17655, DOI 10.1074/jbc.M300770200; Gazdar AF, 2010, J NATL CANCER I, V102, P920, DOI 10.1093/jnci/djq220; Girard L, 2000, CANCER RES, V60, P4894; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Gramling S, 2011, ONCOGENE, V30, P3289, DOI 10.1038/onc.2011.80; Gramling S, 2011, LETT DRUG DES DISCOV, V8, P93, DOI 10.2174/157018011793663840; Gregoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882-06; Gunduz E, 2009, CANCER INVEST, V27, P661, DOI 10.1080/07357900802563010; Hill DA, 2004, J CELL BIOCHEM, V91, P987, DOI 10.1002/jcb.20003; Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885; John T, 2009, ONCOGENE, V28, pS14, DOI 10.1038/onc.2009.197; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Landi MT, 2009, AM J HUM GENET, V85, P679, DOI 10.1016/j.ajhg.2009.09.012; Landi MT, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-203; Liu G, 2005, SEMIN RESP CRIT CARE, V26, P265, DOI 10.1055/s-2005-871983; Morrison AJ, 2006, RES PRO CEL, V41, P109, DOI 10.1007/008; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Naidu SR, 2009, ONCOGENE, V28, P2492, DOI 10.1038/onc.2009.121; Oh J, 2008, J BIOL CHEM, V283, P11924, DOI 10.1074/jbc.M705401200; Otsuki T, 2001, HUM MOL GENET, V10, P2651, DOI 10.1093/hmg/10.23.2651; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Park JH, 2009, DNA REPAIR, V8, P29, DOI 10.1016/j.dnarep.2008.08.011; Patrone G, 2000, BIOTECHNIQUES, V29, P1012, DOI 10.2144/00295st02; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reisman DN, 2005, APPL IMMUNOHISTO M M, V13, P66, DOI 10.1097/00129039-200503000-00011; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Sabah M, 2005, VIRCHOWS ARCH, V446, P251, DOI 10.1007/s00428-004-1190-2; Sakurai K, 2011, CANCER RES, V71, P1680, DOI 10.1158/0008-5472.CAN-10-2345; Sarkar S, 2002, J BIOL CHEM, V277, P36585, DOI 10.1074/jbc.M204244200; Solomon B, 2009, J THORAC ONCOL, V4, P1450, DOI 10.1097/JTO.0b013e3181c4dedb; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Tripathi A, 2003, J EXP CLIN CANC RES, V22, P289; Truong T, 2010, JNCI-J NATL CANCER I, V102, P959, DOI 10.1093/jnci/djq178; Wang M, 2007, J BIOCHEM, V142, P613, DOI 10.1093/jb/mvm176; Xu Y, 2007, J BIOL CHEM, V282, P37429, DOI 10.1074/jbc.M706039200; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Yue JM, 2006, CANCER BIOL THER, V5, P573, DOI 10.4161/cbt.5.6.2872	51	40	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	29					3295	3304		10.1038/onc.2011.81	http://dx.doi.org/10.1038/onc.2011.81			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	795VW	21478907	Green Accepted			2022-12-17	WOS:000293006800008
J	Kreis, NN; Sanhaji, M; Kramer, A; Sommer, K; Rodel, F; Strebhardt, K; Yuan, J				Kreis, N. N.; Sanhaji, M.; Kraemer, A.; Sommer, K.; Roedel, F.; Strebhardt, K.; Yuan, J.			Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells	ONCOGENE			English	Article						targeting cyclin B1; p53 stabilization; HPV 16/18; p14ARF and Ser315 phosphorylation of p53	INHIBITS PROLIFERATION; E6; PHOSPHORYLATION; DEGRADATION; ACTIVATION; INCREASES; APOPTOSIS; PROTEIN; MDM2; ARF	Abrogation of functional p53 is responsible for malignant cell transformation and the maintenance of malignant state of human papillomavirus-infected cancer cells. Thus, restoration of p53 has been regarded as an important strategy for molecular intervention combating papillomavirus-associated malignancies. We show here that depleting cyclin B1 stabilizes and reactivates p53 in papillomavirus-infected cervical cancer cell lines HeLa and CaSki. HeLa cells depleted of cyclin B1 exhibit mitotic defects in spindle formation and chromosome alignment. Downregulation of cyclin B1 increases p14 alternative reading frame of p16, the positive regulator of p53, and decreases phosphorylation of Ser315 in p53. Whereas RO-3306, a selective inhibitor of cyclin-dependent kinase 1 (Cdk1), suppresses this phosphorylation at Ser315 of p53, ZM447439, targeting Aurora A/B kinases, shows no effect. Further analyses in HeLa cells and HCT116 p53(-/-) cells suggest that the Ser315 phosphorylation by Cdk1 regulates negatively the protein stability and the function of p53. Moreover, increased p53 in HeLa cells is functional by showing its increased downstream effectors p21, mouse double minute 2 and Bax. Restoration of p53 and silencing cyclin B1 render cervical carcinoma cells more susceptible to DNA damage agent camptothecin. Taken together, targeting cyclin B1 might be an attractive strategy for preventing and treating papillomavirus-associated cancer by reactivating p53 and by reducing the Cdk1 activity. Oncogene (2010) 29, 5591-5603; doi:10.1038/onc.2010.290; published online 26 July 2010	[Kreis, N. N.; Sanhaji, M.; Kraemer, A.; Strebhardt, K.; Yuan, J.] Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, D-60590 Frankfurt, Germany; [Sommer, K.] Goethe Univ Frankfurt, Sch Med, Dept Traumatol & Reconstruct Surg, D-60590 Frankfurt, Germany; [Roedel, F.] Goethe Univ Frankfurt, Sch Med, Dept Radiotherapy & Oncol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt	Yuan, J (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	yuan@em.uni-frankfurt.de	Kreis, Nina-Naomi/AAF-5407-2019; Strebhardt, Klaus/E-8765-2011	Kreis, Nina-Naomi/0000-0003-4304-0160; Strebhardt, Klaus/0000-0003-2173-9763	Deutsche Krebshilfe [107594, 108553]	Deutsche Krebshilfe(Deutsche Krebshilfe)	This work is supported by the Deutsche Krebshilfe (# 107594 and # 108553). We are grateful to Dr B Vogelstein, Ludwig Center at Johns Hopkins, Howard Hughes Medical Institute, Baltimore, for HCT116 p53(+ / +) and p53(- / -) cell lines, and Dr K Hoppe-Seyler, Deutsches Krebsforschungszentrum, Heidelberg, for CaSki cell line. We thank Ms Roth and Ms Zimmer for their excellent technical support.	Androic I, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-391; Aylon Y, 2007, CELL, V130, P597, DOI 10.1016/j.cell.2007.08.005; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; BUTZ K, 1995, ONCOGENE, V10, P927; Cho NH, 2006, CANCER LETT, V232, P170, DOI 10.1016/j.canlet.2005.02.026; Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158/0008-5472.CAN-04-0204; Dickson MA, 2009, CURR ONCOL, V16, P120; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; Gallagher SJ, 2006, INT J BIOCHEM CELL B, V38, P1637, DOI 10.1016/j.biocel.2006.02.008; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Kreis NN, 2009, CELL CYCLE, V8, P460, DOI 10.4161/cc.8.3.7651; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lu WG, 2001, ONCOGENE, V20, P3206, DOI 10.1038/sj.onc.1204412; Pathirana D, 2009, VACCINE, V27, P4551, DOI 10.1016/j.vaccine.2009.03.086; Pluquet O, 2005, MOL CELL BIOL, V25, P9392, DOI 10.1128/MCB.25.21.9392-9405.2005; Radhakrishnan SK, 2006, CELL CYCLE, V5, P519, DOI 10.4161/cc.5.5.2514; Rampias T, 2009, JNCI-J NATL CANCER I, V101, P412, DOI 10.1093/jnci/djp017; Sanhaji M, 2010, MOL CELL BIOL, V30, P2594, DOI 10.1128/MCB.00098-10; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038/sj.onc.1209202; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757; Zhao M., 2006, Experimental Oncology, V28, P44	32	40	40	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	41					5591	5603		10.1038/onc.2010.290	http://dx.doi.org/10.1038/onc.2010.290			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20661218				2022-12-17	WOS:000282946900006
J	Paggetti, J; Largeot, A; Aucagne, R; Jacquel, A; Lagrange, B; Yang, XJ; Solary, E; Bastie, JN; Delva, L				Paggetti, J.; Largeot, A.; Aucagne, R.; Jacquel, A.; Lagrange, B.; Yang, X-J; Solary, E.; Bastie, J-N; Delva, L.			Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+cells	ONCOGENE			English	Article						MOZ; MLL; HOX genes; human CD34+cells	HEMATOPOIETIC STEM-CELLS; ACUTE MYELOID-LEUKEMIA; ZINC-FINGER PROTEIN; HISTONE ACETYLTRANSFERASE COMPLEXES; CREB-BINDING-PROTEIN; HOMEOBOX GENES; TRANSCRIPTIONAL REGULATION; METHYLATION; H3; METHYLTRANSFERASE	MOZ and MLL, encoding a histone acetyltransferase (HAT) and a histone methyltransferase, respectively, are targets for recurrent chromosomal translocations found in acute myeloblastic or lymphoblastic leukemia. In MOZ (MOnocytic leukemia Zinc-finger protein)/CBP- or mixed lineage leukemia (MLL)-rearranged leukemias, abnormal levels of HOX transcription factors have been found to be critical for leukemogenesis. We show that MOZ and MLL cooperate to regulate these key genes in human cord blood CD34+ cells. These chromatin-modifying enzymes interact, colocalize and functionally cooperate, and both are recruited to multiple HOX promoters. We also found that WDR5, an adaptor protein essential for lysine 4 trimethylation of histone H3 (H3K4me3) by MLL, colocalizes and interacts with MOZ. We detected the binding of the HAT MOZ to H3K4me3, thus linking histone methylation to acetylation. In CD34+ cells, depletion of MLL causes release of MOZ from HOX promoters, which is correlated to defective histone activation marks, leading to repression of HOX gene expression and alteration of commitment of CD34+ cells into myeloid progenitors. Thus, our results unveil the role of the interaction between MOZ and MLL in CD34+ cells in which both proteins have a critical role in hematopoietic cell-fate decision, suggesting a new molecular mechanism by which MOZ or MLL deregulation leads to leukemogenesis. Oncogene (2010) 29, 5019-5031; doi:10.1038/onc.2010.254; published online 28 June 2010	[Paggetti, J.; Largeot, A.; Aucagne, R.; Jacquel, A.; Lagrange, B.; Bastie, J-N; Delva, L.] Univ Burgundy, Fac Med, INSERM, UMR 866, Dijon, France; [Yang, X-J] McGill Univ, Dept Med, Ctr Hlth, Montreal, PQ, Canada; [Solary, E.] Inst Gustave Roussy, INSERM, UMR 1009, F-94805 Villejuif, France; [Bastie, J-N] Univ Hosp CHU, Dept Clin Hematol, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; CHU Dijon Bourgogne	Delva, L (corresponding author), Univ Bourgogne, Fac Med, IFR Sante STIC, INSERM,Ctr Rech,UMR 866, 7 Blvd Jeanne dArc, F-21000 Dijon, France.	Laurent.Delva@u-bourgogne.fr	Paggetti, Jerome/I-2786-2019; Jacquel, Arnaud/O-1928-2017; Jacquel, Arnaud/AAJ-4760-2021	Paggetti, Jerome/0000-0001-9460-5876; Jacquel, Arnaud/0000-0001-5062-8048; Jacquel, Arnaud/0000-0001-5062-8048; Aucagne, Romain/0000-0002-5644-3287; Solary, Eric/0000-0002-8629-1341; DELVA, Laurent/0000-0002-1086-3964; Largeot, Anne/0000-0002-9388-8461; Lagrange, Brice/0000-0002-4131-5995	Fondation de France (Leukemia Committee); Ligue contre le Cancer (Cote d'Or committee); Ligue contre le Cancer (Rhone committee); Conseil Regional de Bourgogne (FABER); Faculty of Medicine, Dijon; National Institute of Cancer; Ligue Nationale contre le Cancer; Agence Nationale de la Recherche of France; Canadian Cancer Society; Ministere de l'Enseignement Superieur et de la Recherche of France; Association pour la Recherche sur le Cancer (ARC); Inserm; Region Bourgogne; Ligue contre le Cancer; Saone-et-Loire committee; National committee	Fondation de France (Leukemia Committee)(Fondation de France); Ligue contre le Cancer (Cote d'Or committee); Ligue contre le Cancer (Rhone committee); Conseil Regional de Bourgogne (FABER)(Region Bourgogne-Franche-Comte); Faculty of Medicine, Dijon; National Institute of Cancer; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Agence Nationale de la Recherche of France(French National Research Agency (ANR)); Canadian Cancer Society(Canadian Cancer Society (CCS)); Ministere de l'Enseignement Superieur et de la Recherche of France; Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Region Bourgogne(Region Bourgogne-Franche-Comte); Ligue contre le Cancer(Ligue nationale contre le cancer); Saone-et-Loire committee; National committee	We gratefully acknowledge Amandine Bataille, Amandine Chlemaire and Franck Menetrier for immunocytofluorescence assays; Andre Bouchot for epifluorescence microscopy; and Christine Arnould for confocal analysis (SERCOBIO, Universite de Bourgogne), and the Etablissement Francais du Sang (EFS) of Bourgogne Franche-Comte, which kindly supplied the cord blood buffy coats. We also thank Mustapha Oulad-Abdelghani for producing the anti-MOZ antibody. We thank Robert Slany, Issai Kitabayashi, Paul Shore, Michael Cleary and Edward Chan for providing plasmids. We appreciate the fine work performed by Magali Belt in correction of English text. This work was supported by funds from the Fondation de France (Leukemia Committee to LD), the Ligue contre le Cancer (Cote d'Or committee to LD), the Ligue contre le Cancer (Rhone committee to LD), the Conseil Regional de Bourgogne (FABER to LD), the Faculty of Medicine (to J-NB) in Dijon, the National Institute of Cancer (to ES), the Ligue Nationale contre le Cancer (Label to ES), the Agence Nationale de la Recherche of France (to ES and LD) and the Canadian Cancer Society (to XJY). JP was supported by fellowships from the Ministere de l'Enseignement Superieur et de la Recherche of France and the Association pour la Recherche sur le Cancer (ARC). AL was supported by fellowships from the Inserm and the Region Bourgogne. RA and AJ were supported by fellowships from the Ligue contre le Cancer, Saone-et-Loire committee and national committee, respectively. BL was supported by fellowships from the Ministere de l'Enseignement Superieur et de la Recherche of France.	Argiropoulos B, 2007, ONCOGENE, V26, P6766, DOI 10.1038/sj.onc.1210760; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; BORRESEN B, 1996, P 10 INT S MOLT SALT, V7, P11; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401; Camos M, 2006, CANCER RES, V66, P6947, DOI 10.1158/0008-5472.CAN-05-4601; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Champagne N, 2001, ONCOGENE, V20, P404, DOI 10.1038/sj.onc.1204114; Chan EM, 2007, EXP HEMATOL, V35, P1782, DOI 10.1016/j.exphem.2007.07.015; Crooks GM, 1999, BLOOD, V94, P519, DOI 10.1182/blood.V94.2.519.414k20_519_528; Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Ernst P, 2004, CURR BIOL, V14, P2063, DOI 10.1016/j.cub.2004.11.012; Ernst P, 2001, MOL CELL BIOL, V21, P2249, DOI 10.1128/MCB.21.7.2249-2258.2001; Esteyries S, 2008, LEUKEMIA, V22, P663, DOI 10.1038/sj.leu.2404930; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Guccione E, 2007, NATURE, V449, P933, DOI 10.1038/nature06166; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Huang G, 2008, BLOOD, V112, P110; Huang Y, 2006, SCIENCE, V312, P748, DOI 10.1126/science.1125162; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jude CD, 2007, CELL STEM CELL, V1, P324, DOI 10.1016/j.stem.2007.05.019; Katsumoto T, 2006, GENE DEV, V20, P1321, DOI 10.1101/gad.1393106; Kindle KB, 2005, MOL CELL BIOL, V25, P988, DOI 10.1128/MCB.25.3.988-1002.2005; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; KNITTEL T, 1995, DEVELOPMENT, V121, P1077; Kohlmann A, 2005, LEUKEMIA, V19, P953, DOI 10.1038/sj.leu.2403746; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; McMahon KA, 2007, CELL STEM CELL, V1, P338, DOI 10.1016/j.stem.2007.07.002; Milne TA, 2005, P NATL ACAD SCI USA, V102, P14765, DOI 10.1073/pnas.0503630102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Nabirochkina E, 2002, MECH DEVELOP, V114, P119, DOI 10.1016/S0925-4773(02)00035-7; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Ohta K, 2005, J HEALTH SCI, V51, P253, DOI 10.1248/jhs.51.253; Ohta K, 2007, BIOCHEM J, V402, P559, DOI 10.1042/BJ20061194; Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367; Perez-Campo FM, 2009, BLOOD, V113, P4866, DOI 10.1182/blood-2008-04-152017; Rokudai S, 2009, J BIOL CHEM, V284, P237, DOI 10.1074/jbc.M805101200; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; Sims RJ, 2005, J BIOL CHEM, V280, P41789, DOI 10.1074/jbc.C500395200; Terranova R, 2006, P NATL ACAD SCI USA, V103, P6629, DOI 10.1073/pnas.0507425103; Thomas T, 2006, GENE DEV, V20, P1175, DOI 10.1101/gad.1382606; Tyagi S, 2007, MOL CELL, V27, P107, DOI 10.1016/j.molcel.2007.05.030; Ullah M, 2008, MOL CELL BIOL, V28, P6828, DOI 10.1128/MCB.01297-08; van Oostveen JW, 1999, LEUKEMIA, V13, P1675, DOI 10.1038/sj.leu.2401562; Voss AK, 2009, DEV CELL, V17, P674, DOI 10.1016/j.devcel.2009.10.006; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Yang XJ, 2007, ONCOGENE, V26, P5408, DOI 10.1038/sj.onc.1210609; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	62	40	40	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	36					5019	5031		10.1038/onc.2010.254	http://dx.doi.org/10.1038/onc.2010.254			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20581860				2022-12-17	WOS:000281620100003
J	Grzmil, M; Rzymski, T; Milani, M; Harris, AL; Capper, RG; Saunders, NJ; Salhan, A; Ragoussis, J; Norbury, CJ				Grzmil, M.; Rzymski, T.; Milani, M.; Harris, A. L.; Capper, R. G.; Saunders, N. J.; Salhan, A.; Ragoussis, J.; Norbury, C. J.			An oncogenic role of eIF3e/INT6 in human breast cancer	ONCOGENE			English	Article						MAD2L1; BCL-XL; PLAU; urokinase-type plasminogen activator; breast cancer	INITIATION-FACTOR EIF3; MAMMARY-TUMOR VIRUS; TRANSLATION INITIATION; MESSENGER-RNA; FISSION YEAST; SUBCELLULAR-LOCALIZATION; MALIGNANT-TRANSFORMATION; PROTEIN-SYNTHESIS; CELL-GROWTH; INT6	Altered expression of the eukaryotic translation initiation factor 3 (eIF3) subunit eIF3e/INT6 has been described in various types of human cancer, but the nature of its involvement in tumorigenesis is not yet clear. Using immunohistochemical analysis of 81 primary breast cancers, we found that high tumor grade correlated significantly with elevated cytoplasmic eIF3e level in epithelial tumor cells. Analysis of protein synthesis after siRNA-mediated knockdown in breast cancer cell lines indicated that eIF3e is not required for bulk translation. Microarray analysis of total and polysomal RNAs nonetheless identified distinct sets of mRNAs regulated either positively or negatively by eIF3e; functional classification of these revealed a marked enrichment of genes involved in cell proliferation, invasion and apoptosis. Validated mRNA targets regulated positively at the translational level by eIF3e included urokinase-type plasminogen activator and apoptotic regulator BCL-XL, whereas synthesis of proteins including the mitotic checkpoint component MAD2L1 was negatively regulated. Finally, eIF3e-depleted breast carcinoma cells showed reduced in vitro invasion and proliferation. Taken together, our study data suggest that eIF3e has a positive role in breast cancer progression. It regulates the translation, and in some cases abundance, of mRNAs involved in key aspects of cancer cell biology. Oncogene (2010) 29, 4080-4089; doi:10.1038/onc.2010.152; published online 10 May 2010	[Grzmil, M.; Capper, R. G.; Saunders, N. J.; Norbury, C. J.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; [Rzymski, T.; Milani, M.; Harris, A. L.] Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, Oxford OX1 3RE, England; [Salhan, A.; Ragoussis, J.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 3RE, England	University of Oxford; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics	Norbury, CJ (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	chris.norbury@path.ox.ac.uk	Ragoussis, Ioannis/AAD-9790-2022; Saunders, Nigel J/W-6745-2019; Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409; Grzmil, Michal/0000-0002-7866-8145; Saunders, Nigel/0000-0002-0160-4573; Ragoussis, Ioannis/0000-0002-8515-0934	Cancer Research UK; Association for International Cancer Research; Wellcome Trust [075491/Z/04]	Cancer Research UK(Cancer Research UK); Association for International Cancer Research; Wellcome Trust(Wellcome TrustEuropean Commission)	We thank Ben Thomas and Sasha Akoulitchev for help and advice with 2D liquid chromatography, Cheng Han for help with the statistical analysis, Dan Scott and other members of the laboratory for their comments on the article. This work was supported by Cancer Research UK, the Association for International Cancer Research and the Wellcome Trust (through grant 075491/Z/04 to JR).	Ahlemann M, 2006, MOL CARCINOGEN, V45, P957, DOI 10.1002/mc.20269; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; BENNE R, 1978, J BIOL CHEM, V253, P3078; Bramham CR, 2007, NAT REV NEUROSCI, V8, P776, DOI 10.1038/nrn2150; Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893; Buchsbaum S, 2007, ONCOGENE, V26, P5132, DOI 10.1038/sj.onc.1210314; Buratti E, 1998, NUCLEIC ACIDS RES, V26, P3179, DOI 10.1093/nar/26.13.3179; Buttitta F, 2005, CLIN CANCER RES, V11, P3198, DOI 10.1158/1078-0432.CCR-04-2308; Chen L, 2007, J BIOL CHEM, V282, P12707, DOI 10.1074/jbc.M700423200; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; De Quinto SL, 2001, RNA, V7, P1213, DOI 10.1017/S1355838201010433; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dong ZZ, 2006, CRIT REV ONCOL HEMAT, V59, P169, DOI 10.1016/j.critrevonc.2006.03.005; Grzmil M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000959; Han B, 2005, ONCOL REP, V14, P105; Hinnebusch AG, 2006, TRENDS BIOCHEM SCI, V31, P553, DOI 10.1016/j.tibs.2006.08.005; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Jivotovskaya AV, 2006, MOL CELL BIOL, V26, P1355, DOI 10.1128/MCB.26.4.1355-1372.2006; Mack DL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1742; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marchetti A, 2001, INT J ONCOL, V18, P175; Mavrakis KJ, 2008, CELL CYCLE, V7, P2791, DOI 10.4161/cc.7.18.6683; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; MERRICK WC, 1979, J BIOL CHEM, V254, P3708; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Miyazaki S, 1997, GENOMICS, V46, P155, DOI 10.1006/geno.1997.4996; Morris C, 2005, ONCOGENE, V24, P1203, DOI 10.1038/sj.onc.1208268; Paquin N, 2008, TRENDS CELL BIOL, V18, P105, DOI 10.1016/j.tcb.2007.12.004; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; Rencus-Lazar S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002239; Saal LH, 2002, GENOME BIOL, V3; Savinainen KJ, 2006, PROSTATE, V66, P1144, DOI 10.1002/pros.20452; Siridechadilok B, 2005, SCIENCE, V310, P1513, DOI 10.1126/science.1118977; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Thumma SC, 2007, CANCER LETT, V258, P1, DOI 10.1016/j.canlet.2007.08.022; Traicoff JL, 2007, J BIOMED SCI, V14, P395, DOI 10.1007/s11373-007-9149-3; Udagawa T, 2008, J BIOL CHEM, V283, P22063, DOI 10.1074/jbc.M710017200; von Arnim AG, 2003, CURR BIOL, V13, pR323, DOI 10.1016/S0960-9822(03)00238-0; Watkins SJ, 2004, CELL PROLIFERAT, V37, P149, DOI 10.1111/j.1365-2184.2004.00305.x; Watkins SJ, 2002, BRIT J CANCER, V86, P1023, DOI 10.1038/sj/bjc/6600222; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Winters ZE, 2001, EUR J CANCER, V37, P2405, DOI 10.1016/S0959-8049(01)00327-6; Yen HCS, 2003, CELL, V112, P207, DOI 10.1016/S0092-8674(03)00043-6; Zhang LL, 2007, J BIOL CHEM, V282, P5790, DOI 10.1074/jbc.M606284200; Zhou CS, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-14	47	40	44	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2010	29	28					4080	4089		10.1038/onc.2010.152	http://dx.doi.org/10.1038/onc.2010.152			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20453879				2022-12-17	WOS:000279892400008
J	Mittendorf, EA; Liu, Y; Tucker, SL; McKenzie, T; Qiao, N; Akli, S; Biernacka, A; Liu, Y; Meijer, L; Keyomarsi, K; Hunt, KK				Mittendorf, E. A.; Liu, Y.; Tucker, S. L.; McKenzie, T.; Qiao, N.; Akli, S.; Biernacka, A.; Liu, Y.; Meijer, L.; Keyomarsi, K.; Hunt, K. K.			A novel interaction between HER2/neu and cyclin E in breast cancer	ONCOGENE			English	Article						breast cancer; HER2/neu; cell cycle regulation; cyclin E	MOLECULAR-WEIGHT FORMS; RECEPTOR STATUS; EXPRESSION; OVEREXPRESSION; AMPLIFICATION; TRASTUZUMAB; INHIBITION; HER-2/NEU; C-ERBB-2; ANTIBODY	HER2/neu (HER2) and cyclin E are important prognostic indicators in breast cancer. As both are involved in cell cycle regulation we analyzed whether there was a direct interaction between the two. HER2 and cyclin E expression levels were determined in 395 breast cancer patients. Patients with HER2-overexpression and high levels of cyclin E had decreased 5-year disease-specific survival compared with low levels of cyclin E (14% versus 89%, P < 0.0001). In vitro studies were performed in which HER2-mediated activity in HER2-overexpressing breast cancer cell lines was downregulated by transfection with HER2 small interfering RNA or treatment with trastuzumab. Cyclin E expression levels were determined by western blot analysis, and functional effects analyzed using kinase assays, MTT assays were used to assess cell viability as a marker of proliferation and fluorescence-activated cell sorting analysis was used to determine cell cycle profiles. Decreased HER2-mediated signaling resulted in decreased expression of cyclin E, particularly the low molecular weight (LMW) isoforms. Decreased HER2 and LMW cyclin E expression had functional consequences, including decreased cyclin E-associated kinase activity and decreased proliferation, because of increased apoptosis and an increased accumulation of cells in the G1 phase. In vivo studies performed in a HER2-overexpressing breast cancer xenograft model confirmed the effects of trastuzumab on cyclin E expression. Given the relationship between HER2 and cyclin E, in vitro clonogenic assays were performed to assess combination therapy targeting both proteins. Isobologram analysis showed a synergistic interaction between the two agents (trastuzumab targeting HER2 and roscovitine targeting cyclin E). Taken together, these studies show that HER2-mediated signaling effects LMW cyclin E expression, which in turn deregulates the cell cycle. LMW cyclin E has prognostic and predictive roles in HER2-overexpressing breast cancer, warranting further study of its potential as a therapeutic target. Oncogene (2010) 29, 3896-3907; doi:10.1038/onc.2010.151; published online 10 May 2010	[Hunt, K. K.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Unit 444, Houston, TX 77030 USA; [Tucker, S. L.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat, Houston, TX 77030 USA; [Tucker, S. L.] Univ Texas MD Anderson Canc Ctr, Dept Computat Biol, Houston, TX 77030 USA; [Akli, S.; Biernacka, A.; Liu, Y.; Keyomarsi, K.; Hunt, K. K.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Meijer, L.] CNRS, Biol Stn, Roscoff, France	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Centre National de la Recherche Scientifique (CNRS)	Hunt, KK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Unit 444, 1515 Holcombe Blvd, Houston, TX 77030 USA.	kkeyomar@mdanderson.org; khunt@mdanderson.org	Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849; , laurent/0000-0003-3511-4916	NIH [T32 CA009599, CA87458, 1K99CA133244-01]; AACR; Susan G Komen for the Cure [PDF0707621]; Clayton Foundation for Research; NCI [P50CA116199]; Susan G Komen Breast Cancer Foundation [BCTR0504200]; NATIONAL CANCER INSTITUTE [R01CA087548, R01CA152228, K99CA133244, T32CA009599, P50CA116199] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AACR; Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); Clayton Foundation for Research; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH T32 CA009599 (Mittendorf); AACR (Mittendorf); Susan G Komen for the Cure PDF0707621 (Keyomarsi and Mittendorf); Clayton Foundation for Research (Keyomarsi); NIH CA87458 (Keyomarsi); NCI P50CA116199 (Keyomarsi); Susan G Komen Breast Cancer Foundation BCTR0504200 (Hunt) and NIH 1K99CA133244-01 (Mittendorf).	Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Akli S, 2003, CANCER BIOL THER, V2, pS38; Akli S, 2007, CANCER RES, V67, P7212, DOI 10.1158/0008-5472.CAN-07-0599; BACUS SS, 1992, CANCER RES, V52, P2580; Brockhoff G, 2007, CELL PROLIFERAT, V40, P488, DOI 10.1111/j.1365-2184.2007.00449.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; Harwell RM, 2000, CANCER RES, V60, P481; KEYOMARSI K, 1994, CANCER RES, V54, P380; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Lambert LA, 2008, CANCER RES, V68, P7966, DOI 10.1158/0008-5472.CAN-08-1333; Le XF, 2006, CELL CYCLE, V5, P1654, DOI 10.4161/cc.5.15.3007; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; MCCANN AH, 1991, CANCER RES, V51, P3296; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Potemski P, 2006, J EXP CLIN CANC RES, V25, P59; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Roh H, 2000, CANCER RES, V60, P560; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Timms JF, 2002, ONCOGENE, V21, P6573, DOI 10.1038/sj.onc.1205847; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wingate H, 2005, J BIOL CHEM, V280, P15148, DOI 10.1074/jbc.M409789200; WRIGHT C, 1989, CANCER RES, V49, P2087; Yakes FM, 2002, CANCER RES, V62, P4132; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	36	40	45	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2010	29	27					3896	3907		10.1038/onc.2010.151	http://dx.doi.org/10.1038/onc.2010.151			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20453888	Green Accepted			2022-12-17	WOS:000279603200003
J	van Dieck, J; Brandt, T; Teufel, DP; Veprintsev, DB; Joerger, AC; Fersht, AR				van Dieck, J.; Brandt, T.; Teufel, D. P.; Veprintsev, D. B.; Joerger, A. C.; Fersht, A. R.			Molecular basis of S100 proteins interacting with the p53 homologs p63 and p73	ONCOGENE			English	Article						S100; p63; p73; tumor suppressor; protein-protein interaction	SQUAMOUS-CELL CARCINOMA; CALCIUM-BINDING PROTEIN; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVITY; DNA-BINDING; KINASE-C; FAMILY; CANCER; EXPRESSION; GENE	S100 proteins modulate p53 activity by interacting with its tetramerization (p53TET, residues 325-355) and transactivation (residues 1-57) domains. In this study, we characterized biophysically the binding of S100A1, S100A2, S100A4, S100A6 and S100B to homologous domains of p63 and p73 in vitro by fluorescence anisotropy, analytical ultracentrifugation and analytical gel filtration. We found that S100A1, S100A2, S100A4, S100A6 and S100B proteins bound different p63 and p73 tetramerization domain variants and naturally occurring isoforms with varying affinities in a calcium-dependent manner. Additional interactions were observed with peptides derived from the p63 and p73 N-terminal transactivation domains. Importantly, S100 proteins bound p63 and p73 with different affinities in their different oligomeric states, similarly to the differential modes of binding to p53. On the basis of our data, we hypothesize that S100 proteins regulate the oligomerization state of all three p53 family members and their isoforms, with a potential physiological relevance in developmental and disease-related processes. The regulation of the p53 family by S100 is complicated and depends on the target preference of each individual S100 protein, the concentration of the proteins and calcium, as well as the splicing variation of p63 or p73. Our results outlining the complexity of the interaction should be considered when studying the functional effects of S100 proteins in their biological context. Oncogene (2010) 29, 2024-2035; doi: 10.1038/onc.2009.490; published online 8 February 2010	[van Dieck, J.; Brandt, T.; Teufel, D. P.; Veprintsev, D. B.; Joerger, A. C.; Fersht, A. R.] Univ Cambridge, MRC Ctr Prot Engn, Cambridge CB2 0QH, Cambs, England	MRC Laboratory Molecular Biology; University of Cambridge	Fersht, AR (corresponding author), Univ Cambridge, MRC Ctr Prot Engn, Hills Rd, Cambridge CB2 0QH, Cambs, England.	arf25@cam.ac.uk	Veprintsev, Dmitry B/H-2228-2012; Fersht, Alan R/B-2189-2008	Veprintsev, Dmitry B/0000-0002-3583-5409; Teufel, Daniel/0000-0002-6527-2117; Joerger, Andreas/0000-0002-1232-0138	Medical Research Council [MC_U105474168] Funding Source: Medline; MRC [MC_U105474168] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Boldrup L, 2009, J PATHOL, V218, P428, DOI 10.1002/path.2560; Brandt T, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-628; Buckiova D, 2009, J COMP NEUROL, V513, P469, DOI 10.1002/cne.21967; Burge S, 2009, P NATL ACAD SCI USA, V106, P3142, DOI 10.1073/pnas.0900383106; Chan WY, 2003, MICROSC RES TECHNIQ, V60, P600, DOI 10.1002/jemt.10302; Danilova N, 2008, MECH DEVELOP, V125, P919, DOI 10.1016/j.mod.2008.09.003; Dean B, 2006, AUST NZ J PSYCHIAT, V40, P217, DOI 10.1080/j.1440-1614.2006.01777.x; DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Dotto JE, 2006, J CUTAN PATHOL, V33, P413, DOI 10.1111/j.0303-6987.2006.00477.x; FANO G, 1995, PROG NEUROBIOL, V46, P71, DOI 10.1016/0301-0082(94)00062-M; Fernandez-Fernandez MR, 2008, PROTEIN SCI, V17, P1663, DOI 10.1110/ps.035527.108; Fernandez-Fernandez MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI 10.1073/pnas.0501459102; Finlan LE, 2007, CELL CYCLE, V6, P1062, DOI 10.4161/cc.6.9.4162; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; Joerger AC, 2007, ONCOGENE, V26, P2226, DOI 10.1038/sj.onc.1210291; Joerger AC, 2009, P NATL ACAD SCI USA, V106, P17705, DOI 10.1073/pnas.0905867106; Kirschner RD, 2008, NUCLEIC ACIDS RES, V36, P2969, DOI 10.1093/nar/gkn132; Langenbacher A, 2008, DEV DYNAM, V237, P3491, DOI 10.1002/dvdy.21704; Lapi E, 2006, ONCOGENE, V25, P3628, DOI 10.1038/sj.onc.1209401; Lauriola L, 2000, INT J CANCER, V89, P345, DOI 10.1002/1097-0215(20000720)89:4<345::AID-IJC5>3.0.CO;2-T; Lin J, 2004, J BIOL CHEM, V279, P34071, DOI 10.1074/jbc.M405419200; Lin J, 2001, J BIOL CHEM, V276, P35037, DOI 10.1074/jbc.M104379200; MacGregor IK, 2004, BIOPHYS CHEM, V108, P165, DOI 10.1016/j.bpc.2003.10.018; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moll UM, 2004, MOL CANCER RES, V2, P371; Mrak RE, 2001, NEUROBIOL AGING, V22, P915, DOI 10.1016/S0197-4580(01)00293-7; Mueller A, 2005, J BIOL CHEM, V280, P29186, DOI 10.1074/jbc.M505000200; Pelosi G, 2002, J PATHOL, V198, P100, DOI 10.1002/path.1166; Pruneri G, 2002, LAB INVEST, V82, P1327, DOI 10.1097/01.LAB.0000032373.99569.73; Rajagopalan S, 2008, NUCLEIC ACIDS RES, V36, P5983, DOI 10.1093/nar/gkn598; Rosenbluth JM, 2008, GENE DEV, V22, P2591, DOI 10.1101/gad.1727408; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Salama I, 2008, EJSO-EUR J SURG ONC, V34, P357, DOI 10.1016/j.ejso.2007.04.009; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; Scotto C, 1999, MOL CELL BIOL, V19, P7168; Scoumanne A, 2005, CANCER BIOL THER, V4, P1178, DOI 10.4161/cbt.4.11.2254; Sedaghat F, 2008, HIPPOKRATIA, V12, P198; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Slomnicki LP, 2009, INT J BIOCHEM CELL B, V41, P784, DOI 10.1016/j.biocel.2008.08.007; Teufel DP, 2007, P NATL ACAD SCI USA, V104, P7009, DOI 10.1073/pnas.0702010104; van Dieck J, 2009, J BIOL CHEM, V284, P13804, DOI 10.1074/jbc.M901351200; Vigliano FA, 2009, FISH SHELLFISH IMMUN, V26, P146, DOI 10.1016/j.fsi.2008.02.016; Vilgelm A, 2008, DRUG RESIST UPDATE, V11, P152, DOI 10.1016/j.drup.2008.08.001; Whitaker M, 2008, PHILOS T R SOC B, V363, P1401, DOI 10.1098/rstb.2008.2259; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2; Zimmer DB, 2003, MICROSC RES TECHNIQ, V60, P552, DOI 10.1002/jemt.10297	56	40	40	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	2010	29	14					2024	2035		10.1038/onc.2009.490	http://dx.doi.org/10.1038/onc.2009.490			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20140014	Bronze			2022-12-17	WOS:000276402800002
J	Puri, C; Chibalina, MV; Arden, SD; Kruppa, AJ; Kendrick-Jones, J; Buss, F				Puri, C.; Chibalina, M. V.; Arden, S. D.; Kruppa, A. J.; Kendrick-Jones, J.; Buss, F.			Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis	ONCOGENE			English	Article						myosin VI; prostate cancer; PSA; VEGF	EPITHELIAL-MESENCHYMAL TRANSITION; UNCONVENTIONAL MYOSIN; MEDIATED ENDOCYTOSIS; SERINE PROTEASES; GOLGI-COMPLEX; MDCK CELLS; E-CADHERIN; PROTEIN; DISABLED-2; MEMBRANE	Tissue expression microarrays, employed to determine the players and mechanisms leading to prostate cancer development, have consistently shown that myosin VI, a unique actin-based motor, is upregulated in medium-grade human prostate cancers. Thus, to understand the role of myosin VI in prostate cancer development, we have characterized its intracellular localization and function in the prostate cancer cell line LNCaP. Using light and electron microscopy, we identified myosin VI on Rab5-positive early endosomes, as well as on recycling endosomes and the trans-Golgi network. Intracellular targeting seems to involve two myosin VI-interacting proteins, GIPC and LMTK2, both of which can be co-immunoprecipitated with myosin VI from LNCaP cells. The absence of Disabled-2 (Dab2), a tumour suppressor and myosin VI-binding partner, inhibits recruitment of myosin VI to endocytic structures at the plasma membrane in LNCaP cells, but interestingly has no effect on endocytosis. Small interfering RNA-mediated down-regulation of myosin VI expression results in a significant reduction in prostate-specific antigen (PSA) and vascular endothelial growth factor (VEGF) secretion in LNCaP cells. Our results suggest that in prostate cancer cells, myosin VI regulates protein secretion, but the overexpression of myosin VI has no major impact on clathrin-mediated endocytosis. Oncogene (2010) 29, 188-200; doi:10.1038/onc.2009.328; published online 26 October 2009	[Puri, C.; Chibalina, M. V.; Arden, S. D.; Kruppa, A. J.; Buss, F.] Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England; [Kendrick-Jones, J.] MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Cambridge; MRC Laboratory Molecular Biology	Buss, F (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	fb1@mole.bio.cam.ac.uk		Buss, Folma/0000-0003-4457-3479	Cancer Research UK; Wellcome Trust; Medical Research Council; MRC [MC_U105184323] Funding Source: UKRI; Medical Research Council [MC_U105184323] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank A Peden for help with transferrin uptake assays and JP Luzio for helpful discussions. This work was funded by the Cancer Research UK project grant (CP), the Wellcome Trust Senior Fellowship (to FB), the Wellcome Trust PhD studentship (AJK) and was supported by the Medical Research Council. CIMR is in receipt of a strategic award from the Wellcome Trust.	Ameen N, 2007, TRAFFIC, V8, P998, DOI 10.1111/j.1600-0854.2007.00587.x; Ang AL, 2004, J CELL BIOL, V167, P531, DOI 10.1083/jcb.200408165; Aschenbrenner L, 2003, MOL BIOL CELL, V14, P2728, DOI 10.1091/mbc.E02-11-0767; Au JSY, 2007, J CELL BIOL, V177, P103, DOI 10.1083/jcb.200608126; Balk SP, 2003, J CLIN ONCOL, V21, P383, DOI 10.1200/JCO.2003.02.083; Borgono CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474; Bunn RC, 1999, MOL BIOL CELL, V10, P819, DOI 10.1091/mbc.10.4.819; Buss F, 2001, EMBO J, V20, P3676, DOI 10.1093/emboj/20.14.3676; Buss F, 1998, J CELL BIOL, V143, P1535, DOI 10.1083/jcb.143.6.1535; Buss F, 2008, BIOCHEM BIOPH RES CO, V369, P165, DOI 10.1016/j.bbrc.2007.11.150; Chibalina MV, 2007, J CELL SCI, V120, P4278, DOI 10.1242/jcs.014217; Clements JA, 2004, CRIT REV CL LAB SCI, V41, P265, DOI 10.1080/10408360490471931; Dance AL, 2004, TRAFFIC, V5, P798, DOI 10.1111/j.1600-0854.2004.00224.x; Dunn TA, 2006, AM J PATHOL, V169, P1843, DOI 10.2353/ajpath.2006.060316; Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Geisbrecht ER, 2002, NAT CELL BIOL, V4, P616, DOI 10.1038/ncb830; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; KELLERMAN KA, 1992, J CELL BIOL, V119, P823, DOI 10.1083/jcb.119.4.823; Lawrence MG, 2007, CELLS TISSUES ORGANS, V185, P111, DOI 10.1159/000101311; Maddugoda MP, 2007, J CELL BIOL, V178, P529, DOI 10.1083/jcb.200612042; Martin DB, 2004, CANCER RES, V64, P347, DOI 10.1158/0008-5472.CAN-03-2062; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Morriswood B, 2007, J CELL SCI, V120, P2574, DOI 10.1242/jcs.007005; Peden AA, 2004, MOL BIOL CELL, V15, P3530, DOI 10.1091/mbc.E03-12-0918; Puri C, 2005, MOL BIOL CELL, V16, P2704, DOI 10.1091/mbc.E04-07-0596; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; Sahlender DA, 2005, J CELL BIOL, V169, P285, DOI 10.1083/jcb.200501162; Schwahn DJ, 1998, ONCOGENE, V17, P1173, DOI 10.1038/sj.onc.1202038; Spudich G, 2007, NAT CELL BIOL, V9, P176, DOI 10.1038/ncb1531; Su AI, 2001, CANCER RES, V61, P7388; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; Veveris-Lowe TL, 2005, ENDOCR-RELAT CANCER, V12, P631, DOI 10.1677/erc.1.00958; Warner CL, 2003, EMBO J, V22, P569, DOI 10.1093/emboj/cdg055; Wei SZ, 2008, PROSTATE, V68, P1387, DOI 10.1002/pros.20806; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Whitbread AK, 2006, BIOL CHEM, V387, P707, DOI 10.1515/BC.2006.089; Yoshida H, 2004, P NATL ACAD SCI USA, V101, P8144, DOI 10.1073/pnas.0400400101	41	40	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	2010	29	2					188	200		10.1038/onc.2009.328	http://dx.doi.org/10.1038/onc.2009.328			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19855435	Green Accepted, Green Submitted			2022-12-17	WOS:000273650000003
J	Vlachos, P; Joseph, B				Vlachos, P.; Joseph, B.			The Cdk inhibitor p57(Kip2) controls LIM-kinase 1 activity and regulates actin cytoskeleton dynamics	ONCOGENE			English	Article						p57(Kip2); LIMK-1; actin cytoskeleton dynamic; cell mobility	CELL-MIGRATION; PROTEIN-KINASE; PROSTATE-CANCER; FOCAL ADHESIONS; DOWN-REGULATION; STRESS FIBERS; EXPRESSION; PHOSPHORYLATION; ACTIVATION; COFILIN	The cyclin-dependent kinase inhibitor p57(Kip2) gene has been suggested to be a tumor suppressor gene, being inactivated in various cancer types, linked to tumor progression and poor patient outcome. Here, we report that p57(Kip2) interacts with the actin cytoskeleton modifying enzyme, LIM-kinase 1 (LIMK-1) but not LIMK-2. This interaction enhances activity of LIMK-1, independently of its activator Rho-associated kinase. This resulted in an increased phosphorylation and consequent inactivation of the actin depolymerization factor, cofilin. In accordance, selective p57(Kip2) expression promotes actin stress fiber formation in cancer cells. Fluorescence recovery after photobleaching analysis of fluorescent-labeled actin further demonstrated that p57(Kip2) expression results in reduction of actin protein mobile fraction, which affects its turnover rate in cell. Finally, we present evidence that the p57(Kip2) control of LIMK-1 ultimately affects cell mobility negatively. Thus, in addition to its established function in control of proliferation and cell death, these results indicate that p57(Kip2) is critical in the regulation of actin cytoskeleton dynamic and by this means migration ability of cancer cells. Oncogene (2009) 28, 4175-4188; doi: 10.1038/onc.2009.269; published online 7 September 2009	[Vlachos, P.; Joseph, B.] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, S-17176 Stockholm, Sweden	Karolinska Institutet	Joseph, B (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, R8-03, S-17176 Stockholm, Sweden.	Bertrand.Joseph@ki.se			Swedish Research Council; Swedish Cancer Society; Ake Wiberg Foundation; Swedish Medical Society; Karolinska Institutet Foundations (KI Cancer)	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Ake Wiberg Foundation; Swedish Medical Society; Karolinska Institutet Foundations (KI Cancer)(Karolinska Institutet)	We thank Dr Y Xiong (University of North Carolina, USA), Dr S Leibovitch (Centre National de la Recherche Scientifique, France), Dr K Mizuno (Tohoku University, Japan), Dr H Toyoshima (Tsukuba University, Japan), Dr P Hotulainen (University of Helsinki, Finland) and Dr S Okret (Karolinska Institute) for providing us with different DNA constructs and HeLa cell line, respectively. This work was supported by the Swedish Research Council, the Swedish Cancer Society, the Ake Wiberg Foundation, the Swedish Medical Society and the Karolinska Institutet Foundations (KI Cancer).	Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Barbe L, 2008, MOL CELL PROTEOMICS, V7, P499, DOI 10.1074/mcp.M700325-MCP200; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Bozidogan O, 2008, TUMORI J, V94, P556; Chim CS, 2005, AM J HEMATOL, V80, P282, DOI 10.1002/ajh.20503; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Davila M, 2003, J BIOL CHEM, V278, P36868, DOI 10.1074/jbc.M306196200; Denicourt C, 2004, GENE DEV, V18, P851, DOI 10.1101/gad.1205304; Dyer MA, 2000, DEVELOPMENT, V127, P3593; Fan GK, 2006, ACTA OTO-LARYNGOL, V126, P301, DOI 10.1080/00016480500388851; Gonzalez S, 2005, CANCER RES, V65, P2186, DOI 10.1158/0008-5472.CAN-04-3047; Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555; Itoh Y, 2007, J BIOL CHEM, V282, P390, DOI 10.1074/jbc.M609944200; Jia JL, 2007, MOL CELL BIOL, V27, P7236, DOI 10.1128/MCB.00780-07; Jin RJ, 2008, CANCER RES, V68, P3601, DOI 10.1158/0008-5472.CAN-08-0073; Joseph B, 2003, P NATL ACAD SCI USA, V100, P15619, DOI 10.1073/pnas.2635658100; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; JOSEPH B, 2009, CELL DEATH IN PRESS; Kobatake T, 2004, ONCOL REP, V12, P1087; Kobayashi M, 2006, EMBO J, V25, P713, DOI 10.1038/sj.emboj.7600973; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Li JQ, 2003, INT J ONCOL, V23, P1537; Matsumoto M, 2000, ANTICANCER RES, V20, P1947; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; MIZUNO K, 1994, ONCOGENE, V9, P1605; Nakai S, 2002, INT J ONCOL, V20, P769; Nan KJ, 2005, WORLD J GASTROENTERO, V11, P1237, DOI 10.3748/wjg.v11.i8.1237; NUNOUE K, 1995, ONCOGENE, V11, P701; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Pateras IS, 2006, INT J CANCER, V119, P2546, DOI 10.1002/ijc.22214; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sakai K, 2004, J NEURO-ONCOL, V68, P217, DOI 10.1023/B:NEON.0000033380.08940.c8; Samuelsson MKR, 2002, BIOCHEM BIOPH RES CO, V296, P702, DOI 10.1016/S0006-291X(02)00912-9; Shin JY, 2000, EXP MOL MED, V32, P79, DOI 10.1038/emm.2000.14; Sidani M, 2007, J CELL BIOL, V179, P777, DOI 10.1083/jcb.200707009; Sui L, 2002, ANTICANCER RES, V22, P3191; Sumi T, 2006, EXP CELL RES, V312, P1021, DOI 10.1016/j.yexcr.2005.12.030; Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Vlachos P, 2007, CELL DEATH DIFFER, V14, P1497, DOI 10.1038/sj.cdd.4402158; Wang W, 2006, J CELL BIOL, V173, P395, DOI 10.1083/jcb.200510115; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yokoo T, 2003, J BIOL CHEM, V278, P52919, DOI 10.1074/jbc.M309334200; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100; Zebda N, 2000, J CELL BIOL, V151, P1119, DOI 10.1083/jcb.151.5.1119; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	51	40	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2009	28	47					4175	4188		10.1038/onc.2009.269	http://dx.doi.org/10.1038/onc.2009.269			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DQ	19734939				2022-12-17	WOS:000272876100004
J	Foltz, G; Yoon, JG; Lee, H; Ryken, TC; Sibenaller, Z; Ehrich, M; Hood, L; Madan, A				Foltz, G.; Yoon, J-G; Lee, H.; Ryken, T. C.; Sibenaller, Z.; Ehrich, M.; Hood, L.; Madan, A.			DNA methyltransferase-mediated transcriptional silencing in malignant glioma: a combined whole-genome microarray and promoter array analysis	ONCOGENE			English	Article						epigenetics; histone modifications; methylation; glioblastoma	TUMOR-SUPPRESSOR GENES; CANCER-CELL-LINES; COLON-CARCINOMA CELLS; POLYMERASE-CHAIN-REACTION; DOWN-REGULATION; BRAIN-TUMORS; SYNDECAN-2 EXPRESSION; TUMORIGENIC ACTIVITY; COLORECTAL-CANCER; INITIATING CELLS	Epigenetic inactivation of tumor suppressor genes is a common feature in human cancer. Promoter hypermethylation and histone deacetylation are reversible epigenetic mechanisms associated with transcriptional regulation. DNA methyltransferases (DNMT1 and DNMT3b) regulate and maintain promoter methylation and are over-expressed in human cancer. We performed whole-genome microarray analysis to identify genes with altered expression after RNAi-induced suppression of DNMT in a glioblastoma multiforme (GBM) cell line. We then identified genes with both decreased expression and evidence of promoter CpG island hypermethylation in GBM tissue samples using a combined whole-genome microarray transcriptome analysis in conjunction with a promoter array analysis after DNA immunoprecipitation with anti-5-methylcytidine. DNMT1 and 3b knockdown resulted in the restored expression of 308 genes that also contained promoter region hypermethylation. Of these, 43 were also found to be downregulated in GBM tissue samples. Three downregulated genes with hypermethylated promoters and restored expression in response to acute DNMT suppression were assayed for methylation changes using bisulfite sequence analysis of the promoter region after chronic DNMT suppression. Restoration of gene expression was not associated with changes in promoter region methylation, but rather with changes in histone methylation and chromatin conformation. Two of the identified genes exhibited growth suppressive activity in in vitro assays. Combining targeted genetic manipulations with comprehensive genomic and expression analyses provides a potentially powerful new approach for identifying epigenetically regulated genes in GBM. Oncogene (2009) 28, 2667-2677; doi: 10.1038/onc.2009.122; published online 25 May 2009	[Foltz, G.; Yoon, J-G; Lee, H.; Madan, A.] Swedish Neurosci Inst, Ctr Adv Brain Tumor Treatment, Seattle, WA 98122 USA; [Foltz, G.; Hood, L.; Madan, A.] Inst Syst Biol, Seattle, WA USA; [Ryken, T. C.; Sibenaller, Z.] Univ Iowa, Dept Neurosurg, Iowa City, IA USA; [Ehrich, M.] Sequenome Inc, San Diego, CA USA	Swedish Medical Center; Institute for Systems Biology (ISB); University of Iowa; Sequenom	Madan, A (corresponding author), Swedish Neurosci Inst, Ctr Adv Brain Tumor Treatment, James Tower Suite 570,500 17th Ave, Seattle, WA 98122 USA.	anup.madan@swedish.org						Abdullah JM, 2007, NEUROL RES, V29, P239, DOI 10.1179/016164107X158965; Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284; Arai E, 2006, INT J CANCER, V119, P288, DOI 10.1002/ijc.21807; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Calvanese V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003294; Chen WY, 2005, CELL CYCLE, V4, P10, DOI 10.4161/cc.4.1.1361; Choe G, 2003, CANCER RES, V63, P2742; Costello JF, 1996, CANCER RES, V56, P2405; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dahl C, 2007, APMIS, V115, P1161, DOI 10.1111/j.1600-0463.2007.apm_855.xml.x; Deng YC, 2003, INT J CANCER, V106, P342, DOI 10.1002/ijc.11228; Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Ehrich M, 2008, P NATL ACAD SCI USA, V105, P4844, DOI 10.1073/pnas.0712251105; Essner JJ, 2006, INT J BIOCHEM CELL B, V38, P152, DOI 10.1016/j.biocel.2005.08.012; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fang JY, 2004, WORLD J GASTROENTERO, V10, P3394; Fears CY, 2006, J BIOL CHEM, V281, P14533, DOI 10.1074/jbc.C600075200; Foltz G, 2006, CANCER RES, V66, P6665, DOI 10.1158/0008-5472.CAN-05-4453; Fontijn D, 2007, MOL CANCER THER, V6, P2807, DOI 10.1158/1535-7163.MCT-07-0044; Girault I, 2003, CLIN CANCER RES, V9, P4415; Gonzalez-Gomez P, 2003, INT J ONCOL, V22, P601; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gronbaek K, 2007, APMIS, V115, P1039, DOI 10.1111/j.1600-0463.2007.apm_636.xml.x; Hambardzumyan D, 2006, CANCER CELL, V10, P454, DOI 10.1016/j.ccr.2006.11.008; Han I, 2004, J MOL HISTOL, V35, P319; Hayashi H, 2007, HUM GENET, V120, P701, DOI 10.1007/s00439-006-0254-6; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Ibanez de Caceres I, 2004, CANCER RES, V64, P6476; James SR, 2006, ONCOGENE, V25, P6975, DOI 10.1038/sj.onc.1209678; Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2; Karpf AR, 2007, CURR OPIN MOL THER, V9, P231; Kim HJ, 2006, CANCER, V107, P1042, DOI 10.1002/cncr.22087; Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552; Kim Y, 2003, ONCOGENE, V22, P826, DOI 10.1038/sj.onc.1206068; Kusano Y, 2004, J BIOCHEM, V135, P129, DOI 10.1093/jb/mvh015; LORENTE A, 2008, BRAIN PATHOL; Martinez R, 2007, CARCINOGENESIS, V28, P1264, DOI 10.1093/carcin/bgm014; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Milutinovic S, 2004, J BIOL CHEM, V279, P27915, DOI 10.1074/jbc.M312823200; Miranda TB, 2007, J CELL PHYSIOL, V213, P384, DOI 10.1002/jcp.21224; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Modrowski D, 2005, BONE, V37, P180, DOI 10.1016/j.bone.2005.04.010; Mueller W, 2007, ONCOGENE, V26, P583, DOI 10.1038/sj.onc.1209805; Park H, 2002, J BIOL CHEM, V277, P29730, DOI 10.1074/jbc.M202435200; Park HJ, 2006, CANCER LETT, V233, P271, DOI 10.1016/j.canlet.2005.03.017; Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Rao SH, 2001, J IMMUNOL, V167, P4494, DOI 10.4049/jimmunol.167.8.4494; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581; Schiappacassi M, 2008, MOL CANCER THER, V7, P1164, DOI 10.1158/1535-7163.MCT-07-2154; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Shi HD, 2003, CANCER RES, V63, P2164; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Shostak KO, 2003, J SURG ONCOL, V82, P57, DOI 10.1002/jso.10180; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stone AR, 2004, AM J PATHOL, V165, P1151, DOI 10.1016/S0002-9440(10)63376-7; Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046; Tan SH, 2007, ONCOL REP, V18, P1225; Wang Z, 2008, CANCER RES, V68, P492, DOI 10.1158/0008-5472.CAN-07-2930; Yan L, 2003, CANCER BIOL THER, V2, P552, DOI 10.4161/cbt.2.5.469; Zhang W, 2007, DIS COLON RECTUM, V50, P1618, DOI 10.1007/s10350-007-0286-6	70	40	43	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2667	2677		10.1038/onc.2009.122	http://dx.doi.org/10.1038/onc.2009.122			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19465937				2022-12-17	WOS:000268211200005
J	Bultema, R; Longnecker, R; Swanson-Mungerson, M				Bultema, R.; Longnecker, R.; Swanson-Mungerson, M.			Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis	ONCOGENE			English	Article						Epstein-Barr virus; LMP2A; Burkitt's lymphoma; Bcl; Myc; transgenic models	MEMBRANE-PROTEIN 2A; ENDEMIC BURKITTS-LYMPHOMA; BCL-X-L; B-CELL; C-MYC; GENE-EXPRESSION; IN-VIVO; CONSTITUTIVE ACTIVATION; EBV; PATHWAY	Despite the identification of Epstein-Barr virus (EBV) in tumors of Burkitt's lymphoma (BL) over 40 years ago, the exact contribution of EBV to BL is undefined. EBV encodes for multiple proteins in latent B cells that affect B cell survival and activation. One such protein, latent membrane protein 2A (LMP2A), protects B cells from numerous pro-apoptotic stimuli. Therefore, we tested whether LMP2A protects B cells from apoptosis induced by aberrant c-MYC expression that precedes and dominates BL. We crossed LMP2A-transgenic mice (LMP2A-Tg), in which all B cells express LMP2A, to a transgenic mouse that expresses a BL translocation of myc (lambda-MYC-Tg mice). LMP2A promotes proliferation and protects B cells from MYC-induced apoptosis in lambda-MYC-Tg mice. LMP2A also accelerates the development of lymphoma in LMP2A/lambda-MYC-Tg mice. Finally, LMP2A increases the expression of Bcl-X-L in both pretumor B cells and tumor cells, suggesting a mechanism for LMP2A-mediated B cell survival in the presence of MYC. These results support a hypothesis that EBV LMP2A promotes tumor development by protecting pre-tumor B cells that would normally apoptose after the c-myc translocation.	[Bultema, R.; Longnecker, R.; Swanson-Mungerson, M.] Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Longnecker, R (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Ward 6-231,303 E Chicago Ave, Chicago, IL 60611 USA.	r-longnecker@northwestern.edu			Public Health Service [CA62234, CA73507]; NATIONAL CANCER INSTITUTE [R01CA133063, R01CA062234, R01CA073507] Funding Source: NIH RePORTER	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	RL is a John Edward Porter Professor in Biomedical Research and supported by the Public Health Service Grants CA62234 and CA73507 from the NCI. The authors thank Dr Herbert C Morse III, the NIAID, and the NCI for the lambda-MYC transgenic mice.	Anderson LJ, 2008, J GEN VIROL, V89, P1563, DOI 10.1099/vir.0.2008/001461-0; Babcock GJ, 2000, IMMUNITY, V13, P497, DOI 10.1016/S1074-7613(00)00049-2; Bell AI, 2006, J GEN VIROL, V87, P2885, DOI 10.1099/vir.0.81906-0; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Chen SY, 2002, J VIROL, V76, P9556, DOI 10.1128/JVI.76.18.9556-9561.2002; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; Fukuda M, 2004, J VIROL, V78, P1697, DOI 10.1128/JVI.78.4.1697-1705.2004; Garrison SP, 2008, MOL CELL BIOL, V28, P5391, DOI 10.1128/MCB.00907-07; Gerbitz A, 1999, ONCOGENE, V18, P1745, DOI 10.1038/sj.onc.1202468; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hsu JL, 2000, CRIT REV ONCOL HEMAT, V34, P27, DOI 10.1016/S1040-8428(00)00046-9; Ikeda A, 2004, J IMMUNOL, V172, P5329, DOI 10.4049/jimmunol.172.9.5329; Kim JS, 2006, J PATHOL, V209, P44, DOI 10.1002/path.1940; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Kurth J, 2000, IMMUNITY, V13, P485, DOI 10.1016/S1074-7613(00)00048-0; Linden M, 2004, BLOOD, V103, P2779, DOI 10.1182/blood-2003-10-3399; Mancao C, 2005, BLOOD, V106, P4339, DOI 10.1182/blood-2005-06-2341; Mancao C, 2007, BLOOD, V110, P3715, DOI 10.1182/blood-2007-05-090142; Newman SC., 2003, BIOSTATISTICAL METHO; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Pan YR, 2008, CELL MICROBIOL, V10, P2447, DOI 10.1111/j.1462-5822.2008.01221.x; Panousis CG, 1997, J VIROL, V71, P4752, DOI 10.1128/JVI.71.6.4752-4760.1997; Park SS, 2005, CANCER RES, V65, P1306, DOI 10.1158/0008-5472.CAN-04-0268; Portis T, 2004, ONCOGENE, V23, P8619, DOI 10.1038/sj.onc.1207905; RICKINSON AB, 2007, EPSTEINBARR VIRUS; Swanson PJ, 2004, J IMMUNOL, V172, P6684, DOI 10.4049/jimmunol.172.11.6684; Swanson-Mungerson MA, 2005, J VIROL, V79, P7355, DOI 10.1128/JVI.79.12.7355-7362.2005; Swanson-Mungerson M, 2006, J VIROL, V80, P6764, DOI 10.1128/JVI.00433-06; Tao Q, 1998, BLOOD, V91, P1373, DOI 10.1182/blood.V91.4.1373; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Thorley-Lawson DA, 2004, NEW ENGL J MED, V350, P1328, DOI 10.1056/NEJMra032015; Vervoorts J, 2006, J BIOL CHEM, V281, P34725, DOI 10.1074/jbc.R600017200; Wang H, 2006, J IMMUNOL, V177, P2793, DOI 10.4049/jimmunol.177.5.2793; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhu D, 2005, BLOOD, V105, P2135, DOI 10.1182/blood-2004-07-2573	39	40	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	11					1471	1476		10.1038/onc.2008.492	http://dx.doi.org/10.1038/onc.2008.492			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19182823	Green Accepted			2022-12-17	WOS:000264354400008
J	Yan, J; Yang, Y; Zhang, H; King, C; Kan, HM; Cai, Y; Yuan, CX; Bloom, GS; Hua, X				Yan, J.; Yang, Y.; Zhang, H.; King, C.; Kan, H-M; Cai, Y.; Yuan, C-X; Bloom, G. S.; Hua, X.			Menin interacts with IQGAP1 to enhance intercellular adhesion of beta-cells	ONCOGENE			English	Article						menin; IQGAP1; intercellular adhesion; migration	MULTIPLE ENDOCRINE NEOPLASIA; E-CADHERIN; GENE; CDC42; PROTEIN; RAC1; SUPPRESSOR; EXPRESSION; MIGRATION; BINDING	Multiple endocrine neoplasia type 1 (MEN1) is a dominantly inherited tumor syndrome that results from the mutation of the MEN1 gene that encodes protein menin. Stable overexpression of MEN1 has been shown to partially suppress the Ras-mediated morphological changes of fibroblast cells. Little is known about the molecular mechanisms by which menin decreases the oncogenic effects on cell morphology and other phenotypes. Here we showed that ectopic expression of menin in pretumor beta-cells increases islet cell adhesion and reduces cell migration. Our further studies revealed that menin interacts with the scaffold protein, IQ motif containing GTPase activating protein 1 (IQGAP1), reduces GTP-Rac1 interaction with IQGAP1 but increases epithelial cadherin (E-cadherin)/beta-catenin interaction with IQGAP1. Consistent with an essential role for menin in regulating beta-cell adhesion in vivo, accumulations of beta-catenin and E-cadherin are reduced at cell junctions in the islets from Men1-excised mice. Together, these results de. ne a novel menin-IQGAP1 pathway that controls cell migration and cell-cell adhesion in endocrine cells.	[Yan, J.; Yang, Y.; Zhang, H.; King, C.; Hua, X.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; [Zhang, H.] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou 510275, Guangdong, Peoples R China; [Kan, H-M; Cai, Y.; Bloom, G. S.] Univ Virginia, Dept Biol, Charlottesville, VA USA; [Yuan, C-X] Univ Penn, Sch Med, Dept Prote Facil, Philadelphia, PA 19104 USA; [Bloom, G. S.] Univ Virginia, Dept Cell Biol, Charlottesville, VA USA	University of Pennsylvania; Pennsylvania Medicine; Sun Yat Sen University; University of Virginia; University of Pennsylvania; University of Virginia	Hua, X (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Canc Biol, 421 Curie Blvd, Philadelphia, PA 19104 USA.	huax@mail.med.upenn.edu	Zhang, Hui/F-9253-2011	Yan, Jizhou/0000-0001-7482-7842	NIH [R01-CA-100912, R01-CA-113962, R01-NS051746]; American Diabetes Association [7-07-RA-60]; NATIONAL CANCER INSTITUTE [R01CA113962, R01CA100912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051746] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The parent clonal beta HC9 insulin-secreting cells (Radvanyi et al., 1993) were obtained from the cell repository of the Diabetes Research Center at the University of Pennsylvania, with permission of Dr FM Matschinsky. We thank Dr Faming Zhang for his gifts of purified MBP-tagged menin and nontagged menin, Dr Martin A Schwartz for mutant human Rac1 vectors and Dr Ruth Kroschewski for the IQGAP1 C-terminal constructs (C1-C4). All confocal images and quantitative analyses of fluorescent intensity were conducted at the Biomedical Imaging Core Facility at the University of Pennsylvania. We thank Peter Blessington, Alicia Nelson, Hai Shen, Mercy Gohil and Elena Blagoi for their technical assistance. A special thanks to Dr Claudia Andl and Dr Margaret Chou for their stimulating discussions. This work was supported in part from NIH grants (R01-CA-100912 and R01-CA-113962 to XH, and R01-NS051746 to GSB), and a grant from the American Diabetes Association (7-07-RA-60 to XH).	Andl CD, 2006, CANCER RES, V66, P9878, DOI 10.1158/0008-5472.CAN-05-4157; Bai F, 2007, MOL CELL BIOL, V27, P1495, DOI 10.1128/MCB.01764-06; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Bensenor LB, 2007, J CELL SCI, V120, P658, DOI 10.1242/jcs.03376; Bertolino P, 2003, CANCER RES, V63, P4836; Brandt DT, 2007, J CELL BIOL, V178, P193, DOI 10.1083/jcb.200612071; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Chen YX, 2006, P NATL ACAD SCI USA, V103, P1018, DOI 10.1073/pnas.0510347103; Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; DONNADIEU E, 1992, J IMMUNOL, V148, P2643; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Fukata M, 2001, MOL CELL BIOL, V21, P2165, DOI 10.1128/MCB.21.6.2165-2183.2001; Grohmanova K, 2004, J BIOL CHEM, V279, P48495, DOI 10.1074/jbc.M408113200; Guru SC, 1999, MAMM GENOME, V10, P592, DOI 10.1007/s003359901051; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Huang SC, 1999, LAB INVEST, V79, P301; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Kim YS, 1999, ONCOGENE, V18, P5936, DOI 10.1038/sj.onc.1203005; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; La P, 2004, ENDOCRINOLOGY, V145, P3443, DOI 10.1210/en.2004-0124; Lakhani VT, 2007, ANNU REV MED, V58, P253, DOI 10.1146/annurev.med.58.100305.115303; Lambert M, 2002, J CELL BIOL, V157, P469, DOI 10.1083/jcb.200107104; Le Clainche C, 2007, J BIOL CHEM, V282, P426, DOI 10.1074/jbc.M607711200; Li SH, 2000, MOL CELL BIOL, V20, P697, DOI 10.1128/MCB.20.2.697-701.2000; Lopez-Egido JR, 2002, EXP CELL RES, V278, P175, DOI 10.1006/excr.2002.5575; Mataraza JM, 2007, CELL SIGNAL, V19, P1857, DOI 10.1016/j.cellsig.2007.04.011; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Noritake J, 2005, J CELL SCI, V118, P2085, DOI 10.1242/jcs.02379; Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Rittmeyer EN, 2008, J CELL SCI, V121, P391, DOI 10.1242/jcs.016881; Schnepp RW, 2006, CANCER RES, V66, P5707, DOI 10.1158/0008-5472.CAN-05-4518; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Watanabe T, 2005, NOVART FDN SYMP, V269, P223; Watanabe T, 2005, NOVART FDN SYMP, V269, P101; Watanabe Takashi, 2005, Novartis Found Symp, V269, P92; Yan JZ, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000047; Yan JZ, 2006, MOL CELL BIOL, V26, P155, DOI 10.1128/MCB.26.1.155-168.2006; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025	50	40	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					973	982		10.1038/onc.2008.435	http://dx.doi.org/10.1038/onc.2008.435			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19079338	Green Accepted			2022-12-17	WOS:000263457400004
J	Tanuma, N; Nomura, M; Ikeda, M; Kasugai, I; Tsubaki, Y; Takagaki, K; Kawamura, T; Yamashita, Y; Sato, I; Sato, M; Katakura, R; Kikuchi, K; Shima, H				Tanuma, N.; Nomura, M.; Ikeda, M.; Kasugai, I.; Tsubaki, Y.; Takagaki, K.; Kawamura, T.; Yamashita, Y.; Sato, I.; Sato, M.; Katakura, R.; Kikuchi, K.; Shima, H.			Protein phosphatase Dusp26 associates with KIF3 motor and promotes N-cadherin-mediated cell-cell adhesion	ONCOGENE			English	Article						DUSP; cadherin; KIF3	LEFT-RIGHT ASYMMETRY; DUAL-SPECIFICITY PHOSPHATASES; TYROSINE PHOSPHATASES; KINESIN SUPERFAMILY; KINASE; COMPLEX; FAMILY	Recent studies have demonstrated essential functions for KIF3, a microtubule-directed protein motor, in subcellular transport of several cancer-relatedproteins, including the beta-catenin-cadherin(s) complex. In this study, we report identification of the protein-phosphatase Dusp26 as a novel regulator of the KIF3 motor. Here we undertake yeast two-hybridscreening and identify Kif3a, a motor subunit of the KIF3 heterotrimeric complex, as a novel Dusp26-binding protein. Co-immunoprecipitation and colocalization experiments revealed that Dusp26 associates not only with Kif3a, but also with Kap3, another subunit of the KIF3 complex. Dephosphorylation experiments in vitro and analysis using mutant forms of Dusp26 in intact cells strongly suggested that Dusp26 is recruited to the KIF3 motor mainly by interaction with Kif3a, and thereby dephosphorylates Kap3. Forced expression of Dusp26, but not its catalytically inactive mutant, promotedd istribution of beta-catenin/N-cadherin, an established KIF3 cargo, to cell-cell junction sites, resulting in increased cell-cell adhesiveness. We also showed that Dusp26 mRNA expression was downregulated in human glioblastoma samples. These results suggest previously unidentified functions of Dusp26 in intracellular transport and cell-cell adhesion. Downregulation of Dusp26 may contribute to malignant phenotypes of glioma.	[Tanuma, N.; Nomura, M.; Kasugai, I.; Shima, H.] Miyagi Canc Ctr, Res Inst, Div Canc Chemotherapy, Natori, Miyagi 9811293, Japan; [Tanuma, N.; Ikeda, M.; Tsubaki, Y.; Takagaki, K.; Kikuchi, K.] Hokkaido Univ, Inst Med Genet, Div Biochem Oncol & Immunol, Sapporo, Hokkaido, Japan; [Kawamura, T.] Univ Tokyo, RCAST, Lab Syst Biol & Med, Tokyo, Japan; [Yamashita, Y.; Katakura, R.] Miyagi Canc Ctr, Div Neurosurg, Natori, Miyagi 9811293, Japan; [Sato, I.] Miyagi Canc Ctr, Res Inst, Sect Clin Res, Natori, Miyagi 9811293, Japan; [Sato, M.] Miyagi Canc Ctr, Div Thorac Surg, Natori, Miyagi 9811293, Japan	Miyagi Cancer Center; Hokkaido University; University of Tokyo; Miyagi Cancer Center; Miyagi Cancer Center; Miyagi Cancer Center	Shima, H (corresponding author), Miyagi Canc Ctr, Res Inst, Div Canc Chemotherapy, 47-1 Nodayama, Natori, Miyagi 9811293, Japan.	shima-hi632@pref.miyagi.jp		Takagaki, Kentaro/0000-0001-8085-6201	Japan Society for the Promotion of Science of Japan	Japan Society for the Promotion of Science of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We acknowledge Dr Konomi Kamada (Hokkaido University, Japan) for kindly providing the plasmid pBTM116-HA, the L40 yeast strain and E. coli HB101, and Dr Toshio Kitamura (University of Tokyo, Japan) for the pMX-puro plasmid and PLAT-E cells. Thanks are also due to E Yoshida for secretarial assistance. This work was supported in part by Grants-in-Aid for Scientific Research (B) and Grants-in-Aid for Scientific Research (C) provided by the Japan Society for the Promotion of Science of Japan.	Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Corbit KC, 2008, NAT CELL BIOL, V10, P70, DOI 10.1038/ncb1670; Guillaud L, 2008, NAT CELL BIOL, V10, P19, DOI 10.1038/ncb1665; Haraguchi K, 2006, J BIOL CHEM, V281, P4094, DOI 10.1074/jbc.M507028200; Hirokawa N, 2000, TRAFFIC, V1, P29, DOI 10.1034/j.1600-0854.2000.010105.x; Hirokawa N, 2006, CELL, V125, P33, DOI 10.1016/j.cell.2006.03.002; Hirokawa N, 2000, NEWS PHYSIOL SCI, V15, P56; Hu YZ, 2006, MOL CELL BIOL, V26, P3282, DOI 10.1128/MCB.26.8.3282-3294.2006; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Karcher RL, 2001, SCIENCE, V293, P1317, DOI 10.1126/science.1061086; Kinoshita E, 2006, MOL CELL PROTEOMICS, V5, P749, DOI 10.1074/mcp.T500024-MCP200; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nishimura T, 2004, NAT CELL BIOL, V6, P328, DOI 10.1038/ncb1118; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Pulido R, 2008, FEBS J, V275, P848, DOI 10.1111/j.1742-4658.2008.06250.x; Takagaki K, 2007, MOL CELL BIOCHEM, V296, P177, DOI 10.1007/s11010-006-9313-5; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; Teng JL, 2005, NAT CELL BIOL, V7, P474, DOI 10.1038/ncb1249; Vasudevan SA, 2005, BIOCHEM BIOPH RES CO, V330, P511, DOI 10.1016/j.bbrc.2005.03.028; Wang JY, 2006, J NEUROCHEM, V98, P89, DOI 10.1111/j.1471-4159.2006.03852.x; Yu W, 2007, ONCOGENE, V26, P1178, DOI 10.1038/sj.onc.1209899	22	40	41	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					752	761		10.1038/onc.2008.431	http://dx.doi.org/10.1038/onc.2008.431			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19043453				2022-12-17	WOS:000263076400012
J	Wen, J; Li, R; Lu, Y; Shupnik, MA				Wen, J.; Li, R.; Lu, Y.; Shupnik, M. A.			Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions	ONCOGENE			English	Article						tamoxifen resistance; BRCA1; ER alpha; coactivators; corepressors	HORMONE-BETA-PROMOTER; RNA-POLYMERASE-II; PROGESTERONE-RECEPTOR; IN-VIVO; ANTIESTROGEN RESISTANCE; SIGNALING PATHWAYS; TISSUE-SPECIFICITY; CYCLE PROGRESSION; UBIQUITIN LIGASE; RESPONSE ELEMENT	The breast cancer susceptibility gene 1 (BRCA1) is mutated in approximately 50% of hereditary breast cancers, and its expression is decreased in 30-40% of sporadic breast cancers, suggesting a general role in breast cancer development. BRCA1 physically and functionally interacts with estrogen receptor-alpha (ER alpha) and several transcriptional regulators. We investigated the relationship between cellular BRCA1 levels and tamoxifen sensitivity. Decreasing BRCA1 expression in breast cancer cells by small interfering RNA alleviated tamoxifen-mediated growth inhibition and abolished tamoxifen suppression of several endogenous ER-targeted genes. ER-stimulated transcription and cytoplasmic signaling was increased without detectable changes in ER or ER coregulator expression. Co-immunoprecipitation studies showed that with BRCA1 knockdown, tamoxifen-bound ER alpha was inappropriately associated with coactivators, and not effectively with corepressors. Chromatin immuno-precipitation studies demonstrated that with tamoxifen, BRCA1 knockdown did not change ER alpha promoter occupancy, but resulted in increased coactivator and decreased corepressor recruitment onto the endogenous cyclin D1 promoter. Our results suggest that decreased BRCA1 levels modify ER alpha-mediated transcription and regulation of cell proliferation in part by altering ER alpha-coregulator association. In the presence of tamoxifen, decreased BRCA1 expression results in increased coactivator and decreased corepressor recruitment on ER-regulated gene promoters.	[Wen, J.; Shupnik, M. A.] Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; [Li, R.; Lu, Y.] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78229 USA; [Shupnik, M. A.] Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA	University of Virginia; University of Texas System; University of Texas Health San Antonio; University of Virginia	Shupnik, MA (corresponding author), Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Jefferson Pk Ave,POB 800578, Charlottesville, VA 22908 USA.	mas3x@virginia.edu		Lu, Yunzhe/0000-0001-7542-6848	National Institutes of Health [DK57082, CA93506]; University of Virginia Cancer Center [P30-CA44579]; Women's Oncology Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028934] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA044579, R01CA093506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064604, R01DK057082] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Virginia Cancer Center; Women's Oncology Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Sarah E Aiyar for technical advice and Dr Sarah Parsons for HER2 antibodies. The authors acknowledge support of the National Institutes of Health (DK57082 to MA Shupnik and CA93506 to R Li), the University of Virginia Cancer Center (P30-CA44579) and Women's Oncology Fund (MA Shupnik).	Basu A, 2005, FRONT BIOSCI-LANDMRK, V10, P2346, DOI 10.2741/1703; Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522; Bissonauth V, 2008, CANCER DETECT PREV, V32, P52, DOI 10.1016/j.cdp.2008.01.005; Chen YM, 1996, CANCER RES, V56, P3168; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Clarke R, 2001, J STEROID BIOCHEM, V76, P71, DOI 10.1016/S0960-0760(00)00193-X; Curtin D, 2004, MOL ENDOCRINOL, V18, P1263, DOI 10.1210/me.2003-0221; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; Dowsett M, 2006, ANN ONCOL, V17, P818, DOI 10.1093/annonc/mdl016; DUBIK D, 1992, ONCOGENE, V7, P1587; Eakin CM, 2007, P NATL ACAD SCI USA, V104, P5794, DOI 10.1073/pnas.0610887104; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2002, CANCER RES, V62, P141; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Ferris HA, 2007, BIOL REPROD, V77, P1073, DOI 10.1095/biolreprod.107.064139; Fink M, 2006, STRAHLENTHER ONKOL, V182, P53; Fleming FJ, 2004, J CLIN ENDOCR METAB, V89, P375, DOI 10.1210/jc.2003-031048; Fox EM, 2008, MOL ENDOCRINOL, V22, P1781, DOI 10.1210/me.2007-0419; Girault I, 2003, CLIN CANCER RES, V9, P1259; Glover JNM, 2004, TRENDS BIOCHEM SCI, V29, P579, DOI 10.1016/j.tibs.2004.09.010; Graham JD, 1995, J BIOL CHEM, V270, P30693, DOI 10.1074/jbc.270.51.30693; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Horner-Glister E, 2005, J MOL ENDOCRINOL, V35, P421, DOI 10.1677/jme.1.01784; Hu YF, 2005, ONCOGENE, V24, P8343, DOI 10.1038/sj.onc.1208985; Jones LP, 2005, ONCOGENE, V24, P3554, DOI 10.1038/sj.onc.1208426; Kenny FS, 1999, CLIN CANCER RES, V5, P2069; Kilker RL, 2006, CANCER RES, V66, P11478, DOI 10.1158/0008-5472.CAN-06-1755; Krum SA, 2003, J BIOL CHEM, V278, P52012, DOI 10.1074/jbc.M308418200; Kurtev V, 2004, J BIOL CHEM, V279, P24834, DOI 10.1074/jbc.M312300200; Lin VY, 2003, J BIOL CHEM, V278, P38125, DOI 10.1074/jbc.M303882200; Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200; Ma YX, 2007, MOL ENDOCRINOL, V21, P1905, DOI 10.1210/me.2006-0397; Ma YX, 2005, ONCOGENE, V24, P1831, DOI 10.1038/sj.onc.1208190; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Murphy L, 2004, CLIN CANCER RES, V10, P1354, DOI 10.1158/1078-0432.CCR-03-0112; Murphy LC, 2000, CANCER RES, V60, P6266; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Petz LN, 2004, J STEROID BIOCHEM, V88, P113, DOI 10.1016/j.jsbmb.2003.11.008; Razandi M, 2004, MOL CELL BIOL, V24, P5900, DOI 10.1128/MCB.24.13.5900-5913.2004; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Schreihofer DA, 2001, ENDOCRINOLOGY, V142, P3361, DOI 10.1210/en.142.8.3361; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shupnik MA, 2004, ONCOGENE, V23, P7979, DOI 10.1038/sj.onc.1208076; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Srinivas G, 2004, MOL CARCINOGEN, V39, P15, DOI 10.1002/mc.10164; Starita LM, 2005, J BIOL CHEM, V280, P24498, DOI 10.1074/jbc.M414020200; Thasni KA, 2008, ANN ONCOL, V19, P696, DOI 10.1093/annonc/mdm557; Tsai HW, 2004, ENDOCRINOLOGY, V145, P2730, DOI 10.1210/en.2003-1470; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu JW, 2005, ENDOCRINOLOGY, V146, P2031, DOI 10.1210/en.2004-0409; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	56	40	40	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					575	586		10.1038/onc.2008.405	http://dx.doi.org/10.1038/onc.2008.405			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18997820	Green Accepted			2022-12-17	WOS:000262866500011
J	Brenet, F; Socci, ND; Sonenberg, N; Holland, EC				Brenet, F.; Socci, N. D.; Sonenberg, N.; Holland, E. C.			Akt phosphorylation of La regulates specific mRNA translation in glial progenitors	ONCOGENE			English	Article						Ras/Akt pathway; La autoantigen; translation; ribonomics; polysomes	GLIOBLASTOMA FORMATION; ENHANCES TRANSLATION; NEURAL PROGENITORS; POLIOVIRUS RNA; AUTOANTIGEN LA; SS-B; PROTEIN; BINDING; OVEREXPRESSION; LOCALIZATION	The Akt signaling pathway activity increases as normal tissue progresses to malignant transformation, and regulates the translation of specific messenger RNAs (mRNAs) through multiple mechanisms. We have identified one such mechanism of Akt-dependent translation control as involving the lupus autoantigen La. La is an RNA-associated protein that contains multiple trafficking elements to support the interaction with RNAs in different subcellular locations. We show here that the La protein is a direct target of the serine/threonine protein kinase Akt on threonine 301, and La nuclear export in mouse glial progenitors, as well as its association with polysomes is modulated by Akt activity. Using a functional approach to determine the network of genes affected by La in the cytoplasm by microarray analysis of polysome-bound mRNAs, we found that La binds 34% of the polysome bound mRNAs and regulates the expression of a specific pool of mRNAs under KRas/Akt activation. Therefore, La appears to be an important contributor to Akt-mediated translational regulation of these transcripts in murine glial cells.	[Brenet, F.; Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA; [Socci, N. D.] Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10021 USA; [Sonenberg, N.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, New York, NY 10021 USA; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Brain Tumor Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; McGill University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Brenet, F (corresponding author), Cornell Univ, Dept Med, Weill Med Coll, 1300 York Ave,Room A635, New York, NY 10021 USA.	fab2008@med.cornell.edu	Brenet, Fabienne/R-1881-2016	Brenet, Fabienne/0000-0003-4098-1096	National Institutes of Health [UO1CA04002]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr Agnes Viale and the members of the Genomic Core Facility (MSKCC) for generation of Affymetrix data, Yelena Lyustikman for reading of the manuscript and Gloria Curto- Gonzalez, Elena Fomchenko and Hiro Momota for discussion and technical suggestions. We also thank Keryx Biopharmaceuticals for generously providing us with perifosine. This work was supported by a National Institutes of Health Grant (UO1CA04002).	Alfano C, 2004, NAT STRUCT MOL BIOL, V11, P323, DOI 10.1038/nsmb747; BABOONIAN C, 1989, CLIN EXP IMMUNOL, V78, P454; BACHMANN M, 1990, EXP CELL RES, V191, P171, DOI 10.1016/0014-4827(90)90002-R; Bayfield MA, 2007, MOL CELL BIOL, V27, P3303, DOI 10.1128/MCB.00026-07; Benjamin D, 2006, MOL CELL BIOL, V26, P9497, DOI 10.1128/MCB.01099-06; Brenet F, 2005, MOL CELL BIOL, V25, P7505, DOI 10.1128/MCB.25.17.7505-7521.2005; Broekhuis CHD, 2000, BIOCHEMISTRY-US, V39, P3023, DOI 10.1021/bi992308c; Cardinali B, 2003, J BIOL CHEM, V278, P35145, DOI 10.1074/jbc.M300722200; CHANG YN, 1994, J VIROL, V68, P7008, DOI 10.1128/JVI.68.11.7008-7020.1994; Crosio C, 2000, NUCLEIC ACIDS RES, V28, P2927, DOI 10.1093/nar/28.15.2927; Crul M, 2002, EUR J CANCER, V38, P1615, DOI 10.1016/S0959-8049(02)00127-2; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; de Silanes IL, 2003, ONCOGENE, V22, P7146, DOI 10.1038/sj.onc.1206862; Dong G, 2004, EMBO J, V23, P1000, DOI 10.1038/sj.emboj.7600115; Evdokimova V, 2006, MOL CELL BIOL, V26, P277, DOI 10.1128/MCB.26.1.277-292.2006; Fan H, 1998, MOL CELL BIOL, V18, P3201, DOI 10.1128/MCB.18.6.3201; Gherzi R, 2007, PLOS BIOL, V5, P82, DOI 10.1371/journal.pbio.0050005; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Gouble A, 2002, CANCER RES, V62, P1489; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; He X, 2007, ONCOGENE, V26, P4961, DOI 10.1038/sj.onc.1210307; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; Intine RV, 2003, MOL CELL, V12, P1301, DOI 10.1016/S1097-2765(03)00429-5; Kim YK, 2001, NUCLEIC ACIDS RES, V29, P5009, DOI 10.1093/nar/29.24.5009; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li XQ, 2006, J BIOL CHEM, V281, P13837, DOI 10.1074/jbc.M602060200; MANNING BD, 2002, SCI STKE, V162, pPE49; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Momota H, 2005, CANCER RES, V65, P7429, DOI 10.1158/0008-5472.CAN-05-1042; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rajasekhar VK, 2004, ONCOGENE, V23, P3248, DOI 10.1038/sj.onc.1207546; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Tessier CR, 2004, CANCER RES, V64, P209, DOI 10.1158/0008-5472.CAN-03-2927; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2	43	40	43	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					128	139		10.1038/onc.2008.376	http://dx.doi.org/10.1038/onc.2008.376			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18836485				2022-12-17	WOS:000262294100013
J	Dorn, GW; Kirshenbaum, LA				Dorn, G. W., II; Kirshenbaum, L. A.			Cardiac reanimation: targeting cardiomyocyte death by BNIP3 and NIX/BNIP3L	ONCOGENE			English	Review						apoptosis; autophagy; heart failure; cardiac hypertrophy; myocardial infarction	STAGE HEART-FAILURE; CELL-DEATH; PROTEIN BNIP3; BCL-2 FAMILY; VENTRICULAR MYOCYTES; MYOCARDIAL-INFARCTION; ENDOPLASMIC-RETICULUM; PHYSIOLOGICAL GROWTH; PATHOLOGICAL GENES; PRESSURE-OVERLOAD	Programmed cardiac myocyte death contributes to pathological ventricular remodeling and the progression of myocardial infarction or pressure overload hypertrophy to dilated cardiomyopathy. Recent work has identified importance of stress-mediated transcriptional induction of BNIP3 (BCL2 and 19-kDa interacting protein-3) and NIX/BNIP3L in cardiac remodeling. Here, the regulatory mechanisms for these two factors in the heart and their effects on programmed cardiomyocyte death are reviewed, with a focus on information derived from studies using mouse models of cardiac BNIP3 and NIX/BNIP3L overexpression and gene ablation. Oncogene (2009) 27, S158-S167; doi: 10.1038/onc.2009.53	[Dorn, G. W., II] Washington Univ, Dept Med, Ctr Pharmacogenom, Sch Med, St Louis, MO 63110 USA; [Kirshenbaum, L. A.] Univ Manitoba, St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Winnipeg, MB, Canada	Washington University (WUSTL); University of Manitoba; Children's Hospital Research Institute of Manitoba	Dorn, GW (corresponding author), Washington Univ, Dept Med, Ctr Pharmacogenom, Sch Med, 660 S Euclid Ave,Campus Box 8086, St Louis, MO 63110 USA.	gdorn@dom.wustl.edu	Kirshenbaum, Lorrie A./F-5742-2014	Ryplanski, Kairee/0000-0002-3737-7181	National Institutes of Health (NIH, Bethesda, MD, USA) [5P50HL077101, 2R01HL059888, 5R01HL080008, 5R01HL087871, 5P50HL077113]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL077101, R01HL059888, R01HL087871, R01HL080008, P50HL077113] Funding Source: NIH RePORTER	National Institutes of Health (NIH, Bethesda, MD, USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	GW Dorn is currently receiving grant support from the National Institutes of Health (NIH, Bethesda, MD, USA) (5P50HL077101; 2R01HL 059888; 5R01H L080008; 5R01HL087871; 5P50HL0771 13). LA Kirschenbaum holds a patent for the NIP3 family of proteins (US patent no. 7, 452,869B2).	Antman EM, 2008, CIRCULATION, V117, P296, DOI 10.1161/CIRCULATIONAHA.107.188209; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Baetz D, 2005, CIRCULATION, V112, P3777, DOI 10.1161/CIRCULATIONAHA.105.573899; BERRY JJ, 1993, J NUCL MED, V34, P39; Birse-Archbold JLA, 2005, J CEREBR BLOOD F MET, V25, P1356, DOI 10.1038/sj.jcbfm.9600133; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Burton TR, 2006, INT J CANCER, V118, P1660, DOI 10.1002/ijc.21547; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; CHEN JC, 1997, SOFT COMPUT, V1, P19; Chen ZY, 2001, AM J PHYSIOL-HEART C, V280, pH2313, DOI 10.1152/ajpheart.2001.280.5.H2313; Cizeau J, 2000, ONCOGENE, V19, P5453, DOI 10.1038/sj.onc.1203929; Condorelli G, 1999, CIRCULATION, V99, P3071, DOI 10.1161/01.CIR.99.23.3071; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Di Napoli P, 2003, AM HEART J, V146, P1105, DOI 10.1016/S0002-8703(03)00445-9; DIWAN A, 2008, J CLIN INVEST, V118, P3870; Diwan A, 2008, CIRCULATION, V117, P396, DOI 10.1161/CIRCULATIONAHA.107.727073; Diwan A, 2007, J CLIN INVEST, V117, P2825, DOI 10.1172/JCI32490; Diwan A, 2007, P NATL ACAD SCI USA, V104, P6794, DOI 10.1073/pnas.0610666104; Diwan A, 2007, PHYSIOLOGY, V22, P56, DOI 10.1152/physiol.00033.2006; Dorn GW, 2009, CARDIOVASC RES, V81, P465, DOI 10.1093/cvr/cvn243; Dorn GW, 2005, TRENDS CARDIOVAS MED, V15, P185, DOI 10.1016/j.tcm.2005.05.009; Foo RSY, 2007, J BIOL CHEM, V282, P5529, DOI 10.1074/jbc.M609046200; Foo RSY, 2005, J CLIN INVEST, V115, P565, DOI 10.1172/JCI200524569; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Francis GS, 1998, CURR OPIN CARDIOL, V13, P156; Frazier DP, 2006, ANTIOXID REDOX SIGN, V8, P1625, DOI 10.1089/ars.2006.8.1625; Galvez AS, 2006, J BIOL CHEM, V281, P1442, DOI 10.1074/jbc.M509056200; Graham RM, 2007, ANTIOXID REDOX SIGN, V9, P1309, DOI 10.1089/ars.2007.1726; GROSSMAN W, 1975, J CLIN INVEST, V56, P56, DOI 10.1172/JCI108079; Hamacher-Brady A, 2007, CELL DEATH DIFFER, V14, P146, DOI 10.1038/sj.cdd.4401936; Hamacher-Brady A, 2006, AUTOPHAGY, V2, P307, DOI 10.4161/auto.2947; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; Hayakawa Y, 2003, CIRCULATION, V108, P3036, DOI 10.1161/01.CIR.0000101920.72665.58; Henriquez M, 2008, CURR MOL MED, V8, P187, DOI 10.2174/156652408784221289; Hunt SA, 2005, CIRCULATION, V112, pE154, DOI 10.1161/CIRCULATIONAHA.105.167586; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Kubli DA, 2008, AM J PHYSIOL-HEART C, V295, pH2025, DOI 10.1152/ajpheart.00552.2008; Latif N, 2000, J AM COLL CARDIOL, V35, P1769, DOI 10.1016/S0735-1097(00)00647-1; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Li Y, 2007, J BIOL CHEM, V282, P35803, DOI 10.1074/jbc.M705231200; MacEwan DJ, 2002, BRIT J PHARMACOL, V135, P855, DOI 10.1038/sj.bjp.0704549; Nakayama H, 2007, J CLIN INVEST, V117, P2431, DOI 10.1172/JCI31060; Nam YJ, 2004, MOL CELL, V15, P901, DOI 10.1016/j.molcel.2004.08.020; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Narula Jagat, 2001, Cardiology Clinics, V19, P113, DOI 10.1016/S0733-8651(05)70198-3; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; OLIVETTI G, 1990, CIRC RES, V67, P23, DOI 10.1161/01.RES.67.1.23; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Regula KM, 2002, CIRC RES, V91, P226, DOI 10.1161/01.RES.0000029232.42227.16; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Rubart M, 2006, ANNU REV PHYSIOL, V68, P29, DOI 10.1146/annurev.physiol.68.040104.124530; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Sandoval H, 2008, NATURE, V454, P232, DOI 10.1038/nature07006; Schmidt-Kastner R, 2004, BRAIN RES, V1001, P133, DOI 10.1016/j.brainres.2003.11.065; Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Siu PM, 2005, J APPL PHYSIOL, V99, P204, DOI 10.1152/japplphysiol.00084.2005; Sowter HM, 2001, CANCER RES, V61, P6669; Stauffer SR, 2007, CURR TOP MED CHEM, V7, P961, DOI 10.2174/156802607780906843; Syed F, 2004, CIRC RES, V95, P1200, DOI 10.1161/01.RES.0000150366.08972.7f; Teiger E, 1996, J CLIN INVEST, V97, P2891, DOI 10.1172/JCI118747; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yurkova N, 2008, CIRC RES, V102, P472, DOI 10.1161/CIRCRESAHA.107.164731; Yussman MG, 2002, NAT MED, V8, P725, DOI 10.1038/nm719; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200	76	40	40	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S158	S167		10.1038/onc.2009.53	http://dx.doi.org/10.1038/onc.2009.53			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641501				2022-12-17	WOS:000268566800014
J	Tang, J; Yang, X; Liu, X				Tang, J.; Yang, X.; Liu, X.			Phosphorylation of Plk1 at Ser326 regulates its functions during mitotic progression	ONCOGENE			English	Article						Plk1; MK2; mitosis; phosphorylation	POLO-LIKE KINASES; P38 MAP KINASE; SACCHAROMYCES-CEREVISIAE; TOPOISOMERASE-II; CELL-DIVISION; ACTIVATION; CHECKPOINT; EXPRESSION; PATHWAY; CANCER	Polo-like kinase 1 (Plk1), the best characterized member of the mammalian polo-like kinase family, is well regulated throughout the cell cycle at the protein expression level. Moreover, it is known that Plk1 kinase activity is also regulated at the post-translational level through phosphorylation. However, the upstream kinases of Plk1 have not been identified. Although the involvement of the p38 MAP kinase pathway in cellular responses to stress has been well documented, the role of this pathway in normal cell cycle progression is unclear. Here, we show that phosphorylated p38 and MAP kinase-activated protein kinase 2 (MK2) are colocalized with Plk1 to the spindle poles during prophase and metaphase. Specific depletion of various members of the p38 MAP kinase pathway by the use of RNA interference revealed that the pathway is required for mitotic progression under normal growth conditions. Furthermore, MK2 directly phosphorylates Ser326 of Plk1. Ectopic expression of Plk1-S326A completely blocked cells at mitosis, likely due to the defect of bipolar spindle formation and subsequent activation of the spindle checkpoint. Only Plk1-S326E, but not the Plk1-S326A, efficiently rescued the p38 or MK2-depletion-induced mitotic defects, further solidifying the requirement of S326 phosphorylation during mitotic progression.	[Tang, J.; Yang, X.; Liu, X.] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; [Tang, J.; Yang, X.; Liu, X.] Purdue Univ, Ctr Canc, W Lafayette, IN 47907 USA; [Yang, X.] Sichuan Univ, Dept Chem, Chengdu 610064, Sichuan, Peoples R China	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Sichuan University	Liu, X (corresponding author), Purdue Univ, Dept Biochem, 175 S Univ St, W Lafayette, IN 47907 USA.	liu8@purdue.edu			National Cancer Institute [K01 CA114401]; NATIONAL CANCER INSTITUTE [K01CA114401] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Raymond Erikson, in whose laboratory the preliminary experiments were performed, for generously providing many cell lines and plasmids. We appreciate Eleanor Erikson, Xiaoyi Zhang and Hongchang Li for helpful discussions and critical reading of the paper. XL is a recipient of the Howard Temin Award from the National Cancer Institute (K01 CA114401).	Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Campos CBL, 2002, NEUROSCIENCE, V112, P583, DOI 10.1016/S0306-4522(02)00096-9; Cha HJ, 2007, J BIOL CHEM, V282, P22984, DOI 10.1074/jbc.M700735200; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Fan L, 2005, CELL CYCLE, V4, P1616, DOI 10.4161/cc.4.11.2125; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Knecht R, 1999, CANCER RES, V59, P2794; Knecht R, 2000, INT J CANCER, V89, P535; Li H, 2008, J BIOL CHEM, V283, P6209, DOI 10.1074/jbc.M709007200; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Lowery DM, 2005, ONCOGENE, V24, P248, DOI 10.1038/sj.onc.1208280; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Mikhailov A, 2004, J CELL BIOL, V166, P517, DOI 10.1083/jcb.200405167; Mulvihill DP, 1999, MOL BIOL CELL, V10, P2771, DOI 10.1091/mbc.10.8.2771; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Petersen J, 2005, NATURE, V435, P507, DOI 10.1038/nature03590; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Tang JB, 2006, P NATL ACAD SCI USA, V103, P11964, DOI 10.1073/pnas.0604987103; Tang JB, 2006, CELL CYCLE, V5, P2484, DOI 10.4161/cc.5.21.3411; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	24	40	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2008	27	52					6635	6645		10.1038/onc.2008.262	http://dx.doi.org/10.1038/onc.2008.262			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368QY	18695677	Green Accepted			2022-12-17	WOS:000260638800002
J	Gentilella, A; Passiatore, G; Deshmane, S; Turco, MC; Khalili, K				Gentilella, A.; Passiatore, G.; Deshmane, S.; Turco, M. C.; Khalili, K.			Activation of BAG3 by Egr-1 in response to FGF-2 in neuroblastoma cells	ONCOGENE			English	Article						BAG3; Egr-1; neuron/neuronal	FIBROBLAST GROWTH FACTOR-2; TRANSCRIPTION FACTOR EGR-1; SMOOTH-MUSCLE-CELLS; BCL-2-BINDING PROTEIN; REACTIVE ASTROCYTES; APOPTOSIS; GENE; SURVIVAL; FAMILY; BRAIN	The co-chaperone protein, BAG3, which belongs to the BAG protein family, has an established antiapoptotic function in different tumor cell lines. Here we demonstrated that treatment of the human neuroblastoma cell line, SK-N-MC, with. broblast growth factor-2 (FGF-2) results in induction of BAG3 expression. Induction of BAG3 protein by FGF-2 occurs at the transcriptional level; it requires the extracellular regulated kinase1/2 pathway and is dependent on the activity of Egr-1 upon the BAG3 promoter. Targeted suppression of BAG3 by small-interfering RNA results in dysregulation of cell-cycle progression most notably at S and G(2) phases, which corroborates the decreased level of cyclin B1 expression. These observations suggest a new role for BAG3 in regulation of the cell cycle.	[Gentilella, A.; Passiatore, G.; Deshmane, S.; Khalili, K.] Temple Univ, Sch Med, Dept Neurosci, Ctr Neurovirol, Philadelphia, PA 19122 USA; [Turco, M. C.] Univ Salerno, Dept Pharmaceut Sci, I-84100 Salerno, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Salerno	Khalili, K (corresponding author), Temple Univ, Sch Med, Dept Neurosci, Ctr Neurovirol, 1900 N 12th St,015-96,Room 203, Philadelphia, PA 19122 USA.	kamel.khalili@temple.edu	TURCO, Maria Caterina/AAC-5282-2022; Gentilella, Antonio/AAA-9864-2020	TURCO, Maria Caterina/0000-0002-7835-359X; 	NIH	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank past and present members of the Department of Neuroscience and Center for Neurovirology for sharing of ideas and reagents, and their encouragement throughout this study. We also thank Dr Francesca Peruzzi, Dr Davide Eletto and Dr Thersa M Sweet for their advices, William Yen and Jessica Otte for their technical support, Dr Martyn White for his time and assistance in the preparation of the manuscript and C Schriver for editorial assistance. This study is dedicated to our friend and colleague, Dr Arturo Leone. This work was made possible by grants awarded by NIH to KK.	Alzheimer C, 2002, ADV EXP MED BIOL, V513, P335; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Carreras I, 2001, AM J PHYSIOL-LUNG C, V281, pL766, DOI 10.1152/ajplung.2001.281.4.L766; Chiappetta G, 2007, J CLIN ENDOCR METAB, V92, P1159, DOI 10.1210/jc.2006-1712; Doong H, 2002, CANCER LETT, V188, P25, DOI 10.1016/S0304-3835(02)00456-1; Doong H, 2003, J BIOL CHEM, V278, P28490, DOI 10.1074/jbc.M209682200; Doong H, 2000, ONCOGENE, V19, P4385, DOI 10.1038/sj.onc.1203797; Gotz R, 2005, NAT NEUROSCI, V8, P1169, DOI 10.1038/nn1524; Gremo F, 2000, INT J DEV NEUROSCI, V18, P271, DOI 10.1016/S0736-5748(99)00095-7; Gritti A, 1996, J NEUROSCI, V16, P1091; Her S, 2004, MOL BRAIN RES, V126, P157, DOI 10.1016/j.molbrainres.2004.04.002; Homma S, 2006, AM J PATHOL, V169, P761, DOI 10.2353/ajpath.2006.060250; Issa Razao, 2005, Angiogenesis, V8, P53, DOI 10.1007/s10456-005-5613-8; Kim MS, 2004, J PATHOL, V202, P103, DOI 10.1002/path.1497; Kontaridis MI, 2002, MOL CELL BIOL, V22, P3875, DOI 10.1128/MCB.22.11.3875-3891.2002; Lee JH, 1999, ONCOGENE, V18, P6183, DOI 10.1038/sj.onc.1203043; Lee MY, 2002, EXP MOL MED, V34, P167, DOI 10.1038/emm.2002.24; Lee MY, 2002, EXP NEUROL, V175, P338, DOI 10.1006/exnr.2002.7903; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Liman J, 2005, MOL CELL BIOL, V25, P3715, DOI 10.1128/MCB.25.9.3715-3725.2005; Lowe B, 2003, ANAL BIOCHEM, V315, P95, DOI 10.1016/S0003-2697(02)00695-4; Midgley VC, 2004, J BIOL CHEM, V279, P40289, DOI 10.1074/jbc.M406063200; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Pagliuca MG, 2003, FEBS LETT, V541, P11, DOI 10.1016/S0014-5793(03)00274-6; Romano MF, 2003, CANCER BIOL THER, V2, P508, DOI 10.4161/cbt.2.5.524; Romano MF, 2003, CELL DEATH DIFFER, V10, P383, DOI 10.1038/sj.cdd.4401167; Rosati A, 2007, INT J BIOCHEM CELL B, V39, P1337, DOI 10.1016/j.biocel.2007.03.007; Rosati A, 2007, J CELL PHYSIOL, V210, P676, DOI 10.1002/jcp.20865; Rossler OG, 2004, AM J PHYSIOL-CELL PH, V286, pC1118, DOI 10.1152/ajpcell.00301.2003; Russo VC, 2004, J CELL PHYSIOL, V199, P371, DOI 10.1002/jcp.10416; SCHWARTZ SM, 1993, J CARDIOVASC PHARM, V21, pS31, DOI 10.1097/00005344-199321001-00007; Smits VAJ, 2000, J BIOL CHEM, V275, P19375, DOI 10.1074/jbc.M001764200; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; TEMPLE S, 1995, NEURON, V15, P249, DOI 10.1016/0896-6273(95)90030-6; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Vogel S, 2006, J CELL PHYSIOL, V206, P25, DOI 10.1002/jcp.20437; Zapata JM, 1998, J BIOL CHEM, V273, P6916, DOI 10.1074/jbc.273.12.6916	41	40	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5011	5018		10.1038/onc.2008.142	http://dx.doi.org/10.1038/onc.2008.142			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469860				2022-12-17	WOS:000258914800004
J	Alm-Kristiansen, AH; Saether, T; Matre, V; Gilfillan, S; Dahle, O; Gabrielsen, OS				Alm-Kristiansen, A. H.; Saether, T.; Matre, V.; Gilfillan, S.; Dahle, O.; Gabrielsen, O. S.			FLASH acts as a co-activator of the transcription factor c-Myb and localizes to active RNA polymerase II foci	ONCOGENE			English	Article						FLASH; CASP8AP2; c-myb; PML; Cajal bodies; RNA polymerase II	PML NUCLEAR-BODIES; CAJAL BODIES; GLUCOCORTICOID-RECEPTOR; GENE-REGULATION; RAG-2 PROMOTER; FACTOR-BINDING; CELL-NUCLEUS; V-MYB; NF-M; CBP	The c-Myb oncoprotein is a DNA-binding transcription factor with a key role in early stages of hematopoiesis. To expand our knowledge of partners cooperating with c-Myb, we performed a yeast two-hybrid screening with full-length c-Myb as bait. Here, we report FLICE-associated huge protein (FLASH)/CASP8AP2 as a novel Myb-interacting protein. We show that FLASH interacts with the DNA-binding domain of c-Myb and enhances c-Myb-dependent reporter activity and expression of endogenous c-Myb target genes. Chromatin immunoprecipitation assays revealed that FLASH and c-Myb both associate with the MYC promoter region as well as with the intronic enhancer of the c-Myb target gene ADA. Furthermore, siRNA knock-down of FLASH or c-Myb both result in a reduction of MYC and ADA expression. The co-activator effect is mediated through the C-terminal part of FLASH, which binds c-Myb. The FLASH-induced enhancement is comparable with the increase seen with the c-Myb co-activator p300. We find FLASH localized in discrete nuclear speckles in several cell lines, co-localized with c-Myb in active RNA polymerase II foci. These results imply a novel molecular mechanism of regulation of c-Myb activity. We propose that c-Myb cooperates with FLASH in foci associated with active RNA polymerase II, leading to enhancement of Myb-dependent gene activation.	[Alm-Kristiansen, A. H.; Saether, T.; Matre, V.; Gilfillan, S.; Dahle, O.; Gabrielsen, O. S.] Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway	University of Oslo	Gabrielsen, OS (corresponding author), Univ Oslo, Dept Mol Biosci, PB1041, N-0316 Oslo, Norway.	o.s.gabrielsen@imbv.uio.no		Saether, Thomas/0000-0003-4976-3810				Barcaroli D, 2006, P NATL ACAD SCI USA, V103, P14802, DOI 10.1073/pnas.0604225103; Barcaroli D, 2006, P NATL ACAD SCI USA, V103, P14808, DOI 10.1073/pnas.0604227103; Berge T, 2007, BLOOD CELL MOL DIS, V39, P278, DOI 10.1016/j.bcmd.2007.05.007; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Carpinelli MR, 2004, P NATL ACAD SCI USA, V101, P6553, DOI 10.1073/pnas.0401496101; Cioce M, 2005, ANNU REV CELL DEV BI, V21, P105, DOI 10.1146/annurev.cellbio.20.010403.103738; Dahle O, 2004, EXP CELL RES, V297, P118, DOI 10.1016/j.yexcr.2004.03.014; Dahle O, 2003, EUR J BIOCHEM, V270, P1338, DOI 10.1046/j.1432-1033.2003.03504.x; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; De Guzman RN, 2006, J MOL BIOL, V355, P1005, DOI 10.1016/j.jmb.2005.09.059; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; ESS KC, 1995, MOL CELL BIOL, V15, P5707; Flotho C, 2006, BLOOD, V108, P1050, DOI 10.1182/blood-2006-01-0322; Fraser P, 2007, NATURE, V447, P413, DOI 10.1038/nature05916; Handwerger KE, 2006, TRENDS CELL BIOL, V16, P19, DOI 10.1016/j.tcb.2005.11.005; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Kasper LH, 2002, NATURE, V419, P738, DOI 10.1038/nature01062; Kino T, 2004, J STEROID BIOCHEM, V92, P357, DOI 10.1016/j.jsbmb.2004.09.003; Kino T, 2003, J BIOL CHEM, V278, P3023, DOI 10.1074/jbc.M209234200; Kittler R, 2004, NATURE, V432, P1036, DOI 10.1038/nature03159; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Milovic-Holm K, 2007, EMBO J, V26, P391, DOI 10.1038/sj.emboj.7601504; Miranda GA, 2002, MOL IMMUNOL, V38, P1151, DOI 10.1016/S0161-5890(02)00007-X; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Obradovic D, 2004, MOL PHARMACOL, V65, P761, DOI 10.1124/mol.65.3.761; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Saether T, 2007, J BIOL CHEM, V282, P13994, DOI 10.1074/jbc.M700755200; Sakamoto H, 2006, BLOOD, V108, P896, DOI 10.1182/blood-2005-09-3846; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sandberg ML, 2005, DEV CELL, V8, P153, DOI 10.1016/j.devcel.2004.12.015; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Sexton T, 2007, NAT STRUCT MOL BIOL, V14, P1049, DOI 10.1038/nsmb1324; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Sun J, 2005, J CELL SCI, V118, P4995, DOI 10.1242/jcs.02613; Vegiopoulos A, 2006, BLOOD, V107, P4703, DOI 10.1182/blood-2005-07-2968; Wang QF, 2000, MOL CELL BIOL, V20, P9203, DOI 10.1128/MCB.20.24.9203-9211.2000; Zimber A, 2004, CELL SIGNAL, V16, P1085, DOI 10.1016/j.cellsig.2004.03.020; Zor T, 2004, J MOL BIOL, V337, P521, DOI 10.1016/j.jmb.2004.01.038	43	40	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4644	4656		10.1038/onc.2008.105	http://dx.doi.org/10.1038/onc.2008.105			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408764				2022-12-17	WOS:000258236300003
J	Lei, M; Erikson, R				Lei, M.; Erikson, Rl			Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint	ONCOGENE			English	Article						checkpoint; DNA damage; nontransformed cell	POLO-LIKE KINASE-1; PROGNOSTIC-SIGNIFICANCE; CANCER-THERAPY; EXPRESSION; POLO-LIKE-KINASE-1; DIFFERENTIATION; TELOMERASE; CARCINOMAS; INHIBITOR; POTENT	We previously reported that polo-like kinase 1 (Plk1) depletion by lentivirus-based RNA interference led to mitotic arrest and apoptosis in cancer cells, whereas normal diploid cell lines, hTERT-RPE1 and MCF10A, survived a similar level of depletion. To study homogeneous cell lines, we generated several Plk1-depleted hTERT-RPE1 and MCF10A clones that were derived from single cells depleted of Plk1. We found that in the longterm, Plk1 depletion slowed proliferation of hTERT-RPE1 cells, apparently due to attenuated progression through S phase. These cells had altered morphology and were elongated compared with control. In contrast, MCF10A clones with mild levels of depletion showed no obvious phenotype. They appeared to have normal proliferation rates with no cell-cycle arrest. However, one MCF10A clone, which was severely depleted of Plk1, although viable, showed sporadic G2/M arrest and apoptosis. This MCF10A clone and all the hTERT-RPE1 clones displayed evidence of DNA-damage checkpoint activation. These data further support the interpretation that cancer cell lines have a much greater requirement for Plk1 than normal nontransformed diploid cells.	[Lei, M.; Erikson, Rl] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Lei, M (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Biolabs Room 2048,16 Divin Ave, Cambridge, MA 02138 USA.	minglei@fas.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059172] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59172] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Angelis KJ, 1999, ELECTROPHORESIS, V20, P2133, DOI 10.1002/(SICI)1522-2683(19990701)20:10<2133::AID-ELPS2133>3.0.CO;2-Q; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Galy A, 2002, DEV BIOL, V248, P251, DOI 10.1006/dbio.2002.0736; GERDES J, 1984, J IMMUNOL, V133, P1710; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Hardy CFJ, 1996, MOL CELL BIOL, V16, P6775; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Knecht R, 1999, CANCER RES, V59, P2794; Knecht R, 2000, INT J CANCER, V89, P535; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Rak DJ, 2006, EXP EYE RES, V82, P648, DOI 10.1016/j.exer.2005.09.002; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; SOULE HD, 1990, CANCER RES, V50, P6075; Spankuch B, 2004, JNCI-J NATL CANCER I, V96, P862, DOI 10.1093/jnci/djh146; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Strebhardt K, 2000, JAMA-J AM MED ASSOC, V283, P479, DOI 10.1001/jama.283.4.479; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Tsvetkov L, 2005, J BIOL CHEM, V280, P11943, DOI 10.1074/jbc.M413514200; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Winkles JA, 2005, ONCOGENE, V24, P260, DOI 10.1038/sj.onc.1208219; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862	29	40	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	28					3935	3943		10.1038/onc.2008.36	http://dx.doi.org/10.1038/onc.2008.36			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18297112				2022-12-17	WOS:000257089000005
J	Li, Y; Ozaki, T; Kikuchi, H; Yamamoto, H; Ohira, M; Nakagawara, A				Li, Y.; Ozaki, T.; Kikuchi, H.; Yamamoto, H.; Ohira, M.; Nakagawara, A.			A novel HECT-type E3 ubiquitin protein ligase NEDL1 enhances the p53-mediated apoptotic cell death in its catalytic activity-independent manner	ONCOGENE			English	Article						apoptosis; cisplatin; DNA damage; HECT-type E3 ubiquitin ligase; NEDL1; p53	GLYCOGEN-SYNTHASE KINASE-3-BETA; AMYOTROPHIC-LATERAL-SCLEROSIS; KINASE-I-EPSILON; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAY; DNA-BINDING; P53; NEUROBLASTOMA; DEGRADATION; NEURONS	NEDL1 (NEDD4-like ubiquitin protein ligase-1) is a newly identified HECT-type E3 ubiquitin protein ligase highly expressed in favorable neuroblastomas as compared with unfavorable ones. In this study, we found that NEDL1 cooperates with p53 to induce apoptosis. During cisplatin (CDDP)-mediated apoptosis in neuroblastoma SH-SY5Y cells, p53 was induced to accumulate in association with an increase in expression levels of NEDL1. Enforced expression of NEDL1 resulted in a decrease in number of G418-resistant colonies in SH-SY5Y and U2OS cells bearing wild-type p53, whereas NEDL1 had undetectable effect on p53-deficient H1299 and SAOS-2 cells. Similarly, enforced expression of NEDL1 increased number of U2OS cells with sub-G1 DNA content. Co-immunoprecipitation and in vitro binding assays revealed that NEDL1 binds to the COOH-terminal region of p53. Luciferase reporter assay showed that NEDL1 has an ability to enhance the transcriptional activity of p53. Small interfering RNA-mediated knockdown of the endogenous NEDL1 conferred the resistance of U2OS cells to adriamycin. It is noteworthy that NEDL1 enhanced pro-apoptotic activity of p53 in its catalytic activity-independent manner. Taken together, our present findings suggest that functional interaction of NEDL1 with p53 might contribute to the induction of apoptosis in cancerous cells bearing wild-type p53.	[Li, Y.; Ozaki, T.; Kikuchi, H.; Yamamoto, H.; Ohira, M.; Nakagawara, A.] Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, Chiba 2608717, Japan; [Li, Y.] Furukawa Elect Corp Ltd, Prod Technol Dev Ctr, Ichihara, Chiba, Japan	Chiba Cancer Center; Furukawa Electric	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp						Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Cluskey S, 2001, J CLIN PATHOL-MOL PA, V54, P386; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; de Aguilar JLG, 2000, NEUROBIOL DIS, V7, P406, DOI 10.1006/nbdi.2000.0295; Di Lello P, 2006, MOL CELL, V22, P731, DOI 10.1016/j.molcel.2006.05.007; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ekegren T, 1999, ACTA NEUROL SCAND, V100, P317; Hetman M, 2000, J NEUROSCI, V20, P2567; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; Kiryu-Seo S, 2005, J NEUROSCI, V25, P1442, DOI 10.1523/JNEUROSCI.4041-04.2005; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kitanaka C, 2002, J NATL CANCER I, V94, P358; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; Martin LJ, 2002, J NEUROBIOL, V50, P181, DOI 10.1002/neu.10026; Martin LJ, 2000, NEUROBIOL DIS, V7, P613, DOI 10.1006/nbdi.2000.0314; Miyazaki K, 2004, J BIOL CHEM, V279, P11327, DOI 10.1074/jbc.M312389200; Miyazaki K, 2003, BIOCHEM BIOPH RES CO, V308, P106, DOI 10.1016/S0006-291X(03)01347-0; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Nakagawara A, 2004, CANCER LETT, V204, P213, DOI 10.1016/S0304-3835(03)00457-9; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Shaw P, 1996, ONCOGENE, V12, P921; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299	29	40	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3700	3709		10.1038/sj.onc.1211032	http://dx.doi.org/10.1038/sj.onc.1211032			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223681				2022-12-17	WOS:000256659300007
J	Cui, Y; Guadagno, TM				Cui, Y.; Guadagno, T. M.			B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells	ONCOGENE			English	Article						B-Raf(V600E); ERK; mps1; spindle checkpoint; melanoma	ACTIVATED PROTEIN-KINASE; B-RAF; ASSEMBLY CHECKPOINT; BRAF MUTATIONS; MAP KINASE; CENTROSOME DUPLICATION; CANCER; PATHWAY; MITOSIS; PHOSPHORYLATION	The B-Raf(V600E) mutant, found in 65% of human melanomas, drives constitutive activation of the extracellular signal-regulated kinase (ERK) pathway and is implicated in tumorigenesis. Recently, we showed that B-Raf is important for spindle formation and the mitotic spindle checkpoint arrest. In this study, we demonstrate that B-Raf(V600E) signaling deregulates the spindle checkpoint as a consequence of stabilizing monopolar spindle 1 (Mps1) levels in human melanoma cells. Upon introducing the B-Raf(V600E) mutant into wild-type B-Raf melanoma cells, Mps1 protein and activity increased 3- and 10-fold, respectively. In addition, Mps1 became hyperphosphorylated, which correlated with stabilization of Mps1 protein levels. In contrast, reduction of B-Raf by RNAi or inactivation of ERK by the MEK inhibitor U0126 resulted in a precipitous decline in Mps1 levels. Together, these results suggest that B-Raf signaling through ERK regulates the stability of Mps1. Finally, B-Raf(V600E) expression induces a mitotic delay due to promoting robust activation of the mitotic spindle checkpoint. These effects were dependent on the induction of Mps1 levels by oncogenic B-Raf(V600E) as shown by depleting Mps1 with short interfering RNA. Collectively, our findings implicate a new mechanism through which B-Raf(V600E) exerts its oncogenic effects in melanoma.	[Cui, Y.; Guadagno, T. M.] H Lee Moffitt Canc Ctr & Res Inst, Cutaneous Oncol Div, Mol Oncol Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Guadagno, TM (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Cutaneous Oncol Div, Mol Oncol Program, Tampa, FL 33612 USA.	guadagnt@moffitt.usf.edu			NIGMS NIH HHS [GM62542] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062542] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Bastian BC, 1998, CANCER RES, V58, P2170; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; Borysov SI, 2006, J BIOL CHEM, V281, P22586, DOI 10.1074/jbc.M601432200; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Eves EM, 2006, MOL CELL, V23, P561, DOI 10.1016/j.molcel.2006.07.015; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Fukushima T, 2003, ONCOGENE, V22, P6455, DOI 10.1038/sj.onc.1206739; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Hingorani SR, 2003, CANCER RES, V63, P5198; Hoeflich MP, 2006, CANCER RES, V66, P999, DOI 10.1158/0008-5472.CAN-05-2720; Horne MM, 2003, J CELL BIOL, V161, P1021, DOI 10.1083/jcb.200304144; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jaspersen SL, 2004, DEV CELL, V7, P263, DOI 10.1016/j.devcel.2004.07.006; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kimura ET, 2003, CANCER RES, V63, P1454; Knauf JA, 2006, J BIOL CHEM, V281, P3800, DOI 10.1074/jbc.M511690200; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kumar R, 2003, CLIN CANCER RES, V9, P3362; Liu ST, 2003, MOL BIOL CELL, V14, P1638, DOI 10.1091/mbc.02-05-0074; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Palframan WJ, 2006, SCIENCE, V313, P680, DOI 10.1126/science.1127205; Park S, 2005, ONCOGENE, V24, P3535, DOI 10.1038/sj.onc.1208435; Peeper DS, 2002, NAT CELL BIOL, V4, P148, DOI 10.1038/ncb742; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Satyamoorthy K, 2003, CANCER RES, V63, P756; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Yuen ST, 2002, CANCER RES, V62, P6451; Zhao Y, 2006, CURR BIOL, V16, P1764, DOI 10.1016/j.cub.2006.07.058	41	40	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3122	3133		10.1038/sj.onc.1210972	http://dx.doi.org/10.1038/sj.onc.1210972			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071315				2022-12-17	WOS:000255897600005
J	Jiang, Y; Prunier, C; Howe, PH				Jiang, Y.; Prunier, C.; Howe, P. H.			The inhibitory effects of Disabled-2 (Dab2) on Wnt signaling are mediated through Axin	ONCOGENE			English	Article						disabled-2 (Dab2); axin; wnt; beta-catenin; differentiation	BETA-CATENIN; NEGATIVE REGULATOR; ENDOCYTOSIS; PROTEIN; DOMAIN; MOUSE; PHOSPHORYLATION; MECHANISM; PATHWAY; ADAPTER	beta-Catenin-mediated Wnt signaling is essential in embryonic development and in adult tissues. Recent studies have demonstrated that Axin not only plays an important inhibitory role in coordinating beta-catenin degradation, but is itself degraded by the low-density-lipoprotein receptor-related protein (LRP) 5/6 Wnt co-receptor. Here, we demonstrate that the endocytic adaptor molecule Disabled-2 (Dab2), which we have previously demonstrated to act as an inhibitor of beta-catenin signaling, interacts with Axin and prevents its interaction with and degradation by the LRP5 co-receptor, thereby increasingits half-life and stabilization. Dab2 levels induced during retinoic acid-induced differentiation of F9, or during transforming growth factor-beta-induced epithelial-mesenchymal transdifferentiation of mouse mammary epithelial cells result in the stabilization of Axin and concomitant inhibition of beta-catenin signaling. Ectopic expression of Dab2 in F9 cells as well as in transformed cell lines results in increased Axin expression and attenuation of Wnt-mediated signaling. We conclude that Dab2 may play an important role in the maintenance of the differentiated state and restrain Wnt- mediated proliferation through its association with and modulation of Axin.	[Jiang, Y.; Howe, P. H.] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; [Prunier, C.] Hop St Antoine, INSERM, U673, F-75571 Paris, France	Cleveland Clinic Foundation; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Howe, PH (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Canc Biol, NB4, Cleveland, OH 44195 USA.	howep@ccf.org	Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273	NCI NIH HHS [R01 CA080095, R01 CA055536-18, R01 CA055536, CA80095, CA55536] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055536, R01CA055536, R01CA080095] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BILIC J, 2007, J CELL SCI, V119, P395; Cadigan KM, 2006, J CELL SCI, V119, P395, DOI 10.1242/jcs.02826; Capelluto DGS, 2002, NATURE, V419, P726, DOI 10.1038/nature01056; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; HERBER B, 1994, ONCOGENE, V9, P1295; Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; KAKIMURA DM, 2001, TRAFFIC, V7, P324; Kleeff J, 2002, DIS COLON RECTUM, V45, P1242, DOI 10.1007/s10350-004-6399-2; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; Lickert H, 2005, DEVELOPMENT, V132, P2599, DOI 10.1242/dev.01842; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Prunier C, 2005, J BIOL CHEM, V280, P17540, DOI 10.1074/jbc.M500974200; Prunier C, 2004, GROWTH FACTORS, V22, P141, DOI 10.1080/08977190410001720860; Shibamoto S, 2004, EXP CELL RES, V292, P11, DOI 10.1016/j.yexcr.2003.08.009; Shibamoto S, 1998, GENES CELLS, V3, P659; Smith ER, 2001, J BIOL CHEM, V276, P47303, DOI 10.1074/jbc.M106158200; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; WILES MV, 1988, DEVELOPMENT, V104, P403; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yamamoto H, 2006, DEV CELL, V11, P213, DOI 10.1016/j.devcel.2006.07.003; Yu A, 2007, DEV CELL, V12, P129, DOI 10.1016/j.devcel.2006.10.015; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185	41	40	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1865	1875		10.1038/sj.onc.1210829	http://dx.doi.org/10.1038/sj.onc.1210829			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17922036	Green Accepted			2022-12-17	WOS:000254150600006
J	Mantovani, G; Bondioni, S; Lania, AG; Rodolfo, M; Peverelli, E; Polentarutti, N; Rodriguez, TV; Ferrero, S; Bosari, S; Beck-Peccoz, P; Spada, A				Mantovani, G.; Bondioni, S.; Lania, A. G.; Rodolfo, M.; Peverelli, E.; Polentarutti, N.; Rodriguez, T. Veliz; Ferrero, S.; Bosari, S.; Beck-Peccoz, P.; Spada, A.			High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells	ONCOGENE			English	Article						melanomas; PKA; cAMP; R1/R2 ratio; proliferation	HL-60 LEUKEMIA-CELLS; RII-BETA-SUBUNIT; KINASE-A; MALIGNANT-MELANOMA; ADENYLYL CYCLASE; MUTATIONS; GROWTH; ALPHA; CAMP; DIFFERENTIATION	The cAMP-protein kinase A (PKA) pathway is the major signal transduction pathway involved in melanocyte-stimulating hormone receptor-mediated signaling and melanin production, whereas its role in the control of melanocyte proliferation is still controversial. In this study, we evaluated the effects of selective activation of the different PKA regulatory subunits type 1A (R1A) and type 2B (R2B) on melanocyte proliferation. Immunohistochemistry demonstrated that normal melanocytes lacked R1A protein whereas this subunit was highly expressed in all human melanomas studied (N = 20) and in six human melanoma cell lines. Pharmacological activation of the R2 subunits by the cAMP analogue 8-Cl-cAMP inhibited proliferation and increased caspase-3 activity by 68.77 +/- 10.5 and 72 +/- 9% respectively, in all cell lines with the exception of the only p53-mutated one. Similar effects were obtained by activating R2 subunits with other analogues and by silencing R1A expression. The antiproliferative and proapoptotic effects of 8-Cl-cAMP were comparable to those observed with commonly used antitumoral drugs. Moreover, 8-Cl-cAMP potentiated the effects of these drugs on both cell proliferation and caspase-3 activity. In conclusion, this study first reports that human melanomas are characterized by a high R1/R2 ratio and that pharmacological and genetic manipulations able to revert this unbalanced expression cause significant antiproliferative and proapoptotic effects in melanoma cells.	[Mantovani, G.; Bondioni, S.; Lania, A. G.; Peverelli, E.; Beck-Peccoz, P.; Spada, A.] Univ Milan, Dept Med Sci, Endocrine Unit, Fdn Policlin Osped Maggiore IRCCS, I-20122 Milan, Italy; [Rodolfo, M.] Ist Nazl Studio & Cura Tumori, IRCCS, Unit Melanoma Genet, I-20133 Milan, Italy; [Polentarutti, N.; Rodriguez, T. Veliz] IRCCS, Ist Clin Humanitas, Dept Immunol & Inflammat, Milan, Italy; [Ferrero, S.; Bosari, S.] AO San Paolo, Dept Med Surg & Dent, Pathol Unit, Milan, Italy; [Ferrero, S.; Bosari, S.] Fdn Osped Maggiore, IRCCS, Milan, Italy	University of Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Humanitas Research Hospital; IRCCS Ca Granda Ospedale Maggiore Policlinico	Spada, A (corresponding author), Univ Milan, Dept Med Sci, Endocrine Unit, Fdn Policlin Osped Maggiore IRCCS, Via F Sforza 35, I-20122 Milan, Italy.	anna.spada@unimi.it	rodolfo, monica/H-2671-2012; lania, andrea/AAA-9020-2019; Bosari, Silvano/K-7744-2016; Mantovani, Giovanna/A-2378-2014	rodolfo, monica/0000-0002-9196-0298; Bosari, Silvano/0000-0002-9744-6951; Mantovani, Giovanna/0000-0002-9065-3886; Peverelli, Erika/0000-0002-4424-7895; Lania, Andrea Gerardo Antonio/0000-0002-5380-2141	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Cho YS, 2000, P NATL ACAD SCI USA, V97, P835, DOI 10.1073/pnas.97.2.835; Cho-Chung YS, 2005, ANN NY ACAD SCI, V1058, P76, DOI 10.1196/annals.1359.014; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CHOCHUNG YS, 1995, CRIT REV ONCOL HEMAT, V21, P2133; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DELUCA M, 1993, J CELL SCI, V105, P1079; Di Stasi D, 2005, INT J CANCER, V115, P224, DOI 10.1002/ijc.20885; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; HANDSCHIN JC, 1979, FEBS LETT, V106, P301, DOI 10.1016/0014-5793(79)80519-0; HUNT G, 1994, PIGM CELL RES, V7, P217, DOI 10.1111/j.1600-0749.1994.tb00052.x; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Lania A, 2001, EUR J ENDOCRINOL, V145, P543, DOI 10.1530/eje.0.1450543; Lania AG, 2004, CANCER RES, V64, P9193, DOI 10.1158/0008-5472.CAN-04-1847; LEVINE N, 1991, JAMA-J AM MED ASSOC, V266, P2730, DOI 10.1001/jama.266.19.2730; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Nesterova M, 1996, EUR J BIOCHEM, V235, P486, DOI 10.1111/j.1432-1033.1996.00486.x; ROHLFF C, 1993, J BIOL CHEM, V268, P5774; Schwede F, 2000, BIOCHEMISTRY-US, V39, P8803, DOI 10.1021/bi000304y; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Tanami H, 2004, ONCOGENE, V23, P8796, DOI 10.1038/sj.onc.1208152; TORTORA G, 1990, P NATL ACAD SCI USA, V87, P705, DOI 10.1073/pnas.87.2.705; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403	25	40	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2008	27	13					1834	1843		10.1038/sj.onc.1210831	http://dx.doi.org/10.1038/sj.onc.1210831			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906691				2022-12-17	WOS:000254150600003
J	Lagadec, C; Adriaenssens, E; Toillon, RA; Chopin, V; Romon, R; Van Coppenolle, F; Hondermarck, H; Le Bourhis, X				Lagadec, C.; Adriaenssens, E.; Toillon, R. A.; Chopin, V.; Romon, R.; Van Coppenolle, F.; Hondermarck, H.; Le Bourhis, X.			Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells	ONCOGENE			English	Article						breast cancer; tamoxifen; TRAIL; apoptosis; tumor xenograft	KAPPA-B; DEATH; MECHANISMS; RECEPTORS; THERAPY; ALPHA	Tamoxifen (TAM), is widely used as a single agent in adjuvant treatment of breast cancer. Here, we investigated the effects of TAM in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in estrogen receptor-alpha (ER-alpha)-positive and -negative breast cancer cells. We showed that cotreatment with TAM and TRAIL synergistically induced apoptosis regardless of ER-alpha status. By contrast, cotreatment did not affect the viability of normal breast epithelial cells. Cotreatment with TAM and TRAIL in breast cancer cells decreased the levels of antiapoptotic proteins including FLIPs and Bcl-2, and enhanced the levels of proapoptotic proteins such as FADD, caspase 8, tBid, Bax and caspase 9. Furthermore, cotreatment-induced apoptosis was efficiently reduced by FADD- or Bid-siRNA, indicating the implication of both extrinsic and intrinsic pathways in synergistic apoptosis induction. Importantly, cotreatment totally arrested tumor growth in an ER-alpha-negative MDA-MB-231 tumor xenograft model. The abrogation of tumor growth correlated with enhanced apoptosis in tumor tissues. Our findings raise the possibility to use TAM in combination with TRAIL for breast cancers, regardless of ER-alpha status.	[Lagadec, C.; Adriaenssens, E.; Toillon, R. A.; Chopin, V.; Romon, R.; Hondermarck, H.; Le Bourhis, X.] Univ Sci & Tech Lille Flandres Artois, IFR147, INSERM, ERI 8,JE2488, F-59655 Villeneuve Dascq, France; Univ Sci & Tech Lille Flandres Artois, IFR147, INSERM, U800, F-59655 Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Le Bourhis, X (corresponding author), Univ Sci & Tech Lille Flandres Artois, IFR147, INSERM, ERI 8,JE2488, F-59655 Villeneuve Dascq, France.	xuefen.lebourhis@univ-lille1.fr	Toillon, Robert-Alain/Q-2286-2018; Le+Bourhis, Xuefen/AAL-5141-2021; Lagadec, chann/E-4250-2010	Toillon, Robert-Alain/0000-0001-5483-2118; Lagadec, chann/0000-0002-5182-2069				Broaddus VC, 2005, J BIOL CHEM, V280, P12486, DOI 10.1074/jbc.M408190200; Chopin V, 2004, EXP CELL RES, V298, P560, DOI 10.1016/j.yexcr.2004.04.038; Duiker EW, 2006, EUR J CANCER, V42, P2233, DOI 10.1016/j.ejca.2006.03.018; Gelmann EP, 1997, SEMIN ONCOL, V24, pS65; Grambihler A, 2003, J BIOL CHEM, V278, P26831, DOI 10.1074/jbc.M303229200; Hawkins RA, 2000, BREAST, V9, P96, DOI 10.1054/brst.2000.0140; JORDAN VC, 1992, CANCER, V70, P977; Kallio A, 2005, APOPTOSIS, V10, P1395, DOI 10.1007/s10495-005-2137-z; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; LOVE RR, 1989, J CLIN ONCOL, V7, P803, DOI 10.1200/JCO.1989.7.6.803; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; McClay EF, 2000, BRIT J CANCER, V83, P16; Nakano H, 2006, CELL DEATH DIFFER, V13, P730, DOI 10.1038/sj.cdd.4401830; Nazarewicz RR, 2007, CANCER RES, V67, P1282, DOI 10.1158/0008-5472.CAN-06-3099; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Yanamadala V, 2007, J BIOL CHEM, V282, P24352, DOI 10.1074/jbc.M702804200	17	40	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2008	27	10					1472	1477		10.1038/sj.onc.1210749	http://dx.doi.org/10.1038/sj.onc.1210749			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17767197				2022-12-17	WOS:000253548200014
J	Andrianifahanana, M; Singh, AP; Nemos, C; Ponnusamy, MP; Moniaux, N; Mehta, PP; Varshney, GC; Batra, SK				Andrianifahanana, M.; Singh, A. P.; Nemos, C.; Ponnusamy, M. P.; Moniaux, N.; Mehta, P. P.; Varshney, G. C.; Batra, S. K.			IFN-gamma-induced expression of MUC4 in pancreatic cancer cells is mediated by STAT-1 upregulation: a novel mechanism for IFN-gamma response	ONCOGENE			English	Article						IFN-gamma; MUC4; STAT-1; pancreatic cancer; regulation	INTERFERON-GAMMA; TRANSCRIPTIONAL ACTIVATION; SERINE PHOSPHORYLATION; UNPHOSPHORYLATED STAT1; GENE-EXPRESSION; GROWTH; ALPHA; ASSOCIATION; INHIBITION; INDUCTION	MUC4 is a transmembrane mucin, which is aberrantly expressed in pancreatic adenocarcinoma with no detectable expression in the normal pancreas. Here, we present a novel mechanism of IFN-gamma-induced expression of MUC4 in pancreatic cancer cells. Our studies highlight the upregulation of STAT-1 as a basis for MUC4 induction and demonstrate that its activation and upregulation by IFN-gamma are two distinct, albeit temporally integrated, signalling events that drive the selective induction of IRF-1 and MUC4, respectively, within a single cell system. The pro. le of interferon regulatory factor (IRF)-1 gene induction by IFN-gamma is consistent with its rapid transactivation by phospho-Y701-STAT-1. In contrast, the induction of the MUC4 mucin gene expression is relatively delayed, and occurs only in response to an increase in STAT-1 expression. A progressive binding of STAT-1 to various gamma-interferon-activated sequences (GAS) in the MUC4 promoter is observed in chromatin immuno-precipitation assay, indicating its direct association. Stimulation of STAT-1 expression by double-stranded polynucleotides or ectopic expression is shown to induce MUC4 expression, without Y701 phosphorylation of STAT-1. This effect is abrogated by short interfering RNA (siRNA)-mediated inhibition of STAT-1 expression, supporting further the relevance of STAT-1 in MUC4 regulation. In conclusion, our findings identify a novel mechanism for MUC4 regulation in pancreatic cancer cells and unfold new perspectives on the foundation of IFN-gamma-dependent gene regulation.	Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE USA; Inst Microbial Technol, Chandigarh, India	University of Nebraska System; University of Nebraska Medical Center; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Mad Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu	Singh, Ajay/AAF-4414-2020; Moniaux, Nicolas/Y-3243-2018	Moniaux, Nicolas/0000-0001-9718-1386; Singh, Ajay/0000-0003-3492-6330; Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X	NCI NIH HHS [CA78590] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Guo GG, 2002, J INTERF CYTOK RES, V22, P555, DOI 10.1089/10799900252982034; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; Lagow EL, 2002, J CELL BIOCHEM, V86, P759, DOI 10.1002/jcb.10261; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; Mao X, 2005, MOL CELL, V17, P761, DOI 10.1016/j.molcel.2005.02.021; Marg A, 2004, J CELL BIOL, V165, P823, DOI 10.1083/jcb.200403057; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; Nelson JD, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj004; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Singh AP, 2007, CANCER RES, V67, P433, DOI 10.1158/0008-5472.CAN-06-3114; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Suzuki K, 1999, P NATL ACAD SCI USA, V96, P2285, DOI 10.1073/pnas.96.5.2285; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Yang J, 2005, CANCER RES, V65, P939; Zhou YH, 2001, ONCOLOGY-BASEL, V60, P330, DOI 10.1159/000058529	25	40	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2007	26	51					7251	7261		10.1038/sj.onc.1210532	http://dx.doi.org/10.1038/sj.onc.1210532			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525742				2022-12-17	WOS:000250955600009
J	Li, W; Xiao, C; Vonderhaar, BK; Deng, CX				Li, W.; Xiao, C.; Vonderhaar, B. K.; Deng, C-X			A role of estrogen/ER alpha signaling in BRCA1-associated tissue-specific tumor formation	ONCOGENE			English	Article						ERK1/2; cyclin D1; ER alpha; BRCA1; mammary tumors	BREAST-CANCER; CELL-CYCLE; BRCA2 MUTATIONS; OVARIAN-CANCER; RECEPTOR; SUSCEPTIBILITY; WOMEN; MICE; TUMORIGENESIS; OOPHORECTOMY	Estrogen and its receptor alpha (ER alpha) have been implicated in the tissue-specific tumorigenesis associated with BRCA1 mutations. However, the majority of breast cancers developed in human BRCA1 mutation carriers are ER alpha-negative, challenging the link between BRCA1 and estrogen/ER alpha in breast cancer formation. Using a mouse model lacking the full-length form of BRCA1, here we show that ERa is highly expressed in the premalignant mammary gland and initiation stages of tumorigenesis, although its expression is gradually diminished during mammary tumor progression. We demonstrate that the absence of full-length BRCA1 increases sensitivity of cells to estrogen-induced extracellular signal-regulated kinase 1/2 phosphorylation and cyclin D1 expression. The absence of BRCA1 turns the proliferation of ER alpha-positive cells from a paracrine fashion to an autocrine or endocrine fashion. Consequently, BRCA1-mutant cells are sensitized to estrogen-induced cell proliferation in vitro and mammary tumorigenesis in vivo. These findings illustrate a molecular mechanism for estrogen/ER alpha signals in BRCA1-associated tissue-specific tumor formation, and identify several key elements in the estrogen/ER alpha-signaling cascade that can serve as potential therapeutic targets for BRCA1-associated tumorigenesis.	Natl Inst Hlth, NIDDK, Genet Dev & Dis Branch, Bethesda, MD 20892 USA; Natl Inst Hlth, Natl Canc Inst, Mammary Biol & Tumorigen Lab, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Deng, CX (corresponding author), Natl Inst Hlth, NIDDK, Genet Dev & Dis Branch, 10-9N105, 10 Ctr Dr, Bethesda, MD 20892 USA.	chuxiad@bdg10.niddk.nih.gov	deng, chuxia/N-6713-2016		NATIONAL CANCER INSTITUTE [ZIABC008226, Z01BC008226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056008] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alberg Anthony J., 1999, Current Opinion in Oncology, V11, P435, DOI 10.1097/00001622-199911000-00003; Bachelier R, 2005, ONCOL REP, V14, P1117; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Calderon-Margalit R, 2004, INT J CANCER, V112, P357, DOI 10.1002/ijc.20429; Chodankar R, 2005, CURR BIOL, V15, P561, DOI 10.1016/j.cub.2005.01.052; Clarke RB, 1997, CANCER RES, V57, P4987; Deng Chu-Xia, 2004, Methods Mol Biol, V280, P185; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Deng CX, 2003, HUM MOL GENET, V12, pR113, DOI 10.1093/hmg/ddg082; Eisinger F, 1999, CANCER-AM CANCER SOC, V85, P2291, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2291::AID-CNCR26>3.0.CO;2-9; Elledge SJ, 2002, CANCER CELL, V1, P129, DOI 10.1016/S1535-6108(02)00041-7; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Gadducci A, 2005, GYNECOL ENDOCRINOL, V20, P343, DOI 10.1080/09513590500128492; Hu YF, 2005, ONCOGENE, V24, P8343, DOI 10.1038/sj.onc.1208985; Huo ZM, 2002, RADIOLOGY, V225, P519, DOI 10.1148/radiol.2252010845; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Karp SE, 1997, CANCER-AM CANCER SOC, V80, P435, DOI 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; Lane D., 1995, COMPLEXITY, V1, P9; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 2003, TRENDS GENET, V19, P312, DOI 10.1016/S0168-9525(03)00110-0; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Russo IH, 1998, J MAMMARY GLAND BIOL, V3, P49, DOI 10.1023/A:1018770218022; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Trauernicht Amy M, 2003, Breast Dis, V18, P11; Turner JMA, 2004, CURR BIOL, V14, P2135, DOI 10.1016/j.cub.2004.11.032; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zhang JR, 2005, MOL CANCER RES, V3, P531, DOI 10.1158/1541-7786.MCR-05-0192; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	34	40	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7204	7212		10.1038/sj.onc.1210527	http://dx.doi.org/10.1038/sj.onc.1210527			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17496925				2022-12-17	WOS:000250955600004
J	Schmitt, E; Beauchemin, M; Bertrand, R				Schmitt, E.; Beauchemin, M.; Bertrand, R.			Nuclear colocalization and interaction between bcl-xL and cdk1(cdc2) duringG(2)/M cell-cycle checkpoint	ONCOGENE			English	Article						bcl-xL; cdk1(cdc2); apoptosis; cell cycle; senescence; DNA damage	DNA TOPOISOMERASE-I; PROTEIN-KINASE; CYTOCHROME-C; MITOCHONDRIAL CONTROL; REGULATED KINASE; HL-60 CELLS; G2 ARREST; S-PHASE; PHOSPHORYLATION; APOPTOSIS	In response to cancer chemotherapeutic drugs, cells rapidly trigger the apoptotic program or undergo growth arrest and senescence at specific phases of the cell cycle. Mitochondrial bcl-xL plays a central role in preventing alteration of mitochondrial dysfunction, cytochrome c release, caspase activation, DNA fragmentation and apoptosis. However, its pleitropic function depends on its subcellular localization. Here, we show that in addition to its mitochondrial effect that delays apoptosis, bcl-xL colocalizes and binds to cdk1( cdc2) during G(2)/M cell-cycle checkpoint and its overexpression stabilizes a G(2)/M-arrest senescence program in surviving cells after DNA damage. Bcl-xL potently inhibits cdk1( cdc2) kinase activity, which is reversible by a synthetic peptide between the 41st amino acid and 60th amino acid surrounding of the Thr47 and Ser62 phosphorylation sites, and Asn52 deamidation site, within the. exible loop domain of bcl-xL. A mutant deleted of this region does not alter the antiapoptotic function of bcl-xL, but impedes its effect on cdk1( cdc2) activity and on the G(2)/M-arrest senescence program after DNA damage. The nuclear interaction of bcl-xL and cdk1( cdc2) suggests that bcl-xL is coupled to the stabilization of a cell-cycle checkpoint induced by DNA damage, and this effect is genetically distinct from its function on apoptosis.	Univ Montreal, Notre Dame Hosp, Res Ctr, Ctr Hosp, Montreal, PQ H2L 4M1, Canada; Canc Montreal, Montreal, PQ, Canada; Univ Montreal, Dept Med, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal	Bertrand, R (corresponding author), Univ Montreal, Notre Dame Hosp, Res Ctr, Ctr Hosp, 1560 Sherbrooke St E Room Y-5634, Montreal, PQ H2L 4M1, Canada.	richard.bertrand@umontreal.ca						Barboule N, 2005, CELL CYCLE, V4, P590; Basu A, 2003, FEBS LETT, V538, P41, DOI 10.1016/S0014-5793(03)00131-5; BERTRAND R, 1993, EXP CELL RES, V207, P388, DOI 10.1006/excr.1993.1206; BERTRAND R, 1992, EUR J CANCER, V28A, P743, DOI 10.1016/0959-8049(92)90107-D; Blagosklonny MV, 1997, CANCER RES, V57, P130; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burri SH, 1999, INT J RADIAT ONCOL, V43, P423, DOI 10.1016/S0360-3016(98)00385-X; Chang BD, 1999, CANCER RES, V59, P3761; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; Du LH, 2005, ONCOGENE, V24, P107, DOI 10.1038/sj.onc.1208189; Fan MY, 2000, CANCER RES, V60, P6403; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Haldar S, 1996, CANCER RES, V56, P1253; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; HOLM C, 1989, CANCER RES, V49, P6365; Jamil S, 2005, BIOCHEM J, V387, P659, DOI 10.1042/BJ20041596; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; LOCK RB, 1990, CANCER RES, V50, P3761; LOCK RB, 1992, CANCER RES, V52, P1817; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OCONNOR PM, 1993, CANCER RES, V53, P4776; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt E, 2002, RRD CANCER, V4, P453; Schmitt E, 1998, CELL DEATH DIFFER, V5, P506, DOI 10.1038/sj.cdd.4400376; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Schmitt E, 2000, BIOCHEM BIOPH RES CO, V270, P868, DOI 10.1006/bbrc.2000.2537; Schmitt E, 2006, J CELL SCI, V119, P4269, DOI 10.1242/jcs.03200; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SHIMIZU T, 1995, CANCER RES, V55, P228; TSAO YP, 1992, CANCER RES, V52, P1823; Vairo G, 1996, ONCOGENE, V13, P1511; Vander Heiden MG, 1999, MOL CELL, V3, P159; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang NC, 2004, ANAL BIOCHEM, V325, P337, DOI 10.1016/j.ab.2003.11.012; Yao SL, 1996, CANCER RES, V56, P4551; Yu Q, 2001, FEBS LETT, V505, P7, DOI 10.1016/S0014-5793(01)02756-9; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	71	40	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5851	5865		10.1038/sj.onc.1210396	http://dx.doi.org/10.1038/sj.onc.1210396			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369848				2022-12-17	WOS:000249123100003
J	Boelaert, K; Smith, VE; Stratford, AL; Kogai, T; Tannahill, LA; Watkinson, JC; Eggo, MC; Franklyn, JA; McCabe, CJ				Boelaert, K.; Smith, V. E.; Stratford, A. L.; Kogai, T.; Tannahill, L. A.; Watkinson, J. C.; Eggo, M. C.; Franklyn, J. A.; McCabe, C. J.			PTTG and PBF repress the human sodium iodide symporter	ONCOGENE			English	Article						PTTG; PBF; NIS; thyroid cancer	TUMOR-TRANSFORMING GENE; PAPILLARY THYROID CARCINOMAS; TRANSCRIPTIONAL ACTIVATION FUNCTION; SODIUM/IODIDE-SYMPORTER; NA+/I-SYMPORTER; GROWTH-FACTOR; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; CHROMATID SEPARATION; PITUITARY-ADENOMAS; FOLLICULAR CELLS	The ability of the thyroid to accumulate iodide provides the basis for radioiodine ablation of differentiated thyroid cancers and their metastases. Most thyroid tumours exhibit reduced iodide uptake, although the mechanisms accounting for this remain poorly understood. Pituitary tumour transforming gene (PTTG) is a proto-oncogene implicated in the pathogenesis of thyroid tumours. We now show that PTTG and its binding factor PBF repress expression of sodium iodide symporter (NIS) messenger RNA (mRNA), and inhibit iodide uptake. This process is mediated at least in part through. fibroblast growth factor-2. In detailed studies of the NIS promoter in rat FRTL-5 cells, PTTG and PBF demonstrated specific inhibition of promoter activity via the human upstream enhancer element (hNUE). Within this similar to 1 kb element, a complex PAX8-upstream stimulating factor 1 (USF1) response element proved critical both to basal promoter activity and to PTTG and PBF repression of NIS. In particular, repression by PTTG was contingent upon the USF1, but not the PAX8, site. Finally, in human primary thyroid cells, PTTG and PBF similarly repressed the NIS promoter via hNUE. Taken together, our data suggest that the reported overexpression of PTTG and PBF in differentiated thyroid cancer has profound implications for activity of the NIS gene, and hence significantly impacts upon the ef. ficacy of radioiodine treatment.	Univ Birmingham, Dept Med, Inst Biomed Res, Div Med Sci, Birmingham B15 2TH, W Midlands, England; Univ Coll Los Angeles, V A Greater Los Angeles Healthcare Syst, Dept Med Endocrinol & Diabet Div, Los Angeles, CA USA	University of Birmingham	McCabe, CJ (corresponding author), Univ Birmingham, Dept Med, Inst Biomed Res, Div Med Sci, Birmingham B15 2TH, W Midlands, England.	mccabcjz@bham.ac.uk	Smith, Vicki E/F-6972-2010	Smith, Vicki E/0000-0003-0757-7198	MRC [G0601811] Funding Source: UKRI; Medical Research Council [G0601811] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Arturi F, 2000, EUR J ENDOCRINOL, V143, P623, DOI 10.1530/eje.0.1430623; Arturi F, 2001, EUR J ENDOCRINOL, V145, P129, DOI 10.1530/eje.0.1450129; Behr M, 1998, BIOCHEM J, V331, P359, DOI 10.1042/bj3310359; Boelaert K, 2004, J MOL ENDOCRINOL, V33, P663, DOI 10.1677/jme.1.01606; Boelaert K, 2003, FASEB J, V17, P1631, DOI 10.1096/fj.02-0948com; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Boelaert K, 2003, LANCET, V361, P796, DOI 10.1016/S0140-6736(03)12720-1; Caillou B, 1998, J CLIN ENDOCR METAB, V83, P4102, DOI 10.1210/jc.83.11.4102; Castro MR, 1999, J ENDOCRINOL, V163, P495, DOI 10.1677/joe.0.1630495; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; Chun JT, 2004, MOL ENDOCRINOL, V18, P2817, DOI 10.1210/me.2004-0020; Cocks HC, 2003, AM J PHYSIOL-ENDOC M, V285, pE460, DOI 10.1152/ajpendo.00519.2002; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; Dohan O, 2003, ENDOCR REV, V24, P48, DOI 10.1210/er.2001-0029; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Eggo MC, 1996, J CLIN ENDOCR METAB, V81, P3056, DOI 10.1210/jc.81.8.3056; EGGO MC, 1995, J CLIN ENDOCR METAB, V80, P1006, DOI 10.1210/jc.80.3.1006; Heaney AP, 2001, J CLIN ENDOCR METAB, V86, P5025, DOI 10.1210/jc.86.10.5025; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Ishikawa H, 2001, J CLIN ENDOCR METAB, V86, P867, DOI 10.1210/jc.86.2.867; Jhiang SM, 1998, ENDOCRINOLOGY, V139, P4416, DOI 10.1210/en.139.10.4416; Kim D, 2005, ONCOGENE, V24, P4861, DOI 10.1038/sj.onc.1208659; Kim DS, 2006, J CLIN ENDOCR METAB, V91, P4603, DOI 10.1210/jc.2006-1291; Kogai T, 2000, P NATL ACAD SCI USA, V97, P8519, DOI 10.1073/pnas.140217197; Kogai T, 1997, ENDOCRINOLOGY, V138, P2227, DOI 10.1210/en.138.6.2227; Lazar V, 1999, J CLIN ENDOCR METAB, V84, P3228, DOI 10.1210/jc.84.9.3228; Lin XQ, 2004, THYROID, V14, P19, DOI 10.1089/105072504322783803; Liou MJ, 2000, CANCER LETT, V160, P75, DOI 10.1016/S0304-3835(00)00565-6; McCabe Chris, 2001, Current Opinion in Pharmacology, V1, P620, DOI 10.1016/S1471-4892(01)00106-0; McCabe CJ, 2003, CLIN ENDOCRINOL, V58, P141, DOI 10.1046/j.1365-2265.2003.01598.x; McCabe CJ, 2002, J CLIN ENDOCR METAB, V87, P4238, DOI 10.1210/jc.2002-020309; Park HJ, 2000, THYROID, V10, P211, DOI 10.1089/thy.2000.10.211; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; Pei L, 2000, J BIOL CHEM, V275, P31191, DOI 10.1074/jbc.M002451200; Puri R, 2001, CANCER LETT, V163, P131, DOI 10.1016/S0304-3835(00)00688-1; Ramsden JD, 2001, J CLIN ENDOCR METAB, V86, P2709, DOI 10.1210/jc.86.6.2709; Ringel MD, 2001, MODERN PATHOL, V14, P289, DOI 10.1038/modpathol.3880305; Romero F, 2001, NUCLEIC ACIDS RES, V29, P1300, DOI 10.1093/nar/29.6.1300; Ryu KY, 1999, THYROID, V9, P405, DOI 10.1089/thy.1999.9.405; Ryu KY, 1998, J CLIN ENDOCR METAB, V83, P3247, DOI 10.1210/jc.83.9.3247; Saez C, 2006, J CLIN ENDOCR METAB, V91, P1404, DOI 10.1210/jc.2005-2532; Saito T, 1998, J CLIN INVEST, V101, P1296, DOI 10.1172/JCI1259; Schmidt D, 2001, CURR OPIN HEMATOL, V8, P1, DOI 10.1097/00062752-200101000-00001; Shibata Y, 2002, JPN J CLIN ONCOL, V32, P233, DOI 10.1093/jjco/hyf058; Smanik PA, 1996, BIOCHEM BIOPH RES CO, V226, P339, DOI 10.1006/bbrc.1996.1358; Smanik PA, 1997, ENDOCRINOLOGY, V138, P3555, DOI 10.1210/en.138.8.3555; Spitzweg C, 1999, THYROID, V9, P821, DOI 10.1089/thy.1999.9.821; Stratford AL, 2005, J CLIN ENDOCR METAB, V90, P4341, DOI 10.1210/jc.2005-0523; Taki K, 2002, MOL ENDOCRINOL, V16, P2266, DOI 10.1210/me.2002-0109; Tanaka K, 2000, EUR J ENDOCRINOL, V142, P340, DOI 10.1530/eje.0.1420340; Yaspo ML, 1998, GENOMICS, V49, P133, DOI 10.1006/geno.1998.5217; Yu R, 2000, MOL ENDOCRINOL, V14, P1137, DOI 10.1210/me.14.8.1137; Yu R, 2001, BRAIN PATHOL, V11, P328; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	59	40	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4344	4356		10.1038/sj.onc.1210221	http://dx.doi.org/10.1038/sj.onc.1210221			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17297475				2022-12-17	WOS:000247620000003
J	Pastural, E; Takahashi, N; Dong, WF; Bainbridge, M; Hull, A; Pearson, D; Huang, S; Lowsky, R; DeCoteau, JF; Geyer, CR				Pastural, E.; Takahashi, N.; Dong, W-F; Bainbridge, M.; Hull, A.; Pearson, D.; Huang, S.; Lowsky, R.; DeCoteau, J. F.; Geyer, C. R.			RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines	ONCOGENE			English	Article						chronic myeloid leukemia; RIZ1; IGF-1; histone methyltransferase	ZINC-FINGER PROTEIN; TUMOR-SUPPRESSOR GENE; ERYTHROID-DIFFERENTIATION; PR DOMAIN; HISTONE METHYLTRANSFERASE; BINDING; IDENTIFICATION; INACTIVATION; EXPRESSION; MUTATIONS	RIZ1 is a histone methyltransferase whose expression and activity are reduced in many cancers. In chronic myelogenous leukemia (CML), blastic transformation is associated with loss of heterozygosity in the region where RIZ1 is located and with decreased RIZ1 expression. Forced RIZ1 expression in model CML blast crisis (BC) cell lines decreases proliferation, increases apoptosis and enhances differentiation. We characterized molecular mechanisms that may contribute to potential CML tumor suppressor properties of RIZ1. Several RIZ1-regulated genes involved in insulin-like growth factor-1 (IGF-1) signaling were identified using cDNA microarrays. RIZ1 was shown to associate with promoter regions of IGF-1 and to increase histone H3 lysine 9 methylation using chromatin immunoprecipitation assays. IGF-1-blocking antibody was used to demonstrate the importance of autocrine IGF-1 signaling in CML-BC cell line viability. Forced RIZ1 expression in CML-BC cell lines decreases IGF-1 receptor activation and activation of downstream signaling components extracellular signal-regulated kinase 1/2 and AKT. These results highlight the therapeutic potential of inhibiting IGF-1 pathway in the acute phase of CML.	Univ Saskatchewan, Genom Med & Pathobiol Grp, Saskatoon, SK S7N 0W0, Canada; Univ Saskatchewan, Dept Pathol, Saskatoon, SK S7N 0W0, Canada; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 0W0, Canada; Burnham Inst, Canc Genet & Epigenet Program, La Jolla, CA 92037 USA; Stanford Univ, Med Ctr, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; Sanford Burnham Prebys Medical Discovery Institute; Stanford University	DeCoteau, JF (corresponding author), Saskatoon Canc Ctr, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.	john.decoteau@usask.ca; ron.geyer@usask.ca						Abbondanza C, 2000, P NATL ACAD SCI USA, V97, P3130, DOI 10.1073/pnas.050015697; Aro ALA, 2002, LEUKEMIA RES, V26, P831, DOI 10.1016/S0145-2126(02)00006-1; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Carling T, 2004, MOL CELL BIOL, V24, P7032, DOI 10.1128/MCB.24.16.7032-7042.2004; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; CHANG HW, 2004, INT J CANCER, V110, P212; Dong WF, 2003, BLOOD, V102, p579A; Du Y, 2001, CANCER RES, V61, P8094; Dumas AR, 2004, LEUKEMIA RES, V28, P1329, DOI 10.1016/j.leukres.2004.04.013; ENDO K, 1993, BRIT J HAEMATOL, V85, P653, DOI 10.1111/j.1365-2141.1993.tb03205.x; Francki A, 2003, J CELL BIOCHEM, V88, P802, DOI 10.1002/jcb.10424; Gazzerro P, 2006, EXP CELL RES, V312, P340, DOI 10.1016/j.yexcr.2005.11.002; HICKS DG, 1985, EXP HEMATOL, V13, P273; Hoeflich A, 2001, CANCER RES, V61, P8601; Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933; Kang CD, 1999, EXP MOL MED, V31, P76, DOI 10.1038/emm.1999.13; Kim KC, 2003, CANCER RES, V63, P7619; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; Medici N, 1999, BIOCHEM BIOPH RES CO, V264, P983, DOI 10.1006/bbrc.1999.1604; Mori N, 1998, BLOOD, V92, P3405, DOI 10.1182/blood.V92.9.3405.421k44_3405_3409; Muraosa Y, 1996, EUR J BIOCHEM, V235, P471, DOI 10.1111/j.1432-1033.1996.00471.x; PEPE MG, 1987, J CELL PHYSIOL, V133, P219, DOI 10.1002/jcp.1041330204; Piao Z, 2000, CANCER RES, V60, P4701; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; SHAPIRO VS, 1995, GENE, V163, P329, DOI 10.1016/0378-1119(95)00420-B; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Takahashi N, 2005, BLOOD, V106, p352A; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; VANDELOOSDRECHT AA, 1994, J IMMUNOL METHODS, V174, P311, DOI 10.1016/0022-1759(94)90034-5; Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200; Woessmann W, 2004, CELL BIOL INT, V28, P403, DOI 10.1016/j.cellbi.2004.03.009; Woessmann W, 2001, EXP CELL RES, V264, P193, DOI 10.1006/excr.2000.5124; Xie M, 1997, J BIOL CHEM, V272, P26360, DOI 10.1074/jbc.272.42.26360	34	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1586	1594		10.1038/sj.onc.1209959	http://dx.doi.org/10.1038/sj.onc.1209959			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953217				2022-12-17	WOS:000244782500008
J	Borczuk, AC; Cappellini, GCA; Kim, HK; Hesdorffer, M; Taub, RN; Powell, CA				Borczuk, A. C.; Cappellini, G. C. A.; Kim, H. K.; Hesdorffer, M.; Taub, R. N.; Powell, C. A.			Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors	ONCOGENE			English	Article						mesothelioma; microarray analysis; bortezomib; drug therapy combination	PLEURAL MESOTHELIOMA; PHASE-II; EXPRESSION; GEMCITABINE; CANCER; CELL; COMBINATION; DOCETAXEL; OVEREXPRESSION; CISPLATIN	Malignant mesothelioma is an aggressive neoplastic proliferation derived from cells lining serosal membranes. The biological and clinical characteristics of epithelial type malignant mesothelioma are distinct from those of biphasic and sarcomatous type tumors. The goal of our study was to examine the molecular basis for this distinction. Microarray analysis confirmed that the molecular signatures of epithelial and biphasic histologic subtypes were distinct. Among the differentially expressed functional gene categories was the ubiquitin-proteasome pathway, which was upregulated in biphasic tumors. Cytotoxicity experiments indicated that 211H cells derived from biphasic tumors were synergistically sensitive to sequential combination regimens containing the proteasome inhibitor bortezomib and oxaliplatin. The mechanism of this synergistic response, which was not detected in cells of epithelial tumor origin, was apoptosis. Together, our results identify the ubiquitin-proteasome pathway as a biomarker of poor prognosis biphasic peritoneal mesothelioma tumors and suggest that proteasome inhibitors could increase the effectiveness of cytotoxic chemotherapy in this subset of patients.	Columbia Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Coll Phys & Surg,Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University	Powell, CA (corresponding author), Columbia Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Coll Phys & Surg,Dept Med, 630 W 168th St,Box 91, New York, NY 10032 USA.	cap6@columbia.edu	Borczuk, Alain/AAI-8226-2021; Powell, Charles A/C-8663-2011; BORCZUK, alain/AHA-5172-2022; Borczuk, Alain/AFU-5278-2022	Borczuk, Alain/0000-0001-6807-8064; Powell, Charles A/0000-0003-3509-891X; Borczuk, Alain/0000-0001-6807-8064				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Borczuk AC, 2005, AM J RESP CRIT CARE, V172, P729, DOI 10.1164/rccm.200504-615OC; Borczuk AC, 2005, CLIN CANCER RES, V11, P3303, DOI 10.1158/1078-0432.CCR-04-1884; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; Fally BN, 2003, J SURG RES, V113, P88, DOI 10.1016/S0022-4804(03)00201-4; Fizazi K, 2003, J CLIN ONCOL, V21, P349, DOI 10.1200/JCO.2003.05.123; Gentiloni N, 1997, J CLIN GASTROENTEROL, V24, P276, DOI 10.1097/00004836-199706000-00023; GOLDBLUM J, 1995, AM J SURG PATHOL, V19, P1124, DOI 10.1097/00000478-199510000-00003; Gordon GJ, 2005, AM J PATHOL, V166, P1827, DOI 10.1016/S0002-9440(10)62492-3; Gordon GJ, 2003, J NATL CANCER I, V95, P598, DOI 10.1093/jnci/95.8.598; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Khalil N, 2001, THORAX, V56, P907, DOI 10.1136/thorax.56.12.907; Kim H, 2003, AM J RESP CELL MOL, V29, P694, DOI 10.1165/rcmb.2003-0061OC; Kitagawa Y, 1996, AM J RESP CELL MOL, V15, P45, DOI 10.1165/ajrcmb.15.1.8679221; Lee JJ, 1996, CANCER EPIDEM BIOMAR, V5, P191; Leu KM, 2004, J CLIN ONCOL, V22, P1706, DOI 10.1200/JCO.2004.08.043; Lopez-Rios F, 2006, CANCER RES, V66, P2970, DOI 10.1158/0008-5472.CAN-05-3907; McShane LM, 2002, BIOINFORMATICS, V18, P1462, DOI 10.1093/bioinformatics/18.11.1462; Mohamed Faheez, 2002, Curr Treat Options Oncol, V3, P375, DOI 10.1007/s11864-002-0003-6; Nawrocki ST, 2004, MOL CANCER THER, V3, P59; Nowak AK, 2002, BRIT J CANCER, V87, P491, DOI 10.1038/sj.bjc.6600505; Pass HI, 2004, CLIN CANCER RES, V10, P849, DOI 10.1158/1078-0432.CCR-0607-3; Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030; REILE H, 1990, ANAL BIOCHEM, V187, P262, DOI 10.1016/0003-2697(90)90454-H; Ricotti L, 2003, CLIN CANCER RES, V9, P900; Robinson BW, 2004, SEMIN ONCOL, V31, P2, DOI 10.1053/j.seminoncol.2004.03.021; Schenkein David P, 2005, Clin Lung Cancer, V7 Suppl 2, pS49, DOI 10.3816/CLC.2005.s.008; Schutte Wolfgang, 2003, Clin Lung Cancer, V4, P294, DOI 10.3816/CLC.2003.n.009; Sebbag G, 2000, BRIT J SURG, V87, P1587, DOI 10.1046/j.1365-2168.2000.01571.x; Singhal S, 2003, CLIN CANCER RES, V9, P3080; Sugarbaker Paul H, 2003, Surg Oncol Clin N Am, V12, P605, DOI 10.1016/S1055-3207(03)00045-0; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; Taub R N, 2000, Curr Treat Options Oncol, V1, P303, DOI 10.1007/s11864-000-0046-5; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Voorhees PM, 2003, CLIN CANCER RES, V9, P6316	37	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					610	617		10.1038/sj.onc.1209809	http://dx.doi.org/10.1038/sj.onc.1209809			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862182				2022-12-17	WOS:000243731600013
J	Ji, Z; Degerny, C; Vintonenko, N; Deheuninck, J; Foveau, B; Leroy, C; Coll, J; Tulasne, D; Baert, JL; Fafeur, V				Ji, Z.; Degerny, C.; Vintonenko, N.; Deheuninck, J.; Foveau, B.; Leroy, C.; Coll, J.; Tulasne, D.; Baert, J-L; Fafeur, V.			Regulation of the Ets-1 transcription factor by sumoylation and ubiquitinylation	ONCOGENE			English	Article						Ets-1; transcription factor; SUMO; ubiquitin	DNA-BINDING; MOLECULAR-BIOLOGY; SUMO MODIFICATION; GENE-EXPRESSION; PHOSPHORYLATION; RECEPTOR; DOMAIN; COACTIVATOR; REPRESSION; INHIBITION	Sumoylation and ubiquitinylation reversibly regulate the activity of transcription factors through covalent attachment to lysine residues of target proteins. We examined whether the Ets-1 transcription factor is modified by sumoylation and/or ubiquitinylation. Among four potential SUMO motifs in Ets-1, we identified lysines 15 and 227 within the (LKYE)-Y-15 and IK(227)QE motifs, as being the sumoylation acceptor sites. Using transfection of Ets-1 wildtype (WT) or its sumoylation deficient version (Ets-1 K15R/K227R), as well as WT or mutant proteins of the SUMO pathway, we further demonstrated that the E2 SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance Ets-1 sumoylation, while a SUMO protease, SENP1, can desumoylate Ets-1. We also found that Ets-1 is modified by K48-linked polyubiquitinylation independently of the sumoylation acceptor sites and is degraded through the 26S proteasome pathway, while sumoylation of Ets-1 does not affect its stability. Finally, sumoylation of Ets-1 leads to reduced transactivation and we demonstrated that previously identified critical lysine residues in Synergistic Control motifs are the sumoylation acceptor sites of Ets-1. These data show that Ets-1 can be modified by sumoylation and/or ubiquitinylation, with sumoylation repressing transcriptional activity of Ets-1 and having no clear antagonistic action on the ubiquitin-proteasome degradation pathway.	Univ Lille 1, Inst Biol Lille, CNRS, UMR 8161,Inst Pasteur Lille,Univ Lille 2, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Fafeur, V (corresponding author), Univ Lille 1, Inst Biol Lille, CNRS, UMR 8161,Inst Pasteur Lille,Univ Lille 2, 1 Rue Calmette,BP 447, F-59021 Lille, France.	veronique.fafeur@ibl.fr	Tulasne, David/AAR-5287-2020; Fafeur, Veronique/L-9072-2018; Tulasne, David/A-8705-2008	Tulasne, David/0000-0002-6764-7242; 				Bohren KM, 2004, J BIOL CHEM, V279, P27233, DOI 10.1074/jbc.M402273200; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004; Cowley DO, 2000, GENE DEV, V14, P366; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; Degerny C, 2005, J BIOL CHEM, V280, P24330, DOI 10.1074/jbc.M411250200; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Dohmen RJ, 2004, BBA-MOL CELL RES, V1695, P113, DOI 10.1016/j.bbamcr.2004.09.021; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Herrera FJ, 2004, CURR BIOL, V14, pR622, DOI 10.1016/j.cub.2004.07.046; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Janknecht R, 1996, ONCOGENE, V12, P1961; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kurihara I, 2005, J BIOL CHEM, V280, P6721, DOI 10.1074/jbc.M411820200; Leight ER, 2005, DEVELOPMENT, V132, P1047, DOI 10.1242/dev.01664; Macauley MS, 2006, J BIOL CHEM, V281, P4164, DOI 10.1074/jbc.M510488200; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Perdomo J, 2005, MOL CELL BIOL, V25, P1549, DOI 10.1128/MCB.25.4.1549-1559.2005; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rabault B, 1996, ONCOGENE, V13, P877; Reveneau S, 2003, ANN NY ACAD SCI, V1010, P100, DOI 10.1196/annals.1299.016; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Takahashi A, 2005, BIOCHEM BIOPH RES CO, V327, P575, DOI 10.1016/j.bbrc.2004.12.045; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; van den Akker E, 2005, J BIOL CHEM, V280, P38035, DOI 10.1074/jbc.M502938200; Wasylyk C, 2005, ONCOGENE, V24, P820, DOI 10.1038/sj.onc.1208226; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yang SH, 2005, EMBO J, V24, P2161, DOI 10.1038/sj.emboj.7600690; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X	53	40	41	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					395	406		10.1038/sj.onc.1209789	http://dx.doi.org/10.1038/sj.onc.1209789			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16862185				2022-12-17	WOS:000243544000008
J	Salatino, M; Beguelin, W; Peters, MG; Carnevale, R; Proietti, CJ; D Galigniana, M; Vedoy, CG; Schillaci, R; Charreau, EH; Sogayar, MC; Elizalde, PV				Salatino, M.; Beguelin, W.; Peters, M. G.; Carnevale, R.; Proietti, C. J.; D Galigniana, M.; Vedoy, C. G.; Schillaci, R.; Charreau, E. H.; Sogayar, M. C.; Elizalde, P. V.			Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation	ONCOGENE			English	Article						caveolin-1; breast cancer; progesterone receptor	ACTIVATED PROTEIN-KINASE; ONCOGENICALLY TRANSFORMED-CELLS; MOUSE MAMMARY ADENOCARCINOMAS; INSENSITIVE PROSTATE-CANCER; ESTROGEN-RECEPTOR-ALPHA; GROWTH-FACTOR RECEPTOR; IN-VIVO; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; MEDROXYPROGESTERONE ACETATE	Progestin regulation of gene expression was assessed in the progestin- dependent murine tumor line C4HD which requires MPA, a synthetic progestin, for in vivo growth and expresses high levels of progesterone receptor ( PR). By using suppressive subtractive hybridization, caveolin-1 was identified as a gene whose expression was increased with in vivo MPA treatment. By Northern and Western blot analysis, we further confirmed that caveolin-1 mRNA and protein expression increased in MPA- treated tumors as compared with untreated tumors. When primary cultures of C4H D cells were treated in vitro with MPA, caveolin-1 levels also increased, effect that was abolished by pre-treatment with progestin antagonist RU486. In addition, MPA promoted strong caveolin-1 promoter transcriptional activation both in mouse and human breast cancer cells. We also showed that MPA regulation of caveolin-1 expression involved in activation of two signaling pathways: MAPK and PI-3K. Short- term MPA treatment of C4HD cells led to tyrosine phosphorylation of caveolin-1 protein, where Src was the kinase involved. Additionally, we showed that MPA- induced association of caveolin- 1 and PR, which was detected by communoprecipitation and by confocal microscopy. Finally, we proved that MPA- induced proliferation of C4HD cells was inhibited by suppression ofcaveol in- 1 expression with antisense oligodeoxynucleotides to caveolin1 mRNA. Furthermore, we observed that inhibition of caveolin- 1 expression abrogated PR capacity to induced luciferase activity from a progesterone response elementdriven reporter plasmid. Comprehensively, our results demonstrated for the. rst time that caveolin- 1 expression is upregulated by progestin in breast cancer. We also demonstrated that caveolin- 1 is a downstream effector of MPA that is partially responsible for the stimulation of growth ofbreast cancer cells.	Consejo Nacl Invest Cient & Tecn, Lab Mol Mechanisms Carcinogenesis, Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Inst Oncol Angel H Roffo, Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, Inst Leloir, RA-1033 Buenos Aires, DF, Argentina; Univ Sao Paulo, Inst Quim, Sao Paulo, Brazil	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; Universidade de Sao Paulo	Elizalde, PV (corresponding author), Consejo Nacl Invest Cient & Tecn, Lab Mol Mechanisms Carcinogenesis, Inst Biol & Med Expt, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	elizalde@dna.uba.ar	Sogayar, Mari C/B-3980-2017	Sogayar, Mari C/0000-0003-4805-4609; Elizalde, Patricia V./0000-0002-5923-9898; GALIGNIANA, MARIO/0000-0002-9130-8574; Peters, Maria/0000-0002-9271-4590				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Balana ME, 2001, ONCOGENE, V20, P34, DOI 10.1038/sj.onc.1204050; Balana ME, 1999, ONCOGENE, V18, P6370, DOI 10.1038/sj.onc.1203028; Ballare C, 2003, MOL CELL BIOL, V23, P1994, DOI 10.1128/MCB.23.6.1994-2008.2003; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Cho KA, 2003, J BIOL CHEM, V278, P27789, DOI 10.1074/jbc.M208105200; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Elizalde PV, 1998, J STEROID BIOCHEM, V67, P305, DOI 10.1016/S0960-0760(98)00123-X; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Galbiati F, 2001, TRENDS MOL MED, V7, P435, DOI 10.1016/S1471-4914(01)02105-0; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; Hayashi K, 2001, CANCER RES, V61, P2361; Ho Shuk-Mei, 2003, Reprod Biol Endocrinol, V1, P73, DOI 10.1186/1477-7827-1-73; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Ismail PM, 2003, STEROIDS, V68, P779, DOI 10.1016/S0039-128X(03)00133-8; Kiss AL, 2005, MOL CELL ENDOCRINOL, V245, P128, DOI 10.1016/j.mce.2005.11.005; Kogo H, 2000, FEBS LETT, V465, P119, DOI 10.1016/S0014-5793(99)01730-5; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KORDON E, 1990, BREAST CANCER RES TR, V17, P33, DOI 10.1007/BF01812682; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Lange CA, 1999, MOL ENDOCRINOL, V13, P829, DOI 10.1210/me.13.6.829; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Lee H, 2002, AM J PATHOL, V161, P1357, DOI 10.1016/S0002-9440(10)64412-4; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li LK, 2001, CANCER RES, V61, P4386; Li SW, 1996, J BIOL CHEM, V271, P3863; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Lydon JP, 2000, J MAMMARY GLAND BIOL, V5, P325, DOI 10.1023/A:1009555013246; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Montecchia MF, 1999, J STEROID BIOCHEM, V68, P11, DOI 10.1016/S0960-0760(98)00166-6; Mouraviev V, 2002, J UROLOGY, V168, P1589, DOI 10.1016/S0022-5347(05)64526-0; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Proietti C, 2005, MOL CELL BIOL, V25, P4826, DOI 10.1128/MCB.25.12.4826-4840.2005; Puricelli L, 2002, INT J CANCER, V100, P642, DOI 10.1002/ijc.10533; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Salatino M, 2004, ONCOGENE, V23, P5161, DOI 10.1038/sj.onc.1207659; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Schlegel A, 2001, BIOCHEM J, V359, P203, DOI 10.1042/0264-6021:3590203; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Sloan EK, 2004, ONCOGENE, V23, P7893, DOI 10.1038/sj.onc.1208062; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Syed V, 2005, ONCOGENE, V24, P1774, DOI 10.1038/sj.onc.1207991; Tahir SA, 2001, CANCER RES, V61, P3882; Thompson TC, 1999, APOPTOSIS, V4, P233, DOI 10.1023/A:1009612708099; Timme TL, 2003, CURR DRUG TARGETS, V4, P251, DOI 10.2174/1389450033491127; Trouet D, 1999, J PHYSIOL-LONDON, V520, P113, DOI 10.1111/j.1469-7793.1999.t01-1-00113.x; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Watson CS, 2003, EXP BIOL MED, V228, P1272, DOI 10.1177/153537020322801106; Way M, 1996, FEBS LETT, V378, P101, DOI 10.1016/0014-5793(96)82884-5; Williams TM, 2005, J BIOL CHEM, V280, P25134, DOI 10.1074/jbc.M501186200; Williams TM, 2004, J BIOL CHEM, V279, P51630, DOI 10.1074/jbc.M409214200; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873; Yang G, 2000, CLIN CANCER RES, V6, P3430	66	40	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7723	7739		10.1038/sj.onc.1209757	http://dx.doi.org/10.1038/sj.onc.1209757			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16799639				2022-12-17	WOS:000242830800007
J	Balkhi, MY; Trivedi, AK; Geletu, M; Christopeit, M; Bohlander, SK; Behre, HM; Behre, G				Balkhi, M. Y.; Trivedi, A. K.; Geletu, M.; Christopeit, M.; Bohlander, S. K.; Behre, H. M.; Behre, G.			Proteomics of acute myeloid leukaemia: cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications	ONCOGENE			English	Article						acute myeloid leukaemia; proteomics; post-translational modification; mass spectrometry	N-ARGININE METHYLATION; C/EBP-ALPHA; O-GLCNAC; EXPRESSION; CANCER; IDENTIFICATION; GLYCOSYLATION; SUPPRESSES; DISEASE; CEBPA	Acute myeloid leukaemia (AML) is characterized by specific cytogenetic aberrations that are strong determinants of prognostic outcome and therapeutic response. Because the pathological outcome of AML patients with cytogenetic abnormalities differs considerably, we hypothesized that their proteome may also differ specifically in their expression pattern, protein interaction pathways and post-translational modifications (PTM). We performed this study using 42 AML patients diagnosed for various cytogenetic abnormalities based on two-dimensional gel electrophoresis and matrix-assisted laser desorption/ ionization time of flight mass spectrometry (MS) and MSMS tandem MS. We could identify signi. cant differences in the proteome and PTM of peptides, later confirmed by other methods, between cytogenetic groups. The interactome analysis based on computational bioinformatics reveals major regulating networks: MAPK8 and MYC for complex aberrant karyotype, TP53 for t(8; 21), TP53-MYC-PRKAC for 11q23 and JUN and MYC for Inv(16). Further, we analysed 42 MS spectra representative of hnRNPH1, calreticulin and hnRNPA2/ B1 in a peak explorer, which reveals a cytogenetic-specific PTM of beta-O-linked N-acetyl glucosamine (O-GlcNAc) of hnRNPH1 in AML patients with 11q23 translocation, an acetylation of calreticulin in t(8; 21) translocation and methylation of hnRNPA2/ B1 in patients with translocations of t(8; 21) and inv(16). This report may lead to a new thinking about AML pathogenesis, as differences at PTM level could be used to distinguish different subtypes of AML.	Univ Halle Wittenberg, Bone Marrow Transplantat Sect, Dept Internal Med Hematol & Oncol 4, State Ctr Cell & Gene Therapy, D-06097 Halle, Germany; Univ Munich, Dept Med 3, Munich, Germany; Univ Halle Wittenberg, Dept Urol, Androl Sect, D-06097 Halle, Germany	Martin Luther University Halle Wittenberg; University of Munich; Martin Luther University Halle Wittenberg	Behre, G (corresponding author), Univ Halle Wittenberg, Bone Marrow Transplantat Sect, Dept Internal Med Hematol & Oncol 4, State Ctr Cell & Gene Therapy, Ernst Grube Str 40, D-06097 Halle, Germany.	gerhard.behre@medizin.uni-halle.de	Trivedi, Arun Kumar/W-1883-2019	Trivedi, Arun Kumar/0000-0002-6316-0947; Bohlander, Stefan/0000-0002-2202-9088; Christopeit, Maximilian/0000-0003-4627-0412				Bienz M, 2005, CLIN CANCER RES, V11, P1416, DOI 10.1158/1078-0432.CCR-04-1552; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Cristea IM, 2004, BLOOD, V103, P3624, DOI 10.1182/blood-2003-09-3295; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Gurbuxani S, 2005, P NATL ACAD SCI USA, V102, P11480, DOI 10.1073/pnas.0500303102; Haferlach T., 2004, Annals of Hematology, V83, pS97; Helbling D, 2005, BLOOD, V106, P1369, DOI 10.1182/blood-2004-11-4392; Helbling D, 2004, P NATL ACAD SCI USA, V101, P13312, DOI 10.1073/pnas.0404731101; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; Khidekel N, 2004, P NATL ACAD SCI USA, V101, P13132, DOI 10.1073/pnas.0403471101; Li C, 1998, ARCH BIOCHEM BIOPHYS, V351, P53, DOI 10.1006/abbi.1997.0526; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lin CH, 2000, J BIOCHEM, V128, P493, DOI 10.1093/oxfordjournals.jbchem.a022779; Lominadze G, 2005, J IMMUNOL, V174, P7257, DOI 10.4049/jimmunol.174.11.7257; Mann M, 2003, NAT BIOTECHNOL, V21, P255, DOI 10.1038/nbt0303-255; Marcucci G, 2004, J CLIN ONCOL, V22, P2410, DOI 10.1200/JCO.2004.03.023; Nedelkov D, 2005, P NATL ACAD SCI USA, V102, P10852, DOI 10.1073/pnas.0500426102; Petricoin EF, 2005, J CLIN ONCOL, V23, P3614, DOI 10.1200/JCO.2005.02.509; Sagil D, 2005, PROTEOMICS, V5, P2689, DOI 10.1002/pmic.200401312; Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413; Schoch C, 2005, GENE CHROMOSOME CANC, V43, P227, DOI 10.1002/gcc.20193; Timchenko LT, 2002, MOL CELL BIOL, V22, P7242, DOI 10.1128/MCB.22.20.7242-7257.2002; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Vosseller K, 2001, BIOCHIMIE, V83, P575, DOI 10.1016/S0300-9084(01)01295-0; Wang ZF, 2004, CELL, V119, P831, DOI 10.1016/j.cell.2004.11.010; Wells L, 2003, BIOCHEM BIOPH RES CO, V302, P435, DOI 10.1016/S0006-291X(03)00175-X; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Zhou J, 2001, LUNG CANCER, V34, P341, DOI 10.1016/S0169-5002(01)00254-9	29	40	43	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7041	7058		10.1038/sj.onc.1209689	http://dx.doi.org/10.1038/sj.onc.1209689			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732326				2022-12-17	WOS:000241910500004
J	Artus, C; Maquarre, E; Moubarak, RS; Delettre, C; Jasmin, C; Susin, SA; Robert-Lezenes, J				Artus, C.; Maquarre, E.; Moubarak, R. S.; Delettre, C.; Jasmin, C.; Susin, S. A.; Robert-Lezenes, J.			CD44 ligation induces caspase-independent cell death via a novel calpain/AIF pathwayin human erythroleukemia cells	ONCOGENE			English	Article						CD44; apoptosis; calpain; AIF; erythroleukemia	ACUTE MYELOID-LEUKEMIA; CYTOCHROME-C RELEASE; ANTI-CD44 MONOCLONAL-ANTIBODIES; CANCER-CELLS; FACTOR AIF; POLY(ADP-RIBOSE) POLYMERASE-1; ERYTHROID-DIFFERENTIATION; NUCLEAR TRANSLOCATION; APOPTOSIS; MITOCHONDRIA	Ligation of the cell surface molecule CD44 by anti-CD44 monoclonal antibodies (mAbs) has been shown to induce cell differentiation, cell growth inhibition and in some cases, apoptosis in myeloid leukemic cells. We report, herein, that exposure of human erythroleukemic HEL cells to the anti-CD44 mAb A3D8 resulted in cell growth inhibition followed by caspase-independent apoptosis-like cell death. This process was associated with the disruption of mitochondrial membrane potential (Delta Psi m), the mitochondrial release of apoptosis-inducing factor (AIF), but not of cytochrome c, and the nuclear translocation of AIF. All these effects including cell death, loss of mitochondrial Delta Psi m and AIF release were blocked by pretreatment with the poly(ADP-ribose) polymerase inhibitor isoquinoline. A significant protection against cell death was also observed by using small interfering RNA for AIF. Moreover, we show that calpain protease was activated before the appearance of apoptosis, and that calpain inhibitors or transfection of calpain-siRNA decrease A3D8-induced cell death, and block AIF release. These data suggest that CD44 ligation triggers a novel caspase-independent cell death pathway via calpain-dependent AIF release in erythroleukemic HEL cells.	Hop Paul Brousse, INSERM, U602, F-94807 Villejuif, France; Inst Pasteur, Apoptose & Syst Immunitaire Grp, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Robert-Lezenes, J (corresponding author), Hop Paul Brousse, INSERM, U602, 14 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	lezenes@vjf.inserm.fr	Delettre, Cécile/AAC-3096-2020; Susin, Santos A/Q-6754-2017	Delettre, Cécile/0000-0003-3269-2155; Susin, Santos A/0000-0002-3366-1628; Moubarak, Rana/0000-0003-2096-1258				Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Altznauer F, 2004, J BIOL CHEM, V279, P5947, DOI 10.1074/jbc.M308576200; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Bras M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P231, DOI 10.1007/s10541-005-0105-4; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; BROWN LR, 1977, BIOCHIM BIOPHYS ACTA, V468, P389, DOI 10.1016/0005-2736(77)90290-5; Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Cerisano V, 2004, ONCOGENE, V23, P5664, DOI 10.1038/sj.onc.1207741; Charrad RS, 2002, BLOOD, V99, P290, DOI 10.1182/blood.V99.1.290; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Chen M, 2004, CARDIOVASC RES, V63, P682, DOI 10.1016/j.cardiores.2004.04.018; Cheung ECC, 2005, J NEUROSCI, V25, P1324, DOI 10.1523/JNEUROSCI.4261-04.2005; Corbiere C, 2004, CELL RES, V14, P188, DOI 10.1038/sj.cr.7290219; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Dejean LM, 2005, MOL BIOL CELL, V16, P2424, DOI 10.1091/mbc.e04-12-1111; Donovan M, 2004, BBA-MOL CELL RES, V1644, P133, DOI 10.1016/j.bbamcr.2003.08.011; Gadhoum Z, 2004, LEUKEMIA LYMPHOMA, V45, P1501, DOI 10.1080/1042819042000206687; Gadhoum Z, 2004, BLOOD, V103, P1059, DOI 10.1182/blood-2003-04-1218; Gao G, 2000, J CELL BIOCHEM, V80, P53; Ghaffari S, 1999, EXP HEMATOL, V27, P978, DOI 10.1016/S0301-472X(99)00023-5; Hafid-Medheb K, 2003, BLOOD, V101, P2575, DOI 10.1182/blood-2002-02-0478; Henry-Mowatt J, 2004, ONCOGENE, V23, P2850, DOI 10.1038/sj.onc.1207534; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; Ishitsuka K, 2005, ONCOGENE, V24, P5888, DOI 10.1038/sj.onc.1208739; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Lipton SA, 2002, CELL, V111, P147, DOI 10.1016/S0092-8674(02)01046-2; Liu T, 2004, ONCOGENE, V23, P39, DOI 10.1038/sj.onc.1206978; Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; Lu T, 2002, BBA-MOL CELL RES, V1590, P16, DOI 10.1016/S0167-4889(02)00193-3; Maquarre E, 2005, LEUKEMIA, V19, P2296, DOI 10.1038/sj.leu.2403944; Mateo W, 2002, BLOOD, V100, P2882, DOI 10.1182/blood-2001-12-0217; Mathiasen IS, 2002, J BIOL CHEM, V277, P30738, DOI 10.1074/jbc.M201558200; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Park YC, 2005, LIFE SCI, V77, P2059, DOI 10.1016/j.lfs.2005.04.021; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Poindessous-Jazat V, 2002, LEUKEMIA, V16, P233, DOI 10.1038/sj.leu.2402350; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Roue G, 2003, BIOCHIMIE, V85, P741, DOI 10.1016/S0300-9084(03)00129-9; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Song GL, 2004, LEUKEMIA RES, V28, P1089, DOI 10.1016/j.leukres.2004.02.005; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yu SW, 2003, NEUROBIOL DIS, V14, P303, DOI 10.1016/j.nbd.2003.08.008; Yuste VJ, 2005, CELL DEATH DIFFER, V12, P1445, DOI 10.1038/sj.cdd.4401687; Zada AAP, 2003, ONCOGENE, V22, P2296, DOI 10.1038/sj.onc.1206330; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	61	40	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5741	5751		10.1038/sj.onc.1209581	http://dx.doi.org/10.1038/sj.onc.1209581			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16636662				2022-12-17	WOS:000240765800005
J	Robinson, HMR; Jones, R; Walker, M; Zachos, G; Brown, R; Cassidy, J; Gillespie, DAF				Robinson, H. M. R.; Jones, R.; Walker, M.; Zachos, G.; Brown, R.; Cassidy, J.; Gillespie, D. A. F.			Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil	ONCOGENE			English	Article						Chk1; 5-fluorouracil; cell cycle checkpoint	DNA-DAMAGE; CHECKPOINT ABROGATION; CHK1; MECHANISMS; PATHWAYS; ARREST; ACTIVATION; SURVIVAL; CANCER; RNA	Chk1 plays a crucial role in the DNA damage and replication checkpoints in vertebrates and may therefore be an important determinant of tumour cell responses to genotoxic anticancer drugs. To evaluate this concept we compared the effects of the nucleoside analogue 5-fluorouracil (5FU) on cell cycle progression and clonogenic survival in DT40 B-lymphoma cells with an isogenic mutant derivative in which Chk1 function was ablated by gene targeting. We show that 5FU activates Chk1 in wild-type DT40 cells and that 5FU-treated cells accumulate in the S phase of the cell cycle due to slowing of the overall rate of DNA replication. In marked contrast, Chk1-deficient DT40 cells fail to slow DNA replication upon initial exposure to 5FU, despite equivalent inhibition of the target enzyme thymidylate synthase, and instead accumulate progressively in the G1 phase of the following cell cycle. This G1 accumulation cannot be reversed rapidly by exogenous thymidine or removal of 5FU, and is associated with increased incorporation of 5FU into genomic DNA and severely diminished clonogenic survival. Taken together, these results demonstrate that a Chk1-dependent replication checkpoint which slows S phase progression can protect tumour cells against the cytotoxic effects of 5FU.	Univ Glasgow, Canc Res Campaign Beatson Lab, Inst Biomed & Life Sci, Glasgow G61 1BD, Lanark, Scotland; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, CRUK Ctr Oncol & Appl Pharmacol, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Glasgow; Beatson Institute; Beatson Institute; University of Glasgow	Gillespie, DAF (corresponding author), Univ Glasgow, Canc Res Campaign Beatson Lab, Inst Biomed & Life Sci, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	d.gillespie@beatson.gla.ac.uk	Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544; Brown, Robert/0000-0001-7960-5755				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; GLAZER RI, 1982, MOL PHARMACOL, V21, P468; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; HEIDELBERGER C, 1983, ADV ENZYMOL RAMB, V54, P57; INGRAHAM HA, 1986, BIOCHEMISTRY-US, V25, P3225, DOI 10.1021/bi00359a022; INGRAHAM HA, 1980, CANCER RES, V40, P998; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; KUFE DW, 1981, J BIOL CHEM, V256, P9802; Liu XJ, 2005, CANCER RES, V65, P6874, DOI 10.1158/0008-5472.CAN-05-0288; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; MAURO DJ, 1993, MOL PHARMACOL, V43, P854; Meyers M, 2005, J BIOL CHEM, V280, P5516, DOI 10.1074/jbc.M412105200; Meyers M, 2001, CANCER RES, V61, P5193; Morgan MA, 2005, CANCER RES, V65, P6835, DOI 10.1158/0008-5472.CAN-04-2246; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Rhind N, 2000, J CELL SCI, V113, P3889; Sampath D, 2003, ONCOGENE, V22, P9063, DOI 10.1038/sj.onc.1207229; SANTI DV, 1974, BIOCHEMISTRY-US, V13, P471, DOI 10.1021/bi00700a012; Shi Z, 2001, CANCER RES, V61, P1065; Tajima A, 2004, GASTROENTEROLOGY, V127, P1678, DOI 10.1053/j.gastro.2004.10.001; Xiao Z, 2005, ONCOGENE, V24, P1403, DOI 10.1038/sj.onc.1208309; Zachos G, 2005, MOL CELL BIOL, V25, P563, DOI 10.1128/MCB.25.2.563-574.2005; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	27	40	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5359	5369		10.1038/sj.onc.1209532	http://dx.doi.org/10.1038/sj.onc.1209532			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16619043				2022-12-17	WOS:000240144900001
J	Muerkoster, SS; Lust, J; Arlt, A; Hasler, R; Witt, M; Sebens, T; Schreiber, S; Folsch, UR; Schafer, H				Mueerkoester, S. Sebens; Lust, J.; Arlt, A.; Haesler, R.; Witt, M.; Sebens, T.; Schreiber, S.; Foelsch, U. R.; Schaefer, H.			Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1 beta and NO lead to inactivation of caspases	ONCOGENE			English	Article						chemoresistance; interleukin-1 beta; pancreatic cancer; nitric oxide	NF-KAPPA-B; NITRIC-OXIDE; APOPTOSIS; CANCER; EXPRESSION; RESISTANCE; CHEMOTHERAPY; PROGRESSION; MECHANISMS; STRATEGIES	Pancreatic cancer exhibits profound chemoresistance resulting either from pre-existing ( intrinsic) mechanisms, or from anticancer drug treatment itself ( acquired chemoresistance). To identify molecular alterations leading to acquired chemoresistance, the chemosensitive pancreatic carcinoma cell line PT45-P1 was exposed to low-dose treatment with etoposide for 6 weeks. Afterwards, these cells (PT45-P1res) were much more resistant to high-dose treatment with anticancer drugs than parental cells. Among several differentially expressed genes in PT45-P1res cells, IL-1 beta was most significantly upregulated, a finding in line with our previous observation that IL-1 beta accounts for intrinsic chemoresistance of pancreatic carcinoma cells. Elevated IL-1 beta expression in PT45-P1res cells was confirmed by real-time PCR and ELISA, and treatment with the IL-1 receptor antagonist restored drug-induced apoptosis. The increased IL-1 beta secretion was accompanied by an elevated formation of nitric oxide ( NO) and a NO-dependent inhibition of the etoposide-induced caspase-3/-7/-8/-9 activity. Caspase activation was restored either by the iNOS inhibitor 1400W, the reducing agent dithiothreitol or the IL-1 receptor antagonist, resulting in greater sensitivity towards anticancer drug treatment. Conversely, IL-1 beta or the NO-donor SNAP decreased caspase activation and apoptosis in etoposide-treated PT45-P1 cells. These data confirm IL-1 beta and NO as determinants of chemoresistance in pancreatic cancer, and indicate that the intrinsic and acquired chemoresistance rely to some extent on common molecular targets beneficial for improved therapeutical strategies.	UKSH, Dept Med 1, Lab Mol Gastroenterol & Hepatol, D-24105 Kiel, Germany; UKSH, Dept Med 1, Mucosal Immunol Res Grp, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital	Schafer, H (corresponding author), UKSH, Dept Med 1, Lab Mol Gastroenterol & Hepatol, Campus Kiel,Schittenhelmstr 12, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Häsler, Robert/A-4908-2009; Schäfer, Heiner/C-1055-2011; Arlt, Alexander/G-7308-2019; Sebens, Susanne/C-1222-2010	Häsler, Robert/0000-0003-4174-8229; Arlt, Alexander/0000-0002-6160-1059; 				Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Arlt A, 2002, CANCER RES, V62, P910; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; BLASZKOWSKY L, 1998, FRONT BIOSCI, V3, P214; BRAMHALL SR, 1995, BRIT J SURG, V82, P111, DOI 10.1002/bjs.1800820137; Brand Randall E., 1998, Current Opinion in Oncology, V10, P362, DOI 10.1097/00001622-199807000-00014; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Friesen C, 1999, LEUKEMIA, V13, P1854, DOI 10.1038/sj.leu.2401333; Jaiswal M, 2001, AM J PHYSIOL-GASTR L, V281, pG626, DOI 10.1152/ajpgi.2001.281.3.G626; KALTHOFF H, 1993, ONCOGENE, V8, P289; Kang HC, 2004, CLIN CANCER RES, V10, P272, DOI 10.1158/1078-0432.CCR-1025-3; Kim KM, 2002, J BIOCHEM MOL BIOL, V35, P127; Kim R, 2004, CANCER-AM CANCER SOC, V101, P2491, DOI 10.1002/cncr.20696; KIM R, 2004, CANCER RES, V59, P3505; Kolb JP, 2000, LEUKEMIA, V14, P1685, DOI 10.1038/sj.leu.2401896; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Lillemoe K D, 1998, Surg Oncol Clin N Am, V7, P199; Maejima Y, 2005, J MOL CELL CARDIOL, V38, P163, DOI 10.1016/j.yjmcc.2004.10.012; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Morisaki T, 2003, CURR MED CHEM, V10, P2517, DOI 10.2174/0929867033456431; Muerkoster S, 2005, CANCER RES, V65, P1316, DOI 10.1158/0008-5472.CAN-04-1626; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Muerkoster S, 2003, INT J CANCER, V104, P469, DOI 10.1002/ijc.10963; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Poppenborg H, 1999, CYTOKINE, V11, P689, DOI 10.1006/cyto.1998.0473; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schmid RM, 2000, GASTROENTEROLOGY, V118, P1208, DOI 10.1016/S0016-5085(00)70374-X; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Sreedhar AS, 2004, PHARMACOL THERAPEUT, V101, P227, DOI 10.1016/j.pharmthera.2003.11.004; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Turzanski J, 2004, LEUKEMIA, V18, P1662, DOI 10.1038/sj.leu.2403457; Wang WX, 1999, CLIN CANCER RES, V5, P119; Yan Y, 2004, BRIT J CANCER, V91, P1349, DOI 10.1038/sj.bjc.6602127	36	40	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3973	3981		10.1038/sj.onc.1209423	http://dx.doi.org/10.1038/sj.onc.1209423			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474845				2022-12-17	WOS:000238668800011
J	Chattopadhyay, A; Tate, SA; Beswick, RW; Wagner, SD; Ferrigno, PK				Chattopadhyay, A; Tate, SA; Beswick, RW; Wagner, SD; Ferrigno, PK			A peptide aptamer to antagonize BCL-6 function	ONCOGENE			English	Article						peptide aptamer; BCL-6; B-cell lymphoma	GERMINAL-CENTER FORMATION; FINGER PROTEIN; POZ DOMAIN; BTB DOMAIN; TRANSCRIPTION; DIFFERENTIATION; IDENTIFICATION; INFLAMMATION; COREPRESSOR; RECRUITMENT	BCL-6 is a transcription factor essential for germinal centre B-cell development. The BCL-6 gene is involved in diffuse large-cell lymphoma and overexpressed in other types of non-Hodgkin's lymphoma and in high-grade breast cancer. BCL-6 is a transcriptional repressor whose N-terminal POZ domain mediates protein-protein interactions to exert its effects. Reasoning that disruption of POZ domain-mediated interactions may be an effective route to antagonizing the effects of BCL-6 in lymphoma, we screened a library for peptide aptamers that specifically bind to BCL-6 POZ and not the POZ domains of related proteins and describe here the first of these reagents, Apt48. Apt 48 binds BCL-6 POZ in a manner distinct from the transcriptional corepressor SMRT, yet was found to prevent BCL-6-mediated repression of a luciferase reporter gene. Apt48 also reproduced several previously validated effects of BCL-6 inhibition. Not ably, expression of the differentiation markers CD69, Blimp-1 and cyclin D2 was increased in B-cell lines when Apt48 was expressed. W e also show that expression of Apt48 restores cytokine-mediated growth arrest to BCL-6 over-expressing cells. Thus, we have identified a peptide aptamer that affects a function of BCL-6 that is required to prevent differentiation of proliferating B cells.	Hammersmith Hosp, Imperial Coll London, Div Invest Sci, Dept Haematol, London W12 0NN, England; MRC, Canc Cell Unit, Hutchison MRC Res Ctr, Cambridge, England; Univ Cambridge, Canc Res UK, Dept Oncol, Hutchison MRC Res Ctr, Cambridge, England	Imperial College London; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Wagner, SD (corresponding author), Hammersmith Hosp, Imperial Coll London, Div Invest Sci, Dept Haematol, Du Cane Rd, London W12 0NN, England.	simon.wagner@imperial.ac.uk; pkf@hutchison-mrc.cam.ac.uk		Wagner, Simon/0000-0002-8914-0370; Ko Ferrigno, Paul/0000-0002-5922-4100	Medical Research Council [MC_U105359876] Funding Source: Medline; MRC [MC_U105359876] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Ahmad KF, 2003, MOL CELL, V12, P1551, DOI 10.1016/S1097-2765(03)00454-4; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Crawford Margaret, 2003, Briefings in Functional Genomics & Proteomics, V2, P72, DOI 10.1093/bfgp/2.1.72; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; GOLEMIS EA, 1999, CURRENT PROTOCOS MOL; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Logarajah S, 2003, ONCOGENE, V22, P5572, DOI 10.1038/sj.onc.1206689; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Okabe S, 1998, MOL CELL BIOL, V18, P4235, DOI 10.1128/MCB.18.7.4235; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; ROSE MD, 1990, METHODS YEAST GENETI; Sambrook J, 2001, MOL CLONING LAB MANU; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; YE BHH, 1993, CANCER RES, V53, P2732	35	40	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2223	2233		10.1038/sj.onc.1209252	http://dx.doi.org/10.1038/sj.onc.1209252			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16331266				2022-12-17	WOS:000236581200009
J	Watanabe, J; Nishiyama, H; Matsui, Y; Ito, M; Kawanishi, H; Kamoto, T; Ogawa, O				Watanabe, J; Nishiyama, H; Matsui, Y; Ito, M; Kawanishi, H; Kamoto, T; Ogawa, O			Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines	ONCOGENE			English	Article						urogenital cancer; cisplatin; dicoumarol; p53; JNK	SUSTAINED ACTIVATION; CARCINOMA-CELLS; BLADDER-CANCER; JNK; OXIDOREDUCTASE-1; PHOSPHORYLATION; INDUCTION; PATHWAYS; JNK/P38; ROS	3-3'-Methylene-bis [4-hydroxycoumarin] (dicoumarol), an inhibitor of NADPH: quinone oxidoreductase 1, has been reported to possess potential antineoplastic effects and the ability to abrogate p53 protein. In the present study, we investigated the cytotoxic effects of dicoumarol in combination with cisplatin ( CDDP), using four bladder (RT112, 253J, J82 and UMUC3) and two prostate (LNCap and PC3) cancer cell lines. Single treatment with 100 mu M dicoumarol suppressed cell proliferation but did not induce apoptosis at 24 h in all cell lines examined. On the other hand, pretreatment with dicoumarol enhanced cytotoxicity of CDDP in three cell lines with wild type of p53(RT112, 253J and LNCap), but not in three other cell lines with mutant p53 or in RT112 stable transfectants with a dominant-negative mutant of p53. In RT112 and LNCap, CDDP induced p53 and p21 expression, while pretreatment of dicoumarol suppressed induction of p53/p21 and resulted in sequential activation of c-Jun N-terminal kinase (JNK) in a time-dependent manner. Furthermore, inhibition of JNK, using SP600125, completely suppressed activity of caspases and poly-(ADP-ribose) polymerase cleavage, leading to suppression of enhancement of CDDP-mediated apoptosis by dicoumarol. These results suggested that dicoumarol could enhance cytotoxicity of CDDP in urogenital cancer cells with wild-type p53 through the p53/p21/JNK pathways.	Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Ogawa, O (corresponding author), Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	ogawao@kuhp.kyoto-u.ac.jp						Anwar A, 2003, J BIOL CHEM, V278, P10368, DOI 10.1074/jbc.M211981200; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Brozovic A, 2004, INT J CANCER, V112, P974, DOI 10.1002/ijc.20522; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; Danson S, 2004, CANCER TREAT REV, V30, P437, DOI 10.1016/j.ctrv.2004.01.002; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Goktas S, 1999, SEMIN ONCOL, V26, P162; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Lewis A, 2004, CLIN CANCER RES, V10, P4550, DOI 10.1158/1078-0432.CCR-03-0667; Madari H, 2003, CANCER RES, V63, P1214; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Martinez LA, 2002, CARCINOGENESIS, V23, P1289, DOI 10.1093/carcin/23.8.1289; Nishiyama H, 2004, EUR UROL, V45, P176, DOI 10.1016/j.eururo.2003.09.011; Siegel D, 2004, MOL PHARMACOL, V65, P1238, DOI 10.1124/mol.65.5.1238; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Vasilevskaya IA, 2004, MOL PHARMACOL, V65, P235, DOI 10.1124/mol.65.1.235; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watanabe J, 2004, UROLOGY, V63, P989, DOI 10.1016/j.urology.2003.11.031; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Zhang YD, 2004, CANCER RES, V64, P1902, DOI 10.1158/0008-5472.CAN-03-3361	25	40	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2500	2508		10.1038/sj.onc.1209162	http://dx.doi.org/10.1038/sj.onc.1209162			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16518417				2022-12-17	WOS:000236948000008
J	White, PC; Shore, AM; Clement, M; McLaren, J; Soeiro, I; Lam, EWF; Brennan, P				White, PC; Shore, AM; Clement, M; McLaren, J; Soeiro, I; Lam, EWF; Brennan, P			Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes	ONCOGENE			English	Article						cyclin D2; phosphatidylinositol 3-kinase; CREB; interelukin-2; Epstein-Barr virus	ANTIGEN RECEPTOR; B-LYMPHOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; TRANSGENIC MICE; CELL; PROLIFERATION; TRANSCRIPTION; ACTIVATION; COOPERATE	Lymphocyte proliferation is key to the regulation of the immune system. Cyclin D2 is the first cell cycle protein induced following stimulation through the T-cell receptor, the B-cell receptor or cytokines. The promoter of this cyclin integrates a diverse range of signals. Through investigating the regulation of this promoter by interleukin-2 and phosphatidylinositol 3-kinase, we have identified a role for the transcription factor CREB, cAMP response element-binding protein. Mutation of the CREB-binding site reduced cyclin D2 promoter activity 5-10-fold. CREB-1 is phosphorylated at serine 133, a critical site for activity, in both T cells and Epstein Barr virus immortalized B cells. The introduction of an S133A mutant of CREB-1 reduces IL-2 induction of cyclin D2 promoter activity, demonstrating a role for this phosphorylation site in promoter activity. Two inhibitors of protein kinase A reduce lymphocyte proliferation and CREB-1 phosphorylation. This study demonstrates that the cyclin D2 promoter is capable of being regulated by PI3K and CREB and identifies CREB-1 and protein kinase A as potential targets for altering lymphocyte proliferation.	Cardiff Univ, Cardiff CF14 4XX, Wales; Canc Res UK Labs, London, England; Hammersmith Hosp, Imperial Coll Sch Med, Sect Canc Cell Biol, London, England	Cardiff University; Cancer Research UK; Imperial College London	Brennan, P (corresponding author), Cardiff Univ, Henry Wellcome Res Bldg,Heath Pk, Cardiff CF14 4XX, Wales.	brennanp@cf.ac.uk	Brennan, Paul/ABB-9196-2021; Lam, Eric W-F/AAW-8566-2020; Brennan, Paul/B-9210-2009	Brennan, Paul/0000-0001-8792-0499; Lam, Eric W-F/0000-0003-1274-3576; Brennan, Paul/0000-0001-8792-0499; McLaren, James/0000-0002-7021-5934				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Appleman LJ, 2000, J IMMUNOL, V164, P144, DOI 10.4049/jimmunol.164.1.144; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Belkowski SM, 1998, J IMMUNOL, V161, P659; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brennan P, 1996, BIOCHEM SOC T, V24, pS3, DOI 10.1042/bst024003s; Brennan P, 2002, ONCOGENE, V21, P1263, DOI 10.1038/sj.onc.1205182; Breslin EM, 2005, BRIT J PHARMACOL, V144, P791, DOI 10.1038/sj.bjp.0706061; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; DELMER A, 1995, BLOOD, V85, P2870, DOI 10.1182/blood.V85.10.2870.bloodjournal85102870; FEUERSTEIN N, 1995, J BIOL CHEM, V270, P9454, DOI 10.1074/jbc.270.16.9454; FEUERSTEIN N, 1995, J IMMUNOL, V154, P68; Frissora F, 2003, EUR J IMMUNOL, V33, P907, DOI 10.1002/eji.200323657; Fruman DA, 2002, P NATL ACAD SCI USA, V99, P359, DOI 10.1073/pnas.012605099; HORI T, 1987, BLOOD, V70, P1069; Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mehl AM, 2001, J BIOL CHEM, V276, P984, DOI 10.1074/jbc.M003758200; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; PALMERO I, 1993, ONCOGENE, V8, P1049; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; SAMPLE J, 1990, J VIROL, V64, P1667, DOI 10.1128/JVI.64.4.1667-1674.1990; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; Solvason N, 2000, INT IMMUNOL, V12, P631, DOI 10.1093/intimm/12.5.631; Spender LC, 2001, J VIROL, V75, P3537, DOI 10.1128/JVI.75.8.3537-3546.2001; Takano Y, 1999, J PATHOL, V189, P194; Teramoto N, 1999, INT J CANCER, V81, P543, DOI 10.1002/(SICI)1097-0215(19990517)81:4<543::AID-IJC7>3.3.CO;2-V; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Waltereit R, 2003, MOL NEUROBIOL, V27, P99, DOI 10.1385/MN:27:1:99; XIE HJ, 1995, J IMMUNOL, V154, P1717; Yu CT, 2001, J IMMUNOL, V166, P284, DOI 10.4049/jimmunol.166.1.284; Zhang CY, 2002, J BIOL CHEM, V277, P48359, DOI 10.1074/jbc.M209329200	38	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2170	2180		10.1038/sj.onc.1209255	http://dx.doi.org/10.1038/sj.onc.1209255			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16301994				2022-12-17	WOS:000236581200004
J	Ko, MJ; Murata, K; Hwang, DS; Parvin, JD				Ko, MJ; Murata, K; Hwang, DS; Parvin, JD			Inhibition of BRCA1 in breast cell lines causes the centrosome duplication cycle to be disconnected from the cell cycle	ONCOGENE			English	Article						BRCA1; centrosome; cell cycle; breast cancer	AMPLIFICATION; INSTABILITY; CHECKPOINT; NUMBER; CANCER	BRCA1-dependent ubiquitination activity regulates centrosome number in several tissue culture cell lines derived from breast cells. In these experiments, we asked how BRCA1 inhibits centrosome amplification. In general, supernumerary centrosomes can accumulate by three mechanisms: (1) failed cytokinesis and the accumulation of centrosomes by duplication in a repeated S-phase of the cell cycle, (2) disruption of the licensing of centrosome doubling such that they duplicate at inappropriate times in the cell cycle, or (3) fragmentation of the centrosomes. In this study, we found that inhibition of BRCA1 caused premature separation of centrioles and reduplication. By blocking cells in early S-phase before centrosome amplification secondary to BRCA1 inhibition could occur and then releasing, we found that inhibition of BRCA1 caused centrosome amplification between late S-phase and G2/M before the cell divided. These results suggest that normal BRCA1 function is critical in these cell lines to prevent centriole separation and centrosome reduplication before mitosis.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Seoul Natl Univ, Inst Mol Biol & Genet, Seoul, South Korea; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Seoul National University (SNU); Harvard University; Harvard Medical School	Parvin, JD (corresponding author), Brigham & Womens Hosp, Dept Pathol, NRB 630,77 Ave Louis Pasteur, Boston, MA 02115 USA.	jparvin@rics.bwh.harvard.edu	Parvin, Jeffrey D/C-8955-2009		NATIONAL CANCER INSTITUTE [R01CA090281] Funding Source: NIH RePORTER; NCI NIH HHS [CA90281] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; D'Assoro AB, 2004, ONCOGENE, V23, P4068, DOI 10.1038/sj.onc.1207568; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; Hsu LC, 2001, CANCER RES, V61, P7713; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Pihan GA, 2003, CANCER RES, V63, P1398; Schlegel BP, 2003, ONCOGENE, V22, P983, DOI 10.1038/sj.onc.1206195; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Suto K, 1999, MOL BIOL CELL, V10, P3331, DOI 10.1091/mbc.10.10.3331; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993; Wyllie FS, 1996, ONCOGENE, V12, P1077; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	16	40	41	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					298	303		10.1038/sj.onc.1209028	http://dx.doi.org/10.1038/sj.onc.1209028			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170356				2022-12-17	WOS:000234583600014
J	Samraj, AK; Stroh, C; Fischer, U; Schulze-Osthoff, K				Samraj, AK; Stroh, C; Fischer, U; Schulze-Osthoff, K			The tyrosine kinase Lck is a positive regulator of the mitochondrial apoptosis pathway by controlling Bak expression	ONCOGENE			English	Article						apoptosis; Bak; Bax; Lck; mitochondria	SRC-FAMILY KINASES; INDUCED CELL-DEATH; NF-KAPPA-B; BCL-2 FAMILY; CASPASE-8 ACTIVATION; SIGNAL-TRANSDUCTION; GENETIC-EVIDENCE; ALPHA-TOXIN; T-CELLS; RECEPTOR	Tyrosine kinases of the Src family have been implicated in key biological processes. Here, we provide evidence that p56(Lck), a lymphoid-specific Src kinase, is involved in the activation of the mitochondrial apoptosis pathway. Lck-deficient T cells were completely resistant to anticancer drugs. In contrast, apoptosis sensitivity to death receptors was not altered, indicating a specific interference of Lck with the mitochondrial pathway. Re-expression of Lck restored sensitivity to drug-induced apoptosis and triggered mitochondrial cytochrome c release and caspase activation. Further analysis identified that the sensitization by Lck was independent of classical mediators of T-cell signaling, but essentially involved the Bcl-2 protein Bak. Expression of Bak was completely absent in Lck-deficient cells, while re-expression of Lck transcriptionally triggered Bak expression and conferred sensitivity to apoptosis, associated with a proapoptotic conformational change of Bak. Furthermore, in vitro the truncated fragment of Bid specifically activated Bak and cytochrome c release only from mitochondria of Lck-expressing cells. These results do not only demonstrate a sentinel role of Lck in drug resistance but also delineate a hitherto unknown pathway of Src kinases in regulation of Bcl-2 proteins.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schulze-Osthoff, K (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	KSO@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bantel H, 2001, J CELL BIOL, V155, P637, DOI 10.1083/jcb.200105081; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Denny MF, 1999, J BIOL CHEM, V274, P5146, DOI 10.1074/jbc.274.8.5146; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Essmann F, 2003, CELL DEATH DIFFER, V10, P1260, DOI 10.1038/sj.cdd.4401301; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; GonzalezGarcia A, 1997, J IMMUNOL, V158, P4104; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gruber C, 2004, BIOCHEM PHARMACOL, V67, P1859, DOI 10.1016/j.bcp.2004.01.026; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hernandez-Hansen V, 2004, J LEUKOCYTE BIOL, V75, P143, DOI 10.1189/jlb.0503224; Hur YG, 2004, J IMMUNOL, V172, P79, DOI 10.4049/jimmunol.172.1.79; Iwamoto KS, 1996, CANCER RES, V56, P3862; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Klee M, 2005, J CELL BIOL, V168, P723, DOI 10.1083/jcb.200408169; Knudson CM, 2001, CANCER RES, V61, P659; Kondo S, 2000, CANCER RES, V60, P4328; Lindenboim L, 2005, CELL DEATH DIFFER, V12, P713, DOI 10.1038/sj.cdd.4401638; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; Manna SK, 2000, J IMMUNOL, V164, P5156, DOI 10.4049/jimmunol.164.10.5156; Melendez J, 2004, J BIOL CHEM, V279, P53516, DOI 10.1074/jbc.M408475200; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; Pedraza LG, 2004, ONCOGENE, V23, P4754, DOI 10.1038/sj.onc.1207635; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Seddon B, 2000, SCIENCE, V290, P127, DOI 10.1126/science.290.5489.127; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; Singer AL, 2002, SCIENCE, V296, P1639, DOI 10.1126/science.1071551; Skorski T, 2002, NAT REV CANCER, V2, P351, DOI 10.1038/nrc799; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Webb BL, 2000, MOL CELL BIOL, V20, P9271, DOI 10.1128/MCB.20.24.9271-9280.2000; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zamoyska R, 2003, IMMUNOL REV, V191, P107, DOI 10.1034/j.1600-065X.2003.00015.x	63	40	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					186	197		10.1038/sj.onc.1209034	http://dx.doi.org/10.1038/sj.onc.1209034			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16116473				2022-12-17	WOS:000234583600003
J	Fontemaggi, G; Gurtner, A; Damalas, A; Costanzo, A; Higashi, Y; Sacchi, A; Strano, S; Piaggio, G; Blandino, G				Fontemaggi, G; Gurtner, A; Damalas, A; Costanzo, A; Higashi, Y; Sacchi, A; Strano, S; Piaggio, G; Blandino, G			delta EF1 repressor controls selectively p53 family members during differentiation	ONCOGENE			English	Article						p73; p63; p53 family; delta EF1 transcriptional repressor	DROSOPHILA ZFH-1; ZINC-FINGER; P73; P63; EXPRESSION; PROLIFERATION; KERATINOCYTES; REGULATOR; PROTEINS; HOMOLOG	The discovery of two new p53 homologs, p73 and p63, has defined a family of transcription factors heavily involved in the control of growth suppression, apoptosis, differentiation and development. While p53-deficient mice undergo spontaneous tumors, p73 and p63 knockout mice exhibit severe developmental defects. We demonstrate here that p73 gene is an in vivo transcriptional target of the muscle regulatory factors MyoD, myogenin, Myf5 and Myf6. Ectopic expression of the transcriptional repressor delta EF1/ZEB/ zfhx1a counteracts MyoD/ Myf5-or MyoD/ Myf6- mediated transcriptional activation of p73. A distinct pattern of in vivo recruitment of muscle regulatory factors and delta EF1 on p73 regulatory regions was found between proliferating and differentiating muscle cells. We also found that dEF1 plays a role in the transcriptional regulation of p53 family members during keratinocytic differentiation. Mouse embryo. fibroblasts derived from delta EF1-deficient mice exhibit unbalanced expression of DNp63, TAp73 and Delta Np73 but not of TAp63 and p53. The analysis of tissues derived from delta EF1+/- mice exhibit a selective enrichment of DNp63 in skin.	Regina Elena Inst Canc Res, Dept Expt Oncol, I-00158 Rome, Italy; Rome Oncogenom Ctr, I-00158 Rome, Italy; Univ Roma Tor Vergata, Dept Dermatol, I-00133 Rome, Italy; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Rome Tor Vergata; Osaka University	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Via Messi Oro,156, I-00158 Rome, Italy.	blandino@ifo.it	Costanzo, Antonio/D-3896-2012; Gurtner, Aymone/J-7217-2018; Fontemaggi, Giulia/K-9702-2016; gurtner, aymone/AAB-8843-2020; strano, sabrina/B-6743-2013; Piaggio, Giulia/J-7214-2018; Piaggio, Giulia/AAD-7336-2022; Costanzo, Antonio/GZG-2433-2022; Higashi, Yukihito/G-5343-2019; Blandino, Giovanni/B-1137-2013; Strano, Sabrina/K-9654-2016	Gurtner, Aymone/0000-0002-7661-9059; Fontemaggi, Giulia/0000-0001-8332-8842; gurtner, aymone/0000-0002-7661-9059; strano, sabrina/0000-0002-6341-4230; Piaggio, Giulia/0000-0003-2114-1892; Costanzo, Antonio/0000-0001-9697-2557; Blandino, Giovanni/0000-0002-6970-2241; 	Telethon [GGP030358] Funding Source: Medline	Telethon(Fondazione Telethon)		Bamberger C, 2002, J INVEST DERMATOL, V118, P133, DOI 10.1046/j.0022-202x.2001.01649.x; Blandino G, 2004, CELL CYCLE, V3, P886; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; FORTINI ME, 1991, MECH DEVELOP, V34, P113, DOI 10.1016/0925-4773(91)90048-B; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; Higashi Y, 1997, J EXP MED, V185, P1467, DOI 10.1084/jem.185.8.1467; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LAI ZC, 1993, P NATL ACAD SCI USA, V90, P4122, DOI 10.1073/pnas.90.9.4122; LUNDELL MJ, 1992, DEV BIOL, V154, P84, DOI 10.1016/0012-1606(92)90050-Q; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Morena A, 2002, BLOOD, V100, P96, DOI 10.1182/blood.V100.1.96; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; Takagi T, 1998, DEVELOPMENT, V125, P21; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607	19	40	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7273	7280		10.1038/sj.onc.1208891	http://dx.doi.org/10.1038/sj.onc.1208891			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007124				2022-12-17	WOS:000233142100003
J	Nitta, E; Izutsu, K; Yamaguchi, Y; Imai, Y; Ogawa, S; Chiba, S; Kurokawa, M; Hirai, H				Nitta, E; Izutsu, K; Yamaguchi, Y; Imai, Y; Ogawa, S; Chiba, S; Kurokawa, M; Hirai, H			Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP	ONCOGENE			English	Article						Evi-1; oligomerization; TGF-beta; CtBP; PR domain	T(3/21) FUSION PRODUCT; ZINC-FINGER PROTEIN; TRANSCRIPTION FACTORS; GROWTH-INHIBITION; BLASTIC CRISIS; SMAD PROTEINS; GENE; EXPRESSION; LEUKEMIA; DIMERIZATION	Evi-1 is a transcription factor that is implicated in leukemic transformation of hematopoietic cells. Two distinct alternative forms, Evi-1a and Evi-1c, are generated from the EVI-1 gene. Whereas Evi-1a is widely recognized as an oncoprotein, a role for Evi-1c, which has an additional PR domain in the amino-terminus of Evi-1a, in leukemogenesis, has not been elucidated thus far. Aberrant oligomerization of transcription factors has recently emerged as a prevalent mechanism for activating their oncogenic potential in hematopoietic malignancies. Here, to study the mechanisms that underlie Evi-1 mediated oncogenesis, we investigated formation of oligomeric complexes by the Evi-1 proteins. We show that Evi-1a forms homo-oligomers, whereas Evi-1c exclusively exists as a monomer in mammalian cells. Remarkably, Evi-1c has lost the ability to interact with CtBP, a transcriptional corepressor that associates with Evi-1a. As a consequence, the ability of Evi-1c to repress transforming growth factor-beta ( TGF-beta) signaling is significantly abrogated. These results identify a novel function of a PR domain to regulate oligomerization of transcription factors and suggest that homo-oligomerization may play a critical role in corepressor recruitment by the Evi-1 proteins. In addition, we found that the chimeric oncoprotein acute myelocytic leukemia ( AML) 1-Evi-1, generated in t( 3; 21) leukemia, also forms homo-oligomers and hetero-oligomers with Evi-1a, while it did not interact with Evi-1c. Consistent with the results, repression of TGF-beta by AML1-Evi-1 was significantly enhanced by Evi-1a, whereas it was hardly affected by the presence of Evi-1c. These results suggest that oligomerization may contribute to the oncogenic potential of Evi-1-containing proteins.	Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan	University of Tokyo	Kurokawa, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan.	kurokawa-tky@umin.ac.jp	Izutsu, Koji/AAI-1125-2019; Ogawa, Seishi/AAE-7088-2019	Izutsu, Koji/0000-0001-9129-8057; Imai, Yoichi/0000-0002-2938-6133				Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; Grignani F, 1999, ONCOGENE, V18, P6313, DOI 10.1038/sj.onc.1203029; Hirai H, 1999, INT J BIOCHEM CELL B, V31, P1367, DOI 10.1016/S1357-2725(99)00064-3; Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933; Huang S, 2002, NAT REV CANCER, V2, P469, DOI 10.1038/nrc819; HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7; Imai Y, 2001, ONCOGENE, V20, P88, DOI 10.1038/sj.onc.1204057; Izutsu K, 2002, ONCOGENE, V21, P2695, DOI 10.1038/sj.onc.1205356; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Jiang GL, 2000, HISTOL HISTOPATHOL, V15, P109, DOI 10.14670/HH-15.109; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; Mizuki M, 2003, CELL MOL BIOL, V49, P907; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ogawa S, 1996, LEUKEMIA, V10, P788; Ogawa S, 1996, ONCOGENE, V13, P183; Ogawa S, 1996, Hum Cell, V9, P323; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459	39	40	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6165	6173		10.1038/sj.onc.1208754	http://dx.doi.org/10.1038/sj.onc.1208754			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15897867	Bronze			2022-12-17	WOS:000231718100010
J	Sasaki, Y; Naishiro, Y; Oshima, Y; Imai, K; Nakamura, Y; Tokino, T				Sasaki, Y; Naishiro, Y; Oshima, Y; Imai, K; Nakamura, Y; Tokino, T			Identification of pigment epithelium-derived factor as a direct target of the p53 family member genes	ONCOGENE			English	Article						PEDF; p53; p73; p63; differentiation	ADENOVIRUS-MEDIATED TRANSFER; SPONTANEOUS TUMORS; CDNA MICROARRAY; CANCER-CELLS; P73; P63; APOPTOSIS; NEUROBLASTOMA; ANGIOGENESIS; HOMOLOG	p63 and p73 show a high degree of structural homology to p53 and are members of a family of transcriptional factors that can activate transcription of p53-responsive genes. p53 is mutated in more than 50% of human cancers, whereas p63 and p73 are rarely mutated. Studies of knockout mice also revealed an unexpected functional diversity among the p53 family. To determine how p63 and p73 are involved in tumorigenesis and normal development, we used cDNA microarray to examine 9216 genes in human colorectal cancer cells. We discovered that the expression of pigment epithelium-derived factor (PEDF) was specifically induced by either p63 or p73, but not by p53. We also report here that the PEDF gene contains a response element specific for p63 and p73 in its promoter region and is a direct target of p63 and p73. Collectively, p63 and p73 may be involved in cell fate by inducing PEDF expression.	Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sch Med,Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	Sapporo Medical University; Sapporo Medical University; University of Tokyo	Tokino, T (corresponding author), Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sch Med,Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	tokino@sapmed.ac.jp	Sasaki, Yasushi/AAA-3079-2019; Tokino, Takashi/AAI-9887-2021	Sasaki, Yasushi/0000-0002-3500-8059; 				BECERRA SP, 1995, J BIOL CHEM, V270, P25992, DOI 10.1074/jbc.270.43.25992; Billon N, 2004, DEVELOPMENT, V131, P1211, DOI 10.1242/dev.01035; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Crawford SE, 2001, J CELL SCI, V114, P4421; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014-5793(02)03093-4; Doll JA, 2003, NAT MED, V9, P774, DOI 10.1038/nm870; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Okabe H, 2001, CANCER RES, V61, P2129; Ono K, 2000, CANCER RES, V60, P5007; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Prabhu NS, 1998, INT J ONCOL, V13, P5; Sasaki Y, 2003, CANCER RES, V63, P8145; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Sasaki Y, 2001, GENE THER, V8, P1401, DOI 10.1038/sj.gt.3301538; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; TANIWAKI T, 1995, J NEUROCHEM, V64, P2509; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; van Bokhoven H, 2002, TRENDS MOL MED, V8, P133, DOI 10.1016/S1471-4914(01)02260-2; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zheng XJ, 2001, FEBS LETT, V489, P4, DOI 10.1016/S0014-5793(00)02437-6	40	40	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5131	5136		10.1038/sj.onc.1208695	http://dx.doi.org/10.1038/sj.onc.1208695			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15856012				2022-12-17	WOS:000230816900013
J	Constantinou, C; Clemens, MJ				Constantinou, C; Clemens, MJ			Regulation of the phosphorylation and integrity of protein synthesis initiation factor eIF4GI and the translational repressor 4E-BP1 by p53	ONCOGENE			English	Article						mTOR; p53; polypeptide chain initiation; protein phosphorylation; rapamycin	CYCLE-DEPENDENT PHOSPHORYLATION; MAMMALIAN TARGET; PHAS-I; TRANSCRIPTIONAL TARGET; (S/T)P SITES; S6 KINASE; RAPAMYCIN; CDC2; BINDING; ACTIVATION	Activation of a temperature-sensitive form of mouse p53 in murine erythroleukaemia cells rapidly inhibits protein synthesis and causes early dephosphorylation and cleavage of protein synthesis initiation factor eIF4GI and the eIF4E-binding protein 4E-BP1. Dephosphorylated 4E-BP1 and the cleaved products of 4E-BP1 and eIF4GI associate with eIF4E under these conditions, concomitant with decreased interaction of full-length eIF4GI with eIF4E. These changes may play an important role in preventing formation of the eIF4F complex and thus the initiation of protein synthesis. As observed previously for eIF4GI, the cleavage of 4E-BP1 is insensitive to the general caspase inhibitor z-VAD.FMK, consistent with a caspase-independent mechanism of factor modi. cation and regulation of protein synthesis. Comparison of the p53-induced patterns of eIF4GI and 4E-BP1 dephosphorylation and cleavage with those caused by the mTOR inhibitor rapamycin indicates that p53 activation and rapamycin have distinct but additive effects. Moreover, p53 activation inhibits rapamycin-insensitive protein kinase activity against 4E-BP1.P53 and rapamycin have additive effects on the inhibition of overall protein synthesis. These data suggest that the inhibition of protein synthesis by p53 is largely independent of the regulation of rapamycin-sensitive mTOR in the system under investigation.	St George Hosp, Sch Med, Dept Basic Med Sch Biochem & Immunol, Transpat Control Grp, London SW17 0RE, England	St Georges University London	Clemens, MJ (corresponding author), St George Hosp, Sch Med, Dept Basic Med Sch Biochem & Immunol, Transpat Control Grp, Cranmer Terrace, London SW17 0RE, England.	m.clemens@sghms.ac.uk						Ababneh M, 2001, BIOCHEM BIOPH RES CO, V283, P507, DOI 10.1006/bbrc.2001.4792; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Bushell M, 2000, CELL DEATH DIFFER, V7, P628, DOI 10.1038/sj.cdd.4400699; Bushell M, 2000, EUR J BIOCHEM, V267, P1083, DOI 10.1046/j.1432-1327.2000.01101.x; Bushell M, 2001, J BIOL CHEM, V276, P23922, DOI 10.1074/jbc.M100384200; Bushell M, 1999, FEBS LETT, V451, P332, DOI 10.1016/S0014-5793(99)00614-6; Constantinou C, 2003, EUR J BIOCHEM, V270, P3122, DOI 10.1046/j.1432-1033.2003.03687.x; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; Edinger AL, 2003, CANCER RES, V63, P8451; Ferguson G, 2003, J BIOL CHEM, V278, P47459, DOI 10.1074/jbc.M307949200; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Jeffrey IW, 2002, CANCER RES, V62, P2272; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Karim MM, 2001, J BIOL CHEM, V276, P20750, DOI 10.1074/jbc.M011068200; Kudchodkar SB, 2004, J VIROL, V78, P11030, DOI 10.1128/JVI.78.20.11030-11039.2004; Lawrence JC, 1997, ADV ENZYME REGUL, V37, P239, DOI 10.1016/S0065-2571(96)00016-7; Li MX, 2003, J BIOL CHEM, V278, P41059, DOI 10.1074/jbc.M307149200; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Martin ME, 2000, BIOCHEM J, V351, P327, DOI 10.1042/0264-6021:3510327; Marx SO, 1999, MOL CELL BIOL, V19, P6041; Miron M, 2003, MOL CELL BIOL, V23, P9117, DOI 10.1128/MCB.23.24.9117-9126.2003; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; Morley SJ, 1997, RNA, V3, P1085; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Park M, 2000, CANCER RES, V60, P542; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; POON RY, 2006, J BIOL CHEM, V271, P13283; Poon RYC, 1997, CANCER RES, V57, P5168; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Prevot D, 2003, BIOL CELL, V95, P141, DOI 10.1016/S0248-4900(03)00031-5; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Tee AR, 2001, CELL DEATH DIFFER, V8, P841, DOI 10.1038/sj.cdd.4400876; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Ueda K, 2003, ONCOGENE, V22, P5586, DOI 10.1038/sj.onc.1206845; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519	58	40	42	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4839	4850		10.1038/sj.onc.1208648	http://dx.doi.org/10.1038/sj.onc.1208648			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15897901				2022-12-17	WOS:000230477900011
J	Jin, ZH; Kurosu, T; Yamaguchi, M; Arai, A; Miura, O				Jin, ZH; Kurosu, T; Yamaguchi, M; Arai, A; Miura, O			Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis	ONCOGENE			English	Article						cell cycle checkpoints; hematopoietic cytokines; Chk1; Akt; GSK3	ACUTE MYELOID-LEUKEMIA; GLYCOGEN-SYNTHASE KINASE-3; CELL-CYCLE ARREST; COLONY-STIMULATING FACTOR; DNA-DAMAGE; PHOSPHATIDYLINOSITOL 3-KINASE; CONSTITUTIVE PHOSPHORYLATION; ERYTHROPOIETIN RECEPTOR; SIGNALING PATHWAY; CHK1	Hematopoietic cytokines play crucial roles in regulation of cell cycle progression and apoptosis of hematopoietic cells. However, the effects of cytokines on cellular responses to chemotherapeutic agents and the mechanisms involved have remained elusive. Here we report that erythropoietin or IL-3 promotes G2/M arrest and prevents apoptosis induced by the topoisomerase II inhibitor etoposide in murine hematopoietic 32D cells and human leukemic UT7 cells. Erythropoietin or IL-3 significantly enhanced etoposide-induced activation-specific phosphorylation of Chk1, a checkpoint kinase that inhibits Cdc2 activation by Cdc25 phosphatases, and led to the inhibition of Cdc2 kinase activity with the persistent inhibitory phosphorylation on Tyr15. The inhibitory Cdc2 phosphorylation and G2/M block by etoposide were enhanced or inhibited by overexpression of Chk1 or by the specific Chk1 inhibitor SB218078, respectively. The G2/M arrest induced by etoposide was also enhanced or inhibited by expression of a constitutively activated or dominant-negative Akt mutant, respectively. Furthermore, SB216763 or LiCl, a specific inhibitor for the GSK3 kinase inhibited by Akt, enhanced the Chk1 phosphorylation and G2/M arrest by etoposide. These results indicate that hematopoietic cytokines protect etoposide-treated cells from DNA damage-induced apoptosis by promoting, through the PI3K/Akt/GSK3 signaling pathway, G2/M checkpoint that is dependent on Chk1-mediated inhibition of Cdc2.	Tokyo Med & Dent Univ, Dept Hematol, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Hematol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	miura.hema@tmd.ac.jp		Miura, Osamu/0000-0002-0981-3054				Arai A, 2002, ONCOGENE, V21, P2641, DOI 10.1038/sj.onc.1205346; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Cheong JW, 2003, LEUKEMIA RES, V27, P1159, DOI 10.1016/S0145-2126(03)00102-4; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Eapen AK, 2001, MOL CELL BIOL, V21, P6113, DOI 10.1128/MCB.21.18.6113-6121.2001; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Henry MK, 2001, BLOOD, V98, P834, DOI 10.1182/blood.V98.3.834; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jackson JR, 2000, CANCER RES, V60, P566; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; King FW, 2004, CELL CYCLE, V3, P634; KOMATSU N, 1991, CANCER RES, V51, P341; Kubota Y, 2004, LEUKEMIA, V18, P1438, DOI 10.1038/sj.leu.2403402; Lowenberg B, 2003, NEW ENGL J MED, V349, P743, DOI 10.1056/NEJMoa025406; Min YH, 2003, LEUKEMIA, V17, P995, DOI 10.1038/sj.leu.2402874; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; Nimbalkar D, 2003, CANCER RES, V63, P1034; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shtivelman E, 2002, CURR BIOL, V12, P919, DOI 10.1016/S0960-9822(02)00843-6; Somervaille TCP, 2001, BLOOD, V98, P1374, DOI 10.1182/blood.V98.5.1374; Sramkoski RM, 1999, CYTOMETRY, V35, P274, DOI 10.1002/(SICI)1097-0320(19990301)35:3<274::AID-CYTO11>3.0.CO;2-O; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	38	40	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					1973	1981		10.1038/sj.onc.1208408	http://dx.doi.org/10.1038/sj.onc.1208408			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15674326				2022-12-17	WOS:000227681900002
J	Carvalho, G; Lefaucheur, C; Cherbonnier, C; Metivier, D; Chapel, A; Pallardy, M; Bourgeade, MF; Charpentier, B; Hirsch, F; Kroemer, G				Carvalho, G; Lefaucheur, C; Cherbonnier, C; Metivier, D; Chapel, A; Pallardy, M; Bourgeade, MF; Charpentier, B; Hirsch, F; Kroemer, G			Chemosensitization by erythropoietin through inhibition of the NF-kappa B rescue pathway	ONCOGENE			English	Article						apoptosis; renal carcinoma; jak; leukemia	ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN GROWTH-HORMONE; CELL-DEATH; MYELODYSPLASTIC SYNDROME; PRACTICE PATTERNS; MULTIPLE-MYELOMA; GENE-EXPRESSION; IN-VIVO; CANCER; APOPTOSIS	Two cell lines that exemplify erythropoietin (EPO) receptor-positive tumors, human renal carcinoma cell lines RCC and the myelomonocytic leukemia cell line U937, were investigated for the apoptosis-modulatory potential of EPO. Cells cultured in the presence of EPO exhibited an elevated apoptotic response to cancer chemotherapeutic agents such as daunorubicin (Dauno) and vinblastine (VBL). Chemosensitization by EPO did not involve an increase in p53 activation, yet correlated with enhanced Bax/Bak-dependent mitochondrial membrane perturbation and caspase maturation. In vitro monotherapy with Dauno or VBL induced the degradation of IkappaBalpha, provoked the translocation of NF-kappaB p65/50 to the nucleus and stimulated the expression of an NF-kappaB-activatable reporter gene. All these signs of NF-kappaB activation were perturbed in the presence of EPO. Inhibition of JAK2, one of the receptor-proximal elements of EPO-mediated signal transduction, greatly diminished the EPO-mediated chemosensitization and NF-kappaB inhibition. EPO lost its death-facilitating effects in the presence of an NF-kappaB inhibitor, underscoring the cause-effect relationship between EPO-mediated chemosensitization and NF-kappaB inhibition. Altogether, these results suggest that, at least in a specific subset of tumors, EPO receptor agonists can prevent activation of the NF-kappaB pathway, thereby enhancing the propensity of EPO receptor-positive tumor cells to undergo apoptosis.	Inst Gustave Roussy, CNRS, UMR8125, F-94805 Villejuif, France; Univ Paris 11, Hop Paul Brousse, INSERM, U542, F-94802 Villejuif, France; IRSN, Fontenay Aux Roses, France; Fac Pharm Paris, INSERM, U461, F-92296 Chatenay Malabry, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	hirsch@babbage.infobiogen.fr	KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; lefaucheur, carmen/F-3502-2013	KROEMER, Guido/0000-0002-9334-4405; chapel, alain/0000-0002-4687-4120				Acs G, 2001, CANCER RES, V61, P3561; Adams JR, 2004, AM J MED, V116, P28, DOI 10.1016/j.amjmed.2003.06.004; Angevin E, 1999, LAB INVEST, V79, P879; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Bunworasate U, 2001, BLOOD, V98, P3492, DOI 10.1182/blood.V98.12.3492; Castedo M, 2002, TRENDS CELL BIOL, V12, P446, DOI 10.1016/S0962-8924(02)02346-2; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Chapel A, 1999, EXP HEMATOL, V27, P250, DOI 10.1016/S0301-472X(98)00009-5; Cherbonnier C, 2003, BRIT J CANCER, V89, P1108, DOI 10.1038/sj.bjc.6601223; Cherbonnier C, 2002, CANCER GENE THER, V9, P497, DOI 10.1038/sj.cgt.7700467; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Durrbach A, 1999, CANCER GENE THER, V6, P564, DOI 10.1038/sj.cgt.7700085; Fine BM, 2004, BLOOD, V103, P1043, DOI 10.1182/blood-2003-05-1518; Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170; Jolly C, 1999, P NATL ACAD SCI USA, V96, P6769, DOI 10.1073/pnas.96.12.6769; Kaltschmidt B, 1999, ONCOGENE, V18, P3213, DOI 10.1038/sj.onc.1202657; Kane RC, 2003, ONCOLOGIST, V8, P508, DOI 10.1634/theoncologist.8-6-508; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Leyland-Jones B, 2003, LANCET ONCOL, V4, P459, DOI 10.1016/S1470-2045(03)01163-X; Littlewood T, 2002, SEMIN ONCOL, V29, P40, DOI 10.1053/sonc.2002.33532; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Minet E, 2000, INT J MOL MED, V5, P253; Mittelman M, 2004, EUR J HAEMATOL, V72, P155, DOI 10.1046/j.0902-4441.2003.00190.x; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Oda A, 1998, BLOOD, V92, P443, DOI 10.1182/blood.V92.2.443.414k25_443_451; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Perfettini JL, 2004, J EXP MED, V199, P629, DOI 10.1084/jem.20031216; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Schwartzberg L, 2003, CLIN THER, V25, P2781, DOI 10.1016/S0149-2918(03)80333-8; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Takeshita A, 2002, LEUKEMIA LYMPHOMA, V43, P261, DOI 10.1080/10428190290006026; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Westenfelder C, 2000, KIDNEY INT, V58, P647, DOI 10.1046/j.1523-1755.2000.00211.x; Williams SA, 2003, CANCER RES, V63, P7338; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yasuda Y, 2003, CARCINOGENESIS, V24, P1021, DOI 10.1093/carcin/bgg060; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	53	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					737	745		10.1038/sj.onc.1208205	http://dx.doi.org/10.1038/sj.onc.1208205			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580299	Bronze			2022-12-17	WOS:000226577100001
J	Volanti, C; Gloire, G; Vanderplasschen, A; Jacobs, N; Habraken, Y; Piette, J				Volanti, C; Gloire, G; Vanderplasschen, A; Jacobs, N; Habraken, Y; Piette, J			Downregulation of ICAM-1 and VCAM-1 expression in endothelial cells treated by photodynamic therapy	ONCOGENE			English	Article						NF-kappa B; pyropheophorbide; photodynamic therapy; endothelial cells; oxidative stress; adhesion molecules	NF-KAPPA-B; PYROPHEOPHORBIDE-A; OXIDATIVE STRESS; IN-VIVO; CHOROIDAL NEOVASCULARIZATION; TUMOR; MATRIX-METALLOPROTEINASE-9; ACTIVATION; PHOTOSENSITIZATION; PHARMACOKINETICS	Photodynamic therapy (PDT) is a treatment for cancer and several noncancerous proliferating cell diseases that depends on the uptake of a photosensitizing compound followed by selective irradiation with visible light. In the presence of oxygen, irradiation leads to the production of reactive oxygen species (ROS). A large production of ROS induces the death of cancer cells by apoptosis or necrosis. A small ROS production can activate various cellular pathways. Here, we show that PDT by pyropheophorbide-a methyl ester (PPME) induces the activation of nuclear factor kappa B (NF-kappaB) in HMEC-1 cells. NF-kappaB is active since it binds to the NF-kappaB sites of both ICAM-1 and vascular cell adhesion molecule-1 (VCAM-1) promoters and induces the transcription of several NF-kappaB target genes such as those of IL-6, ICAM-1, VCAM-I. In contrast, expression of ICAM-1 and VCAM-I at the protein level was not observed, although we measured an IL-6 secretion. Using specific chemical inhibitors, we showed that the lack of ICAM-1 and VCAM-I expression is the consequence of their degradation by lysosomal proteases. The proteasome and calpain pathways were not involved. All these observations were consistent with the fact that no adhesion of granulocytes was observed in these conditions.	Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium; Univ Liege, Dept Immunol & Vaccinol, B-4000 Liege, Belgium; Univ Liege, Inst Pathol B23, Dept Pathol, B-4000 Liege, Belgium	University of Liege; University of Liege; University of Liege	Piette, J (corresponding author), Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium.	jpiette@ulg.ac.be		Jacobs, Nathalie/0000-0002-9895-8465				Aiello L P, 1997, Curr Opin Ophthalmol, V8, P19; Arkell J, 2003, CELL BIOCHEM FUNCT, V21, P381, DOI 10.1002/cbf.1037; BELLNIER DA, 1993, J PHOTOCH PHOTOBIO B, V20, P55, DOI 10.1016/1011-1344(93)80131-R; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cecic I, 2001, PHOTOCHEM PHOTOBIOL, V74, P712, DOI 10.1562/0031-8655(2001)074<0712:IOSNRI>2.0.CO;2; Chen B, 2002, INT J CANCER, V98, P284, DOI 10.1002/ijc.10175; deVree WJA, 1996, CANCER RES, V56, P2908; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dougherty TJ, 2002, J CLIN LASER MED SUR, V20, P3, DOI 10.1089/104454702753474931; Fiore E, 2002, ONCOGENE, V21, P5213, DOI 10.1038/sj.onc.1205684; Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864; Gollnick SO, 1997, CANCER RES, V57, P3904; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; HENDERSON BW, 1995, PHOTOCHEM PHOTOBIOL, V62, P780, DOI 10.1111/j.1751-1097.1995.tb08730.x; Henderson BW, 1997, CANCER RES, V57, P4000; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kolev K, 2003, THROMB HAEMOSTASIS, V90, P528, DOI 10.1160/TH03-02-0070; Korbelik M, 1996, J Clin Laser Med Surg, V14, P329; Krammer B, 2001, ANTICANCER RES, V21, P4271; KROSL G, 1995, BRIT J CANCER, V71, P549, DOI 10.1038/bjc.1995.108; Lee JM, 2003, ANN NEUROL, V54, P379, DOI 10.1002/ana.10671; Levesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289; Marcinkowska A, 2001, FOLIA HISTOCHEM CYTO, V39, P177; Matroule JY, 1999, J BIOL CHEM, V274, P2988, DOI 10.1074/jbc.274.5.2988; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Niziolek M, 2003, PHOTOCHEM PHOTOBIOL, V78, P262, DOI 10.1562/0031-8655(2003)078<0262:CAACAO>2.0.CO;2; Ochsner M, 1997, J PHOTOCH PHOTOBIO B, V39, P1, DOI 10.1016/S1011-1344(96)07428-3; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; Payne JT, 1996, LASER SURG MED, V18, P406, DOI 10.1002/(SICI)1096-9101(1996)18:4<406::AID-LSM10>3.3.CO;2-7; Rousset N, 1999, J PHOTOCH PHOTOBIO B, V52, P65, DOI 10.1016/S1011-1344(99)00104-9; Santos CF, 2003, AM J PHYSIOL-HEART C, V285, pH775, DOI 10.1152/ajpheart.00818.2002; Schmidt-Erfurth U, 1998, OPHTHALMOLOGE, V95, P725, DOI 10.1007/s003470050343; Schreiber S, 2002, INT J CANCER, V99, P279, DOI 10.1002/ijc.10299; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Sharman WM, 1999, DRUG DISCOV TODAY, V4, P507, DOI 10.1016/S1359-6446(99)01412-9; Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2; Wagner JG, 2000, PHARMACOL REV, V52, P349; Wang LX, 2003, J IMMUNOL, V171, P3194, DOI 10.4049/jimmunol.171.6.3194; Woodburn KW, 2002, RETINA-J RET VIT DIS, V22, P391, DOI 10.1097/00006982-200208000-00001; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	42	40	42	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8649	8658		10.1038/sj.onc.1207871	http://dx.doi.org/10.1038/sj.onc.1207871			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467759				2022-12-17	WOS:000224988800011
J	Wu, DQ; Thakore, CU; Wescott, GG; McCubrey, JA; David, MT				Wu, DQ; Thakore, CU; Wescott, GG; McCubrey, JA; David, MT			Integrin signaling links protein kinase C epsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells	ONCOGENE			English	Article						PI3K; Src kinase; integrin-linked kinase; beta-catenin; fibronectin	GLYCOGEN-SYNTHASE KINASE; BETA-CATENIN; ANDROGEN RECEPTOR; CYCLIN D1; INTRAEPITHELIAL NEOPLASIA; PKC-EPSILON; INHIBITION; ACTIVATION; EXPRESSION; APOPTOSIS	Failure of hormone therapy often involves an outgrowth of protein kinase Cepsilon (PKCepsilon)-positive cells in recurrent prostate cancer. Our previous investigations have uncovered evidence of a complex signaling network operating downstream of this oncogenic protein kinase to actively advance the survival and proliferation of prostate cancer cells. In this study, we present evidence of a functional interplay among integrin receptors, PKCe, and protein kinase B (PKB/Akt) in recurrent CWR-R1 prostate cancer cells. Flow cytometry and confocal microscopy provided evidence that PKCepsilon signaling promoted the assembly of matrix adhesions containing an abundance of colocalized actin filaments and beta1 integrins that exhibited an exposed activation epitope on the surface of live CWR-R1 cells. Reciprocal coimmunoprecipitations provided evidence of signaling complexes containing PKCepsilon, beta1 integrins, Src, and PKB/Akt in CWR-R1 cell cultures. An investigation into the functional significance of these interactions, and of their positive influence on beta1 integrins, demonstrated that PKCepsilon and several key components of the PKB/Akt signaling pathway remain constitutively phosphorylated/activated in adherent but not suspension cultures of PTEN-positive CWR-R1 cells. Gene transfer, antisense and pharmacological experiments provided additional support for the hypothesis that a mutually reinforcing signaling loop sustains the activation of beta1 integrins, PKCepsilon, and PKB/Akt in adherent prostate cancer cells.	E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Leo W Jenkins Canc Ctr, Greenville, NC 27858 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	David, MT (corresponding author), E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA.	terriand@mail.ecu.edu		McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [R01 CA98195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 2001, BIOCHEM SOC T, V29, P1, DOI 10.1042/bst029a059; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Bazzoni G, 1998, J BIOL CHEM, V273, P6670, DOI 10.1074/jbc.273.12.6670; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Bernard D, 2003, J CLIN INVEST, V112, P1724; Berrier AL, 2000, J CELL BIOL, V151, P1549, DOI 10.1083/jcb.151.7.1549; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chen S, 1998, MOL ENDOCRINOL, V12, P1558, DOI 10.1210/me.12.10.1558; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chun JS, 1996, J BIOL CHEM, V271, P13008, DOI 10.1074/jbc.271.22.13008; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; Culig ZR, 2003, J UROLOGY, V170, P1363, DOI 10.1097/01.ju.0000075099.20662.7f; de la Taille A, 2003, CLIN CANCER RES, V9, P1801; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; Eder IE, 2002, CANCER GENE THER, V9, P117, DOI 10.1038/sj.cgt.7700416; Eder IE, 2000, CANCER GENE THER, V7, P997, DOI 10.1038/sj.cgt.7700202; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; FONARO M, 2001, CANCER METAST REV, V20, P321; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gounari F, 2002, ONCOGENE, V21, P4099, DOI 10.1038/sj.onc.1205562; Graff Jeremy R, 2002, Expert Opin Ther Targets, V6, P103, DOI 10.1517/14728222.6.1.103; Gregory CW, 2001, CANCER RES, V61, P2892; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ivaska J, 2003, NAT CELL BIOL, V5, P363, DOI 10.1038/ncb957; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; Koren R, 2004, ONCOL REP, V11, P321; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Liao YD, 2003, INT J CANCER, V107, P676, DOI 10.1002/ijc.11471; Linja MJ, 2001, CANCER RES, V61, P3550; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Mackay HJ, 2003, ENDOCR-RELAT CANCER, V10, P389, DOI 10.1677/erc.0.0100389; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; McJilton MA, 2003, ONCOGENE, V22, P7958, DOI 10.1038/sj.onc.1206795; McMenamin ME, 1999, CANCER RES, V59, P4291; Meuillet EJ, 2003, MOL CANCER THER, V2, P389; Moro L, 2004, J BIOL CHEM, V279, P1692, DOI 10.1074/jbc.M307857200; Mousses S, 2001, ONCOGENE, V20, P6718, DOI 10.1038/sj.onc.1204889; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Orchard S, 2002, CURR OPIN DRUG DI DE, V5, P713; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tucker GC, 2002, CURR OPIN PHARMACOL, V2, P394, DOI 10.1016/S1471-4892(02)00175-3; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Wescott G G, 1999, Methods Mol Med, V22, P125, DOI 10.1385/0-89603-612-X:125; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Wu Daqing, 2003, Methods Mol Biol, V218, P143; Wu DQ, 2002, J BIOL CHEM, V277, P40449, DOI 10.1074/jbc.M206270200; Wu DQ, 2002, CANCER RES, V62, P2423; Xie ZH, 2003, CANCER RES, V63, P5370; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008	71	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8659	8672		10.1038/sj.onc.1207900	http://dx.doi.org/10.1038/sj.onc.1207900			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467757				2022-12-17	WOS:000224988800012
J	Vanhecke, D; Janitz, M				Vanhecke, D; Janitz, M			High-throughput gene silencing using cell arrays	ONCOGENE			English	Article						RNA interference; microarray; reverse transfection; cell array	SMALL INTERFERING RNAS; DROSOPHILA CULTURED-CELLS; DOUBLE-STRANDED-RNA; GENOME-WIDE RNAI; MAMMALIAN-CELLS; CAENORHABDITIS-ELEGANS; EXPRESSION; MICROARRAYS; APOPTOSIS; IDENTIFICATION	A recently established transfected cell array (TCA) technology has opened new experimental dimensions in the field of functional genomics. Cell arrays allow for transfection of several thousands different DNA molecules in microarray format. The effects of overexpression of hundreds of proteins on cellular physiology can be observed in a single experiment. The TCA technique has also found its application in RNA interference (RNAi) research. Small interfering RNAs (siRNA) as well as plasmid expressing short hairpin RNAs can be transferred into the cells through the process of reverse transfection. The silencing of numerous genes in spatially separated manner can be thus monitored. This review will provide an overview on current concepts concerning combination of cell array and RNAi for high-throughput loss-of-function studies.	Max Planck Inst Mol Genet, Dept Vertebrate Genom, D-14195 Berlin, Germany	Max Planck Society	Janitz, M (corresponding author), Max Planck Inst Mol Genet, Dept Vertebrate Genom, Fabeckstr 60-62, D-14195 Berlin, Germany.	janitz@molgen.mpg.de	Janitz, Michael/E-9823-2015	Janitz, Michael/0000-0002-4878-0259				Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Cerutti H, 2003, TRENDS GENET, V19, P39, DOI 10.1016/S0168-9525(02)00010-0; Chang FH, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh029; Colosimo A, 2000, BIOTECHNIQUES, V29, P314, DOI 10.2144/00292rv01; Crnkovic-Mertens I, 2003, ONCOGENE, V22, P8330, DOI 10.1038/sj.onc.1206973; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Dieterich C, 2003, NUCLEIC ACIDS RES, V31, P55, DOI 10.1093/nar/gkg007; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; Kumar R, 2003, GENOME RES, V13, P2333, DOI 10.1101/gr.1575003; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Martinez J, 2004, GENE DEV, V18, P975, DOI 10.1101/gad.1187904; Martinez LA, 2002, P NATL ACAD SCI USA, V99, P14849, DOI 10.1073/pnas.222406899; McManus MT, 2002, RNA, V8, P842, DOI 10.1017/S1355838202024032; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Mishina YM, 2004, J BIOMOL SCREEN, V9, P196, DOI 10.1177/1087057103261880; MIYAGISHI M, 2002, NUCL ACIDS RES S, V2, P113; Mousses S, 2003, GENOME RES, V13, P2341, DOI 10.1101/gr.1478703; Murphy D, 2002, ADV PHYSIOL EDUC, V26, P256, DOI 10.1152/advan.00043.2002; Ooi SL, 2003, NAT GENET, V35, P277, DOI 10.1038/ng1258; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2003, CURR OPIN MOL THER, V5, P217; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Pothof J, 2003, GENE DEV, V17, P443, DOI 10.1101/gad.1060703; Price JH, 2002, J CELL BIOCHEM, P194, DOI 10.1002/jcb.10448; REDMOND TM, 2004, MOL CELL PROTEOMICS; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Shirane D, 2004, NAT GENET, V36, P190, DOI 10.1038/ng1290; Silva JM, 2004, P NATL ACAD SCI USA, V101, P6548, DOI 10.1073/pnas.0400165101; Somma MP, 2002, MOL BIOL CELL, V13, P2448, DOI 10.1091/mbc.01-12-0589; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; Trougakos IP, 2004, CANCER RES, V64, P1834, DOI 10.1158/0008-5472.CAN-03-2664; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; van Huijsduijnen RH, 2002, DRUG DISCOV TODAY, V7, P1013, DOI 10.1016/S1359-6446(02)02438-8; VANHECKE D, 2004, IN PRESS ENCY REFERE; Wang JC, 2004, J BIOL CHEM, V279, P29270, DOI 10.1074/jbc.M401242200; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; WOLF DE, 2003, METHOD CELL BIOL, V73, P319; Yang D, 2002, P NATL ACAD SCI USA, V99, P9942, DOI 10.1073/pnas.152327299; Yoshikawa T, 2004, J CONTROL RELEASE, V96, P227, DOI 10.1016/j.jconrel.2004.01.024; Zemanova L, 2003, DRUG DISCOV TODAY, V8, P1085, DOI 10.1016/S1359-6446(03)02833-2; Zheng LX, 2004, P NATL ACAD SCI USA, V101, P135, DOI 10.1073/pnas.2136685100; Ziauddin J, 2001, NATURE, V411, P107, DOI 10.1038/35075114	59	40	48	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8353	8358		10.1038/sj.onc.1208027	http://dx.doi.org/10.1038/sj.onc.1208027			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517016	Bronze			2022-12-17	WOS:000224815900005
J	Ayrault, O; Andrique, L; Larsen, CJ; Seite, P				Ayrault, O; Andrique, L; Larsen, CJ; Seite, P			Human Arf tumor suppressor specifically interacts with chromatin containing the promoter of rRNA genes	ONCOGENE			English	Article						p14(ARF); Topo I; chromatin; ChIP; rRNA genes	DNA TOPOISOMERASE-I; NUCLEAR-MATRIX; CELL-LINES; P53; TRANSCRIPTION; P19(ARF); MDM2; PROTEINS; STABILIZATION; BIOGENESIS	The tumor suppressor Arf (Alternative Reading Frame) protein (p14(ARF) in human and p19(ARF) in mouse) is mainly located in the nucleolus consistent with its subcellular localization, the protein has been shown to specifically interact with 5.8S rRNA and with B23/Nucleophosmin and to regulate ribosome biogenesis. Here, we show that the p14(ARF) protein interacts with chromatin and is recovered by chromatin immunoprecipitation (ChIP) in a fraction that contains a DNA sequence of the rRNA gene promoter. In addition, topoisomerase I (Topo I) that has been shown to interact with p14(ARF) coprecipitates with p14(ARF) containing chromatin. These data, in view of the function for Topo I in rRNA transcription, are consistent with a role for the p14(ARF)-Topo I complex in rRNA transcription and/or maturation.	Lab Oncol Mol EA 3805, F-86022 Poitiers, France		Seite, P (corresponding author), Lab Oncol Mol EA 3805, Pole Biol SAnte 40,Ave Recteur Pineau, F-86022 Poitiers, France.	paule.seite@univ-poitiers.fr		Seite, Paule/0000-0002-7809-7610; Andrique, Laetitia/0000-0001-7840-8135				Arnan C, 2003, J BIOL CHEM, V278, P31319, DOI 10.1074/jbc.M305560200; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; GARG LC, 1987, P NATL ACAD SCI USA, V84, P3185, DOI 10.1073/pnas.84.10.3185; Gladden AB, 2003, J BIOL CHEM, V278, P9754, DOI 10.1074/jbc.M212088200; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; JACKSON DA, 1985, EMBO J, V4, P919, DOI 10.1002/j.1460-2075.1985.tb03719.x; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Olivier A, 2003, ONCOGENE, V22, P1945, DOI 10.1038/sj.onc.1206214; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Pourquier Philippe, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P303; QUELLE DE, 1995, CELL, V83, P993; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; ROSE SM, 1984, J BIOL CHEM, V259, P8534; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; SMITH HC, 1987, BIOCHEM GENET, V25, P863, DOI 10.1007/BF00502606; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; Wadhwa R, 2002, J BIOL CHEM, V277, P36665, DOI 10.1074/jbc.M203222200; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	34	40	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8097	8104		10.1038/sj.onc.1207968	http://dx.doi.org/10.1038/sj.onc.1207968			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361825				2022-12-17	WOS:000224692500007
J	Yao, RS; Wang, Y; Lemon, WJ; Lubet, RA; You, M				Yao, RS; Wang, Y; Lemon, WJ; Lubet, RA; You, M			Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions	ONCOGENE			English	Article						budesonide; lung cancer; chemoprevention; A/J mice; expression profile	FEMALE A/J MICE; PULMONARY CARCINOGENESIS; APOPTOSIS; MYOINOSITOL; PROGRESSION; CARCINOMAS; RESISTANCE; MECHANISMS; HORMONES; PATHWAYS	Budesonide, a glucocorticoid, was proven to be a highly effective agent in preventing the development of lung tumors in A/J mice. In a lung tumor bioassay, budesonide produced 70% inhibition of tumor multiplicity and 94% reduction of total tumor load compared to benzopyrene ( B[ a] P) treated mice. Gene expression array analysis was performed on mouse lung tumors from this bioassay using Affymetrix U74Av2 GeneChips to determine gene expression changes associated with budesonide treatment. We found 363 genes that were changed between lung tumors induced by treatment with B[ a] P and similar tumors treated with budesonide. Among them, 243 genes were overexpressed and 120 genes were underexpressed after budesonide treatment. In addition, 108 genes differentially expressed during mouse lung tumorigenesis (50 genes overexpressed and 58 genes underexpressed) were modulated back to normal levels after budesonide treatment when compared with the controls group. These genes are involved in a broad range of different pathways including control of cell cycle, signal transduction, and apoptosis and may play a role in the observed preventive effect. Our results suggest that budesonide exerts its effects of chemoprevention through growth arrest via Mad2/3 and through apoptosis via Bim/Blk and, by inference, caspase-8/9. Using the pathway visualization tool GenMapp, G protein pathway and MAPK cascade were also regulated by budesonide. Thus, we have determined, for the first time, the expression profiles of genes modulated by budesonide during murine lung tumorigenesis. Our results indicate that the chemopreventive effects of budesonide in the mouse lung tumorigenesis assay involved increase and decrease expression of a wide variety of genes in multiple signaling pathways.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA; NCI, Chemoprevent Branch, Bethesda, MD 20892 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, Campus Box 8109,660 S Euclid Ave, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu						*AM CANC SOC, 2003, CANC FACTS FIG 2003, P4; BELMAN S, 1972, CANCER RES, V32, P450; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Dorscheid DR, 2001, AM J RESP CRIT CARE, V164, P1939, DOI 10.1164/ajrccm.164.10.2103013; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Greenstein S, 2002, CLIN CANCER RES, V8, P1681; Herr I, 2003, CANCER RES, V63, P3112; Herzog CR, 1997, J CELL BIOCHEM, P49; HUANG J, 2003, J BIOL CHEM, V16, P16; KITAZONO AA, 2003, MOL GENET GENOMICS, V24, P24; Li Xia, 2003, Journal of Shanghai Fisheries University, V12, P12; MALKINSON AM, 1992, CANCER RES, V52, pS2670; McDoniels-Silvers AL, 2002, NEOPLASIA, V4, P141, DOI 10.1038/sj.neo.7900217; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Wang Y, 2003, CANCER RES, V63, P4389; Wattenberg LW, 2000, CARCINOGENESIS, V21, P179, DOI 10.1093/carcin/21.2.179; Wattenberg LW, 1996, CANCER RES, V56, P5132; Wattenberg LW, 1997, CARCINOGENESIS, V18, P2015, DOI 10.1093/carcin/18.10.2015; Yao RS, 2003, NEOPLASIA, V5, P41, DOI 10.1016/S1476-5586(03)80016-7; Yao RS, 2002, ONCOGENE, V21, P5814, DOI 10.1038/sj.onc.1205422; Yin XY, 2001, ONCOGENE, V20, P2908, DOI 10.1038/sj.onc.1204417; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	25	40	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7746	7752		10.1038/sj.onc.1207985	http://dx.doi.org/10.1038/sj.onc.1207985			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361829				2022-12-17	WOS:000224306700016
J	Iwai, A; Marusawa, H; Matsuzawa, S; Fukushima, T; Hijikata, M; Reed, JC; Shimotohno, K; Chiba, T				Iwai, A; Marusawa, H; Matsuzawa, S; Fukushima, T; Hijikata, M; Reed, JC; Shimotohno, K; Chiba, T			Siah-1L, a novel transcript variant belonging to the human Siah family of proteins, regulates beta-catenin activity in a p53-dependent manner	ONCOGENE			English	Article						beta-catenin; Siah-1; Siah-1L; p53; hepatocellular carcinoma	HUMAN HEPATOCELLULAR CARCINOMAS; CANCER-CELLS; P53; MUTATIONS; IDENTIFICATION; SUPPRESSION; APOPTOSIS; HOMOLOGS; PATHWAY; GENE	beta-Catenin is a potent oncogenic protein whose cytoplasmic accumulation is a frequent event in cancer cells. The level of beta-catenin is regulated by two mechanisms: the adenomatous polyposis coli/Axin/glycogen synthase kinase 3beta-dependent degradation pathway and the Siah-1/ Siah interacting protein/Ebi-mediated degradation pathway. In this study, we have investigated the functional significance of p53-inducible human Siah-family protein expression in the regulation of beta-catenin activity. We show here by reverse-transcriptase polymerase chain reaction that two mRNA transcripts, designated human Siah-1 and Siah-1L, are generated from the human Siah-1 locus. Interestingly, the expression of Siah-1L was upregulated by p53, whereas human Siah-1 expression was constant. Furthermore, introduction of exogenous Siah-1L protein downregulated beta-catenin protein and promoted apoptosis induced by anticancer drugs in cancer cells that lack endogenous p53. Thus, Siah-1L represents a new member of the human Siah family that is induced in response to p53 and plays an important role in the regulation of beta-catenin activity in tumor cells. These findings also suggest new strategies for restoring tumor suppressive pathways lost in cancer cells that have suffered p53 inactivation.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses,Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Dept Med, Div Gastroenterol & Hepatol, Kyoto, Japan; Burnham Inst, La Jolla, CA 92037 USA	Kyoto University; Kyoto University; Sanford Burnham Prebys Medical Discovery Institute	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses,Sakyo Ku, 53 Kawara Cho, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp		Marusawa, Hiroyuki/0000-0002-4286-2712				Cagatay T, 2002, ONCOGENE, V21, P7971, DOI 10.1038/sj.onc.1205919; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Devereux TR, 2001, MOL CARCINOGEN, V31, P68, DOI 10.1002/mc.1041; Fiucci G, 2004, P NATL ACAD SCI USA, V101, P3510, DOI 10.1073/pnas.0400177101; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Inagawa S, 2002, CLIN CANCER RES, V8, P450; Lee TKW, 2002, CANCER CHEMOTH PHARM, V49, P78, DOI 10.1007/s00280-001-0376-4; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Maeda A, 2002, FEBS LETT, V512, P223, DOI 10.1016/S0014-5793(02)02265-2; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Omer CA, 1999, BIOCHEM BIOPH RES CO, V256, P584, DOI 10.1006/bbrc.1999.0379; Park WS, 2001, J PATHOL, V193, P483; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Ueda Y, 2001, BIOCHEM BIOPH RES CO, V283, P327, DOI 10.1006/bbrc.2001.4788; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	28	40	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7593	7600		10.1038/sj.onc.1208016	http://dx.doi.org/10.1038/sj.onc.1208016			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326481	Green Submitted			2022-12-17	WOS:000224176500017
J	Mahyar-Roemer, M; Fritzsche, C; Wagner, S; Laue, M; Roemer, K				Mahyar-Roemer, M; Fritzsche, C; Wagner, S; Laue, M; Roemer, K			Mitochondrial p53 levels parallel total p53 levels independent of stress response in human colorectal carcinoma and glioblastoma cells	ONCOGENE			English	Article						tumor suppressor; p53; mitochondria; apoptosis	HUMAN CANCER-CELLS; WILD-TYPE P53; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; TRANSCRIPTIONAL TARGET; THERAPEUTIC AGENTS; TUMOR-SUPPRESSOR; BCL-2 FAMILY; PROTEIN; ACTIVATION	p53 can eliminate damaged cells through the induction of mitochondria-mediated apoptosis. Recent observations have provided strong evidence that a fraction of total p53 translocates to mitochondria specifically in response to a death stimulus. Unexpectedly, mutant p53, which is expressed at much higher levels than wild type in unstressed cells, is apparently always present at the mitochondria, independent of apoptotic signal. This prompted us to ask whether cell lines with intact p53-dependent apoptosis and cell cycle arrest pathways exist in which the mitochondrial localization of wild-type p53, like that of mutant, is independent of a death stimulus and instead, correlates with the total p53 levels. Here, we document that human HCT116 colorectal carcinoma cells treated with adriamycin or 5-fluorouracil (5FU) can accumulate total p53 to equally high levels, and mitochondrial p53 to proportionate levels, although only 5FU treatment provoked p53-dependent apoptosis. Along the same line, HCT116 derivatives with increased basal p53 levels, and glioblastoma cells with a doxycycline-inducible p53, also revealed proportionate mitochondrial p53 levels, and even unstressed HCT116 cells had some p53 located at the mitochondria. Finally, mitochondrial and total p53 showed distinct post-translational modi. cations. Thus, cell lines exist in which the mitochondrial p53 levels parallel total levels independent of apoptosis.	Univ Saarland, Sch Med, Dept Virol, D-66421 Homburg, Germany; Univ Saarland, Sch Med, Dept Anat & Cell Biol, Ctr Electron Microscopy, D-66421 Homburg, Germany	Saarland University; Saarland University	Roemer, K (corresponding author), Univ Saarland, Sch Med, Dept Virol, Bldg 47, D-66421 Homburg, Germany.	vinmue@med-rz.uni-saarland.de						Attardi LD, 2000, GENE DEV, V14, P704; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Gao CF, 1999, JPN J CANCER RES, V90, P180, DOI 10.1111/j.1349-7006.1999.tb00731.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Mahyar-Roemer M, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-27; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Robles AI, 2001, CANCER RES, V61, P6660; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	41	40	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6226	6236		10.1038/sj.onc.1207637	http://dx.doi.org/10.1038/sj.onc.1207637			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15247902				2022-12-17	WOS:000223399000007
J	Rodway, H; Llanos, S; Rowe, J; Peters, G				Rodway, H; Llanos, S; Rowe, J; Peters, G			Stability of nucleolar versus non-nucleolar forms of human p14(ARF)	ONCOGENE			English	Article						ARF; MDM; p53; proteasome; ubiquitylation	UBIQUITIN-PROTEIN LIGASE; TUMOR SUPPRESSORS; CELL-CYCLE; P53; MDM2; ARF; LOCUS; E2F1; STABILIZATION; P19(ARF)	Fusion proteins containing the amino-terminal domain of human p14(ARF) linked to green fluorescent protein are able to bind MDM2 and stabilize p53 without localization in the nucleolus. However, these fusion proteins are inherently unstable, with half-lives considerably shorter than either authentic ARF or chimaeras containing the entire coding domain, both of which are predominantly nucleolar. We present evidence that the unstable fusion proteins are significantly stabilized if redirected to the nucleolus by addition of a basic motif based on the nuclear localization signal of SV40 T-antigen. Moreover, the stability of these proteins can be enhanced by modulating the functions of MDM2 and p53. These data are consistent with a model in which ARF interacts with MDM2 in the nucleoplasm but is consequently subject to proteasomal degradation. Nucleolar localization may serve to store or stabilize ARF.	London Res Inst, Canc Res UK, London WC2A 3PX, England	Cancer Research UK	Peters, G (corresponding author), London Res Inst, Canc Res UK, Lincolns Inn Fields, London WC2A 3PX, England.	gordon.peters@cancer.org.uk	, Susana/AAA-9282-2019	Llanos, Susana/0000-0002-8555-9326				Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Clark PA, 2002, ONCOGENE, V21, P4498, DOI 10.1038/sj.onc.1205558; Datta A, 2002, MOL CELL BIOL, V22, P8398, DOI 10.1128/MCB.22.24.8398-8408.2002; David-Pfeuty T, 2002, ONCOGENE, V21, P6779, DOI 10.1038/sj.onc.1205871; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fatyol K, 2001, J BIOL CHEM, V276, P28421, DOI 10.1074/jbc.M102847200; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Kim SH, 2003, P NATL ACAD SCI USA, V100, P211, DOI 10.1073/pnas.0135557100; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; Orlowski M, 2003, ARCH BIOCHEM BIOPHYS, V415, P1, DOI 10.1016/S0003-9861(03)00197-8; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rizos H, 2001, J BIOL CHEM, V276, P41424, DOI 10.1074/jbc.M105299200; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	46	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6186	6192		10.1038/sj.onc.1207854	http://dx.doi.org/10.1038/sj.onc.1207854			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15286709				2022-12-17	WOS:000223399000002
J	Yoshida, K; Inoue, I				Yoshida, K; Inoue, I			Expression of MCM10 and TopBP1 is regulated by cell proliferation and UV irradiation via the E2F transcription factor	ONCOGENE			English	Article						MCM10; TopBP1; DNA replication; UV irradiation; promoter; E2F	DNA-DAMAGE; S-PHASE; REPLICATION ORIGINS; CYCLE PROGRESSION; SACCHAROMYCES-CEREVISIAE; MICROARRAY ANALYSIS; IN-VIVO; PROTEIN; PRB; ACTIVATION	MCM10 and TopBP1 function in the initiation of DNA replication, by regulating the chromatin binding of the DNA polymerase a loading factor, CDC45. TopBP1 is also known as a DNA damage response protein. In this study, we showed that the transcription of human MCM10 and TopBP1 is activated by transcription factors E2F1-3, but not by factors E2F4-7. Analysis of various MCM10 and TopBP1 promoter constructs showed that an E2F-responsive sequence in the vicinity of the transcription initiation site is necessary for the E2F1-induced activation of MCM10 and TopBP1 gene transcription, which is further suppressed by pRb. The promoter activities of human MCM10 and TopBP1 were demonstrated to be growth dependent via the E2F-responsive sequence. Although E2F1 was stabilized by ultraviolet (UV) irradiation, the mRNA expression level of TopBP1 was suppressed in HCT116 human diploid colon cancer cells. We showed, by performing chromatin immunoprecipitation that, in response to UV irradiation but not doxorubicin treatment, E2F4 accumulated on the MCM10 and TopBP1 promoters. Our data suggest a model in which UV irradiation-induced DNA damage depends, at least in part, on the accumulation of the E2F4 transcription factor on the MCM10 and TopBP1 promoters, which results in suppression of DNA replication.	Univ Tokyo, Inst Med Sci, Div Genet Diag, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Yoshida, K (corresponding author), Univ Tokyo, Inst Med Sci, Div Genet Diag, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yoshidak@ims.u-tokyo.ac.jp						Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blattner C, 1999, MOL CELL BIOL, V19, P3704; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; Diffley JFX, 1998, CURR BIOL, V8, pR771, DOI 10.1016/S0960-9822(07)00483-6; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Homesley L, 2000, GENE DEV, V14, P913; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Izumi M, 2000, NUCLEIC ACIDS RES, V28, P4769, DOI 10.1093/nar/28.23.4769; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Lei M, 2001, J CELL SCI, V114, P1447; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lin WC, 2001, GENE DEV, V15, P1833; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Moberg K, 1996, MOL CELL BIOL, V16, P1436; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; Potter T, 2000, RADIAT RES, V154, P151, DOI 10.1667/0033-7587(2000)154[0151:KETURR]2.0.CO;2; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Suzuki S, 1998, GENE, V216, P85, DOI 10.1016/S0378-1119(98)00323-0; Takahashi Y, 2000, GENE DEV, V14, P804; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Van Hatten RA, 2002, J CELL BIOL, V159, P541, DOI 10.1083/jcb.200207090; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Yamamoto RR, 2000, GENETICS, V156, P711; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; Yoshida K, 2004, ONCOGENE, V23, P3802, DOI 10.1038/sj.onc.1207488; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	50	40	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	2004	23	37					6250	6260		10.1038/sj.onc.1207829	http://dx.doi.org/10.1038/sj.onc.1207829			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15195143				2022-12-17	WOS:000223399000009
J	Sarker, KP; Lee, KY				Sarker, KP; Lee, KY			L6 myoblast differentiation is modulated by Cdk5 via the PI3K-AKT-p70S6K signaling pathway	ONCOGENE			English	Article						myoblast; differentiation; Cdk5; signaling	CYCLIN-DEPENDENT KINASE-5; P70 S6 KINASE; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MUSCLE DIFFERENTIATION; TYROSINE KINASE; GENE-EXPRESSION; GROWTH-FACTORS; MAP KINASE; ACTIVATION	Cdk5 regulates myogenesis but the signaling cascade through which Cdk5 modulates this process remains to be characterized. Here, we investigated whether PI3K, Akt, p70S6K, p38 MAPK, p44/42 MAPK, and Egr-1 serve as upstream regulators of Cdk5 during L6 myoblast differentiation. Upon serum reduction, we found that besides elevated expression of Cdk5 and its activator, p35, and increased Cdk5/p35 activity, Egr-1, Akt, p70S6K, and p38 MAPK activity were upregulated in differentiating L6 cells. However, p44/42 MAPK was downregulated and SAPK/JNK was unaffected. LY294002, a PI3K inhibitor, blocked the activation of Akt and p70S6K, indicating that Akt and p70S6K activation is linked to PI3K activation. The lack of LY294002 effect on p38 MAPK suggests that p38 MAPK activation is not associated with PI3K activation. Rapamycin, a specific inhibitor of FRAP/mTOR (the upstream kinase of p70S6K), also blocked p70S6K activation, indicating the involvement of FRAP/mTOR activation. LY294002 and rapamycin also blocked the enhancement of Egr-1 level, Cdk5 activity, and myogenin expression, suggesting that upregulation of these factors is coupled to PI3K-p70S6K activation. Overexpression of dominant-negative-Akt also reduced Cdk5/p35 activity and myogenin expression, indicating that the PI3K-p70S6K-Egr-1-Cdk5 signaling cascade is linked to Akt activation. SB2023580, a p38 MAPK inhibitor, had no effect on p70S6K, Egr-1, or Cdk5 activity, suggesting that p38 MAPK activation lies in a pathway distinct from the PI3K-Akt-p70S6K-Egr-1 pathway that we identify as the upstream modulator of Cdk5 activity during L6 myoblast differentiation.	Univ Calgary, Fac Med, Dept Cell Biol & Anat, Canc Biol Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Cell Biol & Anat, Neurosci Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Lee, KY (corresponding author), Univ Calgary, Fac Med, Dept Cell Biol & Anat, Canc Biol Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	kylee@ucalgary.ca						Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; ARNOLD HH, 1992, SYM SOC EXP BIOL, V46, P37; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; Chen F, 2001, BLOOD, V97, P3763, DOI 10.1182/blood.V97.12.3763; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conejo R, 2002, ONCOGENE, V21, P3739, DOI 10.1038/sj.onc.1205469; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Gao CY, 1997, DEV GENET, V20, P267; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Guidato S, 1998, J NEUROCHEM, V70, P335; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Harada S, 2001, DNA CELL BIOL, V20, P223, DOI 10.1089/104454901750219107; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.3.CO;2-S; Kim S, 2000, J BIOL CHEM, V275, P25979, DOI 10.1074/jbc.M001975200; Kitzmann M, 2001, CELL MOL LIFE SCI, V58, P571, DOI 10.1007/PL00000882; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Laprise P, 2002, J CELL PHYSIOL, V191, P69, DOI 10.1002/jcp.10075; Lazaro JB, 1997, J CELL SCI, V110, P1251; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; Lee KY, 1997, INT J BIOCHEM CELL B, V29, P951, DOI 10.1016/S1357-2725(97)00048-4; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LIU JW, 1991, J BIOL CHEM, V266, P5929; MIYAJIMA M, 1995, NEUROREPORT, V6, P1130, DOI 10.1097/00001756-199505300-00014; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Ostrovsky O, 2003, J BIOL CHEM, V278, P21221, DOI 10.1074/jbc.M211357200; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rosales JL, 2004, J BIOL CHEM, V279, P1224, DOI 10.1074/jbc.M310867200; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sarker KP, 2003, J NEUROCHEM, V85, P50, DOI 10.1046/j.1471-4159.2003.01663.x; Sarker KP, 2000, J MOL NEUROSCI, V15, P243, DOI 10.1385/JMN:15:3:243; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Tamir Y, 2000, J BIOL CHEM, V275, P34424, DOI 10.1074/jbc.M005815200; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Winter B, 2000, J CELL SCI, V113, P4211; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Zetser A, 2001, DEV BIOL, V240, P168, DOI 10.1006/dbio.2001.0465; ZHANG H, 1993, MOL BIOL CELL, V9, P897	46	40	45	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6064	6070		10.1038/sj.onc.1207819	http://dx.doi.org/10.1038/sj.onc.1207819			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208659				2022-12-17	WOS:000223261000006
J	Liang, XQ; Avraham, HK; Jiang, SX; Avraham, S				Liang, XQ; Avraham, HK; Jiang, SX; Avraham, S			Genetic alterations of the NRP/B gene are associated with human brain tumors	ONCOGENE			English	Article						NRP/B; alteration; human brain tumor; nuclear matrix protein; Kelch repeat	NUCLEAR-MATRIX PROTEIN; ACTIN-BINDING PROTEIN; HUMAN BREAST-CANCER; MAP KINASE-KINASE; RETINOBLASTOMA PROTEIN; P53 PATHWAY; CELLS; APOPTOSIS; GROWTH; DIFFERENTIATION	Nearly all brain tumors develop following the progressive accumulation of genetic alterations of oncogenes and tumor suppressor genes (such as p53 and retinoblastoma protein). Furthermore, aberrations in the nuclear matrix often contribute to genomic instabilities and the development of cancer. We have previously shown that nuclear-restricted protein/brain (NRP/B), a member of the BTB/Kelch repeat family, is a nuclear matrix protein normally expressed in neurons but not in astrocytes, and that it is an early and specific marker of neurons during the development of the central nervous system. Here, we show aberrant expression of NRP/B in human brain tissues. NRP/B is expressed in the cytoplasm of human brain tumor cells (glioblastoma, GBM) arising from astrocytes. NRP/B mutations (13 mutations in the Kelch domains, two in the intervening sequence (IVS) domain and two in the BTB domain) were detected in brain tumor cell lines (A-172, CCF-STTG1, SK-N-SH and U87-MG) and in primary human malignant GBM tissues (eight samples). More importantly, we found that NRP/B mutants, but not wild-type (wt) NRP/B, increased the activation of ERK and consequently promoted cell proliferation, attenuated caspase activation and suppressed the cellular apoptosis induced by the stressful stimulus cisplatin (10 mum). These events were observed to occur via a p53-mediated pathway. In addition, while wt NRP/B was associated with actin, mutations in the Kelch domains of NRP/B led to its reduced binding affinity to actin. Thus, alterations and gene mutations within the NRP/B gene may contribute to brain tumorigenesis by promoting cell proliferation, suppressing apoptosis and by affecting nuclear cytoskeleton dynamics.	Harvard Univ, Beth Israel Deaconess Med Ctr, Div Expt Med, Harvard Inst Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Avraham, S (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Expt Med, Harvard Inst Med, 4 Blackfan Circle, Boston, MA 02215 USA.	savraham@bidmc.harvard.edu		Avraham, Hava/0000-0002-7545-3640	NCI NIH HHS [1 R01 CA096805] Funding Source: Medline; NINDS NIH HHS [1 R01 NS046628-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096805] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberti I, 2000, J CELL BIOCHEM, V79, P471, DOI 10.1002/1097-4644(20001201)79:3<471::AID-JCB120>3.3.CO;2-F; Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Back SA, 1998, J NEUROSCI, V18, P6241; Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x; Biernat Wojciech, 1998, Polish Journal of Pathology, V49, P267; Bode J, 2000, J CELL BIOCHEM, P3; BOGLER O, 1995, GLIA, V15, P308, DOI 10.1002/glia.440150311; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brunagel G, 2002, CANCER RES, V62, P2437; Campbell I, 2000, CANCER GENE THER, V7, P1270, DOI 10.1038/sj.cgt.7700226; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Collins VP, 1998, CANCER SURV, V32, P37; DARDICK I, 1981, AM J PATHOL, V103, P10; Davido T, 2000, J CELL BIOCHEM, P136; Davie JR, 2001, PROG NUCLEIC ACID RE, V65, P299; Deppert W, 2000, J CELL BIOCHEM, P115; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Fueyo J, 1998, NEUROLOGY, V51, P1250, DOI 10.1212/WNL.51.5.1250; Fujita M, 2001, CANCER RES, V61, P7722; Getzenberg RH, 1996, CANCER RES, V56, P1690; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Grim J, 1997, CLIN CANCER RES, V3, P2415; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; Hernandez MC, 1997, J NEUROSCI, V17, P3038; Ichimura K, 2000, CANCER RES, V60, P417; Ichimura K, 1996, ONCOGENE, V13, P1065; Kim TA, 2000, GENE, V255, P105, DOI 10.1016/S0378-1119(00)00297-3; Kim TA, 1998, J CELL BIOL, V141, P553, DOI 10.1083/jcb.141.3.553; Konety BR, 1999, J CELL BIOCHEM, P183; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lane DP, 2002, TRENDS MOL MED, V8, pS38, DOI 10.1016/S1471-4914(02)02309-2; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIBERMANN TA, 1985, J CELL SCI, P161; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Meyers S, 2000, J CELL BIOCHEM, P93; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1999, J PATHOL, V187, P112; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; Reilly KM, 2001, SEMIN CANCER BIOL, V11, P177, DOI 10.1006/scbi.2000.0375; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Simon M, 1999, ACTA NEUROPATHOL, V98, P444, DOI 10.1007/s004010051107; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Sotolongo B, 2000, J CELL BIOCHEM, P23; Stein G, 2000, J CELL BIOCHEM, P1; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Ueki K, 1996, CANCER RES, V56, P150; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xing C, 1999, CARCINOGENESIS, V20, P1201, DOI 10.1093/carcin/20.7.1201; Yang H, 2002, MOL CELL BIOL, V22, P3103, DOI 10.1128/MCB.22.9.3103-3110.2002; Ye JP, 1999, J BIOL CHEM, V274, P34974, DOI 10.1074/jbc.274.49.34974; Zhao L, 2000, J BIOL CHEM, V275, P16845, DOI 10.1074/jbc.275.22.16845	68	40	42	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5890	5900		10.1038/sj.onc.1207776	http://dx.doi.org/10.1038/sj.onc.1207776			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208678				2022-12-17	WOS:000222941100003
J	Li, HM; Zhuang, ZH; Wang, Q; Pang, JCS; Wang, XH; Wong, HL; Feng, HC; Jin, DY; Ling, MT; Wong, YC; Eliopoulos, AG; Young, LS; Huang, DP; Tsao, SW				Li, HM; Zhuang, ZH; Wang, Q; Pang, JCS; Wang, XH; Wong, HL; Feng, HC; Jin, DY; Ling, MT; Wong, YC; Eliopoulos, AG; Young, LS; Huang, DP; Tsao, SW			Epstein-Barr virus latent membrane protein 1 (LMP1) upregulates Id1 expression in nasopharyngeal epithelial cells	ONCOGENE			English	Article						Epstein-Barr virus; nasopharyngeal carcinoma; LMP1; Id1; nuclear factor kappa B	NF-KAPPA-B; CELLULAR SIGNALING PATHWAYS; MEMBRANE-PROTEIN; CARCINOMA-CELLS; SEQUENCE; GROWTH; ID-1; DIFFERENTIATION; PHOSPHORYLATION; TRANSFORMATION	Nasopharyngeal carcinoma is closely associated with Epstein-Barr virus (EBV) infection. The EBV-encoded LMP1 has cell transformation property. It suppresses cellular senescence and enhances cell survival in various cell types. Many of the downstream events of LMP1 expression are mediated through its ability to activate NF-kappaB. In this study, we report a novel function of LMP1 to induce Id1 expression in nasopharyngeal epithelial cells (NP69) and human embryonal kidney cells (HEK293). The Id1 is a basic helix-loop-helix (bHLH) protein and a negative transcriptional regulator of p16(INK4a). Expression of Id1 facilitates cellular immortalization and stimulates cell proliferation. With the combination of both specific chemical inhibitors and genetic inhibitors of cell signaling, we showed that induction of Id1 by LMP1 was dependent on its NF-kappaB activation domain at the carboxy-terminal region, CTAR1 and CTAR2. Induction of Id1 by LMP1 may facilitate clonal expansion of premalignant nasopharyngeal epithelial cells infected with EBV and may promote their malignant transformation.	Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Fac Med, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Inst Mol Oncol, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China; Univ Birmingham, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; University of Birmingham	Tsao, SW (corresponding author), Univ Hong Kong, Dept Anat, Room L01-53,Lab Block,Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	gswtsao@hkucc.hku.hk	Feng, Huichen/F-5502-2011; Tsao, George/C-4422-2009; ELIOPOULOS, ARISTIDES/ABI-6632-2020; Young, Lawrence S/B-7213-2009; Li, Hoi Ming/B-5828-2008; ELIOPOULOS, ARISTIDES/R-9449-2018	Feng, Huichen/0000-0003-3069-8174; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761				Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Blake SMS, 2001, VIROLOGY, V282, P278, DOI 10.1006/viro.2001.0828; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Cheung ST, 1998, INT J CANCER, V76, P399, DOI 10.1002/(SICI)1097-0215(19980504)76:3<399::AID-IJC18>3.0.CO;2-6; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; Fielding CA, 2001, J VIROL, V75, P9129, DOI 10.1128/JVI.75.19.9129-9141.2001; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; Hatzivassiliou E, 2002, FRONT BIOSCI, V7, pD319, DOI 10.2741/hatziva; Jeannel D, 1999, CANCER SURV, V33, P125; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Ling MT, 2002, ONCOGENE, V21, P8498, DOI 10.1038/sj.onc.1206007; LO AK, 2003, LAB INVEST, V83, P1; Nehlin JO, 1997, BIOCHEM BIOPH RES CO, V231, P628, DOI 10.1006/bbrc.1997.6152; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Ohtani N, 2003, J CELL BIOL, V162, P173, DOI 10.1083/jcb.200302085; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHAM JST, 1990, INT J RADIAT ONCOL, V19, P929, DOI 10.1016/0360-3016(90)90014-B; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Tsao SW, 2002, SEMIN CANCER BIOL, V12, P473, DOI 10.1016/S1044579X02000901; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wang XH, 2003, ONCOGENE, V22, P109, DOI 10.1038/sj.onc.1206069; Wang XH, 2002, MOL CARCINOGEN, V35, P42, DOI 10.1002/mc.10072; Yang XH, 2000, J VIROL, V74, P883, DOI 10.1128/JVI.74.2.883-891.2000; ZABEL U, 1991, J BIOL CHEM, V266, P252	36	40	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4488	4494		10.1038/sj.onc.1207580	http://dx.doi.org/10.1038/sj.onc.1207580			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064751				2022-12-17	WOS:000221661300014
J	Herbst, A; Salghetti, SE; Kim, SY; Tansey, WP				Herbst, A; Salghetti, SE; Kim, SY; Tansey, WP			Multiple cell-type-specific elements regulate Myc protein stability	ONCOGENE			English	Article						Myc; Myc box; ubiquitin; proteasome; transcription	ACTIVATION-DOMAIN FUNCTION; C-MYC; IN-VIVO; UBIQUITIN; PROTEASOME; DEGRADATION; ONCOPROTEIN; PROTEOLYSIS; TRANSACTIVATION; EXPRESSION	Myc is a highly unstable transcription factor that is destroyed by ubiquitin (Ub)-mediated proteolysis. We have previously identified an amino-terminal 'degron' within Myc that signals its destruction; this degron spans the transcriptional activation domain of Myc, and includes two highly conserved regions called Myc boxes I and II. We now report the identification of a second element-the D-element-which is also required for Myc proteolysis. The centrally located D-element is distinct from the PEST domain in Myc, but includes Myc box III, a third highly conserved region with no previously known function. We show that deletion of the D-element stabilizes the Myc protein without affecting its ubiquitylation, and report that the D-element and the degron act in a cell-type-specific manner to direct Myc proteolysis. These data thus demonstrate that Myc stability is regulated at both the ubiquitylation and postubiquitylation levels, and reveal that substrates of the Ub-proteasome system can be targeted for destruction differently in different cell types.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Genet Program, Stony Brook, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Tansey, WP (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.	tansey@cshl.edu			NCI NIH HHS [CA-13106, CA45508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA045508, P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATCHLEY WR, 1995, P NATL ACAD SCI USA, V92, P10217, DOI 10.1073/pnas.92.22.10217; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Chen L, 2000, ARCH BIOCHEM BIOPHYS, V374, P306, DOI 10.1006/abbi.1999.1603; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; CONKLIN DS, 1993, MOL CELL BIOL, V13, P2041, DOI 10.1128/MCB.13.4.2041; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greer SF, 2003, NAT IMMUNOL, V4, P1074, DOI 10.1038/ni985; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Herbst A, 2000, MOL BIOL REP, V27, P203, DOI 10.1023/A:1011008018565; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOGAN J, 1981, VIROLOGY, V115, P419, DOI 10.1016/0042-6822(81)90126-4; MORTIMER RK, 1986, GENETICS, V113, P35; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; PRASAD I, 1976, J VIROL, V18, P436, DOI 10.1128/JVI.18.2.436-444.1976; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rudolph C, 1999, ANAL BIOCHEM, V269, P66, DOI 10.1006/abio.1999.3095; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; Sherman F., 1986, METHODS YEAST GENETI; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Tanaka M, 1996, P NATL ACAD SCI USA, V93, P4311, DOI 10.1073/pnas.93.9.4311; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tworkowski KA, 2002, ONCOGENE, V21, P8515, DOI 10.1038/sj.onc.1205976; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Xie YM, 2002, NAT CELL BIOL, V4, P1003, DOI 10.1038/ncb889	47	40	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3863	3871		10.1038/sj.onc.1207492	http://dx.doi.org/10.1038/sj.onc.1207492			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021906				2022-12-17	WOS:000221242500013
J	Xie, SQ; Wang, Q; Ruan, Q; Liu, TY; Jhanwar-Uniyal, M; Guan, KL; Dai, W				Xie, SQ; Wang, Q; Ruan, Q; Liu, TY; Jhanwar-Uniyal, M; Guan, KL; Dai, W			MEK1-induced Golgi dynamics during cell cycle progression is partly mediated by Polo-like kinase-3	ONCOGENE			English	Article						Plk3; Golgi breakdown; polo-like kinases; MEK1; cell cycle	MATRIX PROTEIN GM130; MITOTIC PHOSPHORYLATION; CDC2 KINASE; FRAGMENTATION; MITOSIS; APOPTOSIS; COMPLEX; MEK1; IDENTIFICATION; ACTIVATION	MEK1, a gene product that regulates cell growth and differentiation, also plays an important role in Golgi breakdown during the cell cycle. We have recently shown that polo-like kinase (Plk3) is Golgi localized and involved in Golgi dynamics during the cell cycle. To study the mode of action of Plk3 in the Golgi fragmentation cascade, we examined functional as well as physical interactions between Plk3 and MEK1/ERKs. In HeLa cells, although a significant amount of Plk3 signals dispersed in a manner similar to those of Golgi during mitosis concentrated Plk3 was detected at spindle poles, which colocalized with phospho-MEKs and phospho-ERKs. Pull-down assays showed that Plk3 physically interacted with MEK1 and ERK2. Nocodazole activated Plk3 and its activation was blocked by MEK-specific inhibitors (PD98059 or U0126). Moreover, transfection of activated MEK1 resulted in an enhanced kinase activity of Plk3; Plk3-induced fragmentation of Golgi stacks was significantly reduced after treatment with MEK inhibitors. Consistently, ectopic expression of activated MEK1, but not kinase-dead MEK1(K97R), stimulated Plk3 to induce Golgi breakdown and the stimulation was not observed in cells expressing Plk3(K52R). Furthermore, PLK3(-/-) murine embryonic fibroblast cells exhibited a significantly less fragmentation of the Golgi complex than that in wild-type cells after exposed to nocodazole. Thus, our studies strongly suggest that Plk3 may be a key protein kinase mediating MEK1 function in the Golgi fragmentation pathway during cell division.	New York Med Coll, Dept Med, Valhalla, NY 10595 USA; Inst Canc Prevent, Valhalla, NY 10595 USA; Univ Michigan, Dept Biochem, Ann Arbor, MI 48109 USA	New York Medical College; University of Michigan System; University of Michigan	Dai, W (corresponding author), New York Med Coll, Dept Med, Valhalla, NY 10595 USA.	wei_dai@nymc.edu		Dai, Wei/0000-0003-0169-8327	NCI NIH HHS [R01-CA74229] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074229] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Cha HJ, 2001, J CELL BIOL, V153, P1355, DOI 10.1083/jcb.153.7.1355; Colanzi A, 2000, J CELL BIOL, V149, P331, DOI 10.1083/jcb.149.2.331; Colanzi A, 2003, J CELL BIOL, V161, P27, DOI 10.1083/jcb.200208099; Jesch SA, 2001, MOL BIOL CELL, V12, P1811, DOI 10.1091/mbc.12.6.1811; Kano F, 2000, J CELL BIOL, V149, P357, DOI 10.1083/jcb.149.2.357; Kee HJ, 2003, YONSEI MED J, V44, P65, DOI 10.3349/ymj.2003.44.1.65; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; Lowe M, 2000, J CELL BIOL, V149, P341, DOI 10.1083/jcb.149.2.341; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; LUCOCQ J, 1991, J CELL SCI, V100, P753; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; RUAN Q, 2004, IN PRESS EXP CELL RE; Sutterlin C, 2002, CELL, V109, P359, DOI 10.1016/S0092-8674(02)00720-1; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	22	40	41	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3822	3829		10.1038/sj.onc.1207479	http://dx.doi.org/10.1038/sj.onc.1207479			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021912				2022-12-17	WOS:000221242500009
J	Joo, A; Aburatani, H; Morii, E; Iba, H; Yoshimura, A				Joo, A; Aburatani, H; Morii, E; Iba, H; Yoshimura, A			STAT3 and MITF cooperatively induce cellular transformation through upregulation of c-fos expression	ONCOGENE			English	Article						MITF; STAT3; c-fos; cellular transformation	MICROPHTHALMIA TRANSCRIPTION FACTOR; TYROSINE KINASE; MAST-CELLS; GENE-REGULATION; ACTIVATION; PROTEIN; MELANOMA; TRANSACTIVATION; DIFFERENTIATION; TARGET	The signal transducer and activator of transcription ( STAT) family proteins are transcription factors critical in mediating cytokine signaling. Among them, STAT3 is frequently activated in a number of human cancers and transformed cell lines and is implicated in tumorigenesis. However, although constitutively activated STAT3 mutant (STAT3C) leads to cellular transformation, its transformation potential such as colony-forming activity in soft-agar is much weaker than that of v-src. To identify tumorigenic factors that cooperatively induce cellular transformation with STAT3C, we screened the retroviral cDNA library. We found that the microphthalmia-associated transcription factor ( MITF), an essential transcription factor for melanocyte development and pigmentation, induces anchorage-independent growth of NIH-3T3 cells in cooperation with STAT3C. Micro array analysis revealed that c-fos is highly expressed in transformants expressing STAT3C and MITF. Promoter analysis and chromatin immunoprecipitation assay suggested that both STAT3 and MITF can cooperatively upregulate the c-fos gene. In addition, the transformation of NIH-3T3 cells by both MITF and STAT3C was significantly suppressed by a dominant-negative AP-1 retrovirus. These data indicate that MITF and STAT3 cooperatively induce c-fos, resulting in cellular transformation.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Div Genome Sci, Meguro Ku, Tokyo 1538904, Japan; Osaka Univ, Sch Med, Dept Pathol, Osaka 5650871, Japan; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan	Kyushu University; University of Tokyo; Osaka University; University of Tokyo	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013					Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; Carreira S, 2000, J BIOL CHEM, V275, P21920, DOI 10.1074/jbc.M000035200; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Kamaraju AK, 2002, J BIOL CHEM, V277, P15132, DOI 10.1074/jbc.M200004200; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; Kim DS, 2003, J CELL SCI, V116, P1699, DOI 10.1242/jcs.00366; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kitamura Y, 2002, MOL IMMUNOL, V38, P1173, DOI 10.1016/S0161-5890(02)00058-5; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; KULMBURG PA, 1992, J EXP MED, V176, P1773, DOI 10.1084/jem.176.6.1773; Levy C, 2002, J BIOL CHEM, V277, P1962, DOI 10.1074/jbc.M109236200; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P295; Matsui T, 2002, J BIOL CHEM, V277, P36167, DOI 10.1074/jbc.M203184200; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Morii E, 1996, BLOOD, V88, P2488, DOI 10.1182/blood.V88.7.2488.bloodjournal8872488; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nakayama K, 2002, EMBO J, V21, P6174, DOI 10.1093/emboj/cdf596; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Nyormoi O, 2003, CLIN EXP METASTAS, V20, P251, DOI 10.1023/A:1022991302172; Ogihara H, 2001, BLOOD, V97, P645, DOI 10.1182/blood.V97.3.645; ONG EK, 1993, GENE, V134, P235, DOI 10.1016/0378-1119(93)90099-O; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; Sato M, 1999, BIOCHEM BIOPH RES CO, V254, P384, DOI 10.1006/bbrc.1998.9918; Shibahara S, 2001, J INVEST DERM SYMP P, V6, P99, DOI 10.1046/j.0022-202x.2001.00010.x; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tachibana M, 1997, PIGM CELL RES, V10, P25, DOI 10.1111/j.1600-0749.1997.tb00462.x; Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Udono T, 2000, BBA-GENE STRUCT EXPR, V1491, P205, DOI 10.1016/S0167-4781(00)00051-8; Ui M, 2000, BIOCHEM BIOPH RES CO, V278, P97, DOI 10.1006/bbrc.2000.3777; Vachtenheim J, 2001, J INVEST DERMATOL, V117, P1505, DOI 10.1046/j.0022-202x.2001.01563.x; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zanocco-Marani T, 1999, CANCER RES, V59, P5331	43	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					726	734		10.1038/sj.onc.1207174	http://dx.doi.org/10.1038/sj.onc.1207174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737107				2022-12-17	WOS:000188304900011
J	Cuenco, GM; Ren, RB				Cuenco, GM; Ren, RB			Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice	ONCOGENE			English	Article						acute myelogenous leukemia (AML); AML1/MDS1/EVI1; BCR/ABL; EVI1; RUNX1	ACUTE MYELOID-LEUKEMIA; T(3/21) FUSION PRODUCT; TRANSCRIPTION FACTOR; BCR-ABL; MYELOPROLIFERATIVE DISEASE; GROWTH-INHIBITION; GENE CBFB-MYH11; RAPID INDUCTION; PR DOMAIN; EXPRESSION	We have previously shown that BCR/ABL, a fusion protein generated by the t(9;22)(q34;q11) translocation found in the vast majority of chronic myelogenous leukemia (CML), cooperates with AML1/MDS1/EVI1 (AME), a fusion transcription factor generated by a t(3;21)(q26;q22) translocation identified as a secondary mutation in some cases of CML during the blast phase (CML-BC), in the rapid induction of an acute myelogenous leukemia (AML) in mice. In this study, we evaluated the leukemogenic potential of EVI1-, MDS1/EVI1- and AML1-related oncoproteins (AML1Delta, AML1/MDS1). We found that ectopic expression of either EVI1 or MDS1/EVI1 impaired hematopoiesis. However, neither EVI1 nor MDS1/EVI1 was sufficient for inducing AML in mice, although EVI1 did induce some hematologic neoplasia other than AML with a low efficiency. In addition, unlike AME, none of the EVI1- or AML1-related oncoproteins examined were capable of fully cooperating with BCR/ABL in the induction of AML. The results indicate that both the AML1 and EVI1 oncogenic components are required for the leukemogenic potential of AME and for the cooperation of AME and BCR/ABL in the induction of AML.	Brandeis Univ, Dept Biol, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA	Brandeis University	Ren, RB (corresponding author), Brandeis Univ, Dept Biol, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.	ren@brandeis.edu			NATIONAL CANCER INSTITUTE [R01CA068008] Funding Source: NIH RePORTER; NCI NIH HHS [CA68008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; Cuenco GM, 2001, ONCOGENE, V20, P8236, DOI 10.1038/sj.onc.1205095; ERICKSON PF, 1994, CANCER RES, V54, P1782; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FIALKOW PJ, 1991, BLOOD, V77, P1415; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933; Izutsu K, 2002, ONCOGENE, V21, P2695, DOI 10.1038/sj.onc.1205356; JACOBS A, 1991, LEUKEMIA, V5, P277; Kojima K, 1999, BRIT J HAEMATOL, V106, P720, DOI 10.1046/j.1365-2141.1999.01588.x; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Langabeer SE, 2001, BRIT J HAEMATOL, V112, P208, DOI 10.1046/j.1365-2141.2001.02569.x; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Louz D, 2000, LEUKEMIA, V14, P1876, DOI 10.1038/sj.leu.2401887; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; Myint H, 1997, LEUKEMIA RES, V21, P473, DOI 10.1016/S0145-2126(97)00070-2; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; Nucifora G, 1997, LEUKEMIA, V11, P2022, DOI 10.1038/sj.leu.2400880; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; RUSSELL M, 1994, BLOOD, V84, P1243, DOI 10.1182/blood.V84.4.1243.bloodjournal8441243; Scandura JM, 2002, ONCOGENE, V21, P3422, DOI 10.1038/sj.onc.1205315; Senyuk V, 2002, ONCOGENE, V21, P3232, DOI 10.1038/sj.onc.1205436; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	41	40	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					569	579		10.1038/sj.onc.1207143	http://dx.doi.org/10.1038/sj.onc.1207143			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724585				2022-12-17	WOS:000188098300028
J	Krams, M; Parwaresch, R; Sipos, B; Heidorn, K; Harms, D; Rudolph, P				Krams, M; Parwaresch, R; Sipos, B; Heidorn, K; Harms, D; Rudolph, P			Expression of the c-kit receptor characterizes a subset of neuroblastomas with favorable prognosis	ONCOGENE			English	Article						c-kit; transcription; neuroblastoma; differentiation; prognosis	STEM-CELL FACTOR; TRANSCRIPTASE MESSENGER-RNA; TYROSINE KINASE; TELOMERASE ACTIVITY; INTERSTITIAL-CELLS; SIGNALING PATHWAYS; PROGENITOR CELLS; LUNG-CARCINOMA; HUMAN TISSUES; SURVIVAL	Expression of the c-kit proto-oncogene product in neuroblastomas has been reported, but its clinical relevance is unclear. We determined the expression of c-kit by immunohistochemistry in a series of 155 neuroblastomas with long-term follow-up. The specificity of the reaction was verified by Western blot analysis and quantitative RT-PCR, and exon 11 of the kit gene was screened for mutations by PCR and capillary electrophoresis. No mutations were detected, and transcription of the kit gene correlated with protein expression. c-kit expression was associated with lower tumor stages and a low rate of MYCN amplification. More importantly, it coincided with tumor differentiation (P < 0.0001), and portended a favorable outcome with a relative risk of 0.18 (P < 0.0001). In a multivariate analysis of event-free survival, loss of c-kit (relative risk 4.25, P < 0.0001) was an independent prognostic factor next to INSS stage 4 and before MYCN amplification. It is concluded that c-kit is transcriptionally regulated in neuroblastomas. Its expression likely identifies a subset of neuroblastomas with conserved capacity for differentiation, which may represent the embryonal variety of the disease. Assessment of c-kit may improve prognostic models for neuroblastoma and provide a basis for new therapy concepts.	Univ Kiel, Dept Pediat Pathol, D-24098 Kiel, Germany; Univ Kiel, Dept Hematopathol, D-24098 Kiel, Germany; Univ Kiel, Dept Gen Pathol, D-24098 Kiel, Germany	University of Kiel; University of Kiel; University of Kiel	Rudolph, P (corresponding author), Univ Kiel, Dept Pathol, Michaelisstr 11, D-24105 Kiel, Germany.	prudolph@path.uni-kiel.de						Arber DA, 1998, HUM PATHOL, V29, P498, DOI 10.1016/S0046-8177(98)90066-1; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; BECK D, 1995, BLOOD, V86, P3132, DOI 10.1182/blood.V86.8.3132.bloodjournal8683132; Berthold F, 1997, EUR J CANCER, V33, P2092, DOI 10.1016/S0959-8049(97)00237-2; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; COHEN PS, 1994, BLOOD, V84, P3465; De Sepulveda P, 1999, EMBO J, V18, P904; DiPaola RS, 1997, CANCER GENE THER, V4, P176; Hayashi S, 1995, DNA Res, V2, P211, DOI 10.1093/dnares/2.5.211; HIRATA T, 1993, DEVELOPMENT, V119, P49; Hirota Seiichi, 2001, International Journal of Clinical Oncology, V6, P1, DOI 10.1007/PL00012072; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Hornick JL, 2002, AM J CLIN PATHOL, V117, P188; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; IDA JA, 1993, J NEUROSCI RES, V36, P596, DOI 10.1002/jnr.490360512; Jahn T, 2002, ONCOGENE, V21, P4508, DOI 10.1038/sj.onc.1205559; JOSHI VV, 1992, CANCER-AM CANCER SOC, V69, P2197, DOI 10.1002/1097-0142(19920415)69:8<2197::AID-CNCR2820690829>3.0.CO;2-X; Kapur R, 2001, BLOOD, V97, P1975, DOI 10.1182/blood.V97.7.1975; KELLER JR, 1995, BLOOD, V86, P1757, DOI 10.1182/blood.V86.5.1757.bloodjournal8651757; Kindblom LG, 1998, AM J PATHOL, V152, P1259; Krams M, 2002, CANCER, V94, P854, DOI 10.1002/cncr.10256.abs; Krams M, 2003, AM J PATHOL, V162, P1019, DOI 10.1016/S0002-9440(10)63896-5; Krams M, 2001, AM J PATHOL, V159, P1925, DOI 10.1016/S0002-9440(10)63039-8; LAMMIE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1417, DOI 10.1177/42.11.7523489; LEV S, 1994, CRIT REV ONCOGENESIS, V5, P141, DOI 10.1615/CritRevOncog.v5.i2-3.30; MAEDA H, 1992, DEVELOPMENT, V116, P369; Makhlouf HR, 2002, AM J SURG PATHOL, V26, P493, DOI 10.1097/00000478-200204000-00012; MIYAZAWA K, 1995, BLOOD, V85, P641, DOI 10.1182/blood.V85.3.641.bloodjournal853641; Montone KT, 1997, MODERN PATHOL, V10, P939; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NATALI PG, 1992, CANCER RES, V52, P6139; Robinson LLL, 2001, MOL HUM REPROD, V7, P845, DOI 10.1093/molehr/7.9.845; Rudolph P, 2002, VIRCHOWS ARCH, V441, P238, DOI 10.1007/s00428-002-0673-2; Schwartz S, 1999, LEUKEMIA LYMPHOMA, V34, P85, DOI 10.3109/10428199909083383; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Sipos B, 2002, INT J CANCER, V102, P592, DOI 10.1002/ijc.10753; Smithey BE, 2002, AM J SURG PATHOL, V26, P486, DOI 10.1097/00000478-200204000-00011; Timeus F, 1997, EXP HEMATOL, V25, P1253; Torihashi S, 1999, GASTROENTEROLOGY, V117, P140, DOI 10.1016/S0016-5085(99)70560-3; TSUURA Y, 1994, VIRCHOWS ARCH, V424, P135; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x	42	40	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					588	595		10.1038/sj.onc.1207145	http://dx.doi.org/10.1038/sj.onc.1207145			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724587				2022-12-17	WOS:000188098300030
J	Reiter, R; Oh, AS; Wellstein, A; Riegel, AT				Reiter, R; Oh, AS; Wellstein, A; Riegel, AT			Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta 3 on estrogenic ligands with different intrinsic activity	ONCOGENE			English	Article						AIB1; coactivator; estrogen; ER	BREAST-CANCER; ER-ALPHA; TISSUE DISTRIBUTION; EXPRESSION; GROWTH; BETA; HORMONE; MAMMARY; COREGULATORS; SPECIFICITY	The nuclear receptor coactivator amplified in breast cancer 1 (AIB1) and its more active isoform AIB1-Delta3 are overexpressed in breast cancer and preneoplastic breast tissue. However, the impact of these proteins on the transcriptional activity of natural estrogens or selective estrogen receptor modulators (SERMs) has not been determined. Here we show that AIB1-Delta3 causes a significant increase in the efficacy of 17beta-estradiol at both estrogen receptor-alpha (ER-alpha) and ER-beta in ovarian, breast and endometrial cancer cell lines. AIB1-Delta3 also significantly increased the efficacy of the natural estrogen genistein at both ER-alpha and ER-beta, whereas AIB1 had no effect on either the potency or efficacy of genistein at either receptor. The estrogenic efficacy of the partial agonist tamoxifen was significantly increased in all cell lines at ER-alpha by overexpression of AIB1-Delta3 both on transfected and endogenous estrogen responsive genes. In contrast, overexpression of AIB1 or AIB1-Delta3 had no effect on the potency or efficacy of the SERM raloxifene. We conclude that overexpression of the AIB1-Delta3 isoform will increase the estrogenicity of a variety of natural and pharmacologic compounds in tissues that develop hormone-dependent neoplasias and overexpression of these cofactors may be a contributing factor to the hormone-driven development of neoplasia and to antiestrogen resistance of breast cancers.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20057 USA; Georgetown Univ, Dept Pharmacol, Washington, DC 20057 USA	Georgetown University; Georgetown University	Riegel, AT (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Res Bldg,Room E307, Washington, DC 20057 USA.	ariege01@georgetown.edu		Wellstein, Anton/0000-0002-0570-4950; Oh, Annabell S./0000-0002-0676-1164	NCI NIH HHS [P50 CA58185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Bouras T, 2001, CANCER RES, V61, P903; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; Glass CK, 2000, GENE DEV, V14, P121; Guan XY, 1996, CANCER RES, V56, P3446; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Jordan VC, 2002, CANCER CELL, V1, P215, DOI 10.1016/S1535-6108(02)00050-8; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Lamartiniere CA, 2002, J NUTR, V132, p552S, DOI 10.1093/jn/132.3.552S; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390; Liu H, 2002, J BIOL CHEM, V277, P9189, DOI 10.1074/jbc.M108335200; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Murphy LC, 2000, CANCER RES, V60, P6266; Nilsson S, 2002, CRIT REV BIOCHEM MOL, V37, P1, DOI 10.1080/10409230290771438; ONATE SA, 1995, SCIENCE, V270, P1354; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; Reiter R, 2001, J BIOL CHEM, V276, P39736, DOI 10.1074/jbc.M104744200; Roger P, 2001, CANCER RES, V61, P2537; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Tikkanen MK, 2000, P NATL ACAD SCI USA, V97, P12536, DOI 10.1073/pnas.220427297; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Zava DT, 1997, NUTR CANCER, V27, P31, DOI 10.1080/01635589709514498	39	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					403	409		10.1038/sj.onc.1207202	http://dx.doi.org/10.1038/sj.onc.1207202			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14691461				2022-12-17	WOS:000188098300010
J	Fromigue, O; Louis, K; Dayem, M; Milanini, J; Pages, G; Tartare-Deckert, S; Ponzio, G; Hofman, P; Barbry, P; Auberger, P; Mari, B				Fromigue, O; Louis, K; Dayem, M; Milanini, J; Pages, G; Tartare-Deckert, S; Ponzio, G; Hofman, P; Barbry, P; Auberger, P; Mari, B			Gene expression profiling of normal human pulmonary fibroblasts following coculture with non-small-cell lung cancer cells reveals alterations related to matrix degradation, angiogenesis, cell growth and survival	ONCOGENE			English	Article						tumor-stroma; fibroblast; coculture; cDNA arrays; desmoplasia; stromelysin-3	EPITHELIAL-MESENCHYMAL INTERACTIONS; HUMAN BREAST CARCINOMAS; MESSENGER-RNA; PLASMINOGEN-ACTIVATOR; TUMOR PROGRESSION; STROMAL CELLS; OVER-EXPRESSION; RETINOIC ACID; ID PROTEINS; HUMAN COLON	Increasing evidence supports a major role for the microenvironment in carcinoma formation and progression. The influence of the stroma is partly mediated by signalling between epithelial tumor cells and neighboring fibroblasts. However, the molecular mechanisms underlying these interactions are largely unknown. To mimic the initial steps of invasive carcinoma in which tumor cells come in contact with normal stromal cells, we used a coculture model of non-small-cell lung cancer tumor cells and normal pulmonary fibroblasts. Using DNA filter arrays, we first analysed the overall modification of gene expression profile after a 24 h period of coculture. Next, we focused our interest on the transcriptome of the purified fibroblastic fraction of coculture using both DNA filter arrays and a laboratory-made DNA microarray. These experiments allowed the identification of a set of modulated genes coding for growth and survival factors, angiogenic factors, proteases and protease inhibitors, transmembrane receptors, kinases and transcription regulators that can potentially affect the regulation of matrix degradation, angiogenesis, invasion, cell growth and survival. This study represents to our knowledge the first attempt to dissect early global gene transcription occurring in a tumor-stroma coculture model and should help to understand better some of the molecular mechanisms involved in heterotypic signalling between epithelial tumor cells and fibroblasts.	Fac Med Pasteur, INSERM U526, F-06107 Nice 2, France; Fac Med Pasteur, INSERM EPI0215, F-06107 Nice 2, France; Fac Med Pasteur, INSERM U385, F-06107 Nice 2, France; Ctr Antoine Lacassagne, CNRS, UNSA UMR 6543, F-06054 Nice, France; IPMC, CNRS, UNSA UMR 6097, Sophia Antipolis, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Mari, B (corresponding author), Fac Med Pasteur, INSERM U526, Ave Valombrose,IFR 50, F-06107 Nice 2, France.	bmari@unice.fr	Ponzio, Gilles/Q-1256-2016; Hofman, Paul/P-7654-2018; Fromigue, Olivia/B-8225-2013; TARTARE-DECKERT, Sophie/P-6057-2015; Mari, Bernard P/F-8960-2013; AUBERGER, Patrick/G-1491-2013; Pages, Gilles/N-7135-2017; Mari, Bernard/Q-5832-2019; Barbry, Pascal/O-5021-2016; Mari, Bernard P/D-7445-2015; Mari, Bernard P/GVS-3100-2022	Ponzio, Gilles/0000-0003-2741-0248; Hofman, Paul/0000-0003-0431-9353; Fromigue, Olivia/0000-0002-3050-6155; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Mari, Bernard P/0000-0002-0422-9182; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard/0000-0002-0422-9182; Barbry, Pascal/0000-0001-9632-6483; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Milanini, Julie/0000-0002-5861-2830				Ahmed W, 1998, CONNECT TISSUE RES, V37, P263, DOI 10.3109/03008209809002444; ANDERSON IC, 1995, CANCER RES, V55, P4120; Anderson IC, 2000, CANCER RES, V60, P269; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Birckbichler PJ, 2000, CANCER-AM CANCER SOC, V89, P412, DOI 10.1002/1097-0142(20000715)89:2<412::AID-CNCR29>3.0.CO;2-O; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0; Borchers AH, 1997, MOL CARCINOGEN, V19, P258, DOI 10.1002/(SICI)1098-2744(199708)19:4<258::AID-MC7>3.0.CO;2-8; Brown LF, 1999, CLIN CANCER RES, V5, P1041; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Christensen L, 1996, INT J CANCER, V66, P441; Cursio R, 2001, FASEB J, V15, P93, DOI 10.1096/fj.01-0279fje; Dayem MA, 2003, COMP FUNCT GENOM, V4, P47, DOI 10.1002/cfg.239; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; GIOANNI J, 1988, EUR J CANCER CLIN ON, V24, P1445, DOI 10.1016/0277-5379(88)90335-5; Gregoire M, 1995, CANCER METAST REV, V14, P339, DOI 10.1007/BF00690602; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; Hanamura N, 1997, INT J CANCER, V73, P10, DOI 10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4; He C, 2001, J CANCER RES CLIN, V127, P180, DOI 10.1007/s004320000192; Heppner KJ, 1996, AM J PATHOL, V149, P273; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Ingber DE, 2002, DIFFERENTIATION, V70, P547, DOI 10.1046/j.1432-0436.2002.700908.x; ITO A, 1995, BRIT J CANCER, V71, P1039, DOI 10.1038/bjc.1995.200; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kim SH, 2002, ONCOGENE, V21, P8741, DOI 10.1038/sj.onc.1205987; Kleeff J, 1998, INT J CANCER, V77, P860, DOI 10.1002/(SICI)1097-0215(19980911)77:6<860::AID-IJC11>3.0.CO;2-5; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lee HY, 2002, CANCER RES, V62, P3530; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Linder C, 1997, BREAST CANCER RES TR, V42, P207, DOI 10.1023/A:1005769622570; LINGE C, 1989, EXP CELL RES, V185, P519, DOI 10.1016/0014-4827(89)90320-0; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; Mari BP, 1998, J BIOL CHEM, V273, P618, DOI 10.1074/jbc.273.1.618; Mascaux C, 2002, ANTICANCER RES, V22, P1273; Matrisian LM, 2001, CANCER RES, V61, P3844; Maulon L, 2001, ONCOGENE, V20, P1964, DOI 10.1038/sj.onc.1204266; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MITSIADIS TA, 1995, J CELL BIOL, V130, P407, DOI 10.1083/jcb.130.2.407; Moorehead RA, 2003, ONCOGENE, V22, P853, DOI 10.1038/sj.onc.1206188; NOEL AC, 1994, INT J CANCER, V56, P331, DOI 10.1002/ijc.2910560306; Ohga E, 1996, BIOCHEM BIOPH RES CO, V228, P391, DOI 10.1006/bbrc.1996.1672; Ohtani H, 1998, PATHOL INT, V48, P1, DOI 10.1111/j.1440-1827.1998.tb03820.x; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Porte H, 1998, CLIN CANCER RES, V4, P1375; Rabbani SA, 1998, IN VIVO, V12, P135; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; ROUYER N, 1994, INVAS METAST, V14, P269; Sampson MT, 2002, BIOCHEM SOC T, V30, P201, DOI 10.1042/bst0300201; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SESLAR SP, 1993, CANCER RES, V53, P1233; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Umeda T, 1997, J PATHOL, V183, P388; Vitolo D, 2001, J PATHOL, V195, P197, DOI 10.1002/path.938; Wang K, 2002, ONCOGENE, V21, P7598, DOI 10.1038/sj.onc.1205953; WERLING RW, 1993, THROMB HAEMOSTASIS, V69, P366; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726; Wojtukiewicz MZ, 1999, THROMB HAEMOSTASIS, V82, P1659; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wu EX, 2001, J CELL BIOCHEM, V82, P549, DOI 10.1002/jcb.1181; Wu-Wong J Ruth, 2002, Curr Opin Investig Drugs, V3, P1234; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	77	40	41	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8487	8497		10.1038/sj.onc.1206918	http://dx.doi.org/10.1038/sj.onc.1206918			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627989				2022-12-17	WOS:000186650300012
J	George, A; Morse, HC; Justice, MJ				George, A; Morse, HC; Justice, MJ			The homeobox gene Hex induces T-cell-derived lymphomas when overexpressed in hematopoietic precursor cells	ONCOGENE			English	Article						Hex; retroviral transduction; T-cell lymphoma	LEUKEMIC HEMATOPOIESIS; EXPRESSION; DIFFERENTIATION; MOUSE; PROTEIN; MICE; PRH; TRANSFORMATION; ACTIVATION; ZEBRAFISH	Proviral insertions at the viral insertion site Lvis1 occur frequently in B- and T-cell leukemias and lymphomas in AKXD mice and activate two nearby genes, the divergent homeobox gene Hex and the kinesin-related spindle protein gene Eg5. To determine whether Hex misexpression results in the altered differentiation or neoplastic transformation of hematopoietic lineages, we have transplanted mice with bone marrow cells transduced with retrovirus containing the Hex coding region. High levels of Hex expression in hematopoietic precursor cells inhibit contribution to mature blood cell lineages by these precursors. Hex bone marrow transplant recipient mice also develop hematologic neoplasms that appear to originate in the bone marrow. The tumors have clonal rearrangements of the TCR locus, are Thy1(+), and are CD4(+)CD8(+), CD4(-)CD8(-), or mixed, indicating tumor origin from a precursor T-cell population. Tumors in transplant mice contain clonal and transcriptionally active Hex proviral insertions, demonstrating a causal role for Hex misexpression in the onset of these neoplasms. Our results demonstrate that Hex can act as a T lineage oncogene when misexpressed in hematopoietic precursor cells.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, MD PhD Program, Houston, TX 77030 USA; NIAID, Immunopathol Lab, NIH, Rockville, MD USA	Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Justice, MJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	mjustice@bcm.tmc.edu		Morse, Herbert/0000-0002-9331-3705	NATIONAL CANCER INSTITUTE [R01CA063229, R29CA063229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000858] Funding Source: NIH RePORTER; NCI NIH HHS [CA63229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Barbera JPM, 2000, DEVELOPMENT, V127, P2433; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Behrens A, 2001, P NATL ACAD SCI USA, V98, P1769, DOI 10.1073/pnas.98.4.1769; Bogue CW, 2000, DEV DYNAM, V219, P84, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1028>3.0.CO;2-5; Bogue CW, 2003, P NATL ACAD SCI USA, V100, P556, DOI 10.1073/pnas.0236979100; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; GOLDFARB AN, 1994, LEUKEMIA LYMPHOMA, V12, P157, DOI 10.3109/10428199409059586; Hansen GM, 1999, ONCOGENE, V18, P6531, DOI 10.1038/sj.onc.1203023; Hawley RG, 1997, CANCER RES, V57, P337; HAWLEY RG, 1994, GENE THER, V1, P136; Ho CY, 1999, CURR BIOL, V9, P1131, DOI 10.1016/S0960-9822(99)80485-0; Hough MR, 1998, P NATL ACAD SCI USA, V95, P13853, DOI 10.1073/pnas.95.23.13853; HROMAS R, 1993, BIOCHEM BIOPH RES CO, V195, P976, DOI 10.1006/bbrc.1993.2140; Jayaraman PS, 2000, LEUKEMIA RES, V24, P1023, DOI 10.1016/S0145-2126(00)00072-2; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Keng VW, 2000, BIOCHEM BIOPH RES CO, V276, P1155, DOI 10.1006/bbrc.2000.3548; Krosl J, 2000, ONCOGENE, V19, P5134, DOI 10.1038/sj.onc.1203897; Liao W, 2000, DEVELOPMENT, V127, P4303; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Mack DL, 2002, IMMUNOLOGY, V107, P444, DOI 10.1046/j.1365-2567.2002.01523.x; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; Nakagawa T, 2003, ARTERIOSCL THROM VAS, V23, P231, DOI 10.1161/01.ATV.0000052670.55321.87; Newman CS, 1997, MECH DEVELOP, V66, P83, DOI 10.1016/S0925-4773(97)00092-0; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; ROSENBERG N, 1994, SEMIN CANCER BIOL, V5, P95; SAWYERS CL, 2001, MOL BASIS BLOOD DIS; Schaefer LK, 2001, J BIOL CHEM, V276, P43074, DOI 10.1074/jbc.M102552200; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tanaka T, 1999, BIOCHEM J, V339, P111, DOI 10.1042/0264-6021:3390111; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Thorsteinsdottir U, 1997, HEMATOL ONCOL CLIN N, V11, P1221, DOI 10.1016/S0889-8588(05)70491-3	37	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2003	22	43					6764	6773		10.1038/sj.onc.1206822	http://dx.doi.org/10.1038/sj.onc.1206822			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555989				2022-12-17	WOS:000185799300011
J	Ota, J; Yamashita, Y; Okawa, K; Kisanuki, H; Fujiwara, S; Ishikawa, M; Choi, YL; Ueno, S; Ohki, R; Koinuma, K; Wada, T; Compton, D; Kadoya, T; Mano, H				Ota, J; Yamashita, Y; Okawa, K; Kisanuki, H; Fujiwara, S; Ishikawa, M; Choi, YL; Ueno, S; Ohki, R; Koinuma, K; Wada, T; Compton, D; Kadoya, T; Mano, H			Proteomic analysis of hematopoietic stem cell-like fractions in leukemic disorders	ONCOGENE			English	Article						acute myeloid leukemia; proteome; AC133; NuMA	MYELOID DIFFERENTIATION PROGRAM; DNA MICROARRAY ANALYSIS; S-TRANSFERASE-PI; GENE-EXPRESSION; CANCER-CELLS; PROTEINS; NUMA; IDENTIFICATION; PARKINSONISM; ORGANIZATION	DNA microarray analysis has been applied to identify molecular markers of human hematological malignancies. However, the relatively low correlation between the abundance of a given mRNA and that of the encoded protein makes it important to characterize the protein profile directly, or 'proteome,' of malignant cells in addition to the 'transcriptome.' To identify proteins specifically expressed in leukemias, here we isolated AC133(+) hematopoietic stem cell-like fractions from the bone marrow of 13 individuals with various leukemic disorders, and compared their protein profiles by two-dimensional electrophoresis. A total of 11 differentially expressed protein spots corresponding to 10 independent proteins were detected, and peptide fingerprinting combined with mass spectrometry of these proteins revealed them to include NuMA (nuclear protein that associates with the mitotic apparatus), heat shock proteins, and redox regulators. The abundance of NuMA in the leukemic blasts was significantly related to the presence of complex karyotype anomalies. Conditional expression of NuMA in a mouse myeloid cell line resulted in the induction of aneuploidy, cell cycle arrest in G(2)-M phases, and apoptosis. These results demonstrate the potential of proteome analysis with background-matched cell fractions obtained from fresh clinical specimens to provide insight into the mechanism of human leukemogenesis.	Jichi Med Sch, Div Funct Genom, Tochigi 3290498, Japan; Kirin Brewery Co Ltd, Div Pharmaceut, Pharmaceut Res Labs, Takasaki, Gumma 3701925, Japan; Jichi Med Sch, Div Hematol, Tochigi 3290498, Japan; Jichi Med Sch, Div Cardiol, Tochigi 3290498, Japan; Jichi Med Sch, Dept Surg, Tochigi 3290498, Japan; Jichi Med Sch, Dept Gynecol, Tochigi 3290498, Japan; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA; Kirin Brewery Co Ltd, Div Pharmaceut, Prod Dept, R&D Ctr, Maebashi, Gumma 3710853, Japan	Jichi Medical University; Kirin Brewery Company Limited; Jichi Medical University; Jichi Medical University; Jichi Medical University; Jichi Medical University; Dartmouth College; Kirin Brewery Company Limited	Mano, H (corresponding author), Jichi Med Sch, Div Funct Genom, 3311-1 Yakushiji, Tochigi 3290498, Japan.	hmano@jichi.ac.jp		Compton, Duane/0000-0002-4445-9118				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Kaul SC, 1998, ONCOGENE, V17, P907, DOI 10.1038/sj.onc.1202017; KAUL SC, 1995, FEBS LETT, V361, P269, DOI 10.1016/0014-5793(95)00177-B; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lian Z, 2002, BLOOD, V100, P3209, DOI 10.1182/blood-2002-03-0850; Lian Z, 2001, BLOOD, V98, P513, DOI 10.1182/blood.V98.3.513; Makishima H, 2002, BRIT J HAEMATOL, V118, P462, DOI 10.1046/j.1365-2141.2002.03646.x; Matsumine H, 1997, AM J HUM GENET, V60, P588; Miyazato A, 2001, BLOOD, V98, P422, DOI 10.1182/blood.V98.2.422; Ohmine K, 2001, ONCOGENE, V20, P8249, DOI 10.1038/sj.onc.1205029; OKUYAMA T, 1994, CANCER, V74, P1230, DOI 10.1002/1097-0142(19940815)74:4<1230::AID-CNCR2820740409>3.0.CO;2-0; Pang XP, 1997, ONCOL RES, V9, P623; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; ShimodaMatsubayashi S, 1997, NEUROLOGY, V49, P1257, DOI 10.1212/WNL.49.5.1257; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; VOLM M, 1992, CANCER, V70, P764, DOI 10.1002/1097-0142(19920815)70:4<764::AID-CNCR2820700408>3.0.CO;2-M; Watarai H, 2000, ELECTROPHORESIS, V21, P460, DOI 10.1002/(SICI)1522-2683(20000101)21:2<460::AID-ELPS460>3.0.CO;2-P; Yamashita Y, 1996, JPN J CANCER RES, V87, P1106, DOI 10.1111/j.1349-7006.1996.tb03118.x	29	40	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5720	5728		10.1038/sj.onc.1206855	http://dx.doi.org/10.1038/sj.onc.1206855			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944923				2022-12-17	WOS:000184865900024
J	Salvatori, L; Pallante, P; Ravenna, L; Chinzari, P; Frati, L; Russo, MA; Petrangeli, E				Salvatori, L; Pallante, P; Ravenna, L; Chinzari, P; Frati, L; Russo, MA; Petrangeli, E			Oestrogens and selective oestrogen receptor (ER) modulators regulate EGF receptor gene expression through human ER alpha and beta subtypes via an Sp1 site	ONCOGENE			English	Article						oestrogens; SERMs; oestrogen receptor; Sp1; EGF receptor; gene expression	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER CELLS; DEOXYRIBONUCLEIC-ACID; THYROID-HORMONE; ACTIVATION; PROMOTER; ANTIESTROGENS; IDENTIFICATION; TRANSCRIPTION; PHYTOESTROGENS	Through the analysis of the transient expression of the luciferase reporter gene in HeLa cells, an evaluation has been made of the transcriptional activity of oestrogens and of selective oestrogen receptor (ER) modulators (SERMs), mediated by the alpha and beta isoforms of the ER, on the epidermal growth factor receptor gene promoter. Oestrogen-activated ERbeta presents a lower transcriptional activity compared with ERalpha, probably due to structural differences in the AF-1 regions of the receptors. Also SERMs induce different responses depending on the receptor isoform bound. Indeed, the phyto-oestrogens, genistein and daidzein, act as weak agonists of the oestrogenic activity via ERalpha, but as full agonists when bound to ERbeta. The synthetic SERM 40H-tamoxifen, on the other hand, displays an opposite behaviour since it exerts a full agonist action through ERalpha, but acts as a full antagonist via ERbeta. As we have previously shown for ERalpha, an ERbeta/Sp1 functional synergism has also been highlighted, by means of gel mobility shift assays. Moreover, our results show that the sensitivity of target tissues to oestrogens and SERMs can be affected by coexpression of ERs, depending on the formation of appropriate levels of homo- and heterodimers, thus providing a useful approach to predict the effects of hormonal treatment.	CNR, Ist Biol & Patol Mol, I-00137 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Neuromed Inst, I-86077 Pozzilli, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; IRCCS Neuromed	Salvatori, L (corresponding author), CNR, Ist Biol & Patol Mol, Viale Marx N 43, I-00137 Rome, Italy.	luisa.salvatori@ibpm.cnr.it	Salvatori, Luisa/AAK-9365-2021; Frati, Luigi/ABI-7437-2020; Pallante, Pierlorenzo/AAX-8758-2020					BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bramlett KS, 2001, MOL ENDOCRINOL, V15, P909, DOI 10.1210/me.15.6.909; Cosman F, 1999, ENDOCR REV, V20, P418, DOI 10.1210/er.20.3.418; deGraffenried LA, 2002, J STEROID BIOCHEM, V82, P7, DOI 10.1016/S0960-0760(02)00151-6; DEWET JR, 1987, CELL, V54, P313; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; HUDSON LG, 1990, P NATL ACAD SCI USA, V87, P7536, DOI 10.1073/pnas.87.19.7536; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; HUDSON LG, 1989, MOL ENDOCRINOL, V3, P400, DOI 10.1210/mend-3-2-400; Kim K, 2003, MOL ENDOCRINOL, V17, P804, DOI 10.1210/me.2002-0406; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kurzer MS, 1997, ANNU REV NUTR, V17, P353, DOI 10.1146/annurev.nutr.17.1.353; LINGHAM RB, 1988, MOL ENDOCRINOL, V2, P230, DOI 10.1210/mend-2-3-230; Manolagas SC, 2001, ENDOCRINOLOGY, V142, P2200, DOI 10.1210/en.142.6.2200; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; Moore DD, 1995, GLOB MOB SURV; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; NEAL DE, 1985, LANCET, V1, P366; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Salvatori L, 2000, ENDOCRINOLOGY, V141, P2266, DOI 10.1210/en.141.6.2266; Sambrook J., 1982, MOL CLONING; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sun J, 1999, ENDOCRINOLOGY, V140, P800, DOI 10.1210/en.140.2.800; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; van den Wijngaard A, 2000, MOL ENDOCRINOL, V14, P623, DOI 10.1210/me.14.5.623; Yarden RI, 1996, ENDOCRINOLOGY, V137, P2739, DOI 10.1210/en.137.7.2739; YASUI W, 1988, INT J CANCER, V41, P211, DOI 10.1002/ijc.2910410209; Zhang WH, 2000, P NATL ACAD SCI USA, V97, P5936, DOI 10.1073/pnas.97.11.5936	36	40	45	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4875	4881		10.1038/sj.onc.1206784	http://dx.doi.org/10.1038/sj.onc.1206784			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894229				2022-12-17	WOS:000184344600011
J	Miething, C; Grundler, R; Fend, F; Hoepfl, J; Mugler, C; von Schilling, C; Morris, SW; Peschel, C; Duyster, J				Miething, C; Grundler, R; Fend, F; Hoepfl, J; Mugler, C; von Schilling, C; Morris, SW; Peschel, C; Duyster, J			The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model	ONCOGENE			English	Article						NPM-ALK; mouse model; tyrosine kinase; lymphoma	LARGE-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; CHRONIC MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; MYELOPROLIFERATIVE DISEASE; MULTIPLE-MYELOMA; RAPID INDUCTION; TYROSINE KINASE; V-MYC; MICE	A t(2;5) (p23;q35) chromosomal translocation can be found in a high percentage of anaplastic large-cell lymphomas (ALCL). This genetic abnormality leads to the expression of the NPM-ALK fusion protein, which encodes a constitutively active tyrosine kinase that plays a causative role in lymphomagenesis. Employing a modified infection/transplantation protocol utilizing an MSCV-based vector, we were able to reproducibly induce two phenotypically different lymphoma-like diseases dependent on the retroviral titers used. The first phenotype presented as a polyclonal histiocytic malignancy of myeloid/macrophage origin with a short latency period of 3-4 weeks. Clinically, the diseased mice showed rapidly progressive wasting, lymphadenopathy and pancytopenia. Mice displaying the second phenotype developed monoclonal B-lymphoid tumors with a longer latency of approximately 12-16 weeks, primarily involving the spleen and the bone marrow, with less extensive lymph node but also histologically evident extranodal organ infiltration by large immature plasmoblastic cells. The described retroviral mouse model will be useful to analyse the role of NPM-ALK in lymphomagenesis in vivo and may contribute to the development of new treatment options for NPM-ALK induced malignancies.	Tech Univ Munich, Dept Internal Med 3, D-81675 Munich, Germany; Tech Univ Munich, Dept Pathol, D-8000 Munich, Germany; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA	Technical University of Munich; University of Munich; Technical University of Munich; St Jude Children's Research Hospital	Duyster, J (corresponding author), Tech Univ Munich, Dept Internal Med 3, Trogerstr 32, D-81675 Munich, Germany.	justus.duyster@lrz.tum.de	Miething, Cornelius/F-9498-2014	Miething, Cornelius/0000-0003-4699-3805	NATIONAL CANCER INSTITUTE [P30CA021765, R01CA069129] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765, CA69129] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; BEECHAM EJ, 1991, MOL CELL BIOL, V11, P3095, DOI 10.1128/MCB.11.6.3095; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Cheuk W, 2000, AM J SURG PATHOL, V24, P1537, DOI 10.1097/00000478-200011000-00010; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Drexler HG, 2000, LEUKEMIA, V14, P1533, DOI 10.1038/sj.leu.2401878; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Falini B, 1999, BLOOD, V93, P2697; Falini B, 1998, AM J PATHOL, V153, P875, DOI 10.1016/S0002-9440(10)65629-5; HAWLEY RG, 1994, GENE THER, V1, P136; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; LARGAESPADA DA, 1992, ONCOGENE, V7, P811; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; Mason DY, 1998, CANCER RES, V58, P1057; Million RP, 2000, BLOOD, V96, P664; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nieborowska-Skorska M, 2001, CANCER RES, V61, P6517; Parker JR, 2001, PEDIATR DEVEL PATHOL, V4, P397, DOI 10.1007/s10024001-0004-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Potter M, 1999, INT IMMUNOL, V11, P1059, DOI 10.1093/intimm/11.7.1059; POTTER M, 1986, CURR TOP MICROBIOL, V132, P40; Rawat R, 2000, BLOOD, V96, P3514; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Slupianek A, 2001, CANCER RES, V61, P2194; STEIN H, 1985, BLOOD, V66, P848; Stein H, 2000, BLOOD, V96, P3681; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; Tu YP, 2000, CANCER RES, V60, P6763; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466; Zhang W, 2001, IEEE CONTR SYST MAG, V21, P84, DOI 10.1109/37.898794; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	38	40	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4642	4647		10.1038/sj.onc.1206575	http://dx.doi.org/10.1038/sj.onc.1206575			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879008				2022-12-17	WOS:000184157000004
J	Logette, E; Wotawa, A; Solier, S; Desoche, L; Solary, E; Corcos, L				Logette, E; Wotawa, A; Solier, S; Desoche, L; Solary, E; Corcos, L			The human caspase-2 gene: alternative promoters, pre-mRNA splicing and AUG usage direct isoform-specific expression	ONCOGENE			English	Article						caspase-2 gene; casp-2S; casp-2L; AUG; mRNA splicing; transcriptional regulation	PROGRAMMED CELL-DEATH; NEDD2 PRECURSOR; GRANZYME-B; BCL-X; APOPTOSIS; PROTEIN; IDENTIFICATION; ACTIVATION; PRODOMAIN; CASCADE	Caspases have been shown to play important roles in apoptotic cell death, cytokine maturation and cell differentiation. However, the transcriptional regulation of the corresponding CASP genes remains poorly known. We describe a 5.1 kb fragment located upstream of the first translated exon in the human CASP-2 gene, which is known to encode caspase-2L, and -2S protein isoforms. Transient transfection experiments, together with transcription start site mapping and transcript analysis, demonstrate that each caspase mRNA is initiated from separate promoter regions, and produced from alternative splicing events in these regions. The CASP-2L promoter is much stronger than the CASP-2S promoter, in good agreement with the respective transcript levels of the two caspases. In addition, several in-frame translational start sites can be identified for each isoform, one of which is common to both, present in the second common exon, and used efficiently. Surprisingly, the short isoform may also be initiated at a downstream AUG codon within the same exon. Thus, promoter strength, alternative transcriptional initiation and 5'-splicing events regulate the expression of the main caspase-2 isoforms that may be translated from alternative translation initiation codons.	INSERM, U517, Fac Med, F-21000 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Corcos, L (corresponding author), INSERM, U517, Fac Med, 7 Bd Jeanne Arc, F-21000 Dijon, France.		Corcos, Laurent/M-8915-2017; SOLIER, STEPHANIE/AAA-6851-2020; Corcos, Laurent/AAJ-2692-2020	Corcos, Laurent/0000-0001-8019-2505; Solary, Eric/0000-0002-8629-1341; SOLIER, Stephanie/0000-0003-3867-4644				Ahmad M, 1997, CANCER RES, V57, P615; Allet B, 1996, J CELL BIOL, V135, P479, DOI 10.1083/jcb.135.2.479; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Asahi M, 1997, J CEREBR BLOOD F MET, V17, P11, DOI 10.1097/00004647-199701000-00003; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bonfoco E, 2001, J BIOL CHEM, V276, P29242, DOI 10.1074/jbc.M100684200; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; Cote J, 2001, J BIOL CHEM, V276, P8535, DOI 10.1074/jbc.M008924200; Cote J, 2001, P NATL ACAD SCI USA, V98, P938, DOI 10.1073/pnas.031564098; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Droin N, 2001, ONCOGENE, V20, P260, DOI 10.1038/sj.onc.1204066; Droin N, 2000, CANCER RES, V60, P7039; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Ito A, 2000, FEBS LETT, V470, P360, DOI 10.1016/S0014-5793(00)01351-X; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kojima M, 1998, NEUROSCI RES, V31, P211, DOI 10.1016/S0168-0102(98)00039-X; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; KUMAR S, 1995, FEBS LETT, V368, P69, DOI 10.1016/0014-5793(95)00602-6; Kumar Sharad, 1997, Leukemia (Basingstoke), V11, P385; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Liu WF, 2002, J BIOL CHEM, V277, P8273, DOI 10.1074/jbc.M110768200; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Morita Y, 2001, CELL DEATH DIFFER, V8, P614, DOI 10.1038/sj.cdd.4400845; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nishiyama J, 2001, BIOCHEM J, V360, P49, DOI 10.1042/0264-6021:3600049; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Pecci A, 2001, J BIOL CHEM, V276, P21062, DOI 10.1074/jbc.M008665200; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Sato N, 1997, GENE, V202, P127, DOI 10.1016/S0378-1119(97)00463-0; Shikama Y, 2001, EXP CELL RES, V264, P315, DOI 10.1006/excr.2000.5153; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sordet O, 2002, LEUKEMIA, V16, P1569, DOI 10.1038/sj.leu.2402524; Stefanis L, 1998, J NEUROSCI, V18, P9204; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Swanton E, 1999, ONCOGENE, V18, P1781, DOI 10.1038/sj.onc.1202490; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Troy CM, 2000, J NEUROSCI, V20, P1386; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Wotawa A, 2002, CANCER LETT, V185, P181, DOI 10.1016/S0304-3835(02)00287-2	53	40	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					935	946		10.1038/sj.onc.1206172	http://dx.doi.org/10.1038/sj.onc.1206172			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584573				2022-12-17	WOS:000180864300016
J	Sitwala, KV; Adams, K; Markovitz, DM				Sitwala, KV; Adams, K; Markovitz, DM			YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter	ONCOGENE			English	Article						DEK; NF-Y; YY1; transcription; cancer	ACUTE MYELOID-LEUKEMIA; JUVENILE RHEUMATOID-ARTHRITIS; MESSENGER-RNA; EXPRESSION CLONING; PROTEIN; GENES; IDENTIFICATION; CELLS; TRANSLOCATION; ORGANIZATION	The mammalian protein DEK has been implicated in multiple cellular processes, including transcriptional regulation, mRNA processing, and chromatin remodeling, and is associated with a number of clinical autoimmune and neoplastic conditions. The connection between DEK and cancer exists at multiple levels: (a) the t(6;9) chromosomal translocation that characterizes a subtype of acute myelogenous leukemia cases results in the formation of a DEK-CAN fusion oncoprotein; (b) a fragment of dek cDNA is capable of partially reversing the radiation-sensitive phenotype of fibroblasts cultured from ataxia-telangiectasia patients; and (c) increased levels of dek mRNA have been found to be associated with hepatocellular carcinoma, glioblastoma, and melanoma. Despite the growing list of cancer subtypes with a connection to DEK, the factors that mediate its expression have yet to be characterized. Here we undertake the analysis of DEK regulation by mapping the discrete elements within the proximal promoter that are responsible for constitutive transcription of dek in transformed cells. We find that functional elements include an inverted CCAAT box and a YY1 consensus binding site, and the introduction of point mutations into these sites markedly diminishes transcriptional activity. In addition, we identify the transcriptional activator NF-Y as a member of the CCAAT-binding complex, and verify binding of the transcription factor YY1 at its consensus site in the dek promoter. The discovery of NF-Y and YY1 as regulatory determinants of DEK expression is consistent with the well-documented roles of these two factors in cellular proliferation and transformation.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Markovitz, DM (corresponding author), Univ Michigan, Dept Internal Med, 1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	dmarkov@umich.edu			NIAID NIH HHS [AI 36685] Funding Source: Medline; NIGMS NIH HHS [T32 GM07863] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexiadis V, 2000, GENE DEV, V14, P1308; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Arnaudo JP, 1998, J RHEUMATOL, V25, P1861; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong XW, 2000, ARTHRITIS RHEUM-US, V43, P85, DOI 10.1002/1529-0131(200001)43:1<85::AID-ANR11>3.0.CO;2-D; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Duan ZJ, 2001, MOL CELL BIOL, V21, P3083, DOI 10.1128/MCB.21.9.3083-3095.2001; Faulkner NE, 2001, J BIOL CHEM, V276, P25804, DOI 10.1074/jbc.M006454200; FLANAGAN JR, 1995, CELL GROWTH DIFFER, V6, P185; FORNEROD M, 1995, ONCOGENE, V10, P1739; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; Grottke C, 2000, INT J CANCER, V88, P535, DOI 10.1002/1097-0215(20001115)88:4<535::AID-IJC4>3.0.CO;2-V; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; Kondoh N, 1999, CANCER RES, V59, P4990; Kroes RA, 2000, CANCER LETT, V156, P191, DOI 10.1016/S0304-3835(00)00462-6; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; LI XY, 1992, J BIOL CHEM, V267, P8984; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; MEYN MS, 1993, AM J HUM GENET, V53, P1206; Minuzzo M, 2000, P NATL ACAD SCI USA, V97, P6780, DOI 10.1073/pnas.97.12.6780; Murray KJ, 1997, J RHEUMATOL, V24, P560; Petkova V, 2001, J BIOL CHEM, V276, P7932, DOI 10.1074/jbc.M007411200; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SIERAKOWSKA H, 1993, CLIN EXP IMMUNOL, V94, P435; Tanaka H, 1999, MOL PHARMACOL, V55, P356, DOI 10.1124/mol.55.2.356; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381	32	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8862	8870		10.1038/sj.onc.1206041	http://dx.doi.org/10.1038/sj.onc.1206041			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483538				2022-12-17	WOS:000179734400019
J	Pandey, A; Blagoev, B; Kratchmarova, I; Fernandez, M; Nielsen, M; Kristiansen, TZ; Ohara, O; Podtelejnikov, AV; Roche, S; Lodish, HF; Mann, M				Pandey, A; Blagoev, B; Kratchmarova, I; Fernandez, M; Nielsen, M; Kristiansen, TZ; Ohara, O; Podtelejnikov, AV; Roche, S; Lodish, HF; Mann, M			Cloning of a novel phosphotyrosine binding domain containing molecule, Odin, involved in signaling by receptor tyrosine kinases	ONCOGENE			English	Article						proteomics; mass spectrometry; bioinformatics	MASS-SPECTROMETRY; C-FOS; PROTEIN; IDENTIFICATION; SCAFFOLD; GENE; TRANSDUCTION; SHC; ACTIVATION; INDUCTION	We have used a proteomic approach using mass spectrometry to identify signaling molecules involved in receptor tyrosine kinase signaling pathways. Using affinity purification by anti-phosphotyrosine antibodies to enrich for tyrosine phosphorylated proteins, we have identified a novel signaling molecule in the epidermal growth factor receptor signaling pathway. This molecule, designated Odin, contains several ankyrin repeats, two sterile alpha motifs and a phosphotyrosine binding domain and is ubiquitously expressed. Using antibodies against endogenous Odin, we show that it undergoes tyrosine phosphorylation upon addition of growth factors such as EGF or PDGF but not by cytokines such as IL-3 or erythropoietin. Immunofluorescence experiments as well as Western blot analysis on subcellular fractions demonstrated that Odin is localized to the cytoplasm both before and after growth factor treatment. Deletion analysis showed that the phosphotyrosine binding domain of Odin is not required for its tyrosine phosphorylation. Overexpression of Odin, but not an unrelated adapter protein, Grb2, inhibited EGF-induced activation of c-Fos promoter. Microinjection of wild-type or a mutant version lacking the PTB domain into NIH3T3 fibroblasts inhibited PDGF-induced mitogenesis. Taken together, our results indicate that Odin may play a negative role in growth factor receptor signaling pathways.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Univ So Denmark, Ctr Expt Bioinformat, DK-5230 Odense M, Denmark; Kazusa DNA Res Inst, Chiba 2920812, Japan; RIKEN, Res Ctr Allergy & Immunol, Chiba 2920812, Japan; Ctr Rech Biochim Macromol, F-34293 Montpellier, France	Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Southern Denmark; Kazusa DNA Research Institute; RIKEN; Universite de Montpellier	Pandey, A (corresponding author), Univ So Denmark, Ctr Expt Bioinformat, DK-5230 Odense M, Denmark.	Pandey@cebi.sdu.dk; mann@bmb.sdu.dk	Ohara, Osamu/G-5448-2015; Mann, Matthias/A-3454-2013; Pandey, Akhilesh/B-4127-2009; Ohara, Osamu/A-9119-2012; Podtelejnikov, Alexandre/B-6120-2017	Ohara, Osamu/0000-0002-3328-9571; Mann, Matthias/0000-0003-1292-4799; Pandey, Akhilesh/0000-0001-9943-6127; Podtelejnikov, Alexandre/0000-0002-8124-6584; Blagoev, Blagoy/0000-0002-3596-0066; roche, serge/0000-0003-3413-3859; Kratchmarova, Irina/0000-0001-6613-7315	NCI NIH HHS [K01 CA75447] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075447] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CURRAN T, 1985, CANCER SURV, V4, P655; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; Ito M, 1999, MOL CELL BIOL, V19, P7539; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Margolis B, 1999, TRENDS ENDOCRIN MET, V10, P262, DOI 10.1016/S1043-2760(99)00168-X; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Pandey A, 2000, J BIOL CHEM, V275, P38633, DOI 10.1074/jbc.M007849200; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; PANDEY A, 2000, SCI STKE, pPL1; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pawson T, 1994, Princess Takamatsu Symp, V24, P303; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Smalla M, 1999, PROTEIN SCI, V8, P1954, DOI 10.1110/ps.8.10.1954; Steen H, 2002, J BIOL CHEM, V277, P1031, DOI 10.1074/jbc.M109992200; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yaich L, 1998, J BIOL CHEM, V273, P10381, DOI 10.1074/jbc.273.17.10381; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	42	40	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2002	21	52					8029	8036		10.1038/sj.onc.1205988	http://dx.doi.org/10.1038/sj.onc.1205988			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439753				2022-12-17	WOS:000179097200012
J	Wu, KJ; Mattioli, M; Morse, HC; Dalla-Favera, R				Wu, KJ; Mattioli, M; Morse, HC; Dalla-Favera, R			c-MYC activates protein kinase A (PKA) by direct transcriptional activation of the PKA catalytic subunit beta (PKA-C beta) gene	ONCOGENE			English	Article						c-MYC; PKA; transcriptional activation	CYCLIC-AMP; CELL-PROLIFERATION; DIFFERENTIAL EXPRESSION; MYC/MAX/MAD NETWORK; ESTROGEN-RECEPTOR; 3T3 CELLS; BINDING; GROWTH; TRANSFORMATION; MAX	The c-MYC proto-oncogene encodes a ubiquitous transcription factor involved in the control of cell growth and differentiation and broadly implicated in tumorigenesis. Understanding the function of c-MYC and its role in cancer depends upon the identification of c-MYC target genes. Here we show that c-MYC induces the activity of Protein Kinase A (PKA), a key effector of cAMP-mediated signal transduction, by inducing the transcription of the gene encoding the PKA catalytic subunit beta (PKA-Cbeta). c-MYC-mediated induction of PKA-Cbeta gene transcription occurs in multiple tissues, is independent of cell proliferation and is mediated by direct binding of cMYC to the PKA-Cbeta gene promoter sequences. Constitutive expression of PKA-Cbeta in Rat1A cells induces their transformation, and c-MYC-induced transformation can be reverted by pharmacological inhibition of PKA, suggesting that up-regulation of PKA is critical for cMYC-associated tumorigenesis. These results indicate that, by activating PKA, c-MYC can provide endogenous activation of the cAMP signal transduction pathway independently of extracellular signals.	Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; NIAID, Immunopathol Lab, NIH, Bethesda, MD 20892 USA	Columbia University; Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Dalla-Favera, R (corresponding author), Columbia Univ, Inst Canc Genet, New York, NY 10032 USA.	rd10@columbia.edu	Wu, Kou-Juey/P-4654-2015; Mattioli, Michela/K-3951-2013	Mattioli, Michela/0000-0002-1692-9178; Morse, Herbert/0000-0002-9331-3705	NATIONAL CANCER INSTITUTE [R01CA037165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000858] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37165] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; BURGERING BMT, 1994, CELL GROWTH DIFFER, V5, P341; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; Dang CV, 1999, MOL CELL BIOL, V19, P1; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Feuerstein N, 1996, J IMMUNOL, V156, P4582; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; James L, 2002, P NATL ACAD SCI USA, V99, P10429, DOI 10.1073/pnas.162369299; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Pursiheimo JP, 2000, P NATL ACAD SCI USA, V97, P168, DOI 10.1073/pnas.97.1.168; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; SASSON S, 1991, PATHOL BIOL, V39, P59; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; SHUNTOH H, 1992, BIOCHIM BIOPHYS ACTA, V1131, P175, DOI 10.1016/0167-4781(92)90073-9; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.biochem.59.1.971; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	45	40	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7872	7882		10.1038/sj.onc.1205986	http://dx.doi.org/10.1038/sj.onc.1205986			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420224				2022-12-17	WOS:000178946000012
J	Prokhortchouk, E; Hendrich, B				Prokhortchouk, E; Hendrich, B			Methyl-CpG binding proteins and cancer: are MeCpGs more important than MBDs?	ONCOGENE			English	Article						epigenetics; cancer; DNA repair; transcriptional repression; methyl-CpG binding proteins	DNA METHYLATION; INTESTINAL NEOPLASIA; CHROMOSOMAL PROTEIN; TRANSCRIPTIONAL REPRESSOR; HISTONE DEACETYLASE; CHROMATIN STRUCTURE; VERTEBRATE GENOMES; ISLAND METHYLATION; SOMATIC MUTATIONS; MESSENGER-RNA		Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland; Inst Gene Biol, Grp Transcript Control & Oncogenesis, Moscow 117334, Russia	University of Edinburgh; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	Prokhortchouk, E (corresponding author), Univ Edinburgh, Ctr Genome Res, Roger Land Bldg,Kings Bldg, Edinburgh EH9 3JQ, Midlothian, Scotland.		Prokhortchouk, Egor/I-9108-2014; Hendrich, Brian/AAG-5898-2020	Hendrich, Brian/0000-0002-0231-3073				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; Bader S, 2000, BRIT J CANCER, V83, P1646, DOI 10.1054/bjoc.2000.1482; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BULMER M, 1986, MOL BIOL EVOL, V3, P322; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; Chan MF, 2001, MOL CELL BIOL, V21, P7587, DOI 10.1128/MCB.21.22.7587-7600.2001; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; COOPER DN, 1989, HUM GENET, V83, P181, DOI 10.1007/BF00286715; Cormier RT, 2000, CANCER RES, V60, P3965; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; CROSS S, 1997, NAT GENET, V13, P256; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; Esteller M, 2000, CANCER RES, V60, P129; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kanai Y, 1999, BIOCHEM BIOPH RES CO, V264, P962, DOI 10.1006/bbrc.1999.1613; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; Kerr AM, 2001, BRAIN DEV-JPN, V23, P208, DOI 10.1016/S0387-7604(01)00193-0; KERR AM, 1985, BRIT MED J, V291, P579, DOI 10.1136/bmj.291.6495.579; Knudson AG, 1997, ANN NY ACAD SCI, V833, P58, DOI 10.1111/j.1749-6632.1997.tb48593.x; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Muller-Tidow C, 2001, BRIT J CANCER, V85, P1168, DOI 10.1054/bjoc.2001.2041; Nan XS, 1996, MOL CELL BIOL, V16, P414; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Petronzelli F, 2000, J CELL PHYSIOL, V185, P473, DOI 10.1002/1097-4652(200012)185:3<473::AID-JCP19>3.0.CO;2-#; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0	61	40	49	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2002	21	35					5394	5399		10.1038/sj.onc.1205631	http://dx.doi.org/10.1038/sj.onc.1205631			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154402				2022-12-17	WOS:000177197700006
J	Zhan, QM; Jin, SQ; Ng, B; Plisket, J; Shangary, S; Rathi, A; Brown, KD; Baskaran, R				Zhan, QM; Jin, SQ; Ng, B; Plisket, J; Shangary, S; Rathi, A; Brown, KD; Baskaran, R			Caspase-3 mediated cleavage of BRCA1 during UV-induced apoptosis	ONCOGENE			English	Article						DNA repair; BADD45; JNK	DNA-DAMAGE RESPONSE; CELL-CYCLE; ACTIVATION; PROTEIN; GADD45; PHOSPHORYLATION; INDUCTION; BREAST; TRANSCRIPTION; REQUIREMENT	The breast cancer suppressor protein, BRCA1 plays an important role in mediating cell cycle arrest, apoptosis and DNA responses to DNA damage signals. In this study, we show that BRCA1 level is downregulated during UV-induced apoptosis by caspase-3 mediated cleavage. Cleavage of BRCA1 by caspase-3 produced a fragment that contained the C-terminal of the molecule. Accordingly, treatment of cells with caspase-3 inhibitor or mutation of a specific caspase-3 cleavage site (DLLD) at amino acid 1151 - 1154 of BRCA1 abolished cleavage and consequential accumulation of the BRCA1 C-terminal fragment. Whereas expression of the non-cleavable BRCA1 (D/A 1154) mutant conferred the resistance phenotype to UV-induced cell death, expression of the cleaved BRCA1 C-terminus induced cell death in the absence of UV. Examination of the mechanism of C-terminus-induced cell death revealed that the cleaved fragment triggers the apoptotic response through activation of BRCA1 downstream effectors, GADD45 and JNK. Altogether, results of our study demonstrate a functional role for caspase-3 mediated cleavage of BRCA1 during UV-induced apoptosis.	Univ Pittsburgh, Med Ctr, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Pittsburgh Canc Inst, Pittsburgh, PA 15261 USA; Louisiana State Univ, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Louisiana State University System; Louisiana State University System	Baskaran, R (corresponding author), Univ Pittsburgh, Med Ctr, Sch Med, Dept Mol Genet & Biochem, E1205 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	bask@pitt.edu			NATIONAL CANCER INSTITUTE [R01CA093640] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM060945, R01GM060945] Funding Source: NIH RePORTER; NCI NIH HHS [CA 93640] Funding Source: Medline; NIGMS NIH HHS [GM 60945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Afford S, 2000, J CLIN PATHOL-MOL PA, V53, P55, DOI 10.1136/mp.53.2.55; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 2000, CANCER RES, V60, P5037; Chen YM, 1996, CANCER RES, V56, P3168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; D'Amours D, 2001, J CELL SCI, V114, P3771; Deng CX, 2000, BIOESSAYS, V22, P728; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kim JW, 2000, J BIOL CHEM, V275, P8121, DOI 10.1074/jbc.275.11.8121; Larson JS, 1997, CANCER RES, V57, P3351; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Rishi AK, 1999, NUCLEIC ACIDS RES, V27, P3111, DOI 10.1093/nar/27.15.3111; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Shao NS, 1996, ONCOGENE, V13, P1; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; VANDEVIJVER MJ, 1993, ADV CANCER RES, V61, P25; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Wang Y, 2000, GENE DEV, V14, P927; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu V, 2000, BREAST CANCER RES, V2, P82, DOI 10.1186/bcr37; Yuan JY, 1999, NAT CELL BIOL, V1, pE44, DOI 10.1038/10037	40	40	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5335	5345		10.1038/sj.onc.1205665	http://dx.doi.org/10.1038/sj.onc.1205665			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149654				2022-12-17	WOS:000177193900014
J	Zwerner, JP; May, WA				Zwerner, JP; May, WA			Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines	ONCOGENE			English	Article						Ewing's sarcoma; Ewing family tumors; PDGF-C; EWS/FLI	TYROSINE KINASE; MONOCLONAL-ANTIBODY; ALPHA-RECEPTOR; BETA-RECEPTOR; HUMAN GLIOMA; LUNG-CANCER; V-SIS; SARCOMA; TRANSFORMATION; EXPRESSION	Nearly all cases of Ewing Family Tumors (EFT) harbor chimeric EWS/ETS transcription factors which are thought to aberrantly regulate transcriptional targets of phenotypic consequence. We have recently demonstrated that EWS/ETS proteins up-regulate platelet derived growth factor-C (PDGF-C), a novel transforming growth factor. To determine if PDGF-C signaling contributes to the malignant phenotype of EFT cell lines, we attempted to disrupt this presumed autocrine loop. AG1296, a PDGF receptor selective tyrosine kinase inhibitor, markedly inhibits anchorage-independent growth in an EFT cell line. To effect specific disruption, we have developed a dominant negative form of PDGF-C which is appropriately secreted and processed. This mutant has greatly reduced activity as a PDGF receptor agonist. When co-expressed with PDGF-C in a fibroblast transformation model, this dominant negative dramatically inhibits anchorage-independent growth. When this mutant is expressed in EFT cell lines, there is a similar reduction in anchorage-independent growth. This demonstrates that specific inhibition of PDGF-C signaling in EFT cell lines partially reverts their phenotype. These data support a significant role of PDGF-C in the biology of EFT. They also suggest that PDGF-C driven signaling may be a possible therapeutic target of more clinically relevant tyrosine kinase inhibitors.	Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL USA; Univ Alabama, Dept Pediat, Birmingham, AL USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	May, WA (corresponding author), 1824 6th Ave S,Room 569, Birmingham, AL 35242 USA.				NCI NIH HHS [CA 90666, R01 CA090666] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090666] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P3942, DOI 10.1073/pnas.89.9.3942; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; DUAN DSR, 1991, J BIOL CHEM, V266, P413; Ekman S, 1999, ONCOGENE, V18, P2481, DOI 10.1038/sj.onc.1202606; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HERMANSON M, 1992, CANCER RES, V52, P3213; HOROWITZ ME, 1997, EWINGS SARCOMA FAMIL; KOVALENKO M, 1994, CANCER RES, V54, P6106; Krystal GW, 1997, CANCER RES, V57, P2203; Kumar R, 2000, SEMIN ONCOL, V27, P84, DOI 10.1053/sonc.2000.19893; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Look AT, 1995, ADV CANCER RES, V67, P25, DOI 10.1016/S0065-230X(08)60709-5; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MERCOLA M, 1990, GENE DEV, V4, P2333, DOI 10.1101/gad.4.12b.2333; Nakayama Y, 1998, SURG NEUROL, V49, P181, DOI 10.1016/S0090-3019(97)00038-4; NANBERG E, 1993, J BIOL CHEM, V268, P18187; Ostman A, 2001, ADV CANCER RES, V80, P1, DOI 10.1016/S0065-230X(01)80010-5; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Radig K, 1998, PATHOL RES PRACT, V194, P157, DOI 10.1016/S0344-0338(98)80016-2; Rice AB, 1999, AM J PATHOL, V155, P213, DOI 10.1016/S0002-9440(10)65115-2; Ricotti E, 1998, BLOOD, V91, P2397, DOI 10.1182/blood.V91.7.2397.2397_2397_2405; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Scotlandi K, 1998, CANCER RES, V58, P4127; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; Silvany RE, 2000, ONCOGENE, V19, P4523, DOI 10.1038/sj.onc.1203811; Sjoblom T, 2001, CANCER RES, V61, P5778; Sulzbacher I, 2000, MODERN PATHOL, V13, P632, DOI 10.1038/modpathol.3880109; Sundberg C, 1997, AM J PATHOL, V151, P479; Uutela M, 2001, CIRCULATION, V103, P2242; VASSBOTN FS, 1990, BIOCHIM BIOPHYS ACTA, V1054, P246, DOI 10.1016/0167-4889(90)90248-C; VIGNAUD JM, 1994, CANCER RES, V54, P5455; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	41	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3847	3854		10.1038/sj.onc.1205486	http://dx.doi.org/10.1038/sj.onc.1205486			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032822				2022-12-17	WOS:000175847200003
J	Billard, LM; Magdinier, F; Lenoir, GM; Frappart, L; Dante, R				Billard, LM; Magdinier, F; Lenoir, GM; Frappart, L; Dante, R			MeCP2 and MBD2 expression during normal and pathological growth of the human mammary gland	ONCOGENE			English	Article						breast cancer; prenatal developments; methyl binding proteins; RT-PCR	HISTONE DEACETYLASE COMPLEX; BINDING-PROTEIN MECP2; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; CHROMATIN; IDENTIFICATION; CANCER	During the last years, a direct link between DNA methylation and repressive chromatin structure has been established. This structural modification is mediated by histone deacetylases targeted to the methylated sequences by Methyl Binding Proteins (MBD). Human cancer cells exhibit both a global hypomethylation and some localized hypermethylations suggesting that the deregulation of the methylation machinery is a central event in tumorigenesis. Therefore, we have investigated in human tissues the expression of two major MBDs, MeCP2 and MBD2, during the proliferation of normal breast and in benign and neoplasic breast tumors. Quantitation of the transcripts indicates that MBD2 mRNAs are 20-30-fold more abundant than MeCP2 transcripts in the adult and fetal human mammary gland. In pathological tissues samples MBD2 mRNA levels are significantly higher (P = 0.001) in benign tumors compared with normal breast tissues, whereas MeCP2 expression is not modified in these specimens. In neoplasic samples a deregulation of the expression of both genes was found. The amounts of MBD2 and MeCP2 transcripts vary greatly between samples in cancer cells compared to normal breast tissues or benign tumors, and in invasive ductal carcinomas the amount of MBD2 mRNA is significantly (P = 0.03) associated with the tumor size. Taken together these data suggest that upregulation of VBD2 might be associated with breast cell proliferation. In line with this hypothesis MBD2 is also upregulated during the prenatal development of the human mammary gland, but in contrast to that observed in tumor cells, MeCP2 is also coordinately upregulated in the fetal breast tissues, suggesting that deregulation of MeCP2 and MBD2 occurs in human breast cancers.	UCBLI, Genet Lab, UMR 5641, F-67373 Lyon 08, France; Hop Edouard Herriot, Anat Pathol Lab, Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon	Dante, R (corresponding author), UCBLI, Genet Lab, UMR 5641, 8 Ave Rockefeller, F-67373 Lyon 08, France.		Magdinier, Frederique/I-4735-2016	Magdinier, Frederique/0000-0002-0159-9559				ARNAUD M, 1985, BIOCHEM BIOPH RES CO, V13, P108; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bernardino T, 1997, CANCER GENET CYTOGEN, V97, P83, DOI 10.1016/S0165-4608(96)00385-8; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Eads CA, 2001, CANCER RES, V61, P3410; Ehrlich Melanie, 2000, P273; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kanai Y, 1999, BIOCHEM BIOPH RES CO, V264, P962, DOI 10.1006/bbrc.1999.1613; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Magdinier F, 1999, ONCOGENE, V18, P4039, DOI 10.1038/sj.onc.1202780; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; POULSEN HE, 1975, INT HISTOLOGICAL CLA, P13; Ribieras S, 1997, INT J CANCER, V73, P715, DOI 10.1002/(SICI)1097-0215(19971127)73:5<715::AID-IJC17>3.0.CO;2-4; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Russo J., 1987, The mammary gland. Development, regulation, and function., P67; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Tanner JM, 1962, GROWTH ADOLESCENCE, V2nd, P28; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	36	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2002	21	17					2704	2712		10.1038/sj/onc/1205357	http://dx.doi.org/10.1038/sj/onc/1205357			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965543	Green Published			2022-12-17	WOS:000174996500010
J	Shimada, H; Liu, TL; Ochiai, T; Shimizu, T; Haupt, Y; Hamada, H; Abe, T; Oka, M; Takiguchi, M; Hiwasa, T				Shimada, H; Liu, TL; Ochiai, T; Shimizu, T; Haupt, Y; Hamada, H; Abe, T; Oka, M; Takiguchi, M; Hiwasa, T			Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33(ING1) in T.Tn human esophageal carcinoma cells	ONCOGENE			English	Article						p33(ING1); p53; gene therapy; esophageal cancer; Mdm2	CYSTEINE PROTEINASE-INHIBITORS; CANDIDATE TUMOR-SUPPRESSOR; CYCLIN-DEPENDENT KINASES; NIH3T3 MOUSE FIBROBLASTS; P53 GENE; RETINOBLASTOMA PROTEIN; POTENTIAL MEDIATOR; GROWTH CONTROL; MESSENGER-RNA; CANCER-CELLS	To investigate the effect of p33(ING1) on wild-type p53 gene therapy, T.Tn human esophageal carcinoma cells were stably transfected with p33(ING1) cDNA. Infection with Adp53 (recombinant adenovirus containing wild-type p53) into p33-transfected cells reduced cell viability, while infection with empty vector had little effect. This reduced viability was shown to be due to apoptotic cell death by the TUNEL (terminal deoxynucleotidyl transferase-mediated nick end-labeling) assay. Following infection with Ad-p53, levels of p53 were similar in p33-expressing cells and in the parental tine. However, levels of p21 and Mdm2 were elevated in p33-transfected cells. Nonetheless, this enhanced expression of Mdm2 appeared to be ineffective in downregulating p53. Transient transfection with mutant Mdm2 prior to Ad-p53 infection provided a significant protection as compared with cells transfected with wild-type Mdm2. These results imply a synergistic effect between p33 and p53 in the induction of apoptosis of human esophageal carcinoma cells. A role for Mdm2 in this synergism is suggested.	Chiba Univ, Grad Sch Med, Dept Biochem & Genet, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Acad Dept Surg, Chuo Ku, Chiba 2608670, Japan; Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel; Sapporo Med Univ, Dept Mol Med, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Yamaguchi Univ, Sch Med, Dept Surg 2, Yamaguchi 7558505, Japan	Chiba University; Chiba University; Hebrew University of Jerusalem; Sapporo Medical University; Yamaguchi University	Hiwasa, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Biochem & Genet, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	hiwasa@med.m.chiba-u.ac.jp		Haupt, Ygal/0000-0001-5925-0096				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; ASCHELE C, 1992, CANCER RES, V52, P1855; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; Bargou RC, 1996, J EXP MED, V183, P1205, DOI 10.1084/jem.183.3.1205; BENNETT WP, 1992, CANCER RES, V52, P6092; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chang YC, 2000, ONCOGENE, V19, P4713, DOI 10.1038/sj.onc.1203833; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen LS, 2001, CANCER RES, V61, P4345; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Cheung KJ, 2001, CANCER RES, V61, P4974; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; GORCZYCA W, 1992, INT J ONCOL, V1, P639; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Gunduz M, 2000, CANCER RES, V60, P3143; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Helbing CC, 1997, CANCER RES, V57, P1255; Hiwasa T, 1996, INT J ONCOL, V8, P125; Hiwasa T, 1996, J BIOL CHEM, V271, P9181, DOI 10.1074/jbc.271.16.9181; HIWASA T, 1987, CANCER RES, V47, P953; Hiwasa T, 1996, CANCER LETT, V99, P87, DOI 10.1016/0304-3835(95)04041-2; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HOUGHTON JA, 1986, BIOCHEM PHARMACOL, V35, P1351, DOI 10.1016/0006-2952(86)90281-9; Hsing A, 2000, J BIOL CHEM, V275, P26024, DOI 10.1074/jbc.M002455200; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Kobayashi S, 1999, AM J SURG, V177, P497, DOI 10.1016/S0002-9610(99)00085-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; MIYASHITA T, 1995, CELL, V80, P293; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NABEYA Y, 1995, INT J CANCER, V64, P37, DOI 10.1002/ijc.2910640109; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohmori M, 1999, AM J HEMATOL, V62, P118; OKA M, 1995, J INTERF CYTOK RES, V15, P1005, DOI 10.1089/jir.1995.15.1005; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Oki E, 1999, CANCER LETT, V147, P157, DOI 10.1016/S0304-3835(99)00288-8; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shimada H, 2001, SURG TODAY, V31, P597, DOI 10.1007/s005950170093; Shinoura N, 1999, CANCER RES, V59, P5521; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Takahashi K., 1990, JPN J ORAL MAXILLOFA, V36, P307; Tokunaga E, 2000, CANCER LETT, V152, P15, DOI 10.1016/S0304-3835(99)00434-6; Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	71	40	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1208	1216		10.1038/sj.onc.1205176	http://dx.doi.org/10.1038/sj.onc.1205176			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850840				2022-12-17	WOS:000173729400008
J	Gilley, J; Fried, M				Gilley, J; Fried, M			One INK4 gene and no ARF at the Fugu equivalent of the human INK4A/ARF/INK4B tumour suppressor locus	ONCOGENE			English	Article						ARF; INK4A; INK4B; Fugu rubripes; tumour suppressor; evolution	INHIBITOR; CLONING; P53; EXPRESSION; P16(INK4A); SEQUENCE; PATHWAY; CDKN2	The INK4A/ARF/INK4B locus, conserved in mammals, encodes three polypeptides that regulate cell proliferation via the pRb and p53 tumour suppressor pathways. The locus is mutated in many cancers. The related, tandemly-linked INK4A and INK4B genes encode the p16(INK4A) and p15(INK4B) members of the INK4 family of cyclin-dependent kinase inhibitors which block phosphorylation of pRb, whereas the third product, ARF, derived from an alternative reading frame of INK4A, regulates p53 activity. We assessed the status of this unusual locus in the puffer fish, Fugu rubripes, and identified two INK4 genes using degenerate PCR and hybridization analyses. Sequence conservation and conservation of synteny between human and Fugu predict one gene to be an INK4A or INK4B homologue and the other an INK4D homologue. Analysis of the Fugu INK4A/B gene and the surrounding 40-kb of genomic DNA did not reveal the presence of any ARF-encoding potential or another related INK4 gene. We conclude that the gene duplication event that generated adjacent INK4A and INK4B genes and the association of ARF with the ancestral INK4A gene occurred after the divergence of the lineage leading to mammals from fish. Thus, unlike mammals, the fish p53 and pRb tumour suppressor pathways are not regulated by a single locus.	UCSF Canc Res Inst, San Francisco, CA 94115 USA; Imperial Canc Res Fund, Eukaryot Gene Org & Express Lab, London WC2A 3PX, England	University of California System; University of California San Francisco; UCSF Medical Center; Cancer Research UK	Fried, M (corresponding author), UCSF Canc Res Inst, 2340 Sutter St, San Francisco, CA 94115 USA.							Armes N, 1997, GENOME RES, V7, P1138, DOI 10.1101/gr.7.12.1138; Bhaskaran A, 1999, ENVIRON MOL MUTAGEN, V33, P177, DOI 10.1002/(SICI)1098-2280(1999)33:3<177::AID-EM1>3.0.CO;2-X; Brunelli JP, 1999, GENE, V226, P175, DOI 10.1016/S0378-1119(98)00574-5; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dreyling MH, 1998, GENE CHROMOSOME CANC, V22, P72, DOI 10.1002/(SICI)1098-2264(199805)22:1<72::AID-GCC10>3.3.CO;2-G; Elgar G, 1996, HUM MOL GENET, V5, P1437, DOI 10.1093/hmg/5.Supplement_1.1437; Gilley J, 1999, HUM MOL GENET, V8, P1313, DOI 10.1093/hmg/8.7.1313; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Jiang P, 1995, J MOL EVOL, V41, P795; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kazianis S, 1999, ONCOGENE, V18, P5088, DOI 10.1038/sj.onc.1202884; OKUDA T, 1995, GENOMICS, V29, P623, DOI 10.1006/geno.1995.9957; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherburn TE, 1998, DNA CELL BIOL, V17, P975, DOI 10.1089/dna.1998.17.975; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	25	40	40	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7447	7452		10.1038/sj.onc.1204933	http://dx.doi.org/10.1038/sj.onc.1204933			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704876				2022-12-17	WOS:000171894200019
J	Wang, SC; Makino, K; Xia, WY; Kim, JS; Im, SA; Peng, H; Mok, SC; Singletary, SE; Hung, MC				Wang, SC; Makino, K; Xia, WY; Kim, JS; Im, SA; Peng, H; Mok, SC; Singletary, SE; Hung, MC			DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway	ONCOGENE			English	Article						ILK; DOC-2/hDab-2; anoikis; breast cancer; HER-2; neu	INTEGRIN-LINKED KINASE; EPITHELIAL OVARIAN-CANCER; PHOSPHOINOSITIDE-3-OH KINASE; ACTIVATION; EXPRESSION; CLONING; DOMAIN; B/AKT; GENE	DOC-2/hDab-2 was identified due to the loss of its expression in primary ovarian cancer cells. It is believed that loss of DOC-2/hDab-2 expression is one of the early events of ovarian malignancy. These results suggest a function of DOC-2/hDab-2 as a tumor suppressor. However, it is not clear how DOC-2/hDab-2 negatively regulates cancer cell growth. In this report, we demonstrate that DOC-2/hDab-2 expression in breast cancer cells resulted in sensitivity to suspension-induced cell death (anoikis). This event was associated with the down-regulation of the integrin-linked kinase (ILK) activity. Since ILK is a key factor in regulating the cellular signaling in responding to the extracellular signals through adhesion molecules like integrins, our results indicate that DOC-2/hDab-2 may prevent tumor growth and invasion by modulating the anti-apoptotic ILK pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Brigham & Womens Hosp, Dana Farber Harvard Canc Ctr, Div Gynecol Oncol, Lab Gynecol Oncol, Houston, TX USA; Brigham & Womens Hosp, Dana Farber Harvard Canc Ctr, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021; Wang, Shao-Chun/P-9904-2019	Hung, Mien-Chie/0000-0003-4317-4740; Wang, Shao-Chun/0000-0002-5477-1682				Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; YU DH, 1991, ONCOGENE, V6, P1991; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200	14	40	42	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6960	6964		10.1038/sj.onc.1204873	http://dx.doi.org/10.1038/sj.onc.1204873			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687976				2022-12-17	WOS:000171641000018
J	Struss, AK; Romeike, BFM; Munnia, A; Nastainczyk, W; Steudel, WI; Konig, J; Ohgaki, H; Feiden, W; Fischer, U; Meese, E				Struss, AK; Romeike, BFM; Munnia, A; Nastainczyk, W; Steudel, WI; Konig, J; Ohgaki, H; Feiden, W; Fischer, U; Meese, E			PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme	ONCOGENE			English	Article						humoral immune response; SEREX; glioblastoma multiforme; polyclonal antibody; PHD finger; PHF3	HUMAN TUMOR-ANTIGENS; SEROLOGIC RESPONSES; IMMUNE-RESPONSES; PHD FINGER; CANCER; GENE; P53; AUTOANTIBODIES; IDENTIFICATION; LOCALIZATION	Glioblastoma multiforme (GBM), a malignant astrocytic tumour, represents the most frequent tumour of the human brain. Nevertheless, its molecular pathology is not well understood. We utilized the immune system, which contributes to cancer protection, to help identify new GEM-related genes. By screening a human GEM cDNA library with autologous patient serum (SEREX-approach), we isolated a gene termed PHF3 (PHD finger protein 3), The gene product of PHF3 is immunogenic in GEM as tested in an allogenic patient serum screening demonstrating antibodies in 24 of 39 (61.53%) sera, whereas none of the 14 healthy persons had antibodies against PHF3, While previous SEREX studies revealed allogenic antibody responses up to 40%, our results for PHF3 represent the highest reported rate for a specific antibody response. We show that GEM patients with an antibody response against PHF3 show significant better survival than patients without PHF3-specific antibodies. Because the amino acid sequence of PHF3 contains a PHD finger (also termed LAP motif), a TFIIS homology, a proline rich region and nuclear localization signals, it supposedly functions as a transcription factor. A polyclonal antibody generated against PHF3 shows nuclear expression in most investigated formalin-fixed, paraffin embedded tissues. In GEM, PHF3 expression is concentrated in cells surrounding necroses.	Univ Saarlandes Kliniken, Inst Humangenet, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Abt Neuropathol, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Inst Med Biochem, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Neurochirurg Klin, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Inst Bioinformat, D-66421 Homburg, Germany; Int Agcy Res Canc, F-69372 Lyon 8, France	Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; World Health Organization; International Agency for Research on Cancer (IARC)	Meese, E (corresponding author), Univ Saarland, Sch Med, Inst Humangenet, Bldg 60, D-66421 Homburg, Germany.	hgemee@med-rz.uni-sb.de	König, Jochem/T-3500-2019; Romeike, Bernd/K-8516-2019; , PD Dr. med. Bernd FM Romeike/Q-2600-2019; Meese, Eckart Ulrich/ABD-1983-2021	König, Jochem/0000-0003-4683-0360; , PD Dr. med. Bernd FM Romeike/0000-0002-9693-3870; 				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Biernat W, 1997, ACTA NEUROPATHOL, V94, P303, DOI 10.1007/s004010050711; Blaes F, 2000, ANN THORAC SURG, V69, P254, DOI 10.1016/S0003-4975(99)01198-4; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; CHINOT O, 1996, BIOL TUMEURS CEREBRA; Coulson M, 1998, GENOMICS, V48, P381, DOI 10.1006/geno.1997.5201; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; Dietrich PY, 1997, ANN NY ACAD SCI, V824, P124, DOI 10.1111/j.1749-6632.1997.tb46215.x; FOLEY EJ, 1953, CANCER RES, V13, P835; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Gure AO, 2000, P NATL ACAD SCI USA, V97, P4198, DOI 10.1073/pnas.97.8.4198; Hampton TA, 2000, CANCER GENE THER, V7, P446, DOI 10.1038/sj.cgt.7700124; Harlow E, 1998, ANTIBODIES LAB MANUA; Hasenpusch-Theil K, 1999, MAMM GENOME, V10, P294, DOI 10.1007/s003359900989; Heckel D, 1997, HUM MOL GENET, V6, P2031, DOI 10.1093/hmg/6.12.2031; Jung V, 1999, J NEUROPATH EXP NEUR, V58, P993, DOI 10.1097/00005072-199909000-00009; Kleihues P., 2000, PATHOLOGY GENETICS T, P29; KORNBLITH PL, 1983, CANCER, V52, P2230, DOI 10.1002/1097-0142(19831215)52:12<2230::AID-CNCR2820521211>3.0.CO;2-7; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; OLD LJ, 1981, CANCER RES, V41, P361; PREHN RT, 1957, J NATL CANCER I, V18, P769; Rainov NG, 1995, CLIN CANCER RES, V1, P775; Robinson C, 2000, AM J RESP CELL MOL, V22, P550, DOI 10.1165/ajrcmb.22.5.3930; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Scanlan MJ, 1999, INT J CANCER, V83, P456, DOI 10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5; Scarcella DL, 1999, CLIN CANCER RES, V5, P335; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; Shrikant P, 1996, J IMMUNOL, V157, P1819; Soussi T, 2000, CANCER RES, V60, P1777; Suresh MR, 1996, ANTICANCER RES, V16, P2273; Tureci O, 1997, MOL MED TODAY, V3, P342, DOI 10.1016/S1357-4310(97)01081-2; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WELLER RO, 1992, BRAIN PATHOL, V2, P277, DOI 10.1111/j.1750-3639.1992.tb00704.x; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	37	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4107	4114		10.1038/sj.onc.1204552	http://dx.doi.org/10.1038/sj.onc.1204552			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464277				2022-12-17	WOS:000169857200001
J	Adamsky, K; Schilling, J; Garwood, J; Faissner, A; Peles, E				Adamsky, K; Schilling, J; Garwood, J; Faissner, A; Peles, E			Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase beta (RPTP beta) to tenascin C	ONCOGENE			English	Article						tyrosine phosphatase; extracellular matrix; cell adhesion molecule	CHONDROITIN SULFATE PROTEOGLYCAN; GROWTH-ASSOCIATED MOLECULE; HIGH-AFFINITY LIGAND; NERVOUS-SYSTEM; HOMOPHILIC BINDING; NEURITE OUTGROWTH; FOCAL ADHESIONS; PTP-MU; ZETA/BETA; EXPRESSION	The extracellular domain of receptor protein tyrosine phosphatase beta (RPTP beta) is composed of several domains which mediate its interactions with distinct ligands present on the surface of either neurons or glial cells. Here, we demonstrate that the fibronectin type III domain (FNIII) of RPTP beta binds to glial tumor-derived cell lines and primary astrocytes, We used affinity purification to isolate several proteins that specifically bind to the FNIII domain of RPTP beta. One of these, a 240 kDa protein that was purified from U118MG glioblastoma cell, was identified as tenascin C based on the amino acid sequence of several tryptic peptides. The interaction of RPTP beta with tenascin C was found to mediate cell adhesion. Adhesion and spreading of SF763T astrocytoma cells expressing RPTP beta on tenascin C,was specifically abolished by the addition of a soluble fragment containing the FNIII domain of the receptor, RPTP beta -dependent cell adhesion was mediated by binding to the alternatively spliced FNIII repeats A1,2,4 (TnfnA1,2,4) of tenascin C, Furthermore, COS cells expressing RPTP beta adhere to TnfnA1,2,4, while the parental cells did not. These results demonstrate that the FNIII domain of RPTP beta binds to tenascin C and suggest that RPTP beta present on glial tumor cells is a primary adhesion receptor system to the extracellular matrix.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Ctr Neurochim, Unite CNRS UPR 1352, F-67084 Strasbourg, France; Sugen Inc, S San Francisco, CA 94080 USA	Weizmann Institute of Science; Pfizer	Peles, E (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Faissner, Andreas/A-5314-2008	Faissner, Andreas/0000-0002-2211-8259; Peles, Elior/0000-0002-3325-0597				Angers-Loustau A, 1999, BIOCHEM CELL BIOL, V77, P493, DOI 10.1139/bcb-77-6-493; BARNEA G, 1994, J BIOL CHEM, V269, P14349; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Canoll PD, 1996, J NEUROSCI RES, V44, P199, DOI 10.1002/(SICI)1097-4547(19960501)44:3<199::AID-JNR1>3.0.CO;2-B; CANOLL PD, 1993, DEV BRAIN RES, V75, P293, DOI 10.1016/0165-3806(93)90035-9; Chung CY, 1996, MOL BIOL CELL, V7, P883, DOI 10.1091/mbc.7.6.883; FAISSNER A, 1997, CELL TISSUE RES, V290, P385; Fashena SJ, 1997, MOL CELL BIOL, V17, P6859, DOI 10.1128/MCB.17.12.6859; Garwood J, 1999, J NEUROSCI, V19, P3888; Giese A, 1996, J CELL SCI, V109, P2161; Goldmann T, 2000, FOLIA HISTOCHEM CYTO, V38, P19; GRUMET M, 1994, J BIOL CHEM, V269, P12142; JONES FS, 2000, AM J RESP CRIT CARE, V161, P2086; Koch T, 1997, GLIA, V19, P199, DOI 10.1002/(SICI)1098-1136(199703)19:3<199::AID-GLIA3>3.0.CO;2-V; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEVY JB, 1993, J BIOL CHEM, V268, P10573; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MAEDA N, 1994, FEBS LETT, V354, P67, DOI 10.1016/0014-5793(94)01093-5; Margolis RU, 1997, CELL TISSUE RES, V290, P343, DOI 10.1007/s004410050939; Milev P, 1997, J BIOL CHEM, V272, P15501, DOI 10.1074/jbc.272.24.15501; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; MILEV P, 1995, J BIOL CHEM, V270, P24650, DOI 10.1074/jbc.270.42.24650; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Peles E, 1998, TRENDS BIOCHEM SCI, V23, P121, DOI 10.1016/S0968-0004(98)01195-5; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; PHILLIPS GR, 1998, MOL BIOL CELL, V9, P1425; Poliak S, 1999, NEURON, V24, P1037, DOI 10.1016/S0896-6273(00)81049-1; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; Revest JM, 1999, EUR J NEUROSCI, V11, P1134, DOI 10.1046/j.1460-9568.1999.00521.x; Sakurai T, 1996, J NEUROSCI RES, V43, P694, DOI 10.1002/(SICI)1097-4547(19960315)43:6<694::AID-JNR6>3.3.CO;2-9; Sakurai T, 1997, J CELL BIOL, V136, P907, DOI 10.1083/jcb.136.4.907; SAP J, 1994, MOL CELL BIOL, V14, P1; Schaapveld R, 1997, MOL BIOL REP, V24, P247, DOI 10.1023/A:1006870016238; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; Scholze A, 1996, INT J DEV NEUROSCI, V14, P315, DOI 10.1016/0736-5748(96)00016-0; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Shenoi H, 1999, J IMMUNOL, V162, P7120; Snyder SE, 1996, MOL BRAIN RES, V40, P79; Stoker A, 1998, BIOESSAYS, V20, P463, DOI 10.1002/(SICI)1521-1878(199806)20:6<463::AID-BIES4>3.0.CO;2-N; Walzel H, 1999, IMMUNOL LETT, V67, P193, DOI 10.1016/S0165-2478(99)00012-7; Wang J, 1999, MOL CELL NEUROSCI, V14, P370, DOI 10.1006/mcne.1999.0789; Wenk MB, 2000, J CELL BIOL, V150, P913, DOI 10.1083/jcb.150.4.913; Xiao ZC, 1997, J BIOL CHEM, V272, P32092, DOI 10.1074/jbc.272.51.32092; YOKOSAKI Y, 1998, J CELL SCI, V111, P1095; ZAGZAG D, 1995, CANCER RES, V55, P907; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203; Zondag GCM, 1997, BIOCHIMIE, V79, P477, DOI 10.1016/S0300-9084(97)82739-3	57	40	44	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					609	618		10.1038/sj.onc.1204119	http://dx.doi.org/10.1038/sj.onc.1204119			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313993				2022-12-17	WOS:000166755000008
J	Cizeau, J; Ray, R; Chen, G; Gietz, RD; Greenberg, AH				Cizeau, J; Ray, R; Chen, G; Gietz, RD; Greenberg, AH			The C-elegans orthologue ceBNIP3 interacts with CED-9 and CED-3 but kills through a BH3-and caspase-independent mechanism	ONCOGENE			English	Article						ceBNIP3; BNIP3; cell death; CED-9; BH3 domain	PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; BH3 DOMAIN; GENETIC-CONTROL; PROTEIN; MITOCHONDRIAL; APOPTOSIS; HOMOLOG; BNIP3; NIP3	We have studied ceBNIP3, the orthologue of BNIP3 in C, elegans. Sequence analysis reveals that the different domains of BNIP3 have been conserved throughout evolution. ceBNIP3 contains a C-terminal transmembrane (TM) domain, a conserved domain (CD) of 19 amino acids, a BCL-2 homology-3 (BH3)-like domain and a PEST sequence. ceBNIP3 is expressed primarily as a 25 kDa monomer and a 50 kDa homodimer, After transfection, ceBNIP3 protein is rapidly degraded through a ubiquitin-dependent pathway by the proteasome. Like BNIP3, the TM domain of ceBNIP3 mediates the localization of the protein to mitochondria and is also necessary for homodimerization and cell death in mammalian cells. Neither the putative BH3 domain nor conserved domain is necessary for killing. ceBNIP3 protein interacts with CED-9 and BCL-X-L, but unlike other pro-apoptotic BCL-2 family members, the BH3-like domain does not participate in dimerization, The ceBNIP3 TM domain mediates interaction with both CED-9 and BCL-XL. ceBNIP3 interacts with CED-3 but co-expression of CED-3 and ceBNIP3 does not significantly enhance induction of cell death in the presence or absence of CED-4, ceBNIP3 kills mammalian cells by a caspase-independent mechanism. In conclusion, we find that although ceBNIP3 interacts with CED-9 and CED-3 it kills by a BH3- and caspase-independent mechanism.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Fac Med, Dept Biochemn & Med Genet, Winnipeg, MB R3E 0W3, Canada	University of Manitoba; University of Manitoba	Greenberg, AH (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Monney L, 1998, J BIOL CHEM, V273, P6121, DOI 10.1074/jbc.273.11.6121; Ng FWH, 1998, J BIOL CHEM, V273, P3140, DOI 10.1074/jbc.273.6.3140; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Ohi N, 1999, CELL DEATH DIFFER, V6, P314, DOI 10.1038/sj.cdd.4400493; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yasuda M, 1999, CANCER RES, V59, P533; Yasuda M, 1998, ONCOGENE, V17, P2525, DOI 10.1038/sj.onc.1202467; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	41	40	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2000	19	48					5453	5463		10.1038/sj.onc.1203929	http://dx.doi.org/10.1038/sj.onc.1203929			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114722				2022-12-17	WOS:000165396100005
J	Jamerson, MH; Johnson, MD; Dickson, RB				Jamerson, MH; Johnson, MD; Dickson, RB			Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models	ONCOGENE			English	Article						transgenic mice; mammary gland; c-myc; TGF alpha; p53	GROWTH-FACTOR-ALPHA; TRANSGENIC MICE; EPITHELIAL-CELLS; MOUSE MAMMARY; TGF-ALPHA; INDUCED TUMORIGENESIS; FACTOR RECEPTOR; BREAST-CANCER; CHROMOSOMAL INSTABILITY; GLAND INVOLUTION	Recent progress in the study of c-Myc has convincingly demonstrated that it possesses a dual role in regulating both proliferation and apoptosis; however, the manner in which c-Myc influences these cellular response pathways remains incompletely characterized. Deregulation of c-Myc expression, via many mechanisms, is a common feature of multiple cancers and is an especially prominent feature of many breast cancers. Of significant interest to those who study mammary gland development and neoplasia is the unresolved nature and contribution of apoptosis to breast tumorigenesis. Recently, the use of transgenic mice and gene-knockout mice has allowed investigators to evaluate the pathological mechanisms by which different genes influence tumor development and progression. In this review, we address two distinct c-myc-containing bitransgenic murine mammary tumor models and discuss the contribution and possible future directions for resolution of cancer-relevant molecular pathways influenced by c-Myc.	Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA.				NATIONAL CANCER INSTITUTE [R01CA072460] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA72460] Funding Source: Medline; NIA NIH HHS [1R01AG1496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Amundadottir LT, 1996, ONCOGENE, V13, P757; Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; ARTEAGA CL, 1988, CANCER RES, V48, P5023; BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BRINSTER RL, 1983, NATURE, V306, P332, DOI 10.1038/306332a0; BRINSTER RL, 1972, GROWTH NUTRITION MET, P251; Canman C E, 1997, Adv Pharmacol, V41, P429, DOI 10.1016/S1054-3589(08)61068-6; Dahiya R, 1998, BREAST CANCER RES TR, V52, P185, DOI 10.1023/A:1006101729631; Dang CV, 1999, MOL CELL BIOL, V19, P1; De Luca A, 1999, INT J CANCER, V80, P589, DOI 10.1002/(SICI)1097-0215(19990209)80:4<589::AID-IJC17>3.0.CO;2-D; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEMING SL, 1999, P ANN M AACR PHIL PA; DERYNCK R, 1987, CANCER RES, V47, P707; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; EDWARDS PAW, 1988, ONCOGENE, V2, P407; EELES RA, 1993, CANCER SURV, V18, P57; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELSON A, 1995, ONCOGENE, V11, P181; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Harris A L, 1988, Cancer Treat Res, V40, P93; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; JAENISCH R, 1976, P NATL ACAD SCI USA, V73, P1260, DOI 10.1073/pnas.73.4.1260; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEE LW, 1991, CANCER RES, V51, P5238; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; LIAO DJ, 2000, IN PRESS ONCOGENE; LISCIA DS, 1990, DEV BIOL, V140, P123, DOI 10.1016/0012-1606(90)90059-R; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Lozano G, 1998, SEMIN CANCER BIOL, V8, P337, DOI 10.1006/scbi.1998.0096; Martinez-Lacaci I, 1999, CONT CANC RES, V3, P31; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MIYASHITA T, 1995, CELL, V80, P293; Nass SJ, 1998, CLIN CANCER RES, V4, P1813; Nass SJ, 1996, BIOCHEM BIOPH RES CO, V227, P248, DOI 10.1006/bbrc.1996.1497; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PURDIE CA, 1994, ONCOGENE, V9, P603; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Siegel Peter M., 1998, P397; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRANGE R, 1992, DEVELOPMENT, V115, P49; TELANG NT, 1990, CELL REGUL, V1, P863, DOI 10.1091/mbc.1.11.863; TRAVERS MT, 1988, BRIT MED J, V296, P1621, DOI 10.1136/bmj.296.6637.1621; VALVERIUS EM, 1989, MOL ENDOCRINOL, V3, P203, DOI 10.1210/mend-3-1-203; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; WANG JK, 1999, P ANN M AACR PHIL PA; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	75	40	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1065	1071		10.1038/sj.onc.1203268	http://dx.doi.org/10.1038/sj.onc.1203268			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713691				2022-12-17	WOS:000085796400013
J	Rozovskaia, T; Rozenblatt-Rosen, O; Sedkov, Y; Burakov, D; Yano, T; Nakamura, T; Petruck, S; Ben-Simchon, L; Croce, CM; Mazo, A; Canaani, E				Rozovskaia, T; Rozenblatt-Rosen, O; Sedkov, Y; Burakov, D; Yano, T; Nakamura, T; Petruck, S; Ben-Simchon, L; Croce, CM; Mazo, A; Canaani, E			Self-association of the SET domains of human ALL-1 and of Drosophila TRITHORAX and ASH1 proteins	ONCOGENE			English	Article						SET domain; oligomerization; chromatin alterations	ACUTE LEUKEMIAS; GENE-PRODUCT; COMPLEX; CONTAINS; ENCODES; REGION	The human ALL-1 gene is involved in acute leukemia through gene fusions, partial tandem duplications or a specific deletion, Several sequence motifs within the ALL-1 protein, such as the SET domain, PHD fingers and the region with homology to DNA methyl transferase are shared with other proteins involved in transcription regulation through chromatin alterations. However, the function of these motifs is still not clear. Studying ALL-1 presents an additional challenge because the gene is the human homologue of Drosophila trithorax. The latter is a member of the trithorax-Polycomb gene family which acts to determine the body pattern of Drosophila by maintaining expression or repression of the Antennapedia-bithorax homeotic gene complex. Here we apply yeast two hybrid methodology, in vivo immunoprecipitation and in vitro 'pull down' techniques to show self association of the SET motifs of ALL-I, TRITHORAX and ASH1 proteins (Drosophila ASH1 is encoded by a tr trithorax-group gene). Point mutations in evolutionary conserved residues of TRITHORAX SET, abolish the interaction. SET-SET interactions might act in integrating the activity of ALL-1 (TRX and ASH1) protein molecules, simultaneously positioned at different maintenance elements and directing expression of the same or different target genes.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Weizmann Institute of Science; Jefferson University	Canaani, E (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Young, Richard A/F-6495-2012; Rozenblatt-Rosen, Orit/HDN-4182-2022	Young, Richard A/0000-0001-8855-8647; 	NCI NIH HHS [CA 50507] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050507] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cardoso C, 1998, HUM MOL GENET, V7, P679, DOI 10.1093/hmg/7.4.679; Corda Y, 1999, NAT GENET, V21, P204, DOI 10.1038/5991; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; Ekwall K, 1996, J CELL SCI, V109, P2637; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Heim S, 1995, CANC CYTOGENETICS; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Prasad R, 1997, ONCOGENE, V15, P549, DOI 10.1038/sj.onc.1201211; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; RAIMONDI SC, 1993, BLOOD, V81, P2237; Rasio D, 1996, CANCER RES, V56, P1766; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Rozovskaia T, 1999, MOL CELL BIOL, V19, P6441; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tripoulas N, 1996, GENETICS, V143, P913; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286	24	40	48	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					351	357		10.1038/sj.onc.1203307	http://dx.doi.org/10.1038/sj.onc.1203307			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656681				2022-12-17	WOS:000084873700004
J	Glaser, T; Wagenknecht, B; Groscurth, P; Krammer, PH; Weller, M				Glaser, T; Wagenknecht, B; Groscurth, P; Krammer, PH; Weller, M			Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells	ONCOGENE			English	Article						glioma; apoptosis; CD95; chemotherapy; caspases	APO-1/FAS RECEPTOR/LIGAND SYSTEM; ETOPOSIDE-INDUCED APOPTOSIS; TUMOR-CELLS; CD95 LIGAND; GAMMA-IRRADIATION; LEUKEMIA-CELLS; WILD-TYPE; IN-VITRO; EXPRESSION; INDUCTION	Death ligand/receptor interactions and caspase activation mediate drug-induced apoptosis in certain cancer cells. The molecular mechanisms responsible for the chemoresistance of human malignant gliomas are largely unknown. Here, me report that malignant glioma cells co-express CD95 and CD95L without undergoing suicidal or fratricidal apoptosis. Glioma cells do not commit CD95/CD95L-dependent suicide or fratricide even when RNA and protein synthesis are inhibited. This is because ectopic expression of the viral caspase inhibitor, crm-A, or exposure to a neutralizing CD95L antibody, block apoptosis induced by exogenous CD95L but not cell death induced by cytotoxic concentrations of inhibitors of RNA and protein synthesis. Although some cytotoxic drugs enhance the expression of CD95 or CD95L, crm-A fails to block drug-induced cytotoxic and clonogenic cell death, suggesting that the drug-induced changes in CD95 and CD95L expression are epiphenomenal. There is also no difference in drug-induced apoptosis between crm-A-transfected and control cells as assessed by electron microscopy, ill situ DNA end labeling and DNA fragmentation. Further, glioma cells selected for resistance to CD95L do not acquire cross-resistance to chemotherapy. However, the broad spectrum caspase inhibitor, zVAD-fmk, inhibits drug-induced cytotoxic cell death, suggesting a role of crm-A-insensitive caspases in drug-induced apoptosis of glioma cells. Thus, drug resistance of malignant glioma cells may involve deficiencies in two interrelated pathways that mediate death in order tumor cell types: (i) death ligand/receptor signalling; and (ii) caspase activation.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Tubingen, Germany; Univ Zurich, Inst Anat, Zurich, Switzerland; German Canc Res Ctr, D-6900 Heidelberg, Germany	Eberhard Karls University of Tubingen; University of Zurich; Helmholtz Association; German Cancer Research Center (DKFZ)	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Tubingen, Germany.			Weller, Michael/0000-0002-1748-174X				Antoku K, 1997, LEUKEMIA, V11, P1665, DOI 10.1038/sj.leu.2400805; Benjamin CW, 1998, MOL PHARMACOL, V53, P446, DOI 10.1124/mol.53.3.446; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 1998, INT J CANCER, V76, P105; Kataoka T, 1998, J IMMUNOL, V161, P3936; KONDO S, 1995, CANCER RES, V55, P6166; Kondo S, 1998, CANCER RES, V58, P962; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Villunger A, 1997, CANCER RES, V57, P3331; Wagenknecht B, 1998, CELL DEATH DIFFER, V5, P894, DOI 10.1038/sj.cdd.4400435; Weller M, 1997, CELL PHYSIOL BIOCHEM, V7, P282, DOI 10.1159/000154883; Weller M, 1998, BRAIN PATHOL, V8, P285; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1998, INT J CANCER, V79, P640; Winter S, 1998, EUR J PHARMACOL, V341, P323, DOI 10.1016/S0014-2999(97)01478-7; Yu JS, 1996, CANCER RES, V56, P5423; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zipp F, 1997, J IMMUNOL, V159, P2108	30	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	1999	18	36					5044	5053		10.1038/sj.onc.1202882	http://dx.doi.org/10.1038/sj.onc.1202882			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490841				2022-12-17	WOS:000082497100004
J	Kirchhoff, S; Hauser, H				Kirchhoff, S; Hauser, H			Cooperative activity between HER oncogenes and the tumor suppressor IRF-1 results in apoptosis	ONCOGENE			English	Article						interferon regulatory factor-1; HER; apoptosis; cell growth; STAT5; transcriptional activity	EPIDERMAL GROWTH-FACTOR; INTERFERON REGULATORY FACTOR-1; TRANSCRIPTION FACTOR IRF-1; MAJOR HISTOCOMPATIBILITY COMPLEX; CHRONIC MYELOGENOUS LEUKEMIA; HIGHER EUKARYOTIC CELLS; NATURAL-KILLER-CELLS; NF-KAPPA-B; FACTOR-I; FACTOR RECEPTOR	The tumor suppressor transcription factor IRE-I inhibits cell growth. In this report we show that IRF-1 also induces apoptosis of highly transformed and tumorigenic cell lines. This activity of IRF-1 is demonstrated with cell lines expressing HER oncogenes and an activatable IRE-I fusion protein. Growth of cell lines expressing inactive HER1 is inhibited on IRE-I activation. In contrast, the same cells are killed by apoptosis when HER1 and IRE-I are activated simultaneously. We identified promoters stimulated synergistically by IRF-1 and by activated HER1. To determine the signals causing transcriptional synergism and/or apoptosis we tried to modulate these effects by various dominant negative acting proteins. Dominant negative STAT5 alpha: abolished both induction of apoptosis and transcriptional synergy of IRF-1 and HER. Thus, these results provide new insights into the mechanism of oncogene-dependent apoptosis induced by the activation of a tumor suppressor.	GBF, Natl Res Ctr Biotechnol, Dept Gene Regulat & Differentiat, D-38124 Braunschweig, Germany	Helmholtz Association; Helmholtz-Center for Infection Research	Hauser, H (corresponding author), GBF, Natl Res Ctr Biotechnol, Dept Gene Regulat & Differentiat, Mascheroder Weg 1, D-38124 Braunschweig, Germany.							ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Baasner S, 1996, ONCOGENE, V13, P901; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; Bovolenta C, 1998, J BIOL CHEM, V273, P20779, DOI 10.1074/jbc.273.33.20779; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Chai SK, 1997, J IMMUNOL, V159, P4720; Chatterjee-Kishore M, 1998, J BIOL CHEM, V273, P16177, DOI 10.1074/jbc.273.26.16177; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chon SY, 1996, J BIOL CHEM, V271, P17247, DOI 10.1074/jbc.271.29.17247; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DINTER H, 1987, EUR J BIOCHEM, V166, P103, DOI 10.1111/j.1432-1033.1987.tb13488.x; Drew PD, 1995, J INTERF CYTOK RES, V15, P1037, DOI 10.1089/jir.1995.15.1037; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FADOK VA, 1992, J IMMUNOL, V148, P2207; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; Futaki M, 1996, LEUKEMIA RES, V20, P601, DOI 10.1016/0145-2126(96)00013-6; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Hobart M, 1996, TRANSPLANTATION, V62, P1895, DOI 10.1097/00007890-199612270-00037; Horiuchi M, 1997, J BIOL CHEM, V272, P11952, DOI 10.1074/jbc.272.18.11952; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kirchhoff S, 1996, CYTOTECHNOLOGY, V22, P147, DOI 10.1007/BF00353934; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; KIRCHHOFF S, 1998, IN PRESS BIOCHIMIE; KROEMER G, 1995, ADV IMMUNOL, V58, P211, DOI 10.1016/S0065-2776(08)60621-5; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MASSA PT, 1995, J INTERF CYTOK RES, V15, P799, DOI 10.1089/jir.1995.15.799; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Ohteki T, 1998, J EXP MED, V187, P967, DOI 10.1084/jem.187.6.967; OIE H, 1977, J GEN VIROL, V1, P107; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; Sala A, 1996, CANCER RES, V56, P1991; Salkowski CA, 1996, J IMMUNOL, V156, P3107; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Shuai K, 1996, ONCOGENE, V13, P247; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tamura Tomohiko, 1997, Leukemia (Basingstoke), V11, P439; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Wang IM, 1996, MOL CELL BIOL, V16, P6313; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; Yim JH, 1997, J IMMUNOL, V158, P1284; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	81	40	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3725	3736		10.1038/sj.onc.1202704	http://dx.doi.org/10.1038/sj.onc.1202704			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391680				2022-12-17	WOS:000081140200006
J	Drabkin, HA; West, JD; Hotfilder, M; Heng, YM; Erickson, P; Calvo, R; Dalmau, J; Gemmill, RM; Sablitzky, F				Drabkin, HA; West, JD; Hotfilder, M; Heng, YM; Erickson, P; Calvo, R; Dalmau, J; Gemmill, RM; Sablitzky, F			DEF-3(g16/NY-LU-12), an RNA binding protein from the 3p21.3 homozygous deletion region in SCLC	ONCOGENE			English	Article						granulocyte differentiation; zinc finger; POZ domain	CELL LUNG-CANCER; CHROMOSOME 3P21.3; INTERACTION MOTIF; MESSENGER-RNAS; POZ-DOMAIN; GENE; HEL-N1; RECOGNITION; SPECIFICITY; ANTIBODIES	DEF-3(g16/NY-LU-12) encodes a novel RNA binding protein isolated by positional cloning from an SCLC homozygous deletion region in 3p21.3 and, in parallel, as a differentially expressed gene during myelopoiesis from FDCPmix-A4 cells, DEF-3(g16/NY-LU-12) is ubiquitously expressed during mouse embryogenesis and in adult organs while human hematopoietic tissues showed differential expression, The mouse and human proteins are highly conserved containing two RNA recognition motifs (RRMs) and other domains associated with RNA binding and protein-protein interactions. A database search identified related proteins in human, rat, C. elegans and S, pombe including the 3p21.3 co-deleted gene, LUCA15, Recombinant proteins containing the RRMs of DEF-3(g16/NY-LU-12) and LUCA15 specifically bound poly(G) RNA homopolymers in vitro. These RRMs also show similarity to those of the Hu protein family. Since anti-Hu RRM domain antibodies are associated with an anti-tumor effect and paraneoplastic encephalomyelitis, we tested sera from Hu syndrome patients with the RRMs of DEF-3(g16/NY-LU-12) and LUCA15, These were non-reactive. Thus, DEF-3(g16/NY-LU-12) and LUCA15 represent members of a novel family of RNA binding proteins with similar expression patterns and in vitro RNA binding characteristics. They are co-deleted in some lung cancers and immunologically distinct from the Hu proteins.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Univ Hosp Munster, Dept Expt Neurooncol, Munster, Germany; UCL, Windeyer Inst Med Sci, Dept Med, London, England; Hosp Badalona Germans Trias & Pujol, Dept Med, Barcelona, Spain; Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Mol Neurooncol Lab, New York, NY 10021 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Munster; University of London; University College London; Hospital Germans Trias i Pujol; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Drabkin, HA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.		West, James/E-2960-2010; Sablitzky, Fred/A-2276-2011	West, James/0000-0002-6004-0202; Sablitzky, Fred/0000-0001-9718-1546	NCI NIH HHS [CA58187, P30 CA 46934] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046934, P50CA058187] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Cairns P, 1997, CANCER RES, V57, P5356; DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001; DALY MC, 1993, ONCOGENE, V8, P1721; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; Graus F, 1997, J CLIN ONCOL, V15, P2866, DOI 10.1200/JCO.1997.15.8.2866; Grondin B, 1996, J BIOL CHEM, V271, P15458, DOI 10.1074/jbc.271.26.15458; Gure AO, 1998, CANCER RES, V58, P1034; Inoue A, 1996, NUCLEIC ACIDS RES, V24, P2990, DOI 10.1093/nar/24.15.2990; Kaplan J, 1997, NUCLEIC ACIDS RES, V25, P1108, DOI 10.1093/nar/25.6.1108; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; KOK K, 1994, CANCER RES, V54, P4183; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; OHNO T, 1994, ONCOGENE, V9, P3087; Okano HJ, 1997, J NEUROSCI, V17, P3024; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Roche J, 1996, ONCOGENE, V12, P1289; SEKIDO Y, 1994, CANCER RES, V54, P4988; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; vandenBerg A, 1996, GENE CHROMOSOME CANC, V15, P64, DOI 10.1002/(SICI)1098-2264(199601)15:1<64::AID-GCC9>3.0.CO;2-2; VARELLAGARCIA M, 1997, LUNG CANCER, V18, P140; Wei MH, 1996, CANCER RES, V56, P1487; Wu L, 1997, IMMUNITY, V7, P483, DOI 10.1016/S1074-7613(00)80370-2	29	40	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2589	2597		10.1038/sj.onc.1202601	http://dx.doi.org/10.1038/sj.onc.1202601			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353602				2022-12-17	WOS:000079907100006
J	Sala, A; Saitta, B; De Luca, P; Cervellera, MN; Casella, I; Lewis, RE; Watson, R; Peschle, C				Sala, A; Saitta, B; De Luca, P; Cervellera, MN; Casella, I; Lewis, RE; Watson, R; Peschle, C			B-MYB transactivates its own promoter through SP1-binding sites	ONCOGENE			English	Article						B-MYB; cell-cycle; promoter; SP1; transcription	V-MYB; A-MYB; CONSTITUTIVE EXPRESSION; TRANSCRIPTION FACTOR; ACTIVATION; CELLS; SP1; FAMILY; GENE; DIFFERENTIATION	B-MYB is an ubiquitous protein required for mammalian cell growth. In this report we show that B-MYB transactivates its own promoter through a 120 bp segment proximal to the transcription start site. The B-MYB-responsive element does not contain myb-binding sites and gel-shift analysis shows that SP1, but not B-MYB, protein contained in SAOS2 cell extracts binds to the 120 bp B-myb promoter fragment. B-MYB-dependent transactivation is cooperatively increased in the presence of SP1, but not SP3 overexpression, When the SP1 elements of the B-myb promoter are transferred in front of a heterologous promoter, an increased response to B-MYB results. In contrast, c-MYB, the prototype member of the Myb family, is not able to activate the luciferase construct containing the SP1 elements. With the use of an SP1-GAL4 fusion protein, we have determined that the cooperative activation occurs through the domain A of SP1, These observations suggest that B-MYB functions as a coactivator of SP1, and that diverse combinations of myb and SP1 sites may dictate the responsiveness of myb-target genes to the various members of the myb family.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, I-66030 Santa Maria Imbaro, CH, Italy; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Immunol Microbiol, Philadelphia, PA 19107 USA; Dept Reumatol, Philadelphia, PA 19107 USA; Univ Naples Federico II, Dept Genet Mol & Gen Biol, I-80134 Naples, Italy; Univ Nebraska, Med Ctr, Eppley Canc Inst, Omaha, NE 68198 USA; St Marys Hosp, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Ist Super Sanita, Lab Ematol Oncol, I-00161 Rome, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Jefferson University; University of Naples Federico II; University of Nebraska System; University of Nebraska Medical Center; Imperial College London; Ludwig Institute for Cancer Research; Istituto Superiore di Sanita (ISS)	Sala, A (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, Via Nazl, I-66030 Santa Maria Imbaro, CH, Italy.		De Luca, Pasquale/AAL-5673-2021; Lewis, Robert E./H-3404-2019; sala, arturo/C-4959-2008	De Luca, Pasquale/0000-0003-4289-6784; Sala, Arturo/0000-0002-2841-7866; Casella, Ida/0000-0002-3358-4976				ARSURA M, 1992, BLOOD, V79, P2708; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BIES J, 1995, CANCER RES, V55, P501; Bies J, 1996, ONCOGENE, V12, P355; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; ENGELKE U, 1995, VIROLOGY, V208, P467, DOI 10.1006/viro.1995.1177; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1994, ONCOGENE, V9, P2469; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; TASHIRO S, 1995, ONCOGENE, V10, P1699; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	38	40	40	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1333	1339		10.1038/sj.onc.1202421	http://dx.doi.org/10.1038/sj.onc.1202421			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022815				2022-12-17	WOS:000078510900009
J	Chen, P; Gatei, M; O'Connell, MJ; Khanna, KK; Bugg, SJ; Hogg, A; Scott, SP; Hobson, K; Lavin, MF				Chen, P; Gatei, M; O'Connell, MJ; Khanna, KK; Bugg, SJ; Hogg, A; Scott, SP; Hobson, K; Lavin, MF			Chk1 complements the G2/M checkpoint defect and radiosensitivity of ataxia-telangiectasia cells	ONCOGENE			English	Article						ataxia-telangiectasia; chk1; radiosensitivity; G2/M checkpoint; cell cycle	DNA-DAMAGE CHECKPOINT; IONIZING-RADIATION; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; WEE1 KINASE; P53 PROTEIN; ATM; GENE; PATHWAY; PHOSPHORYLATION	Cells from patients with the human genetic disorder ataxia-telangiectasia (A-T) are defective in the activation of cell cycle checkpoints in response to ionizing radiation damage. In order to understand the role of ATM in checkpoint control we investigated whether Schizosaccaromyces pombe chk1, a protein kinase implicated in controlling the G2 DNA damage checkpoint, might alter the radiosensitive phenotype in A-T cells. The fission yeast chk1 gene was cloned into an EBV-based vector under the control of a metallothionein promoter and transfected into A-T lymphoblastoid cells, Induction of chk1 enhanced the survival of an A-T cell line in response to radiation exposure as determined by cell viability and reduction of radiation-induced chromosome aberrations. This can be accounted for at least in part by the restoration of the G2 checkpoint to chk1 expressing cells. There was no evidence that chk1 expression corrected either the G1/S checkpoint or radioresistant DNA synthesis in S phase in these cells. These results suggest that chk1 when overexpressed acts downstream from ATM to restore the G2 checkpoint in these cells and correct the radiosensitive phenotype, These data allow us to dissociate individual checkpoint events and relate them to the radiosensitive phenotype in A-T cells.	Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Peter MacCallum Res Inst, E Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Genet, Parkville, Vic 3052, Australia; Univ Queensland, Royal Brisbane Hosp, Dept Surg, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Peter Maccallum Cancer Center; University of Melbourne; Royal Brisbane & Women's Hospital; University of Queensland	Lavin, MF (corresponding author), Queensland Inst Med Res, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.		Lavin, Martin F/F-5961-2014; Khanna, Kum Kum/I-1747-2013; Hobson, Keith/Q-9306-2019	Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BADIE C, 1995, CANCER RES, V55, P1232; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BATES PR, 1985, INT J RADIAT BIOL, V47, P713, DOI 10.1080/09553008514550951; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; CANMAN CE, 1994, CANCER RES, V54, P5054; Chen P, 1996, INT J RADIAT BIOL, V69, P385, DOI 10.1080/095530096145940; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Flaggs G, 1997, CURR BIOL, V7, P977, DOI 10.1016/S0960-9822(06)00417-9; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GOTOFF SP, 1967, AM J DIS CHILD, V114, P617, DOI 10.1001/archpedi.1967.02090270073006; Honda R, 1997, BIOCHEM BIOPH RES CO, V230, P262, DOI 10.1006/bbrc.1996.5933; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KONIG K, 1980, RADIAT ENVIRON BIOPH, V18, P257, DOI 10.1007/BF01324268; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEEPER DB, 1972, RADIAT RES, V50, P410; LEHMANN AR, 1986, INT J RADIAT BIOL, V49, P639; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MORGAN JL, 1968, AM J DIS CHILD, V116, P557, DOI 10.1001/archpedi.1968.02100020561022; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OGG S, 1994, J BIOL CHEM, V269, P30461; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEDGWICK RP, 1991, HEREDITARY NEUROPATH, P347; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; VOUSDEN KH, 1993, J GEN VIROL, V74, P803, DOI 10.1099/0022-1317-74-5-803; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; Westphal CH, 1997, CURR BIOL, V7, pR789, DOI 10.1016/S0960-9822(06)00406-4; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021	58	40	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					249	256		10.1038/sj.onc.1202257	http://dx.doi.org/10.1038/sj.onc.1202257			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926940				2022-12-17	WOS:000078166000027
J	Ahmadian, A; Ren, ZP; Williams, C; Ponten, F; Odeberg, J; Ponten, J; Uhlen, M; Lundeberg, J				Ahmadian, A; Ren, ZP; Williams, C; Ponten, F; Odeberg, J; Ponten, J; Uhlen, M; Lundeberg, J			Genetic instability in the 9q22.3 region is a late event in the development of squamous cell carcinoma	ONCOGENE			English	Article						p53; 9q22.3; loss of heterozygosity; squamous cell carcinoma; dysplasia	HUMAN P53 GENE; HUMAN HOMOLOG; HUMAN SKIN; ALLELE LOSS; BASAL; CANCER; MUTATIONS; CHROMOSOME-9; HETEROZYGOSITY; POLYMORPHISM	Squamous cell carcinoma (SCC) of the skin represents a group of neoplasms which is associated with exposure to UV light. Recently, we obtained data suggesting that invasive skin cancer and its precursors derive from one original neoplastic clone. Here, the analysis were extended by loss of heterozygosity (LOH) analysis in the chromosome 9q22.3 region. A total of 85 samples, taken from twenty-two sections of sun-exposed sites, corresponding to normal epidermis, morphological normal cells with positive immune-staining for the p53 protein (p53 patches), dysplasias, cancer in situ (CIS) and squamous cell carcinomas (SCC) of the skin were analysed. Overall, about 70% of p53 patches had mutations in the p53 gene but not LOH in the p53 gene or 9q22.3 region. Approximately 70% of the dysplasias showed p53 mutations of which about 40% had LOH in the p53 region but not in the 9q22.3 region. In contrast, about 65% of SCC and CIS displayed LOH in the 9q22.3 region, as well as frequent (80%) mutations and/or LOH in the p53 gene. These findings strongly suggest that alterations in the p53 gene is an early event in the progression towards SCC, whereas malignant development involves LOH and alterations in at least one (or several) tumor suppressor genes located in chromosome 9q22.3.	Royal Inst Technol, Dept Biochem & Biotechnol, S-10044 Stockholm, Sweden; Univ Uppsala Hosp, Dept Pathol, S-75185 Uppsala, Sweden	Royal Institute of Technology; Uppsala University; Uppsala University Hospital	Lundeberg, J (corresponding author), Royal Inst Technol, Dept Biochem & Biotechnol, S-10044 Stockholm, Sweden.		Williams, Cecilia/A-6677-2009; Uhlen, Mathias/B-3262-2016; Odeberg, Jacob O/O-3336-2014; Uhlen, Mathias/AAV-8746-2021; Odeberg, Jacob/I-8314-2016	Williams, Cecilia/0000-0002-0602-2062; Uhlen, Mathias/0000-0002-4858-8056; Odeberg, Jacob O/0000-0003-0996-1644; Odeberg, Jacob/0000-0003-0996-1644				BERG C, 1995, CLIN CHEM, V41, P1461; EKLUND LK, 1997, IN PRESS MOL CARCINO; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HEDRUM A, 1994, BIOTECHNIQUES, V17, P118; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Holmberg E, 1996, BRIT J CANCER, V74, P246, DOI 10.1038/bjc.1996.345; HULTMAN T, 1991, BIOTECHNIQUES, V10, P84; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Ponten F, 1997, MUTAT RES-GENOMICS, V382, P45, DOI 10.1016/S1383-5726(97)00008-3; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; QUINN AG, 1994, J INVEST DERMATOL, V102, P300, DOI 10.1111/1523-1747.ep12371786; QUINN AG, 1994, CANCER RES, V54, P4756; REHMAN I, 1994, LANCET, V344, P788, DOI 10.1016/S0140-6736(94)92343-4; Ren ZP, 1996, ONCOGENE, V12, P765; Ren ZP, 1997, AM J PATHOL, V150, P1791; Unden AB, 1997, CANCER RES, V57, P2336; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; ZAPHIROPOULOS PG, 1994, BIOCHEM BIOPH RES CO, V201, P1495, DOI 10.1006/bbrc.1994.1873	25	40	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1837	1843		10.1038/sj.onc.1202080	http://dx.doi.org/10.1038/sj.onc.1202080			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778050				2022-12-17	WOS:000076303300010
J	Offermanns, S; Simon, MI				Offermanns, S; Simon, MI			Genetic analysis of mammalian G-protein signalling	ONCOGENE			English	Review						G-protein; gene targeting; transgenic mouse; transmembrane signalling	CEREBELLAR PURKINJE-CELLS; LONG-TERM DEPRESSION; MICE LACKING MGLUR1; ALPHA-SUBUNITS; PHOSPHOLIPASE-C; ADENYLYL-CYCLASE; THROMBOXANE A(2); HUMAN PLATELETS; MUTANT MICE; ACTIVATION	Heterotrimeric G-proteins are important signalling proteins which function in all cells of the mammalian organism. Inactivating mutations in a variety of G-protein alpha-subunit genes in mice resulted in mostly unexpected phenotypes and have provided interesting new insight into their biological roles. Whereas the inactivation of some G alpha genes led to mild phenotypes suggesting the presence of redundant or compensatory mechanisms, other G-proteins appear to play highly specific biological or developmental roles. The purpose of this review is to summarize the current knowledge about G-protein functions based on gene-inactivation studies.	CALTECH, Div Biol 147 75, Pasadena, CA 91125 USA; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	California Institute of Technology; Free University of Berlin	Simon, MI (corresponding author), CALTECH, Div Biol 147 75, Pasadena, CA 91125 USA.		Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; Cooper G, 1997, ANNU REV MED, V48, P13, DOI 10.1146/annurev.med.48.1.13; CREPEL F, 1982, TRENDS NEUROSCI, V5, P266, DOI 10.1016/0166-2236(82)90168-0; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Gabbeta J, 1997, P NATL ACAD SCI USA, V94, P8750, DOI 10.1073/pnas.94.16.8750; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hofer D, 1996, P NATL ACAD SCI USA, V93, P6631, DOI 10.1073/pnas.93.13.6631; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Hornquist CE, 1997, J IMMUNOL, V158, P1068; HUNG DT, 1992, J BIOL CHEM, V267, P20831; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.neuro.12.1.85; JIANG HP, 1994, J BIOL CHEM, V269, P7593; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Kano M, 1995, CELL, V83, P1223, DOI 10.1016/0092-8674(95)90147-7; Kano M, 1997, NEURON, V18, P71, DOI 10.1016/S0896-6273(01)80047-7; Kinnamon SC, 1996, CURR OPIN NEUROBIOL, V6, P506, DOI 10.1016/S0959-4388(96)80057-2; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LEE CW, 1994, J BIOL CHEM, V269, P25335; Lindemann B, 1996, CURR BIOL, V6, P1234, DOI 10.1016/S0960-9822(96)00704-X; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, P NATL ACAD SCI USA, V94, P14089, DOI 10.1073/pnas.94.25.14089; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RAYMOND JR, 1994, J BIOL CHEM, V269, P13073; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROUSTAN P, 1995, NEUROREPORT, V6, P1837, DOI 10.1097/00001756-199510020-00004; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Rudolph U, 1996, P NATL ACAD SCI USA, V93, P3209, DOI 10.1073/pnas.93.8.3209; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sowell MO, 1997, P NATL ACAD SCI USA, V94, P7921, DOI 10.1073/pnas.94.15.7921; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; SWEETON D, 1991, DEVELOPMENT, V112, P775; USHIKUBI F, 1994, MOL PHARMACOL, V46, P808; Valenzuela D, 1997, P NATL ACAD SCI USA, V94, P1727, DOI 10.1073/pnas.94.5.1727; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WEINSTEIN LS, 1993, CLIN BIOCHEM, V26, P333, DOI 10.1016/0009-9120(93)90109-J; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WILKIE TM, 1994, SOC GEN PHY, V49, P249; Wong GT, 1996, NATURE, V381, P796, DOI 10.1038/381796a0; WU DQ, 1992, J BIOL CHEM, V267, P25798; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	66	40	40	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1375	1381		10.1038/sj.onc.1202173	http://dx.doi.org/10.1038/sj.onc.1202173			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779985				2022-12-17	WOS:000076161900006
J	Holmgren, L; Jackson, G; Arbiser, J				Holmgren, L; Jackson, G; Arbiser, J			P53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma	ONCOGENE			English	Article						angiogenesis; dormancy; neoplasia	WILD-TYPE P53; ENDOTHELIAL GROWTH-FACTOR; TUMOR-GROWTH; IN-VIVO; EXPRESSION; CANCER; CELLS; APOPTOSIS; INHIBITOR; SUPPRESSION	The p53 tumor-suppressor gene is inactivated in over 50% of all human cancers, In normal cells, p53 induces growth arrest and apoptosis in response to DNA damage. We show that p53 acts as potent tumor-suppressor gene independent of its well-documented effects on tumor-cell proliferation and apoptosis. p53 activates target genes in a murine fibrosarcoma cell-line but does not affect tumor cell-cycle progression or survival. Exogenous expression of wt-p53 does, however, block the angiogenic potential of the tumor cells resulting in formation of dormant tumors in vivo. These data provide evidence that: (1) p53 acts as a tumor suppressor gene independent of its anti-proliferative effects; (2) By inhibiting angiogenesis p53 can indirectly induce apoptosis in vivo but not in vitro; (3) p53-gene therapy which alters a tumors angiogenic potential, can revert tumors to a dormant phenotype.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Harvard Univ, Childrens Hosp, Sch Med, Surg Res Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA	Karolinska Institutet; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Holmgren, L (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.							Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Folkman J., 1995, MOL BASIS CANC, P206; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Holmgren L, 1996, CANCER METAST REV, V15, P241, DOI 10.1007/BF00437478; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEYER JL, 1985, INT J RADIAT ONCOL, V11, P973, DOI 10.1016/0360-3016(85)90120-8; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; RAK J, 1995, CANCER RES, V55, P4575; Sambrook J, 1989, MOL CLONING LAB MANU; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TANAKA T, 1996, ANGIOGENESIS ANTAGON; TEICHER BA, 1992, CANCER RES, V52, P6702; Teicher BA, 1994, RADIAT ONCOL INVEST, V2, P269, DOI DOI 10.1002/ROI.2970020604; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG WW, 1994, CANCER GENE THER, V1, P5	28	40	42	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					819	824		10.1038/sj.onc.1201993	http://dx.doi.org/10.1038/sj.onc.1201993			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9779998				2022-12-17	WOS:000075448800003
J	Shao, NS; Chai, YL; Cui, JQ; Wang, N; Aysola, K; Reddy, ESP; Rao, VN				Shao, NS; Chai, YL; Cui, JQ; Wang, N; Aysola, K; Reddy, ESP; Rao, VN			Induction of apoptosis by Elk-1 and Delta Elk-1 proteins	ONCOGENE			English	Article						Elk-1; Delta Elk-1; apoptosis; calcium ionophore; breast cancer; MCF-7; Rat-1	SIGNAL-TRANSDUCTION PATHWAYS; ETS TRANSCRIPTION FACTOR; TERNARY COMPLEX FACTORS; SERUM RESPONSE ELEMENT; PROGRAMMED CELL-DEATH; ACTIVATION; FAMILY; GENE; PROTOONCOGENE; FIBROBLASTS	Elk-1, an ets related gene codes for at least two splice variants Elk-1, which regulates c-fos transcription and Delta Elk-1, both of which function as transcriptional activators. To investigate the role of Elk-1 and Delta Elk-1 proteins in apoptosis; we have developed rat fibroblast cell lines and human breast cancer cell lines expressing Delta Elk-1 and Delta Elk-1. The expression of Elk-1 and Delta Elk-1 proteins in the Elk-1/Delta Elk-1 transfectants were analysed by immunofluorescence, immunohistochemistry, and Western blot analysis. The Elk-1 unlike Delta Elk-1 transfectants showed a shortened and flattened morphology compared to the parental cells. We have found that calcium ionophore treatment of Rat-1 Elk-1, MCF-7 Elk-1, Rat-1 Delta Elk-1 and MCF-7 Delta Elk-1 transfectants resulted in programmed cell death. These results indicate that constitutive expression of Elk-1 and Delta Elk-1 proteins triggers apoptosis in Rat-1 fibroblasts and breast cancer cells when treated with calcium ionophore.	Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, Philadelphia, PA 19102 USA	Drexel University	Rao, VN (corresponding author), Allegheny Univ Hlth Sci, Dept Human Genet, Div Canc Genet, MS 481,New Coll Bldg,Broad & Vine St, Philadelphia, PA 19102 USA.			Wang, Nan/0000-0003-0330-8636	NCI NIH HHS [CA57322, CA50507, CA58642] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050507, R01CA058642, R01CA057322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Athanasiou M, 1996, ONCOGENE, V12, P337; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COHEN JJ, 1984, J IMMUNOL, V132, P38; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JIMENEZ B, 1995, ONCOGENE, V10, P811; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; JOSEPH R, 1993, MOL BRAIN RES, V17, P70, DOI 10.1016/0169-328X(93)90074-Y; KONDO S, 1994, BRIT J CANCER, V70, P421, DOI 10.1038/bjc.1994.321; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MARIAS R, 1993, CELL, V73, P381; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Nozaki M, 1996, DNA CELL BIOL, V15, P855, DOI 10.1089/dna.1996.15.855; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Preston GA, 1996, MOL CELL BIOL, V16, P211; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAO VN, 1992, ONCOGENE, V7, P65; Rao VN, 1996, ONCOGENE, V12, P523; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SEARLE J, 1982, PATHOL ANNU, V17, P229; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; Shao NS, 1996, ONCOGENE, V13, P1; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YI HK, 1997, ONCOGENE, V14, P1250	42	40	43	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					527	532		10.1038/sj.onc.1201931	http://dx.doi.org/10.1038/sj.onc.1201931			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696047	Bronze			2022-12-17	WOS:000075043000016
J	Barzegar, C; Meazza, R; Pereno, R; Pottin-Clemenceau, C; Scudeletti, M; Brouty-Boye, D; Doucet, C; Taoufik, Y; Ritz, J; Musselli, C; Mishal, Z; Jasmin, C; Indiveri, F; Ferrini, S; Azzarone, B				Barzegar, C; Meazza, R; Pereno, R; Pottin-Clemenceau, C; Scudeletti, M; Brouty-Boye, D; Doucet, C; Taoufik, Y; Ritz, J; Musselli, C; Mishal, Z; Jasmin, C; Indiveri, F; Ferrini, S; Azzarone, B			IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops	ONCOGENE			English	Article						melanomas; IL-15; IL-15R; secretion pattern; tumor progression immunotherapy	NATURAL-KILLER-CELLS; RECEPTOR-GAMMA CHAIN; INTERLEUKIN-2 RECEPTOR; BETA-CHAIN; FUNCTIONAL INTERLEUKIN-2; GROWTH-FACTOR; ALPHA-CHAIN; EXPRESSION; LINE; IDENTIFICATION	IL-15 is a novel cytokine active through the IL-2R beta gamma. Since several human melanoma cell lines display functional IL-2Rs, we studied the IL-15/melanoma cells interactions. Ten out of 17 melanoma cell lines express the IL-15 transcript and four of them express levels of IL-15 mRNA similar to those detected in control activated monocytes, Nine out of ten cell lines also express two transcripts for the IL-15R alpha originated by the alternative splicing of exon'3'. Two melanoma cell lines, MELP and MELREO, derived from patients with rapidly progressive primary melanomas, co-express the two IL-15 transcripts, originated by alternative splicing of exon 'A'. Intracellular II-15 protein was only detected in these two cells lines and it is mainly retained in the Endoplasmic Reticulum (ER), However, a small amount of IL-15 is also found in the GoIgi apparatus and in the early endosomes, suggesting production and intercellular trafficking of endogenous IL-15 protein. Nevertheless, no biologically active IL-15 could be detected in the supernatant of all melanoma cells. The anti IL-15 blocking mAb M111 causes the up regulation of;HLA Class I in dense MELP and MELREO cultures, These data suggest that IL-15 is probably active through juxtacrine loops negatively controlling KLA Class I molecules expression. These data offer, for the first time, a likely explanation to the controversal issue of IL-15 secretion and constitute a natural model for understanding IL-15 routing. Moreover, me identify a subset of melanoma cells producing IL-15, possibly involved in tumor escape mechanisms.	Hop Paul Brousse, INSERM, U268, F-94807 Villejuif, France; IST, CBA, I-16132 Genoa, Italy; Fac Med, DIMI, I-16132 Genoa, Italy; INSERM, U4, CRI, F-94276 Le Kremlin Bicetre, France; Dana Farber Canc Inst, Boston, MA 02115 USA; CNRS, UPS 47, Lab Cytometrie, F-94800 Villejuif, France; Fac Med, DOCS, I-16132 Genoa, Italy	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Harvard University; Dana-Farber Cancer Institute; Centre National de la Recherche Scientifique (CNRS)	Azzarone, B (corresponding author), Hop Paul Brousse, INSERM, U268, F-94807 Villejuif, France.		Ritz, Jerome/C-7929-2009; Meazza, Raffaella/AAC-2425-2019; Azzarone, Bruno/AAH-9251-2019; Indiveri, Francesco/AAE-9086-2020	Ritz, Jerome/0000-0001-5526-4669; Meazza, Raffaella/0000-0003-0242-3157; Azzarone, Bruno/0000-0002-5962-3849; Induveri, Francesco/0000-0002-9280-2232; Ferrini, Silvano/0000-0001-7254-2616				ALILECHE A, 1993, ONCOGENE, V8, P1791; ALTOMONTE M, 1992, NEW ENGL J MED, V327, P959; ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; Azzarone B, 1996, EUR CYTOKINE NETW, V7, P27; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; Care A, 1996, MOL CELL BIOL, V16, P4842; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; Carson WE, 1995, J CLIN INVEST, V96, P2578, DOI 10.1172/JCI118321; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; deJong JLO, 1996, J IMMUNOL, V156, P1339; DOUCET C, 1997, MELANOMA RES S, V7, P75; Ferrini S, 1996, GENE THER, V3, P656; GAMERO AM, 1995, CANCER RES, V55, P4988; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HANS DS, 1996, ONCOGENE, V8, P1015; KATANO M, 1994, CANCER IMMUNOL IMMUN, V39, P161, DOI 10.1007/BF01533381; KAWAHARA A, 1994, MOL CELL BIOL, V14, P5433, DOI 10.1128/MCB.14.8.5433; KAWAMI H, 1993, BIOTHERAPY, V6, P33, DOI 10.1007/BF01877384; LENTER M, 1994, J BIOL CHEM, V269, P12263; Meazza R, 1996, ONCOGENE, V12, P2187; MEAZZA R, 1997, IN PRESS EUR J IMMUN; MOHAMADZADEH M, 1995, J IMMUNOL, V155, P4492; MORIMOTO K, 1994, BLOOD, V83, P657; Mrozek E, 1996, BLOOD, V87, P2632, DOI 10.1182/blood.V87.7.2632.bloodjournal8772632; NAKARAI T, 1994, J EXP MED, V180, P241, DOI 10.1084/jem.180.1.241; PLAISANCE S, 1993, INT J CANCER, V55, P164, DOI 10.1002/ijc.2910550129; RIMOLDI D, 1993, ANTICANCER RES, V13, P555; Tagaya Y, 1996, EMBO J, V15, P4928, DOI 10.1002/j.1460-2075.1996.tb00873.x; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; WALDMANN TA, 1993, IMMUNOL TODAY, V14, P264, DOI 10.1016/0167-5699(93)90043-K	34	40	49	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2503	2512		10.1038/sj.onc.1201775	http://dx.doi.org/10.1038/sj.onc.1201775			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627116				2022-12-17	WOS:000073672300008
J	Arama, E; Yanai, A; Kilfin, G; Bernstein, A; Motro, B				Arama, E; Yanai, A; Kilfin, G; Bernstein, A; Motro, B			Murine NIMA-related kinases are expressed in patterns suggesting distinct functions in gametogenesis and a role in the nervous system	ONCOGENE			English	Article						NIMA; protein kinase; mitosis; meiosis; nervous system	CYCLIN-DEPENDENT KINASE-5; CELL-CYCLE; PROTEIN-KINASE; ASPERGILLUS-NIDULANS; FISSION YEAST; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; MITOTIC REGULATOR; PROMOTING FACTOR; MESSENGER-RNAS	NIMA protein kinase is a major regulator of progression into mitosis in Aspergillus nidulans. Dominant negative forms of NIMA protein prevent entrance into mitosis in HeLa cells, suggesting that mammals have a similar pathway, We have reported previously the isolation of a murine NIMA-related kinase, designated Nek1, and more recently several additional NIMA-related human kinases have been cloned. The existence of several mammalian NIMA-related genes raises the questions of whether the different mammalian members have redundant, overlapping or distinct functions, and whether these functions are related to the role of NIMA in controlling mitosis. To address these questions we have studied the expression patterns of the different murine nek genes. To this end, we isolated a murine nek2 cDNA and compared its patterns of expression, during both gametogenesis and embryogenesis, to those of nek1. Both genes were highly expressed in developing germ cells, albeit in distinct patterns. In both females and males, nek1 is expressed much earlier than nek2, suggesting only limited ability for functional redundancy. Surprisingly, a striking specificity of nek1 expression was found: high levels of nek1 RNA were observed in distinct regions of the nervous system, most notably in neurons of the peripheral ganglia, These patterns suggest that the different mammalian NIMA-related kinases participate in different phases of the meiotic process and may also have functions other than cell cycle control.	Bar Ilan Univ, Dept Life Sci, IL-52900 Ramat Gan, Israel; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada	Bar Ilan University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Motro, B (corresponding author), Bar Ilan Univ, Dept Life Sci, IL-52900 Ramat Gan, Israel.		Arama, Eli/GYJ-0491-2022; /ABF-8487-2022					AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; ANDERSON DJ, 1986, CELL, V47, P1079, DOI 10.1016/0092-8674(86)90823-8; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BORUM K, 1961, EXP CELL RES, V24, P495, DOI 10.1016/0014-4827(61)90449-9; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; CHAPMAN DL, 1994, DEV BIOL, V165, P500, DOI 10.1006/dbio.1994.1270; CHAPMAN DL, 1993, DEVELOPMENT, V118, P229; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; FRY AM, 1995, CURR BIOL, V5, P1122, DOI 10.1016/S0960-9822(95)00227-2; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEDOUARIN NM, 1986, SCIENCE, V231, P1515, DOI 10.1126/science.3952494; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; LU KP, 1994, EMBO J, V13, P2103, DOI 10.1002/j.1460-2075.1994.tb06486.x; MINSHULL J, 1989, J CELL SCI, P77; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTRO B, 1991, DEVELOPMENT, V113, P1207; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; Osmani SA, 1996, BIOCHEM J, V317, P633, DOI 10.1042/bj3170633; PETERS H, 1969, ACTA ENDOCRINOL-COP, V62, P98, DOI 10.1530/acta.0.0620098; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; Russell L. D., 1990, HISTOLOGICAL HISTOPA; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SIMS TJ, 1979, J COMP NEUROL, V183, P707, DOI 10.1002/cne.901830403; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Stern B, 1996, TRENDS GENET, V12, P345; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; WU S, 1995, DEV BIOL, V170, P195, DOI 10.1006/dbio.1995.1207; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x	47	40	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	1998	16	14					1813	1823		10.1038/sj.onc.1201710	http://dx.doi.org/10.1038/sj.onc.1201710			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583679				2022-12-17	WOS:000072994600005
J	Kharbanda, S; Pandey, P; Morris, PL; Whang, Y; Xu, YH; Sawant, S; Zhu, LJ; Kumar, N; Yuan, ZM; Weichselbaum, R; Sawyers, CL; Pandita, TK; Kufe, D				Kharbanda, S; Pandey, P; Morris, PL; Whang, Y; Xu, YH; Sawant, S; Zhu, LJ; Kumar, N; Yuan, ZM; Weichselbaum, R; Sawyers, CL; Pandita, TK; Kufe, D			Functional role for the c-Abl tyrosine kinase in meiosis I	ONCOGENE			English	Article						meiosis; c-Abl; spermatogenesis	ACTIVATED PROTEIN-KINASE; STRESS-RESPONSE; CELLS; MOUSE; GENE; MICE; P53; RECOMBINATION; EXPRESSION; LETHALITY	The c-Abl tyrosine kinase is activated by ionizing radiation and certain other DNA-damaging agents. The DNA-dependent protein kinase (DNA-PK) and the ataxia telangiectasia mutated (ATM) gene product, effecters in the DNA damage response, contribute to the induction of c-Abl activity. The present study demonstrates that c-Abl is expressed in mouse and rat testes, and predominantly in pachytene spermatocytes of meiosis I. The results also demonstrate that c-Abl interacts directly with meiotic chromosomes. In concert with a requirement for c-Abl at the pachytene stage, me show that, in contrast to wild-type mice, testes from Abl(-/-) mice exhibit defects in spermatogenesis. These findings provide the first demonstration that c-Abl plays a functional role in meiosis.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Populat Council, Ctr Biomed Res, New York, NY 10021 USA; Rockefeller Univ, New York, NY 10021 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Columbia Univ, Ctr Radiol Res, New York, NY 10032 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Population Council; Rockefeller University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Chicago; Columbia University	Kharbanda, S (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.		Pandita, Tej K/AAM-9188-2020; Sawyers, Charles/G-5327-2016; Whang, Young/AAK-7435-2021	Whang, Young/0000-0002-1621-6661	NATIONAL CANCER INSTITUTE [R01CA075216, R01CA042802] Funding Source: NIH RePORTER; NCI NIH HHS [CA75216, CA42802, CA55241] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; FUJISAWA M, 1992, MOL CELL ENDOCRINOL, V84, P79, DOI 10.1016/0303-7207(92)90074-G; GOGA A, 1995, ONCOGENE, V11, P791; GOTTLIEB TM, 1993, CELL, V72, pU31; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Hardin JD, 1996, ONCOGENE, V12, P2669; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95, DOI 10.1159/000133899; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; PONZETTO C, 1989, ONCOGENE, V4, P685; ROSS M. H., 1995, HISTOLOGY TEXT ATLAS, P636; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	33	40	43	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1773	1777		10.1038/sj.onc.1201934	http://dx.doi.org/10.1038/sj.onc.1201934			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583675				2022-12-17	WOS:000072994600001
J	Berasain, C; Patil, D; Perara, E; Huang, SM; Mouly, H; Brechot, C				Berasain, C; Patil, D; Perara, E; Huang, SM; Mouly, H; Brechot, C			Oncogenic activation of a human cyclin A2 targeted to the endoplasmic reticulum upon Hepatitis B virus genome insertion	ONCOGENE			English	Article						cyclin A; hepatitis B virus; hepatocellular carcinoma; oncogenic transformation	HUMAN HEPATOCELLULAR-CARCINOMA; HEPATOMA-CELL LINE; S-PHASE; DNA INTEGRATION; TRANSACTIVATOR MHBS(T); MEVALONATE KINASE; TRANSGENIC MICE; EXPRESSION; GENE; TRANSFORMATION	Cyclins are major cell cycle regulators which role in malignant transformation remains controversial. In this report we describe a new mechanism of cyclin oncogenic activation. We demonstrate that an altered form of cyclin A2 (S2A) which N-terminal part is replaced by the hepatitis B virus envelope protein transforms normal rat kidney cells and cooperates with ras to transform rat embryo fibroblasts. In contrast, neither the viral moiety, nor a full length or N-terminally deleted cyclin A2 show these oncogenic properties. S2A oncogenicity arises from its binding to cyclin dependent kinases, since mutation in the MRAIL sequence abolishes transformation and correlates with an abnormal cellular localization in the endoplasmic reticulum membrane. Together, these results implicate modification in the cellular distribution of a cell cycle regulator as a mechanism of virally-induced transformation.	Necker Inst, INSERM, U370, F-75015 Paris, France; Necker Hosp, Liver Unit, F-75015 Paris, France; San Francisco State Univ, Dept Biol, San Francisco, CA 94132 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; California State University System; San Francisco State University	Brechot, C (corresponding author), Necker Inst, INSERM, U370, 156 Rue Vangirard, F-75015 Paris, France.		Berasain, Carmen/E-4139-2016	Berasain, Carmen/0000-0001-7075-2476				ASH JF, 1977, P NATL ACAD SCI USA, V74, P5584, DOI 10.1073/pnas.74.12.5584; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; Bresnahan WA, 1996, CELL GROWTH DIFFER, V7, P1283; BUCHOU T, 1993, ONCOGENE, V8, P1765; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2970, DOI 10.1073/pnas.87.8.2970; Caselmann WH, 1996, ADV VIRUS RES, V47, P253, DOI 10.1016/S0065-3527(08)60737-X; CASTRO A, 1994, BIOCHEM BIOPH RES CO, V201, P1072, DOI 10.1006/bbrc.1994.1814; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; DavidPfeuty T, 1996, ONCOGENE, V13, P1447; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GRAEF E, 1994, ONCOGENE, V9, P81; GRAEF E, 1995, VIROLOGY, V208, P696, DOI 10.1006/viro.1995.1201; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Henkler F, 1996, J VIRAL HEPATITIS, V3, P109, DOI 10.1111/j.1365-2893.1996.tb00001.x; Hildt E, 1996, SEMIN VIROL, V7, P333, DOI 10.1006/smvy.1996.0041; HILDT E, 1993, ONCOGENE, V8, P3359; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; LEBAER J, 1997, GENE DEV, V11, P847; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LOVEC H, 1994, ONCOGENE, V9, P323; Luber B, 1996, ONCOGENE, V12, P1597; MACKAY D, 1993, FEBS LETT, V336, P549, DOI 10.1016/0014-5793(93)80874-T; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.3.CO;2-N; Masuda A, 1996, ONCOGENE, V12, P2081; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MEYER M, 1992, EMBO J, V11, P2991, DOI 10.1002/j.1460-2075.1992.tb05369.x; Mumberg D, 1996, ONCOGENE, V13, P2493; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pineau P, 1996, J VIROL, V70, P7280, DOI 10.1128/JVI.70.10.7280-7284.1996; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROGLER CE, 1992, SEMIN LIVER DIS, V12, P265, DOI 10.1055/s-2007-1007398; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STUART RA, 1993, J BIOL CHEM, V268, P4050; THOMAS L, 1992, J BIOL CHEM, V267, P6183; Verges M, 1997, BIOCHEM BIOPH RES CO, V230, P49, DOI 10.1006/bbrc.1996.5851; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WOODMAN PG, 1993, MOL BIOL CELL, V4, P541, DOI 10.1091/mbc.4.5.541; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; Zerfass K, 1996, J VIROL, V70, P2637, DOI 10.1128/JVI.70.4.2637-2642.1996; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZHANG XK, 1992, BIOCHEM BIOPH RES CO, V188, P344, DOI 10.1016/0006-291X(92)92391-A; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	68	40	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1277	1288		10.1038/sj.onc.1201893	http://dx.doi.org/10.1038/sj.onc.1201893			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546429				2022-12-17	WOS:000072422000006
J	McCracken, S; Kim, CS; Xu, Y; Minden, M; Miyamoto, NG				McCracken, S; Kim, CS; Xu, Y; Minden, M; Miyamoto, NG			An alternative pathway for expression of p56(lck) from type I promoter transcripts in colon carcinoma	ONCOGENE			English	Article						lck; colon cancer; transcription	T-CELL DEVELOPMENT; PP60C-SRC PROTEIN-KINASE; THYMOCYTE DEVELOPMENT; LCK TRANSCRIPTS; GENE-EXPRESSION; HMG DOMAIN; BINDING; ACTIVATION; RECEPTOR; P56LCK	The lymphoid-specific protein tyrosine kinase, p56(lck) which is essential for both T cell development and function, is aberrantly expressed in colon and small lung carcinoma lines, In this paper, we demonstrate p56(lck) is also expressed in colon tumour biopsies due predominantly or exclusively to the use of the lck type I promoter, In T leukaemia lines, the lck type I promoter requires binding sites for both Ets- and Myb-related transcription factors, In contrast, in colon tumour lines the activation of the lck type I promoter requires the Ets but not the Myb binding site, In these lines, a consensus binding site for HMG-related transcription factors, AACAAAG, is required for efficient lck type I promoter activity, Sox-4 is a candidate transcription factor for binding and activating the lck type I promoter in colon carcinoma cells. Go-expression of Ets-1 and Sox-4, but neither protein alone, was sufficient to activate the lck type I promoter in HeLa cells which do not normally express lck transcripts, These results suggest that aberrant expression of p56(lck) from the lck type I promoter in colon carcinoma arises from transcriptional activation mediated by Ets-and HMG-related transcription factors.	UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DIV CELLULAR & MOL BIOL,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; PRINCESS MARGARET HOSP,AMGEN RES INST,TORONTO,ON M5G 2M9,CANADA; BERLEX BIOSCI,DEPT IMMUNOL,RICHMOND,CA 94804	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre								ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CLEVERS HC, 1993, IMMUNOL TODAY, V14, P591, DOI 10.1016/0167-5699(93)90198-T; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GROETTRUP M, 1993, IMMUNOL TODAY, V14, P610, DOI 10.1016/0167-5699(93)90201-U; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; LEIDEN JM, 1994, CURR OPIN IMMUNOL, V6, P231, DOI 10.1016/0952-7915(94)90096-5; LEUNG S, 1993, ONCOGENE, V8, P989; LEUNG S, 1991, J CELL PHYSIOL, V148, P344, DOI 10.1002/jcp.1041480304; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; PARK JS, 1993, ONCOGENE, V8, P2627; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TOMITA N, 1992, CANCER RES, V52, P6840; TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840	34	40	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2929	2937		10.1038/sj.onc.1201474	http://dx.doi.org/10.1038/sj.onc.1201474			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416836				2022-12-17	WOS:A1997YK37700005
J	Mishra, L; Tully, RE; Monga, SPS; Yu, P; Cai, T; Makalowski, W; Mezey, E; Pavan, WJ; Mishra, B				Mishra, L; Tully, RE; Monga, SPS; Yu, P; Cai, T; Makalowski, W; Mezey, E; Pavan, WJ; Mishra, B			Praja1, a novel gene encoding a RING-H2 motif in mouse development	ONCOGENE			English	Article						Praja1 gene; PRAJA1 protein; RING-H2 domain; molecular cloning; liver development; chromosome localization; explant cultures	ZINC-FINGER; PROTEIN; DOMAIN; FAMILY; GRANIN	As part of a cloning strategy to identify genes involved in early mouse liver development we have isolated Praja1, a gene with similar sequences to the Drosophila melanogaster gene goliath (gl) which is involved in the fate of mesodermal cells ultimately forming gut musculatures, fat body, and the heart, Praja1 is a 2.1 kb gene encoding a putative 396 amino acid ORF and includes a COOH-terminal RING-H2 domain, Using the Jackson Laboratory BSS panel, we have localized Praja1 on chromosome X at 36 cM, which may be a candidate gene for mouse sla (sex linked sideroblastic anemia), near the X inactivation center gene, Xist, Northern blot analysis demonstrated three transcripts (3.1, 2.6 and 2.1 kb) in mRNA from adult mouse tissues brain, liver, and kidney as well as in mRNA from developing mouse embryos (days 7, 11, 15 and 17 post coitus, p.c.). In vitro transcription/translation yielded a product with an M-r of 59 kD, Immunohistochemical staining of in vitro liver explant cultures using a heterologous antibody against praja1 demonstrated cytoplasmic staining of cuboidal cells that have hepatocyte morphology and organization, The presence of the RING-H2 domain, a proline-rich region at the COOH-end, and regions rich in acidic amino acids, leads to the hypothesis that the Praja1 product is possibly involved in mediating protein-protein interactions, possibly as part of a protein sorting or transport pathway, This is strengthened by the similarity of Praja1 to rat Neurodap1, whose product has been shown to localize to the endoplasmic reticulum and golgi in brain.	NATL HUMAN GENOME RES INST, LAB GENET DIS RES, CLIN GENE THERAPY BRANCH, NIH, BETHESDA, MD USA; NATL CTR BIOTECHNOL INFORMAT, NIH, BETHESDA, MD USA; JOHNS HOPKINS SCH MED, BALTIMORE, MD USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; Johns Hopkins University; Johns Hopkins Medicine	Mishra, L (corresponding author), VET ADM MED CTR, LAB DEV MOL BIOL, WASHINGTON, DC 20422 USA.		Makalowski, Wojciech/I-2843-2016; Mezey, Eva/A-8105-2008	Mezey, Eva/0000-0002-5907-4691; Pavan, William/0000-0001-8281-5120; Mishra, Lopa/0000-0002-6850-0808; Cai, Tao/0000-0002-2877-8637; Makalowski, Wojciech/0000-0003-2303-9541; Monga, Satdarshan/0000-0002-8437-3378				BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BOUCHARD ML, 1993, GENE, V125, P205, DOI 10.1016/0378-1119(93)90330-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FALCONER DS, 1962, GENET RES, V3, P248, DOI 10.1017/S0016672300035035; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; Herman GE, 1996, MAMM GENOME, V6, pS317; HOUSSAINT E, 1980, CELL DIFFER DEV, V9, P269, DOI 10.1016/0045-6039(80)90026-3; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Konat Gregory W., 1994, P37; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDOUARIN NM, 1975, MED BIOL, V53, P427; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAYAMA M, 1995, J NEUROSCI, V15, P5238; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHEVACH E, 1991, CURRENT PROTOCOLS IM; Silhavy T.J., 1984, EXPT GENE FUSIONS	23	40	41	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	1997	15	19					2361	2368		10.1038/sj.onc.1201405	http://dx.doi.org/10.1038/sj.onc.1201405			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393880				2022-12-17	WOS:A1997YE15700010
J	Hahn, SL; Criqui, P; Wasylyk, B				Hahn, SL; Criqui, P; Wasylyk, B			Modulation of ETS-1 transcriptional activity by huUBC9, a ubiquitin-conjugating enzyme	ONCOGENE			English	Article						transcription activation; ubiquitination; physical interactions; UBC9; Hus5; pointed domain	DNA-BINDING; GENE FAMILY; SECONDARY STRUCTURE; T-CELLS; KAPPA-B; C-JUN; V-ETS; PROTEIN; DOMAIN; PROMOTER	Ets transcription factors have Ets DNA binding domains, that have a winged helix-turn-helix structure. ETS-1, the founding member of the family, is regulated by the Ras and Ca2+ signaling pathways and is implicated in various physiological processes leading to cell growth, differentiation and apoptosis. We have identified ETS-1 interacting factors with a yeast two-hybrid screen. The majority of the positive clones turned out to encode the human homologue of the yeast ubiquitin-conjugating enzymes UBC9 and Hus5. In two different yeast assays, ETS-1 interacted with HuUBC9. In an in vitro GST 'pull-down' assay, ETS-1 and several other Ets family members complexed with huUBC9. Interestingly, in mammalian cells, coexpression of huUBC9 resulted in a substantial increase in the transcriptional activity of ETS-1. Coexpressed huUBC9 did not affect the ETS-1 protein level, and moreover, a point mutation at Cys93, an amino acid known to be essential for ubiquitination, did not abolish the stimulation of the ETS-1 transcriptional activity. Our results indicate that the modulation of ETS-1 activity by huUBC9 results from processes other than ubiquitination and ETS-1 stabilization.	ULP,INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				ALKHODAIRY F, 1995, J CELL SCI, V108, P475; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BELLACOSA A, 1994, J VIROL, V68, P2320, DOI 10.1128/JVI.68.4.2320-2330.1994; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COFFER P, 1994, ONCOGENE, V9, P911; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FISHER RJ, 1994, PROTEIN SCI, V3, P257; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HAHN SL, 1994, ONCOGENE, V9, P2499; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; LEPRINCE D, 1983, NATURE, V306, P295; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; RABAULT B, 1994, J BIOL CHEM, V269, P28143; ROSE MD, 1990, METHODS YEAST GENETI; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1997, IN PRESS RG LANDES C; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	48	40	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 18	1997	15	12					1489	1495		10.1038/sj.onc.1201301	http://dx.doi.org/10.1038/sj.onc.1201301			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333025				2022-12-17	WOS:A1997XW41100013
J	Sheikh, MS; Carrier, F; Johnson, AC; Ogdon, SE; Fornace, AJ				Sheikh, MS; Carrier, F; Johnson, AC; Ogdon, SE; Fornace, AJ			Identification of an additional p53-responsive site in the human epidermal growth factor receptor gene promotor	ONCOGENE			English	Article						p53; EGF-R promotor; transactivation	TUMOR-SUPPRESSOR PROTEIN; HUMAN BREAST-CARCINOMA; DNA-BINDING FUNCTION; WILD-TYPE P53; TRANSCRIPTIONAL REGULATION; INDUCED APOPTOSIS; CELLS; EXPRESSION; RADIATION; ACTIVATION	Exogenously introduced wild-type and mutant p53 have recently been reported to enhance the human epidermal growth factor receptor (EGF-R) gene promoter activity in p53-deficient Saos2 osteosarcoma cells. A p53 binding site residing at position -265/-239 in the EGF-R proximal promoter has also been identified. We investigated the p53 regulation of EGF-R core promoter activity in human cell lines with varying endogenour p53 status. Wild-type and mutant p53(Ala143) enhanced the EGF-R core promotor activity in cells that were either p53-deficient or contained wild-type or mutant endogenous p53. Upon further characterization of the various deletion fragments of the EGF-R promoter, we identified a wild-type p53 responsive 62 bp region residing at position -167/-105. The -167/-105 segment was responsive only to wild-type p53 but not to mutant p53(Ala143) Or p53(His273). The -167/-105 segment of the EGF-R promotor contains one perfect and several imperfect consensus p53-binding half sites; indeed in gel shift experiments the 62 bp -167/-105 segment as well as the oligonucleotides corresponding to two p53 consensus half-sites within the 62 bp fragment, exhibited binding to p53-containing protein complexes. Thus, we have identified an additional wild-type p53 responsive site in the human EGF-R promoter. This site containing consensus p53-binding sequences resides at position -167/-105 and is proximal to recently identified p53 binding element located at position -265/-239 in the EGF-R promotor.	NCI, MOL BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sheikh, MS (corresponding author), NCI, MOL PHARMACOL LAB, NIH, BETHESDA, MD 20892 USA.		Carrier, France/C-3063-2008; Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Carrier, France/0000-0002-5517-5284				ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ARMSTRONG DK, 1994, CANCER RES, V54, P5280; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FINLAY C, 1993, NAT GENET, V4, P42; FISCELLA M, 1994, ONCOGENE, V9, P3249; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Hollander M. C., 1995, DNA REPAIR MECH IMPA, P221; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; JOHNSON GL, 1994, SCIENCE, V266, P1719; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYASHITA T, 1995, CELL, V80, P293; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANTON JB, 1986, CANCER RES, V46, P4701; SCHMIDTULLRICH RK, 1994, INT J RADIAT ONCOL, V29, P813, DOI 10.1016/0360-3016(94)90570-3; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; STOSCHECK CM, 1986, CANCER RES, V46, P1030; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WARMUTH I, 1994, CANCER RES, V54, P374; WEINMANN R, 1992, P NATL ACAD SCI USA, V89, P12028; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHAN QM, 1994, ONCOGENE, V9, P3743	56	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	1997	15	9					1095	1101		10.1038/sj.onc.1201264	http://dx.doi.org/10.1038/sj.onc.1201264			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285564				2022-12-17	WOS:A1997XT16100011
J	Fitz, LJ; Morris, JC; Towler, P; Long, A; Burgess, P; Greco, R; Wang, J; Gassaway, R; Nickbarg, E; Kovacic, S; Ciarletta, A; Giannotti, J; Finnerty, H; Zollner, R; Beier, DR; Leak, LV; Turner, KJ; Wood, CR				Fitz, LJ; Morris, JC; Towler, P; Long, A; Burgess, P; Greco, R; Wang, J; Gassaway, R; Nickbarg, E; Kovacic, S; Ciarletta, A; Giannotti, J; Finnerty, H; Zollner, R; Beier, DR; Leak, LV; Turner, KJ; Wood, CR			Characterization of murine Flt4 ligand VEGF-C	ONCOGENE			English	Article						Flt41; Flt4 ligand; VEGF-C; BIAcore	LYMPHATIC ENDOTHELIUM; GENE	Flt4 is a receptor protein tyrosine kinase that is expressed in the adult lymphatic endothelium and high endothelial venules. We have used a BIAcore assay to identify rodent and human cell conditioned media containing the ligand of Flt4 (Flt4-L). Receptor-based affinity chromatography was used to purify this growth factor, followed by amino acid sequencing and molecular cloning of the murine cDNA, the orthologue of human vascular endothelial growth factor-C and vascular endothelial growth factor related protein. The murine flt4-L gene was localized to chromosome 8 and demonstrated to be widely expressed. Flt4-L was found to have a hydrophobic signal sequence and a pro-peptidelike sequence that is removed to generate the mature N-terminus. In addition, the C-terminal region of Flt4-L has four repeats of a cysteine-rich motif that is presumably also proteolytically processed to generate the 21 000 M-r polypeptide subunit of the Flt4-L homodimer. Recombinant Flt4-L activated Flt4 as judged by induction of tyrosyl phosphorylation, and induced mitogenesis in vitro of lymphatic endothelial cells.	GENET INST INC,CAMBRIDGE,MA 02140; BRIGHAM & WOMENS HOSP,DIV GENET,BOSTON,MA 02115; HOWARD UNIV,COLL MED,DEPT ANAT,WASHINGTON,DC 20059	Harvard University; Brigham & Women's Hospital; Howard University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029028] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000951] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG00951] Funding Source: Medline; NICHD NIH HHS [HD 29028] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEIER DR, 1993, MAMM GENOME, V4, P627, DOI 10.1007/BF00360898; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; FAN YS, 1992, CYTOGENET CELL GENET, V60, P29, DOI 10.1159/000133288; FINNERTY H, 1993, ONCOGENE, V8, P2293; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; LEAK LV, 1994, IN VITRO CELL DEV-AN, V30A, P512, DOI 10.1007/BF02631324; LEAK LV, 1993, ANAT RECORD, V236, P641, DOI 10.1002/ar.1092360408; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; MANLEY DF, 1991, MAMM GENOME, V4, P303; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; [No title captured]	13	40	46	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					613	618		10.1038/sj.onc.1201191	http://dx.doi.org/10.1038/sj.onc.1201191			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247316				2022-12-17	WOS:A1997XN25500014
J	Zheng, GX; Teumer, J; Colmenares, C; Richmond, C; Stavnezer, E				Zheng, GX; Teumer, J; Colmenares, C; Richmond, C; Stavnezer, E			Identification of a core functional and structural domain of the v-Ski oncoprotein responsible for both transformation and myogenesis	ONCOGENE			English	Article						oncogene; v-Ski; mutagenesis; proteolysis	CDNA CLONES; ONCOGENE; GENE; PROTEINS; CELLS; DNA; ACTIVATION; SEQUENCE; VECTORS; VIRUSES	The v-ski oncogene promotes cellular transformation and myogenic differentiation. In quail embryo fibroblasts the two properties are displayed simultaneously and terminal muscle differentiation occurs only among cells already transformed by v-ski. To understand how the two phenotypes are derived from a single gene, we have undertaken to identify functionally important regions in v-ski and to test whether these regions can promote one phenotype without the other. We have generated both random and targeted mutations in v-ski and evaluated the effects of these mutations on expression, intracellular location, transformation, and myogenesis. Among a total of 26 mutants analysed, we have not found complete separation of the myogenic and transforming properties. Mutations in the region of v-Ski encoded by exon 1 of c-ski frequently abolish both its transformation and muscle differentiation activities, whereas mutations outside of this region are always tolerated. When expressed in cells from a minigene containing only the exon 1 sequence, the protein displays the transforming and myogenic activities similar to v-Ski. These results argue that the amino acid sequence encoded by exon 1 contains the core functional domain of the oncoprotein. To determine whether this functional domain has a structural counterpart, we have fragmented the v-Ski protein by limited proteolysis and found a single proteolytically stable domain spanning the entire exon 1-encoded region. Physical studies of the polypeptide encoded by exon 1 confirms that it folds into a compact, globular protein. The finding that both the transforming and myogenic properties of v-ski are inseparable by mutation and are contained in a single domain suggests that they are derived from the same function.	CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106; ORGANOGENESIS INC,CANTON,MA; CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195; UNIV CINCINNATI,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH	Case Western Reserve University; Cleveland Clinic Foundation; University System of Ohio; University of Cincinnati					NCI NIH HHS [CA43600] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043600] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; BOTFIELD MC, 1992, BIOCHEMISTRY-US, V31, P5841, DOI 10.1021/bi00140a020; BOYER PL, 1993, ONCOGENE, V8, P457; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P552; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; COLMENARES C, 1990, CANC BIOL, V1, P383; ENGERT JC, 1995, NUCLEIC ACIDS RES, V23, P2988, DOI 10.1093/nar/23.15.2988; FOSTER DA, 1983, J VIROL, V48, P744, DOI 10.1128/JVI.48.3.744-751.1983; GRIMES HL, 1992, NUCLEIC ACIDS RES, V20, P1511, DOI 10.1093/nar/20.7.1511; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Institutionen B Universitet Uppsala S, 1963, PURE APPL CHEM, V233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; NAGASE T, 1993, J BIOL CHEM, V268, P13710; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P40446	29	40	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					459	471		10.1038/sj.onc.1201205	http://dx.doi.org/10.1038/sj.onc.1201205			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242383				2022-12-17	WOS:A1997XM23800011
J	Zou, TT; Lei, JY; Shi, YQ; Yin, J; Wang, S; Souza, RF; Kong, D; Shimada, Y; Smolinski, KN; Greenwald, BD; Abraham, JM; Harpaz, N; Meltzer, SJ				Zou, TT; Lei, JY; Shi, YQ; Yin, J; Wang, S; Souza, RF; Kong, D; Shimada, Y; Smolinski, KN; Greenwald, BD; Abraham, JM; Harpaz, N; Meltzer, SJ			FHIT gene alterations in esophageal cancer and ulcerative colitis (UC)	ONCOGENE			English	Article						FHIT; mutation; tumor suppressor gene; esophageal carcinoma; UC-associated neoplasms (UCANs)	CELL LUNG-CANCER; SHORT ARM; ADENOMATOUS POLYPOSIS; FRAGILE SITES; CHROMOSOME-3; HETEROZYGOSITY; CARCINOMA; DYSPLASIAS; TUMORS; LINES	FHIT (fragile histidine triad gene), a candidate tumor suppressor gene, was recently identified and cloned at chromosome 3p14.2. Alterations of this gene have been reported in a number of primary human tumors, including colorectal, esophageal, gastric and lung carcinomas, However, some reports have found no abnormalities in this gene, We investigated a total of 63 primary esophageal tumors, nine esophageal cancer cell lines and 17 ulcerative colitis-associated neoplasms (UCANs) for alterations of FHIT, In 13 esophageal tumors, we employed overlapping reverse transcriptase-PCRs (RT-PCRs) to amplify and sequence the complete open reading frame of FHIT, One of 13 primary esophageal tumors analysed by RT-PCR expressed no detectable FHIT transcript; the remaining 12 expressed normal-sized transcripts with wild-type open reading frame sequences, Tn an additional 50 esophageal tumors, the polymorphic microsatellite loci D3S1300 and D3S1313 mere used to evaluate loss of heterozygosity (LOH) at 3p14.2. Eleven of these 50 tumors shelved LOH at one or both loci, Tn all these 11 tumors, genomic PCR and direct sequencing of FHIT exons 5-9 was performed, This analysis revealed that none of these 11 primary esophageal tumors contained any alterations in the FHIT open reading frame or adjacent intron sequences, Finally, among 17 UCANs, the in vitro synthesized protein (IVSP) assay detected no truncated protein products, nor were there any abnormalities in size or DNA sequence of FHIT RT-PCR products, However, in six of nine esophageal carcinoma cell lines, no FHIT RT-PCR product was detectable using either of the overlapping primer sets, Genomic PCR and direct sequencing of exons 5-9, also performed in these nine cell Lines, revealed wild-type sequence in eight cell lines; however, one cell Line contained no exon 5 PCR product, This cell Line also lacked detectable FHIT transcript. These data suggest that the open reading frame of FHIT is not important in the development or progression of most primary esophageal carcinomas or UCANs, although lack of expression of the FHIT transcript may be common in esophageal cancer-derived cell Lines, The possibility of an additional tumor suppressor gene at chromosome 3p14.2 remains to be evaluated.	UNIV MARYLAND,SCH MED,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21201; VET AFFAIRS HOSP,BALTIMORE,MD 21201; KYOTO UNIV,DEPT SURG 1,KYOTO 606,JAPAN; MT SINAI MED CTR,DEPT PATHOL,NEW YORK,NY 10029	University System of Maryland; University of Maryland Baltimore; Kyoto University; Icahn School of Medicine at Mount Sinai			Harpaz, Noam/L-3411-2017	Harpaz, Noam/0000-0003-4923-2200				BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; Druck T, 1997, CANCER RES, V57, P504; Kastury K, 1996, CANCER RES, V56, P978; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LISITSYN NA, 1994, COLD SPRING HARB SYM, V59, P585, DOI 10.1101/SQB.1994.059.01.066; Mao L, 1996, CANCER RES, V56, P5128; MELTZER SJ, 1990, CANCER RES, V50, P3627; MOOIBROEK H, 1987, CANCER GENET CYTOGEN, V27, P361, DOI 10.1016/0165-4608(87)90020-3; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SUTHERLAND GR, 1991, GENET ANAL-BIOMOL E, V8, P161, DOI 10.1016/1050-3862(91)90056-W; TARMIN L, 1995, CANCER RES, V55, P2035; Thiagalingam S, 1996, CANCER RES, V56, P2936; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; Yanagisawa K, 1996, CANCER RES, V56, P5579; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZEIGER MA, 1995, GENE CHROMOSOME CANC, V13, P151, DOI 10.1002/gcc.2870130303; ZEIGER MA, 1994, GENE CHROMOSOME CANC, V11, P15, DOI 10.1002/gcc.2870110104; ZHOU XL, 1995, GENE CHROMOSOME CANC, V13, P285, DOI 10.1002/gcc.2870130409	23	40	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					101	105		10.1038/sj.onc.1201169	http://dx.doi.org/10.1038/sj.onc.1201169			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233782				2022-12-17	WOS:A1997XH58600011
J	Fichter, M; Hinrichs, R; Eissner, G; Scheffer, B; Classen, S; Ueffing, M				Fichter, M; Hinrichs, R; Eissner, G; Scheffer, B; Classen, S; Ueffing, M			Expression of CD44 isoforms in neuroblastoma cells is regulated by PI 3-kinase and protein kinase C	ONCOGENE			English	Article						CD44; PI 3-kinase; PKC	PHOSPHATIDYLINOSITOL 3-KINASE; TUMOR PROGRESSION; VARIANT ISOFORMS; GROWTH-FACTOR; RAS GENE; METASTASIS; DIFFERENTIATION; HYALURONATE; ACTIVATION; BINDING	With respect to a potential role for CD44 in neuronal tumors, we investigated the regulation of variant CD44 exon containing isoforms (CD44V) in the human neuroblastoma cell line SR-N-SH in response to treatment with differentiation-inducing and mitogenic factors, While the standard form of CD44 was expressed at high levels in both treated and untreated cells, variant isoforms were strongly upregulated in response to treatment with 12-O-tetradecanoyl phorbol-13-acetate (TPA), insulinlike growth factor-1 (IGF-1) and platelet-derived growth factor (PDGF) as shown by RT-PCR and immunofluorescence. One of the CD44 isoforms contains sequences encoded by variant exon v6 (CD44V6), which was originally described as a metastasis-associated antigen, Using specific inhibitors, me explored the signal transduction pathways involved in the expression of variant CD44, GF-109203X, a specific inhibitor of protein kinase C effectively blocked TPA- and IGF-1-upregulated expression of CD44v6, Wortmannin, a specific inhibitor of phosphoinositide 3-kinase (PI 3-kinase) partly reduced IGF-1 and PDGF induced CD44v6 expression, The induction of CD44V by TPA, IGF-1 or PDGF was correlated with an increased cellular binding to hyaluronic acid, a major counter receptor for CD44. The increased binding caused by TPA or IGF-1 could specifically be blocked by the above inhibitors, Thus, PKC and PI 3-kinase are likely to transduce growth factor induced signals that upregulate specific CD44 splice variants.	GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT GMBH, NATL RES CTR ENVIRONM & HLTH, D-81377 MUNICH, GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich								ALLEN RW, 1987, J BIOL CHEM, V262, P649; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1978, CANCER RES, V38, P3751; BLOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTIANSEN H, 1995, EUR J CANCER, V31A, P541, DOI 10.1016/0959-8049(95)00030-M; CHRISTIANSEN H, 1995, KLIN PADIATR, V207, P219, DOI 10.1055/s-2008-1046543; COMBARET V, 1995, EUR J CANCER, V31A, P545, DOI 10.1016/0959-8049(95)00027-G; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DOUGHERTY GJ, 1994, J BIOL CHEM, V269, P9074; GROSS N, 1995, EUR J CANCER, V31A, P471, DOI 10.1016/0959-8049(95)00029-I; GROSS N, 1994, CANCER RES, V54, P4238; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HOFMANN M, 1993, CANCER RES, V53, P1516; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JAMAL HH, 1994, ONCOGENE, V9, P417; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KODAKI T, 1995, BIOCHEM SOC T, V23, pS195, DOI 10.1042/bst023195s; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; PAHLMAN S, 1992, CELL GROWTH DIFFER, V3, P783; PONTA H, 1994, INVAS METAST, V14, P82; REBER S, 1990, INT J CANCER, V46, P919, DOI 10.1002/ijc.2910460528; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SADEE W, 1987, CANCER RES, V47, P5207; Sherman L, 1996, CURR TOP MICROBIOL, V213, P249; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; SHTIVELMAN E, 1991, MOL CELL BIOL, V11, P5446, DOI 10.1128/MCB.11.11.5446; Sleeman JP, 1996, CANCER RES, V56, P3134; SOZERI O, 1992, ONCOGENE, V7, P2259; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STAUDER R, 1995, BLOOD, V85, P2885, DOI 10.1182/blood.V85.10.2885.bloodjournal85102885; STAUDER R, 1995, IMMUNOLOGIST, V3, P78; TANABE KK, 1994, CRIT REV ONCOGENESIS, V5, P201, DOI 10.1615/CritRevOncog.v5.i2-3.50; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TERPE HJ, 1994, HISTOCHEMISTRY, V101, P79, DOI 10.1007/BF00269353; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; UEFFING M, 1996, 3 HON KONG INT CANC, P80; VANWEERING DHJ, 1993, PCR METH APPL, V3, P100; WIELENGA VJM, 1993, CANCER RES, V53, P4754; Zhu D, 1996, ONCOGENE, V12, P2309	49	40	40	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	1997	14	23					2817	2824		10.1038/sj.onc.1201127	http://dx.doi.org/10.1038/sj.onc.1201127			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190898				2022-12-17	WOS:A1997XD64300010
J	Nelson, DA; Ludlow, JW				Nelson, DA; Ludlow, JW			Characterization of the mitotic phase pRb-directed protein phosphatase activity	ONCOGENE			English	Article						serine/threonine phosphatase; PP1; cell cycle; retinoblastoma protein; dephosphorylation	SERINE THREONINE PHOSPHATASES; CELL-CYCLE REGULATION; SV40 LARGE-T; RETINOBLASTOMA PROTEIN; CATALYTIC SUBUNIT; SKELETAL-MUSCLE; GENE-PRODUCT; PHOSPHOPROTEIN PHOSPHATASE; TYPE-1; PHOSPHORYLATION	We have previously reported on the M-phase specific dephosphorylation of pRb and identified a type 1 serine/ threonine protein phosphatase (PPI) as the enzyme mediating pRb dephosphorylation. In this report, we have characterized the pRb-directed phosphatase activity found in mitotic cells with respect to dose dependence and demonstrate that the pRb isoform conversion detected in vitro mirrors the pRb isoform conversion which occurs during mitosis of intact cells. Cell fractionation and PP1 catalytic subunit isolation studies support the notion that the pRb-directed phosphatase activity involves subpopulations of PP1 catalytic subunits. Coprecipitation studies revealed that PPI can form a complex with hypophosphorylated pRb which was converted from the hyperphosphorylated form in mitotic cell extracts. Taken together with data from previous reports in the literature, a model for the regulation of PP1 activity towards pRb during mitotic exit is proposed.	UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM & BIOPHYS, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, CTR CANC, DIV DEV THERAPEUT, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester				Nelson, Deirdre/0000-0001-5527-2570	NATIONAL CANCER INSTITUTE [R29CA056940, P30CA011198] Funding Source: NIH RePORTER; NCI NIH HHS [CA11198, CA56940] Funding Source: Medline; NIDCR NIH HHS [DE07202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; BARKER HM, 1990, GENOMICS, V7, P159, DOI 10.1016/0888-7543(90)90536-4; BEGUM N, 1995, J BIOL CHEM, V270, P709, DOI 10.1074/jbc.270.2.709; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRAUTIGAN DL, 1982, BIOCHEMISTRY-US, V21, P1977, DOI 10.1021/bi00538a001; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; GURLEY LR, 1975, J BIOL CHEM, V250, P3936; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KHATRA BS, 1986, J BIOL CHEM, V261, P8944; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; RADULESCU RT, 1995, MED HYPOTHESES, V44, P28, DOI 10.1016/0306-9877(95)90297-X; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VILLAMORUZZI E, 1992, FEBS LETT, V304, P211, DOI 10.1016/0014-5793(92)80621-M; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WOODFORD TA, 1986, J BIOL CHEM, V261, P4669; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x	37	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2407	2415		10.1038/sj.onc.1201081	http://dx.doi.org/10.1038/sj.onc.1201081			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188855				2022-12-17	WOS:A1997WZ68000004
J	Clarke, AR; Howard, LA; Harrison, DJ; Winton, DJ				Clarke, AR; Howard, LA; Harrison, DJ; Winton, DJ			p53, mutation frequency and apoptosis in the murine small intestine	ONCOGENE			English	Article						p53; mutation; apoptosis	RADIATION-INDUCED APOPTOSIS; P53-DEFICIENT MICE; TRANSGENIC MICE; GERMLINE MUTATIONS; MYC TRANSGENE; MOUSE; CARCINOGENESIS; ABNORMALITIES; ACCUMULATION; EPITHELIUM	Normal function of the p53 gene is integral to the cellular response to genotoxic stress, One prediction arising from this is that p53 deficiency results in an increased mutation frequency, However, limited evidence has been produced in support of this idea, In order to further investigate the in vivo role of p53 in surveillance against mutation, and particularly to address the significance of p53-dependent apoptosis, we scored mutation frequency at the Dlb-1 locus within cells of the intestinal epithelium of animals which were wild type, heterozygous or null for p53 and heterozygous (a/b) at the Dlb-1 locus, Using this assay we have shown that loss of a p53-dependent apoptotic pathway is associated with the detectable acquisition of mutations, but only at high levels of DNA damage, These results question the significance of the immediate 'wave' of p53-dependent apoptosis seen in this tissue, particularly as there was a delayed p53-independent apoptotic pathway, We conclude that loss of p53 function only becomes relevant to the in vivo acquisition of mutations and thus tumorigenesis in certain circumstances.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge	Clarke, AR (corresponding author), UNIV EDINBURGH,CRC LABS,DEPT PATHOL,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.		Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BLYTH K, 1995, ONCOGENE, V10, P1717; BOUFFLER SD, 1995, CANCER RES, V55, P3883; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELSON A, 1995, ONCOGENE, V11, P181; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; LEE JM, 1994, ONCOGENE, V9, P3731; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MERRITT AJ, 1994, CANCER RES, V54, P614; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NISHINO H, 1995, ONCOGENE, V11, P263; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; PURDIE CA, 1994, ONCOGENE, V9, P603; Rafferty JA, 1996, ONCOGENE, V12, P693; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P611, DOI 10.1111/j.1365-2184.1982.tb01067.x; WYLLIE AH, 1994, COLD SPRING HARB SYM, V59, P403, DOI 10.1101/SQB.1994.059.01.045; YUAN JL, 1995, CARCINOGENESIS, V16, P2295, DOI 10.1093/carcin/16.10.2295	29	40	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2015	2018		10.1038/sj.onc.1201040	http://dx.doi.org/10.1038/sj.onc.1201040			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160880				2022-12-17	WOS:A1997WW80900002
J	DombroskyFerlan, PM; Corey, SJ				DombroskyFerlan, PM; Corey, SJ			Yeast two-hybrid in vivo association of the Src kinase Lyn with the protooncogene product Cbl but not with the p85 subunit of PI 3-kinase	ONCOGENE			English	Article						Lyn; Cbl; PI 3-kinase; yeast two-hybrid	PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; SH3 DOMAIN; C-CBL; SIGNAL-TRANSDUCTION; 2-HYBRID SYSTEM; PROTEIN; BINDING; CELLS; ACTIVATION	Ligand binding of multi-chain antigen receptors and hematopoietin/cytokine receptors results in rapid activation of protein tyrosine kinase (PTK)-dependent signalling molecules such as phosphatidylinositol 3-kinase (PI 3-kinase). Go-precipitation studies have shown that Src-related PTK, such as Lyn, associates with the p85 regulatory subunit of PI 3-kinase via SH2 and SH3 domain binding with their cognate ligands, More recent studies have shown that the proto-oncogene product Cbl co-precipitates with p85 following engagement of cytokine and antigen receptors, As opposed to in vitro co-precipitation studies, the yeast two-hybrid screen reveals lit vivo protein-protein interactions, Using the yeast two-hybrid screen, we demonstrate an in vivo association of Lyn's SH3 and SH2 domains with the proline-rich domain of Cbl, Lyn's SH3 and SH2 domains do not interact with p85 in the yeast two-hybrid screen, as would be predicted from glutathione-S-transferase (GST) fusion protein pull-down or co-immunoprecipitation studies from whole cell lysates, However, the SH3 domain of p85 interacts with the proline-rich domain of Cbl, When yeast were transformed with catalytic Lyn, an interaction between p85's SH2 domain and Cbl occurred, From the data, we propose the following three step process of PI 3-kinase activation: (1) complexes of Lyn-Cbl and Cbl-p85 exist without ligand stimulation, (2) upon ligand binding, Lyn becomes active and phosphorylates Cbl, and (3) Cbl's tyrosine phosphorylated residue serves as a docking site for the SH2 domains of p85 - thereby stabilizing the complex and activating PI 3-kinase, The yeast two-hybrid system can be used to dissect the precise mechanisms of in vivo protein-protein interactions, including those between phosphotyrosine and SH2-containing proteins.	CHILDRENS HOSP PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15213 USA; CHILDRENS HOSP PITTSBURGH, DEPT PHARMACOL, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, SCH MED, PITTSBURGH, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BARTEL P, 1993, BIOTECHNIQUES, V14, P920; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; COREY SJ, 1994, LEUKEMIA, V8, P1914; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DREBIN JA, 1995, ONCOGENE, V10, P477; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GOLD MR, 1992, J IMMUNOL, V148, P2012; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	26	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	1997	14	17					2019	2024		10.1038/sj.onc.1201031	http://dx.doi.org/10.1038/sj.onc.1201031			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160881	Bronze			2022-12-17	WOS:A1997WW80900003
J	Avigad, S; Barel, D; Blau, O; Malka, A; Zoldan, M; Mor, C; Fogel, M; Cohen, IJ; Stark, B; Goshen, Y; Stein, J; Zaizov, R				Avigad, S; Barel, D; Blau, O; Malka, A; Zoldan, M; Mor, C; Fogel, M; Cohen, IJ; Stark, B; Goshen, Y; Stein, J; Zaizov, R			A novel germ line p53 mutation in intron 6 in diverse childhood malignancies	ONCOGENE			English	Article						p53; germ line mutation; intron; childhood malignancies	TUMOR-SUPPRESSOR GENE; CANCER-PRONE FAMILY; SPLICING MUTATION; FRAUMENI-SYNDROME; PATIENT; EXPRESSION; PREVALENCE; NEOPLASMS; CHILDREN; PROTEIN	Screening for p53 mutations in exons 5 to 8 in 124 pediatric malignancies identified 18 abnormal shifts using single strand conformation polymorphism: 12 were missense mutations and in 6, no mutation was detected in the exon or in the splice donor acceptor sequences. Sequencing was then performed in the adjacent introns, revealing a G to A base substitution at 39 base pairs upstream to exon 7. This mutation was identified in the germ line of five of the patients, and also in the father of one, whose parents mere available. For comparison, of the 184 normal controls similarly screened, only one had this mutation (P=0.036). Positive staining of p53 protein was observed in three of the paraffin embedded tissues that were available: brain tumor, rhabdomyosarcoma, and lymphocytes from a normal lymph node from the rhabdomyosarcoma patient. All tumors with the identified intron mutation were Li-Fraumeni syndrome tumors. Sequencing of all exons including splice sites was performed and revealed no mutation. We suggest that this mutation in intron 6 of the p53 gene stabilizes the mild type p53 protein, resulting in its abnormal accumulation. Mutations in the noncoding region of p53 should be further studied.	RABIN MED CTR,DEPT PATHOL,PETAH TIQWA,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL; KAPLAN MED CTR,DIV IMMUNOL,REHOVOT,ISRAEL	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Kaplan Medical Center	Avigad, S (corresponding author), FELSENSTEIN RES CTR,SCHNEIDER CHILDRENS MED CTR ISRAEL,PETAH TIQWA,ISRAEL.		Cohen, Ian/H-3358-2013					BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BIRCH JM, 1994, CANCER RES, V54, P1298; BRUGIERES L, 1993, CANCER RES, V53, P452; FELIX CA, 1993, ONCOGENE, V8, P1203; FOGEL M, 1990, DIFFERENTIATION, V45, P242, DOI 10.1111/j.1432-0436.1990.tb00478.x; FREBOURG T, 1995, AM J HUM GENET, V56, P608; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; GREENBLATT MS, 1994, CANCER RES, V54, P4855; JOLLY KW, 1994, ONCOGENE, V9, P97; LAW JC, 1991, CANCER RES, V51, P6358; LI FP, 1988, CANCER RES, V48, P5358; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MALKINSON AM, 1994, MOL CARCINOGEN, V10, P61, DOI 10.1002/mc.2940100202; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PELLER S, 1995, DNA CELL BIOL, V14, P98; PLUMMER SJ, 1994, ONCOGENE, V9, P3273; Sambrook J, 1989, MOL CLONING LAB MANU; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRAUSS EA, 1995, CANCER RES, V55, P3237; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839	25	40	44	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1541	1545		10.1038/sj.onc.1200990	http://dx.doi.org/10.1038/sj.onc.1200990			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129144				2022-12-17	WOS:A1997WQ54800004
J	Judware, R; Culp, LA				Judware, R; Culp, LA			Concomitant down-regulation of expression of integrin subunits by N-myc in human neuroblastoma cells: Differential regulation of alpha 2, alpha 3 and beta 1	ONCOGENE			English	Article						integrin; neuroblastoma; N-myc	GENE-EXPRESSION; SIGNAL-TRANSDUCTION; TUMOR PROGRESSION; DNA-BINDING; PROTEIN; ADHESION; MAX; AMPLIFICATION; SEQUENCE; ONCOGENE	Amplification and over-expression of the N-myc oncogene is associated with the progression of neuroblastoma in children and in a nude mouse model system. Neuroblastoma cell lines with widely different levels of N-myc illustrate an inverse relationship between N-myc over-expression and reduced expression of several integrin extracellular matrix receptors. Transfection and over-expression of N-myc in a neuroblastoma cell line not normally expressing the protein resulted in cells that grew loosely associated with tissue culture plates; this correlated with reduced levels of beta 1 integrin subunit. Evidence is now presented that alpha 2 and alpha 3 integrin subunit levels are also reduced in cells that over-express N-myc, with virtually no association of alpha 2 or alpha 3 subunits with beta 1. Consequently, maturation of the beta 1 subunit and cell surface expression of the integrins are greatly reduced in N-myc-transfected cells. A small amount of beta 1 protein does get to the cell surface, however, suggesting that an as yet unidentified alpha subunit is produced by the N-myc-expressing cells. Finally, the observed reductions in integrin protein levels are reflections of greatly reduced levels of integrin alpha 2 and alpha 3 mRNAs, as well as a smaller reduction in beta 1 mRNA (80%, 94% and 52%, respectively). Post-transcriptional mechanisms modulating beta 1 integrin levels are also operative. These results indicate that over-expression of N-myc from a transfected gene in a neuroblastoma cell line that does not normally produce the protein generates cell lines with many of the characteristics of naturally metastatic cells with amplified N-myc genes. Modulation of N-myc and integrin expressions may play a significant role in progression of human neuroblastoma.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,CLEVELAND,OH 44106	Case Western Reserve University					NCI NIH HHS [IF32CA65068] Funding Source: Medline; NINDS NIH HHS [NS17139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA065068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKESON R, 1990, MOL CELL BIOL, V10, P2012, DOI 10.1128/MCB.10.5.2012; ALBELDA SM, 1993, LAB INVEST, V68, P4; ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ATCHLEY WR, 1995, P NATL ACAD SCI USA, V92, P10217, DOI 10.1073/pnas.92.22.10217; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BEDNARCZYK JL, 1992, J BIOL CHEM, V267, P25274; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BERNSTEIN ML, 1992, J CLIN ONCOL, V10, P323, DOI 10.1200/JCO.1992.10.2.323; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BORDOW SB, 1994, CANCER RES, V54, P5036; BRODEUR GM, 1991, BIOCH MOL ASPECTS SE, P251; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; CHENG NC, 1995, ONCOGENE, V10, P291; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DALTON SL, 1995, MOL BIOL CELL, V6, P1781, DOI 10.1091/mbc.6.12.1781; ELLMEIER W, 1992, EMBO J, V11, P2563, DOI 10.1002/j.1460-2075.1992.tb05321.x; Ellmeier W, 1996, GENOMICS, V32, P155, DOI 10.1006/geno.1996.0095; FLICKINGER KS, 1994, EXP CELL RES, V213, P156, DOI 10.1006/excr.1994.1185; HEINO J, 1989, J BIOL CHEM, V264, P380; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JUDWARE R, 1995, CLIN EXP METASTAS, V13, P123, DOI 10.1007/BF00133617; Judware R, 1995, ONCOGENE, V11, P2599; KLEINMAN NR, 1994, BRIT J CANCER, V69, P670, DOI 10.1038/bjc.1994.129; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA A, 1993, ONCOGENE, V8, P1093; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; Norris MD, 1996, NEW ENGL J MED, V334, P231, DOI 10.1056/NEJM199601253340405; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; Sambrook J, 1989, MOL CLONING LAB MANU; SCHMIDT ML, 1984, CELL GROWTH DIFFER, V5, P171; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SPRINGER TA, 1984, J EXP MED, V160, P1901, DOI 10.1084/jem.160.6.1901; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0; ZUTTER MM, 1994, J BIOL CHEM, V269, P463	50	40	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1341	1350		10.1038/sj.onc.1200955	http://dx.doi.org/10.1038/sj.onc.1200955			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178894				2022-12-17	WOS:A1997WP10900009
J	Asimakopoulos, FA; Hinshelwood, S; Gilbert, JGR; Delibrias, CC; Gottgens, B; Fearon, DT; Green, AR				Asimakopoulos, FA; Hinshelwood, S; Gilbert, JGR; Delibrias, CC; Gottgens, B; Fearon, DT; Green, AR			The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera	ONCOGENE			English	Article						polycythemia vera; SHP-1; myeloproliferative disorders	ERYTHROPOIETIN RECEPTOR GENE; PROTEIN-TYROSINE-PHOSPHATASE; VIRUS GP55 GLYCOPROTEIN; ERYTHROID PROGENITORS; MYELOPROLIFERATIVE DISORDERS; MOLECULAR ANALYSIS; DNA METHYLATION; MOTH-EATEN; C-KIT; INTERLEUKIN-3	Polycythemia vera (PV) is an acquired clonal disorder characterized by increased production of mature red cells and growth of erythroid colonies in the absence of erythropoietin. Mutation of the erythropoietin receptor has been demonstrated to cause familial polycythemia, but no mutations have been found in PV, Moreover, both erythroid and myeloid progenitors from patients with PV have been reported to be hypersensitive to a number of different growth factors. Attention has therefore focused on post-receptor signal transduction pathways, The SHP-1 gene is an especially attractive candidate gene. Firstly, SHP-1 binds to and negatively regulates signalling from the erythropoietin receptor and is likely to regulate other cytokine receptors in a similar manner, Secondly, absence of SHP-1 protein in the motheaten mouse is accompanied by increased sensitivity of hematopoietic progenitors to a number of cytokines including erythropoietin, Thirdly, familial or sporadic polycythemia in man may result from mutations of the SHP-1 binding domain of the erythropoietin receptor. We have therefore searched for mutations of the SHP-1 gene in genomic DNA from patients with PV. In this disease the majority of peripheral blood lymphocytes are not part of the malignant clone and a variable proportion of myeloid cells may arise from normal progenitors. We have therefore chosen to study DNA from purified peripheral blood granulocytes obtained from nine women in whom the granulocytes were clonally derived. Southern analysis was used to show that the gene was not rearranged and densitometry confirmed the presence of two copies of the gene in each DNA sample. Sequencing of the entire coding region and all splice junctions revealed no mutations, Hematopoietic transcription factor binding sites in the SHP-1 promoter region were intact and the methylation status of the two SHP-1 promoters in PV patients was identical to that in three normal controls, Finally, we showed that levels of SHP-1 protein in granulocytes from patients was similar to those from normal controls. These results demonstrate that the SHP-1 gene is structurally and transcriptionally intact in patients with PV.	UNIV CAMBRIDGE, CTR MRC, DEPT HAEMATOL, CAMBRIDGE CB2 2QH, ENGLAND; UNIV CAMBRIDGE, DEPT MED, WELLCOME TRUST IMMUNOL UNIT, MRC CTR, CAMBRIDGE CB2 2QH, ENGLAND	University of Cambridge; MRC Laboratory Molecular Biology; University of Cambridge				Gottgens, Berthold/0000-0001-6302-5705; Gilbert, James/0000-0001-8079-3159; Green, Anthony/0000-0002-9795-0218	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASIMAKOPOULOS FA, 1994, BLOOD, V84, P3086, DOI 10.1182/blood.V84.9.3086.bloodjournal8493086; Asimakopoulos FA, 1996, BLOOD, V88, P2690, DOI 10.1182/blood.V88.7.2690.bloodjournal8872690; BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; CHRETIEN S, 1994, BLOOD, V83, P1813; Cooper D. N., 1993, HUMAN GENE MUTATION; CORREA PN, 1994, BLOOD, V83, P99; DAI CH, 1994, BRIT J HAEMATOL, V86, P12, DOI 10.1111/j.1365-2141.1994.tb03246.x; DAI CH, 1992, BLOOD, V80, P891; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; DUDLEY JM, 1990, BRIT J HAEMATOL, V75, P188, DOI 10.1111/j.1365-2141.1990.tb02647.x; EAVES CJ, 1978, BLOOD, V52, P1196; ERIDANI S, 1987, BRIT J HAEMATOL, V67, P387, DOI 10.1111/j.1365-2141.1987.tb06158.x; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; FISHER E, 1994, NAT GENET, V7, P5, DOI 10.1038/ng0594-5; GILLILAND DG, 1991, P NATL ACAD SCI USA, V88, P6848, DOI 10.1073/pnas.88.15.6848; Green AR, 1996, LANCET, V347, P844, DOI 10.1016/S0140-6736(96)91338-0; GREEN MC, 1975, J HERED, V66, P250, DOI 10.1093/oxfordjournals.jhered.a108625; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HESS G, 1994, BRIT J HAEMATOL, V88, P794, DOI 10.1111/j.1365-2141.1994.tb05119.x; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOBAYASHI S, 1993, BRIT J HAEMATOL, V83, P539, DOI 10.1111/j.1365-2141.1993.tb04688.x; KRANTZ SB, 1991, BLOOD, V77, P419; LeCouedic JP, 1996, BLOOD, V87, P1502, DOI 10.1182/blood.V87.4.1502.bloodjournal8741502; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; PRCHAL JF, 1974, NEW ENGL J MED, V290, P1382; PRCHAL JT, 1994, BLOOD, V83, P1; SHULTZ LD, 1984, AM J PATHOL, V116, P179; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SOKOL L, 1995, BLOOD, V86, P15, DOI 10.1182/blood.V86.1.15.bloodjournal86115; SOKOL L, 1994, EXP HEMATOL, V22, P447; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VANZANT G, 1989, EXP HEMATOL, V17, P81; WARD JC, 1992, EXP HEMATOL, V20, P371; WASSERMAN LR, 1995, POLYCYTHEMIA VERA MY; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WINKELMANN JC, 1995, BLOOD, V85, P179, DOI 10.1182/blood.V85.1.179.bloodjournal851179; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; ZON LI, 1992, MOL CELL BIOL, V12, P2949, DOI 10.1128/MCB.12.7.2949	48	40	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	1997	14	10					1215	1222		10.1038/sj.onc.1200942	http://dx.doi.org/10.1038/sj.onc.1200942			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121771				2022-12-17	WOS:A1997WM78200011
J	Sonoda, H; Nishida, K; Yoshioka, T; Ohtani, M; Sugita, K				Sonoda, H; Nishida, K; Yoshioka, T; Ohtani, M; Sugita, K			Oxamflatin: A novel compound which reverses malignant phenotype to normal one via induction of JunD	ONCOGENE			English	Article						transformation; inhibitor; ras; junD; fibronectin	RAS-ONCOGENE; NIH3T3 CELLS; TRANSFORMATION; GENE; EXPRESSION; CANCER; DNA	In the course of screening for inhibitors of tumorigenic phenotype of K-ras-transformed NIH3T3 cells (DT cells), we found a novel compound, oxamflatin, an aromatic sulfonamide hydroxamate derivative, which induces flat phenotype in these cells and suppresses their anchorage-independent growth. In contrast to DT cells, in v-raf-transformed NIH3T3 cells, no change in their morphology and no specific inhibition of their anchorage-independent growth was observed, Interestingly, oxamflatin was effective to NIH3T3 cells transformed by constitutively activated mutant of MEK, indicating the possibility that oncogene-induced morphological change is not necessarily induced by common signaling pathway such as MAP kinase cascade, In oxamflatin-treated DT cells, the expression of transcription factor junD was highly augmented, resulting in trans-activation of fibronectin gene by junD via cyclic AMP responsive element in its promoter, This behavior of junD was confirmed to correlate well with partial blocking of malignant phenotype in DT cells, Thus, oxamflatin can be categorized as the first reagent which induces genes whose products can interfere with oncogene-dependent transformation.			Sonoda, H (corresponding author), SHIONOGI & CO LTD, SHIONOGI RES LABS, FUKUSHIMA KU, SAGISU 5-12-4, OSAKA 553, JAPAN.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BOS JL, 1989, CANCER RES, V49, P4682; CASINI A, 1994, ALCOHOL ALCOHOLISM, V29, P303; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COX AD, 1994, J BIOL CHEM, V269, P19203; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; FUTAMURA M, 1995, ONCOGENE, V10, P1119; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HYNES RO, 1990, FIBRONECTINS, pCH12; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KIM JH, 1994, J BIOL CHEM, V269, P13740; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KREISBERG JI, 1994, KIDNEY INT, V46, P105, DOI 10.1038/ki.1994.249; KUO ML, 1995, BIOCHEM BIOPH RES CO, V212, P767, DOI 10.1006/bbrc.1995.2035; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; NAKAJIMA T, 1992, MOL CELL BIOL, V12, P2837, DOI 10.1128/MCB.12.6.2837; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OHTANI M, 1993, Patent No. 9312075; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SREBROW A, 1993, FEBS LETT, V327, P25, DOI 10.1016/0014-5793(93)81031-T; SUGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P379, DOI 10.1016/S0006-291X(05)80156-1; SUGITA K, 1992, CANCER RES, V52, P168; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; YOSHIDA H, 1992, JPN J CANCER RES, V83, P324, DOI 10.1111/j.1349-7006.1992.tb00109.x; ZHAO JF, 1995, ONCOGENE, V11, P161	35	40	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					143	149						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700540				2022-12-17	WOS:A1996UX31900016
J	Wang, HY; Lian, ZR; Lerch, MM; Chen, ZJ; Xie, WF; Ullrich, A				Wang, HY; Lian, ZR; Lerch, MM; Chen, ZJ; Xie, WF; Ullrich, A			Characterization of PCP-2, a novel receptor protein tyrosine phosphatase of the MAM domain family	ONCOGENE			English	Article						protein tyrosine phosphatase; cell contact; signal transduction; cell adhesion signals	CELL-ADHESION MOLECULE; NERVOUS-SYSTEM; IMMUNOGLOBULIN SUPERFAMILY; CHROMOSOMAL LOCALIZATION; EXTRACELLULAR REGION; HUMAN-PLACENTA; PURIFICATION; EXPRESSION; DROSOPHILA; CLEAVAGE	DNA sequences encoding a novel member of the receptor protein tyrosine phosphatase (R-PTP) family, termed PCP-2, were identified in a human pancreatic adenocarcinoma cDNA library, Human PCP-2 cDNA predicts a protein of 1430 amino acids with a calculated M(r) of 160 kDa, The predicted PCP-2 enzyme consists of a 740 amino acid extracellular region, a single transmembrane domain, and a 666 amino acid intracellular portion, The extracellular sequence contains a MAM (meprin/A5/PTP mu) domain, an immunoglobulin-like domain and four fibronectin type m-like repeats, suggesting that it is a member of the PTP kappa and PTP mu subfamily, The intracellular region contains two tandemly-repeated protein tyrosine phosphatase domains, Northern blot analyses revealed a single transcript of 5.5 kilobases, which is expressed at different levels in many human tissues except spleen and placenta, Upon transfection of PCP-2 cDNA into human embryonic kidney fibroblast 293 cells, a protein with an apparent M(r) of 180 000 was detected by immunoblot analysis, This size was reduced to the predicted M(r) upon treatment with endoglycosidase F, indicating that PCP-2 is glycosylated and, hence, expressed at the cell surface, A potential role of PCP-2 in cell-cell recognition and adhesion is supported by its co-localization with cell adhesion molecules, such as beta-catenin and E-cadherin, at sites of cell-cell contact.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Lerch, Markus M./E-2206-2016; Wang, Hongyang/B-1340-2010; Lian, Zhaorui/AAW-2379-2020	Lerch, Markus M./0000-0002-9643-8263; 				ALEXANDER D R, 1990, New Biologist, V2, P1049; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; BLASCHUK OW, 1990, J MOL BIOL, V211, P679, DOI 10.1016/0022-2836(90)90065-T; Brady-Kalnay S, 1994, ADV PROTEIN PHOSPHAT, V8, P241; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8345; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; Grumet M, 1991, Curr Opin Neurobiol, V1, P370, DOI 10.1016/0959-4388(91)90055-C; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LAU KHW, 1993, CRIT REV ONCOGENESIS, V4, P451; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; MIZUNO K, 1994, FEBS LETT, V355, P223, DOI 10.1016/0014-5793(94)01188-5; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; PALLEN CJ, 1991, BIOCHEM J, V276, P315, DOI 10.1042/bj2760315; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1994, MOL CELL BIOL, V14, P1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONDEREGGER P, 1992, J CELL BIOL, V119, P1387, DOI 10.1083/jcb.119.6.1387; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TONKS NK, 1988, J BIOL CHEM, V263, P6722; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4	42	40	51	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2555	2562						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700514				2022-12-17	WOS:A1996UW48700009
J	Duprez, E; Lillehaug, JR; Naoe, T; Lanotte, M				Duprez, E; Lillehaug, JR; Naoe, T; Lanotte, M			cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha	ONCOGENE			English	Article						acute promyelocytic leukemia; cAMP; NB4; retinoic acid; nuclear receptors; transcription factors; nuclear bodies; differentiation	ACID RECEPTOR-ALPHA; RETINOIC ACID; TRANSLOCATION; PROTEIN; EXTRACTION; ISOFORMS; GENES; LINE	We analysed the expression of retinoid receptors and PML in relation to the morphology of PML-containing nuclear bodies (PODs) in maturation sensitive (NB4) and resistant subclones (NB4-R1 and R2) of the promyelocytic NB4 cell line, The basal level of RAR alpha, RXR alpha and PML mRNA and protein were roughly the same in the three cell lines, While NB4 and NB4-R1 cells express comparable amounts of PML-RAR alpha mRNA and 120 kDa protein, NB4-R2 cells despite normal mRNA levels the 120 kDa protein was not detectable, In NB4-R2 cells however, two novel PML-related entities of 65 kDa and 85 kDa were detected with a anti-PML antibody, in addition to the two PML isoforms of 78 and 97 kDa found in any NB4 cells, Despite the 120 kDa PML-RAR alpha defect, NB4-R2 cells show micropunctuated nuclear bodies typical of APL cells, Contrasting with NS4 cells, neither NB4-R1 cells which express PML-RAR alpha, nor NB4-R2 cells lacking the 120 kDa PML-RAR alpha reorganised nuclear bodies (PODs) in response to RA, Importantly, in RA-primed NB4-R1 cells, a secondary event triggered by cAMP restored PODs, concomitant to maturation, This indicates that the recovery of nuclear bodies in APL is dissociated from the early action of RA in cell maturation, Finally, the key finding of this work is that cAMP signalling ultimately determines the recovery of nuclear bodies associated to cell maturation.	HOP ST LOUIS,CTR G HAYEN,INSERM U301,F-75010 PARIS,FRANCE; NAGOYA UNIV,SCH MED,NAGOYA,AICHI 466,JAPAN	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Nagoya University			Naoe, Tomoki/I-1888-2012; duprez, estelle a/R-2357-2016					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRUEL A, 1995, LEUKEMIA, V9, P1173; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; CHEN Z, 1990, LEUKEMIA, V5, P288; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DIGMAN JDL, 1983, NUCLEIC ACIDS RES, V11, P1495; Duprez E, 1996, ONCOGENE, V12, P2443; DUPREZ E, 1992, LEUKEMIA, V6, P1281; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; KAKIZUKA A, 1991, CELL, V66, P653; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LANOTTE M, 1991, BLOOD, V77, P1082; LAVAU C, 1994, LEUKEMIA, V8, P1615; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Maniatis T, 1989, DECONTAMINATION DILU; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; OLSON IL, 1982, CANCER RES, V42, P3922; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROWLEY JD, 1977, LANCET, V1, P549; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; ZHU J, 1995, LEUKEMIA, V9, P302	38	40	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2451	2459						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649787				2022-12-17	WOS:A1996UQ22000024
J	Lane, DP; Stephen, CW; Midgley, CA; Sparks, A; Hupp, TR; Daniels, DA; Greaves, R; Reid, A; Vojtesek, B; Picksley, SM				Lane, DP; Stephen, CW; Midgley, CA; Sparks, A; Hupp, TR; Daniels, DA; Greaves, R; Reid, A; Vojtesek, B; Picksley, SM			Epitope analysis of the murine p53 tumour suppressor protein	ONCOGENE			English	Article						murine p53; p53; monoclonal antibodies; epitopes	TRANSFORMATION-ASSOCIATED PROTEIN; PHAGE-DISPLAYED PEPTIDES; MONOCLONAL-ANTIBODY; DISCONTINUOUS EPITOPES; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; EXPRESSION; ANTIGEN; MIMICKING; PRODUCE	The identification and characterisation of the p53 tumour suppressor has relied extensively on the use of immunological reagents, To facilitate further characterisation of the murine p53 protein (Mp53), and its interaction with other proteins, we have characterised the antigenic sites of Mp53 in fine detail, Using an overlapping Mp53 peptide library we report the identification by Pepscan ELISA of the epitopes of nine antibodies, We have also used this technique to determine whether corresponding epitopes were present in a human p53 (Hp53) peptide library, This comparison was extended to include polyclonal sera of mice immunized with either Mp53 or Hp53, to compare the overall range of antigenic sites, The range of antigenic sites identified by polyclonal sera is very similar, although the N-terminus of Mp53 is clearly not an immunodominant region, in contrast to the N-terminus of Hp53, However, the N-terminus of Mp53 is immunogenic in rabbits as demonstrated by the Pepscan ELISA of CM5 serum (a rabbit anti-Mp53 serum used in analysing p53 expression in mice), Since, very few new antigenic sites were identified in either Mp53 or Hp53, new approaches will have to be employed to identify novel immunological reagents against human and murine p53.	NINEWELLS HOSP & MED SCH, DEPT PATHOL, DUNDEE DD1 9SY, SCOTLAND; STANFORD UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; MASARYK MEM CANC INST, CR-65653 BRNO, CZECH REPUBLIC	University of Dundee; Stanford University; Masaryk Memorial Cancer Institute	Lane, DP (corresponding author), UNIV DUNDEE, DEPT BIOCHEM, CELL TRANSFORMAT RES GRP, CRC, DUNDEE DD1 4HN, SCOTLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTEK J, 1993, J PATHOL, V169, P27, DOI 10.1002/path.1711690106; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; FELICI F, 1993, GENE, V128, P21, DOI 10.1016/0378-1119(93)90148-V; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREAVES R, 1988, THESIS U LONDON; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; LANE DP, 1994, MOL BIOL REP, V19, P23, DOI 10.1007/BF00987319; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEGROS Y, 1994, ONCOGENE, V9, P3689; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; PEZZELLA F, 1994, J CLIN PATHOL, V47, P592, DOI 10.1136/jcp.47.7.592; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; VOJTESEK B, 1995, ONCOGENE, V10, P389; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	32	40	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2461	2466						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649788				2022-12-17	WOS:A1996UQ22000025
J	Shridhar, V; Rivard, S; Shridhar, R; Mullins, C; Bostick, L; Sakr, W; Grignon, D; Miller, OJ; Smith, DI				Shridhar, V; Rivard, S; Shridhar, R; Mullins, C; Bostick, L; Sakr, W; Grignon, D; Miller, OJ; Smith, DI			A gene from human chromosomal band 3p21.1 encodes a highly conserved arginine-rich protein and is mutated in renal cell carcinomas	ONCOGENE			English	Article						arginine-rich protein; cryptic repeat; 3p21.1 gene; mutations; renal cell carcinoma	LUNG-CANCER; REGION 3P21; SEQUENCE; AMINOACYLASE-1; IDENTIFICATION; POLYMERASE; EXPRESSION	We have identified a gene, called ARP for Arginine-rich protein, in human chromosomal band 3p21. It is approximately 600 Kb telomeric to the ACY1 locus (Miller et al., 1989) and encodes a previously unidentified 234 amino acid long, highly basic protein. This gene is highly conserved at the DNA and RNA level. It is found in all species including hamster, rat, mouse, bovine and yeast. We have detected a point mutation (ATG(50) to AGG) or deletion of ATG(50) in 10 of 21 sporadic renal cell carcinomas. The mutable region is in an imperfect trinucleotide repeat in the coding region which is nonpolymorphic among 50 normal individuals examined. The point mutation (ATG(50) to AGG) or deletion of codon 50 removes a methionine and increases the stretch of arginines encoded by the AGG repeats in the ARP gene.	WAYNE STATE UNIV,SCH MED,DEPT MOLEC BIOL & GENET,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48201	Wayne State University; Wayne State University; Wayne State University					NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZUMA T, 1989, J BIOL CHEM, V264, P16748; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; DALY MC, 1993, AM J HUM GENET, V53, pA290; DRABKIN H, 1990, GENOMICS, V8, P435, DOI 10.1016/0888-7543(90)90029-T; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; ERLANDSSON R, 1990, ONCOGENE, V5, P1207; GEMMILL RM, 1991, GENOMICS, V11, P93, DOI 10.1016/0888-7543(91)90105-N; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GINZINGER DG, 1992, AM J HUM GENET, V50, P826; GOSTOUT B, 1993, AM J HUM GENET, V52, P1182; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MEARS JG, 1978, P NATL ACAD SCI USA, V75, P1222, DOI 10.1073/pnas.75.3.1222; MILLER YE, 1990, GENOMICS, V8, P149, DOI 10.1016/0888-7543(90)90237-O; MILLER YE, 1989, J CLIN INVEST, V83, P2120, DOI 10.1172/JCI114125; NAGEL S, 1995, CANCER RES, V55, P2866; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RALL LB, 1987, METHOD ENZYMOL, V146, P239; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SHRIDHAR V, 1994, SOMAT CELL MOLEC GEN, V20, P255, DOI 10.1007/BF02254716; SLEDDENS HFBM, 1992, NUCLEIC ACIDS RES, V20, P1427; SMITH DI, 1989, AM J HUM GENET, V45, P443; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; WEBER JL, 1993, HUM MOL GENET, V2, P2866; YAMAKAWA K, 1993, AM J HUM GENET, V53, pA390; Young A., 1991, FOCUS, V13, P137	32	40	45	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1931	1939						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649854				2022-12-17	WOS:A1996UK49800012
J	Perez, JL; Jing, SQ; Wong, TW				Perez, JL; Jing, SQ; Wong, TW			Identification of two isoforms of the Cak receptor kinase that are coexpressed in breast tumor cell lines	ONCOGENE			English	Article						receptor kinases; cell adhesion; receptor isoforms	GROWTH-FACTOR; FACTOR-VIII; TYROSINE; SURFACE; DNA	The Cak receptor kinase is a member of a novel family of receptors that are characterized by the unique structure of the ectodomains. We have identified a new isoform of Cak that differs from the original isolate by the deletion of 37 amino acids in the cytoplasmic juxtamembrane sequence. Analysis of the genomic sequence suggests that the two isoforms arise by exon skipping. The isoform-specific insert contains the motif NPXY, which was previously shown to be involved in diverse signaling function in a number of receptors. By RNase protection analyses, we found that the long isoform, Cak I is expressed at three- to sevenfold the abundance of the short isoform (Cak II). By Western blotting, Cak I receptor was found to be expressed in mouse embryos and in adult brain. Cak II protein was not detected in mouse embryos or adult tissues, but is abundantly expressed in some breast tumor cell lines. The expression profile of Cak suggests that its primary function is likely to be in developmental regulation. The coexpression of the Cak isoforms in some epithelial cell lines suggests that heterodimer formation may be a key feature in the function of the rectpror	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; AMGEN INC,THOUSAND OAKS,CA 91320	Rutgers State University New Brunswick; Rutgers State University Medical Center; Amgen					NIGMS NIH HHS [1 F31 GM16363-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM016363] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVES R, 1995, ONCOGENE, V10, P610; BARBACID M, 1993, ONCOGENE, V8, P2033; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CREPARO A, 1995, J BIOL CHEM, V270, P15639; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KANE WH, 1988, BLOOD, V71, P539; KARN T, 1993, ONCOGENE, V8, P3277; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; LAI C, 1994, ONCOGENE, V8, P877; PEREZ JL, 1994, ONCOGENE, V9, P211; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; ZHOU S, 1995, J BIOL CHEM, V270, P14863	28	40	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1469	1477						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622863				2022-12-17	WOS:A1996UF07600011
J	Esteve, P; delPeso, L; Lacal, JC				Esteve, P; delPeso, L; Lacal, JC			Induction of apoptosis by rho in NIH 3T3 cells requires two complementary signals. Ceramides function as a progression factor for apoptosis	ONCOGENE			English	Article						rho; apoptosis; ceramides	GTP-BINDING PROTEIN; ADP-RIBOSYLTRANSFERASE; GROWTH-FACTORS; GENE-PRODUCT; VERO CELLS; DEATH; PROLIFERATION; FIBROBLASTS; INVOLVEMENT; EXPRESSION	We have previously reported that Pho genes, members of the ras superfamily, are tumorigenic when overexpressed in NIH 3T3 cells. As other known oncogenes, they also induce apoptosis after serum deprivation but not in the presence of growth factors. In the present study, we provide evidence that overexpression of the Aplysia Rho protein in NIH 3T3 cells induces the generation of phosphatidylcholine (PC)-derived second messengers as a result of activation of a PC-specific phospholipase D (PC-PLD) as previously reported for ras-transformed cells. In contrast, removal of serum in the Rho transfectants, but not in normal NTH 3T3 cells or cells transformed by the was oncogene, induced the production of ceramides as a result of activation of an sphingomyelinase (SMase). Furthermore, the rho-expressing cells underwent apoptosis in the presence of serum when exogenous ceramides were added, and this process was accelerated if cells were treated with exogenous SMase. Thus, Rho proteins act as an initiation signal that is necessary but not sufficient for the induction of apoptosis in NIH 3T3 cells. We propose here that induction of apoptosis in NM 3T3 cells requires two complementary signals: an initiation signal generated even in the presence of serum which 'primes' the cells, making them sensitive to a progression signal, triggered by serum removal, which we have identified as generation of ceramides.	CSIC, INST INVEST BIOMED, MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			del Peso, Luis/K-9391-2014; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	del Peso, Luis/0000-0003-4014-5688; Lacal, Juan Carlos/0000-0002-1908-2777				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ARENDS MJ, 1994, MOL BIOL HISTOPATHOL, P151; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BALLESTERO RP, 1991, SUPERFAMILY RAS RELA, P237; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; CARNERO A, 1994, ONCOGENE, V9, P1387; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HOFFMAN B, 1994, ONCOGENE, V9, P1807; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; JIMENEZ B, 1995, ONCOGENE, V10, P811; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK R, 1994, MOL CHEM NEUROPATHOL, V21, P287, DOI 10.1007/BF02815356; LACAL JC, 1994, ONCOL REP, V1, P677; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LANG P, 1992, J BIOL CHEM, V267, P11677; LINETTE GP, 1994, CURR OPIN CELL BIOL, V6, P809, DOI 10.1016/0955-0674(94)90049-3; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MORII N, 1992, J BIOL CHEM, V267, P20921; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PERONA R, 1993, ONCOGENE, V8, P1285; RIBEIRO JM, 1993, BIOCHEMISTRY-US, V32, P9129, DOI 10.1021/bi00086a018; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SELF AJ, 1993, ONCOGENE, V8, P655; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SUGAI M, 1992, P NATL ACAD SCI USA, V89, P8903, DOI 10.1073/pnas.89.19.8903; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8	58	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2657	2665						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545123				2022-12-17	WOS:A1995TP18800022
J	Gotoh, N; Muroya, K; Hattori, S; Nakamura, S; Chida, K; Shibuya, M				Gotoh, N; Muroya, K; Hattori, S; Nakamura, S; Chida, K; Shibuya, M			The SH2 domain of Shc suppresses EGF-induced mitogenesis in a dominant negative manner	ONCOGENE			English	Article						EGF receptor; Shc; SH2 domain; mitogenesis; Ras	EPIDERMAL GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; TYROSINE KINASE-ACTIVITY; TRANSFORMING ACTIVITY; SIGNAL TRANSDUCTION; FACTOR RECEPTOR; RAS; GRB2; PROTEIN; BINDING	Recently, we have shown that an EGF-R-mutant lacking the autophosphorylation sites phosphorylates She and retains mitogenic activity, In this report, we have shown that in these cells, in response to EGF, Ras is fully activated with formation of the tyrosine-phosphorylated Shc-Grb2-mSOS complex without the receptor. This pointed out the importance of She in EGF-induced Ras activation, To investigate the mechanism of tyrosine phosphorylation of She by EGF-R, we carried out in vitro kinase assays using immunoprecipitated EGF-R and bacterially-expressed She proteins as substrates, The EGF-R phosphorylated She, but not the She SH2 mutant, lacking binding ability for phosphotyrosine, This suggests that intact She SH2 is essential for the full-length She to become phosphorylated, probably by inducing a conformational change in She. Thus a She SH2 peptide may inhibit competitively She phosphorylation. We microinjected the She SH2 domain into NIH3T3 cells overexpressing the EGF-R. Microinjected She SH2 greatly suppressed EGF-induced DNA synthesis. But microinjection of neither the She SH2 mutant nor PLC-gamma 1 SH2 had any effect, This suppressing effect was rescued by comicroinjection of the full-length She, suggesting She SH2 specifically suppressed the She pathway. Thus we concluded She phosphorylation is crucial, whereas receptor autophosphorylation is dispensable, in EGF-induced mitogenesis.	UNIV TOKYO, INST MED SCI, DEPT GENET, MINATO KU, TOKYO 108, JAPAN; UNIV TOKYO, INST MED SCI, DEPT CANC CELL RES, MINATO KU, TOKYO 108, JAPAN; NATL INST NEUROSCI, DIV BIOCHEM & CELLULAR BIOL, KODAIRA, TOKYO 187, JAPAN	University of Tokyo; University of Tokyo; National Center for Neurology & Psychiatry - Japan								BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI NX, 1994, ONCOGENE, V9, P3457; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	40	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2525	2533						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545109				2022-12-17	WOS:A1995TP18800008
J	Judware, R; Culp, LA				Judware, R; Culp, LA			Over-expression of transfected N-myc oncogene in human SKNSH neuroblastoma cells down-regulates expression of beta 1 integrin subunit	ONCOGENE			English	Article						neuroblastoma; N-myc; integrin; NCAM; transfection	NEURO-BLASTOMA; SIGNAL TRANSDUCTION; GENE-EXPRESSION; ADHESION; MODULATION; ANTIGENS; CULTURE; MAX; HLA	Amplification of the N-myc oncogene is associated with progression of neuroblastoma in humans, Previous studies indicated that neuroblastoma cell lines which are amplified for the N-myc gene and over-express N-myc exhibit enhanced tumorigenic properties when injected into athymic nude mice, In addition, neuroblastoma cells which over-express N-myc (IMR32 cells) expressed little or no beta 1, alpha 2, or alpha 3 integrin subunits, as compared with cells which do not express N-myc (SKNSH cells), In order to probe the possible relationship between N-myc and beta 1 integrin gene expressions more directly, transfection experiments were performed in which an N-myc cDNA (on the episomal expression vector pREP4; high-level constitutive expression is driven by an RSV-LTR promoter) was introduced into SKNSH cells, Expression of N-myc produced significant morphological alterations in transfected cells; one subpopulation of cells remained spread on tissue culture substrata, while a second subpopulation became rounded and grew as multi-cellular aggregates, Spread (attached) cells expressed low levels of N-myc and high levels of beta 1 integrin, while rounded (loose) cells expressed relatively high levels of N-myc and low levels of beta 1 integrin, Maintenance of transfected cells in higher concentrations of selective agent produced a higher proportion of loose cells, which expressed even greater amounts of N-myc and even less beta 1 integrin; a similar effect was observed in attached cells, Interestingly, loose cell populations expressed elevated levels of the neural cell adhesion molecule [NCAM]. The results presented here infer that N-myc regulates the expression of the beta 1 integrin and NCAM cell-surface receptors responsible for cell:extracellular matrix interaction and possibly cell:cell adhesion.			Judware, R (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.				NATIONAL CANCER INSTITUTE [F32CA065068, T32CA059366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017139] Funding Source: NIH RePORTER; NCI NIH HHS [1F32CA65068, CA59366] Funding Source: Medline; NINDS NIH HHS [NS17139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKESON R, 1990, MOL CELL BIOL, V10, P2012, DOI 10.1128/MCB.10.5.2012; ALBELDA SM, 1993, LAB INVEST, V68, P4; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BIEDLER JL, 1973, CANCER RES, V33, P2643; BRADYKALNAY SM, 1993, CLIN EXP METASTAS, V11, P313, DOI 10.1007/BF00058051; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; BRODEUR GM, 1991, BIOCH MOL ASPECTS SE, P251; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; COOPER MJ, 1990, CANCER RES, V50, P3694; FELTNER DE, 1989, J IMMUNOL, V143, P4292; FLICKINGER KS, 1994, EXP CELL RES, V213, P156, DOI 10.1006/excr.1994.1185; Goridis C, 1992, Semin Cell Biol, V3, P189; GROSS N, 1994, INT J CANCER, V59, P141, DOI 10.1002/ijc.2910590124; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JUDWARE R, 1995, CLIN EXP METASTAS, V13, P123, DOI 10.1007/BF00133617; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KLEINMAN NR, 1994, BRIT J CANCER, V69, P670, DOI 10.1038/bjc.1994.129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPSON LA, 1983, J IMMUNOL, V130, P2471; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MOENS CB, 1993, DEVELOPMENT, V119, P485; RASCHELLA G, 1994, CANCER RES, V54, P2251; RETTIG WJ, 1987, CANCER RES, V47, P1383; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	33	40	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2599	2607						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545117				2022-12-17	WOS:A1995TP18800016
J	Taylor, ICA; Roy, S; Varmus, HE				Taylor, ICA; Roy, S; Varmus, HE			Overexpression of the Sky receptor tyrosine kinase at the cell surface or in the cytoplasm results in ligand-independent activation	ONCOGENE			English	Article						Sky receptor tyrosine kinase; dimerization; isoforms	PROTEIN; ONCOGENE	Most receptor tyrosine kinases are activated by dimerization induced by their cognate ligands, Protein S, an abundant serum protein previously shown to be a potent anticoagulation factor, has been proposed to be a ligand for the Sky tyrosine kinase (Stitt et al., 1995), Here we show that Sky, when expressed to high levels, is tyrosine phosphorylated even in the absence of a ligand, Furthermore, a version of Sky (termed Sky Delta SS) engineered to be overexpressed in the cytoplasm and thus in a ligand-free environment, can function as a dimeric tyrosine kinase, Sky Delta SS can transform RatB1a fibroblasts and thus retains all the properties of the full-length Sky kinase, These data suggest that Sky, when overexpressed either at the cell surface or in the cytoplasm, is competent to form dimers even in the absence of its ligand. We also demonstrate that an isoform of Sky, originally reported as Brt and here termed Sky Isoform I, resides in the cytoplasm, Therefore, the activities of Sky Delta SS we describe may reflect those of the naturally occurring Isoform I.	NCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BIESECKER LG, 1993, P NATL ACAD SCI USA, V90, P7044, DOI 10.1073/pnas.90.15.7044; BIESECKER LG, 1995, ONCOGENE, V10, P2239; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; CROSIER PS, 1994, GROWTH FACTORS, V11, P125, DOI 10.3109/08977199409001054; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1994, MOL BASIS BLOOD DISE, P599; DAI W, 1994, ONCOGENE, V9, P975; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GRECO A, 1992, ONCOGENE, V7, P237; LAI C, 1994, ONCOGENE, V9, P2567; MARK MR, 1994, J BIOL CHEM, V269, P10720; MARU Y, 1990, ONCOGENE, V5, P445; OHASHI K, 1994, ONCOGENE, V9, P699; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TAYLOR ICA, 1995, J BIOL CHEM, V270, P6872, DOI 10.1074/jbc.270.12.6872; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x	21	40	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2619	2626						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545119				2022-12-17	WOS:A1995TP18800018
J	THOMAS, RS; TYMMS, MJ; SETH, A; SHANNON, MF; KOLA, I				THOMAS, RS; TYMMS, MJ; SETH, A; SHANNON, MF; KOLA, I			ETS1 TRANSACTIVATES THE HUMAN GM-CSF PROMOTER IN JURKAT T-CELLS STIMULATED WITH PMA AND IONOMYCIN	ONCOGENE			English	Article						GRANULOCYTE-MACROPHAGE; COLONY-STIMULATING FACTOR; GM-CSF; ETS1; ELF1; TRANSCRIPTION	LONG TERMINAL REPEAT; VIRUS TYPE-I; DNA-BINDING; LEUKEMIA-VIRUS; INFLAMMATORY RESPONSES; TRANSCRIPTION FACTORS; C-ETS-1 PROTEIN; GENE PROMOTER; ACTIVATION; EXPRESSION	Activation of T helper cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one such cytokine whose increased expression results partly from increases in transcription. Cis-acting elements with NF kappa B, AP-1 and ETS-like motifs have been identified in the promoter region of the GM-CSF gene, which are important for transcriptional activity following PMA and ionomycin stimulation. A number of the ETS family of transcription factors are expressed in T cells, including ETS1 and ELF1. Here we describe the ability of these factors to interact with a site (GM5), located within the CLE0 element, -47 to -40 upstream of the GM-CSF transcription initiation site. Exogenous ETS1, but not ELF1, can transactivate GM-CSF, through the GM5 site, in a PMA/ionomycin dependent manner. Other unidentified ETS-like factors present in Jurkat cells are also capable of binding GM5. Mutation of the core ETS binding site from -GGAA- to -GGAT- prevents the binding of ETS-like factors with the exception of ETS1. The GM-CSF promoter, modified in this way to be ETS1 specific, is fully responsive to PMA/ionomycin induction, in addition to ETS1 transactivation in the presence of PMA and ionomycin. Together these data suggest that ETS1 may be involved in mediating the increased GM-CSF production associated with T cell activation.	MONASH UNIV,MONASH MED CTR,INST REPROD & DEV,MOLEC GENET & DEV GRP,MELBOURNE,VIC 3168,AUSTRALIA; NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702; INST MED & VET SCI,HANSON CTR CANC RES,DIV HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA	Monash University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Institute Medical & Veterinary Science Australia			Thomas, Ross/C-6434-2008; Kola, Ismail/C-5254-2013					ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ASCIONE R, 1992, INT J ONCOL, V1, P631; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRORSON KA, 1991, J IMMUNOL, V147, P3601; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; FISHER CI, 1991, J IMMUNOL, V6, P1743; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FISHER RJ, 1991, ONCOGENE, V6, P2249; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GITLIN SD, 1991, J VIROL, V65, P5513, DOI 10.1128/JVI.65.10.5513-5523.1991; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KOYANONAKAGAWA N, 1993, INT IMMUNOL, V5, P345, DOI 10.1093/intimm/5.4.345; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MIYAJIMA A, 1988, FASEB J, V2, P2462, DOI 10.1096/fasebj.2.9.2836253; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; NIMER SD, 1988, MOL CELL BIOL, V8, P1979, DOI 10.1128/MCB.8.5.1979; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; POGNONEC P, 1990, ONCOGENE, V5, P603; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAZANAJAONA D, 1992, CELL GROWTH DIFFER, V3, P299; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; SUGIMOTO K, 1990, INT IMMUNOL, V2, P787, DOI 10.1093/intimm/2.8.787; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452	54	40	40	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2135	2143						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478534				2022-12-17	WOS:A1995TF29700025
J	ROYERPOKORA, B; ROGERS, M; ZHU, TH; SCHNEIDER, S; LOOS, U; BOLITZ, U				ROYERPOKORA, B; ROGERS, M; ZHU, TH; SCHNEIDER, S; LOOS, U; BOLITZ, U			THE TTG-2/RBTN2 T-CELL ONCOGENE ENCODES 2 ALTERNATIVE TRANSCRIPTS FROM 2 PROMOTERS - THE DISTAL PROMOTER IS REMOVED BY MOST 11P13 TRANSLOCATIONS IN ACUTE T-CELL LEUKEMIAS (T-ALL)	ONCOGENE			English	Article						T-CELL ONCOGENE; ALTERNATIVE TRANSCRIPTS; DISRUPTION BY TRANSLOCATIONS	ACUTE LYMPHOBLASTIC-LEUKEMIA; BREAKPOINT CLUSTER REGION; CHROMOSOMAL TRANSLOCATIONS; T(11-14)(P13-Q11) TRANSLOCATION; TRANSGENIC MICE; GENE; PROTEIN; DOMAIN; MOTIF; LINE	The TTG-2 gene has been identified at the site of chromosomal translocations in acute T-cell leukemia's (T-ALL). These breakpoints map to a region between 2 and 30 kb upstream of TTG-2 in chromosome 11p13. To establish the role of these translocation breakpoints in the deregulation of TTG-2 in T-ALL we have determined the complete structure of this gene. Isolation of new TTG-2 cDNA clones from fetal liver identified an alternative transcript (TTG-2a) containing two new noncoding 5' exons, Analysis of exon/intron boundaries, identified 6 exons spread over 35 kb in 11p13. The gene encodes two alternative transcripts initiating from two promoters. TTG-2a, from promoter 1 (P1) and TTG-2b, from promoter 2 (P2) differ in the length of the 5' untranslated region, but encode the same protein. A high level of TTG-2a was present in fetal liver and spleen, whereas in adult kidney a low level of TTG-2a and a high level of TTG-2b was found. The transcription start site for TTG-2a was identified by RNase protection experiments and it displayed sequence homology to an initiator element (inr). P1 lacks a TATA box, but binding sites for SP1 and GATA-1 are present. This new genomic organisation revealed that all known chromosomal translocations map upstream of P2, removing P1 and putative upstream regulatory sequences leaving P2 intact. These results show that chromosomal translocations disrupt the TTG-2 gene itself, further confirming its role in the development of T-ALL.			ROYERPOKORA, B (corresponding author), UNIV HEIDELBERG, INST HUMAN GENET, NEUENHEIMER FELD 328, D-69120 HEIDELBERG, GERMANY.		Rogers, Michael A./J-9803-2012	Rogers, Michael A./0000-0002-3728-2107				APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEUG H, 1982, J CELL PHYSIOL, P195; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CHAMPAGNE E, 1989, BLOOD, V73, P1672; CHENG JT, 1990, J EXP MED, V171, P489, DOI 10.1084/jem.171.2.489; CLEARY ML, 1992, CANCER SURV, V15, P89; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; FISCH P, 1992, ONCOGENE, V7, P2389; FITZGERALD TJ, 1992, BLOOD, V80, P3189; FORONI L, 1990, GENE CHROMOSOME CANC, V1, P301, DOI 10.1002/gcc.2870010407; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HARVEY RC, 1989, ONCOGENE, V4, P341; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KURTZBERG J, 1985, J EXP MED, V162, P1561, DOI 10.1084/jem.162.5.1561; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAVID Z, 1980, INT J CANCER, V25, P705, DOI 10.1002/ijc.2910250604; ROYERPOKORA B, 1989, HUM GENET, V82, P264, DOI 10.1007/BF00291167; ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SANCHEZGARCIA I, 1991, ONCOGENE, V6, P577; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YOFFE G, 1989, BLOOD, V74, P374	42	40	40	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1353	1360						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731686				2022-12-17	WOS:A1995QR65100012
J	ROBB, L; RASKO, JEJ; BATH, ML; STRASSER, A; BEGLEY, CG				ROBB, L; RASKO, JEJ; BATH, ML; STRASSER, A; BEGLEY, CG			SCL, A GENE FREQUENTLY ACTIVATED IN HUMAN T-CELL LEUKEMIA, DOES NOT INDUCE LYMPHOMAS IN TRANSGENIC MICE	ONCOGENE			English	Note						TAL1; CD2 ENHANCER; TRANSGENE	LOOP-HELIX GENE; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING MOTIF; C-MYC; TAL-1 GENE; N-MYC; TRANSLOCATION; LOCUS; OVEREXPRESSION; HEMATOPOIESIS	The scl gene is implicated in human T cell acute lymphoblastic leukaemia (T-ALL) through its involvement in the t(1;14)(p32;q11) chromosomal translocation and, more frequently, as a result of a tumour-specific interstitial deletion on chromosome 1. The consequence of both these chromosomal alterations is overexpression of scl in the leukaemic cells. Despite the strong inference of a role in human T-ALL, scl has not yet been demonstrated to be causally involved in neoplastic transformation. We attempted to do this by generating transgenic mice in which scl expression was directed to the T cell lineage using the CD2 enhancer and the strong SR alpha viral promoter (CD2-scl mice). Three transgenic lines, an of which expressed the scl transgene at a high level, were bred and analysed. No alterations in T cell development were seen in the mice. Unexpectedly CD2-scl mice did not develop tumours, nor did the transgene enhance tumourigenesis by Moloney murine leukaemia virus. These findings throw into question the mechanism by which aberrant scl expression contributes to T cell leukaemogenesis.			ROBB, L (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA.		Strasser, Andreas/C-7581-2013; Rasko, John EJ/F-5754-2013	Strasser, Andreas/0000-0002-5020-4891; rasko, John/0000-0003-2975-807X	NCI NIH HHS [CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, 1994, GENE, V138, P93, DOI 10.1016/0378-1119(94)90787-0; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BERNARD O, 1991, ONCOGENE, V6, P1477; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, ONCOGENE, V8, P677; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; ELWOOD NJ, 1993, ONCOGENE, V8, P3093; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FISCH P, 1992, ONCOGENE, V7, P2389; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; HATANO M, 1992, BLOOD S, V80, pA355; HAUPT Y, 1992, ONCOGENE, V7, P981; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; KALLIANPUR AR, 1994, BLOOD, V83, P1200; LANG G, 1991, NUCLEIC ACIDS RES, V19, P5851, DOI 10.1093/nar/19.21.5851; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MOUTHON MA, 1993, BLOOD, V81, P647; NAUMOVSKI L, 1992, BLOOD S1, V80, pA301; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; SOLOMON E, 1991, SCIENCE, V254, P1135; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TAKABE Y, 1988, MOL CELL BIOL, V8, P466; TANIGAWA T, 1994, CELL GROWTH DIFFER, V5, P557; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VISVADER J, 1991, ONCOGENE, V6, P195; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	42	40	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					205	209						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824274				2022-12-17	WOS:A1995QA98000024
J	FOOS, G; GRIMM, S; KLEMPNAUER, KH				FOOS, G; GRIMM, S; KLEMPNAUER, KH			THE CHICKEN A-MYB PROTEIN IS A TRANSCRIPTIONAL ACTIVATOR	ONCOGENE			English	Article							DNA-BINDING DOMAIN; ONCOGENE C-MYB; V-MYB; B-MYB; MIM-1 GENE; TRANS-ACTIVATION; CDNA CLONES; EXPRESSION; DIFFERENTIATION; SEQUENCE	c-myb encodes a trans-activator that is essential for the proliferation of most hematopoietic precursor cells but lacks a major role in non-hematopoietic cells. The recent identification of two myb-related genes (A-myb and B-myb) in several vertebrate species has raised the possibility that these genes perform c-myb like functions in non-hematopoietic cells. Here, we report the isolation and preliminary characterization of the chicken A-myb gene. Like other members of the myb family, the A-myb protein contains an N-terminally located repeat domain that is highly homologous to the DNA-binding domain of the c-myb protein. Unlike c-myb, A-myb is expressed in fibroblasts, suggesting that it functions in non-hematopoietic cells. We demonstrate that A-myb transactivates myb-responsive reporter genes. Furthermore, when stably expressed in a chicken macrophage cell line, A-myb causes activation of several myb-inducible endogenous genes. These findings show that A-myb encodes a transactivating member of the myb family whose functional properties resemble those of the c-myb and v-myb proteins. Thus, our results support the idea that A-myb is a functional equivalent of c-myb.	MAX PLANCK INST IMMUNBIOL,HANS SPERMANN LAB,D-79108 FREIBURG,GERMANY	Max Planck Society								BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; GARCIA A, 1991, ONCOGENE, V6, P265; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LAM EWF, 1992, ONCOGENE, V7, P1885; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; QUEVA C, 1992, DEVELOPMENT, V114, P125; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3173; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	52	40	41	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2481	2488						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058311				2022-12-17	WOS:A1994PC05400007
J	ECCLES, MR; GRUBB, G; OGAWA, O; SZETO, J; REEVE, AE				ECCLES, MR; GRUBB, G; OGAWA, O; SZETO, J; REEVE, AE			CLONING OF NOVEL WILMS-TUMOR GENE (WT1) CDNAS - EVIDENCE FOR ANTISENSE TRANSCRIPTION OF WT1	ONCOGENE			English	Note							DENYS-DRASH SYNDROME; UROGENITAL DEVELOPMENT; MUTATIONS; EXPRESSION; REGION; REPRESSION; OPPOSITE; DELETION; SEQUENCE; PROMOTER	WT1 is a tumor suppressor gene that has been implicated in Wilms tumor, and is expressed in cells of mesodermal origin. The Wit-1 gene is located approximately 2 kb from the WT1 gene, and is expressed coordinately with WT1. WT1 and Wit-1 are bi-directionally transcribed from the same promoter region, We have screened a human fetal kidney cDNA library to identify novel WT1 cDNA clones. Here we report the cloning of cDNA clones which span part of intron 1 of WT1, exon 1, upstream sequences between WT1 and Wit-1 and part of the Wit-1 gene. Northern blot and RNAase protection analysis using subcloned fragments of the cDNAs corresponding to regions from within intron 1 of WT1 suggest that a 7-10 Kb RNA is expressed in human fetal kidney, which overlaps with WT1 and is transcribed in the same direction as Wit-1.			ECCLES, MR (corresponding author), UNIV OTAGO,DEPT BIOCHEM,CANC GENET LAB,POB 56,DUNEDIN,NEW ZEALAND.							ARMSTRONG BC, 1992, CELL GROWTH DIFFER, V3, P385; ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BAIRD PN, 1992, ONCOGENE, V7, P2141; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAMPBELL CE, 1993, IN PRESS ONCOGENE; COPPES MJ, 1992, CANCER RES, V52, P6125; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; COWELL JK, 1991, ONCOGENE, V6, P595; DEAN M, 1983, NATURE, V305, P443, DOI 10.1038/305443a0; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HOFMANN W, 1993, ONCOGENE, V8, P3123; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; KRIEDBERG JA, 1993, CELL, V74, P1; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LOWNDES NF, 1989, MOL CELL BIOL, V9, P3758, DOI 10.1128/MCB.9.9.3758; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; OGAWA O, 1993, HUM MOL GENET, V2, P203, DOI 10.1093/hmg/2.2.203; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SPICER DB, 1992, MOL CELL BIOL, V12, P1324, DOI 10.1128/MCB.12.3.1324; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; WANG ZY, 1992, J BIOL CHEM, V267, P21999; YEGER H, 1992, CELL GROWTH DIFFER, V3, P855	34	40	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2059	2063						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208551				2022-12-17	WOS:A1994NR68500031
J	MIGLARESE, MR; MANNIONHENDERSON, J; WU, H; PARSONS, JT; BENDER, TP				MIGLARESE, MR; MANNIONHENDERSON, J; WU, H; PARSONS, JT; BENDER, TP			THE PROTEIN-TYROSINE KINASE SUBSTRATE CORTACTIN IS DIFFERENTIALLY EXPRESSED IN MURINE-B LYMPHOID TUMORS	ONCOGENE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; ACTIN-BINDING PROTEIN; CENTROCYTIC LYMPHOMA; SIGNAL TRANSDUCTION; RIBONUCLEIC-ACID; MULTIPLE-MYELOMA; CHROMOSOME 11Q13; HUMAN CARCINOMAS; PHOSPHOLIPASE-C; MESSENGER-RNAS	Src family protein tyrosine kinases (PTKs) actively participate in signal transduction during lymphocyte activation. However, little is known about the roles of PTKs acid their substrates in lymphocyte differentiation. To identify PTK substrates that may be differentially expressed during B lymphopoiesis, we screened a panel of murine B lymphoid tumor cell lines representing various developmental stages using monoclonal antibodies (MAbs) specific for pp60(src) substrates. A MAb specific for cortactin, a filamentous-actin binding pp60(src) substrate, immunoprecipitated proteins from murine plasmacytoma cell lines but not from pre-B cell lymphoma or B cell lymphoma cell lines. We have cloned a murine cortactin cDNA which encodes a member of a family of proteins distinguished by amino-terminal repeat domains and carboxy-terminal Src Homology 3 domains. Two members of this family (cortactin and HS1) were differentially expressed in murine B lymphoid tumor cell lines; both were detected in plasmacytoma cell lines, however HS1 was additionally detected in pre-B lymphoma and B lymphoma cell lines. Cortactin RNA was detected in most murine tissues, but was not detected in B lymphocytes or plasma cells. We hypothesize that cortactin expression is associated with transformed plasma cells and not with the terminal differentiation of normal B lymphocytes to plasma cells.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NCI NIH HHS [CA09109, CA29243, P01CA40042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042, R01CA029243, R37CA029243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BERGSAGEL PL, 1992, ONCOGENE, V7, P2059; BERGSAGEL PL, 1992, J IMMUNOL, V148, P590; BROOKES S, 1993, GENE CHROMOSOME CANC, V6, P222, DOI 10.1002/gcc.2870060406; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER MD, 1984, FUNDAMENTAL IMMUNOLO, P43; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FIEDLER W, 1992, BRIT J HAEMATOL, V81, P58, DOI 10.1111/j.1365-2141.1992.tb08171.x; GAZDAR AF, 1986, BLOOD, V67, P1542; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KEARNEY JF, 1975, J IMMUNOL, V115, P671; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KINNON C, 1993, IMMUNOL TODAY, V14, P554, DOI 10.1016/0167-5699(93)90187-P; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LADANYI M, 1992, AM J PATHOL, V141, P949; LAMMIE GA, 1992, ONCOGENE, V7, P2381; MAA MC, 1992, ONCOGENE, V7, P2429; MAGE M, 1981, EUR J IMMUNOL, V11, P228, DOI 10.1002/eji.1830110312; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCMAHON AP, 1987, DIFFERENTIATION, V34, P68, DOI 10.1111/j.1432-0436.1987.tb00052.x; MEDEIROS LJ, 1990, BLOOD, V76, P2086; MELAMED I, 1991, J IMMUNOL, V147, P1139; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; PAWSON T, 1988, ONCOGENE, V3, P491; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RAFFELD M, 1992, LEUKEMIA LYMPHOMA, V8, P161, DOI 10.3109/10428199209054902; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TAGA T, 1992, CRIT REV IMMUNOL, V11, P265; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLIAMS ME, 1993, LEUKEMIA, V7, P1437; WILLIAMS ME, 1993, LEUKEMIA, V7, P241; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WONG S, 1992, ONCOGENE, V7, P2407; WORD CJ, 1981, MOL IMMUNOL, V18, P311, DOI 10.1016/0161-5890(81)90055-9; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; ZHAN X, 1993, J BIOL CHEM, V268, P24427	64	40	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1989	1997						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	7516062				2022-12-17	WOS:A1994NR68500023
J	THOMPSON, J; CHOUDHURY, S; KASHANCHI, F; DONIGER, J; BERNEMAN, Z; FRENKEL, N; ROSENTHAL, LJ				THOMPSON, J; CHOUDHURY, S; KASHANCHI, F; DONIGER, J; BERNEMAN, Z; FRENKEL, N; ROSENTHAL, LJ			A TRANSFORMING FRAGMENT WITHIN THE DIRECT REPEAT REGION OF HUMAN HERPESVIRUS TYPE-6 THAT TRANSACTIVATES HIV-1	ONCOGENE			English	Article							HUMAN CYTOMEGALO-VIRUS; HUMAN PAPILLOMAVIRUS TYPE-16; EPSTEIN-BARR-VIRUS; LYMPHOCYTES-T; EXANTHEM-SUBITUM; READING FRAME; STRAIN AD169; B VIRUS; DNA; IDENTIFICATION	HHV-6 infection has been associated with several malignancies including non-Hodgkin's lymphoma and Hodgkin's disease by the presence of high antibody titer and/or the presence of HHV-6 DNA. To understand their oncogenic potential, SalI restriction fragments from HHV-6 strain U1102 were transfected into NIH3T3 cells to assess transforming ability. A 3.9-kbp SalI-L DNA fragment spanning the junction of the direct repeat left (DR(L)) and unique long segment (U(L)) regions of HHV-6 induced foci of morphologically altered cells. The SalI-L transformed NIH3T3 focal lines induced tumors in nude mice within 2 weeks. The retention of HHV-6 specific DNA observed in SalI-L transformed cells and their tumor-derived lines suggest a possible maintenance function. Since both HHV-6 infection as well as transforming fragments from other DNA viruses have been shown to transactivate the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR), SalI-L was examined for transactivation activity. SalI-L up-regulated HIV-1 LTR CAT 10-15 fold in both monkey CV-1 and human T Jurkat cells. The further study of the SalI-L transforming fragment exhibiting transactivation of HIV-1 LTR will elucidate whether these two activities are encoded by a single gene and will aid in the understanding of the interaction between HHV-6 and HIV-1 as it relates to progression of AIDS and/or AIDS-related malignancies.	GEORGETOWN UNIV, SCH MED, DEPT MICROBIOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, DEPT IMMUNOL, WASHINGTON, DC 20007 USA; TEL AVIV UNIV, DEPT CELL RES & IMMUNOL, IL-69978 TEL AVIV, ISRAEL; NCI, TUMOR CELL BIOL LAB, BETHESDA, MD 20892 USA	Georgetown University; Georgetown University; Tel Aviv University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [CA37259-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA037259, R01CA037259] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABLASHI D, 1993, ARCH VIROL, V129, P363, DOI 10.1007/BF01316913; ABLASHI DV, 1987, NATURE, V329, P207, DOI 10.1038/329207a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERNEMAN ZN, 1992, HUMAN HERPESVIRUS, V6, P81; BERTRAM G, 1991, In Vivo (Attiki), V5, P271; BRADY J, 1983, CANCER CELL, V1, P105; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; DONIGER J, 1987, J BIOL CHEM, V262, P3813; ELBEIK T, 1986, J VIROL, V60, P645, DOI 10.1128/JVI.60.2.645-652.1986; ELLINGER K, 1992, HUMAN HERPESVIRUS, V6, P209; ENSOLI B, 1989, EMBO J, V8, P3019, DOI 10.1002/j.1460-2075.1989.tb08452.x; FRENKEL N, 1990, P NATL ACAD SCI USA, V87, P748, DOI 10.1073/pnas.87.2.748; GENG YQ, 1992, J VIROL, V66, P1564, DOI 10.1128/JVI.66.3.1564-1570.1992; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HORVAT RT, 1991, J VIROL, V65, P2895, DOI 10.1128/JVI.65.6.2895-2902.1991; ISHIGURO N, 1990, ACTA PAEDIATR SCAND, V79, P987, DOI 10.1111/j.1651-2227.1990.tb11369.x; JAHAN N, 1989, J VIROL, V63, P2866, DOI 10.1128/JVI.63.6.2866-2869.1989; JARIWALLA RJ, 1980, P NATL ACAD SCI-BIOL, V77, P2279, DOI 10.1073/pnas.77.4.2279; JARRETT RF, 1988, LEUKEMIA, V2, P496; JOSEPHS SF, 1988, LEUKEMIA, V2, P132; JOSEPHS SF, 1986, SCIENCE, V234, P601, DOI 10.1126/science.3020691; JOSEPHS SF, 1988, J VIROL METHODS, V21, P179, DOI 10.1016/0166-0934(88)90064-X; KELLER JM, 1984, CELL, V36, P381, DOI 10.1016/0092-8674(84)90231-9; KISHI M, 1988, J VIROL, V62, P4824, DOI 10.1128/JVI.62.12.4824-4827.1988; KOUZARIDES T, 1988, VIROLOGY, V165, P151, DOI 10.1016/0042-6822(88)90668-X; LINDQUESTER GJ, 1991, VIROLOGY, V182, P102, DOI 10.1016/0042-6822(91)90653-S; LUSSO P, 1991, NATURE, V349, P533, DOI 10.1038/349533a0; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; MARTIN MED, 1991, J GEN VIROL, V72, P157, DOI 10.1099/0022-1317-72-1-157; MARTIN MED, 1991, J VIROL, V65, P5381, DOI 10.1128/JVI.65.10.5381-5390.1991; MOCARSKI ES, 1988, J GEN VIROL, V69, P2613, DOI 10.1099/0022-1317-69-10-2613; NELSON JA, 1982, J VIROL, V43, P83, DOI 10.1128/JVI.43.1.83-91.1982; NIEDERMAN JC, 1988, LANCET, V2, P817; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RAZZAQUE A, 1990, ONCOGENE, V5, P1365; RAZZAQUE A, 1988, P NATL ACAD SCI USA, V85, P5709, DOI 10.1073/pnas.85.15.5709; REYES GR, 1979, COLD SPRING HARB SYM, V44, P629; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRMER EC, 1991, P NATL ACAD SCI USA, V88, P5922, DOI 10.1073/pnas.88.13.5922; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEEPER TA, 1990, AM J CLIN PATHOL, V93, P776, DOI 10.1093/ajcp/93.6.776; TAKAHASHI K, 1989, J VIROL, V63, P3161, DOI 10.1128/JVI.63.7.3161-3163.1989; TORELLI G, 1991, BLOOD, V77, P2251, DOI 10.1182/blood.V77.10.2251.2251; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; WESTON K, 1986, J MOL BIOL, V192, P177, DOI 10.1016/0022-2836(86)90359-1; YAMANISHI K, 1988, LANCET, V1, P1065; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986	56	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1167	1175						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134119				2022-12-17	WOS:A1994NC04800020
J	HUSSAIN, SP; AGUILAR, F; CERUTTI, P				HUSSAIN, SP; AGUILAR, F; CERUTTI, P			MUTAGENESIS OF CODON-248 OF THE HUMAN P53 TUMOR-SUPPRESSOR GENE BY N-ETHYL-N-NITROSOUREA	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; GENOTYPIC ANALYSIS; DNA-POLYMERASE; NITRIC-OXIDE; MUTATIONS; SEQUENCES; REPAIR; DAMAGE; INVIVO; SITES	Base pair mutations in the p53 tumor suppressor gene are among the most frequently observed genetic changes in human malignancies. Several mutational hotspots have been identified and tumor- and tissue-specific differences have been observed. We studied the mutability of hotspot codon 248, CGG, in human fibroblasts in response to the alkylating agent N-ethyl-N-nitrosourea (ENU) by MspI RFLP/PCR analysis. Alkylating agents are implicated as etiological agents in carcinogenesis in the gut and other tissues in the human. ENU induced preferentially G to A transitions in the non-transcribed strand. The predominant mutation involving the G-residue of the CpG dinudeotide was observed with an absolute frequency of 4 x 10(-7). The corresponding C to T transition in the first position of codon 248 was observed at several fold lower frequency suggesting more efficient excision repair of the transcribed strand. The G to A transition in the third position of codon 248 occurred at low frequency. Our results are compatible with a role for aliphatic alkylating agents in human tumors with codon 248 mutations since almost all mutations reported in this codon are transitions in the CpG-dinucleotide.	SWISS INST EXPTL CANC RES, DEPT CARCINOGENESIS, CH-1066 LAUSANNE, SWITZERLAND	Swiss Institute Experimental Cancer Research				Hussain, S. Perwez/0000-0002-2294-522X				AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; AGUILAR F, 1993, IN PRESS METHODS T B, V1; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTSCH H, 1990, MUTAT RES, V238, P255, DOI 10.1016/0165-1110(90)90017-6; BRONSTEIN SM, 1991, CANCER RES, V51, P5188; CHIOCCA SM, 1992, P NATL ACAD SCI USA, V89, P5331, DOI 10.1073/pnas.89.12.5331; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; FELLEYBOSCO E, 1991, NUCLEIC ACIDS RES, V19, P2913, DOI 10.1093/nar/19.11.2913; HANAWALT PC, 1989, GENOME, V31, P605, DOI 10.1139/g89-113; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1991, CANCER RES, V51, P4102; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; RECIO L, 1990, MUTAGENESIS, V5, P505, DOI 10.1093/mutage/5.5.505; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SANDY MS, 1992, P NATL ACAD SCI USA, V89, P890, DOI 10.1073/pnas.89.3.890; Singer B., 1983, MOL BIOL MUTAGENS CA; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; ZIJLSTRA J, 1990, PROG CLIN BIOL RES, V347, P187	24	40	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					13	18						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	7905619				2022-12-17	WOS:A1994MW24700002
J	CHEN, TM; CHEN, CA; HSIEH, CY; CHANG, DY; CHEN, YH; DEFENDI, V				CHEN, TM; CHEN, CA; HSIEH, CY; CHANG, DY; CHEN, YH; DEFENDI, V			THE STATE OF P53 IN PRIMARY HUMAN CERVICAL CARCINOMAS AND ITS EFFECTS IN HUMAN PAPILLOMAVIRUS-IMMORTALIZED HUMAN CERVICAL CELLS	ONCOGENE			English	Article							WILD-TYPE P53; CELLULAR TUMOR-ANTIGEN; ACTIVATING MUTATIONS; GEL-ELECTROPHORESIS; EPITHELIAL-CELLS; MUTANT P53; PROTEIN; DNA; LINES; TRANSFORMATION	Wild-type (wt) p53 acts as a tumor suppressor, while certain mutant type (mt) p53 may exhibit 'oncogenic' function. We have recently demonstrated that human papillomavirus type 18 (HPV-18) E6 can partially overcome the growth-suppressive effects of wt p53, but it remains unclear what role p53 plays in cervical carcinogenesis. In this report, we have examined nine HPV-immortalized human cervical epithelial cell lines and 13 HPV-positive and two HPV-negative primary cervical cancers for p53 mutations by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP). None of them contained p53 mutations in exons 5-9 where most p53 mutations in human tumors have been found. The entire p53-coding region of the two HPV-negative cervical cancers was sequenced and no mutations were noted. In order to examine the effects of wt p53 and mt p53 on HPV-immortalized human cells, we transfected HPV-immortalized cell lines with wt p53 and a mt p53 (mtp43Val-135). The results indicate that HPV-immortalized cells cannot tolerate large amounts of exogenous wt p53, while mt p53Val-135 can enhance transformation of these cells. The results support the notion that inactivation of wt p53 by E6 may be important for HPV-associated transformation and also suggests that mt p53 can act as an oncogene in HPV-immoralized human cells.	NYU MED CTR,DEPT PATHOL,550 1ST AVE,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; NATL TAIWAN UNIV,COLL MED,DEPT OBSTET & GYNECOL,TAIPEI,TAIWAN; NATL TAIWAN UNIV,COLL MED,DEPT PHARM,TAIPEI,TAIWAN	New York University; New York University; National Taiwan University; National Taiwan University				CHEN, CHI-AN/0000-0001-6670-7939; defendi, vittorio/0000-0002-0707-6900				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN TM, 1992, ONCOGENE, V7, P1541; CROOK T, 1991, ONCOGENE, V6, P873; DEAN SW, 1989, EXP CELL RES, V183, P473, DOI 10.1016/0014-4827(89)90406-0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUJITA M, 1992, CANCER RES, V52, P5323; Gai X X, 1988, Oncogene Res, V3, P377; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSONO S, 1991, ONCOGENE, V6, P237; HOWLEY PM, 1991, CANCER RES, V51, pS5019; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; INOUE H, 1992, VIROLOGY, V187, P343, DOI 10.1016/0042-6822(92)90325-J; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; LEE YY, 1992, P AM ASSOC CANC RES, V33, P339; LEHMAN TA, 1991, CANCER RES, V51, P4090; Manos M. M., 1990, PCR PROTOCOLS GUIDE, P356; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; OKAMOTO A, 1991, CANCER RES, V51, P5632; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PECORARO G, 1991, AM J PATHOL, V138, P1; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RIOU G, 1990, LANCET, V335, P1171; ROVINSKI B, 1988, ONCOGENE, V2, P445; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; WRIGHT PA, 1991, ONCOGENE, V6, P1693; YAGINUMA Y, 1991, CANCER RES, V51, P6506; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	56	40	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1511	1518						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389030				2022-12-17	WOS:A1993LE06400014
J	OEHLER, T; PINTZAS, A; STUMM, S; DARLING, A; GILLESPIE, D; ANGEL, P				OEHLER, T; PINTZAS, A; STUMM, S; DARLING, A; GILLESPIE, D; ANGEL, P			MUTATION OF A PHOSPHORYLATION SITE IN THE DNA-BINDING DOMAIN IS REQUIRED FOR REDOX-INDEPENDENT TRANSACTIVATION OF AP1-DEPENDENT GENES BY V-JUN	ONCOGENE			English	Article							C-JUN; FOS; ONCOGENE; INVITRO; REGION; AP-1	The ability of the nuclear onocprotein Jun to activate transcription is controlled both by level of DNA binding and by the activity of its transactivation domain. Control of DNA binding is achieved by two mechanisms: phosphorylation and redox regulation. Mutation of Ser-226 inhibits phosphorylation of the DNA binding, resulting in enhanced DNA-binding and transactivation activity of Jun. In contrast, mutation of Cys-252, which is the target for repression of DNA-binding activity under oxidative conditions, results in a strong decrease of Jun-specific activation of transcription. However, transactivation by c-Jun-Cys-252 is fully restored upon mutation of Ser-226. Both mutations are also found in the oncogenic counterpart of c-Jun, v-Jun, and are the only differences between these proteins in the DNA-binding domain, suggesting that v-Jun escapes down-modulation of DNA binding by both mechanisms. However, inhibition of phosphorylation of Ser-226 is absolutely required for the ability of v-Jun to activate transcription of AP-1-dependent genes in a redox-independent manner.	KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH, INST GENET, POSTFACH 3640, W-7500 KARLSRUHE 1, GERMANY; BEATSON INST CANC RES, CANC RES CAMPAIGN BEATSON LABS, WOLFSON LAB MOLEC PATHOL, GLASGOW G61 1BD, SCOTLAND	Helmholtz Association; Karlsruhe Institute of Technology; Beatson Institute			Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634; Gillespie, David/0000-0002-6338-0544				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; COHEN DR, 1990, ONCOGENE, V5, P929; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; FRAME MC, 1991, ONCOGENE, V6, P205; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1992, ONCOGENE, V7, P1119; OEHLER T, 1992, MOL CELL BIOL, V12, P5508, DOI 10.1128/MCB.12.12.5508; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	25	40	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1141	1147						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479739				2022-12-17	WOS:A1993KY32800005
J	STACKER, SA; HOVENS, CM; VITALI, A; PRITCHARD, MA; BAKER, E; SUTHERLAND, GR; WILKS, AF				STACKER, SA; HOVENS, CM; VITALI, A; PRITCHARD, MA; BAKER, E; SUTHERLAND, GR; WILKS, AF			MOLECULAR-CLONING AND CHROMOSOMAL LOCALIZATION OF THE HUMAN HOMOLOG OF A RECEPTOR RELATED TO TYROSINE KINASES (RYK)	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; MILLER-DIEKER SYNDROME; CATALYTIC SUBUNIT; CONSERVED FEATURES; CDNA CLONES; CELL-LINE; LOCALIZATION; SEQUENCE; GENE	A cDNA encoding the human homologue of mouse RYK (related to receptor tyrosine kinases) has been cloned from an interleukin 1 (IL-1)-stimulated human hepatoma cDNA library by cross-species hybridization using the mouse RYK cDNA as a probe. The sequence of the 3067-bp cDNA clone encoding human RYK predicts a transmembrane protein with a cytoplasmic domain that contains the consensus sequences (subdomains I-XI) of the protein tyrosine kinase (PTK) family. The highly conserved motif -D-F-G- (subdomain VII) of the catalytic domain of other receptor-type tyrosine kinases is altered to -D-N-A- in human RYK. In addition, a number of other changes were found in the ATP binding site (subdomains I and II) and the motif [-I-H-R-D-L-A-A-R-N-] found in subdomain VI. Comparison of the human and mouse RYK sequences shows a 92% conservation at the nucleotide level and 97% at the amino acid level. There was no significant homology between the extracellular domain of RYK and the other families of receptor tyrosine kinases described to date. RYK therefore appears to define a new subclass of receptor-type tyrosine kinases whose structure has remained highly conserved across species.	LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, PO ROYAL MELBOURNE HOSP, PARKVILLE, VIC 3050, AUSTRALIA; WOMENS & CHILDRENS HOSP, DEPT CYTOGENET & MOLEC GENET, ADELAIDE, SA 5006, AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Womens & Childrens Hospital Australia			Wilks, Andrew F/R-5542-2019; Sutherland, Grant Robert/D-2606-2012	Hovens, Christopher/0000-0002-0610-1289; Wilks, Andrew F/0000-0002-8554-2399; Stacker, Steven/0000-0003-4096-9273				ADAMS RA, 1968, CANCER RES, V28, P1121; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P3018, DOI 10.1021/bi00433a042; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DOBYNS WB, 1991, AM J HUM GENET, V48, P584; EIPERS PG, 1991, GENOMICS, V11, P621, DOI 10.1016/0888-7543(91)90069-Q; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOVENS CH, 1962, P NATL ACAD SCI USA, V89, P11818; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOSIK KS, 1988, NEURON, V1, P127, DOI 10.1016/0896-6273(88)90196-1; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KWIATKOWSKI DJ, 1990, AM J HUM GENET, V46, P559; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMHONWAH AM, 1986, P NATL ACAD SCI USA, V83, P4864, DOI 10.1073/pnas.83.13.4864; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MORAN MF, 1988, ONCOGENE, V3, P665; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; SAMBROK J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; STARK KL, 1991, DEVELOPMENT, V113, P641; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHITEHEAD RH, 1987, CANCER RES, V47, P2683; WILKS AF, 1988, ONCOGENE, V3, P289; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLKS AF, 1992, ADV CANCER RES, V60, P43; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932	40	40	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1347	1356						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386829				2022-12-17	WOS:A1993KY32800028
J	MANAK, JR; PRYWES, R				MANAK, JR; PRYWES, R			PHOSPHORYLATION OF SERUM RESPONSE FACTOR BY CASEIN KINASE .2. EVIDENCE AGAINST A ROLE IN GROWTH-FACTOR REGULATION OF FOS-EXPRESSION	ONCOGENE			English	Article							TERNARY COMPLEX-FORMATION; DNA-BINDING ACTIVITY; C-FOS; TRANSCRIPTIONAL ACTIVATION; GENE-TRANSFER; ELEMENT; PROTEIN; SEQUENCES; P67SRF; CELLS	Serum response factor (SRF) is a transcription factor involved in the serum and growth factor regulation of the c-fos gene. SRF is phosphorylated by casein kinase II (CKII), which causes a large increase in its DNA-binding activity. CKII activity has been shown to be stimulated by growth factors and serum. Since c-fos transcription is induced by a number of the same agents that stimulate CKII activity, and sincefos activation and CKII stimulation demonstrate similar rapid kinetics, a role was proposed for CKII in regulating fos expression via its phosphorylation of SRF. In this report, we provide evidence against this hypothesis by using several different strategies. First, by immunoprecipitation of SRF from cells, we show that the phosphorylation state of SRF does not change upon growth factor treatment. Second, by two-dimensional electrophoresis of lysates from a cell line that overexpresses SRF, we show that, although SRF exists in the cell in several different isoforms, there is no change in their relative amounts upon serum stimulation. Third, we tested the activity of an SRF mutant that binds DNA at constitutively high levels irrespective of CKII phosphorylation. If phosphorylation is regulatory, this mutant would be expected to consitutitively activate (or repress) fos expression. However, when overexpressed stably in cetls this mutant had no effect on endogenous c-fos expression, suggesting that CKII phosphorylation of SRF is not the limiting event for fos activation.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University				Manak, John/0000-0002-6562-7694	NATIONAL CANCER INSTITUTE [R01CA050329] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50329-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; CARROLL D, 1989, J BIOL CHEM, V264, P7345; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HARLOW E, 1988, ANTIBODIES LABORATOR, P641; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KLARLUND JK, 1988, J BIOL CHEM, V263, P15873; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LUO K, 1990, ONCOGENE, V5, P921; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MOHUN TJ, 1991, EMBO J, V10, P933, DOI 10.1002/j.1460-2075.1991.tb08027.x; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; PRYWES R, 1988, COLD SPRING HARB SYM, V53, P739, DOI 10.1101/SQB.1988.053.01.084; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; PRYWES R, 1992, NUCLEIC ACIDS RES, V20, P513, DOI 10.1093/nar/20.3.513; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	54	40	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					703	711						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437853				2022-12-17	WOS:A1993KN00800022
J	MITCHELL, PJ; COOPER, CS				MITCHELL, PJ; COOPER, CS			THE HUMAN TPR GENE ENCODES A PROTEIN OF 2094 AMINO-ACIDS THAT HAS EXTENSIVE COILED-COIL REGIONS AND AN ACIDIC C-TERMINAL DOMAIN	ONCOGENE			English	Note							MET ONCOGENIC REARRANGEMENT; TYROSINE KINASE; ACTIVATION; SEQUENCES; RAF	We recently provided evidence that the human tpr gene encodes a 726 amino acid protein (designated tpr-S) and identified an alternatively spliced transcript that encodes a larger tpr protein with an extended C-terminal domain. In this study, through isolation and sequencing of tpr cDNA clones, we have established that this alternatively spliced transcript encodes a protein of 2094 amino acids (designated tpr-L). The larger tpr protein is predicted to have extensive regions of alpha-helix and several stretches of a heptad repeat that is characteristic of proteins adopting a coiled-coil conformation. Furthermore the carboxy domain of this protein is very rich in acidic residues and exhibits homology (58-80%) to the acidic regions of several nuclear proteins, including the Drosophila engrailed protein, Escherichia coli RNA polymerase sigma subunit and nucleolin. To gain additional insight into the function of tpr we examined the expression of tpr transcripts in tissues from adult rat. The highest levels of tpr transcripts were observed in testis, lung, thymus and spleen.			MITCHELL, PJ (corresponding author), INST CANC RES,MOLEC CARCINOGENESIS SECT,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		Mitchell, Philip J/F-6393-2013					CHAN AML, 1987, ONCOGENE, V1, P229; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRECO A, 1992, ONCOGENE, V7, P237; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KING HWS, 1988, ONCOGENE, V2, P617; KOPCHICK JJ, 1981, ANAL BIOCHEM, V115, P419, DOI 10.1016/0003-2697(81)90027-0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MITCHELL PJ, 1992, ONCOGENE, V7, P383; PARK M, 1986, COLD SPRING HARB SYM, V51, P967, DOI 10.1101/SQB.1986.051.01.110; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; TEMPEST PR, 1986, CARCINOGENESIS, V7, P2051, DOI 10.1093/carcin/7.12.2051; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5	22	40	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2329	2333						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437155				2022-12-17	WOS:A1992JW66500027
J	RAO, VN; REDDY, ESP				RAO, VN; REDDY, ESP			ELK-1 DOMAINS RESPONSIBLE FOR AUTONOMOUS DNA-BINDING, SRE-SRF INTERACTION AND NEGATIVE REGULATION OF DNA-BINDING	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; ETS PROTO-ONCOGENE; C-ETS; V-ETS; TRANSCRIPTIONAL ACTIVATION; C-ETS-1 PROTOONCOGENE; GENE; SEQUENCE	The ets oncogene superfamily consists of a family of sequence-specific DNA-binding transcriptional activator proteins. We have previously identified, cloned and characterized one of the divergent ets-related members elk-1 and shown that it codes for a sequence-specific DNA-binding transcriptional activator. We have also shown that elk-1 forms SRF (Serum Response Factor) dependent ternary complex with SRE (Serum Response Element), similar to p62TCF. In this report, we have mapped the DNA-binding domain of the elk-1 protein (EDB, elk-1 DNA Binding domain) to the 76 amino acid ets homology region. We have also mapped the SRF interaction domain of the elk-1 protein (ESI, elk-1 SRF Interaction domain) to the carboxy-terminal region of the EDB domain. Ternary complex formation by elk-1 requires both EDB and ESI domains of the elk-1 protein. Our results also show that the EDB domain of the elk-1 protein (residues1-89) binds SRE autonomously, unlike full-length elk-1 protein, suggesting the presence of a potential Negative Regulatory DNA binding domain (NRD) which prevents the binding of elk-1 protein to SRE. Interaction of SRF with the ESI domain allows the elk-1 protein to bind to SRE. Thus elk-1 belongs to a class of transcriptional factors that are involved in gene regulation not only by autonomous DNA binding but also by indirect DNA binding through recruitment by cellular factors.			RAO, VN (corresponding author), JEFFERSON CANC INST,BLUMLE LIFE SCI BLDG,233 S 10TH ST,PHILADELPHIA,PA 19107, USA.							ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; CLARK SP, 1983, P NATL ACAD SCI-BIOL, V80, P5037, DOI 10.1073/pnas.80.16.5037; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DIAZ MO, 1986, SCIENCE, V231, P265, DOI 10.1126/science.3455787; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HOLLAND CA, 1987, P NATL ACAD SCI USA, V84, P8662, DOI 10.1073/pnas.84.23.8662; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; POGNONEC P, 1989, ONCOGENE, V4, P691; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1992, GUIDE BOOK ONCOGENES; REDDY ESP, 1990, CANCER RES, V50, P5013; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1990, CANCER BIOL, V1, P47; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	53	40	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2335	2340						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437156				2022-12-17	WOS:A1992JW66500028
J	CHEN, TM; DEFENDI, V				CHEN, TM; DEFENDI, V			FUNCTIONAL INTERACTION OF P53 WITH HPV18 E6, C-MYC AND H-RAS IN 3T3 CELLS	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; CERVICAL-CARCINOMA; SV40-TRANSFORMED CELLS; BIOLOGICAL-ACTIVITIES; CELLULAR ONCOGENE; TRANSFORMING GENE; ESCHERICHIA-COLI; SIMIAN VIRUS-40; DNA	Wild-type (wt) p53 has been suggested to be the product of a tumor-suppressor gene. Recently, it has been shown that the E6 oncoproteins of human papillomavirus (HPV) types 16 and 18, like the SV40 large T antigen, are physically associated with wt p53. We have investigated the functional interaction of wt p53 with the viral oncogene products of HPV16 and 18 and with cellular oncogenes by transfection of NIH3T3 cells with p53 wt alone or with several oncogene(s). We found that over-expression of HPV18 E6, c-myc or activated H-ras, like SV40 large T, can partially overcome the growth-inhibitory effect of wt p53 in NIH3T3 cells, while HPV16 E6 and E7, HPV18 E7, k-fgf, c-fos and mutant (mt) p53 do not. Further studies indicate that HPV18 E6 and c-myc can overcome the antiproliferative effect, but not the antitransforming effect, of wt p53, while activated H-ras can overcome both the antiproliferative and antitransforming effects of wt p53. These data show evidence of a functional interaction between HPV18 E6 and wt p53, and suggest that the cooperation of HPV E6 and cellular oncogenes c-myc and H-ras, which are activated in several cases of human cervical cancers, may be necessary to overcome completely the anti-oncogenic function of p53 in the development of these tumors.	NYU MED CTR, DEPT PATHOL, 550 1ST AVE, NEW YORK, NY 10016 USA; NYU MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University				defendi, vittorio/0000-0002-0707-6900				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BARTLETT PF, 1988, P NATL ACAD SCI USA, V85, P3255, DOI 10.1073/pnas.85.9.3255; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; BOURHIS J, 1990, J CLIN ONCOL, V8, P1789, DOI 10.1200/JCO.1990.8.11.1789; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; CROOK T, 1989, P NATL ACAD SCI USA, V86, P5713, DOI 10.1073/pnas.86.15.5713; CROOK T, 1991, ONCOGENE, V6, P873; DAVID YB, 1988, ONCOGENE, V3, P179; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KURMAN RJ, 1988, AM J OBSTET GYNECOL, V159, P293, DOI 10.1016/S0002-9378(88)80070-X; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHAELMICHALOVITZ D, 1991, J VIROL, V65, P4160, DOI 10.1128/JVI.65.8.4160-4168.1991; MILLER AD, 1984, CELL, V36, P51; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PECORARO G, 1991, AM J PATHOL, V138, P1; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; QUARTO N, 1989, ONCOGENE RES, V5, P101; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RIOU G, 1988, ONCOGENE, V3, P329; RIOU G, 1990, LANCET, V335, P1171; ROMANCZUK H, 1991, J VIROL, V65, P2739, DOI 10.1128/JVI.65.5.2739-2744.1991; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; TUCK SP, 1989, ONCOGENE RES, V4, P81; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0	55	40	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1541	1547						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321402				2022-12-17	WOS:A1992JE81300010
J	KIM, CM; VOGEL, J; JAY, G; RHIM, JS				KIM, CM; VOGEL, J; JAY, G; RHIM, JS			THE HIV TAT GENE TRANSFORMS HUMAN KERATINOCYTES	ONCOGENE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; EPIDERMAL LANGERHANS CELLS; NEOPLASTIC TRANSFORMATION; KAPOSIS-SARCOMA; VIRUS-INFECTION; AIDS; PSORIASIS; ONCOGENE; LESIONS; INVITRO	Skin disorders are frequently seen in patients with the acquired immune deficiency syndrome (AIDS). Since many of these cutaneous manifestations are accompanied by an early onset of epidermal hyperplasia, the keratinocyte is a candidate for infection by the human immunodeficiency virus (HIV). We now report that the HIV tat gene, under the control of the viral long terminal repeat (LTR), can efficiently transform human keratinocytes in culture. Our finding suggests that this activity of the tat gene may be responsible for the epidermal hyperplasia that accompanies psoriasis and precedes the development of squamous cell and basal cell carcinomas in AIDS patients.	JEROME H HOLLAND LAB,VIROL,ROCKVILLE,MD 20855; NCI,CELL & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Jay, Gregory/C-6346-2013		NATIONAL CANCER INSTITUTE [R01CA053633] Funding Source: NIH RePORTER; NCI NIH HHS [CA53633] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHESEBRO B, 1990, J VIROL, V64, P215, DOI 10.1128/JVI.64.1.215-221.1990; COCKERELL CJ, 1990, J AM ACAD DERMATOL, V22, P1260, DOI 10.1016/0190-9622(90)70172-E; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; JOHNSON TM, 1985, NEW ENGL J MED, V313, P1415; KANITAKIS J, 1989, AIDS RES HUM RETROV, V5, P293, DOI 10.1089/aid.1989.5.293; Kaplan M H, 1987, Am J Med, V82, P389, DOI 10.1016/0002-9343(87)90435-9; KAPLAN MK, 1987, J AM ACAD DERMATOL, V17, P485; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KRUEGER G, 1990, J INVEST DERMATOL, V94, P1355; LAZAR AP, 1987, CUTIS, V39, P347; MAHONEY SE, 1991, J CLIN INVEST, V88, P174, DOI 10.1172/JCI115275; MANN DL, 1988, J IMMUNOL, V141, P1131; MATHES BM, 1985, J AM ACAD DERMATOL, V13, P947, DOI 10.1016/S0190-9622(85)70243-5; NIEDT GW, 1985, ARCH PATHOL LAB MED, V109, P727; OVERLY WL, 1987, ANN INTERN MED, V106, P334, DOI 10.7326/0003-4819-106-2-334_1; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; RHIM JS, 1989, ANTICANCER RES, V9, P1345; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RHIM JS, 1989, ONCOGENE, V4, P1403; SADICK NS, 1990, J AM ACAD DERMATOL, V22, P1270, DOI 10.1016/0190-9622(90)70173-F; SITZ KV, 1987, JAMA-J AM MED ASSOC, V257, P340, DOI 10.1001/jama.257.3.340; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; STEIGLEDER GK, 1985, Z HAUTKRANKHEITEN, V60, P1913; STINGL G, 1990, J AM ACAD DERMATOL, V22, P1210, DOI 10.1016/0190-9622(90)70165-E; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TINDALL B, 1989, J AM ACAD DERMATOL, V20, P587, DOI 10.1016/S0190-9622(89)70068-2; TSCHACHLER E, 1987, J INVEST DERMATOL, V88, P233, DOI 10.1111/1523-1747.ep12525402; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WELCH K, 1984, JAMA-J AM MED ASSOC, V252, P1152, DOI 10.1001/jama.252.9.1152	33	40	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1525	1529						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630815				2022-12-17	WOS:A1992JE81300008
J	TASHIRO, S; TAKECHI, M; ASOU, H; TAKAUCHI, K; KYO, T; DOHY, H; KIKUCHI, M; KAMADA, N; TSUJIMOTO, Y				TASHIRO, S; TAKECHI, M; ASOU, H; TAKAUCHI, K; KYO, T; DOHY, H; KIKUCHI, M; KAMADA, N; TSUJIMOTO, Y			CYTOGENETIC 2-18 AND 18-22 TRANSLOCATION IN CHRONIC LYMPHOCYTIC-LEUKEMIA WITH JUXTAPOSITION OF BCL-2 AND IMMUNOGLOBULIN LIGHT CHAIN GENES	ONCOGENE			English	Note							VARIANT T(2-18) TRANSLOCATION; FOLLICULAR LYMPHOMA; B-CELLS; CHROMOSOME-TRANSLOCATION; BREAKPOINT; SURVIVAL; RECOMBINATION; EXPRESSION; CLONING; CLUSTER	The majority of follicular lymphoma cells carry the typical chromosome translocation 14;18, which juxtaposes the bcl-2 gene to the immunoglobulin heavy-chain (IgH) gene. Variant translocations of the bcl-2 gene to the Ig-lambda, or Ig-kappa gene have been found by molecular biological techniques in a significant fraction (approximately 10%) of chronic lymphocytic leukemia (CLL). However, there have been no reports describing the presence of cytogenetic 18;22 and 2;18 translocations in CLL, in spite of extensive karyotypic studies. We present here two cases of CLL, one with cytogenetically detected t(2;18)(p11;q21) and the other with the t(18;22)(q2l;q11). The molecular analysis revealed that these translocations juxtaposed the bcl-2 and immunoglobulin light-chain (IgL) genes. The t(18;22) broke the 5' flanking region of the bcl-2 gene and juxtaposed to the immunoglobulin-lambda light-chain (Ig-lambda) gene in a head-to-head configuration, as in the cases previously described. In the case of the t(2;18), the bcl-2 gene and immunoglobulin-kappa light-Chain (Ig-kappa) gene were juxtaposed in a head-to-tail configuration, which is opposite to that expected from the orientation of the genes on chromosomes. The breakpoint was located within the 5' untranslated region of the bcl-2 gene. The results presented here indicate that the bcl-2/immunoglobulin light-chain (IgL) gene juxtaposition seen in a fraction of CLL is the result of cytogenetically detectable reciprocal chromosome translocations 2;18 and 18;22.	WISTAR INST,36TH ST & SPRUCE,PHILADELPHIA,PA 19104; HIROSHIMA UNIV,NUCL MED & BIOL RES INST,DEPT HEMATOL,HIROSHIMA 730,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT PEDIAT,HIROSHIMA 730,JAPAN; FUKUOKA UNIV,FAC MED,DEPT PATHOL,FUKUOKA 81401,JAPAN; HIROSHIMA RED CROSS HOSP & ATOM BOMB SURVIVORS HOSP,DEPT MED,HIROSHIMA 734,JAPAN	The Wistar Institute; Hiroshima University; Hiroshima University; Fukuoka University					NCI NIH HHS [CA51864] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051864] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; ADACHI M, 1989, ONCOGENE, V4, P1073; AVENTIN A, 1990, BRIT J HAEMATOL, V74, P367, DOI 10.1111/j.1365-2141.1990.tb02599.x; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CROCE CM, 1985, BLOOD, V65, P1; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HIETER PA, 1981, NATURE, V294, P536, DOI 10.1038/294536a0; HILLION J, 1991, ONCOGENE, V6, P169; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KAMADA N, 1981, BLOOD, V58, P1213; LEROUX D, 1990, BRIT J HAEMATOL, V75, P290, DOI 10.1111/j.1365-2141.1990.tb02669.x; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MITELMAN F, 1988, CATALOG CHROMOSOME A; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OSADA H, 1989, JPN J CANCER RES, V80, P711, DOI 10.1111/j.1349-7006.1989.tb01702.x; PECH M, 1984, J MOL BIOL, V176, P189, DOI 10.1016/0022-2836(84)90420-0; POTTER H, 1984, P NATL ACAD SCI USA, V81, P7176; ROWLEY JD, 1982, SCIENCE, V216, P749, DOI 10.1126/science.7079737; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MA, 1987, J IMMUNOL, V139, P3834; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VASICEK TJ, 1990, J EXP MED, V172, P609, DOI 10.1084/jem.172.2.609; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0	29	40	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					573	577						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549371				2022-12-17	WOS:A1992HK00500026
J	KIKUCHI, A; KAIBUCHI, K; HORI, Y; NONAKA, H; SAKODA, T; KAWAMURA, M; MIZUNO, T; TAKAI, Y				KIKUCHI, A; KAIBUCHI, K; HORI, Y; NONAKA, H; SAKODA, T; KAWAMURA, M; MIZUNO, T; TAKAI, Y			MOLECULAR-CLONING OF THE HUMAN CDNA FOR A STIMULATORY GDP/GTP EXCHANGE PROTEIN FOR C-KI-RAS P21 AND SMG P21	ONCOGENE			English	Article							GTP-BINDING PROTEIN; PURIFICATION; PHOSPHORYLATION; MEMBRANES; SEQUENCES; KINASE; WEIGHT; P53	We have previously purified smg GDP dissociation stimulator (GDS) from bovine brain and isolated its cDNA from a bovine brain cDNA library. smg GDS stimulates the GDP/GTP exchange reaction of a group of small GTP-binding proteins (G proteins), including at least c-Ki-ras p21, smg p21A, smg p21B, rhoA p21 and rhoB p21, by stimulating the dissociation of GDP from and the subsequent binding of GTP to each small G protein. In this study, we have isolated and sequenced the cDNA of smg GDS from a human brain cDNA library using the cloned bovine smg GDS cDNA. The cDNA has an open reading frame encoding a protein of 558 amino acids with a calculated M(r) value of 61 122. Human smg GDS shares 93% nucleotide and 96% amino acid sequence homologies with bovine smg GDS. The isolated cDNA is expressed in Escherichia coli, and the encoded protein shows the physical and functional properties similar to those of bovine smg GDS.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University								ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALLESTER R, 1987, J BIOL CHEM, V262, P2688; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FUJIOKA H, 1992, IN PRESS J BIOL CHEM; HANCOCK JF, 1989, CELL, V57, P1107; HATA Y, 1990, J BIOL CHEM, V265, P7104; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HORI Y, 1991, ONCOGENE, V6, P515; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; OHMORI T, 1989, J BIOL CHEM, V264, P1877; SAIKUMAR P, 1988, ONCOGENE RES, V3, P213; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, IN PRESS INT REV CYT; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	40	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					289	293						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549351				2022-12-17	WOS:A1992HG98200013
J	ASKEW, DS; BARTHOLOMEW, C; BUCHBERG, AM; VALENTINE, MB; JENKINS, NA; COPELAND, NG; IHLE, JN				ASKEW, DS; BARTHOLOMEW, C; BUCHBERG, AM; VALENTINE, MB; JENKINS, NA; COPELAND, NG; IHLE, JN			HIS-1 AND HIS-2 - IDENTIFICATION AND CHROMOSOMAL MAPPING OF 2 COMMONLY REARRANGED SITES OF VIRAL INTEGRATION IN A MYELOID-LEUKEMIA	ONCOGENE			English	Article							T-CELL LYMPHOMAS; C-MYB LOCUS; PROVIRAL INSERTION; PROMOTER INSERTION; RETROVIRAL INSERTION; TRANSCRIPTIONAL ACTIVATION; HOMEOBOX GENE; N-MYC; VIRUS; LINE	To identify genes that contribute to myeloid leukemogenesis we have cloned viral integration sites from a CasBrM-MuLV-induced interleukin 3-independent myeloid leukemia cell line. Genomic probes derived from cellular sequences flanking two integrated proviruses were used to screen restriction digests of DNAs from a panel of 52 hematopoietic cell lines, 30 of which were established from CasBrM-MuLV- or MoMuLV-induced mouse leukemias. Probes from one integration site (His-1) defined a region that was rearranged in 3/52 cell lines, and probes from a second integration site (His-2) identified a rearrangement in 2/52 cell lines. Both cases of His-2 rearrangements occurred in concert with viral insertions in the His-1 locus. Genetic mapping of these loci using interspecific backcross analysis assigned the His-1 locus to mouse chromosome 2 and the His-2 locus to mouse chromosome 19. In situ hybridization with a probe from the human homologous region mapped the His-1 locus to human chromosome 2q14-q21. No recombinants were observed between His-2 and Gin-1, a common site of provirus integration in Gross passage A MuLV-induced T-cell leukemias, in 131 backcross animals, suggesting that these loci are tightly linked. The His-1 locus maps to mouse chromosome 2 distinct from any known oncogene or common site of integration but near the proximal breakpoint for a deletion that is observed in over 90% of radiation-induced leukemias.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; NCI, FREDERICK CANC RES & DEV CTR, MAMMALIAN GENET LAB, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; St Jude Children's Research Hospital				Buchberg, Arthur/0000-0002-0543-5631; Askew, David/0000-0002-6477-2515	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765, N01-CO-74101, CA 51020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BAUMBACH WR, 1988, J VIROL, V62, P3151, DOI 10.1128/JVI.62.9.3151-3155.1988; BERNS A, 1988, ARCH VIROL, V102, P1, DOI 10.1007/BF01315558; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; BRECKON G, 1988, KEY CHROMOSOME C, V3; BUCHBERG AM, 1990, MOL CELL BIOL, V10, P4658, DOI 10.1128/MCB.10.9.4658; CANAANI E, 1983, P NATL ACAD SCI USA, V80, P7110; CHEN SJ, 1985, P NATL ACAD SCI USA, V82, P7284, DOI 10.1073/pnas.82.21.7284; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; CUYPERS HT, 1984, CELL, V37, P141; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DOLCETTI R, 1989, ONCOGENE, V4, P1009; GEORGE DL, 1986, P NATL ACAD SCI USA, V83, P1651, DOI 10.1073/pnas.83.6.1651; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; Green EL, 1981, GENETICS PROBABILITY, P77; HAYATA I, 1983, CANCER RES, V43, P367; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IHLE JN, 1989, INT J CELL CLONING, V7, P68, DOI 10.1002/stem.5530070202; IHLE JN, 1982, J IMMUNOL, V129, P2431; IHLE JN, 1989, J VIROL, V63, P2959, DOI 10.1128/JVI.63.7.2959-2966.1989; IHLE JN, 1984, ADV VIRAL ONCOL, V4, P95; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KONO T, 1990, P NATL ACAD SCI USA, V87, P1806, DOI 10.1073/pnas.87.5.1806; LACOMBE C, 1991, J BIOL CHEM, V266, P6952; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LEBEAU MM, 1984, NATURE, V312, P70, DOI 10.1038/312070a0; LI Y, 1984, P NATL ACAD SCI-BIOL, V81, P6808, DOI 10.1073/pnas.81.21.6808; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; PALMER CG, 1990, AM J MED GENET, V36, P214, DOI 10.1002/ajmg.1320360215; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; ROCCHI M, 1986, HUM GENET, V74, P30; SACCHI N, 1986, SCIENCE, V231, P379, DOI 10.1126/science.3941901; Sambrook J., 1989, MOL CLONING LAB MANU; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SIRACUSA LD, 1990, GENOMICS, V6, P491, DOI 10.1016/0888-7543(90)90479-E; SIRACUSA LD, 1991, IN PRESS GENETICS; TRAKHTENBROT L, 1988, LEUKEMIA, V2, P545; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VILLEMUR R, 1987, MOL CELL BIOL, V7, P512, DOI 10.1128/MCB.7.1.512; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WEINSTEIN Y, 1987, J VIROL, V61, P2339, DOI 10.1128/JVI.61.7.2339-2343.1987; WEISS R, 1985, RNA TUMOR VIRUSES, V2; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932	59	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2041	2047						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1682866				2022-12-17	WOS:A1991GX11900015
J	ELLIS, C; LIU, XQ; ANDERSON, D; ABRAHAM, N; VEILLETTE, A; PAWSON, T				ELLIS, C; LIU, XQ; ANDERSON, D; ABRAHAM, N; VEILLETTE, A; PAWSON, T			TYROSINE PHOSPHORYLATION OF GAP AND GAP-ASSOCIATED PROTEINS IN LYMPHOID AND FIBROBLAST CELLS EXPRESSING LCK	ONCOGENE			English	Article							GTPASE ACTIVATING PROTEIN; KINASE P56LCK; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL KINASE; PHOSPHOLIPASE-C; VIRAL ONCOGENE; CD4 RECEPTOR; BINDING; TRANSFORMATION; DOMAINS	The Ras GTPase activating protein (GAP) is a strong candidate for the protein that links protein-tyrosine kinases to the Ras mitogenic pathway. GAP and two associated proteins, p62 and p190, were shown to be phosphorylated on tyrosine in the LSTRA thymoma cell line, in which the p56lck tyrosine kinase is overexpressed as a result of retroviral promoter insertion. In NIH3T3 fibroblasts expressing specific oncogenic and transformation-defective variants of p56lck, we found that the tyrosine phosphorylation of GAP complexes required both enzymatic activation and myristylation of p56lck, and correlated with lck transforming activity. The interaction between p62 and p190 from lck-transformed fibroblasts and GAP could be reconstituted in vitro using bacterial TrpE fusion proteins containing GAP Src homology 2 (SH2) domains. In vitro complex formation was insensitive to the prior denaturation of SH2 ligands, suggesting that SH2-binding sites are formed by linear peptide sequences. These results suggest that the tyrosine phosphorylation of GAP, and its interactions with SH2-binding proteins, may be involved in fibroblast transformation by activated lck, and may participate in signal transduction and cellular transformation in lymphoid cells.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA; MCGILL UNIV, MCGILL CANC CTR, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; McGill University; McGill University	PAWSON, T (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA.		Abraham, Ninan/K-5572-2012; Pawson, Tony J/E-4578-2013	Abraham, Ninan/0000-0002-2747-1246; Liu, X. Johne/0000-0003-3381-5030				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; LEHTO VP, 1988, NATURE, V334, P388, DOI 10.1038/334388a0; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN M, 1990, IN PRESS P NATL ACAD; PAWSON T, 1988, ONCOGENE, V3, P491; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	32	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					895	901						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906156				2022-12-17	WOS:A1991GU62200002
J	KALTHOFF, H; ROEDER, C; HUMBURG, I; THIELE, HG; GRETEN, H; SCHMIEGEL, W				KALTHOFF, H; ROEDER, C; HUMBURG, I; THIELE, HG; GRETEN, H; SCHMIEGEL, W			MODULATION OF PLATELET-DERIVED GROWTH FACTOR-A-CHAIN AND FACTOR-B-CHAIN C-SIS MESSENGER-RNA BY TUMOR-NECROSIS-FACTOR AND OTHER AGENTS IN ADENOCARCINOMA CELLS	ONCOGENE			English	Article							SMOOTH-MUSCLE CELLS; PROTEIN KINASE-C; ENDOTHELIAL-CELLS; HUMAN-FIBROBLASTS; PANCREATIC ADENOCARCINOMA; MOLECULAR-CLONING; GENE-EXPRESSION; FACTOR RECEPTOR; PDGF; LINES	Human Platelet Derived Growth Factors (PDGF) are potent mitogens for mesenchymal cells and encoded by two related genes, the A- (or 1-) and B- (or 2-) chain. The latter is known as the human homolog (c-sis) of the v-sis oncogene. We investigated the expression and cytokine-mediated regulation of PDGF A- and B-chain mRNA in endoderm-derived cells, i.e. cultured human pancreatic adenocarcinoma cells. Northern blot analysis revealed that out of 14 cell lines 11 were positive for the A-chain and 10 for the B-chain. Tumor Necrosis Factor (TNF) -alpha and -beta, but not Interferon (IFN) -gamma, drastically upregulate the mRNA levels for PDGF B-chain and for the A-chain in a dose-dependent manner in nearly every pancreatic tumor cell line investigated (n = 6). With respect to the signal pathway stimulated by TNF, no evidence emerged for an activation of protein kinase A. The inhibition of protein kinase C by staurosporine (in the absence or presence of TNF) as well as its stimulation by PMA resulted in an increased mRNA level for the B-chain, indicating a functional role of PKC in this system. Furthermore, time course experiments and Cycloheximide treatment showed that the A- and B-chain mRNA are regulated by different mechanisms in transformed epithelial cells. Irrespective of these differences, the sum of their biological functions may contribute to the phenomenon of desmoplasia in pancreatic tumors by epithelial/mesenchymal interactions.			KALTHOFF, H (corresponding author), UNIV HAMBURG,MED KLIN 1,IMMUNOL ABT,MARTINSTR 52,W-2000 HAMBURG 20,GERMANY.		Kalthoff, Holger/B-1618-2010					AGGARWAL BB, 1984, THYMIC HORMONES LYMP, P235; ALITALO R, 1987, EMBO J, V6, P1213, DOI 10.1002/j.1460-2075.1987.tb02356.x; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; BIRD TA, 1989, J IMMUNOL, V142, P126; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; CHEN WH, 1982, IN VITRO CELL DEV B, V18, P24; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; FAHRER C, 1989, INT J CANCER, V44, P652, DOI 10.1002/ijc.2910440416; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; FOX PL, 1984, J CELL PHYSIOL, V121, P298, DOI 10.1002/jcp.1041210206; FRIEDMAN BA, 1990, CANCER RES, V50, P533; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; GULLBERG D, 1990, EXP CELL RES, V186, P264, DOI 10.1016/0014-4827(90)90305-T; HAJJAR KA, 1987, J EXP MED, V166, P235, DOI 10.1084/jem.166.1.235; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; HELDIN NE, 1988, P NATL ACAD SCI USA, V85, P9302, DOI 10.1073/pnas.85.23.9302; KAKU M, 1980, GANN, V71, P596; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MAJESKY MW, 1988, P NATL ACAD SCI USA, V85, P1524, DOI 10.1073/pnas.85.5.1524; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; METZGAR RS, 1982, CANCER RES, V42, P601; MORGAN RT, 1980, INT J CANCER, V25, P591, DOI 10.1002/ijc.2910250507; MOTOYAMA T, 1983, JPN J CANCER RES, V74, P679; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; NOGUCHI P, 1979, IN VITRO CELL DEV B, V15, P401; OKABE T, 1983, CANCER, V51, P662, DOI 10.1002/1097-0142(19830215)51:4<662::AID-CNCR2820510419>3.0.CO;2-X; PALOMBELLA VJ, 1988, J CELL PHYSIOL, V135, P23, DOI 10.1002/jcp.1041350104; PAULSSON Y, 1989, EXP CELL RES, V180, P490, DOI 10.1016/0014-4827(89)90075-X; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; PIMENTEL E, 1987, HORMONES GROWTH FACT, P195; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RATNER L, 1989, NUCLEIC ACIDS RES, V17, P4101, DOI 10.1093/nar/17.11.4101; REILLY CF, 1989, BIOCHEM BIOPH RES CO, V160, P1047, DOI 10.1016/S0006-291X(89)80108-1; RO J, 1989, ONCOGENE, V4, P351; ROSS R, 1989, LANCET, V1, P1179; ROZENGURT E, 1985, INT J CANCER, V36, P247, DOI 10.1002/ijc.2910360218; SARIBAN E, 1988, J CLIN INVEST, V82, P1157, DOI 10.1172/JCI113712; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHEURICH P, 1989, J EXP MED, V170, P947, DOI 10.1084/jem.170.3.947; SCHMIEGEL WH, 1988, PANCREAS, V3, P180, DOI 10.1097/00006676-198804000-00012; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SUZUKI H, 1989, AM J PATHOL, V134, P35; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEIMA SM, 1990, EXP CELL RES, V186, P324, DOI 10.1016/0014-4827(90)90312-X; WILLIAMS LT, 1988, MECH CONTROL GENE EX, P351; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	58	40	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1015	1021						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906154				2022-12-17	WOS:A1991GU62200017
J	CECI, JD; KOVATCH, RM; SWING, DA; JONES, JM; SNOW, CM; ROSENBERG, MP; JENKINS, NA; COPELAND, NG; MEISLER, MH				CECI, JD; KOVATCH, RM; SWING, DA; JONES, JM; SNOW, CM; ROSENBERG, MP; JENKINS, NA; COPELAND, NG; MEISLER, MH			TRANSGENIC MICE CARRYING A MURINE AMYLASE-2.2/SV40 T-ANTIGEN FUSION GENE DEVELOP PANCREATIC ACINAR CELL AND STOMACH CARCINOMAS	ONCOGENE			English	Article							AMYLASE GENE; ALPHA-AMYLASES; DIABETIC MICE; HYBRID GENE; EXPRESSION; INSULIN; TUMORS; NEOPLASIA; DNA; ONCOGENES	The mouse pancreatic amylase Amy-2.2 gene was fused to the structural gene for SV40 T antigen, and 51 independent transgenic founder mice carrying the fusion gene were generated. The majority of the founders and 100% of their offspring in the derived transgenic lines developed pancreatic acinar cell carcinomas and stomach carcinomas. Transgenic animals also had a high incidence of metastatic carcinomas in other tissues. The development of stomach carcinomas was unexpected because the Amy-2.2 promoter was not previously known to be expressed in stomach. Northern blot analyses and ribonuclease protection assays showed that Amy-2.2 is expressed in stomach, at approximately 0.05% of the level in pancreas. Expression of the fusion gene in stomach, therefore, appears to represent a previously unrecognized activity of the Amy-2.2 promoter. Examination of young transgenic mice demonstrated that preneoplastic lesions were present in pancreas and stomach before the development of neoplastic lesions in either tissue, consistent with the notion that stomach neoplasms are primary neoplasms and not metastases from the pancreas. Ribonuclease protection assays demonstrated that properly initiated large T and small t antigen transcripts were present in pancreas and stomach during tumorigenesis. T antigen protein was also detected in pancreas and stomach by immunohistochemistry. A time course for tumorigenesis was established for several transgenic mouse lines in which distinct types of lesions appeared at predictable times. This study provides the basis for future analysis of the role of SV40 T antigen in the progression and maintenance of pancreatic and stomach carcinomas.	SQUIBB INST MED RES,DEPT MOLEC BIOL,PRINCETON,NJ 08543; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024872] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIGMS NIH HHS [GM 24872] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BEHRINGER RR, 1988, P NATL ACAD SCI USA, V85, P2648, DOI 10.1073/pnas.85.8.2648; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; BOTTERI FM, 1987, MOL CELL BIOL, V7, P3178, DOI 10.1128/MCB.7.9.3178; CARDESA A, 1979, PATHOLOGY TUMOURS LA, V2, P235; CECI JD, 1989, GENOMICS, V5, P699, DOI 10.1016/0888-7543(89)90111-0; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; DRANGINIS A, 1984, J BIOL CHEM, V259, P2216; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; FOX N, 1989, SCIENCE, V244, P460, DOI 10.1126/science.2785714; GUMUCIO DL, 1985, J BIOL CHEM, V260, P3483; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HARDING JD, 1978, J BIOL CHEM, V253, P8736; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Karn R.C., 1978, ADVANCES IN COMPARATIVE PHYSIOLOGY AND BIOCHEMISTRY, V7, P1; KELLER SA, 1990, GENE DEV, V4, P1316, DOI 10.1101/gad.4.8.1316; KOIKE K, 1989, P NATL ACAD SCI USA, V86, P5615, DOI 10.1073/pnas.86.14.5615; LIKE AA, 1976, SCIENCE, V193, P415, DOI 10.1126/science.180605; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MEISLER MH, 1989, ANNU REV PHYSIOL, V51, P701, DOI 10.1146/annurev.physiol.51.1.701; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Merritt A D, 1977, Adv Hum Genet, V8, P135; MESSING A, 1988, ONCOGENE RES, V3, P87; ODASHIMA S, 1979, PATHOLOGY TUMOURS LA, V2, P147; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; OSBORN L, 1988, J BIOL CHEM, V263, P16519; OSBORN L, 1987, MOL CELL BIOL, V7, P326, DOI 10.1128/MCB.7.1.326; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; PATEL PH, 1987, HOSP PRACT, V22, P131; ROSSINI AA, 1977, DIABETES, V26, P916, DOI 10.2337/diabetes.26.10.916; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMUELSON LC, 1988, MOL CELL BIOL, V8, P3857, DOI 10.1128/MCB.8.9.3857; SANDGREN EP, 1989, ONCOGENE, V4, P715; SCHIBLER U, 1980, J MOL BIOL, V142, P93, DOI 10.1016/0022-2836(80)90208-9; SIRACUSA LD, 1987, GENETICS, V117, P85; TOOZE J, 1980, DNA TUMOR VIRUSES, P799; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987	40	40	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					323	332						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1705690				2022-12-17	WOS:A1991FZ13400020
J	KOLCH, W; WEISSINGER, E; MISCHAK, H; TROPPMAIR, J; SHOWALTER, SD; LLOYD, P; HEIDECKER, G; RAPP, UR				KOLCH, W; WEISSINGER, E; MISCHAK, H; TROPPMAIR, J; SHOWALTER, SD; LLOYD, P; HEIDECKER, G; RAPP, UR			PROBING STRUCTURE AND FUNCTION OF THE RAF PROTEIN-KINASE DOMAIN WITH MONOCLONAL-ANTIBODIES	ONCOGENE			English	Article									NCI,FREDERICK CANC RES FACIL,VIRAL CARCINOGENESIS,FREDERICK,MD 21701; NCI,GENET LAB,BETHESDA,MD 20892; FREDERICK CANC RES FACIL,PROGRAM RESOURCES INC,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kolch, Walter/ABF-2102-2021; Mischak, Harald/E-8685-2011	Troppmair, Jakob/0000-0002-0611-3837; Mischak, Harald/0000-0003-0323-0306; Kolch, Walter/0000-0001-5777-5016				BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRAMSON HN, 1982, J BIOL CHEM, V257, P575; BRYANT D, 1983, J VIROL, V45, P1211, DOI 10.1128/JVI.45.3.1211-1216.1983; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P327, DOI 10.1093/nar/14.1.327; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; HUNTER T, 1986, ENZYMES, V17, P191; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOLCH W, 1988, BIOCHIM BIOPHYS ACTA, V949, P233, DOI 10.1016/0167-4781(88)90087-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVIN LR, 1988, SCIENCE, V240, P68, DOI 10.1126/science.2832943; MOELDERS H, 1985, EMBO (European Molecular Biology Organization) Journal, V4, P693; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1988, HDB ONCOGENES, P213; RAPP UR, 1987, P INT C HORMONES GRO; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; SCHULTZ AM, 1988, ONCOGENE, V2, P187; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SOBEL E, 1985, NUCLEIC ACIDS RES, V14, P363; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WEINMASTER G, 1986, J BIOL CHEM, V261, P328; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726	39	40	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					713	720						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	1693184				2022-12-17	WOS:A1990DG37400012
J	ALCALAY, M; ANTOLINI, F; VANDEVEN, WJ; LANFRANCONE, L; GRIGNANI, F; PELICCI, PG				ALCALAY, M; ANTOLINI, F; VANDEVEN, WJ; LANFRANCONE, L; GRIGNANI, F; PELICCI, PG			CHARACTERIZATION OF HUMAN AND MOUSE C-FES CDNA CLONES AND IDENTIFICATION OF THE 5' END OF THE GENE	ONCOGENE			English	Article									UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY; GASTHUISBERG,CTR HUMAN GENET,B-3000 LEUWEN,BELGIUM	University of Perugia			Lanfrancone, Luisa/AAC-8671-2019; Alcalay, Myriam/AAB-4300-2019; Pelicci, Pier Giuseppe/AAL-6572-2020; Alcalay, Myriam/B-3182-2016	Lanfrancone, Luisa/0000-0002-4523-3815; Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272				BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BISHOP JM, 1982, RNA TUMOR VIRUSES, V2, P267; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P4714, DOI 10.1073/pnas.79.15.4714; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FRANCHINI G, 1981, NATURE, V290, P154, DOI 10.1038/290154a0; FRANCHINI G, 1982, MOL CELL BIOL, V2, P1014, DOI 10.1128/MCB.2.8.1014; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROFFEN J, 1982, SCIENCE, V216, P1136, DOI 10.1126/science.6281890; HAMPE A, 1982, CELL, V30, P775, DOI 10.1016/0092-8674(82)90282-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; HEISTERKAMP N, 1982, NATURE, V299, P747, DOI 10.1038/299747a0; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LANFRANCONE L, 1989, IN PRESS INT J CANCE; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; Maniatis T., 1982, MOL CLONING; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROEBROEK AJM, 1986, MOL BIOL REP, V11, P117, DOI 10.1007/BF00364823; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROEBROEK AJM, 1987, J VIROL, V61, P2009, DOI 10.1128/JVI.61.6.2009-2016.1987; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SELBY MJ, 1984, J BIOL CHEM, V259, P3131; SHEER D, 1983, CHROMOSOMES CANCER, P183; SHERR CJ, 1984, CANCER CELL, V2, P329; SHIBUYA M, 1982, CELL, V30, P787, DOI 10.1016/0092-8674(82)90283-5; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TRUS MD, 1982, J BIOL CHEM, V257, P2730; VANDENBERGHE H, 1979, CANCER, V43, P558, DOI 10.1002/1097-0142(197902)43:2<558::AID-CNCR2820430223>3.0.CO;2-6; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILKS AF, 1988, ONCOGENE, V3, P289	37	40	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					267	275						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2179816				2022-12-17	WOS:A1990CW41500003
J	PATEL, M; LEEVERS, SJ; BRICKELL, PM				PATEL, M; LEEVERS, SJ; BRICKELL, PM			STRUCTURE OF THE COMPLETE HUMAN C-FGR PROTOONCOGENE AND IDENTIFICATION OF MULTIPLE TRANSCRIPTIONAL START SITES	ONCOGENE			English	Article									UNIV COLL & MIDDLESEX SCH MED,DEPT BIOCHEM,MED MOLEC BIOL UNIT,WINDEYER BLDG,CLEVELAND ST,LONDON W1P 6DB,ENGLAND	University of London; University College London								Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRICKELL PM, 1988, BRIT J CANCER, V58, P704, DOI 10.1038/bjc.1988.294; CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GRIFFIN BE, 1984, NATURE, V309, P78, DOI 10.1038/309078a0; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HAMADA H, 1984, MOL CELL BIOL, V4, P2622, DOI 10.1128/MCB.4.12.2622; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INOUE K, 1987, ONCOGENE, V1, P301; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KIOUSSIS D, 1987, EMBO J, V6, P355, DOI 10.1002/j.1460-2075.1987.tb04762.x; KLEIN C, 1988, INT J CANCER, V42, P29, DOI 10.1002/ijc.2910420107; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; ROONEY C, 1989, J VIROL, V63, P1531, DOI 10.1128/JVI.63.4.1531-1539.1989; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978	31	40	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1990	5	2					201	206						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU029	1690869				2022-12-17	WOS:A1990CU02900006
J	SULLIVAN, NF; WILLIS, AE				SULLIVAN, NF; WILLIS, AE			ELEVATION OF C-MYC PROTEIN BY DNA STRAND BREAKAGE	ONCOGENE			English	Article											SULLIVAN, NF (corresponding author), IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND.			Willis, Anne/0000-0002-1470-8531				ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BIRNBOIM HC, 1982, SCIENCE, V215, P1247, DOI 10.1126/science.6276978; BRENT TP, 1988, P NATL ACAD SCI USA, V85, P1759, DOI 10.1073/pnas.85.6.1759; BURGER RM, 1981, J BIOL CHEM, V256, P1636; CERNI C, 1987, EXP CELL RES, V168, P439, DOI 10.1016/0014-4827(87)90016-4; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CLEAVER JE, 1978, BIOCHIM BIOPHYS ACTA, V516, P489, DOI 10.1016/0304-419X(78)90020-3; CRAWFORD D, 1988, ONCOGENE, V3, P27; DEAN M, 1986, J BIOL CHEM, V261, P9161; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; DURKACZ BW, 1981, BIOCHEM BIOPH RES CO, V101, P1433, DOI 10.1016/0006-291X(81)91607-7; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FORNACE AJ, 1976, P NATL ACAD SCI USA, V73, P39, DOI 10.1073/pnas.73.1.39; FUJIWARA Y, 1977, J MOL BIOL, V113, P635, DOI 10.1016/0022-2836(77)90227-3; GOSS P, 1977, CANCER RES, V37, P152; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; IYER VN, 1963, P NATL ACAD SCI USA, V50, P355, DOI 10.1073/pnas.50.2.355; JAMES MR, 1982, BIOCHEMISTRY-US, V21, P4007, DOI 10.1021/bi00260a016; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1984, CURR TOP MICROBIOL, V113, P117; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KURAMOCHI H, 1981, J ANTIBIOT, V34, P576, DOI 10.7164/antibiotics.34.576; LATCHMAN HM, 1984, NATURE, V310, P592; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; MITCHELL DL, 1988, MUTAT RES, V193, P53, DOI 10.1016/0167-8817(88)90007-7; MOORE JP, 1986, J BIOL CHEM, V261, P8158; MOORE JP, 1987, ONCOGENE RES, V2, P65; MORGAN WF, 1983, CANCER RES, V43, P3104; NICKERSON JA, 1989, P NATL ACAD SCI USA, V86, P177, DOI 10.1073/pnas.86.1.177; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RONAI ZA, 1988, ONCOGENE, V2, P201; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; Singer B., 1983, MOL BIOL MUTAGENS CA, P45; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SPECTOR DL, 1987, ONCOGENE, V1, P5; SQUIRES S, 1983, CARCINOGENESIS, V4, P565, DOI 10.1093/carcin/4.5.565; SULLIVAN NF, 1988, CURR TOP MICROBIOL, V141, P208; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TEO IA, 1983, CARCINOGENESIS, V4, P559, DOI 10.1093/carcin/4.5.559; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TSOPANAKIS C, 1978, EUR J BIOCHEM, V90, P337, DOI 10.1111/j.1432-1033.1978.tb12610.x; VANSTRAATEN JP, 1987, ONCOGENE RES, V1, P221; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448	54	40	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1989	4	12					1497	1502						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687769				2022-12-17	WOS:A1989CB65900012
J	ITO, E; SONNENBERG, JL; NARAYANAN, R				ITO, E; SONNENBERG, JL; NARAYANAN, R			NERVE GROWTH FACTOR-INDUCED DIFFERENTIATION IN PC-12 CELLS IS BLOCKED BY FOS ONCOGENE	ONCOGENE			English	Article									ROCHE INST MOLEC BIOL,DEPT MOLEC ONCOL,NUTLEY,NJ 07110		ITO, E (corresponding author), ROCHE RES CTR,DEPT MOLEC GENET,340 KINGSLAND ST,NUTLEY,NJ 07110, USA.			Narayanan, Ramaswamy/0000-0001-9346-9083; Ito, Etsuro/0000-0002-0168-2475				ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1987, ONCOGENE, V2, P79; CURRAN T, 1984, CELL, V36, P259; Curran T, 1988, ONCOGENE HDB, P307; CURRAN T, 1987, UCLA S MOL CELLULAR, V58, P215; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENE LA, 1978, NATURE, V276, P191, DOI 10.1038/276191a0; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GROB PM, 1983, P NATL ACAD SCI-BIOL, V80, P6819, DOI 10.1073/pnas.80.22.6819; HEBY O, 1981, DIFFERENTIATION, V19, P1, DOI 10.1111/j.1432-0436.1981.tb01123.x; HICKOK NJ, 1986, P NATL ACAD SCI USA, V83, P594, DOI 10.1073/pnas.83.3.594; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; MARUYAMA K, 1987, ONCOGENE, V1, P361; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; MULLER R, 1983, EMBO J, V2, P699; NARAYANAN R, 1988, EXP CELL RES, V174, P297, DOI 10.1016/0014-4827(88)90164-4; NARAYANAN R, 1986, BIOCHEM BIOPH RES CO, V141, P1018, DOI 10.1016/S0006-291X(86)80146-2; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REISS M, 1986, BIOCHEM BIOPH RES CO, V137, P244, DOI 10.1016/0006-291X(86)91202-7; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SAFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9	44	40	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1193	1199						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2552373				2022-12-17	WOS:A1989AU50800005
J	PROPST, F; ROSENBERG, MP; OSKARSSON, MK; RUSSELL, LB; NGUYENHUU, MC; NADEAU, J; JENKINS, NA; COPELAND, NG; VANDEWOUDE, GF				PROPST, F; ROSENBERG, MP; OSKARSSON, MK; RUSSELL, LB; NGUYENHUU, MC; NADEAU, J; JENKINS, NA; COPELAND, NG; VANDEWOUDE, GF			GENETIC-ANALYSIS AND DEVELOPMENTAL REGULATION OF TESTIS-SPECIFIC RNA EXPRESSION OF MOS, ABL, ACTIN AND HOX-1.4	ONCOGENE			English	Article									OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT UROL,NEW YORK,NY 10032; JACKSON LAB,BAR HARBOR,ME 04609	United States Department of Energy (DOE); Oak Ridge National Laboratory; Columbia University; Columbia University; Jackson Laboratory	PROPST, F (corresponding author), NCI,FREDERICK CANC RES FACIL,BRI BASIC RES PROGRAM,POB B,FREDERICK,MD 21701, USA.				OFFICE OF THE DIRECTOR, NCI [N01CO023909] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-23909] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; BENNETT D, 1975, CELL, V6, P441, DOI 10.1016/0092-8674(75)90033-1; BENNETT WI, 1971, BIOL REPROD, V5, P30, DOI 10.1093/biolreprod/5.1.30; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CATTANACH BM, 1971, CYTOGENETICS, V10, P318, DOI 10.1159/000130151; CATTANACH BM, 1977, NATURE, V269, P338, DOI 10.1038/269338a0; DUDLEY K, 1984, NUCLEIC ACIDS RES, V12, P4281, DOI 10.1093/nar/12.10.4281; EICHER EM, 1986, ANNU REV GENET, V20, P327, DOI 10.1146/annurev.ge.20.120186.001551; EICHER EM, 1982, SCIENCE, V217, P535, DOI 10.1126/science.7089579; ERICKSON RP, 1985, BIOSCIENCE REP, V5, P1087, DOI 10.1007/BF01119630; Favaloro J, 1980, Methods Enzymol, V65, P718; FUJIMOTO H, 1984, BIOSCIENCE REP, V4, P1037, DOI 10.1007/BF01116696; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HANDEL MA, 1987, J EXP ZOOL, V243, P81, DOI 10.1002/jez.1402430111; Hecht NB., 1986, EXPT APPROACHES MAMM, P151; JONES M, 1980, P NATL ACAD SCI-BIOL, V77, P2651, DOI 10.1073/pnas.77.5.2651; KESHET E, 1988, ONCOGENE, V2, P235; KLEENE KC, 1983, DEV BIOL, V98, P455, DOI 10.1016/0012-1606(83)90375-5; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; LYON MF, 1970, NATURE, V227, P1217, DOI 10.1038/2271217a0; MANIATIS T, 1982, MOL CLONING LABORATO; MINTZ B, 1955, ANAT REC, V122, P443; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OAKBERG EF, 1956, AM J ANAT, V99, P507, DOI 10.1002/aja.1000990307; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PETERS H, 1969, ACTA ENDOCRINOL-COP, V62, P98, DOI 10.1530/acta.0.0620098; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; RAPPOLD GA, 1987, EMBO J, V6, P1975, DOI 10.1002/j.1460-2075.1987.tb02460.x; RAVE N, 1979, NUCLEIC ACIDS RES, V6, P3559, DOI 10.1093/nar/6.11.3559; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RUBIN MR, 1986, SCIENCE, V233, P663, DOI 10.1126/science.3726554; RUSSELL LB, 1983, PROGR TOPICS CYTOG A, V3, P206; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; WATERS SH, 1985, MOL CELL BIOL, V5, P1649, DOI 10.1128/MCB.5.7.1649; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WIELAND SJ, 1979, CELL, V17, P781, DOI 10.1016/0092-8674(79)90318-0; WOLGEMUTH DJ, 1987, P NATL ACAD SCI USA, V84, P5813, DOI 10.1073/pnas.84.16.5813; WOLGEMUTH DJ, 1986, EMBO J, V5, P1229, DOI 10.1002/j.1460-2075.1986.tb04351.x; YELICK PC, 1987, MOL CELL BIOL, V7, P2173, DOI 10.1128/MCB.7.6.2173	49	40	41	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					227	233						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	2895445				2022-12-17	WOS:A1988M593100004
J	Gao, LX; Lang, LW; Zhao, XD; Shay, C; Shull, AY; Teng, Y				Gao, Lixia; Lang, Liwei; Zhao, Xiangdong; Shay, Chloe; Shull, Austin Y.; Teng, Yong			FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma	ONCOGENE			English	Article							GROWTH-FACTOR 19; SKELETAL-MUSCLE MASS; HEPATOCELLULAR-CARCINOMA; CANCER; GENE; EXPRESSION; FGFR4	The fibroblast growth factor 19 gene FGF19 has previously been reported to be amplified in several cancer types and encodes for a key autocrine signaler known to promote tumorigenic growth. Thus, it is imperative to understand which cancers are oncogenically addicted to FGF19 amplification as well as the role it serves in these cancer types. We report for the first time high FGF19 amplification in head and neck squamous cell carcinomas (HNSCC), which is associated with increased autocrine secretion of FGF19 and poor patient outcome in HNSCC. FGF19 amplification corresponded with constitutive activation of FGF receptor 4 (FGFR4)-dependent ERK/AKT-p70S6K-S6 signaling activation in HNSCC cells, and addition of human recombinant FGF19 could promote cell proliferation and soft agar colony formation in HNSCC cells with low FGF19 expression through activation of FGFR4 and downstream signaling cascades. In contrast, FGF19 knockout counteracts the observed effects in HNSCC cells carrying high endogenous FGF19, with knockout of FGF19 significantly suppressing tumor growth in an orthotopic mouse model of HNSCC. Collectively, this study demonstrates that FGF19 gene amplification corresponds with an increased dependency upon FGF19/FGFR4 autocrine signaling in HNSCC, revealing a therapeutic target for this cancer type.	[Gao, Lixia; Lang, Liwei; Zhao, Xiangdong; Teng, Yong] Augusta Univ, Dept Oral Biol & Diagnost Sci, Augusta, GA 30912 USA; [Shay, Chloe] Emory Univ, Emory Childrens Ctr, Atlanta, GA 30322 USA; [Shull, Austin Y.] Presbyterian Coll, Dept Biol, Clinton, SC USA; [Teng, Yong] Augusta Univ, Georgia Canc Ctr, Augusta, GA 30912 USA	University System of Georgia; Augusta University; Emory University; University System of Georgia; Augusta University	Teng, Y (corresponding author), Augusta Univ, Dept Oral Biol & Diagnost Sci, Augusta, GA 30912 USA.; Teng, Y (corresponding author), Augusta Univ, Georgia Canc Ctr, Augusta, GA 30912 USA.	yteng@augusta.edu	Lang, Liwei/I-7744-2019; Teng, Yong/AAK-4160-2020	Teng, Yong/0000-0002-1856-7289; Lang, Liwei/0000-0002-2374-645X	Dental College of Georgia Special Funding Initiative; Department of Defense [W81XWH-14-1-0412]	Dental College of Georgia Special Funding Initiative; Department of Defense(United States Department of Defense)	This work was supported in part by Dental College of Georgia Special Funding Initiative and a grant from the Department of Defense (W81XWH-14-1-0412) (to Y.T.). The authors sincerely thank Dr. Andrew W. Yeudall (Augusta University) for providing HNSCC cells for this study.	Ahn SM, 2014, HEPATOLOGY, V60, P1972, DOI 10.1002/hep.27198; Angelin B, 2012, CELL METAB, V16, P693, DOI 10.1016/j.cmet.2012.11.001; Benoit B, 2017, NAT MED, V23, P990, DOI 10.1038/nm.4363; CARDINALI M, 1995, INT J CANCER, V61, P98, DOI 10.1002/ijc.2910610117; Chi AC, 2015, CA-CANCER J CLIN, V65, P401, DOI 10.3322/caac.21293; de Mello RA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086697; Gao LX, 2018, CELL ONCOL, V41, P85, DOI 10.1007/s13402-017-0354-4; Gao LX, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0478-9; Gibcus JH, 2007, CLIN CANCER RES, V13, P6257, DOI 10.1158/1078-0432.CCR-07-1247; Glass DJ, 2017, CELL METAB, V26, P287, DOI 10.1016/j.cmet.2017.07.017; Hagel M, 2015, CANCER DISCOV, V5, P424, DOI 10.1158/2159-8290.CD-14-1029; Katoh M, 2003, INT J MOL MED, V12, P45; Kir S, 2011, SCIENCE, V331, P1621, DOI 10.1126/science.1198363; Lang LW, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0623-3; Lang LW, 2019, CURR CANCER DRUG TAR, V19, P17, DOI 10.2174/1568009618666180319091731; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Marcelin G, 2014, MOL METAB, V3, P19, DOI 10.1016/j.molmet.2013.10.002; Morrison C, 2006, J CLIN ONCOL, V24, P2376, DOI 10.1200/JCO.2005.03.4827; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Sawey ET, 2011, CANCER CELL, V19, P347, DOI 10.1016/j.ccr.2011.01.040; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; Schwab M, 1999, ONCOGENE AMPLIFICATI, P319; Song KH, 2009, HEPATOLOGY, V49, P297, DOI 10.1002/hep.22627; Teng Y, 2010, BRIT J CANCER, V103, P1066, DOI 10.1038/sj.bjc.6605850; Teng Y, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0485-0; Tiong KH, 2016, ONCOTARGET, V7, P57633, DOI 10.18632/oncotarget.9328; Wan ZY, 2016, HEPATOLOGY, V64, P1289, DOI 10.1002/hep.28639; Xie XY, 2016, ONCOTARGET, V7, P58111, DOI 10.18632/oncotarget.11185; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683; Zhao HK, 2016, ONCOTARGET, V7, P13575, DOI 10.18632/oncotarget.6185; Zhao XD, 2018, MOL CARCINOGEN, V57, P1616, DOI 10.1002/mc.22884; Zhou M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15433	34	39	42	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2394	2404		10.1038/s41388-018-0591-7	http://dx.doi.org/10.1038/s41388-018-0591-7			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30518874				2022-12-17	WOS:000462588000012
J	Yonesaka, K; Takegawa, N; Watanabe, S; Haratani, K; Kawakami, H; Sakai, K; Chiba, Y; Maeda, N; Kagari, T; Hirotani, K; Nishio, K; Nakagawa, K				Yonesaka, Kimio; Takegawa, Naoki; Watanabe, Satomi; Haratani, Koji; Kawakami, Hisato; Sakai, Kazuko; Chiba, Yasutaka; Maeda, Naoyuki; Kagari, Takashi; Hirotani, Kenji; Nishio, Kazuto; Nakagawa, Kazuhiko			An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC	ONCOGENE			English	Article							CELL LUNG-CANCER; MONOCLONAL-ANTIBODY; HER3; GEFITINIB; AMPLIFICATION; EGFR(T790M); PATRITUMAB; SURVIVAL; C-ERBB-3; PROTEIN	EGFR tyrosine kinase inhibitors (TKIs) are standard therapy for EGFR-mutant non-small cell lung cancer (NSCLC); however, these tumours eventually acquire chemoresistance. U3-1402 is an anti-HER3 antibody-drug conjugate with a novel topoisomerase I inhibitor, DXd. In the current study, we evaluated the anticancer efficacy of U3-1402 in EGFR-mutant NSCLC cells with acquired resistance to EGFR-TKIs. HCC827GR5 and PC9AZDR7 are EGFR-TKI-resistant clones for gefitinib and osimertinib, respectively. U3-1402 alone or in combination with the EGFR-TKI erlotinib demonstrated potent anticancer efficacy in HCC827GR5 cells using an in vitro growth inhibition assay and in vivo xenograft mouse model. U3-1402 induced apoptosis in HCC827GR5 cells accompanying phosphorylation of histone H2A.X, a marker of DNA damage, but did not block HER3/PI3K/AKT signalling. Further, we found using flow cytometry that the cell surface HER3 expression level in HCC827GR5 cells was twice that found in HCC827 cells, indicating internalization of U3-1402 was increased in resistant cells. In addition, administration of U3-1402 notably repressed growth of EGFR-TKI osimertinib-resistant PC9AZDR7 xenograft tumours, and that PC9AZDR7 cells expressed five times greater cell surface HER3 than PC9 cells. Furthermore, using immunofluorescent microscopy, HER3 was observed predominantly in the nucleus of PC9 cells, but was localized in the cytoplasm of PC9AZDR7 cells. This finding indicates that altered trafficking of the HER3-U3-1402 complex may accelerate linker payload cleavage by cytoplasmic lysosomal enzymes, resulting in DNA damage. Our results indicate that administration of U3-1402 alone or in combination with an EGFR-TKI may have potential as a novel therapy for EGFR-TKI-resistant EGFR-mutant NSCLC.	[Yonesaka, Kimio; Takegawa, Naoki; Watanabe, Satomi; Haratani, Koji; Kawakami, Hisato; Nakagawa, Kazuhiko] Kindai Univ, Dept Med Oncol, Fac Med, Osaka, Japan; [Sakai, Kazuko; Nishio, Kazuto] Kindai Univ, Dept Genome Biol, Fac Med, Osaka, Japan; [Chiba, Yasutaka] Kindai Univ Hosp, Clin Res Ctr, Osaka, Japan; [Maeda, Naoyuki] Daiichi Sankyo Co Ltd, Biomarker Dept, Shinagawa Ku, Tokyo, Japan; [Kagari, Takashi] Daiichi Sankyo Co Ltd, Biol & Immunooncol Labs, Shinagawa Ku, Tokyo, Japan; [Hirotani, Kenji] Daiichi Sankyo Co Ltd, Oncol Clin Dev Dept, Shinagawa Ku, Tokyo, Japan	Kindai University (Kinki University); Kindai University (Kinki University); Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited	Yonesaka, K (corresponding author), Kindai Univ, Dept Med Oncol, Fac Med, Osaka, Japan.	yonesaka@med.kindai.ac.jp	Watanabe, Satomi/HCI-6317-2022; Kawakami, Hisato/L-6845-2019	Kawakami, Hisato/0000-0002-3280-4850	Daiichi Sankyo Co., Ltd. [U3-1402]	Daiichi Sankyo Co., Ltd.(Daiichi Sankyo Company Limited)	This study was financially supported by Daiichi Sankyo Co., Ltd. U3-1402 and patritumab were provided by Daiichi Sankyo Co., Ltd.	Begnami MD, 2011, J CLIN ONCOL, V29, P3030, DOI 10.1200/JCO.2010.33.6313; Burris HA, 2011, J CLIN ONCOL, V29, P398, DOI 10.1200/JCO.2010.29.5865; Campbell MR, 2010, CLIN CANCER RES, V16, P1373, DOI 10.1158/1078-0432.CCR-09-1218; Cappuzzo F, 2005, BRIT J CANCER, V93, P1334, DOI 10.1038/sj.bjc.6602865; Chen R, 2015, MOL CANCER THER, V14, P1376, DOI 10.1158/1535-7163.MCT-15-0036; Doi T, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.108; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Jia Y, 2016, NATURE, V534, P129, DOI 10.1038/nature17960; Juric D, 2015, CLIN CANCER RES, V21, P2462, DOI 10.1158/1078-0432.CCR-14-2412; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Loganzo F, 2016, MOL CANCER THER, V15, P2825, DOI 10.1158/1535-7163.MCT-16-0408; Loganzo F, 2015, MOL CANCER THER, V14, P952, DOI 10.1158/1535-7163.MCT-14-0862; Mendell J, 2015, EBIOMEDICINE, V2, P264, DOI 10.1016/j.ebiom.2015.02.005; Meulendijks D, 2017, CLIN CANCER RES, V23, P5406, DOI 10.1158/1078-0432.CCR-17-0812; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Ogitani Y, 2016, CLIN CANCER RES, V22, P5097, DOI 10.1158/1078-0432.CCR-15-2822; Reif R, 2016, J BIOL CHEM, V291, P3837, DOI 10.1074/jbc.M115.686782; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shimizu T, 2017, CANCER CHEMOTH PHARM, V79, P489, DOI 10.1007/s00280-016-3231-3; Takegawa N, 2017, INT J CANCER, V141, P1682, DOI 10.1002/ijc.30870; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Trocme E, 2012, INT J CANCER, V130, P1120, DOI 10.1002/ijc.26118; Ueno S, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-3092; Yi ES, 1997, MODERN PATHOL, V10, P142; Yonesaka K, 2016, ONCOGENE, V35, P878, DOI 10.1038/onc.2015.142; Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442; Zhou CC, 2016, J THORAC ONCOL, V11, P174, DOI 10.1016/j.jtho.2015.10.002	30	39	41	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1398	1409		10.1038/s41388-018-0517-4	http://dx.doi.org/10.1038/s41388-018-0517-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30302022				2022-12-17	WOS:000459945800003
J	Zhang, HL; Wang, YL; Dou, JZ; Guo, YM; He, JF; Li, L; Liu, XJ; Chen, R; Deng, R; Huang, J; Xie, RY; Zhao, X; Yu, JX				Zhang, Hailong; Wang, Yanli; Dou, Jinzhuo; Guo, Yanmin; He, Jianfeng; Li, Lian; Liu, Xiaojia; Chen, Ran; Deng, Rong; Huang, Jian; Xie, Ruiyu; Zhao, Xian; Yu, Jianxiu			Acetylation of AGO2 promotes cancer progression by increasing oncogenic miR-19b biogenesis	ONCOGENE			English	Article							RNA-INTERFERENCE; MIR-17-SIMILAR-TO-92 CLUSTER; MICRORNA BIOGENESIS; PHOSPHORYLATION; ARGONAUTE; DICER; COMPLEX; BINDING; METASTASIS; HYPOXIA	Argonaute2 (AGO2) is an effector of small RNA mediated gene silencing. Increasing evidence show that post-translational modifications of AGO2 can change miRNA activity at specific or global levels. Among the six mature miRNAs that are encoded by miR-17-92, miR-19b1 is the most powerful to exert the oncogenic properties of the entire cluster. Here we identify that AGO2 can be acetylated by P300/CBP and deacetylated by HDAC7, and that acetylation occurs at three sites K720, K493, and K355. Mutation of K493R/K720R, but not K355R at AGO2, inhibits miR-19b biogenesis. We demonstrate that acetylation of AGO2 specifically increases its recruiting pre-miR-19b1 to form the miPDC (miRNA precursor deposit complex), thereby to enhance miR-19b maturation. The motif UGUGUG in the terminal-loop of pre-miR-19b1, as a specific processing feature that is recognized and bound by acetylated AGO2, is essential for the assembly of miRISC (miRNA-induced silencing complex) loading complex. Analyses on public clinical data, xenograft mouse models, and IHC and ISH staining of lung cancer tissues, further confirm that the high levels of both AGO2 acetylation and miR-19b correlate with poor prognosis in lung cancer patients. Our finding reveals a novel function of AGO2 acetylation in increasing oncogenic miR-19b biogenesis and suggests that modulation of AGO2 acetylation has potential clinical implications.	[Zhang, Hailong; Wang, Yanli; Dou, Jinzhuo; Guo, Yanmin; He, Jianfeng; Li, Lian; Liu, Xiaojia; Chen, Ran; Deng, Rong; Huang, Jian; Zhao, Xian; Yu, Jianxiu] Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Shanghai 200025, Peoples R China; [Yu, Jianxiu] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Sch Med, Shanghai 200025, Peoples R China; [Yu, Jianxiu] Shanghai Jiao Tong Univ, Dept Pathophysiol, Key Lab Cell Differentiat & Apoptosis, Chinese Minist Educ,Sch Med, Shanghai 200025, Peoples R China; [Xie, Ruiyu] Univ Macau, Fac Hlth Sci, Macau 999078, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of Macau	Zhao, X; Yu, JX (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Shanghai 200025, Peoples R China.; Yu, JX (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Sch Med, Shanghai 200025, Peoples R China.; Yu, JX (corresponding author), Shanghai Jiao Tong Univ, Dept Pathophysiol, Key Lab Cell Differentiat & Apoptosis, Chinese Minist Educ,Sch Med, Shanghai 200025, Peoples R China.	Xianzhao1985@sjtu.edu.cn; Jianxiu.Yu@gmail.com	Huang, Jian/ABF-8355-2021	Xie, Ruiyu/0000-0003-0518-2897	National Natural Science Foundation of China [31671345, 81472571, 81630075, 81602251, 81702837, 81702532, 81721004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from National Natural Science Foundation of China [31671345, 81472571, 81630075, 81602251, 81702837, 81702532, 81721004]	Auyeung VC, 2013, CELL, V152, P844, DOI 10.1016/j.cell.2013.01.031; Bridge KS, 2017, CELL REP, V20, P173, DOI 10.1016/j.celrep.2017.06.027; Bronevetsky Y, 2013, J EXP MED, V210, P417, DOI 10.1084/jem.20111717; Cheloufi S, 2010, NATURE, V465, P584, DOI 10.1038/nature09092; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9899; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Cifuentes D, 2010, SCIENCE, V328, P1694, DOI 10.1126/science.1190809; Dahm GM, 2012, JOVE-J VIS EXP, DOI 10.3791/3851; de Pontual L, 2011, NAT GENET, V43, P1026, DOI 10.1038/ng.915; Diederichs S, 2007, CELL, V131, P1097, DOI 10.1016/j.cell.2007.10.032; Elkayam E, 2012, CELL, V150, P100, DOI 10.1016/j.cell.2012.05.017; Fan Y, 2014, RNA, V20, P765, DOI 10.1261/rna.043026.113; Golden RJ, 2017, NATURE, V542, P197, DOI 10.1038/nature21025; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Horman SR, 2013, MOL CELL, V50, P356, DOI 10.1016/j.molcel.2013.03.015; Hu J, 2016, CANCER CELL, V29, P49, DOI 10.1016/j.ccell.2015.12.005; Huang J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1919; Huberdeau MQ, 2017, EMBO J, V36, P2088, DOI 10.15252/embj.201696386; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Josa-Prado F, 2015, BIOCHEM BIOPH RES CO, V464, P1066, DOI 10.1016/j.bbrc.2015.07.073; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Leung AKL, 2011, MOL CELL, V42, P489, DOI 10.1016/j.molcel.2011.04.015; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Liu X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.458; Liu X, 2012, IMMUNOL LETT, V143, P208, DOI 10.1016/j.imlet.2012.02.014; Liu XH, 2014, MOL CELL, V55, P868, DOI 10.1016/j.molcel.2014.07.017; Liu XH, 2012, MOL CELL, V46, P507, DOI 10.1016/j.molcel.2012.03.010; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Maniataki E, 2005, GENE DEV, V19, P2979, DOI 10.1101/gad.1384005; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; Nowak JS, 2017, RNA, V23, P317, DOI 10.1261/rna.059196.116; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Qi HH, 2008, NATURE, V455, P421, DOI 10.1038/nature07186; Rybak A, 2009, NAT CELL BIOL, V11, P1411, DOI 10.1038/ncb1987; Sahin U, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102957; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Shen J, 2013, NATURE, V497, P383, DOI 10.1038/nature12080; Sun HL, 2016, CANCER CELL, V30, P723, DOI 10.1016/j.ccell.2016.10.001; Tan GS, 2009, NUCLEIC ACIDS RES, V37, P7533, DOI 10.1093/nar/gkp812; Treiber T, 2017, MOL CELL, V66, P270, DOI 10.1016/j.molcel.2017.03.014; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Wang HW, 2009, NAT STRUCT MOL BIOL, V16, P1148, DOI 10.1038/nsmb.1673; Weinmann L, 2009, CELL, V136, P496, DOI 10.1016/j.cell.2008.12.023; Wu C, 2011, MOL CELL BIOL, V31, P4760, DOI 10.1128/MCB.05776-11; Yang JS, 2010, P NATL ACAD SCI USA, V107, P15163, DOI 10.1073/pnas.1006432107; Yoda M, 2013, CELL REP, V5, P715, DOI 10.1016/j.celrep.2013.09.029; Yu JX, 2004, MOL CELL, V15, P83, DOI 10.1016/j.molcel.2004.06.030; Zeng Y, 2008, BIOCHEM J, V413, P429, DOI 10.1042/BJ20080599; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zhao X, 2016, ONCOTARGET, V7, P33136, DOI 10.18632/oncotarget.8887	57	39	40	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1410	1431		10.1038/s41388-018-0530-7	http://dx.doi.org/10.1038/s41388-018-0530-7			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30305728	Green Published, hybrid			2022-12-17	WOS:000459945800004
J	Na'ara, S; Amit, M; Gil, Z				Na'ara, Shorook; Amit, Moran; Gil, Ziv			L1CAM induces perineural invasion of pancreas cancer cells by upregulation of metalloproteinase expression	ONCOGENE			English	Article							PRESENILIN/GAMMA-SECRETASE; DUCTAL ADENOCARCINOMA; MOLECULE L1; ADHESION; ACTIVATION; CARCINOMA; NERVE; DISSEMINATION; CONTRIBUTES; MIGRATION	Pancreas cancer cells have a tendency to invade along nerves. Such cancerous nerve invasion (CNI) is associated with poor outcome; however, the exact mechanism that drives cancer cells to disseminate along nerves is unknown. Immunohistochemical analysis of human pancreatic ductal adenocarcinoma (PDAC) specimens showed overexpression of the L1 cell adhesion molecule (L1CAM) in cancer cells and in adjacent Schwann cells (SC) in invaded nerves. By modeling the neural microenvironment, we found that L1CAM secreted from SCs acts as a strong chemoattractant to cancer cells, through activation of MAP kinase signaling. L1CAM also upregulated expression of metalloproteinase-2 (MMP-2) and MMP-9 by PDAC cells, through STAT3 activation. Using a transgenic Pdx-1-Cre/KrasG12D /p53R172H (KPC) mouse model, we show that treatment with anti-L1CAM Ab significantly reduces CNI in vivo. We provide evidence of a paracrine response between SCs and cancer cells in the neural niche, which promotes cancer invasion via L1CAM secretion.	[Na'ara, Shorook; Amit, Moran; Gil, Ziv] Rambam Healthcare Campus, Lab Appl Canc Res, Head & Neck Ctr, Dept Otolaryngol Head & Neck Surg,Clin Res Inst, Haifa, Israel; [Gil, Ziv] Technion Israel Inst Technol, Rappaport Inst Med & Res, Technion Integrated Canc Ctr, Haifa, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Gil, Z (corresponding author), Rambam Healthcare Campus, Lab Appl Canc Res, Head & Neck Ctr, Dept Otolaryngol Head & Neck Surg,Clin Res Inst, Haifa, Israel.; Gil, Z (corresponding author), Technion Israel Inst Technol, Rappaport Inst Med & Res, Technion Integrated Canc Ctr, Haifa, Israel.	ziv@baseofskull.org			Israeli Science Foundation; Binational US-Israel Science Foundation; ICRF grant (Jacki and Bruce Barron cancer research scholars' program); ICRF grant (Barbara S Goodman research grant); Israel Cancer Association	Israeli Science Foundation(Israel Science Foundation); Binational US-Israel Science Foundation(US-Israel Binational Science Foundation); ICRF grant (Jacki and Bruce Barron cancer research scholars' program); ICRF grant (Barbara S Goodman research grant); Israel Cancer Association	Cindy Cohen is thanked for her editorial assistance. Nofar Rada is thanked for her artistic work. This study was supported by grants from the Israeli Science Foundation, Binational US-Israel Science Foundation, ICRF grant (Jacki and Bruce Barron cancer research scholars' program and Barbara S Goodman research grant) and Israel Cancer Association.	Abiatari I, 2009, INT J ONCOL, V35, P1111, DOI 10.3892/ijo_00000426; Amit M, 2017, ONCOGENE, V36, P3232, DOI 10.1038/onc.2016.483; Amit M, 2016, NAT REV CANCER, V16, P399, DOI 10.1038/nrc.2016.38; Apte MV, 2004, PANCREAS, V29, P179, DOI 10.1097/00006676-200410000-00002; Bapat AA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165586; Ben QW, 2010, ANN SURG ONCOL, V17, P2213, DOI 10.1245/s10434-010-0955-x; Bergmann F, 2010, ONCOL REP, V24, P909, DOI 10.3892/or_00000936; BOCKMAN DE, 1994, GASTROENTEROLOGY, V107, P219, DOI 10.1016/0016-5085(94)90080-9; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; CARTER RL, 1983, J CLIN PATHOL, V36, P269, DOI 10.1136/jcp.36.3.269; Cavel O, 2012, CANCER RES, V72, P5733, DOI 10.1158/0008-5472.CAN-12-0764; Ceyhan GO, 2006, ANN SURG, V244, P274, DOI 10.1097/01.sla.0000217642.68697.55; Colombo F, 2014, P NATL ACAD SCI USA, V111, P16943, DOI 10.1073/pnas.1406097111; Dai H, 2007, HUM PATHOL, V38, P299, DOI 10.1016/j.humpath.2006.08.002; Deborde S, 2016, J CLIN INVEST, V126, P1538, DOI 10.1172/JCI82658; Demir IE, 2014, J NATL CANC I, V106; Demir IE, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00097; Demir Ihsan Ekin, 2010, Cancers (Basel), V2, P1513, DOI 10.3390/cancers2031513; Gavert N, 2008, EXPERT OPIN BIOL TH, V8, P1749, DOI 10.1517/14712598.8.11.1749 ; Geismann C, 2009, CANCER RES, V69, P4517, DOI 10.1158/0008-5472.CAN-08-3493; Gil Z, 2010, J NATL CANCER I, V102, P107, DOI 10.1093/jnci/djp456; Guo K, 2013, MOL CANCER THER, V12, P264, DOI 10.1158/1535-7163.MCT-12-0809; Hauser S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018989; He SB, 2014, P NATL ACAD SCI USA, V111, pE2008, DOI 10.1073/pnas.1402944111; Huang XH, 2013, BRAIN RES, V1530, P13, DOI 10.1016/j.brainres.2013.07.043; Kaifi JT, 2006, WORLD J GASTROENTERO, V12, P94, DOI 10.3748/wjg.v12.i1.94; Lahoud MJ, 2016, WORLD J GASTRO ONCOL, V8, P599, DOI 10.4251/wjgo.v8.i8.599; Maretzky T, 2005, MOL CELL BIOL, V25, P9040, DOI 10.1128/MCB.25.20.9040-9053.2005; Maru N, 2001, HUM PATHOL, V32, P828, DOI 10.1053/hupa.2001.26456; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Na'ara S, 2016, JOVE-J VIS EXP, DOI 10.3791/52990; Riedle S, 2009, BIOCHEM J, V420, P391, DOI 10.1042/BJ20081625; Roh J, 2015, ORAL ONCOL, V51, P16, DOI 10.1016/j.oraloncology.2014.10.004; Saloman JL, 2016, P NATL ACAD SCI USA, V113, P3078, DOI 10.1073/pnas.1512603113; Schafer MKE, 2010, CELL MOL LIFE SCI, V67, P2425, DOI 10.1007/s00018-010-0339-1; Silletti S, 2004, J BIOL CHEM, V279, P28880, DOI 10.1074/jbc.M404075200; Stopczynski RE, 2014, CANCER RES, V74, P1718, DOI 10.1158/0008-5472.CAN-13-2050; Swanson BJ, 2007, CANCER RES, V67, P10222, DOI 10.1158/0008-5472.CAN-06-2483; Takahashi T, 1997, J SURG ONCOL, V65, P164, DOI 10.1002/(SICI)1096-9098(199707)65:3<164::AID-JSO4>3.0.CO;2-4; Torres MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080580; Webber C, 2010, EXP NEUROL, V223, P51, DOI 10.1016/j.expneurol.2009.05.037; Weinspach D, 2014, CLIN EXP METASTAS, V31, P87, DOI 10.1007/s10585-013-9613-6	42	39	39	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					596	608		10.1038/s41388-018-0458-y	http://dx.doi.org/10.1038/s41388-018-0458-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30171263				2022-12-17	WOS:000456589800010
J	Zhao, CH; Li, YT; Qiu, W; He, FX; Zhang, WM; Zhao, D; Zhang, ZW; Zhang, EB; Ma, P; Liu, YQ; Ma, L; Yang, FM; Wang, YW; Shu, YQ				Zhao, Chenhui; Li, Yongting; Qiu, Wen; He, Fengxia; Zhang, Weiming; Zhao, Dan; Zhang, Zhiwei; Zhang, Erbao; Ma, Pei; Liu, Yiqian; Ma, Ling; Yang, Fengming; Wang, Yingwei; Shu, Yongqian			C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation	ONCOGENE			English	Article							RAT THY-1 NEPHRITIS; GLOMERULAR MESANGIAL CELLS; PROMOTES PROLIFERATION; COMPLEMENT-SYSTEM; ANAPHYLATOXIN C5A; CARCINOMA-CELLS; COLON-CANCER; EXPRESSION; GROWTH; PROGRESSION	Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and multiple evidence has confirmed that C5a production is elevated in NSCLC microenvironment. Although NSCLC cell proliferation induced by C5a has been reported, the involved mechanism has not been elucidated. In this study, we examined the proliferation-related genes (i.e., KLF5, GCN5, and GDF15) and C5a receptor (C5aR) expression in tumor tissues as well as C5a concentration in plasma of NSCLC patients, and then determined the roles of KLF5, GCN5, and GDF15 in C5a-triggered NSCLC cell proliferation and the related mechanism both in vitro and in vivo. Our results found that the expression of KLF5, GCN5, GDF15, C5aR, and C5a was significantly upregulated in NSCLC patients. Mechanistic exploration in vitro revealed that C5a could facilitate A549 cell proliferation through increasing KLF5, GCN5, and GDF15 expression. Besides, KLF5 and GCN5 could form a complex, binding to GDF15 promoter in a KLF5-dependent manner and leading to GDF15 gene transcription. More importantly, GCN5-mediated KLF5 acetylation contributing to GDF15 gene transcription and cell proliferation upon C5a stimulation, the region (-103 to + 58 nt) of GDF15 promoter which KLF5 could bind to, and two new KLF5 lysine sites (K335 and K391) acetylated by GCN5 were identified for the first time. Furthermore, our experiment in vivo demonstrated that the growth of xenograft tumors in BALB/c nude mice was greatly suppressed by the silence of KLF5, GCN5, or GDF15. Collectively, these findings disclose that C5a-driven KLF5-GCN5-GDF15 axis had a critical role in NSCLC proliferation and might serve as targets for NSCLC therapy.	[Zhao, Chenhui; Ma, Pei; Liu, Yiqian; Ma, Ling; Yang, Fengming; Shu, Yongqian] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China; [Li, Yongting; Qiu, Wen; Zhao, Dan; Zhang, Zhiwei; Wang, Yingwei] Nanjing Med Univ, Dept Immunol, Nanjing, Jiangsu, Peoples R China; [He, Fengxia] Nanjing Med Univ, Affiliated Hosp 2, Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Zhang, Weiming] Nanjing Med Univ, Affiliated Hosp 1, Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Zhang, Erbao] Nanjing Med Univ, Dept Biochem & Mol Biol, Nanjing, Jiangsu, Peoples R China; [Zhang, Erbao] Nanjing Med Univ, Collaborat Innovat Ctr Canc Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Shu, YQ (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China.	shuyqtg@126.com	Ma, Pei/ABD-6343-2021; Shu, Yongqian/ABD-5698-2021	He, Fengxia/0000-0002-1695-3127	National Natural Science Foundations of China [81272532, 81472626, 81672896]	National Natural Science Foundations of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundations of China (Nos. 81272532, 81472626, and 81672896). We thank Fuqiang Wang for technical assistance.	Afshar-Kharghan V, 2017, J CLIN INVEST, V127, P780, DOI 10.1172/JCI90962; Bruzzese F, 2014, CANCER RES, V74, P3408, DOI 10.1158/0008-5472.CAN-13-2259; Cai KM, 2014, ONCOL REP, V32, P2260, DOI 10.3892/or.2014.3420; Carrillo-Garcia C, 2014, DEVELOPMENT, V141, P773, DOI 10.1242/dev.096131; Chen L, 2013, J BIOL CHEM, V288, P14510, DOI 10.1074/jbc.M113.458737; Corrales L, 2012, J IMMUNOL, V189, P4674, DOI 10.4049/jimmunol.1201654; Dong JT, 2009, CELL MOL LIFE SCI, V66, P2691, DOI 10.1007/s00018-009-0045-z; Du C, 2016, FEBS LETT, V590, P408, DOI 10.1002/1873-3468.12069; Griner SE, 2013, BIOCHEM PHARMACOL, V85, P46, DOI 10.1016/j.bcp.2012.10.007; Guruharsha KG, 2011, CELL, V147, P690, DOI 10.1016/j.cell.2011.08.047; He FX, 2016, J MOL CELL BIOL, V8, P477, DOI 10.1093/jmcb/mjw021; Hou M, 2017, CELL PHYSIOL BIOCHEM, V43, P1767, DOI 10.1159/000484063; Imamura T, 2016, BREAST CANCER-TOKYO, V23, P876, DOI 10.1007/s12282-015-0654-3; Jia L, 2016, ONCOGENE, V35, P2040, DOI 10.1038/onc.2015.263; Kadara H, 2006, CANCER BIOL THER, V5, P518, DOI 10.4161/cbt.5.5.2602; Kaypee S, 2016, PHARMACOL THERAPEUT, V162, P98, DOI 10.1016/j.pharmthera.2016.01.011; Kikuchi H, 2005, GENE, V347, P83, DOI 10.1016/j.gene.2004.12.007; Kim JS, 2005, MOL CANCER THER, V4, P487; Li Q, 2014, CELL PHYSIOL BIOCHEM, V33, P1, DOI 10.1159/000356645; Li XC, 2014, INT J ONCOL, V45, P1507, DOI 10.3892/ijo.2014.2544; Liu K, 2015, INT J MOL SCI, V16, P21897, DOI 10.3390/ijms160921897; Liu T, 2003, CANCER RES, V63, P5034; Lu Y, 2014, ONCOL REP, V32, P2817, DOI 10.3892/or.2014.3489; Maeda Y, 2015, ONCOL REP, V33, P1844, DOI 10.3892/or.2015.3800; Majaz S, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578-016-0114-6; Mamidi S, 2017, IMMUNOBIOLOGY, V222, P45, DOI 10.1016/j.imbio.2015.11.008; Markiewski MM, 2008, NAT IMMUNOL, V9, P1225, DOI 10.1038/ni.1655; Markiewski MM, 2009, CANCER RES, V69, P6367, DOI 10.1158/0008-5472.CAN-09-1918; Nitta H, 2014, ONCOL REP, V32, P1715, DOI 10.3892/or.2014.3341; Noritsugu K, 2017, BIOCHEM BIOPH RES CO, V489, P455, DOI 10.1016/j.bbrc.2017.05.170; Pandey MK, 2017, NATURE, V543, P108, DOI 10.1038/nature21368; Piao CM, 2015, J BIOL CHEM, V290, P10667, DOI 10.1074/jbc.M114.612622; Qiu W, 2012, J PATHOL, V226, P619, DOI 10.1002/path.3011; Riedemann NC, 2003, J IMMUNOL, V170, P503, DOI 10.4049/jimmunol.170.1.503; Sayegh ET, 2014, CANCER MED-US, V3, P747, DOI 10.1002/cam4.241; Takabayashi T, 2004, SURGERY, V135, P544, DOI 10.1016/j.surg.2003.09.010; Tanno T, 2014, BLOOD, V123, P725, DOI 10.1182/blood-2013-08-524025; Towner LD, 2016, J BIOL CHEM, V291, P14927, DOI 10.1074/jbc.M115.708446; Tu M, 2014, MOL MED REP, V10, P663, DOI 10.3892/mmr.2014.2317; Urakawa N, 2015, LAB INVEST, V95, P491, DOI 10.1038/labinvest.2015.36; Vadrevu SK, 2014, CANCER RES, V74, P3454, DOI 10.1158/0008-5472.CAN-14-0157; Wan JH, 2015, NUCLEIC ACIDS RES, V43, P3591, DOI 10.1093/nar/gkv238; Wang JC, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003830; Wang L, 2014, CANCER RES, V74, P4720, DOI 10.1158/0008-5472.CAN-14-0960; Wang YG, 2017, NATURE, V552, P273, DOI 10.1038/nature25003; Yin YW, 2015, GENE EXPRESSION, V16, P187, DOI 10.3727/105221615X14399878166230; Zhang EB, 2017, NUCLEIC ACIDS RES, V45, P3086, DOI 10.1093/nar/gkw1247; Zhang H, 2017, ONCOGENE, V36, P5609, DOI 10.1038/onc.2017.163; Zhang J, 2014, FASEB J, V28, P1511, DOI 10.1096/fj.13-242693; Zheng X, 2018, ONCOGENE, V37, P502, DOI 10.1038/onc.2017.354	50	39	47	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4821	4837		10.1038/s41388-018-0298-9	http://dx.doi.org/10.1038/s41388-018-0298-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29773900	Green Published, hybrid			2022-12-17	WOS:000443146000005
J	Cui, H; Hu, Y; Guo, DD; Zhang, AF; Gu, YJ; Zhang, SD; Zhao, CC; Gong, PH; Shen, XH; Li, YP; Wu, HZ; Wang, L; Zhao, ZJ; Fan, H				Cui, He; Hu, Ying; Guo, Didi; Zhang, Aifeng; Gu, Yuejun; Zhang, Shaodan; Zhao, Chengcheng; Gong, Pihai; Shen, Xiaohui; Li, Yiping; Wu, Huazhang; Wang, Ling; Zhao, Zhujiang; Fan, Hong			DNA methyltransferase 3A isoform b contributes to repressing Ecadherin through cooperation of DNA methylation and H3K27/H3K9 methylation in EMT-related metastasis of gastric cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CLINICAL-SIGNIFICANCE; EXPRESSION; DNMT3A; CELLS; STEM; PROTEINS; SNAIL; GENE	DNA methyltransferase 3A (DNMT3A) has been recognised as a key element of epigenetic regulation in normal development, and the aberrant regulation of DNMT3A is implicated in multiple types of cancers, especially haematological malignancies. However, its clinical significance and detailed functional role in solid tumours remain unknown, although abnormal expression has gained widespread attention in these cancers. Here, we show that DNMT3A isoform b (DNMT3Ab), a member of the DNMT3A isoform family, is critical for directing epithelial-mesenchymal transition (EMT)-associated metastasis in gastric cancer (GC). DNMT3Ab is positively linked to tumour-node-metastasis (TNM) stage, lymph node metastasis and poor prognosis in GC patients. Overexpression of DNMT3Ab promotes GC cell migration and invasion as well as EMT through repression of E-cadherin. Meanwhile, DNMT3Ab promotes lung metastasis of GC in vivo. Mechanistic studies indicate that DNMT3Ab mediates the epigenetic inaction of the E-cadherin gene via DNA hypermethylation and histone modifications of H3K9me2 and H3K27me3. Depletion of DNMT3Ab effectively restores the expression of E-cadherin and reverses TGF-beta-induced EMT by reducing DNA methylation, H3K9me2 and H3K27me3 levels at the E-cadherin promoter. Importantly, DNMT3Ab cooperated with H3K9me2 and H3K27me3 contributes to the transcriptional regulation of E-cadherin in a Snail-dependent manner. Further, gene expression profiling analysis indicates that multiple metastasis-associated genes and oncogenic signalling pathways are regulated in response to DNMT3Ab overexpression. These results identify DNMT3Ab as a crucial regulator of metastasis-related genes in GC. Targeting the DNMT3Ab/Snail/E-cadherin axis may provide a promising therapeutic strategy in the treatment of metastatic GC with high DNMT3Ab expression.	[Cui, He; Hu, Ying; Guo, Didi; Gu, Yuejun; Zhang, Shaodan; Zhao, Chengcheng; Gong, Pihai; Shen, Xiaohui; Wu, Huazhang; Wang, Ling; Zhao, Zhujiang; Fan, Hong] Southeast Univ, Dept Med Genet & Dev Biol, Key Lab Dev Genes & Human Dis, Med Sch,Minist Educ, Nanjing 210009, Jiangsu, Peoples R China; [Cui, He] Jiangsu Prov Hosp, Nanjing 210029, Jiangsu, Peoples R China; [Cui, He] Nanjing Med Univ, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China; [Zhang, Aifeng; Li, Yiping] Southeast Univ, Sch Med, Dept Pathol, Nanjing 210009, Jiangsu, Peoples R China	Southeast University - China; Nanjing Medical University; Nanjing Medical University; Southeast University - China	Fan, H (corresponding author), Southeast Univ, Dept Med Genet & Dev Biol, Key Lab Dev Genes & Human Dis, Med Sch,Minist Educ, Nanjing 210009, Jiangsu, Peoples R China.	fanh@seu.edu.cn		Wu, Huazhang/0000-0002-5482-3761	National Natural Science Foundation of China [81672414, 81472548, 81171915, 81702789]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the grants from National Natural Science Foundation of China (81672414, 81472548, 81171915 and 81702789). We thank Dr. Gang-Ning Liang at the Norris Cancer Center for generously providing the DNMT3Ab constructs. We also appreciate Dr. Jingfei Chen at Department of Oncology, Nanjing First Hospital, Nanjing Medical University, for providing tissue microarrays of GC patients. We also appreciate Dr. Kun Zhang at Department of Oncology, the Third Affiliated Hospital of Harbin Medical University, for providing the clinical samples of GC patients.	Calcagno DQ, 2013, WORLD J GASTROENTERO, V19, P1182, DOI 10.3748/wjg.v19.i8.1182; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cao XY, 2014, WORLD J GASTROENTERO, V20, P8201, DOI 10.3748/wjg.v20.i25.8201; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chaudry SF, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5473197; Chen BF, 2014, EPIGENETICS-US, V9, P669, DOI 10.4161/epi.28324; Chen TP, 2002, J BIOL CHEM, V277, P38746, DOI 10.1074/jbc.M205312200; Cui H, 2015, SCI REP-UK, V5, DOI 10.1038/srep13781; Cui H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123926; DENG G, 1987, CANCER RES, V47, P3195; Deng T, 2009, BIOCHEM BIOPH RES CO, V387, P611, DOI 10.1016/j.bbrc.2009.07.093; Ding WJ, 2008, DIGEST DIS SCI, V53, P2083, DOI 10.1007/s10620-007-0145-2; Fan H, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-12; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Foulks JM, 2012, J BIOMOL SCREEN, V17, P2, DOI 10.1177/1087057111421212; Gaidzik VI, 2018, LEUKEMIA, V32, P30, DOI 10.1038/leu.2017.200; Huang L, 2015, AM J TRANSL RES, V7, P2141; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jung H, 2011, CANCER-AM CANCER SOC, V117, P2371, DOI 10.1002/cncr.25778; Kim BG, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.73; Koike N, 1997, J CANCER RES CLIN, V123, P310, DOI 10.1007/s004320050063; Kokura K, 2010, EMBO J, V29, P3673, DOI 10.1038/emboj.2010.239; La Salle S, 2006, DEV BIOL, V296, P71, DOI 10.1016/j.ydbio.2006.04.436; Ma PP, 2015, CELL REP, V13, P1552, DOI 10.1016/j.celrep.2015.10.031; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Oliveira AMM, 2016, MOL PSYCHIATR, V21, P1130, DOI 10.1038/mp.2015.175; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Peng Z, 2014, WORLD J GASTROENTERO, V20, P5403, DOI 10.3748/wjg.v20.i18.5403; Pistore C, 2017, ONCOGENE, V36, P5551, DOI 10.1038/onc.2017.159; Prieto-Garcia E, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0980-8; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Suetake I, 2011, BIOCHEM J, V437, P141, DOI 10.1042/BJ20110241; Tan EJ, 2015, NUCLEIC ACIDS RES, V43, P162, DOI 10.1093/nar/gku1293; Thakur A, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0104-2; Thrumurthy SG, 2015, NAT REV CLIN ONCOL, V12, P676, DOI 10.1038/nrclinonc.2015.132; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Vogiatzi P, 2007, J CELL PHYSIOL, V211, P287, DOI 10.1002/jcp.20982; Wang Y, 2013, EXP CELL RES, V319, P160, DOI 10.1016/j.yexcr.2012.07.019; Weigt J, 2015, GASTROINTEST TUMORS, V2, P61, DOI 10.1159/000431304; Weis B, 2015, ONCOGENE, V34, P1822, DOI 10.1038/onc.2014.114; Wongtrakoongate P, 2015, WORLD J STEM CELLS, V7, P137, DOI 10.4252/wjsc.v7.i1.137; Yang J, 2011, MOL MED REP, V4, P1139, DOI 10.3892/mmr.2011.578; Yu QM, 2012, J SURG ONCOL, V106, P765, DOI 10.1002/jso.23116; Zhao Zhujiang, 2010, J Biomed Biotechnol, V2010, P737535, DOI 10.1155/2010/737535; Zu LD, 2016, CARCINOGENESIS, V37, P333, DOI 10.1093/carcin/bgw011	45	39	43	1	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4358	4371		10.1038/s41388-018-0285-1	http://dx.doi.org/10.1038/s41388-018-0285-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29717263	hybrid, Green Published			2022-12-17	WOS:000441144300002
J	Zhang, HL; Song, Y; Yang, HM; Liu, ZY; Gao, LF; Liang, XH; Ma, CH				Zhang, Hualin; Song, Yang; Yang, Huimin; Liu, Zhiyan; Gao, Lifen; Liang, Xiaohong; Ma, Chunhong			Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-kappa B/IL-6/STAT3 axis	ONCOGENE			English	Article							TRAIL-INDUCED APOPTOSIS; CD8(+) T-CELLS; UP-REGULATION; POOR-PROGNOSIS; EXPRESSION; IMMUNOGLOBULIN; HEPATOCYTES; CHECKPOINTS; DYSFUNCTION; RESISTANCE	T-cell immunoglobulin and mucin-domain containing-3 (Tim-3), mediating immune exhaustion in tumor microenvironment, has become a promising target for tumor therapy. However, the exact mechanisms for tumor cell-intrinsic Tim-3 in tumor development and its potential contribution in Tim-3-targeted therapy strategy have not been elucidated yet. In this study, we showed that human liver cancer tissues contained high ratio of Tim-3-expressing hepatocytes, and cytokines rich in tumor microenvironment and HBV involved in Tim-3 upregulation in malignant hepatocytes. We demonstrated that hepatocyte-specific Tim-3 overexpression enhances tumor cell growth, whereas Tim-3 inhibition on malignant hepatocytes by anti-Tim-3 antibodies or RNAi suppresses tumor growth both in vitro and in Tim-3 knockout mice. Mechanistically, the hepatocyte-Tim-3 receptor activates NF-kappa B phosphorylation, which in turn stimulates IL-6 secretion and STAT3 phosphorylation. Our results identify tumor cell-intrinsic functions of Tim-3 in tumorigenesis and suggest that blocking Tim-3 in tumor cells might contribute to the clinical efficacy of anti-Tim-3 antibody treatment in the future tumor therapy.	[Zhang, Hualin; Song, Yang; Gao, Lifen; Liang, Xiaohong; Ma, Chunhong] Shandong Univ, Key Lab Infect & Immun Shandong Prov, Minist Educ, Key Lab Expt Teratol, Jinan 250012, Shandong, Peoples R China; [Zhang, Hualin; Song, Yang; Gao, Lifen; Liang, Xiaohong; Ma, Chunhong] Shandong Univ, Sch Basic Med, Dept Immunol, Jinan 250012, Shandong, Peoples R China; [Yang, Huimin] Shandong Univ, Qilu Hosp, Dept Nephrol, Jinan 250012, Shandong, Peoples R China; [Liu, Zhiyan] Shandong Univ, Dept Pathol & Pathophysiol, Jinan 250012, Shandong, Peoples R China; [Ma, Chunhong] Shandong Univ, State Key Lab Microbial Technol, Jinan, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong University; Shandong University	Liang, XH; Ma, CH (corresponding author), Shandong Univ, Key Lab Infect & Immun Shandong Prov, Minist Educ, Key Lab Expt Teratol, Jinan 250012, Shandong, Peoples R China.; Liang, XH; Ma, CH (corresponding author), Shandong Univ, Sch Basic Med, Dept Immunol, Jinan 250012, Shandong, Peoples R China.; Ma, CH (corresponding author), Shandong Univ, State Key Lab Microbial Technol, Jinan, Shandong, Peoples R China.	liangxiaohong@sdu.edu.cn; machunhong@sdu.edu.cn	, 刘志艳/AAN-9477-2020; ma, chunhong/C-6043-2008; Liu, Zhiyan/C-5298-2016	ma, chunhong/0000-0002-8121-4718; Liu, Zhiyan/0000-0001-9668-7756; Liang, xiaohong/0000-0002-7626-3478	National Key Research and Development Program [2016YFE0127000]; National Natural Science Fund for Outstanding Youth Fund [81425012]; National Science Foundation of China [81425012, 81672425, 81372211, 91529305]; Key Research & Development Plan of Shandong Province [2016ZDJS07A17, 2017GSF18185]	National Key Research and Development Program; National Natural Science Fund for Outstanding Youth Fund; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research & Development Plan of Shandong Province	This work was supported by grants from the National Key Research and Development Program (No. 2016YFE0127000), the National Natural Science Fund for Outstanding Youth Fund (81425012), the National Science Foundation of China (No. 81672425, 81425012, 81372211, 91529305), Key Research & Development Plan of Shandong Province (2016ZDJS07A17, 2017GSF18185).	Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Anderson AC, 2012, CURR OPIN IMMUNOL, V24, P213, DOI 10.1016/j.coi.2011.12.005; Aravalli RN, 2013, ARCH TOXICOL, V87, P227, DOI 10.1007/s00204-012-0931-2; Boutros C, 2016, NAT REV CLIN ONCOL, V13, P473, DOI 10.1038/nrclinonc.2016.58; Cao Y, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0053834, 10.1371/journal.pone.0055021]; Dolina JS, 2014, HEPATOLOGY, V59, P1351, DOI 10.1002/hep.26938; Du J, 2009, CELL DEATH DIFFER, V16, P219, DOI 10.1038/cdd.2008.144; Du W., 2017, INT J MOL SCI, V18, P645, DOI [10.3390/ijms18030645, DOI 10.3390/IJMS18030645]; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Huang YH, 2015, NATURE, V517, P386, DOI 10.1038/nature13848; Ju Y, 2010, J HEPATOL, V52, P322, DOI 10.1016/j.jhep.2009.12.005; Kikushige Y, 2015, CELL STEM CELL, V17, P341, DOI 10.1016/j.stem.2015.07.011; Kleffel S, 2015, CELL, V162, P1242, DOI 10.1016/j.cell.2015.08.052; Koyama S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10501; Lee J, 2011, MOL CELL BIOL, V31, P3963, DOI 10.1128/MCB.05297-11; Li H, 2012, HEPATOLOGY, V56, P1342, DOI 10.1002/hep.25777; Liang XH, 2007, J IMMUNOL, V178, P503, DOI 10.4049/jimmunol.178.1.503; Luan F, 2009, GUT, V58, P1528, DOI 10.1136/gut.2008.174029; Marraco SAF, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00310; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Ngiow SF, 2011, CANCER RES, V71, P3540, DOI 10.1158/0008-5472.CAN-11-0096; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Piao YR, 2013, ASIAN PAC J CANCER P, V14, P3897, DOI 10.7314/APJCP.2013.14.6.3897; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Restifo NP, 2016, NAT REV CANCER, V16, P121, DOI 10.1038/nrc.2016.2; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Tomkowicz B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140694; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Voron T, 2015, J EXP MED, V212, P139, DOI 10.1084/jem.20140559; Yan WJ, 2015, GUT, V64, P1593, DOI 10.1136/gutjnl-2014-307671; Yi WJ, 2017, IMMUNOLOGY, V150, P301, DOI 10.1111/imm.12686; Yuan J, 2013, NEOPLASMA; Zhou EC, 2015, INT J CLIN EXP PATHO, V8, P8018; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271; Zhu C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7072; Zhuang XW, 2012, AM J CLIN PATHOL, V137, P978, DOI 10.1309/AJCP9Q6OVLVSHTMY	37	39	52	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2456	2468		10.1038/s41388-018-0140-4	http://dx.doi.org/10.1038/s41388-018-0140-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29449693				2022-12-17	WOS:000431386000009
J	Nishida, J; Miyazono, K; Ehata, S				Nishida, Jun; Miyazono, Kohei; Ehata, Shogo			Decreased TGFBR3/betaglycan expression enhances the metastatic abilities of renal cell carcinoma cells through TGF-beta-dependent and-independent mechanisms	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; ALDEHYDE DEHYDROGENASE; RECEPTOR EXPRESSION; FUNCTIONAL-ANALYSIS; INITIATING CELLS; PROTEIN; TARGET; PROGRESSION; POPULATION; BETAGLYCAN	TGF-beta regulates both the tumor-forming and migratory abilities of various types of cancer cells. However, it is unclear how the loss of TGF-beta signaling components affects these abilities in clear-cell renal cell carcinoma (ccRCC). In this study, we investigated the role of TGFBR3 (TGF-beta type III receptor, also known as betaglycan) in ccRCC. Database analysis revealed decreased expression of TGFBR3 in ccRCC tissues, which correlated with poor prognosis in patients. Orthotopic inoculation experiments using immunocompromised mice indicated that low TGFBR3 expression in ccRCC cells enhanced primary tumor formation and lung metastasis. In the presence of TGFBR3, TGF-beta 2 decreased the aldehyde dehydrogenase (ALDH)-positive ccRCC cell population, in which renal cancer-initiating cells are enriched. Loss of TGFBR3 also enhanced cell migration in cell culture and induced expression of several mesenchymal markers in a TGF-beta-independent manner. Increased lamellipodium formation by FAK-PI3K signaling was observed with TGFBR3 downregulation, and this contributed to TGF-beta-independent cell migration in ccRCC cells. Taken together, our findings reveal that loss of TGFBR3 endows ccRCC cells with multiple metastatic abilities through TGF-beta-dependent and independent pathways.	[Nishida, Jun; Miyazono, Kohei; Ehata, Shogo] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan	University of Tokyo	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp	Nishida, Jun/C-4892-2018	Nishida, Jun/0000-0001-5098-9361; Ehata, Shogo/0000-0002-6740-9391	KAKENHI from the Japan Society for the Promotion of Science (JSPS) [15H05774, 15K08393]; Japan Society for the Promotion of Science (JSPS) [16J05993]; Yasuda Medical Foundation; Grants-in-Aid for Scientific Research [16J05993, 15H05774] Funding Source: KAKEN	KAKENHI from the Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Yasuda Medical Foundation; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr. Yoko Katsuno, Dr. Anna Mizutani, Dr. Yukari Hoshino, Dr. Fumihiko Murai, Dr. Kei Takahashi, and Dr. Luna Taguchi (The University of Tokyo) for technical help; and Dr. Hiroyuki Miyoshi (Keio University) for providing the lentiviral vectors. This work was supported by KAKENHI Grants-in-Aid for Scientific Research (S) (15H05774) (KM) and Scientific Research (C) (15K08393) (SE), and Grant-in-Aid for JSPS Research Fellow (16J05993) (JN) from the Japan Society for the Promotion of Science (JSPS), and the Yasuda Medical Foundation (KM).	Ananth S, 1999, CANCER RES, V59, P2210; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Bernabeu C, 2009, BBA-MOL BASIS DIS, V1792, P954, DOI 10.1016/j.bbadis.2009.07.003; Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; Bilandzic M, 2011, MOL CELL ENDOCRINOL, V339, P180, DOI 10.1016/j.mce.2011.04.014; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Bussolati B, 2008, FASEB J, V22, P3696, DOI 10.1096/fj.08-102590; Capitanio U, 2016, LANCET, V387, P894, DOI 10.1016/S0140-6736(15)00046-X; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Copland JA, 2003, ONCOGENE, V22, P8053, DOI 10.1038/sj.onc.1206835; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dallas NA, 2008, CLIN CANCER RES, V14, P1931, DOI 10.1158/1078-0432.CCR-07-4478; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Ehata S, 2011, ONCOGENE, V30, P1693, DOI 10.1038/onc.2010.546; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Gossage L, 2015, NAT REV CANCER, V15, P55, DOI 10.1038/nrc3844; Heldin CH, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022053; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoshino Y, 2015, AM J PATHOL, V185, P1457, DOI 10.1016/j.ajpath.2015.01.011; Hoshino Y, 2011, J BIOCHEM, V149, P55, DOI 10.1093/jb/mvq114; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Katsuno Y, 2012, J PATHOL, V228, P391, DOI 10.1002/path.4020; Katsura A, 2017, MOL ONCOL, V11, P1241, DOI 10.1002/1878-0261.12098; Kirkbride KC, 2008, J BIOL CHEM, V283, P7628, DOI 10.1074/jbc.M704883200; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kubota SI, 2017, CELL REP, V20, P236, DOI 10.1016/j.celrep.2017.06.010; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Miyazono K, 2012, UPSALA J MED SCI, V117, P143, DOI 10.3109/03009734.2011.638729; Mizutani A, 2016, ONCOGENE, V35, P3514, DOI 10.1038/onc.2015.412; Morikawa M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021873; Murai F, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.26; Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106; Nagata M, 2006, GENES CELLS, V11, P1267, DOI 10.1111/j.1365-2443.2006.01018.x; NAITO S, 1986, CANCER RES, V46, P4109; Namwanje M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021881; Peired AJ, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8342625; Riazalhosseini Y, 2016, NAT REV NEPHROL, V12, P655, DOI 10.1038/nrneph.2016.133; Scelo G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6135; Scharpfenecker M, 2007, J CELL SCI, V120, P964, DOI 10.1242/jcs.002949; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Ueda K., 2013, PLOS ONE, V8, P1; Vanharanta S, 2013, NAT MED, V19, P50, DOI 10.1038/nm.3029; Yokoyama Y, 2017, CANCER RES, V77, P4026, DOI 10.1158/0008-5472.CAN-17-0112	49	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2197	2212		10.1038/s41388-017-0084-0	http://dx.doi.org/10.1038/s41388-017-0084-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29391598	Green Published, hybrid			2022-12-17	WOS:000430589000009
J	NavaneethaKrishnan, S; Rosales, JL; Lee, KY				NavaneethaKrishnan, Saranya; Rosales, Jesusa L.; Lee, Ki-Young			Loss of Cdk5 in breast cancer cells promotes ROS-mediated cell death through dysregulation of the mitochondrial permeability transition pore	ONCOGENE			English	Article							CYCLIN-DEPENDENT KINASE-5; OXIDATIVE STRESS; NEURONAL APOPTOSIS; REPERFUSION INJURY; DNA-DAMAGE; DRP1; PHOSPHORYLATION; FISSION; PROTEIN; FRAGMENTATION	Cdk5, which plays a role in the development and progression of many human cancers, localizes in the mitochondria, a key determinant of apoptotic cell death. Cdk5 is upregulated in breast cancer cells but it was shown that Cdk5 loss increases chemotherapy-induced apoptosis. However, the molecular mechanism by which Cdk5 loss promotes cell death remains unclear. Here, we investigate the possibility that Cdk5 loss activates the intrinsic apoptotic pathway in breast cancer cells. We demonstrate that Cdk5-deficient breast cancer cells exhibit increased mitochondrial depolarization, mitochondrial ROS levels, and mitochondrial fragmentation that is associated with an increase in both intracellular Ca2+ level and calcineurin activity, and DRP1 S637 dephosphorylation. These events accompany increased apoptosis, indicating that Cdk5 loss promotes mitochondria-mediated apoptosis. To define this apoptotic pathway, we utilized various inhibitors of mitochondrial function. Apoptosis is completely prevented by mPTP inhibition, almost fully inhibited by blocking ROS and unaffected by inhibition of mitochondrial fission, suggesting that apoptosis in breast cancer cells due to Cdk5 loss occurs via a novel mPTP-dependent mechanism that acts primarily through ROS increase.	[NavaneethaKrishnan, Saranya; Lee, Ki-Young] Univ Calgary, Arnie Charbonneau Canc Inst, Dept Cell Biol & Anat, Calgary, AB, Canada; [Rosales, Jesusa L.] Univ Calgary, Snyder Inst Chron Dis, Dept Biochem & Mol Biol, Calgary, AB, Canada	University of Calgary; University of Calgary	Lee, KY (corresponding author), Univ Calgary, Arnie Charbonneau Canc Inst, Dept Cell Biol & Anat, Calgary, AB, Canada.	kylee@ucalgary.ca		Rosales, Jesusa/0000-0002-2543-3801	CIHR [MOP-123400]; NSERC [RGPIN/312985-2011]; Alberta Cancer Foundation	CIHR(Canadian Institutes of Health Research (CIHR)); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); Alberta Cancer Foundation	We thank Novartis Pharma AG and Dr. BC Lee for providing SfA and HeLa mitoDSRed2 cells, respectively. We also thank Drs. Timothy Shutt, Karl Riabowol, Susan Lees-Miller, and Derek McKay for their critical reviews of the manuscript. This work was supported in part by grants from the CIHR (MOP-123400) and NSERC (RGPIN/312985-2011) to K-YL and an Alberta Cancer Foundation graduate studentship to SN.	Abdullah C, 2011, CELL CYCLE, V10, P977, DOI 10.4161/cc.10.6.15079; Batandier C, 2004, J BIOL CHEM, V279, P17197, DOI 10.1074/jbc.M310329200; Bernardi P, 2015, PHYSIOL REV, V95, P1111, DOI 10.1152/physrev.00001.2015; Bernardi P, 2015, J MOL CELL CARDIOL, V78, P100, DOI 10.1016/j.yjmcc.2014.09.023; Bolin C, 2012, CELL MOL LIFE SCI, V69, P951, DOI 10.1007/s00018-011-0811-6; Cereghetti GM, 2008, P NATL ACAD SCI USA, V105, P15803, DOI 10.1073/pnas.0808249105; Cho B, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.36; Cho SG, 2010, AM J PHYSIOL-RENAL, V299, pF199, DOI 10.1152/ajprenal.00716.2009; Clarke SJ, 2002, J BIOL CHEM, V277, P34793, DOI 10.1074/jbc.M202191200; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elwi AN, 2012, INT J BIOCHEM CELL B, V44, P1366, DOI 10.1016/j.biocel.2012.05.004; Feldmann G, 2010, CANCER RES, V70, P4460, DOI 10.1158/0008-5472.CAN-09-1107; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; Fitzgerald JC, 2012, CELL DEATH DIFFER, V19, P257, DOI 10.1038/cdd.2011.90; Goodyear S, 2007, EXP MOL PATHOL, V82, P25, DOI 10.1016/j.yexmp.2006.09.002; Halestrap AP, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00234; Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Iqbal S, 2014, AM J PHYSIOL-CELL PH, V306, pC1176, DOI 10.1152/ajpcell.00017.2014; Jahani-Asl A, 2015, HUM MOL GENET, V24, P4573, DOI 10.1093/hmg/ddv188; Jena NR, 2012, J BIOSCIENCES, V37, P503, DOI 10.1007/s12038-012-9218-2; Kalogeris T, 2014, REDOX BIOL, V2, P702, DOI 10.1016/j.redox.2014.05.006; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Kinnally KW, 2011, BBA-MOL CELL RES, V1813, P616, DOI 10.1016/j.bbamcr.2010.09.013; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lemasters JJ, 2002, ANTIOXID REDOX SIGN, V4, P769, DOI 10.1089/152308602760598918; Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009; Leshchenko VV, 2010, BLOOD, V116, P1025, DOI 10.1182/blood-2009-12-257485; Levacque Z, 2012, CELL CYCLE, V11, P4093, DOI 10.4161/cc.21886; Liang Q, 2013, SCI REP-UK, V3, DOI 10.1038/srep02932; Liu JL, 2011, MED ONCOL, V28, P673, DOI 10.1007/s12032-010-9510-7; Meuer K, 2007, CELL DEATH DIFFER, V14, P651, DOI 10.1038/sj.cdd.4402087; Mnatsakanyan N, 2017, J BIOENERG BIOMEMBR, V49, P13, DOI 10.1007/s10863-016-9652-1; Morciano G, 2015, J MOL CELL CARDIOL, V78, P142, DOI 10.1016/j.yjmcc.2014.08.015; Precht TA, 2005, CELL DEATH DIFFER, V12, P255, DOI 10.1038/sj.cdd.4401552; Qu D, 2007, NEURON, V55, P37, DOI 10.1016/j.neuron.2007.05.033; Rosales JL, 2006, BIOESSAYS, V28, P1023, DOI 10.1002/bies.20473; Rosdah AA, 2016, PHARMACOL RES PERSPE, V4, DOI 10.1002/prp2.235; Strock CJ, 2006, CANCER RES, V66, P7509, DOI 10.1158/0008-5472.CAN-05-3048; Sun KH, 2008, J NEUROCHEM, V107, P265, DOI 10.1111/j.1471-4159.2008.05616.x; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Turner C, 2003, CELL DEATH DIFFER, V10, P302, DOI 10.1038/sj.cdd.4401170; Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang SQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0019879; Wang YQ, 2012, AUTOPHAGY, V8, P1462, DOI 10.4161/auto.21211; Weishaupt JH, 2003, MOL CELL NEUROSCI, V24, P489, DOI 10.1016/S1044-7431(03)00221-5; Wesierska-Gadek J, 2005, MOL CANCER THER, V4, P113; Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013; Wu SN, 2011, FEBS J, V278, P941, DOI 10.1111/j.1742-4658.2011.08010.x; Xie Q, 2015, NAT NEUROSCI, V18, P501, DOI 10.1038/nn.3960; Zhang SY, 2015, 2015 IEEE WORKSHOP ON ENVIRONMENTAL, ENERGY AND STRUCTURAL MONITORING SYSTEMS (EESMS), P1, DOI [10.1109/EESMS.2015.7175842, 10.1109/INTMAG.2015.7156970]; Zhu YX, 2011, BLOOD, V117, P3847, DOI 10.1182/blood-2010-08-304022	57	39	40	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1788	1804		10.1038/s41388-017-0103-1	http://dx.doi.org/10.1038/s41388-017-0103-1			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29348461	hybrid, Green Published			2022-12-17	WOS:000428632600008
J	van Voss, MRH; Vesuna, F; Bol, GM; Afzal, J; Tantravedi, S; Bergman, Y; Kammers, K; Lehar, M; Malek, R; Ballew, M; ter Hoeve, N; Abou, D; Thorek, D; Berlinicke, C; Yazdankhah, M; Sinha, D; Le, A; Abrahams, R; Tran, PT; van Diest, PJ; Raman, V				van Voss, M. R. Heerma; Vesuna, F.; Bol, G. M.; Afzal, J.; Tantravedi, S.; Bergman, Y.; Kammers, K.; Lehar, M.; Malek, R.; Ballew, M.; ter Hoeve, N.; Abou, D.; Thorek, D.; Berlinicke, C.; Yazdankhah, M.; Sinha, D.; Le, A.; Abrahams, R.; Tran, P. T.; van Diest, P. J.; Raman, V.			Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment	ONCOGENE			English	Article							RNA HELICASE DDX3; BREAST-CANCER; COMPLEX-I; THERAPEUTIC TARGET; TUMOR-SUPPRESSOR; RESISTANCE; PROTEIN; CELLS; METABOLISM; APOPTOSIS	DDX3 is a DEAD box RNA helicase with oncogenic properties. RK-33 is developed as a small-molecule inhibitor of DDX3 and showed potent radiosensitizing activity in preclinical tumor models. This study aimed to assess DDX3 as a target in breast cancer and to elucidate how RK-33 exerts its anti-neoplastic effects. High DDX3 expression was present in 35% of breast cancer patient samples and correlated with markers of aggressiveness and shorter survival. With a quantitative proteomics approach, we identified proteins involved in the mitochondrial translation and respiratory electron transport pathways to be significantly downregulated after RK-33 or DDX3 knockdown. DDX3 localized to the mitochondria and DDX3 inhibition with RK-33 reduced mitochondrial translation. As a consequence, oxygen consumption rates and intracellular ATP concentrations decreased and reactive oxygen species (ROS) increased. RK-33 antagonized the increase in oxygen consumption and ATP production observed after exposure to ionizing radiation and reduced DNA repair. Overall, we conclude that DDX3 inhibition with RK-33 causes radiosensitization in breast cancer through inhibition of mitochondrial translation, which results in reduced oxidative phosphorylation capacity and increased ROS levels, culminating in a bioenergetic catastrophe.	[van Voss, M. R. Heerma; Vesuna, F.; Bol, G. M.; Tantravedi, S.; Bergman, Y.; Abou, D.; Thorek, D.; Raman, V.] Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, Baltimore, MD USA; [van Voss, M. R. Heerma; Bol, G. M.; ter Hoeve, N.; van Diest, P. J.; Raman, V.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Afzal, J.; Abrahams, R.] Johns Hopkins Univ, Dept Cardiol, Sch Med, Baltimore, MD USA; [Kammers, K.] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Lehar, M.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol, Baltimore, MD 21205 USA; [Malek, R.; Ballew, M.; Tran, P. T.] Johns Hopkins Univ, Dept Radiat Oncol, Sch Med, Baltimore, MD USA; [Berlinicke, C.; Yazdankhah, M.; Sinha, D.] Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Baltimore, MD 21218 USA; [Le, A.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Le, A.; Tran, P. T.; van Diest, P. J.; Raman, V.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Tran, P. T.] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA	Johns Hopkins University; Utrecht University; Utrecht University Medical Center; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Raman, V (corresponding author), Johns Hopkins Univ, Dept Radiol, Sch Med, 720 Rutland Ave,Traylor 340, Baltimore, MD 21205 USA.	vraman2@jhmi.edu	Tran, Phuoc/W-2084-2019; Afzal, Junaid/L-3643-2019; Vesuna, Farhad/G-3179-2010; Heerma van Voss, Marise/N-5637-2016	Tran, Phuoc/0000-0002-0147-0376; Vesuna, Farhad/0000-0002-0356-5096; Afzal, Junaid/0000-0002-2877-234X; Le, Anne/0000-0002-2958-8149; Heerma van Voss, Marise/0000-0001-8368-9859	Utrecht University Alexandre Suerman Stipend (MRHvV); Dutch Cancer Foundation [UU2013-5851]; NIH [R01CA166348, R01CA193895, R01CA140226, R01CA131250]; FAMRI; Safeway; NATIONAL CANCER INSTITUTE [R01CA166348, R01CA140226, R01CA131250, R01CA193895] Funding Source: NIH RePORTER	Utrecht University Alexandre Suerman Stipend (MRHvV); Dutch Cancer Foundation(KWF Kankerbestrijding); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FAMRI; Safeway; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Bob Cole, Tatiana Boronina and Bob O' Meally of the Johns Hopkins Mass Spectrometry and Proteomics core facility for their help with the proteomics experiments; Tri Nguyen for his help with interpretation of the electron microscopy images; the Dawson Laboratory at the Johns Hopkins School of Medicine for their help with the mitochondrial translation assay; and Beth Rodgers, who kindly provided us with S<SUP>35</SUP>-methionine. This work was financially supported by Utrecht University Alexandre Suerman Stipend (MRHvV), the Dutch Cancer Foundation (UU2013-5851; MRHvV), NIH (R01CA166348 to PTT, R01CA193895 to AL, and R01CA140226 and R01CA131250 to VR), FAMRI (VR) and Safeway (VR).	Abaeva IS, 2011, EMBO J, V30, P115, DOI 10.1038/emboj.2010.302; Acin-Perez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8; Angus AGN, 2010, J GEN VIROL, V91, P122, DOI 10.1099/vir.0.015909-0; [Anonymous], 1998, MED RES INV HUM SUBJ; Antonicka H, 2015, CELL REP, V10, P920, DOI 10.1016/j.celrep.2015.01.030; Bol GM, 2015, EMBO MOL MED, V7, P648, DOI 10.15252/emmm.201404368; Bol GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063548; Botlagunta M, 2008, ONCOGENE, V27, P3912, DOI 10.1038/onc.2008.33; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008-5472.CAN-09-1528; Chen CY, 2016, HUM MOL GENET, V25, P2905, DOI 10.1093/hmg/ddw143; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen HH, 2015, ONCOGENE, V34, P2790, DOI 10.1038/onc.2014.190; Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Eiermann W, 2012, ANN ONCOL, V23, P30, DOI 10.1093/annonc/mds192; Farnie G, 2015, ONCOTARGET, V6, P30472, DOI 10.18632/oncotarget.5401; Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094; Fukumura J, 2003, J BIOCHEM, V134, P71, DOI 10.1093/jb/mvg126; Geissler R, 2012, NUCLEIC ACIDS RES, V40, P4998, DOI 10.1093/nar/gks070; Hagerstrand D, 2013, CANCER DISCOV, V3, P1044, DOI 10.1158/2159-8290.CD-12-0592; Huang Z, 2016, INT J CANCER, V139, P23, DOI 10.1002/ijc.29990; Jones RA, 2016, J CLIN INVEST, V126, P3739, DOI 10.1172/JCI81568; Kammers Kai, 2015, EuPA Open Proteom, V7, P11; Kondaskar A, 2011, ACS MED CHEM LETT, V2, P252, DOI 10.1021/ml100281b; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Lai MC, 2008, MOL BIOL CELL, V19, P3847, DOI 10.1091/mbc.E07-12-1264; Lai MC, 2010, MOL CELL BIOL, V30, P5444, DOI 10.1128/MCB.00560-10; Leary SC, 2009, METHODS MOL BIOL, V554, P143, DOI 10.1007/978-1-59745-521-3_10; LeBleu VS, 2014, NAT CELL BIOL, P1001, DOI DOI 10.1038/NCB3039; Lee CS, 2008, NUCLEIC ACIDS RES, V36, P4708, DOI 10.1093/nar/gkn454; Li Y, 2006, CANCER RES, V66, P8520, DOI 10.1158/0008-5472.CAN-05-4364; Li YF, 2007, J BIOL CHEM, V282, P17557, DOI 10.1074/jbc.M701056200; Lu CL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121046; Matassa DS, 2016, CELL DEATH DIFFER, V23, P1542, DOI 10.1038/cdd.2016.39; Moelans CB, 2009, CELL ONCOL, V31, P1, DOI 10.3233/CLO-2009-0461; Oshiumi H, 2010, EUR J IMMUNOL, V40, P940, DOI 10.1002/eji.200940203; Padmanabhan PK, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.315; Pelicano H, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0434-6; Qin B, 2015, CELL REP, V10, P1324, DOI 10.1016/j.celrep.2015.01.066; Qin LL, 2015, CELL REP, V13, P2056, DOI 10.1016/j.celrep.2015.11.015; Rasband W. S, 2015, IMAGEJ; Sansone P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10442; Shih JW, 2008, ONCOGENE, V27, P700, DOI 10.1038/sj.onc.1210687; Shih JW, 2012, BIOCHEM J, V441, P119, DOI 10.1042/BJ20110739; Skrtic M, 2011, CANCER CELL, V20, P674, DOI 10.1016/j.ccr.2011.10.015; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Soto-Rifo R, 2012, EMBO J, V31, P3745, DOI 10.1038/emboj.2012.220; Sun MN, 2011, BBA-MOL CELL RES, V1813, P438, DOI 10.1016/j.bbamcr.2011.01.003; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Tarn WY, 2009, RNA BIOL, V6, P17, DOI 10.4161/rna.6.1.7440; Tu YT, 2015, CELL REP, V10, P854, DOI 10.1016/j.celrep.2015.01.033; van Voss MRH, 2015, ONCOTARGET, V6, P28312, DOI 10.18632/oncotarget.4873; Vellinga TT, 2015, CLIN CANCER RES, V21, P2870, DOI 10.1158/1078-0432.CCR-14-2290; Vermeulen JF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037864; Viale A, 2015, CANCER RES, V75, P3687, DOI 10.1158/0008-5472.CAN-15-0491; WARDMAN P, 1982, INT J RADIAT ONCOL, V8, P399, DOI 10.1016/0360-3016(82)90647-2; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Wilky BA, 2016, ONCOGENE, V35, P2574, DOI 10.1038/onc.2015.336; Xie Min, 2016, Cancer Res, V76, P6340; Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028; Zhang XN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4295; Zhang X, 2012, J RADIAT RES, V53, P257, DOI 10.1269/jrr.11124	63	39	39	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					63	74		10.1038/onc.2017.308	http://dx.doi.org/10.1038/onc.2017.308			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28869602	Green Accepted			2022-12-17	WOS:000422625000007
J	Ashikari, D; Takayama, K; Tanaka, T; Suzuki, Y; Obinata, D; Fujimura, T; Urano, T; Takahashi, S; Inoue, S				Ashikari, D.; Takayama, K.; Tanaka, T.; Suzuki, Y.; Obinata, D.; Fujimura, T.; Urano, T.; Takahashi, S.; Inoue, S.			Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; BINDING-PROTEINS; RECEPTOR; MDM2; PROMOTES; CELLS; EXPRESSION; NETWORK; RNA; TUMORIGENESIS	The androgen receptor (AR) has a central role in prostate cancer progression, particularly treatment-resistance disease including castration-resistant prostate cancer. Loss of the p53 tumor suppressor, a nuclear transcription factor, is also known to contribute to prostate malignancy. Here we report that p53 is translocated to the cytoplasm by androgen-mediated induction of G3BP2, a newly described direct target gene of AR. G3BP2 induces both cell cycle progression and blocks apoptosis. Translocation of p53 is regulated by androgen-dependent sumoylation mediated by the G3BP2-interacting SUMO-E3 ligase, RanBP2. G3BP2 knockdown results in reduced tumor growth and increased nuclear p53 accumulation in mouse xenograft models of prostate cancer with or without long-term androgen deprivation. Moreover, strong cytoplasmic p53 localization is correlated clinically with elevated G3BP2 expression and predicts poor prognosis and disease progression to the hormone-refractory state. Our findings reveal a new AR-mediated mechanism of p53 inhibition that promotes treatment-resistant prostate cancer.	[Ashikari, D.; Takayama, K.; Obinata, D.; Urano, T.; Inoue, S.] Univ Tokyo, Grad Sch Med, Dept Antiaging Med, Tokyo, Japan; [Ashikari, D.; Obinata, D.; Takahashi, S.] Nihon Univ, Sch Med, Dept Urol, Tokyo, Japan; [Takayama, K.; Obinata, D.; Inoue, S.] Tokyo Metropolitan Inst Gerontol, Dept Funct Biogerontol, Tokyo, Japan; [Tanaka, T.] Chiba Univ, Grad Sch Med, Dept Clin Cell Biol, Chiba, Japan; [Tanaka, T.] Chiba Univ, Grad Sch Med, Div Endocrinol & Metab, Chiba, Japan; [Suzuki, Y.] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Lab Funct Genom, Chiba, Japan; [Fujimura, T.] Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo, Japan; [Inoue, S.] Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Hidaka, Japan	University of Tokyo; Nihon University; Tokyo Metropolitan Institute of Gerontology; Chiba University; Chiba University; University of Tokyo; University of Tokyo; Saitama Medical University	Inoue, S (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Funct Biogerontol, Itabashi Ku, 35-2 Sakae Cho, Tokyo 1730015, Japan.	sinoue@tmig.or.jp	Takayama, Kenichi/AAK-9238-2020; Urano, Tomohiko/AFS-9574-2022	Tanaka, Tomoaki/0000-0002-9761-1750	Grants of the Cell Innovation Program; P-Direct from the MEXT, Japan; JSPS, Japan; MHLW, Japan; Program for Promotion of Fundamental Studies in Health Sciences; NIBIO, Japan; Takeda Science Foundation; Mochida Memorial Research Foundation, Japan; Yasuda Memorial Foundation; Princess Takamatsu Cancer Research Fund	Grants of the Cell Innovation Program; P-Direct from the MEXT, Japan; JSPS, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MHLW, Japan; Program for Promotion of Fundamental Studies in Health Sciences; NIBIO, Japan(National Institute of Biomedical Innovation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Mochida Memorial Research Foundation, Japan; Yasuda Memorial Foundation; Princess Takamatsu Cancer Research Fund	We thank Professor Takashi Suzuki (Tohoku University) for comments on our pathological analysis. We thank E Sakamoto and N Sasaki for technical assistance. This work was supported by Grants of the Cell Innovation Program and the P-Direct (both to SI) from the MEXT, Japan; by Grants (to SI and KT) from the JSPS, Japan; by Grants-in-Aid (to SI) from the MHLW, Japan; by the Program for Promotion of Fundamental Studies in Health Sciences (to SI), NIBIO, Japan; by Grants from Takeda Science Foundation (to SI and KT); and by Grants from Mochida Memorial Research Foundation (to KT), Japan, the Yasuda Memorial Foundation (to KT) and Princess Takamatsu Cancer Research Fund (to KT).	Brooks CL, 2011, PROTEIN CELL, V2, P456, DOI 10.1007/s13238-011-1063-9; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Chappell WH, 2012, CELL CYCLE, V11, P4579, DOI 10.4161/cc.22852; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Debes JD, 2002, CANCER LETT, V187, P1, DOI 10.1016/S0304-3835(02)00413-5; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; French J, 2002, HISTOCHEM J, V34, P223, DOI 10.1023/A:1021737413055; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guttler T, 2011, EMBO J, V30, P3457, DOI 10.1038/emboj.2011.287; Guitard E, 2001, CANCER LETT, V162, P213, DOI 10.1016/S0304-3835(00)00638-8; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Irvine K, 2004, INT J DEV BIOL, V48, P1065, DOI 10.1387/ijdb.041893ki; Jenkins LMM, 2012, CARCINOGENESIS, V33, P1441, DOI 10.1093/carcin/bgs145; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kim MM, 2007, ONCOGENE, V26, P4209, DOI 10.1038/sj.onc.1210212; Kluth M, 2014, INT J CANCER, V135, P1369, DOI 10.1002/ijc.28784; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liu CF, 2013, PROSTATE, V73, P418, DOI 10.1002/pros.22583; Lu X, 2013, ONCOGENE, V32, P2900, DOI 10.1038/onc.2012.299; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Misawa A, 2016, J BIOL CHEM, V291, P17861, DOI 10.1074/jbc.M116.718536; Moretti RM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093713; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Obinata D, 2012, INT J CANCER, V130, P1021, DOI 10.1002/ijc.26043; Ohtsubo C, 2009, CANCER SCI, V100, P1291, DOI 10.1111/j.1349-7006.2009.01180.x; Parker F, 1996, MOL CELL BIOL, V16, P2561; Quinn DI, 2000, CANCER RES, V60, P1585; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Santiago A, 2013, MOL BIOL CELL, V24, P2739, DOI 10.1091/mbc.E12-10-0771; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Stattin P, 1996, EUR UROL, V30, P65; Takayama K, 2011, ONCOGENE, V30, P619, DOI 10.1038/onc.2010.436; Takayama K, 2014, CANCER RES, V74, P6542, DOI 10.1158/0008-5472.CAN-14-1030; Takayama K, 2013, INT J UROL, V20, P756, DOI 10.1111/iju.12146; Takayama K, 2013, EMBO J, V32, P1665, DOI 10.1038/emboj.2013.99; Tourriere H, 2003, J CELL BIOL, V160, P823, DOI 10.1083/jcb.200212128; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Werner A, 2012, MOL CELL, V46, P287, DOI 10.1016/j.molcel.2012.02.017; Winslow S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-156	47	39	43	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6272	6281		10.1038/onc.2017.225	http://dx.doi.org/10.1038/onc.2017.225			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28692047				2022-12-17	WOS:000414774800006
J	Wang, Q; Zhu, J; Wang, YW; Dai, Y; Wang, YL; Wang, C; Liu, J; Baker, A; Colburn, NH; Yang, HS				Wang, Q.; Zhu, J.; Wang, Y-W; Dai, Y.; Wang, Y-L; Wang, C.; Liu, J.; Baker, A.; Colburn, N. H.; Yang, H-S			Tumor suppressor Pdcd4 attenuates Sin1 translation to inhibit invasion in colon carcinoma	ONCOGENE			English	Article							MAMMALIAN TARGET; DOWN-REGULATION; DEPENDENT TRANSCRIPTION; EUKARYOTIC TRANSLATION; PROMOTES INVASION; BETA-CATENIN/TCF; EXPRESSION; AKT; COMPLEX; PROTEIN	Programmed cell death 4 (Pdcd4), a tumor invasion suppressor, is frequently downregulated in colorectal cancer and other cancers. In this study, we find that loss of Pdcd4 increases the activity of mammalian target of rapamycin complex 2 (mTORC2) and thereby upregulates Snail expression. Examining the components of mTORC2 showed that Pdcd4 knockdown increased the protein but not mRNA level of stress-activated-protein kinase interacting protein 1 (Sin1), which resulted from enhanced Sin1 translation. To understand how Pdcd4 regulates Sin1 translation, the SIN1 5' untranslated region (5'UTR) was fused with luciferase reporter and named as 5'Sin1-Luc. Pdcd4 knockdown/knockout significantly increased the translation of 5' Sin1-Luc but not the control luciferase without the SIN1 5'UTR, suggesting that Sin1 5'UTR is necessary for Pdcd4 to inhibit Sin1 translation. Ectopic expression of wild-type Pdcd4 and Pdcd4(157-469), a deletion mutant that binds to translation initiation factor 4A (eIF4A), sufficiently inhibited Sin1 translation, and thus suppressed mTORC2 kinase activity and invasion in colon tumor cells. By contrast, Pdcd4(157-469)(D253A, D418A), a mutant that does not bind to eIF4A, failed to inhibit Sin1 translation, and consequently failed to repress mTORC2 activity and invasion. In addition, directly inhibiting eIF4A with silvestrol significantly suppressed Sin1 translation and attenuated invasion. These results indicate that Pdcd4-inhibited Sin1 translation is through suppressing eIF4A, and functionally important for suppression of mTORC2 activity and invasion. Moreover, in colorectal cancer tissues, the Sin1 protein but not mRNA was significantly upregulated while Pdcd4 protein was downregulated, suggesting that loss of Pdcd4 might correlate with Sin1 protein level but not mRNA level in colorectal cancer patients. Taken together, our work reveals a novel mechanism by which Pdcd4 inhibits Sin1 translation to attenuatemTORC2 activity and thereby suppresses invasion.	[Wang, Q.; Yang, H-S] Univ Kentucky, Coll Med, Dept Toxicol & Canc Biol, 350 HSRB,800 Rose St, Lexington, KY 40536 USA; [Zhu, J.; Wang, Y-W] Shandong Univ, Qilu Hosp, Dept Breast Surg, 107 West Wenhua Rd, Jinan, Shandong, Peoples R China; [Dai, Y.] Shandong Univ, Qilu Hosp, Dept Colorectal & Anal Surg, Jinan, Shandong, Peoples R China; [Wang, C.] Univ Kentucky, Coll Publ Hlth, Dept Biostat, Lexington, KY 40536 USA; [Wang, C.; Liu, J.; Yang, H-S] Univ Kentucky, Coll Med, Markey Canc Ctr, Lexington, KY 40536 USA; [Baker, A.; Colburn, N. H.] NCI, Lab Canc Prevent, Ctr Canc Res, Frederick, MD 21701 USA	University of Kentucky; Shandong University; Shandong University; University of Kentucky; University of Kentucky; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yang, HS (corresponding author), Univ Kentucky, Coll Med, Dept Toxicol & Canc Biol, 350 HSRB,800 Rose St, Lexington, KY 40536 USA.; Zhu, J (corresponding author), Shandong Univ, Qilu Hosp, Dept Breast Surg, 107 West Wenhua Rd, Jinan, Shandong, Peoples R China.	drjiangzhu@hotmail.com; hyang3@uky.edu	Zhu, Jiang/AAX-7274-2020; Yang, Hsin-Sheng/A-6419-2008; Yang, Hsin-Sheng/AAF-6793-2020	Zhu, Jiang/0000-0002-7869-9857; Yang, Hsin-Sheng/0000-0002-0566-3036; Yang, Hsin-Sheng/0000-0002-0566-3036	NIH/NCI grant [R01CA129015, R03CA187839]; NCI/NIH center core support grant [P30CA177558]; National Natural Science Foundation of China [81402192]; NCI Center Core Support Grant [P30CA177558]; NATIONAL CANCER INSTITUTE [P30CA177558, R01CA129015, R03CA187839] Funding Source: NIH RePORTER	NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI/NIH center core support grant; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NCI Center Core Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the NIH/NCI grant to H.-S. Yang (R01CA129015 and R03CA187839), NCI/NIH center core support grant to C. Wang (P30CA177558) and National Natural Science Foundation of China grant to J. Zhu (81402192). The Flow Cytometry facility is supported in part by NCI Center Core Support Grant (P30CA177558). We thank Dr Jian-Li Wang (Shandong University) for experimental supports and Ms Donna Gilbreath and Ms Catherine Anthony (Markey Cancer Center) for editing the manuscript.	Cencic R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005223; Chang JH, 2009, P NATL ACAD SCI USA, V106, P3148, DOI 10.1073/pnas.0808275106; Chen CH, 2011, J BIOL CHEM, V286, P40386, DOI 10.1074/jbc.M111.282590; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Fehler O, 2014, NUCLEIC ACIDS RES, V42, P11107, DOI 10.1093/nar/gku800; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Gaubitz C, 2016, TRENDS BIOCHEM SCI, V41, P532, DOI 10.1016/j.tibs.2016.04.001; Glidden EJ, 2012, J BIOL CHEM, V287, P581, DOI 10.1074/jbc.M111.304337; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249; Guo Xiaoling, 2011, Genes Cancer, V2, P818, DOI 10.1177/1947601911431082; Hilliard A, 2006, J IMMUNOL, V177, P8095, DOI 10.4049/jimmunol.177.11.8095; Ikenoue T, 2009, METHOD ENZYMOL, V452, P165, DOI 10.1016/S0076-6879(08)03611-2; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Kogure T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076136; Lankat-Buttgereit B, 2008, BIOL CELL, V100, P703, DOI 10.1042/BC20080052; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Liu PD, 2015, CANCER DISCOV, V5, P1194, DOI 10.1158/2159-8290.CD-15-0460; Liu PD, 2013, NAT CELL BIOL, V15, P1340, DOI 10.1038/ncb2860; Liwak U, 2012, MOL CELL BIOL, V32, P1818, DOI 10.1128/MCB.06317-11; Loh PG, 2009, EMBO J, V28, P274, DOI 10.1038/emboj.2008.278; Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223; Moraitis D, 2014, SURGERY, V156, P1542, DOI 10.1016/j.surg.2014.08.095; Nieves-Alicea R, 2009, BREAST CANCER RES TR, V114, P203, DOI 10.1007/s10549-008-9993-5; Rogers GW, 2002, PROG NUCLEIC ACID RE, V72, P307, DOI 10.1016/S0079-6603(02)72073-4; Roulin D, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-57; Santhanam AN, 2010, ONCOGENE, V29, P3921, DOI 10.1038/onc.2010.158; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Svitkin YV, 2001, RNA, V7, P1743; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Wang Q, 2010, ONCOGENE, V29, P128, DOI 10.1038/onc.2009.302; Wang Q, 2013, EUR J CANCER, V49, P1761, DOI 10.1016/j.ejca.2012.12.014; Wang Q, 2012, BBA-MOL CELL RES, V1823, P1807, DOI 10.1016/j.bbamcr.2012.07.004; Wei N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030311; Wei ZT, 2009, CANCER SCI, V100, P1408, DOI 10.1111/j.1349-7006.2009.01210.x; Wiegering A, 2015, CANCER DISCOV, V5, P768, DOI 10.1158/2159-8290.CD-14-1040; Wolfe AL, 2014, NATURE, V513, P65, DOI 10.1038/nature13485; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xu JF, 2013, CANCER-AM CANCER SOC, V119, P2247, DOI 10.1002/cncr.28023; Yang G, 2015, CELL REP, V12, P937, DOI 10.1016/j.celrep.2015.07.016; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2014, TRANSLATION ITS REGU, P135; Zhang Y., 2015, J NANOMATER, V2015, P1, DOI DOI 10.1080/10298436.2015.1019502; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	49	39	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6225	6234		10.1038/onc.2017.228	http://dx.doi.org/10.1038/onc.2017.228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28692058	Green Accepted			2022-12-17	WOS:000414774800002
J	Valentino, A; Calarco, A; Di Salle, A; Finicelli, M; Crispi, S; Calogero, R; Riccardo, F; Sciarra, A; Gentilucci, A; Galderisi, U; Margarucci, S; Peluso, G				Valentino, A.; Calarco, A.; Di Salle, A.; Finicelli, M.; Crispi, S.; Calogero, Ra; Riccardo, F.; Sciarra, A.; Gentilucci, A.; Galderisi, U.; Margarucci, S.; Peluso, G.			Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: molecular basis and pathophysiological consequences	ONCOGENE			English	Article							FATTY-ACID OXIDATION; CELL-PROLIFERATION; LIPID OXIDATION; BETA-OXIDATION; METABOLISM; EXPRESSION; PROGRESSION; SIGNATURES; MIGRATION; INVASION	Cancer cells reprogram their metabolism to maintain both viability and uncontrolled proliferation. Although an interplay between the genetic, epigenetic and metabolic rewiring in cancer is beginning to emerge, it remains unclear how this metabolic plasticity occurs. Here, we report that in prostate cancer cells (PCCs) microRNAs (miRNAs) greatly contribute to deregulation of mitochondrial fatty acid (FA) oxidation via carnitine system modulation. We provide evidence that the downregulation of hsa-miR-124-3p, hsa-miR-129-5p and hsa-miR-378 induced an increase in both expression and activity of CPT1A, CACT and CrAT in malignant prostate cells. Moreover, the analysis of human prostate cancer and prostate control specimens confirmed the aberrant expression of miR-124-3p, miR-129-5p and miR-378 in primary tumors. Forced expression of the miRNAs mentioned above affected tumorigenic properties, such as proliferation, migration and invasion, in PC3 and LNCaP cells regardless of their hormone sensitivity. CPT1A, CACT and CrAT overexpression allow PCCs to be more prone on FA utilization than normal prostate cells, also in the presence of high pyruvate concentration. Finally, the simultaneous increase of CPT1A, CACT and CrAT is fundamental for PCCs to sustain FA oxidation in the presence of heavy lipid load on prostate cancer mitochondria. Indeed, the downregulation of only one of these proteins reduces PCCs metabolic flexibility with the accumulation of FA-intermediate metabolites in the mitochondria. Together, our data implicate carnitine cycle as a primary regulator of adaptive metabolic reprogramming in PCCs and suggest new potential druggable pathways for prevention and treatment of prostate cancer.	[Valentino, A.; Calarco, A.; Di Salle, A.; Peluso, G.] CNR, IBAF, Via P Castellino,111, Naples, Italy; [Finicelli, M.; Crispi, S.; Margarucci, S.] CNR, Inst Biosci & BioResources, Naples, Italy; [Calogero, Ra; Riccardo, F.] Univ Turin, Lab Immunol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy; [Sciarra, A.; Gentilucci, A.] Univ Sapienza, Policlin Umberto 1, Dept Urol, Prostate Canc Unit, Rome, Italy; [Galderisi, U.] Univ Campania Luigi Vanvitelli, Dept Expt Med, Biotechnol & Mol Biol Sect, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia Agroambientale e Forestale (IBAF-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Bioscienze e Biorisorse (IBBR-CNR); University of Turin; Sapienza University Rome; University Hospital Sapienza Rome; Universita della Campania Vanvitelli	Peluso, G (corresponding author), CNR, IBAF, Via P Castellino,111, Naples, Italy.	gianfranco.peluso@ibaf.cnr.it	Riccardo, Federica/AGT-3153-2022; Calogero, Raffaele/K-9428-2019; SCIARRA, ALESSANDRO/AAC-8088-2021; Antonelli, Alessandro/AAU-2291-2020; Di Salle, A/AAF-5416-2019; Calarco, Anna/P-2568-2019; Finicelli, Mauro/ABC-1392-2020	Riccardo, Federica/0000-0002-9692-0172; Calogero, Raffaele/0000-0002-2848-628X; Di Salle, A/0000-0001-6763-3636; Calarco, Anna/0000-0002-1441-7662; MARGARUCCI, SABRINA/0000-0001-5361-1241; Finicelli, Mauro/0000-0003-2289-0916; Sciarra, Alessandro/0000-0002-7899-8056; Valentino, Anna/0000-0001-8041-2221; Crispi, Stefania/0000-0002-7566-1554	Ministero dell'Istruzione, dell'Universita e della Ricerca of Italy; Progetto PON - 'Ricerca e Competitivita' [PON01_01802, PON01_02512]	Ministero dell'Istruzione, dell'Universita e della Ricerca of Italy(Ministry of Education, Universities and Research (MIUR)); Progetto PON - 'Ricerca e Competitivita'(Ministry of Education, Universities and Research (MIUR))	This work was supported from Ministero dell'Istruzione, dell'Universita e della Ricerca of Italy, Progetto PON - 'Ricerca e Competitivita 2007-2013'- PON01_01802: 'Sviluppo di molecole capaci di modulare vie metaboliche intracellulari redoxsensibili per la prevenzione e la cura di patologie infettive, tumorali, neurodegenerative e loro delivery mediante piattaforme nano tecnologiche', and PON01_02512: 'Ricerca e sviluppo di bioregolatori attivi sui meccanismi epigenetici dei processi infiammatori nelle malattie croniche e degenerative'. Precis: this study reports the critical role of specific miRNAs (hsa-miR-124-3p, hsa-miR-129-5p and hsa-miR-378) to sustain prostate cancer metabolic flexibility via modulation of CPT1A, CACT and CrAT expression.	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Arora Aastha, 2015, Transl Oncogenomics, V7, P11, DOI 10.4137/TOG.S29652; Bastin J, 2014, BIOCHIMIE, V96, P113, DOI 10.1016/j.biochi.2013.05.012; BERTHON P, 1995, INT J ONCOL, V6, P333; Bonnefont Jean-Paul, 2004, Molecular Aspects of Medicine, V25, P495, DOI 10.1016/j.mam.2004.06.004; BRASS EP, 1980, BIOCHEM J, V190, P495, DOI 10.1042/bj1900495; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cardenas-Navia LI, 2008, CANCER RES, V68, P5812, DOI 10.1158/0008-5472.CAN-07-6387; Carrer M, 2012, P NATL ACAD SCI USA, V109, P15330, DOI 10.1073/pnas.1207605109; Costello LC, 2000, ONCOLOGY-BASEL, V59, P269, DOI 10.1159/000012183; Costello LC, 2005, MOL CELL BIOCHEM, V280, P1, DOI 10.1007/s11010-005-8841-8; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; DeBerardinis RJ, 2008, GENET MED, V10, P267, DOI 10.1097/GIM.0b013e31818b0d9b; Dong PX, 2016, ONCOTARGET, V7, P20260, DOI 10.18632/oncotarget.7754; Dossing KBV, 2015, GENES-BASEL, V6, P1, DOI 10.3390/genes6010001; Duan LJ, 2014, FEBS LETT, V588, P1644, DOI 10.1016/j.febslet.2014.03.002; Eaton S, 2002, PROG LIPID RES, V41, P197, DOI 10.1016/S0163-7827(01)00024-8; Eichner LJ, 2010, CELL METAB, V12, P352, DOI 10.1016/j.cmet.2010.09.002; Foster DW, 2004, ANN NY ACAD SCI, V1033, P1, DOI 10.1196/annals.1320.001; Fritz V, 2013, ONCOGENE, V32, P5101, DOI 10.1038/onc.2012.523; Gill BS, 2016, TUMOR BIOL, V37, P5683, DOI 10.1007/s13277-016-4900-x; Giordano A, 2005, CELL DEATH DIFFER, V12, P603, DOI 10.1038/sj.cdd.4401636; Ijlst L, 2001, BIOCHEM BIOPH RES CO, V280, P700, DOI 10.1006/bbrc.2000.4178; Jogl G, 2004, ANN NY ACAD SCI, V1033, P17, DOI 10.1196/annals.1320.002; Johnson IR, 2014, PROSTATE, V74, P547, DOI 10.1002/pros.22777; Khanmi K, 2015, CLIN CHIM ACTA, V451, P154, DOI 10.1016/j.cca.2015.09.022; Kim JY, 2000, AM J PHYSIOL-ENDOC M, V279, pE1039, DOI 10.1152/ajpendo.2000.279.5.E1039; Kurisetty VV, 2014, FRONT BIOSCI-LANDMRK, V19, P1, DOI 10.2741/4192; Li XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070987; Liu XL, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-96; Liu Y, 2006, PROSTATE CANCER P D, V9, P230, DOI 10.1038/sj.pcan.4500879; Liu YY, 2010, ANTICANCER RES, V30, P369; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu JR, 2015, CANCER LETT, V356, P156, DOI 10.1016/j.canlet.2014.04.001; Ma N, 2015, BIOCHEM BIOPH RES CO, V461, P618, DOI 10.1016/j.bbrc.2015.04.075; McDunn JE, 2013, PROSTATE, V73, P1547, DOI 10.1002/pros.22704; Modica-Napolitano JS, 2004, MITOCHONDRION, V4, P755, DOI 10.1016/j.mito.2004.07.027; Muoio DM, 2012, CELL METAB, V15, P764, DOI 10.1016/j.cmet.2012.04.005; Palmieri F, 2010, ESSAYS BIOCHEM, V47, P37, DOI [10.1042/BSE0470037, 10.1042/bse0470037]; Peluso G, 2002, FRONT BIOSCI, V7, pA109, DOI 10.2741/peluso; Pinweha P, 2016, COMPUT STRUCT BIOTEC, V14, P223, DOI 10.1016/j.csbj.2016.05.005; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Price DT, 2002, J UROLOGY, V168, P273, DOI 10.1016/S0022-5347(05)64906-3; Priore P, 2007, BBA-MOL CELL BIOL L, V1771, P1299, DOI 10.1016/j.bbalip.2007.08.005; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; Riehle C, 2012, TRENDS CARDIOVAS MED, V22, P98, DOI 10.1016/j.tcm.2012.07.003; Schaefer A, 2010, UROL ONCOL-SEMIN ORI, V28, P4, DOI 10.1016/j.urolonc.2008.10.021; Schlaepfer IR, 2015, MOL IMAGING BIOL, V17, P529, DOI 10.1007/s11307-014-0814-4; Schlaepfer IR, 2014, MOL CANCER THER, V13, P2361, DOI 10.1158/1535-7163.MCT-14-0183; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shahabi A, 2016, PROSTATE, V76, P1239, DOI 10.1002/pros.23211; Shanware NP, 2011, J MOL MED, V89, P229, DOI 10.1007/s00109-011-0731-9; Shen N, 2016, TUMOR BIOL, V37, P1789, DOI 10.1007/s13277-015-3969-y; Shen RZ, 2010, BIOCHEM BIOPH RES CO, V394, P1047, DOI 10.1016/j.bbrc.2010.03.121; Shi XB, 2015, CANCER RES, V75, P5309, DOI 10.1158/0008-5472.CAN-14-0795; Song CJ, 2015, PROSTATE, V75, P500, DOI 10.1002/pros.22936; Sreekumar A, 2009, NATURE, V457, P910, DOI 10.1038/nature07762; Teahan O, 2011, INT J BIOCHEM CELL B, V43, P1002, DOI 10.1016/j.biocel.2010.07.003; Wang XY, 2016, ONCOL REP, V35, P3115, DOI 10.3892/or.2016.4648; Wu XY, 2014, AM J CLIN EXP UROL, V2, P111	62	39	40	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					6030	6040		10.1038/onc.2017.216	http://dx.doi.org/10.1038/onc.2017.216			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28671672				2022-12-17	WOS:000413841400011
J	Zhang, K; Myllymaki, SM; Gao, P; Devarajan, R; Kytola, V; Nykter, M; Wei, GH; Manninen, A				Zhang, K.; Myllymaki, S-M; Gao, P.; Devarajan, R.; Kytola, V.; Nykter, M.; Wei, G-H; Manninen, A.			Oncogenic K-Ras upregulates ITGA6 expression via FOSL1 to induce anoikis resistance and synergizes with alpha V-Class integrins to promote EMT	ONCOGENE			English	Article							BREAST-CANCER CELLS; PROSTATE-CANCER; SIGNALING PATHWAYS; EPITHELIAL-CELLS; SRC; GROWTH; ALPHA-V-BETA-6; INHIBITION; POLARITY; PLATFORM	In many cancer types, integrin-mediated signaling regulates proliferation, survival and invasion of tumorigenic cells. However, it is still unclear how integrins crosstalk with oncogenes to regulate tumorigenesis and metastasis. Here we show that oncogenic K-Ras(V12) upregulates alpha 6-integrin expression in Madin-Darby canine kidney (MDCK) cells via activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK)/Fos-related antigen 1-signaling cascade. Activated alpha 6-integrins promoted metastatic capacity and anoikis resistance, and led to perturbed growth of MDCK cysts. Transcriptomic analysis of K-Ras(V12)-transformed MDCK cells also revealed robust downregulation of alpha V-class integrins. Re-expression of alpha V-integrin in K-Ras(V12)-transformed MDCK cells synergistically upregulated the expression of Zinc finger E-box-binding homeobox 1 and Twist-related protein 1 and triggered epithelial-mesenchymal transition leading to induced cell motility and invasion. These results delineate the signaling cascades connecting oncogenic K-Ras(V12) with alpha 6- and alpha V-integrin functions to modulate cancer cell survival and tumorigenesis, and reveal new possible strategies to target highly oncogenic K-Ras(V12) mutants.	[Zhang, K.; Myllymaki, S-M; Gao, P.; Devarajan, R.; Wei, G-H; Manninen, A.] Univ Oulu, Fac Biochem & Mol Med, Ctr Excellence Cell Extracellular Matrix Res, Bioctr Oulu, Aapistie 5, SF-90220 Oulu, Finland; [Kytola, V.; Nykter, M.] Univ Tampere, Inst Biomed Technol & BioMediTech, Prostate Canc Res Ctr, Tampere, Finland; [Kytola, V.; Nykter, M.] Tampere Univ Hosp, Tampere, Finland; [Myllymaki, S-M] Univ Helsinki, Inst Biotechnol, Dev Biol Program, Helsinki, Finland	University of Oulu; Tampere University; Tampere University; Tampere University Hospital; University of Helsinki	Manninen, A (corresponding author), Univ Oulu, Fac Biochem & Mol Med, Ctr Excellence Cell Extracellular Matrix Res, Bioctr Oulu, Aapistie 5, SF-90220 Oulu, Finland.	aki.manninen@oulu.fi	Zhang, Kai/M-9831-2017; Devarajan, Raman/GOH-0098-2022; Manninen, Aki/AAC-8067-2019	Zhang, Kai/0000-0003-2962-3976; Manninen, Aki/0000-0002-6263-8101; Wei, Gong-Hong/0000-0001-6546-9334; Devarajan, Raman/0000-0002-8728-0476; Nykter, Matti/0000-0001-6956-2843; Myllymaki, Satu-Marja/0000-0003-0521-5062; gao, ping/0000-0003-1383-3290	Academy of Finland [251314, 135560, 263770, 140974/AM, 284618, 279760/GHW]	Academy of Finland(Academy of Finland)	We thank Dr Ritva Heljasvaara and Dr Heli Ruotsalainen for their help related to mouse work. Riitta Jokela is acknowledged for overall expert technical assistance, Jaana Traskelin for expert technical assistance at Biocenter Oulu Virus Core Laboratory and Veli-Pekka Ronkainen for expert assistance in microscopy at Biocenter Oulu Tissue Imaging Center. This work was funded by Academy of Finland (251314, 135560, 263770, 140974/AM, 284618 and 279760/GHW).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Aoudjit F., 2012, CHEMOTHER RES PRACT, V2012, P1; Arai T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0027782; Armstrong L, 2006, HUM MOL GENET, V15, P1894, DOI 10.1093/hmg/ddl112; Bachman KE, 2005, CURR OPIN ONCOL, V17, P49, DOI 10.1097/01.cco.0000143682.45316.ae; Bandyopadhyay A, 2009, CURR DRUG TARGETS, V10, P645, DOI 10.2174/138945009788680374; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Boggiano JC, 2012, DEV CELL, V22, P695, DOI 10.1016/j.devcel.2012.03.013; Bryant DM, 2008, NAT REV MOL CELL BIO, V9, P887, DOI 10.1038/nrm2523; Bunda S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9859; Bunda S, 2014, P NATL ACAD SCI USA, V111, pE3785, DOI 10.1073/pnas.1406559111; Cariati M, 2008, INT J CANCER, V122, P298, DOI 10.1002/ijc.23103; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen XL, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0091809, 10.1371/journal.pone.0103330, 10.1371/journal.pone.0085716, 10.1371/journal.pone.0115462, 10.1371/journal.pone.0091830, 10.1371/journal.pone.0087752]; Cheng PF, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14183; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dhillon AS, 2015, ONCOGENE, V34, P4421, DOI 10.1038/onc.2014.374; Dohn MR, 2009, J CELL BIOL, V184, P437, DOI 10.1083/jcb.200807096; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Evans RD, 2003, J CELL BIOL, V160, P589, DOI 10.1083/jcb.200209016; Evellin S, 2013, MOL CELL BIOL, V33, P1198, DOI 10.1128/MCB.01054-12; Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370; Ganguly KK, 2013, CELL ADHES MIGR, V7, P251, DOI 10.4161/cam.23840; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Hahm K, 2007, AM J PATHOL, V170, P110, DOI 10.2353/ajpath.2007.060158; Halaoui R, 2015, ONCOGENE, V34, P939, DOI 10.1038/onc.2014.59; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; Hogan C, 2009, NAT CELL BIOL, V11, P460, DOI 10.1038/ncb1853; Huang QL, 2014, NAT GENET, V46, P126, DOI 10.1038/ng.2862; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jiang WG, 2015, SEMIN CANCER BIOL, V35, pS244, DOI 10.1016/j.semcancer.2015.03.008; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Lamb LE, 2011, CANCER RES, V71, P2739, DOI 10.1158/0008-5472.CAN-10-2745; Lee JL, 2014, J CELL SCI, V127, P3217, DOI 10.1242/jcs.146142; Leung CT, 2012, NATURE, V482, P410, DOI 10.1038/nature10826; Li LJ, 2007, MOL CELL BIOL, V27, P5381, DOI 10.1128/MCB.00282-07; Mamuya FA, 2012, J CELL MOL MED, V16, P445, DOI 10.1111/j.1582-4934.2011.01419.x; Manninen A, 2015, EXP CELL RES, V334, P337, DOI 10.1016/j.yexcr.2015.01.003; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Miura P, 2013, GENOME RES, V23, P812, DOI 10.1101/gr.146886.112; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Myllymaki SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019453; Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008-5472.CAN-07-2997; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schuck S, 2004, P NATL ACAD SCI USA, V101, P4912, DOI 10.1073/pnas.0401285101; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Seguin L, 2014, NAT CELL BIOL, V16, P457, DOI 10.1038/ncb2953; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shimizu H, 2003, ONCOGENE, V22, P831, DOI 10.1038/sj.onc.1206203; Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033; Slattum GM, 2014, NAT REV CANCER, V14, P495, DOI 10.1038/nrc3767; Szulc J, 2006, NAT METHODS, V3, P109, DOI 10.1038/NMETH846; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang LF, 2010, P NATL ACAD SCI USA, V107, P7317, DOI 10.1073/pnas.1000031107; Welm Bryan E, 2008, Cell Stem Cell, V2, P90, DOI 10.1016/j.stem.2007.10.002; Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009-0009; Wipff PJ, 2008, EUR J CELL BIOL, V87, P601, DOI 10.1016/j.ejcb.2008.01.012; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Zhang K, 2016, ONCOTARGET, V7, P84178, DOI 10.18632/oncotarget.12390	69	39	42	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5681	5694		10.1038/onc.2017.177	http://dx.doi.org/10.1038/onc.2017.177			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28604746	Green Published, hybrid			2022-12-17	WOS:000412843900003
J	Takahashi, H; Inoue, J; Sakaguchi, K; Takagi, M; Mizutani, S; Inazawa, J				Takahashi, H.; Inoue, J.; Sakaguchi, K.; Takagi, M.; Mizutani, S.; Inazawa, J.			Autophagy is required for cell survival under L-asparaginase-induced metabolic stress in acute lymphoblastic leukemia cells	ONCOGENE			English	Article							MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR; P53 STATUS; SYNTHETASE; EXPRESSION; APOPTOSIS; GENE; SENSITIVITY; CANCER; DISEASE	L-asparaginase has been used for more than three decades in acute lymphoblastic leukemia (ALL) patients and remains an essential drug in the treatment of ALL. Poor response to L-asparaginase is associated with increased risk of therapeutic failure in ALL. However, both the metabolic perturbation and molecular context of L-asparaginase-treated ALL cells has not been fully elucidated. Here we identify that treatment with L-asparaginase results in metabolic shutdown via the reduction of both glycolysis and oxidative phosphorylation, accompanied by mitochondrial damage and activation of autophagy. The autophagy is involved in reducing reactive oxygen species (ROS) level by eliminating injured mitochondria. Inhibition of autophagy enhances L-asparaginase-induced cytotoxicity and overcomes the acquired resistance to L-asparaginase in ALL cells. The ROS-p53-positive feedback loop is an essential mechanism of this synergistic cytotoxicity. Thus, our findings provide the rationale for the future development of combined treatment of L-asparaginase and anti-autophagy drug in ALL patients.	[Takahashi, H.; Inoue, J.; Inazawa, J.] TMDU, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan; [Takahashi, H.; Sakaguchi, K.] Hamamatsu Univ, Sch Med, Dept Pediat, Shizuoka, Japan; [Takahashi, H.; Inoue, J.; Inazawa, J.] TMDU, Bioresource Res Ctr, Tokyo, Japan; [Takagi, M.; Mizutani, S.] TMDU, Dept Pediat & Dev Biol, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Hamamatsu University School of Medicine; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Inoue, J; Inazawa, J (corresponding author), TMDU, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	jun.cgen@mri.tmd.ac.jp; johinaz.cgen@mri.tmd.ac.jp			JSPS [15H05908, C:15K08301]; MEXT; Joint Usage/Research Program of MRI, TMDU; Grants-in-Aid for Scientific Research [16K14630] Funding Source: KAKEN	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Joint Usage/Research Program of MRI, TMDU; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are deeply grateful to N Hattori (Juntendo University, Japan) for use of the extracellular flux analyzer and H Sato, A Hagiwara and Y Noguchi (Ajinomoto Co., Inc., Japan) for the intracellular amino-acid analysis. We thank U Kevin, S Ikeda and T Muramatsu (Tokyo Medical and Dental University, Japan) for editing this article. We also thank R Mori and K Ayako (Tokyo Medical and Dental University, Japan) for technical assistance in lentivirus preparation and gene expression arrays. This study was supported in part by Grant-in-Aid for Scientific Research (C:15K08301) and Grant-in-Aid for Scientific Research on Innovative Areas "Conquering cancer through NEO-dimensional systems understandings" (15H05908) from JSPS and MEXT, and the Joint Usage/Research Program of MRI, TMDU.	Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Aslanian AM, 2001, BIOCHEM J, V358, P59, DOI 10.1042/0264-6021:3580059; Barrera V, 2015, J INFECT DIS, V211, P1977, DOI 10.1093/infdis/jiu592; Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987; Bush A, 2015, THORAX, V70, P1078, DOI 10.1136/thoraxjnl-2015-207349; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Curran E, 2015, BLOOD, V125, P3702, DOI 10.1182/blood-2014-11-551481; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Doria A, 2013, NEW ENGL J MED, V368, P1845, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]; Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113; Fine BM, 2005, CANCER RES, V65, P291; Fujiwara N, 2015, CANCER RES, V75, P3890, DOI 10.1158/0008-5472.CAN-15-0257; Hermanova I, 2016, LEUKEMIA, V30, P209, DOI 10.1038/leu.2015.213; Hermanova I, 2012, EXP HEMATOL, V40, P657, DOI 10.1016/j.exphem.2012.04.005; Holleman A, 2004, NEW ENGL J MED, V351, P533, DOI 10.1056/NEJMoa033513; Hongo T, 1997, BLOOD, V89, P2959, DOI 10.1182/blood.V89.8.2959; Inoue J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007099; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kaspers GJL, 1997, BLOOD, V90, P2723, DOI 10.1182/blood.V90.7.2723.2723_2723_2729; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Laane E, 2009, CELL DEATH DIFFER, V16, P1018, DOI 10.1038/cdd.2009.46; Lee SW, 2015, CANCER LETT, V360, P195, DOI 10.1016/j.canlet.2015.02.012; Locatelli F, 2012, BLOOD, V120, P2807, DOI 10.1182/blood-2012-02-265884; Lorenzi PL, 2014, AUTOPHAGY, V10, P1316, DOI 10.4161/auto.28773; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; OETTGEN HF, 1967, CANCER RES, V27, P2619; Polak A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155893; Ranjan A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122068; Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99; Reddy PNG, 2012, BLOOD, V120, P1691, DOI 10.1182/blood-2010-08-301416; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Sherman BT, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-426; Shimbo K, 2009, RAPID COMMUN MASS SP, V23, P1483, DOI 10.1002/rcm.4026; Song P, 2015, ONCOTARGET, V6, P3861, DOI 10.18632/oncotarget.2869; Stams WAG, 2005, BLOOD, V105, P4223, DOI 10.1182/blood-2004-10-3892; Stams WAG, 2003, BLOOD, V101, P2743, DOI 10.1182/blood-2002-08-2446; Stengel A, 2014, BLOOD, V124, P251, DOI 10.1182/blood-2014-02-558833; Su N, 2008, PEDIATR BLOOD CANCER, V50, P274, DOI 10.1002/pbc.21213; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Ueno T, 1997, LEUKEMIA, V11, P1858, DOI 10.1038/sj.leu.2400834; Velasco-Hernandez T, 2014, BLOOD, V124, P3597, DOI 10.1182/blood-2014-04-567065; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Yu MS, 2012, J CELL MOL MED, V16, P2369, DOI 10.1111/j.1582-4934.2012.01547.x	45	39	40	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4267	4276		10.1038/onc.2017.59	http://dx.doi.org/10.1038/onc.2017.59			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28346428	Green Submitted, Green Published, hybrid			2022-12-17	WOS:000406360600004
J	Wu, H; Zhang, XY; Hu, Z; Hou, Q; Zhang, H; Li, Y; Li, S; Yue, J; Jiang, Z; Weissman, SM; Pan, X; Ju, BG; Wu, S				Wu, H.; Zhang, X-Y; Hu, Z.; Hou, Q.; Zhang, H.; Li, Y.; Li, S.; Yue, J.; Jiang, Z.; Weissman, S. M.; Pan, X.; Ju, B-G; Wu, S.			Evolution and heterogeneity of non-hereditary colorectal cancer revealed by single-cell exome sequencing	ONCOGENE			English	Article							COLON-CANCER; INTRATUMOR HETEROGENEITY; SOMATIC MUTATIONS; EPITHELIAL-CELLS; PROSTATE-CANCER; BREAST-CANCER; IN-VIVO; TUMOR; IDENTIFICATION; INSTABILITY	Recently single-cell whole-exome sequencing (scWES) has deeply expanded and sharpened our knowledge of cancer evolution and subclonality. Herein, with scWES and matched bulk whole-exome sequencing (bulk WES) on two colorectal cancer (CRC) patients with normal or adenomatous polyps, we found that both the adenoma and cancer were of monoclonal origin, and both shared partial mutations in the same signaling pathways, but each showed a specific spectrum of heterogeneous somatic mutations. In addition, the adenoma and cancer further developed intratumor heterogeneity with the accumulation of nonrandom somatic mutations specifically in GPCR, PI3K-Akt and FGFR signaling pathways. We identified novel driver mutations that developed during adenoma and cancer evolution, particularly in OR1B1 (GPCR signaling pathway) for adenoma evolution, and LAMA1 (PI3K-Akt signaling pathway) and ADCY3 (FGFR signaling pathway) for CRC evolution. In summary, we demonstrated that both colorectal adenoma and CRC are monoclonal in origin, and the CRCs further diversified into different subclones with heterogeneous mutation profiles accumulating in GPCR, PI3K-Akt and FGFR signaling pathways. ScWES provides evidence for the importance of mutations in certain pathways that would not be as apparent from bulk sequencing of tumors, and can potentially establish whether specific mutations are mutually exclusive or occur sequentially in the same subclone of cells.	[Wu, H.; Zhang, X-Y; Hu, Z.; Hou, Q.; Zhang, H.; Li, Y.; Li, S.; Yue, J.; Jiang, Z.; Wu, S.] Hangzhou Canc Hosp, Canc Res Inst, 34 Yanguan St, Hangzhou 310002, Zhejiang, Peoples R China; [Wu, H.; Ju, B-G] Sogang Univ, Dept Life Sci, Seoul, South Korea; [Weissman, S. M.; Pan, X.] Yale Sch Med, Dept Genet, New Haven, CT 06510 USA	Sogang University; Yale University	Wu, S (corresponding author), Hangzhou Canc Hosp, Canc Res Inst, 34 Yanguan St, Hangzhou 310002, Zhejiang, Peoples R China.; Ju, BG (corresponding author), Sogang Univ, Dept Life Sci, Seoul, South Korea.; Pan, X (corresponding author), Yale Sch Med, Dept Genet, New Haven, CT 06510 USA.	xinghua.pan@yale.edu; bgju@sogang.ac.kr; wushixiu@medmail.com.cn	Wu, Hongjin/AAF-6122-2019	Wu, Hongjin/0000-0002-2053-7441; Pan, Xinghua (Victor)/0000-0002-7421-8155	Natural Science Foundation of Zhejiang Province [LZ15H220001, LY14H160005]; Zhejiang Medical and Health Ministry Training Program [2015PYA009]; The Science and Technology of Hangzhou Medical and Health Project [2012ZD001]; National Natural Science Foundation of China (CN) [81402529]	Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); Zhejiang Medical and Health Ministry Training Program; The Science and Technology of Hangzhou Medical and Health Project; National Natural Science Foundation of China (CN)(National Natural Science Foundation of China (NSFC))	We thank Dr Sherman Weissman for his critical comments on the manuscript. We are indebted to all the individuals who consented to participate in this study. ScWES and bulk WES was performed at the Genseeq Company. The sequenced data was analyzed by Yunkang Biotechnology Co. Ltd. This work was supported by Natural Science Foundation of Zhejiang Province (LZ15H220001 and LY14H160005), Zhejiang Medical and Health Ministry Training Program (2015PYA009), The Science and Technology of Hangzhou Medical and Health Project (2012ZD001), National Natural Science Foundation of China (CN; 81402529).	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Ashktorab H, 2013, EPIGENETICS-US, V8, P807, DOI 10.4161/epi.25497; Ashktorab H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008879; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; Carethers JM, 2015, GASTROENTEROLOGY, V149, P1177, DOI 10.1053/j.gastro.2015.06.047; Cebrat M, 2004, CANCER LETT, V206, P107, DOI 10.1016/j.canlet.2003.10.024; Charbonneau B, 2012, AM J HEMATOL, V87, P880, DOI 10.1002/ajh.23273; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Farrell CL, 2008, CANCER BIOL THER, V7, P609, DOI 10.4161/cbt.7.4.5623; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Gemoll T., 2015, CANCER RES, V200, P81; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Gylfe AE, 2010, INT J CANCER, V127, P2974, DOI 10.1002/ijc.25529; Helleday T, 2014, NAT REV GENET, V15, P585, DOI 10.1038/nrg3729; Hou Y, 2012, CELL, V148, P873, DOI 10.1016/j.cell.2012.02.028; Huang L, 2015, ANNU REV GENOM HUM G, V16, P79, DOI 10.1146/annurev-genom-090413-025352; Kanojia D, 2015, ONCOTARGET, V6, P42429, DOI 10.18632/oncotarget.6464; Katayama K, 2013, CANCER SCI, V104, P694, DOI 10.1111/cas.12145; Kirley SD, 2005, CANCER BIOL THER, V4, P861, DOI 10.4161/cbt.4.8.1894; Kober P, 2011, MOL CARCINOGEN, V50, P846, DOI 10.1002/mc.20763; Lanza G, 1998, INT J CANCER, V79, P390, DOI 10.1002/(SICI)1097-0215(19980821)79:4<390::AID-IJC14>3.3.CO;2-M; Latini FRM, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-11; Lederer A, 2015, HEPATOLOGY, V62, P841, DOI 10.1002/hep.27885; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lind GE, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-85; Lohr JG, 2014, NAT BIOTECHNOL, V32, P479, DOI 10.1038/nbt.2892; Lum AM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-40; Mangerich A, 2012, P NATL ACAD SCI USA, V109, pE1820, DOI 10.1073/pnas.1207829109; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Palamaro L, 2014, INT REV IMMUNOL, V33, P83, DOI 10.3109/08830185.2013.870171; Patel Swati G, 2012, Curr Gastroenterol Rep, V14, P428, DOI 10.1007/s11894-012-0280-6; Peters U, 2015, GUT, V64, P1623, DOI 10.1136/gutjnl-2013-306705; Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065; Ross JB, 2015, NAT CELL BIOL, V17, P651, DOI 10.1038/ncb3148; Rowe J, 2001, J CELL SCI, V114, P3323; Seneviratne D, 2015, GASTROENTEROLOGY, V148, P181, DOI 10.1053/j.gastro.2014.09.019; Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Strum WB, 2016, NEW ENGL J MED, V374, P1065, DOI [10.1056/NEJMc1604867, 10.1056/NEJMra1513581]; Teng G, 2015, CELL, V162, P751, DOI 10.1016/j.cell.2015.07.009; Tsukahara T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081139; Vasen HFA, 2000, J CLIN ONCOL, V18, p81S; Wang Y, 2014, NATURE, V512, P155, DOI 10.1038/nature13600; Wang ZY, 2012, GYNECOL ONCOL, V127, P403, DOI 10.1016/j.ygyno.2012.08.007; Xu X, 2012, CELL, V148, P886, DOI 10.1016/j.cell.2012.02.025; Yu C, 2014, CELL RES, V24, P701, DOI 10.1038/cr.2014.43; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930; Zhang R, 2014, TUMOR BIOL, V35, P4419, DOI 10.1007/s13277-013-1581-6; Zhang XY, 2016, CANCER RES, V76, P1305, DOI 10.1158/0008-5472.CAN-15-1907	52	39	39	3	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2857	2867		10.1038/onc.2016.438	http://dx.doi.org/10.1038/onc.2016.438			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27941887				2022-12-17	WOS:000401697800008
J	Liao, YH; Chiang, KH; Shieh, JM; Huang, CR; Shen, CJ; Huang, WC; Chen, BK				Liao, Y-H; Chiang, K-H; Shieh, J-M; Huang, C-R; Shen, C-J; Huang, W-C; Chen, B-K			Epidermal growth factor-induced ANGPTL4 enhances anoikis resistance and tumour metastasis in head and neck squamous cell carcinoma	ONCOGENE			English	Article							ANGIOPOIETIN-LIKE 4; COLORECTAL-CANCER; FACTOR RECEPTOR; VASCULAR-PERMEABILITY; ACTIVATION; EXPRESSION; INVASION; ANGIOGENESIS; DEGRADATION; PROGRESSION	Epidermal growth factor (EGF) is important for cancer cell proliferation, angiogenesis and metastasis in many types of cancer. However, the mechanisms involved in EGF-induced head and neck squamous cell carcinoma (HNSCC) metastasis remain largely unknown. In this study, we reveal that angiopoietin-like 4 (ANGPTL4) plays an important role in the regulation of EGF-induced cancer metastasis. We showed that EGF-induced ANGPTL4 expression promoted anoikis resistance and cancer cell migration and invasion in HNSCC. In addition, depletion of ANGPTL4 inhibited EGF-induced cancer cell invasion. Autocrine production of EGF-induced ANGPTL4 regulated the expression of matrix metalloproteinases (MMPs). The induction of MMP-1 gene expression by ANGPTL4-activated integrin beta 1 signalling occurred through the AP-1 binding site in the MMP-1 gene promoter. Furthermore, down-regulation of MMP-1 impeded EGF- and recombinant ANGPTL4-enhanced HNSCC cell migration and invasion. Depletion of ANGPTL4 significantly blocked EGF-primed extravasation and metastatic seeding of tumour cells and MMP-1 expression in lungs. However, no effect of ANGPTL4 on tumour growth was observed. These results suggest that EGF-induced expression and autocrine production of ANGPTL4 enhances HNSCC metastasis via the up-regulation of MMP-1 expression. Inhibition of ANGPTL4 expression may be a potential strategy for the treatment of EGFR-mediated HNSCC metastasis.	[Liao, Y-H; Huang, C-R; Shen, C-J; Huang, W-C; Chen, B-K] Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, Coll Biosci & Biotechnol, Tainan, Taiwan; [Chiang, K-H; Shieh, J-M] Chi Mei Med Ctr, Dept Chest Med, Tainan, Taiwan; [Huang, C-R] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei, Taiwan; [Huang, W-C] Acad Sinica, Inst Cellular & Organism Biol, Taipei, Taiwan; [Chen, B-K] Natl Cheng Kung Univ, Dept Pharmacol, Coll Med, Tainan, Taiwan; [Chen, B-K] Taipei Med Univ, Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan	National Cheng Kung University; Chi Mei Hospital; Taipei Medical University; Academia Sinica - Taiwan; National Cheng Kung University; Taipei Medical University	Huang, WC; Chen, BK (corresponding author), Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, 1 Univ Rd, Tainan 701, Taiwan.	wchuang1@gate.sinica.edu.tw; bkchen58@mail.ncku.edu.tw	Huang, Wan-Chen/N-2472-2019	Huang, Wan-Chen/0000-0002-7341-4373; Chen, Ben-Kuen/0000-0002-4720-4364; Huang, Chi-Ruei/0000-0001-9646-8852	Ministry of Science and Technology of Taiwan [NSC 102-2628-B-006- 011-MY3, MOST 105-2320-B-006-022-MY3]; National Cheng Kung University	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); National Cheng Kung University	This work was supported by the Ministry of Science and Technology of Taiwan [Grant NSC 102-2628-B-006- 011-MY3; MOST 105-2320-B-006-022-MY3]; and National Cheng Kung University [the Headquarters of University Advancement]. We thank for the kind gift of MMP-1 gene promoter-PGL3 from Dr Ju-Ming Wang.	Akishima-Fukasawa Y, 2011, HISTOPATHOLOGY, V59, P470, DOI 10.1111/j.1365-2559.2011.03964.x; Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Carvalho AL, 2005, INT J CANCER, V114, P806, DOI 10.1002/ijc.20740; Chang KY, 2011, CLIN CANCER RES, V17, P7116, DOI 10.1158/1078-0432.CCR-11-0796; Chang WC, 2015, ONCOTARGET, V6, P7741, DOI 10.18632/oncotarget.3482; Dawson JC, 2012, ONCOGENE, V31, P1781, DOI 10.1038/onc.2011.376; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Goh YY, 2010, J BIOL CHEM, V285, P32999, DOI 10.1074/jbc.M110.108175; Huang RL, 2011, BLOOD, V118, P3990, DOI 10.1182/blood-2011-01-328716; Humtsoe JO, 2010, ONCOGENE, V29, P1214, DOI 10.1038/onc.2009.419; Katanasaka Y, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-31; Kersten S, 2009, ARTERIOSCL THROM VAS, V29, P969, DOI 10.1161/ATVBAHA.108.182147; Kim SH, 2011, CANCER RES, V71, P7010, DOI 10.1158/0008-5472.CAN-11-1262; Kimura R, 2011, BBA-MOL CELL RES, V1813, P1543, DOI 10.1016/j.bbamcr.2011.04.008; Kuo TC, 2013, J CLIN INVEST, V123, P1082, DOI 10.1172/JCI64044; Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X; Li YW, 2008, NAT PROTOC, V3, P1703, DOI 10.1038/nprot.2008.172; Maekawa Yuichiro, 2011, Inflammation & Allergy Drug Targets, V10, P229; Mandard S, 2006, J BIOL CHEM, V281, P934, DOI 10.1074/jbc.M506519200; Masuelli L, 2012, J CELL PHYSIOL, V227, P3344, DOI 10.1002/jcp.24034; Mathieu M, 2014, J BIOL CHEM, V289, P8402, DOI 10.1074/jbc.M113.539825; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Murata M, 2009, J ORTHOP RES, V27, P50, DOI 10.1002/jor.20703; Nakayama T, 2011, ONCOL REP, V25, P929, DOI 10.3892/or.2011.1176; Oike Y, 2005, TRENDS MOL MED, V11, P473, DOI 10.1016/j.molmed.2005.08.002; Okochi-Takada E, 2014, ONCOGENE, V33, P2273, DOI 10.1038/onc.2013.174; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Shen XD, 2004, AM J PATHOL, V165, P1315, DOI 10.1016/S0002-9440(10)63390-1; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029; Sun Y, 2014, ONCOL LETT, V8, P211, DOI 10.3892/ol.2014.2071; Tanaka J, 2015, J ORAL PATHOL MED, V44, P126, DOI 10.1111/jop.12212; Terada LS, 2011, CANCER CELL, V19, P297, DOI 10.1016/j.ccr.2011.02.019; Tichet M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7993; Xiao YC, 2015, CANCER LETT, V361, P22, DOI 10.1016/j.canlet.2015.02.021; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200; Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018; Zuo JH, 2011, J CELL BIOCHEM, V112, P2508, DOI 10.1002/jcb.23175	41	39	40	3	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2228	2242		10.1038/onc.2016.371	http://dx.doi.org/10.1038/onc.2016.371			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27797381	Green Published, hybrid			2022-12-17	WOS:000399782700004
J	Sheng, YH; He, Y; Hasnain, SZ; Wang, R; Tong, H; Clarke, DT; Lourie, R; Oancea, I; Wong, KY; Lumley, JW; Florin, TH; Sutton, P; Hooper, JD; McMillan, NA; McGuckin, MA				Sheng, Y. H.; He, Y.; Hasnain, S. Z.; Wang, R.; Tong, H.; Clarke, D. T.; Lourie, R.; Oancea, I.; Wong, K. Y.; Lumley, J. W.; Florin, T. H.; Sutton, P.; Hooper, J. D.; McMillan, N. A.; McGuckin, M. A.			MUC13 protects colorectal cancer cells from death by activating the NF-kappa B pathway and is a potential therapeutic target	ONCOGENE			English	Article							SURFACE MUCIN; MUCOSAL BARRIER; EXPRESSION; ONCOPROTEIN; INFLAMMATION; RESISTANCE; OVEREXPRESSION; ADENOCARCINOMA; SIRNA	MUC13 is a transmembrane mucin glycoprotein that is over produced by many cancers, although its functions are not fully understood. Nuclear factor-kappa B (NF-kappa B) is a key transcription factor promoting cancer cell survival, but therapeutically targeting this pathway has proved difficult because NF-kappa B has pleiotropic functions. Here, we report that MUC13 prevents colorectal cancer cell death by promoting two distinct pathways of NF-kappa B activation, consequently upregulating BCL-XL. MUC13 promoted tumor necrosis factor (TNF)-induced NF-kappa B activation by interacting with TNFR1 and the E3 ligase, cIAP1, to increase ubiquitination of RIPK1. MUC13 also promoted genotoxin-induced NF-kappa B activation by increasing phosphorylation of ATM and SUMOylation of NF-kappa B essential modulator. Moreover, elevated expression of cytoplasmic MUC13 and NF-kappa B correlated with colorectal cancer progression and metastases. Our demonstration that MUC13 enhances NF-kappa B signaling in response to both TNF and DNA-damaging agents provides a new molecular target for specific inhibition of NFB activation. As proof of principle, silencing MUC13 sensitized colorectal cancer cells to killing by cytotoxic drugs and inflammatory signals and abolished chemotherapy-induced enrichment of CD133(+) CD44(+) cancer stem cells, slowed xenograft growth in mice, and synergized with 5-fluourouracil to induce tumor regression. Therefore, these data indicate that combining chemotherapy and MUC13 antagonism could improve the treatment of metastatic cancers.	[Sheng, Y. H.; Hasnain, S. Z.; Wang, R.; Tong, H.; Lourie, R.; Oancea, I.; Wong, K. Y.; McGuckin, M. A.] Univ Queensland, Translat Res Inst, Mater Res Inst, Inflammatory Dis Biol & Therapeut Grp, 37 Kent St, Brisbane, Qld 4102, Australia; [He, Y.; Hooper, J. D.] Univ Queensland, Translat Res Inst, Mater Res Inst, Canc Biol Grp, Brisbane, Qld, Australia; [Clarke, D. T.; McMillan, N. A.] Griffith Univ, Sch Med Sci, Mol Basis Dis Program, Gold Coast Campus, Southport, Qld, Australia; [Lourie, R.; Oancea, I.; Florin, T. H.] Univ Queensland, Translat Res Inst, Mater Res Inst, Inflammatory Bowel Dis Grp, Brisbane, Qld, Australia; [Lumley, J. W.] Wesley Hosp, Auchenflower, Australia; [Sutton, P.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Mucosal Immunol, Melbourne, Vic, Australia; [Sutton, P.] Univ Melbourne, Sch Vet & Agr Sci, Ctr Anim Biotechnol, Melbourne, Vic, Australia; [Sutton, P.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia	Mater Research; University of Queensland; Mater Research; University of Queensland; Griffith University; Mater Research; University of Queensland; Wesley Hospital; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; University of Melbourne	McGuckin, MA (corresponding author), Univ Queensland, Translat Res Inst, Mater Res Inst, Inflammatory Dis Biol & Therapeut Grp, 37 Kent St, Brisbane, Qld 4102, Australia.	michael.mcguckin@mater.uq.edu.au	McGuckin, Michael/G-2310-2010; Oancea, Iulia/F-3202-2017; Hasnain, Sumaira Z/N-3412-2014; McMillan, Nigel/AAQ-5416-2021; sheng, yong H/C-5052-2013; Wang, Ran/AAP-1920-2020; Hooper, John/C-1481-2016	McGuckin, Michael/0000-0002-8375-2675; Oancea, Iulia/0000-0001-5978-5963; Hasnain, Sumaira Z/0000-0001-8577-8628; sheng, yong H/0000-0002-4623-9098; Wang, Ran/0000-0002-1741-6446; Hooper, John/0000-0003-1054-8486; McMillan, Nigel/0000-0002-9471-1406; HE, Yaowu/0000-0002-7828-263X; Sutton, Philip/0000-0003-3129-1800	Australian National Health and Medical Research Council (NHMRC) [1060698]; Mater Foundation; NHMRC Principal Research Fellowship; Australian Government	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Mater Foundation; NHMRC Principal Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Australian Government(Australian GovernmentCGIAR)	This work was supported by the Australian National Health and Medical Research Council (NHMRC) project grant 1060698 and by funding from the Mater Foundation. MAM is supported by an NHMRC Principal Research Fellowship. The Translational Research Institute (TRI) is supported by a grant from the Australian Government. We acknowledge the technical assistance of the TRI core facilities for flow cytometry, microscopy and biological resources. We thank Michael R Tallack for help with Chip analysis and John Silke for providing feedback on our manuscript.	Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Breccia M, 2010, EXPERT OPIN THER TAR, V14, P1157, DOI 10.1517/14728222.2010.522570; Chauhan SC, 2012, MOL CANCER THER, V11, P24, DOI 10.1158/1535-7163.MCT-11-0598; Chauhan SC, 2009, CANCER RES, V69, P765, DOI 10.1158/0008-5472.CAN-08-0587; Chonghaile TN, 2011, SCIENCE, V334, P1129, DOI 10.1126/science.1206727; Deng M, 2013, ASIAN PAC J CANCER P, V14, P127, DOI 10.7314/APJCP.2013.14.1.127; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Gupta BK, 2014, J GASTROENTEROL, V49, P1378, DOI 10.1007/s00535-013-0885-z; Gupta BK, 2012, J HISTOCHEM CYTOCHEM, V60, P822, DOI 10.1369/0022155412460678; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Iwai K, 2012, TRENDS CELL BIOL, V22, P355, DOI 10.1016/j.tcb.2012.04.001; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Jonckheere N, 2014, BBA-REV CANCER, V1846, P142, DOI 10.1016/j.bbcan.2014.04.008; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Khan S, 2014, ONCOTARGET, V5, P7599, DOI 10.18632/oncotarget.2281; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Li F, 2010, BBA-REV CANCER, V1805, P167, DOI 10.1016/j.bbcan.2010.01.002; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Linden SK, 2008, MUCOSAL IMMUNOL, V1, P183, DOI 10.1038/mi.2008.5; McAuley JL, 2007, J CLIN INVEST, V117, P2313, DOI 10.1172/JCI26705; McCool KW, 2012, IMMUNOL REV, V246, P311, DOI 10.1111/j.1600-065X.2012.01101.x; McDermott KM, 2001, INT J CANCER, V94, P783, DOI 10.1002/ijc.1554; McGuckin MA, 2011, NAT REV MICROBIOL, V9, P265, DOI 10.1038/nrmicro2538; Meier P, 2007, MOL CELL, V28, P746, DOI 10.1016/j.molcel.2007.11.016; Nath S, 2014, TRENDS MOL MED, V20, P332, DOI 10.1016/j.molmed.2014.02.007; Nishii Y, 2015, INT J ONCOL, V46, P1781, DOI 10.3892/ijo.2015.2880; Sheng YH, 2013, MUCOSAL IMMUNOL, V6, P557, DOI 10.1038/mi.2012.98; Sheng YH, 2012, J GASTROEN HEPATOL, V27, P28, DOI 10.1111/j.1440-1746.2011.06909.x; Sheng YH, 2011, GUT, V60, P1661, DOI 10.1136/gut.2011.239194; Shimamura T, 2005, CANCER SCI, V96, P265, DOI 10.1111/j.1349-7006.2005.00043.x; Silke J, 2014, IAPS NECROPTOTIC CEL, P57; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Walsh MD, 2007, HUM PATHOL, V38, P883, DOI 10.1016/j.humpath.2006.11.020; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; Wu SY, 2009, PHARM RES-DORDR, V26, P512, DOI 10.1007/s11095-008-9766-1	44	39	40	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					700	713		10.1038/onc.2016.241	http://dx.doi.org/10.1038/onc.2016.241			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27399336	Green Published, hybrid			2022-12-17	WOS:000394167700011
J	Zhou, Z; Wang, M; Li, J; Xiao, M; Chin, YE; Cheng, J; Yeh, ETH; Yang, J; Yi, J				Zhou, Z.; Wang, M.; Li, J.; Xiao, M.; Chin, Y. E.; Cheng, J.; Yeh, E. T. H.; Yang, J.; Yi, J.			SUMOylation and SENP3 regulate STAT3 activation in head and neck cancer	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMA; NF-KAPPA-B; CONSTITUTIVE ACTIVATION; CROSS-TALK; TRANSCRIPTION STAT; SIGNAL TRANSDUCERS; LARYNGEAL-CANCER; CIGARETTE-SMOKE; DE-SUMOYLATION	Hyperphosphorylation of signal transducer and activator of transcription 3 (STAT3) has been found in various types of human cancers, including head and neck cancer (HNC). Although smoking is critical in the development and progression of HNC, how tobacco components activate STAT3 is unclear. We demonstrated that exposure of HNC cell lines to a tobacco extract induced a rapid Y705 phosphorylation of STAT3 and a rapid increase in the SUMO protease SENP3 that depended on a simultaneous increase in reactive oxygen species. We identified that SUMOylation at the lysine 451 site facilitated STAT3 binding to the phosphatase TC45 through an SUMO-interacting motif of TC45. SENP3 could thus enhance STAT3 phosphorylation by de-conjugating the SUMO2/3 modification of STAT3. Knocking-down of SENP3 greatly impaired basal and induced STAT3 phosphorylation by tobacco extract or interleukin 6. A correlation between SENP3 protein levels and STAT3 Y705 phosphorylation levels in human laryngeal carcinoma specimens was found, which was more significant in the specimens derived from the smoker patients and with poor clinicopathological parameters. Our data identified SUMOylation as a previously undescribed post-translational modification of STAT3 and SENP3 as a critical positive modulator of tobacco-or cytokine-induced STAT3 activation. These findings provide novel insights into the hyperphosphorylation of STAT3 in development of HNC.	[Zhou, Z.; Wang, M.; Cheng, J.; Yang, J.; Yi, J.] Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cell Biol,Inst Med Sci, Shanghai Key Lab Tumor Microenviron & Inflammat, Shanghai, Peoples R China; [Zhou, Z.; Li, J.] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Otolaryngol, Shanghai, Peoples R China; [Xiao, M.; Chin, Y. E.] Shanghai Jiao Tong Univ, Sch Med, Chinese Acad Sci, Inst Hlth Sci,Shanghai Inst Biol Sci, Shanghai, Peoples R China; [Yeh, E. T. H.] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; University of Texas System; UTMD Anderson Cancer Center	Yang, J; Yi, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Inst Med Sci, Dept Biochem & Mol Cell Biol, 280 S Chongqing Rd, Shanghai 200025, Peoples R China.	yangjieyj@shsmu.edu.cn; yijing@shsmu.edu.cn			National Ministry of Science and Technology of China [2013CB910900]; National Natural Science Foundation of China [31230037]; Shanghai Municipal Science and Technology Commission [11DZ2260200, 13ZR1425300]	National Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Science and Technology Commission(Science & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by grants from the National Ministry of Science and Technology of China (2013CB910900), the National Natural Science Foundation of China (31230037) and Shanghai Municipal Science and Technology Commission (11DZ2260200, 13ZR1425300). The plasmid Flag-STAT3 and Flag-TC45 were gifts of Dr Guoliang Xu (Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, China).	Arredondo J, 2006, FASEB J, V20, P2093, DOI 10.1096/fj.06-6191com; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Berishaj M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1680; Bito T, 2010, EXP DERMATOL, V19, P654, DOI 10.1111/j.1600-0625.2010.01084.x; BLOT WJ, 1988, CANCER RES, V48, P3282; Bromberg J, 2009, CANCER CELL, V15, P79, DOI 10.1016/j.ccr.2009.01.009; Chen RJ, 2008, TOXICOL SCI, V104, P283, DOI 10.1093/toxsci/kfn086; Chen RM, 2011, ABSTR APPL ANAL, DOI 10.1155/2011/589862; Chen WG, 2004, J ALLERGY CLIN IMMUN, V114, P476, DOI 10.1016/j.jaci.2004.06.042; Chen XT, 2013, J CLIN INVEST, V123, P2576, DOI 10.1172/JCI68143; Csiszar A, 2009, FRONT BIOSCI-LANDMRK, V14, P3128, DOI 10.2741/3440; Droescher M, 2011, J BIOL CHEM, V286, P18731, DOI 10.1074/jbc.M111.235978; Gao LF, 2006, ACTA PHARMACOL SIN, V27, P347, DOI 10.1111/j.1745-7254.2006.00277.x; Gao LF, 2005, ACTA PHARMACOL SIN, V26, P377, DOI 10.1111/j.1745-7254.2005.00053.x; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood DWH, 2004, SEMIN CELL DEV BIOL, V15, P201, DOI 10.1016/j.semcdb.2003.12.001; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Groner B, 2008, SEMIN CELL DEV BIOL, V19, P341, DOI 10.1016/j.semcdb.2008.06.005; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Han Y, 2010, J BIOL CHEM, V285, P12906, DOI 10.1074/jbc.M109.071431; Hashibe M, 2007, J NATL CANCER I, V99, P777, DOI 10.1093/jnci/djk179; He QY, 2015, ONCOTARGET, V6, P16422, DOI 10.18632/oncotarget.3847; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; Hecht SS, 2003, NAT REV CANCER, V3, P733, DOI 10.1038/nrc1190; Hittelman WN, 2001, ANN NY ACAD SCI, V952, P1; Huang C., 2009, 2009 IEEE CIRC SYST, V1, P1, DOI DOI 10.1109/CAS-ICTD.2009.4960873; Huang CT, 2014, BBA-MOL CELL RES, V1843, P483, DOI 10.1016/j.bbamcr.2013.11.015; Huang RY, 2011, ONCOGENE, V30, P106, DOI 10.1038/onc.2010.390; Hunter KD, 2005, NAT REV CANCER, V5, P127, DOI 10.1038/nrc1549; IWAMOTO H, 1975, LARYNGOSCOPE, V85, P1162, DOI 10.1288/00005537-197507000-00007; Johnston PA, 2011, MOL INTERV, V11, P18, DOI 10.1124/mi.11.1.4; Khariwala SS, 2011, HEAD NECK-J SCI SPEC, V34, P441; Kim DY, 2009, J GASTROEN HEPATOL, V24, P646, DOI 10.1111/j.1440-1746.2008.05671.x; Kim PM, 1996, CANCER RES, V56, P1526; Le QT, 2003, CLIN CANCER RES, V9, P4287; Lee TL, 2006, MOL CANCER THER, V5, P8, DOI 10.1158/1535-7163.MCT-05-0069; Leeman RJ, 2006, EXPERT OPIN BIOL TH, V6, P231, DOI 10.1517/14712598.6.3.231; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lewin F, 1998, CANCER-AM CANCER SOC, V82, P1367, DOI 10.1002/(SICI)1097-0142(19980401)82:7&lt;1367::AID-CNCR21&gt;3.0.CO;2-3; Li N, 2011, CANCER CELL, V19, P429, DOI 10.1016/j.ccr.2011.03.018; Liu TY, 2010, EUR J PHARMACOL, V641, P15, DOI 10.1016/j.ejphar.2010.04.062; Liu XD, 2007, BIOCHEM BIOPH RES CO, V353, P121, DOI 10.1016/j.bbrc.2006.11.147; Lou W, 2000, PROSTATE, V42, P239, DOI 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G; Macha MA, 2011, CARCINOGENESIS, V32, P368, DOI 10.1093/carcin/bgq278; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Masuda M, 2002, CANCER RES, V62, P3351; Masuda M, 2010, CURR CANCER DRUG TAR, V10, P117, DOI 10.2174/156800910790980197; Morikawa T, 2011, CLIN CANCER RES, V17, P1452, DOI 10.1158/1078-0432.CCR-10-2694; Nagpal JK, 2002, CANCER, V94, P2393, DOI 10.1002/cncr.10499; Parfenov M, 2014, P NATL ACAD SCI USA, V111, P15544, DOI 10.1073/pnas.1416074111; Perry E, 2004, ONCOGENE, V23, P8908, DOI 10.1038/sj.onc.1208149; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Pilati C, 2011, J EXP MED, V208, P1359, DOI 10.1084/jem.20110283; PRYOR WA, 1983, ENVIRON HEALTH PERSP, V47, P345, DOI 10.1289/ehp.8347345; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; Pryor WA, 1998, CHEM RES TOXICOL, V11, P441, DOI 10.1021/tx970159y; Qu Y, 2013, CANCER RES, V73, P7090, DOI 10.1158/0008-5472.CAN-13-1560; Quon H, 2001, HEAD NECK-J SCI SPEC, V23, P147, DOI 10.1002/1097-0347(200102)23:2<147::AID-HED1010>3.0.CO;2-#; Ren YH, 2014, ONCOTARGET, V5, P7093, DOI 10.18632/oncotarget.2197; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Rothenberg SM, 2012, J CLIN INVEST, V122, P1951, DOI 10.1172/JCI59889; Sang J, 2011, BIOCHEM J, V435, P489, DOI 10.1042/BJ20101474; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Squarize CH, 2006, NEOPLASIA, V8, P733, DOI 10.1593/neo.06274; Sriuranpong V, 2003, CANCER RES, V63, P2948; Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008; Ulane CM, 2003, J VIROL, V77, P6385, DOI 10.1128/JVI.77.11.6385-6393.2003; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wilkinson KA, 2010, BIOCHEM J, V428, P133, DOI 10.1042/BJ20100158; Xi SC, 2005, ONCOGENE, V24, P970, DOI 10.1038/sj.onc.1208316; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Yan S, 2010, EMBO J, V29, P3773, DOI 10.1038/emboj.2010.245; Yang J, 2004, FREE RADICAL BIO MED, V37, P2027, DOI 10.1016/j.freeradbiomed.2004.09.016; Yang J., 2010, 2010 2 INT C SIGN PR; Ye YN, 2004, J PHARMACOL EXP THER, V311, P123, DOI 10.1124/jpet.104.068031; Yeh ETH, 2009, J BIOL CHEM, V284, P8223, DOI 10.1074/jbc.R800050200; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; ZANG LY, 1995, FREE RADICAL BIO MED, V19, P161, DOI 10.1016/0891-5849(94)00236-D; Zhang P, 2011, MOL CANCER RES, V9, P1418, DOI 10.1158/1541-7786.MCR-11-0147; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	85	39	42	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5826	5838		10.1038/onc.2016.124	http://dx.doi.org/10.1038/onc.2016.124			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27181202	Green Published, hybrid			2022-12-17	WOS:000387560800002
J	Garcia-Palmero, I; Torres, S; Bartolome, RA; Pelaez-Garcia, A; Larriba, MJ; Lopez-Lucendo, M; Pena, C; Escudero-Paniagua, B; Munoz, A; Casal, JI				Garcia-Palmero, I.; Torres, S.; Bartolome, R. A.; Pelaez-Garcia, A.; Larriba, M. J.; Lopez-Lucendo, M.; Pena, C.; Escudero-Paniagua, B.; Munoz, A.; Casal, J. I.			Twist1-induced activation of human fibroblasts promotes matrix stiffness by upregulating palladin and collagen alpha 1(VI)	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER-ASSOCIATED FIBROBLASTS; BUNDLING PROTEIN PALLADIN; RENAL-CELL CARCINOMA; POOR-PROGNOSIS; COLON-CANCER; COLORECTAL-CANCER; TUMOR-METASTASIS; BREAST-CANCER; INVADOPODIA FORMATION	The transcription factor Twist1 is involved in the epithelial-mesenchymal transition and contributes to cancer metastasis through mostly unknown mechanisms. In colorectal cancer, Twist1 expression is mainly restricted to the tumor stroma. We found that human fibroblast cell lines stably transfected with Twist1 acquired characteristics of activated cancer-associated fibroblasts (CAFs), such as hyperproliferation, an increased ability to migrate and an alignment of the actin cytoskeleton. Further, Twist1-activated fibroblasts promoted increased matrix stiffness. Using quantitative proteomics, we identified palladin and collagen alpha 1(VI) as two major mediators of the Twist1 effects in fibroblast cell lines. Co-immunoprecipitation studies indicated that palladin and Twist1 interact within the nucleus, suggesting that palladin could act as a transcription regulator. Palladin was found to be more relevant for the cellular biomechanical properties, orientation and polarity, and collagen alpha 1(VI) for the migration and invasion capacity, of Twist1-activated fibroblasts. Both palladin and collagen alpha 1(VI) were observed to be overexpressed in colorectal CAFs and to be associated with poor colorectal cancer patient survival and relapse prediction. Our results demonstrate that Twist1-expressing fibroblasts mimic the properties of CAFs present at the tumor invasive front, which likely explains the prometastatic activities of Twist1. Twist1 appears to require both palladin and collagen alpha 1(VI) as downstream effectors for its prometastatic effects, which could be future therapeutic targets in cancer metastasis.	[Garcia-Palmero, I.; Torres, S.; Bartolome, R. A.; Pelaez-Garcia, A.; Escudero-Paniagua, B.; Casal, J. I.] CSIC, CIB, Dept Cellular & Mol Med, Ramiro de Maeztu 9, Madrid 28040, Spain; [Larriba, M. J.; Munoz, A.] UAM, CSIC, Inst Invest Biomed Alberto Sols, IdiPAZ, Madrid, Spain; [Lopez-Lucendo, M.] CSIC, CIB, Prote Core Facil, Madrid, Spain; [Pena, C.] Hosp Univ Puerta de Hierro, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Hospital Puerta de Hierro-Majadahonda	Casal, JI (corresponding author), CSIC, CIB, Dept Cellular & Mol Med, Ramiro de Maeztu 9, Madrid 28040, Spain.	icasal@cib.csic.es	LARRIBA, MARIA JESUS/O-4652-2014; Munoz, Alberto/O-6393-2014; Casal, Ignacio/M-2312-2014; Bartolome, Ruben A/M-1873-2014	LARRIBA, MARIA JESUS/0000-0001-9035-7414; Munoz, Alberto/0000-0003-3890-4251; Casal, Ignacio/0000-0003-1085-2840; Bartolome, Ruben A/0000-0002-3292-1491; Pelaez Garcia, Alberto/0000-0002-5401-3216	Comunidad de Madrid [S2010/BMD-2344/Colomics2]; Juan de la Cierva programme; Asociacion Espanola Contra el Cancer (AECC); ProteoRed contract; Ministry of Economy and Competitiveness (MINECO); Comunidad de Madrid, 'Asociacion Espanola Contra el Cancer (AECC) [S2010/BMD-2344/Colomics2]; MINECO [BIO2012-31023]; Instituto de Salud Carlos III-FEDER [PRB2 (IPT13/0001-ISCIII-SGEFI/FEDER), RD12/0036/0041, RD12/0036/0021]	Comunidad de Madrid(Comunidad de Madrid); Juan de la Cierva programme; Asociacion Espanola Contra el Cancer (AECC); ProteoRed contract; Ministry of Economy and Competitiveness (MINECO)(Spanish Government); Comunidad de Madrid, 'Asociacion Espanola Contra el Cancer (AECC)(Comunidad de Madrid); MINECO(Spanish Government); Instituto de Salud Carlos III-FEDER(Instituto de Salud Carlos IIIEuropean Commission)	IG-P was supported by a contract S2010/BMD-2344/Colomics2 from the Comunidad de Madrid. ST was a recipient of a Juan de la Cierva programme. RAB was supported by a grant to established research groups of the Asociacion Espanola Contra el Cancer (AECC). ML-L was a recipient of a ProteoRed contract. AP-G and BE-P were FPI fellows from the Ministry of Economy and Competitiveness (MINECO). This research was supported by grants to established research groups of the S2010/BMD-2344/Colomics2 from the Comunidad de Madrid, 'Asociacion Espanola Contra el Cancer (AECC)', BIO2012-31023 from the MINECO, PRB2 (IPT13/0001-ISCIII-SGEFI/FEDER), RD12/0036/0041 and RD12/0036/0021 from the Instituto de Salud Carlos III-FEDER.	Amatangelo MD, 2005, AM J PATHOL, V167, P475, DOI 10.1016/S0002-9440(10)62991-4; Bartolome RA, 2014, ONCOGENE, V33, P1658, DOI 10.1038/onc.2013.117; Bartolome RA, 2015, CANCER RES, V75, P2434, DOI 10.1158/0008-5472.CAN-14-3650; Bartolome RA, 2014, J BIOL CHEM, V289, P34801, DOI 10.1074/jbc.M114.600502; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brentnall TA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030219; Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Cannon AR, 2015, CYTOSKELETON, V72, P402, DOI 10.1002/cm.21239; Chen PW, 2013, TRENDS MOL MED, V19, P410, DOI 10.1016/j.molmed.2013.04.001; Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067; Chin YR, 2010, FEBS LETT, V584, P4769, DOI 10.1016/j.febslet.2010.10.056; Chin YR, 2010, MOL CELL, V38, P333, DOI 10.1016/j.molcel.2010.02.031; Chiu KH, 2011, J PROTEOME RES, V10, P1110, DOI 10.1021/pr1008724; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Endlich N, 2009, KIDNEY INT, V75, P214, DOI 10.1038/ki.2008.486; Goicoechea SM, 2014, ONCOGENE, V33, P1265, DOI 10.1038/onc.2013.68; Goicoechea SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010347; Gomez I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018023; Groulx JF, 2011, MATRIX BIOL, V30, P195, DOI 10.1016/j.matbio.2011.03.002; Gupta V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021494; Larriba MJ, 2009, CARCINOGENESIS, V30, P1459, DOI 10.1093/carcin/bgp140; Jin L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012823; Jin L, 2009, J BIOL CHEM, V284, P2121, DOI 10.1074/jbc.M806095200; Lee KW, 2015, CANCER RES, V75, P73, DOI 10.1158/0008-5472.CAN-14-0350; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Liu TJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142547; Liu XS, 2007, J CELL BIOCHEM, V100, P1288, DOI 10.1002/jcb.21126; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; McLane JS, 2015, BIOPHYS J, V109, P249, DOI 10.1016/j.bpj.2015.06.033; Ohba K, 2014, INT J CLIN EXP PATHO, V7, P3158; Ou DL, 2008, ANTICANCER RES, V28, P1355; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Riaz M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3317; Ronty MJ, 2006, J INVEST DERMATOL, V126, P2387, DOI 10.1038/sj.jid.5700427; Salaria SN, 2007, CANCER BIOL THER, V6, P324, DOI 10.4161/cbt.6.3.3904; Singh P, 2010, ANNU REV CELL DEV BI, V26, P397, DOI 10.1146/annurev-cellbio-100109-104020; Somasundaram R, 1996, J BIOL CHEM, V271, P26884, DOI 10.1074/jbc.271.43.26884; Sung CO, 2011, AM J PATHOL, V179, P1827, DOI 10.1016/j.ajpath.2011.06.032; Torres S, 2015, CLIN CANCER RES, V21, P4892, DOI 10.1158/1078-0432.CCR-14-3096; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Valdes-Mora F, 2009, ANN SURG ONCOL, V16, P78, DOI 10.1245/s10434-008-0166-x; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wan FN, 2015, ONCOTARGET, V6, P27378, DOI 10.18632/oncotarget.4860; Watson MA, 2007, CLIN CANCER RES, V13, P5001, DOI 10.1158/1078-0432.CCR-07-0024; Wei SC, 2015, NAT CELL BIOL, V17, P678, DOI 10.1038/ncb3157; Wendt MK, 2009, FUTURE ONCOL, V5, P1145, DOI 10.2217/FON.09.90; Xie FW, 2009, CLIN EXP METASTAS, V26, P1025, DOI 10.1007/s10585-009-9292-5; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	53	39	40	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5224	5236		10.1038/onc.2016.57	http://dx.doi.org/10.1038/onc.2016.57			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	26973246				2022-12-17	WOS:000386053000002
J	King, MA; Ganley, IG; Flemington, V				King, M. A.; Ganley, I. G.; Flemington, V.			Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells	ONCOGENE			English	Article							MEMBRANE PERMEABILIZATION; SELECTIVE INHIBITOR; AUTOPHAGY; APOPTOSIS; POTENT; RESISTANCE; DISCOVERY; COMPLEX; DEATH; EXPRESSION	Mutations to fibroblast growth factor receptor 3 (FGFR3) and phosphatase and tensin homologue (PTEN) signalling pathway components (for example, PTEN loss, PIK3CA, AKT1, TSC1/2) are common in bladder cancer, yet small-molecule inhibitors of these nodes (FGFR/PTENi) show only modest activity in preclinical models. As activation of autophagy is proposed to promote survival under FGFR/PTENi, we have investigated this relationship in a panel of 18 genetically diverse bladder cell lines. We found that autophagy inhibition does not sensitise bladder cell lines to FGFR/PTENi, but newly identify an autophagy-independent cell death synergy in FGFR3-mutant cell lines between mTOR (mammalian target of rapamycin) pathway inhibitors and chloroquine (CQ)-an anti-malarial drug used as a cancer therapy adjuvant in over 30 clinical trials. The mechanism of synergy is consistent with lysosomal cell death (LCD), including cathepsin-driven caspase activation, and correlates with suppression of cSREBP1 and cholesterol biosynthesis in sensitive cell lines. Remarkably, loss of viability can be rescued by saturating cellular membranes with cholesterol or recapitulated by statin-mediated inhibition, or small interfering RNA knockdown, of enzymes regulating cholesterol metabolism. Modulation of CQ-induced cell death by atorvastatin and cholesterol is reproduced across numerous cell lines, confirming a novel and fundamental role for cholesterol biosynthesis in regulating LCD. Thus, we have catalogued the molecular events underlying cell death induced by CQ in combination with an anticancer therapeutic. Moreover, by revealing a hitherto unknown aspect of lysosomal biology under stress, we propose that suppression of cholesterol metabolism in cancer cells should elicit synergy with CQ and define a novel approach to future cancer treatments.	[King, M. A.] AstraZeneca Oncol, Alderley Pk, Macclesfield, Cheshire, England; [Ganley, I. G.] Univ Dundee, MRC Prot Phosphorylat & Ubiquitylat Unit, Dundee, Scotland; [Flemington, V.] AstraZeneca Oncol, CRUK Cambridge Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England	AstraZeneca; University of Dundee; AstraZeneca; CRUK Cambridge Institute	King, MA; Flemington, V (corresponding author), AstraZeneca, Oncol IMED, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.	matthew.king@astrazeneca.com; vikki.flemington@astrazeneca.com		Ganley, Ian/0000-0003-1481-9407	Medical Research Council [MC_UU_12016/4, MC_UP_A500_1019] Funding Source: Medline; MRC [MC_UU_12016/4] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aits S, 2015, METHOD CELL BIOL, V126, P261, DOI 10.1016/bs.mcb.2014.10.032; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Appelqvist H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050262; Barlaam B, 2015, J MED CHEM, V58, P943, DOI 10.1021/jm501629p; Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622; Ch'ng JH, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.265; Christian AE, 1997, J LIPID RES, V38, P2264; Cufi S, 2013, SCI REP-UK, V3, DOI 10.1038/srep02469; Davies BR, 2012, MOL CANCER THER, V11, P873, DOI 10.1158/1535-7163.MCT-11-0824-T; Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099; Dickstein RJ, 2012, CANCER BIOL THER, V13, P1325, DOI 10.4161/cbt.21793; Dowdle WE, 2014, NAT CELL BIOL, V16, P1069, DOI 10.1038/ncb3053; Du XN, 2012, CANCER RES, V72, P5843, DOI 10.1158/0008-5472.CAN-12-1329; Fan QW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001017; Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168; Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200; Gavine PR, 2012, CANCER RES, V72, P2045, DOI 10.1158/0008-5472.CAN-11-3034; Graham RM, 2014, ONCOTARGET, V5, P1162, DOI 10.18632/oncotarget.1699; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Hao SJ, 2008, GEN PHYSIOL BIOPHYS, V27, P278; Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Ikonen E, 2008, NAT REV MOL CELL BIO, V9, P125, DOI 10.1038/nrm2336; Johansson AC, 2010, APOPTOSIS, V15, P527, DOI 10.1007/s10495-009-0452-5; Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Laforge M, 2007, J VIROL, V81, P11426, DOI 10.1128/JVI.00597-07; Lamoureux F, 2013, CLIN CANCER RES, V19, P833, DOI 10.1158/1078-0432.CCR-12-3114; Lee CM, 2006, BRIT J CANCER, V94, P863, DOI 10.1038/sj.bjc.6603010; Li S, 2016, ONCOGENE, V35, P642, DOI 10.1038/onc.2015.123; MCGOWAN EB, 1989, BIOCHEM BIOPH RES CO, V158, P432, DOI 10.1016/S0006-291X(89)80065-8; Medina MW, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003058; Mirzoeva OK, 2011, J MOL MED, V89, P877, DOI 10.1007/s00109-011-0774-y; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Montaser M, 2002, BIOL CHEM, V383, P1305, DOI 10.1515/BC.2002.147; Pike KG, 2013, BIOORG MED CHEM LETT, V23, P1212, DOI 10.1016/j.bmcl.2013.01.019; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; Romanov J, 2012, EMBO J, V31, P4304, DOI 10.1038/emboj.2012.278; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Roth BD, 2002, PROGR MED CHEM, V40, P1, DOI 10.1016/S0079-6468(08)70080-8; Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757; Seitz C, 2013, INT J CANCER, V132, P2682, DOI 10.1002/ijc.27935; SHOJIKASAI Y, 1988, P NATL ACAD SCI USA, V85, P146, DOI 10.1073/pnas.85.1.146; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Sun CH, 2011, HISTOPATHOLOGY, V58, P1054, DOI 10.1111/j.1365-2559.2011.03856.x; von Schwarzenberg K, 2013, J BIOL CHEM, V288, P1385, DOI 10.1074/jbc.M112.412007; Wang BT, 2011, P NATL ACAD SCI USA, V108, P15201, DOI 10.1073/pnas.1103746108; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Williams SV, 2013, HUM MOL GENET, V22, P795, DOI 10.1093/hmg/dds486; Wu XR, 2009, CANCER METAST REV, V28, P281, DOI 10.1007/s10555-009-9189-4; Xu CX, 2011, CANCER BIOL THER, V12, P549, DOI 10.4161/cbt.12.6.16397; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Ye J RA, 2011, COLD SPRING HARBOR P, V3; Yecies JL, 2011, CANCER RES, V71, P2815, DOI 10.1158/0008-5472.CAN-10-4158; Zou YY, 2013, J THORAC ONCOL, V8, P693, DOI 10.1097/JTO.0b013e31828c7210	57	39	41	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4518	4528		10.1038/onc.2015.511	http://dx.doi.org/10.1038/onc.2015.511			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26853465	Green Published, hybrid			2022-12-17	WOS:000382153100009
J	Hong, SM; Park, CW; Kim, SW; Nam, YJ; Yu, JH; Shin, JH; Yun, CH; Im, SH; Kim, KT; Sung, YC; Choi, KY				Hong, S. M.; Park, C. W.; Kim, S. W.; Nam, Y. J.; Yu, J. H.; Shin, J. H.; Yun, C. H.; Im, S-H; Kim, K-T; Sung, Y. C.; Choi, K. Y.			NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer	ONCOGENE			English	Article							NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE NAMPT; TUMOR-CELL SURVIVAL; METABOLISM; INHIBITION; AUTOPHAGY; ENZYME; BIOSYNTHESIS; HOMEOSTASIS; GLYCOGEN; DEATH	Nicotinamide phosphoribosyltransferase (NAMPT) is a rate-limiting enzyme involved in NAD+ biosynthesis. Although NAMPT has emerged as a critical regulator of metabolic stress, the underlying mechanisms by which it regulates metabolic stress in cancer cells have not been completely elucidated. In this study, we determined that breast cancer cells expressing a high level of NAMPT were resistant to cell death induced by glucose depletion. Furthermore, NAMPT inhibition suppressed tumor growth in vivo in a xenograft model. Under glucose deprivation conditions, NAMPT inhibition was found to increase the mitochondrial reactive oxygen species (ROS) level, leading to cell death. This cell death was rescued by treatment with antioxidants or NAD+. Finally, we showed that NAMPT increased the pool of NAD+ that could be converted to NADPH through the pentose phosphate pathway and inhibited the depletion of reduced glutathione under glucose deprivation. Collectively, our results suggest a novel mechanism by which tumor cells protect themselves against glucose deprivation-induced oxidative stress by utilizing NAMPT to maintain NADPH levels.	[Hong, S. M.; Park, C. W.; Kim, S. W.; Nam, Y. J.; Yu, J. H.; Shin, J. H.; Im, S-H; Kim, K-T; Sung, Y. C.; Choi, K. Y.] Pohang Univ Sci & Technol POSTECH, Div Integrat Biosci & Biotechnol, Pohang, South Korea; [Park, C. W.] Biokogen Inc, POSTECH Biotech Ctr 226, Pohang, South Korea; [Yun, C. H.; Im, S-H] AIM, IBS, Pohang, South Korea	Pohang University of Science & Technology (POSTECH); Institute for Basic Science - Korea (IBS)	Choi, KY (corresponding author), Pohang Univ Sci & Technol POSTECH, Div Integrat Biosci & Biotechnol, PBC, Room 327, Pohang 790784, South Korea.	kchoi@postech.ac.kr	Im, Sin-Hyeog/AAM-9586-2021; Im, Sin-Hyeog/E-6811-2013	Im, Sin-Hyeog/0000-0002-3173-1856; Im, Sin-Hyeog/0000-0002-3173-1856; KIM, KYONG-TAI/0000-0001-7292-2627	National R&D Program for Cancer Control, Ministry for Health and Welfare, Korea [1320240]; National Research Foundation of Korea (NRF) grant - Korea government (MEST) [NRF-2014R1A2A2A01002931]; Next-Generation BioGreen 21 Program, Rural Development Administration, Republic of Korea [PJ01121601]; BK21 Plus - Ministry of Education, Korea [10Z20130012243]	National R&D Program for Cancer Control, Ministry for Health and Welfare, Korea; National Research Foundation of Korea (NRF) grant - Korea government (MEST); Next-Generation BioGreen 21 Program, Rural Development Administration, Republic of Korea; BK21 Plus - Ministry of Education, Korea	This research was supported by the National R&D Program for Cancer Control, Ministry for Health and Welfare, Korea (1320240), by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (NRF-2014R1A2A2A01002931), by the Next-Generation BioGreen 21 Program, Rural Development Administration, Republic of Korea (PJ01121601) and by BK21 Plus funded by the Ministry of Education, Korea (10Z20130012243). We thank Kwan-Suk Lee at the POSTECH animal facility for assistance with animal experiments. Slide scanning images were obtained using Virtual Microscope in UNIST-Olympus Biomed Imaging Center (UOBC). We are grateful to Jin-Hoe Hur and UNIST-Olympus Biomed Imaging Center (UOBC) for providing the data of slide scanning images.	Aykin-Burns N, 2009, BIOCHEM J, V418, P29, DOI 10.1042/BJ20081258; Bajrami I, 2012, EMBO MOL MED, V4, P1087, DOI 10.1002/emmm.201201250; Bi TQ, 2010, CANCER BIOL THER, V10, P119, DOI 10.4161/cbt.10.2.12581; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cerna D, 2012, J BIOL CHEM, V287, P22408, DOI 10.1074/jbc.M112.357301; Chan DA, 2011, NAT REV DRUG DISCOV, V10, P351, DOI 10.1038/nrd3374; Chiarugi A, 2012, NAT REV CANCER, V12, P741, DOI 10.1038/nrc3340; Choi YJ, 2014, HORM METAB RES, V46, P233, DOI 10.1055/s-0034-1370907; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Favaro E, 2012, CELL METAB, V16, P751, DOI 10.1016/j.cmet.2012.10.017; Galli U, 2013, J MED CHEM, V56, P6279, DOI 10.1021/jm4001049; Garten A, 2009, TRENDS ENDOCRIN MET, V20, P130, DOI 10.1016/j.tem.2008.10.004; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Hsu CP, 2009, CIRC RES, V105, P481, DOI 10.1161/CIRCRESAHA.109.203703; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; Leithner K, 2015, ONCOGENE, V34, P1044, DOI 10.1038/onc.2014.47; Li L, 2012, FREE RADICAL BIO MED, V53, P1399, DOI 10.1016/j.freeradbiomed.2012.07.011; Liang HL, 2009, AM J PHYSIOL-RENAL, V296, pF266, DOI 10.1152/ajprenal.90533.2008; Madhok BM, 2011, AM J CLIN ONCOL-CANC, V34, P628, DOI 10.1097/COC.0b013e3181e84dec; Magni G, 2006, MINI-REV MED CHEM, V6, P739, DOI 10.2174/138955706777698688; Park CW, 2013, AUTOPHAGY, V9, P345, DOI 10.4161/auto.23072; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Romero-Garcia S, 2011, CANCER BIOL THER, V12, P939, DOI 10.4161/cbt.12.11.18140; ROUSSET M, 1981, CANCER RES, V41, P1165; Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Simons AL, 2009, J CANCER RES THER, V5, P2, DOI 10.4103/0973-1482.55133; Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002; Stanton RC, 2012, IUBMB LIFE, V64, P362, DOI 10.1002/iub.1017; Tan B, 2013, J BIOL CHEM, V288, P3500, DOI 10.1074/jbc.M112.394510; Tew KD, 2012, ANTIOXID REDOX SIGN, V17, P1728, DOI 10.1089/ars.2012.4640; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Wang B, 2011, ONCOGENE, V30, P907, DOI 10.1038/onc.2010.468; Wang YP, 2014, EMBO J, V33, P1304, DOI 10.1002/embj.201387224; Xiao Y, 2013, NEOPLASIA, V15, P1137, DOI 10.1593/neo.131304; Yang HY, 2007, CELL, V130, P1095, DOI 10.1016/j.cell.2007.07.035; Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672	38	39	43	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3544	3554		10.1038/onc.2015.415	http://dx.doi.org/10.1038/onc.2015.415			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26568303				2022-12-17	WOS:000379621500007
J	Fan, SJ; Snell, C; Turley, H; Li, JL; McCormick, R; Perera, SMW; Heublein, S; Kazi, S; Azad, A; Wilson, C; Harris, AL; Goberdhan, DCI				Fan, S-J; Snell, C.; Turley, H.; Li, J-L; McCormick, R.; Perera, S. M. W.; Heublein, S.; Kazi, S.; Azad, A.; Wilson, C.; Harris, A. L.; Goberdhan, D. C. I.			PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer	ONCOGENE			English	Article							PHOSPHOLIPASE-D; PHOSPHORYLATION; TRANSPORTER; METABOLISM; INITIATION; MECHANISM; GROWTH; 4E-BP1; PROLIFERATION; TRANSLATION	Tumour cells can use strategies that make them resistant to nutrient deprivation to outcompete their neighbours. A key integrator of the cell's responses to starvation and other stresses is amino-acid-dependent mechanistic target of rapamycin complex 1 (mTORC1). Activation of mTORC1 on late endosomes and lysosomes is facilitated by amino-acid transporters within the solute-linked carrier 36 (SLC36) and SLC38 families. Here, we analyse the functions of SLC36 family member, SLC36A4, otherwise known as proton-assisted amino-acid transporter 4 (PAT4), in colorectal cancer. We show that independent of other major pathological factors, high PAT4 expression is associated with reduced relapse-free survival after colorectal cancer surgery. Consistent with this, PAT4 promotes HCT116 human colorectal cancer cell proliferation in culture and tumour growth in xenograft models. Inducible knockdown in HCT116 cells reveals that PAT4 regulates a form of mTORC1 with two distinct properties: first, it preferentially targets eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), and second, it is resistant to rapamycin treatment. Furthermore, in HCT116 cells two non-essential amino acids, glutamine and serine, which are often rapidly metabolised by tumour cells, regulate rapamycin-resistant mTORC1 in a PAT4-dependent manner. Overexpressed PAT4 is also able to promote rapamycin resistance in human embryonic kidney-293 cells. PAT4 is predominantly associated with the Golgi apparatus in a range of cell types, and in situ proximity ligation analysis shows that PAT4 interacts with both mTORC1 and its regulator Rab1A on the Golgi. These findings, together with other studies, suggest that differentially localised intracellular amino-acid transporters contribute to the activation of alternate forms of mTORC1. Furthermore, our data predict that colorectal cancer cells with high PAT4 expression will be more resistant to depletion of serine and glutamine, allowing them to survive and outgrow neighbouring normal and tumorigenic cells, and potentially providing a new route for pharmacological intervention.	[Fan, S-J; Perera, S. M. W.; Heublein, S.; Kazi, S.; Azad, A.; Wilson, C.; Goberdhan, D. C. I.] Univ Oxford, Dept Physiol Anat & Genet, Le Gros Clark Bldg,South Parks Rd, Oxford OX1 3QX, England; [Snell, C.; Turley, H.; Li, J-L; McCormick, R.; Harris, A. L.] Univ Oxford, Weatherall Inst Mol Med, Mol Oncol Unit, Oxford, England	University of Oxford; University of Oxford	Goberdhan, DCI (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Le Gros Clark Bldg,South Parks Rd, Oxford OX1 3QX, England.	deborah.goberdhan@dpag.ox.ac.uk	Harris, Adrian L/ABA-3343-2020; Snell, Cameron/M-7413-2015	Harris, Adrian L/0000-0003-1376-8409; Perera, Sumeth/0000-0003-3385-0063; Snell, Cameron/0000-0001-7847-3041	Cancer Research UK [C191591/A6181, C19591/A9093, C7713/A6174]; Cancer Research UK Oxford Centre Development Fund [C38302/A12278]; Wellcome Trust [WT093326MA]; BBSRC [BB/L007096/1]; Nuffield Medical Fellowship; Studienstiftung des deutschen Volkes; Max Weber Programm Bayern; British Province of the Society of Jesus [626791]; Biotechnology and Biological Sciences Research Council [BB/L007096/1] Funding Source: researchfish; Cancer Research UK [18974, 11359] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Cancer Research UK Oxford Centre Development Fund; Wellcome Trust(Wellcome TrustEuropean Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Nuffield Medical Fellowship; Studienstiftung des deutschen Volkes; Max Weber Programm Bayern; British Province of the Society of Jesus; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK)	We thank Alan McIntyre, Elena Favaro, Thomas Roberts, Aaron Leiblich and Margret Ogmundsdottir for advice and technical help during this study, Katharine Carr, Kristie McCormick and Dan Stevens for critical reading of the manuscript and are especially grateful to Richard Boyd for facilitating key collaborative interactions. This work was supported by Cancer Research UK (C191591/A6181, C19591/A9093, C7713/A6174) and C38302/A12278 grants through the Cancer Research UK Oxford Centre Development Fund, the Wellcome Trust (WT093326MA), the BBSRC (BB/L007096/1), a Nuffield Medical Fellowship to CS, funding from the Studienstiftung des deutschen Volkes and the Max Weber Programm Bayern to SH, and a studentship from The British Province of the Society of Jesus (626791) to SMWP.	Bar-Peled L, 2014, TRENDS CELL BIOL, V24, P400, DOI 10.1016/j.tcb.2014.03.003; Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893; Constantinou C, 2005, ONCOGENE, V24, P4839, DOI 10.1038/sj.onc.1208648; Ducker GS, 2014, ONCOGENE, V33, P1590, DOI 10.1038/onc.2013.92; Goberdhan DCI, 2005, DEVELOPMENT, V132, P2365, DOI 10.1242/dev.01821; Goberdhan DCI, 2010, CURR OPIN INVEST DR, V11, P1360; Grabiner BC, 2014, CANCER DISCOV, V4, P554, DOI 10.1158/2159-8290.CD-13-0929; Heublein S, 2010, ONCOGENE, V29, P4068, DOI 10.1038/onc.2010.177; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hsieh AC, 2010, CLIN CANCER RES, V16, P4914, DOI 10.1158/1078-0432.CCR-10-0433; Jewell JL, 2015, SCIENCE, V347, P194, DOI 10.1126/science.1259472; Jewell JL, 2013, TRENDS BIOCHEM SCI, V38, P233, DOI 10.1016/j.tibs.2013.01.004; Jiang P, 2013, NATURE, V493, P689, DOI 10.1038/nature11776; Kang SA, 2013, SCIENCE, V341, P364, DOI 10.1126/science.1236566; Karim MM, 2001, J BIOL CHEM, V276, P20750, DOI 10.1074/jbc.M011068200; Kim DD, 2012, EXPERT OPIN INV DRUG, V21, P1775, DOI 10.1517/13543784.2012.721353; Li JL, 2007, CANCER RES, V67, P11244, DOI 10.1158/0008-5472.CAN-07-0969; Li JL, 2011, CANCER RES, V71, P6073, DOI 10.1158/0008-5472.CAN-11-1704; Li L, 2010, J BIOL CHEM, V285, P19705, DOI 10.1074/jbc.C110.102483; Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743; Malik AR, 2012, BIOCHIM BIOPHYS ACTA, V1834, P1434; Matsui T, 2013, EMBO REP, V14, P450, DOI 10.1038/embor.2013.32; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Ogmundsdottir MH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036616; Pillai SM, 2011, J BIOL CHEM, V286, P2455, DOI 10.1074/jbc.M110.172403; Rath A, 2009, P NATL ACAD SCI USA, V106, P1760, DOI 10.1073/pnas.0813167106; Rebsamen M, 2015, NATURE, V519, P477, DOI 10.1038/nature14107; Sagne C, 2001, P NATL ACAD SCI USA, V98, P7206, DOI 10.1073/pnas.121183498; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Thomas JD, 2014, CANCER CELL, V26, P754, DOI 10.1016/j.ccell.2014.09.008; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Thwaites DT, 2011, BRIT J PHARMACOL, V164, P1802, DOI 10.1111/j.1476-5381.2011.01438.x; Wang SY, 2015, SCIENCE, V347, P188, DOI 10.1126/science.1257132; Wreden CC, 2003, J NEUROSCI, V23, P1265, DOI 10.1523/JNEUROSCI.23-04-01265.2003; Xu LM, 2011, J BIOL CHEM, V286, P25477, DOI 10.1074/jbc.M111.249631; Yoon MS, 2011, J CELL BIOL, V195, P435, DOI 10.1083/jcb.201107033; Zaytseva YY, 2012, CANCER LETT, V319, P1, DOI 10.1016/j.canlet.2012.01.005; Zhang YJ, 2012, CELL CYCLE, V11, P594, DOI 10.4161/cc.11.3.19096; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60; Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056	43	39	40	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					3004	3015		10.1038/onc.2015.363	http://dx.doi.org/10.1038/onc.2015.363			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26434594	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000377474500006
J	Wilky, BA; Kim, C; McCarty, G; Montgomery, EA; Kammers, K; DeVine, LR; Cole, RN; Raman, V; Loeb, DM				Wilky, B. A.; Kim, C.; McCarty, G.; Montgomery, E. A.; Kammers, K.; DeVine, L. R.; Cole, R. N.; Raman, V.; Loeb, D. M.			RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma	ONCOGENE			English	Article							CELL-GROWTH; PROTEIN; TRANSLATION; TUMOR; RESISTANCE; STRATEGY; SURVIVAL; FUSION	RNA helicase DDX3 has oncogenic activity in breast and lung cancers and is required for translation of complex mRNA transcripts, including those encoding key cell-cycle regulatory proteins. We sought to determine the expression and function of DDX3 in sarcoma cells, and to investigate the antitumor activity of a novel small molecule DDX3 inhibitor, RK-33. Utilizing various sarcoma cell lines, xenografts and human tissue microarrays, we measured DDX3 expression at the mRNA and protein levels, and evaluated cytotoxicity of RK-33 in sarcoma cell lines. To study the role of DDX3 in Ewing sarcoma, we generated stable DDX3-knockdown Ewing sarcoma cell lines using DDX3-specific small hairpin RNA (shRNA), and assessed oncogenic activity. DDX3-knockdown and RK-33-treated Ewing sarcoma cells were compared with wild-type cells using an isobaric mass-tag quantitative proteomics approach to identify target proteins impacted by DDX3 inhibition. Overall, we found high expression of DDX3 in numerous human sarcoma subtypes compared with non-malignant mesenchymal cells, and knockdown of DDX3 by RNA interference inhibited oncogenic activity in Ewing sarcoma cells. Treatment with RK-33 was preferentially cytotoxic to sarcoma cells, including chemotherapy-resistant Ewing sarcoma stem cells, while sparing non-malignant cells. Sensitivity to RK-33 correlated with DDX3 protein expression. Growth of human Ewing sarcoma xenografts expressing high DDX3 was inhibited by RK-33 treatment in mice, without overt toxicity. DDX3 inhibition altered the Ewing sarcoma cellular proteome, especially proteins involved in DNA replication, mRNA translation and proteasome function. These data support further investigation of the role of DDX3 in sarcomas, advancement of RK-33 to Ewing sarcoma clinical trials and development of RNA helicase inhibition as a novel anti-neoplastic strategy.	[Wilky, B. A.; Kim, C.; McCarty, G.; Raman, V.; Loeb, D. M.] Johns Hopkins Univ, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; [Montgomery, E. A.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA; [Kammers, K.] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [DeVine, L. R.; Cole, R. N.] Johns Hopkins Univ, Dept Biol Chem, Baltimore, MD USA; [Raman, V.] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University	Wilky, BA (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, 1120 NW 14th St,Suite 610E, Miami, FL 33136 USA.	b.wilky@med.miami.edu		Wilky, Breelyn/0000-0001-5080-497X	NIH [R01 CA138212, T32 CA009071-31, P30 CA006973, HHSN268201000032C]; Alex's Lemonade Stand Foundation, LLC; Conquer Cancer Foundation/ASCO Young Investigator Award - WWWW Foundation, Inc. (QuadW); Giant Food Children's Cancer Research Fund; Heather Brooke Foundation; German Research Foundation [KA 3884/1-1]; Flight Attendant Medical Research Institute (FAMRI); Alpha Omega Alpha Postgraduate Award; NATIONAL CANCER INSTITUTE [R01CA138212, P30CA006973, T32CA009071] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alex's Lemonade Stand Foundation, LLC; Conquer Cancer Foundation/ASCO Young Investigator Award - WWWW Foundation, Inc. (QuadW); Giant Food Children's Cancer Research Fund; Heather Brooke Foundation; German Research Foundation(German Research Foundation (DFG)); Flight Attendant Medical Research Institute (FAMRI); Alpha Omega Alpha Postgraduate Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors wish to thank Jeffrey Toretsky (Georgetown University), Jonathan Powell (JHU), Lee Helman (NIH), Chand Khanna (Pediatric Oncology Branch NCI) and Nita Ahuja (JHU) for providing cell lines and xenografts. They also credit Richard Jones, MD, Milada Vala and Gabriel Ghaiur, MD, PhD (JHU) for assistance with hematopoietic stem cells experiments; Hao Zhang, PhD (JHU) for assistance with flow cytometry; and Enrico Capobianco at the Center for Computational Analysis at the University of Miami for assistance with STRING networking. This work was supported by grants from the NIH (R01 CA138212 (DL),T32 CA009071-31 (BW), P30 CA006973 and HHSN268201000032C) (RC); a 2013 Reach Award from Alex's Lemonade Stand Foundation, LLC (DL); a Conquer Cancer Foundation/ASCO 2012 Young Investigator Award sponsored by WWWW Foundation, Inc. (QuadW) (BW); additional funding provided from the Giant Food Children's Cancer Research Fund (DL), the Heather Brooke Foundation (DL), German Research Foundation (KA 3884/1-1) (KK), Flight Attendant Medical Research Institute (FAMRI) (VR), and a 2012 Alpha Omega Alpha Postgraduate Award (BW).	Abdelhaleem M, 2004, BBA-REV CANCER, V1704, P37, DOI 10.1016/j.bbcan.2004.05.001; Awad O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013943; Bol GM, 2012, CANC RES CHICAGO IL; Bol GM, 2015, EMBO MOL MED, V7, P648, DOI 10.15252/emmm.201404368; Bol GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063548; Botlagunta M, 2008, ONCOGENE, V27, P3912, DOI 10.1038/onc.2008.33; Chang PC, 2006, ONCOGENE, V25, P1991, DOI 10.1038/sj.onc.1209239; Erkizan HV, 2009, NAT MED, V15, P750, DOI 10.1038/nm.1983; Fukumura J, 2003, J BIOCHEM, V134, P71, DOI 10.1093/jb/mvg126; Garbelli A, 2011, CURR MED CHEM, V18, P3015, DOI 10.2174/092986711796391688; Geissler R, 2012, NUCLEIC ACIDS RES, V40, P4998, DOI 10.1093/nar/gks070; Gonzalez-Nieto D, 2012, BLOOD, V119, P5144, DOI 10.1182/blood-2011-07-368506; HAZELTON BJ, 1987, CANCER RES, V47, P4501; Herbrich SM, 2013, J PROTEOME RES, V12, P594, DOI 10.1021/pr300624g; Italiano A, 2012, GENE CHROMOSOME CANC, V51, P207, DOI 10.1002/gcc.20945; Italiano A, 2011, CANCER-AM CANCER SOC, V117, P1049, DOI 10.1002/cncr.25538; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; Kondaskar A, 2011, ACS MED CHEM LETT, V2, P252, DOI 10.1021/ml100281b; Lai MC, 2008, MOL BIOL CELL, V19, P3847, DOI 10.1091/mbc.E07-12-1264; Lai MC, 2010, MOL CELL BIOL, V30, P5444, DOI 10.1128/MCB.00560-10; Lee CS, 2008, NUCLEIC ACIDS RES, V36, P4708, DOI 10.1093/nar/gkn454; Miao XY, 2013, INT J CLIN EXP PATHO, V6, P179; NYGREN P, 1991, INT J CANCER, V48, P598, DOI 10.1002/ijc.2910480419; Pierce A, 2008, MOL CELL PROTEOMICS, V7, P853, DOI 10.1074/mcp.M700251-MCP200; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Shih JW, 2008, ONCOGENE, V27, P700, DOI 10.1038/sj.onc.1210687; Sison EAR, 2013, BRIT J HAEMATOL, V160, P785, DOI 10.1111/bjh.12205; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Soto-Rifo R, 2012, EMBO J, V31, P3745, DOI 10.1038/emboj.2012.220; Specht K, 2014, GENE CHROMOSOME CANC, V53, P622, DOI 10.1002/gcc.22172; Sun M, 2008, CELL DEATH DIFFER, V15, P1887, DOI 10.1038/cdd.2008.124; Sun MN, 2013, BBA-MOL CELL RES, V1833, P1489, DOI 10.1016/j.bbamcr.2013.02.026; Sun MN, 2011, BBA-MOL CELL RES, V1813, P438, DOI 10.1016/j.bbamcr.2011.01.003; Toretsky JA, 2006, CANCER RES, V66, P5574, DOI 10.1158/0008-5472.CAN-05-3293; Velikodvorskaya T, 2010, CANCER RES, V70, P663; Wang YX, 2011, PROTEOMICS, V11, P2019, DOI 10.1002/pmic.201000722; Wu DW, 2014, ONCOGENE, V33, P1515, DOI 10.1038/onc.2013.107	39	39	40	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2574	2583		10.1038/onc.2015.336	http://dx.doi.org/10.1038/onc.2015.336			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364611				2022-12-17	WOS:000376165700004
J	Li, S; Oh, YT; Yue, P; Khuri, FR; Sun, SY				Li, S.; Oh, Y-T; Yue, P.; Khuri, F. R.; Sun, S-Y			Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells	ONCOGENE			English	Article							TRANSCRIPTION FACTORS; KINASE INHIBITORS; MAMMALIAN TARGET; LIPID-METABOLISM; PHOSPHORYLATION; GROWTH; AKT; ACTIVATION; APOPTOSIS; PATHWAY	Cancer cells feature increased de novo lipogenesis. Sterol regulatory element-binding protein 1 (SREBP1), when presented in its mature form (mSREBP1), enhances lipogenesis by increasing transcription of several of its target genes. Mammalian target of rapamycin (mTOR) complexes, mTORC1 and mTORC2, are master regulators of cellular survival, growth and metabolism. A role for mTORC1 in the regulation of SREBP1 activity has been suggested; however, the connection between mTORC2 and SREBP1 has not been clearly established and hence is the focus of this study. mTOR kinase inhibitors (for example, INK128), which inhibit both mTORC1 and mTORC2, decreased mSREBP1 levels in various cancer cell lines. Knockdown of rictor, but not raptor, also decreased mSREBP1. Consistently, reduced mSREBP1 levels were detected in cells deficient in rictor or Sin1 compared with parent or rictor-deficient cells with re-expression of ectopic rictor. Hence it is mTORC2 inhibition that causes mSREBP1 reduction. As a result, expression of the mSREBP1 target genes acetyl-CoA carboxylase and fatty-acid synthase was suppressed, along with suppressed lipogenesis in cells exposed to INK128. Moreover, mSREBP1 stability was reduced in cells treated with INK128 or rictor knockdown. Inhibition of proteasome, GSK3 or the E3 ubiquitin ligase, FBXW7, prevented mSREBP1 reduction induced by mTORC2 inhibition. Thus mTORC2 inhibition clearly facilitates GSK3-dependent, FBXW7-mediated mSREBP1 degradation, leading to mSREBP1 reduction. Accordingly, we conclude that mTORC2 positively regulates mSREBP1 stability and lipogenesis. Our findings reveal a novel biological function of mTORC2 in the regulation of lipogenesis and warrant further study in this direction.	[Li, S.; Oh, Y-T; Yue, P.; Khuri, F. R.; Sun, S-Y] Emory Univ, Sch Med, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE,C3088, Atlanta, GA 30322 USA; [Li, S.; Oh, Y-T; Yue, P.; Khuri, F. R.; Sun, S-Y] Winship Canc Inst, 1365-C Clifton Rd NE,C3088, Atlanta, GA 30322 USA; [Li, S.] Beijing Inst Basic Med Sci, Dept Biochem & Mol Biol, Beijing, Peoples R China	Emory University; Academy of Military Medical Sciences - China	Sun, SY (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE,C3088, Atlanta, GA 30322 USA.; Sun, SY (corresponding author), Winship Canc Inst, 1365-C Clifton Rd NE,C3088, Atlanta, GA 30322 USA.	ssun@emory.edu	Khuri, Fadlo R./AAU-4942-2020; LI, SHAOHUA/E-2733-2015; Xia, Bo/P-9380-2016	Khuri, Fadlo R./0000-0002-8638-7618; 	NIH/NCI [R01 CA118450, R01 CA160522]; Halpern Research Scholar award; NATIONAL CANCER INSTITUTE [R01CA160522, R01CA118450] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Halpern Research Scholar award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs B Vogelstein, MA Magnuson, B Su, DD Sarbassov and R Schweppes for providing us with some cell lines used in this work. We are also grateful to Dr A Hammond in our department for editing the manuscript. This study was supported by the NIH/NCI R01 CA118450 (SYS) and R01 CA160522 (SYS) and Halpern Research Scholar award (to SYS). FRK and SYS are Georgia Research Alliance Distinguished Cancer Scientists. SYS is a Halpern Research Scholar.	Agarwal NK, 2013, ONCOGENE, V32, P2521, DOI 10.1038/onc.2012.287; Alessi DR, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe27; Bakan I, 2012, CURR OPIN LIPIDOL, V23, P226, DOI 10.1097/MOL.0b013e328352dd03; Bengoechea-Alonso MT, 2009, J BIOL CHEM, V284, P5885, DOI 10.1074/jbc.M807906200; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Espenshade PJ, 2006, J CELL SCI, V119, P973, DOI 10.1242/jcs02866; Griffiths B, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-3; Guo DL, 2011, CANCER DISCOV, V1, P442, DOI 10.1158/2159-8290.CD-11-0102; Guo DL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000446; Hagiwara A, 2012, CELL METAB, V15, P725, DOI 10.1016/j.cmet.2012.03.015; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Koo J, 2015, ONCOTARGET; Koo J, 2014, CANCER RES, V74, P2555, DOI 10.1158/0008-5472.CAN-13-2946; Laplante M, 2010, P NATL ACAD SCI USA, V107, P3281, DOI 10.1073/pnas.1000323107; Lewis CA, 2011, BIOCHEM SOC T, V39, P495, DOI 10.1042/BST0390495; Li WH, 2012, CELL CYCLE, V11, P2348, DOI 10.4161/cc.20811; Li XY, 2014, MOL CANCER THER, V13, P855, DOI 10.1158/1535-7163.MCT-13-0797; Liu W, 2011, BREAST CANCER RES TR, V128, P57, DOI 10.1007/s10549-010-1076-8; Ma KL, 2013, CARDIOVASC RES, V100, P450, DOI 10.1093/cvr/cvt203; MEDES G, 1953, CANCER RES, V13, P27; Peterson TR, 2011, CELL, V146, P408, DOI 10.1016/j.cell.2011.06.034; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Porstmann T, 2009, BIOCHEM SOC T, V37, P278, DOI 10.1042/BST0370278; Preuss E, 2013, J BIOL CHEM, V288, P35287, DOI 10.1074/jbc.M113.495986; Punga T, 2006, J BIOL CHEM, V281, P25278, DOI 10.1074/jbc.M604983200; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Shao W, 2012, CELL METAB, V16, P414, DOI 10.1016/j.cmet.2012.09.002; Shiota C, 2006, DEV CELL, V11, P583, DOI 10.1016/j.devcel.2006.08.013; Sun SY, 2013, CANCER LETT, V340, P1, DOI 10.1016/j.canlet.2013.06.017; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Wang HZ, 2006, REPRODUCTION, V132, P485, DOI 10.1530/rep.1.01213; Williams KJ, 2013, CANCER RES, V73, P2850, DOI 10.1158/0008-5472.CAN-13-0382-T; Yuan MS, 2012, J BIOL CHEM, V287, P29579, DOI 10.1074/jbc.M112.386854; Zhao LQ, 2013, CANCER RES, V73, P1946, DOI 10.1158/0008-5472.CAN-12-3710	36	39	42	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					642	650		10.1038/onc.2015.123	http://dx.doi.org/10.1038/onc.2015.123			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25893295	Green Accepted			2022-12-17	WOS:000369548800011
J	Liu, D; Yang, Z; Wang, T; Yang, Z; Chen, H; Hu, Y; Hu, C; Guo, L; Deng, Q; Liu, Y; Yu, M; Shi, M; Du, N; Guo, N				Liu, D.; Yang, Z.; Wang, T.; Yang, Z.; Chen, H.; Hu, Y.; Hu, C.; Guo, L.; Deng, Q.; Liu, Y.; Yu, M.; Shi, M.; Du, N.; Guo, N.			beta 2-AR signaling controls trastuzumab resistance-dependent pathway	ONCOGENE			English	Article							METASTATIC BREAST-CANCER; BETA-BLOCKERS; KINASE ACTIVATION; STAT3 ACTIVATION; SRC ACTIVATION; UP-REGULATION; STRESS; PTEN; THERAPY; MIR-21	Currently, trastuzumab resistance is a major clinical problem in the treatment of Her2-overexpressing breast cancer. The underlying molecular mechanisms are not fully understood. Our previous study demonstrates that beta 2-adrenergic receptor (beta 2-AR) and Her2 comprise a positive feedback loop in human breast cancer cells and that crosstalk between Her2 and beta 2-AR affects the bio-behaviors of breast cancer cells, suggesting that the beta 2-AR activation may be involved in trastuzumab resistance. In this study, we show that the expression of beta 2-AR, which mediates most catecholamine-induced effects, negatively correlates with trastuzumab response in the patients with Her2-overexpressing breast cancer. Catecholamines potently antagonize the anti-proliferative effects of trastuzumab both in vitro and in vivo. Catecholamine stimulation upregulates the expression of miR-21 and MUC-1 by activating Her2 and STAT3, leading to deficiency of phosphatase and tensin homolog and activation of phosphatidylinositol-3-kinase (PI3K) and Akt. Through inhibition of miR-199a/b-3p, catecholamines induce the mammalian target of rapamycin (mTOR) activation. Thus, trastuzumab resistance-dependent PI3K/Akt/mTOR pathway is controlled by catecholamine-induced beta 2-AR activation. The data indicate that beta 2-AR is a reliable molecular marker for prediction of response probability to trastuzumab-based therapy in breast cancer. We also demonstrate that beta-blocker propranolol not only enhances the antitumor activities of trastuzumab but also re-sensitizes the resistant cells to trastuzumab. Our retrospective study shows that concurrent treatment of a-blocker and trastuzumab significantly improved progression-free survival and overall survival in the patients with Her2-overexpressing metastatic breast cancer, implicating the possibility for combination therapy with trastuzumab plus a-blocker in Her2-overexpressing breast cancer.	[Liu, D.; Yang, Z.; Chen, H.; Hu, Y.; Guo, L.; Deng, Q.; Liu, Y.; Yu, M.; Shi, M.; Guo, N.] Inst Basic Med Sci, Dept Pathophysiol, Beijing 100850, Peoples R China; [Wang, T.] Peoples Liberat Army, Hosp 307, Dept Oncol, Beijing, Peoples R China; [Yang, Z.] Beijing Haiyan Pharmaceut Co Ltd, Yangtze River Pharmaceut Grp, Beijing, Peoples R China; [Hu, C.] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China; [Du, N.] Peoples Liberat Army, Gen Hosp, Affiliated Hosp 1, Dept Oncol, Beijing, Peoples R China	Beijing Institute of Microbiology & Epidemiology; Chinese People's Liberation Army General Hospital	Shi, M (corresponding author), Inst Basic Med Sci, Dept Pathophysiol, Taiping Rd 27, Beijing 100850, Peoples R China.	sm200@sohu.com; dunan05@aliyun.com; ningguo@nic.bmi.ac.cn			National Basic Research Program of China (973 program) [2010CB911904]; National Key Technologies R&D Program for New Drugs [2013ZX09102056]; National High-Tech Research and Development Plan (863 program) [2014AA020604]; National Natural Science Foundation of China [31370825, 81402562, 81272232]; Beijing Natural Science Foundation [7122124, 7132163]	National Basic Research Program of China (973 program)(National Basic Research Program of China); National Key Technologies R&D Program for New Drugs(National Key Technology R&D Program); National High-Tech Research and Development Plan (863 program)(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation)	This work is supported by National Basic Research Program of China (973 program, no. 2010CB911904), National Key Technologies R&D Program for New Drugs (2013ZX09102056), the National High-Tech Research and Development Plan (863 program, no. 2014AA020604), National Natural Science Foundation of China (no. 31370825, 81402562 and 81272232) and Beijing Natural Science Foundation (no. 7122124 and 7132163).	Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426; Antonova L, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2836; Armaiz-Pena GN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2413; Arnould L, 2007, CLIN CANCER RES, V13, P6404, DOI 10.1158/1078-0432.CCR-06-3022; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Barron TI, 2011, J CLIN ONCOL, V29, P2635, DOI 10.1200/JCO.2010.33.5422; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bhola NE, 2011, CLIN CANCER RES, V17, P4996, DOI 10.1158/1078-0432.CCR-10-3406; Campbell JP, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001363; Carbajal L, 2011, MOL ENDOCRINOL, V25, P1055, DOI 10.1210/me.2010-0410; Cardwell CR, 2013, INT J EPIDEMIOL, V42, P1852, DOI 10.1093/ije/dyt196; Cole SW, 2012, CLIN CANCER RES, V18, P1201, DOI 10.1158/1078-0432.CCR-11-0641; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Dominici LS, 2010, CANCER-AM CANCER SOC, V116, P2884, DOI 10.1002/cncr.25152; Esteva FJ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1836; Fessler SP, 2009, BREAST CANCER RES TR, V118, P113, DOI 10.1007/s10549-009-0412-3; Fornari F, 2010, CANCER RES, V70, P5184, DOI 10.1158/0008-5472.CAN-10-0145; Ganz PA, 2011, J CLIN ONCOL, V29, P2612, DOI 10.1200/JCO.2011.35.8820; Garcia-Garcia C, 2012, CLIN CANCER RES, V18, P2603, DOI 10.1158/1078-0432.CCR-11-2750; Garcia-Recio S, 2013, CANCER RES, V73, P6424, DOI 10.1158/0008-5472.CAN-12-4573; Gijsen M, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000563; Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571; Gong C, 2011, J BIOL CHEM, V286, P19127, DOI 10.1074/jbc.M110.216887; Gu L, 2009, CLIN CANCER RES, V15, P7196, DOI 10.1158/1078-0432.CCR-09-0585; Haghikia A, 2011, EUR HEART J, V32, P1287, DOI 10.1093/eurheartj/ehq369; Hara MR, 2011, NATURE, V477, P349, DOI 10.1038/nature10368; Hassan S, 2013, J CLIN INVEST, V123, P874, DOI 10.1172/JCI63324; Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001; Huang TH, 2009, J BIOL CHEM, V284, P18515, DOI 10.1074/jbc.M109.006676; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Kuzumaki N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044368; Lamkin DM, 2011, BRAIN BEHAV IMMUN, V25, P555, DOI 10.1016/j.bbi.2010.12.010; Lappano R, 2011, NAT REV DRUG DISCOV, V10, P47, DOI 10.1038/nrd3320; Liang K, 2010, CANCER CELL, V18, P423, DOI 10.1016/j.ccr.2010.10.025; Lutgendorf SK, 2008, J CLIN ONCOL, V26, P4820, DOI 10.1200/JCO.2007.14.1978; Lutgendorf SK, 2010, J CLIN ONCOL, V28, P4094, DOI 10.1200/JCO.2009.26.9357; Lutgendorf SK, 2009, BRAIN BEHAV IMMUN, V23, P176, DOI 10.1016/j.bbi.2008.04.155; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361; Melhem-Bertrandt A, 2011, J CLIN ONCOL, V29, P2645, DOI 10.1200/JCO.2010.33.4441; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Morrow PK, 2011, J CLIN ONCOL, V29, P3126, DOI 10.1200/JCO.2010.32.2321; Mukohara T, 2011, CANCER SCI, V102, P1, DOI 10.1111/j.1349-7006.2010.01711.x; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Park BH, 2007, CANCER CELL, V12, P297, DOI 10.1016/j.ccr.2007.10.004; Powe DG, 2011, NAT REV CLIN ONCOL, V8, P511, DOI 10.1038/nrclinonc.2011.123; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Seidman AD, 2008, J CLIN ONCOL, V26, P1642, DOI 10.1200/JCO.2007.11.6699; Shi M, 2013, CANCER METAST REV, V32, P603, DOI 10.1007/s10555-013-9440-x; Shi M, 2013, INT J CARDIOL, V167, P1570, DOI 10.1016/j.ijcard.2012.04.093; Shi M, 2011, BREAST CANCER RES TR, V125, P351, DOI 10.1007/s10549-010-0822-2; Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008-5472.CAN-10-0522; Smith C, 1999, CARDIOVASC DRUG THER, V13, P123, DOI 10.1023/A:1007784109255; Sorensen GV, 2013, J CLIN ONCOL, V31, P2265, DOI 10.1200/JCO.2012.43.9190; Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507; Stern HM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3001539; Waller A, 2012, CURR ONCOL, V19, pE53, DOI 10.3747/co.19.882; Woo JK, 2012, ONCOGENE, V31, P2187, DOI 10.1038/onc.2011.410; Xiao R P, 2001, Sci STKE, V2001, pre15, DOI 10.1126/stke.2001.104.re15; Yao MY, 2011, LUNG, V189, P453, DOI 10.1007/s00408-011-9327-y; Yuan GG, 2008, CELL SIGNAL, V20, P1284, DOI 10.1016/j.cellsig.2008.02.017; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309	63	39	42	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					47	58		10.1038/onc.2015.58	http://dx.doi.org/10.1038/onc.2015.58			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25798840				2022-12-17	WOS:000367812400005
J	Brun, SN; Markant, SL; Esparza, LA; Garcia, G; Terry, D; Huang, JM; Pavlyukov, MS; Li, XN; Grant, GA; Crawford, JR; Levy, ML; Conway, EM; Smith, LH; Nakano, I; Berezov, A; Greene, MI; Wang, Q; Wechsler-Reya, RJ				Brun, S. N.; Markant, S. L.; Esparza, L. A.; Garcia, G.; Terry, D.; Huang, J-M; Pavlyukov, M. S.; Li, X-N; Grant, G. A.; Crawford, J. R.; Levy, M. L.; Conway, E. M.; Smith, L. H.; Nakano, I.; Berezov, A.; Greene, M. I.; Wang, Q.; Wechsler-Reya, R. J.			Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma	ONCOGENE			English	Article							CELL LUNG-CANCER; PHASE-II; DRUG-RESISTANCE; EXPRESSION; YM155; INHIBITOR; APOPTOSIS; SUPPRESSANT; DELIVERY; PATHWAY	Medulloblastoma (MB) is a highly malignant brain tumor that occurs primarily in children. Although surgery, radiation and high-dose chemotherapy have led to increased survival, many MB patients still die from their disease, and patients who survive suffer severe long-term side effects as a consequence of treatment. Thus, more effective and less toxic therapies for MB are critically important. Development of such therapies depends in part on identification of genes that are necessary for growth and survival of tumor cells. Survivin is an inhibitor of apoptosis protein that regulates cell cycle progression and resistance to apoptosis, is frequently expressed in human MB and when expressed at high levels predicts poor clinical outcome. Therefore, we hypothesized that Survivin may have a critical role in growth and survival of MB cells and that targeting it may enhance MB therapy. Here we show that Survivin is overexpressed in tumors from patched (Ptch) mutant mice, a model of Sonic hedgehog (SHH)-driven MB. Genetic deletion of survivin in Ptch mutant tumor cells significantly inhibits proliferation and causes cell cycle arrest. Treatment with small-molecule antagonists of Survivin impairs proliferation and survival of both murine and human MB cells. Finally, Survivin antagonists impede growth of MB cells in vivo. These studies highlight the importance of Survivin in SHH-driven MB, and suggest that it may represent a novel therapeutic target in patients with this disease.	[Brun, S. N.; Markant, S. L.; Esparza, L. A.; Wechsler-Reya, R. J.] NCI, Sanford Burnham Med Res Inst, Designated Canc Ctr, Initiat & Maintenance Program, La Jolla, CA 92037 USA; [Brun, S. N.; Markant, S. L.; Esparza, L. A.; Wechsler-Reya, R. J.] Sanford Consortium Regenerat Med, La Jolla, CA USA; [Brun, S. N.; Markant, S. L.; Wechsler-Reya, R. J.] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC USA; [Garcia, G.] SBMRI, Histopathol Core, La Jolla, CA USA; [Terry, D.; Smith, L. H.] SBMRI, Conrad Prebys Ctr Chem Genom, Lake Nona, FL USA; [Huang, J-M; Wang, Q.] Samuel Oschin Comprehens Canc Inst, Cedars Sinai Womens Canc Program, Los Angeles, CA USA; [Pavlyukov, M. S.; Nakano, I.] Ohio State Univ, Dept Neurol Surg, Columbus, OH 43210 USA; [Pavlyukov, M. S.; Nakano, I.] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH 43210 USA; [Li, X-N] Baylor Coll Med, Texas Childrens Canc Ctr, Brain Tumor Program, Houston, TX 77030 USA; [Li, X-N] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Grant, G. A.] Stanford Univ, Lucile Packard Childrens Hosp, Dept Neurosurg, Stanford, CA 94305 USA; [Crawford, J. R.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Crawford, J. R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; [Crawford, J. R.; Levy, M. L.] Rady Childrens Hosp, San Diego, CA USA; [Levy, M. L.] Univ Calif San Diego, Dept Neurosurg, La Jolla, CA 92093 USA; [Conway, E. M.] Univ British Columbia, Ctr Blood Res, Dept Med, Div Hematol, Vancouver, BC V5Z 1M9, Canada; [Smith, L. H.] Sanford Burnham Med Res Inst, Cardiopathobiol Program, Lake Nona, FL USA; [Berezov, A.] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA; [Greene, M. I.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Sanford Burnham Prebys Medical Discovery Institute; Duke University; Cedars Sinai Medical Center; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine; Lucile Packard Children's Hospital (LPCH); Stanford University; University of California System; University of California San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; University of British Columbia; Sanford Burnham Prebys Medical Discovery Institute; Cedars Sinai Medical Center; University of Pennsylvania	Wechsler-Reya, RJ (corresponding author), NCI, Sanford Burnham Med Res Inst, Designated Canc Ctr, Initiat & Maintenance Program, 2880 Torrey Pines Scen Dr, La Jolla, CA 92037 USA.	rwreya@sanfordburnham.org	Pavlyukov, Marat S/E-7314-2014; Levy, Michael/AAL-4647-2020; Nakano, Ichiro/AAR-9562-2020; Crawford, John/ABH-2134-2021; Pavlyukov, Marat S/ABB-6791-2021; Wang, Qiang/N-7310-2015	Nakano, Ichiro/0000-0002-0916-3207; Wang, Qiang/0000-0001-9409-0251; Smith, Layton/0000-0003-2621-9740; Conway, Edward/0000-0003-0081-0305	Canadian Institutes for Health Research (CIHR); Natural Sciences and Engineering Research Council of Canada (NSERC); NCI [5P30CA030199, R01 CA122759]; Cedars-Sinai/Sanford-Burnham Grant Program for Cancer Research; Research Leadership Award from the California Institute for Regenerative Medicine [CIRM LA1-01747];  [5R01CA08948]; NATIONAL CANCER INSTITUTE [R01CA122759, R01CA159859, P30CA030199] Funding Source: NIH RePORTER	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cedars-Sinai/Sanford-Burnham Grant Program for Cancer Research; Research Leadership Award from the California Institute for Regenerative Medicine; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate the support of the Sanford-Burnham Shared Resources, including Amy Cortez, Jonna Hurtado and Yoav Altman (Flow Cytometry); Robbin Newlin (Histopathology); Danielle McAnally, Michael Vicchiarelli and Arianna Mangravita-Novo (Chemical Genomics); Lili Lacarra, Adriana Charbono and Kenny Venegas (Animal facility); and Anthony Pinkerton and members of the Medicinal Chemistry Resource for generation of S12 and LLP3. We are also grateful to Ana Miletic-Sedy and Robert Rickert for sharing Survivin<SUP>fl/fl</SUP> mice; and to Robert Margolis for helpful discussions. We thank the Flanders Institute for Biotechnology (VIB), Belgium, for allowing us to use the Survivin<SUP>fl/fl</SUP> mice. EMC is supported by grants from the Canadian Institutes for Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC). He holds a Tier 1 Canada Research Chair (CRC) in Endothelial Cell Biology. MIG is supported by Grant 5R01CA08948. This work was supported by NCI award number 5P30CA030199 and R01 CA122759 and by the Cedars-Sinai/Sanford-Burnham Grant Program for Cancer Research. RWR is the recipient of a Research Leadership Award from the California Institute for Regenerative Medicine (CIRM LA1-01747).	Adida C, 2000, BRIT J HAEMATOL, V111, P196, DOI 10.1046/j.1365-2141.2000.02328.x; Adida C, 1998, AM J PATHOL, V152, P43; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Arora R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003713; Becker JC, 2012, CANCER IMMUNOL IMMUN, V61, P2091, DOI 10.1007/s00262-012-1266-9; Berezov A, 2012, ONCOGENE, V31, P1938, DOI 10.1038/onc.2011.377; Blomstrand M, 2012, NEURO-ONCOLOGY, V14, P882, DOI 10.1093/neuonc/nos120; Brown MT, 1996, CLIN CANCER RES, V2, P963; Carrasco RA, 2011, MOL CANCER THER, V10, P221, DOI 10.1158/1535-7163.MCT-10-0756; Chakravarti A, 2004, ONCOGENE, V23, P7494, DOI 10.1038/sj.onc.1208049; Cheng Qiuying, 2012, Int J Biochem Mol Biol, V3, P179; Ellis T, 2003, GENESIS, V36, P158, DOI 10.1002/gene.10208; Fangusaro JR, 2006, PEDIATR BLOOD CANCER, V47, P4, DOI 10.1002/pbc.20805; Fangusaro JR, 2005, BRIT J CANCER, V92, P359, DOI 10.1038/sj.bjc.6602317; Fossati P, 2009, CANCER TREAT REV, V35, P79, DOI 10.1016/j.ctrv.2008.09.002; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Grinstein E, 2002, ONCOGENE, V21, P1485, DOI 10.1038/sj.onc.1205211; Grossman D, 2001, CANCER METAST REV, V20, P3, DOI 10.1023/A:1013123532723; Guvenc H, 2013, CLIN CANCER RES, V19, P631, DOI 10.1158/1078-0432.CCR-12-0647; Haberler C, 2006, EUR J CANCER, V42, P2996, DOI 10.1016/j.ejca.2006.05.038; Hall WA, 2006, EXPERT OPIN DRUG DEL, V3, P371, DOI 10.1517/17425247.3.3.371; Huang LN, 2013, MOL BIOL REP, V40, P917, DOI 10.1007/s11033-012-2132-8; Iwasa T, 2008, CLIN CANCER RES, V14, P6496, DOI 10.1158/1078-0432.CCR-08-0468; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Kunwar S, 2007, J CLIN ONCOL, V25, P837, DOI 10.1200/JCO.2006.08.1117; Lewis KD, 2011, INVEST NEW DRUG, V29, P161, DOI 10.1007/s10637-009-9333-6; Li XN, 2007, NEUROPATH APPL NEURO, V33, P67, DOI 10.1111/j.1365-2990.2006.00782.x; Ling X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045571; Machold R, 2005, NEURON, V48, P17, DOI 10.1016/j.neuron.2005.08.028; Markant SL, 2013, CANCER RES, V73, P6310, DOI 10.1158/0008-5472.CAN-12-4258; Minematsu T, 2012, BIOPHARM DRUG DISPOS, V33, P160, DOI 10.1002/bdd.1781; Morrison DJ, 2012, LEUKEMIA, V26, P271, DOI 10.1038/leu.2011.199; Mulhern RK, 2005, J CLIN ONCOL, V23, P5511, DOI 10.1200/JCO.2005.00.703; Nagaraj S, 2007, J IMMUNOTHER, V30, P169, DOI 10.1097/01.cji.0000211329.83890.ba; Nakahara T, 2007, CANCER RES, V67, P8014, DOI 10.1158/0008-5472.CAN-07-1343; Nakahara T, 2011, ANTI-CANCER DRUG, V22, P454, DOI 10.1097/CAD.0b013e328344ac68; Nakahara T, 2011, CANCER SCI, V102, P614, DOI 10.1111/j.1349-7006.2010.01834.x; Nakamura N, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.013243; Northcott PA, 2012, EXPERT REV NEUROTHER, V12, P871, DOI [10.1586/ern.12.66, 10.1586/ERN.12.66]; Okamoto K, 2012, MOL CANCER THER, V11, P204, DOI 10.1158/1535-7163.MCT-11-0638; Olie RA, 2000, CANCER RES, V60, P2805; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Packer R J, 1999, Neuro Oncol, V1, P232, DOI 10.1093/neuonc/1.3.232; Packer RJ, 2008, ARCH NEUROL-CHICAGO, V65, P1419, DOI 10.1001/archneur.65.11.1419; Pan SF, 2010, ACS MED CHEM LETT, V1, P130, DOI 10.1021/ml1000307; Park E, 2011, BLOOD, V118, P2191, DOI 10.1182/blood-2011-04-351239; Rodon J, 2014, CLIN CANCER RES, V20, P1900, DOI 10.1158/1078-0432.CCR-13-1710; Rodel F, 2008, INT J RADIAT ONCOL, V71, P247, DOI 10.1016/j.ijrobp.2008.02.011; Rosa J, 2006, MOL BIOL CELL, V17, P1483, DOI 10.1091/mbc.e05-08-0723; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Saito T, 2008, BRIT J CANCER, V98, P345, DOI 10.1038/sj.bjc.6604160; Serwer LP, 2012, ADV DRUG DELIVER REV, V64, P590, DOI 10.1016/j.addr.2012.01.004; Shirai K, 2009, J NEURO-ONCOL, V91, P353, DOI 10.1007/s11060-008-9720-4; Talbot DC, 2010, CLIN CANCER RES, V16, P6150, DOI 10.1158/1078-0432.CCR-10-1932; Tanioka M, 2011, CANCER CHEMOTH PHARM, V68, P505, DOI 10.1007/s00280-010-1506-7; Tao YF, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-619; Tolcher AW, 2012, ANN ONCOL, V23, P968, DOI 10.1093/annonc/mdr353; Wheatley SP, 2005, INT REV CYTOL, V247, P35, DOI 10.1016/S0074-7696(05)47002-3; Xing Z, 2004, J EXP MED, V199, P69, DOI 10.1084/jem.20031588; Yamanaka K, 2011, CLIN CANCER RES, V17, P5423, DOI 10.1158/1078-0432.CCR-10-3410; Yamashita SI, 2007, ANTICANCER RES, V27, P2803; Yamauchi T, 2012, BIOCHEM BIOPH RES CO, V425, P711, DOI 10.1016/j.bbrc.2012.07.103; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yue ZJ, 2008, J CELL BIOL, V183, P279, DOI 10.1083/jcb.200806118; Zhao XM, 2012, NEURO-ONCOLOGY, V14, P574, DOI 10.1093/neuonc/nos061; Zhu K, 2007, VACCINE, V25, P7955, DOI 10.1016/j.vaccine.2007.08.050	68	39	41	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3770	3779		10.1038/onc.2014.304	http://dx.doi.org/10.1038/onc.2014.304			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25241898	Green Submitted, Green Accepted			2022-12-17	WOS:000358001600003
J	Russo, RIC; Beguelin, W; Flaque, MCD; Proietti, CJ; Venturutti, L; Galigniana, N; Tkach, M; Guzman, P; Roa, JC; O'Brien, NA; Charreau, EH; Schillaci, R; Elizalde, PV				Cordo Russo, R. I.; Beguelin, W.; Diaz Flaque, M. C.; Proietti, C. J.; Venturutti, L.; Galigniana, N.; Tkach, M.; Guzman, P.; Roa, J. C.; O'Brien, N. A.; Charreau, E. H.; Schillaci, R.; Elizalde, P. V.			Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR RECEPTOR; PROGESTERONE-RECEPTOR; CYCLIN D1; CELL-PROLIFERATION; SIGNALING PATHWAYS; IN-VIVO; PI3K INHIBITOR; THERAPY; HER2	Membrane overexpression of ErbB-2/HER2 receptor tyrosine kinase (membrane ErbB-2 (MErbB-2)) has a critical role in breast cancer (BC). We and others have also shown the role of nuclear ErbB-2 (NErbB-2) in BC, whose presence we identified as a poor prognostic factor in MErbB-2-positive tumors. Current anti-ErbB-2 therapies, as with the antibody trastuzumab (Ttzm), target only MErbB-2. Here, we found that blockade of NErbB-2 action abrogates growth of BC cells, sensitive and resistant to Ttzm, in a scenario in which ErbB-2, ErbB-3 and Akt are phosphorylated, and ErbB-2/ErbB-3 dimers are formed. Also, inhibition of NErbB-2 presence suppresses growth of a preclinical BC model resistant to Ttzm. We showed that at the cyclin D1 promoter, ErbB-2 assembles a transcriptional complex with Stat3 (signal transducer and activator of transcription 3) and ErbB-3, another member of the ErbB family, which reveals the first nuclear function of ErbB-2/ErbB-3 dimer. We identified NErbB-2 as the major proliferation driver in Ttzm-resistant BC, and demonstrated that Ttzm inability to disrupt the Stat3/ErbB-2/ErbB-3 complex underlies its failure to inhibit growth. Furthermore, our results in the clinic revealed that nuclear interaction between ErbB-2 and Stat3 correlates with poor overall survival in primary breast tumors. Our findings challenge the paradigm of anti-ErbB-2 drug design and highlight NErbB-2 as a novel target to overcome Ttzm resistance.	[Cordo Russo, R. I.; Beguelin, W.; Diaz Flaque, M. C.; Proietti, C. J.; Venturutti, L.; Galigniana, N.; Tkach, M.; Charreau, E. H.; Schillaci, R.; Elizalde, P. V.] Consejo Nacl Invest Cient & Tecn, Lab Mol Mech Carcinogenesis, Inst Biol & Med Expt IBYME, RA-1428 Buenos Aires, DF, Argentina; [Guzman, P.; Roa, J. C.] Univ La Frontera, Dept Anat Patol BIOREN, Temuco, Chile; [O'Brien, N. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; Universidad de La Frontera; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Elizalde, PV (corresponding author), Consejo Nacl Invest Cient & Tecn, Lab Mol Mech Carcinogenesis, Inst Biol & Med Expt IBYME, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	patriciaelizalde@ibyme.conicet.gov.ar	Russo, Rosalia Cordo/O-9149-2017; Roa, Juan C./K-4749-2014	Russo, Rosalia Cordo/0000-0002-5984-9717; Roa, Juan C./0000-0001-8313-8774; Elizalde, Patricia V./0000-0002-5923-9898; Galigniana, Natalia/0000-0002-0712-719X; Schillaci, Roxana/0000-0002-7776-3378; Diaz Flaque, Maria Celeste/0000-0003-4167-6149	Susan G Komen for the Cure investigator-initiated research Grant [KG090250]; National Agency of Scientific Promotion of Argentina [IDB/PICT 2012-668, PID 2012-066, IDB/PICT 2012-382]; Henry Moore Institute of Argentina [CONICET 1819/03]	Susan G Komen for the Cure investigator-initiated research Grant; National Agency of Scientific Promotion of Argentina(ANPCyT); Henry Moore Institute of Argentina	We thank Mien-Chie Hung (MD Anderson Cancer Center, Houston, TX, USA) for his generous gift of the hErbB-2.NLS, which indeed made this work possible, and AA Molinolo (NIH, Bethesda, MD, USA) for his constant help and support. We also thank J Giudice (Baylor College of Medicine, Houston, TX, USA) for help with quantification of confocal images, and V Chiauzzi for her excellent technical assistance. This work was supported by the Susan G Komen for the Cure KG090250 investigator-initiated research Grant, IDB/PICT 2012-668 and PID 2012-066 from the National Agency of Scientific Promotion of Argentina (all of them awarded to PVE), IDB/PICT 2012-382 from the National Agency of Scientific Promotion of Argentina (awarded to RS) and Oncomed-Reno CONICET 1819/03, from the Henry Moore Institute of Argentina (awarded to PVE and RS).	Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Andrique L, 2012, CELL SIGNAL, V24, P1074, DOI 10.1016/j.cellsig.2012.01.002; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Balana ME, 1999, ONCOGENE, V18, P6370, DOI 10.1038/sj.onc.1203028; Beguelin W, 2010, MOL CELL BIOL, V30, P5456, DOI 10.1128/MCB.00012-10; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Brand TM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071518; Breuleux M, 2006, MOL CANCER RES, V4, P27, DOI 10.1158/1541-7786.MCR-05-0016; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Browne BC, 2009, CURR CANCER DRUG TAR, V9, P419, DOI 10.2174/156800909788166484; Chiu CG, 2010, ANN SURG, V251, P1107, DOI 10.1097/SLA.0b013e3181dbb77e; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Flaque MCD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3587; Diermeier S, 2005, EXP CELL RES, V304, P604, DOI 10.1016/j.yexcr.2004.12.008; Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Ghosh R, 2011, CANCER RES, V71, P1871, DOI 10.1158/0008-5472.CAN-10-1872; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Henderson IC, 1998, BREAST CANCER RES TR, V52, P261, DOI 10.1023/A:1006141703224; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hsieh AC, 2007, BRIT J CANCER, V97, P453, DOI 10.1038/sj.bjc.6603910; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Kataoka Y, 2010, ANN ONCOL, V21, P255, DOI 10.1093/annonc/mdp304; Koninki K, 2010, CANCER LETT, V294, P211, DOI 10.1016/j.canlet.2010.02.002; Koumakpayi IH, 2006, CLIN CANCER RES, V12, P2730, DOI 10.1158/1078-0432.CCR-05-2242; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Landgraf R, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1633; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Lenferink AEG, 2001, CANCER RES, V61, P6583; Leow CC, 2009, MOL CANCER THER, V8, P2131, DOI 10.1158/1535-7163.MCT-08-1038; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; Li LY, 2011, CANCER RES, V71, P4269, DOI 10.1158/0008-5472.CAN-10-3504; Li WL, 1996, ONCOGENE, V12, P2473; Maegawa M, 2007, MOL CANCER RES, V5, P393, DOI 10.1158/1541-7786.MCR-06-0303; Marshall C, 2006, BREAST CANCER RES TR, V96, P163, DOI 10.1007/s10549-005-9073-z; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; O'Brien NA, 2010, MOL CANCER THER, V9, P1489, DOI 10.1158/1535-7163.MCT-09-1171; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Ostrander JH, 2007, CANCER RES, V67, P4199, DOI 10.1158/0008-5472.CAN-06-3409; Proietti CJ, 2009, MOL CELL BIOL, V29, P1249, DOI 10.1128/MCB.00853-08; Rexer Brent N., 2012, Critical Reviews in Oncogenesis, V17, P1; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Rivas MA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3187; Rivas MA, 2010, BREAST CANCER RES TR, V122, P111, DOI 10.1007/s10549-009-0546-3; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Salatino M, 2004, ONCOGENE, V23, P5161, DOI 10.1038/sj.onc.1207659; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Schillaci R, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-74; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2; Tanner M, 2004, MOL CANCER THER, V3, P1585; Tao RH, 2008, J CELL SCI, V121, P3207, DOI 10.1242/jcs.033399; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Wang YC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3067; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yakes FM, 2002, CANCER RES, V62, P4132; Yao E, 2009, CLIN CANCER RES, V15, P4147, DOI 10.1158/1078-0432.CCR-08-2814	67	39	40	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3413	3428		10.1038/onc.2014.272	http://dx.doi.org/10.1038/onc.2014.272			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25174405	Green Published			2022-12-17	WOS:000356871700007
J	Wang, S; Dong, Y; Zhang, Y; Wang, X; Xu, L; Yang, S; Li, X; Dong, H; Xu, L; Su, L; Ng, SSM; Chang, Z; Sung, JJ; Zhang, X; Yu, J				Wang, S.; Dong, Y.; Zhang, Y.; Wang, X.; Xu, L.; Yang, S.; Li, X.; Dong, H.; Xu, L.; Su, L.; Ng, S. S. M.; Chang, Z.; Sung, J. J.; Zhang, X.; Yu, J.			DACT2 is a functional tumor suppressor through inhibiting Wnt/beta-catenin pathway and associated with poor survival in colon cancer	ONCOGENE			English	Article							BETA-CATENIN; COLORECTAL-CANCER; SIGNALING-PATHWAY; WNT; EPIGENETICS; ROLES; TRANSCRIPTION; MECHANISMS; PROTEINS; DAPPER	Dapper homolog (DACT) 2 is one of the Dact gene family members, which are important modulators of Wnt signaling pathway. We aim to clarify its epigenetic inactivation, biological function and clinical implication in colon cancer. DACT2 was silenced in five out of eight colon cancer cell lines, but robustly expressed in normal colon tissues. The loss of DACT2 expression was regulated by promoter hypermethylation. Restoring DACT2 expression in colon cancer cell lines suppressed tumor cell growth by inducing cell apoptosis and inhibiting cell proliferation both in vitro and in vivo. Moreover, DACT2 overexpression effectively reduced lung metastasis of colon cancer cells in nude mice. These effects by DACT2 were attributed to inhibition of Wnt/beta-catenin signaling. Reexpression of DACT2 significantly suppressed the transcriptional activity of both wild-type beta-catenin and degradation-resistant form mutant beta-catenin (S33Y). DACT2 could actively shuttle into and out of nuclei, with its predominant steady-state localization in the cytoplasm dependent on its nuclear export signal. Co-immunoprecipitation results indicated that DACT2 strongly associated beta-catenin as well as lymphoid enhancer-binding factor 1 (LEF1) and directly disrupted the formation of the beta-catenin-LEF1 complex in the nucleus. Whereas in the cytoplasm, DACT2 restored junctional localization of E-cadherin-beta-catenin complexes and prevented beta-catenin nuclear translocation through direct interaction with beta-catenin. DACT2 methylation was detected in 43.3% (29/67) of colon cancer tissues, but none in normal controls. Multivariate analysis revealed that patients with DACT2 methylation had a significant decrease in overall survival (P = 0.006). Kaplan-Meier survival curves showed that DACT2 methylation was significantly associated with shortened survival in stage I-III colon cancer patients. In conclusion, DACT2 acts as a functional tumor suppressor in colon cancer through inhibiting Wnt/beta-catenin signaling. Its methylation at early stages of colon carcinogenesis is an independent prognostic factor.	[Wang, S.; Dong, H.; Xu, L.; Su, L.; Zhang, X.] Univ Sci & Technol Beijing, Sch Chem & Biol Engn, Res Ctr Bioengn & Sensing Technol, Beijing 100083, Peoples R China; [Wang, S.; Dong, Y.; Wang, X.; Xu, L.; Li, X.; Sung, J. J.; Yu, J.] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Inst Digest Dis,Dept Med & Therapeut,State Key La, Shatin, Hong Kong, Peoples R China; [Dong, Y.; Ng, S. S. M.] Chinese Univ Hong Kong, Dept Surg, Shatin, Hong Kong, Peoples R China; [Zhang, Y.; Yang, S.; Chang, Z.] Tsinghua Univ, Sch Life Sci, Sch Med, State Key Lab Biomembrane & Membrane Biotechnol,N, Beijing 100084, Peoples R China	University of Science & Technology Beijing; Chinese University of Hong Kong; Chinese University of Hong Kong; Tsinghua University	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	zhangxueji@ustb.edu.cn; junyu@cuhk.edu.hk	Zhang, Yanquan/D-5615-2017; zhang, xueji/ABE-6497-2020; Yu, Jun/D-8569-2015; Sung, Joseph J. Y./R-3203-2018; Li, Xiao-xing/B-9114-2008; Ng, Simon S. M./M-1219-2018; Chang, Zhijie/AAH-8109-2019	Zhang, Yanquan/0000-0003-3527-9972; zhang, xueji/0000-0002-0035-3821; Yu, Jun/0000-0001-5008-2153; Sung, Joseph J. Y./0000-0003-3125-5199; Li, Xiao-xing/0000-0001-8791-7505; Ng, Simon S. M./0000-0002-5389-9297; Hou, Jian/0000-0003-1590-4013; Chang, Zhijie/0000-0003-1567-3227	Postdoctoral Special Foundation [2012M510317]; National Natural Science Foundation of China [81301775]; Chinese Central Universities Funds [FRF-TP-12-172A]; 863 Program China [2012AA02A506]; 973 Program China [2013CB531401]; Technology and Innovation Project Fund Shenzhen [JSGG20130412171021059]	Postdoctoral Special Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Central Universities Funds; 863 Program China(National High Technology Research and Development Program of China); 973 Program China(National Basic Research Program of China); Technology and Innovation Project Fund Shenzhen	This project was supported by Postdoctoral Special Foundation (2012M510317), National Natural Science Foundation of China (81301775), the Chinese Central Universities Funds (FRF-TP-12-172A), National Natural Science Foundation of China (81301775), 863 Program China (2012AA02A506), 973 Program China (2013CB531401) and Technology and Innovation Project Fund Shenzhen (JSGG20130412171021059).	Angers S, 2006, NAT CELL BIOL, V8, P348, DOI 10.1038/ncb1381; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Brott BK, 2005, DIFFERENTIATION, V73, P323, DOI 10.1111/j.1432-0436.2005.00032.x; Cadigan K.M., 2012, COLD SPRING HARB PER, V4; Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5; Chiba T, 2012, GASTROENTEROLOGY, V143, P550, DOI 10.1053/j.gastro.2012.07.009; Choi SW, 2010, ADV NUTR, V1, P8, DOI 10.3945/an.110.1004; Gao C, 2010, CELL SIGNAL, V22, P717, DOI 10.1016/j.cellsig.2009.11.021; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Hsieh CJ, 1998, CANCER RES, V58, P3942; Ikenoue T, 2002, JPN J CANCER RES, V93, P1213, DOI 10.1111/j.1349-7006.2002.tb01226.x; Jia Y, 2013, J PATHOL, V230, P194, DOI 10.1002/path.4073; Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katsurano M, 2012, ONCOGENE, V31, P342, DOI 10.1038/onc.2011.241; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Kivimae S, 2011, BMC BIOCHEM, V12, DOI 10.1186/1471-2091-12-33; Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173; Liu YH, 2010, J AM SOC NEPHROL, V21, P212, DOI 10.1681/ASN.2008121226; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Metcalfe C, 2011, J CELL SCI, V124, P3537, DOI 10.1242/jcs.091991; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 2009, ADV EXP MED BIOL, V656, P13, DOI 10.1007/978-1-4419-1145-2_2; Parkin DM, 2005, CA CANC J CLIN, V55, P74; Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Suriben R, 2009, NAT GENET, V41, P977, DOI 10.1038/ng.435; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wang SY, 2013, GUT, V62, P833, DOI 10.1136/gutjnl-2011-301776; Wang SY, 2012, MOL MED, V18, P1402, DOI 10.2119/molmed.2012.00243; Waxman JS, 2004, DEVELOPMENT, V131, P5909, DOI 10.1242/dev.01520; Wei W, 2012, MOL CELL BIOL, V32, P3903, DOI 10.1128/MCB.00251-12; Yang J, 2006, J BIOL CHEM, V281, P17751, DOI 10.1074/jbc.M600831200; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Yu J, 2006, HEPATOLOGY, V43, P826, DOI 10.1002/hep.21108; Yu J, 2010, ONCOGENE, V29, P6464, DOI 10.1038/onc.2010.370; Yuan GH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034004; Zhang L, 2006, J BIOL CHEM, V281, P8607, DOI 10.1074/jbc.M600274200	39	39	43	0	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2575	2585		10.1038/onc.2014.201	http://dx.doi.org/10.1038/onc.2014.201			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25023701	Green Published, hybrid			2022-12-17	WOS:000354541300004
J	Shi, Z; Li, Z; Li, ZJ; Cheng, K; Du, Y; Fu, H; Khuri, FR				Shi, Z.; Li, Z.; Li, Z. J.; Cheng, K.; Du, Y.; Fu, H.; Khuri, F. R.			Cables1 controls p21/Cip1 protein stability by antagonizing proteasome subunit alpha type 3	ONCOGENE			English	Article							CHROMOSOME 18Q; MEDIATED DEGRADATION; DEPENDENT REGULATION; COLORECTAL-CANCER; UBIQUITIN LIGASE; OVARIAN-CANCER; S-PHASE; P21; GENE; PHOSPHORYLATION	The cyclin-dependent kinase (CDK) inhibitor 1A, p21/Cip1, is a vital cell cycle regulator, dysregulation of which has been associated with a large number of human malignancies. One critical mechanism that controls p21 function is through its degradation, which allows the activation of its associated cell cycle-promoting kinases, CDK2 and CDK4. Thus delineating how p21 is stabilized and degraded will enhance our understanding of cell growth control and offer a basis for potential therapeutic interventions. Here we report a novel regulatory mechanism that controls the dynamic status of p21 through its interaction with Cdk5 and Abl enzyme substrate 1 (Cables1). Cables1 has a proposed role as a tumor suppressor. We found that upregulation of Cables1 protein was correlated with increased half-life of p21 protein, which was attributed to Cables1/p21 complex formation and supported by their co-localization in the nucleus. Mechanistically, Cables1 interferes with the proteasome (Prosome, Macropain) subunit alpha type 3 (PSMA3) binding to p21 and protects p21 from PSMA3-mediated proteasomal degradation. Moreover, silencing of p21 partially reverses the ability of Cables1 to induce cell death and inhibit cell proliferation. In further support of a potential pathophysiological role of Cables1, the expression level of Cables1 is tightly associated with p21 in both cancer cell lines and human lung cancer patient tumor samples. Together, these results suggest Cables1 as a novel p21 regulator through maintaining p21 stability and support the model that the tumor-suppressive function of Cables1 occurs at least in part through enhancing the tumor-suppressive activity of p21.	[Shi, Z.] Jinan Univ, Coll Life Sci & Technol, Dept Cell Biol, Guangzhou, Guangdong, Peoples R China; [Shi, Z.] Jinan Univ, Coll Life Sci & Technol, Inst Biomed, Guangzhou, Guangdong, Peoples R China; [Shi, Z.; Li, Z.; Li, Z. J.; Cheng, K.; Du, Y.; Fu, H.] Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; [Li, Z. J.] Peking Univ, Hosp 3, Inst Vasc Med, Beijing, Peoples R China; [Cheng, K.] Lishui Inst Agr Sci, Chem Biol Ctr, Lishui, Peoples R China; [Du, Y.; Fu, H.; Khuri, F. R.] Emory Univ, Emory Chem Biol Discovery Ctr, Atlanta, GA 30322 USA; [Fu, H.; Khuri, F. R.] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA	Jinan University; Jinan University; Emory University; Peking University; Emory University; Emory University	Fu, H (corresponding author), Emory Univ, Dept Pharmacol, 5111 Rollins Res Ctr,1510 Clifton Rd, Atlanta, GA 30322 USA.	hfu@emory.edu	Khuri, Fadlo R./AAU-4942-2020	Khuri, Fadlo R./0000-0002-8638-7618; Cheng, Kejun/0000-0002-1936-9129	National Institutes of Health Grant [P01 CA116676]; Georgia Cancer Coalition; Chinese National Natural Science Foundation [31271444, 81201726]; Foundation for Research Cultivation and Innovation of Jinan University [21612407]; Science and Technology Program of Guangzhou [14200010]; Specialized Research Fund for the Doctoral Program of Higher Education [20124401120007]; NATIONAL CANCER INSTITUTE [P01CA116676] Funding Source: NIH RePORTER	National Institutes of Health Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Georgia Cancer Coalition; Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Foundation for Research Cultivation and Innovation of Jinan University; Science and Technology Program of Guangzhou; Specialized Research Fund for the Doctoral Program of Higher Education(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the past and present members of the Fu/Khuri laboratory for many stimulating discussions. We also thank Dr Zukerberg LR and Dr Rueda BR (Massachusetts General Hospital) for sharing reagents. This work was supported by the National Institutes of Health Grant P01 CA116676 (to FRK and HF), Georgia Cancer Coalition (to HF and FRK), the Chinese National Natural Science Foundation No. 31271444 and No. 81201726 (to ZS), the Foundation for Research Cultivation and Innovation of Jinan University No. 21612407 (to ZS), the Science and Technology Program of Guangzhou No. 14200010 (to ZS) and the Specialized Research Fund for the Doctoral Program of Higher Education No. 20124401120007 (to ZS).	Abbas T, 2008, GENE DEV, V22, P2496, DOI 10.1101/gad.1676108; Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Arnason T, 2013, CANCER BIOL THER, V14, P672, DOI 10.4161/cbt.25089; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; Dong Q, 2003, MODERN PATHOL, V16, P863, DOI 10.1097/01.MP.0000084434.88269.0A; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Jin Y, 2008, MOL CELL BIOL, V28, P1218, DOI 10.1128/MCB.01198-07; Kirley SD, 2005, CANCER BIOL THER, V4, P654, DOI 10.4161/cbt.4.6.1732; Kirley SD, 2005, CANCER BIOL THER, V4, P861, DOI 10.4161/cbt.4.8.1894; Komiya T, 1997, CLIN CANCER RES, V3, P1831; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Lopez-Pajares V, 2008, J BIOL CHEM, V283, P13707, DOI 10.1074/jbc.M710030200; Nishitani H, 2008, J BIOL CHEM, V283, P29045, DOI 10.1074/jbc.M806045200; Park DY, 2007, AM J PATHOL, V171, P1509, DOI 10.2353/ajpath.2007.070331; Sakamoto H, 2008, CANCER BIOL THER, V7, P180, DOI 10.4161/cbt.7.2.5253; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Tan DF, 2003, HUM PATHOL, V34, P143, DOI 10.1053/hupa.2003.26; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Tsuji K, 2002, J BIOL CHEM, V277, P2951, DOI 10.1074/jbc.M108535200; Wang N, 2010, EMBO REP, V11, P633, DOI 10.1038/embor.2010.82; Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e; Wu CL, 2001, CANCER RES, V61, P7325; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhu HY, 2005, J BIOL CHEM, V280, P29282, DOI 10.1074/jbc.M407352200; Zirbes TK, 2000, INT J CANCER, V89, P14, DOI 10.1002/(SICI)1097-0215(20000120)89:1<14::AID-IJC3>3.0.CO;2-L; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3; Zukerberg LR, 2004, CANCER RES, V64, P202, DOI 10.1158/0008-5472.CAN-03-2833	31	39	39	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2538	2545		10.1038/onc.2014.171	http://dx.doi.org/10.1038/onc.2014.171			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24975575	Green Accepted			2022-12-17	WOS:000354190400012
J	Kumar, S; Torres, MP; Kaur, S; Rachagani, S; Joshi, S; Johansson, SL; Momi, N; Baine, MJ; Gilling, CE; Smith, LM; Wyatt, TA; Jain, M; Joshi, SS; Batra, SK				Kumar, S.; Torres, M. P.; Kaur, S.; Rachagani, S.; Joshi, S.; Johansson, S. L.; Momi, N.; Baine, M. J.; Gilling, C. E.; Smith, L. M.; Wyatt, T. A.; Jain, M.; Joshi, S. S.; Batra, S. K.			Smoking accelerates pancreatic cancer progression by promoting differentiation of MDSCs and inducing HB-EGF expression in macrophages	ONCOGENE			English	Article							TRANS-RETINOIC ACID; STELLATE CELL ACTIVATION; SUPPRESSOR-CELLS; CIGARETTE-SMOKE; MONOCYTE DIFFERENTIATION; IMMUNE-RESPONSE; MYELOID CELLS; GROWTH-FACTOR; MICE; ADENOCARCINOMA	Smoking is an established risk factor for pancreatic cancer (PC), but late diagnosis limits the evaluation of its mechanistic role in the progression of PC. We used a well-established genetically engineered mouse model (LSL-K-ras(G12D)) of PC to elucidate the role of smoking during initiation and development of pancreatic intraepithelial neoplasia (PanIN). The 10-week-old floxed mice (K-ras(G12D); Pdx-1cre) and their control unfloxed (LSL-K-ras(G12D)) littermates were exposed to cigarette smoke (total suspended particles: 150 mg/m(3)) for 20 weeks. Smoke exposure significantly accelerated the development of PanIN lesions in the floxed mice, which correlated with tenfold increase in the expression of cytokeratin19. The systemic accumulation of myeloid-derived suppressor cells (MDSCs) decreased significantly in floxed mice compared with unfloxed controls (P<0.01) after the smoke exposure with the concurrent increase in the macrophage (P<0.05) and dendritic cell (DCs) (P<0.01) population. Further, smoking-induced inflammation (IFN-gamma, CXCL2; P<0.05) was accompanied by enhanced activation of pancreatic stellate cells and elevated levels of serum retinoic acid-binding protein 4, indicating increased bioavailability of retinoic acid which contributes to differentiation of MDSCs to tumor-associated macrophages (TAMs) and DCs. TAMs predominantly contribute to the increased expression of heparin-binding epidermal growth factor-like growth factor (EGFR ligand) in pre-neoplastic lesions in smoke-exposed floxed mice that facilitate acinar-to-ductal metaplasia (ADM). Further, smoke exposure also resulted in partial suppression of the immune system early during PC progression. Overall, the present study provides a novel mechanism of smoking-induced increase in ADM in the presence of constitutively active K-ras mutation.	[Kumar, S.; Torres, M. P.; Kaur, S.; Rachagani, S.; Joshi, S.; Momi, N.; Baine, M. J.; Jain, M.; Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Torres, M. P.; Batra, S. K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Johansson, S. L.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Gilling, C. E.] Univ Nebraska, Dept Biol, Omaha, NE 68182 USA; [Smith, L. M.] Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE 68198 USA; [Wyatt, T. A.] Univ Nebraska Med Ctr, Div Pulm Crit Care Sleep & Allergy, Omaha, NE 68198 USA; [Jain, M.; Batra, S. K.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA; [Joshi, S. S.] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	sbatra@unmc.edu	Torres, Maria/GVU-3391-2022; Joshi, Sudhanshu/L-2284-2019	Joshi, Sudhanshu/0000-0003-4748-5001	National Institute of Health [R01CA78590, EDRN U01 CA111294, R01 CA133774, R01 CA131944, SPORE P50 CA127297, T32 CA009476, P20 GM103480, R21 CA156037, U54 TMEN CA163120]; NATIONAL CANCER INSTITUTE [U54CA163120, R01CA131944, R21CA156037, R01CA078590, T32CA009476, U01CA111294, P50CA127297, R01CA133774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103480] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Dr Patrick C Swanson, Creighton University, Omaha, for suggestions. We appreciate the UNMC Cell Analysis Facility for analysis and graduate students and technician Erik Moore from Dr Batra's lab for help in sample preparation. This work was supported in part by the grant from National Institute of Health (R01CA78590, EDRN U01 CA111294, R01 CA133774, R01 CA131944, SPORE P50 CA127297, T32 CA009476, P20 GM103480, R21 CA156037 and U54 TMEN CA163120).	Apte MV, 1998, GUT, V43, P128, DOI 10.1136/gut.43.1.128; Bachem MG, 1998, GASTROENTEROLOGY, V115, P421, DOI 10.1016/S0016-5085(98)70209-4; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Blackford A, 2009, CANCER RES, V69, P3681, DOI 10.1158/0008-5472.CAN-09-0015; Braat H, 2012, CANCER LETT, V318, P1, DOI 10.1016/j.canlet.2011.11.034; Bracci PM, 2012, MOL CARCINOGEN, V51, P53, DOI 10.1002/mc.20778; BREITMAN TR, 1981, BLOOD, V57, P1000; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Colby JK, 2008, NEOPLASIA, V10, P782, DOI 10.1593/neo.08330; Ding QR, 2007, J LEUKOCYTE BIOL, V81, P1568, DOI 10.1189/jlb.1106672; Duell EJ, 2002, JNCI-J NATL CANCER I, V94, P297, DOI 10.1093/jnci/94.4.297; Duell EJ, 2012, MOL CARCINOGEN, V51, P40, DOI 10.1002/mc.20786; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Elliott MK, 2006, EXP LUNG RES, V32, P99, DOI 10.1080/01902140600710546; Froeling FEM, 2011, GASTROENTEROLOGY, V141, P1486, DOI 10.1053/j.gastro.2011.06.047; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Habisch Hansjorg, 2010, Cancers (Basel), V2, P1661, DOI 10.3390/cancers2031661; Hengesbach LM, 2004, J NUTR, V134, P2653, DOI 10.1093/jn/134.10.2653; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Hutchison SK, 2008, DIABETES CARE, V31, P1427, DOI 10.2337/dc07-2265; Kroening PR, 2008, J IMMUNOL, V181, P1536, DOI 10.4049/jimmunol.181.2.1536; Kusmartsev S, 2003, CANCER RES, V63, P4441; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Malfertheiner P, 2006, AM J GASTROENTEROL, V101, P160, DOI 10.1111/j.1572-0241.2006.00402.x; Manicassamya S, 2009, SEMIN IMMUNOL, V21, P22, DOI 10.1016/j.smim.2008.07.007; Mathison A, 2010, PANCREATOLOGY, V10, P505, DOI [10.1159/000320540, 10.1016/S1424-3903(10)80035-3]; McCarroll JA, 2006, GUT, V55, P79, DOI 10.1136/gut.2005.064543; McCarroll JA, 2003, PANCREAS, V27, P150, DOI 10.1097/00006676-200308000-00008; Means AL, 2003, GASTROENTEROLOGY, V124, P1020, DOI 10.1053/gast.2003.50150; Mirza N, 2006, CANCER RES, V66, P9299, DOI 10.1158/0008-5472.CAN-06-1690; Mohty M, 2003, BRIT J HAEMATOL, V122, P829, DOI 10.1046/j.1365-2141.2003.04489.x; Momi N, 2013, ONCOGENE, V32, P1384, DOI 10.1038/onc.2012.163; Moniaux N, 2008, BRIT J CANCER, V98, P1540, DOI 10.1038/sj.bjc.6604329; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Nefedova Y, 2007, CANCER RES, V67, P11021, DOI 10.1158/0008-5472.CAN-07-2593; Nouri-Shirazi M, 2003, IMMUNOLOGY, V109, P365, DOI 10.1046/j.1365-2567.2003.01655.x; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Ray KC, 2014, ONCOGENE, V33, P823, DOI 10.1038/onc.2013.3; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Sopori M, 2002, NAT REV IMMUNOL, V2, P372, DOI 10.1038/nri803; Sopori ML, 1998, J NEUROIMMUNOL, V83, P148, DOI 10.1016/S0165-5728(97)00231-2; Toh B, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001162; van Geenen EJM, 2011, AM J GASTROENTEROL, V106, P1161, DOI 10.1038/ajg.2011.43; VANBOCKSTAELE DR, 1993, ANN HEMATOL, V66, P61, DOI 10.1007/BF01695885; Zeidel A, 2002, ACTA ANAESTH SCAND, V46, P959, DOI 10.1034/j.1399-6576.2002.460806.x; Zhang QL, 2012, LECT NOTES CONTR INF, V421, P7; Zhang SB, 1996, INT J IMMUNOPHARMACO, V18, P467, DOI 10.1016/S0192-0561(96)00054-9; Zhao F, 2009, IMMUNOLOGY, V128, P141, DOI 10.1111/j.1365-2567.2009.03105.x	53	39	40	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2052	2060		10.1038/onc.2014.154	http://dx.doi.org/10.1038/onc.2014.154			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909166	Green Accepted			2022-12-17	WOS:000353173400005
J	Xiao, F; Qiu, H; Cui, H; Ni, X; Li, J; Liao, W; Lu, L; Ding, K				Xiao, F.; Qiu, H.; Cui, H.; Ni, X.; Li, J.; Liao, W.; Lu, L.; Ding, K.			MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEIN; TUMOR ANGIOGENESIS; JUVENILE POLYPOSIS; COLORECTAL-CANCER; EXPRESSION; ID1; GENES; DICER; MICE; RNAS	The previous studies in this lab discovered that microRNA-885-3p (miR-885-3p) was regulated by a sulfated polysaccharide that bound to bone morphogenetic protein receptor, type IA (BMPR1A) to inhibit angiogenesis. However, its specific role and its mechanism of action in tumor cells have not been elucidated. We show that miR-885-3p markedly suppresses angiogenesis in vitro and in vivo. MiR-885-3p inhibits Smad1/5/8 phosphorylation and downregulates DNA-binding protein inhibitor ID-1 (Id1), a proangiogenic factor, by targeting BMPR1A, leading to impaired angiogenesis. Overexpression or silencing of BMPR1A affects angiogenesis in a Smad/Id1-dependent manner. We further show that miR-885-3p impairs the growth of HT-29 colon cancer cell xenografts in nude mice by suppressing angiogenesis through disruption of BMPR1A and Smad/Id1 signaling. These results support a novel role for miR-885-3p in tumor angiogenesis by targeting BMPR1A, which regulates a proangiogenic factor, and provide new evidence that targeting miRNAs might be an effective therapeutic strategy for improving colon cancer treatment.	[Xiao, F.; Qiu, H.; Cui, H.; Ni, X.; Li, J.; Liao, W.; Lu, L.; Ding, K.] Chinese Acad Sci, Shanghai Inst Mat Med, Glycochem & Glycobiol Lab, Shanghai 201203, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS	Ding, K (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Glycochem & Glycobiol Lab, 555 Chong Zhi Rd, Shanghai 201203, Peoples R China.	dingkan@simm.ac.cn	CUI, Hengxiang/AAO-1326-2021; Qiu, Hong/C-5888-2011; Liao, Wenfeng/GQP-7033-2022	Qiu, Hong/0000-0002-4088-7828; Ding, Kan/0000-0002-8140-9259	National Natural Science Foundation of China (NSFC) [81171914, 31230022]; New Drug Creation and Manufacturing Program [2012ZX09301001-003]; National Science Fund for Distinguished Young Scholars in China [81125025]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); New Drug Creation and Manufacturing Program; National Science Fund for Distinguished Young Scholars in China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars)	This work was supported by grants from the National Natural Science Foundation of China (NSFC) (81171914, 31230022), the New Drug Creation and Manufacturing Program (2012ZX09301001-003) and the National Science Fund for Distinguished Young Scholars in China (81125025).	Cha ST, 2010, CANCER RES, V70, P2675, DOI 10.1158/0008-5472.CAN-09-2448; Dong Y, 2011, BRIT J CANCER, V104, P893, DOI 10.1038/bjc.2011.57; El-Bizri N, 2008, CIRC RES, V102, P380, DOI 10.1161/CIRCRESAHA.107.161059; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Goulley J, 2007, CELL METAB, V5, P207, DOI 10.1016/j.cmet.2007.01.009; Guled M, 2009, GENE CHROMOSOME CANC, V48, P615, DOI 10.1002/gcc.20669; Huang YP, 2011, CELL CYCLE, V10, P3938, DOI 10.4161/cc.10.22.18107; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Mishina Y, 2004, J BIOL CHEM, V279, P27560, DOI 10.1074/jbc.M404222200; Miyazono Kohei, 2002, Sci STKE, V2002, ppe40, DOI 10.1126/stke.2002.151.pe40; Okamoto K, 2012, EMBO J, V31, P1752, DOI 10.1038/emboj.2012.25; Perk J, 2006, CANCER RES, V66, P10870, DOI 10.1158/0008-5472.CAN-06-2643; Qiu H, 2010, J BIOL CHEM, V285, P32638, DOI 10.1074/jbc.M110.105544; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Suarez Y, 2009, CIRC RES, V104, P442, DOI 10.1161/CIRCRESAHA.108.191270; Valdimarsdottir G, 2002, CIRCULATION, V106, P2263, DOI 10.1161/01.CIR.0000033830.36431.46; Van Hattem WA, 2008, GUT, V57, P623, DOI 10.1136/gut.2007.142927; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; Wu WKK, 2011, CARCINOGENESIS, V32, P247, DOI 10.1093/carcin/bgq243; Xiao F, 2013, GLYCOBIOLOGY, V23, P524, DOI 10.1093/glycob/cwt004; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Zhou XP, 2001, AM J HUM GENET, V69, P704, DOI 10.1086/323703	26	39	45	3	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1968	1978		10.1038/onc.2014.134	http://dx.doi.org/10.1038/onc.2014.134			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882581				2022-12-17	WOS:000352725600011
J	Hosoda, F; Arai, Y; Okada, N; Shimizu, H; Miyamoto, M; Kitagawa, N; Katai, H; Taniguchi, H; Yanagihara, K; Imoto, I; Inazawa, J; Ohki, M; Shibata, T				Hosoda, F.; Arai, Y.; Okada, N.; Shimizu, H.; Miyamoto, M.; Kitagawa, N.; Katai, H.; Taniguchi, H.; Yanagihara, K.; Imoto, I.; Inazawa, J.; Ohki, M.; Shibata, T.			Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer	ONCOGENE			English	Article							DNA COPY NUMBER; TUMOR-SUPPRESSOR; GENE-EXPRESSION; POTENTIAL TARGET; UP-REGULATION; IDENTIFICATION; METHYLGLYOXAL; AMPLIFICATION; PROTEIN; OVEREXPRESSION	Chromosomal abnormalities are good guideposts when hunting for cancer-related genes. We analyzed copy number alterations of 163 primary gastric cancers using array-based comparative genomic hybridization and simultaneously performed a genome-wide integrated analysis of copy number and gene expression using microarray data for 58 tumors. We showed that chromosome 6p21 amplification frequently occurred secondary to ERBB2 amplification, was associated with poorer prognosis and caused overexpression of half of the genes mapped. A comprehensive small interfering RNA knockdown of 58 genes overexpressed in tumors identified 32 genes that reduced gastric cancer cell growth. Enforced expression of 16 of these genes promoted cell growth in vitro, and six genes showing more than two-fold activity conferred tumor-forming ability in vivo. Among these six candidates, GLO1, encoding a detoxifying enzyme glyoxalase I (GLO1), exhibited the strongest tumor-forming activity. Coexpression of other genes with GLO1 enhanced growth-stimulating activity. A GLO1 inhibitor, S-p-bromobenzyl glutathione cyclopentyl diester, inhibited the growth of two-thirds of 24 gastric cancer cell lines examined. The efficacy was found to be associated with the mRNA expression ratio of GLO1 to GLO2, encoding glyoxalase II (GLO2), another constituent of the glyoxalase system. GLO1 downregulation affected cell growth through inactivating central carbon metabolism and reduced the transcriptional activities of nuclear factor kappa B and activator protein-1. Our study demonstrates that GLO1 is a novel metabolic oncogene of the 6p21 amplicon, which promotes tumor growth and aberrant transcriptional signals via regulating cellular metabolic activities for energy production and could be a potential therapeutic target in gastric cancer.	[Hosoda, F.; Arai, Y.; Okada, N.; Shimizu, H.; Miyamoto, M.; Kitagawa, N.; Ohki, M.; Shibata, T.] Natl Canc Ctr, Div Canc Genom, Tokyo 1040045, Japan; [Katai, H.] Natl Canc Ctr, Div Gastr Surg, Tokyo, Japan; [Taniguchi, H.] Natl Canc Ctr, Div Clin Lab, Tokyo, Japan; [Yanagihara, K.] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Translat Res, Chiba, Japan; [Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan; [Imoto, I.] Univ Tokushima, Dept Human Genet & Publ Hlth, Inst Hlth Biosci, Grad Sch, Tokushima 770, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Tokyo Medical & Dental University (TMDU); Tokushima University	Shibata, T (corresponding author), Natl Canc Ctr, Div Canc Genom, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tashibat@ncc.go.jp	Shibata, Tatsuhiro/ABA-8234-2020; Imoto, Issei/AAD-5799-2020; Shibata, Tatsuhiro/AAO-1278-2021		Ministry of Health, Labor and Welfare, Japan; New Energy and Industrial Technology Development Organization (NEDO), Japan; National Institute of Biomedical Innovation (NiBio), Japan; Foundation for Promotion of Cancer Research in Japan; Grants-in-Aid for Scientific Research [22134002, 26293304] Funding Source: KAKEN	Ministry of Health, Labor and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); New Energy and Industrial Technology Development Organization (NEDO), Japan(New Energy and Industrial Technology Development Organization (NEDO)); National Institute of Biomedical Innovation (NiBio), Japan(National Institute of Biomedical Innovation); Foundation for Promotion of Cancer Research in Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Setsuo Hirohashi for generous support and encouragement; Yukihiro Nakanishi for advice on histological classification of gastric tumors; Tokuki Sakiyama and Go Maeno for helping with the analysis of the aCGH data; Jun Yasuda for advice on the RNA interference techniques; Yu Nakamura, Michiyo Fukushima, Satomi Uryu and Yasuko Kuwabara for providing considerable contributions to the sample preparation of BAC DNA and patients' DNA and array hybridization; and Sayaka Kadoguchi and Kenjiro Kami for advice on metabolome analysis. This research was supported in part by a Grant-in-Aid for the Comprehensive 10-Year-Strategy for Cancer Control and from the Ministry of Health, Labor and Welfare, Japan, a grant from the New Energy and Industrial Technology Development Organization (NEDO), Japan and a grant from the National Institute of Biomedical Innovation (NiBio), Japan. MM and NK were recipients of a Research Resident Fellowship from the Foundation for Promotion of Cancer Research in Japan.	Aggarwal BB, 2009, CURR OPIN PHARMACOL, V9, P351, DOI 10.1016/j.coph.2009.06.020; Antognelli C, 2013, INT J BIOCHEM CELL B, V45, P836, DOI 10.1016/j.biocel.2013.01.003; Antognelli C, 2013, PROSTATE, V73, P121, DOI 10.1002/pros.22547; Bair WB, 2010, MELANOMA RES, V20, P85, DOI 10.1097/CMR.0b013e3283364903; Chen J, 2009, AM J PATHOL, V175, P400, DOI 10.2353/ajpath.2009.080972; Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742; de Hemptinne V, 2009, MOL CELL BIOCHEM, V325, P169, DOI 10.1007/s11010-009-0031-7; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Ghiorghi YK, 2007, J BIOL CHEM, V282, P8150, DOI 10.1074/jbc.M610648200; Gorringe KL, 2005, GENE CHROMOSOME CANC, V42, P247, DOI 10.1002/gcc.20136; Hansen F, 2012, METAB BRAIN DIS, V27, P531, DOI 10.1007/s11011-012-9329-3; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Kasugai Y, 2005, CLIN CANCER RES, V11, P8265, DOI 10.1158/1078-0432.CCR-05-1028; Kim DJ, 2010, P NATL ACAD SCI USA, V107, P21418, DOI 10.1073/pnas.1010153107; Kim SS, 2007, CANCER RES, V67, P9616, DOI 10.1158/0008-5472.CAN-07-0644; Kuiper RP, 2003, HUM MOL GENET, V12, P1661, DOI 10.1093/hmg/ddg178; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Lewis BC, 2000, CANCER RES, V60, P6178; Lochhead P, 2008, BRIT MED BULL, V85, P87, DOI 10.1093/bmb/ldn007; Lu XY, 2008, MOL CANCER RES, V6, P937, DOI 10.1158/1541-7786.MCR-07-2115; Maeda S, 2008, CANCER SCI, V99, P836, DOI 10.1111/j.1349-7006.2008.00763.x; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Myllykangas S, 2008, INT J CANCER, V123, P817, DOI 10.1002/ijc.23574; Nakamura Y, 2009, INT J CANCER, V125, P1859, DOI 10.1002/ijc.24538; Obama K, 2006, CLIN CANCER RES, V12, P70, DOI 10.1158/1078-0432.CCR-05-0588; ORAY B, 1982, METHOD ENZYMOL, V90, P542; RANGANATHAN S, 1995, BIOCHEM J, V309, P127, DOI 10.1042/bj3090127; Ranganathan S, 1999, GENE, V240, P149, DOI 10.1016/S0378-1119(99)00420-5; Sakamoto H, 2001, CLIN CANCER RES, V7, P2513; Santarius T, 2010, GENE CHROMOSOME CANC, V49, P711, DOI 10.1002/gcc.20784; Santos GC, 2007, J CLIN PATHOL, V60, P1, DOI 10.1136/jcp.2005.034389; Takada H, 2005, ONCOGENE, V24, P8051, DOI 10.1038/sj.onc.1208952; Tamura G, 2006, WORLD J GASTROENTERO, V12, P192, DOI 10.3748/wjg.v12.i2.192; Tanami H, 2005, LAB INVEST, V85, P1118, DOI 10.1038/labinvest.3700312; Thornalley Paul J., 2008, Drug Metabolism and Drug Interactions, V23, P125; THORNALLEY PJ, 1990, BIOCHEM J, V269, P1; Tsukamoto Y, 2008, J PATHOL, V216, P471, DOI 10.1002/path.2424; Varela-Rey M, 2009, HEPATOLOGY, V50, P443, DOI 10.1002/hep.23033; Vauhkonen H, 2006, CANCER GENET CYTOGEN, V167, P150, DOI 10.1016/j.cancergencyto.2005.11.014; Xue MZ, 2012, BIOCHEM J, V443, P213, DOI 10.1042/BJ20111648; Yagi T, 2003, BLOOD, V102, P1849, DOI 10.1182/blood-2003-02-0578; Yanagihara K, 2004, CANCER SCI, V95, P575, DOI 10.1111/j.1349-7006.2004.tb02489.x; Yang S, 2007, GENOMICS, V89, P451, DOI 10.1016/j.ygeno.2006.12.001	45	39	39	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1196	1206		10.1038/onc.2014.57	http://dx.doi.org/10.1038/onc.2014.57			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662817				2022-12-17	WOS:000350122100012
J	Serasinghe, MN; Missert, DJ; Asciolla, JJ; Podgrabinska, S; Wieder, SY; Izadmehr, S; Belbin, G; Skobe, M; Chipuk, JE				Serasinghe, M. N.; Missert, D. J.; Asciolla, J. J.; Podgrabinska, S.; Wieder, S. Y.; Izadmehr, S.; Belbin, G.; Skobe, M.; Chipuk, J. E.			Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAF(V600E) inhibition and can be targeted to reduce resistance	ONCOGENE			English	Article							BH3 DOMAINS; BRAF; FAMILY; BAX; DIMERIZATION; RESPONSES; SURVIVAL; PATHWAY; POTENT	In theory, pharmacological inhibition of oncogenic signaling is an effective strategy to halt cellular proliferation, induce apoptosis and eliminate cancer cells. In practice, drugs (for example, PLX-4032) that inhibit oncogenes like B-RAFV600E provide relatively short-term success in patients, owing to a combination of incomplete cellular responses and the development of resistance. To define the relationship between PLX-4032-induced responses and resistance, we interrogated the contributions of anti-apoptotic BCL-2 proteins in determining the fate of B-RAFV600E-inhibited melanoma cells. Although PLX-4032 eliminated B-RAFV600E signaling leading to marked cell cycle arrest, only a fraction of cells eventually underwent apoptosis. These data proposed two hypotheses regarding B-RAFV600E inhibition: (1) only a few cells generate a pro-apoptotic signal, or (2) all the cells generate a pro-apoptotic signal but the majority silences this pathway to ensure survival. Indeed, the latter hypothesis is supported by our observations as the addition of ABT-737, an inhibitor to anti-apoptotic BCL-2 proteins, revealed massive apoptosis following PLX-4032 exposure. B-RAFV600E inhibition alone sensitized cells to the mitochondrial pathway of apoptosis characterized by the rapid accumulation of BIM on the outer mitochondrial membrane, which could be functionally revealed by ABT-737 to promote apoptosis and loss of clonogenic survival. Furthermore, PLX-4032-resistant cells demonstrated collateral resistance to conventional chemotherapy, yet could be re-sensitized to PLX-4032 by BCL-2 family inhibition in vivo and conventional chemotherapies in vitro. Our data suggest that inhibiting anti-apoptotic BCL-2 proteins will enhance primary responses to PLX-4032, along with reducing the development of resistance to both targeted and conventional therapies.	[Serasinghe, M. N.; Missert, D. J.; Asciolla, J. J.; Podgrabinska, S.; Wieder, S. Y.; Belbin, G.; Skobe, M.; Chipuk, J. E.] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA; [Serasinghe, M. N.; Missert, D. J.; Asciolla, J. J.; Wieder, S. Y.; Chipuk, J. E.] Dept Dermatol, New York, NY USA; [Serasinghe, M. N.; Missert, D. J.; Asciolla, J. J.; Podgrabinska, S.; Wieder, S. Y.; Skobe, M.; Chipuk, J. E.] Tisch Canc Inst, New York, NY USA; [Missert, D. J.; Izadmehr, S.; Belbin, G.; Skobe, M.; Chipuk, J. E.] Grad Sch Biomed Sci, New York, NY USA; [Izadmehr, S.] Dept Genet & Genom Sci, New York, NY USA; [Chipuk, J. E.] Diabet Obes & Metab Inst, New York, NY USA	Icahn School of Medicine at Mount Sinai	Chipuk, JE (corresponding author), Icahn Sch Med Mt Sinai, Dept Oncol Sci, One Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.	jerry.chipuk@mssm.edu		Chipuk, Jerry Edward/0000-0002-1337-842X; Wieder, Shira/0000-0002-3151-3947	NIH [CA157740, KL2TR000069]; JJR Foundation; Breast Cancer Alliance; Fridolin Charitable Trust; March of Dimes Foundation [FY13-238]; Department of Oncological Sciences at Mount Sinai [PO1]; Albert Einstein College of Medicine; American Skin Association Medical Students Grant; William A. Spivak Fund; Chipuk Laboratory; NATIONAL CANCER INSTITUTE [R01CA157740] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000069] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); JJR Foundation; Breast Cancer Alliance; Fridolin Charitable Trust; March of Dimes Foundation(March of Dimes); Department of Oncological Sciences at Mount Sinai; Albert Einstein College of Medicine; American Skin Association Medical Students Grant; William A. Spivak Fund; Chipuk Laboratory; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank everyone in the Chipuk Laboratory for their assistance and support; Dr Stuart Aaronson, Dr Mark Lebwohl, Dr Emily Bernstein, Dr E Premkumar Reddy and Dr Poulikos Poulikakos for mentorship, guidance and/or discussion about the melanoma field; and Dr Suvendu Das, Eliana Sarrou, Rana Elkholi and Andrew Cruz for technical assistance. This work was supported by: NIH CA157740 (to JEC), NIH KL2TR000069 (to SI), the JJR Foundation (to JEC), the Breast Cancer Alliance (MS), the William A. Spivak Fund (to JEC), and the Fridolin Charitable Trust (to JEC). This work was also supported in part by a Research Grant FY13-238 from the March of Dimes Foundation (to JEC), a developmental PO1 grant from the Department of Oncological Sciences at Mount Sinai (to JEC), an Albert Einstein College of Medicine Research Fellowship (to SYW) and an American Skin Association Medical Students Grant (to SYW).	Anvekar RA, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.161; Anvekar RA, 2011, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00034; Asciolla JJ, 2012, JOVE-J VIS EXP, DOI 10.3791/4291; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Chipuk JE, 2008, P NATL ACAD SCI USA, V105, P20327, DOI 10.1073/pnas.0808036105; Cragg MS, 2008, J CLIN INVEST, V118, P3651, DOI 10.1172/JCI35437; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Letai AG, 2008, NAT REV CANCER, V8, P121, DOI 10.1038/nrc2297; Logue SE, 2009, NAT PROTOC, V4, P1383, DOI 10.1038/nprot.2009.143; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; McArthur GA, 2012, J CLIN ONCOL, V30, P1628, DOI 10.1200/JCO.2011.39.1938; Montagut C, 2009, CANCER LETT, V283, P125, DOI 10.1016/j.canlet.2009.01.022; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Whittaker S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000758; Young A, 2009, ADV CANCER RES, V102, P1, DOI 10.1016/S0065-230X(09)02001-6	30	39	39	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					857	867		10.1038/onc.2014.21	http://dx.doi.org/10.1038/onc.2014.21			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24608435	Green Accepted			2022-12-17	WOS:000349472000006
J	Stampolidis, P; Ullrich, A; Lacobelli, S				Stampolidis, P.; Ullrich, A.; lacobelli, S.			LGALS3BP, lectin galactoside-binding soluble 3 binding protein, promotes oncogenic cellular events impeded by antibody intervention	ONCOGENE			English	Article						LGALS3BP; cancer biomarker; extracellular matrix; integrin signalling; therapeutic target	TUMOR-ASSOCIATED ANTIGEN; EXTRACELLULAR-MATRIX; MAC-2-BINDING PROTEIN; LUNG-CARCINOMA; CANCER; 90K; ACTIVATION; EXPRESSION; INTEGRINS; MARKER	The extracellular matrix protein lectin galactoside-binding soluble 3 binding protein (LGALS3BP) constitutes a negative prognostic marker of cancer onset and progression with increasing value in clinical application. Since its discovery, however, although the glycoprotein has been implicated in a growing number of disease-related processes, its actual role and mechanism of action have remained ambiguous, thus hindering opportunities for therapeutic development. In this study, we have determined that LGALS3BP constitutes a novel ligand for integrins alpha(5)beta(1), alpha(v)beta(1) and alpha(6)beta(1) and have identified that these newly established partnerships at the membrane level are responsible for exerting the molecule's involvement in cancer through manipulation of multiple canonical 'outside-in' integrin signalling events. We demonstrate that LGALS3BP-mediated integrin activation results into signal transmission via Akt, JNK and the Ras cascade via the Raf-ERK axis while p38 activity is kept at baseline levels. Transient cellular adherence to LGALS3BP favours survival and proliferation signalling while apoptosis is kept at bay. Sustained cellular exposure to LGALS3BP significantly supports viability, motility and migration. Importantly, an anti-LGALS3BP antibody, SP2 is capable of impeding these newly defined LGALS3BP-driven processes without, however, compromising cell viability. These novel findings reveal the mechanism of action of LGALS3BP during cellular adherence and warrant its further validation as a potential pharmacological target for anticancer therapies.	[Stampolidis, P.; Ullrich, A.] Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany; [lacobelli, S.] MediaPharma Srl, Chieti, Italy	Max Planck Society	Stampolidis, P (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, Am Klopferspitz 18, D-82152 Bavaria, Germany.	stampoli@biochem.mpg.de						Awasthi N, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-12; Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441-009-0834-6; Block AS, 2011, PROSTATE, V71, P711, DOI 10.1002/pros.21287; Bode AM, 2007, MOL CARCINOGEN, V46, P591, DOI 10.1002/mc.20348; CARLIN CR, 1983, EXP CELL RES, V147, P359, DOI 10.1016/0014-4827(83)90218-5; Cesinaro AM, 2002, J INVEST DERMATOL, V119, P187, DOI 10.1046/j.1523-1747.2002.17642.x; Dreskin SC, 2001, J IMMUNOL, V166, P5646, DOI 10.4049/jimmunol.166.9.5646; Eisenach PA, 2010, J CELL SCI, V123, P4182, DOI 10.1242/jcs.062711; Faccio R, 2002, J CELL SCI, V115, P2919; Fomarini B, 2000, BLOOD, V96, P3282, DOI 10.1182/blood.V96.9.3282.h8003282_3282_3285; Martinez VG, 2011, PHARMACOL REV, V63, P967, DOI 10.1124/pr.111.004523; Geiger B, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005033; Goodman SL, 2012, TRENDS PHARMACOL SCI, V33, P405, DOI 10.1016/j.tips.2012.04.002; Grassadonia A, 2002, GLYCOCONJUGATE J, V19, P551, DOI 10.1023/B:GLYC.0000014085.00706.d4; Han SW, 2006, CANCER RES, V66, P315, DOI 10.1158/0008-5472.CAN-05-2367; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Huxley-Jones J, 2008, DRUG DISCOV TODAY, V13, P685, DOI 10.1016/j.drudis.2008.05.005; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; IACOBELLI S, 1994, BRIT J CANCER, V69, P172, DOI 10.1038/bjc.1994.29; Jarvelainen H, 2009, PHARMACOL REV, V61, P198, DOI 10.1124/pr.109.001289; Kashyap MK, 2010, CANCER BIOL THER, V10, P796, DOI 10.4161/cbt.10.8.12914; Koopmann J, 2004, CANCER-AM CANCER SOC, V101, P1609, DOI 10.1002/cncr.20469; Lacovazzi PA, 2001, CLIN CHEM LAB MED, V39, P961; Lee YJ, 2007, CLIN EXP RHEUMATOL, V25, pS41; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Lu XJ, 2008, PERSPECT MED CHEM, V2, P57; Marchetti A, 2002, CANCER RES, V62, P2535; Mbeunkui F, 2009, CANCER CHEMOTH PHARM, V63, P571, DOI 10.1007/s00280-008-0881-9; Mould A. P., 2011, CURRENT PROTOCOLS CE; Mould A. Paul, 2009, V522, P195, DOI 10.1007/978-1-59745-413-1_13; NATOLI C, 1993, J ACQ IMMUN DEF SYND, V6, P370; Niland S, 2012, J ONCOL, V2012, DOI 10.1155/2012/125278; Ohshima S, 2003, ARTHRITIS RHEUM-US, V48, P2788, DOI 10.1002/art.11287; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Ozaki Y, 2002, CANCER, V95, P1954, DOI 10.1002/cncr.10899; Park YP, 2007, INT J CANCER, V120, P813, DOI 10.1002/ijc.22369; Pelliccia P, 1999, J CLIN IMMUNOL, V19, P143, DOI 10.1023/A:1020562702083; Piccolo E, 2013, J MOL MED, V91, P83, DOI 10.1007/s00109-012-0936-6; Ruegg C, 2003, CELL MOL LIFE SCI, V60, P1135, DOI 10.1007/s00018-003-2297-3; Sardana G, 2007, CLIN CHEM, V53, P429, DOI 10.1373/clinchem.2006.077370; Sasaki T, 1998, EMBO J, V17, P1606, DOI 10.1093/emboj/17.6.1606; SCAMBIA G, 1988, ANTICANCER RES, V8, P761; Snider JL, 2008, J BIOL CHEM, V283, P13952, DOI 10.1074/jbc.M800289200; Srirajaskanthan R, 2010, MOL CELL PROTEOMICS, V9, P656, DOI 10.1074/mcp.M900401-MCP200; ULLRICH A, 1994, J BIOL CHEM, V269, P18401; Ulmer TA, 2006, J CELL BIOCHEM, V98, P1351, DOI 10.1002/jcb.20784; Van Slambrouck S, 2009, INT J ONCOL, V34, P1717, DOI 10.3892/ijo_00000302; Xue H, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-52; Zhang Dong-Sheng, 2003, Ai Zheng, V22, P870; Zhang H, 2004, CANCER SCI, V95, P878, DOI 10.1111/j.1349-7006.2004.tb02197.x	51	39	42	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					39	52		10.1038/onc.2013.548	http://dx.doi.org/10.1038/onc.2013.548			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24362527				2022-12-17	WOS:000349740100004
J	Newbold, A; Salmon, JM; Martin, BP; Stanley, K; Johnstone, RW				Newbold, A.; Salmon, J. M.; Martin, B. P.; Stanley, K.; Johnstone, R. W.			The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the E mu-myc model of B-cell lymphoma	ONCOGENE			English	Article						histone deacetylase inhibitors; CDKN1A; tumor-suppressor protein; cell cycle arrest	HISTONE-DEACETYLASE INHIBITORS; THERAPEUTIC ACTIVITIES; CANCER CELLS; APOPTOSIS; GROWTH; GENE; DIFFERENTIATION; P21(CIP1/WAF1); VORINOSTAT; BUTYRATE	Following the establishment of histone deacetylases (HDACs) as promising therapeutic targets for the reversal of aberrant epigenetic states associated with cancer, the development of HDAC inhibitors (HDACi) and their underlying mechanisms of action has been a significant area of scientific interest. HDACi induce diverse biological responses including the inhibition of cell proliferation by blocking progression through the G1 or G2/M phases of the cell cycle. As a putative tumor-suppressor protein, p21(waf1)/(cip1) influences cell proliferation by inhibiting the activity of cyclin-cyclin-dependent kinase (CDK) complexes at the G1/S and G2/M cell cycle checkpoints. HDACi transcriptionally activate CDKN1A, and it has been proposed that induction of p21waf1/cip1 can determine if a cell undergoes apoptosis or cell cycle arrest following HDACi treatment. In the E mu-myc transgenic mouse model of B-cell lymphoma, knockout of cdkn1a had no effect on disease latency, indicating that p21waf1/cip1 did not function as a tumor suppressor in this system. Although HDACi robustly induced expression of p21waf1/cip1 in wild-type Em-myc lymphomas, deletion of cdkn1a did not sensitize the lymphoma cells to HDACi-induced apoptosis and HDACi-induced cell cycle arrest still occurred. However, knockdown of cdkn1b in cdkn1a knockout lymphomas resulted in defective vorinostat-mediated arrest at G1/S indicating an essential role of p27(Kip1) in mediating this biological response to vorinostat. These data demonstrate that induction of cdkn1a does not regulate HDACi-mediated tumor cell apoptosis and refute the notion that p21(waf1)/(cip1) is an obligate mediator of HDACi-induced cell cycle arrest.	[Newbold, A.; Salmon, J. M.; Martin, B. P.; Stanley, K.; Johnstone, R. W.] Peter MacCallum Canc Ctr, Gene Regulat Lab, Canc Therapeut Program, East Melbourne, Vic 3002, Australia; [Johnstone, R. W.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne	Johnstone, RW (corresponding author), Peter MacCallum Canc Ctr, Gene Regulat Lab, Canc Therapeut Program, St Andrews Pl, East Melbourne, Vic 3002, Australia.	ricky.johnstone@petermac.org	Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237	NHMRC Program; Cancer Council Victoria; Leukemia Foundation of Australia; Victorian Cancer Agency; Victorian Breast Cancer Research Consortium	NHMRC Program(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Leukemia Foundation of Australia; Victorian Cancer Agency; Victorian Breast Cancer Research Consortium	RWJ is a Principal Research Fellow of the National Health and Medical Research Council of Australia (NHMRC) and supported by NHMRC Program and Project Grants, the Cancer Council Victoria, The Leukemia Foundation of Australia, the Victorian Cancer Agency and Victorian Breast Cancer Research Consortium.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Ellis L, 2009, BLOOD, V114, P380, DOI 10.1182/blood-2008-10-182758; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hitomi T, 2003, FEBS LETT, V554, P347, DOI 10.1016/S0014-5793(03)01186-4; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kramer OH, 2008, ONCOGENE, V27, P732, DOI 10.1038/sj.onc.1210677; Lindemann RK, 2007, P NATL ACAD SCI USA, V104, P8071, DOI 10.1073/pnas.0702294104; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Newbold A, 2013, MOL CANC TH IN PRESS; Newbold A, 2008, MOL CANCER THER, V7, P1066, DOI 10.1158/1535-7163.MCT-07-2256; Ocker M, 2007, INT J BIOCHEM CELL B, V39, P1367, DOI 10.1016/j.biocel.2007.03.001; Peart MJ, 2003, CANCER RES, V63, P4460; Pitts TM, 2009, MOL CANCER THER, V8, P342, DOI 10.1158/1535-7163.MCT-08-0534; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Rosato RR, 2004, MOL PHARMACOL, V65, P571, DOI 10.1124/mol.65.3.571; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Svechnikova I, 2007, BIOCHEM BIOPH RES CO, V354, P466, DOI 10.1016/j.bbrc.2006.12.222; Uehara N, 2012, ONCOL REP, V28, P105, DOI 10.3892/or.2012.1758	27	39	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5415	5423		10.1038/onc.2013.482	http://dx.doi.org/10.1038/onc.2013.482			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24292681				2022-12-17	WOS:000345120700003
J	Lai, CH; Park, KS; Lee, DH; Alberobello, AT; Raffeld, M; Pierobon, M; Pin, E; Petricoin, EF; Wang, Y; Giaccone, G				Lai, C-H; Park, K-S; Lee, D-H; Alberobello, A. T.; Raffeld, M.; Pierobon, M.; Pin, E.; Petricoin, E. F., III; Wang, Y.; Giaccone, G.			HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer	ONCOGENE			English	Article						doxorubicin; Ganetespib; hsp90 inhibitor; rip1; SCLC	KAPPA-B ACTIVATION; POTENT ANTITUMOR-ACTIVITY; HSP90 INHIBITOR; SIGNALING PATHWAYS; PROTEIN; APOPTOSIS; CYCLOPHOSPHAMIDE; VINCRISTINE; DEATH; CISPLATIN	Small cell lung cancer (SCLC) at advanced stage is considered an incurable disease. Despite good response to initial chemotherapy, the responses in SCLC patients with metastatic disease are of short duration and resistance inevitably occurs. Although several target-specific drugs have altered the paradigm of treatment for many other cancers, we have yet to witness a revolution of the same magnitude in SCLC treatment. Anthracyclines, such as doxorubicin, have definite activity in this disease, and ganetespib has shown promising activity in preclinical models but underwhelming activity as a single agent in SCLC patients. Using SCLC cell lines, we demonstrated that ganetespib (IC50: 31 nM) was much more potent than 17-allylamino-17-demethoxygeldanamycin (17-AAG), a geldanamycin derivative (IC50: 16 mu M). Ganetespib inhibited SCLC cell growth via induction of persistent G2/M arrest and Caspase 3-dependent cell death. MTS assay revealed that ganetespib synergized with both doxorubicin and etoposide, two topoisomerase II inhibitors commonly used in SCLC chemotherapy. Expression of receptor-interacting serine/threonine-protein kinase 1 (RIP1), a protein that may function as a pro-survival scaffold protein or a pro-death kinase in TNFR1-activated cells, was induced by doxorubicin and downregulated by ganetespib. Depletion of RIP1 by either RIP1 small interfering RNA (siRNA) or ganetespib sensitized doxorubicin-induced cell death, suggesting that RIP1 may promote survival in doxorubicin-treated cells and that ganetespib may synergize with doxorubicin in part through the downregulation of RIP1. In comparison to ganetespib or doxorubicin alone, the ganetespib + doxorubicin combination caused significantly more growth regression and death of human SCLC xenografts in immunocompromised mice. We conclude that ganetespib and doxorubicin combination exhibits significant synergy and is efficacious in inhibiting SCLC growth in vitro and in mouse xenograft models. Our preclinical study suggests that ganetespib and doxorubicin combination therapy may be an effective strategy for SCLC treatment, which warrants clinical testing.	[Lai, C-H; Park, K-S; Lee, D-H; Alberobello, A. T.; Wang, Y.; Giaccone, G.] NCI, Med Oncol Branch, NIH, Bethesda, MD USA; [Raffeld, M.] NCI, Pathol Lab, NIH, Bethesda, MD USA; [Pierobon, M.; Pin, E.; Petricoin, E. F., III] George Masson Univ, Ctr Appl Prote & Mol Med, Manassas, VI USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, Y (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, 3970 Reservoir Rd NW,W503 Res Bldg, Washington, DC 20007 USA.	yw350@georgetown.edu; gg496@georgetown.edu	Giaccone, Giuseppe/E-8297-2017; Pierobon, Mariaelena/GXA-0544-2022	Giaccone, Giuseppe/0000-0002-5023-7562; PIN, ELISA/0000-0002-2158-2674	National Cancer Institute; NATIONAL CANCER INSTITUTE [P30CA051008, Z01BC010854, ZICBC011079] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Leonard M Neckers for stimulating discussion during the course of the study and Dr Weiwen Ying (Synta Pharmaceuticals) for his valuable comments on the manuscript and for providing ganetespib for the study. This research was funded by the National Cancer Institute Intramural Program.	Banerji U, 2003, CURR CANCER DRUG TAR, V3, P385, DOI 10.2174/1568009033481813; Bansal H, 2010, BLOOD, V116, P4591, DOI 10.1182/blood-2009-10-247239; Bian X, 2001, J BIOL CHEM, V276, P48921, DOI 10.1074/jbc.M108674200; Blagosklonny MV, 2001, LEUKEMIA, V15, P1537, DOI 10.1038/sj.leu.2402257; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Califano R, 2012, DRUGS, V72, P471, DOI 10.2165/11597640-000000000-00000; Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31; Chandele A, 2004, NEOPLASIA, V6, P29, DOI 10.1016/S1476-5586(04)80051-4; Choi HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024312; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; COOK RM, 1993, CURR PROB CANCER, V17, P71; Davenport EL, 2007, BLOOD, V110, P2641, DOI 10.1182/blood-2006-11-053728; Declercq W, 2009, CELL, V138, P229, DOI 10.1016/j.cell.2009.07.006; Demidenko ZN, 2006, CELL DEATH DIFFER, V13, P1434, DOI 10.1038/sj.cdd.4401812; Ettinger DS, 2010, J CLIN ONCOL, V28, P2598, DOI 10.1200/JCO.2009.26.7682; FUKUOKA M, 1991, J NATL CANCER I, V83, P855, DOI 10.1093/jnci/83.12.855; Gangadharan C, 2009, J CELL BIOCHEM, V107, P203, DOI 10.1002/jcb.22115; Jackman DM, 2005, LANCET, V366, P1385, DOI 10.1016/S0140-6736(05)67569-1; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kim YS, 2009, CURR TOP MED CHEM, V9, P1479, DOI 10.2174/156802609789895728; Kotani Y, 2012, J CLIN ONCOL M ABS S, V30, P7003; Lally BE, 2007, ONCOLOGIST, V12, P1096, DOI 10.1634/theoncologist.12-9-1096; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105; Nishizuka S, 2003, P NATL ACAD SCI USA, V100, P14229, DOI 10.1073/pnas.2331323100; Park Kang-Seo, 2011, Front Biosci (Elite Ed), V3, P341, DOI 10.2741/e249; Pelayo Alvarez M, 2009, COCHRANE DB SYST REV, V7, DOI DOI 10.1002/SYSTREV14651858.CD001990.PUB2; Pierobon M, 2012, METHODS MOL BIOL, V823, P215, DOI 10.1007/978-1-60327-216-2_14; Powers MV, 2006, ENDOCR-RELAT CANCER, V13, pS125, DOI 10.1677/erc.1.01324; Proia DA, 2012, INVEST NEW DRUG, V30, P2201, DOI 10.1007/s10637-011-9790-6; Proia DA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018552; Robles AI, 2006, CLIN CANCER RES, V12, P6547, DOI 10.1158/1078-0432.CCR-06-1178; Rodina A, 2007, NAT CHEM BIOL, V3, P498, DOI 10.1038/nchembio.2007.10; ROTH BJ, 1992, J CLIN ONCOL, V10, P282, DOI 10.1200/JCO.1992.10.2.282; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Schmittel A, 2011, EXPERT REV ANTICANC, V11, P631, DOI [10.1586/ERA.11.7, 10.1586/era.11.7]; Sculier JP, 1990, LUNG CANCER, V6, P110; Sheehan KM, 2008, ONCOGENE, V27, P323, DOI 10.1038/sj.onc.1210647; SHEPHERD FA, 1987, CANCER TREAT REP, V71, P941; Shibakura M, 2003, INT J CANCER, V103, P380, DOI 10.1002/ijc.10842; Shimamura T, 2012, CLIN CANCER RES, V18, P4973, DOI 10.1158/1078-0432.CCR-11-2967; Singhal SS, 2006, FEBS LETT, V580, P2258, DOI 10.1016/j.febslet.2006.03.038; Sos ML, 2012, P NATL ACAD SCI USA, V109, P17034, DOI 10.1073/pnas.1207310109; Srethapakdi M, 2000, CANCER RES, V60, P3940; Sugimoto K, 2008, ONCOGENE, V27, P3091, DOI 10.1038/sj.onc.1210978; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; von Pawel J, 1999, J CLIN ONCOL, V17, P658, DOI 10.1200/JCO.1999.17.2.658; Wang YS, 2010, CURR OPIN INVEST DR, V11, P1466; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Xu WP, 2007, CLIN CANCER RES, V13, P1625, DOI 10.1158/1078-0432.CCR-06-2966; Ying WW, 2012, MOL CANCER THER, V11, P475, DOI 10.1158/1535-7163.MCT-11-0755; Zhang HB, 2011, NATURE, V471, P373, DOI 10.1038/nature09878	53	39	42	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4867	4876		10.1038/onc.2013.439	http://dx.doi.org/10.1038/onc.2013.439			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24166505	Green Accepted			2022-12-17	WOS:000343240100008
J	Cagnet, S; Faraldo, MM; Kreft, M; Sonnenberg, A; Raymond, K; Glukhova, MA				Cagnet, S.; Faraldo, M. M.; Kreft, M.; Sonnenberg, A.; Raymond, K.; Glukhova, M. A.			Signaling events mediated by alpha 3 beta 1 integrin are essential for mammary tumorigenesis	ONCOGENE			English	Article						integrin signaling; basal-like breast cancer; mouse models of breast cancer; Wnt/beta-catenin pathway; survival; proliferation	FOCAL ADHESION KINASE; BREAST-CANCER CELLS; GENE-EXPRESSION; EPITHELIAL-CELLS; PATHWAY ACTIVATION; BASAL; SURVIVAL; DIFFERENTIATION; LOCALIZATION; PROGENITORS	The constitutive activation of beta-catenin signaling in the mammary basal epithelial cell layer in transgenic K5 Delta N beta cat mice leads to basal-type tumor development. Integrins of the beta 1 family and integrin-mediated signaling events have an important role in breast tumor growth and progression. We show here that the deletion of alpha 3 beta 1 integrin, a major laminin receptor, from the basal layer of the mammary epithelium of K5 Delta N beta cat mice completely prevented the tumorigenesis induced by beta-catenin signaling. Moreover, the depletion of alpha 3 beta 1 integrin from a spontaneously transformed mouse mammary basal epithelial cell line (MEC) prevented the cells from forming colonies in soft agar and greatly reduced tumor development in orthotopic grafts. Inhibition of the integrin signaling intermediates Rac1 or PAK1 (P21-activated Kinase 1) in MEC affected tumor cell growth in soft agar, whereas the expression of activated forms of these effectors in alpha 3-depleted cells rescued the capacity of these cells to grow in non-adherent conditions. Similarly, the tumorigenic potential of alpha 3-depleted cells was restored by the expression of activated PAK1, as assessed by orthotopic transplantation assay. In three-dimensional Matrigel culture, MEC survival and proliferation were affected by the depletion of alpha 3 beta 1 integrin, which also significantly decreased the activation of focal adhesion kinase (FAK), mitogen-activated protein kinase (MAPK) and c-Jun NH2-terminal kinase (JNK). Our data suggest that the activation of signaling cascades downstream from alpha 3 beta 1 and involving the Rac1/PAK1 pathway, MAPK and JNK, promotes prosurvival and proproliferative signals required for the malignant growth of basal mammary epithelial cells, providing further insight into the molecular mechanisms underlying breast cancer initiation and progression.	[Cagnet, S.; Faraldo, M. M.; Raymond, K.; Glukhova, M. A.] Inst Curie, Ctr Rech, Paris, France; [Cagnet, S.; Faraldo, M. M.; Raymond, K.; Glukhova, M. A.] Inst Curie, CNRS, UMR144, Sect Rech, Paris, France; [Kreft, M.; Sonnenberg, A.] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; Netherlands Cancer Institute	Raymond, K (corresponding author), Univ Paris 06, St Antoine Res Ctr, INSERM U938, F-75005 Paris, France.	karine.raymond@inserm.fr; marina.glukhova@curie.fr	Martin-Faraldo, Maria-Luisa/M-5811-2018; Raymond, Karine/E-2693-2017	Raymond, Karine/0000-0001-5892-8117; Faraldo, Marisa/0000-0001-9497-1171	La Ligue Nationale Contre le Cancer; Agence Nationale de la Recherche [ANR-08-BLAN-0078-01]; Association pour la Recherche sur le Cancer	La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Agence Nationale de la Recherche(French National Research Agency (ANR)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	We are particularly grateful to Dr JL Jorcano for providing K5Cre transgenic mice. We thank Dr I Grandjean and S Jannet for excellent assistance with animal care, Z Maciorowski, A Viguier and S Grondin for excellent assistance with FACS analyses and M Denoyelle and A Di Cicco for technical help. We also thank the Nikon Imaging Centre at Institut Curie-CNRS for providing confocal microscopy facilities. This work was supported by La Ligue Nationale Contre le Cancer (Equipe Labelisee e 2009, 2013) and a grant from the Agence Nationale de la Recherche ANR-08-BLAN-0078-01 to MAG. SC received funding from Association pour la Recherche sur le Cancer; MAG is Directeur de Recherche and MMF and KR are Charge de Recherche at the Institut National de la Sante et de la Recherche Medicale (INSERM).	Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Bertucci F, 2012, CURR MOL MED, V12, P96, DOI 10.2174/156652412798376134; Bianchi-Smiraglia A, 2013, ONCOGENE, V32, P3049, DOI 10.1038/onc.2012.320; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Choma DP, 2007, J INVEST DERMATOL, V127, P31, DOI 10.1038/sj.jid.5700505; Choma DP, 2004, J CELL SCI, V117, P3947, DOI 10.1242/jcs.01251; Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; JONJIC N, 1993, PATHOL RES PRACT, V189, P979; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Lahlou H, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2905; Lambert Arthur W, 2012, ISRN Oncol, V2012, P493283, DOI 10.5402/2012/493283; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Manohar A, 2004, J CELL SCI, V117, P4043, DOI 10.1242/jcs.01277; Margadant C, 2009, J CELL SCI, V122, P278, DOI 10.1242/jcs.029108; Mitchell K, 2010, CANCER RES, V70, P6359, DOI 10.1158/0008-5472.CAN-09-4283; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3; Moumen M, MOL CANC; Moumen M, 2012, STEM CELLS, V30, P1246, DOI 10.1002/stem.1090; Novitskaya V, 2010, CANCER RES, V70, P4698, DOI 10.1158/0008-5472.CAN-09-4330; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; Prat A, 2012, NAT REV CLIN ONCOL, V9, P48, DOI 10.1038/nrclinonc.2011.178; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Raymond K, 2005, J CELL SCI, V118, P1045, DOI 10.1242/jcs.01689; Raymond K, 2012, SEMIN CELL DEV BIOL, V23, P599, DOI 10.1016/j.semcdb.2012.03.008; Raymond K, 2011, EMBO J, V30, P1896, DOI 10.1038/emboj.2011.113; Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0; Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005; Sachs N, 2006, J CELL BIOL, V175, P33, DOI 10.1083/jcb.200603073; Sachs N, 2012, P NATL ACAD SCI USA, V109, P21468, DOI 10.1073/pnas.1204614110; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Streuli CH, 2009, BIOCHEM J, V418, P491, DOI 10.1042/BJ20081948; Subbaram S, 2011, EXPERT OPIN THER TAR, V15, P1197, DOI 10.1517/14728222.2011.609557; Taddei I, 2003, J MAMMARY GLAND BIOL, V8, P383, DOI 10.1023/B:JOMG.0000017426.74915.b9; Taddei I, 2008, NAT CELL BIOL, V10, P716, DOI 10.1038/ncb1734; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; Yao ES, 2007, CANCER RES, V67, P659, DOI 10.1158/0008-5472.CAN-06-2768; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020	49	39	40	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4286	4295		10.1038/onc.2013.391	http://dx.doi.org/10.1038/onc.2013.391			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24077284				2022-12-17	WOS:000341156900002
J	Zhang, Z; Yang, M; Chen, R; Su, W; Li, P; Chen, S; Chen, Z; Chen, A; Li, S; Hu, C				Zhang, Z.; Yang, M.; Chen, R.; Su, W.; Li, P.; Chen, S.; Chen, Z.; Chen, A.; Li, S.; Hu, C.			IBP regulates epithelial-to-mesenchymal transition and the motility of breast cancer cells via Rac1, RhoA and Cdc42 signaling pathways	ONCOGENE			English	Article						IBP; EMT; breast cancer; migration; invasion	PROTEIN; EMT; EXPRESSION; GTPASES; DEF6; PROLIFERATION; CYTOSKELETON; ACTIVATOR; SYSTEM; GENE	Epithelial-to-mesenchymal transition (EMT) is a crucial process for the invasion and metastasis of epithelial tumors. However, the molecular mechanisms underlying this transition are poorly understood. In this study, we demonstrate that interferon regulatory factor 4 binding protein (IBP) regulates EMT and the motility of breast cancer cells through Rac1, RhoA and Cdc42 signaling pathways. We found that increased expression of IBP was associated with the progression of breast cancer and that IBP protein levels were significantly elevated in matched distant metastases. High IBP levels also predict shorter overall survival of breast cancer patients. Furthermore, the forced expression of IBP decreased the expression of the epithelial marker E-cadherin but increased the mesenchymal markers in breast cancer cells. In contrast, silencing IBP in metastatic breast tumor cells promoted a shift toward an epithelial morphology concomitant with increased expression of E-cadherin and decreased expression of mesenchymal markers. IBP silencing also reduced the expression of EMT-inducing transcription factors (Snail, Slug, ZEB1 and ZEB2). Moreover, we identified a role for IBP in endogenous EMT induced by epidermal growth factor (EGF) and deletion of IBP attenuated EGF receptor (EGFR) signaling in breast cancer cells. Furthermore, IBP regulates the migration, invasion and matrix metalloprotease production in breast cancer cells as well as actin cytoskeleton rearrangement and the activation of GTP-Rac1, GTP-RhoA and GTP-Cdc42. Taken together, our findings demonstrate an oncogenic property for IBP in promoting the metastatic potential of breast cancer cells.	[Zhang, Z.; Yang, M.; Li, P.; Chen, S.; Chen, Z.; Chen, A.; Li, S.; Hu, C.] Third Mil Med Univ, Southwest Hosp, Fac Med Lab Sci, Dept Clin Biochem, Chongqing 400038, Peoples R China; [Chen, R.] Third Mil Med Univ, Xinqiao Hosp, Dept Pathol, Chongqing 400038, Peoples R China; [Su, W.] Beibei Maternal & Child Hlth Hosp, Dept Lab Med, Chongqing, Peoples R China	Army Medical University; Army Medical University	Hu, C (corresponding author), Third Mil Med Univ, Southwest Hosp, Fac Med Lab Sci, Dept Clin Biochem, 30 Gaotanyan Ctr St, Chongqing 400038, Peoples R China.	chuminhu@163.com			National Natural Science Foundation of China [81201952, 81172538, 81072154]; SRF for ROCS, SEM	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); SRF for ROCS, SEM(Scientific Research Foundation for the Returned Overseas Chinese Scholars)	We thank Wei Sun and Liting Wang (Central Laboratories, TMMU, China) for their help with laser scanning confocal microscopy work. This project was supported by the National Natural Science Foundation of China (no. 81201952, 81172538 and 81072154) and SRF for ROCS, SEM.	ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; Barr S, 2008, CLIN EXP METASTAS, V25, P685, DOI 10.1007/s10585-007-9121-7; Becart S, 2008, IMMUNITY, V29, P704, DOI 10.1016/j.immuni.2008.08.015; Becart S, 2007, J CLIN INVEST, V117, P2164, DOI 10.1172/JCI31640; Bendris Nawal, 2012, Small GTPases, V3, P225, DOI 10.4161/sgtp.20791; Byles V, 2012, ONCOGENE, V31, P4619, DOI 10.1038/onc.2011.612; Canonigo-Balancio AJ, 2009, J IMMUNOL, V183, P7259, DOI 10.4049/jimmunol.0902573; Fanzo JC, 2006, J CLIN INVEST, V116, P703, DOI 10.1172/JCI24096; Gupta S, 2003, HUM IMMUNOL, V64, P389, DOI 10.1016/S0198-8859(03)00024-7; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hardy KM, 2010, J MAMMARY GLAND BIOL, V15, P191, DOI 10.1007/s10911-010-9172-2; Hey F, 2012, J BIOL CHEM, V287, P31073, DOI 10.1074/jbc.M112.346767; Hotfilder M, 1999, BRIT J HAEMATOL, V106, P335, DOI 10.1046/j.1365-2141.1999.01551.x; Hugo HJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-235; Jian CX, 2012, CANCER INVEST, V30, P748, DOI 10.3109/07357907.2012.734355; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Li P, 2009, INT IMMUNOPHARMACOL, V9, P1002, DOI 10.1016/j.intimp.2009.04.008; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Mavrakis KJ, 2004, EXP CELL RES, V294, P335, DOI 10.1016/j.yexcr.2003.12.004; Mimeault M, 2007, ANN ONCOL, V18, P1605, DOI 10.1093/annonc/mdm070; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Oka T, 2007, J BIOL CHEM, V282, P2011, DOI 10.1074/jbc.M605153200; Samson T, 2007, J BIOL CHEM, V282, P15730, DOI 10.1074/jbc.M611197200; Tanaka Y, 2003, IMMUNITY, V18, P403, DOI 10.1016/S1074-7613(03)00054-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Yang MZ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-54; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Zhang ZJ, 2009, CANCER EPIDEMIOL, V33, P130, DOI 10.1016/j.canep.2009.05.004	29	39	43	4	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3374	3382		10.1038/onc.2013.337	http://dx.doi.org/10.1038/onc.2013.337			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23975422	hybrid, Green Published			2022-12-17	WOS:000338779300004
J	Martineau, Y; Azar, R; Muller, D; Lasfargues, C; El Khawand, S; Anesia, R; Pelletier, J; Bousquet, C; Pyronnet, S				Martineau, Y.; Azar, R.; Mueller, D.; Lasfargues, C.; El Khawand, S.; Anesia, R.; Pelletier, J.; Bousquet, C.; Pyronnet, S.			Pancreatic tumours escape from translational control through 4E-BP1 loss	ONCOGENE			English	Article						4E-BP1; pancreatic cancer; translation initiation; eIF4E phosphorylation	4E-BINDING PROTEIN-1; INITIATION; CANCER; PHOSPHORYLATION; MNK1; INHIBITION; ACTIVATION; SURVIVAL; MICE	The mRNA cap-binding protein eIF4E (eukaryotic translation initiation factor 4E) permits ribosome recruitment to capped mRNAs, and its phosphorylated form has an important role in cell transformation. The oncogenic function of eIF4E is, however, antagonised by the hypophosphorylated forms of the inhibitory eIF4E-binding proteins 1 and 2. eIF4E-binding protein 1 and 2 (4E-BP1 and 2) are two major targets of the protein kinase mTOR, and are essential for the antiproliferative effects of mTOR inhibitors. Herein, we report that pancreas expresses specifically and massively 4E-BP1 (4E-BP2 is nearly undetectable). However, 4E-BP1 expression is extinguished in more than half of the human pancreatic ductal adenocarcinomas (PDAC). 4E-BP1 shutoff is recapitulated in a mouse genetic model of PDAC, which is based on a pancreas-specific mutation of Kras, the more frequently mutated oncogene in human pancreatic tumours. 4E-BP1 downregulation enhances eIF4E phosphorylation and facilitates pancreatic cancer cell proliferation in vitro and tumour development in vivo. Furthermore, 4E-BP1 loss combined with the absence of 4E-BP2 renders eIF4E phosphorylation, protein synthesis and cell proliferation resistant to mTOR inhibition. However, proliferation can be better limited by a recently developed compound that mimics the function of 4E-BP1 and 2 independently of mTOR inhibition.	[Martineau, Y.; Azar, R.; Mueller, D.; Lasfargues, C.; El Khawand, S.; Anesia, R.; Bousquet, C.; Pyronnet, S.] Univ Toulouse, CRCT, Equipe Labellise Ligue Contre Canc, F-31432 Toulouse, France; [Martineau, Y.; Azar, R.; Mueller, D.; Lasfargues, C.; El Khawand, S.; Anesia, R.; Bousquet, C.; Pyronnet, S.] Fac Med Toulouse, INSERM, UMR 1037, Lab Excellence Toulouse Canc, F-31073 Toulouse, France; [Azar, R.] Lebanese Univ, Fac Pharm, Dept Clin Pharm, Lebanon, NH USA; [Pelletier, J.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Pelletier, J.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada; [Pyronnet, S.] Univ Rangueil, Ctr Hospitalier, Pole Digestif, Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; McGill University; McGill University; CHU de Toulouse	Pyronnet, S (corresponding author), Univ Toulouse, CRCT, Equipe Labellise Ligue Contre Canc, BP 84225, F-31432 Toulouse, France.	stephane.pyronnet@inserm.fr	Martineau, Yvan/G-2387-2017; Pyronnet, Stéphane/P-2419-2014; Müller, David/G-2517-2017; Bousquet, Corinne/P-2917-2014; Müller, David/P-4964-2017	Martineau, Yvan/0000-0002-0575-4085; Bousquet, Corinne/0000-0002-2501-0593; 	INSERM-Universite Paul Sabatier; La LIGUE; Fondation de France; FRM; ARC; La Ligue Nationale Contre le Cancer; CFP; RITC foundation	INSERM-Universite Paul Sabatier; La LIGUE; Fondation de France(Fondation de France); FRM(Fondation pour la Recherche Medicale); ARC(Australian Research Council); La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); CFP; RITC foundation	This work was supported by grants from INSERM-Universite Paul Sabatier and from La LIGUE ('Comites de Hautes-Pyrenees et de Lot-et-Garonne' and 'Equipes Labellisees' programs) to SP. Yvan Martineau was a recipient of Fondation de France and FRM postdoctoral fellowships. Rania Azar, David Muller and Charline Lasfargues were recipients of doctoral fellowships from ARC, La Ligue Nationale Contre le Cancer and CFP, respectively. Rodica Anesia was supported by the RITC foundation. We thank Dr Marlene Dufresne, Dr Veronique Gigoux and Mr Pascal Clerc for their help in characterising Pdx1Cre-Kras<SUP>G12D</SUP> mice. We thank Professor Nahum Sonenberg for anti-eIF4GI antibody and Dr Philippe Pierre for the anti-puromycin antibody.	Adesso L, 2013, ONCOGENE, V32, P2848, DOI 10.1038/onc.2012.306; Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881; Averous J, 2008, ONCOGENE, V27, P1106, DOI 10.1038/sj.onc.1210715; Azar R, 2009, EMBO J, V28, P3514, DOI 10.1038/emboj.2009.291; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Bidinosti M, 2010, MOL CELL, V37, P797, DOI 10.1016/j.molcel.2010.02.022; Blagden SP, 2011, NAT REV CLIN ONCOL, V8, P280, DOI 10.1038/nrclinonc.2011.16; Bragado MJ, 2000, GASTROENTEROLOGY, V119, P1731, DOI 10.1053/gast.2000.20242; Cencic R, 2011, J VIROL, V85, P6381, DOI 10.1128/JVI.00078-11; Cencic R, 2011, P NATL ACAD SCI USA, V108, P1046, DOI 10.1073/pnas.1011477108; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Mamane Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000242; Martineau Y, 2013, ONCOGENE, V32, P671, DOI 10.1038/onc.2012.116; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; O'Reilly KE, 2009, CLIN CANCER RES, V15, P2872, DOI 10.1158/1078-0432.CCR-08-2336; Pin CL, 2001, J CELL BIOL, V155, P519, DOI 10.1083/jcb.200105060; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Rojo F, 2007, CLIN CANCER RES, V13, P81, DOI 10.1158/1078-0432.CCR-06-1560; Sans MD, 2006, J NUTR, V136, P1792, DOI 10.1093/jn/136.7.1792; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Tsukiyama-Kohara K, 2001, NAT MED, V7, P1128, DOI 10.1038/nm1001-1128; TsukiyamaKohara K, 1996, GENOMICS, V38, P353, DOI 10.1006/geno.1996.0638; Ueda T, 2010, P NATL ACAD SCI USA, V107, P13984, DOI 10.1073/pnas.1008136107; Wander SA, 2011, J CLIN INVEST, V121, P1231, DOI 10.1172/JCI44145; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Wolpin BM, 2009, J CLIN ONCOL, V27, P193, DOI 10.1200/JCO.2008.18.9514	32	39	39	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1367	1374		10.1038/onc.2013.100	http://dx.doi.org/10.1038/onc.2013.100			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23563181				2022-12-17	WOS:000332943500004
J	Zhou, C; Tong, Y; Wawrowsky, K; Melmed, S				Zhou, C.; Tong, Y.; Wawrowsky, K.; Melmed, S.			PTTG acts as a STAT3 target gene for colorectal cancer cell growth and motility	ONCOGENE			English	Article						STAT3; PTTG; transformation	TUMOR-TRANSFORMING GENE; SIGNAL TRANSDUCER; MATRIX METALLOPROTEINASE-2; CONSTITUTIVE ACTIVATION; EXPRESSION; SECURIN; TRANSCRIPTION-3; OVEREXPRESSION; INHIBITOR; IDENTIFICATION	Pituitary tumor-transforming gene (PTTG), the index mammalian securin, is abundantly expressed in several tumors and regulates tumor growth and progression. Molecular mechanisms elucidating PTTG regulation and actions remain elusive. Here, we provide evidence that PTTG acts as a signal transducer and activator of transcription factor 3 (STAT3) target gene. Total STAT3 and Tyr705 phosphorylated STAT3 were concordantly expressed with PTTG in human colorectal tumors (n = 97 and n = 95, respectively, P<0.001). STAT3 specifically bound the human PTTG promoter and induced PTTG transcriptional activity (twofold) as assessed by chromatin immunoprecipitation and luciferase reporter assays. STAT3 transfection increased PTTG mRNA and protein abundance twofold in HCT116 human colon cancer cells, and induction was further enhanced (threefold) by constitutively active STAT3 (STAT3-C), whereas strongly abrogated by dominant-negative STAT3 (STAT3-DN). Attenuating PTTG expression by siRNA in STAT3 HCT116 stable transfectants suppressed cell growth and colony formation in vitro, and PTTG cell knockout also constrained activated STAT3-induced explanted murine tumor growth in vivo. STAT3 increased HCT116 cell migration and invasion up to fivefold, whereas cell mobility was abolished by STAT3-DN (>85%). Impairing PTTG expression by siRNA also strongly suppressed STAT3-faciliated cell migration and invasion by up to 90%. Knocking out PTTG in STAT3-C HCT116 stable transfectants strongly decreased tumor metastases in nude mice, indicating the requirement of PTTG for STAT3-promoted metastasis. These results elucidate a mechanism for tumor cell PTTG regulation, whereby STAT3 induces PTTG expression to facilitate tumor growth and metastasis, and further support the rationale for targeting PTTG to abrogate colorectal cancer growth.	[Zhou, C.; Tong, Y.; Wawrowsky, K.; Melmed, S.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center	Melmed, S (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd,Room 2015, Los Angeles, CA 90048 USA.	melmed@csmc.edu			National Institutes of Health [CA75979]; Doris Factor Molecular Endocrinology Laboratory; NATIONAL CANCER INSTITUTE [R01CA075979, R00CA138914] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Doris Factor Molecular Endocrinology Laboratory; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Bert Vogelstein at Johns Hopkins University (Baltimore, MD, USA) for kindly providing HCT116 PTTG<SUP>+/+</SUP> and HCT116 PTTG<SUP>-/-</SUP> cells; and thank Patricia Lin at the Cedars-Sinai Flow Cytometry Core. This work was supported by National Institutes of Health Grant CA75979 (to SM) and the Doris Factor Molecular Endocrinology Laboratory.	Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Filippella M, 2006, CLIN ENDOCRINOL, V65, P536, DOI 10.1111/j.1365-2265.2006.02630.x; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Hamid T, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-3; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Horsch M, 2009, BRIT J CANCER, V100, P656, DOI 10.1038/sj.bjc.6604882; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Kim CS, 2007, CARCINOGENESIS, V28, P932, DOI 10.1093/carcin/bgl231; Lin L, 2009, ONCOGENE, V28, P961, DOI 10.1038/onc.2008.448; Malik MT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-61; Masuda M, 2002, CANCER RES, V62, P3351; Morikawa T, 2011, CLIN CANCER RES, V17, P1452, DOI 10.1158/1078-0432.CCR-10-2694; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Ogbagabriel S, 2005, MODERN PATHOL, V18, P985, DOI 10.1038/modpathol.3800382; Panguluri SK, 2008, J OVARIAN RES, V1, DOI 10.1186/1757-2215-1-6; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Romero F, 2004, MOL CELL BIOL, V24, P2720, DOI 10.1128/MCB.24.7.2720-2733.2004; Romero F, 2001, NUCLEIC ACIDS RES, V29, P1300, DOI 10.1093/nar/29.6.1300; Salehi F, 2008, ENDOCR-RELAT CANCER, V15, P721, DOI 10.1677/ERC-08-0012; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Silver DL, 2004, CANCER RES, V64, P3550, DOI 10.1158/0008-5472.CAN-03-3959; Song YH, 2008, MOL IMMUNOL, V45, P137, DOI 10.1016/j.molimm.2007.04.031; Tong Y, 2007, ONCOGENE, V26, P5596, DOI 10.1038/sj.onc.1210339; Tsareva SA, 2007, NEOPLASIA, V9, P279, DOI 10.1593/neo.06820; Vlotides G, 2007, ENDOCR REV, V28, P165, DOI 10.1210/er.2006-0042; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wicki A, 2010, SWISS MED WKLY, V140, P14, DOI 10.4414/smw.2010.13112; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383; Yan S, 2009, CANCER RES, V69, P3283, DOI 10.1158/0008-5472.CAN-08-0367; Yu R, 2003, ENDOCRINOLOGY, V144, P4991, DOI 10.1210/en.2003-0305; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zhou CQ, 2005, INT J CANCER, V113, P891, DOI 10.1002/ijc.20642; Zhou CQ, 2008, ENDOCR-RELAT CANCER, V15, P817, DOI 10.1677/ERC-08-0060; Zhou CQ, 2009, MOL ENDOCRINOL, V23, P2000, DOI 10.1210/me.2009-0161; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	46	39	39	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					851	861		10.1038/onc.2013.16	http://dx.doi.org/10.1038/onc.2013.16			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23416975	Green Accepted			2022-12-17	WOS:000331626900006
J	Zheng, Y; Gierut, J; Wang, Z; Miao, J; Asara, JM; Tyner, AL				Zheng, Y.; Gierut, J.; Wang, Z.; Miao, J.; Asara, J. M.; Tyner, A. L.			Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT	ONCOGENE			English	Article						BRK; Sik; PTK6; FAK; AKT; anoikis	BREAST-TUMOR KINASE; BRK; SURVIVAL; EXPRESSION; MIGRATION; GROWTH; PROLIFERATION; BRK/SIK; BINDING; FAK	Protein tyrosine kinase 6 (PTK6) is a non-receptor tyrosine kinase expressed in epithelial cancers. Disruption of Ptk6 decreases azoxymethane-induced colon tumorigenesis in mice by preventing signal transducer and activator of transcription 3 activation. Relocalization of PTK6 in prostate cancers contributes to increased growth. Although not expressed in normal breast or ovary, PTK6 promotes anchorage-independent survival of breast and ovarian tumor cells. We identified several potential PTK6 substrates in the human SW620 colon cancer cell line using mass spectrometry, including FAK (focal adhesion kinase). We show that FAK is a direct substrate of PTK6 in vitro and in vivo. Expression of membrane-targeted active PTK6 (Palm-PTK6-YF) induces constitutive activation of FAK and cell morphology changes, which are independent of SRC family kinases in Src-/-, Yes-/-, Fyn-/- (SYF) mouse embryonic fibroblasts (MEFs). Palm-PTK6-YF expressing SYF cells are transformed and overcome contact inhibition, form colonies in transformation assays, proliferate in suspension and form tumors in a xenograft model. Expression of FAK and Palm-PTK6-YF in Fak-/- MEFs synergistically activates AKT and protects cells against anoikis. However, expression of Palm-PTK6-YF in Akt1/2-/- MEFs fails to protect cells from anoikis, indicating AKT is critical in PTK6 and FAK-mediated survival signaling. In a conditional Pten knockout murine prostate cancer model, we identify prostate epithelial cells with enhanced activation of endogenous PTK6 and FAK at the plasma membrane. Knockdown of PTK6 in the PC3 human prostate cancer cell line disrupts FAK and AKT activation and promotes anoikis, which can be rescued by exogenous expression of FAK. Our data reveal important roles for a PTK6-FAK-AKT signaling axis in promoting anchorage-independent cell survival.	[Zheng, Y.; Gierut, J.; Wang, Z.; Miao, J.; Tyner, A. L.] Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; [Asara, J. M.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; [Asara, J. M.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Tyner, AL (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, M-C 669,900 South Ashland Ave, Chicago, IL 60607 USA.	atyner@uic.edu		Tyner, Angela/0000-0001-7448-8625	NIH [5R01DK044525, 5P01CA120964]; NIH DF/HCC Cancer Center Support Grant [5P30CA006516]; NATIONAL CANCER INSTITUTE [P30CA006516, P01CA120964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044525] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH DF/HCC Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH Grants 5R01DK044525 (ALT), 5P01CA120964 (JMA) and NIH DF/HCC Cancer Center Support Grant 5P30CA006516 (JMA). We thank Wenjun Bie and Min Yuan for technical assistance, Dr Nissim Hay (University of Illinois at Chicago, Chicago, IL, USA) for his gifts of Akt1/2-/- MEFs and PTEN<SUP>fl/fl</SUP>, Probasin-Cre and control mouse tissues, and Dr David D Schlaepfer (University of California, San Diego, CA, USA) for providing FAK expression constructs.	Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Bouchard V, 2007, J CELL PHYSIOL, V212, P717, DOI 10.1002/jcp.21096; Brauer PM, 2010, CELL CYCLE, V9, P4190, DOI 10.4161/cc.9.20.13518; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Castro NE, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2622; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Derry JJ, 2003, ONCOGENE, V22, P4212, DOI 10.1038/sj.onc.1206465; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gierut J, 2011, GASTROENTEROLOGY, V141, P1371, DOI 10.1053/j.gastro.2011.06.071; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Haegebarth A, 2004, J BIOL CHEM, V279, P54398, DOI 10.1074/jbc.M409579200; Irie HY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011729; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Li X, 2012, ONCOGENE, V31, P4372, DOI 10.1038/onc.2011.608; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lim ST, 2008, MOL CELL, V29, P9, DOI 10.1016/j.molcel.2007.11.031; Lin HS, 2004, ARCH OTOLARYNGOL, V130, P311, DOI 10.1001/archotol.130.3.311; Liu L, 2006, ONCOGENE, V25, P4904, DOI 10.1038/sj.onc.1209501; Llor X, 1999, CLIN CANCER RES, V5, P1767; Lofgren KA, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2946; Lukong KE, 2009, CELL SIGNAL, V21, P1415, DOI 10.1016/j.cellsig.2009.04.008; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Palka-Hamblin HL, 2010, J CELL SCI, V123, P236, DOI 10.1242/jcs.053264; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Rasband WS, 1997, IMAGE J; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Sakamoto S, 2010, MOL ASPECTS MED, V31, P205, DOI 10.1016/j.mam.2010.02.001; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Schmandt RE, 2006, CANCER BIOL THER, V5, P1136, DOI 10.4161/cbt.5.9.2953; Serfas MS, 2003, ONCOL RES, V13, P409; Shen CH, 2008, CANCER RES, V68, P7779, DOI 10.1158/0008-5472.CAN-08-0997; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Weaver AM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1794; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Xiang B, 2008, P NATL ACAD SCI USA, V105, P12463, DOI 10.1073/pnas.0805009105; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Zhang XB, 2011, BBA-MOL CELL RES, V1813, P1978, DOI 10.1016/j.bbamcr.2011.03.010; Zheng Y, 2012, J BIOL CHEM, V287, P148, DOI 10.1074/jbc.M111.298117; Zheng Y, 2010, MOL CELL BIOL, V30, P4280, DOI 10.1128/MCB.00024-10; Zouq NK, 2009, J CELL SCI, V122, P357, DOI 10.1242/jcs.030478	50	39	41	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4304	4312		10.1038/onc.2012.427	http://dx.doi.org/10.1038/onc.2012.427			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23027128	Green Submitted, Green Accepted			2022-12-17	WOS:000324168000012
J	Villacorte, M; Suzuki, K; Hirasawa, A; Ohkawa, Y; Suyama, M; Maruyama, T; Aoki, D; Ogino, Y; Miyagawa, S; Terabayashi, T; Tomooka, Y; Nakagata, N; Yamada, G				Villacorte, M.; Suzuki, K.; Hirasawa, A.; Ohkawa, Y.; Suyama, M.; Maruyama, T.; Aoki, D.; Ogino, Y.; Miyagawa, S.; Terabayashi, T.; Tomooka, Y.; Nakagata, N.; Yamada, G.			beta-Catenin signaling regulates Foxa2 expression during endometrial hyperplasia formation	ONCOGENE			English	Article						uterine gland; Wnt/beta-catenin; Foxa2; cyclin; endometrial hyperplasia	CONDITIONAL LOSS; GENE-EXPRESSION; ALPHA-CATENIN; CANCER; UTERUS; MICE; MORPHOGENESIS; CARCINOMA; CYTODIFFERENTIATION; DIFFERENTIATION	The Wnt/beta-catenin signaling is essential for various organogenesis and is often implicated during tumorigenesis. Dysregulated beta-catenin signaling is associated with the formation of endometrial adenocarcinomas (EACs), which is considered as the common form of endometrial cancer in women. In the current study, we investigate the downstream target of Wnt/beta-catenin signaling in the uterine epithelia and the mechanism leading to the formation of endometrial hyperplasia. We report that conditional ablation and activation of beta-catenin in the uterine epithelia lead to aberrant epithelial structures and endometrial hyperplasia formation, respectively. We demonstrate that beta-catenin regulates Foxa2 with its candidate upstream region for the uterine epithelia. Furthermore, knockdown of Foxa2 leads to defects in cell cycle regulation, suggesting a possible function of Foxa2 in the control of cell proliferation. We also observe that beta-catenin and Foxa2 expression levels are augmented in the human specimens of complex atypical endometrial hyperplasia, which is considered to have a greater risk of progression to EACs. Thus, our study indicates that beta-catenin regulates Foxa2 expression, and this interaction is possibly essential to control cell cycle progression during endometrial hyperplasia formation. Altogether, the augmented expression levels of beta-catenin and Foxa2 are essential features during the formation of endometrial hyperplasia.	[Villacorte, M.; Suzuki, K.; Yamada, G.] Wakayama Med Univ, Dept Dev Genet, Inst Adv Med, Wakayama, Kansai 6418509, Japan; [Villacorte, M.; Suzuki, K.; Terabayashi, T.; Yamada, G.] Kumamoto Univ, Global COE Cell Fate Regulat Res & Educ Unit, Kumamoto, Japan; [Villacorte, M.; Suzuki, K.; Yamada, G.] Kumamoto Univ, Dept Organ Format, IMEG, Kumamoto, Japan; [Hirasawa, A.; Maruyama, T.; Aoki, D.] Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo 160, Japan; [Ohkawa, Y.] Kyushu Univ, Fac Med, SSP Stem Cell Unit, Dept Epigenet,Inst Adv Study, Fukuoka 812, Japan; [Suyama, M.] Kyoto Univ, Dept Genome Informat, Ctr Genom Med, Grad Sch Med, Kyoto, Japan; [Ogino, Y.; Miyagawa, S.] Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi, Japan; [Tomooka, Y.] Tokyo Univ Sci, Dept Biol Sci & Technol, Chiba, Japan; [Tomooka, Y.] Tokyo Univ Sci, Tissue Engn Res Ctr, Chiba, Japan; [Nakagata, N.] Kumamoto Univ, CARD, Kumamoto, Japan	Wakayama Medical University; Kumamoto University; Kumamoto University; Keio University; Kyushu University; Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Tokyo University of Science; Tokyo University of Science; Kumamoto University	Yamada, G (corresponding author), Wakayama Med Univ, Dept Dev Genet, Inst Adv Med, 811-1 Kimiidera, Wakayama, Kansai 6418509, Japan.	gensan7@wakayama-med.ac.jp	Ohkawa, Yasuyuki/C-4087-2016; Tabelin, Mylah/AGG-4616-2022; Ohkawa, Yasuyuki/ABG-1839-2021; Aoki, Daisuke/E-6650-2014	Ohkawa, Yasuyuki/0000-0001-6440-9954; Tabelin, Mylah/0000-0002-6383-7049; Ohkawa, Yasuyuki/0000-0001-6440-9954; Terabayashi, Takeshi/0000-0001-7102-784X; Suyama, Mikita/0000-0001-9526-3193; Nakagata, Naomi/0000-0002-5737-9993	Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan [22132006]; National Institutes Health [R01ES016597-01A1]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016597] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [22132005, 23570085] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); National Institutes Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Drs R Behringer, H Sasaki, M M Taketo, W Birchmeier, A Santin, R Nishinakamura, Y Yoshimura, T Kurita, N Shiraki, K Maehara, H Nishida-Fukuda, K Yoshinaga, MA Suico, S Ohta, A Murashima, L Liu, A Omori, M Harada and D Matsumaru for their constructive criticisms We also thank E Chun, Y Sakamoto, Y Yamakawa, T Seki, M Aoki, S Usuki, M Matsumuto, M Etoh, S Fujikawa, Y Endo, S Miyaji and T Iba for technical help. This work was supported by Grant-in-Aid for Scientific Research on Innovative Areas: molecular mechanisms for the establishment of Sex Differences (22132006), Global Center of Excellence program 'Cell Fate Regulation Research and Education Unit' and Grant-in-Aid for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. This work was also supported by the National Institutes Health grant R01ES016597-01A1.	Armaiz-Pena GN, 2009, CLIN CANCER RES, V15, P2971, DOI 10.1158/1078-0432.CCR-08-2525; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERCHUCK A, 1995, CANCER, V76, P2034, DOI 10.1002/1097-0142(19951115)76:10+<2034::AID-CNCR2820761321>3.0.CO;2-U; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; CUNHA GR, 1976, INT REV CYTOL, V47, P137, DOI 10.1016/S0074-7696(08)60088-1; CUNHA GR, 1976, J EXP ZOOL, V196, P361, DOI 10.1002/jez.1401960310; Daikoku T, 2008, NAT MED, V14, P1192, DOI 10.1038/nm1108-1192; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Daikoku T, 2011, GYNECOL ONCOL, V122, P424, DOI 10.1016/j.ygyno.2011.04.022; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; Fujita PA, 2011, NUCLEIC ACIDS RES, V39, pD876, DOI 10.1093/nar/gkq963; Fyles A, 2008, GYNECOL ONCOL, V108, P395, DOI 10.1016/j.ygyno.2007.10.033; Giannini A, 2004, EXP CELL RES, V295, P150, DOI 10.1016/j.yexcr.2003.12.012; Grigoryan T, 2008, GENE DEV, V22, P2308, DOI 10.1101/gad.1686208; Guzzo F, 2012, INT J GYNECOL PATHOL, V31, P211, DOI 10.1097/PGP.0b013e31823bb24d; Hanazono R, 1997, IN VITRO CELL DEV-AN, V33, P668; Hayashi K, 2006, BIOL REPROD, V74, P721, DOI 10.1095/biolreprod.105.049718; Huang WW, 2005, MOL ENDOCRINOL, V19, P669, DOI 10.1210/me.2004-0155; Jeong JW, 2009, ONCOGENE, V28, P31, DOI 10.1038/onc.2008.363; Jeong JW, 2010, BIOL REPROD, V83, P396, DOI 10.1095/biolreprod.109.083154; Kaestner KH, 2010, CURR OPIN GENET DEV, V20, P527, DOI 10.1016/j.gde.2010.06.005; Kawano Y, 2006, ONCOGENE, V25, P6528, DOI 10.1038/sj.onc.1209661; Kobayashi A, 2003, NAT REV GENET, V4, P969, DOI 10.1038/nrg1225; Kurita T, 2001, DEV BIOL, V240, P194, DOI 10.1006/dbio.2001.0458; Matias-Guiu X, 2001, HUM PATHOL, V32, P569, DOI 10.1053/hupa.2001.25929; Mo B, 2006, BIOL REPROD, V75, P387, DOI 10.1095/biolreprod.106.051870; Nei H, 1999, MOL CARCINOGEN, V25, P207, DOI 10.1002/(SICI)1098-2744(199907)25:3<207::AID-MC7>3.3.CO;2-W; Ojalvo LS, 2010, J IMMUNOL, V184, P702, DOI 10.4049/jimmunol.0902360; Perantoni AO, 2003, SEMIN CELL DEV BIOL, V14, P201, DOI 10.1016/S1084-9521(03)00022-3; Rhodes DR, 2005, NAT GENET, V37, P579, DOI 10.1038/ng1578; Sasaki H, 1996, GENES CELLS, V1, P59, DOI 10.1046/j.1365-2443.1996.04004.x; Scholten AN, 2003, J PATHOL, V201, P460, DOI 10.1002/path.1402; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Silverberg SG, 1999, ARCH PATHOL LAB MED, V123, P1035; Suzuki K, 2009, DEVELOPMENT, V136, P367, DOI 10.1242/dev.021295; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Wang YY, 2009, CLIN CANCER RES, V15, P5784, DOI 10.1158/1078-0432.CCR-09-0814; Williamson EA, 2006, ONCOGENE, V25, P1391, DOI 10.1038/sj.onc.1209170; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yu X, 2011, ONCOGENE, V30, P1868, DOI 10.1038/onc.2010.560; Yue XA, 2010, BRAIN RES, V1366, P27, DOI 10.1016/j.brainres.2010.10.032; Zhu HN, 2004, CANCER RES, V64, P7918, DOI 10.1158/0008-5472.CAN-04-2704	42	39	40	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2013	32	29					3477	3482		10.1038/onc.2012.376	http://dx.doi.org/10.1038/onc.2012.376			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	22945641				2022-12-17	WOS:000322014900009
J	Nayak, BK; Feliers, D; Sudarshan, S; Friedrichs, WE; Day, RT; New, DD; Fitzgerald, JP; Eid, A; DeNapoli, T; Parekh, DJ; Gorin, Y; Block, K				Nayak, B. K.; Feliers, D.; Sudarshan, S.; Friedrichs, W. E.; Day, R. T.; New, D. D.; Fitzgerald, J. P.; Eid, A.; DeNapoli, T.; Parekh, D. J.; Gorin, Y.; Block, K.			Stabilization of HIF-2 alpha through redox regulation of mTORC2 activation and initiation of mRNA translation	ONCOGENE			English	Article						mTOR; Nox oxidase; Rictor; p22(phox); HIF-2 alpha; renal cancer	TUMOR-SUPPRESSOR PROTEIN; CANCER; PHOSPHORYLATION; EXPRESSION; CARCINOMA; COMPLEX; EIF4E; AKT; TRANSFORMATION; CONTRIBUTES	Hypoxia inducible factor-2 alpha (HIF-2 alpha) has a critical role in renal tumorigenesis. HIF-2 alpha is stabilized in von Hippel-Lindau (VHL)-deficient renal cell carcinoma through mechanisms that require ongoing mRNA translation. Mammalian target of rapamycin (mTOR) functions in two distinct complexes: Raptor-associated mTORC1 and Rictor-associated mTORC2. Rictor-associated mTORC2 complex has been linked to maintaining HIF-2 alpha protein in the absence of VHL; however, the mechanisms remain to be elucidated. Although Raptor-associated mTORC1 is a known key upstream regulator of mRNA translation, initiation and elongation, the role of mTORC2 in regulating mRNA translation is not clear. Complex assembly of the mRNA cap protein, eukaryotic translation initiation factor 4 (eIF4)E, with activators (eIF4 gamma (eIF4G)) and inhibitors (eIF4E-binding protein 1 (4E-BP1)) are rate-limiting determinants of mRNA translation. Our laboratory has previously demonstrated that reactive oxygen species, mediated by p22(phox)-based Nox oxidases, are enhanced in VHL-deficient cells and have a role in the activation of Akt on S473, a site phosphorylated by the mTORC2 complex. In this study, we examined the role of Rictor-dependent regulation of HIF-2 alpha through eIF4E-dependent mRNA translation and examined the effects of p22(phox)-based Nox oxidases on TORC2 regulation. We demonstrate for the first time that mTORC2 complex stability and activation is redox sensitive, and further defined a novel role for p22(phox)-based Nox oxidases in eIF4E-dependent mRNA translation through mTORC2. Furthermore, we provide the first evidence that silencing of p22(phox) reduces HIF-2 alpha-dependent gene targeting in vitro and tumor formation in vivo. The clinical relevance of these studies is demonstrated.	[Nayak, B. K.; Feliers, D.; Friedrichs, W. E.; Day, R. T.; New, D. D.; Eid, A.; Gorin, Y.; Block, K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Sudarshan, S.; Fitzgerald, J. P.; Parekh, D. J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA; [DeNapoli, T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA; [Block, K.] South Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Block, K (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	block@uthscsa.edu		Feliers, Denis/0000-0003-1952-1386	Veterans Administration; NIH [R01 NCI CA131272, K08 CA138774]; Voelcker Fund Young Investigator Award; Cancer Center Support Grant, National Cancer Institute [5 P30 CA054174-18]; NATIONAL CANCER INSTITUTE [K08CA138774, P30CA054174, R01CA131272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033665] Funding Source: NIH RePORTER	Veterans Administration(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Voelcker Fund Young Investigator Award; Cancer Center Support Grant, National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We acknowledge Dr Goutam Gosh-Choudhury for the HRE responsive element, Cynthia Galindo for technical contributions and Dr Hanna E. Abboud for helpful discussions and critical reading of the manuscript. This study was supported by the Veterans Administration Career Development Award and NIH R01 NCI CA131272 (KB), and NIH K08 CA138774 and Voelcker Fund Young Investigator Award (SS). This study was also supported in part by the Cancer Center Support Grant, National Cancer Institute, 5 P30 CA054174-18 (DJP).	Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Baldewijns MM, 2010, J PATHOL, V221, P125, DOI 10.1002/path.2689; Block K, 2007, J BIOL CHEM, V282, P8019, DOI 10.1074/jbc.M611569200; Block K, 2010, AM J PATHOL, V176, P2447, DOI 10.2353/ajpath.2010.090606; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Feliers D, 2007, AM J PHYSIOL-RENAL, V293, pF607, DOI 10.1152/ajprenal.00497.2006; Foster H, 2010, ANTICANCER RES, V30, P3529; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Kaelin WG, 2007, CLIN CANCER RES, V13, p680S, DOI 10.1158/1078-0432.CCR-06-1865; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lee HJ, 2009, UROLOGY, V73, P394, DOI 10.1016/j.urology.2008.08.472; Pandolfi PP, 2004, ONCOGENE, V23, P3134, DOI 10.1038/sj.onc.1207618; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Toschi A, 2008, J BIOL CHEM, V283, P34495, DOI 10.1074/jbc.C800170200; Villanueva A, 2008, GASTROENTEROLOGY, V135, P1972, DOI 10.1053/j.gastro.2008.08.008; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369	28	39	40	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2013	32	26					3147	3155		10.1038/onc.2012.333	http://dx.doi.org/10.1038/onc.2012.333			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22869144	Green Accepted			2022-12-17	WOS:000321004600005
J	Herglotz, J; Kuvardina, ON; Kolodziej, S; Kumar, A; Hussong, H; Grez, M; Lausen, J				Herglotz, J.; Kuvardina, O. N.; Kolodziej, S.; Kumar, A.; Hussong, H.; Grez, M.; Lausen, J.			Histone arginine methylation keeps RUNX1 target genes in an intermediate state	ONCOGENE			English	Article						epigenetics; stem cell; histone modifications; poised state; RUNX1	HEMATOPOIETIC STEM-CELLS; CHROMATIN SIGNATURES; H3K4 METHYLATION; TRANSCRIPTION; POLYCOMB; LEUKEMIA; AML1; EXPRESSION; COMPLEX; BINDING	The coordinated recruitment of epigenetic regulators of gene expression by transcription factors such as RUNX1 (AML1, acute myeloid leukemia 1) is crucial for hematopoietic differentiation. Here, we identify protein arginine methyltransferase 6 (PRMT6) as a central functional component of a RUNX1 corepressor complex containing Sin3a and HDAC1 in human hematopoietic progenitor cells. PRMT6 is recruited by RUNX1 and mediates asymmetric histone H3 arginine-2 dimethylation (H3R2me2a) at megakaryocytic genes in progenitor cells. H3R2me2a keeps RUNX1 target genes in an intermediate state with concomitant H3K27me3 and H3K4me2 but not H3K4me3. Upon megakaryocytic differentiation PRMT6 binding is lost, the H3R2me2a mark decreases and a coactivator complex containing WDR5/MLL and p300/pCAF is recruited. This leads to an increase of H3K4me3 and H3K9ac, which result in augmented gene expression. Our results provide novel mechanistic insight into how RUNX1 activity in hematopoietic progenitor cells maintains differentiation genes in a suppressed state but poised for rapid transcriptional activation.	[Herglotz, J.; Kuvardina, O. N.; Kolodziej, S.; Kumar, A.; Hussong, H.; Grez, M.; Lausen, J.] Georg Speyer Haus, Inst Biomed Res, D-60596 Frankfurt, Hessen, Germany	Octapharma	Lausen, J (corresponding author), Georg Speyer Haus, Inst Biomed Res, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Hessen, Germany.	lausen@em.uni-frankfurt.de			LOEWE initiatives Onkogene Signaltransduktion Frankfurt (OSF); LOEWE Center for Cell and Gene Therapy Frankfurt (CGT), Ministry of Higher Education, Research and the Arts of the state of Hessen (HMWK) [III L 4-518/55.004, III L 4-518/17004]; institutional funds of the Georg-Speyer-Haus; German Federal Ministry of Health (BMG); HMWK; Deutsche Forschungsgemeinschaft [SPP-1463, LA 1389/5-1]	LOEWE initiatives Onkogene Signaltransduktion Frankfurt (OSF); LOEWE Center for Cell and Gene Therapy Frankfurt (CGT), Ministry of Higher Education, Research and the Arts of the state of Hessen (HMWK); institutional funds of the Georg-Speyer-Haus; German Federal Ministry of Health (BMG); HMWK; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Reinhard Henschler of the Institute for Transfusion Medicine Frankfurt for providing hCD34+ cells. JL is supported by the LOEWE initiatives Onkogene Signaltransduktion Frankfurt (OSF), the LOEWE Center for Cell and Gene Therapy Frankfurt (CGT), Ministry of Higher Education, Research and the Arts of the state of Hessen (HMWK), III L 4-518/55.004 and III L 4-518/17004 and institutional funds of the Georg-Speyer-Haus. The Georg-Speyer-Haus is funded jointly by the German Federal Ministry of Health (BMG) and the HMWK. This project was supported by the Deutsche Forschungsgemeinschaft (SPP-1463, LA 1389/5-1).	Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Balint BL, 2005, MOL CELL BIOL, V25, P5648, DOI 10.1128/MCB.25.13.5648-5663.2005; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Ben-Ami O, 2009, P NATL ACAD SCI USA, V106, P238, DOI 10.1073/pnas.0811466106; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Cui KR, 2009, CELL STEM CELL, V4, P80, DOI 10.1016/j.stem.2008.11.011; de Laat W, 2008, CURR TOP DEV BIOL, V82, P117, DOI 10.1016/S0070-2153(07)00005-1; Demaison C, 2002, HUM GENE THER, V13, P803, DOI 10.1089/10430340252898984; Elagib KE, 2007, CRIT REV EUKAR GENE, V17, P271, DOI 10.1615/CritRevEukarGeneExpr.v17.i4.20; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; Goldfarb AN, 2009, J CELL BIOCHEM, V107, P377, DOI 10.1002/jcb.22142; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; Guccione E, 2007, NATURE, V449, P933, DOI 10.1038/nature06166; Hammoud SS, 2009, NATURE, V460, P473, DOI 10.1038/nature08162; Hannah R, 2011, EXP HEMATOL, V39, P531, DOI 10.1016/j.exphem.2011.02.009; Harada Y, 2009, J CELL PHYSIOL, V220, P16, DOI 10.1002/jcp.21769; Hoogenkamp M, 2007, MOL CELL BIOL, V27, P7425, DOI 10.1128/MCB.00905-07; Hoogenkamp M, 2009, BLOOD, V114, P299, DOI 10.1182/blood-2008-11-191890; Huang G, 2008, NAT GENET, V40, P51, DOI 10.1038/ng.2007.7; Hyllus D, 2007, GENE DEV, V21, P3369, DOI 10.1101/gad.447007; Iberg AN, 2008, J BIOL CHEM, V283, P3006, DOI 10.1074/jbc.C700192200; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Jiang HM, 2005, MOL CELL BIOL, V25, P10675, DOI 10.1128/MCB.25.24.10675-10683.2005; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kirmizis A, 2007, NATURE, V449, P928, DOI 10.1038/nature06160; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kowenz-Leutz E, 2010, EMBO J, V29, P1105, DOI 10.1038/emboj.2010.3; Lausen J, 2004, J BIOL CHEM, V279, P49281, DOI 10.1074/jbc.M407239200; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Mahajan MC, 2009, EXP HEMATOL, V37, P1143, DOI 10.1016/j.exphem.2009.07.001; Michaud-Levesque J, 2009, J BIOL CHEM, V284, P21338, DOI 10.1074/jbc.M109.005322; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; O'Malley BW, 2008, CURR OPIN CELL BIOL, V20, P310, DOI 10.1016/j.ceb.2008.04.005; Oguro H, 2010, CELL STEM CELL, V6, P279, DOI 10.1016/j.stem.2010.01.005; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Orford K, 2008, DEV CELL, V14, P798, DOI 10.1016/j.devcel.2008.04.002; Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025; Owen CJ, 2008, BLOOD, V112, P4639, DOI 10.1182/blood-2008-05-156745; Pencovich N, 2011, BLOOD, V117, pE1, DOI 10.1182/blood-2010-07-295113; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Satoh Y, 2008, J BIOL CHEM, V283, P30045, DOI 10.1074/jbc.M804768200; Shilatifard A, 2008, CURR OPIN CELL BIOL, V20, P341, DOI 10.1016/j.ceb.2008.03.019; Sims RJ, 2008, NAT REV MOL CELL BIO, V9, P815, DOI 10.1038/nrm2502; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Spivakov M, 2007, NAT REV GENET, V8, P263, DOI 10.1038/nrg2046; Surani MA, 2007, CELL, V128, P747, DOI 10.1016/j.cell.2007.02.010; Wang L, 2009, BLOOD CELL MOL DIS, V43, P30, DOI 10.1016/j.bcmd.2009.03.005; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wang W, 2010, BLOOD, V116, P254, DOI 10.1182/blood-2009-11-254664; Wilson NK, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt47; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Xu G, 2006, LEUKEMIA, V20, P1002, DOI 10.1038/sj.leu.2404223; Yu M, 2012, MOL CELL, V45, P330, DOI 10.1016/j.molcel.2011.11.032; Zhang X, 2003, STRUCTURE, V11, P509, DOI 10.1016/S0969-2126(03)00071-6; Zhao X, 2008, GENE DEV, V22, P640, DOI 10.1101/gad.1632608	56	39	39	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2013	32	20					2565	2575		10.1038/onc.2012.274	http://dx.doi.org/10.1038/onc.2012.274			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22777353				2022-12-17	WOS:000319274300008
J	Li, Z; Hann, SR				Li, Z.; Hann, S. R.			Nucleophosmin is essential for c-Myc nucleolar localization and c-Myc-mediated rDNA transcription	ONCOGENE			English	Article						c-Myc; NPM/B23; nucleolus; rRNA	RIBOSOMAL DNA; PROTEIN; DEGRADATION; CELLS; STABILIZATION; ACCUMULATION; PROTEOLYSIS; ISOFORM; NETWORK; PATHWAY	The transcription factor c-Myc has a critical role in cell proliferation and growth. The control of ribosome biogenesis by c-Myc through the regulation of transcription mediated by all three RNA polymerases is essential for c-Myc-driven proliferation. Specifically, in the nucleolus, c-Myc has been shown to be recruited to ribosomal DNA and activate RNA polymerase (pol) I-mediated transcription of ribosomal RNA (rRNA) genes. In addition, c-Myc accumulates in nucleoli upon inhibition of the proteasome, suggesting nucleolar localization also has a role in c-Myc proteolysis. Nucleophosmin (NPM), a predominantly nucleolar protein, is also critical in ribosome biogenesis and, like c-Myc, is found overexpressed in many types of tumors. Previously, we demonstrated that NPM directly interacts with c-Myc and controls c-Myc-induced hyperproliferation and transformation. Here, we show that NPM is necessary for the localization of c-Myc protein to nucleoli, whereas c-Myc nucleolar localization is independent of p53, Mdm2 and ARF. Conversely, high transient NPM expression enhances c-Myc nucleolar localization, leading to increased c-Myc proteolysis. In addition, NPM is necessary for the ability of c-Myc to induce rRNA synthesis in the nucleolus, and constitutive NPM overexpression stimulates c-Myc-mediated rRNA synthesis. Taken together, these results demonstrate an essential role for NPM in c-Myc nucleolar localization and c-Myc-mediated rDNA transcription. Oncogene (2013) 32, 1988-1994; doi:10.1038/onc.2012.227; published online 4 June 2012	[Li, Z.; Hann, S. R.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Vanderbilt University	Hann, SR (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, MCN B-2317, Nashville, TN 37232 USA.	steve.hann@vanderbilt.edu			NCI [RO1 CA109586, CA125760]; NATIONAL CANCER INSTITUTE [R01CA109586, R01CA125760, R56CA109586] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank C Pfarr for pCMV14-NPM-Flag vector, S McMahon for pSUPER retro vector, E Lee for the anti-HA (12CA5), W Tansey for pCGN-HA-Myc1-220 and pCGN-HA-Myc221-439 vectors, E Colombo and PG Pelicci for NPM<SUP>-/-</SUP> p53<SUP>-/-</SUP> MEFs, G Zambetti for ARF<SUP>-/-</SUP> p53<SUP>-/-</SUP> MEFs, E Ruley for p53<SUP>-/-</SUP> MEFs and J Sedivy for c-myc<SUP>-/-</SUP> cells. This work was supported by grants RO1 CA109586 and CA125760 from NCI to SRH.	Albihn A, 2010, ADV CANCER RES, V107, P163, DOI 10.1016/S0065-230X(10)07006-5; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Arabi A, 2003, J CELL SCI, V116, P1707, DOI 10.1242/jcs.00370; Boisvert FM, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.011429; Bonetti P, 2008, J CELL BIOL, V182, P19, DOI 10.1083/jcb.200711040; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646; Dai MS, 2008, J CELL BIOCHEM, V105, P670, DOI 10.1002/jcb.21895; Frehlick LJ, 2007, BIOESSAYS, V29, P49, DOI 10.1002/bies.20512; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Grim JE, 2008, J CELL BIOL, V181, P913, DOI 10.1083/jcb.200802076; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Li J, 2007, CARCINOGENESIS, V28, P1163, DOI 10.1093/carcin/bgm025; Li ZL, 2009, CELL CYCLE, V8, P2703, DOI 10.4161/cc.8.17.9418; Li ZL, 2008, P NATL ACAD SCI USA, V105, P18794, DOI 10.1073/pnas.0806879105; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Murano K, 2008, MOL CELL BIOL, V28, P3114, DOI 10.1128/MCB.02078-07; Okuwaki M, 2008, J BIOCHEM, V143, P441, DOI 10.1093/jb/mvm222; Poortinga G, 2011, NUCLEIC ACIDS RES, V39, P3267, DOI 10.1093/nar/gkq1205; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sanders JA, 2005, BBA-MOL CELL RES, V1743, P141, DOI 10.1016/j.bbamcr.2004.09.009; Shiue CN, 2009, ONCOGENE, V28, P1833, DOI 10.1038/onc.2009.21; Sirri V, 2008, HISTOCHEM CELL BIOL, V129, P13, DOI 10.1007/s00418-007-0359-6; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Stoldt S, 2007, BIOL CELL, V99, P541, DOI 10.1042/BC20060117; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110	34	39	39	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1988	1994		10.1038/onc.2012.227	http://dx.doi.org/10.1038/onc.2012.227			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22665062	Green Accepted			2022-12-17	WOS:000317599900013
J	Zhang, K; Wong, P; Zhang, L; Jacobs, B; Borden, EC; Aster, JC; Bedogni, B				Zhang, K.; Wong, P.; Zhang, L.; Jacobs, B.; Borden, E. C.; Aster, J. C.; Bedogni, B.			A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth	ONCOGENE			English	Article						NIC: Notch1 intracellular domain; Notch1-TM: transmembrane Notch1; NRG1: neuregulin1; ERBB: erythroblastic leukemia viral oncogene homolog or EGF (epidermal growth factor) family of transmembrane receptor tyrosine kinases; p27KIP1: CDKN1B: cyclin-dependent kinase inhibitor 1B	GENE-EXPRESSION PROFILES; STEM-CELLS; NOTCH; INHIBITION; PHOSPHORYLATION; DIFFERENTIATION; PROGRESSION; ACTIVATION; APOPTOSIS; PROLIFERATION	The Notch pathway is an evolutionary conserved signaling cascade that has an essential role in melanoblast and melanocyte stem cell homeostasis. Notch signaling is emerging as a key player in melanoma, the most deadly form of skin cancer. In melanoma, Notch1 is inappropriately reactivated and contributes to melanoma tumorigenicity. Here, we propose a novel mechanism by which Notch1 promotes the disease. We found that Notch1 directly regulates the transcription of neuregulin1 (NRG1) by binding to its promoter region. NRG1 is the ligand for ERBB3 and 4, members of the epidermal growth factor family of receptors that are involved in the genesis and progression of a number of cancers. Notch1 and NRG1 expression are associated in melanoma and inhibition of NRG1 signaling leads to melanoma cell growth inhibition and tumor growth delay. Mechanistically, these effects are associated with the inhibition of the PI3Kinase/Akt signaling pathway and with the accumulation of p27Kip1. On the other end, addition of recombinant NRG1 can partially restore melanoma cell growth that is inhibited by Notch1 ablation. Taken together, our findings underline a new, previously undescribed autocrine signaling loop between Notch1 and NRG1 that controls melanoma growth and provide experimental evidence that the targeting of Notch and ERBB signaling may represent a novel potential therapeutic approach in melanoma.	[Zhang, K.; Wong, P.; Zhang, L.; Bedogni, B.] Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; [Jacobs, B.; Borden, E. C.] Cleveland Clin Fdn, Cleveland, OH 44195 USA; [Aster, J. C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Aster, J. C.] Harvard Univ, Sch Med, Boston, MA USA	Case Western Reserve University; Cleveland Clinic Foundation; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Bedogni, B (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Wood Bldg,Room W420,10900 Euclid Ave, Cleveland, OH 44106 USA.	barbara.bedogni@case.edu			American Cancer Society [ACS-IRG-91-022, ACS-RSG-11-139-01-DDC]; National Institute of Health [P30CA147877]; NATIONAL CANCER INSTITUTE [P30CA147877] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by Grant # ACS-IRG-91-022 and Grant # ACS-RSG-11-139-01-DDC from the American Cancer Society and by start up funds awarded by the National Institute of Health (award number: P30CA147877: New Faculty Recruitment to Enhance Melanoma Research). We thank Drs Scott Welford and David Samols for critical discussion; Dr Marianne Broome Powell for making available many of the melanoma cell lines used in this work.	Altekruse SFKC, 1975, SEER CANC STAT REV; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Bedogni B, 2008, J CLIN INVEST, V118, P3660, DOI 10.1172/JCI36157; Birchmeier C, 2009, EXP CELL RES, V315, P611, DOI 10.1016/j.yexcr.2008.10.035; Brabletz S, 2009, J PATHOL, V217, P307, DOI 10.1002/path.2475; Buac K, 2009, PIGM CELL MELANOMA R, V22, P773, DOI 10.1111/j.1755-148X.2009.00616.x; Calvo M, 2011, GLIA, V59, P554, DOI 10.1002/glia.21124; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Dong YY, 2010, CANCER RES, V70, P5465, DOI 10.1158/0008-5472.CAN-10-0173; Eliasz S, 2010, ONCOGENE, V29, P2488, DOI 10.1038/onc.2010.7; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fukazawa R, 2003, J MOL CELL CARDIOL, V35, P1473, DOI 10.1016/j.yjmcc.2003.09.012; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; Gilbert CA, 2010, CANCER RES, V70, P6870, DOI 10.1158/0008-5472.CAN-10-1378; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hardy KM, 2010, CANCER RES, V70, P10340, DOI 10.1158/0008-5472.CAN-10-0705; Herzog C, 2007, SEER AYA MONOGRAPH, P53; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hovinga KE, 2010, STEM CELLS, V28, P1019, DOI 10.1002/stem.429; Ieguchi K, 2010, J BIOL CHEM, V285, P31388, DOI 10.1074/jbc.M110.113878; Imayoshi I, 2010, J NEUROSCI, V30, P3489, DOI 10.1523/JNEUROSCI.4987-09.2010; Johansson P, 2007, PIGM CELL RES, V20, P216, DOI 10.1111/j.1600-0749.2007.00375.x; Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; Osawa M, 2008, J INVEST DERMATOL, V128, P2571, DOI 10.1038/jid.2008.289; Osipo C, 2008, ONCOGENE, V27, P5019, DOI 10.1038/onc.2008.149; Pahlman S, 2004, SEMIN CANCER BIOL, V14, P365, DOI 10.1016/j.semcancer.2004.04.016; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Pancewicz J, 2010, P NATL ACAD SCI USA, V107, P16619, DOI 10.1073/pnas.1010722107; Pinnix CC, 2009, CANCER RES, V69, P5312, DOI 10.1158/0008-5472.CAN-08-3767; Prickett TD, 2009, NAT GENET, V41, P1127, DOI 10.1038/ng.438; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Rasul S, 2009, BRIT J CANCER, V100, P1879, DOI 10.1038/sj.bjc.6605034; Razorenova O V, 2005, Mol Biol (Mosk), V39, P286; Reschke M, 2008, CLIN CANCER RES, V14, P5188, DOI 10.1158/1078-0432.CCR-08-0186; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Santagata S, 2004, CANCER RES, V64, P6854, DOI 10.1158/0008-5472.CAN-04-2500; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shin I, 2005, J BIOL CHEM, V280, P6055, DOI 10.1074/jbc.M412367200; Sjolund J, 2008, J CLIN INVEST, V118, P217, DOI 10.1172/JCI32086; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Tworkoski K, 2011, MOL CANC RES; Wieduwilt MJ, 2008, CELL MOL LIFE SCI, V65, P1566, DOI 10.1007/s00018-008-7440-8; Woodhoo A, 2009, NAT NEUROSCI, V12, P839, DOI 10.1038/nn.2323; Zhou K, 2010, ANN HEMATOL, V89, P749, DOI 10.1007/s00277-010-0923-3	53	39	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	43					4609	4618		10.1038/onc.2011.606	http://dx.doi.org/10.1038/onc.2011.606			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029WP	22249266	Green Accepted			2022-12-17	WOS:000310528200004
J	Senapati, S; Gnanapragassam, VS; Moniaux, N; Momi, N; Batra, SK				Senapati, S.; Gnanapragassam, V. S.; Moniaux, N.; Momi, N.; Batra, S. K.			Role of MUC4-NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells	ONCOGENE			English	Article						MUC4; pancreatic cancer; metastasis; NIDO domain; MUC4 domains	MUC4 EXPRESSION; ADENOCARCINOMA; EVOLUTION; DIAGNOSIS; BINDING	MUC4 is a large transmembrane type I glycoprotein that is overexpressed in pancreatic cancer (P =C) and has been shown to be associated with its progression and metastasis. However, the exact cellular and molecular mechanism(s) through which MUC4 promotes metastasis of PC cells has been sparsely studied. Here we showed that the nidogen-like (NIDO) domain of MUC4, which is similar to the G1-domain present in the nidogen or entactin (an extracellular matrix protein), contributes to the protein-protein interaction property of MUC4. By this interaction, MUC4 promotes breaching of basement membrane (BM) integrity, and spreading of cancer cells. These observations are corroborated with the data from our study using an engineered MUC4 protein without the NIDO domain, which was ectopically expressed in the MiaPaCa PC cells, lacking endogenous MUC4 and nidogen protein. The in vitro studies demonstrated an enhanced invasiveness of MiaPaCa cells expressing MUC4 (MiaPaCa-MUC4) compared with vector-transfected cells (MiaPaCa-Vec; P = 0.003) or cells expressing MUC4 without the NIDO domain (MiaPaCa-MUC4-NIDOD; P = 0.03). However, the absence of NIDO-domain has no significant role on cell growth and motility (P = 0.93). In the in vivo studies, all the mice orthotopically implanted with MiPaCa-MUC4 cells developed metastasis to the liver as compared with MiaPaCa-Vec or the MiaPaCaMUC4- NIDOD group, hence, supporting our in vitro observations. Additionally, a reduced binding (P = 0.0004) of MiaPaCa-MUC4-NIDOD cells to the fibulin-2 coated plates compared with MiaPaCa-MUC4 cells indicated a possible interaction between the MUC4-NIDO domain and fibulin-2, a nidogen-interacting protein. Furthermore, in PC tissue samples, MUC4 colocalized with the fibulin-2 present in the BM. Altogether, our findings demonstrate that the MUC4-NIDO domain significantly contributes to the MUC4-mediated metastasis of PC cells. This may be partly due to the interaction between the MUC4-NIDO domain and fibulin-2. Oncogene (2012) 31, 3346-3356; doi: 10.1038/onc.2011.505; published online 21 November 2011	[Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Eppley Inst Res Canc & Allied Dis, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu	Moniaux, Nicolas/Y-3243-2018	Moniaux, Nicolas/0000-0001-9718-1386; Senapati, Shantibhusan/0000-0001-7108-8255	National Institutes of Health [CA78590, CA111294, CA127297, CA133774, CA131944]; NATIONAL CANCER INSTITUTE [P50CA127297, R01CA078590, U01CA111294, R01CA133774, R01CA131944] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the grants from National Institutes of Health (CA78590, CA111294, CA127297, CA133774 and CA131944). We thank Ms Kristi L Berger for editing the manuscript. We acknowledge the invaluable technical support from Mr Erik Moore and Kavita Mallya. We also thank Janice A Tayor and James R Talaska of the confocal laser scanning microscope core facility at the UNMC, for their support.	AUMAILLEY M, 1993, KIDNEY INT, V43, P7, DOI 10.1038/ki.1993.3; Bacac M, 2008, ANNU REV PATHOL-MECH, V3, P221, DOI 10.1146/annurev.pathmechdis.3.121806.151523; Casey RC, 2000, CLIN EXP METASTAS, V18, P67, DOI 10.1023/A:1026519016213; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; DiMagno EP, 1999, GASTROENTEROLOGY, V117, P1464, DOI 10.1016/S0016-5085(99)70298-2; Duraisamy S, 2006, GENE, V373, P28, DOI 10.1016/j.gene.2005.12.021; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; Hotary K, 2006, GENE DEV, V20, P2673, DOI 10.1101/gad.1451806; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Langley RR, 2007, ENDOCR REV, V28, P297, DOI 10.1210/er.2006-0027; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Ma C, 2008, COLD SPRING HARB PRO, P5034; Ma C, 2008, GENE DEV, V22, P308, DOI 10.1101/gad.1632008; Moniaux N, 2007, BRIT J CANCER, V97, P345, DOI 10.1038/sj.bjc.6603868; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Piscaglia F, 2009, CELL TISSUE RES, V337, P449, DOI 10.1007/s00441-009-0823-9; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Ries A, 2001, EUR J BIOCHEM, V268, P5119, DOI 10.1046/j.0014-2956.2001.02437.x; Rowe RG, 2008, TRENDS CELL BIOL, V18, P560, DOI 10.1016/j.tcb.2008.08.007; Senapati S, 2008, BRIT J CANCER, V99, P949, DOI 10.1038/sj.bjc.6604632; Senapati S, 2010, TRENDS BIOCHEM SCI, V35, P236, DOI 10.1016/j.tibs.2009.10.003; Singh AP, 2007, ONCOGENE, V26, P30, DOI 10.1038/sj.onc.1209764; Singh AP, 2007, CANCER RES, V67, P433, DOI 10.1158/0008-5472.CAN-06-3114; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Ulazzi L, 2011, MOL CANCER, V6, P17; Yi CH, 2007, AM J PATHOL, V170, P1535, DOI 10.2353/ajpath.2007.060478	30	39	39	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	28					3346	3356		10.1038/onc.2011.505	http://dx.doi.org/10.1038/onc.2011.505			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973NT	22105367	Green Accepted			2022-12-17	WOS:000306367600004
J	Cheriyath, V; Kuhns, MA; Jacobs, BS; Evangelista, P; Elson, P; Downs-Kelly, E; Tubbs, R; Borden, EC				Cheriyath, V.; Kuhns, M. A.; Jacobs, B. S.; Evangelista, P.; Elson, P.; Downs-Kelly, E.; Tubbs, R.; Borden, E. C.			G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer	ONCOGENE			English	Article						G1P3; breast cancer; hyperplasia; apoptosis; tamoxifen resistance; interferon-stimulated genes	GENE-EXPRESSION; PROGNOSTIC MARKER; IMMUNE CELLS; APOPTOSIS; MORPHOGENESIS; INFLAMMATION; SIGNATURE; FAMILY; BCL2; IDENTIFICATION	Hormonally regulated survival factors can have an important role in breast cancer. Here we elucidate G1P3, a survival protein induced by interferons (IFNs), as a target of estrogen signaling and a contributor to poor outcomes in estrogen receptor-positive (ER+) breast cancer. Compared with normal breast tissue, G1P3 was upregulated in the malignant epithelium (50 x higher) and was induced by estrogen ex vivo. In accord with its overexpression in early stages of breast cancer (hyperplasia and ductal carcinoma in situ), in morphogenesis assays G1P3 enhanced the survival of MCF10A acinar luminal cells causing hyperplasia by suppressing detachment-induced loss of mitochondrial potential and apoptosis (anoikis). In cells undergoing anoikis, G1P3 attenuated the induction of Bim protein, a proapoptotic member of the Bcl-2 family and reversed the downmodulation of Bcl-2 protein. Downregulation of G1P3 induced spontaneous apoptosis in BT-549 breast cancer cells and significantly reduced the growth of ER+ breast cancer cell MCF7 (P <= 0.01), further suggesting its prosurvival activity. In agreement with its induction by estrogen, G1P3 antagonized tamoxifen, an inhibitor of ER in MCF7 cells. More importantly, elevated expression of G1P3 was significantly associated with decreased relapse-free and overall survival in ER+ breast cancer patients (P <= 0.01). Our studies suggest that elevated expression of G1P3 may perturb canonical tumor-suppressing activity of IFNs partly by affecting the balance of pro- and antiapoptotic members of Bcl-2 family proteins, leading to breast cancer development and resistance to therapies. Oncogene (2012) 31, 2222-2236; doi:10.1038/onc.2011.393; published online 26 September 2011	[Cheriyath, V.; Kuhns, M. A.; Jacobs, B. S.; Evangelista, P.; Borden, E. C.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA; [Elson, P.] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Downs-Kelly, E.; Tubbs, R.] Cleveland Clin, Dept Mol Pathol, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Cheriyath, V (corresponding author), Cleveland Clin Fdn, Taussig Canc Inst, 9500 Euclid Ave,Mailcode R40, Cleveland, OH 44195 USA.	venu_cheriyath@tamu-commerce.edu; bordene@ccf.org			Clinical and Translational Science Collaborative (CTSC); NCI [CA043703]; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024989] Funding Source: NIH RePORTER	Clinical and Translational Science Collaborative (CTSC); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This study is supported by a Clinical and Translational Science Collaborative (CTSC) award to VC and by NCI CA043703 to ECB. We thank Drs Thomas Budd and Joseph Crowe and Mrs Joanne Lyons for their help in procuring biopsies. Our sincere thanks to Dr Judith Drazba, director of the Cleveland Clinic Imaging Core, Dr John Peterson and Eric Diskin for their kind help with the confocal and light microscopy. We thank Linda Vargo for preparing the specimens for in situ hybridization. We gratefully acknowledge Dr Aejaz Nasir at Eli Lilly and Dr Tim Huang at the Ohio State University for helpful discussions. We also thank Dr George Stark and Dr Thomas Budd at the Cleveland Clinic for critical reading of the manuscript.	Anderson LR, 2010, ONCOGENE, V29, P527, DOI 10.1038/onc.2009.362; Bae SI, 2008, ONCOGENE, V27, P490, DOI 10.1038/sj.onc.1210655; Bani MR, 2004, MOL CANCER THER, V3, P111; Bektas N, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2117; Bharadwaj S, 2005, ONCOGENE, V24, P8291, DOI 10.1038/sj.onc.1208993; Borden EC, 2007, NAT REV DRUG DISCOV, V6, P975, DOI 10.1038/nrd2422; Braig M, 2006, CANCER RES, V66, P2881, DOI 10.1158/0008-5472.CAN-05-4006; Callagy GM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-153; Calogero RA, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1745; Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y; Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547; Cheriyath V, 2010, J INTERFERON CYTOKIN, V31, P173; Cheriyath V, 2007, J CLIN INVEST, V117, P3107, DOI 10.1172/JCI31122; Cheriyath V, 2011, J INTERF CYTOK RES, V31, P173, DOI 10.1089/jir.2010.0105; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215; Dawson SJ, 2010, BRIT J CANCER, V103, P668, DOI 10.1038/sj.bjc.6605736; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; DeNardo DG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1746; DeNardo DG, 2008, CANCER METAST REV, V27, P11, DOI 10.1007/s10555-007-9100-0; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Einav U, 2005, ONCOGENE, V24, P6367, DOI 10.1038/sj.onc.1208797; Eroles P, 2010, CLIN TRANSL ONCOL, V12, P246, DOI 10.1007/s12094-010-0500-1; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; Gimenez-Bonafe P, 2009, CURR CANCER DRUG TAR, V9, P320, DOI 10.2174/156800909788166600; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Hebner C, 2008, ANNU REV PATHOL-MECH, V3, P313, DOI 10.1146/annurev.pathmechdis.3.121806.151526; IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; Luszczek W, 2010, MOL CANCER THER, V9, P2309, DOI 10.1158/1535-7163.MCT-10-0309; Ma XJ, 2006, J CLIN ONCOL, V24, P4611, DOI 10.1200/JCO.2006.06.6944; Mailleux AA, 2008, M S-MED SCI, V24, P246, DOI 10.1051/medsci/2008243246; Mailleux AA, 2008, CELL CYCLE, V7, P57, DOI 10.4161/cc.7.1.5150; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nelson CM, 2005, SEMIN CANCER BIOL, V15, P342, DOI 10.1016/j.semcancer.2005.05.001; Nuovo GJ, 2009, NAT PROTOC, V4, P107, DOI 10.1038/nprot.2008.215; Parker N, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-8; Puisieux A, 2006, BRIT J CANCER, V94, P13, DOI 10.1038/sj.bjc.6602876; Radisky ES, 2007, REV ENDOCR METAB DIS, V8, P279, DOI 10.1007/s11154-007-9037-1; RASMUSSEN UB, 1993, CANCER RES, V53, P4096; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5; Segara D, 2005, CLIN CANCER RES, V11, P3587, DOI 10.1158/1078-0432.CCR-04-1813; Sorbello V, 2003, INT J BIOL MARKER, V18, P123, DOI 10.1177/172460080301800205; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Swan EA, 2003, ORAL ONCOL, V39, P648, DOI 10.1016/S1368-8375(03)00049-6; Tahara E, 2005, CANCER IMMUNOL IMMUN, V54, P729, DOI 10.1007/s00262-004-0645-2; Thomadaki H, 2008, CONNECT TISSUE RES, V49, P261, DOI 10.1080/03008200802147829; Thomadaki H, 2007, CANCER LETT, V247, P48, DOI 10.1016/j.canlet.2006.03.016; Tsai MH, 2007, CANCER RES, V67, P3845, DOI 10.1158/0008-5472.CAN-06-4250; Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105; Weigelt B, 2008, SEMIN CANCER BIOL, V18, P311, DOI 10.1016/j.semcancer.2008.03.013; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Ye H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-69; Zhang HP, 1999, RECURSIVE PARTITIONI	62	39	39	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	17					2222	2236		10.1038/onc.2011.393	http://dx.doi.org/10.1038/onc.2011.393			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21996729				2022-12-17	WOS:000303415900010
J	Chu, IM; Michalowski, AM; Hoenerhoff, M; Szauter, KM; Luger, D; Sato, M; Flanders, K; Oshima, A; Csiszar, K; Green, JE				Chu, I. M.; Michalowski, A. M.; Hoenerhoff, M.; Szauter, K. M.; Luger, D.; Sato, M.; Flanders, K.; Oshima, A.; Csiszar, K.; Green, J. E.			GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells	ONCOGENE			English	Article						GATA3; basal triple-negative breast cancer; lysyl oxidase; differentiation; gene expression profiling	GENE-EXPRESSION; MESENCHYMAL TRANSITION; ENZYME-ACTIVITY; MAMMARY-GLAND; DIFFERENTIATION; GROWTH; MORPHOGENESIS; PROPEPTIDE; MIGRATION; SUBTYPES	Discovery of mechanisms that impede the aggressive and metastatic phenotype of human basal triple-negative-type breast cancers (BTNBCs) could provide novel targets for therapy for this form of breast cancer that has a relatively poor prognosis. Previous studies have demonstrated that expression of GATA3, the master transcriptional regulator of mammary luminal differentiation, can reduce the tumorigenicity and metastatic propensity of the human BTNBC MDA-MB-231 cell line (MB231), although the mechanism for reduced metastases was not elucidated. We demonstrate through gene expression profiling that GATA3 expression in 231 cells resulted in the dramatic reduction in the expression of lysyl oxidase (LOX), a metastasis-promoting, matrix-remodeling protein, in part, through methylation of the LOX promoter. Suppression of LOX expression by GATA3 was further confirmed in the BTNBC Hs578T cell line. Conversely, reduction of GATA3 expression by small interfering RNA in luminal BT474 cells increased LOX expression. Reconstitution of LOX expression in 231-GATA3 cells restored metastatic propensity. A strong inverse association between LOX and GATA3 expression was confirmed in a panel of 51 human breast cancer cell lines. Similarly, human breast cancer microarray data demonstrated that high LOX/low GATA3 expression is associated with the BTNBC subtype of breast cancer and poor patient prognosis. Expression of GATA3 reprograms BTNBCs to a less aggressive phenotype and inhibits a major mechanism of metastasis through inhibition of LOX. Induction of GATA3 in BTNBC cells or novel approaches that inhibit LOX expression or activity could be important strategies for treating BTNBCs. Oncogene (2012) 31, 2017-2027; doi: 10.1038/onc.2011.382; published online 5 September 2011	[Green, J. E.] NCI, Transgen Oncogenesis & Genom Sect, Lab Canc Biol & Genet, Bethesda, MD 20892 USA; [Hoenerhoff, M.] NIEHS, Cellular & Mol Pathol Branch, Natl Toxicol Program, Res Triangle Pk, NC 27709 USA; [Szauter, K. M.; Csiszar, K.] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Hawaii System	Green, JE (corresponding author), NCI, Transgen Oncogenesis & Genom Sect, Lab Canc Biol & Genet, Bldg 37,Room 4054,37 Convent Dr, Bethesda, MD 20892 USA.	jegreen@nih.gov			Center for Cancer Research, NCI, NIH; Department of Defense [W81XWH-10-2-0030]; NATIONAL CANCER INSTITUTE [ZIABC005740] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [U54MD007584] Funding Source: NIH RePORTER	Center for Cancer Research, NCI, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	We thank Drs Lalage Wakefield and Li Yang for helpful scientific discussions. We also thank Lara El-Touny, Dalit Barkan, Zi-Yao Liu, TingHu Qiu, Anthony Vieira, Christina Bennett, Christine Tomlinson, Steven Austin, Christian Mustroph and Wei-Chu Lai for technical assistance; Paul Meltzer for sharing unpublished data; the LRBGE Fluorescence Imaging Core and Chand Khanna for the use of fluorescence microscopy equipment; and Julie Foley and Norris Flagler for technical assistance with image analysis. This research was supported in part by the Intramural Research Program, Center for Cancer Research, NCI, NIH. IMC acknowledges support from the Department of Defense Breast Cancer Research Program (W81XWH-10-2-0030).	Abourbih DA, 2010, MELANOMA RES, V20, P97, DOI 10.1097/CMR.0b013e328336edfe; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849; Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356; Bondareva A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005620; Chu I, 2005, CANCER RES, V65, P18; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Dydensborg AB, 2009, ONCOGENE, V28, P2634, DOI 10.1038/onc.2009.126; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Grimsby JL, 2010, J CELL BIOCHEM, V111, P1231, DOI 10.1002/jcb.22845; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Hoenerhoff MJ, 2009, ONCOGENE, V28, P3022, DOI 10.1038/onc.2009.165; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; Kaneda A, 2004, CANCER RES, V64, P6410, DOI 10.1158/0008-5472.CAN-04-1543; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Kouros-Mehr H, 2006, DEV DYNAM, V235, P3404, DOI 10.1002/dvdy.20978; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Palamakumbura AH, 2009, ONCOGENE, V28, P3390, DOI 10.1038/onc.2009.203; Palamakumbura AH, 2002, ANAL BIOCHEM, V300, P245, DOI 10.1006/abio.2001.5464; Payne SL, 2005, CANCER RES, V65, P11429, DOI 10.1158/0008-5472.CAN-05-1274; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262; Zhou M, 2003, IMMUNOL RES, V28, P25, DOI 10.1385/IR:28:1:25	34	39	39	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	16					2017	2027		10.1038/onc.2011.382	http://dx.doi.org/10.1038/onc.2011.382			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21892208	Green Accepted			2022-12-17	WOS:000303008600003
J	Kumar, SM; Zhang, G; Bastian, BC; Arcasoy, MO; Karande, P; Pushparajan, A; Acs, G; Xu, X				Kumar, S. M.; Zhang, G.; Bastian, B. C.; Arcasoy, M. O.; Karande, P.; Pushparajan, A.; Acs, G.; Xu, X.			Erythropoietin receptor contributes to melanoma cell survival in vivo	ONCOGENE			English	Article						erythropoietin; erythropoietin receptor; melanoma; hypoxia	RECOMBINANT ERYTHROPOIETIN; BREAST-CANCER; CARCINOMA CELLS; TUMOR-GROWTH; NECK-CANCER; EXPRESSION; HYPOXIA; HEAD; PROMOTES; MODELS	Erythropoietin (Epo) is widely used clinically to treat anemia associated with various clinical conditions including cancer. Data from several clinical trials suggest significant adverse effect of Epo treatment on cancer patient survival. However, controversy exists whether Epo receptor (EpoR) is functional in cancer cells. In this study, we demonstrated that EpoR mRNA expression was detectable in 90.1% of 65 melanoma cell lines, and increased copy number of the Epo and EpoR loci occurred in 30 and 24.6% of 130 primary melanomas, respectively. EpoR knockdown in melanoma cells resulted in diminished ERK phosphorylation in response to Epo stimulation, decreased cell proliferation and increased response to the inhibitory effect of hypoxia and cisplatin in vitro. EpoR knockdown significantly decreased melanoma xenograft size and tumor invasion in vivo. On the contrary, constitutive activation of EpoR activated cell proliferation pathways in melanoma cells and resulted in increased cell proliferation and resistance to hypoxia and cisplatin treatment in vitro. EpoR activation resulted in significantly larger xenografts with increased tumor invasion of surrounding tissue in vivo. Daily administration of recombinant Epo fails to stimulate melanoma growth in vivo, but the treatment increased vascular size in the xenografts. Increased local recurrence after excision of the primary tumors was observed after Epo treatment. Epo induced angiogenesis in Matrigel plug assays, and neutralization of Epo secreted by melanoma cells results in decreased angiogenesis. These data support that EpoR is functional in melanoma and EpoR activation may promote melanoma progression, and suggest that Epo may stimulate angiogenesis and increase survival of melanoma cells under hypoxic condition in vivo. Oncogene (2012) 31, 1649-1660; doi:10.1038/onc.2011.366; published online 22 August 2011	[Kumar, S. M.; Pushparajan, A.; Xu, X.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Zhang, G.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Bastian, B. C.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Bastian, B. C.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Arcasoy, M. O.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA; [Karande, P.] Rensselaer Polytechnol Inst, Dept Chem Engn, Troy, NY USA; [Karande, P.] Rensselaer Polytechnol Inst, Dept Biol Engn, Troy, NY USA; [Acs, G.] Moffitt Canc, Dept Anat Pathol, Tampa, FL USA; [Acs, G.] Moffitt Canc, Dept Womens Oncol, Tampa, FL USA	University of Pennsylvania; The Wistar Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Duke University; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Xu, X (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 3400 Spruce St,6 Founders Bldg, Philadelphia, PA 19104 USA.	xug@mail.med.upenn.edu	Zhang, Gao/D-3471-2017	Bastian, Boris/0000-0003-1836-6062	Melanoma Research Foundation;  [CA-093372];  [CA-116103];  [AR-054593];  [CA-100844]; NATIONAL CANCER INSTITUTE [R01CA100844, P50CA093372, R21CA116103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054593] Funding Source: NIH RePORTER	Melanoma Research Foundation; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We are grateful to M Herlyn from the Wistar Institute for providing melanoma cell lines. Financial support was provided by CA-093372, CA-116103, AR-054593 and Melanoma Research Foundation (to X Xu) and CA-100844 (to MO Arcasoy).	Acs G, 2004, CANCER LETT, V214, P243, DOI 10.1016/j.canlet.2004.04.027; Acs G, 2004, CANCER-AM CANCER SOC, V100, P2376, DOI 10.1002/cncr.20244; Acs G, 2001, CANCER RES, V61, P3561; Arcasoy MO, 2005, CLIN CANCER RES, V11, P20; Arcasoy MO, 2003, BIOCHEM BIOPH RES CO, V307, P999, DOI 10.1016/S0006-291X(03)01303-2; Arcasoy MO, 2002, LAB INVEST, V82, P911, DOI 10.1097/01.LAB.0000020415.72863.40; Arcasoy MO, 2008, CLIN CANCER RES, V14, P4685, DOI 10.1158/1078-0432.CCR-08-0264; Beldo-Iniesta C, 2007, CANCER BIOL THER, V6, P1600, DOI 10.4161/cbt.6.10.4726; Bennett CL, 2008, JAMA-J AM MED ASSOC, V299, P914, DOI 10.1001/jama.299.8.914; Blau CA, 2007, STEM CELLS, V25, P2094, DOI 10.1634/stemcells.2007-0229; Bohlius J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007303.pub2; Carlin S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010857; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Daniel RJ, 2002, J INVEST DERMATOL, V119, P1304, DOI 10.1046/j.1523-1747.2002.19533.x; Fu P, 2009, BIOCHEM BIOPH RES CO, V379, P696, DOI 10.1016/j.bbrc.2008.12.146; Hardee ME, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000549; Henke M, 2003, LANCET, V362, P1255, DOI 10.1016/S0140-6736(03)14567-9; Jelkmann W, 2008, CRIT REV ONCOL HEMAT, V67, P39, DOI 10.1016/j.critrevonc.2008.03.006; Jeong JY, 2009, MOL CANCER RES, V7, P1150, DOI 10.1158/1541-7786.MCR-08-0243; Knabe W, 2005, ANAT EMBRYOL, V210, P209, DOI 10.1007/s00429-005-0019-3; Koritzinsky M, 2007, METHOD ENZYMOL, V435, P247, DOI 10.1016/S0076-6879(07)35013-1; Kumar SM, 2005, AM J PATHOL, V166, P823, DOI 10.1016/S0002-9440(10)62303-6; Kumar SM, 2007, CANCER RES, V67, P3177, DOI 10.1158/0008-5472.CAN-06-3312; Lai SY, 2005, ONCOGENE, V24, P4442, DOI 10.1038/sj.onc.1208635; LaMontagne KR, 2006, MOL CANCER THER, V5, P347, DOI 10.1158/1535-7163.MCT-05-0203; Ley CD, 2004, MICROVASC RES, V68, P161, DOI 10.1016/j.mvr.2004.06.002; Leyland-Jones B, 2005, J CLIN ONCOL, V23, P5960, DOI 10.1200/JCO.2005.06.150; Lin WM, 2008, CANCER RES, V68, P664, DOI 10.1158/0008-5472.CAN-07-2615; Mirmohammadsadegh A, 2010, J INVEST DERMATOL, V130, P201, DOI 10.1038/jid.2009.162; Mohyeldin A, 2005, NEOPLASIA, V7, P537, DOI 10.1593/neo.04685; Noguchi Constance Tom, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000860; Okazaki T, 2008, NEOPLASIA, V10, P932, DOI 10.1593/neo.08140; Paragh G, 2009, AM J PATHOL, V174, P1504, DOI 10.2353/ajpath.2009.080592; PHARR PN, 1993, P NATL ACAD SCI USA, V90, P938, DOI 10.1073/pnas.90.3.938; Reynolds CP, 2005, METH MOLEC MED, V111, P335; Seaman ME, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020807; Sinclair AM, 2007, CANCER-AM CANCER SOC, V110, P477, DOI 10.1002/cncr.22832; Sytkowski AJ, 2007, SCI STKE, V2007, ppe38, DOI DOI 10.1126/STKE.3952007PE38; Tovari J, 2005, CANCER RES, V65, P7186, DOI 10.1158/0008-5472.CAN-04-2498; Tovari J, 2008, CURR MOL MED, V8, P481, DOI 10.2174/156652408785747979; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Um M, 2007, CELL SIGNAL, V19, P634, DOI 10.1016/j.cellsig.2006.08.014; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Wright GL, 2004, FASEB J, V18, P1031, DOI 10.1096/fj.03-1289fje; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; Yates CM, 2006, J ENDOCRINOL INVEST, V29, P320, DOI 10.1007/BF03344103; Yu TW, 2008, FRONT BIOSCI-LANDMRK, V13, P2714, DOI 10.2741/2878	48	39	39	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	13					1649	1660		10.1038/onc.2011.366	http://dx.doi.org/10.1038/onc.2011.366			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21860424	Green Published, Green Accepted			2022-12-17	WOS:000302231400004
J	Moore, AE; Young, LE; Dixon, DA				Moore, A. E.; Young, L. E.; Dixon, D. A.			A common single-nucleotide polymorphism in cyclooxygenase-2 disrupts microRNA-mediated regulation	ONCOGENE			English	Article						COX-2; post-transcriptional regulation; microRNA; SNP; polymorphism	GENETIC POLYMORPHISMS; CANCER; RISK; EXPRESSION; ASSOCIATION; CELLS	Elevated expression of the prostaglandin synthase cyclooxygenase-2 (COX-2) is commonly observed in many chronic inflammatory diseases and cancer. However, the mechanisms allowing for pathogenic COX-2 overexpression are largely unknown. The gene for COX-2 (PTGS2) carries a common single-nucleotide polymorphism (SNP) at position 8473 (T8473C), in exon 10 that is associated with diseases in which COX-2 overexpression is a contributing factor. We demonstrate that the T8473C SNP resides within a region that targets COX-2 mRNA for degradation through microRNA-mediated regulation. miR-542-3p was identified to bind transcripts derived from the 8473T allele and promote mRNA decay. By contrast, the presence of the variant 8473C allele interfered with miR-542-3p binding, allowing for mRNA stabilization, and this effect was rescued using a mutated miR-542-3p at the respective 8473 site. Colon cancer cells and tissue displayed COX-2 mRNA levels that were dependent on T8473C allele dosage, and allele-specific expression of COX-2 was observed to be a contributing factor promoting COX-2 overexpression. These findings provide a novel molecular explanation underlying disease susceptibility associated with COX-2 T8473C SNP, and identify it as a potential marker for identifying cancer patients best served through selective COX-2 inhibition. Oncogene (2012) 31, 1592-1598; doi:10.1038/onc.2011.349; published online 8 August 2011	[Dixon, D. A.] Univ S Carolina, Dept Biol Sci, Jones PSC, Columbia, SC 29208 USA; Univ S Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Dixon, DA (corresponding author), Univ S Carolina, Dept Biol Sci, Jones PSC, 712 Main St,Room 614, Columbia, SC 29208 USA.	ddixon@biol.sc.edu			National Institutes of Health [R01CA134609]; American Cancer Society [RSG-06-122-01-CNE]; NATIONAL CANCER INSTITUTE [R01CA134609] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health (R01CA134609) and American Cancer Society (RSG-06-122-01-CNE).	Abdelmohsen K, 2008, P NATL ACAD SCI USA, V105, P20297, DOI 10.1073/pnas.0809376106; Ali IU, 2005, BRIT J CANCER, V93, P953, DOI 10.1038/sj.bjc.6602806; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Birkenkamp-Demtroder K, 2005, GUT, V54, P374, DOI 10.1136/gut.2003.036848; Campa D, 2004, CARCINOGENESIS, V25, P229, DOI 10.1093/carcin/bgh008; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Dimberg J, 1999, GUT, V45, P730, DOI 10.1136/gut.45.5.730; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Ferguson HR, 2008, CANCER EPIDEM BIOMAR, V17, P727, DOI 10.1158/1055-9965.EPI-07-2570; Gong ZH, 2009, INT J COLORECTAL DIS, V24, P647, DOI 10.1007/s00384-009-0656-8; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Langsenlehner U, 2006, CLIN CANCER RES, V12, P1392, DOI 10.1158/1078-0432.CCR-05-2055; Menter DG, 2010, CLIN CANCER RES, V16, P1384, DOI 10.1158/1078-0432.CCR-09-0788; Nasir Aejaz, 2004, Clin Colorectal Cancer, V3, P243, DOI 10.3816/CCC.2004.n.005; Nicoloso MS, 2010, CANCER RES, V70, P2789, DOI 10.1158/0008-5472.CAN-09-3541; Ozhan G, 2010, PANCREAS, V39, P371, DOI 10.1097/MPA.0b013e3181bae9ca; Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867; Sanduja S, 2009, AGING-US, V1, P803, DOI 10.18632/aging.100086; Shen J, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1629; Siezen CLE, 2005, CARCINOGENESIS, V26, P449, DOI 10.1093/carcin/bgh336; Vogel U, 2008, MUTAT RES-FUND MOL M, V639, P89, DOI 10.1016/j.mrfmmm.2007.11.004; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Young LE, 2010, CURR COLORECT CANC R, V6, P60, DOI 10.1007/s11888-010-0044-3; Young LE, 2009, GASTROENTEROLOGY, V136, P1669, DOI 10.1053/j.gastro.2009.01.010	27	39	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1592	1598		10.1038/onc.2011.349	http://dx.doi.org/10.1038/onc.2011.349			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21822307	Green Accepted			2022-12-17	WOS:000302132000011
J	Kais, Z; Chiba, N; Ishioka, C; Parvin, JD				Kais, Z.; Chiba, N.; Ishioka, C.; Parvin, J. D.			Functional differences among BRCA1 missense mutations in the control of centrosome duplication	ONCOGENE			English	Article						BRCA1; breast cancer; centrosomes; RING domain	POLYMERASE-II HOLOENZYME; UBIQUITIN-LIGASE; TRANSCRIPTIONAL ACTIVATION; CANCER SUSCEPTIBILITY; CELL-CYCLE; BREAST; IDENTIFICATION; AMPLIFICATION; INTERACT; BINDING	We analyzed the effects of 14 different missense mutations in the RING domain of BRCA1 on the function of the protein in the control of centrosome number in tissue culture cells. Whereas 2 of the 14 BRCA1 variant proteins were neutral in the centrosome duplication assay, missense mutations of zinc-coordinating residues (C24R, C27A, C39Y, H41F, C44F and C47G) and mutations encoding BRCA1 variants M18T and I42V resulted in BRCA1 proteins that caused centrosome amplification. BRCA1 variant proteins I21V, I31M, L52F and D67Y had an intermediate effect on centrosome duplication. In addition, one of the variants, L52F, caused a peculiar phenotype with amplified centrosomes but the centrioles remained paired. By comparison, other BRCA1 variants that caused centrosome amplification had clustering of supernumerary centrosomes with unpaired centrioles. This surprising phenotype suggests that the BRCA1 protein regulates two functions in the control of centrosome duplication: regulation of centrosome number and regulation of centriole pairing. The L52F is unusual as it is defective in only one of these processes. This study analyzes the function of BRCA1 missense mutations in the control of centrosome duplication, a critical step in the maintenance of genetic stability of mammary epithelial cells, and indicates a new function of BRCA1 in the control of centriole pairing. Oncogene (2012) 31, 799-804; doi:10.1038/onc.2011.271; published online 4 July 2011	[Kais, Z.; Parvin, J. D.] Ohio State Univ, Ctr Comprehens Canc, Dept Biomed Informat, Columbus, OH 43210 USA; [Chiba, N.] Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Immunol, Sendai, Miyagi 980, Japan; [Ishioka, C.] Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Sendai, Miyagi 980, Japan	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Tohoku University; Tohoku University	Parvin, JD (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Dept Biomed Informat, 904 Biomed Res Tower,460 W 12th Ave, Columbus, OH 43210 USA.	Jeffrey.Parvin@osumc.edu	Parvin, Jeffrey D/C-8955-2009	Ishioka, Chikashi/0000-0002-3023-1227	NIH [CA111480]; NATIONAL CANCER INSTITUTE [R01CA111480, P30CA016058] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grant CA111480 (JDP).	Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chiba N, 2002, CANCER RES, V62, P4222; D'Assoro AB, 2001, MARC MALPIG SYMP SER, V7, P103; Easton DF, 2007, AM J HUM GENET, V81, P873, DOI 10.1086/521032; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kais Z, 2008, CANCER BIOL THER, V7, P1540, DOI 10.4161/cbt.7.10.7053; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Morris JR, 2006, HUM MOL GENET, V15, P599, DOI 10.1093/hmg/ddi476; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Ransburgh DJR, 2010, CANCER RES, V70, P988, DOI 10.1158/0008-5472.CAN-09-2850; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sankaran S, 2007, CANCER BIOL THER, V6, P1853, DOI 10.4161/cbt.6.12.5164; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sinilnikova OM, 2006, FAM CANCER, V5, P15, DOI 10.1007/s10689-005-2571-7; Sluder G, 2004, CURR OPIN CELL BIOL, V16, P49, DOI 10.1016/j.ceb.2003.11.006; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Vega A, 2001, Hum Mutat, V17, P520, DOI 10.1002/humu.1136; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	26	39	39	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	6					799	804		10.1038/onc.2011.271	http://dx.doi.org/10.1038/onc.2011.271			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725363	Green Accepted			2022-12-17	WOS:000300222100012
J	Li, X; Law, JWS; Lee, AYW				Li, X.; Law, J. W. S.; Lee, A. Y. W.			Semaphorin 5A and plexin-B3 regulate human glioma cell motility and morphology through Rac1 and the actin cytoskeleton	ONCOGENE			English	Article						glioblastoma; invasion; glial differentiation; GTPases; fascin	FIBRILLARY ACIDIC PROTEIN; HUMAN ASTROCYTOMA-CELLS; AXON GUIDANCE; INDUCED ANGIOGENESIS; PANCREATIC-CANCER; COMPLEMENTARY-DNA; INVASIVE GROWTH; GENE-EXPRESSION; TUMOR-GROWTH; R-RAS	Semaphorins are implicated in glioma progression, although little is known about the underlying mechanisms. We have reported plexin-B3 expression in human gliomas, which upon stimulation by Sema5A causes significant inhibition of cell migration and invasion. The concomitant inactivation of Rac1 is of mechanistic importance because forced expression of constitutively active Rac1 abolishes these inhibitory effects. Furthermore, Sema5A induces prominent cell collapse and ramification of processes reminiscent of astrocytic morphology, which temporally associate with extensive disassembly of actin stress fibers and disruption of focal adhesions, followed by accumulation of actin patches in protrusions. Mechanistically, Sema5A induces transient protein kinase C (PKC) phosphorylation of fascin-1, which can reduce its actin-binding/bundling activities and temporally parallels its translocation from cell body to extending processes. PKC inhibition or fascin-1 knockdown is sufficient to abrogate Sema5A-induced morphological differentiation, whereas the process is hastened by forced expression of fascin-1. Intriguingly, Sema5A induces re-expression of glial fibrillary acidic protein (GFAP), which when silenced restricts differentiation of glioma cells to bipolar instead of multipolar morphology. Therefore, we hypothesize complementary functions of fascin-1 and GFAP in the early and late phases of Sema5A-induced astrocytic differentiation of gliomas, respectively. In summary, Sema5A and plexin-B3 impede motility but promote differentiation of human gliomas. These effects are plausibly compromised in high-grade human astrocytomas in which Sema5A expression is markedly reduced, hence leading to infiltrative and anaplastic characteristics. This is evident by increased invasiveness of glioma cells when endogenous Sema5A is silenced. Therefore, Sema5A and plexin-B3 represent potential novel targets in counteracting glioma progression. Oncogene (2012) 31, 595-610; doi:10.1038/onc.2011.256; published online 27 June 2011	[Lee, A. Y. W.] Natl Univ Singapore, Ctr Life Sci, Inst Life Sci, Dept Physiol,Yong Loo Lin Sch Med,Neurobiol Agein, Singapore 117456, Singapore	National University of Singapore	Lee, AYW (corresponding author), Natl Univ Singapore, Ctr Life Sci, Inst Life Sci, Dept Physiol,Yong Loo Lin Sch Med,Neurobiol Agein, 28 Med Dr, Singapore 117456, Singapore.	phsleeyw@nus.edu.sg	LEE, Alan Yiu Wah/AAE-1845-2022; Lee, Alan Yiu Wah/AAD-4541-2020; Lee, Alan/E-8554-2011	Lee, Alan Yiu Wah/0000-0003-0635-4179; 	National University of Singapore; Biomedical Research Council of Singapore	National University of Singapore(National University of Singapore); Biomedical Research Council of Singapore(Agency for Science Technology & Research (A*STAR))	We are indebted to Dr David Srevatan for providing the Sema5A-Fc expression construct and to Dr Danijela Vignijevic for the pEGFP-fascin plasmid. This work was supported by research grants from the National University of Singapore and the Biomedical Research Council of Singapore.	Adams JC, 2004, CURR OPIN CELL BIOL, V16, P590, DOI 10.1016/j.ceb.2004.07.009; Anilkumar N, 2003, EMBO J, V22, P5390, DOI 10.1093/emboj/cdg521; Artigiani S, 2004, EMBO REP, V5, P710, DOI 10.1038/sj.embor.7400189; Bagci T, 2009, ONCOGENE, V28, P3537, DOI 10.1038/onc.2009.204; Balakrishnan A, 2009, HUM MUTAT, V30, P1167, DOI 10.1002/humu.21017; Banu N, 2006, FASEB J, V20, P2150, DOI 10.1096/fj.05-5698fje; Barberis D, 2004, FASEB J, V18, P592, DOI 10.1096/fj.03-0957fje; Basile JR, 2006, P NATL ACAD SCI USA, V103, P9017, DOI 10.1073/pnas.0508825103; Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Brun M, 2009, J MOL BIOL, V391, P282, DOI 10.1016/j.jmb.2009.06.041; Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101; Catalano A, 2004, FASEB J, V18, P1740, DOI 10.1096/fj.04-2258fje; Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909; Chedotal A, 2007, PROG EXP TUMOR RES, V39, P78, DOI 10.1159/000100048; Christensen C, 2005, CANCER RES, V65, P6167, DOI 10.1158/0008-5472.CAN-04-4309; Coma S, 2010, CANCER RES, V70, P3823, DOI 10.1158/0008-5472.CAN-09-3048; Conrotto P, 2004, ONCOGENE, V23, P5131, DOI 10.1038/sj.onc.1207650; Correa RG, 2001, GENOMICS, V73, P343, DOI 10.1006/geno.2001.6525; Crowe DL, 2004, ANTICANCER RES, V24, P593; DECK JHN, 1978, ACTA NEUROPATHOL, V42, P183, DOI 10.1007/BF00690355; Deryugina EI, 1997, J CELL SCI, V110, P2473; Dhanabal M, 2005, CANCER BIOL THER, V4, P659, DOI 10.4161/cbt.4.6.1733; Driessens MHE, 2002, FEBS LETT, V529, P168, DOI 10.1016/S0014-5793(02)03323-9; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; DUFFY PE, 1982, EXP CELL RES, V139, P145, DOI 10.1016/0014-4827(82)90328-7; Elobeid A, 2000, J NEUROSCI RES, V60, P245, DOI 10.1002/(SICI)1097-4547(20000415)60:2<245::AID-JNR14>3.0.CO;2-1; Feldkamp MM, 1999, ONCOGENE, V18, P7514, DOI 10.1038/sj.onc.1203105; Goldberg JL, 2004, J NEUROSCI, V24, P4989, DOI 10.1523/JNEUROSCI.4390-03.2004; Hilario JD, 2009, DEV BIOL, V326, P190, DOI 10.1016/j.ydbio.2008.11.007; Hu B, 2007, ONCOGENE, V26, P5577, DOI 10.1038/sj.onc.1210348; Hu HL, 2001, NEURON, V32, P39, DOI 10.1016/S0896-6273(01)00453-6; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; Iwadate Y, 2004, CANCER RES, V64, P2496, DOI 10.1158/0008-5472.CAN-03-1254; Kantor DB, 2004, NEURON, V44, P961, DOI 10.1016/j.neuron.2004.12.002; Karayan-Tapon L, 2008, BRIT J CANCER, V99, P1153, DOI 10.1038/sj.bjc.6604641; Kureishy N, 2002, BIOESSAYS, V24, P350, DOI 10.1002/bies.10070; Kusy S, 2005, NEOPLASIA, V7, P457, DOI 10.1593/neo.04721; Li XH, 2010, J BIOL CHEM, V285, P32436, DOI 10.1074/jbc.M110.120451; Lu TP, 2010, CANCER EPIDEM BIOMAR, V19, P2590, DOI 10.1158/1055-9965.EPI-10-0332; McDonough WS, 2005, NEOPLASIA, V7, P862, DOI 10.1593/neo.05190; Mondal S, 2010, BRAIN PATHOL, V20, P190, DOI 10.1111/j.1750-3639.2008.00261.x; Murakami M, 2001, INT J ONCOL, V18, P721; Nakada M, 2006, CANCER RES, V66, P8492, DOI 10.1158/0008-5472.CAN-05-4211; Nasarre C, 2009, CELL ADHES MIGR, V3, P383, DOI 10.4161/cam.3.4.9934; Neufeld G, 2005, FRONT BIOSCI-LANDMRK, V10, P751, DOI 10.2741/1569; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Oinuma I, 2006, J CELL BIOL, V173, P601, DOI 10.1083/jcb.200508204; Oster SF, 2003, DEVELOPMENT, V130, P775, DOI 10.1242/dev.00299; Pan GQ, 2009, WORLD J GASTROENTERO, V15, P2800, DOI 10.3748/wjg.15.2800; Pan GQ, 2010, LIFE SCI, V86, P139, DOI 10.1016/j.lfs.2009.12.004; Restrepo A, 2011, NEURO-ONCOLOGY, V13, P42, DOI 10.1093/neuonc/noq145; Rich JN, 2005, CANCER RES, V65, P4051, DOI 10.1158/0008-5472.CAN-04-3936; Rickman DS, 2001, CANCER RES, V61, P6885; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rieger J, 2003, GLIA, V42, P379, DOI 10.1002/glia.10210; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; RUTKA JT, 1993, CANCER RES, V53, P3624; RUTKA JT, 1994, CANCER RES, V54, P3267; Rutka JT, 1997, J NEUROSURG, V87, P420, DOI 10.3171/jns.1997.87.3.0420; Sadanandam A, 2007, OMICS, V11, P41, DOI 10.1089/omi.2006.0004; Sadanandam A, 2010, INT J CANCER, V127, P1373, DOI 10.1002/ijc.25166; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; Swiercz JM, 2008, J BIOL CHEM, V283, P1893, DOI 10.1074/jbc.M706822200; Swiercz JM, 2004, J CELL BIOL, V165, P869, DOI 10.1083/jcb.200312094; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Walzer T, 2005, EUR J IMMUNOL, V35, P391, DOI 10.1002/eji.200425669; Webb DJ, 2003, CURR OPIN CELL BIOL, V15, P614, DOI 10.1016/S0955-0674(03)00105-4; Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843; Wong CCL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002779; Woodhouse EC, 2003, P NATL ACAD SCI USA, V100, P11463, DOI 10.1073/pnas.2031202100; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	73	39	46	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	5					595	610		10.1038/onc.2011.256	http://dx.doi.org/10.1038/onc.2011.256			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21706053				2022-12-17	WOS:000300221800006
J	Lazzari, C; Prodosmo, A; Siepi, F; Rinaldo, C; Galli, F; Gentileschi, M; Bartolazzi, A; Costanzo, A; Sacchi, A; Guerrini, L; Soddu, S				Lazzari, C.; Prodosmo, A.; Siepi, F.; Rinaldo, C.; Galli, F.; Gentileschi, M.; Bartolazzi, A.; Costanzo, A.; Sacchi, A.; Guerrini, L.; Soddu, S.			HIPK2 phosphorylates Delta Np63 alpha and promotes its degradation in response to DNA damage	ONCOGENE			English	Article						HIPK2; chemotherapy; Delta Np63; phosphorylation; degradation	SQUAMOUS-CELL CARCINOMA; INTERACTING PROTEIN KINASE-2; INDUCED APOPTOSIS; P53 FAMILY; PROTEASOMAL DEGRADATION; TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR; EPITHELIAL-CELLS; CANCER-CELLS; P63	Homeodomain-interacting protein kinase 2 (HIPK2) is an emerging player in cell response to genotoxic agents that senses damage intensity and contributes to the cell's choice between cell cycle arrest and apoptosis. Phosphorylation of p53 at S46, an apoptosis-specific p53 posttranslational modification, is the most characterized HIPK2 function in response to lethal doses of ultraviolet (UV), ionizing radiation or different anticancer drugs, such as cisplatin, roscovitine and doxorubicin (DOX). Indeed, like p53, HIPK2 has been shown to contribute to the effectiveness of these treatments. Interestingly, p53-independent mechanisms of HIPK2-induced apoptosis were described for UV and tumor growth factor-beta treatments; however, it is unknown whether these mechanisms are relevant for the responses to anticancer drugs. Because of the importance of the so-called 'p53-independent apoptosis and drug response' in human cancer chemotherapy, we asked whether p53-independent factor(s) might be involved in HIPK2-mediated chemosensitivity. Here, we show that HIPK2 depletion by RNA interference induces resistance to different anticancer drugs even in p53-null cells, suggesting the involvement of HIPK2 targets other than p53 in response to chemotherapy. In particular, we found that HIPK2 phosphorylates and promotes proteasomal degradation of Delta Np63 alpha, a prosurvival Delta N isoform of the p53 family member, p63. Indeed, effective cell response to different genotoxic agents was shown to require phosphorylation-induced proteasomal degradation of Delta Np63 alpha. In DOX-treated cells, we show that HIPK2 depletion interferes with Delta Np63 alpha degradation, and expression of a HIPK2-resistant Delta Np63 alpha-Delta 390 mutant induces chemoresistance. We identify T397 as the Delta Np63 alpha residue phosphorylated by HIPK2, and show that the non-phosphorylatable Delta Np63 alpha-T397A mutant is not degraded in the face of either HIPK2 overexpression or DOX treatment. These results indicate Delta Np63 alpha as a novel target of HIPK2 in response to genotoxic drugs. Oncogene (2011) 30, 4802-4813; doi: 10.1038/onc.2011.182; published online 23 May 2011	[Lazzari, C.; Prodosmo, A.; Siepi, F.; Rinaldo, C.; Gentileschi, M.; Sacchi, A.; Soddu, S.] Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, I-00158 Rome, Italy; [Galli, F.; Guerrini, L.] Univ Milan, Dept Biomol & Biotechnol Sci, Milan, Italy; [Bartolazzi, A.] Karolinska Hosp, Canc Ctr Karolinska, S-10401 Stockholm, Sweden; [Bartolazzi, A.] St Andrea Univ Hosp, Dept Pathol, Rome, Italy; [Costanzo, A.] Univ Roma Tor Vergata, Dept Dermatol, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Milan; Karolinska Institutet; Karolinska University Hospital; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; University of Rome Tor Vergata	Soddu, S (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, Via Messi dOro 156, I-00158 Rome, Italy.	soddu@ifo.it	Soddu, Silvia/ABH-6774-2020; Costanzo, Antonio/D-3896-2012; Costanzo, Antonio/GZG-2433-2022; prodosmo, andrea/AAA-7766-2020; Soddu, Silvia/K-2467-2018; Rinaldo, Cinzia/A-4252-2015; Bartolazzi, Armando/K-9708-2016	Soddu, Silvia/0000-0001-8526-0044; Costanzo, Antonio/0000-0001-9697-2557; Soddu, Silvia/0000-0001-8526-0044; Rinaldo, Cinzia/0000-0001-6124-762X; Bartolazzi, Armando/0000-0001-7820-5127; PRODOSMO, ANDREA/0000-0001-5828-8586	Ministero della Salute; Scientific Direction of the Regina Elena Cancer Institute; Fondazione Italiana per la Ricerca sul Cancro; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Ministero della Salute(Ministry of Health, Italy); Scientific Direction of the Regina Elena Cancer Institute; Fondazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	We are grateful to all people cited in the text for their kind gifts of cells and reagents and to Dr F Socciarelli for technical support. This work was supported by Ministero della Salute and 'New Idea Award' form the Scientific Direction of the Regina Elena Cancer Institute to SS. FS was a recipient of a fellowship from Fondazione Italiana per la Ricerca sul Cancro.	Barbieri CE, 2005, CANCER RES, V65, P2314, DOI 10.1158/0008-5472.CAN-04-3449; Bon G, 2009, CANCER RES, V69, P5978, DOI 10.1158/0008-5472.CAN-09-0244; Bracaglia G, 2009, EMBO REP, V10, P1327, DOI 10.1038/embor.2009.217; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Calzado MA, 2007, CELL CYCLE, V6, P139, DOI 10.4161/cc.6.2.3788; Calzado MA, 2009, CELL CYCLE, V8, P1659, DOI 10.4161/cc.8.11.8597; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Cecchinelli B, 2006, CELL DEATH DIFFER, V13, P1994, DOI 10.1038/sj.cdd.4401933; Cecchinelli B, 2006, MOL CELL BIOL, V26, P4746, DOI 10.1128/MCB.00959-05; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dauth I, 2007, CANCER RES, V67, P2274, DOI 10.1158/0008-5472.CAN-06-2884; Di Costanzo A, 2009, CELL CYCLE, V8, P1185, DOI 10.4161/cc.8.8.8202; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; Du ZJ, 2010, CANCER SCI, V101, P2417, DOI 10.1111/j.1349-7006.2010.01700.x; Fomenkov A, 2004, CELL CYCLE, V3, P1285, DOI 10.4161/cc.3.10.1155; Galli F, 2010, J CELL SCI, V123, P2423, DOI 10.1242/jcs.061010; Gonfloni S, 2009, NAT MED, V15, P1179, DOI 10.1038/nm.2033; Gresko E, 2009, ONCOGENE, V28, P698, DOI 10.1038/onc.2008.420; Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hofmann TG, 2003, CANCER RES, V63, P8271; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Huang YP, 2008, CELL CYCLE, V7, P2846, DOI 10.4161/cc.7.18.6627; Huang YP, 2010, CELL CYCLE, V9, P328, DOI 10.4161/cc.9.2.10432; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Kanei-Ishii C, 2004, GENE DEV, V18, P816, DOI 10.1101/gad.1170604; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Lanza M, 2006, CELL CYCLE, V5, P1996, DOI 10.4161/cc.5.17.3188; Lavra L, 2011, PLOS ONE IN PRESS; Leong CO, 2007, J CLIN INVEST, V117, P1370, DOI 10.1172/JCI30866; Li QX, 2009, NAT CELL BIOL, V11, P1128, DOI 10.1038/ncb1927; Li XL, 2007, ONCOGENE, V26, P7231, DOI 10.1038/sj.onc.1210523; Li Y, 2008, CELL DEATH DIFFER, V15, P1941, DOI 10.1038/cdd.2008.134; Liefer KM, 2000, CANCER RES, V60, P4016; Lin ZH, 2006, J CANCER RES CLIN, V132, P811, DOI 10.1007/s00432-006-0130-8; MacPartlin M, 2008, J BIOL CHEM, V283, P15754, DOI 10.1074/jbc.M801394200; Moll UM, 2004, MOL CANCER RES, V2, P371; Muller M, 2006, DRUG RESIST UPDATE, V9, P288, DOI 10.1016/j.drup.2007.01.001; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Papoutsaki M, 2005, ONCOGENE, V24, P6970, DOI 10.1038/sj.onc.1208835; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pierantoni GM, 2007, J CLIN INVEST, V117, P693, DOI 10.1172/JCI29852; Puca R, 2010, ONCOGENE, V29, P4378, DOI 10.1038/onc.2010.183; Puca R, 2008, CANCER RES, V68, P3707, DOI 10.1158/0008-5472.CAN-07-6776; Rinaldo C, 2007, BIOCHEM CELL BIOL, V85, P411, DOI 10.1139/O07-071; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Rossi M, 2006, P NATL ACAD SCI USA, V103, P12753, DOI 10.1073/pnas.0603449103; Senoo M, 2001, BRIT J CANCER, V84, P1235, DOI 10.1054/bjoc.2000.1735; Vilgelm A, 2008, DRUG RESIST UPDATE, V11, P152, DOI 10.1016/j.drup.2008.08.001; Wang N, 2010, EMBO REP, V11, P633, DOI 10.1038/embor.2010.82; Wee HJ, 2008, BLOOD, V112, P3777, DOI 10.1182/blood-2008-01-134122; Wesierska-Gadek J, 2007, J CELL BIOCHEM, V100, P865, DOI 10.1002/jcb.21211; Westfall MD, 2005, CELL CYCLE, V4, P710, DOI 10.4161/cc.4.5.1685; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Wu GJ, 2005, CANCER RES, V65, P758; Yamada D, 2009, ONCOGENE, V28, P2535, DOI 10.1038/onc.2009.109; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018; Zangen R, 2005, CELL CYCLE, V4, P1313, DOI 10.4161/cc.4.10.2066; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X	63	39	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	48					4802	4813		10.1038/onc.2011.182	http://dx.doi.org/10.1038/onc.2011.182			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863AH	21602882	Bronze			2022-12-17	WOS:000298134700004
J	Fournier, G; Cabaud, O; Josselin, E; Chaix, A; Adelaide, J; Isnardon, D; Restouin, A; Castellano, R; Dubreuil, P; Chaffanet, M; Birnbaum, D; Lopez, M				Fournier, G.; Cabaud, O.; Josselin, E.; Chaix, A.; Adelaide, J.; Isnardon, D.; Restouin, A.; Castellano, R.; Dubreuil, P.; Chaffanet, M.; Birnbaum, D.; Lopez, M.			Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth	ONCOGENE			English	Article						afadin; breast cancer; migration; invasion; tumorigenicity; SRC and MAPK	ACTIVATED PROTEIN-KINASE; PDZ DOMAIN; ACTIN CYTOSKELETON; ADHERENS JUNCTIONS; NEGATIVE REGULATOR; ADHESION MOLECULE; AF-6; DROSOPHILA; BINDING; AFADIN	Afadin/AF6, an F-actin-binding protein, is ubiquitously expressed in epithelia and has a key role during development, through its regulatory role in cell-cell junction organization. Afadin loss of expression in 15% of breast carcinoma is associated with adverse prognosis and increased risk of metastatic relapse. To determine the role of afadin in breast cancer, we studied the functional consequences of afadin protein extinction using in vitro and in vivo models. Three different breast cancer cell lines representative of the major molecular subtypes were stably repressed for afadin expression (knockdown of afadin (afadin KD)) using RNA interference. Collective and individual migrations as well as Matrigel invasion were markedly increased in afadin KD cells. Heregulin-beta 1 (HRG-beta 1)-induced migration and invasion were increased by twofold in afadin KD cells. Conversely, ectopic expression of afadin in the afadin-negative T47D cell line inhibited spontaneous and HRG-beta 1-induced migrations. RAS/MAPK and SRC kinase pathways were activated in afadin KD cells. Activation levels positively correlated with migration and invasion strength. Use of MEK1/2 (U0126) and SRC kinases (SU6656) inhibitors reduced afadin-dependent migration and invasion. Afadin extinction in the SK-BR-3 cell line markedly accelerated tumor growth development in mouse mammary gland and lung metastasis formation. These results may explain why the loss of afadin expression in tumors correlates with high tumor size and poor metastasis-free survival in patients. Oncogene (2011) 30, 3862-3874; doi:10.1038/onc.2011.106; published online 11 April 2011	[Fournier, G.; Cabaud, O.; Josselin, E.; Chaffanet, M.; Birnbaum, D.; Lopez, M.] INSERM, Oncol Mol Lab, UMR 891, CRCM, F-13009 Marseille, France; [Chaix, A.; Dubreuil, P.] INSERM, Lab Hematopoiese Fonct & Mol, UMR 891, CRCM, F-13009 Marseille, France; [Restouin, A.; Castellano, R.] INSERM, Plateforme TrGET Essais Preclin, UMR 891, CRCM, F-13009 Marseille, France; [Fournier, G.; Cabaud, O.; Josselin, E.; Chaix, A.; Adelaide, J.; Isnardon, D.; Restouin, A.; Castellano, R.; Dubreuil, P.; Chaffanet, M.; Lopez, M.] Inst J Paoli I Calmettes, F-13009 Marseille, France; [Fournier, G.; Cabaud, O.; Josselin, E.; Chaix, A.; Adelaide, J.; Isnardon, D.; Restouin, A.; Castellano, R.; Dubreuil, P.; Chaffanet, M.; Lopez, M.] Univ Aix Marseille 2, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	Lopez, M (corresponding author), INSERM, Oncol Mol Lab, UMR891, 27 Bd Lei Roure, F-13009 Marseille, France.	marc.lopez@inserm.fr	CHAFFANET, Max/AAU-5743-2020; Dubreuil, Patrice/V-4816-2019; ADELAIDE, José JA/O-4390-2017; dubreuil, patrice/F-5346-2011	Dubreuil, Patrice/0000-0003-1155-1150; ADELAIDE, José JA/0000-0003-4364-9857; dubreuil, patrice/0000-0003-1155-1150; Birnbaum, Daniel/0000-0001-7920-9883; CHAFFANET, Max/0000-0002-2344-1488	INSERM; Institut Paoli-Calmettes; Ligue Nationale Contre le Cancer (LNCC); Institut National du Cancer	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Institut Paoli-Calmettes; Ligue Nationale Contre le Cancer (LNCC)(Ligue nationale contre le cancer); Institut National du Cancer(Institut National du Cancer (INCA) France)	We thank F Birg for helpful discussions. We are grateful of M Buchert for providing us with the pCDNA3-FLAG-L-AF6 vector. This work was supported by INSERM, Institut Paoli-Calmettes, and grants from Ligue Nationale Contre le Cancer (LNCC) (Label 2009-2011) and Institut National du Cancer (AO translationnelle). In 2009-2010, GF has been supported by a fellowship from LNCC.	Adelaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536; Bae YH, 2009, J CELL PHYSIOL, V219, P354, DOI 10.1002/jcp.21677; Boettner B, 2003, GENETICS, V165, P159; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Buchert M, 2007, J CELL PHYSIOL, V210, P212, DOI 10.1002/jcp.20853; Carmena A, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000066; Ding ZJ, 2006, J CELL SCI, V119, P4127, DOI 10.1242/jcs.03178; Gaengel K, 2003, DEVELOPMENT, V130, P5413, DOI 10.1242/dev.00759; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Letessier A, 2007, ONCOGENE, V26, P298, DOI 10.1038/sj.onc.1209772; Liedtke M, 2010, BLOOD, V116, P63, DOI 10.1182/blood-2009-09-243386; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Lorger M, 2006, J CELL SCI, V119, P3385, DOI 10.1242/jcs.03027; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; Martuszewska D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004350; Matsuo T, 1999, CELL TISSUE RES, V298, P397, DOI 10.1007/s004410050062; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; Miyata M, 2009, J CELL SCI, V122, P4319, DOI 10.1242/jcs.048439; Nakata S, 2007, J BIOL CHEM, V282, P37815, DOI 10.1074/jbc.M707461200; Nikolopoulos SN, 2000, ONCOGENE, V19, P380, DOI 10.1038/sj.onc.1203310; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265, DOI 10.1016/S0968-0004(00)89040-4; PRASAD R, 1993, CANCER RES, V53, P5624; Radziwill G, 2003, MOL CELL BIOL, V23, P4663, DOI 10.1128/MCB.23.13.4663-4672.2003; Radziwill G, 2007, EMBO J, V26, P2633, DOI 10.1038/sj.emboj.7601706; SAHA V, 1995, GENE CHROMOSOME CANC, V14, P220, DOI 10.1002/gcc.2870140311; Saito S, 1998, DNA Res, V5, P115, DOI 10.1093/dnares/5.2.115; Sawyer JK, 2009, J CELL BIOL, V186, P57, DOI 10.1083/jcb.200904001; Severson EA, 2009, MOL BIOL CELL, V20, P1916, DOI 10.1091/mbc.E08-10-1014; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Speicher S, 2008, CURR BIOL, V18, P831, DOI 10.1016/j.cub.2008.04.072; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Su L, 2003, J BIOL CHEM, V278, P15232, DOI 10.1074/jbc.M211888200; Takahashi K, 1998, MECH DEVELOP, V78, P97, DOI 10.1016/S0925-4773(98)00151-8; Takai Y, 2008, ANNU REV CELL DEV BI, V24, P309, DOI 10.1146/annurev.cellbio.24.110707.175339; TANAKA M, 1995, CANCER RES, V55, P3228; Vadlamudi R, 1999, ONCOGENE, V18, P7253, DOI 10.1038/sj.onc.1203163; Yamamoto T, 1999, BIOCHEM BIOPH RES CO, V259, P103, DOI 10.1006/bbrc.1999.0731; Zhadanov AB, 1999, CURR BIOL, V9, P880, DOI 10.1016/S0960-9822(99)80392-3; Zou L, 2007, BRIT J CANCER, V97, P1361, DOI 10.1038/sj.bjc.6604038	43	39	39	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	36					3862	3874		10.1038/onc.2011.106	http://dx.doi.org/10.1038/onc.2011.106			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	817PV	21478912				2022-12-17	WOS:000294687200004
J	Legros, S; Boxus, M; Gatot, JS; Van Lint, C; Kruys, V; Kettmann, R; Twizere, JC; Dequiedt, F				Legros, S.; Boxus, M.; Gatot, J. S.; Van Lint, C.; Kruys, V.; Kettmann, R.; Twizere, J. C.; Dequiedt, F.			The HTLV-1 Tax protein inhibits formation of stress granules by interacting with histone deacetylase 6	ONCOGENE			English	Article						HTLV-I; Tax; p-bodies; stress	VIRUS TYPE-1 TAX; NF-KAPPA-B; DNA-DAMAGE-RESPONSE; T-LYMPHOTROPIC-VIRUS; I TAX; MESSENGER-RNA; PROCESSING BODIES; EIF2-ALPHA PHOSPHORYLATION; GENE-EXPRESSION; ONCOPROTEIN	Human T cell leukemia virus type-1 (HTLV-1) is the causative agent of a fatal adult T-cell leukemia. Through deregulation of multiple cellular signaling pathways the viral Tax protein has a pivotal role in T-cell transformation. In response to stressful stimuli, cells mount a cellular stress response to limit the damage that environmental forces inflict on DNA or proteins. During stress response, cells postpone the translation of most cellular mRNAs, which are gathered into cytoplasmic mRNA-silencing foci called stress granules (SGs) and allocate their available resources towards the production of dedicated stress-management proteins. Here we demonstrate that Tax controls the formation of SGs and interferes with the cellular stress response pathway. In agreement with previous reports, we observed that Tax relocates from the nucleus to the cytoplasm in response to environmental stress. We found that the presence of Tax in the cytoplasm of stressed cells prevents the formation of SGs and counteracts the shutoff of specific host proteins. Unexpectedly, nuclear localization of Tax promotes spontaneous aggregation of SGs, even in the absence of stress. Mutant analysis revealed that the SG inhibitory capacity of Tax is independent of its transcriptional abilities but relies on its interaction with histone deacetylase 6, a critical component of SGs. Importantly, the stress-protective effect of Tax was also observed in the context of HTLV-1 infected cells, which were shown to be less prone to form SGs and undergo apoptosis under arsenite exposure. These observations identify Tax as the first virally encoded inhibitory component of SGs and unravel a new strategy developed by HTLV-1 to deregulate normal cell processes. We postulate that inhibition of the stress response pathway by Tax would favor cell survival under stressful conditions and may have an important role in HTLV-1-induced cellular transformation. Oncogene (2011) 30, 4050-4062; doi:10.1038/onc.2011.120; published online 2 May 2011	[Legros, S.; Boxus, M.; Kettmann, R.; Twizere, J. C.; Dequiedt, F.] Univ Liege ULg, Gembloux Agrobio Tech, Ctr Mol & Cellular Biol, Gembloux, Belgium; [Gatot, J. S.; Van Lint, C.] Free Univ Brussels ULB, IBMM, Ctr Mol Virol, Gosselies, Belgium; [Kruys, V.] Free Univ Brussels ULB, IBMM, Ctr Mol Biol Gene, Gosselies, Belgium; [Twizere, J. C.; Dequiedt, F.] Univ Liege ULg, GIGA Res, Lab Prot Signaling & Interact, Liege, Belgium	Universite Libre de Bruxelles; Universite Libre de Bruxelles; University of Liege	Dequiedt, F (corresponding author), Univ Liege ULg, Gembloux Agrobio Tech, Ctr Mol & Cellular Biol, 13 Av Marechal Juin,Bat92, B-5030 Namur, Belgium.	fdequiedt@ulg.ac.be	Kruys, Veronique I/N-6613-2018; Twizere, Jean-Claude/AAG-3706-2019	TWIZERE, Jean-Claude/0000-0002-8683-705X; Dequiedt, Franck/0000-0003-1234-7477; Kruys, Veronique/0000-0002-3144-5403	Belgian Foundation Against Cancer [IUAP-BELSPOPVI/28]	Belgian Foundation Against Cancer	We thank all members of the Dequiedt laboratory for helpful and stimulating discussions. This work was supported by the Belgian National Fund for Scientific Research, the Televie (7.4613.09), the Belgian Foundation Against Cancer, the Interuniversity Attraction Poles Program-Belgian Science Policy (IUAP-BELSPOPVI/28). FD and JCT are Research Associates, MB is a Postdoctoral Researcher, SL is a FRIA Fellow and R.K. is a Research Director of the Belgian National Fund for Scientific Research.	Alefantis T, 2005, J BIOMED SCI, V12, P961, DOI 10.1007/s11373-005-9026-x; Anderson P, 2008, TRENDS BIOCHEM SCI, V33, P141, DOI 10.1016/j.tibs.2007.12.003; Anderson P, 2009, NAT REV MOL CELL BIO, V10, P430, DOI 10.1038/nrm2694; Asquith B, 2008, TRENDS IMMUNOL, V29, P4, DOI 10.1016/j.it.2007.09.006; Beckham CJ, 2008, CELL HOST MICROBE, V3, P206, DOI 10.1016/j.chom.2008.03.004; Bex F, 1997, J VIROL, V71, P3484, DOI 10.1128/JVI.71.5.3484-3497.1997; Boxus M, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-76; Buchan JR, 2009, MOL CELL, V36, P932, DOI 10.1016/j.molcel.2009.11.020; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128/JVI.78.21.11823-11832.2004; Chun ACS, 2000, AIDS RES HUM RETROV, V16, P1689, DOI 10.1089/08892220050193155; Dunand-Sauthier I, 2002, MOL BIOL CELL, V13, P1626, DOI 10.1091/mbc.01-06-0301; Durkin SS, 2008, J BIOL CHEM, V283, P36311, DOI 10.1074/jbc.M804931200; Ego T, 2002, ONCOGENE, V21, P7241, DOI 10.1038/sj.onc.1205701; Emara MM, 2007, P NATL ACAD SCI USA, V104, P9041, DOI 10.1073/pnas.0703348104; Esclatine A, 2004, J VIROL, V78, P8582, DOI 10.1128/JVI.78.16.8582-8592.2004; Gatza ML, 2006, J VIROL, V80, P6657, DOI 10.1128/JVI.02270-05; Gilks N, 2004, MOL BIOL CELL, V15, P5383, DOI 10.1091/mbc.E04-08-0715; Gupta SK, 2007, J BIOL CHEM, V282, P29431, DOI 10.1074/jbc.M704110200; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Hook SS, 2002, P NATL ACAD SCI USA, V99, P13425, DOI 10.1073/pnas.172511699; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; Kedersha N, 2007, METHOD ENZYMOL, V431, P61, DOI 10.1016/S0076-6879(07)31005-7; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; Kehn K, 2005, ONCOGENE, V24, P525, DOI 10.1038/sj.onc.1208105; Kinjo T, 2010, J VIROL, V84, P5431, DOI 10.1128/JVI.02460-09; Kwon S, 2007, GENE DEV, V21, P3381, DOI 10.1101/gad.461107; Lamsoul I, 2005, MOL CELL BIOL, V25, P10391, DOI 10.1128/MCB.25.23.10391-10406.2005; Legros S, 2009, FRONT BIOSCI-LANDMRK, V14, P4138, DOI 10.2741/3518; Lodewick J, 2009, VIROLOGY, V386, P68, DOI 10.1016/j.virol.2008.12.043; Lu HX, 2004, J VIROL, V78, P6735, DOI 10.1128/JVI.78.13.6735-6743.2004; Marriott SJ, 2005, ONCOGENE, V24, P5986, DOI 10.1038/sj.onc.1208976; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; McInerney GM, 2005, MOL BIOL CELL, V16, P3753, DOI 10.1091/mbc.E05-02-0124; MIWA M, 1984, GANN, V75, P752; Montero H, 2008, J VIROL, V82, P1496, DOI 10.1128/JVI.01779-07; MYDLARSKI MB, 1993, BRAIN RES, V627, P113, DOI 10.1016/0006-8993(93)90754-B; Nasr R, 2005, ONCOGENE, V24, P419, DOI 10.1038/sj.onc.1208212; Nasr R, 2006, BLOOD, V107, P4021, DOI 10.1182/blood-2005-09-3572; Nejmeddine M, 2005, J BIOL CHEM, V280, P29653, DOI 10.1074/jbc.M502639200; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128/JVI.78.21.11686-11695.2004; Pothof J, 2009, CELL CYCLE, V8, P3462, DOI 10.4161/cc.8.21.9835; Pothof J, 2009, EMBO J, V28, P2090, DOI 10.1038/emboj.2009.156; Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968; Raaben M, 2007, CELL MICROBIOL, V9, P2218, DOI 10.1111/j.1462-5822.2007.00951.x; Schutz S, 2007, CELL HOST MICROBE, V2, P284, DOI 10.1016/j.chom.2007.10.009; Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; SIVANANDHAM M, 1989, IMMUNOL LETT, V23, P149, DOI 10.1016/0165-2478(89)90128-4; Smith JA, 2006, J VIROL, V80, P2019, DOI 10.1128/JVI.80.4.2019-2033.2006; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Tsuji T, 2007, J BIOL CHEM, V282, P13875, DOI 10.1074/jbc.M611629200; Twizere JC, 2003, J NATL CANCER I, V95, P1846, DOI 10.1093/jnci/djg118; Ventoso I, 2006, GENE DEV, V20, P87, DOI 10.1101/gad.357006; Villanueva R, 2006, ONCOL REP, V16, P581; White JP, 2007, CELL HOST MICROBE, V2, P295, DOI 10.1016/j.chom.2007.08.006; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x	61	39	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	38					4050	4062		10.1038/onc.2011.120	http://dx.doi.org/10.1038/onc.2011.120			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823KR	21532619	Green Published			2022-12-17	WOS:000295121600006
J	Xiang, T; Jia, Y; Sherris, D; Li, S; Wang, H; Lu, D; Yang, Q				Xiang, T.; Jia, Y.; Sherris, D.; Li, S.; Wang, H.; Lu, D.; Yang, Q.			Targeting the Akt/mTOR pathway in Brca1-deficient cancers	ONCOGENE			English	Article						Brca1; PKB/Akt; mTOR	AKT ACTIVATION; PALOMID 529; CELL-CYCLE; MTOR; BRCA1; BREAST; EXPRESSION; GENE; INHIBITOR; GROWTH	The breast cancer susceptibility gene 1 (Brca1) has a key role in both hereditary and sporadic mammary tumorigenesis. However, the reasons why Brca1-deficiency leads to the development of cancer are not clearly understood. Activation of Akt kinase is one of the most common molecular alterations associated with human malignancy. Increased Akt kinase activity has been reported in most breast cancers. We previously found that downregulation of Brca1 expression or mutations of the Brca1 gene activate the Akt oncogenic pathway. To further investigate the role of Brca1/Akt in tumorigenesis, we analyzed Brca1/Akt expression in human breast cancer samples and found that reduced expression of Brca1 was highly correlated with increased phosphorylation of Akt. Consistent with the clinical data, knockdown of Akt1 by short-hairpin RNA inhibited cellular proliferation of Brca1 mutant cells. Importantly, depletion of Akt1 significantly reduced tumor formation induced by Brca1-deficiency in mice. The third generation inhibitor of mammalian target of rapamycin (mTOR), Palomid 529, significantly suppressed Brca1-deficient tumor growth in mice through inhibition of both Akt and mTOR signaling. Our results indicate that activation of Akt is involved in Brca1-deficiency mediated tumorigenesis and that the mTOR pathway can be used as a novel target for treatment of Brca1-deficient cancers. Oncogene (2011) 30, 2443-2450; doi:10.1038/onc.2010.603; published online 17 January 2011	[Yang, Q.] Washington Univ, Sch Med, Dept Radiat Oncol, Div Radiat & Canc Biol, St Louis, MO 63108 USA; [Sherris, D.] Paloma Pharmaceut, Jamaica Plain, MA USA; [Li, S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63108 USA; [Li, S.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63108 USA; [Wang, H.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, St Louis, MO USA; [Lu, D.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Cedars Sinai Medical Center; Washington University (WUSTL)	Yang, Q (corresponding author), Washington Univ, Sch Med, Dept Radiat Oncol, Div Radiat & Canc Biol, 4511 Forest Pk, St Louis, MO 63108 USA.	qyang@wustl.edu			Susan G Komen Foundation; Siteman Cancer Center; NIH [CA129440]; NATIONAL CANCER INSTITUTE [R01CA129440] Funding Source: NIH RePORTER	Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); Siteman Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Junjie Chen for providing the wild type and mutant GST-Brca1-BRCT constructs and Bing-Hua Jiang for providing Akt1-473D construct and Thomas Ludwig for providing Brca1<SUP>+/+</SUP> and Brca1<SUP>tr/tr</SUP> MEFs. We thank Buck Rogers, Andrei Laszlo and Xiaowei Wang for proof-reading. This work is supported in part by grants from the Susan G Komen Foundation (QY), Siteman Cancer Center Award (QY) and NIH CA129440 (QY).	Aaltonen K, 2009, BREAST CANCER RES TR, V113, P75, DOI 10.1007/s10549-008-9908-5; Aleskandarany M, 2010, BREAST CANC RES TREA; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Diaz R, 2009, BRIT J CANCER, V100, P932, DOI 10.1038/sj.bjc.6604938; Dinesh KPB, 2006, MOL CELL BIOCHEM, V287, P177, DOI 10.1007/s11010-005-9097-z; Ding SL, 2004, J BIOMED SCI, V11, P911, DOI 10.1159/000081838; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Inoki K, 2006, TRENDS CELL BIOL, V16, P206, DOI 10.1016/j.tcb.2006.02.002; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Lee CH, 2007, ANNU REV PHARMACOL, V47, P443, DOI 10.1146/annurev.pharmtox.47.120505.105359; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; O'Reilly T, 2010, TRANSL ONCOL, V3, P65, DOI 10.1593/tlo.09277; Pallares J, 2005, INT J GYNECOL PATHOL, V24, P247, DOI 10.1097/01.pgp.0000163849.37129.d4; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; van der Groep P, 2009, J CLIN PATHOL, V62, P926, DOI 10.1136/jcp.2009.065524; Wickenden JA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2558; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xiang T, 2008, CANCER RES, V68, P10040, DOI 10.1158/0008-5472.CAN-08-3009; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Xue Q, 2008, CANCER RES, V68, P9551, DOI 10.1158/0008-5472.CAN-08-2058; Yang Q, 2000, BRIT J CANCER, V82, P763, DOI 10.1054/bjoc.1999.0995	40	39	41	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	21					2443	2450		10.1038/onc.2010.603	http://dx.doi.org/10.1038/onc.2010.603			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21242970	Green Accepted			2022-12-17	WOS:000291008000006
J	Mazot, P; Cazes, A; Boutterin, MC; Figueiredo, A; Raynal, V; Combaret, V; Hallberg, B; Palmer, RH; Delattre, O; Janoueix-Lerosey, I; Vigny, M				Mazot, P.; Cazes, A.; Boutterin, M. C.; Figueiredo, A.; Raynal, V.; Combaret, V.; Hallberg, B.; Palmer, R. H.; Delattre, O.; Janoueix-Lerosey, I.; Vigny, M.			The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking	ONCOGENE			English	Article						ALK; neuroblastoma; phosphorylation; ER retention; RTK	ANAPLASTIC LYMPHOMA KINASE; TYROSINE KINASE; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; NPM-ALK; NEUROBLASTOMA; GENE; IDENTIFICATION; GROWTH; PLEIOTROPHIN	Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK), which is transiently expressed during development of the central and peripheral nervous system. ALK has been recently identified as a major neuroblastoma predisposition gene and activating mutations have also been identified in a subset of sporadic neuroblastoma tumors. Two hot spots of ALK mutations have been observed at positions F1174 and R1275. Here, we studied stably transfected cell lines expressing wild-type or F1174L- or R1275Q-mutated ALK in parallel with a neuroblastoma cell line (CLB-GE) in which the allele mutated at position F1174 is amplified. We observed that the mutated ALK variants were essentially intracellular and were largely retained in the reticulum/Golgi compartments. This localization was corroborated by a defect of N-linked glycosylation. Although the mutated receptors exhibited a constitutive activation, the minor pool of receptor addressed to the plasma membrane was much more tyrosine phosphorylated than the intracellular pool. The use of antagonist monoclonal antibodies suggested that the constitutive activity of the mutated receptors did not require the dimerization of the receptor, whereas adequate dimerization triggered by agonist monoclonal antibodies increased this activity. Finally, kinase inactivation of the mutated receptors restored maturation and cell-surface localization. Our results show that constitutive activation of ALK results in its impaired maturation and intracellular retention. Furthermore, they provide a rationale for the potential use of kinase inhibitors and antibodies in ALK-dependent tumors. Oncogene (2011) 30, 2017-2025; doi:10.1038/onc.2010.595; published online 17 January 2011	[Vigny, M.] Univ Paris 06, UPMC, INSERM, UMR S839, F-75005 Paris, France; [Mazot, P.; Boutterin, M. C.; Figueiredo, A.; Vigny, M.] INSERM, UMRS 839, Paris, France; [Mazot, P.; Boutterin, M. C.; Figueiredo, A.; Vigny, M.] IFM, Paris, France; [Cazes, A.; Raynal, V.; Delattre, O.; Janoueix-Lerosey, I.] Ctr Rech, Inst Curie, Paris, France; [Combaret, V.] Ctr Leon Berard, FNCLCC, Lab Rech Translat, F-69373 Lyon, France; [Hallberg, B.; Palmer, R. H.] Umea Univ, Dept Mol Biol, Umea, Sweden	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Centre Leon Berard; Umea University	Vigny, M (corresponding author), Univ Paris 06, UPMC, INSERM, UMR S839, 17 Rue Fer Moulin, F-75005 Paris, France.	marc.vigny@inserm.fr	Cazes, Alex/K-9899-2019; Janoueix-Lerosey, Isabelle/G-1758-2018	Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; Figueiredo, Ana Leonor/0000-0003-2329-2854; delattre, olivier/0000-0002-8730-2276	Inserm [UMR-S839]; Universite Pierre et Marie Curie; Institut National du Cancer,; Nationale contre le Cancer (Equipe labellisee); Association Hubert Gouin, Les Bagouz a Manon, les amis de Claire and Enfance et Sante	Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite Pierre et Marie Curie; Institut National du Cancer,(Institut National du Cancer (INCA) France); Nationale contre le Cancer (Equipe labellisee); Association Hubert Gouin, Les Bagouz a Manon, les amis de Claire and Enfance et Sante	Work at the Institut du Fer a Moulin UMR-S839 was supported by Inserm and Universite Pierre et Marie Curie. The U830 Inserm laboratory is supported by grants from the Institut National du Cancer, the Ligue Nationale contre le Cancer (Equipe labellisee), the Association Hubert Gouin, Les Bagouz a Manon, les amis de Claire and Enfance et Sante. We are grateful to Dr JA Girault for helpful discussions.	Buchwald M, 2010, LEUKEMIA, V24, P1412, DOI 10.1038/leu.2010.114; Caren H, 2008, BIOCHEM J, V416, P153, DOI 10.1042/BJ20081834; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Honorat JF, 2006, BLOOD, V107, P4130, DOI 10.1182/blood-2005-06-2421; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Janoueix-Lerosey I, 2010, ONCOGENE, V29, P1566, DOI 10.1038/onc.2009.518; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.bi.54.070185.003215; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lievens PMJ, 2004, J BIOL CHEM, V279, P43254, DOI 10.1074/jbc.M405247200; Loren CE, 2001, GENES CELLS, V6, P531, DOI 10.1046/j.1365-2443.2001.00440.x; Martinelli E, 2009, CLIN EXP IMMUNOL, V158, P1, DOI 10.1111/j.1365-2249.2009.03992.x; Mathivet T, 2007, CELL SIGNAL, V19, P2434, DOI 10.1016/j.cellsig.2007.07.011; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Moog-Lutz C, 2005, J BIOL CHEM, V280, P26039, DOI 10.1074/jbc.M501972200; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2009, CLIN CANCER RES, V15, P5609, DOI 10.1158/1078-0432.CCR-08-2762; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Mourali J, 2006, MOL CELL BIOL, V26, P6209, DOI 10.1128/MCB.01515-05; Osajima-Hakomori Y, 2005, AM J PATHOL, V167, P213, DOI 10.1016/S0002-9440(10)62966-5; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Perez-Pinera P, 2007, J BIOL CHEM, V282, P28683, DOI 10.1074/jbc.M704505200; Reiner DJ, 2008, CURR BIOL, V18, P1101, DOI 10.1016/j.cub.2008.06.060; Schmidt-Arras DE, 2005, MOL CELL BIOL, V25, P3690, DOI 10.1128/MCB.25.9.3690-3703.2005; Vernersson E, 2006, GENE EXPR PATTERNS, V6, P448, DOI 10.1016/j.modgep.2005.11.006; Webb TR, 2009, EXPERT REV ANTICANC, V9, P331, DOI 10.1586/14737140.9.3.331; Yang HL, 2007, J EXP ZOOL PART B, V308B, P269, DOI 10.1002/jez.b.21146	32	39	43	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	17					2017	2025		10.1038/onc.2010.595	http://dx.doi.org/10.1038/onc.2010.595			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21242967				2022-12-17	WOS:000289977400005
J	Li, J; Cheng, Y; Tai, D; Martinka, M; Welch, DR; Li, G				Li, J.; Cheng, Y.; Tai, D.; Martinka, M.; Welch, D. R.; Li, G.			Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis	ONCOGENE			English	Article						BRMS1; melanoma; tumor progression; prognosis; angiogenesis	BREAST-CANCER METASTASIS; SUPPRESSOR GENE; CARCINOMA METASTASIS; MICROVESSEL DENSITY; OVARIAN-CARCINOMA; CHROMOSOME 11Q13; HIGH-RISK; OSTEOPONTIN; GROWTH; MECHANISMS	Breast cancer metastasis suppressor 1 (BRMS1) has been reported to suppress metastasis without significantly affecting tumorigenicity in breast cancer and ovarian cancer. To investigate the role of BRMS1 in human melanoma progression and prognosis, we established tissue microarray and BRMS1 expression was evaluated by immunohistochemistry in 41 dysplastic nevi, 90 primary melanomas and 47 melanoma metastases. We found that BRMS1 expression was significantly decreased in metastatic melanoma compared with primary melanoma or dysplastic nevi (P = 0.021 and 0.001, respectively, chi(2) test). In addition, reduced BRMS1 staining was significantly correlated with American Joint Committee on Cancer stages (P = 0.011, chi(2) test), but not associated with tumor thickness, tumor ulceration and other clinicopathological parameters. Furthermore, BRMS1 expression was significantly correlated with disease-specific 5-year survival of melanoma patients (P = 0.007, log-rank test). Multivariate Cox regression analysis revealed that BRMS1 staining was an independent prognostic factor for melanoma patients (relative risk 0.51; confidence interval = 0.29-0.91; P = 0.022). Moreover, we demonstrated that BRMS1 overexpression inhibited endothelial cell growth and tube formation ability by suppressing NF-kappa B activity and IL-6 expression in vitro. We also showed that knockdown of BRMS1 increased IL-6 expression and promoted endothelial cell growth and tube formation. In addition, our data revealed that the BRMS1-mediated IL-6 expression is dependent on NF-kappa B. Strikingly, our in vivo studies using nude mice confirmed that BRMS1 inhibited blood vessel formation and the recruitment of CD31-positive cells in matrigel plugs. Taken together, BRMS1 expression was decreased in metastatic melanomas, which resulted in deficient suppression of angiogenesis and contributed to melanoma progression. BRMS1 may serve an important prognostic marker and therapeutic target for melanoma patients. Oncogene (2011) 30, 896-906; doi: 10.1038/onc.2010.470; published online 11 October 2010	[Li, G.] Univ British Columbia, Dept Dermatol & Skin Sci, Jack Bell Res Ctr, Vancouver Coastal Hlth Res Inst, Vancouver, BC V6H 3Z6, Canada; [Martinka, M.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, Dept Pathol, Vancouver, BC V6H 3Z6, Canada; [Welch, D. R.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of British Columbia; Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health Research Institute; University of Alabama System; University of Alabama Birmingham	Li, G (corresponding author), Univ British Columbia, Dept Dermatol & Skin Sci, Jack Bell Res Ctr, Vancouver Coastal Hlth Res Inst, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	gangli@interchange.ubc.ca	Li, Gang/A-8257-2011; Cheng, Yabin/AAY-2178-2020; Welch, Danny R/B-7310-2009; Cheng, Yabin/P-7071-2015	Cheng, Yabin/0000-0002-6205-3648; Welch, Danny R/0000-0002-1951-4947; Cheng, Yabin/0000-0002-6205-3648	Canadian Institutes of Health Research [MOP-84559, MOP-93810]; Canadian Dermatology Foundation; Natural Sciences and Engineering Research Council of Canada; University of British Columbia; CIHR Skin Research Training Centre; NATIONAL CANCER INSTITUTE [R01CA134981, R01CA087728] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Dermatology Foundation; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); University of British Columbia; CIHR Skin Research Training Centre(Canadian Institutes of Health Research (CIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Steve Hendy for technical assistance with EMSA. This work was supported by the Canadian Institutes of Health Research (MOP-84559 and MOP-93810) and Canadian Dermatology Foundation to GL. JL is a recipient of Postgraduate Scholarship from the Natural Sciences and Engineering Research Council of Canada and University of British Columbia Graduate Fellowship. Both JL and YC are recipients of CIHR Skin Research Training Centre Trainee Award.	Angeletti CA, 1996, CANCER-AM CANCER SOC, V78, P409, DOI 10.1002/(SICI)1097-0142(19960801)78:3<409::AID-CNCR5>3.0.CO;2-E; Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; Ballo MT, 2003, SURG CLIN N AM, V83, P323, DOI 10.1016/S0039-6109(02)00096-8; Brawer MK, 1996, EUR UROL, V29, P19; Cicek M, 2005, CANCER RES, V65, P3586, DOI 10.1158/0008-5472.CAN-04-3139; Cicek M, 2009, CLIN EXP METASTAS, V26, P229, DOI 10.1007/s10585-009-9235-1; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; Dai DL, 2005, J CLIN ONCOL, V23, P1473, DOI 10.1200/JCO.2005.07.168; Dai J, 2009, ONCOGENE, V28, P3412, DOI 10.1038/onc.2009.189; Dauda M M, 2005, Niger Postgrad Med J, V12, P125; Diao HY, 2004, IMMUNITY, V21, P539, DOI 10.1016/j.immuni.2004.08.012; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Garate M, 2007, FASEB J, V21, P3705, DOI 10.1096/fj.07-8069com; GASPARINI G, 1993, INT J CANCER, V55, P739, DOI 10.1002/ijc.2910550507; Grossman D, 2001, CANCER METAST REV, V20, P3, DOI 10.1023/A:1013123532723; Hedley BD, 2008, INT J CANCER, V123, P526, DOI 10.1002/ijc.23542; Hersey P, 2003, INTERN MED J, V33, P33, DOI 10.1046/j.1445-5994.2002.00289.x; Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635; HOLLINGSWORTH HC, 1995, AM J PATHOL, V147, P33; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Karst AM, 2009, INT J CANCER, V124, P494, DOI 10.1002/ijc.23973; Kauffman EC, 2003, J UROLOGY, V169, P1122, DOI 10.1097/01.ju.0000051580.89109.4b; Li G, 1998, MELANOMA RES, V8, P17, DOI 10.1097/00008390-199802000-00004; MAEDA K, 1995, BRIT J CANCER, V72, P319, DOI 10.1038/bjc.1995.331; Maffey AH, 2007, MOL CELL ENDOCRINOL, V268, P10, DOI 10.1016/j.mce.2007.01.009; MANSFIELD PF, 1994, CURR PROB SURG, V31, P257; Meehan WJ, 2004, J BIOL CHEM, V279, P1562, DOI 10.1074/jbc.M307969200; Meehan WJ, 2003, CLIN EXP METASTAS, V20, P45, DOI 10.1023/A:1022542519586; Metge BJ, 2008, CLIN EXP METASTAS, V25, P753, DOI 10.1007/s10585-008-9187-x; Ostmeier H, 1999, CANCER-AM CANCER SOC, V85, P2391, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2391::AID-CNCR14>3.0.CO;2-I; Phadke PA, 2008, AM J PATHOL, V172, P809, DOI 10.2353/ajpath.2008.070772; REMMELE W, 1987, PATHOLOGE, V8, P138; Samant RS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-6; Samant RS, 2001, CLIN EXP METASTAS, V18, P683, DOI 10.1023/A:1013124725690; Seraj MJ, 2000, CANCER RES, V60, P2764; Seraj MJ, 2001, CLIN EXP METASTAS, V18, P519, DOI 10.1023/A:1011819621859; Shevde LA, 2002, EXP CELL RES, V273, P229, DOI 10.1006/excr.2001.5452; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Standal T, 2004, EXP ONCOL, V26, P179; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; Thompson JF, 2005, LANCET, V365, P687, DOI 10.1016/S0140-6736(05)17951-3; Tsao H, 2005, DERMATOL CLIN, V23, P323, DOI 10.1016/j.det.2004.09.005; Vaidya KS, 2008, J BIOL CHEM, V283, P28354, DOI 10.1074/jbc.M710068200; WEIDNER N, 1995, AM J PATHOL, V147, P9; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1993, AM J PATHOL, V143, P401; Welch DR, 1997, PATHOBIOLOGY, V65, P311, DOI 10.1159/000164143; WIGGINS DL, 1995, GYNECOL ONCOL, V56, P353, DOI 10.1006/gyno.1995.1062; YAMAZAKI K, 1994, CANCER, V74, P2245, DOI 10.1002/1097-0142(19941015)74:8<2245::AID-CNCR2820740807>3.0.CO;2-X; Yang JY, 2008, CANCER LETT, V269, P46, DOI 10.1016/j.canlet.2008.04.016; Zainabadi K, 2005, GENOMICS, V85, P704, DOI 10.1016/j.ygeno.2005.02.014; Zhang S, 2006, INT J GYNECOL CANCER, V16, P522, DOI 10.1111/j.1525-1438.2006.00547.x	52	39	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					896	906		10.1038/onc.2010.470	http://dx.doi.org/10.1038/onc.2010.470			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	20935672	Green Accepted			2022-12-17	WOS:000287695900002
J	Tonino, SH; van Laar, J; van Oers, MH; Wang, JY; Eldering, E; Kater, AP				Tonino, S. H.; van Laar, J.; van Oers, M. H.; Wang, J. Y.; Eldering, E.; Kater, A. P.			ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia	ONCOGENE			English	Article						CLL; chemoresistance; p53; ROS; platinum-based compounds; Noxa	NUCLEOTIDE EXCISION-REPAIR; DNA-DAMAGE; INDUCE APOPTOSIS; PROTEASOME INHIBITOR; PROGNOSTIC MARKERS; OXIDATIVE STRESS; IN-VITRO; B-CELLS; FLUDARABINE; EXPRESSION	In recent years considerable progress has been made in treatment strategies for chronic lymphocytic leukemia (CLL). However, the disease remains incurable because of the development of chemoresistance. Strategies to overcome resistance mechanisms are therefore highly needed. At least two mechanisms contribute to the development of resistance to drugs; acquired mutations resulting in a dysfunctional p53 response and shifts in the balance between apoptosis-regulating proteins. Platinum-based compounds have been successfully applied in relapsed lymphoma and recently also in high-risk CLL. In this study we investigated the efficacy and mechanism of action of cisplatinum (CDDP) in chemorefractory CLL. Independent of p53-functional status, CDDP acted synergistically with fludarabine (F-ara-A). The response involved generation of reactive oxygen species (ROS), which led to specific upregulation of the proapoptotic BH3-only protein Noxa. Induction of Noxa resulted in cell death by apoptosis as inhibition of caspase activation completely abrogated cell death. Furthermore, drug-resistance upon CD40-ligand stimulation, a model for the protective stimuli provided in lymph nodes, could also be overcome by CDDP/F-ara-A. ROS accumulation resulted in Noxa upregulation mainly at the transcriptional level and this was, at least in part, mediated by the mitogen-activated protein kinase p38. Finally, Noxa RNA-interference markedly decreased sensitivity to CDDP/F-ara-A, supporting a key role for Noxa as mediator between ROS signaling and apoptosis induction. Our data indicate that interference in the cellular redox balance can be exploited to overcome chemoresistance in CLL. Oncogene (2011) 30, 701-713; doi:10.1038/onc.2010.441; published online 11 October 2010	[Tonino, S. H.; van Oers, M. H.; Kater, A. P.] Univ Amsterdam, Acad Med Ctr, Dept Hematol, NL-1105 AZ Amsterdam, Netherlands; [van Laar, J.; Eldering, E.] Univ Amsterdam, Acad Med Ctr, Expt Immunol Lab, NL-1105 AZ Amsterdam, Netherlands; [Wang, J. Y.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Wang, J. Y.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of California System; University of California San Diego; University of California System; University of California San Diego	Kater, AP (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Hematol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	a.p.kater@amc.nl			Netherlands Organization for Health Research and Development; NATIONAL CANCER INSTITUTE [R01CA043054] Funding Source: NIH RePORTER	Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M Baou and GM Cohen of the MRC Toxicology Unit, University of Leicester, United Kingdom for sharing their experience with nucleofection-procedures. APK is personally supported by a 'Veni' grant from the Netherlands Organization for Health Research and Development.	AKABOSHI M, 1994, JPN J CANCER RES, V85, P106, DOI 10.1111/j.1349-7006.1994.tb02893.x; Ali MS, 2005, J INORG BIOCHEM, V99, P795, DOI 10.1016/j.jinorgbio.2004.12.015; Baou M, 2010, HAEMATOL-HEMATOL J, V95, P1510, DOI 10.3324/haematol.2010.022368; Bhalla S, 2009, CLIN CANCER RES, V15, P3354, DOI 10.1158/1078-0432.CCR-08-2365; Bouzar AB, 2009, BRIT J HAEMATOL, V144, P41, DOI 10.1111/j.1365-2141.2008.07426.x; Brozovic A, 2007, CANCER LETT, V251, P1, DOI 10.1016/j.canlet.2006.10.007; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Clohessy JG, 2004, BRIT J HAEMATOL, V125, P655, DOI 10.1111/j.1365-2141.2004.04949.x; Deriano L, 2005, BLOOD, V105, P4776, DOI 10.1182/blood-2004-07-2888; Dicker F, 2006, BLOOD, V108, P3450, DOI 10.1182/blood-2006-04-017749; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; Garrido N, 2008, BIOCHEM J, V414, P93, DOI 10.1042/BJ20071615; GELEZIUNAS R, 1991, J NATL CANCER I, V83, P557, DOI 10.1093/jnci/83.8.557; Gong JG, 1999, NATURE, V399, P806; Hagrman D, 2004, J PHARMACOL EXP THER, V308, P658, DOI 10.1124/jpet.103.059410; Hallaert DYH, 2008, BLOOD, V112, P5141, DOI 10.1182/blood-2008-03-146704; Husain K, 1998, MOL CELL BIOCHEM, V178, P127, DOI 10.1023/A:1006889427520; Kater AP, 2004, BRIT J HAEMATOL, V127, P404, DOI 10.1111/j.1365-2141.2004.05225.x; Kater AP, 2010, CL LYMPH MYELOM LEUK, V10, pS34, DOI 10.3816/CLML.2010.s.005; Li L, 1997, CANCER RES, V57, P1487; Mackus WJM, 2005, LEUKEMIA, V19, P427, DOI 10.1038/sj.leu.2403623; Maggio SC, 2004, CANCER RES, V64, P2590, DOI 10.1158/0008-5472.CAN-03-2631; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; Miller CP, 2009, BLOOD, V113, P4289, DOI 10.1182/blood-2008-08-174797; Monjanel-Mouterde S, 2003, J CLIN PHARM THER, V28, P109, DOI 10.1046/j.1365-2710.2003.00468.x; Morales AA, 2005, INT J CANCER, V113, P730, DOI 10.1002/ijc.20614; Moufarij MA, 2006, BLOOD, V108, P4187, DOI 10.1182/blood-2006-05-023259; Mous R, 2009, LEUKEMIA, V23, P1352, DOI 10.1038/leu.2009.71; Nys K, 2010, J INVEST DERMATOL, V130, P2269, DOI 10.1038/jid.2010.93; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oltra AM, 2001, FREE RADICAL BIO MED, V30, P1286, DOI 10.1016/S0891-5849(01)00521-4; Pedersen IM, 2004, LEUKEMIA LYMPHOMA, V45, P2365, DOI 10.1080/10428190412331272703; Pepper C, 2008, BLOOD, V112, P3807, DOI 10.1182/blood-2008-05-157131; Pettitt AR, 2003, BRIT J HAEMATOL, V121, P692, DOI 10.1046/j.1365-2141.2003.04336.x; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Rosato RR, 2008, MOL CANCER THER, V7, P3285, DOI 10.1158/1535-7163.MCT-08-0385; Rosenwald A, 2004, BLOOD, V104, P1428, DOI 10.1182/blood-2003-09-3236; Roue G, 2008, CLIN CANCER RES, V14, P6907, DOI 10.1158/1078-0432.CCR-08-0388; SEYMOUR JF, 1995, LEUKEMIA LYMPHOMA, V18, P493, DOI 10.3109/10428199509059650; Smit LA, 2007, BLOOD, V109, P1660, DOI 10.1182/blood-2006-05-021683; SPITZ DR, 1993, J CELL PHYSIOL, V156, P72, DOI 10.1002/jcp.1041560111; Tonino SH, 2010, LEUKEMIA, V24, P652, DOI 10.1038/leu.2009.240; Trachootham D, 2008, BLOOD, V112, P1912, DOI 10.1182/blood-2008-04-149815; Tsimberidou AM, 2008, J CLIN ONCOL, V26, P196, DOI 10.1200/JCO.2007.11.8513; Van Bockstaele F, 2009, BLOOD REV, V23, P25, DOI 10.1016/j.blre.2008.05.003; Vogler M, 2009, BLOOD, V113, P4403, DOI 10.1182/blood-2008-08-173310; Witte AB, 2005, FREE RADICAL BIO MED, V39, P696, DOI 10.1016/j.freeradbiomed.2005.04.025; Zenz T, 2008, BLOOD, V112, P3322, DOI 10.1182/blood-2008-04-154070; Zhou Y, 2003, BLOOD, V101, P4098, DOI 10.1182/blood-2002-08-2512	51	39	39	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2011	30	6					701	713		10.1038/onc.2010.441	http://dx.doi.org/10.1038/onc.2010.441			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	20935673	Green Accepted			2022-12-17	WOS:000287192000007
J	Goh, SH; Hong, SH; Hong, SH; Lee, BC; Ju, MH; Jeong, JS; Cho, YR; Kim, IH; Lee, YS				Goh, S-H; Hong, S-H; Hong, S-H; Lee, B-C; Ju, M-H; Jeong, J-S; Cho, Y-R; Kim, I-H; Lee, Y-S			eIF3m expression influences the regulation of tumorigenesis-related genes in human colon cancer	ONCOGENE			English	Article						eukaryotic translation initiation factor; eIF3m; cell proliferation; cell death; ribonomics	INITIATION-FACTOR EIF3; MIGRATION INHIBITORY FACTOR; MALIGNANT-TRANSFORMATION; TRANSLATIONAL CONTROL; BREAST-CANCER; GROWTH; OVEREXPRESSION; ACTIVATION; DYSADHERIN; COMPLEXES	Abnormal regulation of gene expression is essential for tumorigenesis. Recent studies indicate that regulation of oncogene expression and neoplastic transformation are controlled by subunits of eukaryotic translation initiation factors (eIFs). Here we focused on eIF3 performing a pivotal role in protein synthesis and the differential expression of its subunits in cancer. The most uncharacterized non-core subunit eIF3m was confirmed to be highly expressed in human cancer cell lines and colon cancer patient tissues. By expression silencing with eIF3m-specific small interfering RNA (siRNA), we confirmed that eIF3m influences cell proliferation, cell cycle progression and cell death in human colon cancer cell line HCT-116. Using a ribonomics approach, we identified a subset of elF3m-influenced genes and showed that the expression of two highly represented tumorigenesis-related genes, MIF and MT2, were affected by eIF3m at the mRNA level. We also confirmed eIF3m-dependent regulation of MT2A downstream molecule CDC25A, which is necessary for cell cycle progression in HCT-116 cells. These results suggest that eIF3m mediates regulation of tumorigenesis-related genes in human colon cancer. Further investigations on tumorigenesis-related genes and their regulation by eIFs will provide clues for designing targeted therapy for cancer. Oncogene (2011) 30, 398-409; doi: 10.1038/onc.2010.422; published online 13 September 2010	[Lee, Y-S] Natl Canc Ctr, Res Inst, Funct Genom Branch, Div Convergence Technol, Goyang 410769, Gyeonggi Do, South Korea; [Ju, M-H; Jeong, J-S] Dong A Univ, Dept Pathol, Coll Med, Pusan, South Korea	National Cancer Center - Korea (NCC); Dong A University	Lee, YS (corresponding author), Natl Canc Ctr, Res Inst, Funct Genom Branch, Div Convergence Technol, 111 Jungbalsan Ro,809 Madu Dong, Goyang 410769, Gyeonggi Do, South Korea.	yslee2@ncc.re.kr			National Cancer Center [NCC 0710660, NCC 0810160]	National Cancer Center	We thank Dr Sri Ram for editorial assistance of manuscript. This study was funded by Intramural Research Grants of the National Cancer Center (NCC 0710660, NCC 0810160).	Ahlemann M, 2006, MOL CARCINOGEN, V45, P957, DOI 10.1002/mc.20269; Bach JP, 2009, CANCER-AM CANCER SOC, V115, P2031, DOI 10.1002/cncr.24245; Bifulco C, 2008, CURR PHARM DESIGN, V14, P3790, DOI 10.2174/138161208786898608; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Doldan A, 2008, MOL CARCINOGEN, V47, P235, DOI 10.1002/mc.20379; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Dong ZZ, 2006, CRIT REV ONCOL HEMAT, V59, P169, DOI 10.1016/j.critrevonc.2006.03.005; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Green EM, 2007, NEURON, V55, P615, DOI 10.1016/j.neuron.2007.07.024; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Humphries A, 2008, NAT REV CANCER, V8, P415, DOI 10.1038/nrc2392; Ino Y, 2002, P NATL ACAD SCI USA, V99, P365, DOI 10.1073/pnas.012425299; Jin RX, 2004, PATHOL ONCOL RES, V10, P74, DOI 10.1007/BF02893459; Jin RX, 2002, CARCINOGENESIS, V23, P81, DOI 10.1093/carcin/23.1.81; Kim JH, 2006, MOL CELL, V24, P173, DOI 10.1016/j.molcel.2006.08.016; Koch G, 1980, Ann N Y Acad Sci, V339, P280, DOI 10.1111/j.1749-6632.1980.tb15984.x; Komatsu K, 2000, CLIN CANCER RES, V6, P172; L'Esperance S, 2006, INT J ONCOL, V29, P5; LeFebvre AK, 2006, J BIOL CHEM, V281, P22917, DOI 10.1074/jbc.M605418200; Legendre H, 2003, MODERN PATHOL, V16, P491, DOI 10.1097/01.MP.0000068235.45178.C1; Lim D, 2009, CANCER LETT, V276, P109, DOI 10.1016/j.canlet.2008.10.038; Mack DL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1742; Mauro VP, 2002, P NATL ACAD SCI USA, V99, P12031, DOI 10.1073/pnas.192442499; Morris C, 2007, EMBO REP, V8, P596, DOI 10.1038/sj.embor.7400955; Nam JS, 2007, CANCER LETT, V255, P161, DOI 10.1016/j.canlet.2007.02.018; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Ramachandran A, 2000, J GASTROEN HEPATOL, V15, P109, DOI 10.1046/j.1440-1746.2000.02059.x; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Rosenwald IB, 2004, ONCOGENE, V23, P3230, DOI 10.1038/sj.onc.1207552; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Tomko RJ, 2009, CELL CYCLE, V8, P299, DOI 10.4161/cc.8.2.7595; Zhang LL, 2008, J BIOL CHEM, V283, P24047, DOI 10.1074/jbc.M800956200; Zhang LL, 2007, J BIOL CHEM, V282, P5790, DOI 10.1074/jbc.M606284200; Zhou CS, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-14	36	39	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2011	30	4					398	409		10.1038/onc.2010.422	http://dx.doi.org/10.1038/onc.2010.422			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20838379				2022-12-17	WOS:000286621600003
J	Krig, SR; Miller, JK; Frietze, S; Beckett, LA; Neve, RM; Farnham, PJ; Yaswen, PI; Sweeney, CA				Krig, S. R.; Miller, J. K.; Frietze, S.; Beckett, L. A.; Neve, R. M.; Farnham, P. J.; Yaswen, P. I.; Sweeney, C. A.			ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells	ONCOGENE			English	Article						ZNF217; ErbB3; CtBP2; 20q13; breast cancer	COMPARATIVE GENOMIC HYBRIDIZATION; TERMINAL BINDING-PROTEINS; LUNG-CANCER; TRANSCRIPTION FACTORS; TAMOXIFEN RESISTANCE; REPRESSOR COMPLEX; TUMOR-GROWTH; THERAPY; GENES; HER3	Understanding the mechanisms underlying ErbB3 overexpression in breast cancer will facilitate the rational design of therapies to disrupt ErbB2-ErbB3 oncogenic function. Although ErbB3 overexpression is frequently observed in breast cancer, the factors mediating its aberrant expression are poorly understood. In particular, the ErbB3 gene is not significantly amplified, raising the question as to how ErbB3 overexpression is achieved. In this study we showed that the ZNF217 transcription factor, amplified at 20q13 in similar to 20% of breast tumors, regulates ErbB3 expression. Analysis of a panel of human breast cancer cell lines (n=50) and primary human breast tumors (n=15) showed a strong positive correlation between ZNF217 and ErbB3 expression. Ectopic expression of ZNF217 in human mammary epithelial cells induced ErbB3 expression, whereas ZNF217 silencing in breast cancer cells resulted in decreased ErbB3 expression. Although ZNF217 has previously been linked with transcriptional repression because of its close association with C-terminal-binding protein (CtBP)1/2 repressor complexes, our results show that ZNF217 also activates gene expression. We showed that ZNF217 recruitment to the ErbB3 promoter is CtBP1/2-independent and that ZNF217 and CtBP1/2 have opposite roles in regulating ErbB3 expression. In addition, we identify ErbB3 as one of the mechanisms by which ZNF217 augments PI-3K/Akt signaling. Oncogene (2010) 29, 5500-5510; doi:10.1038/onc.2010.289; published online 26 July 2010	[Krig, S. R.; Miller, J. K.; Sweeney, C. A.] Univ Calif Davis, Ctr Canc, Div Basic Sci, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Frietze, S.; Farnham, P. J.] Univ Calif Davis, Div Biostat, Dept Publ Hlth, Davis, CA 95616 USA; [Beckett, L. A.] Genentech Inc, San Francisco, CA 94080 USA; [Neve, R. M.] Univ Calif Davis, Genome Ctr, Dept Pharmacol, Davis, CA 95616 USA; [Yaswen, P. I.] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	University of California System; University of California Davis; University of California System; University of California Davis; Roche Holding; Genentech; University of California System; University of California Davis; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Krig, SR (corresponding author), Univ Calif Davis, Ctr Canc, Div Basic Sci, Dept Biochem & Mol Med, Res Bldg 3,Room 1100A,4645 2nd Ave, Sacramento, CA 95817 USA.	skrig@ucdavis.edu; casweeney@ucdavis.edu		Farnham, Peggy/0000-0003-4469-7914	NIH [R01 CA118384, RO1 CA45250, U54 CA112970]; Office of Energy Research, Office of Health and Biological Research, US Department of Energy [DE-AC03-76SF00098]; NIH Center for Research Resources (NCRR) [UL1 RR024146]; DOD [W81XWH-06-1-0402]; Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [UL1 RR024146]; NIH Roadmap for Medical Research; NATIONAL CANCER INSTITUTE [R01CA118384, U54CA112970, P30CA093373, R01CA045240] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024146] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of Energy Research, Office of Health and Biological Research, US Department of Energy(United States Department of Energy (DOE)); NIH Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); DOD(United States Department of Defense); Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by NIH grant R01 CA118384 (CS); NIH grant RO1 CA45250 (PJF); U54 CA112970 (PY, RN), and the Office of Energy Research, Office of Health and Biological Research, US Department of Energy under Contract No. DE-AC03-76SF00098 (PY) and NIH Center for Research Resources (NCRR) UL1 RR024146 (LAB). JM was a recipient of a DOD Breast Cancer Research Program Predoctoral fellowship: W81XWH-06-1-0402. We thank Dr Nelly Auersperg (U Vancouver) for the recombinant adenoviral ZNF217 construct and Jeremy Semeiks for his assistance with the adenoviral transduction experiments. We thank Dr Jeffrey Hildebrand for the CtBP2-null mef-90 fibroblasts and Dr Merlin Crossly for the CtBP2_ pcDNA_ 3.1 expression construct. We thank Dr Hongwu Chen for the pCmX vector, Dr James Trimmer for the co-REST ascites and Dr Martha Stampfer for the HMEC 184 cells. CTCS statistical support is made possible by Grant Number UL1 RR024146 from the Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. A special thank you to members of the Farnham lab for valuable discussions.	Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Chinnadurai G, 2007, INT J BIOCHEM CELL B, V39, P1593, DOI 10.1016/j.biocel.2007.01.025; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; *CORETEAM R D, 2006, R LANG ENV STAT COMP; Cowger JJM, 2007, ONCOGENE, V26, P3378, DOI 10.1038/sj.onc.1210126; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Folgiero V, 2007, CANCER RES, V67, P1645, DOI 10.1158/0008-5472.CAN-06-2980; Folgiero V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001592; Frank DA, 2009, IDRUGS, V12, P29; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Heidenreich Olaf, 2009, V487, P221, DOI 10.1007/978-1-60327-547-7_11; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Huang GQ, 2005, HUM MOL GENET, V14, P3219, DOI 10.1093/hmg/ddi352; IWABUCHI H, 1995, CANCER RES, V55, P6172; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Krig SR, 2007, J BIOL CHEM, V282, P9703, DOI 10.1074/jbc.M611752200; Lee JY, 2007, SCIENCE, V317, P206, DOI 10.1126/science.1146073; Li PX, 2007, INT J CANCER, V120, P1863, DOI 10.1002/ijc.22300; Liu BL, 2007, INT J CANCER, V120, P1874, DOI 10.1002/ijc.22423; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Nonet GH, 2001, CANCER RES, V61, P1250; O'Geen H, 2006, BIOTECHNIQUES, V41, P577, DOI 10.2144/000112268; Plowright L, 2009, BRIT J CANCER, V100, P470, DOI 10.1038/sj.bjc.6604857; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06; Sassen A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1843; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shakya A, 2009, NAT CELL BIOL, V11, P320, DOI 10.1038/ncb1840; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; Sithanandam G, 2008, CANCER GENE THER, V15, P413, DOI 10.1038/cgt.2008.15; SolinasToldo S, 1996, CANCER RES, V56, P3803; Tanner MM, 1995, CLIN CANCER RES, V1, P1455; Thillainadesan G, 2008, MOL CELL BIOL, V28, P6066, DOI 10.1128/MCB.00246-08; Ursini-Siegel J, 2007, NAT REV CANCER, V7, P389, DOI 10.1038/nrc2127; Wang SE, 2008, MOL CELL BIOL, V28, P5605, DOI 10.1128/MCB.00787-08; Xue CS, 2006, CANCER RES, V66, P1418, DOI 10.1158/0008-5472.CAN-05-0550; Yen L, 2006, CANCER RES, V66, P11279, DOI 10.1158/0008-5472.CAN-06-2319; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	46	39	42	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	40					5500	5510		10.1038/onc.2010.289	http://dx.doi.org/10.1038/onc.2010.289			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20661224	Green Submitted, Green Accepted			2022-12-17	WOS:000282945800007
J	Wimmer, P; Schreiner, S; Everett, RD; Sirma, H; Groitl, P; Dobner, T				Wimmer, P.; Schreiner, S.; Everett, R. D.; Sirma, H.; Groitl, P.; Dobner, T.			SUMO modification of E1B-55K oncoprotein regulates isoform-specific binding to the tumour suppressor protein PML	ONCOGENE			English	Article						HAdV5 E1B-55K; PML isoforms; SUMO	ACUTE PROMYELOCYTIC LEUKEMIA; E4 ORF3 PROTEIN; REGION-1B 55-KDA ONCOPROTEIN; ADENOVIRUS E4ORF6 PROTEIN; NUCLEAR-BODY FORMATION; SIMPLEX-VIRUS TYPE-1; TRANSFORMED-CELLS; RAR-ALPHA; PREMATURE SENESCENCE; DNA-DAMAGE	The E1B-55K product from human adenovirus is a substrate of the small ubiquitin-related modifier (SUMO)-conjugation system. SUMOylation of E1B-55K is required to transform primary mammalian cells in cooperation with adenovirus E1A and to repress p53 tumour suppressor functions. The biochemical consequences of SUMO1 conjugation of 55K have so far remained elusive. Here, we report that E1B-55K physically interacts with different isoforms of the tumour suppressor protein promyelocytic leukaemia (PML). We show that E1B-55K binds to PML isoforms IV and V in a SUMO1-dependent and -independent manner. Interaction with PML-IV promotes the localization of 55K to PML-containing subnuclear structures (PML-NBs). In virus-infected cells, this process is negatively regulated by other viral proteins, indicating that binding to PML is controlled through reversible SUMOylation in a timely coordinated manner. These results together with earlier work are consistent with the idea that SUMOylation regulates targeting of E1B-55K to PML-NBs, known to control transcriptional regulation, tumour suppression, DNA repair and apoptosis. Furthermore, they suggest that SUMO1-dependent modulation of p53-dependent growth suppression through E1B-55K PML-IV interaction has a key role in adenovirus-mediated cell transformation. Oncogene (2010) 29, 5511-5522; doi:10.1038/onc.2010.284; published online 19 July 2010	[Wimmer, P.; Schreiner, S.; Groitl, P.; Dobner, T.] Heinrich Pette Inst Expt Virol & Immunol, Dept Mol Virol, D-20251 Hamburg, Germany; [Sirma, H.] Univ Med Ctr, Inst Pathol, Hamburg, Germany	Heinrich Pette Institute; University of Hamburg; University Medical Center Hamburg-Eppendorf	Dobner, T (corresponding author), Heinrich Pette Inst Expt Virol & Immunol, Dept Mol Virol, Martinistr 52, D-20251 Hamburg, Germany.	thomas.dobner@hpi.uni-hamburg.de		Schreiner, Sabrina/0000-0002-5744-7159	Studienstiftung des Deutschen Volkes e.V., Bonn, Germany [41, 53175]; Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit; Deutsche Forschungsgemeinschaft (DFG); Stiftung fur neurovirale Erkrankungen; MRC [MC_U130169966] Funding Source: UKRI; Medical Research Council [MC_U130169966] Funding Source: researchfish	Studienstiftung des Deutschen Volkes e.V., Bonn, Germany; Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Stiftung fur neurovirale Erkrankungen; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	PW was supported by grants from the 'Studienstiftung des Deutschen Volkes e.V.', Ahrstrasse 41, 53175 Bonn, Germany. We thank Philippe Gripon for providing the described HepaRG cell line and Roel van Driel/Ineke van der Kraan for the 5E10 antibody. The Heinrich-Pette-Institute is supported by the 'Freie und Hansestadt Hamburg' and the 'Bundesministerium fur Gesundheit'. This work was supported by grants from the 'Deutsche Forschungsgemeinschaft (DFG)' and by the 'Stiftung fur neurovirale Erkrankungen' to HS.	ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Baker A, 2007, J VIROL, V81, P7034, DOI 10.1128/JVI.00029-07; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Borden KLB, 2009, FRONT BIOSCI-LANDMRK, V14, P497, DOI 10.2741/3258; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Cerec V, 2007, HEPATOLOGY, V45, P957, DOI 10.1002/hep.21536; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; Condemine W, 2006, CANCER RES, V66, P6192, DOI 10.1158/0008-5472.CAN-05-3792; Dallaire F, 2009, J VIROL, V83, P5329, DOI 10.1128/JVI.00089-09; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dobner T, 2001, CURR TOP MICROBIOL, V259, P25; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Endter C, 2005, ONCOGENE, V24, P55, DOI 10.1038/sj.onc.1208170; Endter C, 2001, P NATL ACAD SCI USA, V98, P11312, DOI 10.1073/pnas.191361798; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Everett RD, 2008, J VIROL, V82, P2661, DOI 10.1128/JVI.02308-07; Everett RD, 2007, BIOCHIMIE, V89, P819, DOI 10.1016/j.biochi.2007.01.004; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GODDARD AD, 1995, MAMM GENOME, V6, P732, DOI 10.1007/BF00354296; GODDARD AD, 1992, LEUKEMIA, V6, pS117; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699; Groitl Peter, 2007, Methods Mol Med, V130, P29; Guccione E, 2004, ONCOGENE, V23, P4662, DOI 10.1038/sj.onc.1207631; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hartl B, 2008, ONCOGENE, V27, P3673, DOI 10.1038/sj.onc.1211039; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Herrmann F, 2005, J BIOL CHEM, V280, P38005, DOI 10.1074/jbc.M502458200; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; Hoppe A, 2006, J VIROL, V80, P3042, DOI 10.1128/JVI.80.6.3042-3049.2006; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kindsmuller K, 2007, P NATL ACAD SCI USA, V104, P6684, DOI 10.1073/pnas.0702158104; Kindsmuller K, 2009, J VIROL, V83, P9045, DOI 10.1128/JVI.00728-09; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Konig C, 1999, J VIROL, V73, P2253; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lawrence JM, 2007, STEM CELLS, V25, P2033, DOI 10.1634/stemcells.2006-0724; LEE K, 1995, SMALL SCALE PREPARAT; Leppard KN, 2009, J GEN VIROL, V90, P95, DOI 10.1099/vir.0.005512-0; Lethbridge KJ, 2003, J GEN VIROL, V84, P259, DOI 10.1099/vir.0.18820-0; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Limb GA, 2002, INVEST OPHTH VIS SCI, V43, P864; Lukashchuk V, 2010, J VIROL, V84, P4026, DOI 10.1128/JVI.02597-09; Martin MED, 1999, MOL CELL BIOL, V19, P3403; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; Melnick A, 1999, LEUKEMIA, V13, P1534, DOI 10.1038/sj.leu.2401513; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Muller S, 2008, CELL CYCLE, V7, P754, DOI 10.4161/cc.7.6.5495; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; Nevels M, 2001, J VIROL, V75, P3089, DOI 10.1128/JVI.75.7.3089-3094.2001; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Regad T, 2009, NAT NEUROSCI, V12, P132, DOI 10.1038/nn.2251; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Salomoni P, 2009, CELL DEATH DIFFER, V16, P1083, DOI 10.1038/cdd.2009.63; Salomoni P, 2008, CELL RES, V18, P620, DOI 10.1038/cr.2008.58; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; Schreck KC, 2009, NAT NEUROSCI, V12, P108, DOI 10.1038/nn0209-108; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Sieber T, 2007, J VIROL, V81, P95, DOI 10.1128/JVI.01608-06; Stracker TH, 2005, J VIROL, V79, P6664, DOI 10.1128/JVI.79.11.6664-6673.2005; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; STUURMAN N, 1992, J CELL SCI, V101, P773; Takahashi Y, 2004, ONCOGENE, V23, P2819, DOI 10.1038/sj.onc.1207533; Tavalai N, 2008, BBA-MOL CELL RES, V1783, P2207, DOI 10.1016/j.bbamcr.2008.08.004; Torok D, 2009, FRONT BIOSCI-LANDMRK, V14, P1325, DOI 10.2741/3311; Ullman AJ, 2008, J VIROL, V82, P7325, DOI 10.1128/JVI.00723-08; Ullman AJ, 2007, J VIROL, V81, P4744, DOI 10.1128/JVI.02385-06; Van Damme E, 2010, INT J BIOL SCI, V6, P51, DOI 10.7150/ijbs.6.51; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YOUNGHUSBAND HB, 1985, CAN J BIOCHEM CELL B, V63, P654, DOI 10.1139/o85-083; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	93	39	41	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	40					5511	5522		10.1038/onc.2010.284	http://dx.doi.org/10.1038/onc.2010.284			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20639899				2022-12-17	WOS:000282945800008
J	Olivares-Illana, V; Fahraeus, R				Olivares-Illana, V.; Fahraeus, R.			p53 isoforms gain functions	ONCOGENE			English	Review						p53; endoplasmic reticulum stress; senescence; alternative gene expression	ENDOPLASMIC-RETICULUM STRESS; MESSENGER-RNA TRANSLATION; UNFOLDED PROTEIN RESPONSE; RIBOSOME ENTRY SITE; ONCOGENE-INDUCED SENESCENCE; TUMOR-SUPPRESSOR; ER STRESS; CELLULAR SENESCENCE; DNA-DAMAGE; MDM2	Many different cell stress pathways converge on p53 to induce a number of distinct cell biological responses such as G1 or G2 arrest, senescence or apoptosis. One of the outstanding questions with regard to p53 is how the cells can differentiate between different stresses so that p53 activation leads to the correct response. It has been known for some time that the p53 gene expresses isoforms that carry unique domains and properties, and more recent works have started to reveal some of their functions. The alternative mRNA translation product p53/47, which lacks the first 40 codons, including the first of p53's two trans-activation domains, is being linked to endoplasmic reticulum stress and the unfolded protein response to which it causes a specific G2 arrest. On the other hand, p53 itself induces G1 arrest and has no effect on the G2. The two isoforms Delta 133p53, which lacks the first 133 amino acids, and p53 beta, which carries an alternative C-terminus, are derived from alternative promoter usage or splicing, respectively, and are together implied in controlling cellular senescence. Hence, through different mechanisms of gene expression control, alternative levels of p53 isoforms help the cell to differentiate between p53 activation and the response to diverse stresses. This holds promise to a better understanding of how upstream and downstream p53 pathways have evolved relative to specific p53 domains. Oncogene (2010) 29, 5113-5119; doi:10.1038/onc.2010.266; published online 12 July 2010	[Olivares-Illana, V.; Fahraeus, R.] Univ Paris 07, Inst Genet Mol, INSERM Cibles Therapeut, Hop St Louis, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Fahraeus, R (corresponding author), Univ Paris 07, Inst Genet Mol, INSERM Cibles Therapeut, Hop St Louis, 27 Rue Juliette Dodu, F-75010 Paris, France.	robin.fahraeus@inserm.fr	Olivares-Illana, Vanesa/AAF-9710-2021; fahraeus, robin/K-8726-2014	Olivares-Illana, Vanesa/0000-0001-6949-5986	La Ligue Contre le Cancer; French National Cancer Institute (INCa)	La Ligue Contre le Cancer(Ligue nationale contre le cancer); French National Cancer Institute (INCa)(Institut National du Cancer (INCA) France)	We apologize to those whose works have not been cited in this article owing to lack of space. This article is supported by the La Ligue Contre le Cancer and the French National Cancer Institute (INCa).	Adams PD, 2009, MOL CELL, V36, P2, DOI 10.1016/j.molcel.2009.09.021; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bourougaa K, 2010, MOL CELL, V38, P78, DOI 10.1016/j.molcel.2010.01.041; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Candeias MM, 2006, ONCOGENE, V25, P6936, DOI 10.1038/sj.onc.1209996; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Efeyan A, 2007, CANCER RES, V67, P7350, DOI 10.1158/0008-5472.CAN-07-0200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Feldser DM, 2007, CANCER CELL, V11, P461, DOI 10.1016/j.ccr.2007.02.026; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Grover R, 2009, ONCOGENE, V28, P2766, DOI 10.1038/onc.2009.138; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hermeking H, 2006, SEMIN CANCER BIOL, V16, P183, DOI 10.1016/j.semcancer.2006.03.002; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Lane DP, 2010, CELL CYCLE, V9, P748, DOI 10.4161/cc.9.4.10616; Ledoux S, 2003, CANCER RES, V63, P7284; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Moll UM, 2004, MOL CANCER RES, V2, P371; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Powell DJ, 2008, CELL CYCLE, V7, P950, DOI 10.4161/cc.7.7.5626; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Rajagopalan S, 2008, NUCLEIC ACIDS RES, V36, P5983, DOI 10.1093/nar/gkn598; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rosenbluth JM, 2008, GENE DEV, V22, P2591, DOI 10.1101/gad.1727408; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Sivan G, 2008, CELL CYCLE, V7, P741, DOI 10.4161/cc.7.6.5596; Urano F, 2000, J CELL SCI, V113, P3697; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	56	39	39	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	37					5113	5119		10.1038/onc.2010.266	http://dx.doi.org/10.1038/onc.2010.266			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20622898				2022-12-17	WOS:000281867200001
J	Dash, R; Su, ZZ; Lee, SG; Azab, B; Boukerche, H; Sarkar, D; Fisher, PB				Dash, R.; Su, Z-Z; Lee, S-G; Azab, B.; Boukerche, H.; Sarkar, D.; Fisher, P. B.			Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1	ONCOGENE			English	Article						CCN1; SARI; transcriptional regulation; AP-1; c-Jun	HUMAN BREAST-CANCER; DIFFERENTIATION-ASSOCIATED GENE-7; TISSUE GROWTH-FACTOR; ACTIVATOR PROTEIN-1; CELL-PROLIFERATION; NUDE-MICE; C-JUN; CYR61; EXPRESSION; TRANSCRIPTION	Enhanced expression of the CCN family of secretory integrin-binding proteins correlates with many essential components of the cancerous state, including tumor cell adhesion, proliferation, invasion and migration. Consequently, CCN1 expression is elevated in various cancers, including breast cancer, and its expression directly correlates with poor patient prognosis. Using subtraction-hybridization, combined with induction of cancer cell terminal differentiation, we cloned SARI (suppressor of activator protein (AP)-1, regulated by interferon (IFN)), an IFN-beta-inducible, potent tumor suppressor gene that exerts cancer-selective growth inhibitory effects. Forced expression of SARI using an adenovirus (Ad. SARI) inhibits AP-1 function and downregulates CCN1 expression in multiple cancer lineages, resulting in a profound inhibition in anchorage-independent cell growth and tumor cell invasion. Overexpression of SARI reduces CCN1-promoter activity through inhibition of AP-1 binding. Accordingly, SARI selectively blocks expression of the transformed state in rat embryo fibroblast cells that stably overexpress c-Jun. These results illustrate that SARI inhibits AP-1 transactivating factor binding to the cis-element of the CCN1 promoter, possibly through its interaction with c-Jun. Overall, SARI can directly inhibit CCN1-induced transformation by inhibiting the transcription of CCN1, as well as indirectly by inhibiting the expression of c-Jun (and hence blocking AP-1 activity). In these contexts, transformed cells 'addicted' to AP-1 activity are rendered susceptible to SARI-mediated inhibition of expression of the transformed phenotype. Oncogene (2010) 29, 4412-4423; doi: 10.1038/onc.2010.194; published online 7 June 2010	[Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, Dept Human & Mol Genet, Sch Med, VCU Inst Mol Med, Richmond, VA 23298 USA; [Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, VCU Massey Canc Ctr, Sch Med, Richmond, VA 23298 USA; [Lee, S-G] Kyung Hee Univ, Canc Prevent Mat Dev Res Ctr, Coll Oriental Med, Seoul, South Korea; [Boukerche, H.] Univ Lyon 1, INSERM, F-69365 Lyon, France	Virginia Commonwealth University; Virginia Commonwealth University; Kyung Hee University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Fisher, PB (corresponding author), Virginia Commonwealth Univ, Dept Human & Mol Genet, Sch Med, VCU Inst Mol Med, 1101 E Marshall St,Sanger Hall Bldg,Room 11-015, Richmond, VA 23298 USA.	pbfisher@vcu.edu	Azab, Belal/AAJ-5652-2021; Lee, Seok-Geun/B-3408-2011	Azab, Belal/0000-0003-0293-6489; Lee, Seok-Geun/0000-0002-0060-5777; dash, rupesh/0000-0001-5740-7053	National Institutes of Health [R01 CA097318, P01 CA104177]; National Foundation for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA097318, P01CA104177] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Foundation for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by National Institutes of Health Grants R01 CA097318 and P01 CA104177; and by the National Foundation for Cancer Research. DS is a Harrison Endowed Scholar in Cancer Research. PBF holds the Thelma Newmeyer Corman Chair in Cancer Research.	ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; DASH R, 2010, CANC GENE THER; Echlin DR, 2000, ONCOGENE, V19, P1752, DOI 10.1038/sj.onc.1203491; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Gery S, 2005, CLIN CANCER RES, V11, P7243, DOI 10.1158/1078-0432.CCR-05-0231; Grotendorst GR, 2000, ENDOCRINOLOGY, V141, P2254, DOI 10.1210/en.141.6.2254; Han JS, 2003, EUR J BIOCHEM, V270, P3408, DOI 10.1046/j.1432-1033.2003.03723.x; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang WG, 2004, ENDOCR-RELAT CANCER, V11, P781, DOI 10.1677/erc.1.00825; Lebedeva IV, 2003, ONCOGENE, V22, P8758, DOI 10.1038/sj.onc.1206891; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Lee SG, 2008, ONCOGENE, V27, P1114, DOI 10.1038/sj.onc.1210713; Leu SJ, 2004, J BIOL CHEM, V279, P44177, DOI 10.1074/jbc.M407850200; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATTHEW GF, 1907, T ROYAL SOC CANADA, V1, P7; Menendez JA, 2005, ONCOGENE, V24, P761, DOI 10.1038/sj.onc.1208238; Nguyen N, 2006, CANCER RES, V66, P2658, DOI 10.1158/0008-5472.CAN-05-2082; O'Kelly J, 2008, INT J ONCOL, V33, P59; OKELLY KH, 2005, CCN PROTEINS; Roskelley CD, 2002, SEMIN CANCER BIOL, V12, P97, DOI 10.1006/scbi.2001.0417; RYSECK RP, 1991, ONCOGENE, V6, P533; Sarkar D, 2005, P NATL ACAD SCI USA, V102, P14034, DOI 10.1073/pnas.0506837102; Schraml BU, 2009, NATURE, V460, P405, DOI 10.1038/nature08114; Shimizu T, 2005, ONCOL REP, V14, P441; Su Z, 2001, NUCLEIC ACIDS RES, V29, P1661, DOI 10.1093/nar/29.8.1661; Su ZZ, 2008, P NATL ACAD SCI USA, V105, P20906, DOI 10.1073/pnas.0807975106; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Taddei I, 2003, J MAMMARY GLAND BIOL, V8, P383, DOI 10.1023/B:JOMG.0000017426.74915.b9; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsai MS, 2002, ONCOGENE, V21, P964, DOI 10.1038/sj/onc/1205131; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Vellon L, 2005, ONCOGENE, V24, P3759, DOI 10.1038/sj.onc.1208452; Williams KL, 2001, EUR J IMMUNOL, V31, P1620, DOI 10.1002/1521-4141(200105)31:5<1620::AID-IMMU1620>3.0.CO;2-3; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; Zullo AJ, 2007, J IMMUNOL, V178, P58, DOI 10.4049/jimmunol.178.1.58	44	39	52	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	2010	29	31					4412	4423		10.1038/onc.2010.194	http://dx.doi.org/10.1038/onc.2010.194			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20531301				2022-12-17	WOS:000280559100005
J	Noetzel, E; Rose, M; Sevinc, E; Hilgers, RD; Hartmann, A; Naami, A; Knuchel, R; Dahl, E				Noetzel, E.; Rose, M.; Sevinc, E.; Hilgers, R-D; Hartmann, A.; Naami, A.; Knuechel, R.; Dahl, E.			Intermediate filament dynamics and breast cancer: Aberrant promoter methylation of the Synemin gene is associated with early tumor relapse	ONCOGENE			English	Article						tumor suppressor gene; SYNM; promoter methylation; epigenetics; recurrence-free survival; pyrosequencing	PROTEIN SYNEMIN; VIMENTIN FILAMENTS; MYOEPITHELIAL CELL; DNA METHYLATION; EXPRESSION; HYPERMETHYLATION; IDENTIFICATION; MARKER; DISEASE	Synemin (SYNM) is a type IV intermediate filament that has recently been shown to interact with the LIM domain protein zyxin, thereby possibly modulating cell adhesion and cell motility. Owing to this multiplicity of potential functions relevant to cancer development, we initiated a study to decipher SYNM expression and regulation in benign human breast tissue and breast cancer. Dot blot array analysis showed significant SYNM mRNA downregulation in 86% (n = 100, P < 0.001) of breast cancers compared with their normal tissue counterparts, a result that was confirmed by real-time PCR analysis (n = 36, P < 0.0001). Immunohistochemistry analysis showed abundant SYNM protein expression in healthy myoepithelial breast cells, whereas SYNM expression loss was evident in 57% (n = 37, P < 0.001) of breast cancer specimens. Next, we analyzed methylation of the SYNM promoter to clarify whether the SYNM gene can be silenced by epigenetic means. Indeed, methylation-specific PCR analysis showed tumor-specific SYNM promoter methylation in 27% (n = 195) of breast cancers. As expected, SYNM promoter methylation was tightly associated (P < 0.0001) with SYNM expression loss. In-depth analysis of the SYNM promoter by pyrosequencing showed extensive CpG methylation of DNA elements supposed to regulate gene transcription. Demethylating treatment of SYNM methylated breast cancer cell lines with 5-aza-2-deoxycytidine clearly reestablished the SYNM expression. Statistical analysis of the patient cohort showed a close association between SYNM promoter methylation and unfavorable recurrence-free survival (hazard ratio = 2.941, P = 0.0282). Furthermore, SYNM methylation positively correlated with lymph node metastases (P = 0.0177) and advanced tumor grade (P = 0.0275), suggesting that SYNM methylation is associated with aggressive forms of breast cancer. This is the first study on the epigenetic regulation of the SYNM gene in a cancer entity. We provide first hints that SYNM could represent a novel putative breast tumor suppressor gene that is prone to epigenetic silencing. SYNM promoter methylation may become a useful predictive biomarker to stratify breast cancer patients' risk for tumor relapse. Oncogene (2010) 29, 4814-4825; doi:10.1038/onc.2010.229; published online 14 June 2010	[Noetzel, E.; Rose, M.; Sevinc, E.; Naami, A.; Knuechel, R.; Dahl, E.] Rhein Westfal TH Aachen, Fac Med, Mol Oncol Grp, Inst Pathol, Aachen, Germany; [Hilgers, R-D] Rhein Westfal TH Aachen, Dept Med Stat, Aachen, Germany; [Hartmann, A.] Univ Erlangen Nurnberg, Dept Pathol, Erlangen, Germany	RWTH Aachen University; RWTH Aachen University; University of Erlangen Nuremberg	Dahl, E (corresponding author), Rhein Westfal TH Aachen, Univ Hosp, Mol Oncol Grp, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.	edahl@ukaachen.de	Noetzel-Reiss, Erik/GYV-0999-2022; Hilgers, Ralf-Dieter/C-7090-2013	Noetzel-Reiss, Erik/0000-0003-3163-6848; Hilgers, Ralf-Dieter/0000-0002-5945-1119	BMBF [01KW0401]	BMBF(Federal Ministry of Education & Research (BMBF))	We thank Sonja von Serenyi and Sevim Alkaya for excellent technical assistance and Monika Klinkhammer-Schalke, as well as Armin Pauer from the Tumor Registry Regensburg for continuous help in obtaining clinical follow-up data. We are thankful to Professor Matthias Durst (Friedrich-Schiller University Jena, Germany) for kindly providing patient samples and follow-up data. This work is a research project within the German Human Genome Project and has been supported by the BMBF Grants 01KW0401 to ED.	[Anonymous], 1997, J CLIN PATHOL; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; Bellin RM, 1999, J BIOL CHEM, V274, P29493, DOI 10.1074/jbc.274.41.29493; Bellin RM, 2001, J BIOL CHEM, V276, P32330, DOI 10.1074/jbc.M104005200; Bharadwaj S, 2005, ONCOGENE, V24, P8291, DOI 10.1038/sj.onc.1208993; Bilak SR, 1998, ARCH BIOCHEM BIOPHYS, V355, P63, DOI 10.1006/abbi.1998.0702; Blake DJ, 2002, TRENDS CARDIOVAS MED, V12, P224, DOI 10.1016/S1050-1738(02)00166-4; Brandes JC, 2007, ONCOGENE, V26, P6229, DOI 10.1038/sj.onc.1210433; Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dahl E, 2005, J PATHOL, V205, P21, DOI 10.1002/path.1687; Dahl E, 2006, CLIN CANCER RES, V12, P3950, DOI 10.1158/1078-0432.CCR-05-2090; Deugnier MA, 2002, BREAST CANCER RES, V4, P224, DOI 10.1186/bcr459; Dobrovic A, 1997, CANCER RES, V57, P3347; ELSTON CW, 1993, J CLIN PATHOL, V46, P189; ETIENNE J, 1990, ANN BIOL CLIN-PARIS, V48, P681; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; GRANGER BL, 1980, CELL, V22, P727, DOI 10.1016/0092-8674(80)90549-8; Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herrmann H, 2007, NAT REV MOL CELL BIO, V8, P562, DOI 10.1038/nrm2197; Hirako Y, 2003, CELL TISSUE RES, V313, P195, DOI 10.1007/s00441-003-0732-2; Hoque MO, 2008, CANCER RES, V68, P2661, DOI 10.1158/0008-5472.CAN-07-5913; Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011; Lakhani SR, 2001, BREAST CANCER RES, V3, P1, DOI 10.1186/bcr260; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Mizuno Y, 2001, P NATL ACAD SCI USA, V98, P6156, DOI 10.1073/pnas.111153298; Mook S, 2009, BREAST CANCER RES TR, V116, P295, DOI 10.1007/s10549-008-0130-2; Nguyen M, 2000, ONCOGENE, V19, P3449, DOI 10.1038/sj.onc.1203677; Noetzel E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-154; Omary MB, 2004, NEW ENGL J MED, V351, P2087, DOI 10.1056/NEJMra040319; Pan YH, 2008, FASEB J, V22, P3196, DOI 10.1096/fj.08-106187; REMMELE W, 1987, PATHOLOGE, V8, P138; Schmitt-Graeff A, 2006, HUM PATHOL, V37, P1200, DOI 10.1016/j.humpath.2006.04.017; Sun N, 2010, EXP CELL RES, V316, P491, DOI 10.1016/j.yexcr.2009.10.015; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Tawk M, 2003, EXP NEUROL, V183, P499, DOI 10.1016/S0014-4886(03)00240-1; Titeux M, 2001, EUR J BIOCHEM, V268, P6435, DOI 10.1046/j.0014-2956.2001.02594.x; Van Rossen E, 2009, HISTOCHEM CELL BIOL, V131, P313, DOI 10.1007/s00418-008-0544-2; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83; Whipple RA, 2008, CANCER RES, V68, P5678, DOI 10.1158/0008-5472.CAN-07-6589; Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606; Wiesmann F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2319; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115	46	39	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	34					4814	4825		10.1038/onc.2010.229	http://dx.doi.org/10.1038/onc.2010.229			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20543860				2022-12-17	WOS:000281326400007
J	Fishler, T; Li, YY; Wang, RH; Kim, HS; Sengupta, K; Vassilopoulos, A; Lahusen, T; Xu, X; Lee, MH; Liu, Q; Elledge, SJ; Ried, T; Deng, CX				Fishler, T.; Li, Y-Y; Wang, R-H; Kim, H-S; Sengupta, K.; Vassilopoulos, A.; Lahusen, T.; Xu, X.; Lee, M-H; Liu, Q.; Elledge, S-J; Ried, T.; Deng, C-X			Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53	ONCOGENE			English	Article						Chk1; mitotic catastrophe; genome integrity; mammary cancer; SB-218078	CELL-CYCLE CHECKPOINT; PHASE-I TRIAL; DNA-DAMAGE; SPINDLE CHECKPOINT; BRCA1; KINASE; BREAST; INHIBITOR; LACKING; ARREST	Checkpoint kinase 1 (Chk1) is a key element in the DNA-damage response pathway that is required for maintaining genomic stability. To study the potential role of Chk1 in mammary tumorigenesis, we disrupted it using a Cre/loxP system. We showed that although Chk1 heterozygosity caused abnormal development of the mammary gland, it was not sufficient to induce tumorigenesis. Simultaneous deletion of one copy of p53 failed to rescue the developmental defects; however, it synergistically induced mammary tumor formation in Chk(;)(1+/-) MMTV-Cre animals with a median time to tumor latency of about 10 months. Chk1 deficiency caused a preponderance of abnormalities, including prolongation, multipolarity, misalignment, mitotic catastrophe and loss of spindle checkpoint, that are accompanied by reduced expression of several cell cycle regulators, including Mad2. On the other hand, we also showed that Chk1 deficiency inhibited mammary tumor formation in mice carrying a homozygous deletion of p53, uncovering a complex relationship between Chk1 and p53. Furthermore, inhibition of Chk1 with a specific inhibitor, SB-218078, or acute deletion of Chk1 using small hairpin RNA killed mammary tumor cells effectively. These data show that Chk1 is critical for maintaining genome integrity and serves as a double-edged sword for cancer: although its inhibition kills cancer cells, it also triggers tumorigenesis when favorable mutations are accumulated for cell growth. Oncogene (2010) 29, 4007-4017; doi:10.1038/onc.2010.163; published online 17 May 2010	[Deng, C-X] NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; [Sengupta, K.; Ried, T.] NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Liu, Q.; Elledge, S-J] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 9000 Rockville Pike,Bldg 10 Rm 9N105, Bethesda, MD 20892 USA.	chuxiad@bdg10.niddk.nih.gov	deng, chuxia/N-6713-2016	Lee, Mi-Hye/0000-0002-5484-3383	National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA; NATIONAL CANCER INSTITUTE [ZIABC010836, ZIABC010835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056004, ZIADK056011, ZIADK056001, ZIADK056010, ZIADK056009] Funding Source: NIH RePORTER	National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We gratefully acknowledge members of Deng laboratory for a critical reading of the article. This work was supported by the Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA.	Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Blagden S, 2005, CURR DRUG TARGETS, V6, P325, DOI 10.2174/1389450053765824; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Brodie SG, 2001, ONCOGENE, V20, P1445, DOI 10.1038/sj.onc.1204222; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Carrassa L, 2009, J CELL MOL MED, V13, P1565, DOI [10.1111/j.1582-4934.2008.00362.x, 10.1111/j.1582-4934.2009.00362.x]; Collura A, 2005, MOL CELL BIOL, V25, P7889, DOI 10.1128/MCB.25.17.7889-7899.2005; Deng Chu-Xia, 2004, Methods Mol Biol, V280, P185; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Deng CX, 2003, HUM MOL GENET, V12, pR113, DOI 10.1093/hmg/ddg082; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Durkin SG, 2006, ONCOGENE, V25, P4381, DOI 10.1038/sj.onc.1209466; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fuse E, 1998, CANCER RES, V58, P3248; HARPER JW, 1993, CELL, V75, P805; Hotte SJ, 2006, ANN ONCOL, V17, P334, DOI 10.1093/annonc/mdj076; Jackson JR, 2000, CANCER RES, V60, P566; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kortmansky J, 2005, J CLIN ONCOL, V23, P1875, DOI 10.1200/JCO.2005.03.116; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Li W, 2007, ONCOGENE, V26, P7204, DOI 10.1038/sj.onc.1210527; Liu QH, 2000, GENE DEV, V14, P1448; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Margolis RL, 2005, CANCER CELL, V8, P353, DOI 10.1016/j.ccr.2005.10.017; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Padilla-Nash HM, 2006, NAT PROTOC, V1, P3129, DOI 10.1038/nprot.2006.358; Peddibhotla S, 2009, P NATL ACAD SCI USA, V106, P5159, DOI 10.1073/pnas.0806671106; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Puc J, 2005, CELL CYCLE, V4, P927, DOI 10.4161/cc.4.7.1795; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Takai H, 2000, GENE DEV, V14, P1439; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wang X, 2006, ONCOGENE, V25, P7148, DOI 10.1038/sj.onc.1209707; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yarden RI, 2001, J CELL BIOCHEM, V83, P521, DOI 10.1002/jcb.1257; Zachos G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003; Zhang WH, 2008, CELL CYCLE, V7, P1668, DOI 10.4161/cc.7.11.5982; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	48	39	41	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2010	29	28					4007	4017		10.1038/onc.2010.163	http://dx.doi.org/10.1038/onc.2010.163			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20473325	Green Accepted			2022-12-17	WOS:000279892400002
J	Shouse, GP; Nobumori, Y; Liu, X				Shouse, G. P.; Nobumori, Y.; Liu, X.			A B56 gamma mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A	ONCOGENE			English	Article						p53; PP2A; B56 gamma; Thr55 phosphorylation; lung cancer	A-BETA-SUBUNIT; REGULATORY SUBUNIT; P53; GENE; HOLOENZYME; COMPLEXES; COLON	Earlier studies have shown both p53-dependent and -independent tumor-suppressive functions of B56 gamma-specific protein phosphatase 2A (B56 gamma-PP2A). In the absence of p53, B56 gamma-PP2A can inhibit cell proliferation and cell transformation by an unknown mechanism. In the presence of p53, on DNA damage, a complex including B56 gamma-PP2A and p53 is formed, which leads to Thr55 dephosphorylation of p53, induction of the p53 transcriptional target p21 and inhibition of cell proliferation. In spite of its significance in inhibition of cell proliferation, no B56 gamma mutations have been linked to human cancer to date. In this study, we first differentiate between the p53-dependent and -independent functions of B56 gamma-PP2A by identifying a domain of the B56 gamma protein required for interaction with p53. Within this region, we identify a B56 gamma mutation, F395C, in lung cancer that disrupts the B56 gamma-p53 interaction. More importantly, we show that F395C is unable to promote p53 Thr55 dephosphorylation, transcriptional activation of p21 and the p53-dependent tumor-suppressive function of PP2A. This finding provides a mechanistic basis for the p53-dependent and -independent functions of B56 gamma-PP2A and establishes a critical link between B56 gamma-PP2A p53-dependent tumor-suppressive function and tumorigenesis. Oncogene (2010) 29, 3933-3941; doi:10.1038/onc.2010.161; published online 17 May 2010	[Shouse, G. P.; Nobumori, Y.; Liu, X.] Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Liu, X (corresponding author), Univ Calif Riverside, Dept Biochem, 5414 Boyce Hall, Riverside, CA 92521 USA.	xuan.liu@ucr.edu		Shouse, Geoffrey/0000-0002-7917-5713	NIH, National Institute of Cancer [CA075180]; NATIONAL CANCER INSTITUTE [R01CA075180, R29CA075180] Funding Source: NIH RePORTER	NIH, National Institute of Cancer(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr B Shen at the City of Hope for assistance in searching public databases for mutations in the B56 gamma gene and to P Podlesny for generating B56 gamma mutant plasmid constructs. We thank all members of our laboratory for many helpful discussions. This work was supported by NIH grant CA075180 from the National Institute of Cancer.	Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Esplin ED, 2006, GENE CHROMOSOME CANC, V45, P182, DOI 10.1002/gcc.20284; Forester CM, 2007, P NATL ACAD SCI USA, V104, P19867, DOI 10.1073/pnas.0709879104; Grochola LF, 2009, CLIN CANCER RES, V15, P6301, DOI 10.1158/1078-0432.CCR-09-0797; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; Li HH, 2007, EMBO J, V26, P402, DOI 10.1038/sj.emboj.7601519; Margolis SS, 2006, CELL, V127, P759, DOI 10.1016/j.cell.2006.10.035; NETO E, 2006, P NATL ACAD SCI USA, V97, P3491; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Riedel CG, 2006, NATURE, V441, P53, DOI 10.1038/nature04664; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Shouse GP, 2008, MOL CELL BIOL, V28, P448, DOI 10.1128/MCB.00983-07; Suzuki Y, 2004, GENOME RES, V14, P1711, DOI 10.1101/gr.2435604; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033	27	39	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2010	29	27					3933	3941		10.1038/onc.2010.161	http://dx.doi.org/10.1038/onc.2010.161			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20473327	Green Accepted			2022-12-17	WOS:000279603200006
J	Bosco, EE; Nakai, Y; Hennigan, RF; Ratner, N; Zheng, Y				Bosco, E. E.; Nakai, Y.; Hennigan, R. F.; Ratner, N.; Zheng, Y.			NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation	ONCOGENE			English	Article						Rac1; NF2/merlin; neurofibromatosis type 2; Wnt signaling; contact inhibition; proliferation	NF2 TUMOR-SUPPRESSOR; BETA-CATENIN; EXCHANGE FACTOR; INCREASED EXPRESSION; SCHWANNOMA CELLS; GENE-PRODUCT; RHO-GTPASES; MERLIN; COMPLEX; GROWTH	The neuro. bromatosis type 2 (NF2) tumor suppressor gene encodes merlin, a membrane/cytoskeleton protein necessary for the maintenance of contact inhibition of growth in cells. Bi-allelic inactivation of NF2 is known to cause multiple cancers in both humans and mice. However, the mechanism through which merlin exerts its tumor-suppressive function remains obscure. In this report, we show that NF2 knockout mouse embryonic fibroblasts lost contact inhibition of cell proliferation and contained significantly increased canonical Wnt signaling. Inhibition of Rac1, the activity of which is inversely regulated by NF2, through the use of a dominant-negative mutant, small hairpin RNA or a small molecule inhibitor in NF2-deficient cells, was able to suppress elevated Wnt signals as shown by reduced activity of the T-cell factor 4 (TCF4) transcription factor. Dominant-negative TCF4 or Rac1 mutant, as well as a small molecule inhibition of Wnt, were able to curb NF2 deficiency-elicited cell proliferation at the confluent state. Thus, Rac1-mediated canonical Wnt signaling is essential for the loss of contact inhibition in NF2-deficient cells. Oncogene (2010) 29, 2540-2549; doi:10.1038/onc.2010.20; published online 15 February 2010	[Bosco, E. E.; Nakai, Y.; Ratner, N.; Zheng, Y.] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH USA; [Hennigan, R. F.] Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Zheng, Y (corresponding author), Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Yi.Zheng@cchmc.org	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074; RATNER, NANCY/0000-0001-5030-9354; Nakai-Futatsugi, Yoko/0000-0003-4187-6060	NIH [R01 CA125658, R01 CA118032, T32 CA117846]; NATIONAL CANCER INSTITUTE [T32CA117846, R01CA118032, R01CA141341, R01CA125658] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all members of the Zheng laboratory for thought-provoking discussions. This study was supported by NIH R01 CA125658 (YZ), NIH R01 CA118032 (NR) and NIH T32 CA117846 (EEB). EEB and YN performed experiments, analyzed results and made the figures; RFH provided key reagents, NR collaborated on experimental design, EEB and YZ designed the research and wrote the paper.	Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; Ammoun S, 2008, CANCER RES, V68, P5236, DOI 10.1158/0008-5472.CAN-07-5849; Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Chadee DN, 2006, P NATL ACAD SCI USA, V103, P4463, DOI 10.1073/pnas.0510651103; Colomba A, 2008, ONCOGENE, V27, P2728, DOI 10.1038/sj.onc.1210921; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007; Fernandez-Valle C, 2002, NAT GENET, V31, P354, DOI 10.1038/ng930; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Giovannini M, 2000, GENE DEV, V14, P1617; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Johnson KC, 2002, ONCOGENE, V21, P5990, DOI 10.1038/sj.onc.1205693; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lau YKI, 2008, CANCER RES, V68, P5733, DOI 10.1158/0008-5472.CAN-08-0190; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Lyons LS, 2006, MOL ENDOCRINOL, V20, P1061, DOI 10.1210/me.2005-0346; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; Minke KS, 2009, EUR J HAEMATOL, V82, P165, DOI 10.1111/j.1600-0609.2008.01188.x; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Nakai Y, 2006, J NEUROSCI, V26, P3390, DOI 10.1523/JNEUROSCI.4865-05.2006; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sampietro J, 2006, MOL CELL, V24, P293, DOI 10.1016/j.molcel.2006.09.001; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Tang XL, 2007, NAT CELL BIOL, V9, P1199, DOI 10.1038/ncb1641; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Upadhyay G, 2008, ONCOGENE, V27, P5845, DOI 10.1038/onc.2008.202; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200	35	39	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2540	2549		10.1038/onc.2010.20	http://dx.doi.org/10.1038/onc.2010.20			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20154721	Green Accepted			2022-12-17	WOS:000277169400009
J	Fougere, M; Gaudineau, B; Barbier, J; Guaddachi, F; Feugeas, JP; Auboeuf, D; Jauliac, S				Fougere, M.; Gaudineau, B.; Barbier, J.; Guaddachi, F.; Feugeas, J-P; Auboeuf, D.; Jauliac, S.			NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene	ONCOGENE			English	Article						NFAT3; LCN2; estrogen receptor alpha; motility; breast	GELATINASE-ASSOCIATED LIPOCALIN; ESTROGEN-RECEPTOR-ALPHA; T-CELLS; PANCREATIC-CANCER; NUCLEAR FACTOR; EXPRESSION; NGAL; IDENTIFICATION; INVASION; PROTEIN	NFAT1 and NFAT5 act as pro-invasive and promigratory transcription factors in breast carcinoma, contributing to the formation of metastases. We report that NFAT3 is specifically expressed in estrogen receptor a positive (ERA +) breast cancer cells. We show that NFAT3 inhibits by itself the invasion capacity of ERA + breast cancer cells and needs to cooperate with ERA to inhibit their migration. Conversely, NFAT3 downregulation results in actin reorganization associated with increased migration and invasion capabilities. NFAT3 signaling reduces migration through inhibition of Lipocalin 2 (LCN2) gene expression. Collectively, our study unravels an earlier unknown NFAT3/LCN2 axis that critically controls motility in breast cancer. Oncogene (2010) 29, 2292-2301; doi: 10.1038/onc.2009.499; published online 25 January 2010	[Fougere, M.; Gaudineau, B.; Guaddachi, F.; Feugeas, J-P; Jauliac, S.] Univ Paris Diderot, Hop St Louis, Inst Hematol, CNRS,UMR7212,INSERM,U944, F-75475 Paris 10, France; [Barbier, J.; Auboeuf, D.] Hop St Louis, INSERM, Inst Hematol, U685,AVENIR,Ctr Hayem, Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Jauliac, S (corresponding author), Univ Paris Diderot, Hop St Louis, Inst Hematol, CNRS,UMR7212,INSERM,U944, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	sebastien.jauliac@inserm.fr	Auboeuf, Didier/M-4610-2014; Jauliac, Sebastien/B-7847-2010	Jauliac, Sebastien/0000-0002-1712-3416; Auboeuf, Didier/0000-0002-3757-0002	Conseil Regional d'Ile-de-France; Ministere de la Recherche; INSERM Region Ile-de-France; ARC; Canceropole Ile-de-France; Research Ministry; INSERM AVENIR; Ligue Nationale contre le Cancer; Comitede Paris of Ligue Nationale contre le Cancer; Comite Tumeurs de la Fondation de France	Conseil Regional d'Ile-de-France(Region Ile-de-France); Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France); INSERM Region Ile-de-France(Region Ile-de-France); ARC(Australian Research Council); Canceropole Ile-de-France(Region Ile-de-France); Research Ministry; INSERM AVENIR(Institut National de la Sante et de la Recherche Medicale (Inserm)); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Comitede Paris of Ligue Nationale contre le Cancer; Comite Tumeurs de la Fondation de France	We thank H de The, D Auboeuf and members of their laboratories for insightful discussions. We thank E Turpin, P Bertheau for providing their microarray data. We thank J L Poyet for providing the T7-pcDNA3 vector and G lazennec for the ER alpha expression vector. We thank T Hoey for providing the human NFAT3 expression vector. We thank J-C Gluckman for reading the paper. We thank N Setterblad at the Service Commun d'Imagerie Cellulaire et Moleculaire of the Institut Universitaire d'Hematologie IFR105 for confocal microscopy. The Service Commun d'Imagerie Cellulaire et Moleculaire is supported by grants from the Conseil Regional d'Ile-de-France and the Ministere de la Recherche. M Fougere was supported by a doctoral grant from INSERM Region Ile-de-France and an ARC fellowship. B Gaudineau was supported by a grant from the Canceropole Ile-de-France and J Barbier by a grant from the Research Ministry. This work was supported by the INSERM AVENIR Program and grants from Ligue Nationale contre le Cancer, the Comitede Paris of Ligue Nationale contre le Cancer, ARC, and the Comite Tumeurs de la Fondation de France and the Canceropole Ile-de-France.	Ayers M, 2004, J CLIN ONCOL, V22, P2284, DOI 10.1200/JCO.2004.05.166; Baksh S, 2002, MOL CELL, V10, P1071, DOI 10.1016/S1097-2765(02)00701-3; Bauer M, 2008, BREAST CANCER RES TR, V108, P389, DOI 10.1007/s10549-007-9619-3; Benedito AB, 2005, J BIOL CHEM, V280, P2818, DOI 10.1074/jbc.M408741200; Bertheau P, 2007, PLOS MED, V4, P585, DOI 10.1371/journal.pmed.0040090; Buchholz M, 2006, EMBO J, V25, P3714, DOI 10.1038/sj.emboj.7601246; Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074-7613(02)00329-1; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Dutertre M, 2003, MOL ENDOCRINOL, V17, P1296, DOI 10.1210/me.2001-0316; Ellison G, 2002, J CLIN PATHOL-MOL PA, V55, P294, DOI 10.1136/mp.55.5.294; Flower DR, 1996, BIOCHEM J, V318, P1; Fowler AM, 2004, FASEB J, V18, P81, DOI 10.1096/fj.03-0038com; Friedl A, 1999, HISTOCHEM J, V31, P433, DOI 10.1023/A:1003708808934; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Furutani M, 1998, CANCER LETT, V122, P209, DOI 10.1016/S0304-3835(97)00391-1; Gruvberger S, 2001, CANCER RES, V61, P5979; Gwira JA, 2005, J BIOL CHEM, V280, P7875, DOI 10.1074/jbc.M413192200; Hill-Eubanks DC, 2003, TRENDS CARDIOVAS MED, V13, P56, DOI 10.1016/S1050-1738(02)00212-8; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; Holzmann K, 2004, CANCER RES, V64, P4428, DOI 10.1158/0008-5472.CAN-04-0431; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Leng X, 2008, ONCOGENE, V27, P6110, DOI 10.1038/onc.2008.209; Leng XH, 2009, CANCER RES, V69, P8579, DOI 10.1158/0008-5472.CAN-09-1934; Li CI, 2001, J NATL CANCER I, V93, P1008, DOI 10.1093/jnci/93.13.1008; Lim R, 2007, INT J CANCER, V120, P2426, DOI 10.1002/ijc.22352; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Mancini M, 2009, NAT REV CANCER, V9, P810, DOI 10.1038/nrc2735; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; Nielsen BS, 1996, GUT, V38, P414, DOI 10.1136/gut.38.3.414; Platet N, 2000, MOL ENDOCRINOL, V14, P999, DOI 10.1210/me.14.7.999; Playford RJ, 2006, GASTROENTEROLOGY, V131, P809, DOI 10.1053/j.gastro.2006.05.051; PRICE JE, 1990, CANCER RES, V50, P717; Provatopoulou X, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-390; Qin X, 2008, CELL MOL LIFE SCI, V65, P2752, DOI 10.1007/s00018-008-8273-1; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shi H, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-83; Stoesz SP, 1998, INT J CANCER, V79, P565, DOI 10.1002/(SICI)1097-0215(19981218)79:6<565::AID-IJC3>3.3.CO;2-6; THOMPSON EW, 1988, CANCER RES, V48, P6764; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Zhang H, 2005, J BIOL CHEM, V280, P43188, DOI 10.1074/jbc.M506598200; Zhang JH, 2008, MOL ENDOCRINOL, V22, P1416, DOI 10.1210/me.2007-0420; Zhong L, 2004, PROTEOMICS, V4, P1216, DOI 10.1002/pmic.200200679	47	39	42	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	15					2292	2301		10.1038/onc.2009.499	http://dx.doi.org/10.1038/onc.2009.499			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101218				2022-12-17	WOS:000276685200014
J	Lauring, J; Cosgrove, DP; Fontana, S; Gustin, JP; Konishi, H; Abukhdeir, AM; Garay, JP; Mohseni, M; Wang, GM; Higgins, MJ; Gorkin, D; Reis, M; Vogelstein, B; Polyak, K; Cowherd, M; Buckhaults, PJ; Park, BH				Lauring, J.; Cosgrove, D. P.; Fontana, S.; Gustin, J. P.; Konishi, H.; Abukhdeir, A. M.; Garay, J. P.; Mohseni, M.; Wang, G. M.; Higgins, M. J.; Gorkin, D.; Reis, M.; Vogelstein, B.; Polyak, K.; Cowherd, M.; Buckhaults, P. J.; Park, B. H.			Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations	ONCOGENE			English	Article						Akt1; oncogene; knock in; gene targeting; breast epithelial cells	PLECKSTRIN HOMOLOGY DOMAIN; PTEN LOSS; PHOSPHOINOSITIDE 3-KINASE; HIGH-FREQUENCY; CANCER; ACTIVATION; CARCINOMA; GENE; CORRELATE; PATHWAY	An oncogenic mutation (G49A:E17K) in the AKT1 gene has been described recently in human breast, colon, and ovarian cancers. The low frequency of this mutation and perhaps other selective pressures have prevented the isolation of human cancer cell lines that harbor this mutation thereby limiting functional analysis. Here, we create a physiologic in vitro model to study the effects of this mutation by using somatic cell gene targeting using the nontumorigenic human breast epithelial cell line, MCF10A. Surprisingly, knock in of E17K into the AKT1 gene had minimal phenotypic consequences and importantly, did not recapitulate the biochemical and growth characteristics seen with somatic cell knock in of PIK3CA hotspot mutations. These results suggest that mutations in critical genes within the PI3-kinase (PI3K) pathway are not functionally equivalent, and that other cooperative genetic events may be necessary to achieve oncogenic PI3K pathway activation in cancers that contain the AKT1 E17K mutation. Oncogene (2010) 29, 2337-2345; doi:10.1038/onc.2009.516; published online 25 January 2010	[Lauring, J.; Cosgrove, D. P.; Fontana, S.; Gustin, J. P.; Konishi, H.; Abukhdeir, A. M.; Garay, J. P.; Mohseni, M.; Wang, G. M.; Higgins, M. J.; Gorkin, D.; Reis, M.; Vogelstein, B.; Park, B. H.] Johns Hopkins Univ, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Sch Med, Baltimore, MD 21231 USA; [Polyak, K.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; [Cowherd, M.; Buckhaults, P. J.] Univ S Carolina, Sch Med, Columbia, SC USA	Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Lauring, J (corresponding author), Johns Hopkins Univ, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Sch Med, 1650 Orleans St,Room 146, Baltimore, MD 21231 USA.	jlaurin1@jhmi.edu; bpark2@jhmi.edu	Reis, Marcelo Martins/H-9370-2012	Reis, Marcelo Martins/0000-0002-4706-1041; Gorkin, David/0000-0003-4944-4107; Abukhdeir, Abde/0000-0003-1172-5819; Konishi, Hiroyuki/0000-0003-1131-4905; Lauring, Josh/0000-0002-4312-704X; Higgins, Michaela Jane/0000-0002-9065-8652	Flight Attendant Medical Research Institute (FAMRI); V Foundation; Maryland Cigarette Restitution Fund; National Institutes of Health [CA88843, CA088843-08, T32 CA09071-27, CA109274]; trust of Ruby J Nelson in loving memory of Charlotte R Nelson; Avon Foundation; American Society of Clinical Oncology Foundation; Department of Defense [W81XWH-06-1-0325, BC083057]; FAMRI; Susan G Komen Foundation; Medical Scientist Training Program Fellowship; Mary Kay Ash Charitable Foundation; Stewart Trust Fund; Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE [P50CA088843, R01CA109274, T32CA009071, R37CA043460, R55CA109274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007814] Funding Source: NIH RePORTER	Flight Attendant Medical Research Institute (FAMRI); V Foundation; Maryland Cigarette Restitution Fund; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); trust of Ruby J Nelson in loving memory of Charlotte R Nelson; Avon Foundation; American Society of Clinical Oncology Foundation; Department of Defense(United States Department of Defense); FAMRI; Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); Medical Scientist Training Program Fellowship; Mary Kay Ash Charitable Foundation; Stewart Trust Fund; Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	JL receives support from the Flight Attendant Medical Research Institute (FAMRI), the V Foundation, and the Maryland Cigarette Restitution Fund, National Institutes of Health Grants CA88843, CA088843-08, The Susan G Komen for the Cure Career Catalyst Grant funded by the trust of Ruby J Nelson in loving memory of Charlotte R Nelson, and the Avon Foundation. DC receives support from National Institutes of Health Grant T32 CA09071-27 and a Young Investigator Award from the American Society of Clinical Oncology Foundation. JP Gustin is a recipient of a Department of Defense Breast Cancer Research Program Predoctoral Fellowship Award W81XWH-06-1-0325. JP Garay is a recipient of a Research Supplement to promote diversity in health-related research. HK is a recipient of a Young Clinical Scientist Award from FAMRI. AMA is supported by a Susan G Komen Foundation Postdoctoral Fellowship Award. GW is a recipient of a Medical Scientist Training Program Fellowship. MM is recipient of a Department of Defense Breast Cancer Predoctoral Training Award (BC083057). BHP acknowledges support from the Avon Foundation, Susan G Komen for the Cure, the Mary Kay Ash Charitable Foundation, the Stewart Trust Fund, National Institutes of Health Grants CA109274 and CA88843, FAMRI, and the Breast Cancer Research Foundation.	Abubaker J, 2007, LEUKEMIA, V21, P2368, DOI 10.1038/sj.leu.2404873; Abukhdeir AM, 2006, BREAST CANCER RES TR, V99, P23, DOI 10.1007/s10549-006-9177-0; Arena S, 2007, CANCER RES, V67, P8468, DOI 10.1158/0008-5472.CAN-07-1126; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Bleeker FE, 2008, ONCOGENE, V27, P5648, DOI 10.1038/onc.2008.170; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Cohen Y, 2010, GYNECOL ONCOL, V116, P88, DOI 10.1016/j.ygyno.2009.09.038; Davies MA, 2008, BRIT J CANCER, V99, P1265, DOI 10.1038/sj.bjc.6604637; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Denley A, 2008, METHOD ENZYMOL, V438, P291, DOI 10.1016/S0076-6879(07)38020-8; Di Nicolantonio F, 2008, P NATL ACAD SCI USA, V105, P20864, DOI 10.1073/pnas.0808757105; Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569; Gustin JP, 2009, P NATL ACAD SCI USA, V106, P2835, DOI 10.1073/pnas.0813351106; Hayes MP, 2006, CLIN CANCER RES, V12, P5932, DOI 10.1158/1078-0432.CCR-06-1375; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Kim MS, 2008, BRIT J CANCER, V98, P1533, DOI 10.1038/sj.bjc.6604212; Konishi H, 2007, NAT PROTOC, V2, P2865, DOI 10.1038/nprot.2007.409; Konishi H, 2007, CANCER RES, V67, P8460, DOI 10.1158/0008-5472.CAN-07-0108; Lauring J, 2008, BLOOD, V111, P856, DOI 10.1182/blood-2007-05-088674; Oda K, 2005, CANCER RES, V65, P10669, DOI 10.1158/0008-5472.CAN-05-2620; Perez-Tenorio G, 2007, CLIN CANCER RES, V13, P3577, DOI 10.1158/1078-0432.CCR-06-1609; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Shoji K, 2009, BRIT J CANCER, V101, P145, DOI 10.1038/sj.bjc.6605109; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Workman P, 2004, BIOCHEM SOC T, V32, P393, DOI 10.1042/BST0320393; Yoon DS, 2002, AM J PATHOL, V161, P391, DOI 10.1016/S0002-9440(10)64194-6	30	39	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	16					2337	2345		10.1038/onc.2009.516	http://dx.doi.org/10.1038/onc.2009.516			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20101210	Green Accepted			2022-12-17	WOS:000276951500003
J	Li, J; Lu, Y; Zhang, J; Kang, H; Qin, Z; Chen, C				Li, J.; Lu, Y.; Zhang, J.; Kang, H.; Qin, Z.; Chen, C.			PI4KII alpha is a novel regulator of tumor growth by its action on angiogenesis and HIF-1 alpha regulation	ONCOGENE			English	Article						phosphatidylinositol 4-kinase type II alpha (PI4KII alpha); tumor; angiogenesis; hypoxia-inducible factor-1 alpha (HIF-1 alpha)	HYPOXIA-INDUCIBLE FACTOR; II PHOSPHATIDYLINOSITOL 4-KINASE; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; NITRIC-OXIDE; FACTOR-1; PATHWAY; ALPHA; PROGRESSION; MODULATION	Tumor growth is the orchestration of various oncogenes and tumor suppressors, and the regulation of these genes offers a rational therapeutic approach to cancer treatment. In this study, we found a new regulator of tumor growth, phosphatidylinositol 4-kinase type II alpha (PI4KII alpha), the mechanism of which is involved in angiogenesis and hypoxia-inducible factor HIF-1 alpha regulation. Results obtained from a human cancer tissue microarray showed that PI4KII alpha protein expression increases markedly in seven types of cancers compared with normal tissues. Suppression of PI4KII alpha leads to retarded tumor growth in nude mice. Downregulation of PI4KII alpha in cancer cells eliminates tumor cell-induced endothelial cell tubulogenesis and migration, and results in impaired angiogenesis. Further investigation showed that PI4KII alpha can directly regulate HIF-1 alpha expression and that the expression of these two proteins is correlated in vivo. At the same time, downregulation of PI4KII alpha markedly reduces HER-2 autophosphorylation, and PI4KII alpha specifically triggers HIF-1 alpha accumulation through a phosphatidylinositol 3-kinase (PI3K)- and extracellular signal-regulated protein kinase (ERK)-dependent pathway, suggesting that PI4KII alpha may regulate HIF-1 alpha through the HER-2/PI3K, ERK cascade. In summary, we discovered a pivotal role for PI4KII alpha in the regulation of tumor growth. Our results shed new light on understanding the novel functions of PI4KII alpha in cancer and suggest that PI4KII alpha may be a promising specific target for tumor therapy. Oncogene (2010) 29, 2550 - 2559; doi:10.1038/onc.2010.14; published online 15 February 2010	[Li, J.; Lu, Y.; Zhang, J.; Qin, Z.; Chen, C.] Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, Beijing 100101, Peoples R China; [Lu, Y.; Zhang, J.; Qin, Z.] Chinese Acad Sci, Univ Tokyo Joint Lab Struct Virol & Immunol, Inst Biophys, Beijing, Peoples R China; [Kang, H.] Capital Med Univ, Dept Gen Surg, Xuanwu Hosp, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS; Capital Medical University	Chen, C (corresponding author), Chinese Acad Sci, Natl Lab Biomacromol, Inst Biophys, 15 Datun Rd, Beijing 100101, Peoples R China.	zhihai@ibp.ac.cn; changchen@moon.ibp.ac.cn		Zhang, Jinhua/0000-0001-8957-8893	'863' National High-Technology Development Program of China [0A200202D03]; National Basic Research Program of China [2006CB911001, 2005CB522804]; National Natural Science Foundation of China [90606020, 30770512]	'863' National High-Technology Development Program of China(National High Technology Research and Development Program of China); National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Shane Minogue and Konstantin V Kandror for gifted plasmids and Pietro De Camilli for PI4KII alpha antibody, Wei Liang, Xiyun Yan and Yi Zhu for sharing materials, and Guoheng Xu and Qinwei Yin for valuable discussions. We are grateful to Nanping Wang for his great support. We also thank Junfeng Hao and Xudong Zhao for technical assistance. The work was supported by the '863' National High-Technology Development Program of China (0A200202D03), the National Basic Research Program of China (2006CB911001, 2005CB522804) and the National Natural Science Foundation of China (90606020, 30770512).	Craige B, 2008, MOL BIOL CELL, V19, P1415, DOI 10.1091/mbc.E07-12-1239; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; DRABKIN DL, 1949, AM J MED SCI, V217, P710; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Garcia-Cardena G, 1998, J NATL CANCER I, V90, P560, DOI 10.1093/jnci/90.8.560; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006; GRANT DS, 1992, J CELL PHYSIOL, V153, P614, DOI 10.1002/jcp.1041530324; Guo J, 2003, P NATL ACAD SCI USA, V100, P3995, DOI 10.1073/pnas.0230488100; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Heilmeyer LMG, 2003, IUBMB LIFE, V55, P59, DOI 10.1080/1521654031000090896; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; HSUAN JJ, 1993, ANTICANCER RES, V13, P2521; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; KAUFFMANNZEH A, 1994, J BIOL CHEM, V269, P31243; Koesters R, 2003, CANCER LETT, V198, P123, DOI 10.1016/S0304-3835(03)00367-7; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Minogue S, 2006, J CELL SCI, V119, P571, DOI 10.1242/jcs.02752; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; Pan WJ, 2008, SCIENCE, V321, P1350, DOI 10.1126/science.1160741; Qin YB, 2009, J BIOL CHEM, V284, P22544, DOI 10.1074/jbc.M109.014399; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V319, P1, DOI 10.1016/j.bbrc.2004.04.150; Salazar G, 2009, J BIOL CHEM, V284, P1790, DOI 10.1074/jbc.M805991200; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Simonton DK, 2009, PERSPECT PSYCHOL SCI, V4, P2, DOI 10.1111/j.1745-6924.2009.01093.x; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Wang YJ, 2003, CELL, V114, P299, DOI 10.1016/S0092-8674(03)00603-2; Waugh MG, 2003, BIOCHEM J, V373, P57, DOI 10.1042/BJ20030089; Weber G, 1996, ANTICANCER RES, V16, P3271; Xu Z, 2006, MOL ENDOCRINOL, V20, P2890, DOI 10.1210/me.2006-0193; Yamamoto S, 2004, ANN SURG ONCOL, V11, P697, DOI 10.1245/ASO.2004.10.018; Zhong H, 2000, CANCER RES, V60, P1541	41	39	42	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	17					2550	2559		10.1038/onc.2010.14	http://dx.doi.org/10.1038/onc.2010.14			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20154717				2022-12-17	WOS:000277169400010
J	Watson, IR; Li, BK; Roche, O; Blanch, A; Ohh, M; Irwin, MS				Watson, I. R.; Li, B. K.; Roche, O.; Blanch, A.; Ohh, M.; Irwin, M. S.			Chemotherapy induces NEDP1-mediated destabilization of MDM2	ONCOGENE			English	Article						chemotherapy; MDM2; NEDD8; NEDP1; p53	DNA-DAMAGE; IN-VIVO; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; COP9 SIGNALOSOME; P53; NEDD8; PROTEINS; PROTEASE; PATHWAY	MDM2 is an E3 ligase that promotes ubiquitin-mediated destruction of p53. Cellular stresses such as DNA damage can lead to p53 activation due in part to MDM2 destabilization. Here, we show that the stability of MDM2 is regulated by an ubiquitin-like NEDD8 pathway and identify NEDP1 as a chemotherapy-induced isopeptidase that deneddylates MDM2, resulting in MDM2 destabilization concomitant with p53 activation. Concordantly, RNAi-mediated knockdown of endogenous NEDP1 blocked diminution of MDM2 levels and increased chemoresistance of tumor cells. These findings unveil the regulation of MDM2 stability through NEDP1 as a common molecular determinant governing chemotherapy-induced p53-dependent cell death. Oncogene (2010) 29, 297-304; doi:10.1038/onc.2009.314; published online 28 September 2009	[Watson, I. R.; Li, B. K.; Roche, O.; Ohh, M.; Irwin, M. S.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Irwin, M. S.] Hosp Sick Children, Dept Paediat & Cell Biol, Cell Biol Program, Toronto, ON M5G 1X8, Canada; [Irwin, M. S.] Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada; [Irwin, M. S.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Irwin, MS (corresponding author), Hosp Sick Children, Dept Paediat & Cell Biol, Cell Biol Program, 555 Univ Ave,Black Wing 9th Floor, Toronto, ON M5G 1X8, Canada.	michael.ohh@utoronto.ca; meredith.irwin@sickkids.ca	Roche, UCLM/F-5697-2019; Roche, Olga/K-9342-2014	Roche, UCLM/0000-0003-1884-8256; Watson, Ian/0000-0002-6025-3080; Li, Kincheon/0000-0001-6640-2625	Canadian Cancer Society Research Institute (CCSRI) [018460, 018054]; Hospital for Sick Children Foundation; Canadian Institutes of Health Research (CIHR) Canada	Canadian Cancer Society Research Institute (CCSRI)(Canadian Cancer Society (CCS)); Hospital for Sick Children Foundation; Canadian Institutes of Health Research (CIHR) Canada(Canadian Institutes of Health Research (CIHR))	We thank Lynn Cheng, Joanne Lau, Roxana Sufan and Ryan Russell for their technical assistance. We thank Drs Uri Tabori and Loretta Lau for helpful discussions. We thank Drs Stephen Meyn and Paul Bradshaw for providing AT reagents. This work was supported by funds from the Canadian Cancer Society Research Institute (CCSRI 018460 to MO and 018054 to MSI). IRW is a recipient of the Hospital for Sick Children Foundation Student Scholarship and the Canadian Institutes of Health Research (CIHR) Canada Graduate Scholarship. OR is a recipient of the CIHR Fellowship. MO and MSI are Canada Research Chairs.	Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Chan Y, 2008, J CELL SCI, V121, P3218, DOI 10.1242/jcs.030445; Gan-Erdene T, 2003, J BIOL CHEM, V278, P28892, DOI 10.1074/jbc.M302890200; Hetfeld BKJ, 2008, APOPTOSIS, V13, P187, DOI 10.1007/s10495-007-0164-7; Huang HY, 2008, CLIN CANCER RES, V14, P6023, DOI 10.1158/1078-0432.CCR-08-0252; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Jones J, 2008, J PROTEOME RES, V7, P1274, DOI 10.1021/pr700749v; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Koschny R, 2006, PATHOL RES PRACT, V202, P23, DOI 10.1016/j.prp.2005.10.010; Lau L, 2007, ONCOGENE, V26, P1920, DOI 10.1038/sj.onc.1209981; Lee MH, 2006, NAT CELL BIOL, V8, P1424, DOI 10.1038/ncb1512; Levav-Cohen Y, 2005, GROWTH FACTORS, V23, P183, DOI 10.1080/08977190500196218; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LUNA RMD, 1995, NATURE, V378, P203; Mendoza HM, 2003, J BIOL CHEM, V278, P25637, DOI 10.1074/jbc.M212948200; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Morimoto M, 2003, BIOCHEM BIOPH RES CO, V301, P392, DOI 10.1016/S0006-291X(02)03051-6; Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414; Paunu N, 2002, CANCER RES, V62, P3798; Rabut G, 2008, EMBO REP, V9, P969, DOI 10.1038/embor.2008.183; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Suzuki H, 2008, LUNG CANCER, V59, P24, DOI 10.1016/j.lungcan.2007.08.002; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Watson IR, 2006, J BIOL CHEM, V281, P34096, DOI 10.1074/jbc.M603654200; Wu JT, 2005, NAT CELL BIOL, V7, P1014, DOI 10.1038/ncb1301; Wu K, 2003, J BIOL CHEM, V278, P28882, DOI 10.1074/jbc.M302888200; Xirodimas DP, 2008, BIOCHEM SOC T, V36, P802, DOI 10.1042/BST0360802; Xirodimas DP, 2008, EMBO REP, V9, P280, DOI 10.1038/embor.2008.10; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yamoah K, 2005, METHOD ENZYMOL, V398, P509, DOI 10.1016/S0076-6879(05)98042-7; Zhang XC, 2008, J CELL BIOCHEM, V103, P1219, DOI 10.1002/jcb.21504; Zhou LH, 2005, BIOCHEM J, V389, P307, DOI 10.1042/BJ20041991	34	39	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					297	304		10.1038/onc.2009.314	http://dx.doi.org/10.1038/onc.2009.314			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19784069				2022-12-17	WOS:000273650000012
J	Switzer, CH; Ridnour, LA; Cheng, RYS; Sparatore, A; Del Soldato, P; Moody, TW; Vitek, MP; Roberts, DD; Wink, DA				Switzer, C. H.; Ridnour, L. A.; Cheng, R. Y. S.; Sparatore, A.; Del Soldato, P.; Moody, T. W.; Vitek, M. P.; Roberts, D. D.; Wink, D. A.			Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity	ONCOGENE			English	Article						dithiolethione; PP2A; Akt; cancer; breast; lung	PROTEIN PHOSPHATASE 2A; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TUMOR-SUPPRESSOR; HEME OXYGENASE-1; KINASE-B; TYROSINE PHOSPHORYLATION; REGULATORY SUBUNITS; 3T3-L1 ADIPOCYTES; C-MYC; PATHWAY	The chemopreventative effects of dithiolethione compounds are attributed to their activation of antioxidant response elements (AREs) by reacting with the Nrf2/Keap1 protein complex. In this study, we show anti-proliferative effects of the dithiolethione compound ACS1 in human cancer cell lines (A549 and MDA-MB-231) by increasing the activity of the tumor suppressor protein phoshatase 2A (PP2A). ACS-1 inhibited epidermal growth factor (EGF)-induced cellular proliferation in a concentration-and time-dependent manner. Akt activation, as determined by serine-473 phosphorylation, was inhibited by ACS-1 in cells stimulated with either EGF or fibronectin. Furthermore, ACS-1 inhibited mammalian target of rapamycin signaling and decreased c-myc protein levels. ACS-1 did not proximally alter EGF receptor or integrin signaling, but caused a concentration-dependent increase in PP2A activity. The effect of ACS-1 on Akt activation was not observed in the presence of the PP2A inhibitor okadaic acid. ACS-1 effects on PP2A activity were independent of ARE activation and cAMP formation. In addition to ACS-1, other dithiolethione compounds showed similar effects in reducing Akt activation, suggesting that this class of compounds may have other effects beyond chemoprevention. Oncogene (2009) 28, 3837-3846; doi:10.1038/onc.2009.244; published online 24 August 2009	[Switzer, C. H.; Ridnour, L. A.; Cheng, R. Y. S.; Wink, D. A.] NCI, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA; [Sparatore, A.] Univ Milan, Dipartimento Sci Farmaceut Pietro Pratesi, Milan, Italy; [Del Soldato, P.] Sulfidris, Milan, Italy; [Vitek, M. P.] Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA; [Roberts, D. D.] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Milan; Duke University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wink, DA (corresponding author), NCI, Radiat Biol Branch, NIH, Bldg 10,Room B3-B35, Bethesda, MD 20892 USA.	wink@mail.nih.gov	Switzer, Christopher/D-9203-2013; Roberts, David D./A-9699-2008; Sparatore, Anna/J-8634-2015; Cheng, Robert/E-9799-2013	Roberts, David D./0000-0002-2481-2981; Sparatore, Anna/0000-0003-2135-2649; Azad, Mahan/0000-0002-8633-3513; Cheng, Robert/0000-0003-0287-6439; Wink, David/0000-0002-5652-7480; Vitek, Michael/0000-0001-8140-8048; Ridnour, Lisa A./0000-0001-9446-8349	NATIONAL CANCER INSTITUTE [ZIASC009174, Z01BC010899] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 BC010899-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arnold HK, 2008, CANCER METAST REV, V27, P147, DOI 10.1007/s10555-008-9128-9; Bae EJ, 2007, HEPATOLOGY, V46, P730, DOI 10.1002/hep.21769; Bass SE, 2009, CLIN CANCER RES, V15, P1964, DOI 10.1158/1078-0432.CCR-08-1870; Busserolles J, 2006, INT J BIOCHEM CELL B, V38, P1510, DOI 10.1016/j.biocel.2006.03.013; Cai WJ, 2007, CARDIOVASC RES, V76, P29, DOI 10.1016/j.cardiores.2007.05.026; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202; Dulak J, 2008, CIRCULATION, V117, P231, DOI 10.1161/CIRCULATIONAHA.107.698316; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Feschenko MS, 2002, J PHARMACOL EXP THER, V302, P111, DOI 10.1124/jpet.302.1.111; Guadagni F, 2007, ANTICANCER RES, V27, P3147; Hamada T, 1999, AM J MED SCI, V318, P146, DOI 10.1097/00000441-199909000-00009; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Isenberg JS, 2007, BRIT J PHARMACOL, V151, P142, DOI 10.1038/sj.bjp.0707198; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kim SG, 1998, BIOCHEM PHARMACOL, V55, P1585, DOI 10.1016/S0006-2952(97)00669-2; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Kwak MK, 2001, MUTAT RES-FUND MOL M, V480, P305, DOI 10.1016/S0027-5107(01)00190-7; Lam S, 2002, JNCI-J NATL CANCER I, V94, P1001; Lee JS, 2005, CANCER LETT, V224, P171, DOI 10.1016/j.canlet.2004.09.042; Li L, 2007, FREE RADICAL BIO MED, V42, P706, DOI 10.1016/j.freeradbiomed.2006.12.011; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Longin S, 2007, J BIOL CHEM, V282, P26971, DOI 10.1074/jbc.M704059200; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Matsuoka Y, 2003, BRIT J PHARMACOL, V138, P1303, DOI 10.1038/sj.bjp.0705182; Moody TW, 2010, LUNG CANCER, V68, P154, DOI 10.1016/j.lungcan.2009.06.012; Paugh SW, 2006, MOL PHARMACOL, V70, P41, DOI 10.1124/mol.105.020552; Perrotti D, 2008, CANCER METAST REV, V27, P159, DOI 10.1007/s10555-008-9119-x; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Prickett TD, 2006, J BIOL CHEM, V281, P30503, DOI 10.1074/jbc.M601054200; Qiao M, 2008, CELL CYCLE, V7, P2991, DOI 10.4161/cc.7.19.6784; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Rocher G, 2007, J BIOL CHEM, V282, P5468, DOI 10.1074/jbc.M609712200; Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047; Sarnataro D, 2006, MOL PHARMACOL, V70, P1298, DOI 10.1124/mol.106.025601; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sawai H, 2006, ONCOGENE, V25, P3237, DOI 10.1038/sj.onc.1209356; Schmidt A, 2006, MICROVASC RES, V71, P152, DOI 10.1016/j.mvr.2006.01.001; Trotta R, 2007, J EXP MED, V204, P2397, DOI 10.1084/jem.20070419; Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; Xing YN, 2008, CELL, V133, P154, DOI 10.1016/j.cell.2008.02.041; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhang YS, 2008, MOL CANCER THER, V7, P3470, DOI 10.1158/1535-7163.MCT-08-0625	49	39	39	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	43					3837	3846		10.1038/onc.2009.244	http://dx.doi.org/10.1038/onc.2009.244			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512KT	19701246	Green Accepted			2022-12-17	WOS:000271248400007
J	Bachmaier, R; Aryee, DNT; Jug, G; Kauer, M; Kreppel, M; Lee, KA; Kovar, H				Bachmaier, R.; Aryee, D. N. T.; Jug, G.; Kauer, M.; Kreppel, M.; Lee, K. A.; Kovar, H.			O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma	ONCOGENE			English	Article						EWS-FLI1; Ewing's sarcoma; post-translational modification; O-GlcNAc; phosphorylation; transcription	RNA-POLYMERASE-II; DON 6-DIAZO-5-OXO-L-NORLEUCINE; N-ACETYLGLUCOSAMINE; TYROSINE KINASE; FUSION PROTEIN; PHASE-I; EWS; DOMAIN; PHOSPHORYLATION; GLYCOPROTEIN	The oncogene EWS-FLI1 encodes a chimeric transcription factor expressed in Ewing's sarcoma family tumors (ESFTs). EWS-FLI1 target gene expression is thought to drive ESFT pathogenesis and, therefore, inhibition of EWS-FLI1 activity holds high therapeutic promise. As the activity of many transcription factors is regulated by post-translational modi. cations, we studied the presence of modi. cations on EWS-FLI1. The immuno-purified fusion-protein was recognized by an antibody specific for O-linked beta-N-acetylglucosaminylation, and bound readily to a phosphoprotein-specific dye. Inhibition of Ser/Thr-specific phophatases increased EWS-FLI1 molecular weight and reduced its O-GlcNAc content, suggesting that phosphorylation and O-GlcNAcylation of EWS-FLI1 interact dynamically. By mutation analysis, O-GlcNAcylation was delineated to Ser/Thr residues of the amino-terminal EWS transcriptional-activation domain. Metabolic inhibition of the hexosamine biosynthetic pathway abrogated O-GlcNAcylation of EWS-FLI1 and interfered specifically with transcriptional activation of the EWS-FLI1 target Id2. These results suggest that drugs modulating glycosylation of EWS-FLI1 interfere functionally with its activity and might, therefore, constitute promising additions to the current ESFT chemotherapy.	[Bachmaier, R.; Aryee, D. N. T.; Jug, G.; Kauer, M.; Kreppel, M.; Kovar, H.] St Anna Kinder Krebsforsch, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Lee, K. A.] Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	Saint Anna Children's Hospital; Hong Kong University of Science & Technology	Kovar, H (corresponding author), St Anna Kinder Krebsforsch, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.	heinrich.kovar@ccri.at		Kovar, Heinrich/0000-0001-6873-9109	Austrian Science Fund (FWF) [P18046-B12]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	This study was supported in part by Grant P18046-B12 of the Austrian Science Fund ( FWF).	Araya N, 2005, BIOCHEM BIOPH RES CO, V329, P653, DOI 10.1016/j.bbrc.2005.02.018; Aryee DNT, 2006, CANCER RES, V66, P9862, DOI 10.1158/0008-5472.CAN-05-4042; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Guinamard R, 1997, SCAND J IMMUNOL, V45, P587, DOI 10.1046/j.1365-3083.1997.d01-447.x; Gupta Ramneek, 2002, Pac Symp Biocomput, P310; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kim J, 1999, P NATL ACAD SCI USA, V96, P14300, DOI 10.1073/pnas.96.25.14300; Kim J, 2000, FEBS LETT, V474, P121, DOI 10.1016/S0014-5793(00)01590-8; Kovar H, 2005, SEMIN CANCER BIOL, V15, P189, DOI 10.1016/j.semcancer.2005.01.004; LYNCH G, 1982, AM J CLIN ONCOL-CANC, V5, P541; Martin K, 2003, PROTEOMICS, V3, P1244, DOI 10.1002/pmic.200300445; Matsuoka Y, 2002, HYBRIDOMA HYBRIDOM, V21, P233, DOI 10.1089/153685902760213831; Ng KP, 2007, P NATL ACAD SCI USA, V104, P479, DOI 10.1073/pnas.0607007104; Ohlson J, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni169; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; RAHMAN A, 1985, INVEST NEW DRUG, V3, P369; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Spahn L, 2003, ONCOGENE, V22, P6819, DOI 10.1038/sj.onc.1206810; SULLIVAN MP, 1988, CANCER CHEMOTH PHARM, V21, P78, DOI 10.1007/BF00262746; Wang M, 1999, EXP CELL RES, V246, P38, DOI 10.1006/excr.1998.4280; Wells L, 2002, MOL CELL PROTEOMICS, V1, P791, DOI 10.1074/mcp.M200048-MCP200; Zhang XK, 2005, J BIOCHEM, V137, P297, DOI 10.1093/jb/mvi032	24	39	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1280	1284		10.1038/onc.2008.484	http://dx.doi.org/10.1038/onc.2008.484			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151750	Green Accepted			2022-12-17	WOS:000263906200012
J	Ho, VM; Schaffer, BE; Karnezis, AN; Park, KS; Sage, J				Ho, V. M.; Schaffer, B. E.; Karnezis, A. N.; Park, K. S.; Sage, J.			The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras	ONCOGENE			English	Article						K-Ras; Rb; p130; p107; lung adenocarcinoma; mouse model	TUMOR-SUPPRESSOR; N-RAS; CANCER; PRB; PROTEIN; P107; DIFFERENTIATION; MOUSE; TUMORIGENESIS; PROGRESSION	Mutations of the retinoblastoma tumor suppressor gene RB are frequently observed in human cancers, but rarely in non-small cell lung carcinomas (NSCLCs). Emerging evidence also suggests that the RB-related gene p130 is inactivated in a subset of human NSCLCs. To directly test the specific tumor suppressor roles of RB and p130 in NSCLC, we crossed Rb and p130 conditional mutant mice to mice carrying a conditional oncogenic K-Ras allele. In this model, controlled oncogenic K-Ras activation leads to the development of adenocarcinoma, a major subtype of NSCLC. We found that loss of p130 accelerated the death of mice, providing direct evidence in vivo that p130 is a tumor suppressor gene, albeit a weak one in this context. Loss of Rb increased the efficiency of lung cancer initiation and resulted in the development of high-grade adenocarcinomas and rapid death. Thus, despite the low frequency of RB mutations in human NSCLCs and reports that K-Ras activation and loss of RB function are rarely found in the same human tumors, loss of Rb clearly cooperates with activation of oncogenic K-Ras in lung adenocarcinoma development in mice.	[Ho, V. M.; Schaffer, B. E.; Park, K. S.; Sage, J.] Stanford Med Sch, Dept Pediat & Genet, Stanford, CA 94305 USA; [Karnezis, A. N.] Univ Calif San Francisco, Canc Res Inst, Dept Pathol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA	Stanford University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Sage, J (corresponding author), Stanford Med Sch, Dept Pediat & Genet, 269 Campus Dr,CCSR1215A, Stanford, CA 94305 USA.	julien.sage@stanford.edu			NATIONAL CANCER INSTITUTE [R01CA114102] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA114102-02, R01 CA114102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Caterina C, 2005, ONCOGENE, V24, P5821, DOI 10.1038/sj.onc.1208880; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Claudio PP, 2000, CLIN CANCER RES, V6, P754; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Dannenberg Jan-Hermen, 2006, V42, P183, DOI 10.1007/002; Dannenberg JH, 2004, GENE DEV, V18, P2952, DOI 10.1101/gad.322004; DeGregori J, 2006, MOL CELL BIOL, V26, P1165, DOI 10.1128/MCB.26.4.1165-1169.2006; Geng Y, 1996, ONCOGENE, V12, P1173; Grasemann C, 2005, ONCOGENE, V24, P6441, DOI 10.1038/sj.onc.1208792; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kaye FJ, 2002, ONCOGENE, V21, P6908, DOI 10.1038/sj.onc.1205834; Lara MF, 2008, MOL CARCINOGEN, V47, P105, DOI 10.1002/mc.20367; Lee KY, 1999, MOL CELL BIOL, V19, P7724; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; Olsson AY, 2007, ONCOGENE, V26, P1028, DOI 10.1038/sj.onc.1209854; RODENHUIS S, 1990, AM REV RESPIR DIS, V142, pS27, DOI 10.1164/ajrccm/142.6_Pt_2.S27; Ruiz S, 2005, CANCER RES, V65, P9678, DOI 10.1158/0008-5472.CAN-05-1853; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Suzuki T, 2006, EMBO J, V25, P3422, DOI 10.1038/sj.emboj.7601215; Takahashi C, 2006, NAT GENET, V38, P118, DOI 10.1038/ng1703; Takahashi C, 2004, MOL CELL BIOL, V24, P10406, DOI 10.1128/MCB.24.23.10406-10415.2004; Takahashi C, 2003, MOL CELL BIOL, V23, P5256, DOI 10.1128/MCB.23.15.5256-5268.2003; Takahashi C, 2006, CANCER RES, V66, P9345, DOI 10.1158/0008-5472.CAN-06-1250; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; TRAVIS WD, 1995, CANCER-AM CANCER SOC, V75, P191, DOI 10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Wikenheiser-Brokamp KA, 2006, CELL MOL LIFE SCI, V63, P767, DOI 10.1007/s00018-005-5487-3; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; Williams JP, 2006, MOL CELL BIOL, V26, P1170, DOI 10.1128/MCB.26.4.1170-1182.2006; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738	37	39	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1393	1399		10.1038/onc.2008.491	http://dx.doi.org/10.1038/onc.2008.491			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19151761	Green Accepted			2022-12-17	WOS:000264116000012
J	Bugni, JM; Meira, LB; Samson, LD				Bugni, J. M.; Meira, L. B.; Samson, L. D.			Alkylation-induced colon tumorigenesis in mice deficient in the Mgmt and Msh6 proteins	ONCOGENE			English	Article						colorectal cancer; Mgmt; Msh6; mismatch repair; azoxymethane	INVITRO DNA-REPLICATION; MISMATCH-REPAIR; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; INTESTINAL TUMORIGENESIS; METHYLTRANSFERASE GENE; MUTATION FREQUENCY; KNOCKOUT MICE; APOPTOSIS; CANCER; DAMAGE	O-6-methylguanine DNA methyltransferase (MGMT) suppresses mutations and cell death that result from alkylation damage. MGMT expression is lost by epigenetic silencing in a variety of human cancers including nearly half of sporadic colorectal cancers, suggesting that this loss maybe causal. Using mice with a targeted disruption of the Mgmt gene, we tested whether Mgmt protects against azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF), against AOM and dextran sulfate sodium (DSS)-induced colorectal adenomas and against spontaneous intestinal adenomas in Apc(Min) mice. We also examined the genetic interaction of the Mgmt null gene with a DNA mismatch repair null gene, namely Msh6. Both Mgmt and Msh6 independently suppress AOM-induced ACF, and combination of the two mutant alleles had a multiplicative effect. This synergism can be explained entirely by the suppression of alkylationinduced apoptosis when Msh6 is absent. In addition, following AOM_DSS treatment Mgmt protected against adenoma formation to the same degree as it protected against AOM-induced ACF formation. Finally, Mgmt de. ciency did not affect spontaneous intestinal adenoma development in Apc(Min/+) mice, suggesting that Mgmt suppresses intestinal cancer associated with exogenous alkylating agents, and that endogenous alkylation does not contribute to the rapid tumor development seen in Apc(Min/+) mice.	MIT, Biol Engn Dept, Cambridge, MA 02139 USA; MIT, Ctr Environm Hlth Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Samson, LD (corresponding author), MIT, Dept Environm Hlth Sci, Bldg 56-235, Cambridge, MA 02139 USA.	lsamson@mit.edu	Meira, Lisiane/AAA-4326-2020	Meira, Lisiane/0000-0003-4289-2986	NIH [ES02109, CA75576]; NCI [CA14051]; NATIONAL CANCER INSTITUTE [R01CA075576, P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This research was supported by NIH Grants ES02109 and CA75576. We acknowledge the MIT CCR Histology facility (NCI Grant: CA14051), especially Alicia Caron. LDS is an American Cancer Society Research Professor.	Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; AQUILINA G, 1992, CANCER RES, V52, P6471; Baker SM, 1998, CANCER RES, V58, P1087; Edelmann W, 1999, CANCER RES, V59, P1301; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Esteller M, 2001, CANCER RES, V61, P3225; Fang QM, 2005, BIOCHEMISTRY-US, V44, P15396, DOI 10.1021/bi051460d; Fox EJ, 2006, J MOL DIAGN, V8, P68, DOI 10.2353/jmoldx.2006.050084; Glassner BJ, 1999, MUTAGENESIS, V14, P339, DOI 10.1093/mutage/14.3.339; Haigis KM, 2002, P NATL ACAD SCI USA, V99, P8927, DOI 10.1073/pnas.132275099; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; Hecht SS, 1999, MUTAT RES-FUND MOL M, V424, P127, DOI 10.1016/S0027-5107(99)00014-7; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907; Kaina B, 2003, BIOCHEM PHARMACOL, V66, P1547, DOI 10.1016/S0006-2952(03)00510-0; Kaina B, 1997, MUTAT RES-FUND MOL M, V381, P227, DOI 10.1016/S0027-5107(97)00187-5; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; Kellett M, 1992, Epithelial Cell Biol, V1, P147; Kohonen-Corish MRJ, 2002, CANCER RES, V62, P2092; Kuraguchi M, 2001, CANCER RES, V61, P7934; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; Lind GE, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-28; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; MYRNES B, 1984, CARCINOGENESIS, V5, P1061, DOI 10.1093/carcin/5.8.1061; Nagasaka T, 2008, INT J CANCER, V122, P2429, DOI 10.1002/ijc.23398; Reitmair AH, 1996, CANCER RES, V56, P2922; Sakumi K, 1997, CANCER RES, V57, P2415; Sandercock LE, 2004, ONCOGENE, V23, P5931, DOI 10.1038/sj.onc.1207791; Sedgwick B, 1997, CARCINOGENESIS, V18, P1561, DOI 10.1093/carcin/18.8.1561; Sieber OM, 2004, CANCER RES, V64, P8876, DOI 10.1158/0008-5472.CAN-04-2958; SNOW ET, 1984, J BIOL CHEM, V259, P8095; Sohn OS, 2001, CANCER RES, V61, P8435; Stojic L, 2004, DNA REPAIR, V3, P1091, DOI 10.1016/j.dnarep.2004.06.006; Taniguchi K, 2006, ONCOLOGY-BASEL, V71, P124, DOI 10.1159/000100522; Toft NJ, 2000, CARCINOGENESIS, V21, P593, DOI 10.1093/carcin/21.4.593; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wali RK, 1999, CARCINOGENESIS, V20, P2355, DOI 10.1093/carcin/20.12.2355; WEI X, 1993, P NATL ACAD SCI USA, V90, P2117, DOI 10.1073/pnas.90.6.2117; Xu-Welliver M, 2002, CARCINOGENESIS, V23, P823, DOI 10.1093/carcin/23.5.823; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451	43	39	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2009	28	5					734	741		10.1038/onc.2008.426	http://dx.doi.org/10.1038/onc.2008.426			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	403IN	19029948	Green Submitted, Green Accepted			2022-12-17	WOS:000263076400010
J	Chen, C; Zhou, Z; Liu, R; Li, Y; Azmi, PB; Seth, AK				Chen, C.; Zhou, Z.; Liu, R.; Li, Y.; Azmi, P. B.; Seth, A. K.			The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11	ONCOGENE			English	Article						WWP1; ErbB2; EGFR; RNF11; PY motif; WW domain	GROWTH-FACTOR RECEPTOR; MEDIATES UBIQUITINATION; BREAST-CANCER; DEGRADATION; RNF11; TARGET; MONOUBIQUITINATION; LOCALIZATION; MECHANISMS; INTERACTS	The WW domain containing E3 ubiquitin protein ligase 1 (WWP1) is a homologous to the E6-associated protein C terminus-type E3 ligase frequently overexpressed in human prostate and breast cancers due to gene amplification. Previous studies suggest that WWP1 promotes cell proliferation and survival; however, the mechanism of WWP1 action is still poorly understood. Here, we showed that WWP1 upregulates and maintains erythroblastic leukemia viral oncogene homolog 2 (ErbB2) and epithelial growth factor receptor (EGFR) in multiple cell lines. WWP1 depletion dramatically attenuates the EGF-induced ERK phosphorylation. WWP1 forms a protein complex with RING finger protein 11 (RNF11), a negative regulator of ErbB2 and EGFR. The protein protein interaction is through the first and third WW domains of WWP1 and the PY motif of RNF11. Although WWP1 is able to ubiquitinate RNF11 in vitro and in vivo, WWP1 neither targets RNF11 for degradation nor changes RNF11's cellular localization. Importantly, inhibition of RNF11 can rescue WWP1 siRNA-induced ErbB2 and EGFR downregulation and growth arrest. Finally, we demonstrated that RNF11 is overexpressed in a panel of prostate and breast cancer cell lines with WWP1 expression. These findings suggest that WWP1 may promote cell proliferation and survival partially through suppressing RNF11-mediated ErbB2 and EGFR downregulation. Oncogene (2008) 27, 6845-6855; doi: 10.1038/onc.2008.288; published online 25 August 2008	[Chen, C.; Zhou, Z.; Liu, R.; Li, Y.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; [Azmi, P. B.; Seth, A. K.] Univ Toronto, Div Mol & Cellular Biol, Sunnybrook Res Inst, Toronto, ON, Canada; [Azmi, P. B.; Seth, A. K.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	Albany Medical College; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Chen, C (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, MS355,Mail Code 165,47 New Scotland Ave, Albany, NY 12208 USA.	chenc@mail.amc.edu			American Cancer Society; Department of Defense Prostate Cancer Research Program [W81XWH-07-1-0191]; Susan G Komen Breast Cancer Foundation [BCTR0503705]; Canadian Breast Cancer Research Alliance special program	American Cancer Society(American Cancer Society); Department of Defense Prostate Cancer Research Program(United States Department of Defense); Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Canadian Breast Cancer Research Alliance special program	We thank Dr Roger Y Tsien for the mCherry vector. This work was supported in part by a grant from American Cancer Society (Chen C), a grant from the Department of Defense Prostate Cancer Research Program (W81XWH-07-1-0191, Chen C), a grant (BCTR0503705) from the Susan G Komen Breast Cancer Foundation (Chen C), and from the Canadian Breast Cancer Research Alliance special program grant on metastasis to Arun Seth.	Anderson LR, 2007, J NEUROPATH EXP NEUR, V66, P955, DOI 10.1097/nen.0b013e3181567f17; Angers A, 2004, J BIOL CHEM, V279, P11471, DOI 10.1074/jbc.M309934200; Azmi P, 2005, EUR J CANCER, V41, P2549, DOI 10.1016/j.ejca.2005.08.020; Burger A, 2006, NEOPLASIA, V8, P689, DOI 10.1593/neo.06469; Chen C, 2007, ONCOGENE, V26, P2386, DOI 10.1038/sj.onc.1210021; Chen C, 2007, INT J CANCER, V121, P2834; Chen C, 2007, CANCER METAST REV, V26, P587, DOI 10.1007/s10555-007-9091-x; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Flasza M, 2006, MOL MEMBR BIOL, V23, P269, DOI 10.1080/09687860600665010; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Kitching R, 2003, BBA-MOL BASIS DIS, V1639, P104, DOI 10.1016/j.bbadis.2003.07.001; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Laine A, 2007, ONCOGENE, V26, P1477, DOI 10.1038/sj.onc.1209924; Li HX, 2004, ONCOGENE, V23, P1801, DOI 10.1038/sj.onc.1207319; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Martin-Serrano J, 2005, J CELL BIOL, V168, P89, DOI 10.1083/jcb.200408155; Moren A, 2005, J BIOL CHEM, V280, P22115, DOI 10.1074/jbc.M414027200; Mosser EA, 1998, BIOCHEMISTRY-US, V37, P13686, DOI 10.1021/bi981310l; Murdaca J, 2004, J BIOL CHEM, V279, P26754, DOI 10.1074/jbc.M311802200; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Seo SR, 2004, EMBO J, V23, P3780, DOI 10.1038/sj.emboj.7600398; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Shen R, 2006, J BIOL CHEM, V281, P3569, DOI 10.1074/jbc.M506761200; Subramaniam V, 2003, BRIT J CANCER, V89, P1538, DOI 10.1038/sj.bjc.6601301; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097-2765(02)00774-8; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Woelk T, 2006, NAT CELL BIOL, V8, P1246, DOI 10.1038/ncb1484; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zhang XL, 2004, BIOCHEM BIOPH RES CO, V316, P139, DOI 10.1016/j.bbrc.2004.02.033	36	39	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2008	27	54					6845	6855		10.1038/onc.2008.288	http://dx.doi.org/10.1038/onc.2008.288			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IS	18724389				2022-12-17	WOS:000261108000005
J	Yeung, BHY; Kwan, BWY; He, QY; Lee, AS; Liu, J; Wong, AST				Yeung, B. H. Y.; Kwan, B. W. Y.; He, Q. Y.; Lee, A. S.; Liu, J.; Wong, A. S. T.			Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis	ONCOGENE			English	Article						GRP78; unfolded protein response; BRCA1; ovarian cancer; breast cancer; apoptosis	CANCER; BREAST; CHAPERONE; CELLS; GRP78	The tumor suppressor BRCA1 is mutated in a high percentage of familial breast and ovarian cancer, but our understanding of its mechanisms of action remains incomplete. We report here that glucose-regulated protein (GRP)-78, a critical regulator of the unfolded protein response (UPR), is a novel downstream target of BRCA1. We showed that overexpression of wild-type BRCA1 suppressed the expression of GRP78, whereas expression of mutant BRCA1 gene or targeted inhibition of endogenous BRCA1 using small-interfering RNA (siRNA) enhanced GRP78 expression. Knockdown of BRCA1 also led to induction of other components of UPR, such as GRP94 and CHOP. Consistent with a role of BRCA1 knockdown in mediating cell survival, forced expression of GRP78 stimulated cell proliferation and prevented apoptosis, including that induced by endoplasmic reticulum stress and chemotherapy, in ovarian OVCAR-3 and breast MCF-7 cancer cells. Overexpression of wild-type BRCA1 could increase the apoptosis of GRP78-over-expressing cells. Conversely, knockdown GRP78 by siRNA sensitized ovarian and breast cancer cells to apoptosis. This effect was reduced when the expression of BRCA1 was simultaneously knockdown by siRNA, indicating that BRCA1 also negatively regulates GRP78mediated cell survival and resistance to apoptosis.	[Yeung, B. H. Y.; Kwan, B. W. Y.; Wong, A. S. T.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Peoples R China; [He, Q. Y.] Jinan Univ, Inst Life & Hlth Engn, Guangzhou, Peoples R China; [Lee, A. S.] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; [Liu, J.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Hong Kong; Jinan University; University of Southern California; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Wong, AST (corresponding author), Univ Hong Kong, Sch Biol Sci, 4S-14 Kadoorie Biol Sci Bldg,Pokfulam Rd, Hong Kong, Peoples R China.	awong1@hku.hk	Wong, Alice/AFJ-4595-2022; He, Qing-Yu/H-7078-2014	Wong, Alice/0000-0002-0676-6475; He, Qing-Yu/0000-0003-0503-9492; Lee, Amy/0000-0002-0378-5443	Hong Kong Research Grants Council [7484/04M]	Hong Kong Research Grants Council(Hong Kong Research Grants Council)	The present work was supported by Hong Kong Research Grants Council Grant (7484/04M) (AST Wong).	Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; He QY, 2005, GYNECOL ONCOL, V98, P68, DOI 10.1016/j.ygyno.2005.04.002; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Lee K, 2003, J BIOL CHEM, V278, P11818, DOI 10.1074/jbc.M210475200; Lou ZK, 2005, NAT STRUCT MOL BIOL, V12, P589, DOI 10.1038/nsmb953; Ma YX, 2003, ONCOGENE, V22, P10, DOI 10.1038/sj.onc.1206061; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zeng LF, 2004, EMBO J, V23, P950, DOI 10.1038/sj.emboj.7600106; Zheng WX, 2000, GYNECOL ONCOL, V76, P294, DOI 10.1006/gyno.1999.5664; Zhou CY, 2003, ONCOGENE, V22, P2396, DOI 10.1038/sj.onc.1206319	20	39	43	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2008	27	53					6782	6789		10.1038/onc.2008.290	http://dx.doi.org/10.1038/onc.2008.290			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO	18776923				2022-12-17	WOS:000260866200008
J	Elcheva, I; Tarapore, RS; Bhatia, N; Spiegelman, VS				Elcheva, I.; Tarapore, R. S.; Bhatia, N.; Spiegelman, V. S.			Overexpression of mRNA-binding protein CRD-BP in malignant melanomas	ONCOGENE			English	Article						CRD-BP; beta-TrCP; mRNA stability; melanoma; Wnt/beta-catenin signaling; NF-kappa B	NF-KAPPA-B; UBIQUITIN LIGASE RECEPTOR; C-MYC; BETA-CATENIN; CODING REGION; CELLS; ACTIVATION; EXPRESSION; CANCER; HOMOLOG	Wnt/beta-catenin signaling pathway plays an important role in embryogenesis, stem cell maintenance, tumorigenesis and aging. Here, we show that RNA-binding protein, coding region determinant-binding protein (CRD-BP) (a transcriptional target of Wnt signaling pathway), is highly expressed in primary human malignant melanomas and melanoma cell lines with activated Wnt/beta-catenin signaling pathway. Upregulation of CRD-BP is associated with an elevated level of beta-TrCP1 ubiquitin ligase receptor and activation of nuclear transcriptional factors-kappa B (NF-kappa B) signaling. Knockdown of CRD-BP inhibits NF-kappa B activity, induces apoptosis, and suppresses proliferation and tumorigenic properties of melanoma cells.	[Elcheva, I.; Tarapore, R. S.; Bhatia, N.; Spiegelman, V. S.] Univ Wisconsin, Dept Dermatol, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Tarapore, R. S.; Spiegelman, V. S.] Univ Wisconsin, Mol & Environm Toxicol Ctr, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Spiegelman, V. S.] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Sch Med & Publ Hlth, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Spiegelman, VS (corresponding author), Univ Wisconsin, Dept Dermatol, Sch Med, 445 Henry Mall,Room 301, Madison, WI 53706 USA.	spiegelman@dermatology.wisc.edu	Tarapore, Rohinton/J-8300-2012	Spiegelman, Vladimir S/0000-0003-4847-155X	NCI [CA121851]; NATIONAL CANCER INSTITUTE [R01CA121851] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs N Maddodi, S Devi, J Ross, P Robbins, K Kinzler and B Vogelstein for their generous gifts of reagents, S Reagan-Shaw for statistical analysis, Drs V Setaluri and S Fuchs for critical reading of the paper, and Dr K Spiegelman and Ms I Larsen for help with the paper preparation. This study was supported by NCI Grant CA121851 ( to VSS).	Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Bhatia N, 2002, ONCOGENE, V21, P1501, DOI 10.1038/sj.onc.1205311; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Dimitriadis E, 2007, INT J CANCER, V121, P486, DOI 10.1002/ijc.22716; Doyle GA, 2000, CANCER RES, V60, P2756; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Herlyn M, 2006, INT J CANCER, V118, P523, DOI 10.1002/ijc.21605; Hussein MR, 2003, J PATHOL, V199, P275, DOI 10.1002/path.1300; Ioannidis P, 2003, ANTICANCER RES, V23, P2179; Ioannidis P, 2001, INT J CANCER, V94, P480, DOI 10.1002/ijc.1512; Liu J, 2007, ONCOGENE, V26, P1954, DOI 10.1038/sj.onc.1209994; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Noubissi FK, 2006, NATURE, V441, P898, DOI 10.1038/nature04839; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Ross J, 2001, ONCOGENE, V20, P6544, DOI 10.1038/sj.onc.1204838; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Smalley KSM, 2004, J INVEST DERMATOL, V123, pXVI, DOI 10.1111/j.0022-202X.2004.23430.x; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Sparanese D, 2007, NUCLEIC ACIDS RES, V35, P1209, DOI 10.1093/nar/gkl1148; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Spiegelman VS, 2002, J BIOL CHEM, V277, P36624, DOI 10.1074/jbc.M204524200; Ueda Y, 2006, PIGM CELL RES, V19, P112, DOI 10.1111/j.1600-0749.2006.00304.x; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Wang H, 2008, ONCOGENE, V27, P1905, DOI 10.1038/sj.onc.1210823; Weeraratna AT, 2005, CANCER METAST REV, V24, P237, DOI 10.1007/s10555-005-1574-z; Yang JM, 2001, CANCER RES, V61, P4901	32	39	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5069	5074		10.1038/onc.2008.141	http://dx.doi.org/10.1038/onc.2008.141			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18454174				2022-12-17	WOS:000258914800009
J	Nam, CH; Lobato, MN; Appert, A; Drynan, LF; Tanaka, T; Rabbitts, TH				Nam, C-H; Lobato, M. N.; Appert, A.; Drynan, L. F.; Tanaka, T.; Rabbitts, T. H.			An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions	ONCOGENE			English	Article						antibody; leukaemia; LMO2; scFv; gene therapy; X-SCID	T-CELL PROLIFERATION; TRANSGENIC MICE; CHROMOSOMAL TRANSLOCATION; INTRACELLULAR ANTIBODIES; PROTEIN RBTN2; HIGH-AFFINITY; DOMAIN; GENE; LMO2; EXPRESSION	The LIM-domain protein LMO2 is a T-cell oncogenic protein first recognized by gene activation through chromosomal translocations, but it is also responsible for leukaemias arising as secondary, adverse effects in an X-SCID gene therapy trial. There are no specific reagents currently available to analyse the LMO2 multiprotein complex or to combat LMO2-dependent leukaemias. Accordingly, we have isolated an anti-LMO2 single chain Fv antibody fragment to determine if intracellular interference with LMO2-protein complexes can avert LMO2-dependent functions in normal and cancer settings. The anti-LMO2 single chain Fv, obtained using Intracellular Antibody Capture (IAC) technology, is specifc for LMO2 among the LIM-only protein family and binds LMO2 through the third and fourth LIM fingers. Using vector-mediated expression of anti-LMO2 scFv, we show inhibition of Lmo2-dependent erythropoiesis but not endothelial development. We also demonstrate inhibition of Lmo2-dependent leukaemia in a mouse T-cell tumour-igenesis transplantation assay with retroviral-mediated expression of anti-LMO2 scFv. Our studies establish that interference with the LMO2 multiprotein complex inhibits both normal and tumourigenic roles. The antibody fragment is a tool for dissecting LMO2 function in haematopoiesis and leukaemia and is a lead for development of therapeutics against LMO2-dependent T-ALL.	[Tanaka, T.; Rabbitts, T. H.] St James Univ Hosp, Leeds Inst Mol Med, Sect Expt Therapeut, Leeds LS9 7TF, W Yorkshire, England; [Nam, C-H; Lobato, M. N.; Appert, A.; Drynan, L. F.; Rabbitts, T. H.] MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Saint James's University Hospital; University of Leeds; MRC Laboratory Molecular Biology	Rabbitts, TH (corresponding author), St James Univ Hosp, Leeds Inst Mol Med, Sect Expt Therapeut, Wellcome Trust Brenner Bldg, Leeds LS9 7TF, W Yorkshire, England.	thr@leeds.ac.uk	Drynan, Lesley/V-2984-2019; Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609	Medical Research Council; MRC [G0600914] Funding Source: UKRI; Medical Research Council [G0600914, MC_U105178807] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Medical Research Council. CHN was supported by a fellowship from the Lady Tata Memorial Trust. We would like to thank Dr T Kitamura ( University of Tokyo) for PlatE packaging cells and Dr D Baltimore ( California Institute of Technology) for pMIG vector.	ALDERTON G, 2007, NATURE REV CANC, V7, P570; Bai SH, 2006, CRIT REV THER DRUG, V23, P437, DOI 10.1615/CritRevTherDrugCarrierSyst.v23.i6.10; FIZZOTTI M, 1994, LEUKEMIA, V8, P1124; Forster A, 2005, COLD SH Q B, V70, P275, DOI 10.1101/sqb.2005.70.008; Grutz G, 1998, ONCOGENE, V17, P2799, DOI 10.1038/sj.onc.1202502; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Holt L J, 2000, Nucleic Acids Res, V28, pE72, DOI 10.1093/nar/28.15.e72; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LARSON RC, 1994, ONCOGENE, V9, P3675; Nam CH, 2006, MOL THER, V13, P15, DOI 10.1016/j.ymthe.2005.09.010; NEALE GAM, 1995, BLOOD, V86, P3060; Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387; Racevskis J, 1999, BBA-GENE STRUCT EXPR, V1445, P148, DOI 10.1016/S0167-4781(99)00037-8; Sheets MD, 1998, P NATL ACAD SCI USA, V95, P6157, DOI 10.1073/pnas.95.11.6157; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; Tanaka T, 2003, J MOL BIOL, V331, P1109, DOI 10.1016/S0022-2836(03)00836-2; Tanaka T, 2003, EMBO J, V22, P1025, DOI 10.1093/emboj/cdg106; Tanaka T, 2007, EMBO J, V26, P3250, DOI 10.1038/sj.emboj.7601744; Tse E, 2002, J MOL BIOL, V317, P85, DOI 10.1006/jmbi.2002.5403; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890	26	39	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4962	4968		10.1038/onc.2008.130	http://dx.doi.org/10.1038/onc.2008.130			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18438427				2022-12-17	WOS:000258596900010
J	Horn, S; Bergholz, U; Jucker, M; McCubrey, JA; Trumper, L; Stocking, C; Basecke, J				Horn, S.; Bergholz, U.; Juecker, M.; McCubrey, J. A.; Truemper, L.; Stocking, C.; Baesecke, J.			Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells	ONCOGENE			English	Article						leukemia; oncogenic transformation; phosphoinositide 3-kinase; signal transduction	ACUTE MYELOID-LEUKEMIA; 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; ACUTE MYELOGENOUS LEUKEMIA; PIK3CA GENE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; HUMAN CANCER; IN-VIVO; C-MYC; CONSTITUTIVE PHOSPHORYLATION	Constitutive activation of the phosphoinositide 3-kinase ( PI3K)-AKT pathway is observed in up to 70% of acute myelogenous leukemia. To investigate the relevance of an intrinsic PI3K-AKT pathway activation in hematopoietic malignancies, we analysed the effect of point mutations in the catalytic ( p110 alpha) and regulatory ( p85 alpha) subunit of class IA PI3K. We demonstrated that mutations in the helical ( E542K, E545A) and kinase domain ( H1047R) of p110 alpha constitutively activate the PI3K-AKT pathway and lead to factor-independent growth of early hematopoietic cells. Proliferation and survival of the cells were inhibited in a time- and dose-dependent manner using either PI3K or AKT inhibitors. The mammalian target of rapamycin ( mTOR) was demonstrated to be important for mitogenic, but not antiapoptotic signaling of mutant p110a. In a syngenic mouse model, hematopoietic cells expressing mutated p110 alpha induced a leukemia-like disease characterized by anemia, neoplastic infiltration of hematopoietic organs and 90% mortality within 5 weeks, whereas activated mutants of the receptor tyrosine kinase c-KIT led to 100% mortality within 10 days. Our data show that point mutations in the p110 alpha subunit of class IA PI3K confer factor independence to hematopoietic cells in vitro and leukemogenic potential in vivo, but have lower transforming activity than a deregulated class III receptor tyrosine kinase.	[Horn, S.; Truemper, L.; Baesecke, J.] Univ Gottingen, Dept Hematol & Oncol, D-37075 Gottingen, Germany; [Bergholz, U.; Stocking, C.] Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Program Area Cellular Dysregulat, Mol Pathol Grp, D-2000 Hamburg, Germany; [Juecker, M.] Univ Med Ctr Hamburg Eppendorf, Dept Biochem & Mol Biol Cellular Signal Transduct, Hamburg, Germany; [McCubrey, J. A.] Univ Greenville, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC USA	University of Gottingen; Heinrich Pette Institute; University of Hamburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Basecke, J (corresponding author), Univ Gottingen, Dept Hematol & Oncol, Robert Koch Str 40, D-37075 Gottingen, Germany.	jbaesec@gwdg.de		McCubrey, James/0000-0001-6027-3156				Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; Billottet C, 2006, ONCOGENE, V25, P6648, DOI 10.1038/sj.onc.1209670; Borlado LR, 2000, FASEB J, V14, P895; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; Bousquet M, 2005, BRIT J HAEMATOL, V131, P411, DOI 10.1111/j.1365-2141.2005.05784.x; Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170; Cammenga J, 2005, BLOOD, V106, P3958, DOI 10.1182/blood-2005-02-0583; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Dutton A, 2005, J PATHOL, V205, P498, DOI 10.1002/path.1725; Frohling S, 2005, J CLIN ONCOL, V23, P6285, DOI 10.1200/JCO.2005.05.010; Gilliland DG, 2002, CURR OPIN HEMATOL, V9, P274, DOI 10.1097/00062752-200207000-00003; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Hashimoto K, 2003, BLOOD, V101, P1094, DOI 10.1182/blood-2002-01-0177; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; Hummerdal P, 2006, EUR J HAEMATOL, V77, P86, DOI 10.1111/j.0902-4441.2006.t01-1-EJH2605.x; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Jucker M, 2002, LEUKEMIA, V16, P894, DOI 10.1038/sj.leu.2402484; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kornblau SM, 2006, BLOOD, V108, P2358, DOI 10.1182/blood-2006-02-003475; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Li VSW, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-29; Luo JM, 2003, LEUKEMIA, V17, P1, DOI 10.1038/sj.leu.2402725; Malempati S, 2006, LEUKEMIA, V20, P1572, DOI 10.1038/sj.leu.2404317; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Min YH, 2004, CANCER RES, V64, P5225, DOI 10.1158/0008-5472.CAN-04-0174; Min YH, 2003, LEUKEMIA, V17, P995, DOI 10.1038/sj.leu.2402874; Muller CI, 2007, LEUKEMIA RES, V31, P27, DOI 10.1016/j.leukres.2006.04.011; Nyakern M, 2006, LEUKEMIA, V20, P230, DOI 10.1038/sj.leu.2404057; Philp AJ, 2001, CANCER RES, V61, P7426; Recher C, 2005, BLOOD, V105, P2527, DOI 10.1182/blood-2004-06-2494; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rudelius M, 2006, BLOOD, V108, P1668, DOI 10.1182/blood-2006-04-015586; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Schade AE, 2006, BLOOD, V107, P4834, DOI 10.1182/blood-2005-08-3076; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Shelton JG, 2004, CELL CYCLE, V3, P503; Shivakrupa R, 2003, CANCER RES, V63, P4412; STOCKING C, 1993, GROWTH FACTORS, V8, P197, DOI 10.3109/08977199309011023; Sujobert P, 2005, BLOOD, V106, P1063, DOI 10.1182/blood-2004-08-3225; Uddin S, 2006, BLOOD, V108, P4178, DOI 10.1182/blood-2006-04-016907; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wick MJ, 2003, J BIOL CHEM, V278, P42913, DOI 10.1074/jbc.M304172200; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220	53	39	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4096	4106		10.1038/onc.2008.40	http://dx.doi.org/10.1038/onc.2008.40			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18317450				2022-12-17	WOS:000257325100009
J	Shankar, E; Sivaprasad, U; Basu, A				Shankar, E.; Sivaprasad, U.; Basu, A.			Protein kinase C epsilon confers resistance of MCF-7 cells to TRAIL by Akt-dependent activation of Hdm2 and downregulation of p53	ONCOGENE			English	Article						Akt; Bid; p53; PKC epsilon; TRAIL	BREAST-CANCER CELLS; CASPASE ACTIVATION; INDUCED APOPTOSIS; DEATH RECEPTORS; MDM2; PHOSPHORYLATION; UBIQUITINATION; PROMOTES; GENE; DEGRADATION	Protein kinase C epsilon (PKC epsilon) acts as an antiapoptotic protein and inhibits tumor necrosis factor-alpha (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in MCF-7 breast cancer cells. Members of the TNF receptor superfamily trigger apoptosis independent of the tumor suppressor protein p53, which primarily affects DNA damage-induced apoptosis. We have previously shown that PKCe acts upstream of Akt to inhibit receptor-initiated cell death. Since Akt can regulate p53, we have examined the involvement of p53 in PKC epsilon-mediated TRAIL resistance. Overexpression of PKCe in MCF-7 cells (MCF-7/PKC epsilon) caused a decrease in p53 and an increase in human homolog of murine double minute 2 (Hdm2) and phospho-Hdm2. Depletion of p53 by siRNA attenuated, whereas depletion of Hdm2 enhanced TRAIL-mediated apoptosis. Knockdown of Akt decreased Hdm2 phosphorylation, increased p53 level and potentiated TRAIL-induced cell death. Depletion of PKCe from MCF-7 cells caused an increase in p53, whereas knockdown of p53 caused a decrease in Bid mRNA. Depletion of Akt from MCF-7/PKCe cells resulted in an increase in p53 and Bid. These results suggest that PKCe mediates TRAIL resistance by Akt-mediated phosphorylation of Hdm2 resulting in suppression of p53 expression and down-regulation of Bid in MCF-7 breast cancer cells.	[Shankar, E.; Sivaprasad, U.; Basu, A.] Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA; [Shankar, E.; Basu, A.] Univ N Texas, Hlth Sci Ctr, Inst Canc Res, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center	Basu, A (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	abasu@hsc.unt.edu	Shankar, Eswar/E-5139-2015	Shankar, Eswar/0000-0001-8968-838X; Basu, Alakananda/0000-0002-1656-0788	NATIONAL CANCER INSTITUTE [R01CA071727] Funding Source: NIH RePORTER; NCI NIH HHS [CA71727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Basu A, 2002, J BIOL CHEM, V277, P41850, DOI 10.1074/jbc.M205997200; Basu A, 1999, BIOCHEMISTRY-US, V38, P4245, DOI 10.1021/bi982854q; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Ehrhardt H, 2008, ONCOGENE, V27, P783, DOI 10.1038/sj.onc.1210666; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Li S, 2007, MOL CANCER THER, V6, P1031, DOI 10.1158/1535-7163.MCT-06-0643; LIU X, 2004, CANCER RES, V83, P5078; Lu DM, 2004, INT J ONCOL, V25, P671; Lu DM, 2006, J BIOL CHEM, V281, P22799, DOI 10.1074/jbc.M603390200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Toole A, 2001, BIOCHEM J, V359, P119, DOI 10.1042/0264-6021:3590119; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Rozan LM, 2007, CELL DEATH DIFFER, V14, P3, DOI 10.1038/sj.cdd.4402058; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Sivaprasad U, 2007, CELL DEATH DIFFER, V14, P851, DOI 10.1038/sj.cdd.4402077; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Weber HO, 2005, ONCOGENE, V24, P1965, DOI 10.1038/sj.onc.1208389; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	40	39	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	28					3957	3966		10.1038/onc.2008.39	http://dx.doi.org/10.1038/onc.2008.39			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18317451				2022-12-17	WOS:000257089000007
J	Nowacki, S; Skowron, M; Oberthuer, A; Fagin, A; Voth, H; Brors, B; Westermann, F; Eggert, A; Hero, B; Berthold, F; Fischer, M				Nowacki, S.; Skowron, M.; Oberthuer, A.; Fagin, A.; Voth, H.; Brors, B.; Westermann, F.; Eggert, A.; Hero, B.; Berthold, F.; Fischer, M.			Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma	ONCOGENE			English	Article						CADM1; neuroblastoma; tumor suppressor; outcome assessment (health care); cell proliferation; disease progression	LACTATE-DEHYDROGENASE RELEASE; PROMOTER METHYLATION; ADHESION MOLECULE; IMMUNOGLOBULIN SUPERFAMILY; STAGE NEUROBLASTOMA; CERVICAL-CANCER; LUNG-CANCER; TSLC1 GENE; IN-SILICO; CARCINOMA	Cell adhesion molecule 1 (CADM1) is a putative tumour suppressor gene, which is downregulated in many solid tumours. In neuroblastoma, loss of CADM1 expression has recently been found in disseminated tumours with adverse outcome, prompting us to investigate its role in neuroblastoma tumour progression. Oligonucleotide-microarray analysis of 251 neuroblastoma specimens demonstrated that CADM1 downregulation is associated with unfavourable prognostic markers like disseminated stage 4, age > 18 months, MYCN amplification and chromosome 11q alterations (P < 0.001 each). Furthermore, low CADM1 expression was signficantly correlated with unfavourable gene expression-based classification (P < 0.001) and adverse patient outcome (P < 0.001). Bisulphite sequencing and genetic analysis of 18 primary neuroblastomas suggested that neither haploinsufficiency nor hypermethylation is regularly involved in CADM1 gene silencing in neuroblastoma, which is in contrast to results obtained in other malignancies. In addition, no mutations disrupting the CADM1 reading frame were found in 25 primary neuroblastomas. Over-expression of CADM1 in neuroblastoma cells resulted in significant reduction of proliferation, viability and colony formation in soft agar. Collectively, our results suggest that downregulation of CADM1 tumour suppressor gene expression is a critical event in neuroblastoma pathogenesis resulting in tumour progression and unfavourable patient outcome.	[Nowacki, S.; Skowron, M.; Oberthuer, A.; Voth, H.; Hero, B.; Berthold, F.; Fischer, M.] Univ Cologne, Childrens Hosp, Dept Pediat Oncol & Hematol, D-50924 Cologne, Germany; [Brors, B.] German Canc Res Ctr, Dept Theoret Bioinformat B080, D-6900 Heidelberg, Germany; [Fagin, A.; Eggert, A.] Univ Hosp Essen, Dept Pediat Oncol & Hematol, Essen, Germany; [Westermann, F.] German Canc Res Ctr, Dept Tumor Genet B030, D-6900 Heidelberg, Germany	University of Cologne; Helmholtz Association; German Cancer Research Center (DKFZ); University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ)	Fischer, M (corresponding author), Univ Cologne, Childrens Hosp, Dept Pediat Oncol & Hematol, Kerpener St 62, D-50924 Cologne, Germany.	matthias.fischer@uk-koeln.de	Westermann, Frank/F-7509-2013; Brors, Benedikt/E-5620-2013; Eggert, Angelika/AAE-6907-2022	Brors, Benedikt/0000-0001-5940-3101; Eggert, Angelika/0000-0003-3476-8184				Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; CICCARONE V, 1989, CANCER RES, V49, P219; De Preter K, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r84; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; Ehrlich M, 2006, ONCOGENE, V25, P2636, DOI 10.1038/sj.onc.1209145; Fischer M, 2006, CLIN CANCER RES, V12, P5118, DOI 10.1158/1078-0432.CCR-06-0985; Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348; Fukuhara H, 2002, JPN J CANCER RES, V93, P605, DOI 10.1111/j.1349-7006.2002.tb01297.x; Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001; Heller G, 2007, BREAST CANCER RES TR, V103, P283, DOI 10.1007/s10549-006-9377-7; Houshmandi SS, 2006, NEUROLOGY, V67, P1863, DOI 10.1212/01.wnl.0000244472.56198.84; Ito A, 2003, BLOOD, V101, P2601, DOI 10.1182/blood-2002-07-2265; Ito T, 2003, CANCER RES, V63, P6320; Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84; Katoh M, 2004, ONCOL REP, V12, P429; Katoh M, 2003, INT J ONCOL, V23, P1213; Kikuchi S, 2006, CANCER-AM CANCER SOC, V106, P1751, DOI 10.1002/cncr.21800; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Li JD, 2005, GYNECOL ONCOL, V96, P150, DOI 10.1016/j.ygyno.2004.08.050; Lombet A, 2001, EUR J BIOCHEM, V268, P1352, DOI 10.1046/j.1432-1327.2001.02002.x; Mao XL, 2004, ONCOGENE, V23, P5632, DOI 10.1038/sj.onc.1207756; Mertens F, 1997, CANCER RES, V57, P2765; Murakami Y, 2005, CANCER SCI, V96, P543, DOI 10.1111/j.1349-7006.2005.00089.x; Naishiro Y, 2005, ONCOGENE, V24, P3141, DOI 10.1038/sj.onc.1208517; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Oberthuer A, 2004, CLIN CANCER RES, V10, P4307, DOI 10.1158/1078-0432.CCR-03-0813; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Ojeda SR, 2006, ENDOCRINOLOGY, V147, P1166, DOI 10.1210/en.2005-1136; RACHER AJ, 1990, CYTOTECHNOLOGY, V3, P301, DOI 10.1007/BF00365494; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Steenbergen RDM, 2004, JNCI-J NATL CANCER I, V96, P294, DOI 10.1093/jnci/djh031; Surace EI, 2004, J NEUROPATH EXP NEUR, V63, P1015, DOI 10.1093/jnen/63.10.1015; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; Waha A, 2003, J NEUROPATH EXP NEUR, V62, P1192, DOI 10.1093/jnen/62.11.1192; Wakayama T, 2003, BIOL REPROD, V68, P1755, DOI 10.1095/biolreprod.102.012344; Worsham MJ, 2006, ARCH OTOLARYNGOL, V132, P668, DOI 10.1001/archotol.132.6.668	40	39	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	23					3329	3338		10.1038/sj.onc.1210996	http://dx.doi.org/10.1038/sj.onc.1210996			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18084322				2022-12-17	WOS:000256111400011
J	Garzia, L; D'Angelo, A; Amoresano, A; Knauer, SK; Cirulli, C; Campanella, C; Stauber, RH; Steegborn, C; Iolascon, A; Zollo, M				Garzia, L.; D'Angelo, A.; Amoresano, A.; Knauer, S. K.; Cirulli, C.; Campanella, C.; Stauber, R. H.; Steegborn, C.; Iolascon, A.; Zollo, M.			Phosphorylation of nm23-H1 by CKI induces its complex formation with h-prune and promotes cell motility	ONCOGENE			English	Article						h-prune; nm23; CKI; motility; IC261	NUCLEOSIDE DIPHOSPHATE KINASE; CASEIN KINASE-1; INHIBITORY-ACTIVITY; GLYCOGEN-SYNTHASE; GENE-EXPRESSION; BREAST-CANCER; BETA-CATENIN; PROTEIN; OVEREXPRESSION; BINDING	The combination of an increase in the cAMP-phosphodiesterase activity of h-prune and its interaction with nm23-H1 have been shown to be key steps in the induction of cellular motility in breast cancer cells. Here we present the molecular mechanisms of this interaction. The region of the nm23-h-prune interaction lies between S120 and S125 of nm23, where missense mutants show impaired binding; this region has been highly conserved throughout evolution, and can undergo serine phosphorylation by casein kinase I. Thus, the casein kinase I delta-epsilon specific inhibitor IC261 impairs the formation of the nm23-h-prune complex, which translates 'in vitro' into inhibition of cellular motility in a breast cancer cellular model. A competitive permeable peptide containing the region for phosphorylation by casein kinase I impairs cellular motility to the same extent as IC261. The identification of these two modes of inhibition of formation of the nm23-H1-h-prune protein complex pave the way toward new challenges, including translational studies using IC261 or this competitive peptide 'in vivo' to inhibit cellular motility induced by nm23-H1-h-prune complex formation during progression of breast cancer.	[Garzia, L.; D'Angelo, A.; Iolascon, A.; Zollo, M.] CEINGE, Ctr Ingn Genet & Biotecnol Avsnzate, I-80131 Naples, Italy; [Amoresano, A.; Cirulli, C.] Univ Naples Federico II, Complesso Univ Monte S Angelo, Dipartimento Chim Organ & Biochim, Naples, Italy; [Knauer, S. K.; Stauber, R. H.] Georg Speyer Haus, Frankfurt, Germany; [Campanella, C.] Univ Naples Federico II, Dipartimento Biol Struct & Funz, Naples, Italy; [Stauber, R. H.] Univ Hosp Mainz, Lab Mol Tumour Biol, Dept Otolaryngol, Mainz, Germany; [Steegborn, C.] Ruhr Univ Bochum, Dept Phys Chem, Bochum, Germany; [Zollo, M.] Univ Naples Federico II, Fac Sci Biotechnol, Dipartimento Biochim & Biotecnol Med, Naples, Italy	CEINGE Biotecnologie Avanzate; University of Naples Federico II; University of Naples Federico II; University Hospital Mainz; Ruhr University Bochum; University of Naples Federico II	Zollo, M (corresponding author), CEINGE, Ctr Ingn Genet & Biotecnol Avsnzate, Via Comunale Margherita 482, I-80131 Naples, Italy.	zollo@ceinge.unina.it	Iolascon, Achille/A-4461-2014; Knauer, Shirley K/E-7931-2012	Knauer, Shirley K/0000-0003-4321-0924; Stauber, Roland/0000-0002-1341-4523; AMORESANO, Angela/0000-0002-8386-655X	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P17, DOI 10.1016/S0968-0004(97)01162-6; Biondi RM, 1996, FEBS LETT, V399, P183, DOI 10.1016/S0014-5793(96)01299-9; BOMINAAR AA, 1994, FEBS LETT, V353, P5, DOI 10.1016/0014-5793(94)00997-X; Cong F, 2004, MOL CELL BIOL, V24, P2000, DOI 10.1128/MCB.24.5.2000-2011.2004; Cooper CD, 2002, J BIOL CHEM, V277, P44962, DOI 10.1074/jbc.M209427200; Crawford RM, 2005, BIOCHEM J, V392, P201, DOI 10.1042/BJ20050269; Crawford RM, 2006, MOL CELL BIOL, V26, P5921, DOI 10.1128/MCB.00315-06; D'Angelo A, 2004, CELL CYCLE, V3, P758; D'Angelo A, 2004, CANCER CELL, V5, P137, DOI 10.1016/S1535-6108(04)00021-2; ENGEL M, 1994, BIOCHEM BIOPH RES CO, V199, P1041, DOI 10.1006/bbrc.1994.1334; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; Forus A, 2001, ONCOGENE, V20, P6881, DOI 10.1038/sj.onc.1204874; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; GARZIA L, 2003, BIOTECHNIQUES, V384, P390; Garzia L, 2006, J BIOENERG BIOMEMBR, V38, P205, DOI 10.1007/s10863-006-9036-z; Heo YJ, 1997, J CHROMATOGR A, V781, P251; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Izeradjene K, 2004, CANCER RES, V64, P8036, DOI 10.1158/0008-5472.CAN-04-0762; KANTOR JD, 1993, CANCER RES, V53, P1971; Kim MS, 2002, BIOCHEM BIOPH RES CO, V291, P663, DOI 10.1006/bbrc.2002.6503; Kim YI, 2003, BIOCHEM BIOPH RES CO, V307, P281, DOI 10.1016/S0006-291X(03)01195-1; Knauer SK, 2005, ANAL CHEM, V77, P4815, DOI 10.1021/ac050413o; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Kobayashi T, 2006, MOL CELL BIOL, V26, P898, DOI 10.1128/MCB.26.3.898-911.2006; KURET J, 1985, EUR J BIOCHEM, V151, P39, DOI 10.1111/j.1432-1033.1985.tb09066.x; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Lascu I, 2000, J BIOENERG BIOMEMBR, V32, P213; Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200; Li GB, 2004, J BIOL CHEM, V279, P15938, DOI 10.1074/jbc.M314116200; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; MARIN O, 1994, EUR J BIOCHEM, V223, P647, DOI 10.1111/j.1432-1033.1994.tb19037.x; Marin O, 2003, P NATL ACAD SCI USA, V100, P10193, DOI 10.1073/pnas.1733909100; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; MEGGIO F, 1993, BIOCHIM BIOPHYS ACTA, V1164, P223, DOI 10.1016/0167-4838(93)90252-M; Middelhaufe S, 2007, BIOCHEM J, V407, P199, DOI 10.1042/BJ20070408; Mocan I, 2007, BIOCHEM J, V403, P149, DOI 10.1042/BJ20061141; Otsuki Y, 2001, P NATL ACAD SCI USA, V98, P4385, DOI 10.1073/pnas.071411598; Pagano MA, 2004, BIOCHEM BIOPH RES CO, V321, P1040, DOI 10.1016/j.bbrc.2004.07.067; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; Reymond A, 1999, ONCOGENE, V18, P7244, DOI 10.1038/sj.onc.1203140; Steeg PS, 2005, AM J PATHOL, V166, P1291, DOI 10.1016/S0002-9440(10)62348-6; STEEG PS, 1988, CANCER RES, V48, P6550; Tseng YH, 2001, CANCER RES, V61, P2071; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; Zhang BL, 2004, MOL CELL BIOL, V24, P6205, DOI 10.1128/MCB.24.14.6205-6214.2004; Zollo M, 2005, CLIN CANCER RES, V11, P199	47	39	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1853	1864		10.1038/sj.onc.1210822	http://dx.doi.org/10.1038/sj.onc.1210822			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906697				2022-12-17	WOS:000254150600005
J	Han, SU; Kwak, TH; Her, KH; Cho, YH; Choi, C; Lee, HJ; Hong, S; Park, YS; Kim, YS; Kim, TA; Kim, SJ				Han, S-U; Kwak, T-H; Her, K. H.; Cho, Y-H; Choi, C.; Lee, H-J; Hong, S.; Park, Y. S.; Kim, Y-S; Kim, T-A; Kim, S-J			CEACAM5 and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling	ONCOGENE			English	Article						carcinoembryonic antigen; TGF-beta; Smad3; gastric cancer	BILIARY GLYCOPROTEIN CD66A; CELL-ADHESION MOLECULE-1; HUMAN-TUMOR-MARKER; CARCINOEMBRYONIC ANTIGEN; CEA FAMILY; EXPRESSION; SMAD3; CANCER; TUMORIGENICITY; INHIBITOR	The carcinoembryonic antigen (CEAs) family consists of a large group of evolutionarily and structurally divergent glycoproteins. The transforming growth factor-beta (TGF-beta) signaling pathway has been implicated in the stimulation of CEA secretion in TGF-beta-sensitive colon cells, thereby possibly modulating cell adhesion and differentiation. However, the specific CEAs targeted by TGF-beta signaling or underlying mechanism of the expression of CEAs has not yet been clarified. In this study, we investigated the specific CEAs targeted by the TGF-beta signaling pathway. In nine human gastric cancer cell lines examined, TGF-beta-responsive cell lines showed positive expression of CEAs. Expression patterns of CEA proteins correlated well with the level of CEA (CEACAM5) and CEACAM6 transcripts in these cell lines, but CEACAM1 expression was not observed in all of these cells. To investigate the role of TGF-beta signaling in CEA expression, we selected two TGF-beta unresponsive gastric cancer cell lines; SNU638 cells that contain a mutation in the TGF-beta type II receptor and SNU484 cells that express low to undetectable level of the TGF-beta pathway intermediate protein, Smad3. Restoration of TGF-beta signaling in these cells induced expression of the CEAs and increased activity of both CEA (CEACAM5) and CEACAM6 promoters. CEA expression was observed in the epithelium of the stomach of wild-type mice, but was markedly decreased in Smad3 null mice. These findings suggest that CEA (CEACAM5) and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling.	[Han, S-U; Kwak, T-H; Her, K. H.; Cho, Y-H; Choi, C.; Lee, H-J; Hong, S.; Park, Y. S.; Kim, T-A; Kim, S-J] Natl Canc Inst, Lab Canc Biol & Genet, Natl Inst Hlth, Bethesda, MD 20892 USA; [Lee, H-J] KRIBB, Div Mol Therapeut, Taejon, South Korea; [Kim, Y-S] Hanyang Univ, Coll Med, Dept Biochem, Seoul 133791, South Korea; [Kim, S-J] Gachon Univ Med & Sci, Lee Gil Ya Canc & Diabet Inst, Lab Cell Regulat & Carcinogenesis, Inchon, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Hanyang University; Gachon University	Kim, SJ (corresponding author), Natl Canc Inst, Lab Canc Biol & Genet, Natl Inst Hlth, Bldg 37,Room 5046D,900 Rockville Pike, Bethesda, MD 20892 USA.	kims@mail.nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; Bessa X, 2002, GASTROENTEROLOGY, V122, P1122, DOI 10.1053/gast.2002.32369; CHAKRABARTY S, 1998, CANCER RES, V48, P4059; Chang J, 1997, CANCER RES, V57, P2856; CHEVINSKY AH, 1991, SEMIN SURG ONCOL, V7, P162, DOI 10.1002/ssu.2980070309; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; GOLD P, 1965, J EXP MED, V122, P467, DOI 10.1084/jem.122.3.467; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; Han SU, 2004, ONCOGENE, V23, P1333, DOI 10.1038/sj.onc.1207259; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huang J, 1999, J CELL SCI, V112, P4193; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; Ilantzis C, 2002, NEOPLASIA, V4, P151, DOI 10.1038/sj.neo.7900201; KAMMERER R, 1994, INT J CANCER, V57, P341, DOI 10.1002/ijc.2910570309; Kammerer R, 2001, J IMMUNOL, V166, P6537, DOI 10.4049/jimmunol.166.11.6537; Kammerer R, 1998, EUR J IMMUNOL, V28, P3664, DOI 10.1002/(SICI)1521-4141(199811)28:11<3664::AID-IMMU3664>3.0.CO;2-D; Kang SH, 1999, BRIT J CANCER, V80, P1144, DOI 10.1038/sj.bjc.6690478; Kim DY, 2000, J SURG ONCOL, V74, P185, DOI 10.1002/1096-9098(200007)74:3<185::AID-JSO4>3.3.CO;2-S; KIM J, 1992, INT J CANCER, V52, P718, DOI 10.1002/ijc.2910520509; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; Massague J, 2000, GENE DEV, V14, P627; MYEROFF LL, 1995, CANCER RES, V55, P5545; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Ordonez C, 2000, CANCER RES, V60, P3419; Park JG, 1997, INT J CANCER, V70, P443, DOI 10.1002/(SICI)1097-0215(19970207)70:4<443::AID-IJC12>3.0.CO;2-G; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Screaton RA, 2000, J CELL BIOL, V150, P613, DOI 10.1083/jcb.150.3.613; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zimmermann W, 1998, CELL ADHES COMMUN S, V5, P31	33	39	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					675	683		10.1038/sj.onc.1210686	http://dx.doi.org/10.1038/sj.onc.1210686			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17653079				2022-12-17	WOS:000252674900011
J	Sugino, Y; Misawa, A; Inoue, J; Kitagawa, M; Hosoi, H; Sugimoto, T; Imoto, I; Inazawa, J				Sugino, Y.; Misawa, A.; Inoue, J.; Kitagawa, M.; Hosoi, H.; Sugimoto, T.; Imoto, I.; Inazawa, J.			Epigenetic silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression of neuroblastomas	ONCOGENE			English	Article						neuroblastoma; PTGER2; tumor suppressor; DNA methylation; histone modification; cAMP	CPG ISLAND AMPLIFICATION; COLORECTAL-CANCER; DNA METHYLATION; CHROMATIN-STRUCTURE; GENE-EXPRESSION; CELL-LINES; APOPTOSIS; GROWTH; ACTIVATION; EP2	We previously identified a cluster of prostanoid receptor genes, prostaglandin D2 receptor (PTGDR) and prostaglandin E receptor 2 (PTGER2), as possible targets for DNA methylation in advanced types of neuroblastoma ( NB) using bacterial artificial chromosome array-based methylated CpG island amplification method. Among them, in this study, we found that PTGER2 was frequently silenced in NB cell lines, especially in those with MYCN amplification, through epigenetic mechanisms. In NB cell lines, DNA methylation pattern within a part of CpG island was inversely correlated with PTGER2 expression, and histone H3 and H4 deacetylation and histone H3 lysine 9 methylation within the putative promoter region were more directly correlated with silencing of this gene. Methylation of PTGER2 was observed more frequently in advanced-type of primary NBs compared with early-stage tumors. Growth of NB cells lacking endogenous PTGER2 expression was inhibited by restoration of the gene product by transient and stable transfection. A PTGER2-selective agonist, butaprost, increased intracellular cyclic adenosine monophosphate ( cAMP) level, inhibited cell growth and induced apoptosis of NB cells stably expressing exogenous PTGER2. 8-Bromo-cAMP also inhibited growth of NB cells lacking PTGER2 expression, but not cells expressing this gene. Taken together, it is suggested that NB cells may lose responsiveness to PTGER2-mediated growth inhibition/apoptosis through epigenetic silencing of PTGER2 and/or disruption of downstream cAMP-dependent pathway during the neuroblastomagenesis.	Tokyo Med & Dent Univ, Sch Biomed Sci, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan; Japan Sci & Technol Corp, Core Res Evolutionary Sci & Technol, Satiama, Japan; Kyoto Prefectural Univ Med, Dept Pediat, Kyoto, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Pathol & Immunol, Tokyo, Japan; Tokyo Med & Dent Univ, Grad Sch, Hard Tissue Genom Res Ctr, Dept Genom Med, Tokyo, Japan; Tokyo Med & Dent Univ, Cent Ctr Excellence Program Mol D & R T & B 21st, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Kyoto Prefectural University of Medicine; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	Imoto, Issei/AAD-5799-2020; imoto, Issei/D-8065-2012					Abe M, 2005, CANCER RES, V65, P828; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chen TC, 1998, LAB INVEST, V78, P165; Fedyk ER, 1996, MOL IMMUNOL, V33, P33, DOI 10.1016/0161-5890(95)00130-1; Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781; FULTON AM, 1989, J CELL PHYSIOL, V139, P93, DOI 10.1002/jcp.1041390114; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; Hoshino T, 2003, J BIOL CHEM, V278, P12752, DOI 10.1074/jbc.M212097200; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Johnsen JI, 2004, CANCER RES, V64, P7210, DOI 10.1158/0008-5472.CAN-04-1795; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840; Mejia MD, 2002, ARCH MED RES, V33, P466, DOI 10.1016/S0188-4409(02)00384-3; Misawa A, 2005, CANCER RES, V65, P10233, DOI 10.1158/0008-5472.CAN-05-1073; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Okuyama T, 2002, J LAB CLIN MED, V140, P92, DOI 10.1067/mlc.2002.125784; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Saito-Ohara F, 2003, CANCER RES, V63, P1876; SANTORO MG, 1977, CANCER RES, V37, P3774; Schubeler D, 2000, MOL CELL BIOL, V20, P9103, DOI 10.1128/MCB.20.24.9103-9112.2000; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005; Suda M, 1996, ENDOCRINOLOGY, V137, P1698, DOI 10.1210/en.137.5.1698; Takadera T, 2004, NEUROCHEM INT, V45, P713, DOI 10.1016/j.neuint.2004.02.005; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thompson PM, 2001, MED PEDIATR ONCOL, V36, P28, DOI 10.1002/1096-911X(20010101)36:1<28::AID-MPO1008>3.0.CO;2-0; Toyota M, 1999, CANCER RES, V59, P2307; Wang D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Wang DZ, 2005, CANCER RES, V65, P1822, DOI 10.1158/0008-5472.CAN-04-3671; Wang WH, 2005, INORG CHEM COMMUN, V8, P109, DOI 10.1016/j.inoche.2004.11.025; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamada N, 2006, INT J CANCER, V119, P1850, DOI 10.1002/ijc.22047; Yan P, 2003, GENE CHROMOSOME CANC, V36, P129, DOI 10.1002/gcc.10150; Yang QW, 2004, CLIN CANCER RES, V10, P8493, DOI 10.1158/1078-0432.CCR-04-1331; Yang QW, 2003, CANCER RES, V63, P6299	44	39	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7401	7413		10.1038/sj.onc.1210550	http://dx.doi.org/10.1038/sj.onc.1210550			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17533365				2022-12-17	WOS:000251282000002
J	Chipoy, C; Brounais, B; Trichet, V; Battaglia, S; Berreur, M; Oliver, L; Juin, P; Redini, F; Heymann, D; Blanchard, F				Chipoy, C.; Brounais, B.; Trichet, V.; Battaglia, S.; Berreur, M.; Oliver, L.; Juin, P.; Redini, F.; Heymann, D.; Blanchard, F.			Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53	ONCOGENE			English	Article						osteosarcoma; osteoblast; oncostatin M; STAT5; p53; apoptosis	SIGNAL TRANSDUCER; OSTEOBLAST DIFFERENTIATION; MITOCHONDRIAL-MEMBRANE; HEMATOPOIETIC-CELLS; GROWTH-HORMONE; DNA-DAMAGE; T-CELLS; GENE; PROTEIN; BAX	Oncostatin M ( OSM), a cytokine of the interleukin- 6 family, induces growth arrest and differentiation of osteoblastic cells into glial- like/ osteocytic cells. Here, we asked whether OSM regulates apoptosis of normal or transformed ( osteosarcoma) osteoblasts. We show that OSM sensitizes cells to apoptosis induced by various death inducers such as staurosporine, ultraviolet or tumor necrosis factor-alpha. Apoptosis is mediated by the mitochondrial pathway, with release of cytochrome c from the mitochondria to the cytosol and activation of caspases- 9 and - 3. DNA micro-arrays revealed that OSM modulates the expression of Bax, Bad, Bnip3, Bcl- 2 and Mcl- 1. Pharmacological inhibitors, dominant- negative signal transducer and activator of transcriptions ( STATs), stable RNA interference and knockout cells indicated that the transcription factors p53 and STAT5, which are activated by OSM, are implicated in the sensitization to apoptosis, being responsible for Bax induction and Bcl- 2 reduction, respectively. These results indicate that, in addition to growth arrest and induced differentiation, OSM also sensitizes normal and transformed osteoblasts to apoptosis by a mechanism implicating ( i) activation and nuclear translocation of STAT5 and p53 and ( ii) an increased Bax/ Bcl- 2 ratio. Therefore, association of OSM with kinase inhibitors such as Sts represents new therapeutic opportunities for wild- type p53 osteosarcoma.	Univ Nantes, Fac Med, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, EA3822, F-44035 Nantes 1, France; INSERM, ER17, Nantes, France; INSERM, U601, Nantes, France	Nantes Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Chipoy, C (corresponding author), Univ Nantes, Fac Med, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, EA3822, 1 Rue Gaston Veil, F-44035 Nantes 1, France.	celine.chipoy@univ-nantes.fr	Heymann, Dominique/AAC-6014-2019; JUIN, Philippe/Q-1338-2019; ROYER, Bénédicte BROUNAIS-LE/AAY-8894-2020; Blanchard, Frederic/AAS-1930-2021; BATTAGLIA, Severine/K-8715-2015; Oliver, Lisa/L-3070-2015	Heymann, Dominique/0000-0001-7777-0669; JUIN, Philippe/0000-0002-4997-3888; ROYER, Bénédicte BROUNAIS-LE/0000-0002-4556-9853; Blanchard, Frederic/0000-0003-1055-2573; Oliver, Lisa/0000-0002-5588-7564; Trichet, Valerie/0000-0003-4183-9032				Auernhammer CJ, 2004, J ENDOCRINOL, V180, P479, DOI 10.1677/joe.0.1800479; Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Baumann H, 2000, J BIOL CHEM, V275, P22014, DOI 10.1074/jbc.M002830200; Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666; Bellini MH, 1998, J ENDOCRINOL INVEST, V21, P1; Buitenhuis M, 2004, INT J BIOCHEM CELL B, V36, P2120, DOI 10.1016/j.biocel.2003.11.008; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CASEY G, 1991, ONCOGENE, V6, P1791; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chen SH, 2004, CYTOKINE GROWTH F R, V15, P379, DOI 10.1016/j.cytogfr.2004.06.002; Chipoy C, 2004, J BONE MINER RES, V19, P1850, DOI 10.1359/JBMR.040817; Debierre-Grockiego F, 2004, APOPTOSIS, V9, P717, DOI 10.1023/B:APPT.0000045785.65546.a2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Fuchs B, 2002, CLIN ORTHOP RELAT R, P40; Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Heath C, 2004, J BIOL CHEM, V279, P6666, DOI 10.1074/jbc.M308743200; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127; Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200; Le Meur N, 2004, NUCLEIC ACIDS RES, V32, P5349, DOI 10.1093/nar/gkh870; Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Sims NA, 2000, J CLIN INVEST, V106, P1095, DOI 10.1172/JCI10753; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200; Trichet V, 2006, J IMMUNOL, V177, P6129, DOI 10.4049/jimmunol.177.9.6129; WADAYAMA B, 1994, CANCER RES, V54, P3042; Wang XY, 2006, J CELL BIOL, V172, P115, DOI 10.1083/jcb.200507106; Wei QZ, 2005, J BIOL CHEM, V280, P37790, DOI 10.1074/jbc.M502974200	38	39	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2007	26	46					6653	6664		10.1038/sj.onc.1210492	http://dx.doi.org/10.1038/sj.onc.1210492			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17471233				2022-12-17	WOS:000250081500007
J	Zisman-Rozen, S; Fink, D; Ben-Izhak, O; Fuchs, Y; Brodski, A; Kraus, MH; Bejar, J; Ron, D				Zisman-Rozen, S.; Fink, D.; Ben-Izhak, O.; Fuchs, Y.; Brodski, A.; Kraus, M. H.; Bejar, J.; Ron, D.			Downregulation of Sef, an inhibitor of receptor tyrosine kinase signaling, is common to a variety of human carcinomas	ONCOGENE			English	Article						Sef; RTK; cancer	PROSTATE-CANCER; SPECIFICITY; EXPRESSION; PATHWAYS; ISOFORM; GRADE	Carcinomas are tumors of epithelial origin accounting for over 80% of all human malignancies. A substantial body of evidence implicates oncogenic signaling by receptor tyrosine kinases ( RTKs) in carcinoma development. Here we investigated the expression of Sef, a novel inhibitor of RTK signaling, in normal human epithelial tissues and derived malignancies. Human Sef ( hSef) was highly expressed in normal epithelial cells of breast, prostate, thyroid gland and the ovarian surface. By comparison, substantial downregulation of hSef expression was observed in the majority of tumors originating from these epithelia. Among 186 primary carcinomas surveyed by RNA in situ hybridization, hSef expression was undetectable in 116 cases including 72/99 ( 73%) breast, 11/ 16 ( 69%) thyroid, 16/ 31 ( 52%) prostate and 17/ 40 ( 43%) ovarian carcinomas. Moderate reduction of expression was observed in 17/ 186, and marked reduction in 40/ 186 tumors. Only 13/ 186 cases including 12 low- grade and one intermediate grade tumor retained high hSef expression. The association of hSef downregulation and tumor progression was statistically significant ( P<0.001). Functionally, ectopic expression of hSef suppressed proliferation of breast carcinoma cells, whereas inhibition of endogenous hSef expression accelerated fibroblast growth factor and epidermal growth factor- dependent proliferation of cervical carcinoma cells. The inhibitory effect of hSef on cell proliferation combined with consistent downregulation in human carcinoma indicates a tumor suppressor- like role for hSef, and implicates loss of hSef expression as a common mechanism in epithelial neoplasia.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Rambam Med Ctr, Dept Pathol, Haifa, Israel; Bnai Zion Med Ctr, Dept Gen Surg, Haifa, Israel; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Bnai Zion Med Ctr, Dept Pathol, Haifa, Israel	Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Bnai Zion Medical Center; University of Alabama System; University of Alabama Birmingham; Bnai Zion Medical Center	Ron, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	dinar@tx.technion.ac.il						Bell DA, 2005, MODERN PATHOL, V18, pS19, DOI 10.1038/modpathol.3800306; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Darby S, 2006, ONCOGENE, V25, P4122, DOI 10.1038/sj.onc.1209428; De Marzo AM, 1999, UROLOGY, V53, P29, DOI 10.1016/S0090-4295(98)00536-6; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; Grose R, 2005, CYTOKINE GROWTH F R, V16, P179, DOI 10.1016/j.cytogfr.2005.01.003; Harduf H, 2005, DEV DYNAM, V233, P301, DOI 10.1002/dvdy.20364; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; KOSARY CL, 1994, SEMIN SURG ONCOL, V10, P31, DOI 10.1002/ssu.2980100107; Matsumoto S, 1997, GENE CHROMOSOME CANC, V20, P268; Normanno N, 2005, CURR DRUG TARGETS, V6, P243, DOI 10.2174/1389450053765879; Preger E, 2004, P NATL ACAD SCI USA, V101, P1229, DOI 10.1073/pnas.0307952100; SHAOUL E, 1995, ONCOGENE, V10, P1553; Sher I, 2006, J BIOL CHEM, V281, P5178, DOI 10.1074/jbc.M509500200; TAVASSOLI FA, 2003, GENETICS TUMORS BREA, P18; Thompson N, 2005, CURR OPIN PHARMACOL, V5, P350, DOI 10.1016/j.coph.2005.04.007; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; Xiong SQ, 2003, J BIOL CHEM, V278, P50273, DOI 10.1074/jbc.M306936200; Yang RB, 2003, J BIOL CHEM, V278, P33232, DOI 10.1074/jbc.M305022200; Ziv I, 2006, J BIOL CHEM, V281, P39225, DOI 10.1074/jbc.M607327200	22	39	42	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6093	6098		10.1038/sj.onc.1210424	http://dx.doi.org/10.1038/sj.onc.1210424			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17420726				2022-12-17	WOS:000249277200012
J	Perrin, D; Ballestar, E; Fraga, MF; Frappart, L; Esteller, M; Guerin, JF; Dante, R				Perrin, D.; Ballestar, E.; Fraga, M. F.; Frappart, L.; Esteller, M.; Guerin, J-F; Dante, R.			Specific hypermethylation of LINE-1 elements during abnormal overgrowth and differentiation of human placenta	ONCOGENE			English	Article						DNA methylation; repetitive elements; human; partial hydatidiform mole (PHM); triploid diandric embryos; 5-methylcytosine antibody	DNA METHYLATION; CPG ISLAND; 5-METHYLCYTOSINE CONTENT; HYPOMETHYLATION; CANCER; EXPRESSION; BRCA1; ASSOCIATION; PHENOTYPE; SEQUENCES	In human post-natal somatic cells, low global levels of DNA methylation have been associated with the hypomethylation of several repetitive elements, a feature that has been proposed to be a surrogate epigenetic marker. These data, mainly derived from the analysis of cancer cells, suggest a potential association between loss of cell-growth control and altered differentiation with hypomethylation of repetitive sequences. Partial hydatidiform moles (PHMs) can be used as an alternative model for investigating this association in a non-tumorigenic context. This gestational disease is characterized by abnormal overgrowth and differentiation of the placenta and spontaneous abortion. Here, we comprehensively analyse the DNA methylation of these trophoblastic tissues in both PHM and normal placenta at global and sequence-specific levels. Analysis of the global 5-methylcytosine content and immunohistochemistry indicate that PHM and normal placenta have identical global levels of DNA methylation. In contrast, bisulfite genomic sequencing shows that, whereas Alu, NBL2 and satellite 2 repetitive elements are equally methylated, LINE-1 sequences are hypermethylated in PHM tissues (similar to 2-fold relative to normal placenta). Interestingly, altered demethylation is also found in triploid diandric embryos that originate from dispermic fertilization of an oocyte, a common event responsible for most PHMs. In conclusion, alterations of DNA methylation do not seem to be randomly distributed in PHM, as several repeated elements remain unaltered, whereas LINE-1 sequences are hypermethylated. In addition, our findings suggest that the hypomethylation of repetitive elements in cancer is directly linked to the neoplasic process and not a simple consequence of loss of growth control observed in most of the cancer cells.	Ctr Leon Berard, INSERM Unite 590, Oncol Mol Lab, F-69373 Lyon 08, France; Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Madrid, Spain; Hop Edouard Herriot, Anat Pathol Lab, Lyon, France; Univ Lyon 1, Lab Biol Reprod & Dev, F-69365 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centro Nacional de Investigaciones Oncologicas (CNIO); CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Dante, R (corresponding author), Ctr Leon Berard, INSERM Unite 590, Oncol Mol Lab, 28 Rue Laennec, F-69373 Lyon 08, France.	dante@univ-lyon1.fr	Ballestar, Esteban/ABG-8561-2020; Fraga, Mario F/H-7824-2017; Esteller, Manel/L-5956-2014	Fraga, Mario F/0000-0001-8450-2603; Esteller, Manel/0000-0003-4490-6093; Ballestar, Esteban/0000-0002-1400-2440				[Anonymous], 2003, WHO CLASSIFICATION T; Bariol C, 2003, AM J PATHOL, V162, P1361, DOI 10.1016/S0002-9440(10)63932-6; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Chalitchagorn K, 2004, ONCOGENE, V23, P8841, DOI 10.1038/sj.onc.1208137; Chen HZ, 2005, J SOC GYNECOL INVEST, V12, P214, DOI 10.1016/j.jsgi.2005.01.009; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; FEINBERG AP, 1988, CANCER RES, V48, P1159; Fraga ME, 2002, BIOTECHNIQUES, V33, P632, DOI 10.2144/02333rv01; GAMASOSA MA, 1983, BIOCHIM BIOPHYS ACTA, V740, P212, DOI 10.1016/0167-4781(83)90079-9; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P3087, DOI 10.1093/nar/11.10.3087; Genest DR, 2001, INT J GYNECOL PATHOL, V20, P315, DOI 10.1097/00004347-200110000-00001; Ghabreau L, 2004, VIRCHOWS ARCH, V445, P129, DOI 10.1007/s00428-004-1059-4; HJELLE BL, 1982, NUCLEIC ACIDS RES, V10, P3459, DOI 10.1093/nar/10.11.3459; Hoffmann MJ, 2005, BIOCHEM CELL BIOL, V83, P296, DOI 10.1139/o05-036; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222; JEANPIERRE M, 1994, ANN GENET-PARIS, V37, P163; Judson H, 2002, NATURE, V416, P539, DOI 10.1038/416539a; Lee C, 1997, HUM GENET, V100, P291, DOI 10.1007/s004390050508; Magdinier F, 2002, MOL HUM REPROD, V8, P630, DOI 10.1093/molehr/8.7.630; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585; Morgan HD, 2005, HUM MOL GENET, V14, pR47, DOI 10.1093/hmg/ddi114; Nishiyama R, 2005, MOL CANCER RES, V3, P617, DOI 10.1158/1541-7786.MCR-05-0146; Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006; Tsien F, 2002, CYTOGENET GENOME RES, V98, P13, DOI 10.1159/000068543; Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987; Widschwendter M, 2004, CANCER RES, V64, P4472, DOI 10.1158/0008-5472.CAN-04-0238; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032; Young LE, 2004, ANIM REPROD SCI, V82-3, P61, DOI 10.1016/j.anireprosci.2004.05.020; Zaragoza MV, 2000, AM J HUM GENET, V66, P1807, DOI 10.1086/302951	32	39	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2518	2524		10.1038/sj.onc.1210039	http://dx.doi.org/10.1038/sj.onc.1210039			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043645				2022-12-17	WOS:000245831000013
J	Ose, T; Kadowaki, Y; Fukuhara, H; Kazumori, H; Ishihara, S; Udagawa, J; Otani, H; Takasawa, S; Okamoto, H; Kinoshita, Y				Ose, T.; Kadowaki, Y.; Fukuhara, H.; Kazumori, H.; Ishihara, S.; Udagawa, J.; Otani, H.; Takasawa, S.; Okamoto, H.; Kinoshita, Y.			Reg I-knockout mice reveal its role in regulation of cell growth that is required in generation and maintenance of the villous structure of small intestine	ONCOGENE			English	Article						Reg; knockout mice; growth factor; small intestine	TRANSGENIC MICE; FACTOR-ALPHA; REGENERATING ISLETS; MENETRIERS DISEASE; PROGENITOR CELLS; GASTRIC-MUCOSA; GENE FAMILY; STEM-CELL; PROTEIN; EXPRESSION	Reg I (regenerating gene product I) is a growth factor that plays a central role in the generation and regeneration of the gastric mucosal architecture. On the other hand, mouse Reg I mRNA is expressed at the highest levels in the small intestine among the gastrointestinal tissues. In the current study, with the aim to clarify the role of Reg I protein in the small intestine, the temporal and spatial pattern of Reg I expression and the phenotype of Reg I-knockout mice in the tissue were examined. In the wild-type mice, immunohistochemistry localized Reg I protein expression in absorptive cells located in the lower half of the intestinal villi. Reg I expression was undetectable until embryonic day 13 (E13), when the fetal intestine still lacks villous structure; however, it dramatically increased at E17 along with the formation and maturation of the fetal intestinal villi. In the small intestine of the adult Reg I-knockout mice, less densely packed, round-shaped aberrant morphology of the absorptive cells was observed light microscopically, and electron microscopical examination revealed a strikingly loose connection of these cells to the basement membrane. Antiproliferating cell nuclear antigen staining and anti-Ki67 staining demonstrated the marked decrease in the number of proliferating cells in the small intestinal mucosa of the knockout mice. The cell migration speed visualized by one shot labeling of 5-bromodeoxyuridine was significantly slower in the knockout mice. These phenotypes of Reg I-knockout mice emerged, in accordance with the temporal pattern of Reg I expression described above, from E17. Reg I was considered to be a regulator of cell growth that is required to generate and maintain the villous structure of the small intestine.	Shimane Univ, Dept Gastroenterol & Hepatol, Sch Med, Izumo, Shimane 6938501, Japan; Shimane Univ, Dept Anat, Sch Med, Izumo, Shimane 6938501, Japan; Tohoku Univ, Grad Sch Med, Dept Biochem, Sendai, Miyagi 980, Japan; Tohoku Univ, Grad Sch Med, Dept Adv Biol Sci Regenerat, Kotobiken Med Labs, Sendai, Miyagi 980, Japan	Shimane University; Shimane University; Tohoku University; Tohoku University	Kadowaki, Y (corresponding author), Shimane Univ, Dept Gastroenterol & Hepatol, Sch Med, 89-1 Enya cho, Izumo, Shimane 6938501, Japan.	y-kado@momo.so-net.ne.jp						Asahara M, 1996, GASTROENTEROLOGY, V111, P45, DOI 10.1053/gast.1996.v111.pm8698224; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Brittan M, 2004, GUT, V53, P899, DOI 10.1136/gut.2003.025478; DEMPSEY PJ, 1992, GASTROENTEROLOGY, V103, P1950, DOI 10.1016/0016-5085(92)91455-D; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Fukui H, 1998, GASTROENTEROLOGY, V115, P1483, DOI 10.1016/S0016-5085(98)70027-7; Hartupee JC, 2001, BBA-GENE STRUCT EXPR, V1518, P287, DOI 10.1016/S0167-4781(00)00284-0; Kadowaki Y, 2002, FEBS LETT, V530, P59, DOI 10.1016/S0014-5793(02)03398-7; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Kayahara T, 2003, FEBS LETT, V535, P131, DOI 10.1016/S0014-5793(02)03896-6; Kazumori H, 2000, GASTROENTEROLOGY, V119, P1610, DOI 10.1053/gast.2000.20262; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Lickert H, 2001, MECH DEVELOP, V105, P181, DOI 10.1016/S0925-4773(01)00390-2; Macadam RCA, 2000, BRIT J CANCER, V83, P188; Miyaoka Y, 2004, ONCOGENE, V23, P3572, DOI 10.1038/sj.onc.1207333; Perfetti R, 1996, J GERONTOL A-BIOL, V51, pB308, DOI 10.1093/gerona/51A.5.B308; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Potten CS, 2003, DIFFERENTIATION, V71, P28, DOI 10.1046/j.1432-0436.2003.700603.x; SBARBATI R, 1982, J ANAT, V135, P477; SHARP R, 1995, DEVELOPMENT, V121, P149; Stappenbeck TS, 1998, CURR OPIN CELL BIOL, V10, P702, DOI 10.1016/S0955-0674(98)80110-5; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; TERAZONO K, 1990, DIABETOLOGIA, V33, P250, DOI 10.1007/BF00404804; Unno M, 2002, DIABETES, V51, pS478, DOI 10.2337/diabetes.51.2007.S478; van Es JH, 2005, NAT CELL BIOL, V7, P381, DOI 10.1038/ncb1240; Walters JRF, 2005, CURR OPIN GASTROEN, V21, P135, DOI 10.1097/01.mog.0000153309.13080.8b; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; Zenilman ME, 1996, GASTROENTEROLOGY, V110, P1208, DOI 10.1053/gast.1996.v110.pm8613011	31	39	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					349	359		10.1038/sj.onc.1209799	http://dx.doi.org/10.1038/sj.onc.1209799			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16909126				2022-12-17	WOS:000243544000004
J	Ferretti, E; Di Marcotullio, L; Gessi, M; Mattei, T; Greco, A; Po, A; De Smaele, E; Giangaspero, F; Riccardi, R; Di Rocco, C; Pazzaglia, S; Maroder, M; Alimandi, M; Screpanti, I; Gulino, A				Ferretti, E.; Di Marcotullio, L.; Gessi, M.; Mattei, T.; Greco, A.; Po, A.; De Smaele, E.; Giangaspero, F.; Riccardi, R.; Di Rocco, C.; Pazzaglia, S.; Maroder, M.; Alimandi, M.; Screpanti, I.; Gulino, A.			Alternative splicing of the ErbB-4 cytoplasmic domain and its regulation by hedgehog signaling identify distinct medulloblastoma subsets	ONCOGENE			English	Article						medulloblastoma; ErbB-4; alternative splicing; hedgehog; Gli1	CHILDHOOD MEDULLOBLASTOMA; EXPRESSION; ISOFORM; CELLS; CANCER; PROLIFERATION; TRANSCRIPTION; RECEPTORS; RENKCTD11; VARIANTS	Medulloblastoma (MB) results from aberrant development of cerebellar neurons in which altered hedgehog (Hh) signalling plays a major role. We investigated the possible influence of Hh signalling on ErbB-receptor expression in MB, in particular that of the ErbB-4 CYT-1 and CYT-2 isoforms generated by alternative splicing of the cytoplasmic domain. ErbB-4 expression was downregulated in Hh-induced MBs from Patched- 1(+/-) mice. Hh signalling (reflected by enhanced expression of the Gli1 transcription factor) inhibited ErbB-4 expression in mouse cerebellar granule progenitors and human MB cells. Analysis of 26 human primary MBs revealed a subset of 11 tumors characterized by low Gli1 levels, upregulated ErbB-4 expression and increased CYT-1: CYT-2 ratios. Interestingly, CYT-1 and Gli1 levels were inversely correlated. ErbB-4 CYT-1 and CYT-2 had different phenotypic effects in cultured MB cells: in response to neuregulin treatment, CYT-2 overexpression inhibited proliferation whereas CYT-1, which includes a phosphatidylinositol 3-kinase (PI3K)-binding site that is missing in CYT-2, enhanced resistance to starvation- and etoposide-induced apoptosis by activating PI3K/Akt signalling. CYT-1: CYT-2 ratios displayed correlation with tumor histotype and ErbB-2 levels, which are established prognostic indices for MB. These findings demonstrate that low-level Hh signalling in human MB is associated with the selective maintenance of high ErbB-4 CYT-1 expression, an alteration that exerts tumor-promoting effects.	Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Natl Neurol Inst C Besta, Div Neuropathol, Milan, Italy; Neuromed Inst, Isernia, Italy; Catholic Univ Rome, Dept Pediat, Rome, Italy; Catholic Univ Rome, Inst Neurosurg, Rome, Italy; ENEA CR, Biotechnol Unit, Rome, Italy; Cenci Bolognetti Fdn, Inst Pasteur, Rome, Italy	Sapienza University Rome; IRCCS Istituto Neurologico Besta; IRCCS Neuromed; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Italian National Agency New Technical Energy & Sustainable Economics Development; Fondazione Cenci Bolognetti	Gulino, A (corresponding author), Univ Roma La Sapienza, Dept Expt Med & Pathol, 324 Viale Regina Elena, I-00161 Rome, Italy.	alberto.gulino@uniroma1.it	Giangaspero, Felice/Z-4961-2019; De Smaele, Enrico/C-1124-2013; Mattei, Tobias A./U-7166-2019; Gessi, Marco/K-2572-2018; Po, Agnese/AEQ-0192-2022; Giangaspero, Felice/AAH-9253-2020; Po, Agnese/G-8754-2015; Alimandi, Maurizio/AAG-9246-2019; Ferretti, Elisabetta/G-5413-2013	Giangaspero, Felice/0000-0001-5382-2380; De Smaele, Enrico/0000-0003-4524-4423; Po, Agnese/0000-0002-9346-8782; Giangaspero, Felice/0000-0001-5382-2380; Po, Agnese/0000-0002-9346-8782; Alimandi, Maurizio/0000-0002-1409-6803; DI MARCOTULLIO, LUCIA/0000-0003-0274-7178; RICCARDI, RICCARDO/0000-0001-7515-6622; Ferretti, Elisabetta/0000-0001-7265-6429	Telethon [GGP04168] Funding Source: Medline	Telethon(Fondazione Telethon)		Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Argenti B, 2005, J NEUROSCI, V25, P8338, DOI 10.1523/JNEUROSCI.2438-05.2005; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Di Marcotullio L, 2004, P NATL ACAD SCI USA, V101, P10833, DOI 10.1073/pnas.0400690101; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; Ferretti E, 2005, TRENDS MOL MED, V11, P537, DOI 10.1016/j.molmed.2005.10.005; Fox IJ, 2005, J NEUROSCI RES, V79, P584, DOI 10.1002/jnr.20381; Gajjar A, 2004, J CLIN ONCOL, V22, P984, DOI 10.1200/JCO.2004.06.032; Gambarotta G, 2004, J BIOL CHEM, V279, P48808, DOI 10.1074/jbc.M408374200; GIANGASPERO F, 2002, PATHOLOGY GENETICS T, P129; Gilbertson R, 2001, GENE CHROMOSOME CANC, V31, P288, DOI 10.1002/gcc.1146; Gilbertson RJ, 1998, CANCER RES, V58, P3932; Gilbertson RJ, 1997, CANCER RES, V57, P3272; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2000, TRENDS CARDIOVAS MED, V10, P304, DOI 10.1016/S1050-1738(01)00065-2; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Marti E, 2002, TRENDS NEUROSCI, V25, P89, DOI 10.1016/S0166-2236(02)02062-3; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Omerovic J, 2004, EXP CELL RES, V294, P469, DOI 10.1016/j.yexcr.2003.12.002; Ozaki M, 1998, NEUROSCI RES, V30, P351, DOI 10.1016/S0168-0102(98)00013-3; Pazzaglia S, 2002, ONCOGENE, V21, P7580, DOI 10.1038/sj.onc.1205973; Rieff HI, 1999, J NEUROSCI, V19, P10757, DOI 10.1523/JNEUROSCI.19-24-10757.1999; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	29	39	40	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	55					7267	7273		10.1038/sj.onc.1209716	http://dx.doi.org/10.1038/sj.onc.1209716			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16878160				2022-12-17	WOS:000242244700005
J	Yang, H; Zhang, Y; Zhao, R; Wen, YY; Fournier, K; Wu, HB; Yang, HY; Diaz, J; Laronga, C; Lee, MH				Yang, H.; Zhang, Y.; Zhao, R.; Wen, Y. -Y; Fournier, K.; Wu, H. -B; Yang, H. -Y; Diaz, J.; Laronga, C.; Lee, M. -H			Negative cell cycle regulator 14-3-3 sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt	ONCOGENE			English	Article						p27; 14-3-3; Akt; tumor suppression	FORKHEAD TRANSCRIPTION FACTOR; DEPENDENT KINASE INHIBITOR; BREAST-CANCER; CYTOPLASMIC LOCALIZATION; PROTEIN-KINASE; DNA-DAMAGE; PHOSPHORYLATION; P27(KIP1); GROWTH; BRCA1	The 14-3-3 sigma (sigma) protein is a human cancer marker downregulated in various tumors, but its function has not been fully established. 14-3-3 sigma is a negative regulator of cell cycle when overexpressed, but it is not clear whether 14-3-3 sigma regulates cyclin-dependent kinase inhibitor p27(kip1) to negatively affect cell cycle progression. Protein kinase B/Akt is a crucial regulator of oncogenic signal and can phosphorylate p27(Kip1) to enhance p27(kip1)degradation, thereby promoting cell growth. Here, we show that 14-3-3 sigma-mediated cell cycle arrest concurred with p27(kip1) upregulation and Akt inactivation. We show that 14-3-3 sigma blocks Akt-mediated acceleration of P27(kip1) turnover rate. 14-3-3 sigma inhibits Akt-mediated p27(kip1) phosphorylation that targets p27(kip1) for nuclear export and degradation. 14-3-3 sigma inhibits cell survival and tumorigenicity of Akt-activating breast cancer cell. Low expression of 14-3-3 sigma in human primary breast cancers correlates with cytoplasmic location of p27(kip1). These data provide an insight into 14-3-3 sigma activity and rational cancer gene therapy by identifying 14-3-3 sigma as a positive regulator of p27 and as a potential anticancer agent.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, Program Genes & Dev, Grad Sch Biomed Sci, Houston, TX USA; Eastern Virginia Med Sch, Dept Surg, Norfolk, VA 23501 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Biol Program, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci Houston, Program Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Eastern Virginia Medical School; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Box 79, Houston, TX 77030 USA.	mhlee@mdanderson.org		Lee, Mong-Hong/0000-0001-8675-8215	NCI NIH HHS [R01CA089266, CA16672, R01 CA089266, R56 CA089266] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R56CA089266, R01CA089266] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; ALBERTSEN HM, 1994, NAT GENET, V7, P472, DOI 10.1038/ng0894-472; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee MH, 2001, CELL MOL LIFE SCI, V58, P1907, DOI 10.1007/PL00000826; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Newman L, 2001, MOL CARCINOGEN, V30, P169, DOI 10.1002/mc.1025; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YANG H, 2006, IN PRESS MOL CANC TH; YANG H, 2006, IN PRESS CANC RES; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Yang HY, 2001, ONCOGENE, V20, P3695, DOI 10.1038/sj.onc.1204472; YANG HY, 2006, IN PRESS J CELL BIOC; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhang YJ, 2004, ONCOGENE, V23, P7132, DOI 10.1038/sj.onc.1207918; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	39	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4585	4594		10.1038/sj.onc.1209481	http://dx.doi.org/10.1038/sj.onc.1209481			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16532026				2022-12-17	WOS:000239457500008
J	Archangelo, LF; Glaser, J; Krause, A; Bohlander, SK				Archangelo, L. Froehlich; Glaeser, J.; Krause, A.; Bohlander, S. K.			The novel CALM interactor CATS influences the subcellular localization of the leukemogenic fusion protein CALM/AF10	ONCOGENE			English	Article						CALM/AF10; PICALM; leukemia; nucleolus	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CALM-AF10 FUSION; LEUCINE-ZIPPER; MOLECULAR CHARACTERIZATION; COATED PITS; CLATHRIN; AF10; GENE; MLL	The Clathrin Assembly Lymphoid Myeloid leukemia gene (CALM or PICALM) was first identified as the fusion partner of AF10 in the t(10;11)(p13;q14) translocation, which is observed in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and malignant lymphoma. The CALM/AF10 fusion protein plays a crucial role in t(10;11)(p13;q14) associated leukemogenesis. Using the N-terminal half of CALM as a bait in a yeast two-hybrid screen, a novel protein named CATS (CALM interacting protein expressed in thymus and spleen) was identified. Multiple tissue Northern blot analysis showed predominant expression of CATS in thymus, spleen and colon. CATS codes for two protein isoforms of 238 and 248 amino acids (aa). The interaction between CALM and CATS could be confirmed using pull down assays, co-immunoprecipitation and colocalization experiments. The CATS interaction domain of CALM was mapped to aa 221-335 of CALM. This domain is contained in the CALM/AF10 fusion protein. CATS localizes to the nucleus and shows a preference for nucleoli. Expression of CATS was able to markedly increase the nuclear localization of CALM and of the leukemogenic fusion protein CALM/AF10. The possible implications of these findings for CALM/AF10-mediated leukemogenesis are discussed.	Univ Munich, Dept Med 3, Grosshadern Hosp, D-81377 Munich, Germany; GSF Munich, Clin Cooperat Grp Leukemia, Munich, Germany; Univ Gottingen, Inst Human Genet, D-3400 Gottingen, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Gottingen	Bohlander, SK (corresponding author), Univ Munich, Dept Med 3, Grosshadern Hosp, Marchioninistr 15, D-81377 Munich, Germany.	sbohlan@gwdg.de	Archangelo, Leticia Fröhlich/P-7048-2015; Krause, Alexandre/K-7221-2013	Archangelo, Leticia Fröhlich/0000-0003-2264-4504; Bohlander, Stefan/0000-0002-2202-9088				Abdou SMH, 2002, LEUKEMIA LYMPHOMA, V43, P89, DOI 10.1080/10428190290000437; Asnafi V, 2003, BLOOD, V102, P1000, DOI 10.1182/blood-2002-09-2913; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bohlander SK, 2000, LEUKEMIA, V14, P93, DOI 10.1038/sj.leu.2401614; Carlson KM, 2000, LEUKEMIA, V14, P100, DOI 10.1038/sj.leu.2401629; Chao MM, 2004, BLOOD, V104, p922A, DOI 10.1182/blood.V104.11.3380.3380; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; De Camilli P, 2002, FEBS LETT, V513, P11, DOI 10.1016/S0014-5793(01)03306-3; Delabesse E, 2004, BLOOD, V104, p315A; Deshpande A, 2003, BLOOD, V102, p216A; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; Dreyling MH, 1998, BLOOD, V91, P4662; Evans PR, 2002, CURR OPIN STRUC BIOL, V12, P814, DOI 10.1016/S0959-440X(02)00395-0; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Jones LK, 2001, LEUKEMIA, V15, P910, DOI 10.1038/sj.leu.2402140; Kalthoff C, 2002, J BIOL CHEM, V277, P8209, DOI 10.1074/jbc.M111587200; Klebig ML, 2003, P NATL ACAD SCI USA, V100, P8360, DOI 10.1073/pnas.1432634100; Kobayashi H, 1997, GENE CHROMOSOME CANC, V20, P253, DOI 10.1002/(SICI)1098-2264(199711)20:3<253::AID-GCC5>3.0.CO;2-1; Krause A, 2004, BLOOD, V104, p791A, DOI 10.1182/blood.V104.11.2895.2895; Kumon K, 1999, GENE CHROMOSOME CANC, V25, P33, DOI 10.1002/(SICI)1098-2264(199905)25:1<33::AID-GCC5>3.0.CO;2-3; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; Nakamura F, 2003, AM J HEMATOL, V72, P138, DOI 10.1002/ajh.10265; Narita M, 1999, BRIT J HAEMATOL, V105, P928, DOI 10.1046/j.1365-2141.1999.01433.x; Netzer C, 2001, HUM MOL GENET, V10, P3017, DOI 10.1093/hmg/10.26.3017; Nonet ML, 1999, MOL BIOL CELL, V10, P2343, DOI 10.1091/mbc.10.7.2343; Perrin L, 2003, MOL CELL BIOL, V23, P119, DOI 10.1128/MCB.23.1.119-130.2003; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Salmon-Nguyen F, 2000, CANCER GENET CYTOGEN, V122, P137, DOI 10.1016/S0165-4608(00)00277-6; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Silliman CC, 1998, LEUKEMIA, V12, P1404, DOI 10.1038/sj.leu.2401109; Stahelin RV, 2003, J BIOL CHEM, V278, P28993, DOI 10.1074/jbc.M302865200; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	39	39	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4099	4109		10.1038/sj.onc.1209438	http://dx.doi.org/10.1038/sj.onc.1209438			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491119				2022-12-17	WOS:000238802400010
J	Frame, FM; Rogoff, HA; Pickering, MT; Cress, WD; Kowalik, TF				Frame, F. M.; Rogoff, H. A.; Pickering, M. T.; Cress, W. D.; Kowalik, T. F.			E2F1 induces MRN foci formation and a cell cycle checkpoint response in human fibroblasts	ONCOGENE			English	Article						E2F1; DNA damage; cell cycle checkpoint; apoptosis	NIJMEGEN BREAKAGE SYNDROME; DNA-DAMAGE CHECKPOINT; TRANSCRIPTION FACTOR; MRE11 COMPLEX; NUCLEAR FOCI; HISTONE H2AX; S-PHASE; ATAXIA-TELANGIECTASIA; TUMOR SUPPRESSION; GROWTH CONTROL	Deregulation of the Rb/E2F pathway in human fibroblasts results in an E2F1-mediated apoptosis dependent on Atm, Nbs1, Chk2 and p53. Here, we show that E2F1 expression results in MRN foci formation, which is independent of the Nbs1 interacting region and the DNA-binding domain of E2F1. E2F1-induced MRN foci are similar to irradiation-induced foci (IRIF) that result from double-strand DNA breaks because they correlate with 53BP1 and gamma H2AX foci, do not form in NBS cells, do form in AT cells and do not correlate with cell cycle entry. In fact, we find that in human fibroblasts deregulated E2F1 causes a G1 arrest, blocking serum-induced cell cycle progression, in part through an Nbs1/53BP1/p53/p21(WAF1/CIP1) checkpoint pathway. This checkpoint protects against apoptosis because depletion of 53BP1 or p21(WAF1/CIP1) increases both the rate and extent of apoptosis. Nbs1 and p53 contribute to both checkpoint and apoptosis pathways. These results suggest that E2F1-induced foci generate a cell cycle checkpoint that, with sustained E2F1 activity, eventually yields to apoptosis. Uncontrolled proliferation due to Rb/E2F deregulation as well as inactivation of both checkpoint and apoptosis programs would then be required for transformation of normal cells to tumor cells.	Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA; Univ Massachusetts, Program Immunol & Virol, Worcester, MA USA; H Lee Moffitt Comprehens Canc Ctr, Mol Oncol Program, Tampa, FL USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; H Lee Moffitt Cancer Center & Research Institute	Kowalik, TF (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, 55 Lake Ave N, Worcester, MA 01655 USA.	timothy.kowalik@umassmed.edu		Frame, Fiona/0000-0002-2377-1110	NCI NIH HHS [CA90489, CA86038] Funding Source: Medline; NIAID NIH HHS [5T32 AI09749] Funding Source: Medline; NIDDK NIH HHS [DK32520] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090489, R01CA086038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Castillo JP, 2000, J VIROL, V74, P8028, DOI 10.1128/JVI.74.17.8028-8037.2000; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lindstrom MS, 2003, ONCOGENE, V22, P4993, DOI 10.1038/sj.onc.1206659; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Lombard DB, 2000, CANCER RES, V60, P2331; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; PICKERING MT, 2005, ONOCOGENE; Powers JT, 2004, MOL CANCER RES, V2, P203; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; TAALMAN RDFM, 1983, MUTAT RES, V112, P23, DOI 10.1016/0167-8817(83)90021-4; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200	49	39	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3258	3266		10.1038/sj.onc.1209352	http://dx.doi.org/10.1038/sj.onc.1209352			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16434972				2022-12-17	WOS:000237951200004
J	Wu, M; Wallace, MR; Muir, D				Wu, M; Wallace, MR; Muir, D			Nf1 haploinsufficiency augments angiogenesis	ONCOGENE			English	Article						neurofibromatosis; vasculature; Nf1 haploinsufficiency; endothelial cell; inflammatory cells	DEFICIENT SCHWANN-CELLS; NEUROFIBROMATOSIS 1; FACTOR MIDKINE; MAST-CELLS; EXPRESSION; MOUSE; COMPLICATION; ENCODES; CULTURE	Mutations in the NF1 tumor-suppressor gene underlie neuro. bromatosis type 1 (NF1), in which patients are predisposed to certain tumors such as neuro. bromas and may associate with vascular disorder. Plexiform neuro. bromas are slow growing benign tumors that are highly vascular and can progress to malignancy. The development of neuro. bromas requires loss of both Nf1 alleles in Schwann cells destined to become neoplastic and may be exacerbated by Nf1 heterozygosity in other non-neoplastic cells. This study tested the hypothesis that Nf1 heterozygosity exaggerates angiogenesis. We found that Nf1 heterozygous mice showed increased neovascularization in both the retina and cornea in response to hypoxia and bFGF, respectively, compared to their wild-type litter-mates. The increase in corneal neovascularization was associated with heightened endothelial cell proliferation and migration, and increased infiltration of inflammatory cells. In addition, Nf1 heterozygous endothelial cell cultures showed an exaggerated proliferative response to angiogenic factors, particularly to bFGF. These findings support the conclusion that Nf1 heterozygosity in endothelial cells and perhaps inflammatory cells augments angiogenesis, which may promote neurofibroma formation in NF1.	Univ Florida, Dept Pediat, Div Neurol, Gainesville, FL 32610 USA; Univ Florida, Dept Microbiol & Mol Genet, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, UF Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Wu, M (corresponding author), Univ Florida, Coll Med, Dept Pediat Neuro, Box 100296, Gainesville, FL 32610 USA.	wumin@ufl.edu						Arbiser JL, 1998, J AM ACAD DERMATOL, V38, P950, DOI 10.1016/S0190-9622(98)70158-6; Bajenaru ML, 2003, CANCER RES, V63, P8573; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; DUPREZ K, 1991, MICROSURG, V12, P1, DOI 10.1002/micr.1920120102; Friedman JM, 2002, GENET MED, V4, P105, DOI 10.1097/00125817-200205000-00002; Gitler AD, 2003, NAT GENET, V33, P75, DOI 10.1038/ng1059; Hamilton SJ, 2001, AM J MED GENET, V100, P95, DOI 10.1002/1096-8628(20010422)100:2<95::AID-AJMG1235>3.0.CO;2-T; Hamilton SJ, 2000, CLIN GENET, V58, P341, DOI 10.1034/j.1399-0004.2000.580501.x; HIROTA S, 1993, ARCH PATHOL LAB MED, V117, P996; Ingram DA, 2000, J EXP MED, V191, P181, DOI 10.1084/jem.191.1.181; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; JOHNSON MD, 1989, ARCH PATHOL LAB MED, V113, P1263; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; Mashour GA, 2001, ONCOGENE, V20, P97, DOI 10.1038/sj.onc.1204026; Mashour GA, 1999, J INVEST DERMATOL, V113, P398, DOI 10.1046/j.1523-1747.1999.00699.x; Morello F, 2001, J VASC INTERV RADIOL, V12, P773, DOI 10.1016/S1051-0443(07)61454-7; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; MUIR D, 1990, ANAL BIOCHEM, V185, P377, DOI 10.1016/0003-2697(90)90310-6; Ozerdem Ugur, 2004, Angiogenesis, V7, P307, DOI 10.1007/s10456-004-6643-3; Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299; Rasmussen SA, 2001, AM J HUM GENET, V68, P1110, DOI 10.1086/320121; RICCARDI VM, 1981, BIRTH DEFECTS-ORIG, V17, P129; SHEELA S, 1990, J CELL BIOL, V111, P645, DOI 10.1083/jcb.111.2.645; SIDE L, 1998, NEUROFIBROMATOSIS TY; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Song L, 2003, IN VITRO CELL DEV-AN, V39, P313; Wolkenstein P, 2001, ARCH DERMATOL, V137, P233; Wu M, 2005, J NEUROSCI RES, V82, P357, DOI 10.1002/jnr.20646; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Yang FC, 2003, J CLIN INVEST, V112, P1851, DOI 10.1172/JCI200319195; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	36	39	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2297	2303		10.1038/sj.onc.1209264	http://dx.doi.org/10.1038/sj.onc.1209264			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16288202				2022-12-17	WOS:000236764300002
J	Beitzinger, M; Oswald, C; Beinoraviciute-Kellner, R; Stiewe, T				Beitzinger, M; Oswald, C; Beinoraviciute-Kellner, R; Stiewe, T			Regulation of telomerase activity by the p53 family member p73	ONCOGENE			English	Article						telomerase; hTERT; p53; p73	REVERSE-TRANSCRIPTASE GENE; HUMAN TUMOR-CELLS; WILD-TYPE P53; DOWN-REGULATION; IN-VIVO; NEGATIVE REGULATION; IMMORTAL CELLS; FEEDBACK LOOP; CANCER-CELLS; C-MYC	The terminal ends of eukaryotic chromosomes, termed telomeres, progressively shorten during each round of cell division eventually leading cells into senescence. Tumor cells typically overcome this barrier to unlimited proliferation by activation of the human telomerase reverse transcriptase (hTERT) gene. In contrast, in most human somatic cells hTERT expression is tightly repressed by multiple tumor suppressors. Here, we studied the regulation of hTERT by the p53 family member p73. We show that forced expression of p73 or activation of endogenous p73 by E2F1 results in the downregulation of telomerase activity. Vice versa, siRNA-mediated knockdown of p73 induces hTERT expression. Responsiveness to p73 is conferred by Sp1 binding sites within the hTERT core promoter. In tumor cells, p73 isoforms lacking the transactivation domain (DNp73) are frequently over-expressed and believed to function as oncogenes. We show that DNp73 antagonizes the repressive effect of the proapoptotic p53 family members on hTERT expression and, in addition, induces hTERT expression in telomerase-negative cells by interfering with E2F-RB-mediated repression of the hTERT core promoter. These data provide evidence that the p73 gene functions as an important regulator of telomerase activity with implications for embryonic development, cellular differentiation and tumorigenesis.	Univ Wurzburg, Mol Tumor Biol Grp, Rudolf Virchow Ctr, D-97078 Wurzburg, Germany	University of Wurzburg	Stiewe, T (corresponding author), Univ Wurzburg, Mol Tumor Biol Grp, Rudolf Virchow Ctr, Verbacher Str 9, D-97078 Wurzburg, Germany.	thorsten.stiewe@virchow.uni-wuerzburg.de		Stiewe, Thorsten/0000-0003-0134-7826				Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Guilleret I, 2002, CARCINOGENESIS, V23, P2025, DOI 10.1093/carcin/23.12.2025; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Moll UM, 2004, MOL CANCER RES, V2, P371; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Putzer B, 2003, CELL DEATH DIFFER, V10, P612, DOI 10.1038/sj.cdd.4401205; Putzer BM, 2000, GENE THER, V7, P1317, DOI 10.1038/sj.gt.3301235; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; Slade N, 2004, CELL DEATH DIFFER, V11, P357, DOI 10.1038/sj.cdd.4401335; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Stiewe T, 2002, CANCER RES, V62, P3598; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stiewe T, 2003, J BIOL CHEM, V278, P14230, DOI 10.1074/jbc.M300357200; Suske G, 2000, Methods Mol Biol, V130, P175; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; WALDMAN T, 1995, CANCER RES, V55, P5187; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Wege H, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng003; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Won J, 2004, P NATL ACAD SCI USA, V101, P11328, DOI 10.1073/pnas.0401801101; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu D, 1996, LEUKEMIA, V10, P1354; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	56	39	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					813	826		10.1038/sj.onc.1209125	http://dx.doi.org/10.1038/sj.onc.1209125			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16205639				2022-12-17	WOS:000235212700001
J	Bhonde, MR; Hanski, ML; Notter, M; Gillissen, BF; Daniel, PT; Zeitz, M; Hanski, C				Bhonde, MR; Hanski, ML; Notter, M; Gillissen, BF; Daniel, PT; Zeitz, M; Hanski, C			Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth	ONCOGENE			English	Article						colon carcinoma; chemotherapy; irinotecan; apoptosis; cell cycle arrest	COLORECTAL-CANCER CELLS; POLY(ADP-RIBOSE) POLYMERASE CLEAVAGE; HUMAN GLIOBLASTOMA CELLS; P53 WILD-TYPE; G(2) ARREST; MITOTIC CATASTROPHE; IRINOTECAN CPT-11; IN-VITRO; SENESCENCE; LINES	Knowledge of the type of biological reaction to chemotherapy is a prerequisite for its rational enhancement. We previously showed that irinotecan-induced DNA damage triggers in the HCT116p53(wt) colon carcinoma cell line a long-term cell cycle arrest and in HCT116p53(-/-) cells apoptosis (Magrini et al., 2002). To compare the contribution of long-term cell cycle arrest and that of apoptosis to inhibition of cell proliferation after irinotecan-induced DNA damage, we used this isogenic system as well as the cell lines LS174T (p53(wt)) and HT-29 (p53(mut)). Both p53wt cell lines responded to damage by undergoing a long-term tetraploid G1 arrest, whereas the p53mut cell lines underwent apoptosis. Cell cycle arrest as well as apoptosis caused a similar delay in cell proliferation. Irinotecan treatment also induced in mouse tumours derived from the p53wt cell lines a tetraploid G1 arrest and in those derived from the p53-deficient cell lines a transient G2/M arrest and apoptosis. The delay of tumour growth was in the same range in both groups, that is, arrest-and apoptosis-mediated tumour growth inhibition was comparable. In conclusion, cell cycle arrest as well as apoptosis may be equipotent mechanisms mediating the chemotherapeutic effects of irinotecan.	Charite Univ Med Berlin, Dept Gastroenterol, D-12200 Berlin, Germany; Charite Univ Med Berlin, Dept Hematol, Berlin, Germany; Charite, Dept Clin & Mol Oncol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hanski, ML (corresponding author), Charite Univ Med Berlin, Dept Gastroenterol, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	christoph.hanski@charite.de		Gillissen, Bernhard/0000-0002-1815-2091				Abal M, 2004, ONCOGENE, V23, P1737, DOI 10.1038/sj.onc.1207299; Andreassen PR, 2001, CANCER RES, V61, P7660; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Bartussek C, 1999, EXP CELL RES, V253, P432, DOI 10.1006/excr.1999.4654; Bhonde MR, 2005, ONCOGENE, V24, P148, DOI 10.1038/sj.onc.1207842; Boyer J, 2004, CLIN CANCER RES, V10, P2158, DOI 10.1158/1078-0432.CCR-03-0362; Brown JM, 1999, CANCER RES, V59, P1391; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Clifford B, 2003, CANCER RES, V63, P4074; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; Cusack JC, 2001, CANCER RES, V61, P3535; Ducreux M, 2003, ANN ONCOL, V14, P17, DOI 10.1093/annonc/mdg724; Goldwasser F, 1996, CANCER RES, V56, P4430; Gunasekar P, 2001, TOXICOL SCI, V64, P83, DOI 10.1093/toxsci/64.1.83; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hirose Y, 2001, CANCER RES, V61, P1957; Jacob S, 2001, CANCER RES, V61, P6555; Jansen WJM, 1997, INT J CANCER, V70, P335, DOI 10.1002/(SICI)1097-0215(19970127)70:3<335::AID-IJC15>3.0.CO;2-E; Koike M, 2004, CANCER SCI, V95, P541, DOI 10.1111/j.1349-7006.2004.tb03246.x; Koizumi F, 2004, INT J CANCER, V108, P464, DOI 10.1002/ijc.11539; Liu MC, 2002, SEMIN ONCOL, V29, P246, DOI 10.1053/sonc.2002.32900; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; Magrini R, 2002, INT J CANCER, V101, P23, DOI 10.1002/ijc.10565; Mathijssen RHJ, 2001, CLIN CANCER RES, V7, P2182; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Miknyoczki SJ, 2003, MOL CANCER THER, V2, P371; Monks A, 2000, INVEST NEW DRUG, V18, P95, DOI 10.1023/A:1006313611677; Motwani M, 2001, CLIN CANCER RES, V7, P4209; Nabha SM, 2002, CLIN CANCER RES, V8, P2735; Paradis V, 2001, HUM PATHOL, V32, P327, DOI 10.1053/hupa.2001.22747; Pavillard V, 2002, CANCER CHEMOTH PHARM, V49, P329, DOI 10.1007/s00280-001-0416-0; Prewett MC, 2002, CLIN CANCER RES, V8, P994; Roninson IB, 2003, CANCER RES, V63, P2705; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt CA, 2001, DRUG RESIST UPDATE, V4, P132, DOI 10.1054/drup.2001.0188; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Stewart ZA, 2003, TRENDS PHARMACOL SCI, V24, P139, DOI 10.1016/S0165-6147(03)00026-9; te Poele RH, 2002, CANCER RES, V62, P1876; te Poele RH, 1999, BRIT J CANCER, V81, P1285; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Vanhoefer U, 2001, J CLIN ONCOL, V19, P1501, DOI 10.1200/JCO.2001.19.5.1501; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Wang YL, 2004, ONCOGENE, V23, P1283, DOI 10.1038/sj.onc.1207244; Waxman DJ, 2003, CANCER RES, V63, P8563; Whitacre CM, 1999, CLIN CANCER RES, V5, P665; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	52	39	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					165	175		10.1038/sj.onc.1209017	http://dx.doi.org/10.1038/sj.onc.1209017			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170360				2022-12-17	WOS:000234583600001
J	Vogler, M; Giagkousiklidis, S; Genze, F; Gschwend, JE; Debatin, KM; Fulda, S				Vogler, M; Giagkousiklidis, S; Genze, F; Gschwend, JE; Debatin, KM; Fulda, S			Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity	ONCOGENE			English	Article						apoptosis; Smac; cancer; IAP	MITOCHONDRIA-DERIVED ACTIVATOR; OVARIAN-CARCINOMA CELLS; MEDIATED APOPTOSIS; IN-VIVO; LINKED INHIBITOR; PROSTATE-CANCER; IAP PROTEINS; SMAC/DIABLO; XIAP; CASPASES	While second mitochondria derived activator of caspase (Smac) has been described to sensitize for apoptosis, its effect on cell viability in the absence of apoptotic stimuli has remained unclear. Here, we report that Smac inhibits clonogenic tumor growth by blocking random migration and proliferation and by enhancing apoptosis in a cell density and cell type dependent manner in SH-EP neuroblastoma cells. Inhibition of clonogenic survival by overexpression of full-length or processed Smac strictly depended on low cell density, and was reversible by replatement at high density. We discovered that Smac inhibits cell motility and random migration at low cell density. In addition, Smac enhanced apoptosis and inhibited protein, but not mRNA expression of XIAP, survivin and other short-lived proteins (FLIP, p21), indicating that Smac may globally inhibit protein expression. Also, Smac inhibited proliferation and increased polynucleation with no evidence for polyploidy, cell cycle arrest or senescence indicating that Smac impaired cell division. Interestingly, inhibition of clonogenic capacity by Smac occurred independent of its apoptosis promoting activity. By demonstrating that Smac restrains clonogenic tumor growth, our findings may have important implications for control of tumor growth and/or its metastatic spread. Thus, Smac agonists may be useful in cancer therapy, for example, for tumor control in minimal residual disease.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany; Univ Hosp, Dept Urol, D-89075 Ulm, Germany	Ulm University; Ulm University	Fulda, S (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	simone.fulda@medizin.uni-ulm.de	Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Vogler, Meike/0000-0003-2650-586X; Fulda, Simone/0000-0002-0459-6417				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Creagh EM, 2004, J BIOL CHEM, V279, P26906, DOI 10.1074/jbc.M313859200; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Geisbrecht ER, 2004, CELL, V118, P111, DOI 10.1016/j.cell.2004.06.020; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hao YY, 2004, NAT CELL BIOL, V6, P849, DOI 10.1038/ncb1159; Hasenjager A, 2004, ONCOGENE, V23, P4523, DOI 10.1038/sj.onc.1207594; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Jia L, 2003, ONCOGENE, V22, P1589, DOI 10.1038/sj.onc.1206322; Kuefer R, 2004, BRIT J CANCER, V90, P535, DOI 10.1038/sj.bjc.6601510; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; McNeish IA, 2005, EXP CELL RES, V302, P69, DOI 10.1016/j.yexcr.2004.08.029; McNeish IA, 2003, EXP CELL RES, V286, P186, DOI 10.1016/S0014-4827(03)00073-9; Mizutani Y, 2005, J CLIN ONCOL, V23, P448, DOI 10.1200/JCO.2005.02.191; Ng CP, 2002, MOL CANCER THER, V1, P1051; Pei ZF, 2004, HEPATOLOGY, V39, P1371, DOI 10.1002/hep.20203; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Shiozaki EN, 2004, TRENDS BIOCHEM SCI, V29, P486, DOI 10.1016/j.tibs.2004.07.003; Silke J, 2004, J BIOL CHEM, V279, P4313, DOI 10.1074/jbc.M305661200; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Vaux DL, 2003, BIOCHEM BIOPH RES CO, V304, P499, DOI 10.1016/S0006-291X(03)00622-3; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yan Y, 2004, BRIT J CANCER, V91, P1349, DOI 10.1038/sj.bjc.6602127; Yang LL, 2003, CANCER RES, V63, P831; Yang QH, 2004, J BIOL CHEM, V279, P16963, DOI 10.1074/jbc.M401253200; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	37	39	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7190	7202		10.1038/sj.onc.1208876	http://dx.doi.org/10.1038/sj.onc.1208876			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16091752				2022-12-17	WOS:000232990100008
J	Bernassola, F; Oberst, A; Melino, G; Pandolfi, PP				Bernassola, F; Oberst, A; Melino, G; Pandolfi, PP			The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63	ONCOGENE			English	Article						p63; PML; nuclear body; transcription	PREMATURE SENESCENCE; ONCOGENIC RAS; P53 HOMOLOG; PML; EXPRESSION; P73; CANCER; DELTA-NP63-ALPHA; CARCINOMAS; ENCODES	p63 plays unique developmental roles in epidermal morphogenesis, despite its structural similarity with p53. The p63 gene has two distinct promoters, coding for proteins containing an N-terminal transactivation domain ( TA isoforms) and for proteins lacking this region (Delta N isoforms). The full-length transcriptionally active TAp63 isoforms are capable of transactivating the majority of the p53 target promoters thus inducing cell cycle arrest and apoptosis. On the contrary, the Delta Np63 isoforms seem to counteract the transactivation activities of p53 and TAp63 proteins, thus possibly conferring a proliferative advantage to cancer cells. However, the molecular mechanisms controlling the transcriptional activity of p63 remain largely unclear. Here we present data indicating that (i) the promyelocytic leukaemia protein ( PML) physically interacts with p63, (ii) p63 is localized into the PML nuclear-bodies ( PML-NBs) in vivo, and (iii) PML regulates p63 transcriptional activity. We show that the interaction of p63 with PML increases the levels of p63 in cultured cells as well as its ability to transactivate the p53-responsive elements of the GADD45, p21 and bax promoters. These data are consistent with a general role for PML as a functional modulator of all the p53 family members. Our findings strengthen the relevance of the cross talk between PML and the p53 family members, imply a new tumour suppressive function of PML and unveil a possible role for PML in epidermal morphogenesis and differentiation.	Mem Sloan Kettering Canc Ctr, Dept Pathol, Canc Biol & Genet Program, New York, NY 10021 USA; Univ Roma Tor Vergata, Dept Expt Med, IDI, IRCCS,Biochem Lab, I-00133 Rome, Italy; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	Memorial Sloan Kettering Cancer Center; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of Leicester	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org			NCI NIH HHS [CA-71692] Funding Source: Medline; Telethon [GGP04110] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA071692, R01CA071692] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Telethon(Fondazione Telethon); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duijf PHG, 2002, HUM MOL GENET, V11, P799, DOI 10.1093/hmg/11.7.799; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nylander K, 2002, J PATHOL, V198, P417, DOI 10.1002/path.1231; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Park BJ, 2000, CANCER RES, V60, P3370; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Urist MJ, 2002, AM J PATHOL, V161, P1199, DOI 10.1016/S0002-9440(10)64396-9; Weber A, 2002, VIRCHOWS ARCH, V441, P428, DOI 10.1007/s00428-002-0705-y; Weber A, 2002, INT J CANCER, V99, P22, DOI 10.1002/ijc.10296; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	29	39	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6982	6986		10.1038/sj.onc.1208843	http://dx.doi.org/10.1038/sj.onc.1208843			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007146				2022-12-17	WOS:000232701700013
J	Papoutsaki, M; Moretti, F; Lanza, M; Marinari, B; Sartorelli, V; Guerrini, L; Chimenti, S; Levrero, M; Costanzo, A				Papoutsaki, M; Moretti, F; Lanza, M; Marinari, B; Sartorelli, V; Guerrini, L; Chimenti, S; Levrero, M; Costanzo, A			A p38-dependent pathway regulates Delta Np63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytes	ONCOGENE			English	Article						p53; p63; apoptosis; p38; keratinocytes	JUN NH2-TERMINAL KINASE; P53; P63; PHOSPHORYLATION; ACTIVATION; EXPRESSION; DAMAGE	The p53 protein plays a pivotal role in determining the quality of the response to DNA damage through its transcriptional activity. Upon DNA damage, p53 is activated by post-translational modi. cations, binds its cognate sequences on the promoters of its target genes and stimulates transcription. In proliferating keratinocytes, the activity of p53 is blunted by its inhibitor Delta Np63 alpha. Here, we describe a novel mechanism through which Delta Np63 functions in order to prevent the survival and propagation of ultraviolet (UV)-damaged keratinocytes. We found that UVB stimulation induces the rapid phosphorylation of DNp63, which precedes DNp63 transcriptional downregulation and protein degradation, which is mediated by the p38 MAPK. Phosphorylated Delta Np63 has a lower affinity for p53REs and detaches from cell cycle arrest and apoptotic promoters, thus allowing the rapid activation of p53-dependent transcriptional apoptotic program.	Univ Roma Tor Vergata, Dept Dermatol, Dermatol Clin, I-00133 Rome, Italy; CRS Regina Elena Canc Ctr, Fondaz A Cesalpino, I-00153 Rome, Italy; NIMAS, Muscle Biol Lab, Muscle Gene Express Grp, NIH, Bethesda, MD USA; Univ Milan, Dipartimento Genet & Biol Microorganismi, I-20122 Milan, Italy; Univ Roma La Sapienza, Dept Internal Med, Rome, Italy	University of Rome Tor Vergata; National Institutes of Health (NIH) - USA; University of Milan; Sapienza University Rome	Levrero, M (corresponding author), Univ Roma Tor Vergata, Dept Dermatol, Dermatol Clin, Viale Oxford 81, I-00133 Rome, Italy.	levmax@tin.it; antonio.costanzo@uniroma2.it	Costanzo, Antonio/GZG-2433-2022; Costanzo, Antonio/D-3896-2012; Levrero, Massimo/G-5680-2016	Costanzo, Antonio/0000-0001-9697-2557; Levrero, Massimo/0000-0002-4978-0875	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041126, Z01AR041126] Funding Source: NIH RePORTER; Telethon [E.1325] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Telethon(Fondazione Telethon)		BODE AM, 2003, SCI STKE, pRE2; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2000, CANCER RES, V60, P896; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Cleaver JE, 2002, FRONT BIOSCI-LANDMRK, V7, pD1024, DOI 10.2741/cleaver; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Diepgen TL, 2002, BRIT J DERMATOL, V146, P1, DOI 10.1046/j.1365-2133.146.s61.2.x; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hildesheim J, 2002, CANCER RES, V62, P7305; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Liefer KM, 2000, CANCER RES, V60, P4016; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Park BJ, 2000, CANCER RES, V60, P3370; Qin JZ, 2002, ONCOGENE, V21, P2991, DOI 10.1038/sj.onc.1205404; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sinha RP, 2002, PHOTOCH PHOTOBIO SCI, V1, P225, DOI 10.1039/b201230h; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Wu XW, 2002, FRONT BIOSCI, V7, pD151, DOI 10.2741/wu1; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	27	39	41	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6970	6975		10.1038/sj.onc.1208835	http://dx.doi.org/10.1038/sj.onc.1208835			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007154				2022-12-17	WOS:000232701700011
J	Lin, HK; Bergmann, S; Pandolfi, PP				Lin, HK; Bergmann, S; Pandolfi, PP			Deregulated TGF-beta signaling in leukemogenesis	ONCOGENE			English	Article						TGF-beta; cPML; SARA; Smad2/3; PML-RAR alpha	GROWTH-FACTOR-BETA; ACUTE PROMYELOCYTIC LEUKEMIA; FYVE DOMAIN PROTEIN; MONOCYTIC DIFFERENTIATION; TARGETED DISRUPTION; HEMATOPOIETIC-CELLS; EARLY ENDOSOMES; PML PROTEIN; LIPID RAFTS; IN-VIVO	Cellular homeostasis is tightly controlled by the various pathways that regulate cell proliferation and cell death. Breaking this balance is often associated with cancer development. The transforming growth factor-beta (TGF-beta) pathway plays an important role in cellular homeostasis by regulating cell growth inhibition, cellular senescence, differentiation and apoptosis. Deregulated TGF-beta signaling is known to be involved in a variety of human cancers, including those of the colon, pancreas, breast and prostate. While TGF-beta is a potent negative regulator of hematopoiesis, the role of aberrant TGF-beta signaling in leukemogenesis remains largely unknown. Recently, evidence demonstrating deregulated TGF-beta signaling in leukemogenesis, particularly in acute promyelocytic leukemia (APL), has started to emerge. In this review, we summarize the current progress towards the understanding of the molecular mechanisms by which aberrant TGF-beta signaling may participate in leukemogenesis.	Sloan Kettering Inst, Mem Sloan Kettering Canc Ctr, Dept Pathol, Canc Biol & Genet Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Sloan Kettering Inst, Mem Sloan Kettering Canc Ctr, Dept Pathol, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.	p-pandolfi@ski.mskcc.org						Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Datto MB, 1999, MOL CELL BIOL, V19, P2495; DeCoteau JF, 1997, P NATL ACAD SCI USA, V94, P5877, DOI 10.1073/pnas.94.11.5877; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Fortunel NO, 2000, BLOOD, V96, P2022; Fortunel NO, 2003, ONCOL RES, V13, P445; GOEY H, 1989, J IMMUNOL, V143, P877; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Imai Y, 2001, ONCOGENE, V20, P88, DOI 10.1038/sj.onc.1204057; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Itoh F, 2002, GENES CELLS, V7, P321, DOI 10.1046/j.1365-2443.2002.00519.x; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Jordan CT, 2004, ONCOGENE, V23, P7178, DOI 10.1038/sj.onc.1207935; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim SJ, 2003, LEUKEMIA, V17, P1731, DOI 10.1038/sj.leu.2403069; KRONENWETT R, 2005, IN PRESS ONCOGENE; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Larsson J, 2003, BLOOD, V102, P3129, DOI 10.1182/blood-2003-04-1300; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Le Roy C, 2004, NATURE, V431, P142, DOI 10.1038/431142a; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LeBousseKerdiles MC, 1996, BLOOD, V88, P4534, DOI 10.1182/blood.V88.12.4534.bloodjournal88124534; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Martinez-Alvarez C, 2004, DEV BIOL, V265, P207, DOI 10.1016/j.ydbio.2003.09.022; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mitani K, 2004, ONCOGENE, V23, P4263, DOI 10.1038/sj.onc.1207777; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Mori A, 2000, ACTA HAEMATOL-BASEL, V103, P220, DOI 10.1159/000041054; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; Pandolfi PP, 2001, HUM MOL GENET, V10, P769, DOI 10.1093/hmg/10.7.769; Parton RG, 2004, TRENDS CELL BIOL, V14, P141, DOI 10.1016/j.tcb.2004.02.001; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; RAZA A, 1992, BLOOD, V79, P1037; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Romano LA, 2000, DEV BIOL, V223, P91, DOI 10.1006/dbio.2000.9750; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Scandura JM, 2004, P NATL ACAD SCI USA, V101, P15231, DOI 10.1073/pnas.0406771101; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; TESTA U, 1993, J IMMUNOL, V150, P2418; TESTA U, 1994, CANCER RES, V54, P4508; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; VanRanst PCF, 1996, EXP HEMATOL, V24, P1509; Wang ZG, 1998, SCIENCE, V279, P1547; Warner JK, 2004, ONCOGENE, V23, P7164, DOI 10.1038/sj.onc.1207933; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	65	39	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5693	5700		10.1038/sj.onc.1208923	http://dx.doi.org/10.1038/sj.onc.1208923			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123802				2022-12-17	WOS:000231452800004
J	Riz, I; Hawley, RG				Riz, I; Hawley, RG			G(1)/S transcriptional networks modulated by the HOX11/TLX1 oncogene of T-cell acute lymphoblastic leukemia	ONCOGENE			English	Review						T-cell acute lymphoblastic leukemia; HOX11 oncogene; oligonucleotide microarrays; G1/S transcriptional networks	PROTEIN PHOSPHATASE 2A; CREB-BINDING PROTEIN; SV40 SMALL T; NF-KAPPA-B; C-MYC; HOMEOBOX GENE; BETA-CATENIN; PRE-TCR; THYMOCYTE DIFFERENTIATION; ACETYLTRANSFERASE COMPLEX	The HOX11/TLXI homeobox gene is aberrantly expressed in a subset of T-cell acute lymphoblastic leukemia (T-ALL). Here, we employed oligonucleotide microarrays to compare the expression profiles of the K3P and Sil leukemic cell lines originating from patients with HOX11+ T-ALL to that of Jurkat cells, which originated from a distinct subtype of T-ALL (TAL1(+)). To distinguish potential HOX11 target genes from those characteristic of the stage of HOX11 leukemic arrest, we also performed gene expression analysis on Jurkat cells, genetically engineered to express exogenous HOX11. The resulting HOX11 gene expression signature, which was validated for representative signaling pathways by transient transfection of reporter constructs, was characterized by elevated expression of transcriptional programs involved in cell proliferation, including those regulated by E2F, c-Myc and cAMP response element-binding protein. We subsequently showed that ectopic HOX11 expression resulted in hyperphosphorylation of the retinoblastoma protein (Rb), which correlated with inhibition of the major Rb serine/threonine phosphatase PP1. HOX11 also inhibited PP2A serine/threonine phosphatase activity concomitant with stimulation of the AKT/PKB signaling cascade. These results suggest that transcriptional deregulation of G(1)/S growth-control genes, mediated in large part through blockade of PP1/PP2A phosphatase activity, plays an important role in HOX11 pathobiology.	George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA	George Washington University	Hawley, RG (corresponding author), George Washington Univ, Med Ctr, Dept Anat & Cell Biol, 2300 Eye St,NW, Washington, DC 20037 USA.	rghawley@gwu.edu		Hawley, Robert/0000-0003-3512-5818	NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR016209] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065519, R01HL066305] Funding Source: NIH RePORTER; NCRR NIH HHS [R24RR16209, R24 RR016209] Funding Source: Medline; NHLBI NIH HHS [R01 HL066305, R01 HL066305-05, R01HL66305, R01HL65519, R01 HL065519, R01 HL066305-04] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; Agata Y, 2001, J EXP MED, V193, P873, DOI 10.1084/jem.193.7.873; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; Allen TD, 2000, LEUKEMIA LYMPHOMA, V39, P241, DOI 10.3109/10428190009065824; Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chen QH, 2003, ONCOGENE, V22, P992, DOI 10.1038/sj.onc.1206193; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Ciofani M, 2004, J IMMUNOL, V172, P5230, DOI 10.4049/jimmunol.172.9.5230; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cohen PTW, 2002, J CELL SCI, V115, P241; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; Dominguez-Caceres MA, 2004, ONCOGENE, V23, P7378, DOI 10.1038/sj.onc.1208002; Du J, 2002, NUCLEIC ACIDS RES, V30, P5465, DOI 10.1093/nar/gkf678; DUBE ID, 1991, BLOOD, V78, P2996; Ebert BL, 2004, BLOOD, V104, P923, DOI 10.1182/blood-2004-01-0274; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Fry CJ, 1999, J BIOL CHEM, V274, P15883, DOI 10.1074/jbc.274.22.15883; Fujimoto M, 2000, J IMMUNOL, V165, P1799, DOI 10.4049/jimmunol.165.4.1799; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Goodman RH, 2000, GENE DEV, V14, P1553; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; Grady GC, 2004, J IMMUNOL, V173, P1802, DOI 10.4049/jimmunol.173.3.1802; Greene WK, 1998, MOL CELL BIOL, V18, P7030, DOI 10.1128/MCB.18.12.7030; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; HAWLEY RG, 1994, ONCOGENE, V9, P1; Hawley RG, 1997, CANCER RES, V57, P337; HAWLEY RG, 1994, GENE THER, V1, P136; HAWLEY RG, 1995, ONCOGENE, V11, P1113; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kang-Decker N, 2004, CANCER CELL, V5, P177, DOI 10.1016/S1535-6108(04)00022-4; Karsunky H, 2002, ONCOGENE, V21, P1571, DOI 10.1038/sj/onc/1205216; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Keller G, 1998, BLOOD, V92, P877, DOI 10.1182/blood.V92.3.877.415k11_877_887; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Krasnoselskaya-Riz I, 2002, AIDS RES HUM RETROV, V18, P591, DOI 10.1089/088922202753747941; Kutney SN, 2004, J BIOL CHEM, V279, P30850, DOI 10.1074/jbc.M404969200; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; Luo Q, 2004, ONCOGENE, V23, P1088, DOI 10.1038/sj.onc.1207225; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Ma YH, 2003, J BIOL CHEM, V278, P16770, DOI 10.1074/jbc.M212702200; Mathieu N, 2000, J EXP MED, V192, P625, DOI 10.1084/jem.192.5.625; Owens BM, 2004, METH MOLEC MED, V105, P311; Owens BM, 2003, BLOOD, V101, P4966, DOI 10.1182/blood-2002-09-2857; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; Ramezani A, 2003, BLOOD, V101, P4717, DOI 10.1182/blood-2002-09-2991; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RIZ I, 2003, APPL GENOMICS PROTEO, V1, P95; Rudenko A, 2003, EMBO REP, V4, P59, DOI 10.1038/sj.embor.embor712; Schmidt T, 1998, EMBO J, V17, P5349, DOI 10.1093/emboj/17.18.5349; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Schneider R, 2004, J BIOL CHEM, V279, P23859, DOI 10.1074/jbc.C400151200; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Shen WF, 2001, MOL CELL BIOL, V21, P7509, DOI 10.1128/MCB.21.21.7509-7522.2001; Sonoki T, 2001, BLOOD, V98, P2837, DOI 10.1182/blood.V98.9.2837; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Tan PK, 2003, NUCLEIC ACIDS RES, V31, P5676, DOI 10.1093/nar/gkg763; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Trop S, 2001, BLOOD, V97, P2269, DOI 10.1182/blood.V97.8.2269; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Varas A, 2003, TRENDS IMMUNOL, V24, P197, DOI 10.1016/S1471-4906(03)00033-4; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; VON LM, 1992, MOL CELL BIOL, V12, P3346; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Yalcin A, 2003, J NEUROCHEM, V84, P397, DOI 10.1046/j.1471-4159.2003.01540.x; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yu WM, 2003, ONCOGENE, V22, P5995, DOI 10.1038/sj.onc.1206846; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	102	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5561	5575		10.1038/sj.onc.1208727	http://dx.doi.org/10.1038/sj.onc.1208727			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	15897879	Green Accepted			2022-12-17	WOS:000231296100004
J	Lazzereschi, D; Nardi, F; Turco, A; Ottini, L; D'Amico, C; Mariani-Costantini, R; Gulino, A; Coppa, A				Lazzereschi, D; Nardi, F; Turco, A; Ottini, L; D'Amico, C; Mariani-Costantini, R; Gulino, A; Coppa, A			A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours	ONCOGENE			English	Article						TGF-beta signalling; Smad4; thyroid tumours; somatic mutations; abnormal splicing; molecular pathology	GROWTH-FACTOR-BETA; COLORECTAL CANCERS; JUVENILE POLYPOSIS; MESSENGER-RNA; SOMATIC ALTERATIONS; DPC4/SMAD4 GENE; CHROMOSOME 18Q; II RECEPTOR; CELLS; DPC4	Sensitivity to transforming growth factor-beta is impaired in thyroid tumours. Similar to Mad - Mother Against Decapentaplegic-(Smad)4 is frequently altered in cancers, but its involvement in this system is unknown. We analysed 56 thyroid tumours of various histotypes for Smad4 mutations by PCR-SSCP and sequencing, linking them to Smad4 reactivity as examined by immunohistochemistry (IHC), and 29 of them also for abnormalities in RNA expression due to alternative splicing. In all, 15/56 cases (27%), both benign and malignant lesions, harbour alterations of Smad4 coding sequence. We found several novel intragenic mutations (13 missense, two silent, one frameshift and one large insertion-deletion), with high incidence in the linker region. A subset of mutated tumours failed to express Smad4 protein by IHC. We have also detected four alternatively spliced tumour-associated Smad4 isoforms, lacking portions of the linker region, and three more due to unreported internal exon-exon rearrangements. Smad4 is both frequently mutated and deregulated by aberrant splicing in thyroid tumours and these alterations may contribute as an early event to thyroid tumorigenesis.	Univ Roma La Sapienza, Fac Med 1, Dept Expt Med & Pathol, I-00161 Rome, Italy; Univ G Dannunzio, Fac Med, Dept Oncol & Neurosci, I-66013 Chieti, Italy; Univ G dAnnunzio, Ageing Res Ctr, I-66013 Chieti, Italy	Sapienza University Rome; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara	Lazzereschi, D (corresponding author), Univ Roma La Sapienza, Fac Med 1, Dept Expt Med & Pathol, V Regina Elena 324, I-00161 Rome, Italy.	davide.lazzereschi@uniroma1.it; anna.coppa@uniroma1.it	coppa, anna/N-3274-2016; Mariani-Costantini, Renato/B-6637-2012	Mariani-Costantini, Renato/0000-0002-4440-1848; coppa, anna/0000-0001-9758-5444; OTTINI, LAURA/0000-0001-8030-0449				Bai RY, 2002, NAT CELL BIOL, V4, P181, DOI 10.1038/ncb753; BERTAUX F, 1991, BIOCHEM BIOPH RES CO, V178, P586, DOI 10.1016/0006-291X(91)90148-Z; Blaker H, 2002, ONCOGENE, V21, P158, DOI 10.1038/sj.onc.1205041; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Carneiro C, 1998, ONCOGENE, V16, P1455, DOI 10.1038/sj.onc.1201662; COLLETTA G, 1989, CANCER RES, V49, P3457; Coppa A, 1997, J CELL PHYSIOL, V172, P200, DOI 10.1002/(SICI)1097-4652(199708)172:2<200::AID-JCP7>3.0.CO;2-S; COPPA A, 1995, CELL GROWTH DIFFER, V6, P281; Costamagna E, 2004, J BIOL CHEM, V279, P3439, DOI 10.1074/jbc.M307138200; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Ermak G, 1996, CLIN CANCER RES, V2, P1251; Ferrand M, 2003, J BIOL CHEM, V278, P3793, DOI 10.1074/jbc.M209513200; Fluge O, 2001, ONCOGENE, V20, P885, DOI 10.1038/sj.onc.1204161; Gallione CJ, 2004, LANCET, V363, P852, DOI 10.1016/S0140-6736(04)15732-2; Hahn SA, 1998, CANCER RES, V58, P1124; Hayashi M, 2002, BIOCHEM BIOPH RES CO, V297, P1253, DOI 10.1016/S0006-291X(02)02371-9; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Iacobuzio-Donahue CA, 2004, CLIN CANCER RES, V10, P1597, DOI 10.1158/1078-0432.CCR-1121-3; Jones JB, 2000, NUCLEIC ACIDS RES, V28, P2363, DOI 10.1093/nar/28.12.2363; Ju HR, 2003, CANCER LETT, V196, P197, DOI 10.1016/S0304-3835(03)00237-4; Kageyama H, 1998, CANCER LETT, V122, P187, DOI 10.1016/S0304-3835(97)00389-3; Kim SK, 1996, CANCER RES, V56, P2519; Koyama M, 1999, MUTAT RES-GENOMICS, V406, P71, DOI 10.1016/S1383-5726(99)00003-5; Kuang CZ, 2004, ONCOGENE, V23, P1021, DOI 10.1038/sj.onc.1207219; Lazzereschi D, 1997, CANCER RES, V57, P2071; Maru D, 2004, ONCOGENE, V23, P859, DOI 10.1038/sj.onc.1207194; Miyaki M, 2003, BIOCHEM BIOPH RES CO, V306, P799, DOI 10.1016/S0006-291X(03)01066-0; Moore PS, 2001, BRIT J CANCER, V84, P253, DOI 10.1054/bjoc.2000.1567; Nicolussi A, 2003, MOL CELL ENDOCRINOL, V207, P1, DOI 10.1016/S0303-7207(03)00238-7; Ohtaki N, 2001, INT J ONCOL, V18, P265; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takakura S, 1999, GENE CHROMOSOME CANC, V24, P264, DOI 10.1002/(SICI)1098-2264(199903)24:3<264::AID-GCC12>3.0.CO;2-Y; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Turco A, 1999, INT J CANCER, V80, P85, DOI 10.1002/(SICI)1097-0215(19990105)80:1<85::AID-IJC17>3.0.CO;2-P; Woodford-Richens KL, 2001, AM J PATHOL, V159, P1293, DOI 10.1016/S0002-9440(10)62516-3; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866	43	39	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5344	5354		10.1038/sj.onc.1208603	http://dx.doi.org/10.1038/sj.onc.1208603			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15940269				2022-12-17	WOS:000231158500008
J	Zirn, B; Samans, B; Spangenberg, C; Graf, N; Eilers, M; Gessler, M				Zirn, B; Samans, B; Spangenberg, C; Graf, N; Eilers, M; Gessler, M			All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo	ONCOGENE			English	Article						Wilms tumor; nephroblastoma; retinoic acid; ATRA; TGF beta	TISSUE GROWTH-FACTOR; COLORECTAL-CANCER; TGF-BETA; NEUROBLASTOMA; CARCINOMA; PROGRESSION; DEHYDROGENASE/REDUCTASE; DIFFERENTIATION; ADENOCARCINOMA; PROLIFERATION	Wilms tumor is one of the most frequent neoplasias in children. Our previous microarray screening in a large series of Wilms tumors revealed several candidate genes that are deregulated in advanced tumors and are part of the retinoic acid signaling pathway. To investigate whether retinoic acid could be employed as a novel therapeutic agent in these tumors, we treated cultured Wilms tumor cells with different concentrations of all-trans retinoic acid (ATRA) and assessed gene expression changes by real-time RT-PCR as well as microarray analysis. Several genes like RARRES1, RARRES3, CTGF, CKS2, CCNA2, IGFBP3, UBE2C, CCL2 or ITM2B that were previously found to be deregulated in advanced tumors exhibited opposite expression changes after ATRA treatment. In addition to enhanced retinoid signaling, the transforming growth factor-beta (TGF beta) pathway was strongly activated by ATRA treatment of Wilms tumor cells. Both the retinoic acid and the TGFbeta pathway mediate inhibition of cell growth. These findings represent the first molecular evidence of a potential benefit from ATRA treatment in Wilms tumors.	Univ Wurzburg, Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany; Univ Marburg, Inst Mol Biol & Tumor Res, Marburg, Germany; Univ Mainz, Dept Mol Genet, D-6500 Mainz, Germany; Univ Saarland, Dept Paediat Oncol & Haematol, Childrens Hosp, Saarland, Germany	University of Wurzburg; Philipps University Marburg; Johannes Gutenberg University of Mainz; Saarland University	Gessler, M (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany.	gessler@biozentrum.uni-wuerzburg.de	Graf, Norbert/H-1328-2011	Graf, Norbert/0000-0002-2248-323X; Gessler, Manfred/0000-0002-7915-6045; Eilers, Martin/0000-0002-0376-6533				Adamson PC, 1997, J CLIN ONCOL, V15, P3330, DOI 10.1200/JCO.1997.15.11.3330; Bahnassy AA, 2004, BMC GASTROENTEROL, V4, DOI 10.1186/1471-230X-4-22; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; Burrow CR, 2000, PEDIATR NEPHROL, V14, P240, DOI 10.1007/s004670050049; Casanova B, 2001, LEUKEMIA, V15, P1521, DOI 10.1038/sj.leu.2402243; Cerignoli F, 2002, CANCER RES, V62, P1196; Chang CC, 2004, JNCI-J NATL CANCER I, V96, P364, DOI 10.1093/jnci/djh059; Cheung B, 1998, ONCOGENE, V17, P751, DOI 10.1038/sj.onc.1201982; Choi MC, 2004, ONCOGENE, V23, P7095, DOI 10.1038/sj.onc.1207932; Farias EF, 2002, CELL GROWTH DIFFER, V13, P335; Fleischer A, 2002, ONCOGENE, V21, P3181, DOI 10.1038/sj.onc.1205464; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Gonzalez AM, 2002, P NATL ACAD SCI USA, V99, P16075, DOI 10.1073/pnas.252649399; Imai S, 1997, FEBS LETT, V411, P102, DOI 10.1016/S0014-5793(97)00673-X; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Kansra S, 2000, INT J CANCER, V87, P373, DOI 10.1002/1097-0215(20000801)87:3<373::AID-IJC10>3.0.CO;2-X; Kastner P, 1997, DEVELOPMENT, V124, P313; Kedishvili NY, 2002, J BIOL CHEM, V277, P28909, DOI 10.1074/jbc.M202588200; Koliopanos A, 2002, WORLD J SURG, V26, P420, DOI 10.1007/s00268-001-0242-x; Li P, 2004, J PEDIATR SURG, V39, P1512, DOI 10.1016/j.jpedsurg.2004.06.011; Lobbert RW, 1998, GENE CHROMOSOME CANC, V21, P347, DOI 10.1002/(SICI)1098-2264(199804)21:4<347::AID-GCC9>3.0.CO;2-Z; Pendaries V, 2003, ONCOGENE, V22, P8212, DOI 10.1038/sj.onc.1206913; Petridou E, 2001, ONCOLOGY-BASEL, V60, P252, DOI 10.1159/000055326; REYNOLDS CP, 1991, PROG CLIN BIOL RES, V366, P203; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; Salmivirta K, 2002, EXP CELL RES, V279, P188, DOI 10.1006/excr.2002.5611; Shyu RY, 2003, BRIT J CANCER, V89, P146, DOI 10.1038/sj.bjc.6601049; Sriuranpong V, 2004, CLIN CANCER RES, V10, P4944, DOI 10.1158/1078-0432.CCR-03-0757; Urbanowicz-Kachnowicz I, 1999, INT J CANCER, V82, P98, DOI 10.1002/(SICI)1097-0215(19990702)82:1<98::AID-IJC17>3.0.CO;2-A; Xie D, 2004, CLIN CANCER RES, V10, P2072, DOI 10.1158/1078-0432.CCR-0659-03; Xie W, 2003, CANCER J, V9, P302, DOI 10.1097/00130404-200307000-00013; Xie W, 2002, CANCER RES, V62, P497; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; Zirn B, 2005, CANCER LETT, V220, P115, DOI 10.1016/j.canlet.2004.08.001	36	39	39	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5246	5251		10.1038/sj.onc.1208725	http://dx.doi.org/10.1038/sj.onc.1208725			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897880				2022-12-17	WOS:000230964600011
J	Martinez, A; Zudaire, E; Julian, M; Moody, TW; Cuttitta, F				Martinez, A; Zudaire, E; Julian, M; Moody, TW; Cuttitta, F			Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo	ONCOGENE			English	Article						GRP; lung cancer; angiogenesis; nonpeptidic antagonist; tumor growth	MICROVASCULAR ENDOTHELIAL-CELLS; LUNG-CANCER CELLS; BOMBESIN-LIKE PEPTIDES; AUTOCRINE GROWTH; GENE-EXPRESSION; POTENTIAL ROLE; NUDE-MICE; RECEPTOR; HYPOXIA; ANTAGONISTS	Angiogenesis is becoming a major target for antitumor therapies, and identifying new angiogenic factors and their specific inhibitors may provide new avenues for tumor management. Here we identify gastrin-releasing peptide (GRP) as a new angiogenic molecule that is secreted by tumors and acts directly upon GRP receptors in the endothelial cells. Addition of GRP increases endothelial cell migration and cord formation in vitro, and induces angiogenesis in an in vivo assay. We have recently identified a small molecule GRP blocker, compound 77427. This inhibitor significantly reduced endothelial cell cord formation in vitro and angiogenesis in vivo. Conversely, when applied to VEGF-induced angiogenesis, the small molecule did not have any effect, demonstrating its specificity. Furthermore, this GRP blocker was able to reduce lung tumor cell growth in vitro as demonstrated by MTT and clonogenic assays. When applied to a xenograft model with lung cancer cells, compound 77427 reduced tumor volume to undetectable sizes, although when the treatment was suspended, tumors began to grow again at normal rates. Our collective observations indicate that GRP is a new angiogenic peptide and that its inhibition offers an attractive tool to reduce tumor burden.	NCI, Cell & Canc Biol Branch, NIH, Bethesda, MD 20892 USA; NCI, Vasc Biol Fac, NIH, Bethesda, MD 20892 USA; San Pablo CEU Univ, Dept Chem Sci, Madrid 28668, Spain	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); San Pablo CEU University	Martinez, A (corresponding author), CSIC, Inst Cajal, Dept Cell Biol & Neuroanat, Av Doctor Arce 37, E-28002 Madrid, Spain.	amartinez@cajal.csic.es	Cuttitta, Frank/B-4758-2016; Martinez, Alfredo/GQH-5998-2022	Martinez, Alfredo/0000-0003-4882-4044	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC000173, Z01SC000192] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISBY JE, 2003, ANGIOGENESIS, V6, P289; Chaudhry A, 1999, CLIN CANCER RES, V5, P3385; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Damge C, 1998, EUR J PHARMACOL, V347, P77, DOI 10.1016/S0014-2999(98)00088-0; Festuccia C, 2002, EXP CELL RES, V280, P1, DOI 10.1006/excr.2002.5609; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Groger M, 2000, J IMMUNOL, V165, P5428, DOI 10.4049/jimmunol.165.10.5428; Hayashi S, 2001, EXP NEUROL, V171, P285, DOI 10.1006/exnr.2001.7759; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; JOHNSON DE, 1989, AM REV RESPIR DIS, V140, P1807, DOI 10.1164/ajrccm/140.6.1807; Kiaris H, 1999, ONCOGENE, V18, P7168, DOI 10.1038/sj.onc.1203213; Kim S, 2002, ANN SURG, V235, P621, DOI 10.1097/00000658-200205000-00003; Lango MN, 2002, J NATL CANCER I, V94, P375; Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1; Levine L, 2003, CANCER RES, V63, P3495; Lockwood CJ, 2004, J CLIN ENDOCR METAB, V89, P1467, DOI 10.1210/jc.2003-030141; Los M, 2001, SEMIN ONCOL, V28, P93, DOI 10.1053/sonc.2001.20752; Lui VWY, 2003, ONCOGENE, V22, P6183, DOI 10.1038/sj.onc.1206720; Mantey SA, 2001, J BIOL CHEM, V276, P9219, DOI 10.1074/jbc.M008737200; Martinez A, 2004, CANCER RES, V64, P6489, DOI 10.1158/0008-5472.CAN-04-0103; Martinez A, 2002, J NATL CANCER I, V94, P1226; Martinez A, 2004, ENDOCRINOLOGY, V145, P3858, DOI 10.1210/en.2003-1251; Michiels C, 1998, CELL ADHES COMMUN, V5, P367, DOI 10.3109/15419069809010782; Moody TW, 1996, PEPTIDES, V17, P1337, DOI 10.1016/S0196-9781(96)00195-7; Moody TW, 2004, J BIOL CHEM, V279, P23580, DOI 10.1074/jbc.M401938200; Moody TW, 2003, EUR J PHARMACOL, V474, P21, DOI 10.1016/S0014-2999(03)01996-4; Moody TW, 2003, LUNG CANCER-J IASLC, V39, P279, DOI 10.1016/S0169-5002(02)00525-1; Moody TW, 1996, J CELL BIOCHEM, P247; Nock BA, 2005, J MED CHEM, V48, P100, DOI 10.1021/jm049437y; Ohinata K, 2000, FEBS LETT, V473, P207, DOI 10.1016/S0014-5793(00)01529-5; Ohinata K, 2001, PEPTIDES, V22, P1809, DOI 10.1016/S0196-9781(01)00524-1; Otto M, 2001, PATHOBIOLOGY, V69, P159, DOI 10.1159/000048771; Safronova O, 2003, INFLAMM RES, V52, P480, DOI 10.1007/s00011-003-1205-5; Salcedo R, 2000, FASEB J, V14, P2055, DOI 10.1096/fj.99-0963com; Scheurer SB, 2004, PROTEOMICS, V4, P1737, DOI 10.1002/pmic.200300689; Schuller HM, 2000, EUR J PHARMACOL, V393, P265, DOI 10.1016/S0014-2999(00)00094-7; Shi YH, 2004, WORLD J GASTROENTERO, V10, P1082; Shimizu K, 2004, BIOL PHARM BULL, V27, P599, DOI 10.1248/bpb.27.599; SHIRAHIGE Y, 1994, BIOMED PHARMACOTHER, V48, P465, DOI 10.1016/0753-3322(94)90007-8; SISSONS M, 1990, PHYSIOL BOHEMOSLOV, V39, P305; Soffer SZ, 2001, J PEDIATR SURG, V36, P1177, DOI 10.1053/jpsu.2001.25747; VIGNE P, 1995, EUR J BIOCHEM, V233, P414, DOI 10.1111/j.1432-1033.1995.414_2.x; Wachsberger P, 2003, CLIN CANCER RES, V9, P1957; Whitley JC, 2000, J ENDOCRINOL, V166, P649, DOI 10.1677/joe.0.1660649	44	39	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4106	4113		10.1038/sj.onc.1208581	http://dx.doi.org/10.1038/sj.onc.1208581			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15750618				2022-12-17	WOS:000229680300009
J	Kim, H; Kim, YN; Kim, H; Kim, CW				Kim, H; Kim, YN; Kim, H; Kim, CW			Oxidative stress attenuates Fas-mediated apoptosis in Jurkat T cell line through Bfl-1 induction	ONCOGENE			English	Article						hydrogen peroxide; apoptosis; Bfl-1; NF-kappa B	NF-KAPPA-B; HYDROGEN-PEROXIDE; REDOX REGULATION; HUMAN A1; GROWTH ARREST; UP-REGULATION; BCL-X; ACTIVATION; EXPRESSION; PROMOTER	Many types of mammalian cells produce ROS in response to many different stimuli to modulate a number of cellular functions, including apoptosis. However, the correlation between ROS and apoptosis remains controversial, and the mechanisms whereby ROS-induced signals are propagated to critical downstream targets remain largely undefined. Here, we demonstrate that hydrogen peroxide ( H2O2) upregulates the expression of Bfl-1, an antiapoptotic member of the Bcl-2 family, and that this is responsible for the antiapoptotic activity of ROS. When Jurkat, human leukemic T cells, were pretreated with 100 muM H2O2 and then treated with anti-Fas antibody, apoptosis was impaired without change of cell surface Fas expression. An investigation of the expression patterns of Bcl-2 family genes revealed that H2O2 treatment induced Bfl-1 gene expression, but left other genes unchanged, and this Bfl-1 expression and H2O2-induced antiapoptotic effect was inhibited by antioxidants or NF-kappaB inhibitor. In addition, an electromobility shift assay revealed that the p65/p50 subunits of NF-kappaB activated by H2O2 bound to a bfl-1 promoter. Neither the induction of Bfl-1 nor the antiapoptotic effect of H2O2 was detected in Bfl-1-knockdown Jurkat cell line containing Bfl-1 antisense (Bfl-1AS). These data indicate that oxidative stress induces the expression of Bfl-1 via NF-kappaB activation, and this early-response gene protects cells from Fas-mediated apoptosis. This may be a cellular survival mechanism of cells exposed to phagocytes-derived ROS.	Seoul Natl Univ, Coll Med, Dept Pathol, Tumor Immun Med Res Ctr, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Inst Canc Res, Dept Biochem & Mol Biol, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Kim, CW (corresponding author), Seoul Natl Univ, Coll Med, Dept Pathol, Tumor Immun Med Res Ctr, 28 Yongon Dong, Seoul 110799, South Korea.	cwkim@plaza.snu.ac.kr	Kim, Chul-Woo/F-7008-2011	Kim, Hyungsoo/0000-0002-8189-5939				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Crossthwaite AJ, 2002, J NEUROCHEM, V80, P24, DOI 10.1046/j.0022-3042.2001.00637.x; Edelstein LC, 2003, MOL CELL BIOL, V23, P2749, DOI 10.1128/MCB.23.8.2749-2761.2003; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fujita T, 2002, AM J RESP CELL MOL, V27, P542, DOI 10.1165/rcmb.4775; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilston V, 2001, FREE RADICAL RES, V35, P681, DOI 10.1080/10715760100301201; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Hehner SP, 2000, J IMMUNOL, V165, P4319, DOI 10.4049/jimmunol.165.8.4319; Heinrichs S, 2003, ONCOGENE, V22, P555, DOI 10.1038/sj.onc.1206138; Hildeman DA, 2003, P NATL ACAD SCI USA, V100, P15035, DOI 10.1073/pnas.1936213100; Hildeman DA, 2002, CURR OPIN IMMUNOL, V14, P354, DOI 10.1016/S0952-7915(02)00335-7; Kamata H, 2002, FEBS LETT, V519, P231, DOI 10.1016/S0014-5793(02)02712-6; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; KAZMI SMI, 1995, J CELL BIOCHEM, V57, P299, DOI 10.1002/jcb.240570214; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee KM, 2001, CELL SIGNAL, V13, P645, DOI 10.1016/S0898-6568(01)00178-4; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XY, 2001, CANCER RES, V61, P1699; Malmberg KJ, 2001, J IMMUNOL, V167, P2595, DOI 10.4049/jimmunol.167.5.2595; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Moreb JS, 1997, LEUKEMIA, V11, P998, DOI 10.1038/sj.leu.2400719; Moreb JS, 2001, BLOOD, V97, P578, DOI 10.1182/blood.V97.2.578; Otsuji M, 1996, P NATL ACAD SCI USA, V93, P13119, DOI 10.1073/pnas.93.23.13119; Preston TJ, 2003, EXP CELL RES, V285, P146, DOI 10.1016/S0014-4827(03)00015-6; Pugazhenthi S, 2003, J NEUROCHEM, V84, P982, DOI 10.1046/j.1471-4159.2003.01606.x; Reth M, 2002, NAT IMMUNOL, V3, P1129, DOI 10.1038/ni1202-1129; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmielau J, 2001, CANCER RES, V61, P4756; Sen CK, 1996, BIOCHEM BIOPH RES CO, V218, P148, DOI 10.1006/bbrc.1996.0026; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Valencia A, 2004, FREE RADICAL BIO MED, V36, P1112, DOI 10.1016/j.freeradbiomed.2004.02.013; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Xu D, 2002, DEV CELL, V2, P251, DOI 10.1016/S1534-5807(02)00132-6; Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	47	39	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1252	1261		10.1038/sj.onc.1208282	http://dx.doi.org/10.1038/sj.onc.1208282			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592513				2022-12-17	WOS:000226898700012
J	Patzke, S; Hauge, H; Sioud, M; Finne, EF; Sivertsen, EA; Delabie, J; Stokke, T; Hans-Christian, A				Patzke, S; Hauge, H; Sioud, M; Finne, EF; Sivertsen, EA; Delabie, J; Stokke, T; Hans-Christian, A			Identification of a novel centrosome/microtubule-associated coiled-coil protein involved in cell-cycle progression and spindle organization	ONCOGENE			English	Article						centrosome; MAP; mitosis; mitotic spindle; cell; cycle arrest; RNA interference	DNA-REPLICATION; ETHIDIUM-BROMIDE; MITOTIC SPINDLE; KEN BOX; S-PHASE; CENTROSOME; CHECKPOINT; CYTOKINESIS; PHOSPHORYLATION; SIMIAN-VIRUS-40	Here we describe the identication of a novel vertebrate-specific centrosome/spindle pole-associated protein (CSPP) involved in cell-cycle regulation. The protein is predicted to have a tripartite domain structure, where the N- and C-terminal domains are linked through a coiled-coil mid-domain. Experimental analysis of the identified domains revealed that spindle association is dependent on the N- terminal and the coiled-coil mid domain. The expression of CSPP at the mRNA level was detected in all tested cell lines and in testis tissue. Ectopic expression of CSPP in HEK293T cells blocked cell-cycle progression in early G(1) phase and in mitosis in a dose-dependent manner. Interestingly, mitosis-arrested cells contained aberrant spindles and showed impairment of chromosome congression. Inhibition of CSPP gene expression by small interfering RNAs induced cell-cycle arrest/delay in S phase. This phenotype was characterized by elevated levels of cyclin A, decreased levels of cyclin E and hyperphosphorylation of the S-phase checkpoint kinase Chk1. The activation of Chk1 may indicate a replication stress response due to an inappropriate G(1)/S-phase transition. Taken together, we demonstrate that CSPP is associated with centrosomes and microtubules and may play a role in the regulation of G(1)/S-phase progression and spindle assembly.	Norwegian Radium Hosp, Dept Immunol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Radiat Biol, N-0310 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo	Hans-Christian, A (corresponding author), Norwegian Radium Hosp, Dept Immunol, N-0310 Oslo, Norway.	h.c.asheim@labmed.uio.no	Patzke, Sebastian/G-9909-2019	Patzke, Sebastian/0000-0001-6821-197X; Delabie, Jan/0000-0001-5023-0689; Sivertsen, Einar Andreas/0000-0003-0591-3653				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Augustin A, 2003, J CELL SCI, V116, P1551, DOI 10.1242/jcs.00341; Balczon R, 2002, CELL MOTIL CYTOSKEL, V52, P183, DOI 10.1002/cm.10043; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOHMER RM, 1981, CYTOMETRY, V2, P31, DOI 10.1002/cyto.990020107; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Clay-Farrace L, 2003, EMBO J, V22, P704, DOI 10.1093/emboj/cdg046; Delattre M, 2004, J CELL SCI, V117, P1619, DOI 10.1242/jcs.01128; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Fisk HA, 2002, CURR OPIN CELL BIOL, V14, P700, DOI 10.1016/S0955-0674(02)00385-X; FUNDERUD S, 1990, EUR J IMMUNOL, V20, P201, DOI 10.1002/eji.1830200129; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Gromley A, 2003, J CELL BIOL, V161, P535, DOI 10.1083/jcb.200301105; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Khodjakov A, 2003, J CELL BIOL, V160, P671, DOI 10.1083/jcb.200208143; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Lange BMH, 2002, CURR OPIN CELL BIOL, V14, P35, DOI 10.1016/S0955-0674(01)00291-5; LARSEN JK, 1986, CYTOMETRY, V7, P54, DOI 10.1002/cyto.990070108; Leirdal M, 2002, BIOCHEM BIOPH RES CO, V295, P744, DOI 10.1016/S0006-291X(02)00736-2; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nedelec F, 2003, CURR OPIN CELL BIOL, V15, P118, DOI 10.1016/S0955-0674(02)00014-5; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Odeberg J, 2000, BIOMOL ENG, V17, P1, DOI 10.1016/S1389-0344(00)00057-5; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Patzke S, 2002, VIROLOGY, V303, P164, DOI 10.1006/viro.2002.1615; Pfleger CM, 2000, GENE DEV, V14, P655; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Quintyne NJ, 2002, J CELL BIOL, V159, P245, DOI 10.1083/jcb.200203089; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; RASMUSSEN AM, 1992, J IMMUNOL METHODS, V146, P195, DOI 10.1016/0022-1759(92)90228-L; RIEDER CL, 1992, J CELL SCI, V102, P387; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	59	39	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1159	1173		10.1038/sj.onc.1208267	http://dx.doi.org/10.1038/sj.onc.1208267			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15580290				2022-12-17	WOS:000226898700004
J	Dai, W				Dai, W			Polo-like kinases, an introduction	ONCOGENE			English	Editorial Material						polo-like kinases; cell cycle checkpoints; cell division; mitosis	PROTEIN-SERINE/THREONINE KINASE; CAENORHABDITIS-ELEGANS CONTAINS; CELL-DIVISION; BOX DOMAIN; MITOSIS; GENE; IDENTIFICATION; PRK; SAK		New York Med Coll, Dept Med, Div Mol Carcinogenesis, Valhalla, NY 10595 USA; New York Med Coll, Brandar Canc Res Inst, Valhalla, NY 10595 USA	New York Medical College; New York Medical College	Dai, W (corresponding author), New York Med Coll, Dept Med, Div Mol Carcinogenesis, Valhalla, NY 10595 USA.	wei_dai@nymc.edu						Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Chase D, 2000, DNA SEQUENCE, V11, P327, DOI 10.3109/10425170009033251; Dai Wei, 2003, Prog Cell Cycle Res, V5, P327; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Liu JJ, 2004, J BIOL CHEM, V279, P21367, DOI 10.1074/jbc.M400482200; Lowery DM, 2004, CELL CYCLE, V3, P128; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Ouyang B, 1999, DNA SEQUENCE, V10, P109, DOI 10.3109/10425179909008427; Pak DTS, 2003, SCIENCE, V302, P1368, DOI 10.1126/science.1082475; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164	23	39	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2005	24	2					214	216		10.1038/sj.onc.1208270	http://dx.doi.org/10.1038/sj.onc.1208270			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640836				2022-12-17	WOS:000226183100001
J	Endter, C; Hartl, B; Spruss, T; Hauber, J; Dobner, T				Endter, C; Hartl, B; Spruss, T; Hauber, J; Dobner, T			Blockage of CRM1-dependent nuclear export of the adenovirus type 5 early region 1B 55-kDa protein augments oncogenic transformation of primary rat cells	ONCOGENE			English	Article						E1B-55kDa; PML; p53; nucleocytoplasmic shuttling	E1B 55-KILODALTON ONCOPROTEIN; E1B-58KD TUMOR-ANTIGEN; 5 E4ORF3 PROTEIN; WILD-TYPE P53; TRANSCRIPTIONAL REPRESSION; P53-DEPENDENT APOPTOSIS; MONOCLONAL-ANTIBODIES; SUMO-1 MODIFICATION; INFECTED-CELLS; CELLULAR P53	The 55-kDa gene product from subgroup C adenovirus type 5 (Ad5) early region 1 (E1B-55kDa) plays a central role in the oncogenic transformation of primary rodent cells primarily by inactivating transcriptional and presumably other functional properties of the tumor suppressor protein p53. We have previously shown that Ad5 E1B-55kDa possesses a leucine-rich nuclear export signal (NES), which confers rapid nucleocytoplasmic shuttling via the CRM1-dependent export pathway. In this study we report that an export-deficient mutant of the viral protein (E1B-NES) substantially enhances focus formation of primary baby rat kidney cells in combination with Ad E1A. Transformed rat cells stably expressing the E1B-NES protein exhibited increased tumorigenicity and accelerated tumor growth in nude mice compared to transformants containing the wild-type E1B product. This 'gain of function' correlated with enhanced inhibition of p53 transactivation in transient reporter assays and the accumulation of the mutant protein and p53 in several dot-like subnuclear aggregates. Interestingly, these structures also contained a large fraction of cellular promyelocytic leukemia protein (PML), a known regulator of p53. These data indicate that E1B-NES promotes oncogenic transformation by combinatorial mechanisms that involve modulation of p53 in the context of PML nuclear bodies. In sum, these results extend our previous observation that inhibition of PML activities by E1B-55kDa is required for efficient focus formation and provide further support for the view that blocking p53 transcriptional functions is the principal mechanism by which the Ad protein contributes to complete cell transformation in conjunction with Ad E1A.	Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93047 Regensburg, Germany; Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	University of Regensburg; Heinrich Pette Institute	Dobner, T (corresponding author), Univ Regensburg, Inst Med Mikrobiol & Hyg, Landshuterstr 22, D-93047 Regensburg, Germany.	thomas.dobner@klinik.uni-regensburg.de						Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BERNARDS R, 1984, BIOCHIM BIOPHYS ACTA, V783, P187, DOI 10.1016/0167-4781(84)90029-0; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Dosch T, 2001, J VIROL, V75, P5677, DOI 10.1128/JVI.75.12.5677-5683.2001; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Endter C, 2001, P NATL ACAD SCI USA, V98, P11312, DOI 10.1073/pnas.191361798; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grand RJA, 1999, ONCOGENE, V18, P955, DOI 10.1038/sj.onc.1202358; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; Hutton FG, 2000, ONCOGENE, V19, P452, DOI 10.1038/sj.onc.1203316; Konig C, 1999, J VIROL, V73, P2253; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; Lethbridge KJ, 2003, J GEN VIROL, V84, P259, DOI 10.1099/vir.0.18820-0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Maheswaran S, 1998, ONCOGENE, V16, P2041, DOI 10.1038/sj.onc.1201741; MAK I, 1988, VIROLOGY, V163, P201, DOI 10.1016/0042-6822(88)90248-6; Martin MED, 1999, MOL CELL BIOL, V19, P3403; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; Nevels M, 1999, ONCOGENE, V18, P9, DOI 10.1038/sj.onc.1202284; Nevels M, 1999, J VIROL, V73, P1591, DOI 10.1128/JVI.73.2.1591-1600.1999; Nevels M, 2001, J VIROL, V75, P3089, DOI 10.1128/JVI.75.7.3089-3094.2001; Nevels M, 2000, J VIROL, V74, P5168, DOI 10.1128/JVI.74.11.5168-5181.2000; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Punga T, 2000, FEBS LETT, V476, P248, DOI 10.1016/S0014-5793(00)01739-7; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SAWADA Y, 1988, VIROLOGY, V166, P281, DOI 10.1016/0042-6822(88)90175-4; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; VANDENHEUVEL SJL, 1992, J VIROL, V66, P591, DOI 10.1128/JVI.66.1.591-595.1992; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; Wang J, 2004, J CELL BIOL, V164, P515, DOI 10.1083/jcb.200305142; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; Zhao LY, 2003, J VIROL, V77, P13171, DOI 10.1128/JVI.77.24.13171-13181.2003; Zhao LY, 2003, J VIROL, V77, P11809, DOI 10.1128/JVI.77.21.11809-11821.2003	59	39	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					55	64		10.1038/sj.onc.1208170	http://dx.doi.org/10.1038/sj.onc.1208170			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15480414				2022-12-17	WOS:000226125800008
J	Mengwasser, J; Piau, A; Schlag, P; Sleeman, JP				Mengwasser, J; Piau, A; Schlag, P; Sleeman, JP			Differential immunization identifies PHB1/PHB2 as blood-borne tumor antigens	ONCOGENE			English	Article						prohibitin; colorectal; differential immunization; serum ELISA; diagnosis	ENDOPLASMIC-RETICULUM; PROHIBITIN; PROTEINS; MARKERS; RB; CANCER; MITOCHONDRIA; REPRESSION; RECEPTOR; RESPOND	Early diagnosis of cancer is crucial for successful treatment. Noninvasive assays for detecting tumor-derived antigens in serum and other bodily fluids have the potential to screen healthy individuals for hitherto undetected cancers. Very few such assays have been successfully developed, in part because identifying potential target antigens remains a challenge. To identify new blood-borne tumor antigens for the purpose of establishing such assays, we have developed a novel technique called differential immunization. Using this method, we have identified PHB1 and PHB2, proteins thought to function as mitochondrial chaperones and transcriptional regulators, as antigens released from colorectal tumors in vivo. Serum from colorectal patients contains significantly higher levels of these antigens compared to serum from healthy volunteers. These data demonstrate that differential immunization is an effective new method for identifying tumor-derived antigens in serum.	Forschungszentrum Karlsruhe, Inst Genet & Toxikol, D-76021 Karlsruhe, Germany; Humboldt Univ, Charite, Robert Rossle Clin, D-13125 Berlin, Germany	Helmholtz Association; Karlsruhe Institute of Technology; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Sleeman, JP (corresponding author), Forschungszentrum Karlsruhe, Inst Genet & Toxikol, Postfach 3640, D-76021 Karlsruhe, Germany.	sleeman@itg.fzk.de	Sleeman, Jonathan P/H-2515-2013	Sleeman, Jonathan P/0000-0003-1718-7687				Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Ardekani Ali M, 2002, Expert Rev Mol Diagn, V2, P312, DOI 10.1586/14737159.2.4.312; Bacher S, 2002, BIOCHIMIE, V84, P1207; Bangma CH, 2000, MICROSC RES TECHNIQ, V51, P430, DOI 10.1002/1097-0029(20001201)51:5<430::AID-JEMT5>3.0.CO;2-1; Bast RC, 2001, J CLIN ONCOL, V19, P1865, DOI 10.1200/JCO.2001.19.6.1865; Berger KH, 1998, MOL CELL BIOL, V18, P4043, DOI 10.1128/MCB.18.7.4043; Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014; Bok RA, 2002, NAT REV CANCER, V2, P918, DOI 10.1038/nrc951; Coates PJ, 2001, EXP CELL RES, V265, P262, DOI 10.1006/excr.2001.5166; DEXTER DL, 1979, CANCER RES, V39, P1020; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Harlow E, 1998, ANTIBODIES LAB MANUA; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; LIU XT, 1994, BIOCHEM BIOPH RES CO, V201, P409, DOI 10.1006/bbrc.1994.1716; Maggino T, 2000, EUR J GYNAECOL ONCOL, V21, P64; Molina R, 1996, ANTICANCER RES, V16, P2295; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Niebuhr K, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P398; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Piper PW, 2002, MECH AGEING DEV, V123, P287, DOI 10.1016/S0047-6374(01)00326-8; Sleeman JP, 1999, ONCOGENE, V18, P4485, DOI 10.1038/sj.onc.1202808; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944	29	39	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7430	7435		10.1038/sj.onc.1207987	http://dx.doi.org/10.1038/sj.onc.1207987			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15286703				2022-12-17	WOS:000224021400013
J	Moore, R; Champeval, D; Denat, L; Tan, SS; Faure, F; Julien-Grille, S; Larue, L				Moore, R; Champeval, D; Denat, L; Tan, SS; Faure, F; Julien-Grille, S; Larue, L			Involvement of cadherins 7 and 20 in mouse embryogenesis and melanocyte transformation	ONCOGENE			English	Article						cell adhesion molecule; melanoma; orthologous gene; anterior regionalization; segmentation; modifier	NEURAL CREST; EXPRESSION; ADHESION; CANCER; INVASION; TUBE; IDENTIFICATION; MIGRATION; LINEAGE; CLONING	We have determined the expression profiles of cdh7, and the related cdh20 during development. Both transcripts are found in the adult brain, but only cadherin-20 mRNA was detected during embryogenesis. In mouse embryos, cadherin-20 is synthesized by the forebrain, anterior neural ridge, developing visual system, primitive external granular layer of the cerebellum and a subset of neural crest cells likely to develop into melanoblasts. We found that the other embryonic tissues in which cadherin-20 was synthesized depended on genetic background. Melanoma cell lines contained transcripts for cadherin-7 but not for cadherin-20. The majority of the malignant melanoma cell lines produced N-cadherin (N-Cad) and/or cadherin-7 whereas melanocyte cell lines did not. The converse was observed for E-cadherin (E-Cad). Our data suggest that during development cadherin-20 is a key player in compartmentalization of the neural tube and establishment of neural circuitry. Finally, during oncogenesis, cadherin-7, N-cad and E-cad could be used as an efficient marker set for melanoma.	Inst Curie, CNRS, UMR146, F-91405 Orsay, France; Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3052, Australia; Inst Curie, INSERM, U520, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Larue, L (corresponding author), Inst Curie, CNRS, UMR146, Bat 110, F-91405 Orsay, France.	lionel.larue@curie.fr	Larue, Lionel/F-7355-2013; faure, florence/P-9064-2016; Larue, Lionel/I-6532-2016	faure, florence/0000-0002-8359-4283; 				Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; ESPESETH A, 1995, MOL CELL NEUROSCI, V6, P199, DOI 10.1006/mcne.1995.1017; Faulkner-Jones BE, 1999, MOL CELL NEUROSCI, V14, P1, DOI 10.1006/mcne.1999.0764; Feltes CM, 2002, CANCER RES, V62, P6688; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Goding CR, 2000, GENE DEV, V14, P1712; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Haenig B, 2002, MECH DEVELOP, V117, P321, DOI 10.1016/S0925-4773(02)00196-X; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Inoue T, 1997, DEV BIOL, V183, P183, DOI 10.1006/dbio.1996.8501; Jouneau A, 2000, PIGM CELL RES, V13, P260, DOI 10.1034/j.1600-0749.2000.130408.x; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; Kawano R, 2002, J BIOL CHEM, V277, P47679, DOI 10.1074/jbc.M205328200; Kools P, 2000, GENOMICS, V68, P283, DOI 10.1006/geno.2000.6305; Le Douarin NM, 1999, NEURAL CREST; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; Locascio A, 2002, P NATL ACAD SCI USA, V99, P16841, DOI 10.1073/pnas.262525399; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; Nakagawa S, 1998, DEVELOPMENT, V125, P2963; Nishimura EK, 1999, DEV BIOL, V215, P155, DOI 10.1006/dbio.1999.9478; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; Pla P, 2001, J CELL PHYSIOL, V189, P121, DOI 10.1002/jcp.10008; Posthaus H, 2003, FEBS LETT, V536, P203, DOI 10.1016/S0014-5793(02)03897-8; REDIES C, 1995, EXP CELL RES, V220, P243, DOI 10.1006/excr.1995.1313; SHIMAMURA K, 1992, DEV BIOL, V152, P242, DOI 10.1016/0012-1606(92)90132-Z; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Stoykova A, 1997, DEVELOPMENT, V124, P3765; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Tomita K, 2000, CANCER RES, V60, P3650	33	39	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6726	6735		10.1038/sj.onc.1207675	http://dx.doi.org/10.1038/sj.onc.1207675			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273735				2022-12-17	WOS:000223653600004
J	Takaoka, M; Harada, H; Deramaudt, TB; Oyama, K; Andl, CD; Johnstone, CN; Rhoades, B; Enders, GH; Opitz, OG; Nakagawa, H				Takaoka, M; Harada, H; Deramaudt, TB; Oyama, K; Andl, CD; Johnstone, CN; Rhoades, B; Enders, GH; Opitz, OG; Nakagawa, H			Ha-Ras(G12V) induces senescence in primary and immortalized human esophageal keratinocytes with p53 dysfunction	ONCOGENE			English	Article						Ras; p53; telomerase; esophagus; keratinocytes; senescence	GROWTH-FACTOR RECEPTOR; HUMAN-DIPLOID FIBROBLASTS; TUMOR-SUPPRESSOR; ONCOGENIC RAS; PREMATURE SENESCENCE; P53-INDEPENDENT PATHWAY; CELL-PROLIFERATION; P16(INK4A); MOUSE; TRANSFORMATION	Oncogenic Ras induces premature senescence in primary cells. Such an oncogene-induced senescence involves activation of tumor suppressor genes that provide a checkpoint mechanism against malignant transformation. In mouse, the ARF-p53 pathway mediates Ha-Ras(G12V) - induced senescence, and p19(ARF-/-) and p53(-/-) cells undergo transformation upon Ras activation. In addition, mouse cells, unlike human cells, express constitutively active telomerase and have long telomeres. However, it is unclear how Ras activation affects human cells of epithelial origin with p53 mutation and/or telomerase activation. In order to address this question, Ha-Ras(G12V) was expressed ectopically in primary as well as hTERT-immortalized human esophageal keratinocytes stably expressing dominant- negative p53 mutants. In human esophageal keratinocytes, we found that Ha-Ras(G12V) induced senescence regardless of p53 status and telomerase activation. Ras activation resulted in changes of cellular morphology, activation of senescence-associated beta-galactosidase, and suppression of cell proliferation, all coupled with reduction in the hyperphosphorylated form of the retinoblastoma protein (pRb). Furthermore, Ha-Ras(G12V) upregulated p16(INK4a) and downregulated cyclin-dependent kinase Cdk4 in human esophageal keratinocytes. Thus, Ras-mediated senescence may involve distinct mechanisms between human and mouse cells. Inactivation of the pRb pathway may be necessary for Ras to overcome senescence and transform human esophageal epithelial cells.	Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Univ Freiburg, Dept Med, D-7800 Freiburg, Germany	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Freiburg	Nakagawa, H (corresponding author), Univ Penn, Div Gastroenterol, 638B CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	nakagawh@mail.med.upenn.edu			NCI NIH HHS [P01-CA098101] Funding Source: Medline; NIDDK NIH HHS [P30 DK50306, R21 DK64249] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA098101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK064249, P30DK050306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Concin N, 2003, INT J ONCOL, V22, P51; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; Deng QD, 2004, J BIOL CHEM, V279, P1050, DOI 10.1074/jbc.M308644200; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Drayton S, 2003, CANCER CELL, V4, P301, DOI 10.1016/S1535-6108(03)00242-3; Ferbeyre G, 2000, GENE DEV, V14, P2015; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Gadducci A, 2002, EUR J GYNAECOL ONCOL, V23, P390; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; Harada H, 2003, MOL CANCER RES, V1, P729; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; HOLLSTEIN MC, 1988, CANCER RES, V48, P5119; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; ITAKURA Y, 1994, CANCER, V74, P795, DOI 10.1002/1097-0142(19940801)74:3<795::AID-CNCR2820740303>3.0.CO;2-I; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakagawa H, 2003, GASTROINTESTINAL CAN, P241; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Opitz OG, 2002, J CLIN INVEST, V110, P761, DOI 10.1172/JCI200215324; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; Schreiber FS, 2004, GASTROENTEROLOGY, V127, P250, DOI 10.1053/j.gastro.2004.03.058; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sigal A, 2000, CANCER RES, V60, P6788; Suliman Y, 2001, CANCER RES, V61, P6467; Suzuki H, 2003, BIOCHEM BIOPH RES CO, V312, P1273, DOI 10.1016/j.bbrc.2003.11.071; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; WEINBERG RA, 1989, CANCER RES, V49, P3713; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WEINBERG WC, 1994, CANCER RES, V54, P5584; YANO H, 1991, CANCER, V67, P91, DOI 10.1002/1097-0142(19910101)67:1<91::AID-CNCR2820670118>3.0.CO;2-A; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	52	39	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6760	6768		10.1038/sj.onc.1207923	http://dx.doi.org/10.1038/sj.onc.1207923			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273725				2022-12-17	WOS:000223653600007
J	Winteringham, LN; Kobelke, S; Williams, JH; Ingley, E; Klinken, SP				Winteringham, LN; Kobelke, S; Williams, JH; Ingley, E; Klinken, SP			Myeloid Leukemia Factor 1 inhibits erythropoietin-induced differentiation, cell cycle exit and p27(Kip1) accumulation	ONCOGENE			English	Article						Mlf1; erythroleukemia; p27(Kip1)	TERMINAL ERYTHROID-DIFFERENTIATION; MYELODYSPLASTIC SYNDROME; DEPENDENT KINASES; PROGENITOR CELLS; UP-REGULATION; IN-VITRO; LINE M1; EXPRESSION; GENE; PROTEIN	Myeloid leukemia factor 1 (MLF1) is a novel oncoprotein involved in translocations associated with acute myeloid leukemia (AML), especially erythroleukemias. In this study, we demonstrate that ectopic expression of Mlf1 prevented J2E erythroleukemic cells from undergoing biological and morphological maturation in response to erythropoietin (Epo). We show that Mlf1 inhibited Epo-induced cell cycle exit and suppressed a rise in the cell cycle inhibitor p27(Kip1). Unlike differentiating J2E cells, Mlf1-expressing cells did not downregulate Cul1 and Skp2, components of the ubiquitin E3 ligase complex SCFSkp2 involved in the proteasomal degradation of p27(Kip1). In contrast, Mlf1 did not interfere with increases in p27(Kip1) and terminal differentiation initiated by thyroid hormone withdrawal from erythroid cells, or cytokine-stimulated maturation of myeloid cells. These data demonstrate that Mlf1 interferes with an Epo-responsive pathway involving p27(Kip1) accumulation, which inhibits cell cycle arrest essential for erythroid terminal differentiation.	Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6000, Australia; Univ Western Australia, Med Res Ctr, Perth, WA 6000, Australia	University of Western Australia; University of Western Australia	Klinken, SP (corresponding author), Western Australian Inst Med Res, Lab Canc Med, Level 6,MRF Bldg,50 Murray St, Perth, WA 6000, Australia.	pklinken@waimr.uwa.edu.au	Ingley, Evan/C-2401-2013; Winteringham, Louise/H-6105-2014	Ingley, Evan/0000-0002-8112-9134; Williams, James/0000-0002-0950-1958; Winteringham, Louise/0000-0002-8117-5069				Bouscary D, 2003, BLOOD, V101, P3436, DOI 10.1182/blood-2002-07-2332; BUSFIELD SJ, 1992, BLOOD, V80, P412; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; Dai MS, 2000, BLOOD, V96, P3985, DOI 10.1182/blood.V96.12.3985.h8003985_3985_3987; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Hitzler JK, 1999, AM J PATHOL, V155, P53, DOI 10.1016/S0002-9440(10)65098-5; Hochheimer A, 2002, NATURE, V420, P439, DOI 10.1038/nature01167; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; Ingley E, 2001, J BIOL CHEM, V276, P43428, DOI 10.1074/jbc.M106645200; Jacobs-Helber SM, 2002, J BIOL CHEM, V277, P4859, DOI 10.1074/jbc.M107243200; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Lim R, 2002, J BIOL CHEM, V277, P40997, DOI 10.1074/jbc.M206041200; Matsumoto N, 2000, LEUKEMIA, V14, P1757, DOI 10.1038/sj.leu.2401897; Matushansky I, 2000, BLOOD, V96, P2755, DOI 10.1182/blood.V96.8.2755.h8002755_2755_2764; Matushansky I, 2000, P NATL ACAD SCI USA, V97, P14317, DOI 10.1073/pnas.250488697; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Ohno K, 2000, GENE, V260, P133, DOI 10.1016/S0378-1119(00)00447-9; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; Rylski M, 2003, MOL CELL BIOL, V23, P5031, DOI 10.1128/MCB.23.14.5031-5042.2003; Tamir A, 2000, CELL GROWTH DIFFER, V11, P269; Tanaka H, 2000, BLOOD, V95, P1264, DOI 10.1182/blood.V95.4.1264.004k09_1264_1273; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Whyatt David J., 1997, Genes and Function, V1, P11; Williams JH, 1999, EMBO J, V18, P5559, DOI 10.1093/emboj/18.20.5559; Yamaguchi Y, 1998, BLOOD, V91, P450, DOI 10.1182/blood.V91.2.450.450_450_457; Yoneda-Kato N, 1999, BLOOD, V94, p484A; YonedaKato N, 1996, ONCOGENE, V12, P265	32	39	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5105	5109		10.1038/sj.onc.1207661	http://dx.doi.org/10.1038/sj.onc.1207661			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15122318				2022-12-17	WOS:000222237300019
J	Menendez, JA; Oza, BP; Atlas, E; Verma, VA; Mehmi, I; Lupu, R				Menendez, JA; Oza, BP; Atlas, E; Verma, VA; Mehmi, I; Lupu, R			Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells	ONCOGENE			English	Article						fatty acid synthase; estradiol; tamoxifen; cerulenin; C75; RNA interference; small interfering RNA; estrogen receptor; apoptosis; endometrial cancer	BREAST-CANCER; FOOD-INTAKE; PROGESTERONE-RECEPTOR; ANTIBIOTIC CERULENIN; RIBONUCLEIC-ACID; RNA INTERFERENCE; LIPID-METABOLISM; GENE-EXPRESSION; IN-VITRO; ACTIVATION	Overexpression of the lipogenic enzyme fatty acid synthase (FAS) is a common molecular feature in subsets of sex-steroid-related tumors including endometrium and breast carcinomas that are associated with poor prognosis. Pharmacological inhibition of tumor-associated FAS hyperactivity is under investigation as a chemotherapeutic target. We examined the effects of the mycotoxin cerulenin (a covalent FAS inactivator), and the novel small compound C75 ( a slow-binding FAS inhibitor) on estradiol (E-2)- and tamoxifen (TAM)-stimulated ER-driven molecular responses in Ishikawa cells, an in vitro model of well-differentiated human endometrial carcinoma. We evaluated the effects of FAS inhibition on E-2- and TAM-induced estrogen receptor ( ER) transcriptional activity by using transient cotransfection assays with an estrogen-response element reporter construct (ERE-Luciferase). Antiestrogenic effects of cerulenin and C75 were observed by dose-dependent inhibition of E-2- stimulated ERE-dependent transcription, whereas FAS inhibitors did not significantly increase the levels of ERE transcriptional activity in the absence of E-2. Moreover, pharmacological blockade of FAS activity completely abolished TAM-stimulated ERE activity. To address the reliability of transient transfection assays, the effects of FAS inhibitors on E-2- inducible gene products were evaluated. FAS blockade induced a dose-dependent decrease in E-2- inducible alkaline phosphatase activity. E-2- stimulated accumulation of progesterone receptor (PR) and HER-2/neu oncogene was abolished in the presence of FAS blockers. FAS inhibition also resulted in a marked downregulation of E-2-stimulated ERalpha expression, and noticeably impaired E-2- induced ERalpha nuclear accumulation. A dose-dependent decrease in cell proliferation and cell viability was observed after FAS blockade. A Cell Death ELISA, detecting DNA fragmentation, demonstrated that FAS inhibitors stimulated apoptosis of Ishikawa cells. The analysis of critical E-2- and TAM-related cell cycle proteins revealed an increase of both the expression and the nuclear accumulation of cyclin-dependent kinase inhibitors p21(WAF1/CIP1) and p27(Kip1) following FAS inhibition. To rule out non-FAS cerulenin- and C75-related effects, we finally monitored ER signaling after silencing of FAS gene expression using the highly sequence-specific mechanism of RNA interference (RNAi). The concentrations of E-2 and TAM inducing half-maximal ERE activity (EC50) dramatically increased (4100 times) in FAS RNAi-transfected Ishikawa cells. Moreover, depletion of FAS by RNAi also caused loss of ERalpha expression, downregulation of PR, and accumulation of p21(WAF1/CIP1) and p27(Kip1) in E-2- stimulated Ishikawa cells. If chemically stable FAS inhibitors or cell-selective vector systems able to deliver RNAi targeting FAS gene demonstrate systemic anticancer effects in vivo, our results render FAS as a novel target for the prevention and treatment of endometrial carcinoma.	Evanston NW Healthcare Res Inst, Dept Med, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Lupu, R (corresponding author), Evanston NW Healthcare Res Inst, Dept Med, 1001 Univ Pl, Evanston, IL 60201 USA.	r-lupu@northwestern.edu	MENENDEZ, JAVIER A/C-6148-2016	MENENDEZ, JAVIER A/0000-0001-8733-4561; Verma, Vishal/0000-0001-7600-4372				ALBERT JL, 1990, CANCER RES, V50, P3306; Alo PL, 1999, TUMORI, V85, P35, DOI 10.1177/030089169908500108; Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Atanaskova N, 2002, ONCOGENE, V21, P4000, DOI 10.1038/sj.onc.1205506; Bamberger AM, 1999, VIRCHOWS ARCH, V434, P423, DOI 10.1007/s004280050361; Barsalou A, 1998, J BIOL CHEM, V273, P17138, DOI 10.1074/jbc.273.27.17138; Beato M, 1996, STEROIDS, V61, P240, DOI 10.1016/0039-128X(96)00030-X; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; CHALBOS D, 1992, J STEROID BIOCHEM, V43, P223, DOI 10.1016/0960-0760(92)90211-Z; CHRISTIE WW, 1981, BIOCHIM BIOPHYS ACTA, V666, P284, DOI 10.1016/0005-2760(81)90118-1; Colacurci N, 2000, PANMINERVA MED, V42, P45; Cosman F, 1999, ENDOCR REV, V20, P418, DOI 10.1210/er.20.3.418; De Schrijver E, 2003, CANCER RES, V63, P3799; Dils R, 1975, Methods Enzymol, V35, P74, DOI 10.1016/0076-6879(75)35140-9; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ESCOT C, 1990, J CLIN ENDOCR METAB, V70, P1319, DOI 10.1210/jcem-70-5-1319; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Favoni RE, 1998, TRENDS PHARMACOL SCI, V19, P406, DOI 10.1016/S0165-6147(98)01252-8; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Gallo MA, 1997, SEMIN ONCOL, V24, pS71; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Goldstein SR, 2000, EUR J CANCER, V36, pS54; Harborth J, 2001, J CELL SCI, V114, P4557; Hata H, 1998, ONCOLOGY-BASEL, V55, P35, DOI 10.1159/000055257; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; HOLINKA CF, 1986, J STEROID BIOCHEM, V25, P781, DOI 10.1016/0022-4731(86)90308-0; JAMIL A, 1991, J MOL ENDOCRINOL, V6, P215, DOI 10.1677/jme.0.0060215; JENSEN V, 1993, BREAST CANC RES TREA, V27, P1; JOYEUX C, 1989, MOL ENDOCRINOL, V3, P681, DOI 10.1210/mend-3-4-681; KALKHOVEN E, 1994, MOL CELL ENDOCRINOL, V102, P45, DOI 10.1016/0303-7207(94)90096-5; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kawata M, 2001, ARCH HISTOL CYTOL, V64, P353, DOI 10.1679/aohc.64.353; Kim EK, 2002, AM J PHYSIOL-ENDOC M, V283, pE867, DOI 10.1152/ajpendo.00178.2002; KRISHNA PLB, 2001, CANCER RES, V61, P6137; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Kumar MV, 2002, P NATL ACAD SCI USA, V99, P1921, DOI 10.1073/pnas.042683699; Kusakabe T, 2000, J HISTOCHEM CYTOCHEM, V48, P613, DOI 10.1177/002215540004800505; Lasset C, 2001, LANCET, V357, P66, DOI 10.1016/S0140-6736(05)71563-4; Lessey BA, 1996, J STEROID BIOCHEM, V59, P31, DOI 10.1016/S0960-0760(96)00103-3; Li JN, 2001, CANCER RES, V61, P1493; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; Lupu R, 2003, INT J ONCOL, V23, P1407; Markogiannakis E, 1997, LIFE SCI, V61, P1083, DOI 10.1016/S0024-3205(97)00617-6; Menendez JA, 2004, INT J ONCOL, V24, P591; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; MOELLING K, 1990, FEBS LETT, V261, P373, DOI 10.1016/0014-5793(90)80595-A; Nishida M, 1996, Hum Cell, V9, P109; Nishida Masato, 2002, Hum Cell, V15, P104, DOI 10.1111/j.1749-0774.2002.tb00105.x; OMURA S, 1976, BACTERIOL REV, V40, P681, DOI 10.1128/MMBR.40.3.681-697.1976; PEREZ L, 1991, FEBS LETT, V280, P129, DOI 10.1016/0014-5793(91)80220-W; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Persson I, 2000, J STEROID BIOCHEM, V74, P357, DOI 10.1016/S0960-0760(00)00113-8; Pisha Emily, 1997, Methods in Cell Science, V19, P37, DOI 10.1023/A:1009746605060; Pizer ES, 1997, INT J GYNECOL PATHOL, V16, P45, DOI 10.1097/00004347-199701000-00008; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 1998, CANCER-AM CANCER SOC, V83, P528, DOI 10.1002/(SICI)1097-0142(19980801)83:3<528::AID-CNCR22>3.0.CO;2-X; Pizer ES, 2000, CANCER RES, V60, P213; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; RONCARI DAK, 1974, CAN J BIOCHEM CELL B, V52, P221, DOI 10.1139/o74-035; Sakamoto T, 2002, MOL CELL ENDOCRINOL, V192, P93, DOI 10.1016/S0303-7207(02)00086-2; Schwartz LB, 1997, AM J OBSTET GYNECOL, V176, P129, DOI 10.1016/S0002-9378(97)80025-7; Shimokawa T, 2002, P NATL ACAD SCI USA, V99, P66, DOI 10.1073/pnas.012606199; Shiozawa T, 1998, MOL HUM REPROD, V4, P899, DOI 10.1093/molehr/4.9.899; Shurbaji MS, 1996, HUM PATHOL, V27, P917, DOI 10.1016/S0046-8177(96)90218-X; Simard J, 1997, CANCER RES, V57, P3494; SIMON SM, 1992, J BIOL CHEM, V267, P3922; Smith SMR, 2000, AM J SURG, V180, P249, DOI 10.1016/S0002-9610(00)00453-0; Swinnen JV, 2002, INT J CANCER, V98, P19, DOI 10.1002/ijc.10127; Swinnen JV, 1997, CANCER RES, V57, P1086; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WEISS L, 1986, BIOL CHEM H-S, V367, P905, DOI 10.1515/bchm3.1986.367.2.905; WITKOWSKI A, 1991, EUR J BIOCHEM, V198, P571, DOI 10.1111/j.1432-1033.1991.tb16052.x; Wortman MD, 2003, NAT MED, V9, P483, DOI 10.1038/nm0503-483; Ye QN, 2000, BBA-GENE STRUCT EXPR, V1493, P373, DOI 10.1016/S0167-4781(00)00202-5; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	89	39	40	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4945	4958		10.1038/sj.onc.1207476	http://dx.doi.org/10.1038/sj.onc.1207476			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15094777				2022-12-17	WOS:000222104200016
J	Manenti, G; Galbiati, F; Gianni-Barrera, R; Pettinicchio, A; Acevedo, A; Dragani, TA				Manenti, G; Galbiati, F; Gianni-Barrera, R; Pettinicchio, A; Acevedo, A; Dragani, TA			Haplotype sharing suggests that a genomic segment containing six genes accounts for the pulmonary adenoma susceptibility 1 (Pas1) locus activity in mice	ONCOGENE			English	Article						genetic susceptibility; inbred strains; lung tumors; Kras2	QUANTITATIVE TRAIT LOCUS; LUNG-TUMOR SUSCEPTIBILITY; BUTYLATED HYDROXYTOLUENE; CANCER; MOUSE; PROTEIN; RISK; CARCINOGENESIS; TUMORIGENESIS; POLYMORPHISM	The pulmonary adenoma susceptibility 1 (Pas1) locus affects inherited predisposition and resistance to chemically induced lung tumorigenesis in mice. The A/J and C57BL/6J mouse strains carry the susceptibility and resistance allele, respectively. We identified and geno-typed 65 polymorphisms in the Pas1 locus region in 29 mouse inbred strains, and delimited the Pas1 locus to a minimal region of 468 kb containing six genes. That region defined a core Pas1 haplotype with 42 tightly linked markers, including intragenic polymorphisms in five genes (Bcat1, Lrmp, Las1, Ghiso, and Kras2) and amino-acid changes in three genes ( Lrmp, Las1, Lmna-rs1). In (A/J x C57BL/6J) F1 mouse lung tumors, the Lmna-rs1 gene was completely downregulated, whereas allele-specific downregulation of the C57BL/6J-derived allele was observed at the Las1 gene, suggesting the potential role of these genes in tumor suppression. These results indicate a complex multigenic nature of the Pas1 locus, and point to a functional role for both intronic and exonic polymorphisms of the Pas1 haplotype in lung tumor susceptibility.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ La Laguna, Fac Med, Tenerife, Spain	Fondazione IRCCS Istituto Nazionale Tumori Milan; Universidad de la Laguna	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	dragani@istitutotumori.mi.it	Dragani, Tommaso A./K-4493-2016; Arozena, Abraham Acevedo/L-6584-2018; Gianni-Barrera, Roberto/ACU-4280-2022; Manenti, Giacomo/J-3339-2017	Dragani, Tommaso A./0000-0001-5915-4598; Arozena, Abraham Acevedo/0000-0001-6127-7116; Gianni-Barrera, Roberto/0000-0001-6303-4513; Manenti, Giacomo/0000-0002-4887-4482				AKAMATSU Y, 1975, J NATL CANCER I, V55, P893, DOI 10.1093/jnci/55.4.893; Askling J, 1999, AM J RESP CRIT CARE, V160, P1668, DOI 10.1164/ajrccm.160.5.9904045; Bauer AK, 2001, EXP LUNG RES, V27, P197, DOI 10.1080/019021401300053948; BEHRENS TW, 1994, J IMMUNOL, V153, P682; Brownson RC, 2000, CANCER CAUSE CONTROL, V11, P853, DOI 10.1023/A:1008999202040; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; Darvasi A, 2002, TRENDS GENET, V18, P489, DOI 10.1016/S0168-9525(02)02767-1; De Luca M, 2003, NAT GENET, V34, P429, DOI 10.1038/ng1218; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; Dragani TA, 2003, CANCER RES, V63, P3011; Eden A, 1999, FEBS LETT, V457, P255, DOI 10.1016/S0014-5793(99)01054-6; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kawakami K, 2001, CLIN CANCER RES, V7, P4096; Liang TB, 2003, P NATL ACAD SCI USA, V100, P4690, DOI 10.1073/pnas.0737182100; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; MALKINSON AM, 1984, J NATL CANCER I, V73, P925; Manenti G, 1999, GENOME RES, V9, P639; Manenti G, 2002, INT J CANCER, V99, P555, DOI 10.1002/ijc.10386; Maria DA, 2003, ONCOGENE, V22, P426, DOI 10.1038/sj.onc.1206157; Mayne ST, 1999, AM J EPIDEMIOL, V149, P13; RE FC, 1992, MOL CARCINOGEN, V5, P155, DOI 10.1002/mc.2940050211; Shaughnessy JD, 1999, ONCOGENE, V18, P2069; Steinmetz LM, 2002, NATURE, V416, P326, DOI 10.1038/416326a; TRAININ N, 1967, INT J CANCER, V2, P326, DOI 10.1002/ijc.2910020407; Wade CM, 2002, NATURE, V420, P574, DOI 10.1038/nature01252; Wang M, 2003, CANCER RES, V63, P3317; Webb KE, 2003, EXP HEMATOL, V31, P488, DOI 10.1016/S0301-472X(03)00065-1; Wiltshire T, 2003, P NATL ACAD SCI USA, V100, P3380, DOI 10.1073/pnas.0130101100; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721; Zhang ZQ, 2003, P NATL ACAD SCI USA, V100, P12642, DOI 10.1073/pnas.2133947100	35	39	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4495	4504		10.1038/sj.onc.1207584	http://dx.doi.org/10.1038/sj.onc.1207584			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064703				2022-12-17	WOS:000221661300015
J	Noble, JR; Zhong, ZH; Neumann, AA; Melki, JR; Clark, SJ; Reddel, RR				Noble, JR; Zhong, ZH; Neumann, AA; Melki, JR; Clark, SJ; Reddel, RR			Alterations in the p16(INK4a) and p53 tumor suppressor genes of hTERT-immortalized human fibroblasts	ONCOGENE			English	Article						telomerase; hTERT; immortalization p16INK4a; CDKN2A; TP53	MAMMARY EPITHELIAL-CELLS; LIFE-SPAN; TELOMERASE ACTIVITY; ASSOCIATION; EXPRESSION; RECONSTITUTION; INACTIVATION; QUANTITATION; METHYLATION; ELONGATION	Exogenous expression of the catalytic subunit of telomerase, hTERT, in a normal human foreskin fibroblast cell strain resulted in telomerase activity and an extended proliferative lifespan prior to a period of crisis. Three immortalized cell lines with stably maintained telomere lengths were established from cells that escaped crisis. Each of these cultures underwent a significant downregulation of p16(INK4a) expression due to gene deletion events. One cell line also acquired mutations in both alleles of the p53 tumor suppressor gene. Downregulation of p16(INK4a) and loss of wild-type p53 expression occurred after escape from crisis, so these mutations are most likely not required for immortalization of these cells but rather were selected for during continuous growth in vitro. These findings emphasize the need for caution in the use of hTERT-immortalized cells in studies of normal cell biology or in tissue engineering and the need to monitor for genetic instability and the accumulation of mutations in both the p16(INK4a)/pRb and p53 pathways.	Childrens Med Res Inst, Sydney, NSW 2145, Australia; Univ Sydney, Sydney Canc Ctr, Sydney, NSW 2006, Australia	Children's Medical Research Institute - Australia; University of Sydney; University of Sydney	Reddel, RR (corresponding author), Childrens Med Res Inst, 214 Hawkesbury Rd, Sydney, NSW 2145, Australia.	rreddel@cmri.usyd.edu.au	Reddel, Roger R/A-6635-2014; Clark, Susan J/U-7365-2019; Neumann, Axel/D-3319-2012; Clark, Susan J/B-2272-2008	Reddel, Roger R/0000-0002-6302-6107; Clark, Susan J/0000-0001-5925-5030; Clark, Susan J/0000-0001-5925-5030				Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; Colgin LM, 2000, NEOPLASIA, V2, P426, DOI 10.1038/sj.neo.7900112; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Franco S, 2001, EXP CELL RES, V268, P14, DOI 10.1006/excr.2001.5264; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; Harland M, 2000, GENE CHROMOSOME CANC, V28, P45, DOI 10.1002/(SICI)1098-2264(200005)28:1<45::AID-GCC6>3.3.CO;2-6; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Holland EA, 1995, ONCOGENE, V11, P2289; Huschtscha LI, 1998, CANCER RES, V58, P3508; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kaul SC, 2003, EXP CELL RES, V286, P96, DOI 10.1016/S0014-4827(03)00101-0; Kim H, 2002, BIOCHEM J, V365, P765, DOI 10.1042/BJ20011848; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MacKenzie KL, 2000, EXP CELL RES, V259, P336, DOI 10.1006/excr.2000.4982; McGregor F, 2002, CANCER RES, V62, P4757; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Noble JR, 1996, ONCOGENE, V13, P1259; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Paul CL, 1996, BIOTECHNIQUES, V21, P126; Perrem K, 1999, ONCOGENE, V18, P3383, DOI 10.1038/sj.onc.1202752; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROONEY D, 1992, HUMAN CYTOGENETICS P, V1; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Toouli CD, 2002, ONCOGENE, V21, P128, DOI 10.1038/sj.onc.1205014; Tsutsui T, 2002, CARCINOGENESIS, V23, P2111, DOI 10.1093/carcin/23.12.2111; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682	44	39	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3116	3121		10.1038/sj.onc.1207440	http://dx.doi.org/10.1038/sj.onc.1207440			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14743210				2022-12-17	WOS:000220845200016
J	Bar, J; Cohen-Noyman, E; Geiger, B; Oren, M				Bar, J; Cohen-Noyman, E; Geiger, B; Oren, M			Attenuation of the p53 response to DNA damage by high cell density	ONCOGENE			English	Article						p53; cell density; microenvironment; DNA damage; apoptosis	TUMOR-SUPPRESSOR; BETA-CATENIN; RETINOBLASTOMA PROTEIN; SIGNAL-TRANSDUCTION; APOPTOTIC RESPONSE; CONTACT INHIBITION; GROWTH SUPPRESSION; E-CADHERIN; S-PHASE; CYCLE	The p53 tumor suppressor is critical for preventing cancer progression. Numerous observations suggest that p53 function can be modulated by the cells' microenvironment. We addressed specifically the impact of cell crowding on the induction of p53 by DNA damage. We report that cell crowding attenuates markedly p53 upregulation, transcriptional activation and subsequent p53- dependent apoptosis following exposure to genotoxic stress. The p53 protein remains short- lived in confluent cultures regardless of the extent of DNA damage, even though it undergoes efficient phosphorylation on the mouse equivalent of human p53 serine 15. This inhibitory effect of cell crowding is not a secondary consequence of density-dependent cell cycle arrest ( contact inhibition). Microscopic examination indicates that dense cultures display prominent cadherin- mediated cell - cell junctions, and only poor cell - matrix focal adhesions, whereas sparse cells possess conspicuous matrix adhesions and essentially no cell - cell contacts. High- density cell culture might recapitulate the microenvironment of cells in a living organism, where the response of p53 to DNA damage is reported to be low in some organs and ages. The impact of cell density on p53 activation may have important bearings on the involvement of p53 in tumor suppression and the cellular response to anticancer therapy.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, POB26, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il	Bar, Jair/AAS-5743-2021	Bar, Jair/0000-0002-1224-3646; Oren, Moshe/0000-0003-4311-7172	NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bachelder RE, 1999, J BIOL CHEM, V274, P20733, DOI 10.1074/jbc.274.29.20733; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Danielsen T, 1998, BRIT J CANCER, V78, P1547, DOI 10.1038/bjc.1998.722; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumaz N, 2001, BIOCHEM J, V359, P459, DOI 10.1042/0264-6021:3590459; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; HAUPT Y, 1995, ONCOGENE, V10, P1563; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Hussain SP, 2001, LUNG CANCER, V34, pS7, DOI 10.1016/S0169-5002(01)00339-7; Ilic D, 1998, J CELL BIOL, V143, P547; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Komarova EA, 1997, CANCER RES, V57, P5217; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; Levenberg S, 1998, J CELL SCI, V111, P347; Lewis JM, 2002, P NATL ACAD SCI USA, V99, P3627, DOI 10.1073/pnas.062698499; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; MacCallum DE, 1996, ONCOGENE, V13, P2575; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McKay BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/sj.onc.1204901; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nigro JM, 1997, CANCER RES, V57, P3635; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; RITTLING SR, 1992, ONCOGENE, V7, P935; Rubin H, 2001, CANCER RES, V61, P799; Sadot E, 2002, J CELL SCI, V115, P2771; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Seluanov A, 2001, MOL CELL BIOL, V21, P1552, DOI 10.1128/MCB.21.5.1552-1564.2001; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Sheikh MS, 1999, ONCOGENE, V18, P4153, DOI 10.1038/sj.onc.1202763; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; von Schlippe M, 2000, J CELL SCI, V113, P425; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; Wilson JW, 1998, AM J PATHOL, V153, P899, DOI 10.1016/S0002-9440(10)65631-3; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	75	39	40	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2128	2137		10.1038/sj.onc.1207325	http://dx.doi.org/10.1038/sj.onc.1207325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14755247	Bronze			2022-12-17	WOS:000220280900002
J	Pupa, SM; Argraves, SW; Forti, S; Casalini, P; Berno, V; Agresti, R; Aiello, P; Invernizzi, A; Baldassari, P; Otwal, W; Mortarini, R; Anichini, A; Menard, S				Pupa, SM; Argraves, SW; Forti, S; Casalini, P; Berno, V; Agresti, R; Aiello, P; Invernizzi, A; Baldassari, P; Otwal, W; Mortarini, R; Anichini, A; Menard, S			Immunological and pathobiological roles of fibulin-1 in breast cancer	ONCOGENE			English	Article						B and T lymphocytes; tumour antigen; SEREX; fibulin-1; breast cancer	EXTRACELLULAR-MATRIX; IMMUNE-RESPONSES; HUMAN OVARIAN; ELEVATED EXPRESSION; DENDRITIC CELLS; CARCINOMA; ANTIGEN; PROTEIN; IDENTIFICATION; ANTIBODY	Fibulin- 1 ( Fbln- 1) is an immunogenic breast cancer-related glycoprotein identified by serological analysis of cDNA expression library ( SEREX) strategy. Here, we show that dendritic cells from two breast cancer patients elicited a CD4(+)- mediated T- cell response to Fbln- 1 presentation. In both patients, an antibody response to Fbln- 1 was also found. By contrast, a Fbln- 1- seronegative patient and a weakly seropositive patient demonstrated no such T- cell response. Analysis of human breast cancers for Fbln- 1 RNA and protein expression revealed the presence of Fbln- 1C and - 1D variants. Fbln- 1 was detected in the cytoplasm and at the cell surface of different human breast carcinoma cell lines. Immunohistochemical analysis of 528 archival primary breast carcinomas showed the expression of Fbln- 1 in 35% of the cases. When the immunohistochemical findings were compared against pathobiological information associated with each specimen, an inverse relationship between Fbln- 1 and cathepsin D expression was observed ( P = 0.04). Furthermore, even though long- term survival was similar between Fbln- 1-positive and - negative cases, the survival of Fbln- 1- positive cases improved when a lymphoid infiltrate was present at the tumour site. Taken together, our findings of an Fbln-1-specific immunity and the improved survival associated with Fbln- 1 expression in the presence of lymphoid infiltration point to a role of Fbln- 1 in tumour immunosurveillance.	Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, Mol Targeting Unit, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Gen Oncol Breast Unit B, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, Human Tumor Immunobiol Unit, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Menard, S (corresponding author), Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, Mol Targeting Unit, Via Venezian 1, I-20133 Milan, Italy.	sylvie.menard@istitutotumori.mi.it	Berno, Valeria/AAN-3997-2020; menard, sylvie mm/C-7940-2011; Agresti, Roberto/AAB-6062-2019; Anichini, Andrea/K-1434-2016; Mortarini, Roberta/C-9483-2017; Pupa, Serenella/K-6388-2016	Berno, Valeria/0000-0001-5848-494X; Agresti, Roberto/0000-0003-4700-1951; Anichini, Andrea/0000-0001-5096-5538; Mortarini, Roberta/0000-0001-7732-0561; Pupa, Serenella/0000-0002-4592-6830				ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; Clinton GM, 1996, P NATL ACAD SCI USA, V93, P316, DOI 10.1073/pnas.93.1.316; Du MJ, 2002, BIOCHEM BIOPH RES CO, V296, P962, DOI 10.1016/S0006-291X(02)02041-7; Forti S, 2002, BREAST CANCER RES TR, V73, P245, DOI 10.1023/A:1015854415746; Greene LM, 2003, BRIT J CANCER, V88, P871, DOI 10.1038/sj.bjc.6600802; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; Jager E, 1998, J EXP MED, V187, P265, DOI 10.1084/jem.187.2.265; Jager E, 2000, P NATL ACAD SCI USA, V97, P4760, DOI 10.1073/pnas.97.9.4760; Liu YJ, 2001, NAT IMMUNOL, V2, P585, DOI 10.1038/89726; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; MARTIGNONE S, 1992, CLIN EXP METASTAS, V10, P379, DOI 10.1007/BF00133466; Menard S, 1999, BREAST CANCER RES TR, V55, P169; Moll F, 2002, ONCOGENE, V21, P1097, DOI 10.1038/sj.onc.1205171; Nakatsura T, 2002, EUR J IMMUNOL, V32, P826, DOI 10.1002/1521-4141(200203)32:3<826::AID-IMMU826>3.0.CO;2-Y; Niu Y, 2002, INT J CANCER, V98, P754, DOI 10.1002/ijc.10136; Old LJ, 1998, J EXP MED, V187, P1163, DOI 10.1084/jem.187.8.1163; Parmiani G, 2002, JNCI-J NATL CANCER I, V94, P805, DOI 10.1093/jnci/94.11.805; PEREIRA H, 1995, HISTOPATHOLOGY, V27, P219, DOI 10.1111/j.1365-2559.1995.tb00213.x; Pupa SM, 2003, J CELL BIOCHEM, V89, P647, DOI 10.1002/jcb.10563; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Pupa SM, 2002, ANN ONCOL, V13, P483, DOI 10.1093/annonc/mdf111; Qing J, 1997, ONCOGENE, V15, P2159, DOI 10.1038/sj.onc.1201385; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Roger P, 1998, AM J PATHOL, V153, P1579, DOI 10.1016/S0002-9440(10)65746-X; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Sahin U, 1997, CURR OPIN IMMUNOL, V9, P709, DOI 10.1016/S0952-7915(97)80053-2; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Struss AK, 2001, ONCOGENE, V20, P4107, DOI 10.1038/sj.onc.1204552; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4; Twal WO, 2001, J CELL SCI, V114, P4587; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703	33	39	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2153	2160		10.1038/sj.onc.1207323	http://dx.doi.org/10.1038/sj.onc.1207323			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14691454				2022-12-17	WOS:000220280900005
J	Wang, W; Ungermannova, D; Jin, JP; Harper, JW; Liu, XD				Wang, W; Ungermannova, D; Jin, JP; Harper, JW; Liu, XD			Negative regulation of SCFSkp2 ubiquitin ligase by TGF-beta signaling	ONCOGENE			English	Article						Skp2; p27(Kip1); TGF-beta; protein degradation; ubiquitin; Cdc34 and Cks1	ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE ARREST; BOX PROTEIN SKP2; DEPENDENT KINASE; GROWTH-INHIBITION; MAMMALIAN-CELLS; CDK INHIBITORS; HUMAN CUL-1; S-PHASE; DEGRADATION	TGF-beta is a multifunctional growth factor whose best-known function is to inhibit cell growth and suppress tumor formation. TGF-beta causes cells to accumulate in mid-to-late G1 phase by blocking the transition from G1 to S. It has been shown that TGF-beta inhibits Cdk2-cyclin E kinase activity by promoting the binding of cell cycle inhibitor p27(Kip1) to the kinase complexes. Here, we show that TGF-beta treatment leads to stabilization of p27(Kip1) during G1 to S transition. We found that TGF-beta negatively regulates components of the SCF complex, which degrades the p27(Kip1) during the G1 to S transition, through two distinct mechanisms. Using a pulse-chase analysis, we demonstrated that the stability of Skp2 decreases in the presence of TGF-beta. Destabilization of Skp2 by ubiquitin-mediated proteolysis was also demonstrated that in an in vitro degradation system, using cell extracts prepared from TGF-beta-treated cultured cells. In addition, TGF-beta treatment decreases the levels of Cks1 mRNA. The deficiency of Cks1 in TGF-beta-treated cells likely contributes to the stabilization of p27(Kip1) and destabilization of Skp2, because in the absence of Cks1, SCFSkp2 cannot ubiquitinate p27(Kip1); instead, self-ubiquitination of Skp2 occurs. Thus, stabilization of the cell cycle inhibitor p27(Kip1) and cell growth inhibition in response to TGF-beta occur in part through limiting the threshold of the SCFSkp2 ubiquitin ligase by transcriptional and post-transcriptional mechanisms.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA	University of Colorado System; University of Colorado Boulder; Baylor College of Medicine	Liu, XD (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	xuedong.liu@colorado.edu	Jin, Jianping/K-5002-2018	Jin, Jianping/0000-0003-4175-9104; LIU, XUEDONG/0000-0001-7209-4964; Harper, Jeffrey/0000-0002-6944-7236	NCI NIH HHS [CA95527-01, R01 CA095527] Funding Source: Medline; NIA NIH HHS [R01 AG011085] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Iavarone A, 1997, NATURE, V387, P417; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Liu XD, 2000, ONCOGENE, V19, P5926, DOI 10.1038/sj.onc.1203991; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; SIMON KE, 1995, CELL GROWTH DIFFER, V6, P1261; Sitry D, 2002, J BIOL CHEM, V277, P42233, DOI 10.1074/jbc.M205254200; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang W, 2003, J BIOL CHEM, V278, P32390, DOI 10.1074/jbc.M305241200; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	59	39	40	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1064	1075		10.1038/sj.onc.1207204	http://dx.doi.org/10.1038/sj.onc.1207204			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14676846				2022-12-17	WOS:000188749900005
J	Mao, JH; Wu, D; Perez-Losada, J; Nagase, H; DelRosario, R; Balmain, A				Mao, JH; Wu, D; Perez-Losada, J; Nagase, H; DelRosario, R; Balmain, A			Genetic interactions between Pten and p53 in radiation-induced lymphoma development	ONCOGENE			English	Article						Pten; p53; loss of heterozygosity; intragenic deletion; radiation induced lymphoma	TUMOR-SUPPRESSOR GENE; MUTATIONS; TRANSCRIPTION; INACTIVATION; IRRADIATION; LOCUS; MDM2; FORM	Genetic analysis of radiation-induced lymphomas from p53 heterozygous or null mice has revealed a high frequency of genetic alterations on mouse chromosome 19. Detailed microsatellite analysis of chromosome 19 deletions identified three independent regions of loss of heterozygosity, one of which was refined to a 0.3 Mb interval that contained the Pten tumor suppressor gene. More than 50% of radiation-induced tumors from p53+/- and p53-/- mice showed heterozygous loss of one Pten allele. In most cases, the remaining allele was wild type and expressed, suggesting that Pten is a haploinsufficient tumor suppressor gene for mouse lymphoma development. This conclusion was supported by the detection of specific intragenic deletions in Pten in tumors that retained one wild-type allele. Pten heterozygous mice were just as sensitive as p53+/- mice to induction of tumors by radiation, and surprisingly, the double p53+/-Pten+/- mice were equivalent to p53 null mice in radiation sensitivity. Despite the fact that Pten appears to be a haploinsufficient tumor suppressor gene, most tumors from both the single and double heterozygous mice had lost the remaining wild-type allele. The mechanism of loss in all cases involved the complete chromosome, suggesting that it is driven by other tumor suppressor genes on this chromosome. This sensitized screen therefore identified complementary roles for Pten and p53 pathways in suppression of tumor development induced by radiation exposure.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	University of California System; University of California San Francisco; Roswell Park Cancer Institute	Balmain, A (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94143 USA.	abalmain@cc.ucsf.edu	Mao, Jian-Hua/EIZ-8595-2022; Pérez-Losada, Jesús/A-5883-2019	Mao, Jian-Hua/0000-0001-9320-6021; Pérez-Losada, Jesús/0000-0003-2400-624X	NATIONAL CANCER INSTITUTE [U01CA084244] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA84244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Butler MP, 1999, GENE CHROMOSOME CANC, V24, P322, DOI 10.1002/(SICI)1098-2264(199904)24:4<322::AID-GCC5>3.0.CO;2-9; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Frisk T, 2002, GENE CHROMOSOME CANC, V35, P74, DOI 10.1002/gcc.10098; Gronbaek K, 1998, BLOOD, V91, P4388; Herranz M, 2000, LEUKEMIA, V14, P1325, DOI 10.1038/sj.leu.2401813; Izumoto S, 2001, J NEURO-ONCOL, V53, P21, DOI 10.1023/A:1011839920176; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; Santos J, 2002, ONCOGENE, V21, P6680, DOI 10.1038/sj.onc.1205846; Santos J, 2001, ONCOGENE, V20, P2186, DOI 10.1038/sj.onc.1204297; Shin KH, 2002, INT J ONCOL, V21, P997; Sjoling A, 2003, GENE CHROMOSOME CANC, V36, P70, DOI 10.1002/gcc.10143; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774	32	39	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8379	8385		10.1038/sj.onc.1207083	http://dx.doi.org/10.1038/sj.onc.1207083			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627978				2022-12-17	WOS:000186650300001
J	Altomonte, M; Fonsatti, E; Visintin, A; Maio, M				Altomonte, M; Fonsatti, E; Visintin, A; Maio, M			Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?	ONCOGENE			English	Review						HLA class II; MHC class II; signaling; immunotherapy; melanoma; monoclonal antibodies	MHC CLASS-II; SQUAMOUS-CELL CARCINOMA; HUMAN-LEUKOCYTE ANTIGEN; TUMOR-NECROSIS-FACTOR; BARE LYMPHOCYTE SYNDROME; DR EXPRESSION; PROGNOSTIC-SIGNIFICANCE; SIGNAL-TRANSDUCTION; BREAST-CARCINOMA; IFN-GAMMA	Intracellular signals, delivered in professional antigen-presenting cells following the engagement of major histocompatibility complex(MHC) class II molecules, activate a variety of cellular functions that also contribute to efficient antigen presentation. As far as human malignancies, the signaling ability of human leukocyte antigens (HLA) class II molecules is a rather well-characterized event in hematologic tumors; in contrast, very limited evidences are available in solid neoplasias of different histotypes that may constitutively express HLA class II antigens. Among solid malignancies, a significant proportion of human cutaneous melanomas have been shown to express HLA class II molecules, and cutaneous melanoma undoubtedly represents a 'model disease' to investigate tumor immunobiology, to unveil the molecular basis underlying the interactions between neoplastic cells and host's immune system, and ultimately to set up new bio-immunotherapeutic approaches. Upcoming preclinical evidences unveil a signaling potential of HLA-DR antigens expressed on melanoma cells, and suggest for the clinical implication of HLA class II molecules as novel therapeutic targets. Therefore, in this review, we will focus on the emerging role of HLA class II antigens as intracellular signal transducing elements in neoplastic cells of the melanocytic lineage, emphasizing their foreseeable role in targeted therapy of human melanoma and potentially of HLA class II antigens-positive tumors of different histology.	IRCCS, Ctr Riferimento Oncol, Dept Med Oncol, Canc Bioimmunotherapy Unit, I-33081 Aviano, Italy	IRCCS Aviano (CRO)	Altomonte, M (corresponding author), IRCCS, Ctr Riferimento Oncol, Dept Med Oncol, Canc Bioimmunotherapy Unit, Via Pedemontana Occ 12, I-33081 Aviano, Italy.	maltomonte@cro.it	altomonte, maresa/G-7734-2011	Altomonte, Maresa/0000-0001-8021-1921; Maio, Michele/0000-0002-0323-6321; coral, sandra/0000-0002-1308-3082				ALBINO AP, 1986, J EXP MED, V164, P1710, DOI 10.1084/jem.164.5.1710; Altomonte M, 1999, J CELL PHYSIOL, V179, P251, DOI 10.1002/(SICI)1097-4652(199906)179:3<251::AID-JCP2>3.3.CO;2-G; ALTOMONTE M, 1993, J IMMUNOL, V151, P5115; ALTOMONTE M, 2003, IN PRESS J CELL PHYS; ANDRE P, 1994, J EXP MED, V179, P763, DOI 10.1084/jem.179.2.763; ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; BARTEK J, 1987, BRIT J CANCER, V56, P727, DOI 10.1038/bjc.1987.278; BERNARD D, 1984, CLIN EXP IMMUNOL, V56, P215; Bernsen MR, 2003, BRIT J CANCER, V88, P424, DOI 10.1038/sj.bjc.6600703; Brasanac D, 1999, NEOPLASMA, V46, P173; BRUNNER CA, 1991, EUR J CANCER, V27, P411, DOI 10.1016/0277-5379(91)90374-M; Byrne SN, 2003, CANCER IMMUNOL IMMUN, V52, P396, DOI 10.1007/s00262-003-0380-0; CABRERA T, 1995, SCAND J IMMUNOL, V41, P398, DOI 10.1111/j.1365-3083.1995.tb03584.x; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; Chang Eun-Sook, 1995, Journal of Korean Medical Science, V10, P334; CHIA CP, 1994, J IMMUNOL, V153, P3398; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; CONCHA A, 1991, CANCER BIOL, V2, P47; Coral S, 1997, CELL GROWTH DIFFER, V8, P581; Dechant M, 2002, BLOOD, V100, P4574, DOI 10.1182/blood-2002-03-0687; ESTEBAN F, 1989, INT J CANCER, V43, P436, DOI 10.1002/ijc.2910430316; Feinmesser M, 2000, J CLIN PATHOL, V53, P286, DOI 10.1136/jcp.53.4.286; Garban F, 1998, EXP HEMATOL, V26, P874; GLEW SS, 1992, CANCER RES, V52, P4009; Goodwin BL, 2001, CELL GROWTH DIFFER, V12, P327; GUTIERREZ J, 1987, EXP CLIN IMMUNOGENET, V4, P144; HARTON JA, 1995, IMMUNITY, V3, P349, DOI 10.1016/1074-7613(95)90119-1; Heike M, 1996, J IMMUNOL, V156, P2205; HILDERS CGJM, 1995, GYNECOL ONCOL, V57, P366, DOI 10.1006/gyno.1995.1156; HILTON DA, 1990, CANCER, V66, P1154, DOI 10.1002/1097-0142(19900915)66:6<1154::AID-CNCR2820660613>3.0.CO;2-3; HOUCK JR, 1990, ARCH OTOLARYNGOL, V116, P1181; HURLIMANN J, 1985, INT J CANCER, V35, P753, DOI 10.1002/ijc.2910350610; Ioachim E, 2000, HISTOL HISTOPATHOL, V15, P721, DOI 10.14670/HH-15.721; Ishigami S, 1998, ONCOLOGY-BASEL, V55, P65, DOI 10.1159/000011837; KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295; KORETZ K, 1989, INT J CANCER, V44, P816, DOI 10.1002/ijc.2910440512; Kunihiro M, 1998, ONCOLOGY-BASEL, V55, P326, DOI 10.1159/000011870; Laufer TM, 1997, J IMMUNOL, V159, P5914; LAZARIS AC, 1995, DIS COLON RECTUM, V38, P739, DOI 10.1007/BF02048033; Lazzaro B, 2001, APPL IMMUNOHISTO M M, V9, P234, DOI 10.1097/00022744-200109000-00007; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Lovig T, 2002, BRIT J CANCER, V87, P756, DOI 10.1038/sj.bjc.6600507; Lu Y, 1997, IMMUNOL CELL BIOL, V75, P325, DOI 10.1038/icb.1997.50; LUCIN K, 1994, PATHOL RES PRACT, V190, P1134; MA XC, 1994, ACTA ONCOL, V33, P187, DOI 10.3109/02841869409098403; MAIO M, 1989, INT J CANCER, V44, P554, DOI 10.1002/ijc.2910440330; MARSDEN S, 2000, HIST EUROPEAN HOUSIN, P26; MATTIJSSEN V, 1991, INT J CANCER, P95; MOLLER P, 1989, AM J PATHOL, V135, P73; MORITA M, 1995, J SURG ONCOL, V59, P233, DOI 10.1002/jso.2930590407; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; Nagy ZA, 2002, NAT MED, V8, P801, DOI 10.1038/nm736; NATALI PG, 1983, CANCER RES, V43, P660; NORHEIMANDERSEN S, 1993, BRIT J CANCER, V68, P80; Ostmeier H, 2001, BRIT J DERMATOL, V145, P203, DOI 10.1046/j.1365-2133.2001.04335.x; Ostmeier H, 1999, CANCER-AM CANCER SOC, V85, P2391, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2391::AID-CNCR14>3.0.CO;2-I; PEREZ M, 1986, J IMMUNOGENET, V13, P247; Piskurich JF, 1998, J IMMUNOL, V160, P233; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; Renkvist N, 2001, CANCER IMMUNOL IMMUN, V50, P3, DOI 10.1007/s002620000169; Ricaniadis N, 2001, EUR J SURG ONCOL, V27, P88, DOI 10.1053/ejso.1999.1018; ROGNUM TO, 1983, BRIT J CANCER, V48, P543, DOI 10.1038/bjc.1983.227; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SADANAGA N, 1994, CANCER-AM CANCER SOC, V74, P586, DOI 10.1002/1097-0142(19940715)74:2<586::AID-CNCR2820740209>3.0.CO;2-4; Saito T, 1997, CANCER LETT, V115, P121, DOI 10.1016/S0304-3835(97)04754-X; SCHICK MR, 1993, J IMMUNOL, V151, P4090; SCHOLL PR, 1994, IMMUNOL TODAY, V15, P418, DOI 10.1016/0167-5699(94)90271-2; SCHWAB M, 2000, PATHOLOGY GENETICS T, P153; SI ZY, 1993, INT J CANCER, V54, P37, DOI 10.1002/ijc.2910540107; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Stockmeyer B, 2002, BRIT J HAEMATOL, V118, P959, DOI 10.1046/j.1365-2141.2002.03722.x; STPIERRE Y, 1989, J IMMUNOL, V143, P808; Sumiyoshi K, 1999, ONCOL REP, V6, P301; Szollosi J, 1996, J IMMUNOL, V157, P2939; TARAMELLI D, 1986, CANCER RES, V46, P433; Tatsumi T, 2003, CLIN CANCER RES, V9, P947; Ting JPY, 1997, J IMMUNOL, V159, P5457; Trieb K, 1998, PATHOL RES PRACT, V194, P679, DOI 10.1016/S0344-0338(98)80126-X; Truman JP, 1996, CELL IMMUNOL, V172, P149, DOI 10.1006/cimm.1996.0227; Truman JP, 1996, EXP HEMATOL, V24, P1409; van der Stoep N, 2002, INT J CANCER, V97, P501, DOI 10.1002/ijc.1623; VANDUINEN SG, 1988, CANCER RES, V48, P1019; Vora AR, 1997, BRIT J CANCER, V76, P836, DOI 10.1038/bjc.1997.472; WADE WF, 1993, IMMUNOL TODAY, V14, P539, DOI 10.1016/0167-5699(93)90184-M; Westerheide SD, 1997, J IMMUNOL, V158, P4812; WINTZER HO, 1990, BRIT J CANCER, V62, P289, DOI 10.1038/bjc.1990.280; Yazawa T, 1999, J PATHOL, V187, P191, DOI 10.1002/(SICI)1096-9896(199901)187:2<191::AID-PATH206>3.0.CO;2-3; Yazawa T, 2002, AM J PATHOL, V161, P291, DOI 10.1016/S0002-9440(10)64181-8; Yazawa T, 1993, APPL IMMUNOHISTO M M, V1, P289; ZUK JA, 1988, J PATHOL, V155, P301, DOI 10.1002/path.1711550405; ZUK JA, 1987, J PATHOL, V152, P275, DOI 10.1002/path.1711520406	94	39	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6564	6569		10.1038/sj.onc.1206960	http://dx.doi.org/10.1038/sj.onc.1206960			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528281				2022-12-17	WOS:000185700700013
J	Oosterhoff, JK; Penninkhof, F; Brinkmann, AO; Grootegoed, JA; Blok, LJ				Oosterhoff, JK; Penninkhof, F; Brinkmann, AO; Grootegoed, JA; Blok, LJ			REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells	ONCOGENE			English	Article						REPS2; POB1; prostate cancer; internalization; EGF signalling	RAL-BINDING PROTEIN-1; CLATHRIN-MEDIATED ENDOCYTOSIS; PUTATIVE EFFECTOR PROTEIN; GTPASE; IDENTIFICATION; INVOLVEMENT; PATHWAYS; COMPLEX; RLIP76; GENES	During progression of prostate cancer, cellular changes occur, leading to a transition from androgen-dependent to androgen-independent growth. One aspect of this transition is a switch from androgens to growth factors, like epidermal growth factor (EGF), as primary regulators of proliferation. We examined the involvement of REPS2/POB1 in this process. REPS2/POB1 is an EH domain-containing protein, reported to be involved in signalling via RatBP1 and to play a role in endocytosis of EGF receptors. Furthermore, the protein is relatively highly expressed in androgen-dependent as compared to androgen-independent human prostate cancer cell lines and xenografts. Next to the known REPS2/POB1 protein, an open reading frame encoding REPS2/POB1, with 139 additional amino-acid residues at the NH2-terminus, was cloned and found to be expressed in prostate cancer cells. Overexpression, by transient transfection, of both forms of REPS2/POB1 in prostate cancer cell lines, induced apoptosis within 48 h. At shorter time intervals after transfection, signalling towards a TPA response element luciferase reporter was found to be inhibited. From these experiments, it is concluded that REPS2/POB1, through its influence on the Ral signalling pathway, is involved in growth factor signalling. Decreased expression of REPS2/POB1 during progression of prostate cancer may therefore result in loss of control of growth factor signalling and consequently in loss of control of cell proliferation.	Erasmus Univ, Erasmus MC, Dept Reprod & Dev, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Blok, LJ (corresponding author), Erasmus Univ, Erasmus MC, Dept Reprod & Dev, POB 1738, NL-3000 DR Rotterdam, Netherlands.							ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Chang GTG, 1997, CANCER RES, V57, P4075; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; JANSSEN T, 1995, PROSTATE, V27, P277, DOI 10.1002/pros.2990270507; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kariya K, 2000, J BIOL CHEM, V275, P18399, DOI 10.1074/jbc.M000521200; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Matsubara K, 1997, FEBS LETT, V410, P169, DOI 10.1016/S0014-5793(97)00633-9; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Osada M, 1999, MOL CELL BIOL, V19, P6333; Park SH, 1995, ONCOGENE, V11, P2349; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Russell PJ, 1998, CLIN CHEM, V44, P705; VANSTEENBRUGGE GJ, 1991, J STEROID BIOCHEM, V40, P207, DOI 10.1016/0960-0760(91)90184-7; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086	23	39	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2920	2925		10.1038/sj.onc.1206397	http://dx.doi.org/10.1038/sj.onc.1206397			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771942				2022-12-17	WOS:000182824800006
J	Van Etten, RA				Van Etten, RA			Studying the pathogenesis of BCR-ABL(+) leukemia in mice	ONCOGENE			English	Article						CML; tyrosine kinase; retrovirus; Philadelphia chromosome	CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; CHRONIC MYELOID-LEUKEMIA; COLONY-STIMULATING FACTOR; HEMATOPOIETIC-CELL LINES; GROWTH-FACTOR INDEPENDENCE; SERINE THREONINE KINASE; DNA-BINDING ACTIVITY; TYROSINE KINASE; C-ABL	Animal models of BCR-ABL(+) leukemias have provided important new knowledge about the molecular pathophysiology of these diseases, and answered questions that are difficult or impossible to address using BCR-ABL-expressing cell lines or primary Ph+ leukemia samples from patients. The power of mouse models lies in their ability to recapitulate precisely the phenotypes of BCR-ABL(+) leukemias in vivo, but this comes at the price of significant complexity. Here I review recent studies of leukemias induced in mice by BCR-ABL with an emphasis on the intricate nature of these diseases and the need for careful pathological and molecular analysis.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Van Etten, RA (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA.				NCI NIH HHS [CA90576] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090576] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SM, 1996, BLOOD, V87, P238; Andreasson P, 1997, GENE CHROMOSOME CANC, V20, P299; BRUNEL V, 1996, LEUKEMIA, V10, P2003; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GROOPMAN JE, 1981, ANN INTERN MED, V94, P95, DOI 10.7326/0003-4819-94-1-95; Gross AW, 2000, ONCOGENE, V19, P6286, DOI 10.1038/sj.onc.1204023; HAN XD, 1991, P NATL ACAD SCI USA, V88, P10129, DOI 10.1073/pnas.88.22.10129; Hannemann JR, 1998, BRIT J HAEMATOL, V102, P475, DOI 10.1046/j.1365-2141.1998.00803.x; Hariharan I K, 1988, Oncogene Res, V3, P387; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; Liu JX, 1996, MOL CELL BIOL, V16, P998; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Million RP, 2002, BLOOD, V99, P4568, DOI 10.1182/blood-2001-12-0244; Million RP, 2000, BLOOD, V96, P664; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Okuda K, 1996, ONCOGENE, V13, P1147; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Perlingeiro RCR, 2001, DEVELOPMENT, V128, P4597; Peters DG, 2001, ONCOGENE, V20, P2636, DOI 10.1038/sj.onc.1204374; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; Shuai K, 1996, ONCOGENE, V13, P247; SKORSKI T, 1995, CANCER RES, V55, P2275; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Tomasson MH, 2000, J CLIN INVEST, V105, P423, DOI 10.1172/JCI8902; Tomasson MH, 2001, BLOOD, V97, P1435, DOI 10.1182/blood.V97.5.1435; Van Etten R A, 2001, Curr Oncol Rep, V3, P228; Van Limbergen H, 2001, GENE CHROMOSOME CANC, V30, P274, DOI 10.1002/1098-2264(2000)9999:9999<1::AID-GCC1089>3.3.CO;2-T; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VANETTEN RA, 1995, ONCOGENE, V10, P1977; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Wu Y, 1998, ONCOGENE, V16, P141, DOI 10.1038/sj.onc.1201524; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	74	39	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	2002	21	56					8643	8651		10.1038/sj.onc.1206091	http://dx.doi.org/10.1038/sj.onc.1206091			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476310	Green Published			2022-12-17	WOS:000179734300013
J	Hopkins-Donaldson, S; Yan, P; Bourloud, KB; Muhlethaler, A; Bodmer, JL; Gross, N				Hopkins-Donaldson, S; Yan, P; Bourloud, KB; Muhlethaler, A; Bodmer, JL; Gross, N			Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells	ONCOGENE			English	Article						apoptosis; caspases; doxorubicin; caspase-8; neuroblastoma	DRUG-INDUCED APOPTOSIS; WILD-TYPE P53; CHEMOTHERAPEUTIC DRUGS; CANCER-THERAPY; PATHWAYS; FAS; MITOCHONDRIA; EXPRESSION; RESISTANCE; TRIGGERS	Death induced by doxorubicin (dox) in neuroblastoma (NB) cells was originally thought to occur via the Fas pathway, however since studies suggest that caspase-8 expression is silenced in most high stage NB tumors, it is more probable that dox-induced death occurs via a different mechanism. Caspase-8 silenced N-type invasive NB cell tines LAN-1 and IMR-32 were investigated for their sensitivity to dox, and compared to S-type noninvasive SH-EP NB cells expressing caspase-8. All cell lines had similar sensitivities to dox, independently of caspase-8 expression. Dox induced caspase-3, -7, -8 and -9 and Bid cleavage in S-type cells and death was blocked by caspase inhibitors but not by oxygen radical scavenger BHA. In contrast, dox-induced death in N-type cells was caspase-independent and was inhibited by BHA. Dox induced a drop in mitochondrial membrane permeability in all cell lines. Dox-induced death in S-type cells gave rise to apoptotic nuclei, whereas in N-type cells nuclei were non-apoptotic in morphology. Transfection of SH-EP cells with a dominant negative FADD mutant inhibited TRAIL-induced death, but had no effect on dox-induced apoptosis. These results suggest that S-type cells undergo apoptosis after dox treatment independently of death receptors, whereas N-type cells are killed by a caspase-independent mechanism.	CHU Vaudois, Dept Pediat Oncohematol, CH-1011 Lausanne, Switzerland; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne	Gross, N (corresponding author), CHU Vaudois, Dept Pediat Oncohematol, CH-1011 Lausanne, Switzerland.		, Mühlethaler-Mottet/H-2848-2019	, Mühlethaler-Mottet/0000-0001-8274-0907				Bian X, 2001, J BIOL CHEM, V276, P48921, DOI 10.1074/jbc.M108674200; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Ferreira CG, 2000, CANCER RES, V60, P7133; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Goldman SC, 1996, AM J PATHOL, V148, P1381; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Kataoka T, 1998, J IMMUNOL, V161, P3936; LaQuaglia MP, 1996, J PEDIATR SURG, V31, P315, DOI 10.1016/S0022-3468(96)90025-1; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; McKenzie PP, 1999, CLIN CANCER RES, V5, P4199; Miyazaki K, 2001, J BIOCHEM-TOKYO, V129, P963, DOI 10.1093/oxfordjournals.jbchem.a002944; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Oue T, 1996, J PEDIATR SURG, V31, P251, DOI 10.1016/S0022-3468(96)90009-3; Sartorius UA, 2002, INT J CANCER, V97, P584, DOI 10.1002/ijc.10096; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Spix C, 2001, EUR J CANCER, V37, P722, DOI 10.1016/S0959-8049(01)00003-X; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108	28	39	41	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					6132	6137		10.1038/sj.onc.1205879	http://dx.doi.org/10.1038/sj.onc.1205879			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203125				2022-12-17	WOS:000177671300016
J	Campuzano, S				Campuzano, S			Emc, a negative HLH regulator with multiple functions in Drosophila development	ONCOGENE			English	Article						Drosophila; extramacrochaetae; HLH; transcription factor; development	LOOP-HELIX PROTEINS; ACHAETE-SCUTE COMPLEX; PERIPHERAL NERVOUS-SYSTEM; SENSORY ORGAN DEVELOPMENT; SEX DETERMINATION SIGNAL; X-A RATIO; DNA-BINDING; PRONEURAL CLUSTERS; EXTRAMACROCHAETAE PROTEIN; WING MORPHOGENESIS	Expression and functional analyses of Emc have demonstrated that it is a prototype for a protein required for multiple processes in development. Initially characterized as a negative regulator of sensory organ development, it was later found to regulate many other developmental processes and cell proliferation. Its ability to block the function of bRLH proteins by forming heterodimers, which are ineffective in DNA binding, accounts for the role of Emc in preventing the acquisition of several cell fates which are under the control of bHLH proteins. However, while maintaining this repressive molecular mechanism, emc also appears to act as a positive regulator of differentiation.	Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Campuzano, S (corresponding author), Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain.		Campuzano Corrales, Sonsoles/K-1363-2014	Campuzano Corrales, Sonsoles/0000-0003-1834-0508				Affolter M, 2000, CURR OPIN CELL BIOL, V12, P731, DOI 10.1016/S0955-0674(00)00160-5; ALONSO LAG, 1988, ROUX ARCH DEV BIOL, V197, P328, DOI 10.1007/BF00375952; ARMAND P, 1994, MOL CELL BIOL, V14, P4145, DOI 10.1128/MCB.14.6.4145; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BALCELLS L, 1988, EMBO J, V7, P3899, DOI 10.1002/j.1460-2075.1988.tb03276.x; Baonza A, 1999, MECH DEVELOP, V80, P133, DOI 10.1016/S0925-4773(98)00198-1; Baonza A, 2001, DEVELOPMENT, V128, P3889; Baonza A, 2000, DEVELOPMENT, V127, P2383; BATE M, 1978, HDB SENSORY PHYSL, V1; BAUMANN P, 1993, DEVELOPMENT, P65; Baylies MK, 1998, CELL, V93, P921, DOI 10.1016/S0092-8674(00)81198-8; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; BROWN NL, 1995, CELL, V80, P879, DOI 10.1016/0092-8674(95)90291-0; CABRERA CV, 1994, DEVELOPMENT, V120, P3595; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CARMENA A, 1995, GENE DEV, V9, P2373, DOI 10.1101/gad.9.19.2373; Carrera P, 1998, P NATL ACAD SCI USA, V95, P10779, DOI 10.1073/pnas.95.18.10779; Castanon I, 2001, DEVELOPMENT, V128, P3145; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CAUDY M, 1988, GENE DEV, V2, P843, DOI 10.1101/gad.2.7.843; Chen CM, 1996, MECH DEVELOP, V57, P215, DOI 10.1016/0925-4773(96)00548-5; CLINE TW, 1988, GENETICS, V119, P829; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; CUBAS P, 1994, DEVELOPMENT, V120, P2555; CUBAS P, 1992, EMBO J, V11, P3385, DOI 10.1002/j.1460-2075.1992.tb05417.x; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DAMBLYCHAUDIERE C, 1988, ROUX ARCH DEV BIOL, V197, P419, DOI 10.1007/BF00398993; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; De Celis JF, 1998, INT J DEV BIOL, V42, P335; DECELIS JF, 1994, MECH DEVELOP, V46, P109, DOI 10.1016/0925-4773(94)90080-9; DECELIS JF, 1995, MECH DEVELOP, V53, P209, DOI 10.1016/0925-4773(95)00436-5; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P246; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Dokucu ME, 1996, DEVELOPMENT, V122, P4139; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ELLIS HM, 1994, MECH DEVELOP, V47, P65, DOI 10.1016/0925-4773(94)90096-5; ERICKSON JW, 1993, GENE DEV, V7, P1688, DOI 10.1101/gad.7.9.1688; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; Freeman M, 1997, DEVELOPMENT, V124, P261; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GARCIABELLIDO A, 1978, GENETICS, V88, P469; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GOMEZSKARMETA JL, 1995, GENE DEV, V9, P1869, DOI 10.1101/gad.9.15.1869; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HOCH M, 1994, DEVELOPMENT, V120, P3439; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; KING PH, 1994, J NEUROSCI, V14, P1943; Lai EC, 1998, CELL, V93, P1103, DOI 10.1016/S0092-8674(00)81454-3; Lai EC, 1997, DEVELOPMENT, V124, P4847; Lee T, 1996, GENE DEV, V10, P2912, DOI 10.1101/gad.10.22.2912; Leviten MW, 1997, DEVELOPMENT, V124, P4039; Lisbin MJ, 2001, GENE DEV, V15, P2546, DOI 10.1101/gad.903101; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; MARTINEZ C, 1993, MOL CELL BIOL, V13, P3514, DOI 10.1128/MCB.13.6.3514; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Modolell J, 1998, INT J DEV BIOL, V42, P275; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Norton JD, 2000, J CELL SCI, V113, P3897; Ohshiro T, 1997, DEVELOPMENT, V124, P3975; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; RODRIGUEZ I, 1990, EMBO J, V9, P3583, DOI 10.1002/j.1460-2075.1990.tb07569.x; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; SKAER H, 1993, DEV DROSPHILE MELANO; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; Takahisa M, 1996, GENE DEV, V10, P1783, DOI 10.1101/gad.10.14.1783; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; TORRES M, 1991, DEVELOPMENT, V113, P715; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WIE X, 2001, MECH DEVELOP, V100, P217; YOUNGERSHEPHERD S, 1992, CELL, V70, P911, DOI 10.1016/0092-8674(92)90242-5	86	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 20	2001	20	58					8299	8307		10.1038/sj.onc.1205162	http://dx.doi.org/10.1038/sj.onc.1205162			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512HT	11840322				2022-12-17	WOS:000173319500003
J	Zhang, DM; Vuocolo, S; Masciullo, V; Sava, T; Giordano, A; Soprano, DR; Soprano, KJ				Zhang, DM; Vuocolo, S; Masciullo, V; Sava, T; Giordano, A; Soprano, DR; Soprano, KJ			Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppression	ONCOGENE			English	Article						RB; RB-2/p130; ovarian carcinoma; retinoic acid	NEURONAL DIFFERENTIATION; RETINOBLASTOMA PROTEIN; ADENOCARCINOMA CELLS; CARCINOMA-CELLS; B-LYMPHOCYTES; CANCER CELLS; G(1) CONTROL; ACID; PHOSPHORYLATION; INHIBITION	We have examined the effect of all-trans-retinoic acid (RA) on cell cycle gene expression in RA sensitive CAOV3 and RA resistant SK-OV3 ovarian carcinoma cell lines. Gene expression was analysed by multiprobe RNAse protection, Western blotting and in vitro kinase assays. No differences were observed between RA sensitive and RA resistant ovarian carcinoma cells in the levels of expression of many cell cycle genes including cyclin A, B and E, cdk 2,4 and 6, E2F-1, E2F-2, E2F-3, E2F-4, E2F-5, DP-1 and DP-2. However, RA sensitive CA-OV3 cells expressed higher levels of p53, p27, p21, and p16 compared to RA resistant SK-OV3 cells. In addition, RA treatment of CA-OV3 cells resulted in a significant decrease in hyperphosphorylated RB and RB-2/p130 and corresponding significant increases in the levels of hypophosphorylated and/or partially phosphorylated RB-2/p130 protein and hypophosphorylated RB. Also, RA treatment increased expression of the cdk inhibitor p27 and decreased activity of cdk 2, cdk 4 and cdk 6. Finally, amounts of p27-cyclin E and RB-2/p130-E2F4 complexes were found to increase in CA-OV3 cells growth arrested by RA. These results suggest that the pocket protein pathways are critical targets for retinoid suppression of ovarian carcinoma cell growth.	Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University	Soprano, KJ (corresponding author), Temple Univ, Sch Med, Dept Biochem, 3400 N Broad St, Philadelphia, PA 19140 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X	NATIONAL CANCER INSTITUTE [R01CA064945, R01CA060999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER; NCI NIH HHS [CA60999, CA64945] Funding Source: Medline; NIDDK NIH HHS [DK 49045] Funding Source: Medline; NINDS NIH HHS [NS36466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Borriello A, 2000, ONCOGENE, V19, P51, DOI 10.1038/sj.onc.1203231; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CALIARO MJ, 1994, INT J CANCER, V56, P743, DOI 10.1002/ijc.2910560522; Chao WR, 1997, CANCER LETT, V115, P1, DOI 10.1016/S0304-3835(97)04598-9; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Claudio PP, 1996, CANCER RES, V56, P2003; Daly M, 1998, SEMIN ONCOL, V25, P255; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; GRUNT TW, 1991, J CELL SCI, V100, P657; GRUNT TW, 1992, J CELL PHYSIOL, V151, P13, DOI 10.1002/jcp.1041510104; GRUNT TW, 1992, J CELL SCI, V103, P501; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hoskins WJ, 1995, J CELL BIOCHEM, P189; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Mangelsdorf David J., 1994, P319; Matsuo T, 1998, ONCOGENE, V16, P3337, DOI 10.1038/sj.onc.1201830; MAYOL X, 1993, ONCOGENE, V8, P2561; Mayol X, 1996, ONCOGENE, V13, P237; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; MAYOL X, 1995, ONCOGENE, V11, P801; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Naderi S, 1999, BLOOD, V94, P1348, DOI 10.1182/blood.V94.4.1348.416k29_1348_1358; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Seewaldt VL, 1999, EXP CELL RES, V249, P70, DOI 10.1006/excr.1999.4462; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Soprano DR, 1996, ONCOGENE, V12, P577; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Sueoka N, 1999, CANCER RES, V59, P3838; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; Watanabe Y, 1999, BRAIN RES, V842, P342, DOI 10.1016/S0006-8993(99)01844-2; Weber E, 1999, INT J CANCER, V80, P935, DOI 10.1002/(SICI)1097-0215(19990315)80:6<935::AID-IJC21>3.0.CO;2-E; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65; Wu SJ, 1998, ONCOGENE, V17, P2839, DOI 10.1038/sj.onc.1202208; Wu SJ, 1997, EXP CELL RES, V237, P118, DOI 10.1006/excr.1997.3769; Wu SJ, 1998, J CELL BIOCHEM, V68, P378, DOI 10.1002/(SICI)1097-4644(19980301)68:3<378::AID-JCB8>3.0.CO;2-R; Wu SJ, 1997, EXP CELL RES, V232, P277, DOI 10.1006/excr.1997.3495; Zancai P, 1998, ONCOGENE, V17, P1827, DOI 10.1038/sj.onc.1202089; Zhang DM, 2000, J CELL PHYSIOL, V185, P1, DOI 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	52	39	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2001	20	55					7935	7944		10.1038/sj.onc.1204971	http://dx.doi.org/10.1038/sj.onc.1204971			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753676				2022-12-17	WOS:000172288700002
J	Tauber, B; Dobner, T				Tauber, B; Dobner, T			Adenovirus early E4 genes in viral oncogenesis	ONCOGENE			English	Review						Ad E4 gene function; transformation; oncogenesis	REGION-4 34-KILODALTON PROTEIN; CELLULAR TRANSCRIPTION FACTOR; PRODUCTIVELY INFECTED-CELLS; READING FRAME-1 ENCODES; P53 TUMOR-SUPPRESSOR; DNA-BINDING ACTIVITY; E4ORF6 PROTEIN; MAMMARY-TUMORS; 55-KILODALTON PROTEIN; LYTIC INFECTION	Previous investigations into potential transforming activities of adenovirus (Ad) early genes were largely overshadowed by the more obvious roles of EIA and E1B products. One exception was an Ad9 E4 protein (ORF1) shown to enhance transformation of cultured cells and promote mammary tumors in female rats. Recently, significant advances in understanding Ad E4 gene products at the molecular level have revealed that these proteins possess an unexpectedly diverse collection of functions, which not only orchestrate many viral processes, but overlap with oncogenic transformation of primary mammalian cells. Operating through a. complex network of protein interactions with key viral and cellular regulatory components, Ad E4 products are apparently involved in transcription, apoptosis, cell cycle control, DNA repair, cell signaling, posttranslational modifications and the integrity of nuclear multiprotein complexes known as PML oncogenic domains (POD). Some of these functions directly relate to known transforming and oncogenic processes, or implicate mechanisms such as modulating the function and subcellular localization of cellular PDZ domain-containing proteins, POD reorganization, targeted proteolytic degradation, inhibition of DNA double-strand break repair and 'hit-and-run' mutagenesis. Here, we summarize the recent data and discuss how E4 gene product interactions may contribute to viral oncogenesis.	Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93053 Regensburg, Germany	University of Regensburg	Dobner, T (corresponding author), Univ Regensburg, Inst Med Mikrobiol & Hyg, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	thomas.dobner@klinik.uni-regensburg.de						ANKERST J, 1974, INT J CANCER, V13, P286, DOI 10.1002/ijc.2910130303; ANKERST J, 1989, J NATL CANCER I, V81, P294, DOI 10.1093/jnci/81.4.294; BERNARDS R, 1984, J VIROL, V50, P847, DOI 10.1128/JVI.50.3.847-853.1984; Boyer J, 1999, VIROLOGY, V263, P307, DOI 10.1006/viro.1999.9866; Boyer JL, 2000, J BIOL CHEM, V275, P14969, DOI 10.1074/jbc.M000566200; BRACKMANN KH, 1980, J BIOL CHEM, V255, P6772; BRIDGE E, 1990, VIROLOGY, V174, P345, DOI 10.1016/0042-6822(90)90088-9; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Cathomen T, 2000, J VIROL, V74, P11407, DOI 10.1128/JVI.74.23.11407-11412.2000; Cress WD, 1996, MOL CELL BIOL, V16, P2119; Cress WD, 1996, CURR TOP MICROBIOL, V208, P63; CUTT JR, 1987, J VIROL, V61, P543, DOI 10.1128/JVI.61.2.543-552.1987; DIX I, 1995, J GEN VIROL, V76, P1051, DOI 10.1099/0022-1317-76-4-1051; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dobner T, 2001, CURR TOP MICROBIOL, V259, P25; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DOWNEY JF, 1983, J VIROL, V45, P514, DOI 10.1128/JVI.45.2.514-523.1983; ESCHE H, 1979, J VIROL, V30, P21, DOI 10.1128/JVI.30.1.21-31.1979; ESCHE H, 1982, J VIROL, V41, P1076, DOI 10.1128/JVI.41.3.1076-1082.1982; ESCHE H, 1982, J GEN VIROL, V60, P99, DOI 10.1099/0022-1317-60-1-99; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLINT SJ, 1976, J MOL BIOL, V106, P749, DOI 10.1016/0022-2836(76)90263-1; FLINT SJ, 1975, J MOL BIOL, V96, P47, DOI 10.1016/0022-2836(75)90181-3; FLINT SJ, 1976, VIROLOGY, V72, P456, DOI 10.1016/0042-6822(76)90174-4; FREYER GA, 1984, NUCLEIC ACIDS RES, V12, P3503, DOI 10.1093/nar/12.8.3503; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Goodrum FD, 1999, J VIROL, V73, P7474, DOI 10.1128/JVI.73.9.7474-7488.1999; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; GRAHAM FL, 1984, ADENOVIRUSES, P339; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grifman M, 1999, J VIROL, V73, P10010, DOI 10.1128/JVI.73.12.10010-10019.1999; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HARDY S, 1989, MOL CELL BIOL, V9, P4495, DOI 10.1128/MCB.9.10.4495; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HERISSE J, 1981, NUCLEIC ACIDS RES, V9, P4023, DOI 10.1093/nar/9.16.4023; HORWITZ MS, 1996, FIELDS VIROLOGY, V2, P2149; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; Javier R, 1996, BREAST CANCER RES TR, V39, P57, DOI 10.1007/BF01806078; JAVIER R, 1991, J VIROL, V65, P3192, DOI 10.1128/JVI.65.6.3192-3202.1991; JAVIER R, 1992, SCIENCE, V257, P1267, DOI 10.1126/science.1519063; JAVIER RT, 1994, J VIROL, V68, P3917, DOI 10.1128/JVI.68.6.3917-3924.1994; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JONSSON N, 1977, CANCER, V39, P2513, DOI 10.1002/1097-0142(197706)39:6<2513::AID-CNCR2820390631>3.0.CO;2-7; Kleinberger T, 2000, APOPTOSIS, V5, P211, DOI 10.1023/A:1009644210581; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Konig C, 1999, J VIROL, V73, P2253; KOVESDI I, 1986, SCIENCE, V231, P719, DOI 10.1126/science.2935935; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; Nevels M, 1999, ONCOGENE, V18, P9, DOI 10.1038/sj.onc.1202284; Nevels M, 1999, J VIROL, V73, P1591, DOI 10.1128/JVI.73.2.1591-1600.1999; Nevels M, 2001, J VIROL, V75, P3089, DOI 10.1128/JVI.75.7.3089-3094.2001; Nevels M, 2000, J VIROL, V74, P5168, DOI 10.1128/JVI.74.11.5168-5181.2000; NEVINS JR, 1996, FIELDS VIROLOGY, V1, P301; Nicolas AL, 2000, VIROLOGY, V266, P211, DOI 10.1006/viro.1999.0062; O'Connor RJ, 2000, J VIROL, V74, P5819, DOI 10.1128/JVI.74.13.5819-5824.2000; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; OCONNOR RJ, 1991, NUCLEIC ACIDS RES, V19, P6579, DOI 10.1093/nar/19.23.6579; OHMAN K, 1995, INT J ONCOL, V6, P663; Orlando JS, 1999, J VIROL, V73, P4600, DOI 10.1128/JVI.73.6.4600-4610.1999; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; SARNOW P, 1982, J MOL BIOL, V162, P565, DOI 10.1016/0022-2836(82)90389-8; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; Schaley J, 2000, J VIROL, V74, P2084, DOI 10.1128/JVI.74.5.2084-2093.2000; SHIROKI K, 1984, J VIROL, V50, P854, DOI 10.1128/JVI.50.3.854-863.1984; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; TAUBER B, 2001, IN PRESS GENE; TERRIS B, 1995, CANCER RES, V55, P1590; Thomas DL, 1999, J VIROL, V73, P3071, DOI 10.1128/JVI.73.4.3071-3079.1999; Thomas DL, 2001, J VIROL, V75, P557, DOI 10.1128/JVI.75.2.557-568.2001; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; VIRTANEN A, 1984, J VIROL, V51, P822, DOI 10.1128/JVI.51.3.822-831.1984; WEIDEN MD, 1994, P NATL ACAD SCI USA, V91, P153, DOI 10.1073/pnas.91.1.153; Weiss RS, 1997, J VIROL, V71, P4385, DOI 10.1128/JVI.71.6.4385-4394.1997; Weiss RS, 1996, J VIROL, V70, P862, DOI 10.1128/JVI.70.2.862-872.1996; Weiss RS, 1997, J VIROL, V71, P7873, DOI 10.1128/JVI.71.10.7873-7880.1997; Weiss RS, 1997, J VIROL, V71, P1857, DOI 10.1128/JVI.71.3.1857-1870.1997; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Wienzek S, 2001, J VIROL, V75, P5391, DOI 10.1128/JVI.75.11.5391-5397.2001; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamano S, 1999, J VIROL, V73, P10095, DOI 10.1128/JVI.73.12.10095-10103.1999; ZALMANZON ES, 1987, EKSP ONKOL, V9, P3; Zheng P, 1998, NATURE, V396, P373, DOI 10.1038/24628; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	106	39	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2001	20	54					7847	7854		10.1038/sj.onc.1204914	http://dx.doi.org/10.1038/sj.onc.1204914			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753667				2022-12-17	WOS:000172336500004
J	Kuppumbatti, YS; Rexer, B; Nakajo, S; Nakaya, K; Mira-y-Lopez, R				Kuppumbatti, YS; Rexer, B; Nakajo, S; Nakaya, K; Mira-y-Lopez, R			CRBP suppresses breast cancer cell survival and anchorage-independent growth	ONCOGENE			English	Article						FABP; soft agar; anoikis; retinol; retinoic acid	RETINOL-BINDING PROTEIN; EPITHELIAL-CELLS; CARCINOMA CELLS; LIPID BODIES; ACID; APOPTOSIS; GENE; EXPRESSION; INHIBITION; TISSUE	We showed earlier that cellular retinol-binding protein (CRBP) expression is downregulated in a subset of human breast cancers. We have now investigated the outcome of ectopic CRBP expression in MTSV1-7 cells, a SV40 T antigen-transformed human breast epithelial cell line devoid of endogenous CRBP expression. We found that: (i) CRBP did not inhibit adherent cell growth but suppressed foci formation in post-confluent cultures and colony formation in soft agar; (ii) this effect was due to CRBP inhibition of cell survival, as demonstrated by viability and TUNEL assays of cells in soft-agar or plated on polyHEMA-coated dishes; (iii) CRBP inhibited protein kinase B/Akt activation in cells in suspension but not in adherent cells and the CRBP suppression of anchorage-independent growth was mimicked by cell treatment with the phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002; (iv) CRBP enhanced retinyl ester formation and storage but did not regulate retinoic acid synthesis or retinoic acid receptor activity. Ectopic CRBP-mediated inhibition of anchorage-independent cell survival and colony formation in the absence of significantly altered responses to either retinol or retinoic acid was also documented in T47D human breast cancer cells. In conclusion, the data suggest two novel and linked CRBP functions in mammary epithelial cells: inhibition of the PI3K/Akt survival pathway and suppression of anchorage-independent growth.	Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Tokyo 142, Japan	Icahn School of Medicine at Mount Sinai; Vanderbilt University; Showa University	Kuppumbatti, YS (corresponding author), Mt Sinai Sch Med, Dept Med, 1 Gustave L Levy Pl, New York, NY 10029 USA.				NCI NIH HHS [CA54273] Funding Source: Medline; NICHD NIH HHS [5T32HD07043] Funding Source: Medline; NIDDK NIH HHS [R01DK32642] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007043] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA054273, R29CA054273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032642] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; BUSCH C, 1990, METHOD ENZYMOL, V189, P315; Chang TH, 2000, CANCER RES, V60, P1129; DAWSON MI, 1995, CANCER RES, V55, P4446; Folli C, 2001, P NATL ACAD SCI USA, V98, P3710, DOI 10.1073/pnas.061455898; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; HUYNH HT, 1995, CANCER RES, V55, P2225; Jing YK, 1997, CANCER RES, V57, P1668; Kuppumbatti YS, 2000, J NATL CANCER I, V92, P475, DOI 10.1093/jnci/92.6.475; Li GY, 1999, CANCER RES, V59, P6267; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Mira-y-Lopez R, 2000, J CELL PHYSIOL, V185, P302, DOI 10.1002/1097-4652(200011)185:2<302::AID-JCP15>3.0.CO;2-#; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; PAPPAS RS, 1993, BIOL REPROD, V48, P235, DOI 10.1095/biolreprod48.2.235; Ruff SJ, 2000, FEBS LETT, V487, P282, DOI 10.1016/S0014-5793(00)02366-8; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Sapi E, 1999, CANCER RES, V59, P5578; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Shi YE, 1997, CANCER RES, V57, P3084; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; Vogel S, 2001, J BIOL CHEM, V276, P1353, DOI 10.1074/jbc.M005118200; Wang HL, 2000, ONCOGENE, V19, P2455, DOI 10.1038/sj.onc.1203575; Yamamoto M, 1998, EUR J BIOCHEM, V257, P344, DOI 10.1046/j.1432-1327.1998.2570344.x; Yu WG, 1998, AM J PATHOL, V152, P759; Yu WG, 2000, BLOOD, V95, P1078, DOI 10.1182/blood.V95.3.1078.003k16_1078_1085	31	39	40	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7413	7419		10.1038/sj.onc.1204749	http://dx.doi.org/10.1038/sj.onc.1204749			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704871				2022-12-17	WOS:000171894200014
J	Atlas, E; Stramwasser, M; Mueller, CR				Atlas, E; Stramwasser, M; Mueller, CR			A CREB site in the BRCA1 proximal promoter acts as a constitutive transcriptional element	ONCOGENE			English	Article						BRCA1; expression; transcription; CREB; sporadic breast cancer	SPORADIC BREAST-CANCER; RESPONSE ELEMENT; BINDING PROTEIN; OVARIAN-CANCER; MESSENGER-RNA; GENE-EXPRESSION; CPG ISLAND; METHYLATION; CELLS; ACTIVATION	Transcriptional regulation of the BRCA1 proximal promoter has been suggested to play a role in the decreased expression of BRCA1 observed in sporadic breast cancer. Computer analysis of the sequence of the proximal promoter reveals the presence of a potential CREB site. We have identified CREB/ATF-1 as the factor interacting with this site in nuclear extracts from MCF-7 and T-47D cells. This site is shown to be important for the constitutive expression of the promoter in these cells, as well as in Hep G2 cells. Despite the presence of this site, the BRCA1 promoter is not responsive to cAMP induction. It appears that CREB acts as a constitutive positive element for BRCA1 expression and that any mechanism inactivating CREB function would have a dramatic effect on BRCA1 expression.	Queens Univ, Dept Biochem, Canc Res Labs, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Mueller, CR (corresponding author), Queens Univ, Dept Biochem, Canc Res Labs, Botterell Hall, Kingston, ON K7L 3N6, Canada.	muellerc@post.queensu.ca						Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Cui JQ, 1998, ONCOL REP, V5, P591; De Cesare D, 1999, TRENDS BIOCHEM SCI, V24, P281, DOI 10.1016/S0968-0004(99)01414-0; Dobrovic A, 1997, CANCER RES, V57, P3347; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Eggers A, 1998, J BIOL CHEM, V273, P18499, DOI 10.1074/jbc.273.29.18499; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Husain A, 1998, CANCER RES, V58, P1120; Kobayashi M, 1997, BIOCHEM BIOPH RES CO, V241, P169, DOI 10.1006/bbrc.1997.7781; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Sawada J, 1999, J BIOL CHEM, V274, P35475, DOI 10.1074/jbc.274.50.35475; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	38	39	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7110	7114		10.1038/sj.onc.1204890	http://dx.doi.org/10.1038/sj.onc.1204890			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704836				2022-12-17	WOS:000171739300015
J	King, JG; Khalili, K				King, JG; Khalili, K			Inhibition of human brain tumor cell growth by the anti-inflammatory drug, flurbiprofen	ONCOGENE			English	Article						glioblastoma multiforme (GBM); non-steroidal anti-inflammatory drugs; COX-2; p53 induction	PRIMITIVE NEUROECTODERMAL TUMORS; COLON-CANCER CELLS; IN-VITRO; CYCLOOXYGENASE-2 EXPRESSION; R-FLURBIPROFEN; APOPTOSIS; SULINDAC; TOXICITY; MODELS; MOUSE	Despite many efforts to alter the relentlessly aggressive progression of tumors of neural origin, individuals bearing these tumors exhibit poor prognosis for longterm survival. In an attempt to find an effective treatment, we examined the efficacy of the non-steroidal anti-inflammatory drug, flurbiprofen, to suppress the growth of tumor cell lines derived from medulloblastoma and glioblastoma multiforme. Results from cell proliferation assays have revealed that flurbiprofen effectively inhibits the growth of various tumor cells in a dose-dependent manner and causes a noticeable change in the progression of cells through cell cycle stages. Treatment of tumor cells with flurbiprofen reduced the number of cells in G1 and G2, and significantly increased their numbers in S phase, suggesting that, flurbiprofen accelerates G1/S entry, and/or delays cell exit from S to G2/M stages. Results from RNase protection assay and Western blot analysis showed that while treatment of cells with flurbiprofen causes a minor change in the RNA level of different cyclins, there is a significant decrease in the level of cyclin B protein upon flurbiprofen treatment. Examination of tumor suppressors by RNase protection technique showed a subtle increase in the levels of several tumor suppressors upon flurbiprofen treatment. Interestingly, at the protein level, p53 tumor suppressor was substantially increased upon flurbiprofen treatment, yet the level of p21, a downstream target for p53 remained unchanged. Curiously, treatment of the cells with flurbiprofen enhanced the level of COX-2 expression. Results from co-immunoprecipitation showed association of COX-2 with p53 in tumor cells. These observations suggest that the interaction of COX-2 with p53 may cause p21-independent suppression of tumor cell growth upon flurbiprofen treatment.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Lab Canc Biol & Intervent, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Lab Canc Biol & Intervent, 1900 N 12th St,015-96,Room 203, Philadelphia, PA 19122 USA.							Deininger MH, 1999, ACTA NEUROPATHOL, V98, P240, DOI 10.1007/s004010051075; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; Goldberg Y, 1996, ONCOGENE, V12, P893; Gottifredi V, 1999, J CELL SCI, V112, P2397; Grubbs CJ, 2000, CANCER RES, V60, P5599; HART MN, 1973, CANCER, V32, P890, DOI 10.1002/1097-0142(197310)32:4<890::AID-CNCR2820320421>3.0.CO;2-O; Joki T, 2000, CANCER RES, V60, P4926; Keller JJ, 1999, GUT, V45, P822, DOI 10.1136/gut.45.6.822; Kleihues P, 2000, PATHOLOGY GENETICS T; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; Matsuhashi N, 1997, GUT, V40, P344, DOI 10.1136/gut.40.3.344; MOLENAAR WM, 1994, CRIT REV ONCOL HEMAT, V17, P1, DOI 10.1016/1040-8428(94)90036-1; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Souza RF, 2000, CANCER RES, V60, P5767; Taylor MT, 2000, CANCER RES, V60, P6607; Tegeder I, 2001, FASEB J, V15, P595, DOI 10.1096/fasebj.15.3.595; von Knethen A, 1999, J IMMUNOL, V163, P2858; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Wechter WJ, 2000, CANCER RES, V60, P2203; Wechter WJ, 2000, LIFE SCI, V66, P745, DOI 10.1016/S0024-3205(99)00645-1; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 1996, AM J PHYSIOL, V270, P393; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	24	39	39	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2001	20	47					6864	6870		10.1038/sj.onc.1204907	http://dx.doi.org/10.1038/sj.onc.1204907			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687965				2022-12-17	WOS:000171641000007
J	Fardioni-Laurens, L; Bosq, J; Janot, F; Vayssade, M; Le Bihan, ML; Kaghad, M; Caput, D; Benard, J; Ahomadegbe, JC				Fardioni-Laurens, L; Bosq, J; Janot, F; Vayssade, M; Le Bihan, ML; Kaghad, M; Caput, D; Benard, J; Ahomadegbe, JC			P73 expression in basal layers of head and neck squamous epithelium: a role in differentiation and carcinogenesis in concert with p53 and p63?	ONCOGENE			English	Article						p73; differentiation; carcinogenesis; head and neck tissues	TUMOR-SUPPRESSOR GENE; WILD-TYPE P73; P53-RELATED PROTEIN; BREAST CANCERS; CELL CARCINOMA; HOMOLOG; OVEREXPRESSION; NEUROBLASTOMA; HETEROZYGOSITY; INACTIVATION	P73, a p53-homologue gene, has been studied for its possible role in head and neck squamous epithelium (HNSE) differentiation and carcinogenesis. P73 RNA and protein were analysed in 50 biopsies, including well- and moderately-differentiated carcinomas, and 21 matched normal adjacent tissues. P73 immunohistochemical analyses revealed intense p73 nuclear staining in basal and parabasal cells of normal squamous epithelium, in contrast with complete absence of staining in the more superficial cell layers. Moderately-differentiated carcinomas demonstrated homogeneous and diffuse staining in all tumour cells, while only basal cells were stained in well-differentiated carcinomas as in normal tissue. No correlation was observed between p73 and p53 protein expression. Immunostaining for p63, another p53-related protein previously described as being involved in HNSE morphogenesis and overexpressed in head and neck squamous cell carcinomas (HNSCC), was found to be similar to p73 labelling in carcinomas, but spread to the more differentiated layers in normal epithelium. Biallelic expression of p73 was found in tumours as well as in matched normal tissues. Comparison of p73 transcript levels between tumours and normal tissues showed decreased mRNA expression in 5/17 (30%) tumours independently of the differentiation status. Mutation and loss of heterozygosity analyses of the p73 gene revealed wild type status and no deletion. Our results strongly suggest that: (i) p73 is associated with homeostasis and control of differentiation of head and neck squamous epithelium probably in concert with p53 and p63; (ii) down-regulation of p73 expression could participate in HNSE carcinogenesis.	Inst Gustave Roussy, Dept Biol Clin, Unite Marqueurs Genet Canc, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Anat Pathol, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Chirurg Cervicofaciale, F-94805 Villejuif, France; UPJV, Fac Pharm, F-80037 Amiens, France; Sanofi Rech, F-31676 Labege, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Picardie Universites; Universite de Picardie Jules Verne (UPJV); Sanofi-Aventis; Sanofi France	Ahomadegbe, JC (corresponding author), Inst Gustave Roussy, Dept Biol Clin, Unite Marqueurs Genet Canc, F-94805 Villejuif, France.		AMSELLEM, Sophie/B-3645-2012					Ahomadegbe JC, 2000, ONCOGENE, V19, P5413, DOI 10.1038/sj.onc.1203914; AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; Brash DE, 1998, CANCER SURV, V32, P69; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; Cai YYC, 2000, CARCINOGENESIS, V21, P683, DOI 10.1093/carcin/21.4.683; Casciano I, 1999, CELL DEATH DIFFER, V6, P391, DOI 10.1038/sj.cdd.4400522; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; Han S, 1999, EUR J SURG ONCOL, V25, P194, DOI 10.1053/ejso.1998.0626; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kang MJ, 2000, CLIN CANCER RES, V6, P1767; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Liefer KM, 2000, CANCER RES, V60, P4016; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Shishikura T, 1999, INT J CANCER, V84, P321, DOI 10.1002/(SICI)1097-0215(19990621)84:3<321::AID-IJC21>3.0.CO;2-S; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zaika AI, 1999, CANCER RES, V59, P3257; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061	42	39	43	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5302	5312		10.1038/sj.onc.1204687	http://dx.doi.org/10.1038/sj.onc.1204687			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536043				2022-12-17	WOS:000170575500006
J	Rahmani, M; Peron, P; Weitzman, J; Bakiri, L; Lardeux, B; Bernuau, D				Rahmani, M; Peron, P; Weitzman, J; Bakiri, L; Lardeux, B; Bernuau, D			Functional cooperation between JunD and NF-kappa B in rat hepatocytes	ONCOGENE			English	Article						NF-kappa B; p65; AP-1; JunD; hepatocytes	TUMOR-NECROSIS-FACTOR; GM-CSF PROMOTER; C-JUN; GLUCOCORTICOID RECEPTOR; LIVER-REGENERATION; TRANSCRIPTION FACTORS; AP-1 COMPLEX; DNA-BINDING; ACTIVATES TRANSCRIPTION; HEPATIC REGENERATION	AP-I and NF-kappaB are rapidly activated during liver regeneration. Whether these parallel inductions have potential functional implications is not known. Isolated rat hepatocytes were stimulated with two mitogens, epidermal growth factor or hepatocyte growth factor and with tumor necrosis factor, a cytokine involved in the liver regenerative response in vivo and a strong inducer of NF-kappaB. All three cytokines increased AP-1 and NF-kappaB binding to their cognate cis-element and induced a 2.5-fold activation of NF-kappaB-dependent transcription. Inactivation of AP-I by TAM67, a dominant negative mutant of AP-I drastically inhibited basal and cytokine-induced NF-kappaB transactivation. Overexpression of Jun D, but not of the other Jun or Fos proteins increased by threefold NF-kappaB transactivation. Functional cooperation between JunD and p65 was demonstrated in a simple Gal-hybrid system. Finally, a twofold decrease in NF-kappaB transactivation was found in hepatocytes isolated from JunD (-/-) mice compared with hepatocytes from JunD(+/+) mice. Altogether these data demonstrate a functional cooperation of p65 with JunD, a major constituent of AP-1 in normal hepatocytes.	Univ Paris 07, INSERM, U327, Biol Cellulaire Lab, F-75018 Paris, France; Univ Paris 07, F-75018 Paris, France; Inst Pasteur, Dept Biotechnol, CNRS, Unite Virus Oncogenes,URA 1644, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Bernuau, D (corresponding author), Univ Paris 07, INSERM, U327, Biol Cellulaire Lab, 16 Rue Henri Huchard, F-75018 Paris, France.		Bakiri, Latifa/N-5780-2014; Bakiri, Latifa/AAP-1674-2020	Rahmani, Mohamed/0000-0002-3992-8039; bakiri, latifa/0000-0002-6300-2420; Weitzman, Jonathan/0000-0001-8445-0102				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALCORN JA, 1990, HEPATOLOGY, V11, P909, DOI 10.1002/hep.1840110602; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BALAVOINE S, 1990, EUR J BIOCHEM, V189, P617, DOI 10.1111/j.1432-1033.1990.tb15530.x; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bannister AJ, 1995, ONCOGENE, V11, P2509; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; FAUSTO N, 1989, LAB INVEST, V60, P4; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Han YQ, 1997, J BIOL CHEM, V272, P9825; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HIRAI SI, 1990, ONCOGENE, V5, P39; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kaabache T, 1995, ANAL BIOCHEM, V232, P225, DOI 10.1006/abio.1995.0011; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; Kirillova I, 1999, CELL GROWTH DIFFER, V10, P819; Kralova J, 1996, ONCOGENE, V12, P2595; Le Cam A, 1995, Methods Mol Biol, V48, P141; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LIN L, 1998, CELL, V70, P777; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MARODER M, 1993, MOL ENDOCRINOL, V7, P570, DOI 10.1210/me.7.4.570; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; Menegazzi M, 1997, HEPATOLOGY, V25, P585, DOI 10.1002/hep.510250316; METTOUCHI A, 1997, MOL CELL BIOL, V17, P3020; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; Nadori F, 1997, HEPATOLOGY, V26, P1477; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; Peron P, 2001, J BIOL CHEM, V276, P10524, DOI 10.1074/jbc.M005919200; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Rahmani M, 1999, J HEPATOL, V30, P916, DOI 10.1016/S0168-8278(99)80148-2; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; Thepot D, 2000, DEVELOPMENT, V127, P143; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMPSON NL, 1986, CANCER RES, V46, P3111; TSUBOI A, 1994, BIOCHEM BIOPH RES CO, V199, P1064, DOI 10.1006/bbrc.1994.1337; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WANG SR, 1985, IN VITRO CELL DEV B, V21, P526; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	71	39	40	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5132	5142		10.1038/sj.onc.1204678	http://dx.doi.org/10.1038/sj.onc.1204678			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526502				2022-12-17	WOS:000170464000007
J	Baba, M; Hirai, S; Kawakami, S; Kishida, T; Sakai, N; Kaneko, S; Yao, M; Shuin, T; Kubota, Y; Hosaka, M; Ohno, S				Baba, M; Hirai, S; Kawakami, S; Kishida, T; Sakai, N; Kaneko, S; Yao, M; Shuin, T; Kubota, Y; Hosaka, M; Ohno, S			Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth	ONCOGENE			English	Article						VHL; tumor suppressor; contact inhibition; renal cell carcinoma; epithelial cells	HIPPEL-LINDAU GENE; BIOLOGICALLY-ACTIVE PRODUCT; F-BOX PROTEIN; BETA-CATENIN; DEPENDENT PROTEOLYSIS; SOMATIC MUTATIONS; UBIQUITIN LIGASE; RENAL-CARCINOMA; HUMAN TISSUES; CYCLE ARREST	In spite of the general recognition of von Hippel-Lindau (VHL) as a tumor suppressor gene, the physiological and pathological importance of VHL protein in cell growth regulation and tumorigenesis remains unclear, Here we show that in normal human renal proximal tubule epithelial cells (RPTEC), the steady-state amount of VHL protein is strictly regulated by cell density. The cellular VHL content is more than 100-fold higher in dense cultures than in sparse cultures, The increase in VHL protein at high cell density was also observed for NIH3T3 fibroblasts, suggesting the generality of the phenomenon. The growth rates of renal cell carcinoma cells lacking an intact VHL gene and their derivatives with wild-type or mutant VHL expression vector do not differ significantly when they are growing in log-phase. Importantly, however, there is a difference when they reach confluency: cells lacking wild-type VHL grew continuously, while cells expressing exogenous VHL protein showed relatively limited cell growth. Using an ecdysone-inducible VHL expressing cell line, we also show that the growth inhibition at high cell density can be released by attenuating the VHL expression, Taken together, we propose that VHL protein functions as a growth suppressor at high cell density, and this might be the basis of the tumor suppressor function of VHL.	Yokohama City Univ, Sch Med, Dept Biol Mol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Urol, Yokohama, Kanagawa 2360004, Japan; Kochi Med Sch, Dept Urol, Kochi 7838505, Japan	Yokohama City University; Yokohama City University; Kochi University	Hirai, S (corresponding author), Yokohama City Univ, Sch Med, Dept Biol Mol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.		Baba, Masaya/ABE-4893-2020; Baba, Masaya/L-7490-2013; Ohno, Shigeo/B-1768-2010	Baba, Masaya/0000-0002-5308-6683; Ohno, Shigeo/0000-0002-1294-5269				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Corless CL, 1997, HUM PATHOL, V28, P459, DOI 10.1016/S0046-8177(97)90035-6; Feng H, 1999, NAT CELL BIOL, V1, P486, DOI 10.1038/70272; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GAO JZ, 1995, CANCER RES, V55, P743; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; JUDAH F, 1995, NAT MED, V1, P27; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kandikonda S, 1996, CELL ADHES COMMUN, V4, P13, DOI 10.3109/15419069609010760; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kim M, 1998, BIOCHEM BIOPH RES CO, V253, P672, DOI 10.1006/bbrc.1998.9839; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; LAMIELL JM, 1989, MEDICINE, V68, P1; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Lieubeau-Teillet B, 1998, CANCER RES, V58, P4957; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Los M, 1996, LAB INVEST, V75, P231; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Okuda H, 1999, BIOCHEM BIOPH RES CO, V263, P491, DOI 10.1006/bbrc.1999.1347; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; SHUIN T, 1994, CANCER RES, V54, P2852; Soler C, 1999, FEBS LETT, V442, P178, DOI 10.1016/S0014-5793(98)01648-2; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; Wada H, 1999, J BIOL CHEM, V274, P36025, DOI 10.1074/jbc.274.50.36025; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Ye Y, 1998, INT J CANCER, V78, P62, DOI 10.1002/(SICI)1097-0215(19980925)78:1<62::AID-IJC11>3.0.CO;2-7	50	39	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2001	20	22					2727	2736		10.1038/sj.onc.1204397	http://dx.doi.org/10.1038/sj.onc.1204397			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420685				2022-12-17	WOS:000168712000001
J	Suzuki, T; Shiratori, M; Furuichi, Y; Matsumoto, T				Suzuki, T; Shiratori, M; Furuichi, Y; Matsumoto, T			Diverged nuclear localization of Werner helicase in human and mouse cells	ONCOGENE			English	Article						aging; nucleolar localization signal; rRNA transcription; Werner syndrome; WRN	SYNDROME PROTEIN; SYNDROME GENE; DNA HELICASE; WRN GENE; SEQUENCE; CLONING	Werner syndrome (WS) is a rare autosomal recessive genetic disorder causing premature aging and rare cancers. A gene responsible for WS (WRN) encodes a protein with 1432 amino acids (a.a.) homologous to the E. coli RecQ-type DNA helicase, Transcriptional activation facilitated nucleolar localization of human WRN protein (hWRNp) and serum starvation induced translocation of hWRNp from the nucleoli to the nucleoplasm in human cultured cells, suggesting a nucleolar-nucleoplasm trafficking of hWRNp depending on transcriptional state, Mutant hWRNp lacking the C-terminal 30 a.a. residues (Delta 1403-1432) failed to localize in the nucleolus, whereas Delta 1405-1432 can migrate into the nucleolus. Here we identify a region putative for nucleolar localization signal (NoLS) containing sequence of two positively charged amino acids (Arg(1403)-Lys(1404)) in the C-terminal area of hWRNp, By contrast, the mouse homolog (mWRNp) exists only in the nucleoplasm, We show that the inability of mWRNp to migrate into the nucleolus is due to a difference of a sequence in the region corresponding to the NoLS of hWRNp. In addition, mouse cells cannot recognize the NoLS of hWRNp, Our study suggests that defect in nucleolar function of hWRNp may be linked to the premature aging which is not observed in mWRN(-/-) mice.	AGENE Res Inst, Kanagawa 2470063, Japan		Matsumoto, T (corresponding author), AGENE Res Inst, 200 Kajiwara, Kanagawa 2470063, Japan.							CHIU SM, 1982, BIOCHIM BIOPHYS ACTA, V699, P15, DOI 10.1016/0167-4781(82)90166-X; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; Imamura O, 1997, GENOMICS, V41, P298, DOI 10.1006/geno.1997.4661; Kitao S, 1999, GENOMICS, V61, P268, DOI 10.1006/geno.1999.5959; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Lombard DB, 2000, MOL CELL BIOL, V20, P3286, DOI 10.1128/MCB.20.9.3286-3291.2000; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Matsumoto T, 1998, INT J MOL MED, V1, P71; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; SALK D, 1985, ADV EXP MED BIOL, V190, P305; Shiratori M, 1999, J CELL BIOL, V144, P1, DOI 10.1083/jcb.144.1.1; STEWART SE, 1989, MOL CELL BIOL, V9, P3464, DOI 10.1128/MCB.9.8.3464; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Wang L, 2000, GENETICS, V154, P357; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	24	39	42	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2551	2558		10.1038/sj.onc.1204344	http://dx.doi.org/10.1038/sj.onc.1204344			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420665				2022-12-17	WOS:000168652500006
J	Wang, PL; Sait, F; Winter, G				Wang, PL; Sait, F; Winter, G			The 'wildtype' conformation of p53: epitope mapping using hybrid proteins	ONCOGENE			English	Article						p53 conformation; epitope mapping; recombination; p53-DNA interaction	HUMAN PAPILLOMAVIRUS TYPE-16; DNA-BINDING DOMAIN; TUMOR-SUPPRESSOR PROTEIN; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; MURINE P53; SIMIAN VIRUS-40; E6 ONCOPROTEIN; MUTATIONS; PRODUCE	The function of p53 correlates with its 'wildtype' conformation, specifically recognized by antibodies PAb1620 and PAb246, and many cancer-associated mutations cause loss of this conformation. The epitopes of these antibodies were identified using hybrid p53 proteins created by a new method. Plasmids carrying homologous genes cut at appropriate sites recombined efficiently when transformed into RecE(+) E, coli, PAb1620 and PAb246 recognize mouse but not chicken p53; we created mouse-chicken hybrids of the p53 core domain and tested antibody reactivity, PAb246 binding mapped to residues 201-212, while PAb1620 required both residues 145-157 and 201-212 (human p53 numbering used throughout). An alanine-scan show-ed that the key residues for PAb246 and PAb1620 are completely distinct: PAb246 recognizes residues 202-204 (Tyr-Pro-Glu) while PAb1620 recognizes residues Arg156, Leu206, Arg209, and Gln/Asn210, the last two residues being essential, Both antibody epitopes are far from the p53 interface with DNA, but near the epitope of the 'mutant' conformation antibody PAb240, These epitope locations may help in dissecting the interactions of p53, including those with E6/E6-AP and in its DNA-bound state.	Ctr Prot Engn, Cambridge CB2 2QH, England; Mol Biol Lab, Cambridge CB2 2QH, England	University of Cambridge; MRC Laboratory Molecular Biology	Wang, PL (corresponding author), Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.							BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Cohen PA, 1999, FEBS LETT, V463, P179, DOI 10.1016/S0014-5793(99)01603-8; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GILLEN JR, 1981, J BACTERIOL, V145, P521, DOI 10.1128/JB.145.1.521-532.1981; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL AR, 1995, ONCOGENE, V10, P561; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KOLODNER R, 1994, MOL MICROBIOL, V11, P23, DOI 10.1111/j.1365-2958.1994.tb00286.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lane DP, 1996, ONCOGENE, V12, P2461; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEGROS Y, 1994, ONCOGENE, V9, P3689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Li XQ, 1996, J BIOL CHEM, V271, P4447; McLure KG, 1996, ONCOGENE, V13, P1297; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILNER J, 1987, ONCOGENE, V1, P453; MOLINARI M, 1995, ONCOGENE, V10, P1849; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Ravera MW, 1998, ONCOGENE, V16, P1993, DOI 10.1038/sj.onc.1201717; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; VOJTESEK B, 1995, ONCOGENE, V10, P389; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG PL, 2001, DIS MARKERS, V16; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	44	39	40	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2318	2324		10.1038/sj.onc.1204316	http://dx.doi.org/10.1038/sj.onc.1204316			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402327				2022-12-17	WOS:000168404500014
J	Sebti, SM; Hamilton, AD				Sebti, SM; Hamilton, AD			Design of growth factor antagonists with antiangiogenic and antitumor properties	ONCOGENE			English	Article						platelet-derived growth factor; angiogenesis; oncogenesis; cancer drug discovery	PDGF BETA-RECEPTOR; CRYSTAL-STRUCTURE; FACTOR-BB; BINDING; IDENTIFICATION; RECOGNITION; MOLECULE; REGION; DOMAIN; CHAIN	This review describes our recent efforts in the development of novel therapies for cancer. Our primary approach is to design synthetic agents that antagonize the function of growth factors that are critically involved in oncogenesis and angiogenesis. We achieve this by designing synthetic molecules that can recognize the exterior surface of the growth factor and so block the interaction with its receptor tyrosine kinase, A key step is the construction of synthetic agents that contain a large (>400 Angstrom (2)) and functionalized surface area to recognize a complementary surface on the target growth factor. In the course of this work,ve have discovered a molecule, GFB-111, that binds to PDGF, prevents it from binding to its receptor tyrosine kinase, blocks PDGF-induced receptor autophosphorylation, activation of Erk1 and Erk2 kinases and DNA synthesis, The binding affinity for PDGF is high (IC50=250 nM) and selective over EGF, IGF-1, aFGF, bFGF and HRG beta, In nude mouse models GFB-111 also shows significant inhibition of tumor growth and angiogenesis.	Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Dept Oncol & Biochem & Mol Biol, Drug Discovery Program, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06511 USA	State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Dept Oncol & Biochem & Mol Biol, Drug Discovery Program, Tampa, FL 33612 USA.				NCI NIH HHS [P01 CA78038-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON M, 1995, GROWTH FACTORS, V12, P159, DOI 10.3109/08977199509028962; Babine RE, 1997, CHEM REV, V97, P1359, DOI 10.1021/cr960370z; BACH AC, 1994, J AM CHEM SOC, V116, P3207, DOI 10.1021/ja00087a006; Blaskovich MA, 2000, NAT BIOTECHNOL, V18, P1065, DOI 10.1038/80257; BRANDON C, 1991, INTRO PROTEIN STRUCT; CAMPION SR, 1994, PROG NUCLEIC ACID RE, V49, P353; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ENGSTROM U, 1992, J BIOL CHEM, V267, P16581; FENSTERMAKER RA, 1993, J BIOL CHEM, V268, P10482; FIONA J, 1994, NEW MOL TARGETS CANC, P52; Hamuro Y, 1997, ANGEW CHEM INT EDIT, V36, P2680, DOI 10.1002/anie.199726801; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HENRIKSEN R, 1993, CANCER RES, V53, P4550; JOHNSSON A, 1985, P NATL ACAD SCI USA, V82, P1721, DOI 10.1073/pnas.82.6.1721; LAROCHELLE WJ, 1992, J BIOL CHEM, V267, P17074; MIDDAUGH CR, 1992, BIOCHEMISTRY-US, V31, P9016, DOI 10.1021/bi00152a044; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; Rockwell Patricia, 1995, Molecular and Cellular Differentiation, V3, P315; SEBTI SM, 2000, EXPERT OPINION INVES; SEYMOUR L, 1993, BREAST CANCER RES TR, V26, P247, DOI 10.1007/BF00665802; Sun JZ, 1999, CANCER RES, V59, P4919; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006	26	39	43	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 27	2000	19	56					6566	6573		10.1038/sj.onc.1204121	http://dx.doi.org/10.1038/sj.onc.1204121			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426641				2022-12-17	WOS:000167704000002
J	Kuraguchi, M; Edelmann, W; Yang, K; Lipkin, M; Kucherlapati, R; Brown, AMC				Kuraguchi, M; Edelmann, W; Yang, K; Lipkin, M; Kucherlapati, R; Brown, AMC			Tumor-associated Apc mutations in Mlh1(-/-) Apc(1638N) mice reveal a mutational signature of Mlh1 deficiency	ONCOGENE			English	Article						Mlh1; Apc; colorectal cancer; mouse models; mutation analysis	NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH REPAIR DEFICIENCY; CARCINOMA CELL-LINES; FAMILIAL ADENOMATOUS POLYPOSIS; MULTIPLE INTESTINAL NEOPLASIA; BETA-CATENIN; SUPPRESSOR PROTEIN; DNA MISMATCH; MOUSE MODEL; SACCHAROMYCES-CEREVISIAE	Apc(1638N) mice, which are heterozygous for a germline mutation in Ape, typically de, clop three to five spontaneous intestinal tumors per animal, in most cases this is associated,vith allelic loss of wildtype Ape. We have previously reported that the multiplicity of intestinal tumors is increased dramatically by crossing Apc(1638N) with an Mlh1-deficient mouse strain that represents an animal model of hereditary non-polyposis colorectal cancer (HNPCC). The increased tumor multiplicity in these mice was associated with somatic mutations in the Ape tumor suppressor gene, Here, we have examined the nature and distribution of 91 Ape mutations implicated in the de, development of intestinal tumors in Mlh1 (-/-) Apc(1638N) animals. Protein truncation mutations were detected in a majority of tumor samples, indicating that the prevailing mechanism of Ape mutation in tumors is altered from allelic loss to intragenic mutation as a result of Mlh1 deficiency, The observed mutations were a mixture of base substitutions (27%) and frameshifts (73%). Most frameshifts wire detected within dinucleotide repeats and there were prominent mutational hotspots within sequences of this sort at codons 927-929, 1209-1211 and 1461-1464, The observed Ape mutations caused protein truncation upstream of the third 20 amino acid beta -catenin binding domain and the first Axin-binding SAMP repeat, yielding Ape proteins that are predicted to be deficient in destabilizing beta -catenin, Our results reveal a characteristic mutational signature in APC that is attributable to Mlh1 deficiency. This demonstrates a direct effect of Mlh1 deficiency in the mutation of Apc in these tumors, and provides data that clarify the role of Mlh1 in mammalian DNA mismatch repair.	Rockefeller Univ, Strang Canc Res Lab, New York, NY 10021 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Cornell Univ, Weill Med Coll, Dept Cell Biol & Anat, New York, NY 10021 USA	Rockefeller University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Cornell University	Brown, AMC (corresponding author), Rockefeller Univ, Strang Canc Res Lab, 1230 York Ave, New York, NY 10021 USA.		Kucherlapati, Raju/ABC-8807-2021		DIVISION OF CANCER PREVENTION AND CONTROL [N01CN065031] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA047207, R01CA067944, R01CA076329] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CN-65031, CA76329, CA67944, R01 CA047207] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRANCH P, 1995, CANCER RES, V55, P2304; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 1999, CANCER RES, V59, P1301; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Habraken Y, 1997, CURR BIOL, V7, P790, DOI 10.1016/S0960-9822(06)00337-X; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kitaeva MN, 1997, CANCER RES, V57, P4478; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LEVY DB, 1994, CANCER RES, V54, P5953; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MIYAKI M, 1994, CANCER RES, V54, P3011; Miyaki M, 1999, CANCER RES, V59, P4506; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Ohzeki S, 1997, CARCINOGENESIS, V18, P1127, DOI 10.1093/carcin/18.6.1127; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Peltomaki P, 1997, ADV CANCER RES, V71, P93, DOI 10.1016/S0065-230X(08)60097-4; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1997, CANCER RES, V57, P4624; Saparbaev M, 1996, GENETICS, V142, P727; Shoemaker AR, 2000, ONCOGENE, V19, P2774, DOI 10.1038/sj.onc.1203574; Shoemaker AR, 1997, CANCER RES, V57, P1999; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SMITH KJ, 1994, CANCER RES, V54, P3672; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Umar A, 1998, GENETICS, V148, P1637; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Yang K, 1997, J EXP ZOOL, V277, P245, DOI 10.1002/(SICI)1097-010X(19970215)277:3<245::AID-JEZ5>3.3.CO;2-N	60	39	44	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5755	5763		10.1038/sj.onc.1203962	http://dx.doi.org/10.1038/sj.onc.1203962			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126362				2022-12-17	WOS:000165477700007
J	Gouble, A; Morello, D				Gouble, A; Morello, D			Synchronous and regulated expression of two AU-binding proteins, AUF1 and HuR, throughout murine development	ONCOGENE			English	Article						AU-rich element; c-myc mRNA; murine development; hnRNP proteins; mRNA turnover	MESSENGER-RNA STABILITY; RICH ELEMENT; NEUROGENIC CELLS; TRANSGENIC MICE; ELAV PROTEINS; GENE; IDENTIFICATION; DEGRADATION; GROWTH; PURIFICATION	The AUF1 (hnRNPD) and HuR (ELAV-like) proteins, potential trans-acting factors for regulated mRNA decay, bind in vitro to A+U-rich elements (AREs) found in the 3' untranslated region (3' UTR) of many labile transcripts. In an effort to determine whether these trans-acting factors are likely to play a role in embryogenesis, we have analysed their expression during mouse development both at the mRNA and protein levels. We show that AUF1 and HuR are expressed at all the developmental stages analysed from day 8.5 of embryonic development to adulthood. Expression levels are dynamic, varying between tissues and developmental stages. However, a strong positive correlation between AUF1 and HuR protein levels was observed in all examined tissues. Finally, we compared AUF1 and HuR expression with accumulation of one common target mRNA, c-myc. The similar spatio-temporal distribution of these proteins and of c-myc mRNA is in agreement with a potential concerted role in ARE-mediated control of mRNA stability.	Univ Toulouse 3, CNRS, UMR 5547, Ctr Dev Biol, F-31062 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Morello, D (corresponding author), Univ Toulouse 3, CNRS, UMR 5547, Ctr Dev Biol, Batiment 4R3,118 Route Narbonne, F-31062 Toulouse 4, France.							Akamatsu W, 1999, P NATL ACAD SCI USA, V96, P9885, DOI 10.1073/pnas.96.17.9885; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Antic D, 1998, J CELL SCI, V111, P183; Atasoy U, 1998, J CELL SCI, V111, P3145; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bhattacharya S, 1999, NUCLEIC ACIDS RES, V27, P1464, DOI 10.1093/nar/27.6.1464; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DREZEN JM, 1993, J IMMUNOL, V150, P2805; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HENICS T, 1994, J BIOL CHEM, V269, P5377; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; Kiledjian M, 1997, MOL CELL BIOL, V17, P4870, DOI 10.1128/MCB.17.8.4870; Lafon I, 1998, ONCOGENE, V16, P3413, DOI 10.1038/sj.onc.1201895; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MARUSICH MF, 1992, DEV BIOL, V149, P295, DOI 10.1016/0012-1606(92)90285-O; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1985, IMMUNOGENETICS, V22, P441, DOI 10.1007/BF00418090; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; Nabors LB, 1998, J NEUROIMMUNOL, V92, P152, DOI 10.1016/S0165-5728(98)00196-9; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; NANBU R, 1993, J BIOCHEM-TOKYO, V114, P432, DOI 10.1093/oxfordjournals.jbchem.a124193; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Perron M, 1999, MECH DEVELOP, V84, P139, DOI 10.1016/S0925-4773(99)00056-8; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	51	39	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5377	5384		10.1038/sj.onc.1203910	http://dx.doi.org/10.1038/sj.onc.1203910			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103939				2022-12-17	WOS:000165302300009
J	Yun, CW; Lee, JH; Park, H; Jin, YM; Park, S; Park, K; Cho, H				Yun, CW; Lee, JH; Park, H; Jin, YM; Park, S; Park, K; Cho, H			Chemotherapeutic drug, adriamycin, restores the function of p53 protein in hepatitis B virus X (HBx) protein-expressing liver cells	ONCOGENE			English	Article						HBx; p53; liver cancer; chemotherapeutic drug; subcellular localization; cytoplasmic sequestration	WILD-TYPE P53; P53-DEPENDENT APOPTOSIS; GENE-PRODUCT; TRANSCRIPTIONAL ACTIVITY; ADENOVIRUS TYPE-5; GENOTOXIC STRESS; GROWTH ARREST; CANCER; DNA; TRANSACTIVATION	Hepatitis B virus X (HBx) protein implicated in the development of liver cancer may inhibit the function of p53 tumor suppressor protein through cytoplasmic retention of p53 protein. Here, we attempt to investigate whether the functional inhibition of p53 protein by HBx protein is reversible. First, we provide the evidence for the association of endogenous p53 protein with HBx by co-immunoprecipitation in stable Chang cells that express HBx protein in an inducible manner (ChangX-34), By immunofluorescence microscopy, the major location of p53 protein of ChangX-34 cells was confirmed at the nuclear periphery as well as in the cytoplasm where HBx protein is mainly expressed. Surprisingly, anticancer drug, adriamycin induces the nuclear translocation of p53 protein sequestered in the cytoplasm, This change is accompanied by the restoration of p53 activity, which results in increased transcriptional activity at the p53-responsive DNA elements as well as increase of p21(WAF1) mRNA expression. Further, we observed the induction of cell death and G1 arrest in these cells upon adriamycin treatment regardless of HBx expression. Together, we demonstrate that functional inhibition of p53 protein through its cytoplasmic retention by HBx protein is reversible. These results may be extended into other tumors of which p53 activity is modulated by viral oncoproteins.	Ajou Univ, Sch Med, Dept Biochem, Suwon 442749, South Korea; Ajou Univ Hosp, Dept Pathol, Suwon 442749, South Korea; Ajou Univ, Sch Med, Dept Microbiol, Suwon 442749, South Korea; Samsung Biomed Res Inst, Ctr Mol Med, Seoul, South Korea	Ajou University; Ajou University; Ajou University Hospital; Ajou University; Samsung; Sungkyunkwan University (SKKU); Samsung Medical Center	Cho, H (corresponding author), Ajou Univ, Sch Med, Dept Biochem, Wonchon Dong 5, Suwon 442749, South Korea.			Cho, Hyeseong/0000-0002-4672-8887; Yun, Chawon/0000-0002-0046-4732				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chresta CM, 1996, CANCER RES, V56, P1834; Doitsh G, 1999, ONCOGENE, V18, P7506, DOI 10.1038/sj.onc.1203209; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; GIACCIA AJ, 1998, GENE DEV, V12, P3158; Gonin S, 1999, ONCOGENE, V18, P8011, DOI 10.1038/sj.onc.1203319; Greenblatt MS, 1997, CANCER RES, V57, P426; Harris MP, 1996, CANCER GENE THER, V3, P121; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; HENKLER F, 1995, CANCER RES, V55, P6084; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; Houghton Janet A., 1999, Current Opinion in Oncology, V11, P475, DOI 10.1097/00001622-199911000-00008; JIANG D, 1993, ONCOGENE, V8, P2805; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kim JR, 1998, EXP MOL MED, V30, P145, DOI 10.1038/emm.1998.21; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Lee H, 1995, J BIOL CHEM, V270, P31405, DOI 10.1074/jbc.270.52.31405; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Lin Y, 1997, CANCER RES, V57, P5137; MACGUIRE HF, 1991, SCIENCE, V252, P842; McCormick F, 1999, CANCER J SCI AM, V5, P139; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NATOLI G, 1995, J HEPATOL, V22, P14; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PRICE BD, 1994, CANCER RES, V54, P896; QIN S, 1998, HEPATOLOGY, V27, P1109; QUADRI I, 1995, P NATL ACAD SCI USA, V92, P1003; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; Thomas M, 1996, ONCOGENE, V13, P265; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; Urban S, 1997, HEPATOLOGY, V26, P1045, DOI 10.1002/hep.510260437; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163	53	39	41	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5163	5172		10.1038/sj.onc.1203896	http://dx.doi.org/10.1038/sj.onc.1203896			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064453				2022-12-17	WOS:000090124100005
J	Leung, SY; Yuen, ST; Chan, TL; Chan, ASY; Ho, JWC; Kwan, K; Fan, YW; Hung, KN; Chung, LP; Wyllie, AH				Leung, SY; Yuen, ST; Chan, TL; Chan, ASY; Ho, JWC; Kwan, K; Fan, YW; Hung, KN; Chung, LP; Wyllie, AH			Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation	ONCOGENE			English	Article						microsatellite instability; chromosomal instability; p53 mutation; colon carcinoma; glioma; Turcot's syndrome	COMPARATIVE GENOMIC HYBRIDIZATION; WILD-TYPE P53; MICROSATELLITE INSTABILITY; P53-DEFICIENT MICE; CLINICOPATHOLOGICAL VARIABLES; SECONDARY GLIOBLASTOMAS; GLIOMA PROGRESSION; SOMATIC MUTATIONS; DNA CONTENT; CELL-LINES	We have previously reported high-frequency microsatellite instability (MSI-H) and germ-line mismatch repair gene mutation in patients with unusually young onset of high-grade glioma. Some of these patients developed metachronous MSI-H colorectal cancer and conformed to the diagnosis of Turcot's syndrome. Frameshift mutation of TGF beta RII was present in all the colorectal carcinomas but not in brain tumours. We further characterized the genetic pathways of tumour evolution in these metachronous gliomas and colorectal carcinomas. All MSI-H glioblastomas had inactivation of both alleles of the p53 gene and showed over-expression of the p53 protein while none of the colorectal carcinomas had p53 mutation or protein over-expression. Flow cytometry and comparative genomic hybridization revealed that all glioblastomas were chromosomal unstable with aneuploid DNA content, and with a variable number of chromosomal arm aberrations. In contrast, the colorectal carcinomas had diploid or near-diploid DNA content with few chromosomal arm aberrations. The pattern of chromosomal aberrations in the two organs was different. Loss of 9p was consistently observed in all glioblastomas but not in colorectal carcinomas. Epidermal growth factor receptor amplification was absent in all glioblastomas and colorectal carcinomas. Our results suggest that both the frequency of p53 mutation and its effects differ greatly in the two organs. Following loss of mismatch repair function, p53 inactivation and chromosomal instability are not necessary for development of colorectal carcinoma, but are required for genesis of glioblastoma.	Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Hereditary Gastrointestinal Canc Registry, Hong Kong, Hong Kong, Peoples R China; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Cambridge	Leung, SY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		Yuen, Siu/K-6311-2014; Chung, Lap Ping/C-4258-2009; Leung, Suet Yi/C-4340-2009; Leung, Suet Yi/T-9620-2019	Leung, Suet Yi/0000-0001-8614-4619				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; Bocker T, 1996, J PATHOL, V179, P15; BOUFFLER SD, 1995, CANCER RES, V55, P3883; CARDER P, 1993, ONCOGENE, V8, P1397; Chan TL, 1999, GENE CHROMOSOME CANC, V25, P75, DOI 10.1002/(SICI)1098-2264(199906)25:2<75::AID-GCC1>3.3.CO;2-T; Cheng Y, 1999, HUM PATHOL, V30, P1284, DOI 10.1016/S0046-8177(99)90057-6; Cottu PH, 1996, ONCOGENE, V13, P2727; CURTIS LJ, 2000, IN PRESS J PATHOL; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Feeley KM, 1999, J PATHOL, V188, P14, DOI 10.1002/(SICI)1096-9896(199905)188:1<14::AID-PATH323>3.0.CO;2-Q; Forster S, 1998, SURGERY, V123, P13, DOI 10.1067/msy.1998.83304; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Gafanovich A, 1999, CANCER-AM CANCER SOC, V85, P504; Harada K, 1998, CANCER RES, V58, P4694; HARVEY M, 1993, ONCOGENE, V8, P2457; HEDLEY DW, 1983, J HISTOCHEM CYTOCHEM, V31, P1333, DOI 10.1177/31.11.6619538; HUNTER SB, 1995, J NEUROPATH EXP NEUR, V54, P57, DOI 10.1097/00005072-199501000-00007; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kleihues P, 1997, BRAIN PATHOL, V7, P1131, DOI 10.1111/j.1750-3639.1997.tb00993.x; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; Leung SY, 1998, AM J PATHOL, V153, P1181, DOI 10.1016/S0002-9440(10)65662-3; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTHE RA, 1993, CANCER RES, V53, P5849; MELING GI, 1993, BRIT J CANCER, V67, P93, DOI 10.1038/bjc.1993.15; Miyaki M, 1997, ONCOGENE, V15, P2877, DOI 10.1038/sj.onc.1201668; MOHAPATRA G, 1995, GENE CHROMOSOME CANC, V13, P86, DOI 10.1002/gcc.2870130203; Nishizaki T, 1998, GENE CHROMOSOME CANC, V21, P340, DOI 10.1002/(SICI)1098-2264(199804)21:4<340::AID-GCC8>3.0.CO;2-Z; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; PURDIE CA, 1994, ONCOGENE, V9, P603; REMVIKOS Y, 1995, GENE CHROMOSOME CANC, V12, P272, DOI 10.1002/gcc.2870120406; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Schlegel J, 1996, J NEUROPATH EXP NEUR, V55, P81, DOI 10.1097/00005072-199601000-00008; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Tohma Y, 1998, J NEUROPATH EXP NEUR, V57, P684, DOI 10.1097/00005072-199807000-00005; TSUKADA T, 1993, ONCOGENE, V8, P3313; VONDEIMLING A, 1993, BRAIN PATHOL, V3, P19; VONDEIMLING A, 1995, GLIA, V15, P328, DOI 10.1002/glia.440150312; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Weber RG, 1996, ONCOGENE, V13, P983; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Yuen ST, 1997, BRIT J CANCER, V76, P1610, DOI 10.1038/bjc.1997.605	45	39	42	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					4079	4083		10.1038/sj.onc.1203740	http://dx.doi.org/10.1038/sj.onc.1203740			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962567				2022-12-17	WOS:000088825300016
J	Ronchini, C; Capobianco, AJ				Ronchini, C; Capobianco, AJ			Notch(ic)-ER chimeras display hormone-dependent transformation, nuclear accumulation, phosphorylation and CBF1 activation	ONCOGENE			English	Article						notch; hormone inducible activity; phosphorylation; CBF-1; nuclear localization	HUMAN ESTROGEN-RECEPTOR; CELL-FATE; NEOPLASTIC TRANSFORMATION; DROSOPHILA NOTCH; IN-VIVO; CONDITIONAL TRANSFORMATION; INTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; TYROSINE KINASES; FUSION PROTEINS	Notch genes encode a family of evolutionarily conserved transmembrane receptors that are involved in many distinct cellular processes such as differentiation, proliferation and apoptosis. Notch function has been shown to be required both during development and in adult life. Moreover, several studies on spontaneous human tumors and in experimental models demonstrate that three of the four mammalian Notch genes can act as oncogenes. The mechanism by which Notch proteins induce neoplastic transformation is not known. In order to determine the early signaling events mediated by Notch during cellular transformation we constructed several inducible alleles of Notch(ic) by fusing portions of Notch(ic) to the hormone-binding domain of the estrogen receptor. Here we show that Notch(ic)-ER chimeras are conditionally activated by 4-Hydroxytamoxifen (OHT) in a dose-dependent manner. Clonal RKE cell lines expressing Notch(ic)-ER chimeras display hormone-dependent transformation in vitro. Transformation mediated by Notch(ic)-ER is reversible and chronic stimulation is necessary for the maintenance of the transformed phenotype. In response to hormone activation Notch(ic)-ER chimeras become hyperphosphorylated and accumulate in the nuclear of the cell; indicating that both phosphorylation and nuclear localization are required for Notch transforming activity.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Capobianco, AJ (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet, 231 Bethesda Ave, Cincinnati, OH 45267 USA.		Ronchini, Chiara/K-3935-2013	Ronchini, Chiara/0000-0003-3908-4021; Capobianco, Anthony/0000-0002-3706-6797	NATIONAL CANCER INSTITUTE [R01CA083736] Funding Source: NIH RePORTER; NCI NIH HHS [R0I CA 83736] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD I, 1995, MECH DEVELOP, V53, P73, DOI 10.1016/0925-4773(95)00425-4; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Dumont E, 2000, ONCOGENE, V19, P556, DOI 10.1038/sj.onc.1203352; ECCLES SA, 1994, INVAS METAST, V14, P337; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FuentesPanana EM, 1998, J VIROL, V72, P693; GALLAHAN D, 1987, J VIROL, V61, P218, DOI 10.1128/JVI.61.1.218-220.1987; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Grignani F, 1998, CANCER RES, V58, P14; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lofts F J, 1992, Cancer Treat Res, V61, P161; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; NYE JS, 1994, DEVELOPMENT, V120, P2421; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Rehberger S, 1997, EXP CELL RES, V233, P363, DOI 10.1006/excr.1997.3562; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; STIFANI S, 1992, NAT GENET, V2, P343, DOI 10.1038/ng1292-343a; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Vigo E, 1999, MOL CELL BIOL, V19, P6379; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	57	39	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2000	19	34					3914	3924		10.1038/sj.onc.1203719	http://dx.doi.org/10.1038/sj.onc.1203719			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951584				2022-12-17	WOS:000088614300010
